,drug_name,pubmed_id,title,authors,mesh_terms,paper_url
0,ketorolac,27042717,[Muscle-skeletal pain].,"['Vygonskaya MV', 'Filatova EG']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Chronic Pain', 'Combined Modality Therapy', 'Humans', 'Ketorolac/adverse effects/therapeutic use', 'Low Back Pain/*physiopathology/*therapy', 'Musculoskeletal Pain/*physiopathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/27042717/
1,ketorolac,37097781,What is the analgesic ceiling dose of ketorolac for treating acute pain in the ED?,"['Jaglal R', 'Nemec EC 2nd']","['Humans', '*Ketorolac/therapeutic use', '*Acute Pain/drug therapy', 'Analgesics/adverse effects', 'Pain Management', 'Pain, Postoperative/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37097781/
2,ketorolac,28526155,"Ketorolac, Oxymorphone, Tapentadol, and Tramadol: A Comprehensive Review.","['Vadivelu N', 'Chang D', 'Helander EM', 'Bordelon GJ', 'Kai A', 'Kaye AD', 'Hsu D', 'Bang D', 'Julka I']","['Analgesics, Opioid/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Humans', 'Ketorolac/adverse effects/*therapeutic use', 'Oxymorphone/adverse effects/*therapeutic use', 'Pain/*drug therapy', 'Pain Measurement', 'Phenols/adverse effects/*therapeutic use', 'Tapentadol', 'Tramadol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28526155/
3,ketorolac,27993418,Comparison of Intravenous Ketorolac at Three Single-Dose Regimens for Treating Acute Pain in the Emergency Department: A Randomized Controlled Trial.,"['Motov S', 'Yasavolian M', 'Likourezos A', 'Pushkar I', 'Hossain R', 'Drapkin J', 'Cohen V', 'Filk N', 'Smith A', 'Huang F', 'Rockoff B', 'Homel P', 'Fromm C']","['Acute Pain/*drug therapy/physiopathology', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', '*Emergency Service, Hospital', 'Female', 'Humans', 'Injections, Intravenous', 'Ketorolac/*administration & dosage/pharmacology/*therapeutic use', 'Male', 'Pain Measurement', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27993418/
4,ketorolac,29247538,Narrative review shows that the short-term use of ketorolac is safe and effective in the management of moderate-to-severe pain in children.,"['Marzuillo P', 'Calligaris L', 'Amoroso S', 'Barbi E']","['Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Child', 'Child, Preschool', 'Humans', 'Infant', 'Ketorolac/*pharmacology', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29247538/
5,ketorolac,35274178,The Efficacy of Local Anesthesia for Postoperative Pain Control in Breast Augmentation Surgery: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.,"['Chen IC', 'Kang YN', 'Wang HJ', 'Chiu WK', 'Chen C']","['Analgesics/therapeutic use', '*Anesthesia, Local/methods', 'Anesthetics, Local', 'Bupivacaine/therapeutic use', 'Female', 'Humans', 'Ketorolac/therapeutic use', '*Mammaplasty/adverse effects/methods', 'Narcotics/therapeutic use', 'Network Meta-Analysis', 'Pain, Postoperative/drug therapy/prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35274178/
6,ketorolac,27931700,Pediatric Tonsillectomy and Ketorolac.,"['Phillips-Reed LD', 'Austin PN', 'Rodriguez RE']","['Adolescent', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Child', 'Child, Preschool', 'Hemorrhage/chemically induced', 'Humans', 'Infant', 'Ketorolac/*adverse effects', '*Tonsillectomy']",https://pubmed.ncbi.nlm.nih.gov/27931700/
7,ketorolac,11027904,Pain responses in methadone-maintained opioid abusers.,"['Compton P', 'Charuvastra VC', 'Kintaudi K', 'Ling W']","['Adult', 'Cold Temperature/adverse effects', 'Drug Interactions/*physiology', 'Female', 'Humans', 'Hydromorphone/administration & dosage/adverse effects', 'Ketorolac/administration & dosage/adverse effects', 'Male', 'Methadone/*adverse effects', 'Middle Aged', 'Opioid-Related Disorders/drug therapy/*physiopathology', 'Pain/*drug therapy/physiopathology', 'Pain Measurement/statistics & numerical data', 'Pain Threshold/drug effects/physiology', 'Pressure/adverse effects', 'Reaction Time/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/11027904/
8,ketorolac,37088148,A possible role for ketorolac in the management of increased biliary drain output.,"['Yu AT', 'Khajoueinejad N', 'Gross A', 'Golas BJ', 'Cohen NA']","['Humans', 'Ketorolac/therapeutic use', '*Cholestasis/etiology', 'Treatment Outcome', '*Jaundice', '*Adenocarcinoma/complications', 'Drainage']",https://pubmed.ncbi.nlm.nih.gov/37088148/
9,ketorolac,29426743,Bridging multimodal pain management provides 48-hour pain control in patients undergoing total shoulder replacement.,"['Boddu C', 'Genza A', 'McCann PD']","['Acetaminophen/therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics, Non-Narcotic/therapeutic use', 'Analgesics, Opioid/administration & dosage', 'Anesthetics, Local/*administration & dosage', 'Anti-Inflammatory Agents/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal', 'Arthroplasty, Replacement, Shoulder/*adverse effects', 'Bupivacaine/*administration & dosage', 'Cryotherapy', 'Dexamethasone/therapeutic use', 'Female', 'Humans', 'Ketorolac/therapeutic use', 'Length of Stay', 'Liposomes', 'Male', 'Middle Aged', 'Narcotics/therapeutic use', 'Nerve Block', 'Pain Management/*methods', 'Pain Measurement', 'Pain, Postoperative/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/29426743/
10,ketorolac,15195936,Multimodal acute pain management.,['Skinner HB'],"['Analgesia, Epidural', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid', '*Anesthesia, Conduction', 'Anesthesia, Spinal', 'Anesthetics, Local', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', '*Arthroplasty', 'Arthroplasty, Replacement, Hip', 'Arthroplasty, Replacement, Knee', 'Bupivacaine', 'Drug Therapy, Combination', 'Humans', 'Ketorolac/pharmacology/therapeutic use', 'Nerve Block', 'Pain Measurement', 'Pain, Postoperative/physiopathology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/15195936/
11,ketorolac,17464604,"Reduced hospital stay and narcotic consumption, and improved mobilization with local and intraarticular infiltration after hip arthroplasty: a randomized clinical trial of an intraarticular technique versus epidural infusion in 80 patients.","['Andersen KV', 'Pfeiffer-Jensen M', 'Haraldsted V', 'Soballe K']","['Aged', 'Amides/*administration & dosage/adverse effects', 'Analgesia/*methods', 'Analgesia, Epidural/*methods', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Anesthetics, Local/*administration & dosage/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Arthroplasty, Replacement, Hip/*adverse effects', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intra-Articular', 'Ketorolac/*administration & dosage/adverse effects', '*Length of Stay', 'Male', 'Middle Aged', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Recovery of Function', 'Ropivacaine', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17464604/
12,ketorolac,14516415,Effect of oral ketorolac and gender on human cold pressor pain tolerance.,"['Compton P', 'Charuvastra VC', 'Ling W']","['Administration, Oral', 'Adult', 'Analysis of Variance', 'Cold Temperature/*adverse effects', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Ketorolac/*administration & dosage', 'Male', 'Middle Aged', 'Pain/*drug therapy/physiopathology', 'Pain Threshold/*drug effects/physiology', '*Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/14516415/
13,ketorolac,29771750,Injectable Nonsteroidal Anti-Inflammatory Drugs in Sport.,['Matava MJ'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', '*Athletes', 'Athletic Injuries/*drug therapy', 'Humans', 'Inflammation/*drug therapy', 'Injections', 'Ketorolac/administration & dosage/adverse effects/therapeutic use', 'Pain', '*Pain Management', 'Soft Tissue Injuries/drug therapy', 'Sports']",https://pubmed.ncbi.nlm.nih.gov/29771750/
14,ketorolac,37733089,Opioid-free percutaneous nephrolithotomy: an initial experience.,"['Khargi R', 'Yaghoubian AJ', 'Blake RM', 'Ricapito A', 'Connors C', 'Gallante B', 'Khusid JA', 'Atallah W', 'Gupta M']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Ketorolac/therapeutic use', '*Nephrolithotomy, Percutaneous/adverse effects', 'Retrospective Studies', 'Prospective Studies', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37733089/
15,ketorolac,19641054,An evaluation of perioperative pregabalin for prevention and attenuation of postoperative shoulder pain after laparoscopic cholecystectomy.,"['Chang SH', 'Lee HW', 'Kim HK', 'Kim SH', 'Kim DK']","['Adult', 'Analgesics/*administration & dosage/adverse effects', '*Cholecystectomy, Laparoscopic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Ketorolac/administration & dosage', 'Pain Measurement', 'Pain, Postoperative/*prevention & control', 'Pregabalin', 'Prospective Studies', 'Severity of Illness Index', 'Shoulder Pain/*prevention & control', 'Sleep/drug effects', 'Time Factors', 'gamma-Aminobutyric Acid/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/19641054/
16,ketorolac,22391075,Aspirin-sensitive asthma and upper airway diseases.,"['Chang JE', 'Chin W', 'Simon R']","['Administration, Intranasal', 'Administration, Oral', 'Animals', 'Asthma, Aspirin-Induced/*diagnosis/immunology/*therapy', '*Desensitization, Immunologic', 'Drug Dosage Calculations', 'Humans', 'Immunization', 'Ketorolac/administration & dosage/adverse effects', 'Respiratory Tract Diseases/*diagnosis/immunology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/22391075/
17,ketorolac,28238723,Non-steroidal Anti-inflammatory Drugs Are Caspase Inhibitors.,"['Smith CE', 'Soti S', 'Jones TA', 'Nakagawa A', 'Xue D', 'Yin H']","['Anti-Inflammatory Agents, Non-Steroidal/*chemistry/metabolism/pharmacology', 'Caspase Inhibitors/*chemistry/metabolism/pharmacology', 'Caspases/chemistry/*metabolism', 'Caspases, Initiator/chemistry/metabolism', 'Cell Line', 'Cell Survival/drug effects', 'High-Throughput Screening Assays', 'Humans', 'Ibuprofen/chemistry/metabolism/pharmacology', 'Inhibitory Concentration 50', 'Ketorolac/chemistry/metabolism/pharmacology', 'Naproxen/chemistry/metabolism/pharmacology', 'Small Molecule Libraries/chemistry/metabolism/pharmacology', 'Substrate Specificity']",https://pubmed.ncbi.nlm.nih.gov/28238723/
18,ketorolac,32877323,Injectable Ketorolac and Corticosteroid Use in Athletes: A Systematic Review.,"['Jelsema TR', 'Tam AC', 'Moeller JL']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/therapeutic use', 'Athletic Injuries/*drug therapy', 'Humans', 'Injections, Intramuscular', 'Ketorolac/*administration & dosage/adverse effects/therapeutic use', 'Musculoskeletal System/injuries', 'Myalgia/drug therapy', 'Return to Sport', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/32877323/
19,ketorolac,24564610,Characterization and treatment of postsurgical dental implant pain employing intranasal ketorolac.,"['Bockow R', 'Korostoff J', 'Pinto A', 'Hutcheson M', 'Secreto SA', 'Bodner L', 'Hersh EV']","['Acetaminophen/therapeutic use', 'Administration, Intranasal', 'Adult', 'Analgesia, Patient-Controlled/methods', 'Analgesics, Non-Narcotic/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Cohort Studies', '*Dental Implantation, Endosseous', 'Dental Implants', 'Female', 'Humans', 'Ketorolac/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Nasal Mucosa/drug effects', 'Operative Time', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Pilot Projects', 'Rhinitis/chemically induced', 'Time Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24564610/
20,buspirone,11414551,Pharmacotherapy of generalized anxiety disorder.,['Davidson JR'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*drug therapy/epidemiology/psychology', 'Benzodiazepines', 'Buspirone/therapeutic use', 'Comorbidity', 'Depressive Disorder/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Hydroxyzine/therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11414551/
21,buspirone,29543325,Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users.,"['Baandrup L', 'Ebdrup BH', 'Rasmussen JO', 'Lindschou J', 'Gluud C', 'Glenthoj BY']","['Adult', 'Antidepressive Agents/therapeutic use', 'Aspartic Acid/therapeutic use', 'Benzodiazepines/administration & dosage/*adverse effects', 'Buspirone/therapeutic use', 'Carbamazepine/therapeutic use', 'Ethylamines/therapeutic use', 'Flumazenil/therapeutic use', 'Homeopathy', 'Humans', 'Imidazoles/therapeutic use', 'Lithium Compounds/therapeutic use', 'Melatonin/therapeutic use', 'Paroxetine/therapeutic use', 'Pregabalin/therapeutic use', 'Progesterone/therapeutic use', 'Pyridines/therapeutic use', 'Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*drug therapy', 'Sulfides/therapeutic use', '*Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/29543325/
22,buspirone,2836673,Biology of anxiety.,['Teicher MH'],"['Agoraphobia/*genetics/physiopathology', 'Anxiety Disorders/*physiopathology', 'Buspirone/pharmacology', 'Fear/*drug effects', 'Humans', 'Panic/*drug effects/physiology', 'Phobic Disorders/*genetics', 'Receptors, GABA-A/*physiology']",https://pubmed.ncbi.nlm.nih.gov/2836673/
23,buspirone,25389538,[Clinical potential and possibilities of using buspirone in the treatment of anxiety disorders].,"['Dzampaev AT', 'Suvorova IA', 'Damulin IV']","['Anti-Anxiety Agents/adverse effects/*therapeutic use', 'Anxiety Disorders/diagnosis/*drug therapy/epidemiology', 'Buspirone/adverse effects/*therapeutic use', 'Comorbidity', 'Humans', 'Panic Disorder/diagnosis/drug therapy/epidemiology', 'Phobic Disorders/diagnosis/drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/25389538/
24,buspirone,8884163,A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder.,"['Carpenter LL', 'McDougle CJ', 'Epperson CN', 'Price LH']","['1-Naphthylamine/adverse effects/analogs & derivatives/therapeutic use', 'Adult', 'Aged', 'Antidepressive Agents/adverse effects/therapeutic use', 'Buspirone/adverse effects/therapeutic use', 'Child', 'Clomipramine/adverse effects/therapeutic use', 'Clonazepam/adverse effects/therapeutic use', 'Costs and Cost Analysis', 'Dopamine Antagonists/adverse effects/therapeutic use', 'Drug Interactions', 'Drug Tolerance', 'Fenfluramine/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/therapeutic use', 'Humans', 'Lithium/adverse effects/therapeutic use', 'Obsessive-Compulsive Disorder/*drug therapy', 'Paroxetine/adverse effects/therapeutic use', 'Risk Assessment', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Sertraline', 'Tryptophan/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8884163/
25,buspirone,15264994,Paroxetine in the treatment of generalised anxiety disorder.,"['Snyderman SH', 'Rynn MA', 'Bellew K', 'Rickels K']","['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents, Second-Generation/administration & dosage/adverse effects/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*drug therapy', 'Benzodiazepines/therapeutic use', 'Buspirone/therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Paroxetine/administration & dosage/adverse effects/*therapeutic use', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15264994/
26,buspirone,2884874,Evaluation of the safety and side effects of antianxiety agents.,['Schnabel T Jr'],"['Anti-Anxiety Agents/*adverse effects/therapeutic use', 'Benzodiazepines', 'Buspirone', 'Clinical Trials as Topic', 'Drug Interactions', 'Ethanol/pharmacology', 'Humans', 'Pyrimidines/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2884874/
27,buspirone,10622687,The use of benzodiazepines in anxiety and other disorders.,"['Argyropoulos SV', 'Nutt DJ']","['Anti-Anxiety Agents/*administration & dosage', 'Antidepressive Agents/therapeutic use', 'Anxiety/*drug therapy', 'Benzodiazepines/*administration & dosage', 'Buspirone/therapeutic use', 'Carbolines/therapeutic use', 'Humans', 'Mental Disorders/drug therapy', 'Receptors, GABA-A/drug effects', 'Sleep Wake Disorders/drug therapy', 'Substance Withdrawal Syndrome/psychology']",https://pubmed.ncbi.nlm.nih.gov/10622687/
28,buspirone,17094922,Strategies for managing antidepressant-induced sexual dysfunction: a review.,['Taylor MJ'],"['Antidepressive Agents/administration & dosage/*adverse effects', 'Bupropion/administration & dosage/adverse effects', 'Buspirone/administration & dosage/adverse effects', 'Depressive Disorder/*drug therapy', 'Erectile Dysfunction/*chemically induced/drug therapy', 'Female', 'Ginkgo biloba', 'Granisetron/administration & dosage/adverse effects', 'Humans', 'Male', 'Randomized Controlled Trials as Topic', 'Sexual Dysfunction, Physiological/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17094922/
29,buspirone,26171486,[The current concept of augmentation of treatment efficiency with antidepressant medication].,"['Damulin IV', 'Suvorova IA']","['Anti-Anxiety Agents/adverse effects/*therapeutic use', 'Antidepressive Agents/*therapeutic use', 'Buspirone/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder, Major/*drug therapy', 'Drug Synergism', 'Drug Therapy, Combination', 'Humans', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/26171486/
30,buspirone,9934947,Buspirone: future directions.,"['Apter JT', 'Allen LA']","['Anti-Anxiety Agents/*therapeutic use', 'Anxiety Disorders/drug therapy', 'Behavioral Symptoms/drug therapy', 'Buspirone/*therapeutic use', 'Forecasting', 'Humans', 'Selective Serotonin Reuptake Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9934947/
31,buspirone,8646275,Augmentation with buspirone: a review.,"['Harvey KV', 'Balon R']","['Anti-Anxiety Agents/*therapeutic use', 'Buspirone/*therapeutic use', 'Depressive Disorder/drug therapy', 'Drug Interactions', 'Humans', 'Obsessive-Compulsive Disorder/drug therapy', 'Panic Disorder/drug therapy', 'Schizophrenia/drug therapy', 'Serotonin Receptor Agonists/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8646275/
32,buspirone,2836252,"Buspirone, a new approach to the treatment of anxiety.",['Taylor DP'],"['Anxiety Disorders/*drug therapy', 'Buspirone/*therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Humans', 'Receptors, GABA-A/metabolism', 'Serotonin/physiology']",https://pubmed.ncbi.nlm.nih.gov/2836252/
33,buspirone,10714619,Augmentation strategies in depression 2000.,['Nelson JC'],"['Antidepressive Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Buspirone/therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Lithium/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Pindolol/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Triiodothyronine/therapeutic use', 'Tryptophan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10714619/
34,buspirone,28472575,Beyond anxiety and agitation: A clinical approach to akathisia.,"['Tachere RO', 'Modirrousta M']","['Adult', 'Antidepressive Agents/adverse effects/therapeutic use', 'Antiemetics/adverse effects/therapeutic use', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Anxiety/diagnosis/*etiology', 'Buspirone/adverse effects/therapeutic use', 'Cinnarizine/adverse effects/therapeutic use', 'Diltiazem/adverse effects/therapeutic use', 'Drug-Related Side Effects and Adverse Reactions/diagnosis', 'Female', 'Humans', 'Methyldopa/adverse effects/therapeutic use', 'Psychomotor Agitation/*complications/*diagnosis/etiology', 'Reserpine/adverse effects/therapeutic use', 'Suicidal Ideation']",https://pubmed.ncbi.nlm.nih.gov/28472575/
35,buspirone,1976621,Pharmacologic management of aggression in the elderly.,"['Yudofsky SC', 'Silver JM', 'Hales RE']","['Aged', 'Aggression/*drug effects', 'Antipsychotic Agents/*therapeutic use', 'Benzodiazepines/*therapeutic use', 'Buspirone/therapeutic use', 'Dementia/drug therapy/psychology', 'Haloperidol/therapeutic use', 'Humans', 'Lorazepam/therapeutic use', 'Neurocognitive Disorders/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1976621/
36,buspirone,9796861,Overcoming treatment resistance in depression.,['Nelson JC'],"['Antidepressive Agents/administration & dosage/*therapeutic use', 'Buspirone/therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Administration Schedule', 'Drug Resistance', 'Drug Therapy, Combination', 'Humans', 'Lithium/therapeutic use', 'Pindolol/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Treatment Outcome', 'Triiodothyronine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9796861/
37,buspirone,36917730,"Usefulness of Therapeutic Drug Monitoring and Pharmacogenetics for a Patient Treated with Olanzapine, Buspirone, and Fluvoxamine: A Case Study.","['Ding J', 'Yang L', 'Zhang Y', 'Meng Z', 'Ren J', 'Zhang S', 'Liu J', 'Cui X']","['Humans', 'Olanzapine', '*Fluvoxamine/therapeutic use', '*Buspirone/therapeutic use', 'Pharmacogenetics', 'Drug Monitoring/methods', 'Benzodiazepines']",https://pubmed.ncbi.nlm.nih.gov/36917730/
38,buspirone,1429411,Buspirone-associated mental status changes.,"['Soni P', 'Weintraub AL']","['Anxiety Disorders/*drug therapy/psychology', 'Buspirone/*adverse effects/therapeutic use', 'Child', 'Child Abuse/*complications/psychology', 'Child of Impaired Parents/*psychology', 'Female', 'Foster Home Care/psychology', 'Humans', 'Male', '*Mental Status Schedule', 'Parent-Child Relations']",https://pubmed.ncbi.nlm.nih.gov/1429411/
39,buspirone,2701745,"Buspirone and diazepam: comparison of subjective, psychomotor and biological effects.","['Boulenger JP', 'Squillace K', 'Simon P', 'Herrou M', 'Leymarie P', 'Zarifian E']","['Arousal/*drug effects', 'Attention/drug effects', 'Buspirone/*pharmacology', 'Catecholamines/urine', 'Color Perception/drug effects', 'Diazepam/*pharmacology', 'Discrimination Learning/drug effects', 'Double-Blind Method', 'Humans', 'Hydrocortisone/urine', 'Mental Recall/drug effects', 'Psychomotor Performance/*drug effects', 'Randomized Controlled Trials as Topic', 'Verbal Learning/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2701745/
40,indomethacin,2658608,Indomethacin-induced oligohydramnios.,"['Goldenberg RL', 'Davis RO', 'Baker RC']","['Adult', 'Amniotic Fluid/*drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Indomethacin/administration & dosage/*adverse effects', 'Obstetric Labor, Premature/prevention & control', 'Pregnancy', 'Ultrasonography', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2658608/
41,indomethacin,7982337,Treatment of polyhydramnios with indomethacin.,"['Kramer WB', 'Van den Veyver IB', 'Kirshon B']","['Amniotic Fluid/drug effects', 'Contraindications', 'Cyclooxygenase Inhibitors/therapeutic use', 'Female', 'Fetal Monitoring', 'Fetus/drug effects', 'Humans', 'Indomethacin/adverse effects/pharmacology/*therapeutic use', 'Polyhydramnios/*drug therapy/etiology', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7982337/
42,indomethacin,8504626,Pharmacokinetics of indomethacin in the elderly.,"['Oberbauer R', 'Krivanek P', 'Turnheim K']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Indomethacin/administration & dosage/*pharmacokinetics', 'Injections, Intravenous', 'Intestinal Absorption', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8504626/
43,indomethacin,935518,"Prostaglandins, indomethacin and dysmenorrhea.","['Lundstrom V', 'Green K', 'Wiqvist N']","['Diarrhea/chemically induced', 'Dysmenorrhea/*drug therapy/physiopathology', 'Female', 'Humans', 'Indomethacin/adverse effects/pharmacology/*therapeutic use', 'Menstruation', 'Nausea/chemically induced', 'Prostaglandins F/*blood', 'Uterine Contraction/*drug effects', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/935518/
44,indomethacin,2800992,Indomethacin as an analgesic after hysterectomy.,"['Engel C', 'Lund B', 'Kristensen SS', 'Axel C', 'Nielsen JB']","['Administration, Rectal', 'Adolescent', 'Adult', 'Double-Blind Method', 'Female', 'Hemorrhage/physiopathology', 'Humans', 'Hysterectomy/*adverse effects', 'Indomethacin/administration & dosage/*therapeutic use', 'Injections, Intravenous', 'Middle Aged', 'Morphine Derivatives/therapeutic use', 'Nicotinic Acids/therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*prevention & control', 'Placebos', '*Premedication', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2800992/
45,indomethacin,1346283,Indomethacin and postprandial gallbladder emptying.,"[""O'Donnell LJ"", 'Wilson P', 'Guest P', 'Catnach SM', 'McLean A', 'Wickham JE', 'Fairclough PD']","['Adult', 'Cholelithiasis/physiopathology/*prevention & control', 'Drug Administration Schedule', '*Eating', 'Female', 'Gallbladder Emptying/*drug effects/physiology', 'Humans', 'Indomethacin/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1346283/
46,indomethacin,7671547,Patent ductus arteriosus. Clinical relevance of prostaglandins and prostaglandin inhibitors in PDA pathophysiology and treatment.,['Hammerman C'],"['Ductus Arteriosus/anatomy & histology/drug effects/physiology', 'Ductus Arteriosus, Patent/*drug therapy/pathology/*physiopathology', 'Female', 'Humans', 'Indomethacin/administration & dosage/pharmacology/*therapeutic use', 'Infant, Newborn', '*Infant, Premature', 'Infant, Premature, Diseases/*drug therapy/*physiopathology', 'Oxygen/blood', 'Pregnancy', 'Prostaglandins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/7671547/
47,indomethacin,26409201,Novel nanostructured supramolecular hydrogels for the topical delivery of anionic drugs.,"['Limon D', 'Amirthalingam E', 'Rodrigues M', 'Halbaut L', 'Andrade B', 'Garduno-Ramirez ML', 'Amabilino DB', 'Perez-Garcia L', 'Calpena AC']","['Administration, Cutaneous', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/metabolism/pharmacology', 'Dermatitis/drug therapy', 'Drug Compounding', 'Drug Delivery Systems/adverse effects', 'Drug Liberation', 'Drug Stability', 'Humans', 'Hydrogels', 'Ibuprofen/*administration & dosage/adverse effects/metabolism/pharmacology', 'Imidazoles/adverse effects/*chemistry', 'In Vitro Techniques', 'Indomethacin/*administration & dosage/adverse effects/metabolism/pharmacology', 'Nanofibers/adverse effects/chemistry', 'Nanostructures/adverse effects/*chemistry', 'Rabbits', 'Skin Absorption', 'Skin Tests', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/26409201/
48,indomethacin,16125046,Antiprostaglandin drugs.,"['Vermillion ST', 'Robinson CJ']","['Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Female', 'Fetal Monitoring', 'Humans', 'Indomethacin/adverse effects/pharmacokinetics/*therapeutic use', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/16125046/
49,indomethacin,6391883,Indomethacin sustained-release?,['Green JA'],"['Clinical Trials as Topic', 'Delayed-Action Preparations', 'Humans', 'Indomethacin/*administration & dosage/adverse effects/blood/metabolism/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6391883/
50,indomethacin,7386499,Indomethacin-associated acute renal failure.,"['Gary NE', 'Dodelson R', 'Eisinger RP']","['Acute Kidney Injury/*chemically induced', 'Humans', 'Hypertension/chemically induced', 'Indomethacin/*adverse effects/therapeutic use', 'Kidney Glomerulus/drug effects', 'Male', 'Middle Aged', 'Proteinuria/chemically induced', 'Tendinopathy/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7386499/
51,indomethacin,24896759,Pharmacologic prophylaxis alone is not adequate to prevent post-ERCP pancreatitis.,"['Arain MA', 'Freeman ML']","['Cholangiopancreatography, Endoscopic Retrograde/*adverse effects', 'Drug Therapy, Combination', 'Humans', 'Indomethacin/administration & dosage/*therapeutic use', 'Nitrates/administration & dosage/*therapeutic use', 'Pancreatitis/drug therapy/etiology/*prevention & control', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24896759/
52,indomethacin,3963018,Flurbiprofen in the treatment of ankylosing spondylitis. A comparison with indomethacin.,"['Lomen PL', 'Turner LF', 'Lamborn KR', 'Brinn EL']","['Adolescent', 'Adult', 'Drug Evaluation', 'Female', 'Flurbiprofen/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Pain/*drug therapy', 'Propionates/*therapeutic use', 'Spondylitis, Ankylosing/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3963018/
53,indomethacin,28611459,Smart pH-sensitive nanoassemblies with cleavable PEGylation for tumor targeted drug delivery.,"['Zhao G', 'Long L', 'Zhang L', 'Peng M', 'Cui T', 'Wen X', 'Zhou X', 'Sun L', 'Che L']","['Animals', 'Antineoplastic Agents/administration & dosage/chemistry/pharmacokinetics', 'Cell Proliferation/*drug effects', 'Docetaxel/*administration & dosage/chemistry/pharmacokinetics', 'Drug Carriers/*administration & dosage/chemistry', '*Drug Delivery Systems', 'Humans', 'Hydrogen-Ion Concentration', 'Indomethacin/administration & dosage/chemistry/pharmacokinetics', 'Male', 'Nanostructures/administration & dosage/chemistry', 'Neoplasms, Experimental/*drug therapy/pathology', 'Polyethylene Glycols/*chemistry', 'Polyethyleneimine/*chemistry', 'Rats', 'Rats, Sprague-Dawley', 'Tissue Distribution', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/28611459/
54,indomethacin,1617881,Polyhydramnios: does reducing the amniotic fluid volume decrease the incidence of prematurity?,['Rodriguez MH'],"['Amniocentesis/methods/standards', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Female', 'Humans', 'Incidence', 'Indomethacin/administration & dosage/pharmacokinetics/therapeutic use', 'Obstetric Labor, Premature/epidemiology/*etiology', 'Polyhydramnios/complications/diagnostic imaging/*therapy', 'Pregnancy', 'Pregnancy Outcome', 'Ultrasonography, Prenatal']",https://pubmed.ncbi.nlm.nih.gov/1617881/
55,indomethacin,165855,Peripheral neuropathy and indomethacin.,"['Eade OE', 'Acheson ED', 'Cuthbert MF', 'Hawkes CH']","['Aged', 'Arthritis, Rheumatoid/complications/drug therapy', 'Female', 'Humans', 'Indomethacin/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Movement', 'Peripheral Nervous System Diseases/*chemically induced/complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/165855/
56,indomethacin,389838,A comparative study with indomethacin and combined indomethacin sodium-salicylate in rheumatoid arthritis.,"['Torgyan S', 'Wagner L', 'Neumann T', 'Pakuts B', 'Csanyi M']","['Adult', 'Aged', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sodium Salicylate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/389838/
57,indomethacin,29228444,Rectal indomethacin or intravenous gabexate mesylate as prophylaxis for acute pancreatitis post-endoscopic retrograde cholangiopancreatography.,"['Guglielmi V', 'Tutino M', 'Guerra V', 'Giorgio P']","['Acute Disease', 'Administration, Intravenous', 'Administration, Rectal', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/economics/*therapeutic use', 'Cholangiopancreatography, Endoscopic Retrograde/*adverse effects/economics', 'Costs and Cost Analysis', 'Female', 'Gabexate/*administration & dosage/economics/*therapeutic use', 'Humans', 'Indomethacin/*administration & dosage/economics/*therapeutic use', 'Male', 'Middle Aged', 'Pancreatitis/economics/*etiology/*prevention & control', 'Retrospective Studies', 'Serine Proteinase Inhibitors/*administration & dosage/economics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29228444/
58,indomethacin,22288307,Acute nephrotoxicity of NSAID from the foetus to the adult.,"['Musu M', 'Finco G', 'Antonucci R', 'Polati E', 'Sanna D', 'Evangelista M', 'Ribuffo D', 'Schweiger V', 'Fanos V']","['Acute Kidney Injury/*chemically induced/epidemiology/pathology', 'Adult', 'Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects/pharmacokinetics', 'Child', 'Female', 'Humans', 'Indomethacin/administration & dosage/*adverse effects/pharmacokinetics', 'Infant, Newborn', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/22288307/
59,indomethacin,356250,The long-term efficacy and tolerability of Voltaren (diclofenac sodium) and indomethacin in rheumatoid arthritis.,['Bijlsma A'],"['Adult', 'Arthritis, Rheumatoid/*drug therapy', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Diclofenac/administration & dosage/adverse effects/*therapeutic use', 'Digestive System/drug effects', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Indomethacin/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Phenylacetates/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/356250/
60,simvastatin,17044581,Statin-induced rhabdomyolysis.,"['Schreiber DH', 'Anderson TR']","['Aged', 'Cyclosporine/pharmacology', 'Cytochrome P-450 Enzyme System/drug effects', 'Drug Interactions', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology', 'Immunosuppressive Agents/pharmacology', 'Male', 'Rhabdomyolysis/*chemically induced/diagnosis/therapy', 'Simvastatin/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17044581/
61,simvastatin,12860216,"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).","['Jones PH', 'Davidson MH', 'Stein EA', 'Bays HE', 'McKenney JM', 'Miller E', 'Cain VA', 'Blasetto JW']","['Adult', 'Aged', 'Aged, 80 and over', 'Atorvastatin', 'Cholesterol, LDL/blood/*drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Fluorobenzenes/*administration & dosage/adverse effects/*therapeutic use', 'Heptanoic Acids/*administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/*therapeutic use', 'Hypercholesterolemia/blood/*drug therapy', 'Male', 'Middle Aged', 'Pravastatin/*administration & dosage/adverse effects/*therapeutic use', '*Pyrimidines', 'Pyrroles/*administration & dosage/adverse effects/*therapeutic use', 'Rosuvastatin Calcium', 'Simvastatin/*administration & dosage/adverse effects/*therapeutic use', '*Sulfonamides', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12860216/
62,simvastatin,34627266,Simvastatin induced ferroptosis for triple-negative breast cancer therapy.,"['Yao X', 'Xie R', 'Cao Y', 'Tang J', 'Men Y', 'Peng H', 'Yang W']","['Animals', 'Cell Line, Tumor', 'Delayed-Action Preparations', 'Drug Carriers/chemistry/pharmacokinetics', 'Female', 'Ferroptosis/*drug effects', 'Humans', 'MCF-7 Cells', 'Magnetite Nanoparticles/chemistry', 'Mice, Nude', 'Signal Transduction/drug effects', '*Simvastatin/chemistry/pharmacokinetics/pharmacology', 'Triple Negative Breast Neoplasms/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/34627266/
63,simvastatin,11401190,Simvastatin-associated memory loss.,"['Orsi A', 'Sherman O', 'Woldeselassie Z']","['Anticholesteremic Agents/*adverse effects', 'Humans', 'Hypercholesterolemia/*drug therapy', 'Male', 'Memory Disorders/*chemically induced', 'Middle Aged', 'Pravastatin/pharmacology/therapeutic use', 'Recovery of Function/drug effects', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11401190/
64,simvastatin,21171671,Niacin extended release (ER)/simvastatin (Simcor(R)): a guide to its use in lipid regulation.,['Lyseng-Williamson KA'],"['Clinical Trials as Topic', 'Delayed-Action Preparations/adverse effects/*therapeutic use', 'Drug Combinations', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Lipids/blood', 'Niacin/administration & dosage/adverse effects/*therapeutic use', 'Simvastatin/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21171671/
65,simvastatin,21736529,Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.,"['Filippatos TD', 'Elisaf MS']","['Adult', 'Cardiovascular Diseases/epidemiology', 'Diabetes Complications/blood/drug therapy/metabolism', 'Drug Combinations', 'Drug Monitoring', 'Dyslipidemias/blood/*drug therapy/metabolism', 'Fenofibrate/*administration & dosage/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Hypertriglyceridemia/blood/drug therapy/metabolism', 'Hypolipidemic Agents/*administration & dosage/adverse effects/therapeutic use', 'Lipoproteins/blood', 'Risk Factors', 'Simvastatin/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21736529/
66,simvastatin,11575710,Ezetimibe (Schering-Plough).,['Meng CQ'],"['Animals', 'Anticholesteremic Agents/administration & dosage/*pharmacology/therapeutic use', 'Arteriosclerosis/drug therapy', 'Azetidines/administration & dosage/chemistry/*pharmacology/therapeutic use', 'Bile/metabolism', 'Cholesterol/metabolism', 'Cholesterol, LDL/biosynthesis', 'Clinical Trials, Phase II as Topic', 'Down-Regulation', 'Drug Combinations', 'Drug Evaluation, Preclinical', 'Drug Therapy, Combination', '*Drugs, Investigational', 'Ezetimibe', 'Forecasting', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypercholesterolemia/drug therapy', 'Intestinal Absorption/drug effects', 'Intestinal Mucosa/metabolism', 'Intestines/drug effects', 'Molecular Structure', 'Simvastatin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11575710/
67,simvastatin,25387217,"Clinical pharmacology of albiglutide, a GLP-1 receptor agonist.","['Young MA', 'Wald JA', 'Matthews JE', 'Scott R', 'Hodge RJ', 'Zhi H', 'Reinhardt RR']","['Absorption, Physiological', 'Blood Glucose/drug effects', 'Drug Interactions', 'Drug Therapy, Combination', 'Glucagon-Like Peptide 1/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Glucagon-Like Peptide-1 Receptor', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Incretins/administration & dosage/pharmacokinetics/*pharmacology', 'Kidney/drug effects', 'Liver/drug effects', 'Receptors, Glucagon/*agonists', 'Simvastatin/therapeutic use', 'Warfarin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25387217/
68,simvastatin,32754265,Calcium Supplement by Tetracycline guided amorphous Calcium Carbonate potentiates Osteoblast promotion for Synergetic Osteoporosis Therapy.,"['Wang J', 'Tao S', 'Jin X', 'Song Y', 'Zhou W', 'Lou H', 'Zhao R', 'Wang C', 'Hu F', 'Yuan H']","['Animals', 'Calcium Carbonate/*administration & dosage/chemistry/pharmacology', 'Cell Differentiation', 'Cell Line', 'Disease Models, Animal', 'Drug Delivery Systems', 'Drug Synergism', 'Female', 'Humans', 'Mice', 'Osteoblasts/*cytology/drug effects/metabolism', 'Osteoporosis/*drug therapy/metabolism', 'Rats', 'Simvastatin/*administration & dosage/chemistry/pharmacology', 'Tetracycline/*administration & dosage/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32754265/
69,simvastatin,16918265,Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction.,"['Robinson JG', 'Davidson MH']","['Anticholesteremic Agents/administration & dosage/*therapeutic use', 'Atorvastatin', 'Azetidines/administration & dosage/metabolism/pharmacology/*therapeutic use', 'C-Reactive Protein/analysis/drug effects', 'Cardiovascular Diseases/blood/prevention & control', 'Drug Therapy, Combination', 'Ezetimibe', 'Heptanoic Acids/administration & dosage/pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*therapeutic use', 'Hypercholesterolemia/blood/drug therapy', 'Intestinal Absorption/drug effects/physiology', 'Lipoproteins, LDL/blood/*drug effects', 'Phytosterols/blood', 'Pravastatin/administration & dosage/pharmacology/therapeutic use', 'Pyrroles/administration & dosage/pharmacology/therapeutic use', 'Simvastatin/administration & dosage/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16918265/
70,simvastatin,18973399,Niacin extended-release/simvastatin.,"['Sanford M', 'Curran MP']","['Animals', 'Clinical Trials as Topic', 'Drug Combinations', 'Flushing', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Hypercholesterolemia/*drug therapy', 'Niacin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Simvastatin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Vitamins/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18973399/
71,simvastatin,32819403,Simvastatin induces adverse effects on proliferation and mineralization of human primary osteoblasts.,"['Sabandal MMI', 'Schafer E', 'Aed J', 'Jung S', 'Kleinheinz J', 'Sielker S']","['Adult', '*Anticholesteremic Agents/adverse effects', 'Cell Differentiation', 'Cell Proliferation', 'Female', 'Humans', 'Male', '*Osteoblasts/drug effects', '*Osteogenesis/drug effects', '*Simvastatin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32819403/
72,simvastatin,15592632,Simvastatin improved arterial compliance in high-risk patients.,"['Saliashvili G', 'Davis WW', 'Harris MT', 'Le NA', 'Brown WV']","['Adult', 'Arteries/*physiopathology', 'Compliance/drug effects', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Plethysmography', 'Simvastatin/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15592632/
73,simvastatin,28972463,Inhaled simvastatin nanoparticles for inflammatory lung disease.,"['Tulbah AS', 'Pisano E', 'Scalia S', 'Young PM', 'Traini D', 'Ong HX']","['Administration, Inhalation', 'Anti-Inflammatory Agents/administration & dosage/chemistry/*pharmacology', 'Biological Transport', 'Chemistry, Pharmaceutical/methods', 'Chronic Disease', 'Drug Carriers/chemistry', 'Drug Liberation', 'Epithelial Cells', 'Humans', 'Inflammation/drug therapy', 'Lactic Acid/*chemistry', 'Lung Diseases/*drug therapy', 'Mucus/drug effects/metabolism', 'Nanoparticles/*chemistry', 'Particle Size', 'Polyglycolic Acid/*chemistry', 'Polylactic Acid-Polyglycolic Acid Copolymer', 'Simvastatin/administration & dosage/chemistry/*pharmacology', 'Surface Properties']",https://pubmed.ncbi.nlm.nih.gov/28972463/
74,simvastatin,18481486,Rhabdomyolysis induced by simvastatin-fluconazole combination.,"['Hazin R', 'Abuzetun JY', 'Suker M', 'Porter J']","['Acute Kidney Injury', 'Aged', 'Antifungal Agents/administration & dosage/*adverse effects', 'Biomarkers', 'Creatine Kinase/blood', 'Drug Interactions', 'Drug Therapy, Combination', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Hypolipidemic Agents/administration & dosage/*adverse effects', 'Male', 'Myoglobinuria', 'Rhabdomyolysis/*chemically induced/diagnosis/therapy', 'Simvastatin/administration & dosage/*adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18481486/
75,simvastatin,25466697,Myopathy during treatment with the antianginal drug ranolazine.,"['Kassardjian CD', 'Tian X', 'Vladutiu G', 'Wong LJ', 'Milone M']","['Acetanilides/administration & dosage/*adverse effects', 'Angina Pectoris/*drug therapy', 'Anticholesteremic Agents/administration & dosage/*adverse effects', 'Biopsy', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/administration & dosage/*adverse effects', 'Female', 'Humans', 'Middle Aged', 'Muscular Diseases/blood/*chemically induced/pathology', 'Piperazines/administration & dosage/*adverse effects', 'Ranolazine', 'Simvastatin/administration & dosage/*adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25466697/
76,simvastatin,19968571,Ezetimibe/simvastatin.,"['Montecucco F', 'Quercioli A', 'Mach F']","['Animals', 'Anticholesteremic Agents/*adverse effects/therapeutic use', 'Azetidines/*adverse effects/therapeutic use', 'Drug Combinations', 'Ezetimibe', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Hypercholesterolemia/blood/drug therapy', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19968571/
77,simvastatin,15571475,Simvastatin: a review.,"['Pedersen TR', 'Tobert JA']","['Clinical Trials as Topic', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Hypercholesterolemia/*drug therapy/metabolism', 'Simvastatin/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15571475/
78,simvastatin,25804051,[Hypolipidemic and pleiotropic effects of a combination of simvastatin and ezetimibe in patients with different types of hyperlipidemia].,"['Sumarokov AB', 'Kukharchuk VV']","['Anticholesteremic Agents/administration & dosage/adverse effects/*pharmacology', 'Azetidines/administration & dosage/adverse effects/*pharmacology', '*Drug Synergism', 'Ezetimibe', 'Humans', 'Hyperlipidemias/*drug therapy', '*Randomized Controlled Trials as Topic', 'Simvastatin/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25804051/
79,simvastatin,25041770,Rhabdomyolysis in association with simvastatin and dosage increment in clarithromycin.,"['Page SR', 'Yee KC']","['Aged, 80 and over', 'Clarithromycin/administration & dosage/*adverse effects', 'Cytochrome P-450 CYP3A Inhibitors/administration & dosage/adverse effects', 'Drug Interactions/physiology', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects', 'Rhabdomyolysis/*chemically induced/*diagnosis', 'Simvastatin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25041770/
80,acetaminophen,24779190,"Paracetamol: mechanism of action, applications and safety concern.","['Jozwiak-Bebenista M', 'Nowak JZ']","['Acetaminophen/adverse effects/pharmacology/*therapeutic use', 'Analgesics, Non-Narcotic/*therapeutic use', 'Animals', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/24779190/
81,acetaminophen,12749738,Tramadol/paracetamol.,"['McClellan K', 'Scott LJ']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Acute Disease', 'Administration, Oral', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Biological Availability', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Combinations', 'Humans', 'Pain/*drug therapy', 'Tramadol/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12749738/
82,acetaminophen,25732401,"Acetaminophen: old drug, new issues.","['Aminoshariae A', 'Khan A']","['Acetaminophen/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Drug Labeling', 'Female', 'Humans', 'Pregnancy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/25732401/
83,acetaminophen,29473717,Interventions for paracetamol (acetaminophen) overdose.,"['Chiew AL', 'Gluud C', 'Brok J', 'Buckley NA']","['Acetaminophen/pharmacokinetics/*poisoning', 'Acetylcysteine/therapeutic use', 'Analgesics, Non-Narcotic/pharmacokinetics/*poisoning', 'Antidotes/therapeutic use', 'Charcoal/therapeutic use', 'Cysteamine/therapeutic use', 'Dimercaprol/therapeutic use', 'Drug Overdose/mortality/therapy', 'Gastric Lavage', 'Humans', 'Intestinal Absorption', 'Liver Failure, Acute/chemically induced/epidemiology/surgery', 'Liver Transplantation', 'Methionine/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29473717/
84,acetaminophen,34655316,"Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study.","['Lyngstad G', 'Skjelbred P', 'Swanson DM', 'Skoglund LA']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Codeine/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34655316/
85,acetaminophen,7002186,Kinetics and metabolism of paracetamol and phenacetin.,['Prescott LF'],"['Acetaminophen/administration & dosage/*metabolism', 'Administration, Oral', 'Adult', 'Animals', 'Biotransformation', 'Humans', 'Intestinal Absorption', 'Kinetics', 'Metabolic Clearance Rate', 'Phenacetin/adverse effects/*metabolism', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/7002186/
86,acetaminophen,26013309,Acetaminophen (paracetamol) oral absorption and clinical influences.,"['Raffa RB', 'Pergolizzi JV Jr', 'Taylor R Jr', 'Decker JF', 'Patrick JT']","['Acetaminophen/*administration & dosage/metabolism', 'Administration, Oral', 'Analgesics/administration & dosage/metabolism', 'Analgesics, Non-Narcotic/*administration & dosage/metabolism', 'Analgesics, Opioid/administration & dosage/metabolism', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/metabolism', 'Drug Overdose', 'Gastrointestinal Absorption/*drug effects/physiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/26013309/
87,acetaminophen,24128822,Acetaminophen (paracetamol).,"['Twycross R', 'Pace V', 'Mihalyo M', 'Wilcock A']","['Acetaminophen/*administration & dosage/*adverse effects', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology/*prevention & control', 'Dose-Response Relationship, Drug', 'Humans', 'Pain/*complications/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24128822/
88,acetaminophen,31638270,Acetaminophen-Induced Liver Damage in Hepatic Steatosis.,"['Garcia-Roman R', 'Frances R']","['Acetaminophen/administration & dosage/*adverse effects/pharmacokinetics', 'Animals', 'Chemical and Drug Induced Liver Injury/*etiology/physiopathology', 'Glutathione/metabolism', 'Hepatocytes/pathology', 'Humans', 'Non-alcoholic Fatty Liver Disease/*complications', 'Obesity/complications', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/31638270/
89,acetaminophen,15733027,Tolerability of paracetamol.,"['Graham GG', 'Scott KF', 'Day RO']","['Acetaminophen/*adverse effects/*metabolism/therapeutic use', 'Chemical and Drug Induced Liver Injury/etiology', 'Humans', 'Molecular Structure', '*Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15733027/
90,acetaminophen,31256492,Paracetamol allergy in clinical practice.,"['Thompson G', 'Bundell C', 'Lucas M']","['Acetaminophen/*adverse effects/therapeutic use', 'Allergy and Immunology', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Drug Hypersensitivity/*diagnosis/physiopathology', 'Humans', 'Referral and Consultation']",https://pubmed.ncbi.nlm.nih.gov/31256492/
91,acetaminophen,25429980,"Acetaminophen/paracetamol: A history of errors, failures and false decisions.","['Brune K', 'Renner B', 'Tiegs G']","['Acetaminophen/*adverse effects/history/pharmacology/*therapeutic use', 'Adult', 'Analgesics, Non-Narcotic/*adverse effects/history/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Child', 'History, 19th Century', 'History, 20th Century', 'History, 21st Century', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25429980/
92,acetaminophen,22039164,Paracetamol and cyclooxygenase inhibition: is there a cause for concern?,"['Hinz B', 'Brune K']","['Acetaminophen/adverse effects/*pharmacology', 'Analgesics, Non-Narcotic/adverse effects/*pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology', 'Asthma/chemically induced', 'Blood Platelet Disorders/chemically induced', 'Cardiovascular Diseases/chemically induced', 'Cyclooxygenase 2 Inhibitors/adverse effects/*pharmacology', 'Gastrointestinal Diseases/chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/22039164/
93,acetaminophen,38597946,[Pharmacological pain management in cancer patients].,"['Mutherig A', 'Scheffler G', 'Schuler US']","['Humans', '*Cancer Pain/drug therapy', '*Pain Management/methods', 'Neoplasms/complications/drug therapy', 'Analgesics/therapeutic use/administration & dosage/adverse effects', 'Analgesics, Opioid/therapeutic use/adverse effects/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use/administration & dosage', 'Practice Guidelines as Topic', 'Acetaminophen/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38597946/
94,acetaminophen,33224416,Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety.,"['Alaje EO', 'Udoh EE', 'Akande PA', 'Odey FA', 'Meremikwu MM']","['Acetaminophen/*administration & dosage/adverse effects', 'Antipyretics/*administration & dosage/adverse effects', 'Body Temperature/drug effects', 'Child, Preschool', 'Female', 'Fever/*drug therapy', 'Hospitals, Teaching', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects', 'Infant', 'Male', 'Nigeria', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/33224416/
95,acetaminophen,24762895,"Ibuprofen and/or paracetamol (acetaminophen) for pain relief after surgical removal of lower wisdom teeth, a Cochrane systematic review.","['Bailey E', 'Worthington H', 'Coulthard P']","['Acetaminophen/administration & dosage/*therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Ibuprofen/administration & dosage/*therapeutic use', 'Molar, Third/*surgery', 'Pain Management/*methods', 'Tooth Extraction/*methods']",https://pubmed.ncbi.nlm.nih.gov/24762895/
96,acetaminophen,15662293,Drug interactions with paracetamol.,"['Toes MJ', 'Jones AL', 'Prescott L']","['*Acetaminophen/adverse effects/pharmacokinetics/pharmacology', '*Analgesics, Non-Narcotic/adverse effects/pharmacokinetics/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Area Under Curve', 'Chemical and Drug Induced Liver Injury/etiology', '*Drug Interactions', 'Gastric Emptying/drug effects', 'Half-Life', 'Humans', 'International Normalized Ratio', 'Intestinal Absorption']",https://pubmed.ncbi.nlm.nih.gov/15662293/
97,acetaminophen,33516238,"Bioavailable turmeric extract for knee osteoarthritis: a randomized, non-inferiority trial versus paracetamol.","['Singhal S', 'Hasan N', 'Nirmal K', 'Chawla R', 'Chawla S', 'Kalra BS', 'Dhal A']","['Acetaminophen/adverse effects/*therapeutic use', 'Adult', 'Curcuma/adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'India', 'Male', 'Middle Aged', 'Osteoarthritis, Knee/*drug therapy', 'Pain Measurement', 'Plant Extracts/adverse effects/*therapeutic use', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33516238/
98,acetaminophen,19087009,Peri-operative use of paracetamol.,"['Oscier CD', 'Milner QJ']","['Acetaminophen/adverse effects/pharmacology/*therapeutic use', 'Analgesics, Non-Narcotic/adverse effects/pharmacology/*therapeutic use', 'Drug Administration Routes', 'Drug Administration Schedule', 'Humans', 'Pain, Postoperative/*prevention & control', 'Postoperative Care/methods']",https://pubmed.ncbi.nlm.nih.gov/19087009/
99,acetaminophen,33786837,The efficacy and safety of paracetamol for pain relief: an overview of systematic reviews.,"['Abdel Shaheed C', 'Ferreira GE', 'Dmitritchenko A', 'McLachlan AJ', 'Day RO', 'Saragiotto B', 'Lin C', 'Langendyk V', 'Stanaway F', 'Latimer J', 'Kamper S', 'McLachlan H', 'Ahedi H', 'Maher CG']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects/therapeutic use', 'Case-Control Studies', 'Craniotomy', 'Data Management', 'Humans', 'Low Back Pain/drug therapy', 'Osteoarthritis/drug therapy', 'Pain/*drug therapy', 'Pain Management/*methods', 'Placebos/administration & dosage', 'Prospective Studies', 'Randomized Controlled Trials as Topic', 'Safety', 'Tension-Type Headache/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33786837/
100,Lincomycine,7791427,Clindamycin and metronidazole.,"['Falagas ME', 'Gorbach SL']","['Animals', 'Bacterial Infections/*drug therapy', 'Clindamycin/adverse effects/chemistry/*therapeutic use', 'Drug Resistance, Microbial', 'Humans', 'Metronidazole/adverse effects/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7791427/
101,Lincomycine,9508961,Clindamycin in dentistry.,['van der Bijl P'],"['Anti-Bacterial Agents/adverse effects/chemistry/*therapeutic use', 'Bacterial Infections/drug therapy', 'Clindamycin/adverse effects/chemistry/*therapeutic use', '*Dental Care', 'Drug Resistance, Microbial', 'Humans', 'Mouth Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9508961/
102,Lincomycine,3320618,Clindamycin.,['Klainer AS'],"['Bacterial Infections/*drug therapy', 'Clindamycin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/3320618/
103,Lincomycine,1436926,Clindamycin.,['Soper DE'],"['Bacterial Infections/*drug therapy', '*Clindamycin/adverse effects/chemistry/therapeutic use', 'Costs and Cost Analysis', 'Female', 'Genital Diseases, Female/*drug therapy/microbiology', 'Humans', 'Pregnancy', 'Surgical Wound Infection/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1436926/
104,Lincomycine,1167742,Lincomycin-curare interaction.,"['Samuelson RJ', 'Giesecke AT Jr', 'Kallus FT', 'Stanley VF']","['Anesthesia, Inhalation', 'Animals', 'Cats', 'Curare/adverse effects/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Electric Stimulation', 'Halothane', 'Humans', 'Lincomycin/adverse effects/*pharmacology', 'Nitrous Oxide', 'Oxygen', 'Respiratory Paralysis/chemically induced', 'Sciatic Nerve/*drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1167742/
105,Lincomycine,26216470,Clindamycin-induced hypersensitivity reaction.,"['Bulloch MN', 'Baccas JT', 'Arnold S']","['Administration, Intravenous', '*Anaphylaxis/chemically induced/physiopathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects/therapeutic use', 'Clindamycin/administration & dosage/*adverse effects/therapeutic use', '*Drug Hypersensitivity/diagnosis/physiopathology', 'Female', 'Humans', 'Middle Aged', 'Periodontal Abscess/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26216470/
106,Lincomycine,20700874,[Persistent neutropenia].,"['Burki S', 'Oestmann A', 'Vogel D', 'Oertle S']","['Adrenal Cortex Hormones/administration & dosage/therapeutic use', 'Aged', 'Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/therapeutic use', 'Clindamycin/administration & dosage/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Diclofenac/administration & dosage/adverse effects/therapeutic use', 'Female', 'Histones/immunology', 'Humans', '*Lupus Erythematosus, Systemic/chemically induced/drug therapy', '*Neutropenia/diagnosis/drug therapy/etiology', 'Sialadenitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20700874/
107,Lincomycine,17723089,Clindamycin-induced Sweet's syndrome.,"['Clark BM', 'Homeyer DC', 'Glass KR', ""D'Avignon LC""]","['Administration, Oral', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Clindamycin/administration & dosage/*adverse effects', 'Diabetes Mellitus, Type 2/complications', 'Female', 'Humans', 'Injections, Intravenous', 'Kidney Failure, Chronic/complications', 'Middle Aged', 'Periapical Abscess/drug therapy', 'Renal Dialysis', 'Sweet Syndrome/*chemically induced', 'Tooth Extraction']",https://pubmed.ncbi.nlm.nih.gov/17723089/
108,Lincomycine,14762701,"Lincomycin, clindamycin and their applications.","['Spizek J', 'Rezanka T']","['Animals', 'Anti-Bacterial Agents/biosynthesis/chemistry/pharmacology/therapeutic use', 'Antiprotozoal Agents/pharmacology/therapeutic use', 'Bacterial Infections/drug therapy/microbiology', 'Clindamycin/chemistry/metabolism/*pharmacology/therapeutic use', 'Drug Resistance, Bacterial', 'Eukaryota/*drug effects', 'Gram-Negative Bacteria/*drug effects', 'Gram-Positive Bacteria/*drug effects', 'Humans', 'Lincomycin/biosynthesis/chemistry/*pharmacology/therapeutic use', 'Protein Biosynthesis/drug effects', 'Protein Synthesis Inhibitors/chemistry/metabolism/pharmacology/therapeutic use', 'Protozoan Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/14762701/
109,Lincomycine,29141062,Management of Severe Acne Vulgaris With Topical Therapy.,"['Stein Gold L', 'Baldwin HE', 'Lin T']","['Acne Vulgaris/*drug therapy/pathology', 'Administration, Cutaneous', 'Benzoyl Peroxide/administration & dosage/therapeutic use', 'Clindamycin/administration & dosage/analogs & derivatives/therapeutic use', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Humans', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/29141062/
110,Lincomycine,2971690,Use of oral and topical agents for acne in pregnancy.,"['Rothman KF', 'Pochi PE']","['Abnormalities, Drug-Induced', 'Acne Vulgaris/*drug therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Benzoyl Peroxide/administration & dosage', 'Clindamycin/administration & dosage', 'Erythromycin/therapeutic use', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Salicylates/therapeutic use', 'Tetracyclines/adverse effects/therapeutic use', 'Tretinoin/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2971690/
111,Lincomycine,6386254,Other antibiotics.,['Hayashi K'],"['Anti-Bacterial Agents/adverse effects/metabolism/*therapeutic use', 'Chloramphenicol/therapeutic use', 'Clindamycin/therapeutic use', 'Colistin/therapeutic use', 'Erythromycin/therapeutic use', 'Fosfomycin/therapeutic use', 'Humans', 'Lincomycin/therapeutic use', '*Orthopedics', 'Polymyxin B/therapeutic use', 'Tetracyclines/therapeutic use', 'Vancomycin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6386254/
112,Lincomycine,1124747,Clindamycin-associated colitis.,"['Unger JL', 'Penka WE', 'Lyford C']","['Adenocarcinoma/surgery', 'Administration, Oral', 'Adult', 'Aged', 'Cephalothin/therapeutic use', 'Clindamycin/administration & dosage/*adverse effects/therapeutic use', 'Colitis/*chemically induced/drug therapy/pathology', 'Colon/pathology', 'Diarrhea/chemically induced', 'Female', 'Finger Injuries/surgery', 'Humans', 'Lung Neoplasms/surgery', 'Male', 'Middle Aged', 'Pneumonia/drug therapy', 'Postoperative Complications/drug therapy', 'Prednisone/therapeutic use', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1124747/
113,Lincomycine,30645928,A case of Clindamycin-induced aphagia.,"['Callens R', 'Van Eygen S', ""D'Heygere F""]","['Aged, 80 and over', 'Clindamycin/administration & dosage/*adverse effects', 'Deglutition Disorders/*chemically induced', 'Feeding Behavior', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/30645928/
114,Lincomycine,5828940,Lincomycin in hospital practice.,"['Duncan IB', 'Jeans B']","['Bronchitis/*drug therapy', 'Diarrhea/etiology', 'Drug Resistance, Microbial', 'Humans', 'In Vitro Techniques', 'Lincomycin/adverse effects/*pharmacology/*therapeutic use', 'Pneumonia/*drug therapy', 'Staphylococcal Infections/*drug therapy', 'Staphylococcus/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/5828940/
115,Lincomycine,130836,Potential hazards of clindamycin in acne therapy.,['Basler RS'],"['Acne Vulgaris/*drug therapy', 'Administration, Oral', 'Adult', 'Clindamycin/administration & dosage/*adverse effects', 'Colitis/*chemically induced', 'Enterocolitis, Pseudomembranous/chemically induced', 'Female', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/130836/
116,Lincomycine,563932,Clindamycin in infective endocarditis.,"['Cherubin CE', 'Nair SR']","['Clindamycin/administration & dosage/pharmacology/*therapeutic use', 'Endocarditis, Bacterial/complications/*drug therapy', 'Humans', 'Injections, Intramuscular', 'Staphylococcal Infections/drug therapy', 'Staphylococcus aureus/drug effects', 'Streptococcal Infections/drug therapy', 'Substance-Related Disorders/complications']",https://pubmed.ncbi.nlm.nih.gov/563932/
117,Lincomycine,321712,Clindamycin and colitis: a review.,['Tedesco FJ'],"['Adolescent', 'Adult', 'Aged', 'Cholestyramine Resin/therapeutic use', 'Clindamycin/administration & dosage/*adverse effects', 'Colon/pathology', 'Diarrhea/chemically induced', 'Diphenoxylate/therapeutic use', 'Enterocolitis, Pseudomembranous/*chemically induced/drug therapy/pathology', 'Female', 'Humans', 'Intestinal Mucosa/pathology', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/321712/
118,Lincomycine,7470716,Antibiotics for gram-positive organisms.,['Pagan FS'],"['Anti-Bacterial Agents/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Clindamycin/therapeutic use', 'Cloxacillin/therapeutic use', 'Erythromycin/therapeutic use', 'Fusidic Acid/therapeutic use', 'Humans', 'Lincomycin/therapeutic use', 'Penicillins/therapeutic use', 'Vancomycin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7470716/
119,Lincomycine,28417476,Clindamycin-associated acute generalized exanthematous pustulosis.,"['Croy C', 'Buehrle K', 'Austin Szwak J']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Clindamycin/administration & dosage/*adverse effects', 'Humans', 'Male', 'Vancomycin/administration & dosage', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28417476/
120,CAPECITABINE,29152729,Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update.,"['Amstutz U', 'Henricks LM', 'Offer SM', 'Barbarino J', 'Schellens JHM', 'Swen JJ', 'Klein TE', 'McLeod HL', 'Caudle KE', 'Diasio RB', 'Schwab M']","['Antimetabolites, Antineoplastic/*administration & dosage/adverse effects/pharmacokinetics', 'Capecitabine/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Decision-Making', 'Dihydrouracil Dehydrogenase (NADP)/*genetics/metabolism', 'Drug Dosage Calculations', 'Fluorouracil/*administration & dosage/adverse effects/pharmacokinetics', 'Genotype', 'Humans', 'Patient Selection', 'Pharmacogenetics/*standards', 'Pharmacogenomic Testing/*standards', '*Pharmacogenomic Variants', 'Phenotype', 'Precision Medicine/*standards', 'Predictive Value of Tests']",https://pubmed.ncbi.nlm.nih.gov/29152729/
121,CAPECITABINE,37594133,5Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review).,"['Alzahrani SM', 'Al Doghaither HA', 'Al-Ghafari AB', 'Pushparaj PN']","['Humans', 'Capecitabine/adverse effects', '*Fluorouracil/therapeutic use', 'Cell Division', 'Cell Membrane', '*Colorectal Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37594133/
122,CAPECITABINE,38412399,Topical Diclofenac for Prevention of Capecitabine-Associated Hand-Foot Syndrome: A Double-Blind Randomized Controlled Trial.,"['Santhosh A', 'Sharma A', 'Bakhshi S', 'Kumar A', 'Sharma V', 'Malik PS', 'Pramanik R', 'Gogia A', 'Prasad CP', 'Sehgal T', 'Gund S', 'Dev A', 'Cheung WY', 'Pandey RM', 'Kumar S', 'Gupta I', 'Batra A']","['Humans', '*Capecitabine/adverse effects/administration & dosage/therapeutic use', 'Double-Blind Method', '*Hand-Foot Syndrome/prevention & control/etiology', '*Diclofenac/adverse effects/administration & dosage/analogs & derivatives', 'Female', 'Male', 'Middle Aged', 'Aged', '*Antimetabolites, Antineoplastic/adverse effects/administration & dosage', 'Breast Neoplasms/drug therapy', 'Administration, Topical', 'Adult', 'Gastrointestinal Neoplasms/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38412399/
123,CAPECITABINE,30341682,Pyrotinib: First Global Approval.,['Blair HA'],"['*Acrylamides/administration & dosage/adverse effects/therapeutic use', '*Aminoquinolines/administration & dosage/adverse effects/therapeutic use', 'Anthracyclines/pharmacology', '*Antineoplastic Agents/administration & dosage/therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Bridged-Ring Compounds/pharmacology', 'Capecitabine/pharmacology/therapeutic use', 'Humans', '*Protein Kinase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Receptor, ErbB-2/*antagonists & inhibitors', 'Taxoids/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30341682/
124,CAPECITABINE,33300950,Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment: The SYSUCC-001 Randomized Clinical Trial.,"['Wang X', 'Wang SS', 'Huang H', 'Cai L', 'Zhao L', 'Peng RJ', 'Lin Y', 'Tang J', 'Zeng J', 'Zhang LH', 'Ke YL', 'Wang XM', 'Liu XM', 'Chen QJ', 'Zhang AQ', 'Xu F', 'Bi XW', 'Huang JJ', 'Li JB', 'Pang DM', 'Xue C', 'Shi YX', 'He ZY', 'Lin HX', 'An X', 'Xia W', 'Cao Y', 'Guo Y', 'Su YH', 'Hua X', 'Wang XY', 'Hong RX', 'Jiang KK', 'Song CG', 'Huang ZZ', 'Shi W', 'Zhong YY', 'Yuan ZY']","['Adult', 'Capecitabine/*administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Disease-Free Survival', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Hand-Foot Syndrome/etiology', 'Humans', 'Maintenance Chemotherapy', 'Mastectomy', 'Middle Aged', 'Neoplasm Grading', 'Neoplasm Staging', 'Neoplasm, Residual', 'Observation', 'Triple Negative Breast Neoplasms/*drug therapy/mortality/pathology/surgery']",https://pubmed.ncbi.nlm.nih.gov/33300950/
125,CAPECITABINE,38381429,Total Neoadjuvant Therapy With PD-1 Blockade for High-Risk Proficient Mismatch Repair Rectal Cancer.,"['Li Y', 'Pan C', 'Gao Y', 'Zhang L', 'Ji D', 'Cui X', 'Zhang X', 'Cai Y', 'Zhang Y', 'Yao Y', 'Wang L', 'Leng J', 'Zhan T', 'Wu D', 'Gao Z', 'Sun YS', 'Li Z', 'Luo H', 'Wu A']","['Humans', '*Rectal Neoplasms/therapy/genetics/pathology', 'Female', 'Male', 'Middle Aged', '*Neoadjuvant Therapy', '*DNA Mismatch Repair', '*Capecitabine/therapeutic use/administration & dosage', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Immune Checkpoint Inhibitors/therapeutic use', 'Oxaliplatin/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Adult', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38381429/
126,CAPECITABINE,35200546,Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.,"['Al-Toubah T', 'Morse B', 'Strosberg J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Capecitabine/therapeutic use', 'Humans', '*Neuroendocrine Tumors/drug therapy/pathology', 'Retrospective Studies', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35200546/
127,CAPECITABINE,39550662,[Not Available].,"['Fiordelisi M', 'Masucci S', 'Bianco A', 'Bellero M', 'Toma D', 'Campo N', 'Zichi C', 'Marino D', 'Sperti E', 'Valabrega G', 'Cena C', 'Fazzina G', 'Gasco A']","['Humans', 'Adenocarcinoma/drug therapy', '*Capecitabine/adverse effects/administration & dosage', 'Clinical Decision-Making', 'Dietary Supplements', '*Herb-Drug Interactions', '*Pharmacists', 'Plant Preparations/adverse effects/administration & dosage', 'Professional Role', 'Rectal Neoplasms/drug therapy', '*Artificial Intelligence']",https://pubmed.ncbi.nlm.nih.gov/39550662/
128,CAPECITABINE,38710003,"Capecitabine or Capecitabine Plus Oxaliplatin Versus Fluorouracil Plus Cisplatin in Definitive Concurrent Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma (CRTCOESC): A Multicenter, Randomized, Open-Label, Phase 3 Trial.","['Jia R', 'Shan T', 'Zheng A', 'Zhang Y', 'Lu P', 'Zhang G', 'Wang F', 'Xu Z', 'Zheng G', 'Tang D', 'Zhang W', 'Li W', 'Li R', 'Guo Y', 'Liu L', 'Luo X', 'Zheng Y', 'Chang Z', 'Wang Q', 'Wang X', 'Yuan X', 'Kong G', 'Li S', 'Yang R', 'Zhou D', 'Ren J', 'Yin W', 'Li J', 'Zhang J', 'Wang Z', 'Sheng M', 'Xu B', 'Li L', 'Liu X', 'Lu Z', 'Wan L', 'Zhou F', 'Gao S']","['Humans', '*Capecitabine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Female', '*Fluorouracil/analogs & derivatives/administration & dosage/adverse effects/therapeutic use', '*Cisplatin/administration & dosage/adverse effects/therapeutic use', '*Esophageal Neoplasms/therapy/pathology/mortality', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Aged', '*Chemoradiotherapy/adverse effects', '*Esophageal Squamous Cell Carcinoma/therapy/mortality/pathology', '*Oxaliplatin/administration & dosage/therapeutic use/adverse effects', 'Adult', 'Oxaloacetates']",https://pubmed.ncbi.nlm.nih.gov/38710003/
129,CAPECITABINE,29252007,A review of capecitabine-based adjuvant therapy for gastric cancer in the Chinese population.,"['Cheng X', 'Lu Y']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Capecitabine/adverse effects/*therapeutic use', '*Chemotherapy, Adjuvant', 'China/epidemiology', 'Combined Modality Therapy', 'Deoxycytidine/analogs & derivatives/therapeutic use', 'Disease-Free Survival', 'Fluorouracil/analogs & derivatives/therapeutic use', 'Gastrectomy', 'Humans', 'Oxaloacetates', 'Stomach Neoplasms/*drug therapy/epidemiology/pathology/*surgery']",https://pubmed.ncbi.nlm.nih.gov/29252007/
130,CAPECITABINE,30348537,DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.,"['Henricks LM', 'Lunenburg CATC', 'de Man FM', 'Meulendijks D', 'Frederix GWJ', 'Kienhuis E', 'Creemers GJ', 'Baars A', 'Dezentje VO', 'Imholz ALT', 'Jeurissen FJF', 'Portielje JEA', 'Jansen RLH', 'Hamberg P', 'Ten Tije AJ', 'Droogendijk HJ', 'Koopman M', 'Nieboer P', 'van de Poel MHW', 'Mandigers CMPW', 'Rosing H', 'Beijnen JH', 'Werkhoven EV', 'van Kuilenburg ABP', 'van Schaik RHN', 'Mathijssen RHJ', 'Swen JJ', 'Gelderblom H', 'Cats A', 'Guchelaar HJ', 'Schellens JHM']","['Aged', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Capecitabine/*administration & dosage/adverse effects', 'Case-Control Studies', 'Dihydrouracil Dehydrogenase (NADP)/*genetics', 'Female', 'Fluorouracil/*administration & dosage/adverse effects', 'Gene Frequency', 'Heterozygote', 'Homozygote', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/*drug therapy/enzymology/pathology', 'Netherlands', '*Pharmacogenomic Variants', 'Prospective Studies', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30348537/
131,CAPECITABINE,38684357,Capecitabine-induced severe adverse events-therapeutic drug monitoring and DPYD-gene analysis are recommended.,"['Perera J', 'Susstrunk J', 'Thurneysen C', 'Steinemann D']","['Humans', '*Capecitabine/adverse effects/therapeutic use', '*Drug Monitoring/methods', '*Antimetabolites, Antineoplastic/adverse effects/therapeutic use', 'Male', '*Dihydrouracil Dehydrogenase (NADP)/genetics', 'Middle Aged', 'Female', 'Aged', 'Colectomy', 'Genotype']",https://pubmed.ncbi.nlm.nih.gov/38684357/
132,CAPECITABINE,38950321,Randomized Phase II Trial of Immunotherapy-Based Total Neoadjuvant Therapy for Proficient Mismatch Repair or Microsatellite Stable Locally Advanced Rectal Cancer (TORCH).,"['Xia F', 'Wang Y', 'Wang H', 'Shen L', 'Xiang Z', 'Zhao Y', 'Zhang H', 'Wan J', 'Zhang H', 'Wang Y', 'Wu R', 'Wang J', 'Yang W', 'Zhou M', 'Zhou S', 'Chen Y', 'Zhang Z', 'Wu X', 'Xuan Y', 'Wang R', 'Sun Y', 'Tong T', 'Zhang X', 'Wang L', 'Huang D', 'Sheng W', 'Yan H', 'Yang X', 'Shen Y', 'Xu Y', 'Zhao R', 'Mo M', 'Cai G', 'Cai S', 'Xu Y', 'Zhang Z']","['Humans', '*Rectal Neoplasms/therapy/genetics/pathology', '*Neoadjuvant Therapy/adverse effects', 'Male', 'Middle Aged', 'Female', 'Aged', '*DNA Mismatch Repair', 'Prospective Studies', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Adenocarcinoma/therapy/genetics/pathology/drug therapy', 'Microsatellite Instability', 'Immunotherapy/methods', 'Capecitabine/administration & dosage/therapeutic use', 'Oxaliplatin/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38950321/
133,CAPECITABINE,38547438,Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.,"['Gallois C', 'Shi Q', 'Pederson LD', 'Andre T', 'Iveson TJ', 'Sobrero AF', 'Alberts S', 'de Gramont A', 'Meyerhardt JA', 'George T', 'Schmoll HE', 'Souglakos I', 'Harkin A', 'Labianca R', 'Sinicrope FA', 'Oki E', 'Shields AF', 'Boukovinas I', 'Kerr R', 'Lonardi S', 'Yothers G', 'Yoshino T', 'Goldberg RM', 'Taieb J', 'Papamichael D']","['Humans', '*Oxaliplatin/administration & dosage/therapeutic use/adverse effects', '*Colonic Neoplasms/drug therapy/pathology/mortality', 'Aged', 'Chemotherapy, Adjuvant', 'Female', 'Male', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Organoplatinum Compounds/administration & dosage/adverse effects/therapeutic use', '*Neoplasm Staging', 'Age Factors', '*Capecitabine/administration & dosage/adverse effects/therapeutic use', '*Leucovorin/administration & dosage/therapeutic use/adverse effects', 'Middle Aged', 'Fluorouracil/administration & dosage/adverse effects', 'Disease-Free Survival', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38547438/
134,CAPECITABINE,32541327,Adjuvant chemotherapy in colon cancer: state of the art and future perspectives.,['Iveson T'],"['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Capecitabine/administration & dosage/adverse effects', 'Chemotherapy, Adjuvant', 'Circulating Tumor DNA/genetics', 'Colonic Neoplasms/*drug therapy/genetics/pathology', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Neoplasm Staging', 'Oxaliplatin/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32541327/
135,CAPECITABINE,28978604,Oxaliplatin-induced posterior reversible encephalopathy syndrome (PRES).,"['Janjua TK', 'Hassan M', 'Afridi HK', 'Zahid NA']","['Adenocarcinoma/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Anus Neoplasms/drug therapy', 'Capecitabine/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Organoplatinum Compounds/administration & dosage/*adverse effects', 'Oxaliplatin', 'Posterior Leukoencephalopathy Syndrome/chemically induced/*diagnosis/diagnostic imaging', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28978604/
136,CAPECITABINE,38101610,Dihydroartemisinin inhibits the development of colorectal cancer by GSK-3beta/TCF7/MMP9 pathway and synergies with capecitabine.,"['Dai X', 'Chen W', 'Qiao Y', 'Chen X', 'Chen Y', 'Zhang K', 'Zhang Q', 'Duan X', 'Li X', 'Zhao J', 'Tian F', 'Liu K', 'Dong Z', 'Lu J']","['Humans', 'Capecitabine/pharmacology/therapeutic use', 'Glycogen Synthase Kinase 3 beta', '*Colorectal Neoplasms/pathology', 'Matrix Metalloproteinase 9', 'Molecular Docking Simulation', 'Cell Line, Tumor', 'Cell Proliferation', 'T Cell Transcription Factor 1', '*Artemisinins']",https://pubmed.ncbi.nlm.nih.gov/38101610/
137,CAPECITABINE,38820768,Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway.,"['Park SJ', 'Kweon S', 'Moyo MK', 'Kim HR', 'Choi JU', 'Lee NK', 'Maharjan R', 'Cho YS', 'Park JW', 'Byun Y']","['*Tumor Microenvironment/drug effects', '*Colorectal Neoplasms/drug therapy/pathology/immunology', 'Animals', '*Membrane Proteins/metabolism', '*Oxaliplatin/pharmacology/therapeutic use/administration & dosage', '*Liver Neoplasms/secondary/drug therapy/pathology/immunology', 'Administration, Oral', 'Cell Line, Tumor', '*Nucleotidyltransferases/metabolism', 'Mice', 'Mice, Inbred BALB C', 'Capecitabine/pharmacology/therapeutic use/administration & dosage', 'Humans', 'Signal Transduction/drug effects', 'Female', 'Deoxycholic Acid/chemistry/pharmacology', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/pharmacology', 'Tumor-Associated Macrophages/drug effects/immunology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38820768/
138,CAPECITABINE,29117285,Topical Timolol for Paronychia and Pseudopyogenic Granuloma in Patients Treated With Epidermal Growth Factor Receptor Inhibitors and Capecitabine.,"['Cubiro X', 'Planas-Ciudad S', 'Garcia-Muret MP', 'Puig L']","['Administration, Topical', 'Aged', 'Angiolymphoid Hyperplasia with Eosinophilia/*chemically induced/*drug therapy', 'Antimetabolites, Antineoplastic/*adverse effects/therapeutic use', 'Capecitabine/*adverse effects/therapeutic use', 'Cohort Studies', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/pathology', 'Paronychia/*chemically induced/*drug therapy', 'Prognosis', 'Retrospective Studies', 'Timolol/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29117285/
139,CAPECITABINE,34100299,Gender-dependent association of TYMS-TSER polymorphism with 5-fluorouracil or capecitabine-based chemotherapy toxicity.,"['Ioannou C', 'Ragia G', 'Balgkouranidou I', 'Xenidis N', 'Amarantidis K', 'Koukaki T', 'Biziota E', 'Kakolyris S', 'Manolopoulos VG']","['Adult', 'Aged', 'Aged, 80 and over', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage', 'Capecitabine/*administration & dosage/adverse effects', 'Female', 'Fluorouracil/*administration & dosage/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy/genetics', 'Polymorphism, Genetic/*genetics', '*Sex Characteristics', 'Thymidylate Synthase/*genetics']",https://pubmed.ncbi.nlm.nih.gov/34100299/
140,fexofenadine,38470381,Allergic Rhinitis: A Review.,"['Bernstein JA', 'Bernstein JS', 'Makol R', 'Ward S']","['Humans', 'Budesonide/administration & dosage/therapeutic use', 'Cetirizine/therapeutic use', 'Fluticasone/administration & dosage/therapeutic use', 'Histamine H1 Antagonists/administration & dosage/therapeutic use', 'Immunoglobulin E/immunology', 'Mometasone Furoate/administration & dosage/therapeutic use', 'Olopatadine Hydrochloride/administration & dosage/therapeutic use', 'Pruritus/etiology', '*Rhinitis, Allergic/complications/diagnosis/immunology/therapy', 'Rhinorrhea/etiology', 'Sneezing', 'Triamcinolone/administration & dosage/therapeutic use', '*Glucocorticoids/administration & dosage/therapeutic use', 'Rhinitis/drug therapy', '*Histamine Antagonists/administration & dosage/therapeutic use', 'Administration, Intranasal']",https://pubmed.ncbi.nlm.nih.gov/38470381/
141,fexofenadine,30626077,Antihistamines for Allergic Rhinitis Treatment from the Viewpoint of Nonsedative Properties.,"['Kawauchi H', 'Yanai K', 'Wang DY', 'Itahashi K', 'Okubo K']","['Animals', 'Brain/drug effects/pathology', 'Histamine Antagonists/chemistry/pharmacology/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/chemistry/pharmacology/*therapeutic use', 'Humans', 'Receptors, Histamine/metabolism', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30626077/
142,fexofenadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
143,fexofenadine,9951950,Second-generation antihistamines: a comparative review.,"['Slater JW', 'Zechnich AD', 'Haxby DG']","['Asthma/drug therapy', 'Dermatitis, Atopic/drug therapy', 'Drug Interactions', '*Histamine H1 Antagonists/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9951950/
144,fexofenadine,33030434,Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.,"['Iriarte Sotes P', 'Armisen M', 'Usero-Barcena T', 'Rodriguez Fernandez A', 'Otero Rivas MM', 'Gonzalez MT', 'Meijide Calderon A', 'Veleiro B']","['Administration, Oral', 'Animals', 'Anti-Allergic Agents/*therapeutic use', 'Chronic Urticaria/*drug therapy', 'Clinical Trials as Topic', 'Drug Dosage Calculations', 'Drug-Related Side Effects and Adverse Reactions', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33030434/
145,fexofenadine,9274181,Is my antihistamine safe?,['Ashworth L'],"['Adverse Drug Reaction Reporting Systems', 'Histamine Antagonists/*adverse effects', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Patient Selection', 'Terfenadine/*adverse effects/*analogs & derivatives', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/9274181/
146,fexofenadine,12371532,Urticaria to cetirizine.,"['Tella R', 'Gaig P', 'Bartra J', 'Garcia-Ortega P']","['Adult', 'Cetirizine/*adverse effects', 'Drug Hypersensitivity/etiology', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects', 'Humans', 'Urticaria/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12371532/
147,fexofenadine,17680969,Formaldehyde-induced urticarial vasculitis.,"['Pellizzari M', 'Marshman G']","['Adult', 'Drug Therapy, Combination', 'Formaldehyde/*adverse effects', 'Glucocorticoids/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Male', 'Occupational Exposure/adverse effects', 'Prednisolone/therapeutic use', 'Serum Sickness/chemically induced', 'Students, Medical', 'Terfenadine/analogs & derivatives/therapeutic use', 'Urticaria/*chemically induced/drug therapy', 'Vasculitis, Leukocytoclastic, Cutaneous/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17680969/
148,fexofenadine,21370726,Urticaria due to antihistamines.,"['Sanchez Morillas L', 'Rojas Perez-Ezquerra P', 'Reano Martos M', 'Sanz ML', 'Laguna Martinez JJ']","['Administration, Oral', 'Butyrophenones/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Drug Hypersensitivity/diagnosis/*etiology', 'Female', 'Histamine H1 Antagonists/administration & dosage/*adverse effects', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Middle Aged', 'Piperidines/administration & dosage/*adverse effects', 'Terfenadine/administration & dosage/adverse effects/*analogs & derivatives', 'Urticaria/diagnosis/*etiology']",https://pubmed.ncbi.nlm.nih.gov/21370726/
149,fexofenadine,17112309,Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs.,['Bressler R'],"['Aged', 'Beverages/*adverse effects', 'Citrus paradisi/*adverse effects/metabolism', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/drug effects/metabolism', 'Drug-Related Side Effects and Adverse Reactions/etiology', '*Food-Drug Interactions', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/17112309/
150,fexofenadine,28066101,"Comparison of efficacy, safety, and cost-effectiveness of montelukast-levocetirizine and montelukast-fexofenadine in patients of allergic rhinitis: A randomized, double-blind clinical trial.","['Mahatme MS', 'Dakhale GN', 'Tadke K', 'Hiware SK', 'Dudhgaonkar SD', 'Wankhede S']","['Acetates/*administration & dosage/adverse effects/economics', 'Anti-Allergic Agents/administration & dosage/adverse effects/economics', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/economics', 'Cetirizine/*administration & dosage/adverse effects/economics', 'Cost-Benefit Analysis/*methods', 'Cyclopropanes', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Prospective Studies', 'Quinolines/*administration & dosage/adverse effects/economics', 'Rhinitis, Allergic/*diagnosis/*drug therapy/economics', 'Sulfides', 'Terfenadine/administration & dosage/adverse effects/*analogs & derivatives/economics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28066101/
151,fexofenadine,9506246,Fexofenadine.,"['Markham A', 'Wagstaff AJ']","['Animals', 'Histamine Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9506246/
152,fexofenadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
153,fexofenadine,20480793,Second-generation antihistamines for the treatment of chronic idiopathic urticaria.,['Belsito DV'],"['Brain/metabolism', 'Chronic Disease', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Quality of Life', 'Receptors, Histamine H1/drug effects/metabolism', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20480793/
154,fexofenadine,12113226,H1-antihistamines in children.,['Simons FE'],"['Asthma/drug therapy', 'Child', 'Conjunctivitis, Allergic/drug therapy', 'Dermatitis, Atopic/drug therapy', 'Heart/drug effects', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Otitis Media/drug therapy', 'Respiratory Tract Infections/drug therapy', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12113226/
155,fexofenadine,16209158,Review of H1 antihistamines in the treatment of chronic idiopathic urticaria.,['Monroe E'],"['Anti-Inflammatory Agents/therapeutic use', 'Chronic Disease', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16209158/
156,fexofenadine,25592003,Comparison of the efficacy of olopatadine and fexofenadine in chronic idiopathic urticaria patients: a crossover study.,"['Tanizaki H', 'Yamamoto Y', 'Nakamizo S', 'Otsuka A', 'Miyachi Y', 'Kabashima K']","['Adult', 'Anti-Allergic Agents/*therapeutic use', 'Chronic Disease', 'Cross-Over Studies', 'Dibenzoxepins/*therapeutic use', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Olopatadine Hydrochloride', 'Terfenadine/*analogs & derivatives/therapeutic use', 'Treatment Outcome', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25592003/
157,fexofenadine,21345359,Novel strategies for microdose studies using non-radiolabeled compounds.,"['Maeda K', 'Sugiyama Y']","['Chromatography, Liquid/methods', 'Clinical Trials, Phase I as Topic/*methods', 'Dose-Response Relationship, Drug', '*Drug Design', 'Drug Interactions', 'Humans', 'Pharmaceutical Preparations/*administration & dosage/metabolism', 'Pharmacokinetics', 'Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/21345359/
158,fexofenadine,22267446,Fluorodeoxyglucose-induced allergic reaction: a case report.,"['Codreanu I', 'Dasanu CA', 'Weinstein GS', 'Divgi C']","['Anti-Allergic Agents/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Carcinoma, Squamous Cell/*diagnostic imaging/therapy', 'Diphenhydramine/therapeutic use', 'Drug Hypersensitivity/drug therapy/*prevention & control', 'Fluorodeoxyglucose F18/*adverse effects', 'Head and Neck Neoplasms/*diagnostic imaging/therapy', 'Humans', 'Hypopharyngeal Neoplasms/*diagnostic imaging/therapy', 'Male', 'Middle Aged', 'Multimodal Imaging', 'Positron-Emission Tomography', 'Prednisone/therapeutic use', 'Pyriform Sinus/*diagnostic imaging', 'Radiopharmaceuticals/*adverse effects', 'Secondary Prevention', 'Squamous Cell Carcinoma of Head and Neck', 'Terfenadine/analogs & derivatives/therapeutic use', 'Tomography, X-Ray Computed', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22267446/
159,fexofenadine,27197662,The Pharmacokinetic Exposure to Fexofenadine is Volume-Dependently Reduced in Healthy Subjects Following Oral Administration With Apple Juice.,"['Luo J', 'Imai H', 'Ohyama T', 'Hashimoto S', 'Hasunuma T', 'Inoue Y', 'Kotegawa T', 'Ohashi K', 'Uemura N']","['Administration, Oral', '*Beverages', 'Female', '*Healthy Volunteers', 'Humans', 'Male', '*Malus', 'Terfenadine/administration & dosage/*analogs & derivatives/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27197662/
160,ipratropium,12643359,The 'crashing asthmatic.'.,['Higgins JC'],"['Adrenergic beta-Agonists/*therapeutic use', 'Albuterol/administration & dosage/*therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Furans/therapeutic use', 'Glucocorticoids/*therapeutic use', 'Humans', 'Intubation, Intratracheal', 'Ipratropium/administration & dosage/*therapeutic use', 'Methylprednisolone Hemisuccinate/*therapeutic use', '*Nebulizers and Vaporizers', 'Phenols/therapeutic use', 'Respiratory Function Tests', 'Status Asthmaticus/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12643359/
161,ipratropium,33621253,Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.,"['Xu H', 'Tong L', 'Gao P', 'Hu Y', 'Wang H', 'Chen Z', 'Fang L']","['Administration, Inhalation', 'Adolescent', 'Albuterol/metabolism/*therapeutic use', 'Anti-Asthmatic Agents/therapeutic use', 'Asthma/*drug therapy/metabolism', 'Bronchodilator Agents/therapeutic use', 'Child', 'Child, Preschool', 'China', 'Disease Progression', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ipratropium/metabolism/*therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/33621253/
162,ipratropium,19967500,Anticholinergic treatment in airways diseases.,"['Flynn RA', 'Glynn DA', 'Kennedy MP']","['Asthma/*drug therapy', 'Cholinergic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Chronic Disease', 'Cost-Benefit Analysis', 'Humans', 'Ipratropium/administration & dosage/adverse effects/*therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Randomized Controlled Trials as Topic', 'Scopolamine Derivatives/administration & dosage/adverse effects/*therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/19967500/
163,ipratropium,2962075,Ipratropium bromide and airways obstruction in childhood.,['Milner AD'],"['Age Factors', 'Airway Obstruction/*drug therapy', 'Asthma/*drug therapy', 'Atropine Derivatives/*therapeutic use', 'Bronchiolitis, Viral/drug therapy', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2962075/
164,ipratropium,12169757,Anticholinergics in the treatment of chronic obstructive pulmonary disease.,"['Beeh KM', 'Welte T', 'Buhl R']","['Adrenergic beta-Agonists/pharmacology/therapeutic use', 'Cholinergic Antagonists/*pharmacology/*therapeutic use', 'Humans', 'Ipratropium/pharmacology/therapeutic use', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Scopolamine Derivatives/pharmacology/therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/12169757/
165,ipratropium,33639629,Nebulized Ipratropium Bromide-induced Anisocoria: Why Is Anisocoria Observed?,"['Derinoz-Guleryuz O', 'Fidanci I', 'Men-Atmaca Y']","['Anisocoria/*diagnosis/*etiology/prevention & control', 'Child', 'Disease Management', 'Disease Susceptibility', 'Emergency Medical Services', 'Humans', 'Ipratropium/administration & dosage/*adverse effects', 'Nebulizers and Vaporizers', 'Symptom Assessment']",https://pubmed.ncbi.nlm.nih.gov/33639629/
166,ipratropium,3155676,Ipratropium bromide.,"['Massey KL', 'Gotz VP']","['Animals', 'Asthma/drug therapy', 'Atropine Derivatives/*therapeutic use', 'Biotransformation', 'Bronchitis/drug therapy', 'Chemical Phenomena', 'Chemistry', 'Drug Therapy, Combination', 'Female', 'Humans', 'Intestinal Absorption', 'Ipratropium/administration & dosage/adverse effects/metabolism/pharmacology/*therapeutic use', 'Kinetics', 'Lung Diseases, Obstructive/*drug therapy', 'Pregnancy', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3155676/
167,ipratropium,19834421,Ipratropium bromide for acute asthma exacerbations in the emergency setting: a literature review of the evidence.,"['Dotson K', 'Dallman M', 'Bowman CM', 'Titus MO']","['Acute Disease', 'Asthma/*drug therapy', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Child', 'Emergency Treatment', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/19834421/
168,ipratropium,28249059,An overlooked Rx for nasal obstruction relief.,['Leventhal WD'],"['Humans', 'Ipratropium/*administration & dosage', 'Nasal Decongestants/administration & dosage', 'Nasal Obstruction/*drug therapy', 'Nasal Sprays']",https://pubmed.ncbi.nlm.nih.gov/28249059/
169,ipratropium,10565879,Anticholinergic bronchodilators.,['Witek TJ Jr'],"['Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Albuterol/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Cholinergic Antagonists/administration & dosage/*therapeutic use', 'Drug Combinations', 'Humans', 'Ipratropium/administration & dosage/therapeutic use', 'Lung Diseases, Obstructive/drug therapy/physiopathology', 'Muscarinic Antagonists/therapeutic use', 'Nasal Mucosa/drug effects/metabolism', 'Respiratory Mechanics/drug effects', 'Rhinitis/drug therapy', 'Scopolamine Derivatives/administration & dosage/therapeutic use', 'Tiotropium Bromide', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10565879/
170,ipratropium,8610719,Optimal pharmacologic treatment of the critically ill patient with obstructive airways disease.,['Siefkin AD'],"['Adrenal Cortex Hormones/therapeutic use', 'Adrenergic beta-Agonists/therapeutic use', 'Asthma/drug therapy', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Critical Illness', 'Drug Combinations', 'Humans', 'Ipratropium/therapeutic use', 'Lung Diseases, Obstructive/*drug therapy/physiopathology', 'Muscarinic Antagonists/therapeutic use', 'Pulmonary Ventilation']",https://pubmed.ncbi.nlm.nih.gov/8610719/
171,ipratropium,1460208,Intranasal anticholinergic therapy of rhinorrhea.,['Meltzer EO'],"['Administration, Intranasal', 'Humans', 'Ipratropium/administration & dosage/adverse effects', 'Nasal Mucosa/drug effects/*metabolism', 'Parasympatholytics/*administration & dosage', 'Rhinitis/*drug therapy', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Virus Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1460208/
172,ipratropium,15987237,Ipratropium bromide HFA.,['Wellington K'],"['Administration, Inhalation', '*Aerosol Propellants', 'Bronchial Spasm/*drug therapy/etiology', 'Cholinergic Antagonists/*administration & dosage', 'Humans', 'Ipratropium/*administration & dosage', 'Lung Diseases, Obstructive/complications/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15987237/
173,ipratropium,2523291,Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD.,"['LeDoux EJ', 'Morris JF', 'Temple WP', 'Duncan C']","['Administration, Inhalation', 'Aged', 'Atropine Derivatives/*administration & dosage', 'Double-Blind Method', 'Drug Combinations', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/*administration & dosage/therapeutic use', 'Lung Diseases, Obstructive/drug therapy/*physiopathology', 'Male', 'Metaproterenol/*administration & dosage/therapeutic use', 'Middle Aged', 'Placebos', 'Random Allocation', 'Spirometry', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/2523291/
174,ipratropium,19916997,Inhaled tiotropium bromide and risk of stroke.,"['Grosso A', 'Douglas I', 'Hingorani AD', 'MacAllister R', 'Hubbard R', 'Smeeth L']","['Administration, Inhalation', 'Aged', 'Albuterol/administration & dosage/adverse effects/*analogs & derivatives', 'Androstadienes/administration & dosage/*adverse effects', 'Bronchodilator Agents/administration & dosage/*adverse effects', 'Cholinergic Antagonists/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Female', 'Fluticasone', 'Humans', 'Ipratropium/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Risk Factors', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/administration & dosage/*adverse effects', 'Stroke/*chemically induced', 'Tiotropium Bromide', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/19916997/
175,ipratropium,2139094,Long-term safety and efficacy study of intranasal ipratropium bromide.,"['Milford CA', 'Mugliston TA', 'Lund VJ', 'Mackay IS']","['Administration, Intranasal', 'Adolescent', 'Adult', 'Aged', 'Atropine Derivatives/*administration & dosage', 'Clinical Trials as Topic', 'Epistaxis/chemically induced', 'Female', 'Headache/chemically induced', 'Humans', 'Ipratropium/*administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nasal Mucosa/drug effects', 'Rhinitis/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2139094/
176,ipratropium,154164,Intranasal ipratropium: inhibition of methacholine induced hypersecretion.,['Borum P'],"['Administration, Intranasal', 'Adult', 'Airway Resistance/drug effects', 'Atropine Derivatives/*pharmacology', 'Depression, Chemical', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Ipratropium/administration & dosage/*pharmacology', 'Male', 'Methacholine Compounds/administration & dosage/*pharmacology', 'Nasal Mucosa/drug effects/*metabolism', 'Placebos', 'Rhinitis/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/154164/
177,ipratropium,6459357,Combination bronchodilator therapy in asthma.,"['Ruffin RE', 'McIntyre E', 'Crockett AJ', 'Zielonka K', 'Alpers JH']","['Adult', 'Aged', 'Asthma/*drug therapy', 'Atropine Derivatives/*therapeutic use', 'Bronchodilator Agents/*therapeutic use', 'Drug Therapy, Combination', 'Ethanolamines/*therapeutic use', 'Female', 'Fenoterol/adverse effects/*therapeutic use', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/adverse effects/*therapeutic use', 'Male', 'Maximal Midexpiratory Flow Rate', 'Middle Aged', 'Parasympatholytics/therapeutic use', 'Sympathomimetics/therapeutic use', 'Vital Capacity']",https://pubmed.ncbi.nlm.nih.gov/6459357/
178,ipratropium,2947463,Concomitant bronchodilator therapy and ipratropium bromide. A clinical review.,['Chervinsky P'],"['Asthma/drug therapy/physiopathology', 'Atropine Derivatives/*therapeutic use', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Drug Evaluation', 'Drug Therapy, Combination', 'Forced Expiratory Volume', 'Humans', 'Ipratropium/administration & dosage/*therapeutic use', 'Lung Diseases, Obstructive/drug therapy/physiopathology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2947463/
179,ipratropium,27418820,Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.,"['Bhattacharya A', 'Bhargava S', 'Singh V', 'Talwar D', 'Whig J', 'Rebello J', 'Purandare S', 'Gogtay J']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/*administration & dosage/adverse effects', 'Adult', '*Aerosol Propellants/adverse effects', 'Aged', 'Albuterol/*administration & dosage/adverse effects', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Combinations', 'Equipment Design', 'Female', 'Forced Expiratory Volume', 'Humans', '*Hydrocarbons, Fluorinated/adverse effects', 'India', 'Ipratropium/*administration & dosage/adverse effects', 'Lung/*drug effects/physiopathology', 'Male', '*Metered Dose Inhalers', 'Middle Aged', 'Muscarinic Antagonists/*administration & dosage/adverse effects', 'Pulmonary Disease, Chronic Obstructive/diagnosis/*drug therapy/physiopathology', 'Severity of Illness Index', 'Therapeutic Equivalency', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27418820/
180,pentoxifylline,32851663,Antioxidants for female subfertility.,"['Showell MG', 'Mackenzie-Proctor R', 'Jordan V', 'Hart RJ']","['Abortion, Spontaneous/epidemiology', 'Administration, Oral', 'Antioxidants/*administration & dosage/adverse effects', 'Female', 'Humans', 'Infertility, Female/*drug therapy', 'Live Birth/epidemiology', 'Minerals/administration & dosage', 'Oxidative Stress', 'Pentoxifylline/adverse effects/therapeutic use', 'Placebos/administration & dosage', 'Pregnancy', 'Pregnancy Rate', 'Pregnancy, Multiple', 'Randomized Controlled Trials as Topic', 'Vitamins/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32851663/
181,pentoxifylline,28027781,Use of pentoxifylline and tocopherol in radiation-induced fibrosis and fibroatrophy.,"['Patel V', 'McGurk M']","['Antioxidants/*therapeutic use', 'Atrophy/drug therapy/etiology', 'Fibrosis/drug therapy/etiology', 'Humans', 'Pentoxifylline/*therapeutic use', 'Radiation Injuries/*drug therapy/*pathology', 'Radiotherapy/adverse effects', 'Tocopherols/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28027781/
182,pentoxifylline,26558813,Potential benefits of pentoxifylline on wound healing.,"['Ahmadi M', 'Khalili H']","['Animals', 'Burns/drug therapy/pathology', 'Humans', 'Pentoxifylline/*administration & dosage/pharmacology', 'Pressure Ulcer/drug therapy/pathology', 'Surgical Flaps/physiology', 'Vasodilator Agents/*administration & dosage/pharmacology', 'Wound Healing/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26558813/
183,pentoxifylline,8157787,Pentoxifylline.,"['Samlaska CP', 'Winfield EA']","['Animals', 'Blood Coagulation/drug effects', 'Connective Tissue/drug effects', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Fibrinolysis/drug effects', 'Humans', '*Pentoxifylline/chemistry/immunology/pharmacology/therapeutic use', 'Skin Diseases/drug therapy', 'Skin Neoplasms/drug therapy', 'Viscosity', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8157787/
184,pentoxifylline,8288739,Pentoxifylline: actions and applications in assisted reproduction.,['Yovich JL'],"['Acrosome/drug effects/physiology', 'Animals', 'Female', 'Humans', 'Infertility, Male/*therapy', 'Male', 'Mice', 'Pentoxifylline/*pharmacology/therapeutic use', 'Reactive Oxygen Species/metabolism', '*Reproductive Techniques', 'Sperm Motility/drug effects', 'Spermatozoa/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/8288739/
185,pentoxifylline,23729466,The use of antioxidants in radiotherapy-induced skin toxicity.,"['Amber KT', 'Shiman MI', 'Badiavas EV']","['Antioxidants/*therapeutic use', 'Ascorbic Acid/therapeutic use', 'Free Radical Scavengers/therapeutic use', 'Humans', 'Neoplasms/*radiotherapy', 'Pentoxifylline/therapeutic use', 'Polyphenols/therapeutic use', 'Radiodermatitis/*drug therapy', 'Radiotherapy/adverse effects', 'Sucralfate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23729466/
186,pentoxifylline,1550512,Methylxanthines in surgery: a bright future?,"['Tuckey JA', 'Parry BR', 'McCall JL']","['Humans', 'Neoplasms/drug therapy', 'Pentoxifylline/pharmacology/*therapeutic use', 'Respiratory Distress Syndrome/drug therapy', 'Shock, Septic/drug therapy', '*Surgical Procedures, Operative/trends', 'Theophylline/pharmacology/*therapeutic use', 'Xanthines/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1550512/
187,pentoxifylline,20081612,The management of alcoholic hepatitis.,['Forrest EH'],"['Adrenal Cortex Hormones/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Epidemiologic Methods', 'Hepatitis, Alcoholic/complications/diagnosis/*drug therapy', 'Humans', 'Middle Aged', 'Pentoxifylline/adverse effects/*therapeutic use', 'Sepsis/drug therapy/etiology', 'Treatment Outcome', 'Tumor Necrosis Factor-alpha/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/20081612/
188,pentoxifylline,33112447,Does in vitro application of pentoxifylline have beneficial effects in assisted male reproduction?,"['Mahaldashtian M', 'Khalili MA', 'Nottola SA', 'Woodward B', 'Macchiarelli G', 'Miglietta S']","['Humans', '*Infertility, Male/drug therapy', 'Male', '*Pentoxifylline/pharmacology/therapeutic use', 'Reproduction', 'Sperm Injections, Intracytoplasmic', 'Sperm Motility', 'Spermatozoa']",https://pubmed.ncbi.nlm.nih.gov/33112447/
189,pentoxifylline,22680624,Pentoxifylline use in dermatology.,"['Cakmak SK', 'Cakmak A', 'Gonul M', 'Kilic A', 'Gul U']","['Animals', 'Cytokines/metabolism', 'Down-Regulation/drug effects', 'Drug Costs', 'Humans', 'Microcirculation/drug effects', 'Pentoxifylline/economics/pharmacology/*therapeutic use', 'Phosphodiesterase Inhibitors/economics/pharmacology/*therapeutic use', 'Skin Diseases/*drug therapy/physiopathology', 'Tumor Necrosis Factor-alpha/biosynthesis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22680624/
190,pentoxifylline,16117244,"Immunomodulation, part I: pentoxifylline.",['Bell SG'],"['Clinical Trials as Topic', 'Cytokines/drug effects/immunology', 'Humans', 'Immunologic Factors/immunology/pharmacology/*therapeutic use', 'Infant, Newborn', 'Inflammation', 'Intensive Care, Neonatal/methods', 'Pentoxifylline/immunology/pharmacology/*therapeutic use', 'Phosphodiesterase Inhibitors/immunology/pharmacology/*therapeutic use', 'Sepsis/*drug therapy/immunology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16117244/
191,pentoxifylline,9143855,Optimal management of chronic leg ulcers in the elderly.,['Goodfield M'],"['Administration, Oral', 'Aged', 'Aging/*pathology', 'Arterial Occlusive Diseases/physiopathology', 'Aspirin/administration & dosage/pharmacology/therapeutic use', 'Bandages', 'Combined Modality Therapy', 'Diabetes Mellitus/physiopathology', 'Humans', 'Hypertension/physiopathology', 'Leg Ulcer/diagnosis/*drug therapy/therapy', 'Metabolic Diseases/physiopathology', 'Pentoxifylline/administration & dosage/pharmacology/therapeutic use', 'Phosphodiesterase Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Platelet Aggregation Inhibitors/administration & dosage/pharmacology/therapeutic use', 'Pressure Ulcer/physiopathology', 'Skin Transplantation', 'Vasculitis/physiopathology', 'Venous Insufficiency/physiopathology', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/9143855/
192,pentoxifylline,9673656,Pharmacologic management of peripheral vascular disease.,"['McNamara DB', 'Champion HC', 'Kadowitz PJ']","['Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Arterial Occlusive Diseases/*drug therapy/etiology', 'Cardiovascular Agents/adverse effects/*therapeutic use', 'Cyclooxygenase Inhibitors/adverse effects/therapeutic use', 'Humans', 'Ischemia/*drug therapy/etiology', 'Leg/*blood supply', 'Pentoxifylline/adverse effects/therapeutic use', 'Platelet Aggregation Inhibitors/adverse effects/therapeutic use', 'Prostaglandins, Synthetic/adverse effects/therapeutic use', 'Vasodilator Agents/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9673656/
193,pentoxifylline,16687988,Idiopathic atrophie blanche.,"['Amato L', 'Chiarini C', 'Berti S', 'Massi D', 'Fabbri P']","['Administration, Oral', 'Adult', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Atrophy/diagnosis/drug therapy/pathology', 'Dapsone/administration & dosage/therapeutic use', 'Diagnosis, Differential', 'Drug Therapy, Combination', 'Female', 'Humans', 'Leg Ulcer/*diagnosis/drug therapy/pathology', 'Pentoxifylline/administration & dosage/therapeutic use', 'Skin/pathology', 'Skin Diseases, Vesiculobullous/*diagnosis/drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/16687988/
194,pentoxifylline,19094840,Pentoxifylline: a drug with wide spectrum applications in dermatology.,['Zargari O'],"['Adult', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/pharmacology/*therapeutic use', 'Antifibrinolytic Agents/pharmacokinetics/pharmacology/therapeutic use', 'Behcet Syndrome/drug therapy', 'Child', 'Child, Preschool', 'Graft vs Host Disease/drug therapy', 'HIV Infections/drug therapy', 'Hemorheology/drug effects', 'Humans', 'Infant', 'Leishmaniasis, Cutaneous/drug therapy', 'Leprosy/drug therapy', 'Mice', 'Mice, Nude', 'Pentoxifylline/pharmacokinetics/pharmacology/*therapeutic use', 'Phosphodiesterase Inhibitors/pharmacokinetics/pharmacology/therapeutic use', 'Sarcoidosis/drug therapy', 'Skin Diseases/drug therapy', 'Tumor Necrosis Factor-alpha/antagonists & inhibitors', 'Vascular Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19094840/
195,pentoxifylline,25353639,Is pentoxifylline effective in alcoholic hepatitis? First update.,"['Rada G', 'Arteaga M', 'Candia R']","['Adrenal Cortex Hormones/administration & dosage', 'Hepatitis, Alcoholic/*drug therapy/mortality/physiopathology', 'Humans', 'Pentoxifylline/administration & dosage/*therapeutic use', 'Phosphodiesterase Inhibitors/administration & dosage/therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tumor Necrosis Factor-alpha/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/25353639/
196,pentoxifylline,30890334,Microfluidic assemblies designed for assessment of drug effects on deformability of human erythrocytes.,"['Xing F', 'Xun S', 'Zhu Y', 'Hu F', 'Drevensek-Olenik I', 'Zhang X', 'Pan L', 'Xu J']","['Blood Flow Velocity/drug effects', 'Dose-Response Relationship, Drug', 'Equipment Design', 'Erythrocyte Deformability/*drug effects', 'Ethanol/administration & dosage/toxicity', 'Humans', 'Hydrogen Peroxide/administration & dosage/toxicity', 'In Vitro Techniques', '*Lab-On-A-Chip Devices', 'Microfluidic Analytical Techniques/*instrumentation/methods', 'Pentoxifylline/administration & dosage/toxicity']",https://pubmed.ncbi.nlm.nih.gov/30890334/
197,pentoxifylline,21748765,Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial.,"['Zein CO', 'Yerian LM', 'Gogate P', 'Lopez R', 'Kirwan JP', 'Feldstein AE', 'McCullough AJ']","['Adiponectin/blood', 'Adult', 'Alanine Transaminase/metabolism', 'Apoptosis/drug effects', 'Aspartate Aminotransferases/metabolism', 'Biopsy', 'Fatty Liver/*drug therapy/*pathology', 'Female', 'Humans', 'Insulin Resistance', 'Liver/*pathology', 'Male', 'Middle Aged', 'Non-alcoholic Fatty Liver Disease', 'Pentoxifylline/*administration & dosage/adverse effects', 'Placebos', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects', 'Treatment Outcome', 'Tumor Necrosis Factor-alpha/blood']",https://pubmed.ncbi.nlm.nih.gov/21748765/
198,pentoxifylline,8172380,Pentoxifylline for intermittent claudication. A critical review.,['Ernst E'],"['Blood Viscosity/drug effects', 'Clinical Trials as Topic', 'Humans', 'Intermittent Claudication/blood/*drug therapy', 'Pentoxifylline/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8172380/
199,pentoxifylline,9251897,Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis.,"['Windmeier C', 'Gressner AM']","['Animals', 'Humans', 'Liver Cirrhosis/*drug therapy', 'Pentoxifylline/pharmacokinetics/*pharmacology/therapeutic use', 'Vasodilator Agents/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9251897/
200,candesartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
201,candesartan,38861046,Comparative efficacy and safety of six angiotensin II receptor blockers in hypertensive patients: a network meta-analysis.,"['Zhang Z', 'Yang H', 'Guo H']","['Humans', '*Angiotensin Receptor Antagonists/therapeutic use/adverse effects/administration & dosage', '*Antihypertensive Agents/therapeutic use/adverse effects', 'Blood Pressure/drug effects', '*Hypertension/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38861046/
202,candesartan,15592574,Candesartan.,"['Gleiter CH', 'Jagle C', 'Gresser U', 'Morike K']","['Angiotensin Receptor Antagonists', 'Animals', 'Benzimidazoles/chemistry/*pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Germany', 'Humans', 'Randomized Controlled Trials as Topic', 'Receptors, Angiotensin/therapeutic use', 'Tetrazoles/chemistry/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15592574/
203,candesartan,28841231,Noncholestatic acute hepatocellular injury following candesartan administration.,"['Lammel-Lindemann JA', 'Flores-Villalba E', 'Martagon AJ', 'DeObeso-Gonzalez E', 'Puente-Gallegos F']","['Adult', 'Amlodipine/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*adverse effects', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*adverse effects', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Chemical and Drug Induced Liver Injury/blood/*diagnosis/etiology', 'Dose-Response Relationship, Drug', 'Humans', 'Hypertension/blood/*drug therapy', 'Liver Function Tests', 'Male', 'Tetrazoles/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28841231/
204,candesartan,16451099,Indapamide sustained release: a review of its use in the treatment of hypertension.,"['Robinson DM', 'Wellington K']","['Animals', 'Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Diuretics/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Indapamide/*administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16451099/
205,candesartan,13678870,Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial.,"['Granger CB', 'McMurray JJ', 'Yusuf S', 'Held P', 'Michelson EL', 'Olofsson B', 'Ostergren J', 'Pfeffer MA', 'Swedberg K']","['Aged', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/*therapeutic use', 'Biphenyl Compounds', 'Cardiac Output, Low/drug therapy/epidemiology', 'Comorbidity', 'Cough/chemically induced', 'Female', 'Follow-Up Studies', 'Heart Failure/*drug therapy/epidemiology', 'Humans', 'Hypotension/chemically induced', 'Kidney Diseases/chemically induced', 'Male', 'Tetrazoles/*therapeutic use', 'Treatment Outcome', 'Ventricular Dysfunction, Left/*drug therapy/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/13678870/
206,candesartan,17020420,Candesartan for the management of heart failure: more than an alternative.,['McKelvie RS'],"['Angiotensin II Type 1 Receptor Blockers/metabolism/pharmacokinetics/*therapeutic use', 'Benzimidazoles/metabolism/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Heart Failure/*drug therapy', 'Humans', 'Stroke Volume/drug effects', 'Tetrazoles/metabolism/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17020420/
207,candesartan,15969893,Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.,"['Bonner G', 'Fuchs W']","['*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Benzimidazoles/pharmacokinetics/pharmacology/*therapeutic use', 'Biphenyl Compounds/pharmacokinetics/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Female', 'Germany', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Tetrazoles/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15969893/
208,candesartan,16230887,"Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.","['Bhatia V', 'Bhatia R', 'Mathew B']","['Adrenergic beta-Antagonists/therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy', 'Humans', 'Losartan/therapeutic use', 'Mineralocorticoid Receptor Antagonists/therapeutic use', 'Tetrazoles/therapeutic use', 'Valine/analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/16230887/
209,candesartan,27250611,[What are the effects of fixed-dose combination of candesartan and amlodipine].,"['Vitovec J', 'Spinar J']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Drug Combinations', 'Humans', 'Hypertension/drug therapy', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27250611/
210,candesartan,31732254,Discovery of candesartan cilexetic as a novel neddylation inhibitor for suppressing tumor growth.,"['Ni S', 'Chen X', 'Yu Q', 'Xu Y', 'Hu Z', 'Zhang J', 'Zhang W', 'Li B', 'Yang X', 'Mao F', 'Huang J', 'Sun Y', 'Li J', 'Jia L']","['A549 Cells', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/*pharmacology', 'Benzimidazoles/administration & dosage/chemistry/*pharmacology', 'Biphenyl Compounds/administration & dosage/chemistry/*pharmacology', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', '*Drug Discovery', 'Drug Screening Assays, Antitumor', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Injections, Subcutaneous', 'Mice', 'Mice, Nude', 'Molecular Structure', 'Neoplasms, Experimental/drug therapy/pathology', 'Structure-Activity Relationship', 'Tetrazoles/administration & dosage/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/31732254/
211,candesartan,30265168,"The Precision HYpertenSIon Care (PHYSIC) study: a double-blind, randomized, repeated cross-over study.","['Sundstrom J', 'Lind L', 'Nowrouzi S', 'Lytsy P', 'Marttala K', 'Ekman I', 'Ohagen P', 'Ostlund O']","['Adult', 'Aged', 'Amlodipine/administration & dosage', 'Antihypertensive Agents/administration & dosage', 'Benzimidazoles/administration & dosage', 'Biomarkers/metabolism', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Blood Pressure Determination', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage', 'Hypertension/epidemiology/*therapy', 'Lisinopril/administration & dosage', 'Male', 'Middle Aged', '*Precision Medicine', 'Randomized Controlled Trials as Topic', 'Research Design', 'Risk Factors', 'Tetrazoles/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30265168/
212,candesartan,38418298,Safety and efficacy of candesartan versus valsartan combined with amlodipine on peripheral and central blood pressure.,"['Hanna SM', 'Rabea HM', 'Abdelrahim MEA', 'Mahmoud HB']","['Humans', '*Amlodipine/adverse effects', 'Valsartan/pharmacology/therapeutic use', 'Blood Pressure', '*Hypertension/drug therapy', 'Prospective Studies', 'Valine/pharmacology/therapeutic use', 'Antihypertensive Agents/adverse effects', 'Tetrazoles/adverse effects', 'Drug Therapy, Combination', '*Benzimidazoles', '*Biphenyl Compounds']",https://pubmed.ncbi.nlm.nih.gov/38418298/
213,candesartan,10980901,Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure.,"['Ennezat PV', 'Berlowitz M', 'Sonnenblick EH', 'Le Jemtel TH']","['Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Animals', 'Antihypertensive Agents/therapeutic use', 'Benzimidazoles/therapeutic use', 'Biphenyl Compounds', 'Drug Therapy, Combination', 'Enalapril/administration & dosage/therapeutic use', 'Heart Failure/*drug therapy/physiopathology', 'Humans', 'Randomized Controlled Trials as Topic', 'Tetrazoles/therapeutic use', 'Ventricular Dysfunction, Left/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/10980901/
214,candesartan,29701105,A prospective study of the impact of AGTR1 A1166C on the effects of candesartan in patients with heart failure.,"['de Denus S', 'Dube MP', 'Fouodjio R', 'Huynh T', 'LeBlanc MH', 'Lepage S', 'Sheppard R', 'Giannetti N', 'Lavoie J', 'Mansour A', 'Provost S', 'Normand V', 'Mongrain I', 'Langlois M', ""O'Meara E"", 'Ducharme A', 'Racine N', 'Guertin MC', 'Turgeon J', 'Phillips MS', 'Rouleau JL', 'Tardif JC', 'White M']","['Aged', 'Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biomarkers/blood', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Female', 'Heart Failure/blood/*drug therapy/genetics', 'Humans', 'Kidney Function Tests', 'Male', 'Natriuretic Peptide, Brain/blood', 'Peptide Fragments/blood', 'Pharmacogenetics', '*Polymorphism, Single Nucleotide', 'Prospective Studies', 'Receptor, Angiotensin, Type 1/*genetics', 'Renin-Angiotensin System/*drug effects/genetics', 'Tetrazoles/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29701105/
215,candesartan,17339065,Angiotensin receptor blockade in diabetic renal disease--focus on candesartan.,"['Garcia Donaire JA', 'Ruilope LM']","['Angiotensin II Type 1 Receptor Blockers/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Diabetic Angiopathies/prevention & control', 'Diabetic Nephropathies/*drug therapy/epidemiology/*prevention & control', 'Glomerular Filtration Rate/drug effects', 'Humans', 'Hypertension/prevention & control', 'Kidney Failure, Chronic/prevention & control', 'Renal Circulation/drug effects/physiology', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17339065/
216,candesartan,21421652,A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.,"['Zhenfeng Zheng', 'Huilan Shi', 'Junya Jia', 'Dong Li', 'Shan Lin']","['Antihypertensive Agents/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Losartan/adverse effects/pharmacology/*therapeutic use', 'Publication Bias', 'Regression Analysis', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21421652/
217,candesartan,10073836,Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.,"['Bell TP', 'DeQuattro V', 'Lasseter KC', 'Ruff D', 'Hardison JD', 'Cushing D', 'Kezer AE', 'Michelson EL']","['Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds/*administration & dosage', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Posture', 'Prodrugs/administration & dosage', '*Tetrazoles']",https://pubmed.ncbi.nlm.nih.gov/10073836/
218,candesartan,19101048,"Angiotensin converting-enzyme inhibitors and candesartan have no effects on atrial fibrillation after cardiac surgery: comment on: Mehmet Ozaydin et al. ""Effect of renin-angiotensin aldosterone system blockers on postoperative atrial fibrillation"".","['Mariscalco G', 'Dominici C', 'Banach M', 'Sala A']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage', 'Atrial Fibrillation/*drug therapy/etiology/metabolism', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Cardiac Surgical Procedures/*adverse effects', 'Humans', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Postoperative Complications/*drug therapy/etiology/metabolism', 'Prospective Studies', 'Renin-Angiotensin System/*drug effects/physiology', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/19101048/
219,candesartan,27651039,Angiotensin II receptor blocker combined with eplerenone or hydrochlorothiazide for hypertensive patients with diabetes mellitus.,"['Karashima S', 'Yoneda T', 'Kometani M', 'Ohe M', 'Mori S', 'Sawamura T', 'Furukawa K', 'Yamagishi M', 'Takeda Y']","['Adult', 'Aged', 'Angiotensin Receptor Antagonists/administration & dosage', 'Antihypertensive Agents/administration & dosage', '*Benzimidazoles/administration & dosage/adverse effects', 'Biphenyl Compounds', 'Blood Pressure/*drug effects', '*Diabetes Mellitus, Type 2/complications/diagnosis/drug therapy', 'Drug Monitoring/methods', 'Drug Therapy, Combination/methods', 'Eplerenone', 'Essential Hypertension', 'Female', 'Glycated Hemoglobin/analysis', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', 'Hypertension/complications/diagnosis/drug therapy', 'Male', 'Middle Aged', 'Mineralocorticoid Receptor Antagonists/administration & dosage', 'Spironolactone/administration & dosage/adverse effects/*analogs & derivatives', '*Tetrazoles/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27651039/
220,ketoprofen,27103611,Topical NSAIDs for chronic musculoskeletal pain in adults.,"['Derry S', 'Conaghan P', 'Da Silva JA', 'Wiffen PJ', 'Moore RA']","['Administration, Topical', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects', 'Chronic Pain/*drug therapy', 'Diclofenac/*administration & dosage/adverse effects', 'Humans', 'Ketoprofen/*administration & dosage/adverse effects', 'Musculoskeletal Pain/*drug therapy', 'Numbers Needed To Treat', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27103611/
221,ketoprofen,11317922,[Allergies to ketoprofen gels].,['Milpied-Homsi B'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*adverse effects', 'Dermatitis, Allergic Contact/diagnosis/*etiology', 'Dermatitis, Photoallergic/diagnosis/etiology', 'Drug Eruptions/diagnosis/*etiology', 'Female', 'Follow-Up Studies', 'Gels/adverse effects', 'Humans', 'Ketoprofen/administration & dosage/*adverse effects', 'Male', 'Photosensitivity Disorders/*complications/diagnosis/prevention & control', 'Skin Tests', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/11317922/
222,ketoprofen,28474616,Ketoprofen-induced photoallergic dermatitis.,"['Loh TY', 'Cohen PR']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Dermatitis, Photoallergic/etiology/*pathology', 'Exanthema/chemically induced/drug therapy/pathology', 'Humans', 'Ketoprofen/*adverse effects/therapeutic use', 'Photosensitivity Disorders/chemically induced/*pathology', 'Sunscreening Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28474616/
223,ketoprofen,19832694,Ketoprofen allergic reactions.,"['Cantisani C', 'Grieco T', 'Faina V', 'Mattozzi C', 'Bohnenberger H', 'Silvestri E', 'Calvieri S']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Cross Reactions/immunology', 'Dermatitis, Photoallergic/etiology/*immunology', 'Drug Delivery Systems', 'Drug Hypersensitivity/etiology/*immunology', 'Humans', 'Ketoprofen/*adverse effects/chemistry/therapeutic use', 'Musculoskeletal Diseases/*drug therapy', 'Patents as Topic']",https://pubmed.ncbi.nlm.nih.gov/19832694/
224,ketoprofen,38813682,Efficacy and safety of simple analgesics for acute treatment of episodic tension-type headache in adults: a network meta-analysis.,"['Xie R', 'Li J', 'Jing Y', 'Tian J', 'Li H', 'Cai Y', 'Wang Y', 'Chen W', 'Xu F']","['Humans', '*Tension-Type Headache/drug therapy', '*Analgesics/adverse effects/therapeutic use/administration & dosage', 'Adult', '*Network Meta-Analysis', '*Ibuprofen/adverse effects/administration & dosage/therapeutic use', 'Acetaminophen/therapeutic use/adverse effects/administration & dosage', 'Bayes Theorem', 'Treatment Outcome', 'Diclofenac/adverse effects/therapeutic use/administration & dosage', 'Randomized Controlled Trials as Topic', 'Naproxen/therapeutic use/adverse effects/administration & dosage', 'Ketoprofen/adverse effects/therapeutic use/administration & dosage/analogs & derivatives', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use/administration & dosage', 'Female', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38813682/
225,ketoprofen,16274258,Topical ketoprofen patch.,['Mazieres B'],"['Administration, Cutaneous', '*Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Humans', '*Ketoprofen/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16274258/
226,ketoprofen,7002065,Clotrimazole in rheumatoid arthritis.,"['Wojtulewski JA', 'Gow PJ', 'Walter J', 'Grahame R', 'Gibson T', 'Panayi GS', 'Mason J']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Clotrimazole/adverse effects/*therapeutic use', 'Double-Blind Method', 'Humans', 'Imidazoles/*therapeutic use', 'Ketoprofen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7002065/
227,ketoprofen,7938218,Photochemical and photobiological properties of ketoprofen associated with the benzophenone chromophore.,"['Bosca F', 'Miranda MA', 'Carganico G', 'Mauleon D']","['Dermatitis, Phototoxic/etiology', 'Humans', 'In Vitro Techniques', 'Ketoprofen/adverse effects/chemistry/*radiation effects', 'Lipid Peroxidation/drug effects/radiation effects', 'Molecular Structure', 'Photochemistry']",https://pubmed.ncbi.nlm.nih.gov/7938218/
228,ketoprofen,7506182,Tolerability of nimesulide and ketoprofen in paediatric patients with traumatic or surgical fractures.,"['Facchini R', 'Selva G', 'Peretti G']","['Adolescent', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Child', 'Female', 'Fractures, Bone/*drug therapy', 'Humans', 'Ketoprofen/adverse effects/*therapeutic use', 'Male', 'Pain/*drug therapy', 'Sulfonamides/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7506182/
229,ketoprofen,796946,A clinical study of ketoprofen suppositories.,"['Fournie A', 'Ayrolles C']","['*Anti-Inflammatory Agents', 'Arthritis, Rheumatoid/*drug therapy', 'Benzophenones/*administration & dosage', 'Clinical Trials as Topic', 'Humans', 'Ketoprofen/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/796946/
230,ketoprofen,39809346,Investigation of the suitability of confocal Raman spectroscopy for the demonstration of bioequivalence of topical products.,"['Gaiser A', 'Lunter D']","['*Therapeutic Equivalency', '*Spectrum Analysis, Raman/methods', 'Animals', 'Swine', '*Skin Absorption', '*Skin/metabolism', '*Ketoprofen/pharmacokinetics/administration & dosage/chemistry', 'Humans', 'Administration, Cutaneous', 'Male']",https://pubmed.ncbi.nlm.nih.gov/39809346/
231,ketoprofen,33932737,Future prospects of ketoprofen in improving the safety of the gastric mucosa.,"['Kuczynska J', 'Nieradko-Iwanicka B']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Gastric Mucosa/*drug effects', 'Humans', 'Ketoprofen/*administration & dosage', 'Stomach Ulcer/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/33932737/
232,ketoprofen,23711416,Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis.,"['Sarzi-Puttini P', 'Atzeni F', 'Lanata L', 'Bagnasco M']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Diclofenac/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Ketoprofen/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Pain/diagnosis/*drug therapy', 'Pain Measurement', 'Patient Selection', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23711416/
233,ketoprofen,24359044,Paracetamol vs dexketoprofen for perineal pain relief after episiotomy or perineal tear.,"['Akil A', 'Api O', 'Bektas Y', 'Yilmaz AO', 'Yalti S', 'Unal O']","['Acetaminophen/*therapeutic use', 'Adult', 'Analgesics, Non-Narcotic/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Double-Blind Method', 'Episiotomy/adverse effects', 'Female', 'Humans', 'Infusions, Intravenous', 'Ketoprofen/*analogs & derivatives/therapeutic use', 'Pain/*drug therapy/etiology', 'Perineum/injuries', 'Pregnancy', 'Tromethamine/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24359044/
234,ketoprofen,25567464,Ataxia caused by a single dose of dexketoprofen trometamol.,"['Avci S', 'Genc S', 'Aydin M', 'Buyukcam F', 'Ozkan S']","['Administration, Oral', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects', 'Ataxia/*chemically induced', 'Dose-Response Relationship, Drug', 'Female', 'Follow-Up Studies', 'Humans', 'Ketoprofen/administration & dosage/adverse effects/*analogs & derivatives', 'Tromethamine/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25567464/
235,ketoprofen,126848,A comparative trial of azapropazone and ketoprofen in the treatment of acute backache.,"['Hingorani K', 'Templeton JS']","['Acute Disease', 'Adult', 'Aged', 'Apazone/adverse effects/*therapeutic use', 'Back Pain/*drug therapy', 'Benzophenones/*therapeutic use', 'Female', 'Humans', 'Ketoprofen/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Triazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/126848/
236,ketoprofen,25412595,Esophagitis due to dexketoprofen trometamol: a rare case report.,"['Olmez S', 'Donmez S', 'Aslan M', 'Karadas S', 'Yavuz A']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Chest Pain/chemically induced', 'Deglutition Disorders/chemically induced', 'Diagnosis, Differential', 'Esophagitis/*chemically induced/diagnosis', 'Esophagoscopy', 'Heartburn/chemically induced', 'Humans', 'Ketoprofen/adverse effects/*analogs & derivatives/therapeutic use', 'Male', 'Risk Factors', 'Tromethamine/*adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25412595/
237,ketoprofen,773499,Four new anti-inflammatory drugs: responses and variations.,"['Huskisson EC', 'Woolf DL', 'Balme HW', 'Scott J', 'Franklin S']","['Anti-Inflammatory Agents/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Fenoprofen/adverse effects/therapeutic use', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Ketoprofen/adverse effects/therapeutic use', 'Naproxen/adverse effects/therapeutic use', 'Pain']",https://pubmed.ncbi.nlm.nih.gov/773499/
238,ketoprofen,30876777,Intradermal mesotherapy versus systemic therapy in the treatment of musculoskeletal pain: A prospective randomized study.,['Kocak AO'],"['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/therapeutic use', 'Emergency Service, Hospital', 'Female', 'Follow-Up Studies', 'Humans', 'Injections, Intravenous', 'Ketoprofen/administration & dosage/*analogs & derivatives/therapeutic use', 'Male', '*Mesotherapy', 'Middle Aged', 'Musculoskeletal Pain/*drug therapy', 'Piroxicam/administration & dosage/*analogs & derivatives/therapeutic use', 'Prospective Studies', 'Treatment Outcome', 'Tromethamine/*administration & dosage/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30876777/
239,ketoprofen,21052564,Pain and ketoprofen: what is its role in clinical practice?,"['Sarzi-Puttini P', 'Atzeni F', 'Lanata L', 'Bagnasco M', 'Colombo M', 'Fischer F', ""D'Imporzano M""]","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Calcinosis/prevention & control', 'Cardiovascular Diseases/chemically induced/epidemiology', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Administration Routes', 'Gout/drug therapy', 'Humans', 'Hyperalgesia/drug therapy/physiopathology', 'Ketoprofen/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Osteoarthritis/drug therapy', 'Pain/classification/*drug therapy/epidemiology/physiopathology', 'Pain Perception/drug effects/physiology', 'Pain, Postoperative/drug therapy', 'Postoperative Complications/prevention & control', 'Soft Tissue Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21052564/
240,Torasemide,36917048,Heart Failure With Preserved Ejection Fraction: A Review.,"['Redfield MM', 'Borlaug BA']","['Humans', 'Diabetes Mellitus, Type 2/complications', 'Dyspnea/etiology', 'Glucose/analysis', '*Heart Failure/etiology/mortality/physiopathology/therapy', 'Hypertension/complications', 'Obesity/complications', 'Quality of Life', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Stroke Volume/physiology']",https://pubmed.ncbi.nlm.nih.gov/36917048/
241,Torasemide,39291563,Preface.,['Gogtay J'],"['Humans', '*Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Diuretics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291563/
242,Torasemide,38441582,Cardiac Amyloidosis Due to Transthyretin Protein: A Review.,"['Ruberg FL', 'Maurer MS']","['Humans', '*Amyloidosis/complications/epidemiology/genetics/metabolism', '*Cardiomyopathies/etiology/genetics/metabolism', '*Heart Failure/etiology/genetics/metabolism', 'Immunoglobulin Light-chain Amyloidosis', '*Prealbumin/genetics/metabolism', 'Black or African American/ethnology/genetics/statistics & numerical data', 'United States/epidemiology', 'Africa, Western', 'Protein Folding']",https://pubmed.ncbi.nlm.nih.gov/38441582/
243,Torasemide,36648467,Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.,"['Mentz RJ', 'Anstrom KJ', 'Eisenstein EL', 'Sapp S', 'Greene SJ', 'Morgan S', 'Testani JM', 'Harrington AH', 'Sachdev V', 'Ketema F', 'Kim DY', 'Desvigne-Nickens P', 'Pitt B', 'Velazquez EJ']","['Humans', 'Female', 'Middle Aged', 'Aged', 'Male', '*Furosemide/therapeutic use', 'Torsemide/therapeutic use', 'Patient Discharge', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use/adverse effects', 'Treatment Outcome', '*Heart Failure/drug therapy', 'Hospitalization']",https://pubmed.ncbi.nlm.nih.gov/36648467/
244,Torasemide,32829662,Pathophysiology of Diuretic Resistance and Its Implications for the Management of Chronic Heart Failure.,"['Wilcox CS', 'Testani JM', 'Pitt B']","['Diuretics/administration & dosage/*therapeutic use', 'Drug Resistance/*physiology', 'Heart Failure/*drug therapy/physiopathology', 'Humans', 'Kidney Tubules/drug effects/*physiopathology', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/32829662/
245,Torasemide,39291562,Guest Editorial.,['Bansal S'],"['Humans', '*Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Diuretics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291562/
246,Torasemide,39291566,Loop Diuretics Unique Mechanism of Action.,"['Solanki D', 'Choudhary S', 'Vora A', 'Ghose T', 'Mantri RR', 'Modi N', 'Sawhney J', 'Singhal A', 'Kumar A', 'Edakutty R', 'Pande A', 'Ahuja R', 'Francis F', 'Mohanasundaram S']","['Humans', 'Furosemide/pharmacology/therapeutic use', 'Heart Failure/complications/drug therapy/physiopathology', '*Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291566/
247,Torasemide,7954543,Efficacy and tolerance of low-dose loop diuretics in hypertension.,"['Schmieder RE', 'Rockstroh JK']","['Blood Pressure/drug effects', 'Diuretics/adverse effects/pharmacology/*therapeutic use', 'Drug Tolerance', 'Humans', 'Hypertension/*drug therapy', 'Loop of Henle/drug effects', 'Sulfonamides/therapeutic use', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/7954543/
248,Torasemide,34731652,EMPEROR-Preserved: A promise fulfilled.,"['Bhatt DL', 'Verma S', 'Pitt B']","['*Heart Failure/drug therapy', 'Humans', '*Sodium-Glucose Transporter 2 Inhibitors', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/34731652/
249,Torasemide,39291573,Torsemide in the Management of Pulmonary Edema.,"['Vora A', 'Sharma A', 'Sivakadaksham', 'Sundar RH', 'Mandal SC', 'Chatterjee N', 'Agarwal A', 'Bhatnagar MK', 'Gupta A', 'Thaploo R', 'Francis F', 'Mohanasundaram S']","['Humans', 'Furosemide/pharmacology/therapeutic use', '*Heart Failure/drug therapy/complications', '*Pulmonary Edema/drug therapy/etiology', '*Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use', '*Torsemide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291573/
250,Torasemide,31699358,Meta-Analysis Comparing Torsemide Versus Furosemide in Patients With Heart Failure.,"['Abraham B', 'Megaly M', 'Sous M', 'Fransawyalkomos M', 'Saad M', 'Fraser R', 'Topf J', 'Goldsmith S', 'Simegn M', 'Bart B', 'Azzo Z', 'Mesiha N', 'Sharma R']","['Furosemide/*therapeutic use', 'Heart Failure/*drug therapy/physiopathology', 'Humans', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Stroke Volume/drug effects/*physiology', 'Torsemide/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31699358/
251,Torasemide,39291572,Torsemide in the Management of Essential Hypertension.,"['Bhattacharyya K', 'Tiwaskar M', 'Datta A', 'Chandani AL', 'Agrawal SK', 'Abdullakutty J', 'Badani R', 'Doshi D', 'Singh V', 'Advani P', 'Varghese K', 'Pandey AK', 'Francis F', 'Sugumaran A']","['Humans', '*Antihypertensive Agents/pharmacology/therapeutic use', 'Blood Pressure/drug effects', '*Essential Hypertension/drug therapy', '*Hypertension/drug therapy', '*Torsemide/pharmacology/therapeutic use', '*Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291572/
252,Torasemide,8565430,Diabetes and hypertension.,['Smolar EN'],"['Antihypertensive Agents/adverse effects/*therapeutic use', 'Diabetes Mellitus/*drug therapy/genetics', 'Diabetic Angiopathies/drug therapy/genetics', 'Diabetic Nephropathies/drug therapy/genetics', 'Humans', 'Hypertension/*drug therapy/genetics', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/8565430/
253,Torasemide,7506334,Pharmacokinetics and pharmacodynamics of torasemide in health and disease.,['Brater DC'],"['Diuretics/*pharmacokinetics/*pharmacology', 'Heart Failure/*drug therapy/metabolism', 'Humans', 'Kidney Diseases/*drug therapy/metabolism', 'Sulfonamides/*pharmacokinetics/*pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/7506334/
254,Torasemide,39291570,Torsemide in Edema Associated with Chronic Kidney Disease.,"['Chafekar D', 'Mukhopadhyay P', 'Ambekar N', 'Kumar S', 'George J', 'Khullar D', 'Saxena S', 'Shah J', 'Mavani S', 'Ruhela V', 'Goyal M', 'Francis F', 'Mohanasundaram S']","['Humans', 'Acute Kidney Injury/complications/drug therapy', '*Edema/etiology/drug therapy', '*Renal Insufficiency, Chronic/complications/drug therapy', '*Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use', '*Torsemide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39291570/
255,Torasemide,8435374,Clinicopharmacological reappraisal of the potency of diuretics.,"['Reyes AJ', 'Leary WP']","['Clopamide/pharmacology', 'Diuretics/*pharmacology/therapeutic use', 'Furosemide/pharmacology', 'Humans', 'Hydrochlorothiazide/pharmacology', 'Muzolimine/pharmacology', 'Natriuresis/*drug effects', 'Pyridines/pharmacology', 'Sulfonamides/pharmacology', 'Torsemide', 'Xipamide/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8435374/
256,Torasemide,32783109,Comparative effects of furosemide and other diuretics in the treatment of heart failure: a systematic review and combined meta-analysis of randomized controlled trials.,"['Eid PS', 'Ibrahim DA', 'Zayan AH', 'Elrahman MMA', 'Shehata MAA', 'Kandil H', 'Abouibrahim MA', 'Duy LM', 'Shinkar A', 'Elfaituri MK', 'Minh LHN', 'Fahmy MM', 'Tam DNH', 'Vuong NL', 'Shah J', 'Do VBD', 'Hirayama K', 'Huy NT']","['Diuretics/therapeutic use', '*Furosemide/therapeutic use', '*Heart Failure/drug therapy', 'Humans', 'Randomized Controlled Trials as Topic', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/32783109/
257,Torasemide,36546712,Heart failure: an update from the last years and a look at the near future.,"['Riccardi M', 'Sammartino AM', 'Piepoli M', 'Adamo M', 'Pagnesi M', 'Rosano G', 'Metra M', 'von Haehling S', 'Tomasoni D']","['Humans', '*Acetazolamide/pharmacology/therapeutic use', '*Heart Failure', 'Sodium Potassium Chloride Symporter Inhibitors', 'Stroke Volume', 'Ventricular Function, Left']",https://pubmed.ncbi.nlm.nih.gov/36546712/
258,Torasemide,30741178,Death: The Simple Clinical Trial Endpoint.,"['Eisenstein EL', 'Prather K', 'Greene SJ', 'Harding T', 'Harrington A', 'Gabriel D', 'Jones I', 'Mentz RJ', 'Velazquez EJ', 'Anstrom KJ']","['Clinical Trials as Topic', 'Data Collection', 'Diuretics/therapeutic use', '*Endpoint Determination', 'Furosemide/therapeutic use', '*Heart Failure/drug therapy', 'Humans', '*Mortality', 'Torsemide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30741178/
259,Torasemide,29039840,[Use of loop diuretics in heart failure: Current aspects].,"['Kurlykina NV', 'Seredenina EM', 'Orlova YA']","['Heart Failure/diagnosis/*drug therapy/physiopathology', 'Humans', 'Sodium Potassium Chloride Symporter Inhibitors/*pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29039840/
260,bumetanide,35524444,Clarifications regarding bumetanide for neonatal seizures.,['Staley KJ'],"['Bumetanide/therapeutic use', '*Epilepsy', 'Humans', 'Infant, Newborn', '*Infant, Newborn, Diseases', 'Seizures/drug therapy', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Solute Carrier Family 12, Member 2']",https://pubmed.ncbi.nlm.nih.gov/35524444/
261,bumetanide,32094236,BRASH syndrome.,"['Srivastava S', 'Kemnic T', 'Hildebrandt KR']","['Antihypertensive Agents/adverse effects', '*Atrioventricular Block', '*Bradycardia', 'Bumetanide/adverse effects', 'Carvedilol/adverse effects', 'Female', 'Humans', '*Hyperkalemia', 'Metolazone/adverse effects', 'Middle Aged', '*Renal Insufficiency', '*Shock', 'Syndrome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32094236/
262,bumetanide,8233492,Ototoxicity of loop diuretics.,['Rybak LP'],"['Animals', 'Bumetanide/adverse effects', 'Cochlea/*drug effects', 'Diuretics/*adverse effects', 'Ethacrynic Acid/adverse effects', 'Furosemide/adverse effects', 'Hearing Disorders/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/8233492/
263,bumetanide,22293138,Aquaporins in drug discovery and pharmacotherapy.,"['Huber VJ', 'Tsujita M', 'Nakada T']","['Acetazolamide/pharmacology', 'Animals', 'Aquaporins/antagonists & inhibitors/chemistry/*metabolism', 'Biological Transport/drug effects', 'Brain Edema/*drug therapy/metabolism/pathology', 'Bumetanide/pharmacology', 'Drug Discovery', 'Humans', 'Molecular Targeted Therapy', 'Neoplasms/*drug therapy/metabolism/pathology', 'Niacinamide/analogs & derivatives/pharmacology', 'Thiadiazoles/pharmacology', 'Water/*metabolism', 'Water-Electrolyte Balance/drug effects', 'Water-Electrolyte Imbalance/*drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/22293138/
264,bumetanide,35524446,Bumetanide for neonatal seizures: No light in the pharmacokinetic/dynamic tunnel.,"['Kaila K', 'Loscher W']","['Bumetanide/therapeutic use', '*Epilepsy/drug therapy', 'Humans', 'Infant, Newborn', '*Infant, Newborn, Diseases/drug therapy', 'Seizures/drug therapy', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Solute Carrier Family 12, Member 2']",https://pubmed.ncbi.nlm.nih.gov/35524446/
265,bumetanide,3511654,Disposition and response to bumetanide and furosemide.,['Brater DC'],"['Adult', 'Aged', 'Biological Availability', '*Bumetanide/metabolism/pharmacology', '*Diuretics/metabolism/pharmacology', '*Furosemide/metabolism/pharmacology', 'Heart Failure/metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Kidney Transplantation', 'Kinetics', 'Liver Cirrhosis/metabolism', 'Middle Aged', 'Nephrotic Syndrome/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3511654/
266,bumetanide,37021422,"Bumetanide, a Diuretic That Can Help Children with Autism Spectrum Disorder.","['Shaker E', 'El Agami O', 'Salamah A']","['Child', 'Humans', 'Bumetanide/therapeutic use', 'Diuretics/therapeutic use', '*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37021422/
267,bumetanide,3511657,Diuretic therapeutics in the pediatric patient.,"['Witte MK', 'Stork JE', 'Blumer JL']","['Acid-Base Equilibrium', 'Bumetanide/metabolism/therapeutic use', 'Calcium/urine', 'Child', 'Child, Preschool', 'Chlorides/metabolism', 'Diuretics/adverse effects/metabolism/pharmacology/*therapeutic use', 'Ethacrynic Acid/metabolism/therapeutic use', 'Furosemide/metabolism/therapeutic use', 'Glomerular Filtration Rate', 'Glomerulonephritis/drug therapy', 'Humans', 'Hydrocephalus/drug therapy', 'Infant', 'Infant, Newborn', 'Infant, Premature', 'Kidney/blood supply/drug effects/embryology/physiology', 'Kinetics', 'Metabolic Clearance Rate', 'Nephrotic Syndrome/drug therapy', 'Prostaglandins/biosynthesis', 'Pulmonary Edema/drug therapy', 'Regional Blood Flow', 'Water-Electrolyte Balance']",https://pubmed.ncbi.nlm.nih.gov/3511657/
268,bumetanide,22536874,Unexpected extra-renal effects of loop diuretics in the preterm neonate.,"['Cotton R', 'Suarez S', 'Reese J']","['Biomarkers/metabolism', 'Bronchopulmonary Dysplasia/drug therapy', 'Bumetanide/*pharmacology/therapeutic use', 'Central Nervous System/drug effects/metabolism', 'Diuretics/*pharmacology/therapeutic use', 'Ductus Arteriosus/drug effects', 'Furosemide/*pharmacology/therapeutic use', 'Gastrointestinal Tract/drug effects', 'Humans', 'Hyaline Membrane Disease/drug therapy', 'Infant, Newborn', '*Infant, Premature', '*Intensive Care, Neonatal', 'Lung/drug effects', 'Muscle, Smooth, Vascular/drug effects', 'gamma-Aminobutyric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/22536874/
269,bumetanide,29483603,"Bumetanide for autism: more eye contact, less amygdala activation.","['Hadjikhani N', 'Asberg Johnels J', 'Lassalle A', 'Zurcher NR', 'Hippolyte L', 'Gillberg C', 'Lemonnier E', 'Ben-Ari Y']","['Adolescent', 'Adult', 'Amygdala/diagnostic imaging/*drug effects/*physiology', 'Autistic Disorder/diagnostic imaging/*physiopathology', 'Bumetanide/*pharmacology/therapeutic use', 'Double-Blind Method', 'Emotions/drug effects/physiology', 'Female', 'Fixation, Ocular/drug effects/physiology', 'Humans', 'Magnetic Resonance Spectroscopy', 'Male', 'Pilot Projects', 'Sodium Potassium Chloride Symporter Inhibitors/pharmacology/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29483603/
270,bumetanide,15162897,Food: an unrecognized source of loop diuretic resistance.,"['Bard RL', 'Bleske BE', 'Nicklas JM']","['Administration, Oral', 'Area Under Curve', '*Bumetanide/metabolism/pharmacokinetics/pharmacology', 'Clinical Trials as Topic', 'Diuresis/*drug effects', '*Diuretics/metabolism/pharmacokinetics/pharmacology', '*Food', '*Furosemide/metabolism/pharmacokinetics/pharmacology', 'Humans', 'Intestinal Absorption', 'Sulfonamides/metabolism/pharmacokinetics/pharmacology', 'Torsemide']",https://pubmed.ncbi.nlm.nih.gov/15162897/
271,bumetanide,36562420,A new role for an old drug: acetazolamide in decompensated heart failure.,['Doggrell SA'],"['Humans', '*Acetazolamide/therapeutic use', 'Bumetanide', 'Diuretics/therapeutic use', 'Quality of Life', 'Treatment Outcome', '*Heart Failure/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36562420/
272,bumetanide,34883135,CNS pharmacology of NKCC1 inhibitors.,"['Loscher W', 'Kaila K']","['Animals', 'Bumetanide/*pharmacokinetics', 'Central Nervous System/*drug effects', 'Humans', 'Sodium Potassium Chloride Symporter Inhibitors/*pharmacokinetics', 'Solute Carrier Family 12, Member 2/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34883135/
273,bumetanide,33385505,Treating Autism With Bumetanide: Are Large Multicentric and Monocentric Trials on Selected Populations Complementary?,"['Lemonnier E', 'Rabiei H', 'Makowski D', 'Hadjikhani N', 'Ben-Ari Y']","['*Autism Spectrum Disorder/drug therapy', '*Autistic Disorder', 'Bumetanide/pharmacology', 'Child', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/33385505/
274,bumetanide,34860628,Long-term bumetanide administration altered behavioral pattern in mosaic Down's Syndrome: A case report.,"['Gharaylou Z', 'Shafaghi L', 'Pestehei SK', 'Hadjighassem M']","['Humans', '*Down Syndrome/complications', 'Bumetanide/pharmacology', 'Trisomy', 'Mosaicism']",https://pubmed.ncbi.nlm.nih.gov/34860628/
275,bumetanide,35292925,A Phase III Study of Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents Aged Between 7 and 17 Years with Autism Spectrum Disorder (SIGN 1 Trial): Participant Baseline Characteristics.,"['Georgoula C', 'Ferrin M', 'Pietraszczyk-Kedziora B', 'Hervas A', 'Marret S', 'Oliveira G', 'Rosier A', 'Crutel V', 'Besse E', 'Severo CA', 'Ravel D', 'Fuentes J']","['Humans', 'Child', 'Male', 'Adolescent', 'Female', '*Autism Spectrum Disorder/drug therapy', 'Bumetanide/adverse effects', '*Autistic Disorder/diagnosis', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35292925/
276,bumetanide,3330836,Loop diuretics.,"['Greger R', 'Wangemann P']","['Animals', 'Bumetanide/pharmacology', 'Diuresis/drug effects', '*Diuretics/pharmacology', 'Dose-Response Relationship, Drug', 'Furosemide/pharmacology', 'Humans', 'Kidney/*physiology', 'Sodium Chloride/metabolism', 'Structure-Activity Relationship', 'Sulfonamides/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3330836/
277,bumetanide,6872415,Bumetanide and furosemide.,"['Brater DC', 'Chennavasin P', 'Day B', 'Burdette A', 'Anderson S']","['Administration, Oral', 'Biological Availability', 'Bumetanide/administration & dosage/*urine', 'Diuretics/*urine', 'Dose-Response Relationship, Drug', 'Furosemide/administration & dosage/*urine', 'Humans', 'Injections, Intravenous', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6872415/
278,bumetanide,37794745,Bumetanide oral solution for the treatment of children and adolescents with autism spectrum disorder: Results from two randomized phase III studies.,"['Fuentes J', 'Parellada M', 'Georgoula C', 'Oliveira G', 'Marret S', 'Crutel V', 'Albarran C', 'Lambert E', 'Penelaud PF', 'Ravel D', 'Ben Ari Y']","['Humans', 'Child', 'Adolescent', 'Bumetanide/adverse effects', '*Autism Spectrum Disorder/drug therapy', 'Treatment Outcome', '*Autistic Disorder', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37794745/
279,bumetanide,9158273,Frusemide-induced bullous pemphigoid.,"['Panayiotou BN', 'Prasad MV', 'Zaman MN']","['Aged', 'Bumetanide/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Female', 'Furosemide/*adverse effects', 'Humans', 'Male', 'Pemphigoid, Bullous/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9158273/
280,aztreonam,37846568,Treatment approaches for severe Stenotrophomonas maltophilia infections.,"['Mojica MF', 'Bonomo RA', 'van Duin D']","['Humans', '*Stenotrophomonas maltophilia', 'Combined Modality Therapy', 'Aztreonam', 'Microbial Sensitivity Tests', 'Minocycline']",https://pubmed.ncbi.nlm.nih.gov/37846568/
281,aztreonam,37754204,Ceftobiprole for Treatment of Complicated Staphylococcus aureus Bacteremia.,"['Holland TL', 'Cosgrove SE', 'Doernberg SB', 'Jenkins TC', 'Turner NA', 'Boucher HW', 'Pavlov O', 'Titov I', 'Kosulnykov S', 'Atanasov B', 'Poromanski I', 'Makhviladze M', 'Anderzhanova A', 'Stryjewski ME', 'Assadi Gehr M', 'Engelhardt M', 'Hamed K', 'Ionescu D', 'Jones M', 'Saulay M', 'Smart J', 'Seifert H', 'Fowler VG Jr']","['Adult', 'Humans', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Bacteremia/drug therapy/microbiology', 'Cephalosporins/administration & dosage/adverse effects/therapeutic use', '*Daptomycin/administration & dosage/adverse effects/therapeutic use', 'Methicillin-Resistant Staphylococcus aureus', '*Staphylococcal Infections/drug therapy/microbiology', '*Staphylococcus aureus', 'Treatment Outcome', 'Double-Blind Method', 'Administration, Intravenous', 'Aztreonam/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37754204/
282,aztreonam,20431562,Inhaled aztreonam.,"[""O'Sullivan BP"", 'Yasothan U', 'Kirkpatrick P']","['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Aztreonam/administration & dosage/adverse effects/*therapeutic use', 'Cystic Fibrosis/*complications/microbiology', 'Drug Discovery', 'Humans', 'Lysine/chemistry', 'Pseudomonas Infections/complications/*drug therapy/microbiology', 'Pseudomonas aeruginosa/isolation & purification', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20431562/
283,aztreonam,37823536,Management strategies for severe Pseudomonas aeruginosa infections.,"['Do Rego H', 'Timsit JF']","['Humans', '*Pseudomonas Infections/drug therapy', 'Anti-Bacterial Agents/therapeutic use', 'Aztreonam/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37823536/
284,aztreonam,33998665,Antibiotic regimens for late-onset neonatal sepsis.,"['Korang SK', 'Safi S', 'Nava C', 'Greisen G', 'Gupta M', 'Lausten-Thomsen U', 'Jakobsen JC']","['Amikacin/adverse effects/therapeutic use', 'Ampicillin/adverse effects/therapeutic use', 'Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Aztreonam/adverse effects/therapeutic use', 'Bias', 'Cefazolin/adverse effects/therapeutic use', 'Clavulanic Acid/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Floxacillin/adverse effects/therapeutic use', 'Gentamicins/adverse effects/therapeutic use', 'Humans', 'Infant, Newborn', 'Neonatal Sepsis/*drug therapy', 'Randomized Controlled Trials as Topic', 'Ticarcillin/adverse effects/therapeutic use', 'Vancomycin/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33998665/
285,aztreonam,8442309,Aztreonam.,['Cunha BA'],"['*Aztreonam/adverse effects/pharmacokinetics/therapeutic use', 'Gram-Negative Aerobic Bacteria/*drug effects', 'Gram-Negative Bacterial Infections/*drug therapy', 'Humans', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8442309/
286,aztreonam,38258529,Ceftazidime-avibactam and aztreonam combination for Carbapenem-resistant Enterobacterales bloodstream infections with presumed Metallo-beta-lactamase production: a systematic review and meta-analysis.,"['Gupta N', 'Boodman C', 'Prayag P', 'Manesh A', 'Kumar TP']","['Humans', '*Anti-Bacterial Agents/pharmacology/administration & dosage', '*Azabicyclo Compounds/pharmacology/administration & dosage', '*Aztreonam/pharmacology/administration & dosage', 'Bacteremia/drug therapy/microbiology/mortality', 'beta-Lactamases/metabolism', '*Carbapenem-Resistant Enterobacteriaceae/drug effects/isolation & purification', '*Ceftazidime/pharmacology/administration & dosage', 'Drug Combinations', 'Drug Therapy, Combination', '*Enterobacteriaceae Infections/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/38258529/
287,aztreonam,15123864,Aztreonam.,"['Kapoor S', 'Gathwala G']","['Anti-Bacterial Agents/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Aztreonam/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Child', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/15123864/
288,aztreonam,31828337,Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study.,"['Cornely OA', 'Cisneros JM', 'Torre-Cisneros J', 'Rodriguez-Hernandez MJ', 'Tallon-Aguilar L', 'Calbo E', 'Horcajada JP', 'Queckenberg C', 'Zettelmeyer U', 'Arenz D', 'Rosso-Fernandez CM', 'Jimenez-Jorge S', 'Turner G', 'Raber S', ""O'Brien S"", 'Luckey A']","['Adult', 'Anti-Bacterial Agents/adverse effects', 'Azabicyclo Compounds/adverse effects', '*Aztreonam/adverse effects', 'Ceftazidime', 'Drug Combinations', 'Humans', '*Intraabdominal Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31828337/
289,aztreonam,38277033,Evaluation of the MTS aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-beta-lactamase-producing Enterobacterales.,"['Emilie CM', 'Alice CM', 'Marine G', 'Farfour E', 'Pourbaix A', 'Dortet L', 'Lucie L', 'Marc V']","['Humans', '*Aztreonam/pharmacology', '*Anti-Bacterial Agents/pharmacology/therapeutic use', 'Ceftazidime/therapeutic use', 'beta-Lactamases', 'Drug Combinations', 'Microbial Sensitivity Tests', '*Azabicyclo Compounds']",https://pubmed.ncbi.nlm.nih.gov/38277033/
290,aztreonam,38289725,Sequential Treatment Failure With Aztreonam-Ceftazidime-Avibactam Followed by Cefiderocol Due to Preexisting and Acquired Mechanisms in a New Delhi Metallo-beta-lactamase-Producing Escherichia coli Causing Fatal Bloodstream Infection.,"['Senchyna F', 'Murugesan K', 'Rotunno W', 'Nadimpalli SS', 'Deresinski S', 'Banaei N']","['Humans', '*Azabicyclo Compounds/therapeutic use/administration & dosage', '*beta-Lactamases/genetics/metabolism', '*Aztreonam/therapeutic use/administration & dosage/pharmacology', '*Drug Combinations', '*Ceftazidime/therapeutic use/administration & dosage', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', '*Escherichia coli/drug effects/genetics/enzymology/isolation & purification', '*Escherichia coli Infections/drug therapy/microbiology', 'Fatal Outcome', '*Cefiderocol', '*Bacteremia/drug therapy/microbiology', '*Cephalosporins/therapeutic use/administration & dosage', '*Treatment Failure', 'Microbial Sensitivity Tests', 'Male', 'Drug Resistance, Multiple, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/38289725/
291,aztreonam,2230052,Aztreonam.,"['Tunkel AR', 'Scheld WM']","['*Aztreonam/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Bacterial Infections/*drug therapy', 'Gram-Negative Bacteria/drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2230052/
292,aztreonam,37982631,"In vitro activity of ceftazidime-avibactam, imipenem-relebactam, aztreonam-avibactam, and comparators toward carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates.","['Li D', 'Yu H', 'Huang X', 'Long S', 'Zhang J']","['Humans', 'Aztreonam/pharmacology/therapeutic use', 'Klebsiella pneumoniae', 'Bacterial Proteins', 'beta-Lactamases', 'Anti-Bacterial Agents/pharmacology/therapeutic use', '*Carbapenem-Resistant Enterobacteriaceae', 'Imipenem/pharmacology/therapeutic use', 'Carbapenems/pharmacology/therapeutic use', '*Klebsiella Infections/drug therapy/microbiology', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/37982631/
293,aztreonam,7791420,Aztreonam.,"['Johnson DH', 'Cunha BA']","['Aztreonam/pharmacokinetics/*therapeutic use', 'Gram-Negative Bacterial Infections/*drug therapy', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/7791420/
294,aztreonam,34397982,Evaluation of Antibiotic Allergies in Surgical Patients.,"['Larry RC', 'Bertram CM']","['Aminoglycosides/administration & dosage/adverse effects', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Aztreonam/administration & dosage/adverse effects', 'Cefazolin/administration & dosage/adverse effects', 'Clindamycin/administration & dosage/adverse effects', 'Drug Hypersensitivity/diagnosis/immunology', 'Humans', 'Hypersensitivity/*diagnosis', 'Retrospective Studies', 'Vancomycin/administration & dosage/adverse effects', 'beta-Lactams/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34397982/
295,aztreonam,39389071,"Aztreonam-avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trial.","['Carmeli Y', 'Cisneros JM', 'Paul M', 'Daikos GL', 'Wang M', 'Torre-Cisneros J', 'Singer G', 'Titov I', 'Gumenchuk I', 'Zhao Y', 'Jimenez-Rodriguez RM', 'Liang L', 'Chen G', 'Pyptiuk O', 'Aksoy F', 'Rogers H', 'Wible M', 'Arhin FF', 'Luckey A', 'Leaney JL', 'Pypstra R', 'Chow JW']","['Humans', 'Male', 'Female', '*Aztreonam/therapeutic use/administration & dosage', '*Meropenem/therapeutic use', 'Middle Aged', '*Anti-Bacterial Agents/therapeutic use/adverse effects', 'Aged', '*Gram-Negative Bacterial Infections/drug therapy/mortality', '*Intraabdominal Infections/drug therapy/microbiology', 'Prospective Studies', '*Azabicyclo Compounds/therapeutic use/adverse effects', 'Adult', 'Gram-Negative Bacteria/drug effects', 'Pneumonia, Ventilator-Associated/drug therapy/microbiology', 'Drug Combinations', 'Treatment Outcome', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/39389071/
296,aztreonam,20836577,Aztreonam lysine for inhalation solution: in cystic fibrosis.,['Plosker GL'],"['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Aztreonam/administration & dosage/adverse effects/*therapeutic use', 'Cystic Fibrosis/*drug therapy/microbiology', 'Humans', 'Lysine/administration & dosage/adverse effects/*therapeutic use', 'Pharmaceutical Solutions', 'Pseudomonas Infections/drug therapy/microbiology', 'Pseudomonas aeruginosa/drug effects']",https://pubmed.ncbi.nlm.nih.gov/20836577/
297,aztreonam,1436929,Aztreonam.,['Clark P'],"['*Aztreonam/adverse effects/chemistry/therapeutic use', 'Bacterial Infections/*drug therapy', 'Costs and Cost Analysis', 'Female', 'Genital Diseases, Female/*drug therapy/microbiology', 'Humans', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1436929/
298,aztreonam,22029514,Aztreonam inhalation solution for suppressive treatment of chronic Pseudomonas aeruginosa lung infection in cystic fibrosis.,['Assael BM'],"['Administration, Inhalation', 'Adolescent', 'Adult', 'Aerosols', 'Anti-Bacterial Agents/*pharmacokinetics/therapeutic use', 'Aztreonam/*pharmacokinetics/therapeutic use', 'Bacterial Load', 'Child', 'Chronic Disease', 'Cystic Fibrosis/complications/*physiopathology', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Humans', 'Lung/*drug effects/microbiology/physiopathology', 'Nebulizers and Vaporizers', 'Pseudomonas Infections/complications/*drug therapy/microbiology/physiopathology', 'Pseudomonas aeruginosa/*drug effects/physiology', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22029514/
299,aztreonam,1902290,The use of aztreonam in pediatric patients: a review.,"['Bosso JA', 'Black PG']","['Adult', 'Aztreonam/administration & dosage/pharmacokinetics/*therapeutic use', 'Bacterial Infections/*drug therapy', '*Gram-Negative Aerobic Bacteria', 'Humans', 'Infant, Newborn', 'Meningitis/drug therapy', 'Pseudomonas aeruginosa', 'Respiratory Tract Infections/drug therapy', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1902290/
300,atenolol,17686376,The vasodilatory beta-blockers.,"['Pedersen ME', 'Cockcroft JR']","['Adrenergic beta-Antagonists/adverse effects/*pharmacology/*therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Antioxidants/pharmacology/therapeutic use', 'Atenolol/pharmacology/therapeutic use', 'Benzopyrans/pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiac Output/drug effects', 'Cardiovascular Diseases/physiopathology/prevention & control', 'Carvedilol', 'Endothelium, Vascular/*drug effects', 'Ethanolamines/pharmacology/therapeutic use', 'Hemodynamics/*drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Nebivolol', 'Propanolamines/pharmacology/therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilation/*drug effects', 'Ventricular Function, Left/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17686376/
301,atenolol,18404602,Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension.,"['Gojanovic B', 'Feihl F', 'Liaudet L', 'Waeber B']","['Adult', 'Aged', 'Angiotensin II/antagonists & inhibitors', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Atenolol/administration & dosage', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination', 'Enzyme Inhibitors/adverse effects/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Indoles/administration & dosage', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/*drug effects', 'Sympathetic Nervous System/drug effects', 'Verapamil/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18404602/
302,atenolol,2871805,Use of beta adrenoceptor blockade during and after acute myocardial infarction.,['Sleight P'],"['Adrenergic beta-Antagonists/*therapeutic use', 'Arrhythmias, Cardiac/drug therapy', 'Atenolol/administration & dosage/therapeutic use', 'Cardiotonic Agents/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Fibrinolytic Agents/administration & dosage', 'Heart Rupture/prevention & control', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/therapeutic use', 'Myocardial Infarction/*drug therapy/mortality/prevention & control', 'Random Allocation', 'Retrospective Studies', 'Risk', 'Streptokinase/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2871805/
303,atenolol,2508047,New antiarrhythmic agents in pediatrics.,"['Case CL', 'Trippel DL', 'Gillette PC']","['Action Potentials/drug effects', 'Amiodarone/pharmacology', 'Anilides/pharmacology', 'Anti-Arrhythmia Agents/administration & dosage/pharmacokinetics/*pharmacology', 'Atenolol/pharmacology', 'Child', 'Child, Preschool', 'Encainide', 'Flecainide/pharmacology', 'Heart Conduction System/drug effects', 'Humans', 'Infant', '*Pediatrics']",https://pubmed.ncbi.nlm.nih.gov/2508047/
304,atenolol,15616067,Atenolol administration via a nasogastric tube after abdominal surgery: an unreliable route.,"['Gosgnach M', 'Aymard G', 'Huraux C', 'Fleron MH', 'Coriat P', 'Diquet B']","['Abdomen/*surgery', 'Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics', 'Area Under Curve', 'Atenolol/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Half-Life', 'Heart Rate/drug effects', 'Humans', '*Intubation, Gastrointestinal']",https://pubmed.ncbi.nlm.nih.gov/15616067/
305,atenolol,3288468,"Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Potassium/blood', 'Random Allocation', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/3288468/
306,atenolol,22149523,Carvedilol: a third-generation beta-blocker should be a first-choice beta-blocker.,"['DiNicolantonio JJ', 'Hackam DG']","['Adrenergic beta-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Animals', 'Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Atenolol/adverse effects/pharmacokinetics/therapeutic use', 'Biomarkers/blood', 'Carbazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Carvedilol', 'Humans', 'Hypertension/blood/*drug therapy/metabolism/physiopathology', 'Metoprolol/adverse effects/pharmacokinetics/therapeutic use', 'Myocardial Infarction/etiology/prevention & control', 'Propanolamines/adverse effects/pharmacokinetics/*therapeutic use', 'Secondary Prevention', 'Sympathetic Nervous System/drug effects', 'Vasodilator Agents/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22149523/
307,atenolol,9850301,Irbesartan treatment in hypertension.,['Brown MJ'],"['Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Atenolol/therapeutic use', 'Biphenyl Compounds/pharmacokinetics/*therapeutic use', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Renin-Angiotensin System/drug effects', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9850301/
308,atenolol,1897264,A comparison of Chinese traditional and Western medical approaches for the treatment of mild hypertension.,"['Wong ND', 'Ming S', 'Zhou HY', 'Black HR']","['Aged', 'Atenolol/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'China', 'Diastole', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', '*Medicine, Chinese Traditional', 'Middle Aged', 'Multivariate Analysis', 'Systole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/1897264/
309,atenolol,4044884,Treatment of social phobia with atenolol.,"['Gorman JM', 'Liebowitz MR', 'Fyer AJ', 'Campeas R', 'Klein DF']","['Adult', 'Atenolol/adverse effects/*therapeutic use', 'Autonomic Nervous System/physiopathology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phobic Disorders/*drug therapy/physiopathology', 'Social Behavior']",https://pubmed.ncbi.nlm.nih.gov/4044884/
310,atenolol,9631898,Septal panniculitis induced by atenolol--a case report.,"['Fragasso G', 'Ciboddo G', 'Pagnotta P', 'Chierchia SL']","['Adrenergic beta-Antagonists/*adverse effects/therapeutic use', 'Aged', 'Angina, Unstable/drug therapy', 'Atenolol/*adverse effects/therapeutic use', 'Female', 'Humans', 'Panniculitis/*chemically induced', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/9631898/
311,atenolol,1590224,Safety of combined intravenous beta-adrenergic blockade (atenolol or metoprolol) and thrombolytic therapy in acute myocardial infarction.,"['Green BK', 'Gordon GD', 'Horak AR', 'Millar RN', 'Commerford PJ']","['Administration, Oral', 'Adult', 'Aspirin/therapeutic use', 'Atenolol/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Metoprolol/*administration & dosage/adverse effects', 'Middle Aged', 'Myocardial Infarction/*drug therapy/mortality/pathology', 'Recurrence', '*Thrombolytic Therapy']",https://pubmed.ncbi.nlm.nih.gov/1590224/
312,atenolol,2872875,Long-acting beta-adrenergic antagonists as preparation for surgery in thyrotoxicosis.,"['Gerst PH', 'Fildes J', 'Baylor P', 'Zonszein J']","['Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Atenolol/administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Female', 'Graves Disease/*surgery', 'Humans', 'Middle Aged', 'Nadolol', '*Premedication', 'Propanolamines/administration & dosage/therapeutic use', 'Pulse/drug effects', '*Thyroidectomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2872875/
313,atenolol,1671244,How much drug in the tablet?,['Herxheimer A'],"['Aged', 'Atenolol/administration & dosage', 'Biological Availability', '*Chemistry, Pharmaceutical', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Mathematics', 'Middle Aged', 'Pharmacokinetics', 'Product Surveillance, Postmarketing/*standards', 'Tablets/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/1671244/
314,atenolol,28601540,Atrial Fibrillation in Anaphylaxis.,"['Rojas-Perez-Ezquerra P', 'Noguerado-Mellado B', 'Morales-Cabeza C', 'Zambrano Ibarra G', 'Datino Romaniega T']","['Actinidia/adverse effects/immunology', 'Administration, Intravenous', 'Adult', 'Aged, 80 and over', 'Anaphylaxis/*complications/drug therapy/etiology', 'Animals', 'Anisakis/immunology/parasitology', 'Anti-Arrhythmia Agents/administration & dosage/immunology/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Arachis/adverse effects/immunology', 'Atenolol/*administration & dosage/immunology/therapeutic use', 'Atrial Fibrillation/drug therapy/*etiology', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Chlorpheniramine/*administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Epinephrine/administration & dosage/*therapeutic use', 'Food Hypersensitivity/*complications/diagnosis/drug therapy/etiology', 'Gadiformes/immunology/parasitology', 'Histamine H1 Antagonists/administration & dosage/therapeutic use', 'Humans', 'Hypodermoclysis', 'Male', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Urticaria/*complications/etiology/immunology']",https://pubmed.ncbi.nlm.nih.gov/28601540/
315,atenolol,3049118,"The efficacy and tolerability of atenolol, nifedipine, and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Patient Compliance', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3049118/
316,atenolol,15581720,[Perioperative administration of betablockers: a practice survey].,"['Danton N', 'Viale JP', 'Gueugniaud PY', 'Lehot JJ', 'Piriou V']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Anesthesiology/*trends', 'Atenolol/adverse effects/therapeutic use', 'Attitude of Health Personnel', 'Data Collection', 'France', 'Humans', '*Perioperative Care', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/15581720/
317,atenolol,9504355,Nebivolol vs atenolol and placebo in essential hypertension: a double-blind randomised trial.,"['Van Nueten L', 'Taylor FR', 'Robertson JI']","['Adolescent', 'Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Aged', 'Atenolol/adverse effects/*therapeutic use', 'Benzopyrans/adverse effects/*therapeutic use', 'Double-Blind Method', 'Ethanolamines/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nebivolol']",https://pubmed.ncbi.nlm.nih.gov/9504355/
318,atenolol,8004839,Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.,"['Ram CV', 'Ames RP', 'Applegate WB', 'Burris JF', 'Davidov ME', 'Mroczek WJ']","['Adolescent', 'Adult', 'Aged', 'Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Atenolol/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Cholesterol/blood', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Cholesterol, VLDL/blood', 'Double-Blind Method', 'Drug Combinations', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pulse/drug effects', 'Safety', 'Single-Blind Method', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/8004839/
319,atenolol,8491252,Dose proportional absorption of 25-150 mg atenolol.,"['Wakelkamp M', 'Alvan G', 'Paintaud G', 'Hedman A']","['Administration, Oral', 'Adult', 'Atenolol/administration & dosage/*pharmacokinetics', 'Biological Availability', 'Female', 'Humans', '*Intestinal Absorption', 'Male']",https://pubmed.ncbi.nlm.nih.gov/8491252/
320,ciprofloxacin,3292209,"Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.","['Campoli-Richards DM', 'Monk JP', 'Price A', 'Benfield P', 'Todd PA', 'Ward A']","['Animals', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/pharmacokinetics/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/3292209/
321,ciprofloxacin,2667104,Tolerance of intravenous ciprofloxacin.,"['Thorsteinsson SB', 'Rahm V', 'Bergan T']","['Ciprofloxacin/*administration & dosage/adverse effects', 'Drug Tolerance', 'Evaluation Studies as Topic', 'Humans', 'Infusions, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/2667104/
322,ciprofloxacin,3281368,Ciprofloxacin in management of urinary tract infection.,"['Tolkoff-Rubin NE', 'Rubin RH']","['Bacterial Infections/*drug therapy', 'Ciprofloxacin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Microbial Sensitivity Tests', 'Prostatitis/drug therapy', 'Urinary Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3281368/
323,ciprofloxacin,21075583,Ciprofloxacin-induced torsade de pointes.,"['Ibrahim M', 'Omar B']","['Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Electrocardiography', 'Heart/drug effects/physiopathology', 'Humans', 'Male', 'Torsades de Pointes/*chemically induced/physiopathology', 'Treatment Outcome', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21075583/
324,ciprofloxacin,19534690,Efficacy of fluoroquinolones against pathogenic oral bacteria.,"['Nunez Otero V', 'Limeres Posse J', 'Carmona IT', 'Diz Dios P']","['Aza Compounds/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Fluoroquinolones/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', '*Levofloxacin', 'Mouth Diseases/*drug therapy', 'Moxifloxacin', 'Ofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', '*Oral Medicine', 'Quinolines/chemistry/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19534690/
325,ciprofloxacin,15243351,"[Pharmacokinetics and dose adaptation of ofloxacine, pefloxacine and ciprofloxacine during haemodialysis and continuous ambulatory peritoneal dialysis].","['Daniel JP', 'Moulin B', 'Christmann D']","['Anti-Infective Agents/*administration & dosage/*pharmacokinetics', 'Ciprofloxacin/*administration & dosage/*pharmacokinetics', 'Fluoroquinolones/*administration & dosage/*pharmacokinetics', 'Humans', 'Kidney Failure, Chronic/*metabolism', 'Ofloxacin/*administration & dosage/*pharmacokinetics', '*Peritoneal Dialysis, Continuous Ambulatory', '*Renal Dialysis', 'Pefloxacin']",https://pubmed.ncbi.nlm.nih.gov/15243351/
326,ciprofloxacin,38970065,"An open-label, randomized, non-inferiority trial of the efficacy and safety of ciprofloxacin versus an aminoglycoside + ciprofloxacin in the treatment of bubonic plague (IMASOY): study protocol for a randomized control trial-an update to the published protocol.","['Randremanana RV', 'Raberahona M', 'de Dieu Randria MJ', 'Bourner J', 'Zadonirina G', 'Razananaivo H', 'Mayouya-Gamana T', 'Mangahasimbola R', 'Pesonel E', 'Gillesen A', 'Rajerison M', 'Andrianaivoarimanana V', 'Edwards T', 'Horby P', 'Olliaro P']","['*Ciprofloxacin/adverse effects/administration & dosage/therapeutic use', 'Treatment Outcome', 'Humans', '*Anti-Bacterial Agents/adverse effects/administration & dosage/therapeutic use', 'Plague/drug therapy', 'Randomized Controlled Trials as Topic', 'Equivalence Trials as Topic', 'Drug Therapy, Combination', 'Animals', 'Aminoglycosides/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38970065/
327,ciprofloxacin,12869605,Fluoroquinolone therapy and Achilles tendon rupture.,"['Vanek D', 'Saxena A', 'Boggs JM']","['Achilles Tendon/*drug effects', 'Adult', 'Aged', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Muscular Diseases/chemically induced', 'Risk Factors', 'Rupture', 'Tendon Injuries/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12869605/
328,ciprofloxacin,25680964,[DRESS syndrome induced by ciprofloxacine].,"['Sahnoun R', 'El Aidli S', 'Zaiem A', 'Lakhoua G', 'Kastalli S', 'Daghfous R']","['Anti-Bacterial Agents/*adverse effects', 'Ciprofloxacin/*adverse effects', 'Drug Hypersensitivity Syndrome/*etiology', 'Female', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25680964/
329,ciprofloxacin,29637871,Community Acquired Pseudomonas Aeruginosa Pneumonia in a Young Athlete Man: A Case Report and Literature Review.,"['Rahdar HA', 'Kazemian H', 'Bimanand L', 'Shahraki-Zahedani S', 'Feyisa SG', 'Taki E', 'Havaei SA', 'Karami-Zarandi M']","['Adult', '*Athletes', 'Ciprofloxacin/administration & dosage/therapeutic use', 'Community-Acquired Infections/complications/*diagnosis/drug therapy/microbiology', 'Cross Infection/complications/diagnosis/drug therapy/microbiology', 'Fatal Outcome', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pneumonia/complications/*diagnosis/drug therapy/microbiology', 'Pseudomonas Infections/complications/*diagnosis/drug therapy/microbiology', 'Pseudomonas aeruginosa/drug effects/*pathogenicity', 'Risk Factors', 'Smoking/adverse effects', 'Thoracic Injuries/complications', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/29637871/
330,ciprofloxacin,2924060,Ciprofloxacin.,"['Smyth EG', 'Pallet AP']","['Ciprofloxacin/pharmacokinetics/pharmacology/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2924060/
331,ciprofloxacin,22645722,Inhaled antibiotics for lower respiratory tract infections: focus on ciprofloxacin.,['Serisier DJ'],"['Administration, Inhalation', 'Animals', 'Anti-Bacterial Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Bronchiectasis/drug therapy', 'Ciprofloxacin/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cystic Fibrosis/*drug therapy', 'Humans', 'Liposomes/administration & dosage', 'Nebulizers and Vaporizers', 'Pseudomonas Infections/drug therapy', 'Pulmonary Disease, Chronic Obstructive/drug therapy', 'Respiratory Tract Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22645722/
332,ciprofloxacin,18979434,[Fluorquinolone associated tendon rupture].,"['Ratz Bravo A', 'Stoll R', 'Burr P', 'Haschke M']","['Achilles Tendon/*drug effects/injuries', 'Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Athletic Injuries/*chemically induced', 'Chlamydia Infections/drug therapy', 'Ciprofloxacin/adverse effects/therapeutic use', 'Female', 'Fluoroquinolones/*adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Ofloxacin/adverse effects/therapeutic use', 'Risk Factors', 'Rupture, Spontaneous', 'Soccer/*injuries', 'Switzerland', 'Tendon Injuries/*chemically induced', 'Urethritis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18979434/
333,ciprofloxacin,31556841,Evolving Antibiotic Resistance of Aeromonas Species in Finger Replantation.,"['Mokhtar K', 'Culnan DM', 'Lineaweaver WC']","['Aeromonas/*drug effects', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Cefepime/pharmacology/therapeutic use', 'Ciprofloxacin/pharmacology/therapeutic use', 'Drug Resistance, Microbial/*drug effects', 'Humans', 'Leeching/adverse effects/*methods', 'Microbial Sensitivity Tests', 'Replantation/adverse effects/*methods']",https://pubmed.ncbi.nlm.nih.gov/31556841/
334,ciprofloxacin,23256815,Medicinal potential of ciprofloxacin and its derivatives.,"['Castro W', 'Navarro M', 'Biot C']","['Acquired Immunodeficiency Syndrome/drug therapy', 'Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Ciprofloxacin/analogs & derivatives/pharmacology/*therapeutic use', 'Humans', 'Malaria, Falciparum/drug therapy', 'Microbial Sensitivity Tests', 'Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23256815/
335,ciprofloxacin,22186073,[Efficacy and future of the aerosoltherapy in the treatment of cystic fibrosis patients infected by Pseudomonas aeruginosa].,"['Rognon A', 'Curti C', 'Montana M', 'Terme T', 'Rathelot P', 'Vanelle P']","['Administration, Inhalation', 'Aerosols', 'Amikacin/administration & dosage/adverse effects/therapeutic use', 'Anti-Infective Agents/*administration & dosage/adverse effects/*therapeutic use', 'Ciprofloxacin/administration & dosage/therapeutic use', 'Colistin/administration & dosage/adverse effects/therapeutic use', 'Cystic Fibrosis/*complications', 'Drug Therapy, Combination', 'Fluoroquinolones/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Pseudomonas Infections/*drug therapy/*etiology/microbiology', 'Pseudomonas aeruginosa/drug effects', 'Tobramycin/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22186073/
336,ciprofloxacin,26164023,Ciprofloxacin as a Trigger for Bullous Pemphigoid: The Second Case in the Literature.,"['Cozzani E', 'Chinazzo C', 'Burlando M', 'Romagnoli M', 'Parodi A']","['Administration, Oral', 'Aged, 80 and over', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Humans', 'Pemphigoid, Bullous/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/26164023/
337,ciprofloxacin,25189336,Bilateral Achilles Tendon Ruptures Associated With Ciprofloxacin Use in the Setting of Minimal Change Disease: Case Report and Review of the Literature.,"['Kawtharani F', 'Masrouha KZ', 'Afeiche N']","['Achilles Tendon/diagnostic imaging/*drug effects/pathology', 'Aged', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Ciprofloxacin/*adverse effects/therapeutic use', 'Cross Infection/drug therapy', 'Glucocorticoids/administration & dosage', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Nephrosis, Lipoid/complications/*drug therapy', 'Pneumonia/drug therapy', 'Rupture', 'Tendon Injuries/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25189336/
338,ciprofloxacin,1504404,Ciprofloxacin-induced psychosis.,['Reeves RR'],"['Ciprofloxacin/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Psychoses, Substance-Induced/drug therapy/*etiology', 'Thiothixene/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1504404/
339,ciprofloxacin,2055655,"MICs of ciprofloxacin and trimethoprim for Escherichia coli: influence of pH, inoculum size and various body fluids.","['Aagaard J', 'Gasser T', 'Rhodes P', 'Madsen PO']","['Animals', 'Body Fluids/chemistry/drug effects/microbiology', 'Chronic Disease', 'Ciprofloxacin/administration & dosage/pharmacology/*therapeutic use', 'Dogs', 'Dose-Response Relationship, Drug', 'Escherichia coli Infections/*drug therapy/microbiology/urine', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Prostatitis/*drug therapy/microbiology/urine', 'Trimethoprim/administration & dosage/pharmacology/*therapeutic use', 'Urine/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2055655/
340,ondansetron,7586904,Ondansetron clinical pharmacokinetics.,"['Roila F', 'Del Favero A']","['Animals', 'Humans', 'Ondansetron/chemistry/*pharmacokinetics/pharmacology', 'Serotonin Antagonists/chemistry/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7586904/
341,ondansetron,38311315,The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).,"['Nelson-Piercy C', 'Dean C', 'Shehmar M', 'Gadsby R', ""O'Hara M"", 'Hodson K', 'Nana M']","['Humans', 'Female', 'Pregnancy', '*Hyperemesis Gravidarum/therapy/diagnosis', '*Antiemetics/therapeutic use/administration & dosage', '*Ondansetron/therapeutic use/administration & dosage', 'Morning Sickness/therapy', 'Nausea/etiology/therapy', 'Pyridoxine/therapeutic use/administration & dosage', 'Metoclopramide/therapeutic use/administration & dosage', 'Severity of Illness Index', 'Pregnancy Complications/drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/38311315/
342,ondansetron,38409683,Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis.,"['Ismail S', 'Funk MJ', 'Flythe JE']","['Humans', '*Renal Dialysis/adverse effects', '*Death, Sudden, Cardiac/etiology', '*Ondansetron/therapeutic use/adverse effects', 'Male', 'Female', 'Middle Aged', 'Kidney Failure, Chronic/therapy/complications/mortality', 'Antiemetics/adverse effects/therapeutic use', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38409683/
343,ondansetron,27730793,Ondansetron-Induced Life Threatening Hypokalemia.,"['Mathew SK', 'Kutty KK', 'Ramya I', 'Padmakumar C', 'Pius P']","['Antiemetics/*administration & dosage/*adverse effects', 'Fever/etiology', 'Humans', 'Hypokalemia/*chemically induced', 'Male', 'Middle Aged', 'Muscle Hypotonia/*etiology', 'Nausea/*drug therapy/etiology', 'Ondansetron/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27730793/
344,ondansetron,8427720,Ondansetron.,"['Roila F', 'Tonato M', 'Basurto C', 'Bracarda S', 'Sassi M', 'Lupattelli M', 'Picciafuoco M', 'Ballatori E', 'Del Favero A']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Cisplatin/therapeutic use', 'Dexamethasone/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Ondansetron/*therapeutic use', '*Serotonin Antagonists', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/8427720/
345,ondansetron,27678496,Inadvertent spinal injection of ondansetron.,"['Loh MH', 'Lean LL', 'Ng BSW', 'Loh WN']","['Adult', 'Analgesics, Opioid/administration & dosage', 'Anesthesia, Spinal/*methods', 'Cesarean Section/*methods', 'Female', 'Humans', 'Injections, Spinal', 'Ondansetron/*administration & dosage/adverse effects', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/27678496/
346,ondansetron,8478782,An overview of ondansetron for chemotherapy-induced nausea and emesis.,['San Angel F'],"['Antineoplastic Agents/*adverse effects', 'Clinical Trials as Topic', 'Humans', 'Nausea/chemically induced/*drug therapy/nursing', 'Ondansetron/adverse effects/pharmacology/*therapeutic use', 'Vomiting/chemically induced/*drug therapy/nursing']",https://pubmed.ncbi.nlm.nih.gov/8478782/
347,ondansetron,31730152,Intravenous Ondansetron in Pregnancy and Risk of Congenital Malformations.,"['Huybrechts KF', 'Hernandez-Diaz S', 'Straub L', 'Gray KJ', 'Zhu Y', 'Mogun H', 'Bateman BT']","['*Abnormalities, Drug-Induced', 'Administration, Oral', 'Adult', 'Antiemetics/administration & dosage/*adverse effects', 'Cleft Lip/chemically induced', 'Cleft Palate/chemically induced', 'Female', 'Follow-Up Studies', 'Heart Defects, Congenital/chemically induced', 'Humans', 'Injections, Intravenous', 'Nausea/drug therapy', 'Ondansetron/administration & dosage/*adverse effects', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Trimester, First', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/31730152/
348,ondansetron,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
349,ondansetron,19490041,Ondansetron and seizures.,"['Singh NN', 'Rai A', 'Selhorst JB', 'Acharya JN']","['Adult', 'Electroencephalography', 'Epilepsy/drug therapy/physiopathology', 'Epilepsy, Tonic-Clonic/chemically induced', 'Female', 'Follow-Up Studies', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Migraine Disorders/drug therapy', 'Nausea/drug therapy', 'Ondansetron/administration & dosage/*adverse effects/*therapeutic use', 'Receptors, Serotonin/drug effects/physiology', 'Recurrence', 'Seizures/*chemically induced/physiopathology', 'Serotonin/physiology', 'Serotonin Antagonists/administration & dosage/*adverse effects/*therapeutic use', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19490041/
350,ondansetron,1425627,Safety of ondansetron.,"['Castle WM', 'Jukes AJ', 'Griffiths CJ', 'Roden SM', 'Greenstreet YL']","['Drug Tolerance', 'Humans', 'Ondansetron/adverse effects/*therapeutic use', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/1425627/
351,ondansetron,38723364,Surgical removal of extended-release buprenorphine depot due to adverse reactions.,"['Burton A', 'DeBona DJ', 'Handzel M', 'Kelly-Pisciotti S', 'Qiao M', 'Rojek D', 'Acquisto NM']","['Delayed-Action Preparations/administration & dosage/adverse effects', 'Drug Implants', '*Buprenorphine/administration & dosage/adverse effects', '*Opioid-Related Disorders/drug therapy', '*Narcotic Antagonists/administration & dosage/adverse effects', 'Nausea/chemically induced/therapy', 'Vomiting/chemically induced/therapy', 'Emergency Service, Hospital', 'Tachycardia/chemically induced/therapy', 'Hyperglycemia/chemically induced/therapy', 'Humans', 'Male', 'Adult', 'Injections, Subcutaneous', 'Ondansetron/pharmacology/therapeutic use', 'Drug Resistance', 'Antiemetics/pharmacology/therapeutic use', 'Device Removal']",https://pubmed.ncbi.nlm.nih.gov/38723364/
352,ondansetron,11925283,Ondansetron in the treatment of cognitive decline in Alzheimer dementia.,"['Dysken M', 'Kuskowski M', 'Love S']","['Aged', 'Alzheimer Disease/complications/*drug therapy/psychology', 'Cognition Disorders/*drug therapy/etiology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Neuropsychological Tests', 'Ondansetron/*adverse effects/*therapeutic use', 'Serotonin Antagonists/*adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11925283/
353,ondansetron,7795925,Ondansetron and opiate craving. A novel pharmacological approach to addiction.,"['Sell LA', 'Cowen PJ', 'Robson PJ']","['Female', 'Humans', 'Male', 'Methadone/administration & dosage/*therapeutic use', '*Narcotics', 'Ondansetron/administration & dosage/*therapeutic use', 'Substance Withdrawal Syndrome/diagnosis/*drug therapy', '*Substance-Related Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7795925/
354,ondansetron,7965657,"Ondansetron absorption in adults: effect of dosage form, food, and antacids.","['Bozigian HP', 'Pritchard JF', 'Gooding AE', 'Pakes GE']","['Absorption', 'Administration, Oral', 'Adult', 'Antacids/*pharmacology', 'Biological Availability', 'Chemistry, Pharmaceutical', 'Cross-Over Studies', 'Drug Interactions', 'Fasting', 'Food', 'Humans', 'Male', 'Ondansetron/*administration & dosage/*pharmacokinetics/pharmacology', 'Solutions', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/7965657/
355,ondansetron,24314899,Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis.,"['Freedman SB', 'Uleryk E', 'Rumantir M', 'Finkelstein Y']","['Antiemetics/administration & dosage/*adverse effects', 'Arrhythmias, Cardiac/*chemically induced', 'Emergency Treatment', 'Humans', 'Monitoring, Physiologic', 'Ondansetron/administration & dosage/*adverse effects', '*Product Surveillance, Postmarketing', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/24314899/
356,ondansetron,12962170,Ondansetron-induced multifocal encephalopathy.,"['Ritter MJ', 'Goodman BP', 'Sprung J', 'Wijdicks EF']","['Antiemetics/administration & dosage/*adverse effects', 'Brain Diseases/*chemically induced', 'Dystonia/*chemically induced', 'Female', 'Hand', 'Humans', 'Mandible', 'Middle Aged', 'Mouth', 'Ocular Motility Disorders/*chemically induced', 'Ondansetron/administration & dosage/*adverse effects', 'Postoperative Nausea and Vomiting/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12962170/
357,ondansetron,8239673,[An outline of 5-HT3 receptor antagonists (1)--In pharmacological actions].,"['Tsukagoshi S', 'Ohta J', 'Taguchi T']","['Antiemetics/*pharmacology', 'Antineoplastic Agents/adverse effects', 'Humans', 'Ondansetron/pharmacology', 'Receptors, Serotonin/*drug effects', 'Serotonin Antagonists/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8239673/
358,ondansetron,17279232,Preventing recurrence of severe morning sickness.,"['Koren G', 'Maltepe C']","['Antiemetics/administration & dosage/*therapeutic use', 'Dicyclomine', 'Doxylamine/administration & dosage/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Morning Sickness/*drug therapy/prevention & control', 'Ondansetron/administration & dosage/*therapeutic use', 'Pregnancy', 'Pyridoxine/administration & dosage/therapeutic use', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/17279232/
359,ondansetron,11973189,Ondansetron orally disintegrating tablet versus placebo for the prevention of postdischarge nausea and vomiting after ambulatory surgery.,"['Gan TJ', 'Franiak R', 'Reeves J']","['Administration, Oral', 'Adult', 'Aged', '*Ambulatory Surgical Procedures', 'Antiemetics/*therapeutic use', 'Humans', 'Middle Aged', 'Ondansetron/administration & dosage/*therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/11973189/
360,pantoprazole,38875111,Stress Ulcer Prophylaxis during Invasive Mechanical Ventilation.,"['Cook D', 'Deane A', 'Lauzier F', 'Zytaruk N', 'Guyatt G', 'Saunders L', 'Hardie M', 'Heels-Ansdell D', 'Alhazzani W', 'Marshall J', 'Muscedere J', 'Myburgh J', 'English S', 'Arabi YM', 'Ostermann M', 'Knowles S', 'Hammond N', 'Byrne KM', 'Chapman M', 'Venkatesh B', 'Young P', 'Rajbhandari D', 'Poole A', 'Al-Fares A', 'Reis G', 'Johnson D', 'Iqbal M', 'Hall R', 'Meade M', 'Hand L', 'Duan E', 'Clarke F', 'Dionne JC', 'Tsang JLY', 'Rochwerg B', 'Karachi T', 'Lamontagne F', ""D'Aragon F"", 'St Arnaud C', 'Reeve B', 'Geagea A', 'Niven D', 'Vazquez-Grande G', 'Zarychanski R', 'Ovakim D', 'Wood G', 'Burns KEA', 'Goffi A', 'Wilcox ME', 'Henderson W', 'Forrest D', 'Fowler R', 'Adhikari NKJ', 'Ball I', 'Mele T', 'Binnie A', 'Trop S', 'Mehta S', 'Morgan I', 'Loubani O', 'Vanstone M', 'Fiest K', 'Charbonney E', 'Cavayas YA', 'Archambault P', 'Rewa OG', 'Lau V', 'Kristof AS', 'Khwaja K', 'Williamson D', 'Kanji S', 'Sy E', 'Dennis B', 'Reynolds S', 'Marquis F', 'Lellouche F', 'Rahman A', 'Hosek P', 'Barletta JF', 'Cirrone R', 'Tutschka M', 'Xie F', 'Billot L', 'Thabane L', 'Finfer S']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Critical Illness/therapy', 'Double-Blind Method', '*Gastrointestinal Hemorrhage/etiology/prevention & control', 'Intensive Care Units', '*Pantoprazole/therapeutic use/adverse effects/administration & dosage', '*Peptic Ulcer/prevention & control', 'Pneumonia, Ventilator-Associated/etiology', '*Proton Pump Inhibitors/therapeutic use/adverse effects/administration & dosage', '*Respiration, Artificial/adverse effects', 'Stress, Physiological']",https://pubmed.ncbi.nlm.nih.gov/38875111/
361,pantoprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
362,pantoprazole,30354950,Pantoprazole in Patients at Risk for Gastrointestinal Bleeding in the ICU.,"['Krag M', 'Marker S', 'Perner A', 'Wetterslev J', 'Wise MP', 'Schefold JC', 'Keus F', 'Guttormsen AB', 'Bendel S', 'Borthwick M', 'Lange T', 'Rasmussen BS', 'Siegemund M', 'Bundgaard H', 'Elkmann T', 'Jensen JV', 'Nielsen RD', 'Liboriussen L', 'Bestle MH', 'Elkjaer JM', 'Palmqvist DF', 'Backlund M', 'Laake JH', 'Badstolokken PM', 'Gronlund J', 'Breum O', 'Walli A', 'Winding R', 'Iversen S', 'Jarnvig IL', 'White JO', 'Brand B', 'Madsen MB', 'Quist L', 'Thornberg KJ', 'Moller A', 'Wiis J', 'Granholm A', 'Anthon CT', 'Meyhoff TS', 'Hjortrup PB', 'Aagaard SR', 'Andreasen JB', 'Sorensen CA', 'Haure P', 'Hauge J', 'Hollinger A', 'Scheuzger J', 'Tuchscherer D', 'Vuilliomenet T', 'Takala J', 'Jakob SM', 'Vang ML', 'Paelestik KB', 'Andersen KLD', 'van der Horst ICC', 'Dieperink W', 'Fjolner J', 'Kjer CKW', 'Solling C', 'Solling CG', 'Karttunen J', 'Morgan MPG', 'Sjobo B', 'Engstrom J', 'Agerholm-Larsen B', 'Moller MH']","['Aged', 'Critical Illness/mortality/*therapy', 'Female', 'Gastrointestinal Hemorrhage/epidemiology/*prevention & control', 'Humans', 'Injections, Intravenous', 'Intensive Care Units', 'Male', 'Middle Aged', 'Pantoprazole/adverse effects/*therapeutic use', 'Peptic Ulcer/*prevention & control', 'Proton Pump Inhibitors/adverse effects/*therapeutic use', 'Risk Factors', 'Single-Blind Method', 'Stress, Physiological', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/30354950/
363,pantoprazole,16520709,Intravenous proton pump inhibitors.,['Baker DE'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage/pharmacokinetics', 'Benzimidazoles/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Drug Interactions', 'Esomeprazole/*administration & dosage/*analogs & derivatives/pharmacokinetics', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Intravenous', 'Lansoprazole', 'Pantoprazole', '*Proton Pump Inhibitors', 'Stomach/chemistry', 'Sulfoxides/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16520709/
364,pantoprazole,37635269,Pharmacological treatment of gastro-oesophageal reflux in children.,"['Tighe MP', 'Andrews E', 'Liddicoat I', 'Afzal NA', 'Hayen A', 'Beattie RM']","['Adolescent', 'Child', 'Humans', 'Infant', 'Infant, Newborn', '*Esomeprazole', '*Gastroesophageal Reflux/complications/drug therapy', 'Omeprazole', 'Pantoprazole', 'Proton Pump Inhibitors/therapeutic use', 'Rabeprazole', 'Ranitidine']",https://pubmed.ncbi.nlm.nih.gov/37635269/
365,pantoprazole,32711578,"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Ochoa D', 'Roman M', 'Cabaleiro T', 'Saiz-Rodriguez M', 'Mejia G', 'Abad-Santos F']","['Adult', 'Anti-Ulcer Agents/blood/*pharmacokinetics', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/genetics', 'Dietary Fats/*administration & dosage', 'Fasting/metabolism', 'Female', '*Food-Drug Interactions', 'Genotype', 'Humans', 'Male', 'Omeprazole/blood/*pharmacokinetics', 'Pantoprazole/blood/*pharmacokinetics', 'Proton Pump Inhibitors/blood/*pharmacokinetics', 'Rabeprazole/blood/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32711578/
366,pantoprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
367,pantoprazole,28913918,Clopidogrel in Critically Ill Patients.,"['Schoergenhofer C', 'Hobl EL', 'Schellongowski P', 'Heinz G', 'Speidl WS', 'Siller-Matula JM', 'Schmid M', 'Sunder-Plassmann R', 'Stimpfl T', 'Hackl M', 'Jilma B']","['Activation, Metabolic', 'Aged', 'Austria', 'Biomarkers/blood', 'Blood Platelets/*drug effects/metabolism', 'Cell Adhesion Molecules/blood', 'Clopidogrel/administration & dosage/adverse effects/blood/*pharmacokinetics', '*Critical Illness', 'Cytochrome P-450 CYP2C19/genetics/metabolism', 'Down-Regulation', 'Drug Monitoring/methods', 'Drug Resistance', 'Female', 'Half-Life', 'Humans', 'Male', 'Microfilament Proteins/blood', 'Middle Aged', 'Pantoprazole/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Phosphoproteins/blood', 'Platelet Aggregation/*drug effects', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Platelet Function Tests', 'Proton Pump Inhibitors/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Vasodilator-Stimulated Phosphoprotein']",https://pubmed.ncbi.nlm.nih.gov/28913918/
368,pantoprazole,15190384,Understanding NSAID-PPI-COX-2 interrelationships.,['Singh G'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Aspirin/adverse effects/therapeutic use', 'Benzimidazoles/therapeutic use', 'Cyclooxygenase Inhibitors/adverse effects/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Helicobacter Infections/*drug therapy', '*Helicobacter pylori', 'Humans', 'Omeprazole/analogs & derivatives', 'Pantoprazole', '*Proton Pump Inhibitors', 'Randomized Controlled Trials as Topic', 'Sulfoxides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15190384/
369,pantoprazole,31152740,"Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.","['Moayyedi P', 'Eikelboom JW', 'Bosch J', 'Connolly SJ', 'Dyal L', 'Shestakovska O', 'Leong D', 'Anand SS', 'Stork S', 'Branch KRH', 'Bhatt DL', 'Verhamme PB', ""O'Donnell M"", 'Maggioni AP', 'Lonn EM', 'Piegas LS', 'Ertl G', 'Keltai M', 'Bruns NC', 'Muehlhofer E', 'Dagenais GR', 'Kim JH', 'Hori M', 'Steg PG', 'Hart RG', 'Diaz R', 'Alings M', 'Widimsky P', 'Avezum A', 'Probstfield J', 'Zhu J', 'Liang Y', 'Lopez-Jaramillo P', 'Kakkar AK', 'Parkhomenko AN', 'Ryden L', 'Pogosova N', 'Dans AL', 'Lanas F', 'Commerford PJ', 'Torp-Pedersen C', 'Guzik TJ', 'Vinereanu D', 'Tonkin AM', 'Lewis BS', 'Felix C', 'Yusoff K', 'Metsarinne KP', 'Fox KAA', 'Yusuf S']","['Aged', 'Aspirin/*administration & dosage/adverse effects', 'Cardiovascular Diseases/diagnosis/*drug therapy', 'Double-Blind Method', 'Drug Administration Schedule', 'Enterocolitis, Pseudomembranous/chemically induced/microbiology', 'Factor Xa Inhibitors/*administration & dosage/adverse effects', 'Female', 'Gastrointestinal Hemorrhage/chemically induced/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Pantoprazole/*administration & dosage/adverse effects', 'Peripheral Arterial Disease/diagnosis/*drug therapy', 'Platelet Aggregation Inhibitors/*administration & dosage/adverse effects', 'Prospective Studies', 'Proton Pump Inhibitors/*administration & dosage/adverse effects', 'Risk Assessment', 'Risk Factors', 'Rivaroxaban/*administration & dosage/adverse effects', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31152740/
370,pantoprazole,38602780,The Effects of Pantoprazole on Kidney Outcomes: Post Hoc Observational Analysis from the COMPASS Trial.,"['Pyne L', 'Smyth A', 'Molnar AO', 'Moayyedi P', 'Muehlhofer E', 'Yusuf S', 'Eikelboom J', 'Bosch J', 'Walsh M']","['Humans', '*Pantoprazole/therapeutic use', '*Proton Pump Inhibitors/therapeutic use/adverse effects', 'Male', 'Female', 'Aged', 'Middle Aged', 'Glomerular Filtration Rate/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38602780/
371,pantoprazole,11402494,Pantoprazole.,['Poole P'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Benzimidazoles/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Enzyme Inhibitors/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Esophagitis/*drug therapy/etiology', 'Gastroesophageal Reflux/complications/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', 'Pantoprazole', '*Proton Pump Inhibitors', 'Sulfoxides/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11402494/
372,pantoprazole,39163076,A Very Rare Side Effect of a Very Commonly Used Drug: Pantoprazole-induced Seizure.,"['Anandan S', 'Rajendran SS', 'Somarajan SA', 'Udayan A']","['*Pantoprazole/adverse effects', 'Humans', '*Proton Pump Inhibitors/adverse effects', '*Seizures/chemically induced', '*Hypocalcemia/chemically induced', '2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects', 'Male', 'Hypokalemia/chemically induced', 'Middle Aged', 'Magnesium Deficiency/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/39163076/
373,pantoprazole,36194219,Effect of a Postoperative Multimodal Opioid-Sparing Protocol vs Standard Opioid Prescribing on Postoperative Opioid Consumption After Knee or Shoulder Arthroscopy: A Randomized Clinical Trial.,"['Gazendam A', 'Ekhtiari S', 'Horner NS', 'Simunovic N', 'Khan M', 'de Sa DL', 'Madden K', 'Ayeni OR']","['Acetaminophen/adverse effects/therapeutic use', 'Adult', '*Analgesics, Non-Narcotic/adverse effects/therapeutic use', '*Analgesics, Opioid/adverse effects/therapeutic use', 'Anti-Ulcer Agents/adverse effects/therapeutic use', '*Arthroscopy', 'Clinical Protocols', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hydromorphone/adverse effects/therapeutic use', '*Knee Joint/surgery', 'Male', 'Naproxen/adverse effects/therapeutic use', 'Ontario', '*Pain, Postoperative/drug therapy/etiology', 'Pantoprazole/adverse effects/therapeutic use', 'Patient Education as Topic', 'Postoperative Care', '*Shoulder Joint/surgery']",https://pubmed.ncbi.nlm.nih.gov/36194219/
374,pantoprazole,25826037,[Exfoliative esophagitis while taking dabigatran].,"['Scheppach W', 'Meesmann M']","['2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', 'Aged', 'Anti-Ulcer Agents/therapeutic use', 'Antithrombins/*adverse effects/therapeutic use', 'Atrial Fibrillation/*drug therapy', 'Benzimidazoles/*adverse effects/therapeutic use', 'Dabigatran', 'Endoscopy, Digestive System', 'Esophagitis/*chemically induced/pathology/therapy', 'Female', 'Fluid Therapy', 'Humans', 'Hypertension/*drug therapy', 'Pantoprazole', 'beta-Alanine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25826037/
375,pantoprazole,36174588,Pantoprazole Induced Acute Interstitial Nephritis in a Patient with Diabetic Ketoacidosis.,"['Tas N', 'Mengen E', 'Goncu S', 'Tasar S', 'Kiremitci S', 'Ucakturk A']","['Humans', 'Child', '*Diabetic Ketoacidosis/chemically induced/diagnosis/complications', 'Pantoprazole/adverse effects', 'Acute Disease', '*Pancreatitis/complications', '*Diabetes Mellitus, Type 1/complications/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36174588/
376,pantoprazole,29315506,Optimization of Voriconazole Therapy for the Treatment of Invasive Fungal Infections in Adults.,"['Mangal N', 'Hamadeh IS', 'Arwood MJ', 'Cavallari LH', 'Samant TS', 'Klinker KP', 'Bulitta J', 'Schmidt S']","['Adult', 'Aged', 'Antifungal Agents/*administration & dosage/adverse effects/blood/pharmacokinetics', 'Aspergillosis/blood/diagnosis/*drug therapy/microbiology', 'Aspergillus/classification/drug effects', 'Candida/classification/drug effects', 'Candidiasis/blood/diagnosis/*drug therapy/microbiology', 'Cytochrome P-450 CYP2C19/genetics/metabolism', '*Drug Dosage Calculations', 'Drug Interactions', 'Drug Monitoring', 'Female', 'Genotype', 'Humans', 'Invasive Fungal Infections/blood/diagnosis/*drug therapy/microbiology', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', '*Models, Biological', 'Pantoprazole/adverse effects', 'Pharmacogenomic Variants', 'Phenotype', 'Proton Pump Inhibitors/adverse effects', 'Risk Assessment', 'Voriconazole/*administration & dosage/adverse effects/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/29315506/
377,pantoprazole,39511890,Proton pump inhibitor attenuates acidic microenvironment to improve the therapeutic effects of MSLN-CAR-T cells on the brain metastasis.,"['Zhai X', 'Mao L', 'Kang Q', 'Liu J', 'Zhou Y', 'Wang J', 'Yang X', 'Wang D', 'Wang J', 'Li Y', 'Duan J', 'Zhang T', 'Lin S', 'Zhao T', 'Li J', 'Wu M', 'Yu S']","['*Tumor Microenvironment/drug effects', '*Mesothelin', 'Humans', 'Animals', 'Mice', '*Brain Neoplasms/secondary/drug therapy/therapy', 'Cell Line, Tumor', '*Proton Pump Inhibitors/pharmacology/therapeutic use', 'Female', 'Xenograft Model Antitumor Assays', 'Triple Negative Breast Neoplasms/drug therapy/pathology/therapy/metabolism', 'Immunotherapy, Adoptive/methods', 'Receptors, Chimeric Antigen/metabolism', 'Pantoprazole/pharmacology', 'Hydrogen-Ion Concentration']",https://pubmed.ncbi.nlm.nih.gov/39511890/
378,pantoprazole,36896929,Gastric calcinosis ulcer in a renal transplanted patient.,"['Olmedo Moreno C', 'Hernan Ocana P', 'Rodriguez Gil Y', 'Diaz Tasende J']","['Humans', 'Middle Aged', 'Female', '*Kidney Transplantation', '*Calcinosis/etiology/diagnostic imaging', 'Stomach Ulcer/etiology/complications', 'Endoscopy, Digestive System', 'Postoperative Complications/etiology', 'Pantoprazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36896929/
379,pantoprazole,26242498,[Proton Pump Inhibitor and High-dose Methotrexate: Two Cases Reports].,"['Evrard J', 'Farnier E', 'Carcel C', 'Lachenal F', 'Vial T', 'Pont E']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*adverse effects/pharmacokinetics', 'Acute Kidney Injury/*chemically induced/prevention & control/therapy', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Carcinoma, Squamous Cell/drug therapy', 'Combined Modality Therapy', 'Comorbidity', 'Cyclophosphamide/administration & dosage', 'Dose-Response Relationship, Drug', 'Doxorubicin/administration & dosage', 'Drug Eruptions/*etiology', 'Drug Interactions', 'Humans', 'Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Male', 'Methotrexate/administration & dosage/*adverse effects/pharmacokinetics', 'Mucositis/*chemically induced', 'Omeprazole/administration & dosage/*adverse effects/pharmacokinetics', 'Otorhinolaryngologic Neoplasms/drug therapy', 'Pancytopenia/*chemically induced', 'Pantoprazole', 'Polypharmacy', 'Prednisone/administration & dosage', 'Proton Pump Inhibitors/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Rituximab/administration & dosage', 'Vincristine/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/26242498/
380,methocarbamol,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
381,methocarbamol,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
382,methocarbamol,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
383,methocarbamol,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
384,methocarbamol,18049062,How to try this: detecting delirium.,['Waszynski CM'],"['Algorithms', 'Analgesics, Opioid/*adverse effects', '*Auditory Perceptual Disorders', '*Confusion', 'Delirium/chemically induced/*diagnosis/nursing', 'Humans', 'Hydromorphone/*adverse effects', 'Male', 'Methocarbamol/*adverse effects', 'Muscle Relaxants, Central/adverse effects', '*Psychomotor Agitation', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/18049062/
385,methocarbamol,37481407,Impact of methocarbamol on opioid use after ventral incisional hernia repair.,"['Desai S', 'Carbonell C', 'Hoffman K', 'Hammond B', 'Crosier C', 'Blackhurst D', 'Carbonell AM', 'Love MW', 'Cobb WS', 'Warren JA']","['Humans', 'Analgesics, Opioid/therapeutic use', '*Methocarbamol/therapeutic use', '*Incisional Hernia/surgery', ""Practice Patterns, Physicians'"", '*Hernia, Ventral/surgery', '*Opioid-Related Disorders/prevention & control', 'Pain, Postoperative/drug therapy/surgery', 'Herniorrhaphy', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/37481407/
386,methocarbamol,7097192,A fatal methocarbamol intoxication.,"['Kemal M', 'Imami R', 'Poklis A']","['Adult', 'Alcoholic Intoxication', 'Chromatography, Gas', 'Chromatography, High Pressure Liquid', 'Chromatography, Thin Layer', 'Ethanol/blood', 'Female', 'Humans', 'Methocarbamol/*poisoning', 'Spectrophotometry, Ultraviolet', 'Toxicology/methods']",https://pubmed.ncbi.nlm.nih.gov/7097192/
387,methocarbamol,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
388,methocarbamol,13618740,Use of methocarbamol in orthopedics.,['LEWIS WB'],"['*Cardiovascular Agents', '*Disease', 'Humans', '*Methocarbamol', 'Muscle Relaxants, Central/*therapeutic use', '*Muscles', '*Muscular Diseases', '*Nervous System Diseases', '*Orthopedics', '*Spasm']",https://pubmed.ncbi.nlm.nih.gov/13618740/
389,methocarbamol,461786,Urticaria of the colon.,"['Yousefzadeh DK', 'Teplick JG']","['Cecal Diseases/*complications', 'Colonic Diseases/chemically induced/complications/*diagnostic imaging', 'Drug Hypersensitivity/complications', 'Humans', 'Intestinal Obstruction/*complications/diagnostic imaging', 'Male', 'Methocarbamol/adverse effects', 'Middle Aged', 'Radiography', 'Thioridazine/adverse effects', 'Urticaria/chemically induced/complications/*diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/461786/
390,methocarbamol,31306155,Multimodal analgesia for craniotomy.,"['Ban VS', 'Bhoja R', 'McDonagh DL']","['Analgesia/adverse effects/*methods', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Analgesics, Opioid/administration & dosage/adverse effects', 'Anesthesiologists/organization & administration', 'Anesthetics, Local/administration & dosage/adverse effects', 'Central Nervous System Diseases/diagnosis/etiology', 'Craniotomy/*adverse effects', 'Evidence-Based Medicine/methods', 'Humans', 'Nerve Block/methods', 'Neurosurgeons/organization & administration', 'Pain Management/adverse effects/*methods', 'Pain, Postoperative/*drug therapy/etiology', 'Patient Care Team/*organization & administration', 'Patient Safety', 'Perioperative Care/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31306155/
391,methocarbamol,38320820,Atypical neuroleptic malignant syndrome in an incarcerated patient: a demographic who may be at increased risk.,"['Zabel M', 'Kandukuri R']","['Male', 'Humans', '*Neuroleptic Malignant Syndrome/diagnosis/etiology/drug therapy', '*Mutism', '*Antipsychotic Agents/adverse effects', 'Demography', '*Prisoners']",https://pubmed.ncbi.nlm.nih.gov/38320820/
392,methocarbamol,20810461,Strychnine poisoning: gone but not forgotten.,"['Parker AJ', 'Lee JB', 'Redman J', 'Jolliffe L']","['Critical Care/methods', 'Critical Illness/therapy', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Follow-Up Studies', 'Humans', 'Intubation, Intratracheal', 'Methocarbamol/*poisoning', 'Middle Aged', 'Pesticides/*poisoning', 'Risk Assessment', 'Strychnine/*poisoning', '*Suicide, Attempted', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20810461/
393,methocarbamol,2083431,Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner.,['Stanko JR'],"['Humans', '*Muscle Relaxants, Central/administration & dosage/pharmacology/therapeutic use', 'Muscle Spasticity/drug therapy', 'Temporomandibular Joint Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2083431/
394,methocarbamol,4451234,Tetanus: conservative management made easier by combination of muscle relaxants.,['Anah CO'],"['Adolescent', 'Child', 'Diazepam/*administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Methocarbamol/*administration & dosage/therapeutic use', 'Muscle Rigidity/etiology', 'Tetanus/complications/*drug therapy/physiopathology', 'Tetanus Antitoxin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4451234/
395,methocarbamol,37284760,Association Between Postoperative Methocarbamol and Postoperative Pain Opioid Dose Requirements: A Retrospective Cohort Study.,"['Komatsu R', 'Singleton MD', 'Wu J', 'Dinges EM', 'Bollag LA']","['Humans', '*Analgesics, Opioid/therapeutic use', 'Retrospective Studies', '*Methocarbamol/therapeutic use', 'Pain, Postoperative/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37284760/
396,methocarbamol,7101197,Teratogens associated with congenital contractures in humans and in animals.,"['Hall JG', 'Reed SD']","['Animals', 'Arthrogryposis/chemically induced/*etiology', 'Bacterial Infections/*complications', 'Ethanol/toxicity', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Methocarbamol/toxicity', 'Muscular Dystrophies/complications', 'Myasthenia Gravis/complications', 'Plants, Toxic', 'Pregnancy', 'Pregnancy Complications', '*Teratogens', 'Tetracycline/adverse effects', 'Virus Diseases/*complications']",https://pubmed.ncbi.nlm.nih.gov/7101197/
397,methocarbamol,6731242,Black widow spider bite.,['Kobernick M'],"['Antivenins/therapeutic use', '*Black Widow Spider', 'Calcium Gluconate/therapeutic use', 'Diazepam/therapeutic use', 'Humans', 'Hypertension/etiology', 'Methocarbamol/therapeutic use', 'Muscle Spasticity/etiology', 'Spider Bites/complications/*diagnosis/therapy', 'Spider Venoms', '*Spiders']",https://pubmed.ncbi.nlm.nih.gov/6731242/
398,methocarbamol,9204163,Pain reduction in breast augmentation using methocarbamol.,['Schneider MS'],"['Adult', '*Breast Implants', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Methocarbamol/*administration & dosage/adverse effects', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Pain Measurement', 'Pain, Postoperative/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/9204163/
399,methocarbamol,31094132,Green Urine And Altered Mental Status: A Case Of Intoxication.,"['Gangwani MK', 'Aziz M', 'Asif R', 'Ali SA']","['Aged', 'Benzodiazepines/*poisoning', 'Humans', 'Male', 'Mental Disorders/*chemically induced', 'Urinalysis', 'Urine/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31094132/
400,doxazosin,36196467,Role of alpha1-blockers in the current management of hypertension.,"['Li H', 'Xu TY', 'Li Y', 'Chia YC', 'Buranakitjaroen P', 'Cheng HM', 'Van Huynh M', 'Sogunuru GP', 'Tay JC', 'Wang TD', 'Kario K', 'Wang JG']","['Adrenergic alpha-Antagonists/therapeutic use', 'Aged', 'Aldosterone', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Diuretics/therapeutic use', 'Doxazosin/therapeutic use', 'Humans', '*Hypertension/drug therapy', 'Renin']",https://pubmed.ncbi.nlm.nih.gov/36196467/
401,doxazosin,31714582,Efficacy of alpha-Blockers on Hemodynamic Control during Pheochromocytoma Resection: A Randomized Controlled Trial.,"['Buitenwerf E', 'Osinga TE', 'Timmers HJLM', 'Lenders JWM', 'Feelders RA', 'Eekhoff EMW', 'Haak HR', 'Corssmit EPM', 'Bisschop PHLT', 'Valk GD', 'Veldman RG', 'Dullaart RPF', 'Links TP', 'Voogd MF', 'Wietasch GJKG', 'Kerstens MN']","['Adrenal Gland Neoplasms/*surgery', 'Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use', 'Blood Pressure/*drug effects', 'Doxazosin/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenoxybenzamine/administration & dosage/therapeutic use', 'Pheochromocytoma/*surgery', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31714582/
402,doxazosin,38379309,Safety and Feasibility of Opening Tamsulosin Capsules for Enteral Feeding Tube Administration.,"['Fazio V', 'Altshuler J', 'Song YB']","['Humans', '*Tamsulosin/administration & dosage', 'Retrospective Studies', 'Male', '*Enteral Nutrition/methods', 'Female', '*Capsules', 'Middle Aged', 'Aged', '*Feasibility Studies', 'Adrenergic alpha-1 Receptor Antagonists/administration & dosage', 'Doxazosin/administration & dosage', 'Adult', 'Hypotension/prevention & control/chemically induced', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/38379309/
403,doxazosin,34456560,Doxazosin Attenuates Liver Fibrosis by Inhibiting Autophagy in Hepatic Stellate Cells via Activation of the PI3K/Akt/mTOR Signaling Pathway.,"['Xiu AY', 'Ding Q', 'Li Z', 'Zhang CQ']","['Adrenergic alpha-1 Receptor Antagonists/administration & dosage/*pharmacology', 'Animals', 'Apoptosis/drug effects', 'Autophagy/drug effects', 'Carbon Tetrachloride', 'Cell Line', 'Cell Proliferation/drug effects', 'Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Doxazosin/administration & dosage/*pharmacology', 'Hepatic Stellate Cells/*drug effects/metabolism', 'Humans', 'Liver Cirrhosis/*drug therapy', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Phosphatidylinositol 3-Kinase/metabolism', 'Proto-Oncogene Proteins c-akt/metabolism', 'Signal Transduction/drug effects', 'TOR Serine-Threonine Kinases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34456560/
404,doxazosin,14681504,"The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia.","['McConnell JD', 'Roehrborn CG', 'Bautista OM', 'Andriole GL Jr', 'Dixon CM', 'Kusek JW', 'Lepor H', 'McVary KT', 'Nyberg LM Jr', 'Clarke HS', 'Crawford ED', 'Diokno A', 'Foley JP', 'Foster HE', 'Jacobs SC', 'Kaplan SA', 'Kreder KJ', 'Lieber MM', 'Lucia MS', 'Miller GJ', 'Menon M', 'Milam DF', 'Ramsdell JW', 'Schenkman NS', 'Slawin KM', 'Smith JA']","['*5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Analysis of Variance', 'Disease Progression', 'Double-Blind Method', 'Doxazosin/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Enzyme Inhibitors/adverse effects/*therapeutic use', 'Finasteride/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/classification/*drug therapy/surgery', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/14681504/
405,doxazosin,17563267,Finasteride and doxazosin alone or in combination for the treatment of benign prostatic hyperplasia.,"['Bhardwa J', 'Goldstraw M', 'Tzortzis S', 'Kirby R']","['5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/administration & dosage/*therapeutic use', 'Aged', 'Doxazosin/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Finasteride/administration & dosage/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17563267/
406,doxazosin,9021791,"Measures of Proscar, Hytrin, and Cardura side effects.",['Frankel S'],"['Adrenergic alpha-Antagonists/adverse effects', 'Doxazosin/*adverse effects', 'Finasteride/*adverse effects', 'Humans', 'Male', 'Prazosin/adverse effects/*analogs & derivatives', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9021791/
407,doxazosin,39160179,Change in prostate tissue gene expression following finasteride or doxazosin administration in the medical therapy for prostatic symptoms (MTOPS) study.,"['Choi HY', 'Torkko KC', 'Lucia MS', 'Mozhui K', 'Choi WY', 'Clark PE', 'Fowke JH']","['*Prostate/metabolism', 'Gene Expression Regulation/drug effects', '*Finasteride/pharmacology/therapeutic use', '*Doxazosin/pharmacology/therapeutic use', 'Urological Agents/pharmacology/therapeutic use', 'Drug Resistance', '*Prostatic Diseases/drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/39160179/
408,doxazosin,38206436,The combination of doxazosin and metyrosine as a preoperative treatment for pheochromocytomas and paragangliomas.,"['Ohmachi Y', 'Yamamoto M', 'Inaba Y', 'Makino S', 'Urai S', 'Matsumoto R', 'Bando H', 'Kanie K', 'Tsujimoto Y', 'Motomura Y', 'Sasaki Y', 'Oi-Yo Y', 'Yamamoto N', 'Suzuki M', 'Takahashi M', 'Iguchi G', 'Kanzawa M', 'Furukawa J', 'Shigemura K', 'Mizobuchi S', 'Ogawa W', 'Fukuoka H']","['Humans', '*Doxazosin/therapeutic use/administration & dosage', 'Female', 'Male', '*Pheochromocytoma/surgery/drug therapy', 'Middle Aged', '*Adrenal Gland Neoplasms/surgery/drug therapy', 'Retrospective Studies', '*Paraganglioma/drug therapy/surgery', 'Adult', 'Aged', '*alpha-Methyltyrosine/therapeutic use/administration & dosage/pharmacology', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use/administration & dosage', 'Drug Therapy, Combination', 'Preoperative Care/methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38206436/
409,doxazosin,19110560,Assessment of therapeutic drug efficiency.,"['Pokrovskii VM', 'Kompaniets OG']","['Adrenergic alpha-Antagonists/therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/*drug effects', 'Calcium Channel Blockers/therapeutic use', 'Doxazosin/therapeutic use', 'Heart Rate/*drug effects', 'Humans', 'Nifedipine/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19110560/
410,doxazosin,12230262,Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.,"['Pool JL', 'Kirby RS']","['Adrenergic alpha-Antagonists/pharmacokinetics/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Blood-Brain Barrier', 'Doxazosin/pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quinazolines/pharmacokinetics/*therapeutic use', 'Receptors, Adrenergic, alpha-1/*classification/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12230262/
411,doxazosin,33566468,Otorhinolaryngological adverse effects of urological drugs.,"['Maia NPD', 'Lopes KC', 'Gananca FF']","['Adrenergic alpha-Antagonists', 'Doxazosin', 'Humans', 'Male', '*Pharmaceutical Preparations', 'Prazosin', '*Prostatic Hyperplasia', 'Tadalafil', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/33566468/
412,doxazosin,10750258,The role of alpha 1-blockers in combination therapy for hypertension.,['Zusman RM'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Diabetes Mellitus, Type 2/drug therapy', 'Doxazosin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hyperlipidemias/drug therapy', 'Hypertension/*drug therapy', 'Male', 'Prazosin/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10750258/
413,doxazosin,34414962,Efficacy and tolerability of doxazosin gastro-intestinal therapeutic system versus tamsulosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: A systematic review and meta-analysis.,"['Guo J', 'Tang R']","['Humans', 'Male', '*Doxazosin/adverse effects/therapeutic use', '*Lower Urinary Tract Symptoms/drug therapy/etiology', '*Prostatic Hyperplasia/complications', '*Tamsulosin/adverse effects/therapeutic use', 'Treatment Outcome', '*Urological Agents/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34414962/
414,doxazosin,9609620,Alpha-blockade therapy for benign prostatic hyperplasia: from a nonselective to a more selective alpha1A-adrenergic antagonist.,"['Beduschi MC', 'Beduschi R', 'Oesterling JE']","['Adrenergic alpha-Antagonists/*therapeutic use', 'Clinical Trials as Topic', 'Doxazosin/therapeutic use', 'Humans', 'Male', 'Prazosin/analogs & derivatives/therapeutic use', 'Prostatic Hyperplasia/*drug therapy', 'Sulfonamides/therapeutic use', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/9609620/
415,doxazosin,11750252,"Terazosin, doxazosin, and prazosin: current clinical experience.","['Akduman B', 'Crawford ED']","['Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Adult', 'Aged', 'Doxazosin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prazosin/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Prostatic Hyperplasia/complications/*drug therapy', 'Randomized Controlled Trials as Topic', 'Receptors, Adrenergic, alpha/classification']",https://pubmed.ncbi.nlm.nih.gov/11750252/
416,doxazosin,36883885,A Double-Blind Randomized Controlled Trial of Doxazosin for Co-Occurring PTSD and Alcohol Use Disorder in Veterans.,"['Back SE', 'Flanagan JC', 'Mintz J', 'Brady KT', 'Jones J', 'Jarnecke AM', 'Joseph JE', 'Shirley DW', 'Malcolm RJ', 'Hamner M', 'Litz BT', 'Niles BL', 'Young-McCaughan S', 'Keane TM', 'Peterson AL']","['Humans', '*Veterans', '*Stress Disorders, Post-Traumatic/complications/diagnosis/drug therapy', 'Doxazosin/therapeutic use', '*Alcoholism/diagnosis/drug therapy/epidemiology', 'Treatment Outcome', 'Adrenergic alpha-1 Receptor Antagonists/adverse effects', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36883885/
417,doxazosin,1353110,The cardiovascular effects of alpha-receptor blocking agents.,['Leren P'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Animals', 'Antihypertensive Agents/*therapeutic use', 'Cardiomegaly/drug therapy', 'Cardiovascular System/*drug effects', 'Cost-Benefit Analysis', 'Doxazosin', 'Humans', 'Hypertension/*drug therapy', 'Lipids/blood', 'Prazosin/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1353110/
418,doxazosin,12296615,"The effect of doxazosin on sexual function in patients with benign prostatic hyperplasia, hypertension, or both.",['Flack JM'],"['Adrenergic alpha-Antagonists/*adverse effects', 'Aged', 'Doxazosin/*adverse effects', 'Erectile Dysfunction/*chemically induced', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/12296615/
419,doxazosin,31177904,Management of Insomnia and Anxiety in Myasthenia Gravis.,"['Jordan H', 'Ortiz N']","['Adult', 'Antihypertensive Agents/*administration & dosage', 'Anxiety/*psychology', 'Depression/psychology', 'Doxazosin/*administration & dosage', 'Female', 'Humans', 'Myasthenia Gravis/*complications', 'Sleep Initiation and Maintenance Disorders/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31177904/
420,vincristine,26505486,Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.,['Ansell SM'],"['Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Bleomycin/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dacarbazine/administration & dosage/adverse effects/therapeutic use', 'Disease-Free Survival', 'Doxorubicin/administration & dosage/adverse effects/therapeutic use', 'Hodgkin Disease/*drug therapy/metabolism/mortality/pathology', 'Humans', 'Mechlorethamine/administration & dosage/adverse effects/therapeutic use', 'Molecular Targeted Therapy', 'Prednisone/administration & dosage/adverse effects/therapeutic use', 'Procarbazine/administration & dosage/adverse effects/therapeutic use', 'Programmed Cell Death 1 Receptor/*antagonists & inhibitors', 'Vinblastine/administration & dosage/adverse effects/therapeutic use', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26505486/
421,vincristine,15481055,"Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.","['Kantarjian H', 'Thomas D', ""O'Brien S"", 'Cortes J', 'Giles F', 'Jeha S', 'Bueso-Ramos CE', 'Pierce S', 'Shan J', 'Koller C', 'Beran M', 'Keating M', 'Freireich EJ']","['Adolescent', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Bone Marrow/drug effects', 'Central Nervous System Neoplasms/drug therapy', 'Cyclophosphamide/administration & dosage/adverse effects/*therapeutic use', 'Dexamethasone/administration & dosage/adverse effects/*therapeutic use', 'Doxorubicin/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy/mortality', 'Prognosis', 'Remission Induction', 'Risk', 'Survival Analysis', 'Vincristine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15481055/
422,vincristine,715485,Vincristine-induced dysphagia.,"['Chisholm RC', 'Curry SB']","['Breast Neoplasms/drug therapy', 'Deglutition Disorders/*chemically induced', 'Female', 'Humans', 'Middle Aged', 'Vincristine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/715485/
423,vincristine,23329395,Vincristine sulfate liposome injection: a guide to its use in refractory or relapsed acute lymphoblastic leukemia.,"['Harrison TS', 'Lyseng-Williamson KA']","['Animals', 'Antineoplastic Agents, Phytogenic/*administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Cholesterol/chemistry', 'Clinical Trials as Topic', 'Drug Carriers/chemistry', 'Humans', 'Infusions, Intravenous', 'Liposomes', 'Practice Guidelines as Topic', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy', 'Secondary Prevention', 'Sphingomyelins/chemistry', 'Tissue Distribution', 'Vincristine/*administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23329395/
424,vincristine,1384143,ABVD in the treatment of Hodgkin's disease.,"['Bonfante V', 'Santoro A', 'Viviani S', 'Valagussa P', 'Bonadonna G']","['Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bleomycin/administration & dosage/adverse effects', 'Combined Modality Therapy', 'Dacarbazine/administration & dosage/adverse effects', 'Doxorubicin/administration & dosage/adverse effects', 'Hodgkin Disease/*drug therapy', 'Humans', 'Italy', 'Vinblastine', 'Vincristine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1384143/
425,vincristine,6876287,Vincristine-induced bladder neuropathy.,"['Wheeler JS Jr', 'Siroky MB', 'Bell R', 'Babayan RK']","['Drug Therapy, Combination', 'Humans', 'Lymphoma/drug therapy', 'Male', 'Middle Aged', 'Testicular Neoplasms/drug therapy', 'Urinary Bladder, Neurogenic/*chemically induced', 'Urodynamics', 'Vincristine/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6876287/
426,vincristine,14738143,"Efficacy of vinblastine, bleomycin, methotrexate (VBM) combination chemotherapy with involved field radiotherapy in early stage (I-IIA) Hodgkin disease patients.","['Martinelli G', 'Cocorocchio E', 'Saletti PC', 'Orecchia R', 'Bernier J', 'Tradati N', 'Santoro P', 'Robertson C', 'Peccatori FA', 'Zucca E', 'Cavalli F']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bleomycin/adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Female', 'Hodgkin Disease/*drug therapy/pathology/*radiotherapy', 'Humans', 'Male', 'Methotrexate/adverse effects/*therapeutic use', 'Middle Aged', 'Neoplasm Staging', 'Radiotherapy/*methods', 'Retrospective Studies', 'Survival Rate', 'Treatment Outcome', 'Vincristine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14738143/
427,vincristine,19275512,Nonpegylated liposomal doxorubicin in the treatment of B-cell non-Hodgkin's lymphoma: where we stand.,"['Visani G', 'Isidori A']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Cyclophosphamide/administration & dosage', 'Dose-Response Relationship, Drug', 'Doxorubicin/*administration & dosage/adverse effects', 'Humans', 'Liposomes', 'Lymphoma, AIDS-Related/drug therapy', 'Lymphoma, B-Cell/*drug therapy', 'Middle Aged', 'Prednisolone/administration & dosage', 'Vincristine/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19275512/
428,vincristine,6989508,A critical review of the use of vincristine (VCR) as a tumour cell synchronizing agent in cancer therapy.,['Camplejohn RS'],"['Animals', 'Cell Cycle/*drug effects', 'Cyclophosphamide/therapeutic use', 'Cytological Techniques', 'Drug Therapy, Combination', 'Humans', 'Interphase/drug effects', 'Kinetics', 'Metaphase/drug effects', 'Methotrexate/therapeutic use', 'Mice', 'Neoplasms/drug therapy/*pathology', 'Vincristine/administration & dosage/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6989508/
429,vincristine,284172,Accidental intrathecal administration of vincristine.,"['Shepherd DA', 'Steuber CP', 'Starling KA', 'Fernbach DJ']","['Child, Preschool', 'Humans', 'Injections, Spinal', 'Leukemia, Lymphoid/drug therapy', '*Medication Errors', 'Nervous System Diseases/chemically induced', 'Vincristine/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/284172/
430,vincristine,21265011,Risk of azole-enhanced vincristine neurotoxicity in pediatric patients with hematological malignancies: old problem - new dilemma.,"['Pana ZD', 'Roilides E']","['*Antifungal Agents/pharmacokinetics/therapeutic use/urine', '*Antineoplastic Agents, Phytogenic/adverse effects/pharmacokinetics/therapeutic use', 'Cytochrome P-450 Enzyme System/metabolism', 'Drug Interactions', 'Hematologic Neoplasms/*drug therapy', 'Humans', '*Itraconazole/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors', '*Vincristine/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21265011/
431,vincristine,3596472,"OPEC chemotherapy (vincristine, prednisolone, etoposide and chlorambucil) for refractory and recurrent Hodgkin's disease.","['Barnett MJ', 'Man AM', 'Richards MA', 'Waxman JH', 'Wrigley PF', 'Lister TA']","['Adolescent', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Bone Marrow/drug effects', 'Chlorambucil/administration & dosage/adverse effects/therapeutic use', 'Etoposide/administration & dosage/adverse effects/therapeutic use', 'Hodgkin Disease/*drug therapy', 'Humans', 'Leukocyte Count', 'Mechlorethamine/therapeutic use', 'Middle Aged', 'Prednisolone/administration & dosage/adverse effects/therapeutic use', 'Procarbazine/therapeutic use', 'Prognosis', 'Vinblastine/therapeutic use', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3596472/
432,vincristine,3190743,"Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.","['Horton JK', 'Houghton PJ', 'Houghton JA']","['Animals', 'Drug Resistance', 'Female', 'Humans', 'Mice', 'Mice, Inbred CBA', 'Mitosis/*drug effects', 'Neoplasm Transplantation', 'Neoplasms, Experimental/*drug therapy/metabolism', 'Transplantation, Heterologous', 'Vincristine/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3190743/
433,vincristine,25597374,Half-and-half nails in a pediatric patient after chemotherapy.,"['Afsar FS', 'Ozek G', 'Vergin C']","['Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*adverse effects/therapeutic use', 'Asparaginase/administration & dosage/adverse effects/therapeutic use', 'Child', 'Daunorubicin/administration & dosage/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Female', 'Humans', 'Nail Diseases/*chemically induced/diagnosis', 'Nails/*drug effects', 'Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Prednisone/administration & dosage/adverse effects/therapeutic use', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25597374/
434,vincristine,438873,Chemotherapy as an adjunct in the initial management of cerebellar medulloblastomas. A preliminary report.,"['Venes JL', 'McIntosh S', ""O'Brien RT"", 'Schwartz AD']","['Administration, Oral', 'Cerebellar Neoplasms/*drug therapy/radiotherapy', 'Child', 'Child, Preschool', 'Cyclophosphamide/administration & dosage/adverse effects/*therapeutic use', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Injections, Intravenous', 'Male', 'Medulloblastoma/*drug therapy/radiotherapy', 'Neoplasm Recurrence, Local', 'Time Factors', 'Vincristine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/438873/
435,vincristine,6546971,Effective treatment of advanced multiple myeloma refractory to alkylating agents.,"['Barlogie B', 'Smith L', 'Alexanian R']","['Alkylating Agents/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Cyclophosphamide/adverse effects/therapeutic use', 'Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Doxorubicin/administration & dosage/adverse effects/therapeutic use', 'Drug Resistance', 'Humans', 'Melphalan/therapeutic use', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Plasma Cells/analysis', 'Prednisone/adverse effects/therapeutic use', 'RNA, Neoplasm/analysis', 'Vincristine/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6546971/
436,vincristine,28834048,Medication contaminants as a potential cause of anaphylaxis to vincristine.,"['Hill DA', 'Leahy AB', 'Sciasci J', ""O'Neill SP"", 'Reilly A', 'Balamuth N', 'Seeholzer SH', 'Spergel JM', 'Brown-Whitehorn TF']","['Adolescent', '*Anaphylaxis/chemically induced/mortality', 'Child', 'Child, Preschool', '*Drug Contamination', 'Female', 'Humans', 'Infant', 'Male', 'Mass Spectrometry', 'Neoplasms/*drug therapy', 'Risk Factors', 'Vincristine/*administration & dosage/*adverse effects/analysis']",https://pubmed.ncbi.nlm.nih.gov/28834048/
437,vincristine,33283553,Genetic factors influencing the development of vincristine-induced neurotoxicity.,"['Pozzi E', 'Fumagalli G', 'Chiorazzi A', 'Canta A', 'Cavaletti G']","['Antineoplastic Agents, Phytogenic/administration & dosage/*adverse effects', 'Genotype', 'Humans', 'Neurotoxicity Syndromes/*etiology', 'Peripheral Nervous System Diseases/chemically induced/genetics', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Risk Factors', 'Vincristine/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33283553/
438,vincristine,20532679,Use of pyridoxine and pyridostigmine in children with vincristine-induced neuropathy.,"['Akbayram S', 'Akgun C', 'Dogan M', 'Sayin R', 'Caksen H', 'Oner AF']","['Adolescent', 'Antineoplastic Agents, Phytogenic/administration & dosage/*adverse effects', 'Child', 'Child, Preschool', 'Cholinesterase Inhibitors/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Polyneuropathies/chemically induced/diagnosis/*drug therapy', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/diagnosis/drug therapy', 'Pyridostigmine Bromide/*therapeutic use', 'Pyridoxine/*therapeutic use', 'Treatment Outcome', 'Vincristine/administration & dosage/*adverse effects', 'Vitamin B Complex/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20532679/
439,vincristine,39495861,Vincristine loaded pegylated liposomal drug delivery for efficient treatment of acute lymphoblastic leukaemia.,"['Wang H', 'Qian Y', 'Sun G']","['*Liposomes', '*Polyethylene Glycols/chemistry', '*Vincristine/administration & dosage/chemistry', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Humans', 'Cell Line, Tumor', 'Animals', 'Antineoplastic Agents, Phytogenic/administration & dosage/chemistry/pharmacology/pharmacokinetics', 'Drug Liberation', 'Particle Size', 'Drug Delivery Systems/methods', 'Cell Survival/drug effects']",https://pubmed.ncbi.nlm.nih.gov/39495861/
440,gentamicin,1078798,Chronic polymicrobial bacteremia.,"['Grajwer LA', 'Mukhopadhyay D', 'Grossman BJ']","['Adolescent', 'Ampicillin/therapeutic use', 'Blood Bactericidal Activity', 'Carbenicillin/blood/therapeutic use', 'Chronic Disease', '*Enterobacteriaceae Infections/blood/drug therapy', 'Female', 'Gentamicins/adverse effects/pharmacology/therapeutic use', 'Humans', 'Kanamycin/blood/therapeutic use', 'Probenecid/therapeutic use', '*Sepsis/blood/drug therapy', 'Vestibule, Labyrinth/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1078798/
441,gentamicin,27206240,"Use of Gentamicin as Empiric Coverage for Ventilator-Associated Pneumonia: The ""Con"" Perspective.","['Byrnes M', 'Dorman R']","['Anti-Bacterial Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Drug Therapy, Combination', 'Gentamicins/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Pneumonia, Ventilator-Associated/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27206240/
442,gentamicin,807310,"Comparative activity of tobramycin and gentamicin against Pseudomonas, Proteus and Providencia species.","['Ducan IB', 'Penner JL']","['Drug Resistance, Microbial', 'Gentamicins/administration & dosage/pharmacology', 'Humans', 'Microbial Sensitivity Tests', 'Proteus/*drug effects', 'Proteus vulgaris/drug effects', 'Providencia/*drug effects', 'Pseudomonas aeruginosa/*drug effects', 'Tobramycin/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/807310/
443,gentamicin,358884,Gentamicin in 1978.,"['Appel GB', 'Neu HC']","['Amikacin/pharmacology', 'Animals', 'Bacterial Infections/drug therapy', 'Drug Synergism', 'Ear Diseases/chemically induced', 'Gentamicins/adverse effects/metabolism/*pharmacology/therapeutic use', 'Humans', 'Kidney/metabolism', 'Kidney Diseases/chemically induced', 'Netilmicin/therapeutic use', 'Penicillin Resistance', 'Penicillins/pharmacology', 'Respiratory Tract Infections/drug therapy', 'Sisomicin/therapeutic use', 'Tobramycin/therapeutic use', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/358884/
444,gentamicin,15150688,[Characterization of custom-made biomaterials containing antibiotics].,"['Pfefferle HJ', 'Nies B']","['Anti-Bacterial Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Bacterial Infections/*drug therapy/microbiology', 'Biological Availability', '*Bone Cements', 'Drug Carriers', 'Drug Compounding', 'Gentamicins/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Methylmethacrylates/adverse effects/pharmacokinetics/*therapeutic use', 'Microbial Sensitivity Tests', 'Osteomyelitis/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/15150688/
445,gentamicin,938081,Gentamicin dosage in children.,"['Taylor M', 'Keane C']","['Bacterial Infections/drug therapy', 'Child', 'Child, Preschool', 'Gentamicins/*administration & dosage/blood/therapeutic use', 'Humans', 'Infant', 'Injections, Intramuscular']",https://pubmed.ncbi.nlm.nih.gov/938081/
446,gentamicin,31279530,Electrospinning of silica nanoparticles-entrapped nanofibers for sustained gentamicin release.,"['Chen X', 'Xu C', 'He H']","['Anti-Bacterial Agents/*administration & dosage/pharmacokinetics/pharmacology', 'Biocompatible Materials/chemistry', 'Delayed-Action Preparations/*chemistry', 'Drug Liberation', 'Escherichia coli/drug effects', 'Escherichia coli Infections/drug therapy/microbiology', 'Gentamicins/*administration & dosage/pharmacokinetics/pharmacology', 'Humans', 'Nanofibers/*chemistry/ultrastructure', 'Nanoparticles/chemistry', 'Porosity', 'Silicon Dioxide/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31279530/
447,gentamicin,2281427,Inhaled micronised gentamicin powder: a new delivery system.,"['Goldman JM', 'Bayston SM', ""O'Connor S"", 'Meigh RE']","['Administration, Inhalation', 'Administration, Intranasal', 'Bronchoalveolar Lavage Fluid/chemistry', 'Bronchoscopy', 'Cough/chemically induced', 'Fiber Optic Technology', 'Gentamicins/*administration & dosage/adverse effects/analysis', 'Humans', 'Middle Aged', 'Powders']",https://pubmed.ncbi.nlm.nih.gov/2281427/
448,gentamicin,1130930,Nephrotoxicity of combined cephalothin-gentamicin regimen.,"['Cabanillas F', 'Burgos RC', 'Rodriguez C', 'Baldizon C']","['Acute Kidney Injury/*chemically induced', 'Aged', 'Blood Urea Nitrogen', 'Bronchopneumonia/drug therapy', 'Cephalothin/administration & dosage/*adverse effects/therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Gentamicins/administration & dosage/*adverse effects/therapeutic use', 'Humans', 'Kidney Tubular Necrosis, Acute/*chemically induced', 'Kidney Tubules/pathology', 'Middle Aged', 'Proteus Infections/drug therapy', 'Pseudomonas Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1130930/
449,gentamicin,32641561,Acute kidney failure after intra-articular use of gentamicin sponge.,"['Gommans EPAT', 'Aarnoudse ALHJ', 'van Wensen RJA', 'van Erp-van Boekel AAW', 'Grouls RJE', 'van der Linden CMJ']","['Acute Kidney Injury/*chemically induced', 'Aged', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Gentamicins/administration & dosage/*adverse effects', 'Hip Prosthesis/*adverse effects', 'Humans', 'Male', 'Prosthesis-Related Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/32641561/
450,gentamicin,15713316,The influence of cyclic loading on gentamicin release from acrylic bone cements.,"['Hendriks JG', 'Neut D', 'Hazenberg JG', 'Verkerke GJ', 'van Horn JR', 'van der Mei HC', 'Busscher HJ']","['Arthroplasty, Replacement, Hip/adverse effects/*methods', 'Bone Cements/*therapeutic use', 'Drug Delivery Systems/*methods', 'Gentamicins/*administration & dosage', 'Hip Prosthesis', 'Humans', 'Infection Control/methods', 'Materials Testing', '*Weight-Bearing']",https://pubmed.ncbi.nlm.nih.gov/15713316/
451,gentamicin,9726669,Unilateral vestibulotoxicity due to systemic gentamicin therapy.,"['Waterston JA', 'Halmagyi GM']","['Aged', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Caloric Tests', 'Female', 'Gentamicins/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Vertigo', 'Vestibular Diseases/*chemically induced/diagnosis/physiopathology', 'Vestibule, Labyrinth/drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9726669/
452,gentamicin,21197583,Local antibiotic delivery with demineralized bone matrix.,"['Lewis CS', 'Supronowicz PR', 'Zhukauskas RM', 'Gill E', 'Cobb RR']","['Alkaline Phosphatase/metabolism', 'Animals', 'Anti-Bacterial Agents/*administration & dosage/*pharmacology', '*Bone Demineralization Technique', 'Bone Matrix/*metabolism', 'Cell Adhesion/drug effects', 'Cell Proliferation/drug effects', 'Drug Delivery Systems/*methods', 'Gentamicins/*administration & dosage/*pharmacology', 'Humans', 'Kinetics', 'Microbial Sensitivity Tests', 'Osseointegration/drug effects', 'Osteoblasts/cytology/drug effects/enzymology', 'Osteogenesis/drug effects', 'Rats', 'Staphylococcus aureus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21197583/
453,gentamicin,6337803,"Netilmicin (Netromycin, Schering-Plough).",['Guay DR'],"['Animals', 'Bacteria/drug effects', 'Chemical Phenomena', 'Chemistry', 'Costs and Cost Analysis', 'Gentamicins/*therapeutic use', 'Humans', 'Kinetics', 'Netilmicin/adverse effects/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6337803/
454,gentamicin,1147809,Ocular penetration of topically applied gentamicin.,"['Ellerhost B', 'Golden B', 'Jarudi N']","['Animals', 'Conjunctiva/analysis', 'Cornea/analysis', 'Eye/*metabolism', 'Gentamicins/*administration & dosage/analysis/metabolism', 'Humans', 'Male', 'Ophthalmic Solutions', 'Rabbits']",https://pubmed.ncbi.nlm.nih.gov/1147809/
455,gentamicin,9812246,The use of once-daily dosing of gentamicin in obstetrics and gynecology.,"['Wiesenfeld HC', 'Heine RP']","['Bacterial Infections/*drug therapy', 'Drug Administration Schedule', 'Drug Costs', 'Drug Resistance, Microbial', 'Female', 'Genital Diseases, Female/*drug therapy', 'Gentamicins/*administration & dosage/adverse effects/pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9812246/
456,gentamicin,943947,Placental transfer of clindamycin and gentamicin in term pregnancy.,"['Weinstein AJ', 'Gibbs RS', 'Gallagher M']","['Bacterial Infections/prevention & control', 'Cesarean Section', 'Clindamycin/administration & dosage/*metabolism/therapeutic use', 'Female', 'Fetal Blood/metabolism', 'Gentamicins/administration & dosage/*metabolism/therapeutic use', 'Humans', 'Infant, Newborn', 'Kinetics', '*Maternal-Fetal Exchange', 'Placenta/*metabolism', '*Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/943947/
457,gentamicin,994263,Increased dosage requirements of gentamicin in burn patients.,"['Zaske DE', 'Sawchuk RJ', 'Gerding DN', 'Strate RG']","['Adolescent', 'Adult', 'Burns/*complications', 'Child', 'Child, Preschool', 'Gentamicins/*administration & dosage/blood/therapeutic use', 'Half-Life', 'Humans', 'Infant', 'Middle Aged', 'Pseudomonas Infections/drug therapy', 'Wound Infection/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/994263/
458,gentamicin,31102287,A review of population pharmacokinetic models of gentamicin in paediatric patients.,"['Crcek M', 'Zdovc J', 'Kerec Kos M']","['Anti-Bacterial Agents/*administration & dosage/*pharmacokinetics', 'Child', 'Databases, Factual', 'Gentamicins/*administration & dosage/*pharmacokinetics', 'Humans', 'Infusions, Intravenous/methods', 'Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/31102287/
459,gentamicin,7970794,Gentamicin vestibulotoxicity.,"['Halmagyi GM', 'Fattore CM', 'Curthoys IS', 'Wade S']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Gentamicins/administration & dosage/*adverse effects/blood', 'Humans', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Kidney Diseases/chemically induced/complications', 'Male', 'Middle Aged', 'Vestibular Diseases/*chemically induced/complications']",https://pubmed.ncbi.nlm.nih.gov/7970794/
460,prazosin,35688992,Pharmacological Management of Nightmares Associated with Posttraumatic Stress Disorder.,"['Geldenhuys C', 'van den Heuvel LL', 'Steyn P', 'Seedat S']","['Dreams', 'Humans', 'Prazosin/pharmacology/therapeutic use', 'Sleep', '*Sleep Wake Disorders/drug therapy', '*Stress Disorders, Post-Traumatic/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35688992/
461,prazosin,29414272,Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans.,"['Raskind MA', 'Peskind ER', 'Chow B', 'Harris C', 'Davis-Karim A', 'Holmes HA', 'Hart KL', 'McFall M', 'Mellman TA', 'Reist C', 'Romesser J', 'Rosenheck R', 'Shih MC', 'Stein MB', 'Swift R', 'Gleason T', 'Lu Y', 'Huang GD']","['Adrenergic alpha-1 Receptor Antagonists/*administration & dosage/adverse effects', 'Adult', 'Combined Modality Therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Dreams/*drug effects', 'Female', 'Hospitals, Veterans', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*administration & dosage/adverse effects', 'Psychiatric Status Rating Scales', 'Psychotherapy', 'Sleep/drug effects', 'Sleep Wake Disorders/*drug therapy', 'Stress Disorders, Post-Traumatic/*drug therapy/psychology/therapy', 'Suicidal Ideation', 'Treatment Failure', 'United States', '*Veterans']",https://pubmed.ncbi.nlm.nih.gov/29414272/
462,prazosin,1689172,Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia.,['Lepor H'],"['Adrenergic alpha-Agonists/pharmacology', 'Adrenergic alpha-Antagonists/*therapeutic use', 'Brimonidine Tartrate', 'Carbachol/pharmacology', 'Humans', 'Male', 'Muscle Contraction/drug effects', 'Phenylephrine/pharmacology', 'Prazosin/analogs & derivatives/therapeutic use', 'Prostatic Hyperplasia/*drug therapy', 'Quinoxalines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1689172/
463,prazosin,3884988,Vasodilator drugs in the treatment of hypertension.,['Kincaid-Smith P'],"['Calcium Channel Blockers/therapeutic use', 'Captopril/administration & dosage/therapeutic use', 'Cardiac Output/drug effects', 'Diazoxide/adverse effects/therapeutic use', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/*drug therapy', 'Infusions, Parenteral', 'Minoxidil/administration & dosage/adverse effects/therapeutic use', 'Prazosin/therapeutic use', 'Renal Circulation/drug effects', 'Vasodilator Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3884988/
464,prazosin,9021791,"Measures of Proscar, Hytrin, and Cardura side effects.",['Frankel S'],"['Adrenergic alpha-Antagonists/adverse effects', 'Doxazosin/*adverse effects', 'Finasteride/*adverse effects', 'Humans', 'Male', 'Prazosin/adverse effects/*analogs & derivatives', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9021791/
465,prazosin,1676077,Alpha-blocker therapy of hypertension. An unfulfilled promise.,"['Khoury AF', 'Kaplan NM']","['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Doxazosin', 'Humans', 'Hypertension/*drug therapy', 'Lipids/blood', 'Prazosin/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1676077/
466,prazosin,9061268,Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.,"['Eri LM', 'Tveter KJ']","['Adrenergic alpha-Antagonists/adverse effects/economics/*therapeutic use', 'Aged', 'Enzyme Inhibitors/adverse effects/economics/*therapeutic use', 'Finasteride/adverse effects/economics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', ""Practice Patterns, Physicians'"", 'Prazosin/adverse effects/*analogs & derivatives/economics/therapeutic use', 'Prevalence', 'Prostatectomy/*economics', 'Prostatic Hyperplasia/*drug therapy/*economics/epidemiology/surgery', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9061268/
467,prazosin,9160069,Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.,"['McKiernan JM', 'Lowe FC']","['Adrenergic alpha-Antagonists/administration & dosage/*adverse effects/therapeutic use', 'Aged', 'Aged, 80 and over', 'Clinical Trials as Topic', 'Dizziness/chemically induced', 'Humans', 'Hypotension/etiology', 'Male', 'Prazosin/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Prospective Studies', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9160069/
468,prazosin,30395035,Factors Affecting Urinary Retention in Critically Ill Trauma Patients.,"['Fowler S', 'Urban S', 'Taggart H']","['Adult', 'Catheters, Indwelling/*adverse effects', 'Cohort Studies', 'Critical Illness/*therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prognosis', 'Retrospective Studies', 'Risk Factors', 'Spinal Injuries/complications', 'Tamsulosin/*therapeutic use', 'Trauma Centers', 'Treatment Outcome', 'Urinary Catheterization/adverse effects/methods', 'Urinary Retention/*drug therapy/etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/30395035/
469,prazosin,39044238,Effect of low-dose terazosin on arterial stiffness improvement: A pilot study.,"['Guan Y', 'Zhang Y', 'Chen L', 'Ren Y', 'Nie H', 'Ji T', 'Yan J', 'Zhang C', 'Ruan L']","['Humans', '*Vascular Stiffness/drug effects', 'Pilot Projects', 'Male', 'Female', 'Aged', '*Prazosin/analogs & derivatives/pharmacology/administration & dosage/therapeutic use', 'Middle Aged', '*Pulse Wave Analysis', 'Hypertension/drug therapy/physiopathology', 'Ankle Brachial Index']",https://pubmed.ncbi.nlm.nih.gov/39044238/
470,prazosin,690251,Pharmacokinetics of prazosin in man.,"['Hobbs DC', 'Twomey TM', 'Palmer RF']","['Biological Availability', 'Blood Proteins/metabolism', 'Capsules', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Prazosin/administration & dosage/*blood', 'Protein Binding', 'Quinazolines/*blood', 'Solutions']",https://pubmed.ncbi.nlm.nih.gov/690251/
471,prazosin,25036580,Prazosin in the treatment of PTSD.,['Green B'],"['Adolescent', 'Adrenergic alpha-1 Receptor Antagonists/administration & dosage/adverse effects/*pharmacology', 'Adult', 'Humans', 'Prazosin/administration & dosage/adverse effects/*pharmacology', 'Stress Disorders, Post-Traumatic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25036580/
472,prazosin,11750252,"Terazosin, doxazosin, and prazosin: current clinical experience.","['Akduman B', 'Crawford ED']","['Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Adult', 'Aged', 'Doxazosin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prazosin/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Prostatic Hyperplasia/complications/*drug therapy', 'Randomized Controlled Trials as Topic', 'Receptors, Adrenergic, alpha/classification']",https://pubmed.ncbi.nlm.nih.gov/11750252/
473,prazosin,1353110,The cardiovascular effects of alpha-receptor blocking agents.,['Leren P'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Animals', 'Antihypertensive Agents/*therapeutic use', 'Cardiomegaly/drug therapy', 'Cardiovascular System/*drug effects', 'Cost-Benefit Analysis', 'Doxazosin', 'Humans', 'Hypertension/*drug therapy', 'Lipids/blood', 'Prazosin/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1353110/
474,prazosin,7436166,Increased plasma norepinephrine levels during prazosin therapy for severe congestive heart failure.,"['Colucci WS', 'Williams GH', 'Braunwald E']","['Heart Failure/*drug therapy', 'Humans', 'Norepinephrine/*blood', 'Posture', 'Prazosin/*therapeutic use', 'Quinazolines/*therapeutic use', 'Sympathetic Nervous System/drug effects', 'Time Factors', '*Vasodilator Agents']",https://pubmed.ncbi.nlm.nih.gov/7436166/
475,prazosin,38896813,"Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.","['Hart A', 'Aldridge G', 'Zhang Q', 'Narayanan NS', 'Simmering JE']","['Humans', 'Male', '*Doxazosin/therapeutic use', 'Aged', '*Prazosin/analogs & derivatives/therapeutic use', '*Lewy Body Disease/drug therapy', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Quinazolines/therapeutic use/adverse effects', 'Aged, 80 and over', 'Tamsulosin/therapeutic use', 'Prostatic Hyperplasia/drug therapy', 'Neuroprotective Agents/therapeutic use/pharmacology', 'Middle Aged', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38896813/
476,prazosin,2872811,Efficacy of terazosin as an antihypertensive agent.,"['Luther RR', 'Glassman HN', 'Jordan DC', 'Sperzel WD']","['Adolescent', 'Adrenergic alpha-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Adult', 'Black or African American', 'Age Factors', 'Aged', 'Antihypertensive Agents/administration & dosage', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', '*Prazosin/*analogs & derivatives', 'Random Allocation', 'White People']",https://pubmed.ncbi.nlm.nih.gov/2872811/
477,prazosin,29879245,History of posttraumatic stress disorder . priapism . Dx?,"['Dickison C', 'Venable CA']","['Adult', 'Black or African American', 'Antihypertensive Agents/adverse effects/therapeutic use', 'Humans', 'Male', 'Prazosin/*adverse effects/*therapeutic use', 'Priapism/*chemically induced/*therapy', 'Sertraline/*adverse effects/*therapeutic use', 'Stress Disorders, Post-Traumatic/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29879245/
478,prazosin,884789,"Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography.","['Awan NA', 'Miller RR', 'DeMaria AN', 'Maxwell KS', 'Neumann A', 'Mason DT']","['Administration, Oral', 'Adult', 'Aged', '*Ambulatory Care', 'Blood Pressure/drug effects', 'Cardiac Output/drug effects', 'Chronic Disease', 'Coronary Disease/complications', 'Drug Evaluation', 'Dyspnea/drug therapy', 'Echocardiography', 'Exercise Test', 'Female', 'Heart Failure/*drug therapy/etiology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Middle Aged', 'Prazosin/administration & dosage/*therapeutic use', 'Quinazolines/*therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/884789/
479,prazosin,15155119,Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.,['Doggrell SA'],"['Clinical Trials as Topic', 'Doxazosin/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Drug Synergism', '*Drug Therapy, Combination', 'Finasteride/*therapeutic use', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prostatic Hyperplasia/*drug therapy', 'Sulfonamides/therapeutic use', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/15155119/
480,orphenadrine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
481,orphenadrine,29079070,Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.,"['Polito NB', 'Fellows SE']","['Adrenergic Uptake Inhibitors/pharmacology/therapeutic use', 'Chlorpromazine/pharmacology/therapeutic use', 'Dopamine Antagonists/pharmacology/therapeutic use', 'Dopamine D2 Receptor Antagonists/pharmacology/therapeutic use', 'Emergency Service, Hospital/organization & administration', 'GABA-B Receptor Agonists/pharmacology/therapeutic use', 'Hiccup/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/29079070/
482,orphenadrine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
483,orphenadrine,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
484,orphenadrine,9195597,Dopamine/glutamate interactions in Parkinson's disease.,"['Lange KW', 'Kornhuber J', 'Riederer P']","['Animals', 'Basal Ganglia/physiopathology', 'Dopamine/*physiology', 'Excitatory Amino Acid Antagonists/therapeutic use', 'Glutamic Acid/*physiology', 'Humans', 'Parkinson Disease/drug therapy/*physiopathology', 'Synaptic Transmission/physiology']",https://pubmed.ncbi.nlm.nih.gov/9195597/
485,orphenadrine,11277,Extrapyramidal effects of neuroleptics.,"['Korczyn AD', 'Goldberg GJ']","['Adult', 'Age Factors', 'Antipsychotic Agents/adverse effects', 'Clinical Trials as Topic', 'Dyskinesia, Drug-Induced/physiopathology', 'Extrapyramidal Tracts/*drug effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Orphenadrine/therapeutic use', 'Parkinson Disease/drug therapy', 'Parkinson Disease, Secondary/*chemically induced', 'Phenothiazines', 'Sex Factors', 'Time Factors', 'Tranquilizing Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11277/
486,orphenadrine,2083431,Review of oral skeletal muscle relaxants for the craniomandibular disorder (CMD) practitioner.,['Stanko JR'],"['Humans', '*Muscle Relaxants, Central/administration & dosage/pharmacology/therapeutic use', 'Muscle Spasticity/drug therapy', 'Temporomandibular Joint Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2083431/
487,orphenadrine,9889660,[Atypical acute dystonia].,"['Nielsen AS', 'Mors NP']","['Acute Disease', 'Adult', 'Antipsychotic Agents/*adverse effects', 'Aphonia/chemically induced/diagnosis', 'Dyskinesia, Drug-Induced/diagnosis', 'Dystonia/*chemically induced/diagnosis', 'Humans', 'Male', 'Muscle Relaxants, Central/*adverse effects', 'Orphenadrine/*adverse effects', 'Perphenazine/*adverse effects', 'Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9889660/
488,orphenadrine,6933954,Cardiotoxicity from orphenadrine intoxication in humans.,"['Malizia E', 'Sarcinelli L', 'Pascarella M', 'Ambrosini M', 'Smeriglio M', 'Russo A']","['Adolescent', 'Adult', 'Female', 'Heart Diseases/*chemically induced/physiopathology', 'Humans', 'Male', 'Orphenadrine/*poisoning', 'Suicide']",https://pubmed.ncbi.nlm.nih.gov/6933954/
489,orphenadrine,25445036,Effects of antihistamines on the function of human alpha7-nicotinic acetylcholine receptors.,"['Sadek B', 'Khanian SS', 'Ashoor A', 'Prytkova T', 'Ghattas MA', 'Atatreh N', 'Nurulain SM', 'Yang KH', 'Howarth FC', 'Oz M']","['Allosteric Regulation', 'Animals', 'Binding Sites', 'Cells, Cultured', 'Histamine H1 Antagonists/chemistry/metabolism/*pharmacology', 'Histamine H2 Antagonists/chemistry/metabolism/pharmacology', 'Histamine H3 Antagonists/chemistry/metabolism/pharmacology', 'Humans', 'Ketamine/chemistry/metabolism/pharmacology', 'Kinetics', '*Models, Molecular', 'Molecular Conformation', 'Molecular Docking Simulation', 'Nerve Tissue Proteins/*antagonists & inhibitors/genetics/metabolism', 'Oocytes/cytology/drug effects/metabolism', 'Protein Structure, Tertiary', 'Pyrilamine/chemistry/metabolism/*pharmacology', 'Recombinant Proteins/chemistry/metabolism', 'Xenopus laevis', 'alpha7 Nicotinic Acetylcholine Receptor/*antagonists & inhibitors/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25445036/
490,orphenadrine,2578597,Analgesic effects of antihistaminics.,"['Rumore MM', 'Schlichting DA']","['*Analgesia', 'Anesthetics, Local/pharmacology', 'Animals', 'Anxiety/drug therapy', 'Bradykinin/pharmacology', 'Brain/metabolism', 'Calcium/metabolism', 'Cyclic AMP/metabolism', 'Cyclic GMP/metabolism', 'Drug Interactions', 'Female', 'Histamine H1 Antagonists/*pharmacology', 'Histamine Release', 'Humans', 'Kinetics', 'Muscle Contraction/drug effects', 'Narcotics/pharmacology', 'Nociceptors/drug effects', 'Prostaglandins/pharmacology', 'Structure-Activity Relationship', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2578597/
491,orphenadrine,781839,Advances in the management of parkinson's disease.,['Marsden CD'],"['Amantadine/therapeutic use', 'Anesthesia', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Orphenadrine/therapeutic use', 'Parasympatholytics/therapeutic use', 'Parkinson Disease/diagnosis/*drug therapy/surgery', 'Social Adjustment', 'Trihexyphenidyl/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/781839/
492,orphenadrine,24579304,"Ex vivo percutaneous absorption of ketamine, bupivacaine, diclofenac, gabapentin, orphenadrine, and pentoxifylline: comparison of versatile cream vs. reference cream.","['Wang X', 'Black L']","['Administration, Cutaneous', 'Amines/pharmacokinetics', 'Analgesics/administration & dosage/*pharmacokinetics', 'Bupivacaine/pharmacokinetics', 'Chemistry, Pharmaceutical', 'Cyclohexanecarboxylic Acids/pharmacokinetics', 'Diclofenac/pharmacokinetics', 'Gabapentin', 'Humans', 'Ketamine/pharmacokinetics', 'Ointments', 'Orphenadrine/pharmacokinetics', 'Pentoxifylline/pharmacokinetics', '*Skin Absorption', 'gamma-Aminobutyric Acid/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/24579304/
493,orphenadrine,34184488,[The efficacy of the combination of diclofenac and orphenadrine in the treatment of dorsalgia].,"['Zyryanov SK', 'Butranova OI', 'Putsman GA']","['Adult', 'Analgesics', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', '*Diclofenac/therapeutic use', 'Humans', 'Moscow', '*Orphenadrine']",https://pubmed.ncbi.nlm.nih.gov/34184488/
494,orphenadrine,20890791,"Opiate sparing effect of fixed combination of diclophenac and orphenadrine after unilateral total hip arthroplasty: A double-blind, randomized, placebo-controlled, multi-centre clinical trial.","['Gombotz H', 'Lochner R', 'Sigl R', 'Blasl J', 'Herzer G', 'Trimmel H']","['Adult', 'Aged', 'Aged, 80 and over', 'Analgesics/adverse effects/*therapeutic use', '*Arthroplasty, Replacement, Hip', 'Diclofenac/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Narcotics/*administration & dosage', 'Orphenadrine/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/20890791/
495,orphenadrine,6101910,Adverse effects of anticholinergic antiparkinsonian drugs in tardive dyskinesia. An investigation of mechanism.,"['Burnett GB', 'Prange AJ Jr', 'Wilson IC', 'Jolliff LA', 'Creese IC', 'Synder SH']","['Adult', 'Aged', 'Antiparkinson Agents/*adverse effects', 'Antipsychotic Agents/blood', 'Benztropine/adverse effects', 'Dopamine/metabolism', 'Dyskinesia, Drug-Induced/blood/*etiology/metabolism', 'Female', 'Growth Hormone/blood', 'Humans', 'Male', 'Middle Aged', 'Orphenadrine/adverse effects', 'Parasympatholytics/*adverse effects', 'Prolactin/blood', 'Sex Factors', 'Thyrotropin/blood', 'Trihexyphenidyl/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6101910/
496,orphenadrine,24552880,Abuse liability of centrally acting non-opioid analgesics and muscle relaxants--a brief update based on a comparison of pharmacovigilance data and evidence from the literature.,"['Gahr M', 'Freudenmann RW', 'Eller J', 'Schonfeldt-Lecuona C']","['Adolescent', 'Adult', 'Aged', 'Analgesics, Non-Narcotic/*adverse effects', 'Central Nervous System Agents/adverse effects', 'Databases, Pharmaceutical', 'Female', 'Germany/epidemiology', 'Humans', 'Male', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', '*Pharmacovigilance', 'Substance-Related Disorders/*epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24552880/
497,orphenadrine,800383,A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.,"['Capstick N', 'Pudney H']","['Clinical Trials as Topic', 'Depression/chemically induced/*drug therapy', 'Fluphenazine/*adverse effects', 'Humans', 'Orphenadrine/*analogs & derivatives/*therapeutic use', 'Parkinson Disease, Secondary/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/800383/
498,orphenadrine,3760245,Pharmacokinetics of diphenhydramine and a demethylated metabolite following intravenous and oral administration.,"['Blyden GT', 'Greenblatt DJ', 'Scavone JM', 'Shader RI']","['Administration, Oral', 'Adult', 'Chromatography, Gas', 'Diphenhydramine/administration & dosage/*analogs & derivatives/*metabolism', 'Female', 'Half-Life', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Male', 'Orphenadrine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3760245/
499,orphenadrine,216517,Prochlorperazine in childhood: side-effects.,"['Lankamp DJ', 'Willemse J', 'Pikaar SA', 'van Heyst AN']","['Adolescent', 'Child', 'Child, Preschool', 'Consciousness Disorders/chemically induced', 'Dyskinesia, Drug-Induced/etiology', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Muscle Hypertonia/chemically induced', 'Nervous System Diseases/*chemically induced/drug therapy', 'Prochlorperazine/administration & dosage/*adverse effects/antagonists & inhibitors', 'Pyramidal Tracts']",https://pubmed.ncbi.nlm.nih.gov/216517/
500,Lenalidomide,38084760,"Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Sonneveld P', 'Dimopoulos MA', 'Boccadoro M', 'Quach H', 'Ho PJ', 'Beksac M', 'Hulin C', 'Antonioli E', 'Leleu X', 'Mangiacavalli S', 'Perrot A', 'Cavo M', 'Belotti A', 'Broijl A', 'Gay F', 'Mina R', 'Nijhof IS', 'van de Donk NWCJ', 'Katodritou E', 'Schjesvold F', 'Sureda Balari A', 'Rosinol L', 'Delforge M', 'Roeloffzen W', 'Silzle T', 'Vangsted A', 'Einsele H', 'Spencer A', 'Hajek R', 'Jurczyszyn A', 'Lonergan S', 'Ahmadi T', 'Liu Y', 'Wang J', 'Vieyra D', 'van Brummelen EMJ', 'Vanquickelberghe V', 'Sitthi-Amorn A', 'de Boer CJ', 'Carson R', 'Rodriguez-Otero P', 'Blade J', 'Moreau P']","['Humans', 'Antibodies, Monoclonal/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Lenalidomide/administration & dosage/adverse effects', '*Multiple Myeloma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38084760/
501,Lenalidomide,32325490,"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.","['Voorhees PM', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Chari A', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Efebera YA', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Murphy S', 'Lutska Y', 'Pei H', 'Ukropec J', 'Vermeulen J', 'de Boer C', 'Hoehn D', 'Lin TS', 'Richardson PG']","['Adult', 'Aged', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bortezomib/*administration & dosage/adverse effects', 'Combined Modality Therapy', 'Dexamethasone/*administration & dosage', 'Female', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Multiple Myeloma/drug therapy/mortality/pathology/*therapy', 'Patient Selection', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/32325490/
502,Lenalidomide,37738563,Tafasitamab and lenalidomide in large B-cell lymphoma: real-world outcomes in a multicenter retrospective study.,"['Qualls DA', 'Lambert N', 'Caimi PF', 'Merrill M', 'Pullarkat P', 'Godby RC', 'Bond DA', 'Wehmeyer GT', 'Romancik J', 'Amoozgar B', 'Leslie L', 'Nastoupil LJ', 'Crombie JL', 'Abramson JS', 'Khurana A', 'Nowakowski GS', 'Maddocks K', 'Rutherford SC', 'Kahl B', 'Okwali M', 'Buege MJ', 'Seshan V', 'Batlevi CL', 'Salles G']","['Humans', 'Lenalidomide/therapeutic use', 'Treatment Outcome', 'Retrospective Studies', '*Lymphoma, Large B-Cell, Diffuse/drug therapy', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37738563/
503,Lenalidomide,31141632,Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.,"['Facon T', 'Kumar S', 'Plesner T', 'Orlowski RZ', 'Moreau P', 'Bahlis N', 'Basu S', 'Nahi H', 'Hulin C', 'Quach H', 'Goldschmidt H', ""O'Dwyer M"", 'Perrot A', 'Venner CP', 'Weisel K', 'Mace JR', 'Raje N', 'Attal M', 'Tiab M', 'Macro M', 'Frenzel L', 'Leleu X', 'Ahmadi T', 'Chiu C', 'Wang J', 'Van Rampelbergh R', 'Uhlar CM', 'Kobos R', 'Qi M', 'Usmani SZ']","['Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Dexamethasone/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lenalidomide/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Multiple Myeloma/*drug therapy', 'Neutropenia/chemically induced', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/31141632/
504,Lenalidomide,38832972,"Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","['Facon T', 'Dimopoulos MA', 'Leleu XP', 'Beksac M', 'Pour L', 'Hajek R', 'Liu Z', 'Minarik J', 'Moreau P', 'Romejko-Jarosinska J', 'Spicka I', 'Vorobyev VI', 'Besemer B', 'Ishida T', 'Janowski W', 'Kalayoglu-Besisik S', 'Parmar G', 'Robak P', 'Zamagni E', 'Goldschmidt H', 'Martin TG', 'Manier S', 'Mohty M', 'Oprea C', 'Bregeault MF', 'Mace S', 'Berthou C', 'Bregman D', 'Klippel Z', 'Orlowski RZ']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Bortezomib/administration & dosage/adverse effects/therapeutic use', '*Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Kaplan-Meier Estimate', '*Lenalidomide/administration & dosage/adverse effects/therapeutic use', '*Multiple Myeloma/drug therapy/mortality', 'Neoplasm, Residual', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38832972/
505,Lenalidomide,26927826,[Lenalidomide nephrotoxicity].,"['Kheder El-Fekih R', 'Izzedine H']","['Graft vs Host Disease/chemically induced/immunology', 'Humans', 'Immunologic Factors/administration & dosage/*adverse effects/pharmacokinetics', 'Kidney/*drug effects/pathology', 'Kidney Tubules/drug effects/pathology', 'Lenalidomide', 'Necrosis/chemically induced', 'Nephritis, Interstitial/chemically induced', 'Prevalence', '*Renal Insufficiency/epidemiology/metabolism', 'Thalidomide/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26927826/
506,Lenalidomide,30897038,AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.,"['Leonard JP', 'Trneny M', 'Izutsu K', 'Fowler NH', 'Hong X', 'Zhu J', 'Zhang H', 'Offner F', 'Scheliga A', 'Nowakowski GS', 'Pinto A', 'Re F', 'Fogliatto LM', 'Scheinberg P', 'Flinn IW', 'Moreira C', 'Cabecadas J', 'Liu D', 'Kalambakas S', 'Fustier P', 'Wu C', 'Gribben JG']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Female', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Lymphoma, B-Cell, Marginal Zone/*drug therapy', 'Lymphoma, Follicular/*drug therapy', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/drug therapy', 'Placebos', 'Rituximab/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30897038/
507,Lenalidomide,32511983,"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.","['Salles G', 'Duell J', 'Gonzalez Barca E', 'Tournilhac O', 'Jurczak W', 'Liberati AM', 'Nagy Z', 'Obr A', 'Gaidano G', 'Andre M', 'Kalakonda N', 'Dreyling M', 'Weirather J', 'Dirnberger-Hertweck M', 'Ambarkhane S', 'Fingerle-Rowson G', 'Maddocks K']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Drug Resistance, Neoplasm/*drug effects', 'Female', 'Follow-Up Studies', 'Humans', 'Lenalidomide/administration & dosage', 'Lymphoma, Large B-Cell, Diffuse/*drug therapy/pathology', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy/pathology', 'Prospective Studies', '*Salvage Therapy', 'Survival Rate', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32511983/
508,Lenalidomide,35660812,"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma.","['Richardson PG', 'Jacobus SJ', 'Weller EA', 'Hassoun H', 'Lonial S', 'Raje NS', 'Medvedova E', 'McCarthy PL', 'Libby EN', 'Voorhees PM', 'Orlowski RZ', 'Anderson LD Jr', 'Zonder JA', 'Milner CP', 'Gasparetto C', 'Agha ME', 'Khan AM', 'Hurd DD', 'Gowin K', 'Kamble RT', 'Jagannath S', 'Nathwani N', 'Alsina M', 'Cornell RF', 'Hashmi H', 'Campagnaro EL', 'Andreescu AC', 'Gentile T', 'Liedtke M', 'Godby KN', 'Cohen AD', 'Openshaw TH', 'Pasquini MC', 'Giralt SA', 'Kaufman JL', 'Yee AJ', 'Scott E', 'Torka P', 'Foley A', 'Fulciniti M', 'Hebert K', 'Samur MK', 'Masone K', 'Maglio ME', 'Zeytoonjian AA', 'Nadeem O', 'Schlossman RL', 'Laubach JP', 'Paba-Prada C', 'Ghobrial IM', 'Perrot A', 'Moreau P', 'Avet-Loiseau H', 'Attal M', 'Anderson KC', 'Munshi NC']","['Adult', 'Antineoplastic Agents/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Bortezomib/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease Progression', 'Disease-Free Survival', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', '*Maintenance Chemotherapy/methods', 'Melphalan/administration & dosage', '*Multiple Myeloma/diagnosis/drug therapy/surgery', '*Stem Cell Transplantation', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35660812/
509,Lenalidomide,32586576,Immunomodulatory Agents in Follicular Lymphoma.,"['Ysebaert L', 'Morschhauser F']","['Antineoplastic Agents/pharmacology/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Biomarkers, Tumor', 'Humans', 'Immune Checkpoint Inhibitors/pharmacology/therapeutic use', 'Immunologic Factors/pharmacology/*therapeutic use', 'Immunological Synapses/drug effects', 'Immunomodulation/*drug effects', 'Lenalidomide/pharmacology/therapeutic use', 'Lymphoma, Follicular/diagnosis/*drug therapy/etiology/mortality', 'Molecular Targeted Therapy', 'Treatment Outcome', 'Tumor Microenvironment/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/32586576/
510,Lenalidomide,38820500,Randomized study of induction with bendamustine-rituximab +/- bortezomib and maintenance with rituximab +/- lenalidomide for MCL.,"['Smith MR', 'Jegede OA', 'Martin P', 'Till BG', 'Parekh SS', 'Yang DT', 'Hsi ED', 'Witzig T', 'Dave S', 'Scott D', 'Hanson C', 'Kostakoglu Shields L', 'Abdel-Samad N', 'Casulo C', 'Bartlett NL', 'Caimi PF', 'Al Baghdadi T', 'Blum KA', 'Romer MD', 'Inwards DJ', 'Lerner RE', 'Wagner LI', 'Little RF', 'Friedberg JW', 'Leonard JP', 'Kahl BS']","['Humans', '*Rituximab/administration & dosage/therapeutic use', '*Bendamustine Hydrochloride/administration & dosage/therapeutic use', '*Bortezomib/administration & dosage/therapeutic use', '*Lenalidomide/administration & dosage/therapeutic use', 'Female', 'Male', 'Middle Aged', 'Aged', '*Lymphoma, Mantle-Cell/drug therapy/mortality/pathology', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Maintenance Chemotherapy', 'Aged, 80 and over', 'Adult', 'Induction Chemotherapy', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38820500/
511,Lenalidomide,38899693,Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.,"['Melani C', 'Lakhotia R', 'Pittaluga S', 'Phelan JD', 'Huang DW', 'Wright G', 'Simard J', 'Muppidi J', 'Thomas CJ', 'Ceribelli M', 'Tosto FA', 'Yang Y', 'Xu W', 'Davies-Hill T', 'Pack SD', 'Peer CJ', 'Arisa O', 'Mena E', 'Lindenberg L', 'Bergvall E', 'Portell CA', 'Farah RJ', 'Lee ST', 'Pradhan A', 'Morrison C', 'Tadese A', 'Juanitez AM', 'Lu C', 'Jacob A', 'Simmons H', 'Figg WD', 'Steinberg SM', 'Jaffe ES', 'Roschewski M', 'Staudt LM', 'Wilson WH']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Adenine/analogs & derivatives/adverse effects/therapeutic use/administration & dosage', '*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bridged Bicyclo Compounds, Heterocyclic/adverse effects/therapeutic use/administration & dosage', '*Lenalidomide/adverse effects/administration & dosage/therapeutic use', '*Lymphoma, Large B-Cell, Diffuse/drug therapy/mortality', 'Molecular Targeted Therapy', '*Piperidines/adverse effects/therapeutic use/administration & dosage', 'Prednisone/adverse effects/administration & dosage/therapeutic use', 'Progression-Free Survival', 'Pyrazoles/adverse effects/therapeutic use/administration & dosage', 'Pyrimidines/adverse effects/therapeutic use/administration & dosage', 'Recurrence', 'Sulfonamides/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38899693/
512,Lenalidomide,32976949,Mechanisms of lenalidomide sensitivity and resistance.,"['Martinez-Hoyer S', 'Karsan A']","['Adaptor Proteins, Signal Transducing/antagonists & inhibitors', 'Anemia, Macrocytic/drug therapy/physiopathology', 'Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Antineoplastic Agents/*pharmacology/therapeutic use', 'Autophagy/drug effects', 'Cell Differentiation/drug effects', 'Chromosome Deletion', 'Chromosomes, Human, Pair 5', 'Cytokines/metabolism', 'Disease Progression', 'Drug Resistance, Neoplasm/physiology', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Ikaros Transcription Factor/antagonists & inhibitors', 'Immunologic Factors/*pharmacology/therapeutic use', 'Lenalidomide/*pharmacology/therapeutic use', 'Megakaryocytes/drug effects', 'Multiple Myeloma/drug therapy/physiopathology', 'Neoplasm Proteins/antagonists & inhibitors', 'Neovascularization, Pathologic/drug therapy/physiopathology', 'Phosphoprotein Phosphatases/antagonists & inhibitors', 'Ubiquitin-Protein Ligases/antagonists & inhibitors/physiology']",https://pubmed.ncbi.nlm.nih.gov/32976949/
513,Lenalidomide,32430504,Genetics of progression from MDS to secondary leukemia.,"['Menssen AJ', 'Walter MJ']","['Cell Count', 'Clonal Evolution', 'DNA Methylation/drug effects', 'DNA Mutational Analysis', 'Disease Progression', 'Epigenesis, Genetic', 'Hematopoietic Stem Cells/pathology', 'Humans', 'Lenalidomide/pharmacology/therapeutic use', 'Leukemia, Myeloid, Acute/etiology/*genetics/prevention & control', 'Mutation', 'Myelodysplastic Syndromes/drug therapy/*genetics/pathology', 'Myelopoiesis', 'Neoplastic Stem Cells/pathology', 'Prognosis', 'Tumor Burden', 'Exome Sequencing', 'Whole Genome Sequencing']",https://pubmed.ncbi.nlm.nih.gov/32430504/
514,Lenalidomide,37506339,"Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.","['Rosinol L', 'Oriol A', 'Rios R', 'Blanchard MJ', 'Jarque I', 'Bargay J', 'Hernandez MT', 'Cabanas V', 'Carrillo-Cruz E', 'Sureda A', 'Martinez-Lopez J', 'Krsnik I', 'Gonzalez ME', 'Casado LF', 'Marti JM', 'Encinas C', 'de Arriba F', 'Palomera L', 'Sampol A', 'Gonzalez-Montes Y', 'Cabezudo E', 'Paiva B', 'Puig N', 'Cedena MT', 'de la Cruz J', 'Mateos MV', 'San Miguel J', 'Lahuerta JJ', 'Blade J']","['Humans', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Dexamethasone/therapeutic use', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/therapy']",https://pubmed.ncbi.nlm.nih.gov/37506339/
515,Lenalidomide,37500385,[Treatment of lower risk myelodysplastic syndromes].,['Park S'],"['Humans', '*Myelodysplastic Syndromes/complications/drug therapy', 'Lenalidomide/therapeutic use', '*Anemia/drug therapy/complications', '*Hematinics/therapeutic use', 'Risk', '*Thrombocytopenia/complications']",https://pubmed.ncbi.nlm.nih.gov/37500385/
516,Lenalidomide,38977707,Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.,"['Chari A', 'Kaufman JL', 'Laubach J', 'Sborov DW', 'Reeves B', 'Rodriguez C', 'Silbermann R', 'Costa LJ', 'Anderson LD Jr', 'Nathwani N', 'Shah N', 'Bumma N', 'Holstein SA', 'Costello C', 'Jakubowiak A', 'Wildes TM', 'Orlowski RZ', 'Shain KH', 'Cowan AJ', 'Pei H', 'Cortoos A', 'Patel S', 'Lin TS', 'Voorhees PM', 'Usmani SZ', 'Richardson PG']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Antibodies, Monoclonal/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Bortezomib/therapeutic use/administration & dosage', 'Dexamethasone/administration & dosage/therapeutic use', 'Lenalidomide/therapeutic use/administration & dosage', '*Multiple Myeloma/drug therapy/mortality/therapy/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/38977707/
517,Lenalidomide,31652094,Randomized Trial of Lenalidomide Versus Observation in Smoldering Multiple Myeloma.,"['Lonial S', 'Jacobus S', 'Fonseca R', 'Weiss M', 'Kumar S', 'Orlowski RZ', 'Kaufman JL', 'Yacoub AM', 'Buadi FK', ""O'Brien T"", 'Matous JV', 'Anderson DM', 'Emmons RV', 'Mahindra A', 'Wagner LI', 'Dhodapkar MV', 'Rajkumar SV']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Lenalidomide/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Quality of Life', 'Smoldering Multiple Myeloma/*drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/31652094/
518,Lenalidomide,35717005,Evidence-based recommendations for induction and maintenance treatment of newly diagnosed transplant-ineligible multiple myeloma patients.,"['Rafae A', 'Ehsan H', 'Wahab A', 'Khan SI', 'Khan I', 'Ashraf S', 'Ali S', 'Khalid F', 'Neupane K', 'Valent J', 'Khouri J', 'Samaras C', 'Mazzoni S', 'Anwer F']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Bortezomib', 'Dexamethasone', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Humans', 'Lenalidomide/therapeutic use', '*Multiple Myeloma/diagnosis/drug therapy', 'Transplantation, Autologous']",https://pubmed.ncbi.nlm.nih.gov/35717005/
519,Lenalidomide,33763699,"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.","['Facon T', 'Venner CP', 'Bahlis NJ', 'Offner F', 'White DJ', 'Karlin L', 'Benboubker L', 'Rigaudeau S', 'Rodon P', 'Voog E', 'Yoon SS', 'Suzuki K', 'Shibayama H', 'Zhang X', 'Twumasi-Ankrah P', 'Yung G', 'Rifkin RM', 'Moreau P', 'Lonial S', 'Kumar SK', 'Richardson PG', 'Rajkumar SV']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Boron Compounds/administration & dosage/adverse effects', 'Dexamethasone/administration & dosage/adverse effects', 'Disease-Free Survival', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Lenalidomide/administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Multiple Myeloma/diagnosis/drug therapy/mortality', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/33763699/
520,leflunomide,30173215,Rheumatoid Arthritis: A Brief Overview of the Treatment.,"['Bullock J', 'Rizvi SAA', 'Saleh AM', 'Ahmed SS', 'Do DP', 'Ansari RA', 'Ahmed J']","['Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antirheumatic Agents/adverse effects/therapeutic use', 'Arthritis, Rheumatoid/complications/*drug therapy/surgery', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Interleukin 1 Receptor Antagonist Protein/therapeutic use', 'Leflunomide/therapeutic use', 'Physical Therapy Modalities', 'Risk Factors', 'Tumor Necrosis Factor-alpha/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30173215/
521,leflunomide,30114347,Takayasu arteritis: an update.,"['Keser G', 'Aksu K', 'Direskeneli H']","['Antibodies, Monoclonal, Humanized/therapeutic use', 'Biomarkers/metabolism', 'Endovascular Procedures/*methods', 'Guidelines as Topic', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Leflunomide/therapeutic use', 'Physical Examination', 'Prognosis', 'Radiology, Interventional', '*Takayasu Arteritis/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30114347/
522,leflunomide,21962758,Leflunomide in dermatology.,['Boyd AS'],"['Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Psoriasis/drug therapy', 'Skin Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21962758/
523,leflunomide,39504368,Mitochondrial elongation impairs breast cancer metastasis.,"['Minarrieta L', 'Annis MG', 'Audet-Delage Y', 'Kuasne H', 'Pacis A', 'St-Louis C', 'Nowakowski A', 'Biondini M', 'Khacho M', 'Park M', 'Siegel PM', 'St-Pierre J']","['Humans', '*Breast Neoplasms/pathology/metabolism/genetics', 'Female', '*Mitochondria/metabolism/pathology', '*Mitochondrial Dynamics/drug effects', 'Animals', 'Cell Line, Tumor', '*Neoplasm Metastasis', 'Mice', 'Mitochondrial Proteins/metabolism/genetics', 'Leflunomide/pharmacology', 'Dynamins/metabolism/genetics']",https://pubmed.ncbi.nlm.nih.gov/39504368/
524,leflunomide,36710223,"Biological and immunosuppressive medications in pregnancy, breastfeeding and fertility in immune mediated diseases.","['Ibarra Barrueta O', 'Garcia Martin E', 'Lopez Sanchez P', 'Ramirez Herraiz E', 'Merino Bohorquez V', 'Ais Larisgoitia A']","['Pregnancy', 'Humans', 'Male', 'Female', '*Antirheumatic Agents/adverse effects', 'Breast Feeding', 'Leflunomide/therapeutic use', 'Prospective Studies', 'Tumor Necrosis Factor Inhibitors', 'Immunosuppressive Agents/adverse effects', 'Fertility']",https://pubmed.ncbi.nlm.nih.gov/36710223/
525,leflunomide,12661795,Leflunomide.,"['Cohen SB', 'Iqbal I']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Female', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide', 'Male', 'Middle Aged', 'Product Surveillance, Postmarketing', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12661795/
526,leflunomide,28867467,Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis.,"['Alfaro-Lara R', 'Espinosa-Ortega HF', 'Arce-Salinas CA']","['Alanine Transaminase/blood', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Antirheumatic Agents/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Aspartate Aminotransferases/blood', 'C-Reactive Protein/analysis', 'Chemical and Drug Induced Liver Injury/etiology', 'Clinical Trials as Topic', 'Disability Evaluation', 'Drug Therapy, Combination', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Leflunomide/adverse effects/*therapeutic use', 'Methotrexate/adverse effects/*therapeutic use', 'Treatment Outcome', 'gamma-Glutamyltransferase/analysis']",https://pubmed.ncbi.nlm.nih.gov/28867467/
527,leflunomide,29357281,Leflunomide: A promising drug with good antitumor potential.,"['Zhang C', 'Chu M']","['Angiogenesis Inhibitors/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Humans', 'Immunologic Factors/pharmacology/therapeutic use', 'Isoxazoles/pharmacology/*therapeutic use', 'Leflunomide', 'Neoplasms/*drug therapy/pathology', 'Neoplastic Stem Cells/drug effects/pathology']",https://pubmed.ncbi.nlm.nih.gov/29357281/
528,leflunomide,27283340,Challenges and treatment options for rheumatoid arthritis during pregnancy.,"['Gerosa M', 'Schioppo T', 'Meroni PL']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/*epidemiology', 'Biological Products/therapeutic use', 'Female', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Isoxazoles/therapeutic use', 'Leflunomide', 'Methotrexate/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy/*epidemiology', 'Sulfasalazine/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27283340/
529,leflunomide,14971821,Leflunomide-induced acute hepatitis.,"['Sevilla-Mantilla C', 'Ortega L', 'Agundez JA', 'Fernandez-Gutierrez B', 'Ladero JM', 'Diaz-Rubio M']","['Adjuvants, Immunologic/*adverse effects/therapeutic use', 'Aged', 'Anion Exchange Resins/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Chemical and Drug Induced Liver Injury/drug therapy/*etiology/pathology', 'Cholestyramine Resin/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Liver/pathology']",https://pubmed.ncbi.nlm.nih.gov/14971821/
530,leflunomide,31324351,[Treatment of giant cell arteritis].,"['Samson M', 'Greigert H', 'Ghesquiere T', 'Bonnotte B']","['Abatacept/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antibodies, Monoclonal, Humanized/*therapeutic use', 'Aspirin/therapeutic use', 'Azathioprine/therapeutic use', 'Drug Administration Schedule', 'Giant Cell Arteritis/complications/*drug therapy', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Methotrexate/*therapeutic use', 'Prednisone/*therapeutic use', 'Ustekinumab/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31324351/
531,leflunomide,17094333,Leflunomide in clinical practice.,"['Pinto P', 'Dougados M']","['Antirheumatic Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Isoxazoles/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/17094333/
532,leflunomide,39320955,Leflunomide nanocarriers: a new prospect of therapeutic applications.,['Zewail M'],"['*Leflunomide/chemistry/therapeutic use/pharmacology/pharmacokinetics', 'Humans', '*Hydroxybutyrates/chemistry', '*Antirheumatic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use/pharmacology', '*Toluidines/chemistry/therapeutic use/pharmacokinetics', 'Animals', 'Nanoparticles/chemistry', 'Nitriles/chemistry', 'Drug Carriers/chemistry', 'Crotonates/chemistry/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Neoplasms/drug therapy', 'Multiple Sclerosis/drug therapy', 'Isoxazoles/chemistry/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39320955/
533,leflunomide,12003373,Leflunomide for the treatment of rheumatoid arthritis and autoimmunity.,"['Sanders S', 'Harisdangkul V']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Autoimmune Diseases/*drug therapy', 'Clinical Trials as Topic', 'Humans', 'Isoxazoles/adverse effects/*therapeutic use', 'Leflunomide']",https://pubmed.ncbi.nlm.nih.gov/12003373/
534,leflunomide,12783594,Leflunomide for the treatment of rheumatoid arthritis.,"['Miceli-Richard C', 'Dougados M']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Contraindications', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/adverse effects/*pharmacology', 'Isoxazoles/adverse effects/*pharmacology', 'Leflunomide', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/12783594/
535,leflunomide,22961090,Leflunomide: friend or foe for systemic lupus erythematosus?,"['Wu GC', 'Xu XD', 'Huang Q', 'Wu H']","['Animals', 'Autoimmunity', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Isoxazoles/adverse effects/pharmacology/*therapeutic use', 'Leflunomide', 'Lupus Erythematosus, Systemic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22961090/
536,leflunomide,15182800,Leflunomide-induced aseptic meningitis.,"['Cohen JD', 'Jorgensen C', 'Sany J']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Humans', 'Isoxazoles/*adverse effects/therapeutic use', 'Leflunomide', 'Male', 'Meningitis, Aseptic/*chemically induced', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/15182800/
537,leflunomide,29039518,Leflunomide inhibits proliferation and tumorigenesis of oral squamous cell carcinoma.,"['Ren A', 'Fu G', 'Qiu Y', 'Cui H']","['Animals', 'Apoptosis/drug effects', 'Carcinogenesis/*drug effects', 'Carcinoma, Squamous Cell/*etiology/*pathology', 'Cell Cycle/drug effects', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Disease Models, Animal', 'Humans', 'Isoxazoles/*pharmacology', 'Leflunomide', 'Mice', 'Mouth Neoplasms/*etiology/*pathology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/29039518/
538,leflunomide,32356683,Noninfectious aortitis: A case report.,"['Jaikaran O', 'Nicoara M', 'Hingorani A']","['Abdominal Pain/etiology', 'Aged', 'Aortitis/diagnostic imaging/drug therapy/*etiology', 'Back Pain/etiology', 'Glucocorticoids/therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Leflunomide/therapeutic use', 'Male', 'Methylprednisolone/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32356683/
539,leflunomide,15172042,Leflunomide.,"['Cannon GW', 'Kremer JM']","['Antirheumatic Agents/*pharmacology/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Drug Monitoring/methods', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/*pharmacology/therapeutic use', 'Isoxazoles/*pharmacology/therapeutic use', 'Joints/drug effects/pathology', 'Leflunomide', 'Liver/drug effects/pathology', 'Methotrexate/*therapeutic use', 'Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/15172042/
540,zolpidem,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
541,zolpidem,32044373,On the pathophysiology and treatment of akinetic mutism.,"['Arnts H', 'van Erp WS', 'Lavrijsen JCM', 'van Gaal S', 'Groenewegen HJ', 'van den Munckhof P']","['Adrenergic Uptake Inhibitors/*therapeutic use', '*Akinetic Mutism/drug therapy/pathology/physiopathology', 'Animals', 'Dopamine Agonists/*therapeutic use', 'Dopamine Uptake Inhibitors/*therapeutic use', '*Dopaminergic Neurons/drug effects/pathology/physiology', 'GABA-A Receptor Agonists/*therapeutic use', '*Gray Matter/drug effects/pathology/physiopathology', 'Humans', '*Motivation/drug effects/physiology', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32044373/
542,zolpidem,19584967,Novel zolpidem formulations.,['Owen RT'],"['Administration, Oral', 'Administration, Sublingual', 'Aerosols', 'Delayed-Action Preparations', 'Dosage Forms', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/*pharmacokinetics/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19584967/
543,zolpidem,31880796,Comparison of Lemborexant With Placebo and Zolpidem Tartrate Extended Release for the Treatment of Older Adults With Insomnia Disorder: A Phase 3 Randomized Clinical Trial.,"['Rosenberg R', 'Murphy P', 'Zammit G', 'Mayleben D', 'Kumar D', 'Dhadda S', 'Filippov G', 'LoPresti A', 'Moline M']","['Aged', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Middle Aged', 'Polysomnography', 'Pyridines/*therapeutic use', 'Pyrimidines/*therapeutic use', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31880796/
544,zolpidem,38153735,Effect of Psychological and Medication Therapies for Insomnia on Daytime Functions: A Randomized Clinical Trial.,"['Morin CM', 'Chen SJ', 'Ivers H', 'Beaulieu-Bonneau S', 'Krystal AD', 'Guay B', 'Belanger L', 'Cartwright A', 'Simmons B', 'Lamy M', 'Busby M', 'Edinger JD']","['Adult', 'Female', 'Humans', 'Middle Aged', 'Behavior Therapy', 'Fatigue', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Trazodone', 'Zolpidem/therapeutic use', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38153735/
545,zolpidem,31953863,"Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder.","['Dauvilliers Y', 'Zammit G', 'Fietze I', 'Mayleben D', 'Seboek Kinter D', 'Pain S', 'Hedner J']","['Adult', 'Benzimidazoles/*administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Imidazoles', 'Middle Aged', 'Orexin Receptor Antagonists/adverse effects/therapeutic use', 'Pyrrolidines/*administration & dosage/adverse effects/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Triazoles/*administration & dosage/adverse effects/therapeutic use', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31953863/
546,zolpidem,38630476,Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.,"['Takeshima M', 'Yoshizawa K', 'Ogasawara M', 'Kudo M', 'Itoh Y', 'Ayabe N', 'Mishima K']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', 'Eszopiclone', 'Hypnotics and Sedatives/adverse effects', '*Indenes', 'Japan', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Failure', '*Triazolam', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38630476/
547,zolpidem,18221242,Zolpidem therapy for movement disorders.,['Abe K'],"['Animals', 'GABA Agonists/*therapeutic use', 'Humans', 'Movement Disorders/*drug therapy', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18221242/
548,zolpidem,37993186,Pharmacology in Treatment of Patients with Disorders of Consciousness.,['Marino MH'],"['Humans', '*Consciousness/physiology', 'Zolpidem/therapeutic use', 'Consciousness Disorders/drug therapy', '*Brain Injuries', 'Amantadine/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37993186/
549,zolpidem,8853211,Polysomnographic effects of hypnotic drugs. A review.,"['Parrino L', 'Terzano MG']","['Adult', 'Anti-Anxiety Agents/pharmacology/*therapeutic use', 'Azabicyclo Compounds', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/pharmacology/*therapeutic use', 'Middle Aged', 'Piperazines/pharmacology/therapeutic use', 'Polysomnography/*drug effects', 'Pyridines/pharmacology/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8853211/
550,zolpidem,27974380,Incorporation of Zolpidem into Hair and Its Distribution after a Single Administration.,"['Shima N', 'Sasaki K', 'Kamata T', 'Matsuta S', 'Wada M', 'Kakehashi H', 'Nakano S', 'Kamata H', 'Nishioka H', 'Sato T', 'Tsuchihashi H', 'Miki A', 'Katagi M']","['Adult', 'Biological Transport', 'Chromatography, Liquid', 'Drug Monitoring/*methods', 'Female', 'Hair/*chemistry', 'Healthy Volunteers', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*pharmacokinetics', 'Limit of Detection', 'Male', 'Pyridines/administration & dosage/*pharmacokinetics', 'Reproducibility of Results', 'Substance Abuse Detection/*methods', 'Tandem Mass Spectrometry', 'Time Factors', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/27974380/
551,zolpidem,15651908,Zolpidem: a review of its use in the management of insomnia.,"['Swainston Harrison T', 'Keating GM']","['Age Factors', 'Clinical Trials as Topic/methods', 'Drug Administration Schedule', 'Drug Evaluation/methods', 'GABA Agonists/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*therapeutic use', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Substance Withdrawal Syndrome/etiology', 'Treatment Outcome', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15651908/
552,zolpidem,34818157,Successful accelerated taper for sleeping aid.,"['Franck L', 'Prescott D', 'Smith S']","['Drug Administration Schedule', 'Humans', 'Male', 'Middle Aged', 'Sleep Aids, Pharmaceutical/*administration & dosage', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Treatment Outcome', 'Zolpidem/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/34818157/
553,zolpidem,22424586,Zolpidem for insomnia.,"['Greenblatt DJ', 'Roth T']","['Animals', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/22424586/
554,zolpidem,15352681,Zolpidem for postanoxic spasticity.,"['Shadan FF', 'Poceta JS', 'Kline LE']","['Adult', 'GABA Agonists/*therapeutic use', 'Heart Arrest/complications', 'Humans', 'Male', 'Muscle Spasticity/*drug therapy/etiology', 'Pyridines/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/15352681/
555,zolpidem,11062863,The effect of zolpidem and zopiclone on memory.,"['Isawa S', 'Suzuki M', 'Uchiumi M', 'Murasaki M']","['Adult', 'Azabicyclo Compounds', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Memory, Short-Term/drug effects', 'Mental Recall/drug effects', 'Piperazines/*pharmacology', 'Pyridines/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11062863/
556,zolpidem,16696581,Zolpidem extended-release.,"['Moen MD', 'Plosker GL']","['Adolescent', 'Adult', 'Delayed-Action Preparations/*administration & dosage/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Evaluation', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/pharmacokinetics', 'Male', 'Middle Aged', 'Polysomnography', 'Practice Guidelines as Topic', 'Pyridines/*administration & dosage/pharmacokinetics', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy/metabolism', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16696581/
557,zolpidem,19644424,Catatonia recognition and treatment.,"['Cottencin O', 'Danel T', 'Goudemand M', 'Thomas P', 'Consoli SM']","['Catatonia/*diagnosis/*drug therapy', 'Female', 'Humans', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Pyridines/administration & dosage/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/19644424/
558,zolpidem,28262178,Zolpidem's use for insomnia.,"['Monti JM', 'Spence DW', 'Buttoo K', 'Pandi-Perumal SR']","['Humans', 'Hypnotics and Sedatives/administration & dosage/pharmacokinetics/*pharmacology', 'Pyridines/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28262178/
559,zolpidem,30870203,A Pilot Crossover Trial of Sleep Medications for Sleep-disturbed Methadone Maintenance Patients.,"['Stein MD', 'Kurth ME', 'Anderson BJ', 'Blevins CE']","['Actigraphy', 'Adult', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'GABA-A Receptor Agonists/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Male', 'Methadone/*therapeutic use', 'Middle Aged', 'Mirtazapine/*therapeutic use', '*Opiate Substitution Treatment', 'Pilot Projects', 'Serotonin Antagonists/therapeutic use', 'Sleep/*drug effects', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Latency/drug effects', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30870203/
560,metformin,25456737,Metformin: from mechanisms of action to therapies.,"['Foretz M', 'Guigas B', 'Bertrand L', 'Pollak M', 'Viollet B']","['AMP-Activated Protein Kinases/metabolism', 'Animals', 'Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Energy Metabolism/drug effects', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Metformin/*therapeutic use', 'Oxidative Phosphorylation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25456737/
561,metformin,24393785,Metformin--mode of action and clinical implications for diabetes and cancer.,"['Pernicova I', 'Korbonits M']","['AMP-Activated Protein Kinases/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Energy Metabolism/drug effects', 'Glucagon/metabolism', 'Gluconeogenesis/drug effects', 'Humans', 'Liver/*drug effects/metabolism', 'Metformin/*pharmacology/therapeutic use', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24393785/
562,metformin,37397787,Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes.,"['Dutta S', 'Shah RB', 'Singhal S', 'Dutta SB', 'Bansal S', 'Sinha S', 'Haque M']","['Female', 'Humans', '*Metformin/pharmacology/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy', 'Hypoglycemic Agents/pharmacology/therapeutic use', '*Neoplasms/drug therapy', 'Glucose/metabolism', 'AMP-Activated Protein Kinases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37397787/
563,metformin,37786390,Early Metformin in Gestational Diabetes: A Randomized Clinical Trial.,"['Dunne F', 'Newman C', 'Alvarez-Iglesias A', 'Ferguson J', 'Smyth A', 'Browne M', ""O'Shea P"", 'Devane D', 'Gillespie P', 'Bogdanet D', 'Kgosidialwa O', 'Egan A', 'Finn Y', 'Gaffney G', 'Khattak A', ""O'Keeffe D"", 'Liew A', ""O'Donnell M""]","['Adult', 'Female', 'Humans', 'Infant, Newborn', 'Pregnancy', 'Birth Weight', '*Diabetes, Gestational/drug therapy', 'Hypoglycemic Agents/administration & dosage/adverse effects/therapeutic use', 'Insulin/administration & dosage/therapeutic use', '*Metformin/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37786390/
564,metformin,28258677,Metformin - its potential anti-cancer and anti-aging effects.,"['Podhorecka M', 'Ibanez B', 'Dmoszynska A']","['Animals', 'Antineoplastic Agents/pharmacokinetics', 'Cell Death/drug effects', 'Glucose/metabolism', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Metformin/*pharmacology', 'Neoplasms/*drug therapy', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28258677/
565,metformin,35640743,Metformin: Is it a drug for all reasons and diseases?,"['Triggle CR', 'Mohammed I', 'Bshesh K', 'Marei I', 'Ye K', 'Ding H', 'MacDonald R', 'Hollenberg MD', 'Hill MA']","['Animals', '*Diabetes Mellitus, Type 2/drug therapy', 'Female', 'Humans', 'Hypoglycemic Agents/pharmacology/therapeutic use', 'Insulin/metabolism', 'Mammals/metabolism', '*Metformin/pharmacology/therapeutic use', 'Reproducibility of Results', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35640743/
566,metformin,32994049,Metformin and Systemic Metabolism.,['He L'],"['Animals', 'Glucose/metabolism', 'Glycolysis/drug effects', 'Humans', 'Hyperglycemia/*drug therapy/metabolism', 'Intestinal Mucosa/drug effects/metabolism', 'Intestines/drug effects/microbiology', 'Lipid Metabolism/drug effects', 'Liver/drug effects/metabolism', 'Metabolism/drug effects', 'Metformin/administration & dosage/pharmacokinetics/*pharmacology', 'Microbiota/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32994049/
567,metformin,21241070,Clinical pharmacokinetics of metformin.,"['Graham GG', 'Punt J', 'Arora M', 'Day RO', 'Doogue MP', 'Duong JK', 'Furlong TJ', 'Greenfield JR', 'Greenup LC', 'Kirkpatrick CM', 'Ray JE', 'Timmins P', 'Williams KM']","['Administration, Oral', 'Biological Availability', 'Blood Glucose/*analysis', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Half-Life', 'Humans', 'Hypoglycemic Agents/administration & dosage/*pharmacokinetics/therapeutic use', 'Injections, Intravenous', 'Metformin/administration & dosage/*pharmacokinetics/therapeutic use', 'Organic Cation Transport Proteins/*genetics/metabolism', 'Polymorphism, Single Nucleotide', 'Renal Insufficiency/metabolism']",https://pubmed.ncbi.nlm.nih.gov/21241070/
568,metformin,33689478,The intersection of metformin and inflammation.,"['Bharath LP', 'Nikolajczyk BS']","['Animals', 'Anti-Inflammatory Agents/*therapeutic use', 'Autophagy-Related Proteins/metabolism', 'Humans', 'Inflammation/*drug therapy/metabolism/pathology', 'Inflammation Mediators/metabolism', 'Metformin/*therapeutic use', 'Mitochondria/*drug effects/metabolism/pathology', 'Mitophagy/*drug effects', 'Signal Transduction']",https://pubmed.ncbi.nlm.nih.gov/33689478/
569,metformin,26059289,Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention.,"['Hostalek U', 'Gwilt M', 'Hildemann S']","['Diabetes Mellitus, Type 2/*prevention & control', 'Humans', 'Hypoglycemic Agents/pharmacology/therapeutic use', 'Metformin/adverse effects/pharmacology/*therapeutic use', 'Prediabetic State/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26059289/
570,metformin,37344841,Metformin and cancer hallmarks: shedding new lights on therapeutic repurposing.,"['Hua Y', 'Zheng Y', 'Yao Y', 'Jia R', 'Ge S', 'Zhuang A']","['Humans', '*Metformin/pharmacology/therapeutic use', 'Blood Glucose', 'Drug Repositioning', '*Neoplasms/drug therapy/pathology', '*Insulins/therapeutic use', 'Hypoglycemic Agents/pharmacology/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37344841/
571,metformin,33524789,The effects of metformin on autophagy.,"['Lu G', 'Wu Z', 'Shang J', 'Xie Z', 'Chen C', 'Zhang C']","['Animals', 'Autophagy/*drug effects', 'Autophagy-Related Proteins/*metabolism', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Metformin/adverse effects/*therapeutic use', 'Signal Transduction']",https://pubmed.ncbi.nlm.nih.gov/33524789/
572,metformin,9428832,"Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial.","['Garber AJ', 'Duncan TG', 'Goodman AM', 'Mills DJ', 'Rohlf JL']","['Adult', 'Aged', 'Analysis of Variance', 'Blood Glucose/metabolism', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Metformin/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9428832/
573,metformin,35124206,"Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications.","['Feng J', 'Wang X', 'Ye X', 'Ares I', 'Lopez-Torres B', 'Martinez M', 'Martinez-Larranaga MR', 'Wang X', 'Anadon A', 'Martinez MA']","['Humans', 'Hypoglycemic Agents/adverse effects', '*Metformin/pharmacology/therapeutic use', 'Mitochondria']",https://pubmed.ncbi.nlm.nih.gov/35124206/
574,metformin,17728845,Pioglitazone and metformin.,"['Hill NR', 'Matthews DR']","['Animals', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Metformin/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', 'Therapeutic Equivalency', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728845/
575,metformin,17139584,[Oral antidiabetic therapy].,"['Schneider S', 'Pazdzierny G', 'Klein HH']","['Administration, Oral', 'Cardiovascular Diseases/*prevention & control', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/complications/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Metformin/administration & dosage/adverse effects/*therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17139584/
576,metformin,26651913,[Metformin and the obstetric patient].,"['Pedersen KD', 'Bulow NS', 'Aaboe K', 'Galsgaard J', 'Odgaard HS', 'Mathiesen ER', 'Lauenborg J']","['Breast Feeding', 'Diabetes, Gestational/*drug therapy', 'Female', 'Humans', '*Hypoglycemic Agents/adverse effects/pharmacology/therapeutic use', '*Metformin/adverse effects/pharmacology/therapeutic use', 'Polycystic Ovary Syndrome/*drug therapy', 'Pregnancy', 'Pregnancy Trimester, Second', 'Pregnancy Trimester, Third', 'Prenatal Exposure Delayed Effects']",https://pubmed.ncbi.nlm.nih.gov/26651913/
577,metformin,29291990,A reappraisal on metformin.,"['Adak T', 'Samadi A', 'Unal AZ', 'Sabuncuoglu S']","['Animals', 'Diabetes Mellitus, Type 2/drug therapy', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/pharmacokinetics/*pharmacology/therapeutic use', 'Metformin/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29291990/
578,metformin,12093242,Metformin: an update.,"['Kirpichnikov D', 'McFarlane SI', 'Sowers JR']","['Animals', 'Cardiovascular Diseases/mortality/prevention & control', 'Diabetes Mellitus, Type 2/*complications', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hyperglycemia/complications/*drug therapy', 'Hypoglycemic Agents/adverse effects/*pharmacology/therapeutic use', 'Metformin/adverse effects/*pharmacology/therapeutic use', 'Polycystic Ovary Syndrome/drug therapy', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12093242/
579,metformin,23410645,Use of noninsulin antidiabetic medications in hospitalized patients.,['Kopecky C'],"['Benzamides/pharmacology/therapeutic use', 'Biguanides/pharmacology/therapeutic use', 'Bromocriptine/administration & dosage/therapeutic use', 'Diabetes Mellitus/*drug therapy/nursing', 'Dipeptidyl-Peptidase IV Inhibitors/administration & dosage/therapeutic use', 'Glycoside Hydrolase Inhibitors', '*Hospitalization', 'Humans', 'Hypoglycemia/chemically induced', 'Hypoglycemic Agents/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Incretins/administration & dosage/therapeutic use', 'Islet Amyloid Polypeptide/agonists', 'Metformin/pharmacology/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/metabolism/therapeutic use', 'Thiazolidinediones/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23410645/
580,ibuprofen,391117,Ibuprofen.,['Kantor TG'],"['Analgesics', 'Anti-Inflammatory Agents', 'Arthritis/drug therapy', 'Digestive System/drug effects', 'Drug Interactions', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/391117/
581,ibuprofen,36477458,Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus.,"['Hundscheid T', 'Onland W', 'Kooi EMW', 'Vijlbrief DC', 'de Vries WB', 'Dijkman KP', 'van Kaam AH', 'Villamor E', 'Kroon AA', 'Visser R', 'Mulder-de Tollenaer SM', 'De Bisschop B', 'Dijk PH', 'Avino D', 'Hocq C', 'Zecic A', 'Meeus M', 'de Baat T', 'Derriks F', 'Henriksen TB', 'Kyng KJ', 'Donders R', 'Nuytemans DHGM', 'Van Overmeire B', 'Mulder AL', 'de Boode WP']","['Humans', 'Infant', 'Infant, Newborn', '*Bronchopulmonary Dysplasia/etiology', '*Ductus Arteriosus, Patent/diagnostic imaging/drug therapy/mortality/therapy', 'Echocardiography', '*Enterocolitis, Necrotizing/etiology', '*Ibuprofen/administration & dosage/adverse effects/therapeutic use', 'Indomethacin/adverse effects/therapeutic use', 'Infant, Extremely Premature', 'Infant, Low Birth Weight', 'Infant, Newborn, Diseases/drug therapy/therapy', '*Watchful Waiting']",https://pubmed.ncbi.nlm.nih.gov/36477458/
582,ibuprofen,19949916,"Ibuprofen: pharmacology, efficacy and safety.",['Rainsford KD'],"['Adult', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology', 'Child', 'Dose-Response Relationship, Drug', 'Fever/drug therapy/physiopathology', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*pharmacology', 'Inflammation/*drug therapy/physiopathology', 'Nonprescription Drugs/administration & dosage/adverse effects/pharmacology', 'Pain/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/19949916/
583,ibuprofen,36903343,Ibuprofen: Toxicology and Biodegradation of an Emerging Contaminant.,"['Jan-Roblero J', 'Cruz-Maya JA']","['Humans', 'Ibuprofen/chemistry', 'Bacteria', 'Biodegradation, Environmental', '*Drug-Related Side Effects and Adverse Reactions', 'Technology', '*Water Pollutants, Chemical/analysis']",https://pubmed.ncbi.nlm.nih.gov/36903343/
584,ibuprofen,33224416,Ibuprofen versus paracetamol for treating fever in preschool children in Nigeria: a randomized clinical trial of effectiveness and safety.,"['Alaje EO', 'Udoh EE', 'Akande PA', 'Odey FA', 'Meremikwu MM']","['Acetaminophen/*administration & dosage/adverse effects', 'Antipyretics/*administration & dosage/adverse effects', 'Body Temperature/drug effects', 'Child, Preschool', 'Female', 'Fever/*drug therapy', 'Hospitals, Teaching', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects', 'Infant', 'Male', 'Nigeria', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/33224416/
585,ibuprofen,20150507,Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review.,"['Pierce CA', 'Voss B']","['Acetaminophen/adverse effects/*therapeutic use', 'Adult', 'Age Factors', 'Analgesics, Non-Narcotic/adverse effects/*therapeutic use', 'Child', 'Female', 'Fever/drug therapy', 'Humans', 'Ibuprofen/adverse effects/*therapeutic use', 'Male', 'Odds Ratio', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/20150507/
586,ibuprofen,2000781,Ibuprofen: a monograph.,['Aycock DG'],"['Drug Interactions', 'Humans', '*Ibuprofen/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2000781/
587,ibuprofen,28516288,Efficacy and Safety of Ibuprofen in Infants Aged Between 3 and 6 Months.,"['Ziesenitz VC', 'Zutter A', 'Erb TO', 'van den Anker JN']","['Analgesia', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Fever/drug therapy', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Infant', 'Pain/drug therapy', 'Pain Management']",https://pubmed.ncbi.nlm.nih.gov/28516288/
588,ibuprofen,39318339,Short-term Dual Therapy or Mono Therapy With Acetaminophen and Ibuprofen for Fever: A Network Meta-Analysis.,"['De la Cruz-Mena JE', 'Veroniki AA', 'Acosta-Reyes J', 'Estupinan-Bohorquez A', 'Ibarra JA', 'Pana MC', 'Sierra JM', 'Florez ID']","['Child', 'Humans', '*Acetaminophen/therapeutic use/administration & dosage', 'Analgesics, Non-Narcotic/therapeutic use/administration & dosage', '*Antipyretics/therapeutic use/administration & dosage', 'Drug Therapy, Combination', '*Fever/drug therapy', '*Ibuprofen/therapeutic use/administration & dosage', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/39318339/
589,ibuprofen,26334726,Pharmacokinetics and Bioavailability of a Fixed-Dose Combination of Ibuprofen and Paracetamol after Intravenous and Oral Administration.,"['Atkinson HC', 'Stanescu I', 'Frampton C', 'Salem II', 'Beasley CP', 'Robson R']","['Acetaminophen/*administration & dosage/adverse effects/blood/*pharmacokinetics', 'Administration, Intravenous', 'Administration, Oral', 'Adolescent', 'Adult', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Drug Combinations', 'Female', 'Healthy Volunteers', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects/blood/*pharmacokinetics', 'Male', 'Middle Aged', 'Therapeutic Equivalency', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26334726/
590,ibuprofen,34655316,"Analgesic effect of oral ibuprofen 400, 600, and 800 mg; paracetamol 500 and 1000 mg; and paracetamol 1000 mg plus 60 mg codeine in acute postoperative pain: a single-dose, randomized, placebo-controlled, and double-blind study.","['Lyngstad G', 'Skjelbred P', 'Swanson DM', 'Skoglund LA']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Codeine/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34655316/
591,ibuprofen,30569859,Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties.,"['Petito ES', 'Foster DJR', 'Ward MB', 'Sykes MJ']","['Administration, Oral', 'Humans', 'Ibuprofen/administration & dosage/chemistry/*pharmacokinetics', '*Models, Molecular', 'Quantitative Structure-Activity Relationship', 'Serum Albumin, Human/chemistry/drug effects', 'Warfarin/administration & dosage/chemistry/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/30569859/
592,ibuprofen,21815877,New therapeutic strategies for the treatment of patent ductus arteriosus in preterm infants.,['Dani C'],"['Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Ductus Arteriosus, Patent/*drug therapy', 'Humans', 'Ibuprofen/*administration & dosage', 'Infant, Newborn', 'Infant, Premature', 'Infant, Premature, Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21815877/
593,ibuprofen,11713940,Stevens-Johnson Syndrome and cholestatic hepatitis.,"['Morelli MS', ""O'Brien FX""]","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology', 'Cholestasis/*etiology', 'Female', 'Humans', 'Ibuprofen/administration & dosage/adverse effects', 'Stevens-Johnson Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/11713940/
594,ibuprofen,19462922,Rationale for faster oral delivery to overcome the pathophysiology associated with dental pain--biopharmaceutic and pharmacokinetic challenges.,['Srinivas NR'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics/*therapeutic use', 'Biopharmaceutics', 'Chemistry, Pharmaceutical', 'Humans', 'Ibuprofen/administration & dosage/pharmacokinetics/therapeutic use', 'Intestinal Absorption', 'Meloxicam', 'Thiazines/administration & dosage/pharmacokinetics/therapeutic use', 'Thiazoles/administration & dosage/pharmacokinetics/therapeutic use', 'Toothache/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19462922/
595,ibuprofen,11467102,Ibuprofen to rofecoxib: what does it all mean and what do I do now?,"['Varga J', 'Dickman A']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Drug Administration Schedule', 'Drug Costs', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/adverse effects/classification/economics/*therapeutic use', 'Lactones/classification/economics/*therapeutic use', 'Neoplasms/complications', 'Pain/*drug therapy/etiology/prevention & control', '*Patient Selection', 'Risk Factors', 'Sulfones', 'Terminal Care/methods']",https://pubmed.ncbi.nlm.nih.gov/11467102/
596,ibuprofen,9013378,"Pharmacodynamics and pharmacokinetics of the profens: enantioselectivity, clinical implications, and special reference to S(+)-ibuprofen.",['Evans AM'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology', 'Humans', 'Ibuprofen/pharmacokinetics/*pharmacology/therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/9013378/
597,ibuprofen,17137543,Is any one analgesic superior for episodic tension-type headache?,"['Verhagen AP', 'Damen L', 'Berger MY', 'Passchier J', 'Merlijn V', 'Koes BW']","['Acetaminophen/therapeutic use', 'Analgesics/*classification/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Chronic Disease', 'Diclofenac/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Ibuprofen/adverse effects/*therapeutic use', 'Ketoprofen/therapeutic use', 'Naproxen/therapeutic use', 'Nonprescription Drugs/adverse effects/*therapeutic use', 'Secondary Prevention', 'Tension-Type Headache/*drug therapy/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17137543/
598,ibuprofen,31935712,Synthesis of bifunctional carbon quantum dots for bioimaging and anti-inflammation.,"['Qu Z', 'Liu L', 'Sun T', 'Hou J', 'Sun Y', 'Yu M', 'Diao Y', 'Lu S', 'Zhao W', 'Wang L']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/chemistry/pharmacology', 'Carbon/*chemistry', 'Carrageenan/adverse effects', 'Disease Models, Animal', 'Drug Stability', 'HeLa Cells', 'Humans', 'Ibuprofen/*administration & dosage/chemistry/pharmacology', 'Inflammation/chemically induced/*drug therapy', 'Male', 'Mice', 'Microwaves', 'Molecular Imaging', 'Quantum Dots/chemistry']",https://pubmed.ncbi.nlm.nih.gov/31935712/
599,ibuprofen,30544105,Effective Ibuprofen Desensitization in a Patient with Myopericarditis.,"['Cortellini G', 'Lippolis D', 'Amati S', 'Piovaccari G', 'Cortellini F', 'Ballardini G']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/immunology', 'Desensitization, Immunologic/*methods', 'Drug Administration Schedule', 'Drug Hypersensitivity/diagnosis/immunology/*prevention & control', 'Humans', 'Ibuprofen/*administration & dosage/adverse effects/immunology', 'Male', 'Myocarditis/diagnosis/*drug therapy/immunology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30544105/
600,modafinil,35366192,Benefits and Harms of 'Smart Drugs' (Nootropics) in Healthy Individuals.,"['Schifano F', 'Catalani V', 'Sharif S', 'Napoletano F', 'Corkery JM', 'Arillotta D', 'Fergus S', 'Vento A', 'Guirguis A']","['Brain', '*Central Nervous System Stimulants/adverse effects', 'Cognition', 'Humans', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', '*Nootropic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35366192/
601,modafinil,30468674,Modafinil and orexin system: interactions and medico-legal considerations.,"['Salerno M', 'Villano I', 'Nicolosi D', 'Longhitano L', 'Loreto C', 'Lovino A', 'Sessa F', 'Polito AN', 'Monda V', 'Chieffi S', 'Messina A', 'Monda M', 'Zammit C', 'Tafuri D', 'Messina G', 'Carotenuto M']","['Animals', 'Attention/drug effects/physiology', 'Central Nervous System/*drug effects/metabolism/physiology', 'Cognition/drug effects/physiology', 'Humans', 'Modafinil/metabolism/pharmacokinetics/*pharmacology', 'Neurons/drug effects/metabolism/physiology', 'Orexins/*metabolism', 'Wakefulness/*drug effects/physiology', 'Wakefulness-Promoting Agents/metabolism/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30468674/
602,modafinil,9628108,Idiopathic hypersomnia.,"['Billiard M', 'Merle C', 'Carlander B', 'Ondze B', 'Alvarez D', 'Besset A']","['Adolescent', 'Adult', 'Benzhydryl Compounds/adverse effects/therapeutic use', 'Central Nervous System Stimulants/therapeutic use', 'Child', 'Diagnosis, Differential', 'Disorders of Excessive Somnolence/*diagnosis/drug therapy/genetics', 'Female', 'Humans', 'Male', 'Modafinil', 'Pedigree', 'Polysomnography']",https://pubmed.ncbi.nlm.nih.gov/9628108/
603,modafinil,33085721,Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.,"['Elliott J', 'Johnston A', 'Husereau D', 'Kelly SE', 'Eagles C', 'Charach A', 'Hsieh SC', 'Bai Z', 'Hossain A', 'Skidmore B', 'Tsakonas E', 'Chojecki D', 'Mamdani M', 'Wells GA']","['Adult', 'Amphetamine/adverse effects/therapeutic use', 'Atomoxetine Hydrochloride/adverse effects/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology/pathology', 'Bayes Theorem', 'Bupropion/adverse effects/therapeutic use', 'Central Nervous System Stimulants/*adverse effects', 'Dextroamphetamine/adverse effects/therapeutic use', 'Drug-Related Side Effects and Adverse Reactions/classification/*epidemiology/pathology', 'Female', 'Guanfacine/adverse effects/therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate/adverse effects/therapeutic use', 'Male', 'Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', 'Network Meta-Analysis', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33085721/
604,modafinil,31375202,Precision Medicine for Idiopathic Hypersomnia.,"['Arnulf I', 'Leu-Semenescu S', 'Dodet P']","['Central Nervous System Stimulants/therapeutic use', 'Clarithromycin/therapeutic use', 'Flumazenil/therapeutic use', 'GABA Modulators/*therapeutic use', 'Humans', 'Idiopathic Hypersomnia/*drug therapy/metabolism/physiopathology', 'Mazindol/therapeutic use', 'Modafinil/therapeutic use', 'Orexins/metabolism', 'Piperidines/therapeutic use', 'Polysomnography', 'Precision Medicine', 'Sleep', 'Sodium Oxybate/therapeutic use', 'Wakefulness', 'Wakefulness-Promoting Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31375202/
605,modafinil,34173288,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173288/
606,modafinil,37194538,[Psychostimulants: An Overview].,"['Fukumoto S', 'Imanari E', 'Tomari S', 'Higashi T', 'Kosaka H']","['Humans', '*Central Nervous System Stimulants/therapeutic use', 'Lisdexamfetamine Dimesylate/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Methylphenidate/therapeutic use', 'Modafinil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37194538/
607,modafinil,37921201,Headache improves with armodafinil.,['Barone DA'],"['Humans', 'Modafinil/therapeutic use', '*Narcolepsy', 'Caffeine/therapeutic use', '*Cataplexy', 'Headache/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37921201/
608,modafinil,33435717,A Review of Pharmacologic Neurostimulant Use During Rehabilitation and Recovery After Brain Injury.,"['Kakehi S', 'Tompkins DM']","['*Brain Injuries/drug therapy', 'Humans', 'Modafinil', 'Prospective Studies', 'Risk Assessment', '*Stroke']",https://pubmed.ncbi.nlm.nih.gov/33435717/
609,modafinil,38508480,Severe Fatigue in Inflammatory Bowel Disease: Dopaminergic Therapy With Modafinil or Vitamin Therapy With Thiamine.,"['Bager P', 'Hvas CL', 'Dahlerup JF']","['Humans', '*Modafinil/therapeutic use', '*Fatigue/drug therapy', '*Inflammatory Bowel Diseases/drug therapy/complications', '*Thiamine/therapeutic use', 'Treatment Outcome', 'Male', 'Female', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38508480/
610,modafinil,36759544,In utero exposure to ADHD medication and long-term offspring outcomes.,"['Bang Madsen K', 'Robakis TK', 'Liu X', 'Momen N', 'Larsson H', 'Dreier JW', 'Kildegaard H', 'Groth JB', 'Newcorn JH', 'Hove Thomsen P', 'Munk-Olsen T', 'Bergink V']","['Adult', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Pregnancy', 'Amphetamines/adverse effects/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Clonidine/adverse effects/therapeutic use', 'Cohort Studies', 'Denmark/epidemiology', 'Gestational Age', '*Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', '*Mothers/psychology', 'Neurodevelopmental Disorders/chemically induced', '*Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Registries']",https://pubmed.ncbi.nlm.nih.gov/36759544/
611,modafinil,33201262,"Cognitive enhancement effects of stimulants: a randomized controlled trial testing methylphenidate, modafinil, and caffeine.","['Repantis D', 'Bovy L', 'Ohla K', 'Kuhn S', 'Dresler M']","['Adult', 'Attention/drug effects', 'Caffeine/*pharmacology', 'Central Nervous System Stimulants/*pharmacology', 'Cognition/*drug effects', 'Double-Blind Method', 'Fatigue/prevention & control', 'Humans', 'Male', 'Methylphenidate/*pharmacology', 'Modafinil/*pharmacology', 'Nootropic Agents/*pharmacology', 'Pilot Projects', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33201262/
612,modafinil,33242419,"Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: a randomised, placebo-controlled, crossover, double-blind trial.","['Nourbakhsh B', 'Revirajan N', 'Morris B', 'Cordano C', 'Creasman J', 'Manguinao M', 'Krysko K', 'Rutatangwa A', 'Auvray C', 'Aljarallah S', 'Jin C', 'Mowry E', 'McCulloch C', 'Waubant E']","['Adult', 'Amantadine/administration & dosage/adverse effects/*pharmacology', 'Central Nervous System Stimulants/administration & dosage/adverse effects/*pharmacology', 'Cross-Over Studies', 'Double-Blind Method', 'Drug Administration Schedule', '*Drug-Related Side Effects and Adverse Reactions', 'Fatigue/*drug therapy/*etiology', 'Female', 'Humans', 'Male', 'Methylphenidate/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Modafinil/administration & dosage/adverse effects/*pharmacology', 'Multiple Sclerosis/*complications', '*Outcome Assessment, Health Care', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33242419/
613,modafinil,22310006,[Modafinil in the treatment of depression].,['Videbech P'],"['Antidepressive Agents/adverse effects/*therapeutic use', 'Benzhydryl Compounds/adverse effects/*therapeutic use', 'Bipolar Disorder/drug therapy', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Depressive Disorder, Major/drug therapy', 'Drug Interactions', 'Humans', 'Modafinil', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22310006/
614,modafinil,24107292,"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.","['Dauvilliers Y', 'Bassetti C', 'Lammers GJ', 'Arnulf I', 'Mayer G', 'Rodenbeck A', 'Lehert P', 'Ding CL', 'Lecomte JM', 'Schwartz JC']","['Adult', 'Benzhydryl Compounds/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Histamine Agonists/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Middle Aged', 'Modafinil', 'Narcolepsy/*drug therapy', 'Piperidines/administration & dosage/adverse effects/*pharmacology', 'Placebos', 'Severity of Illness Index', 'Treatment Outcome', 'Wakefulness-Promoting Agents/administration & dosage/adverse effects/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24107292/
615,modafinil,30767208,Modafinil protects hippocampal neurons by suppressing excessive autophagy and apoptosis in mice with sleep deprivation.,"['Cao Y', 'Li Q', 'Liu L', 'Wu H', 'Huang F', 'Wang C', 'Lan Y', 'Zheng F', 'Xing F', 'Zhou Q', 'Li Q', 'Shi H', 'Zhang B', 'Wang Z', 'Wu X']","['Animals', 'Apoptosis/*drug effects', 'Autophagy/*drug effects', 'Central Nervous System Stimulants/*pharmacology', 'Hippocampus/*drug effects', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Modafinil/*pharmacology', 'Neurons/*drug effects', 'Protective Agents/*pharmacology', 'Sleep Deprivation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30767208/
616,modafinil,37155992,Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.,"['Pitre T', 'Mah J', 'Roberts S', 'Desai K', 'Gu Y', 'Ryan C', 'Busse JW', 'Zeraatkar D']","['Humans', 'Autoreceptors', '*Disorders of Excessive Somnolence/drug therapy/etiology', 'Modafinil/adverse effects', 'Network Meta-Analysis', '*Sleep Apnea, Obstructive/complications/drug therapy', '*Wakefulness-Promoting Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37155992/
617,modafinil,34173695,European guideline and expert statements on the management of narcolepsy in adults and children.,"['Bassetti CLA', 'Kallweit U', 'Vignatelli L', 'Plazzi G', 'Lecendreux M', 'Baldin E', 'Dolenc-Groselj L', 'Jennum P', 'Khatami R', 'Manconi M', 'Mayer G', 'Partinen M', 'Pollmacher T', 'Reading P', 'Santamaria J', 'Sonka K', 'Dauvilliers Y', 'Lammers GJ']","['Adult', '*Cataplexy', 'Child', 'Humans', 'Modafinil/therapeutic use', '*Narcolepsy/diagnosis/drug therapy', 'Sleep', '*Sodium Oxybate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34173695/
618,modafinil,35670369,"Cognitive enhancement: Effects of methylphenidate, modafinil, and caffeine on latent memory and resting state functional connectivity in healthy adults.","['Becker M', 'Repantis D', 'Dresler M', 'Kuhn S']","['Adult', 'Brain/diagnostic imaging', 'Brain Mapping/methods', 'Caffeine/pharmacology', '*Central Nervous System Stimulants/pharmacology', 'Cognition', 'Double-Blind Method', 'Humans', 'Magnetic Resonance Imaging/methods', 'Male', '*Methylphenidate/pharmacology', 'Modafinil/pharmacology', 'Neural Pathways/diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/35670369/
619,modafinil,32601988,Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.,"['Tardelli VS', 'Bisaga A', 'Arcadepani FB', 'Gerra G', 'Levin FR', 'Fidalgo TM']","['Amphetamine/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Cocaine/therapeutic use', 'Double-Blind Method', 'Humans', 'Lisdexamfetamine Dimesylate/therapeutic use', 'Methylphenidate/therapeutic use', 'Modafinil/therapeutic use', 'Prescription Drugs/*therapeutic use', 'Randomized Controlled Trials as Topic/methods', 'Substance-Related Disorders/*diagnosis/*drug therapy/psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32601988/
620,lorazepam,15762814,The effects of benzodiazepines on cognition.,['Stewart SA'],"['Activities of Daily Living/psychology', 'Anti-Anxiety Agents/adverse effects/pharmacology/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/*pharmacology/therapeutic use', 'Cognition/*drug effects', 'Cognition Disorders/*chemically induced/epidemiology/psychology', 'Female', 'Humans', 'Long-Term Care/statistics & numerical data', 'Lorazepam/adverse effects/pharmacology/therapeutic use', 'Middle Aged', 'Patient Education as Topic', 'Substance Withdrawal Syndrome/psychology']",https://pubmed.ncbi.nlm.nih.gov/15762814/
621,lorazepam,11949276,Lorazepam.,['Noerr B'],"['Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Anxiety/drug therapy/*prevention & control', 'Asphyxia Neonatorum/drug therapy/nursing', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care Units, Neonatal', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Neonatal Nursing/methods', 'Risk Assessment', 'Seizures/drug therapy/nursing', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/11949276/
622,lorazepam,21360232,Delirium and sedation in the ICU.,['Frontera JA'],"['Conscious Sedation/*adverse effects', 'Delirium/*chemically induced/diagnosis/mortality', 'Dexmedetomidine/administration & dosage/adverse effects', 'Diagnosis, Differential', 'Hospital Mortality', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', '*Intensive Care Units', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/administration & dosage/adverse effects', 'Neurologic Examination/drug effects', 'Prognosis', 'Risk Factors', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/21360232/
623,lorazepam,32340820,Efficacy of ketamine for initial control of acute agitation in the emergency department: A randomized study.,"['Lin J', 'Figuerado Y', 'Montgomery A', 'Lee J', 'Cannis M', 'Norton VC', 'Calvo R', 'Sikand H']","['Adult', 'Aged', 'Aged, 80 and over', 'Anesthetics, Dissociative/administration & dosage/*therapeutic use', 'Anti-Anxiety Agents/administration & dosage/therapeutic use', 'Antipsychotic Agents/administration & dosage/therapeutic use', '*Emergency Service, Hospital', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Male', 'Middle Aged', 'Pilot Projects', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'United States']",https://pubmed.ncbi.nlm.nih.gov/32340820/
624,lorazepam,24741200,Lorazepam-induced diplopia.,"['Lucca JM', 'Ramesh M', 'Parthasarathi G', 'Ram D']","['Adult', 'Anti-Anxiety Agents/administration & dosage/*adverse effects/therapeutic use', 'Diplopia/*chemically induced/diagnosis', 'Humans', 'Lorazepam/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Obsessive-Compulsive Disorder/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24741200/
625,lorazepam,3605432,Lorazepam for psychogenic catatonia.,"['Salam SA', 'Pillai AK', 'Beresford TP']","['Adult', 'Aged', 'Catatonia/*drug therapy/psychology', 'Humans', 'Injections, Intramuscular', 'Lorazepam/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Psychophysiologic Disorders/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/3605432/
626,lorazepam,39936259,"[Acute psychosis after ""puff bar"" use].","['Tehrani FM', 'Badawey J']","['Humans', 'Male', 'Adolescent', '*Psychoses, Substance-Induced/etiology/diagnosis', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Electrocardiography', 'Acute Disease', 'Cannabinoids/adverse effects', 'Long QT Syndrome/chemically induced', 'Lorazepam/therapeutic use/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39936259/
627,lorazepam,30810723,Association of Delirium Response and Safety of Pharmacological Interventions for the Management and Prevention of Delirium: A Network Meta-analysis.,"['Wu YC', 'Tseng PT', 'Tu YK', 'Hsu CY', 'Liang CS', 'Yeh TC', 'Chen TY', 'Chu CS', 'Matsuoka YJ', 'Stubbs B', 'Carvalho AF', 'Wada S', 'Lin PY', 'Chen YW', 'Su KP']","['Antipsychotic Agents/administration & dosage/*therapeutic use', 'Delirium/drug therapy/*prevention & control', 'Drug Therapy, Combination', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Indenes/administration & dosage/therapeutic use', 'Lorazepam/administration & dosage/therapeutic use', 'Network Meta-Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30810723/
628,lorazepam,18073360,Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial.,"['Pandharipande PP', 'Pun BT', 'Herr DL', 'Maze M', 'Girard TD', 'Miller RR', 'Shintani AK', 'Thompson JL', 'Jackson JC', 'Deppen SA', 'Stiles RA', 'Dittus RS', 'Bernard GR', 'Ely EW']","['Aged', 'Coma/*chemically induced/diagnosis', '*Conscious Sedation/economics', 'Delirium/*chemically induced/diagnosis', 'Dexmedetomidine/*administration & dosage/adverse effects/economics', 'Double-Blind Method', 'Female', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/economics', 'Intensive Care Units/economics', 'Lorazepam/*administration & dosage/adverse effects/economics', 'Male', 'Middle Aged', 'Neuropsychological Tests', '*Respiration, Artificial/economics']",https://pubmed.ncbi.nlm.nih.gov/18073360/
629,lorazepam,28975307,Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial.,"['Hui D', 'Frisbee-Hume S', 'Wilson A', 'Dibaj SS', 'Nguyen T', 'De La Cruz M', 'Walker P', 'Zhukovsky DS', 'Delgado-Guay M', 'Vidal M', 'Epner D', 'Reddy A', 'Tanco K', 'Williams J', 'Hall S', 'Liu D', 'Hess K', 'Amin S', 'Breitbart W', 'Bruera E']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Anxiety Agents/*administration & dosage/adverse effects', 'Antipsychotic Agents/*administration & dosage/adverse effects', 'Delirium/*drug therapy/etiology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Haloperidol/*administration & dosage/adverse effects', 'Hospitalization', 'Humans', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoplasms/*complications/psychology/therapy', '*Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/28975307/
630,lorazepam,20138190,Atypical behavioural effects of lorazepam: clues to the design of novel therapies?,"['Giersch A', 'Boucart M', 'Elliott M', 'Vidailhet P']","['Attention/drug effects', 'Benzodiazepines/pharmacokinetics/*pharmacology/*therapeutic use', 'Cognition/*drug effects', 'Drug Discovery/*methods', 'Humans', 'Lorazepam/pharmacokinetics/*pharmacology/*therapeutic use', 'Memory/drug effects', 'Mental Disorders/*drug therapy', 'Receptors, GABA-A/drug effects', 'Visual Perception/drug effects']",https://pubmed.ncbi.nlm.nih.gov/20138190/
631,lorazepam,2905805,"Lormetazepam, memory and information processing: a review.","['Bhatti JZ', 'Alford CA', 'Hindmarch I']","['Anti-Anxiety Agents/*pharmacology', '*Benzodiazepines', 'Humans', 'Lorazepam/*analogs & derivatives/pharmacology', 'Memory/*drug effects', 'Mental Processes/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/2905805/
632,lorazepam,22721935,Homicide by methane gas.,"['De-Giorgio F', 'Grassi VM', 'Vetrugno G', 'Rossi R', 'Fucci N', ""d'Aloja E"", 'Pascali VL']","['Female', 'Forensic Pathology', '*Gases', '*Homicide', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Lorazepam/administration & dosage/adverse effects', 'Lung/pathology', 'Male', 'Methane/*poisoning', 'Middle Aged', 'Myocardium/pathology', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/22721935/
633,lorazepam,13599,Intramuscular premedication with lorazepam.,['Mundeleer P'],"['Adult', 'Age Factors', 'Aged', 'Amnesia/chemically induced', 'Anti-Anxiety Agents/*administration & dosage', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', '*Preanesthetic Medication']",https://pubmed.ncbi.nlm.nih.gov/13599/
634,lorazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
635,lorazepam,30762,Clinical pharmacokinetics of lorazepam: a review.,"['Kyriakopoulos AA', 'Greenblatt DJ', 'Shader RI']","['Administration, Oral', 'Age Factors', 'Anti-Anxiety Agents/*metabolism', 'Chromatography, Gas', 'Dose-Response Relationship, Drug', 'Glucuronates/metabolism', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Kidney Failure, Chronic/metabolism', 'Kinetics', 'Lorazepam/administration & dosage/blood/*metabolism/urine', 'Metabolic Clearance Rate', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/30762/
636,lorazepam,16179702,Status epilepticus: an evidence based guide.,['Walker M'],"['Anticonvulsants/adverse effects/*therapeutic use', 'Chronic Disease', 'Critical Care', 'Drug Administration Routes', 'Emergency Treatment', 'Evidence-Based Medicine', 'Humans', 'Lorazepam/administration & dosage/adverse effects', 'Midazolam/*administration & dosage/adverse effects', 'Phenobarbital/administration & dosage/adverse effects', 'Phenytoin/administration & dosage', 'Prognosis', 'Randomized Controlled Trials as Topic', 'Referral and Consultation', '*Status Epilepticus/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16179702/
637,lorazepam,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
638,lorazepam,1806620,Agitation in the demented elderly: a role for benzodiazepines?,"['Ancill RJ', 'Carlyle WW', 'Liang RA', 'Holliday SG']","['Aged', 'Alprazolam/adverse effects/*therapeutic use', 'Dementia/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Lorazepam/adverse effects/*therapeutic use', 'Male', 'Motor Activity/drug effects', 'Psychomotor Agitation/*drug therapy/psychology', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/1806620/
639,lorazepam,11697755,"Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration.","['Wermeling DP', 'Miller JL', 'Archer SM', 'Manaligod JM', 'Rudy AC']","['Administration, Intranasal', 'Adult', 'Anti-Anxiety Agents/administration & dosage/blood/*pharmacokinetics', 'Area Under Curve', 'Biological Availability', 'Cross-Over Studies', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Lorazepam/administration & dosage/blood/*pharmacokinetics', 'Male', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/11697755/
640,mirtazapine,34823736,Understanding Stimulant Use and Use Disorders in a New Era.,"['Ciccarone D', 'Shoptaw S']","['Adrenergic alpha-2 Receptor Antagonists/therapeutic use', 'Adult', 'Anticonvulsants/therapeutic use', 'Behavior Therapy/methods', 'Bupropion/therapeutic use', 'Central Nervous System Stimulants/*adverse effects/pharmacology', 'Cocaine-Related Disorders/drug therapy/*epidemiology/mortality', 'Cognitive Dysfunction/chemically induced/epidemiology', 'Comorbidity', 'Dopamine Uptake Inhibitors/therapeutic use', 'Female', 'Humans', 'Illicit Drugs/adverse effects/pharmacology', 'Male', 'Mental Disorders/chemically induced/epidemiology', 'Methamphetamine/*adverse effects/pharmacology', 'Mirtazapine/therapeutic use', 'Neurobiology', 'Neurodegenerative Diseases/chemically induced/epidemiology', 'Opiate Overdose/*epidemiology/mortality', 'Substance Withdrawal Syndrome/*therapy', 'Topiramate/therapeutic use', 'Transgender Persons', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/34823736/
641,mirtazapine,35234292,Pharmacotherapy for post traumatic stress disorder (PTSD).,"['Williams T', 'Phillips NJ', 'Stein DJ', 'Ipser JC']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Amitriptyline/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', '*Antipsychotic Agents/therapeutic use', 'Humans', 'Middle Aged', 'Mirtazapine/therapeutic use', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Stress Disorders, Post-Traumatic/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/35234292/
642,mirtazapine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
643,mirtazapine,36253442,Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.,"['Kishi T', 'Ikuta T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Matsuda Y', 'Iwata N']","['Female', 'Humans', 'Adult', '*Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/therapeutic use', 'Sertraline/therapeutic use', 'Citalopram/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use', 'Fluoxetine/therapeutic use', 'Paroxetine/therapeutic use', 'Mirtazapine/therapeutic use', 'Amitriptyline/therapeutic use', 'Desvenlafaxine Succinate/therapeutic use', 'Fluvoxamine/therapeutic use', 'Reboxetine/therapeutic use', 'Network Meta-Analysis', 'Antidepressive Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36253442/
644,mirtazapine,11607047,A review of the pharmacological and clinical profile of mirtazapine.,"['Anttila SA', 'Leinonen EV']","['Animals', 'Antidepressive Agents, Tricyclic/*therapeutic use', 'Drug Interactions', 'Humans', 'Mianserin/adverse effects/*analogs & derivatives/pharmacology/*therapeutic use', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/11607047/
645,mirtazapine,30081645,Clinical Management of Bleeding Risk With Antidepressants.,"['Bixby AL', 'VandenBerg A', 'Bostwick JR']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Antidepressive Agents/administration & dosage/*adverse effects', 'Bupropion/adverse effects', 'Gastrointestinal Hemorrhage/chemically induced/epidemiology', 'Hemorrhage/*chemically induced/epidemiology/*therapy', 'Humans', 'Mirtazapine/adverse effects', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30081645/
646,mirtazapine,34029378,New generation antidepressants for depression in children and adolescents: a network meta-analysis.,"['Hetrick SE', 'McKenzie JE', 'Bailey AP', 'Sharma V', 'Moller CI', 'Badcock PB', 'Cox GR', 'Merry SN', 'Meader N']","['Adolescent', 'Antidepressive Agents/adverse effects/*therapeutic use', 'Bias', 'Child', 'Citalopram/therapeutic use', 'Depressive Disorder, Major/*drug therapy/psychology', 'Desvenlafaxine Succinate/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Fluoxetine/therapeutic use', 'Humans', 'Male', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Paroxetine/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Suicidal Ideation', 'Venlafaxine Hydrochloride/therapeutic use', 'Vilazodone Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34029378/
647,mirtazapine,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
648,mirtazapine,38451521,Drug Efficacy in the Treatment of Antipsychotic-Induced Akathisia: A Systematic Review and Network Meta-Analysis.,"['Gerolymos C', 'Barazer R', 'Yon DK', 'Loundou A', 'Boyer L', 'Fond G']","['Humans', '*Antipsychotic Agents/adverse effects', 'Biperiden', 'Cyproheptadine', 'Gallopamil', 'Mianserin', 'Mirtazapine/therapeutic use', 'Network Meta-Analysis', 'Propranolol', 'Randomized Controlled Trials as Topic', 'Trazodone', 'Vitamin B 6', '*Akathisia, Drug-Induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38451521/
649,mirtazapine,34051293,Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.,"['Hunter CN', 'Abdel-Aal HH', 'Elsherief WA', 'Farag DE', 'Riad NM', 'Alsirafy SA']","['Anorexia/drug therapy/etiology', '*Cachexia/drug therapy/etiology', 'Double-Blind Method', 'Hand Strength', 'Humans', 'Mirtazapine/therapeutic use', '*Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/34051293/
650,mirtazapine,29862972,[Antipsychotic induced rhabdomyolysis].,"['Ratnam C', 'Saguin E', 'Keou S', 'Plantamura J', 'Mennessier C', 'Lahutte B', 'Delacour H']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Humans', 'Male', 'Mianserin/adverse effects/*analogs & derivatives/therapeutic use', 'Mirtazapine', 'Rhabdomyolysis/*chemically induced/diagnosis', 'Stress Disorders, Post-Traumatic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29862972/
651,mirtazapine,37943296,Pharmacological update of mirtazapine: a narrative literature review.,"['Hassanein EHM', 'Althagafy HS', 'Baraka MA', 'Abd-Alhameed EK', 'Ibrahim IM']","['Humans', '*Mirtazapine/therapeutic use/pharmacology', 'Animals', 'Antidepressive Agents/therapeutic use/pharmacology', 'Antidepressive Agents, Tricyclic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37943296/
652,mirtazapine,38403888,The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds.,"['Gheysens T', 'Van Den Eede F', 'De Picker L']","['Humans', '*Hyponatremia/chemically induced/epidemiology', '*Antidepressive Agents/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Mirtazapine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38403888/
653,mirtazapine,38206631,Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.,"['Arrieta O', 'Cardenas-Fernandez D', 'Rodriguez-Mayoral O', 'Gutierrez-Torres S', 'Castanares D', 'Flores-Estrada D', 'Reyes E', 'Lopez D', 'Barragan P', 'Soberanis Pina P', 'Cardona AF', 'Turcott JG']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Anorexia/drug therapy/etiology', 'Appetite Stimulants/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/complications/drug therapy', 'Double-Blind Method', '*Lung Neoplasms/complications/drug therapy', 'Mirtazapine/therapeutic use', 'Quality of Life/psychology', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38206631/
654,mirtazapine,36999619,Antidepressants for the treatment of depression in people with cancer.,"['Vita G', 'Compri B', 'Matcham F', 'Barbui C', 'Ostuzzi G']","['Adult', 'Humans', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Depression/drug therapy/etiology', '*Depressive Disorder, Major/drug therapy', 'Mirtazapine/therapeutic use', '*Neoplasms/drug therapy', 'Selective Serotonin Reuptake Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/36999619/
655,mirtazapine,37467797,Relationship between circulating mitochondrial DNA and microRNA in patients with major depression.,"['Ogata H', 'Higasa K', 'Kageyama Y', 'Tahara H', 'Shimamoto A', 'Takekita Y', 'Koshikawa Y', 'Nonen S', 'Kato T', 'Kinoshita T', 'Kato M']","['Humans', '*MicroRNAs/genetics/metabolism', 'DNA, Mitochondrial', '*Depressive Disorder, Major/drug therapy/genetics', 'Mirtazapine/therapeutic use', 'Depression', '*Cell-Free Nucleic Acids/genetics/metabolism', 'Mitochondria/metabolism', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37467797/
656,mirtazapine,12647431,[Mirtazapine--an antidepressant].,['Landowski J'],"['*Antidepressive Agents, Tricyclic/administration & dosage/pharmacology', 'Anxiety/etiology', 'Depressive Disorder/complications/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', '*Mianserin/administration & dosage/analogs & derivatives/pharmacology', 'Mirtazapine', 'Sleep Initiation and Maintenance Disorders/etiology', 'Syndrome', 'Thinness/etiology']",https://pubmed.ncbi.nlm.nih.gov/12647431/
657,mirtazapine,34688369,"Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.","['Banerjee S', 'High J', 'Stirling S', 'Shepstone L', 'Swart AM', 'Telling T', 'Henderson C', 'Ballard C', 'Bentham P', 'Burns A', 'Farina N', 'Fox C', 'Francis P', 'Howard R', 'Knapp M', 'Leroi I', 'Livingston G', 'Nilforooshan R', 'Nurock S', ""O'Brien J"", 'Price A', 'Thomas AJ', 'Tabet N']","['Aged, 80 and over', '*Anti-Anxiety Agents/adverse effects/therapeutic use', 'Brief Psychiatric Rating Scale', 'Caregivers/psychology', 'Dementia/*complications', 'Double-Blind Method', 'Female', 'Humans', 'Male', '*Mirtazapine/adverse effects/therapeutic use', 'Psychomotor Agitation/*drug therapy', 'Quality of Life/psychology', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/34688369/
658,mirtazapine,33432919,Residual daytime effects of esmirtazapine.,['Ivgy-May N'],"['Disease Progression', 'Double-Blind Method', 'Humans', 'Mirtazapine', '*Sleep Initiation and Maintenance Disorders']",https://pubmed.ncbi.nlm.nih.gov/33432919/
659,mirtazapine,36470132,Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment.,"['Yeh TC', 'Correll CU', 'Yang FC', 'Chen MH', 'Tseng PT', 'Hsu CW', 'Carvalho AF', 'Stubbs B', 'Thompson T', 'Chu CS', 'Yu CL', 'Il Shin J', 'Yang SN', 'Tu YK', 'Liang CS']","['Humans', '*Clozapine/therapeutic use', 'Network Meta-Analysis', 'Entropy', 'Memantine', 'Mirtazapine/pharmacology/therapeutic use', '*Antipsychotic Agents/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36470132/
660,famciclovir,29431387,Herpes Zoster and Postherpetic Neuralgia: Prevention and Management.,"['Saguil A', 'Kane S', 'Mercado M', 'Lauters R']","['Antiviral Agents/therapeutic use', 'Female', 'Herpes Zoster/complications/*drug therapy/prevention & control', 'Herpes Zoster Vaccine/*administration & dosage', 'Humans', 'Male', 'Neuralgia, Postherpetic/*drug therapy/prevention & control', 'Skin/pathology/virology']",https://pubmed.ncbi.nlm.nih.gov/29431387/
661,famciclovir,28971780,Herpes Labialis: An Update.,"['Leung AKC', 'Barankin B']","['Administration, Cutaneous', 'Administration, Oral', 'Antiviral Agents/*administration & dosage/pharmacokinetics', 'Herpes Labialis/*drug therapy/virology', 'Humans', 'Pain/drug therapy/etiology', 'Patents as Topic', '*Quality of Life', 'Recurrence', 'Time Factors', 'Virus Shedding/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28971780/
662,famciclovir,17143845,Recommendations for the management of herpes zoster.,"['Dworkin RH', 'Johnson RW', 'Breuer J', 'Gnann JW', 'Levin MJ', 'Backonja M', 'Betts RF', 'Gershon AA', 'Haanpaa ML', 'McKendrick MW', 'Nurmikko TJ', 'Oaklander AL', 'Oxman MN', 'Pavan-Langston D', 'Petersen KL', 'Rowbotham MC', 'Schmader KE', 'Stacey BR', 'Tyring SK', 'van Wijck AJ', 'Wallace MS', 'Wassilew SW', 'Whitley RJ']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Antiviral Agents/*therapeutic use', 'Bromodeoxyuridine/analogs & derivatives/therapeutic use', 'Famciclovir', 'Herpes Zoster/complications/*drug therapy/epidemiology/physiopathology', 'Herpesvirus 3, Human/pathogenicity', 'Humans', 'Immunocompetence', 'Immunocompromised Host', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17143845/
663,famciclovir,23343513,Selective anti-herpesvirus agents.,['De Clercq E'],"['Animals', 'Antiviral Agents/*chemistry/pharmacology/*therapeutic use', 'Cytomegalovirus/*drug effects', 'Herpesviridae Infections/*drug therapy', 'Herpesvirus 3, Human/*drug effects', 'Humans', 'Simplexvirus/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/23343513/
664,famciclovir,33672709,Advances and Perspectives in the Management of Varicella-Zoster Virus Infections.,"['Andrei G', 'Snoeck R']","['Antiviral Agents/*pharmacology', 'Encephalitis, Varicella Zoster/*drug therapy', 'Herpesvirus 3, Human/*drug effects', 'Humans', 'Microbial Sensitivity Tests', 'Pyrimidine Nucleosides/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33672709/
665,famciclovir,19615937,A perspective on antiviral resistance.,['Griffiths PD'],"['Antiviral Agents/*pharmacology', '*Drug Resistance, Viral', 'HIV/*drug effects', 'Hepatitis B virus/*drug effects', 'Humans', 'Orthomyxoviridae/*drug effects', 'Simplexvirus/*drug effects', 'Virus Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19615937/
666,famciclovir,8063023,Acyclovir--and beyond.,['Darby G'],"['Acyclovir/analogs & derivatives/*therapeutic use', 'Arabinofuranosyluracil/analogs & derivatives/therapeutic use', 'Cytomegalovirus Infections/drug therapy', 'Ganciclovir/therapeutic use', 'Guanine', 'Herpes Simplex/*drug therapy', 'Herpesvirus 3, Human/drug effects', 'Humans', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8063023/
667,famciclovir,8582118,Pharmacokinetics of new antiherpetic agents.,['Rolan P'],"['2-Aminopurine/analogs & derivatives/pharmacokinetics', 'Acyclovir/analogs & derivatives/pharmacokinetics', 'Animals', 'Antiviral Agents/*pharmacokinetics/therapeutic use', 'Famciclovir', 'Guanine', 'Herpesviridae Infections/*drug therapy/metabolism', 'Humans', 'Prodrugs/pharmacokinetics', 'Valacyclovir', 'Valine/analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8582118/
668,famciclovir,9875415,Current status of anti-HBV chemotherapy.,"['Hong JH', 'Choi Y', 'Chun BK', 'Lee K', 'Chu CK']","['Animals', 'Antiviral Agents/*pharmacology/*therapeutic use', 'Hepatitis B/*drug therapy/prevention & control/virology', 'Hepatitis B virus/*drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9875415/
669,famciclovir,21486500,Chickenpox.,"['Breuer J', 'Fifer H']","['*Chickenpox/immunology', '*Chickenpox Vaccine/administration & dosage', 'Evidence-Based Medicine', 'Humans', 'Immunocompromised Host', 'Incidence', 'India', 'Vaccines, Attenuated/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/21486500/
670,famciclovir,18337531,Treatment of herpes zoster.,"['Opstelten W', 'Eekhof J', 'Neven AK', 'Verheij T']","['2-Aminopurine/administration & dosage/analogs & derivatives/therapeutic use', 'Acyclovir/administration & dosage/analogs & derivatives/therapeutic use', 'Antiviral Agents/administration & dosage/*therapeutic use', 'Famciclovir', 'Glucocorticoids/administration & dosage/*therapeutic use', 'Herpes Zoster/*drug therapy', 'Herpes Zoster Ophthalmicus/*drug therapy/prevention & control', 'Humans', 'Neuralgia, Postherpetic/*drug therapy/prevention & control', 'Prednisolone/administration & dosage/therapeutic use', 'Time Factors', 'Valacyclovir', 'Valine/administration & dosage/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18337531/
671,famciclovir,15934343,[Antiherpetic therapy].,"['Dediulescu L', 'Dediulescu DF']","['2-Aminopurine/*analogs & derivatives/therapeutic use', 'Acyclovir/*analogs & derivatives/therapeutic use', '*Antiviral Agents/therapeutic use', 'Bromodeoxyuridine/*analogs & derivatives/therapeutic use', 'Cidofovir', 'Cytosine/*analogs & derivatives/therapeutic use', 'Drug Combinations', 'Famciclovir', 'Foscarnet/therapeutic use', 'Ganciclovir/therapeutic use', 'Humans', 'Idoxuridine/therapeutic use', '*Keratitis, Herpetic/drug therapy', 'Oligonucleotides/therapeutic use', 'Ophthalmic Solutions', 'Organophosphonates/therapeutic use', 'Treatment Outcome', 'Valacyclovir', 'Valine/*analogs & derivatives/therapeutic use', 'Vidarabine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934343/
672,famciclovir,22568134,[Anti alpha-herpesvirus drugs].,"['Koshizuka T', 'Suzutani T']","['Antiviral Agents/*pharmacology', 'Herpes Simplex/drug therapy', 'Herpesvirus 1, Human/*drug effects', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/22568134/
673,famciclovir,17029141,Recurrent benign lymphocytic meningitis.,"['Shalabi M', 'Whitley RJ']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Adult', 'Aged', 'Antiviral Agents/*therapeutic use', 'Famciclovir', 'Female', '*Herpesvirus 2, Human', 'Humans', 'Male', 'Meningitis, Viral/*prevention & control', 'Middle Aged', 'Recurrence', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17029141/
674,famciclovir,23235944,Emerging concepts in the management of acute retinal necrosis.,"['Wong RW', 'Jumper JM', 'McDonald HR', 'Johnson RN', 'Fu A', 'Lujan BJ', 'Cunningham ET Jr']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Antiviral Agents/therapeutic use', 'Cytomegalovirus Retinitis/diagnosis/therapy/virology', 'Eye Infections, Viral/*diagnosis/*therapy/virology', 'Famciclovir', 'Fluorescein Angiography', 'Ganciclovir/analogs & derivatives/therapeutic use', 'Herpes Simplex/diagnosis/therapy/virology', 'Humans', 'Laser Coagulation', 'Retinal Necrosis Syndrome, Acute/*diagnosis/*therapy/virology', 'Valacyclovir', 'Valganciclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23235944/
675,famciclovir,16556084,Genital herpes: antiviral therapy for symptom relief and prevention of transmission.,"['Gupta R', 'Wald A']","['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Antiviral Agents/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Famciclovir', 'Female', 'Herpes Genitalis/drug therapy/*prevention & control/*transmission', 'Humans', 'Male', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16556084/
676,famciclovir,29896665,Antiviral Drugs Against Alphaherpesvirus.,['Shiraki K'],"['Acyclovir/administration & dosage/analogs & derivatives', 'Animals', 'Antiviral Agents/*administration & dosage', 'Clinical Trials as Topic', 'Guanine', 'Herpes Simplex/*drug therapy/virology', 'Herpes Zoster/*drug therapy/virology', 'Herpesvirus 3, Human/drug effects/genetics/physiology', 'Humans', 'Oxadiazoles/administration & dosage', 'Simplexvirus/drug effects/genetics/physiology']",https://pubmed.ncbi.nlm.nih.gov/29896665/
677,famciclovir,9675639,Antiviral therapy of herpes simplex and varicella-zoster virus infections.,['Wutzler P'],"['2-Aminopurine/analogs & derivatives/therapeutic use', 'Acyclovir/analogs & derivatives/therapeutic use', 'Administration, Oral', 'Antiviral Agents/*therapeutic use', 'Arabinofuranosyluracil/analogs & derivatives/therapeutic use', 'Bromodeoxyuridine/analogs & derivatives/therapeutic use', 'Chickenpox/drug therapy', 'Drug Resistance, Microbial', 'Encephalitis, Viral/mortality', 'Famciclovir', 'Herpes Genitalis/drug therapy', 'Herpes Labialis/drug therapy', 'Herpes Simplex/*drug therapy', 'Herpes Zoster/*drug therapy', 'Humans', 'Immunocompromised Host/drug effects', 'Prodrugs/therapeutic use', 'Simplexvirus', 'Valacyclovir', 'Valine/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9675639/
678,famciclovir,34443515,Synthesis and Biological Evaluation of Amidinourea Derivatives against Herpes Simplex Viruses.,"['Toscani A', 'Denaro R', 'Pacheco SFC', 'Biolatti M', 'Anselmi S', ""Dell'Oste V"", 'Castagnolo D']","['Acyclovir/adverse effects/pharmacology', 'Antiviral Agents/pharmacology', 'Drug Resistance, Viral/genetics', 'Guanidine/*analogs & derivatives/chemical synthesis/pharmacology', 'Herpes Simplex/*drug therapy/virology', 'Herpesvirus 1, Human/*drug effects/pathogenicity', 'Humans', 'Simplexvirus/*drug effects/genetics/pathogenicity', 'Urea/*analogs & derivatives/chemical synthesis/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34443515/
679,famciclovir,15341504,Brivudin (bromovinyl deoxyuridine).,"['Keam SJ', 'Chapman TM', 'Figgitt DP']","['Acute Disease', 'Antiviral Agents/administration & dosage/adverse effects/*therapeutic use', 'Bromodeoxyuridine/administration & dosage/adverse effects/*analogs & derivatives/*therapeutic use', 'Herpes Zoster/*drug therapy', 'Humans', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15341504/
680,lidocaine,20205487,Pilsicainide.,['Plosker GL'],"['Anti-Arrhythmia Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Humans', 'Lidocaine/administration & dosage/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Tachycardia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20205487/
681,lidocaine,30117019,Perioperative Use of Intravenous Lidocaine.,"['Beaussier M', 'Delbos A', 'Maurice-Szamburski A', 'Ecoffey C', 'Mercadal L']","['Administration, Intravenous', 'Analgesics/pharmacokinetics/pharmacology/*therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Anesthetics, Local/pharmacokinetics/pharmacology/*therapeutic use', 'Animals', 'Humans', 'Hyperalgesia/prevention & control', 'Lidocaine/pharmacokinetics/pharmacology/*therapeutic use', 'Pain, Postoperative/*drug therapy', 'Perioperative Period', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30117019/
682,lidocaine,7040025,Lidocaine clinical pharmacokinetics.,"['Pieper JA', 'Slaughter RL', 'Anderson GD', 'Wyman MG', 'Lalka D']","['Humans', 'Kinetics', 'Lidocaine/administration & dosage/adverse effects/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/7040025/
683,lidocaine,15054144,ELA-max: A new topical lidocaine formulation.,['Goldman RD'],"['Administration, Topical', 'Adolescent', 'Adult', 'Anesthetics, Local/*administration & dosage/therapeutic use', 'Child', 'Child, Preschool', 'Humans', 'Lidocaine/*administration & dosage/therapeutic use', 'Nonprescription Drugs', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15054144/
684,lidocaine,27731571,Local Anesthetics Systemic Toxicity.,"['Jayanthi R', 'Nasser K', 'Monica K']","['Administration, Intravenous', 'Adult', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Diazepam/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lidocaine/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Seizures/*chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27731571/
685,lidocaine,10867254,"pH, pK(a) and dermal delivery.","['Hadgraft J', 'Valenta C']","['Administration, Cutaneous', 'Humans', 'Hydrogen-Ion Concentration', 'Ibuprofen/*administration & dosage/chemistry', 'Lidocaine/*administration & dosage/chemistry', 'Permeability']",https://pubmed.ncbi.nlm.nih.gov/10867254/
686,lidocaine,6200230,Current understanding of lidocaine as an antiarrhythmic agent: a review.,['Anderson JL'],"['Age Factors', 'Arrhythmias, Cardiac/*drug therapy', 'Cardiac Complexes, Premature/prevention & control', 'Electrophysiology', 'Heart Conduction System/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Lidocaine/administration & dosage/adverse effects/*therapeutic use', 'Models, Chemical', 'Myocardial Infarction/complications', 'Nervous System/drug effects', 'Tachycardia/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/6200230/
687,lidocaine,1517667,The effects of lidocaine on intracranial hypertension.,"['Brucia JJ', 'Owen DC', 'Rudy EB']","['Craniocerebral Trauma/*complications', 'Evaluation Studies as Topic', 'Humans', 'Injections, Intravenous', 'Instillation, Drug', 'Intubation, Intratracheal/*adverse effects', 'Lidocaine/administration & dosage/pharmacology/*therapeutic use', 'Pseudotumor Cerebri/*drug therapy/etiology/nursing', 'Suction/*adverse effects', 'Trachea']",https://pubmed.ncbi.nlm.nih.gov/1517667/
688,lidocaine,8275285,Emla cream and its current uses.,"['Lee JJ', 'Rubin AP']","['Administration, Cutaneous', '*Anesthetics, Local/administration & dosage/adverse effects/chemistry', 'Child', 'Dermatologic Surgical Procedures', 'Drug Combinations', 'Humans', '*Lidocaine/administration & dosage/adverse effects/chemistry', 'Lidocaine, Prilocaine Drug Combination', 'Ointments', '*Prilocaine/administration & dosage/adverse effects/chemistry']",https://pubmed.ncbi.nlm.nih.gov/8275285/
689,lidocaine,29536530,The Use and Method of Action of Intravenous Lidocaine and Its Metabolite in Headache Disorders.,"['Berk T', 'Silberstein SD']","['Anesthetics/administration & dosage/metabolism/pharmacokinetics/*pharmacology', 'Headache Disorders/*drug therapy', 'Humans', 'Lidocaine/administration & dosage/metabolism/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29536530/
690,lidocaine,901735,Lignocaine kinetics in cardiac patients and aged subjects.,"['Nation RL', 'Triggs EJ', 'Selig M']","['Adult', 'Aged', '*Aging', 'Half-Life', 'Heart Diseases/*blood', 'Humans', 'Infusions, Parenteral', 'Injections, Intravenous', 'Kinetics', 'Lidocaine/administration & dosage/adverse effects/*blood', 'Male', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/901735/
691,lidocaine,6437131,The effect of intra-venous lidocaine and several different doses oral tocainide HCl on tinnitus. A dose-finding study.,"['Hulshof JH', 'Vermeij P']","['Administration, Oral', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Lidocaine/*administration & dosage/adverse effects/*analogs & derivatives/blood', 'Loudness Perception/drug effects', 'Male', 'Middle Aged', 'Random Allocation', 'Tinnitus/*drug therapy/etiology', 'Tocainide']",https://pubmed.ncbi.nlm.nih.gov/6437131/
692,lidocaine,16572926,Pharmacological concept for topical synergistic analgesia of peripheral neuromuscular pain.,['Liedtke RK'],"['Administration, Cutaneous', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Anesthetics, Local/administration & dosage/adverse effects/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'Humans', 'Lidocaine/administration & dosage/adverse effects/therapeutic use', 'Neuromuscular Diseases/*drug therapy', 'Pain/*drug therapy', 'Peripheral Nervous System', 'Sodium Channel Blockers/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16572926/
693,lidocaine,38701900,The role of lidocaine in cancer progression and patient survival.,"['Chida K', 'Kanazawa H', 'Kinoshita H', 'Roy AM', 'Hakamada K', 'Takabe K']","['Humans', '*Lidocaine/therapeutic use/pharmacology', '*Neoplasms/drug therapy/pathology', '*Anesthetics, Local/therapeutic use/pharmacology/administration & dosage', 'Animals', '*Disease Progression', 'Tumor Microenvironment/drug effects', 'Antineoplastic Agents/therapeutic use/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38701900/
694,lidocaine,1466212,Lidocaine pretreatment effectively decreases the incidence of hiccups during methohexitone administration for dilatation and curettage.,"['Weksler N', 'Stav A', 'Ovadia L', 'Berman M', 'Segal A', 'Ribac L', 'Lemberg L']","['Abortion, Induced', 'Adult', '*Anesthesia, Intravenous', '*Dilatation and Curettage', 'Double-Blind Method', 'Female', 'Hiccup/*prevention & control', 'Humans', 'Incidence', 'Lidocaine/administration & dosage/*therapeutic use', 'Methohexital/*adverse effects', 'Pregnancy', '*Premedication']",https://pubmed.ncbi.nlm.nih.gov/1466212/
695,lidocaine,7793583,Modulating effects of lignocaine on propofol.,"['Tham CS', 'Khoo ST']","['Adolescent', 'Adult', 'Aged', 'Akathisia, Drug-Induced/etiology/prevention & control', 'Anesthesia, Intravenous/*adverse effects', 'Female', 'Forearm/blood supply', 'Hand/blood supply', 'Humans', 'Hypotension/chemically induced', 'Incidence', 'Injections, Intravenous/adverse effects', 'Lidocaine/administration & dosage/adverse effects/*pharmacology', 'Male', 'Middle Aged', 'Pain/chemically induced/*prevention & control', 'Propofol/*adverse effects', 'Single-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/7793583/
696,lidocaine,22382793,"A randomized double-blind study comparing intradermal anesthetic tolerability, efficacy, and cost-effectiveness of lidocaine, buffered lidocaine, and bacteriostatic normal saline for peripheral intravenous insertion.","['Ganter-Ritz V', 'Speroni KG', 'Atherton M']","['Analysis of Variance', '*Catheterization, Peripheral', 'Cost-Benefit Analysis', 'Double-Blind Method', 'Female', 'Humans', '*Infusions, Intravenous', 'Injections, Intradermal/economics', 'Lidocaine/administration & dosage/adverse effects/economics/*therapeutic use', 'Male', 'Middle Aged', 'Perioperative Care', 'Sodium Chloride/administration & dosage/adverse effects/economics/*therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/22382793/
697,lidocaine,9278213,The effect of age on plasma MEGX concentrations.,"['Orlando R', 'Palatini P']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*blood', 'Fluorescence Polarization Immunoassay', 'Humans', 'Lidocaine/*administration & dosage/*analogs & derivatives/blood/pharmacokinetics', 'Male', 'Middle Aged', 'Reference Values', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/9278213/
698,lidocaine,10730547,Lidocaine patch 5%.,"['Comer AM', 'Lamb HM']","['Absorption', 'Administration, Cutaneous', 'Anesthetics, Local/administration & dosage/*pharmacokinetics/therapeutic use', 'Herpes Zoster/complications', 'Humans', 'Lidocaine/administration & dosage/*pharmacokinetics/therapeutic use', 'Neuralgia/drug therapy', 'Pain/*drug therapy', 'Sodium Channels/drug effects']",https://pubmed.ncbi.nlm.nih.gov/10730547/
699,lidocaine,1525460,The effects of lignocaine on human sperm motility.,"['Bennett SJ', 'Bolton V', 'Parsons J']","['Humans', 'Lidocaine/*pharmacology', 'Male', 'Sperm Capacitation/*drug effects', 'Sperm Motility/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1525460/
700,Atazanavir,28579422,Atazanavir-Associated Crystalline Nephropathy.,"['Santoriello D', 'Al-Nabulsi M', 'Reddy A', 'Salamera J', ""D'Agati VD"", 'Markowitz GS']","['Atazanavir Sulfate/*adverse effects', 'Crystallization', 'HIV Protease Inhibitors/*adverse effects', 'Humans', 'Kidney Diseases/*chemically induced', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28579422/
701,Atazanavir,35538801,Azapeptides -A History of Synthetic Milestones and Key Examples.,"['Fan Cheng K', 'VanPatten S', 'He M', 'Al-Abed Y']","['Humans', '*Peptidomimetics', '*Aza Compounds/chemistry', 'Atazanavir Sulfate', 'Goserelin', '*HIV Infections', 'Peptides/chemistry', 'Amino Acids/chemistry', 'Carbon', 'Nitrogen']",https://pubmed.ncbi.nlm.nih.gov/35538801/
702,Atazanavir,33299085,Identifying side effects of commonly used drugs in the treatment of Covid 19.,"['Aygun I', 'Kaya M', 'Alhajj R']","['Atazanavir Sulfate/adverse effects/*therapeutic use', 'COVID-19/*metabolism/pathology', 'Drug Interactions', 'Heparin/adverse effects/*therapeutic use', 'Humans', 'SARS-CoV-2/*metabolism', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33299085/
703,Atazanavir,31939539,HIV-related nephropathy: new aspects of an old paradigm.,"['Reghine EL', 'Foresto RD', 'Kirsztajn GM']","['AIDS-Associated Nephropathy/*etiology/pathology', 'Acute Kidney Injury/*etiology/pathology', 'Anti-HIV Agents/adverse effects', 'Antiretroviral Therapy, Highly Active/adverse effects', 'Atazanavir Sulfate/adverse effects', 'Chronic Disease', 'HIV Infections/*complications/drug therapy', 'Humans', 'Kidney/pathology', 'Risk Factors', 'Tenofovir/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31939539/
704,Atazanavir,26545091,Drug updates and approvals: 2015 in review.,"['Klibanov OM', 'Phan D', 'Ferguson K']","['Amlodipine/therapeutic use', 'Antibodies, Monoclonal/administration & dosage', 'Antibodies, Monoclonal, Humanized', 'Atazanavir Sulfate/therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Benzazepines/therapeutic use', 'Ceftazidime/therapeutic use', 'Cobicistat/therapeutic use', '*Drug Approval', 'Drug Combinations', 'Humans', 'Injections, Subcutaneous', 'Ivabradine', 'Liraglutide/therapeutic use', 'Nurse Practitioners', 'Perindopril/therapeutic use', 'Pyridines/therapeutic use', 'Thiazoles/therapeutic use', 'United States', '*United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/26545091/
705,Atazanavir,32061722,Laser ablation for pharmaceutical nanoformulations: Multi-drug nanoencapsulation and theranostics for HIV.,"['Singh A', 'Kutscher HL', 'Bulmahn JC', 'Mahajan SD', 'He GS', 'Prasad PN']","['Atazanavir Sulfate/chemical synthesis/chemistry/pharmacology', 'Blood-Brain Barrier/drug effects', 'Curcumin/chemical synthesis/chemistry/pharmacology', 'Drug Carriers/chemical synthesis/chemistry/pharmacology', '*Drug Compounding', 'HIV Infections/*drug therapy/virology', 'HIV-1/drug effects/pathogenicity', 'Humans', 'Laser Therapy', 'Nanoparticles/*chemistry/therapeutic use', 'Precision Medicine', 'Ritonavir/chemical synthesis/chemistry/pharmacology', 'Theranostic Nanomedicine/*trends']",https://pubmed.ncbi.nlm.nih.gov/32061722/
706,Atazanavir,12225250,Atazanavir: a novel HIV-1 protease inhibitor.,['Piliero PJ'],"['Animals', 'Atazanavir Sulfate', 'Clinical Trials as Topic/statistics & numerical data', 'HIV Infections/*drug therapy/enzymology', 'HIV Protease Inhibitors/chemistry/pharmacokinetics/*therapeutic use', 'HIV-1/drug effects/*enzymology', 'Humans', 'Oligopeptides/chemistry/pharmacokinetics/*therapeutic use', 'Pyridines/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12225250/
707,Atazanavir,17376023,Atazanavir: simplicity and convenience in different scenarios.,['Perez-Elias MJ'],"['Area Under Curve', 'Atazanavir Sulfate', 'Drug Interactions', 'Female', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/adverse effects/pharmacology/*therapeutic use', '*HIV-1', 'Half-Life', 'Humans', 'Male', 'Multicenter Studies as Topic', 'Oligopeptides/adverse effects/pharmacology/*therapeutic use', 'Pyridines/adverse effects/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17376023/
708,Atazanavir,28595364,Antiretroviral unbound concentration during pregnancy: piece of interest in the puzzle?,"['Metsu D', 'Toutain PL', 'Chatelut E', 'Delobel P', 'Gandia P']","['Atazanavir Sulfate/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Blood Proteins/chemistry/metabolism', 'Darunavir/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'HIV Infections/*drug therapy/metabolism', 'HIV Protease Inhibitors/adverse effects/chemistry/*pharmacokinetics/therapeutic use', 'Hepatocytes/drug effects/metabolism', 'Humans', 'Pregnancy', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/28595364/
709,Atazanavir,20116616,[Adverse effects of atazanavir].,"['Palacios R', 'Gonzalez M', 'Ruiz J', 'Santos J']","['Anti-HIV Agents/administration & dosage/adverse effects/therapeutic use', 'Atazanavir Sulfate', 'Carbohydrate Metabolism/drug effects', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Therapy, Combination', 'Dyslipidemias/chemically induced', 'Gastrointestinal Diseases/chemically induced', 'Glucose/metabolism', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Hyperbilirubinemia/*chemically induced', 'Hyperinsulinism/chemically induced', 'Insulin Resistance', 'Oligopeptides/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Pyridines/administration & dosage/*adverse effects/pharmacology/therapeutic use', 'Urolithiasis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/20116616/
710,Atazanavir,27190354,Renal effects of novel antiretroviral drugs.,"['Milburn J', 'Jones R', 'Levy JB']","['Adenine/adverse effects/analogs & derivatives', 'Alanine', 'Anti-HIV Agents/*adverse effects', 'Atazanavir Sulfate/adverse effects', 'Cobicistat/adverse effects', 'Creatinine', 'Disease Progression', 'HIV Infections/complications/*drug therapy', 'Heterocyclic Compounds, 3-Ring/adverse effects', 'Humans', 'Oxazines', 'Piperazines', 'Proteinuria/chemically induced/complications', 'Pyridones', 'Quinolones/adverse effects', 'Raltegravir Potassium/adverse effects', 'Renal Insufficiency, Chronic/*chemically induced/complications/metabolism', 'Tenofovir/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/27190354/
711,Atazanavir,25392858,Is it time to revise antiretrovirals dosing? a pharmacokinetic viewpoint.,"['Cattaneo D', 'Baldelli S', 'Castoldi S', 'Charbe N', 'Cozzi V', 'Fucile S', 'Clementi E']","['Anti-Retroviral Agents/*administration & dosage/*pharmacokinetics', 'Atazanavir Sulfate', 'Drug Monitoring', 'HIV Infections/*drug therapy', 'Humans', 'Lopinavir/administration & dosage/pharmacokinetics', 'Nevirapine/administration & dosage/pharmacokinetics', 'Oligopeptides/administration & dosage/pharmacokinetics', 'Plasma/*chemistry', 'Pyridines/administration & dosage/pharmacokinetics', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/25392858/
712,Atazanavir,31638397,Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids.,"['Elkhabaz A', 'Moseson DE', 'Brouwers J', 'Augustijns P', 'Taylor LS']","['Atazanavir Sulfate/*administration & dosage/*chemistry', 'Biological Transport/*drug effects/*physiology', 'Body Fluids/*metabolism', 'Chemistry, Pharmaceutical/methods', 'Crystallization', 'Diffusion', 'Humans', 'Kinetics', 'Solubility', 'Thermodynamics', 'Triazoles/*administration & dosage/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/31638397/
713,Atazanavir,29735845,A first-line antiretroviral therapy-resistant HIV patient with rhinoentomophthoromycosis.,"['Dhurat R', 'Kothavade RJ', 'Kumar A']","['Adult', 'Anti-Retroviral Agents/*therapeutic use', 'Antifungal Agents/*therapeutic use', 'Atazanavir Sulfate/therapeutic use', 'Conidiobolus/*drug effects', '*Drug Resistance, Fungal', 'Drug Resistance, Viral', 'HIV Infections', 'Humans', 'Immunocompromised Host', 'Itraconazole/*therapeutic use', 'Lamivudine/therapeutic use', 'Male', 'Potassium Iodide/therapeutic use', 'Ritonavir/therapeutic use', 'Tenofovir/therapeutic use', 'Zygomycosis/complications/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/29735845/
714,Atazanavir,31562781,Association of Pharmacogenetic Markers With Atazanavir Exposure in HIV-Infected Women.,"['Tamraz B', 'Huang Y', 'French AL', 'Kassaye S', 'Anastos K', 'Nowicki MJ', 'Gange S', 'Gustafson DR', 'Bacchetti P', 'Greenblatt RM', 'Hysi PG', 'Aouizerat BE']","['ATP Binding Cassette Transporter, Subfamily B/genetics', 'Area Under Curve', 'Atazanavir Sulfate/administration & dosage/*pharmacokinetics', 'Chromatography, High Pressure Liquid', 'Citrus sinensis', 'Cytochrome P-450 CYP3A Inhibitors/pharmacology', 'Diarrhea/epidemiology', 'Dose-Response Relationship, Drug', 'Female', 'Genotype', 'HIV Infections/*drug therapy/epidemiology', 'HIV Protease Inhibitors/administration & dosage/*pharmacokinetics', 'Hair/chemistry', 'Heroin Dependence/epidemiology', 'Humans', 'Hydrogen-Ion Concentration', 'Longitudinal Studies', 'MicroRNAs', 'Polymorphism, Single Nucleotide', 'Racial Groups', 'Receptors, Cell Surface/*genetics', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/31562781/
715,Atazanavir,34727835,Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients.,"['Singkham N', 'Avihingsanon A', 'Brundage RC', 'Birnbaum AK', 'Thammajaruk N', 'Ruxrungtham K', 'Bunupuradah T', 'Kiertiburanakul S', 'Chetchotisakd P', 'Punyawudho B']","['Adult', '*Anti-HIV Agents', 'Atazanavir Sulfate/adverse effects', 'Female', '*HIV Infections/drug therapy', 'Humans', 'Liver-Specific Organic Anion Transporter 1/genetics', 'Male', 'Pharmacogenetics', 'Ritonavir', 'Thailand']",https://pubmed.ncbi.nlm.nih.gov/34727835/
716,Atazanavir,28134625,Autophagy facilitates macrophage depots of sustained-release nanoformulated antiretroviral drugs.,"['Gnanadhas DP', 'Dash PK', 'Sillman B', 'Bade AN', 'Lin Z', 'Palandri DL', 'Gautam N', 'Alnouti Y', 'Gelbard HA', 'McMillan J', 'Mosley RL', 'Edagwa B', 'Gendelman HE', 'Gorantla S']","['Acquired Immunodeficiency Syndrome/*drug therapy/metabolism', 'Animals', 'Anti-Retroviral Agents/*pharmacology', 'Atazanavir Sulfate/pharmacology', 'Autophagy/*drug effects', 'Basic Helix-Loop-Helix Leucine Zipper Transcription Factors/metabolism', 'Female', 'HIV-1/*metabolism', 'Heterocyclic Compounds, 3-Ring/pharmacology', 'Humans', 'Macrophages/*metabolism', 'Male', 'Mice', '*Nanoparticles', 'Oxazines', 'Piperazines', 'Pyridines/pharmacology', 'Pyridones', 'Pyrroles/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28134625/
717,Atazanavir,26026666,Pharmacodynamics of folic acid receptor targeted antiretroviral nanotherapy in HIV-1-infected humanized mice.,"['Puligujja P', 'Arainga M', 'Dash P', 'Palandri D', 'Mosley RL', 'Gorantla S', 'Poluektova L', 'McMillan J', 'Gendelman HE']","['Animals', 'Anti-Retroviral Agents/administration & dosage/*pharmacokinetics', 'Atazanavir Sulfate/administration & dosage/pharmacokinetics', 'CD4 Lymphocyte Count', 'Delayed-Action Preparations/administration & dosage/*pharmacokinetics', 'Drug Carriers/administration & dosage/*metabolism', 'Folate Receptors, GPI-Anchored/*metabolism', 'Folic Acid/administration & dosage/metabolism', 'HIV Infections/drug therapy', 'Humans', 'Injections, Intramuscular', 'Mice, SCID', 'Nanomedicine/*methods', 'Nanoparticles/administration & dosage/*metabolism', 'Poloxamer/administration & dosage/metabolism', 'RNA, Viral/blood', 'Ritonavir/administration & dosage/pharmacokinetics', 'Treatment Outcome', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/26026666/
718,Atazanavir,15353575,Atazanavir.,"['Orrick JJ', 'Steinhart CR']","['Atazanavir Sulfate', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Resistance, Viral', 'HIV Infections/drug therapy/virology', '*HIV Protease Inhibitors/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'In Vitro Techniques', '*Oligopeptides/adverse effects/pharmacokinetics/therapeutic use', '*Pyridines/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15353575/
719,Atazanavir,29232276,Contemporary protease inhibitors and cardiovascular risk.,"['Lundgren J', 'Mocroft A', 'Ryom L']","['Antiretroviral Therapy, Highly Active/*adverse effects/methods', 'Atazanavir Sulfate/adverse effects/therapeutic use', 'Cardiovascular Diseases/*chemically induced/*epidemiology', 'Darunavir/adverse effects/therapeutic use', 'HIV Infections/*complications/*drug therapy', 'HIV Protease Inhibitors/*adverse effects/*therapeutic use', 'Humans', 'Risk Assessment', 'Ritonavir/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29232276/
720,sumatriptan,16995362,[Medication-overuse headache].,"['Rabe K', 'Katsarava Z']","['Acute Disease', 'Analgesics/administration & dosage/*adverse effects', 'Analgesics, Non-Narcotic/administration & dosage/adverse effects', 'Chronic Disease', 'Ergotamine/administration & dosage/adverse effects', 'Female', 'Headache/*chemically induced/diagnosis/drug therapy', 'Headache Disorders, Secondary/*diagnosis/prevention & control', 'Humans', 'Male', 'Migraine Disorders/*chemically induced/drug therapy', 'Prognosis', 'Recurrence', 'Serotonin Receptor Agonists/administration & dosage/therapeutic use', 'Sumatriptan/administration & dosage/therapeutic use', 'Tension-Type Headache/chemically induced/drug therapy', 'Time Factors', 'Vasoconstrictor Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16995362/
721,sumatriptan,27807736,[Analgesic drugs during pregnancy].,"['Hultzsch S', 'Schaefer C']","['Abnormalities, Drug-Induced/etiology', 'Acetaminophen/adverse effects/therapeutic use', 'Acute Pain/*drug therapy', 'Analgesics/*adverse effects/*therapeutic use', 'Analgesics, Opioid/adverse effects/therapeutic use', 'Anticonvulsants/adverse effects/therapeutic use', 'Chronic Pain/*drug therapy', 'Female', 'Gestational Age', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Infant, Newborn', 'Long-Term Care', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Risk Factors', 'Sumatriptan/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27807736/
722,sumatriptan,20430313,Meeting acute migraine treatment needs through novel treatment formulations.,['Silberstein SD'],"['Analgesics, Non-Narcotic/*administration & dosage/therapeutic use', 'Diclofenac/*administration & dosage/therapeutic use', 'Dihydroergotamine/*administration & dosage/therapeutic use', 'Drug Administration Routes', 'Drug Delivery Systems', 'Drug Prescriptions', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20430313/
723,sumatriptan,15853561,Sumatriptan: a decade of use and experience in the treatment of migraine.,"['Sheftell FD', 'Bigal ME', 'Tepper SJ', 'Rapoport AM']","['Clinical Trials as Topic/*trends', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15853561/
724,sumatriptan,12534326,Tolerability of the triptans: clinical implications.,"['Nappi G', 'Sandrini G', 'Sances G']","['Brain/drug effects', 'Cardiovascular System/drug effects', 'Drug Interactions', 'Female', 'Fetus/drug effects', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/drug effects', 'Serotonin Receptor Agonists/*adverse effects', 'Sumatriptan/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12534326/
725,sumatriptan,26255952,The pharmacokinetics and clinical efficacy of AVP-825: a potential advancement for acute treatment of migraine.,['Cady R'],"['Administration, Intranasal', 'Drugs, Investigational', 'Humans', 'Migraine Disorders/*drug therapy', 'Randomized Controlled Trials as Topic', 'Serotonin Receptor Agonists/*administration & dosage/adverse effects', 'Sumatriptan/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26255952/
726,sumatriptan,15549517,Acute drug treatment of migraine attack.,"['Narbone MC', 'Abbate M', 'Gangemi S']","['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antiemetics/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Contraindications', 'Ergot Alkaloids/adverse effects/therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/adverse effects/therapeutic use', 'Sumatriptan/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15549517/
727,sumatriptan,17955173,Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment.,['Tfelt-Hansen P'],"['Administration, Oral', 'Biological Availability', 'Humans', 'Infusions, Parenteral', 'Injections, Subcutaneous', 'Migraine Disorders/*drug therapy/physiopathology', 'Piperidines/*administration & dosage/blood/pharmacokinetics', 'Serotonin Receptor Agonists/*administration & dosage/blood/pharmacokinetics', 'Sumatriptan/*administration & dosage/blood/pharmacokinetics', 'Time Factors', 'Treatment Outcome', 'Tryptamines/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/17955173/
728,sumatriptan,18778579,Cutaneous allodynia and migraine: another view.,['Dahlof C'],"['Humans', 'Hyperalgesia/*drug therapy/*physiopathology', 'Migraine Disorders/*drug therapy/*physiopathology', 'Serotonin Receptor Agonists/pharmacokinetics/*therapeutic use', 'Sumatriptan/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18778579/
729,sumatriptan,22444161,"Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.","['Dahlof C', 'Maassen Van Den Brink A']","['Animals', 'Dihydroergotamine/chemistry/pharmacokinetics/*therapeutic use', 'Ergotamine/chemistry/pharmacokinetics/*therapeutic use', 'Humans', 'Methysergide/chemistry/pharmacokinetics/*therapeutic use', 'Migraine Disorders/*drug therapy/metabolism', 'Sumatriptan/chemistry/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22444161/
730,sumatriptan,25219631,Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches.,"['Lecchi M', ""D'Alonzo L"", 'Negro A', 'Martelletti P']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics/*therapeutic use', 'Aspirin/administration & dosage/pharmacokinetics/*therapeutic use', 'Dose-Response Relationship, Drug', 'Headache/*drug therapy', 'Humans', 'Migraine Disorders/drug therapy', 'Practice Guidelines as Topic', 'Sumatriptan/administration & dosage/therapeutic use', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/25219631/
731,sumatriptan,11668885,Efficacy of sumatriptan in the treatment of migraine: a review of the literature.,['McAlhany A'],"['Adult', 'Child', 'Clinical Trials as Topic', 'Humans', 'Migraine Disorders/*drug therapy/nursing', 'Sumatriptan/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11668885/
732,sumatriptan,12474651,[The problems of migraine headache treatment].,"['Vilionskis A', 'Vaitkus A']","['Aged', 'Analgesics/administration & dosage/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Aspirin/administration & dosage/therapeutic use', 'Dihydroergotamine/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Methysergide/administration & dosage/therapeutic use', 'Migraine Disorders/chemically induced/diagnosis/*drug therapy/etiology/prevention & control', 'Oxazolidinones/administration & dosage/therapeutic use', 'Serotonin Antagonists/administration & dosage/therapeutic use', 'Serotonin Receptor Agonists/administration & dosage/therapeutic use', 'Stress, Psychological/complications', 'Sumatriptan/administration & dosage/therapeutic use', 'Time Factors', 'Tryptamines', 'Vasoconstrictor Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12474651/
733,sumatriptan,20464603,New acute treatments for headache.,['Rapoport AM'],"['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Clinical Trials as Topic', 'Diclofenac/administration & dosage/therapeutic use', 'Dipeptides/*therapeutic use', 'Drug Administration Routes', 'Headache Disorders/*drug therapy', 'Humans', 'Piperazines', 'Quinazolines/*therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Sumatriptan/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20464603/
734,sumatriptan,12463280,Eletriptan: pharmacological differences and clinical results.,['Giffin N'],"['Humans', 'Indoles/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/*pharmacology/therapeutic use', 'Serotonin Receptor Agonists/*pharmacology/therapeutic use', 'Sumatriptan/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463280/
735,sumatriptan,12463281,Almotriptan: pharmacological differences and clinical results.,['Pascual J'],"['Administration, Oral', 'Humans', 'Indoles/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Recurrence', 'Serotonin Receptor Agonists/*pharmacology/therapeutic use', 'Sumatriptan/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463281/
736,sumatriptan,31425447,PARACENTRAL ACUTE MIDDLE MACULOPATHY FOLLOWING ORAL INTAKE OF SUMATRIPTAN.,"['Zonnevylle KE', 'Jacob J', 'Luyten S', 'Stanescu-Segall D']","['Acute Disease', 'Administration, Oral', 'Humans', '*Macular Degeneration/chemically induced/diagnostic imaging', '*Retinal Diseases/chemically induced/diagnostic imaging', '*Sumatriptan/administration & dosage/adverse effects', 'Tomography, Optical Coherence']",https://pubmed.ncbi.nlm.nih.gov/31425447/
737,sumatriptan,32843411,Vasospasm induced myocardial ischaemia secondary to sumatriptan use.,"['Okonkwo K', 'Ojha U']","['Coronary Angiography', '*Coronary Vasospasm/chemically induced/diagnosis', 'Electrocardiography', 'Humans', 'Male', 'Middle Aged', 'Migraine Disorders/drug therapy', '*Myocardial Ischemia/chemically induced/diagnosis', 'Sumatriptan/*adverse effects/therapeutic use', 'Vasoconstrictor Agents/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32843411/
738,sumatriptan,21469920,"Sumatriptan needle-free subcutaneous (Sumavel((R)) DosePro) approved for the acute treatment of migraine, with or without aura, and cluster headaches.",['Freitag FG'],"['Cluster Headache/*drug therapy/physiopathology', 'Drug Administration Routes', 'Drug Delivery Systems', 'Female', 'Humans', 'Injections, Subcutaneous', 'Male', 'Migraine Disorders/*drug therapy/physiopathology', 'Serotonin 5-HT1 Receptor Agonists/*administration & dosage/adverse effects/*therapeutic use', 'Sumatriptan/*administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21469920/
739,Etiracetam,30036676,Levetiracetam.,"['Howard P', 'Remi J', 'Remi C', 'Charlesworth S', 'Whalley H', 'Bhatia R', 'Hitchens M', 'Mihalyo M', 'Wilcock A']","['Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Levetiracetam/adverse effects/pharmacology/*therapeutic use', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/30036676/
740,Etiracetam,35838207,Management of epilepsy in brain tumor patients.,"['van der Meer PB', 'Taphoorn MJB', 'Koekkoek JAF']","['Anticonvulsants/adverse effects/therapeutic use', 'Benzodiazepines/therapeutic use', '*Brain Neoplasms/complications/drug therapy', '*Epilepsy/drug therapy/etiology/prevention & control', 'Humans', 'Isocitrate Dehydrogenase', 'Lacosamide/therapeutic use', 'Levetiracetam/therapeutic use', 'Seizures/chemically induced/etiology', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35838207/
741,Etiracetam,31774955,Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.,"['Kapur J', 'Elm J', 'Chamberlain JM', 'Barsan W', 'Cloyd J', 'Lowenstein D', 'Shinnar S', 'Conwit R', 'Meinzer C', 'Cock H', 'Fountain N', 'Connor JT', 'Silbergleit R']","['Adolescent', 'Adult', 'Anticonvulsants/adverse effects/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Drug Resistance', 'Female', 'Humans', 'Hypotension/chemically induced', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Levetiracetam/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Phenytoin/adverse effects/*analogs & derivatives/therapeutic use', 'Status Epilepticus/*drug therapy', 'Valproic Acid/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31774955/
742,Etiracetam,31917143,Pyridoxine supplementation for levetiracetam-related neuropsychiatric adverse events: A systematic review.,"['Romoli M', 'Perucca E', 'Sen A']","['Anticonvulsants/*adverse effects', 'Diagnostic Tests, Routine', 'Dietary Supplements', 'Drug Therapy, Combination', 'Epilepsy/drug therapy/psychology', 'Humans', 'Levetiracetam/*adverse effects', 'Mental Disorders/*chemically induced/*drug therapy/psychology', 'Prospective Studies', 'Pyridoxine/*administration & dosage', 'Quality of Life/psychology', 'Retrospective Studies', 'Vitamin B Complex/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31917143/
743,Etiracetam,33573557,"Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.","['Kaplan YC', 'Demir O']","['Anticonvulsants/adverse effects', 'Breast Feeding', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lamotrigine/adverse effects', 'Levetiracetam/adverse effects', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/drug therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33573557/
744,Etiracetam,31033711,Brivaracetam for epilepsy.,"['Hellerslia V', 'Asistido JM', 'Iyamu A']","['Anticonvulsants/*therapeutic use', 'Drug Costs', 'Epilepsy/*drug therapy', 'Humans', 'Insurance Coverage/economics', 'Levetiracetam/administration & dosage/adverse effects/economics/therapeutic use', 'Practice Guidelines as Topic', 'Pyrrolidinones/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31033711/
745,Etiracetam,32385134,Levetiracetam Versus Phenobarbital for Neonatal Seizures: A Randomized Controlled Trial.,"['Sharpe C', 'Reiner GE', 'Davis SL', 'Nespeca M', 'Gold JJ', 'Rasmussen M', 'Kuperman R', 'Harbert MJ', 'Michelson D', 'Joe P', 'Wang S', 'Rismanchi N', 'Le NM', 'Mower A', 'Kim J', 'Battin MR', 'Lane B', 'Honold J', 'Knodel E', 'Arnell K', 'Bridge R', 'Lee L', 'Ernstrom K', 'Raman R', 'Haas RH']","['Anticonvulsants/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Epilepsy, Benign Neonatal/diagnosis/*drug therapy/*physiopathology', 'Female', 'Humans', 'Infant, Newborn', 'Levetiracetam/*therapeutic use', 'Male', 'Phenobarbital/*therapeutic use', 'Seizures/diagnosis/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/32385134/
746,Etiracetam,35523739,Individualizing doses of antiepileptic drugs.,"['Liparoti G', 'Burchiani B', 'Mencaroni E', 'Tripodi D', 'Di Cara G', 'Verrotti A']","['*Anticonvulsants/adverse effects', '*Carbamazepine/therapeutic use', 'Humans', 'Lamotrigine', 'Levetiracetam', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/35523739/
747,Etiracetam,32859841,Levetiracetam-Induced Hepatic Dysfunction.,"['Gayatri P', 'Selvam MM', 'Sreeharsha SV']","['*Anticonvulsants/adverse effects', 'Humans', 'Levetiracetam/adverse effects', '*Piracetam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32859841/
748,Etiracetam,35976303,"Status epilepticus: review on diagnosis, monitoring and treatment.","['Pinto LF', 'Oliveira JPS', 'Midon AM']","['Anticonvulsants/therapeutic use', 'Benzodiazepines/therapeutic use', 'Humans', 'Levetiracetam/therapeutic use', 'Seizures/complications', '*Status Epilepticus/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35976303/
749,Etiracetam,29208197,[Treatment of rolandic epilepsy].,"['Miranda MJ', 'Ahmad BB']","['Anticonvulsants/*therapeutic use', 'Child', 'Cognition Disorders/etiology', 'Electroencephalography', 'Epilepsy, Rolandic/complications/diagnosis/*drug therapy', 'Humans', 'Levetiracetam/therapeutic use', 'Thiazines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29208197/
750,Etiracetam,36842341,Epilepsy and brain tumors: Two sides of the same coin.,"['Aronica E', 'Ciusani E', 'Coppola A', 'Costa C', 'Russo E', 'Salmaggi A', 'Perversi F', 'Maschio M']","['Humans', 'Anticonvulsants/therapeutic use', '*Epilepsy/complications', 'Levetiracetam/therapeutic use', 'Valproic Acid/therapeutic use', '*Brain Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/36842341/
751,Etiracetam,34286461,Levetiracetam for Seizure Prophylaxis in Neurocritical Care: A Systematic Review and Meta-analysis.,"['Fang T', 'Valdes E', 'Frontera JA']","['Adolescent', '*Anticonvulsants/therapeutic use', 'Child', 'Humans', 'Levetiracetam/therapeutic use', 'Prospective Studies', 'Retrospective Studies', '*Seizures/drug therapy/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34286461/
752,Etiracetam,34164804,Rapid administration of undiluted intravenous levetiracetam.,"['Haller JT', 'Bonnin S', 'Radosevich J']","['Adult', 'Anticonvulsants/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', '*Epilepsy/drug therapy', 'Humans', 'Levetiracetam/therapeutic use', '*Piracetam/adverse effects', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34164804/
753,Etiracetam,36209676,Treatment of benzodiazepine-resistant status epilepticus: Systematic review and network meta-analyses.,"['Jain P', 'Aneja S', 'Cunningham J', 'Arya R', 'Sharma S']","['Adult', 'Child', 'Humans', 'Anticonvulsants/therapeutic use', '*Benzodiazepines/pharmacology', 'Levetiracetam/therapeutic use', 'Network Meta-Analysis', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'Valproic Acid/therapeutic use', '*Drug Resistance', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36209676/
754,Etiracetam,33839453,"Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: A systematic review.","['Steinhoff BJ', 'Klein P', 'Klitgaard H', 'Laloyaux C', 'Moseley BD', 'Ricchetti-Masterson K', 'Rosenow F', 'Sirven JI', 'Smith B', 'Stern JM', 'Toledo M', 'Zipfel PA', 'Villanueva V']","['*Anticonvulsants/adverse effects', 'Humans', 'Levetiracetam/therapeutic use', 'Nitriles', 'Observational Studies as Topic', 'Pyridones', '*Pyrrolidinones', 'Retrospective Studies', 'Topiramate/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33839453/
755,Etiracetam,32203691,"Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.","['Chamberlain JM', 'Kapur J', 'Shinnar S', 'Elm J', 'Holsti M', 'Babcock L', 'Rogers A', 'Barsan W', 'Cloyd J', 'Lowenstein D', 'Bleck TP', 'Conwit R', 'Meinzer C', 'Cock H', 'Fountain NB', 'Underwood E', 'Connor JT', 'Silbergleit R']","['Adolescent', 'Adult', 'Age Distribution', 'Age Factors', 'Aged', 'Aged, 80 and over', 'Anticonvulsants/*administration & dosage/adverse effects', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Humans', 'Infant', 'Levetiracetam/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/*analogs & derivatives', 'Status Epilepticus/*drug therapy', 'Valproic Acid/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32203691/
756,Etiracetam,11449876,Levetiracetam.,"['Nash EM', 'Sangha KS']","['*Anticonvulsants/adverse effects/pharmacokinetics/therapeutic use', 'Area Under Curve', 'Biological Availability', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Half-Life', 'Humans', 'Intestinal Absorption', 'Levetiracetam', '*Piracetam/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/11449876/
757,Etiracetam,37378757,Antiseizure medications for idiopathic generalized epilepsies: a systematic review and network meta-analysis.,"['Chu H', 'Zhang X', 'Shi J', 'Zhou Z', 'Yang X']","['Humans', 'Child', '*Valproic Acid/adverse effects', 'Topiramate/therapeutic use', 'Network Meta-Analysis', 'Levetiracetam/therapeutic use', 'Ethosuximide/adverse effects', 'Anticonvulsants/adverse effects', '*Epilepsy, Generalized/drug therapy', 'Seizures/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37378757/
758,Etiracetam,34570177,Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial.,"['Vossel K', 'Ranasinghe KG', 'Beagle AJ', 'La A', 'Ah Pook K', 'Castro M', 'Mizuiri D', 'Honma SM', 'Venkateswaran N', 'Koestler M', 'Zhang W', 'Mucke L', 'Howell MJ', 'Possin KL', 'Kramer JH', 'Boxer AL', 'Miller BL', 'Nagarajan SS', 'Kirsch HE']","['Aged', 'Aged, 80 and over', 'Alzheimer Disease/complications/*drug therapy', 'Anticonvulsants/*therapeutic use', 'Cognition/*drug effects', 'Cross-Over Studies', 'Double-Blind Method', 'Executive Function/drug effects', 'Female', 'Humans', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Seizures/etiology']",https://pubmed.ncbi.nlm.nih.gov/34570177/
759,furosemide,27238657,Furosemide.,"['Carone L', 'Oxberry SG', 'Twycross R', 'Charlesworth S', 'Mihalyo M', 'Wilcock A']","['Diuretics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Furosemide/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Hospice Care', 'Humans', 'Internet', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/27238657/
760,furosemide,34851962,Diuretic effect of co-administration of furosemide and albumin in comparison to furosemide therapy alone: An updated systematic review and meta-analysis.,"['Lee TH', 'Kuo G', 'Chang CH', 'Huang YT', 'Yen CL', 'Lee CC', 'Fan PC', 'Chen JJ']","['Albumins/*administration & dosage/therapeutic use', 'Diuretics/*administration & dosage/therapeutic use', 'Drug Combinations', 'Furosemide/*administration & dosage/therapeutic use', 'Humans', 'Nephrotic Syndrome/*drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34851962/
761,furosemide,2185908,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I).,"['Ponto LL', 'Schoenwald RD']","['Acute Kidney Injury/drug therapy', 'Furosemide/metabolism/*pharmacokinetics/pharmacology/therapeutic use', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/drug therapy', 'Liver Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185908/
762,furosemide,46960,Diuretic-induced oedema.,"['MacGregor GA', 'Tasker PR', 'de Wardener HE']","['Adult', 'Aldosterone/blood', 'Blood Volume', 'Body Weight', 'Chlorthalidone/adverse effects/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Edema/blood/*chemically induced/drug therapy/urine', 'Female', 'Furosemide/adverse effects/pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Potassium/administration & dosage/blood/urine', 'Renin/blood', 'Sodium/administration & dosage/blood/urine', 'Spironolactone/adverse effects/therapeutic use', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/46960/
763,furosemide,7752014,Furosemide-associated fever.,"['Clegg HW', 'Riopel DA']","['Child, Preschool', 'Female', 'Fever of Unknown Origin/*chemically induced/diagnosis', 'Follow-Up Studies', 'Furosemide/*adverse effects/therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7752014/
764,furosemide,2191821,Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II).,"['Ponto LL', 'Schoenwald RD']","['Animals', 'Furosemide/*pharmacokinetics/pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2191821/
765,furosemide,25786394,Intravenous Furosemide for Acute Decompensated Congestive Heart Failure: What Is the Evidence?,"['Owen DR', 'MacAllister R', 'Sofat R']","['Administration, Intravenous', 'Administration, Oral', 'Diuretics/*administration & dosage/adverse effects/pharmacokinetics', 'Evidence-Based Medicine', 'Furosemide/*administration & dosage/adverse effects/pharmacokinetics', 'Heart Failure/diagnosis/*drug therapy/physiopathology', 'Humans', 'Patient Selection', 'Practice Guidelines as Topic', 'Risk Factors', 'Treatment Outcome', 'Water-Electrolyte Balance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25786394/
766,furosemide,8425583,Inhaled loop diuretics as potential new anti-asthmatic drugs.,"['Bianco S', 'Pieroni MG', 'Refini RM', 'Robuschi M', 'Vaghi A', 'Sestini P']","['Administration, Inhalation', 'Animals', 'Asthma/*drug therapy', 'Bronchoconstriction/drug effects', 'Diuretics/*administration & dosage/pharmacology', 'Drug Evaluation', 'Drug Evaluation, Preclinical', 'Furosemide/administration & dosage', 'Humans', 'Loop of Henle/drug effects']",https://pubmed.ncbi.nlm.nih.gov/8425583/
767,furosemide,22825380,[Loop diuretics: facts and fallacies].,"['Meschi M', 'Detrenis S', 'Bianchi L', 'Sacco M', 'Bertorelli M', 'Boffetti F', 'Caiazza A', 'Savazzi G']","['Drinking', 'Drug Administration Routes', 'Edema/*drug therapy/etiology', 'Furosemide/administration & dosage/pharmacology/therapeutic use', 'Heart Failure/complications/physiopathology', 'Humans', 'Hydrostatic Pressure', 'Liver Cirrhosis/complications/physiopathology', 'Loop of Henle/drug effects/physiopathology', 'Natriuresis/drug effects', 'Nephrotic Syndrome/complications/physiopathology', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/pharmacology/*therapeutic use', 'Water-Electrolyte Imbalance/etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/22825380/
768,furosemide,19333124,Advances in the pharmacological management of breathlessness.,"['Currow DC', 'Ward AM', 'Abernethy AP']","['Dyspnea/*drug therapy/therapy', 'Furosemide/administration & dosage/*therapeutic use', 'Humans', 'Morphine/*therapeutic use', 'Narcotics/*therapeutic use', 'Nebulizers and Vaporizers', 'Palliative Care', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19333124/
769,furosemide,39579977,Hypertonic saline in acute decompensated heart failure (HSHF).,"['Agrawal S', 'Abhishek Batta S', 'Rao T', 'Selvam S']","['Humans', 'Saline Solution, Hypertonic/administration & dosage/therapeutic use', '*Heart Failure/drug therapy/physiopathology', 'Male', 'Female', 'Acute Disease', 'Middle Aged', '*Furosemide/therapeutic use/administration & dosage', 'Treatment Outcome', 'Aged', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug']",https://pubmed.ncbi.nlm.nih.gov/39579977/
770,furosemide,24239195,Forced diuresis with the RenalGuard system: impact on contrast induced acute kidney injury.,['Solomon R'],"['Acute Kidney Injury/*chemically induced/*prevention & control', 'Contrast Media/*adverse effects', 'Diuresis/drug effects/physiology', 'Diuretics/*administration & dosage/pharmacology', 'Furosemide/*administration & dosage/pharmacology', 'Humans', 'Pilot Projects', 'Randomized Controlled Trials as Topic', 'Time Factors', 'Urinary Catheterization/methods']",https://pubmed.ncbi.nlm.nih.gov/24239195/
771,furosemide,8375728,"Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.","['Cornelison TL', 'Reed E']","['Animals', 'Antineoplastic Agents/*adverse effects', 'Carboplatin/adverse effects', 'Cisplatin/*adverse effects', '*Fluid Therapy', 'Furosemide/adverse effects/therapeutic use', 'Humans', 'Kidney/*drug effects/pathology/physiopathology', 'Mannitol/therapeutic use', 'Organoplatinum Compounds/*adverse effects', 'Saline Solution, Hypertonic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8375728/
772,furosemide,357764,Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.,"['Araoye MA', 'Chang MY', 'Khatri IM', 'Freis ED']","['Blood Pressure/*drug effects', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Hydrochlorothiazide/administration & dosage/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Systole/drug effects']",https://pubmed.ncbi.nlm.nih.gov/357764/
773,furosemide,940030,Diuretic effect of furosemide in acute glomerulonephritis.,"['Pruitt AW', 'Boles A']","['Acute Disease', 'Administration, Oral', 'Adolescent', 'Blood Urea Nitrogen', 'Child', 'Child, Preschool', 'Diuresis/*drug effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Furosemide/administration & dosage/blood/*therapeutic use', 'Glomerulonephritis/blood/*drug therapy', 'Half-Life', 'Humans', 'Injections, Intravenous']",https://pubmed.ncbi.nlm.nih.gov/940030/
774,furosemide,5565464,Frusemide in heart failure of infancy.,['Richardson H'],"['Administration, Oral', 'Aortic Coarctation/drug therapy', 'Body Weight/drug effects', 'Chlorides/urine', 'Ductus Arteriosus, Patent/drug therapy', 'Female', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Heart Failure/*drug therapy/urine', 'Heart Septal Defects, Ventricular/drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*drug therapy', 'Injections, Intramuscular', 'Male', 'Mitral Valve Stenosis/drug therapy', 'Osmolar Concentration', 'Potassium/urine', 'Pulmonary Edema/drug therapy', 'Respiration/drug effects', 'Sodium/urine', 'Urine']",https://pubmed.ncbi.nlm.nih.gov/5565464/
775,furosemide,319263,An optimal diuretic regimen for cirrhotic ascites. A controlled trial evaluating safety and efficacy of spironolactone and furosemide.,"['Fuller RK', 'Khambatta PB', 'Gobezie GC']","['Ascites/diet therapy/*drug therapy/etiology', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Diuretics/adverse effects', 'Furosemide/*therapeutic use', 'Humans', 'Liver Cirrhosis/*complications', 'Plasma Volume/drug effects', 'Sodium/administration & dosage', 'Spironolactone/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/319263/
776,furosemide,9158273,Frusemide-induced bullous pemphigoid.,"['Panayiotou BN', 'Prasad MV', 'Zaman MN']","['Aged', 'Bumetanide/therapeutic use', 'Diuretics/*adverse effects/therapeutic use', 'Female', 'Furosemide/*adverse effects', 'Humans', 'Male', 'Pemphigoid, Bullous/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9158273/
777,furosemide,1994940,Oral labetalol in hypertensive urgencies.,"['Zell-Kanter M', 'Leikin JB']","['Administration, Oral', 'Adult', 'Blood Pressure/drug effects', 'Clinical Protocols/*standards', '*Emergencies', 'Emergency Service, Hospital', 'Female', 'Furosemide/administration & dosage/therapeutic use', 'Hospitals, University', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Illinois', 'Injections, Intravenous', 'Labetalol/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/1994940/
778,furosemide,4550872,"Bumetanide: potent new ""loop"" diuretic.","['Asbury MJ', 'Gatenby PB', ""O'Sullivan S"", 'Bourke E']","['Administration, Oral', 'Adult', 'Aged', 'Butylamines/therapeutic use', 'Chlorides/urine', 'Clinical Trials as Topic', 'Diuretics/administration & dosage/adverse effects/*therapeutic use', 'Edema/drug therapy', 'Female', 'Furosemide/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Phenols/therapeutic use', 'Placebos', 'Potassium/urine', 'Sodium/urine', 'Sulfonamides/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4550872/
779,Ranitidina,6312110,Ranitidine.,['Strum WB'],"['Aged', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Cimetidine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Humans', 'Male', 'Mice', 'Ranitidine/adverse effects/metabolism/*therapeutic use', 'Rats', 'Stomach Ulcer/drug therapy', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6312110/
780,Ranitidina,6317325,Ranitidine hydrochloride.,"['Gaginella TS', 'Bauman JH']","['Animals', 'Carcinogens', 'Chemical Phenomena', 'Chemistry', 'Drug Interactions', 'Duodenal Ulcer/drug therapy', 'Humans', 'Kinetics', 'Mutagens', '*Ranitidine/adverse effects/metabolism/pharmacology/therapeutic use', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6317325/
781,Ranitidina,1958166,Ranitidine and depression.,['Stocky A'],"['Aged', 'Depressive Disorder/*chemically induced/diagnosis/*psychology', 'Esophagitis, Peptic/*drug therapy/*psychology', 'Female', 'Humans', 'Life Change Events', 'Ranitidine/administration & dosage/*adverse effects', 'Recurrence', 'Risk Factors', 'Sick Role', 'Stomach Ulcer/*drug therapy/*psychology', 'Substance Withdrawal Syndrome/*diagnosis/*psychology']",https://pubmed.ncbi.nlm.nih.gov/1958166/
782,Ranitidina,33155242,How often we diagnose allergy to ranitidine?,"['Bocsan IC', 'Sabin O', 'Matei D', 'Muntean A', 'Buzoianu AD']","['Drug Hypersensitivity/*diagnosis/drug therapy', 'Histamine H2 Antagonists/administration & dosage/*adverse effects', 'Humans', 'Ranitidine/administration & dosage/*adverse effects', 'Rhinitis, Allergic/*diagnosis/drug therapy', 'Skin Tests']",https://pubmed.ncbi.nlm.nih.gov/33155242/
783,Ranitidina,2874464,Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia.,"['Gwee MC', 'Cheah LS']","['*Anesthesia', 'Animals', 'Antihypertensive Agents/adverse effects', 'Bradycardia/chemically induced', 'Cholinesterase Inhibitors/pharmacology', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Confusion/chemically induced', 'Cytochrome P-450 Enzyme System/pharmacology', 'Diarrhea/chemically induced', 'Drug Interactions', 'Erectile Dysfunction/chemically induced', 'Ganglionic Blockers/pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Mixed Function Oxygenases/antagonists & inhibitors', 'Neuromuscular Blocking Agents/pharmacology', 'Peptic Ulcer/drug therapy', 'Ranitidine/*adverse effects/pharmacology/therapeutic use', 'Receptors, Cholinergic/*drug effects/physiology', 'Receptors, Histamine H2/drug effects', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2874464/
784,Ranitidina,4076334,Ranitidine-associated hallucinations.,"['Price W', 'Coli L', 'Brandstetter RD', 'Gotz VP']","['Aged', 'Duodenal Ulcer/drug therapy', 'Female', 'Hallucinations/*chemically induced', 'Humans', 'Ranitidine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4076334/
785,Ranitidina,7751419,Clinical aspects of cardiovascular effects of H2-receptor antagonists.,"['Hinrichsen H', 'Halabi A', 'Kirch W']","['Animals', 'Atrioventricular Node/drug effects', 'Blood Pressure/drug effects', 'Bradycardia/chemically induced', 'Cardiovascular System/*drug effects', 'Cimetidine/adverse effects/pharmacology', 'Electrocardiography/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Histamine H2 Antagonists/chemistry/*pharmacology', 'Humans', 'Ranitidine/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7751419/
786,Ranitidina,9440055,Ranitidine bismuth citrate plus clarithromycin for the eradication of H. pylori.,"['Dixon JS', 'Pipkin GA', 'Mills JG', 'Wood JR']","['Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Bismuth/adverse effects/*therapeutic use', 'Clarithromycin/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Drug Synergism', 'Drug Therapy, Combination', 'Helicobacter Infections/*drug therapy', '*Helicobacter pylori', 'Histamine H2 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Ranitidine/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9440055/
787,Ranitidina,10930892,Review article: treatment of Helicobacter pylori infection with ranitidine bismuth citrate- or proton pump inhibitor-based triple therapies.,"['Van Oijen AH', 'Verbeek AL', 'Jansen JB', 'De Boer WA']","['Amoxicillin/administration & dosage/therapeutic use', 'Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/*therapeutic use', 'Bismuth/administration & dosage/*therapeutic use', 'Clarithromycin/administration & dosage/therapeutic use', 'Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Helicobacter Infections/*drug therapy', 'Helicobacter pylori/*drug effects', 'Humans', 'Nitroimidazoles/administration & dosage/therapeutic use', 'Penicillins/administration & dosage/therapeutic use', '*Proton Pump Inhibitors', 'Ranitidine/administration & dosage/*analogs & derivatives/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10930892/
788,Ranitidina,2718500,Ranitidine-induced chest pain.,"['Shimp LA', 'Smith MA', 'Wahr DW']","['Chest Pain/*chemically induced', 'Duodenal Ulcer/drug therapy', 'Female', 'Humans', 'Middle Aged', 'Ranitidine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2718500/
789,Ranitidina,7510614,Safety profile of ranitidine. A review.,['Wormsley KG'],"['Diarrhea/chemically induced', 'Drug Interactions', 'Gastric Mucosa/drug effects', 'Headache/chemically induced', 'Humans', 'Peptic Ulcer/*drug therapy', 'Ranitidine/*adverse effects/pharmacokinetics', 'Recurrence', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/7510614/
790,Ranitidina,8854394,Pharmacokinetics of oral ranitidine in Mexicans.,"['Castaneda-Hernandez G', 'Flores-Murrieta FJ', 'Granados-Soto V', 'Herrera-Abarca A', 'Perez-Urizar J', 'Herrera JE', 'Hong E']","['Administration, Oral', 'Adult', 'Chromatography, High Pressure Liquid', 'Ethnicity', 'Half-Life', 'Humans', 'Male', 'Mexico', 'Ranitidine/administration & dosage/blood/*pharmacokinetics', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/8854394/
791,Ranitidina,26992900,Oral intake of ranitidine increases urinary excretion of N-nitrosodimethylamine.,"['Zeng T', 'Mitch WA']","['Administration, Oral', 'Adult', 'Carcinogens/pharmacokinetics', 'Dimethylnitrosamine/*urine', 'Female', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Nitrosamines/pharmacokinetics/urine', 'Ranitidine/*administration & dosage/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26992900/
792,Ranitidina,12604553,ABT-773: pharmacokinetics and interactions with ranitidine and sucralfate.,"['Pletz MW', 'Preechachatchaval V', 'Bulitta J', 'Allewelt M', 'Burkhardt O', 'Lode H']","['Adult', 'Anti-Ulcer Agents/adverse effects/*pharmacology', 'Area Under Curve', 'Biological Assay', 'Chromatography, Liquid', 'Cross-Over Studies', 'Drug Interactions', 'Erythromycin/adverse effects/*analogs & derivatives/*pharmacokinetics/*pharmacology', 'Female', 'Humans', '*Ketolides', 'Male', 'Mass Spectrometry', 'Microbial Sensitivity Tests', 'Ranitidine/adverse effects/*pharmacokinetics/*pharmacology', 'Sucralfate/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12604553/
793,Ranitidina,3717435,Depression associated with ranitidine.,"['Billings RF', 'Stein MB']","['Adult', 'Aged', 'Depressive Disorder/*chemically induced', 'Female', 'Humans', 'Male', 'Peptic Ulcer/drug therapy/prevention & control', 'Ranitidine/*adverse effects/therapeutic use', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/3717435/
794,Ranitidina,33762718,The added value of H(2) antagonists in premedication regimens during paclitaxel treatment.,"['Cox JM', 'van Doorn L', 'Malmberg R', 'Oomen-de Hoop E', 'Bosch TM', 'van den Bemt PMLA', 'Boere IA', 'Jager A', 'Mathijssen RHJ', 'van Leeuwen RWF']","['Adult', 'Aged', 'Aged, 80 and over', 'Chemoprevention/adverse effects/methods', 'Clemastine/administration & dosage', 'Dexamethasone/administration & dosage', 'Drug Hypersensitivity/epidemiology/pathology/*prevention & control', 'Drug Therapy, Combination', 'Equivalence Trials as Topic', 'Female', 'Histamine H2 Antagonists/administration & dosage/therapeutic use', 'Humans', 'Infusions, Intravenous', 'Male', 'Medical Futility', 'Middle Aged', 'Neoplasms/*drug therapy/epidemiology/pathology', 'Netherlands/epidemiology', 'Paclitaxel/administration & dosage/*adverse effects', 'Premedication/adverse effects/*methods', 'Ranitidine/administration & dosage/*therapeutic use', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33762718/
795,Ranitidina,1483989,Ranitidine--rifampicin interaction.,"['Purohit SD', 'Johri SC', 'Gupta PR', 'Mehta YR', 'Bhatnagar M']","['Adult', 'Alanine Transaminase/blood', 'Bilirubin/blood', 'Drug Interactions', 'Female', 'Gastric Acidity Determination', 'Gastrointestinal Motility/drug effects', 'Humans', 'Male', 'Middle Aged', 'Ranitidine/administration & dosage/*therapeutic use', 'Rifampin/pharmacokinetics/*therapeutic use', 'Tuberculosis, Pulmonary/*drug therapy/metabolism/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1483989/
796,Ranitidina,19694603,Hypersensitivity reaction to ranitidine: description of a case and review of the literature.,"['Foti C', 'Cassano N', 'Panebianco R', 'Calogiuri GF', 'Vena GA']","['Anaphylaxis/*chemically induced', 'Anesthesia, Intravenous', '*Drug Hypersensitivity', 'Female', 'Histamine H2 Antagonists/administration & dosage/*adverse effects', 'Humans', 'Middle Aged', 'Peptic Ulcer/drug therapy', 'Ranitidine/administration & dosage/*adverse effects', 'Receptors, Histamine H2']",https://pubmed.ncbi.nlm.nih.gov/19694603/
797,Ranitidina,1687002,Histamine and histamine type-2 receptor antagonists in psoriasis. Mechanisms and speculations.,['Nielsen HJ'],"['Cyclosporine/adverse effects/pharmacology/therapeutic use', 'Histamine/physiology', 'Histamine Antagonists/*pharmacology', 'Histamine H2 Antagonists/*pharmacology', 'Humans', 'Methotrexate/adverse effects/pharmacology/therapeutic use', 'Psoriasis/*drug therapy/physiopathology', 'Ranitidine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1687002/
798,Ranitidina,33855953,The Effects of Ranitidine Treatment on the Risk of Necrotizing Enterocolitis in Preterm Infants: A Case-Control Study.,"['Zvizdic Z', 'Milisic E', 'Jonuzi A', 'Terzic S', 'Zvizdic D', 'Vranic S']","['Anti-Ulcer Agents/*administration & dosage/*adverse effects', 'Case-Control Studies', 'Critical Illness', 'Cross Infection/complications', 'Enterocolitis, Necrotizing/*chemically induced', 'Female', 'Humans', 'Infant, Newborn', 'Infant, Newborn, Diseases', 'Male', 'Peptic Ulcer/*prevention & control', 'Ranitidine/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33855953/
799,carisoprodol,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
800,carisoprodol,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
801,carisoprodol,8322081,Carisoprodol (Soma): a new and cautious perspective on an old agent.,"['Littrell RA', 'Hayes LR', 'Stillner V']","['Carisoprodol/*adverse effects/pharmacokinetics', 'Drug and Narcotic Control', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Substance-Related Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8322081/
802,carisoprodol,22939305,Pharmacogenomics and the future of toxicology testing.,"['Agrawal YP', 'Rennert H']","['Autopsy', 'Databases, Genetic', 'Drug Labeling', 'Humans', 'Pharmaceutical Preparations/analysis/metabolism', 'Pharmacogenetics/*methods', 'Toxicity Tests/*methods']",https://pubmed.ncbi.nlm.nih.gov/22939305/
803,carisoprodol,2671968,Is this really a muscle cramp?,['Eaton JM'],"['Carisoprodol/therapeutic use', 'Electromyography', 'Humans', '*Muscle Cramp/diagnosis/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/2671968/
804,carisoprodol,15542749,Recent trends of drug abuse and drug-associated deaths in Korea.,"['Chung H', 'Park M', 'Hahn E', 'Choi H', 'Choi H', 'Lim M']","['Drug Overdose', 'Humans', '*Illicit Drugs', 'Korea/epidemiology', 'Poison Control Centers/statistics & numerical data/trends', 'Substance-Related Disorders/*mortality']",https://pubmed.ncbi.nlm.nih.gov/15542749/
805,carisoprodol,6999895,Centrally acting oral skeletal muscle relaxants.,['Elenbaas JK'],"['Analgesics/therapeutic use', 'Drug Combinations', 'Drug Evaluation', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Kinetics', 'Muscle Relaxants, Central/metabolism/pharmacology/*therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/6999895/
806,carisoprodol,27550152,The Pharmacology and Toxicology of the 'Holy Trinity'.,"['Horsfall JT', 'Sprague JE']","['Analgesics, Opioid/administration & dosage/*adverse effects', 'Animals', 'Benzodiazepines/administration & dosage/*adverse effects', 'Carisoprodol/administration & dosage/*adverse effects', 'Contraindications', 'Dopamine/metabolism', 'Drug Dosage Calculations', 'Drug Synergism', 'Drug Therapy, Combination', 'Euphoria/*drug effects', 'GABA Modulators/administration & dosage/*adverse effects', 'Humans', 'Neuromuscular Agents/administration & dosage/*adverse effects', 'Nucleus Accumbens/*drug effects/metabolism/physiopathology', 'Opioid-Related Disorders/metabolism/physiopathology/psychology', 'Practice Guidelines as Topic', 'Respiration/drug effects', 'Respiratory Insufficiency/*chemically induced/metabolism/physiopathology', 'Risk Assessment', 'Signal Transduction/drug effects', 'gamma-Aminobutyric Acid/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27550152/
807,carisoprodol,25018153,Somadril and edgework in South Sulawesi.,"['Hardon AP', 'Ihsan A']","['Carisoprodol/*administration & dosage', 'Developing Countries', 'Female', 'Humans', 'Indonesia', 'Male', 'Muscle Relaxants, Central/*administration & dosage', 'Self Medication', '*Sex Workers', 'Sexual Behavior/*psychology', 'Substance-Related Disorders/*psychology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25018153/
808,carisoprodol,8635759,Acute overdose of zolpidem.,"['Winek CL', 'Wahba WW', 'Janssen JK', 'Rozin L', 'Rafizadeh V']","['Aged', 'Drug Overdose', 'Fatal Outcome', 'Female', 'Humans', 'Hypnotics and Sedatives/blood/*poisoning', 'Pyridines/blood/*poisoning', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8635759/
809,carisoprodol,22687764,Postmortem drug concentration intervals for the non-intoxicated state - A review.,['Linnet K'],"['Dose-Response Relationship, Drug', 'Drug Stability', 'Drug Tolerance', '*Forensic Toxicology', 'Humans', 'Pharmaceutical Preparations/*blood', 'Pharmacokinetics', 'Postmortem Changes', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/22687764/
810,carisoprodol,1985650,Carbidopa-levodopa overdose.,['Sporer KA'],"['Acetaminophen/poisoning', 'Carbidopa/*poisoning', 'Carisoprodol/poisoning', 'Female', 'Humans', 'Hydrocodone/poisoning', 'Ibuprofen/poisoning', 'Levodopa/*poisoning', 'Middle Aged', 'Poisoning/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/1985650/
811,carisoprodol,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
812,carisoprodol,4894737,Codeine and its alternates for pain and cough relief. 2. Alternates for pain relief.,"['Eddy NB', 'Friebel H', 'Hahn KJ', 'Halbach H']","['Amides/therapeutic use', 'Analgesics/therapeutic use', 'Animals', 'Antitussive Agents/therapeutic use', 'Azepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Cats', 'Chickens', 'Codeine/*therapeutic use', 'Cough/*drug therapy', 'Cyclazocine/therapeutic use', 'Dextropropoxyphene/therapeutic use', 'Diphenylacetic Acids/therapeutic use', 'Dogs', 'Ducks', 'Guinea Pigs', 'Humans', 'Indenes/therapeutic use', 'Indoles/therapeutic use', 'Isoquinolines/therapeutic use', 'Mice', 'Morphinans/therapeutic use', 'Nalorphine/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Pain/*drug therapy', 'Pentazocine/therapeutic use', 'Phenethylamines/therapeutic use', 'Pyrrolidines/therapeutic use', 'Rats', 'Substance-Related Disorders', 'Thalidomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4894737/
813,carisoprodol,9439144,Carisoprodol: a drug of continuing abuse.,"['Reeves RR', 'Pinkofsky HB', 'Carter OS']","['Adult', 'Carisoprodol/*adverse effects', 'Drug Prescriptions', 'Drug and Narcotic Control', 'Female', 'Humans', 'Male', 'Muscle Relaxants, Central/*adverse effects', 'Substance Withdrawal Syndrome/*etiology', 'Substance-Related Disorders/*etiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/9439144/
814,carisoprodol,29457627,Combination pharmacotherapy for the treatment of fibromyalgia in adults.,"['Thorpe J', 'Shum B', 'Moore RA', 'Wiffen PJ', 'Gilron I']","['5-Hydroxytryptophan/therapeutic use', 'Acetaminophen/therapeutic use', 'Adult', 'Amitriptyline/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', 'Carisoprodol/therapeutic use', 'Drug Therapy, Combination/methods', 'Duloxetine Hydrochloride/therapeutic use', 'Fibromyalgia/*drug therapy', 'Fluoxetine/therapeutic use', 'Humans', 'Magnesium/therapeutic use', 'Malates/therapeutic use', 'Melatonin/therapeutic use', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Muscle Relaxants, Central/therapeutic use', 'Pregabalin/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29457627/
815,carisoprodol,17896902,Is the frequency of carisoprodol withdrawal syndrome increasing?,"['Reeves RR', 'Hammer JS', 'Pendarvis RO']","['Adult', 'Anxiety/etiology', 'Carisoprodol/administration & dosage/*adverse effects/metabolism', 'Female', 'Hallucinations/etiology', 'Humans', 'Meprobamate/metabolism', 'Muscle Relaxants, Central/administration & dosage/adverse effects/metabolism', 'Self Administration', 'Sleep Initiation and Maintenance Disorders/etiology', 'Substance Withdrawal Syndrome/diagnosis/*etiology/metabolism', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/17896902/
816,carisoprodol,1097611,Carisoprodol in the treatment of myofascial pain-dysfunction syndrome.,"['Gallardo F', 'Molgo J', 'Miyazaki C', 'Rossi E']","['Adolescent', 'Adult', 'Aged', 'Carisoprodol/*therapeutic use', 'Clinical Trials as Topic', '*Facial Muscles', 'Female', 'Humans', 'Male', '*Masticatory Muscles', 'Middle Aged', 'Muscular Diseases/*drug therapy', 'Pain/*drug therapy', 'Placebos/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/1097611/
817,carisoprodol,20828952,Pharmacogenetics and forensic toxicology.,"['Musshoff F', 'Stamer UM', 'Madea B']","['Analgesics, Opioid/pharmacokinetics', 'Anticonvulsants/pharmacokinetics', 'Antidepressive Agents/pharmacokinetics', 'Benzodiazepines/pharmacokinetics', 'Biomarkers/analysis', 'Carisoprodol/pharmacokinetics', 'Cytochrome P-450 Enzyme System/genetics', 'Ethnicity/genetics', '*Forensic Toxicology', 'Genetic Variation', 'Humans', 'Membrane Transport Proteins/genetics', 'Molecular Targeted Therapy', 'Muscle Relaxants, Central/pharmacokinetics', 'N-Methyl-3,4-methylenedioxyamphetamine/pharmacokinetics', '*Pharmacogenetics', 'Postmortem Changes']",https://pubmed.ncbi.nlm.nih.gov/20828952/
818,amitriptyline,26488799,Topical amitriptyline and ketamine for the treatment of neuropathic pain.,['Mercadante S'],"['Administration, Topical', 'Amitriptyline/administration & dosage/*therapeutic use', 'Analgesics/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/*therapeutic use', 'Neuralgia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26488799/
819,amitriptyline,12638679,Drug-induced toxic myocarditis.,"['Ansari A', 'Maron BJ', 'Berntson DG']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Aged', 'Amitriptyline/*adverse effects/therapeutic use', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Female', 'Heart Failure/*diagnosis/*etiology', 'Humans', 'Myocarditis/*chemically induced/complications/*diagnosis', 'Perphenazine/*adverse effects/therapeutic use', 'Schizophrenia, Paranoid/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12638679/
820,amitriptyline,19590258,Torticollis under cyclobenzaprine.,"['Reuss R', 'Reuter I', 'Jauss M', 'Fischer F', 'Muller SC', 'Stolz E']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Biperiden/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Myoclonus/chemically induced/drug therapy', 'Torticollis/*chemically induced/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19590258/
821,amitriptyline,7044154,Trazodone in depressed outpatients.,"['Rickels K', 'Case WG']","['Adult', 'Ambulatory Care', 'Amitriptyline/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Piperazines/*therapeutic use', 'Trazodone/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7044154/
822,amitriptyline,3893842,Discrepancies between pharmacokinetic studies of amitriptyline.,"['Schulz P', 'Dick P', 'Blaschke TF', 'Hollister L']","['Amitriptyline/administration & dosage/*metabolism/therapeutic use', 'Depressive Disorder/drug therapy', 'Half-Life', 'Humans', 'Kinetics', 'Models, Biological', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/3893842/
823,amitriptyline,20883117,Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.,"['Darwish M', 'Hellriegel ET']","['Aged', 'Amitriptyline/administration & dosage/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Animals', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Food-Drug Interactions', 'Humans', 'Muscle Relaxants, Central/administration & dosage/*pharmacokinetics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Spasm/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20883117/
824,amitriptyline,30618472,Induction of Psychosis by Cyclobenzaprine.,"['Cohen JY', 'Guilbault A']","['Adult', 'Amitriptyline/adverse effects/*analogs & derivatives', 'Antidepressive Agents, Tricyclic/*adverse effects', 'Bipolar Disorder/*drug therapy', 'Borderline Personality Disorder/*drug therapy', 'Female', 'Humans', 'Muscle Relaxants, Central/*adverse effects', 'Psychoses, Substance-Induced/*etiology', 'Tranquilizing Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30618472/
825,amitriptyline,7203728,Pharmacokinetics of amitriptyline in the elderly.,"['Henry JF', 'Altamura C', 'Gomeni R', 'Hervy MP', 'Forette F', 'Morselli PL']","['Aged', 'Amitriptyline/adverse effects/*metabolism/pharmacology', 'Electrocardiography', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/7203728/
826,amitriptyline,2147517,Cardiovascular effects of paroxetine.,"['Kuhs H', 'Rudolf GA']","['Adult', 'Amitriptyline/adverse effects/therapeutic use', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Middle Aged', 'Paroxetine', 'Piperidines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2147517/
827,amitriptyline,19882939,[Antidepressants in migraine prophylaxis].,['Nagata E'],"['Amitriptyline/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Depression/complications/drug therapy', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Migraine Disorders/complications/*prevention & control', 'Practice Guidelines as Topic', '*Premedication']",https://pubmed.ncbi.nlm.nih.gov/19882939/
828,amitriptyline,6764165,Evaluation of amoxapine.,"['Kinney JL', 'Evans RL Jr']","['Amitriptyline/therapeutic use', '*Amoxapine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', '*Dibenzoxazepines', 'Double-Blind Method', 'Humans', 'Imipramine/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6764165/
829,amitriptyline,3133714,Trazodone for deafferentation pain. Comparison with amitriptyline.,"['Ventafridda V', 'Caraceni A', 'Saita L', 'Bonezzi C', 'De Conno F', 'Guarise G', 'Ramella G', 'Silvani V', 'Tamburini M', 'Toscani F']","['Adult', 'Afferent Pathways/physiopathology', 'Aged', 'Amitriptyline/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Middle Aged', 'Neuralgia/*drug therapy/etiology', 'Random Allocation', 'Trazodone/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3133714/
830,amitriptyline,24129218,Lessons learned from hospice care.,['Martin CM'],"['Aged', 'Aged, 80 and over', 'Amitriptyline/administration & dosage/adverse effects/therapeutic use', 'Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Drug Monitoring/methods/standards', 'Fentanyl/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Health Services for the Aged/organization & administration/standards/trends', '*Hospice Care/organization & administration/standards/trends', 'Humans', 'Nausea/drug therapy', 'Pruritus/drug therapy', 'Transdermal Patch', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24129218/
831,amitriptyline,23645641,Neuropsychiatric side effects of cyclobenzaprine.,"['Shprecher D', 'Sloan CT', 'Sederholm B']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Antidepressive Agents/*adverse effects/therapeutic use', 'Delirium/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Movement Disorders/*etiology', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Oxycodone/*adverse effects', 'Pain/drug therapy', 'Serotonin Syndrome/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/23645641/
832,amitriptyline,2612556,Amitriptyline: linear or nonlinear kinetics in every day practice?,"['Vandel S', 'Bertschy G', 'Vandel B', 'Allers G', 'Volmat R']","['Amitriptyline/administration & dosage/blood/*pharmacokinetics', 'Biotransformation', 'Depression/*drug therapy', 'Humans', 'Linear Models', 'Nortriptyline/*blood']",https://pubmed.ncbi.nlm.nih.gov/2612556/
833,amitriptyline,31974296,No benefit from amitriptyline for chronic low back pain?,"['Khong TK', 'Lall K']","['Amitriptyline/*administration & dosage', 'Chronic Pain/*drug therapy', 'Humans', 'Low Back Pain/*drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31974296/
834,amitriptyline,27113954,Very Low Dose Amitriptyline for Clozapine-Associated Sialorrhea.,"['Sinha S', 'Simlai J', 'Praharaj SK']","['Amitriptyline/*administration & dosage', 'Antidepressive Agents, Tricyclic/*administration & dosage', 'Antipsychotic Agents/*adverse effects', 'Clozapine/*adverse effects', 'Humans', 'Male', 'Schizophrenia/diagnosis/drug therapy', 'Sialorrhea/*chemically induced/diagnosis/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27113954/
835,amitriptyline,3894196,Long-term amitriptyline in chronic depression.,"['Giller E Jr', 'Bialos D', 'Harkness L', 'Jatlow P', 'Waldo M']","['Amitriptyline/adverse effects/blood/*therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nortriptyline/blood', 'Recurrence', 'Substance Withdrawal Syndrome/etiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3894196/
836,amitriptyline,9522337,[Unmasking pheochromocytoma by amitriptyline].,['Kuhs H'],"['Adrenal Gland Neoplasms/*diagnosis/psychology', 'Amitriptyline/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Blood Pressure/drug effects', 'Catecholamines/urine', 'Depressive Disorder/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Female', 'Heart Rate/drug effects', 'Humans', 'Middle Aged', 'Patient Care Team', 'Pheochromocytoma/*diagnosis/psychology']",https://pubmed.ncbi.nlm.nih.gov/9522337/
837,amitriptyline,3545354,A comparison of the antidepressant action of citalopram and amitriptyline.,"['Shaw DM', 'Thomas DR', 'Briscoe MH', 'Watkins SE', 'Crimmins R', 'Harris B', 'Lovett J', 'Raj M', 'Lloyd AT', 'Osborne C', 'et al.']","['Adolescent', 'Adult', 'Aged', 'Amitriptyline/adverse effects/*therapeutic use', 'Antidepressive Agents/*therapeutic use', 'Citalopram', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Humans', 'Middle Aged', 'Propylamines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3545354/
838,Almotriptan,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
839,Almotriptan,27910087,Menstrual Migraine and Treatment Options: Review.,"['Maasumi K', 'Tepper SJ', 'Kriegler JS']","['Female', 'Humans', 'Menstruation/drug effects/physiology', 'Migraine Disorders/*drug therapy/physiopathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27910087/
840,Almotriptan,18223456,Triptans in pregnancy.,"['Soldin OP', 'Dahlin J', ""O'Mara DM""]","['Animals', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', '*Prenatal Exposure Delayed Effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18223456/
841,Almotriptan,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
842,Almotriptan,14988742,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['Clinical Trials as Topic/*statistics & numerical data', 'Databases, Factual/*statistics & numerical data', 'Humans', 'Statistics as Topic']",https://pubmed.ncbi.nlm.nih.gov/14988742/
843,Almotriptan,15595988,Migraine pathophysiology and its clinical implications.,['Silberstein SD'],"['Animals', 'Brain/*blood supply/drug effects/*physiopathology', 'Brain Stem/blood supply/drug effects/physiopathology', 'Cerebrovascular Circulation/drug effects', 'Humans', 'Indoles/*administration & dosage', 'Migraine Disorders/*drug therapy/*physiopathology', '*Models, Neurological', 'Neural Pathways/*blood supply/drug effects', '*Neurons', 'Nociceptors/blood supply/drug effects', 'Serotonin Receptor Agonists/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15595988/
844,Almotriptan,26252584,Acute Migraine Treatment.,['Becker WJ'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Dihydroergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Tryptamines/*therapeutic use', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26252584/
845,Almotriptan,15595989,What do patients want from acute migraine treatment?,['Gallagher R'],"['Acute Disease', 'Analgesics/*therapeutic use', '*Attitude to Health', 'Clinical Trials as Topic', 'Disease Progression', 'Humans', 'Indoles/*therapeutic use', 'Migraine Disorders/diagnosis/*drug therapy/*epidemiology/prevention & control', 'Patient Acceptance of Health Care/statistics & numerical data', 'Patient Satisfaction/statistics & numerical data', ""*Practice Patterns, Physicians'"", 'Secondary Prevention', 'Serotonin Receptor Agonists/*therapeutic use', 'Treatment Outcome', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15595989/
846,Almotriptan,22644903,Treatment of perimenstrual migraine with triptans: an update.,"['Casolla B', 'Lionetto L', 'Candela S', ""D'Alonzo L"", 'Negro A', 'Simmaco M', 'Martelletti P']","['Female', 'Humans', 'Migraine Disorders/*drug therapy/epidemiology/physiopathology', 'Premenstrual Syndrome/*drug therapy/epidemiology/physiopathology', 'Randomized Controlled Trials as Topic/methods/trends', 'Sumatriptan/therapeutic use', 'Treatment Outcome', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22644903/
847,Almotriptan,12117355,Mechanisms of action of the 5-HT1B/1D receptor agonists.,"['Tepper SJ', 'Rapoport AM', 'Sheftell FD']","['Carbazoles/pharmacology', 'Humans', 'Indoles/pharmacology', 'Migraine Disorders/*drug therapy/*metabolism', 'Oxazolidinones/pharmacology', 'Piperidines/pharmacology', 'Pyrrolidines/pharmacology', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/*drug effects', 'Serotonin Receptor Agonists/*pharmacology', 'Sumatriptan/pharmacology', 'Triazoles/pharmacology', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12117355/
848,Almotriptan,30845850,Almotriptan: a review of 20 years' clinical experience.,"['Pascual J', 'Vila C']","['Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*pharmacology', 'Tryptamines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30845850/
849,Almotriptan,20017750,Early treatment of acute migraine: new evidence of benefits.,['Valade D'],"['Clinical Trials as Topic', 'Drug Administration Schedule', 'Humans', 'Migraine Disorders/*drug therapy', 'Time', 'Tryptamines/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/20017750/
850,Almotriptan,18715329,Pathways to the best fit of triptans for migraine patients.,['Buzzi MG'],"['Biotransformation/genetics', 'Clinical Trials as Topic', 'Cytochrome P-450 CYP2D6/deficiency/genetics/physiology', 'Drug Interactions', 'Genetic Variation', 'Humans', 'Meta-Analysis as Topic', 'Metabolic Networks and Pathways/genetics', 'Migraine Disorders/*drug therapy/genetics', 'Molecular Structure', 'Pharmacogenetics/trends', 'Serotonin Receptor Agonists/adverse effects/classification/pharmacokinetics/*therapeutic use', 'Tryptamines/adverse effects/chemistry/classification/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18715329/
851,Almotriptan,18451718,Acute migraine therapy: recent evidence from randomized comparative trials.,"['Mett A', 'Tfelt-Hansen P']","['Acute Disease', 'Analgesics/classification/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antiemetics/therapeutic use', 'Caffeine/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Drug Therapy, Combination', 'Ergotamine/therapeutic use', 'Humans', 'Indomethacin/therapeutic use', 'Migraine Disorders/*therapy', 'Prochlorperazine/therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Receptor Agonists/classification/*therapeutic use', 'Treatment Outcome', 'Tryptamines/classification/therapeutic use', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18451718/
852,Almotriptan,21070229,Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine.,['Tfelt-Hansen P'],"['Azepines/*adverse effects/*therapeutic use', 'Calcitonin Gene-Related Peptide Receptor Antagonists', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Headache/prevention & control', 'Humans', 'Imidazoles/*adverse effects/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tryptamines/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21070229/
853,Almotriptan,11236625,Almotriptan: a balanced approach to migraine.,['Cull R'],"['Cost-Benefit Analysis', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Female', 'Humans', 'Indoles/economics/*therapeutic use', 'Male', 'Migraine Disorders/*drug therapy/economics', 'Serotonin Receptor Agonists/economics/*therapeutic use', 'Treatment Outcome', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11236625/
854,Almotriptan,15926006,Early triptan intervention in migraine: an overview.,"['Moschiano F', ""D'Amico D"", 'Allais G', 'Rigamonti A', 'Melzi P', 'Schieroni F', 'Bussone G']","['Humans', 'Indoles/*therapeutic use', 'Migraine Disorders/*drug therapy/physiopathology', 'Serotonin Receptor Agonists/*therapeutic use', 'Time Factors', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15926006/
855,Almotriptan,27521843,Comparative tolerability of treatments for acute migraine: A network meta-analysis.,"['Thorlund K', 'Toor K', 'Wu P', 'Chan K', 'Druyts E', 'Ramos E', 'Bhambri R', 'Donnet A', 'Stark R', 'Goadsby PJ']","['Humans', 'Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Clinical Trials as Topic/methods', 'Drug Therapy, Combination', '*Migraine Disorders/diagnosis/drug therapy/epidemiology', 'Naproxen/administration & dosage', 'Sumatriptan/administration & dosage', 'Treatment Outcome', '*Tryptamines/administration & dosage', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/27521843/
856,Almotriptan,20187858,Almotriptan for the treatment of acute migraine: a review of early intervention trials.,"['Antonaci F', 'De Cillis I', 'Cuzzoni MG', 'Allena M']","['Acute Disease', 'Clinical Trials as Topic', 'Disability Evaluation', 'Humans', 'Migraine Disorders/*drug therapy', 'Pain Measurement', 'Serotonin Receptor Agonists/*therapeutic use', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20187858/
857,Almotriptan,30526161,Pharmacotherapy for acute migraines in children and adolescents.,"['Barbanti P', 'Grazzi L', 'Egeo G']","['Acetaminophen/administration & dosage', 'Adolescent', 'Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage', 'Child', 'Humans', 'Migraine Disorders/*drug therapy', '*Quality of Life', 'Randomized Controlled Trials as Topic', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30526161/
858,amlodipine,9156957,Amlodipine: an overview of its pharmacodynamic and pharmacokinetic properties.,['van Zwieten PA'],"['Amlodipine/*pharmacokinetics/*pharmacology', 'Angina Pectoris/drug therapy', 'Animals', 'Humans', 'Hypertension/drug therapy', 'In Vitro Techniques']",https://pubmed.ncbi.nlm.nih.gov/9156957/
859,amlodipine,32937023,Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.,"['Jin X', 'Kim MH', 'Han KH', 'Hong SJ', 'Ahn JC', 'Sung JH', 'Cho JM', 'Lee HC', 'Choi SY', 'Lee K', 'Kim WS', 'Rhee MY', 'Kim JH', 'Hong SP', 'Yoo BS', 'Cho EJ', 'Lee JH', 'Kim PJ', 'Park CG', 'Hyon MS', 'Shin JH', 'Lee SH', 'Sung KC', 'Hwang J', 'Kwon K', 'Chae IH', 'Seo JS', 'Kim H', 'Lee H', 'Cho Y', 'Kim HS']","['Aged', 'Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Female', 'Humans', '*Hypertension/drug therapy', 'Male', 'Middle Aged', 'Rosuvastatin Calcium/*administration & dosage/therapeutic use', 'Telmisartan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32937023/
860,amlodipine,27731568,Amlodipine-Induced Gingival Overgrowth.,"['Jayanthi R', 'Rajan PB']","['Adult', 'Aged', 'Amlodipine/administration & dosage/*adverse effects', 'Antihypertensive Agents/therapeutic use', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Female', 'Gingival Overgrowth/*chemically induced', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/27731568/
861,amlodipine,8195445,Amlodipine-induced gingival overgrowth.,"['Seymour RA', 'Ellis JS', 'Thomason JM', 'Monkman S', 'Idle JR']","['Adult', 'Aged', 'Amlodipine/*adverse effects/analysis/blood/pharmacokinetics', 'Collagen', 'Dental Plaque Index', 'Epithelium/pathology', 'Female', 'Fibroblasts/pathology', 'Gingival Crevicular Fluid/chemistry', 'Gingival Hyperplasia/*chemically induced/pathology', 'Humans', 'Male', 'Middle Aged', 'Periodontal Index', 'Periodontal Pocket/complications']",https://pubmed.ncbi.nlm.nih.gov/8195445/
862,amlodipine,33430665,Calcium Channel Blockers in Conjunction with Standard Iron-Chelating Agents for beta-Thalassemia Major: Systematic Literature Search.,"['Alali MA', 'Alanazi KMA', 'Alsayil SN', 'Omari Z', 'Shaaban A']","['Amlodipine/administration & dosage/adverse effects/therapeutic use', 'Biomarkers', 'Calcium Channel Blockers/administration & dosage/adverse effects/*therapeutic use', 'Chelation Therapy', 'Drug Therapy, Combination', 'Humans', 'Iron Chelating Agents/administration & dosage/adverse effects/*therapeutic use', 'Iron Overload/diagnosis/*drug therapy/*etiology/metabolism', 'Magnetic Resonance Imaging', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'beta-Thalassemia/*complications/diagnosis/genetics']",https://pubmed.ncbi.nlm.nih.gov/33430665/
863,amlodipine,19405551,Olmesartan medoxomil/amlodipine.,"['Sanford M', 'Keam SJ']","['Amlodipine/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/therapeutic use', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy', 'Imidazoles/adverse effects/pharmacology/*therapeutic use', 'Olmesartan Medoxomil', 'Randomized Controlled Trials as Topic', 'Tetrazoles/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19405551/
864,amlodipine,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
865,amlodipine,25268343,Cutaneous adverse reactions to calcium channel blockers.,"['Tuchinda P', 'Kulthanan K', 'Khankham S', 'Jongjarearnprasert K', 'Dhana N']","['Adolescent', 'Adult', 'Amlodipine/administration & dosage/*adverse effects', 'Calcium Channel Blockers/administration & dosage/*adverse effects', 'Diltiazem/administration & dosage/*adverse effects', 'Drug Eruptions/*epidemiology', 'Female', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25268343/
866,amlodipine,10437993,Amlodipine treatment of cocaine dependence.,"['Malcolm R', 'Brady KT', 'Moore J', 'Kajdasz D']","['Adult', 'Amlodipine/adverse effects/*therapeutic use', 'Calcium Channel Blockers/adverse effects/*therapeutic use', 'Cocaine-Related Disorders/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Motivation']",https://pubmed.ncbi.nlm.nih.gov/10437993/
867,amlodipine,27715071,[Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension].,['Sliva J'],"['Amlodipine/administration & dosage/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Drug Combinations', 'Essential Hypertension', 'Humans', 'Hypertension/*drug therapy', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/27715071/
868,amlodipine,23324513,Antidepressant-selective gynecomastia.,"['Kaufman KR', 'Podolsky D', 'Greenman D', 'Madraswala R']","['Aged', 'Amlodipine/administration & dosage/adverse effects/therapeutic use', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Drug Therapy, Combination', 'Duloxetine Hydrochloride', 'Fluorobenzenes/administration & dosage/adverse effects/therapeutic use', 'Gynecomastia/*chemically induced', 'Humans', 'Male', 'Pyrimidines/administration & dosage/adverse effects/therapeutic use', 'Rosuvastatin Calcium', 'Sertraline/administration & dosage/adverse effects/therapeutic use', 'Sulfonamides/administration & dosage/adverse effects/therapeutic use', 'Thiophenes/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23324513/
869,amlodipine,24121218,[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].,['Simonyi G'],"['Amlodipine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Blood Pressure/*drug effects', 'Calcium Channel Blockers/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Humans', 'Hungary', 'Hypertension/*drug therapy/metabolism/physiopathology', 'Ramipril/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Assessment of Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/24121218/
870,amlodipine,25331664,"[Myopathy and rhabdomyolysis after treatment with simvastatin, amlodipine, and roxithromycin].","['Skovbolling SL', 'Lindelof M']","['Aged', 'Amlodipine/administration & dosage/*adverse effects/therapeutic use', 'Anti-Bacterial Agents/administration & dosage/*adverse effects/therapeutic use', 'Antihypertensive Agents/administration & dosage/*adverse effects/therapeutic use', 'Drug Interactions', 'Humans', 'Hypertension/drug therapy', 'Male', 'Muscular Diseases/*chemically induced/pathology', 'Rhabdomyolysis/*chemically induced/pathology', 'Roxithromycin/administration & dosage/*adverse effects/therapeutic use', 'Simvastatin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25331664/
871,amlodipine,27250611,[What are the effects of fixed-dose combination of candesartan and amlodipine].,"['Vitovec J', 'Spinar J']","['Amlodipine/*administration & dosage', 'Antihypertensive Agents/*administration & dosage', 'Benzimidazoles/*administration & dosage', 'Biphenyl Compounds', 'Drug Combinations', 'Humans', 'Hypertension/drug therapy', 'Tetrazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27250611/
872,amlodipine,30362840,Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.,"['Angeli F', 'Trapasso M', 'Signorotti S', 'Verdecchia P', 'Reboldi G']","['Amlodipine/*administration & dosage/adverse effects/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/pharmacology', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacology', 'Celecoxib/*administration & dosage/adverse effects/pharmacology', 'Drug Combinations', 'Humans', 'Hypertension/*drug therapy/etiology', 'Osteoarthritis/complications/*drug therapy', 'Pain/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/30362840/
873,amlodipine,23094638,The effects of telmisartan and amlodipine in treatment-naive and previously treated hypertensive patients: a subanalysis from a 4 x 4 factorial design study.,"['Punzi HA', 'Dahlof B', 'Webster D', 'Majul CR', 'Oigman W', 'Olvera R', 'Seeber M', 'Kobe M', 'Schumacher H']","['Adult', 'Aged', 'Amlodipine/adverse effects/pharmacology/*therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Benzoates/adverse effects/pharmacology/*therapeutic use', 'Blood Pressure/drug effects/physiology', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Telmisartan', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23094638/
874,amlodipine,26432745,Missing diagnosis: gingival hypertrophy due to amlodipine.,"['Tomar LR', 'Aggarwal A']","['Amlodipine/*adverse effects/therapeutic use', 'Calcium Channel Blockers/adverse effects/therapeutic use', '*Diagnostic Errors', 'Female', 'Gingiva/drug effects/*pathology', 'Gingival Hypertrophy/*chemically induced/diagnosis', 'Humans', 'Hypertension/drug therapy', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/26432745/
875,amlodipine,10437739,Safety and efficacy of angiotensin II receptor antagonists.,['Neutel JM'],"['Amlodipine/adverse effects/therapeutic use', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Follow-Up Studies', 'Humans', 'Hypertension/*drug therapy', 'Monitoring, Physiologic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10437739/
876,amlodipine,38584159,"Efficacy and safety of a four-drug, quarter-dose treatment for hypertension: the QUARTET USA randomized trial.","['Huffman MD', 'Baldridge AS', 'Lazar D', 'Abbas H', 'Mejia J', 'Flowers FM', 'Quintana A', 'Jackson A', 'Kandula NR', 'Lloyd-Jones DM', 'Persell SD', 'Khan SS', 'Paparello JJ', 'Chopra A', 'Tripathi P', 'Vu MH', 'Chow CK', 'Ciolino JD']","['Humans', 'Female', 'Male', '*Hypertension/drug therapy', 'Middle Aged', '*Biphenyl Compounds', '*Antihypertensive Agents/therapeutic use/adverse effects/administration & dosage', 'Double-Blind Method', '*Benzimidazoles/therapeutic use/adverse effects/administration & dosage', '*Amlodipine/administration & dosage/adverse effects/therapeutic use', '*Tetrazoles/therapeutic use/adverse effects/administration & dosage', '*Blood Pressure/drug effects', 'Aged', 'Treatment Outcome', '*Bisoprolol/therapeutic use/administration & dosage', 'Indapamide/therapeutic use/administration & dosage/adverse effects', 'Adult', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38584159/
877,Ultram,26218943,"Tramadol, Pharmacology, Side Effects, and Serotonin Syndrome: A Review.","['Beakley BD', 'Kaye AM', 'Kaye AD']","['Analgesics, Opioid/*adverse effects', 'Animals', 'Drug Interactions', 'Humans', 'Risk Factors', 'Serotonin Syndrome/*chemically induced/*diagnosis/epidemiology', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26218943/
878,Ultram,15509185,Clinical pharmacology of tramadol.,"['Grond S', 'Sablotzki A']","['Acute Disease', 'Analgesics, Opioid/adverse effects/*pharmacokinetics/*pharmacology', 'Animals', 'Chronic Disease', 'Clinical Trials as Topic', 'Humans', 'Models, Biological', 'Pain/drug therapy', 'Tramadol/adverse effects/*pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15509185/
879,Ultram,12749738,Tramadol/paracetamol.,"['McClellan K', 'Scott LJ']","['Acetaminophen/administration & dosage/adverse effects/*therapeutic use', 'Acute Disease', 'Administration, Oral', 'Analgesics/administration & dosage/adverse effects/*therapeutic use', 'Biological Availability', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Combinations', 'Humans', 'Pain/*drug therapy', 'Tramadol/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12749738/
880,Ultram,9771272,Remifentanil and tramadol.,['Duthie DJ'],"['Analgesics, Opioid/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Piperidines/pharmacokinetics/*pharmacology', 'Remifentanil', 'Tramadol/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9771272/
881,Ultram,27861439,"Trends in Tramadol: Pharmacology, Metabolism, and Misuse.","['Miotto K', 'Cho AK', 'Khalil MA', 'Blanco K', 'Sasaki JD', 'Rawson R']","['Acute Pain/*drug therapy', 'Analgesics, Opioid/administration & dosage/adverse effects/*pharmacokinetics', 'Animals', 'Chronic Pain/*drug therapy', 'Cytochrome P-450 CYP3A/genetics/metabolism', 'Cytochrome P-450 Enzyme System/genetics/metabolism', 'Drug Compounding', 'Drug Interactions', 'Genotype', 'Humans', 'Opioid-Related Disorders/*epidemiology', 'Pharmacogenetics', 'Pharmacogenomic Variants', 'Phenotype', 'Polymorphism, Genetic', '*Prescription Drug Misuse', 'Risk Factors', 'Tramadol/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27861439/
882,Ultram,15771942,Tramadol-associated pericarditis.,"['Krantz MJ', 'Garcia JA', 'Mehler PS']","['Aged', 'Aged, 80 and over', 'Analgesics, Opioid/*adverse effects', 'Humans', 'Male', 'Pericarditis/*chemically induced/diagnosis', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/15771942/
883,Ultram,29752906,Tramadol: Understanding the Risk of Serotonin Syndrome and Seizures.,"['Hassamal S', 'Miotto K', 'Dale W', 'Danovitch I']","['Analgesics, Opioid/*adverse effects', 'Anticonvulsants/therapeutic use', 'Humans', 'Risk Factors', 'Seizures/*chemically induced', 'Serotonin Syndrome/*chemically induced/complications/diagnosis/drug therapy', 'Tramadol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29752906/
884,Ultram,30594783,An overview of tramadol and its usage in pain management and future perspective.,"['Subedi M', 'Bajaj S', 'Kumar MS', 'Yc M']","['Analgesics, Opioid/*pharmacokinetics/*therapeutic use', 'Animals', 'Chronic Pain/*drug therapy/metabolism/psychology', 'Drug Interactions', 'Forecasting', 'Humans', 'Pain Management/*methods/psychology', 'Tramadol/*pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30594783/
885,Ultram,17315416,Tramadol: does it have a role in cancer pain management?,['Prommer EE'],"['Analgesics, Opioid/adverse effects/chemistry/pharmacokinetics/*therapeutic use', 'Humans', 'Neoplasms/*complications', 'Pain/*drug therapy/*etiology', 'Tramadol/adverse effects/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17315416/
886,Ultram,16451094,Tramadol sustained-release capsules.,['Keating GM'],"['Analgesics, Opioid/*administration & dosage/adverse effects/pharmacokinetics', 'Capsules', 'Delayed-Action Preparations', 'Humans', 'Pain/*drug therapy/metabolism', 'Tramadol/*administration & dosage/adverse effects/pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16451094/
887,Ultram,30892453,Opioids in the immune system: from experimental studies to clinical practice.,"['Moyano J', 'Aguirre L']","['Adaptive Immunity/drug effects', 'Analgesics, Opioid/administration & dosage/*pharmacology', 'Fentanyl/administration & dosage/pharmacology', 'Humans', 'Immune System/*drug effects', 'Morphine/administration & dosage/pharmacology', 'Perioperative Period', 'Remifentanil/administration & dosage/pharmacology', 'Tramadol/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30892453/
888,Ultram,34196947,"Tapentadol Versus Tramadol: A Narrative and Comparative Review of Their Pharmacological, Efficacy and Safety Profiles in Adult Patients.","['Roulet L', 'Rollason V', 'Desmeules J', 'Piguet V']","['Analgesics, Opioid/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Cytochrome P-450 CYP2D6/genetics', 'Dose-Response Relationship, Drug', 'Humans', 'Liver Failure/metabolism', 'Pain/drug therapy/physiopathology', 'Renal Insufficiency/metabolism', 'Tapentadol/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Tramadol/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34196947/
889,Ultram,32295441,The effect of tramadol on blood glucose concentrations: a systematic review.,"['Nakhaee S', 'Brent J', 'Hoyte C', 'Farrokhfall K', 'Shirazi FM', 'Askari M', 'Mehrpour O']","['Analgesics, Opioid/administration & dosage/*adverse effects', 'Animals', 'Blood Glucose/analysis/*drug effects', 'Humans', 'Hyperglycemia/chemically induced', 'Hypoglycemia/chemically induced', 'Tramadol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32295441/
890,Ultram,15461118,Tramadol (Ultram) concentrations in death investigation and impaired driving cases and their significance.,"['Clarkson JE', 'Lacy JM', 'Fligner CL', 'Thiersch N', 'Howard J', 'Harruff RC', 'Logan BK']","['Analgesics, Opioid/*blood/pharmacology/poisoning', '*Automobile Driving', '*Cause of Death', 'Central Nervous System Depressants/poisoning', 'Drug Interactions', 'Forensic Medicine', 'Humans', 'Muscle Relaxants, Central/poisoning', 'Reference Values', 'Tramadol/*blood/pharmacology/poisoning']",https://pubmed.ncbi.nlm.nih.gov/15461118/
891,Ultram,25776506,"Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems.","['Vazzana M', 'Andreani T', 'Fangueiro J', 'Faggio C', 'Silva C', 'Santini A', 'Garcia ML', 'Silva AM', 'Souto EB']","['Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics', 'Animals', 'Chemistry, Pharmaceutical/methods', 'Dizziness/chemically induced/metabolism', 'Drug Delivery Systems/*trends', 'Humans', 'Pharmaceutical Preparations/*administration & dosage/*metabolism', 'Tramadol/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/25776506/
892,Ultram,7517822,Tramadol for the management of acute pain.,['Lehmann KA'],"['Administration, Oral', 'Adult', 'Child', 'Clinical Trials as Topic', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Pain/*drug therapy', 'Pain, Postoperative/drug therapy', 'Self Administration', 'Tramadol/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7517822/
893,Ultram,26749092,Current Pharmacological Management of Premature Ejaculation: A Systematic Review and Meta-analysis.,"['Castiglione F', 'Albersen M', 'Hedlund P', 'Gratzke C', 'Salonia A', 'Giuliano F']","['Administration, Cutaneous', 'Analgesics, Opioid/pharmacology/*therapeutic use', 'Anesthetics, Local/administration & dosage/pharmacology/*therapeutic use', 'Benzylamines/therapeutic use', 'Humans', 'Male', 'Naphthalenes/therapeutic use', 'Phosphodiesterase 5 Inhibitors/pharmacology/*therapeutic use', 'Premature Ejaculation/*drug therapy/physiopathology', 'Reaction Time/drug effects', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use', 'Tramadol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26749092/
894,Ultram,33181582,Tramadol Treatment for Chemotherapy-induced Mucositis Pain in Children.,"['Yaffe Ornstein M', 'Stocki D', 'Levin D', 'Dvir R', 'Manisterski M', 'Berger-Achituv S', 'Rosenfeld Keidar H', 'Peled Y', 'Hazan S', 'Rosenberg T', 'Oppenheimer N', 'Elhasid R']","['Analgesics, Opioid', '*Antineoplastic Agents/therapeutic use', 'Child', 'Humans', '*Mucositis/chemically induced/drug therapy', 'Pain/chemically induced/drug therapy', 'Retrospective Studies', '*Tramadol/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33181582/
895,Ultram,31637686,Mania induced by tramadol-venlafaxine combination.,"['Hefzi N', 'Grekin J', 'Ahmed A']","['Analgesics, Opioid', '*Bipolar Disorder/chemically induced', '*Depressive Disorder, Major/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Tramadol/adverse effects/therapeutic use', '*Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31637686/
896,Ezetimibe,39084839,Therapy for Hyperlipidemia.,"['Wright J', 'Subramanian S']","['Humans', '*Hyperlipidemias/drug therapy', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/therapeutic use', 'Ezetimibe/therapeutic use', 'Anticholesteremic Agents/therapeutic use', 'PCSK9 Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/39084839/
897,Ezetimibe,28073228,[Statin intolerance].,['Tonstad S'],"['Biological Products/administration & dosage/therapeutic use', 'Ezetimibe/administration & dosage/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/*adverse effects', 'Hypolipidemic Agents/administration & dosage/therapeutic use', 'Muscular Diseases/*chemically induced/diagnosis/drug therapy', 'PCSK9 Inhibitors', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28073228/
898,Ezetimibe,32648167,Rosuvastatin/Ezetimibe: A Review in Hypercholesterolemia.,['Lamb YN'],"['Anticholesteremic Agents/*therapeutic use', 'Cholesterol, LDL/metabolism', 'Drug Therapy, Combination/methods', 'Ezetimibe/*therapeutic use', 'Humans', 'Hypercholesterolemia/*drug therapy/metabolism', 'Rosuvastatin Calcium/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32648167/
899,Ezetimibe,26324293,[Statin intolerance].,"['Graversen CB', 'Larsen ML', 'Schmidt EB']","['Anticholesteremic Agents/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Ezetimibe/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Muscular Diseases/*chemically induced/drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/26324293/
900,Ezetimibe,35863366,"Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.","['Kim BK', 'Hong SJ', 'Lee YJ', 'Hong SJ', 'Yun KH', 'Hong BK', 'Heo JH', 'Rha SW', 'Cho YH', 'Lee SJ', 'Ahn CM', 'Kim JS', 'Ko YG', 'Choi D', 'Jang Y', 'Hong MK']","['*Anticholesteremic Agents/adverse effects', '*Atherosclerosis/drug therapy', '*Cardiovascular Diseases/drug therapy', 'Cholesterol, LDL', 'Drug Therapy, Combination', 'Ezetimibe/adverse effects', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Rosuvastatin Calcium', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35863366/
901,Ezetimibe,37486464,Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention.,"['Michaeli DT', 'Michaeli JC', 'Albers S', 'Boch T', 'Michaeli T']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Proprotein Convertase 9', '*Anticholesteremic Agents/adverse effects', 'Secondary Prevention/methods', 'Hypolipidemic Agents/pharmacology/therapeutic use', 'Ezetimibe/therapeutic use', '*Cardiovascular Diseases/prevention & control/chemically induced', '*Hypertriglyceridemia/drug therapy', 'Pharmaceutical Preparations', 'Angiopoietin-Like Protein 3']",https://pubmed.ncbi.nlm.nih.gov/37486464/
902,Ezetimibe,29777433,Are PCSK9 Inhibitors Cost Effective?,"['Korman MJ', 'Retterstol K', 'Kristiansen IS', 'Wisloff T']","['Anticholesteremic Agents/*economics/therapeutic use', 'Cost-Benefit Analysis/*statistics & numerical data', 'Drug Therapy, Combination/economics', 'Enzyme Inhibitors/*economics/therapeutic use', 'Ezetimibe/economics/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/economics/therapeutic use', 'Hypercholesterolemia/drug therapy/*economics', 'PCSK9 Inhibitors', 'Quality-Adjusted Life Years']",https://pubmed.ncbi.nlm.nih.gov/29777433/
903,Ezetimibe,36342163,Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.,"[""O'Donoghue ML"", 'Rosenson RS', 'Gencer B', 'Lopez JAG', 'Lepor NE', 'Baum SJ', 'Stout E', 'Gaudet D', 'Knusel B', 'Kuder JF', 'Ran X', 'Murphy SA', 'Wang H', 'Wu Y', 'Kassahun H', 'Sabatine MS']","['Humans', '*Anticholesteremic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Atherosclerosis/drug therapy', 'Cardiovascular Diseases/drug therapy', 'Double-Blind Method', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', '*Hypercholesterolemia/drug therapy', '*Lipoprotein(a)/analysis/antagonists & inhibitors', '*RNA, Small Interfering/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Liver/drug effects/metabolism', 'PCSK9 Inhibitors/therapeutic use', 'Ezetimibe/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36342163/
904,Ezetimibe,35262430,Comparative efficacy of non-statin lipid-lowering therapies in patients with hypercholesterolemia at increased cardiovascular risk: a network meta-analysis.,"['Burnett H', 'Fahrbach K', 'Cichewicz A', 'Jindal R', 'Tarpey J', 'Durand A', 'Di Domenico M', 'Reichelt A', 'Viljoen A']","['*Anticholesteremic Agents/adverse effects/therapeutic use', 'Bayes Theorem', '*Cardiovascular Diseases/etiology/prevention & control', 'Cholesterol', 'Cholesterol, LDL', 'Ezetimibe/therapeutic use', 'Heart Disease Risk Factors', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', '*Hypercholesterolemia/complications/drug therapy', '*Hyperlipidemias/drug therapy', 'Network Meta-Analysis', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35262430/
905,Ezetimibe,35533049,Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis.,"['Tummala R', 'Gupta M', 'Devanabanda AR', 'Bandyopadhyay D', 'Aronow WS', 'Ray KK', 'Mamas M', 'Ghosh RK']","['*Atherosclerosis/drug therapy', 'Cholesterol, LDL', 'Dicarboxylic Acids', 'Ezetimibe/therapeutic use', 'Fatty Acids', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', '*Hyperlipidemias/chemically induced/drug therapy', 'Hypolipidemic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35533049/
906,Ezetimibe,35832642,Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.,"['Chilbert MR', 'VanDuyn D', 'Salah S', 'Clark CM', 'Ma Q']","['*Anticholesteremic Agents', 'Cholesterol', 'Cholesterol, LDL', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Ezetimibe/therapeutic use', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Rosuvastatin Calcium/therapeutic use', 'Simvastatin', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35832642/
907,Ezetimibe,27864787,Glycaemic Effects of Non-statin Lipid-Lowering Therapies.,"['Collins PD', 'Sattar N']","['Anticholesteremic Agents/therapeutic use', 'Blood Glucose/*metabolism', 'Cardiovascular Diseases/prevention & control', 'Diabetes Mellitus, Type 2/complications/*drug therapy/physiopathology', 'Diabetic Angiopathies/blood/*drug therapy/physiopathology', 'Ezetimibe/therapeutic use', 'Fibric Acids/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hypercholesterolemia/blood/*drug therapy/physiopathology', 'Hypolipidemic Agents/*adverse effects/*therapeutic use', 'Lipid Metabolism/drug effects', 'Meta-Analysis as Topic', 'Niacin/therapeutic use', 'PCSK9 Inhibitors', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27864787/
908,Ezetimibe,37770770,"Efficacy and Safety of Single-Pill Combination of Rosuvastatin and Ezetimibe in Chinese Patients with Primary Hypercholesterolemia Inadequately Controlled by Statin Treatment (ROZEL): A Randomized, Double-Blind, Double Dummy, Active-Controlled Phase 3 Clinical Trial.","['Su Q', 'Liu Y', 'Zhang G', 'Xu L', 'Wang M', 'Mei S', 'Garon G', 'Wu Y', 'Lv Q', 'Ma C']","['Humans', '*Anticholesteremic Agents/administration & dosage/therapeutic use', 'Cholesterol, LDL', 'Double-Blind Method', 'East Asian People', '*Ezetimibe/administration & dosage/therapeutic use', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors', '*Hypercholesterolemia/drug therapy', '*Rosuvastatin Calcium/administration & dosage/therapeutic use', 'Treatment Outcome', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/37770770/
909,Ezetimibe,35918009,Lipid Lowering Therapy: An Era Beyond Statins.,"['Abdul-Rahman T', 'Bukhari SMA', 'Herrera EC', 'Awuah WA', 'Lawrence J', 'de Andrade H', 'Patel N', 'Shah R', 'Shaikh R', 'Capriles CAA', 'Ulusan S', 'Ahmad S', 'Corriero AC', 'Mares AC', 'Goel A', 'Hajra A', 'Bandyopadhyay D', 'Gupta R']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', '*Anticholesteremic Agents/adverse effects', 'Cholesterol, LDL/therapeutic use', '*Cardiovascular Diseases/etiology/prevention & control', 'Ezetimibe/pharmacology/therapeutic use', '*Dyslipidemias/drug therapy', 'Cholesterol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35918009/
910,Ezetimibe,31357887,Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.,"['Ballantyne CM', 'Laufs U', 'Ray KK', 'Leiter LA', 'Bays HE', 'Goldberg AC', 'Stroes ES', 'MacDougall D', 'Zhao X', 'Catapano AL']","['Aged', 'Anticholesteremic Agents/*administration & dosage/adverse effects', 'Biomarkers/blood', 'Cardiovascular Diseases/blood/diagnosis/*prevention & control', 'Cholesterol, LDL/*blood', 'Dicarboxylic Acids/*administration & dosage/adverse effects', 'Double-Blind Method', 'Down-Regulation', 'Drug Combinations', 'Ezetimibe/*administration & dosage/adverse effects', 'Fatty Acids/*administration & dosage/adverse effects', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypercholesterolemia/blood/diagnosis/*drug therapy', 'Male', 'Middle Aged', 'Time Factors', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/31357887/
911,Ezetimibe,37495276,Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous Coronary Intervention.,"['Lee SJ', 'Joo JH', 'Park S', 'Kim C', 'Choi DW', 'Hong SJ', 'Ahn CM', 'Kim JS', 'Kim BK', 'Ko YG', 'Choi D', 'Jang Y', 'Nam CM', 'Hong MK']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Rosuvastatin Calcium', '*Anticholesteremic Agents/therapeutic use', '*Drug-Eluting Stents', 'Treatment Outcome', 'Drug Therapy, Combination', 'Ezetimibe/therapeutic use', '*Myocardial Infarction/drug therapy', 'Lipids', '*Percutaneous Coronary Intervention']",https://pubmed.ncbi.nlm.nih.gov/37495276/
912,Ezetimibe,36813611,Current and future options in cholesterol lowering treatments.,['Elis A'],"['Humans', 'Cholesterol, LDL', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Cholesterol', 'Ezetimibe/therapeutic use', 'Drug Therapy, Combination', '*Anticholesteremic Agents/therapeutic use/adverse effects', 'Proprotein Convertase 9/genetics']",https://pubmed.ncbi.nlm.nih.gov/36813611/
913,Ezetimibe,31758270,Management of Lipid Abnormalities in Patients with Diabetes.,"['Sillars A', 'Sattar N']","['Diabetes Mellitus, Type 1/complications', 'Diabetes Mellitus, Type 2/*complications', 'Dyslipidemias/*drug therapy/etiology', 'Ezetimibe/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use', 'Hypolipidemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31758270/
914,Ezetimibe,27005745,Statin-related myotoxicity.,"['Fernandes V', 'Santos MJ', 'Perez A']","['Clinical Trials as Topic', 'Comorbidity', 'Creatine Kinase/blood', 'Cytochrome P-450 CYP3A/physiology', 'Dietary Supplements', 'Disease Management', 'Disease Susceptibility', 'Drug Interactions', 'Drug Substitution', 'Exercise', 'Ezetimibe/therapeutic use', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology', 'Incidence', 'Male', 'Meta-Analysis as Topic', 'Muscular Diseases/*chemically induced/epidemiology/genetics/physiopathology', 'Rhabdomyolysis/chemically induced/epidemiology/physiopathology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27005745/
915,Ezetimibe,35063734,Niemann-Pick C1-Like 1 inhibitors for reducing cholesterol absorption.,"['Zhang R', 'Liu W', 'Zeng J', 'Meng J', 'Jiang H', 'Wang J', 'Xing D']","['*Anticholesteremic Agents/pharmacology', 'Biological Transport', 'Cholesterol/pharmacology', 'Ezetimibe/pharmacology/therapeutic use', 'Humans', '*Hypercholesterolemia', 'Intestinal Absorption', 'Membrane Transport Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35063734/
916,trimethoprim,10405706,Trimethoprim-sulfamethoxazole.,['Smilack JD'],"['*Anti-Infective Agents/pharmacology/therapeutic use', 'Humans', '*Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10405706/
917,trimethoprim,7633023,Hyperkalemia and high-dose trimethoprim/sulfamethoxazole.,"['Hsu I', 'Wordell CJ']","['Acquired Immunodeficiency Syndrome/complications', 'Clinical Trials as Topic', 'Dapsone/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hyperkalemia/*chemically induced', 'Pneumonia, Pneumocystis/drug therapy', 'Retrospective Studies', 'Trimethoprim, Sulfamethoxazole Drug Combination/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7633023/
918,trimethoprim,6985448,"Trimethoprim: mechanisms of action, antimicrobial activity, bacterial resistance, pharmacokinetics, adverse reactions, and therapeutic indications.","['Gleckman R', 'Blagg N', 'Joubert DW']","['Bacterial Infections/drug therapy', 'Drug Combinations/therapeutic use', 'Drug Resistance, Microbial', 'Female', 'Humans', 'Pregnancy', 'Sulfamethoxazole/therapeutic use', 'Trimethoprim/adverse effects/metabolism/*pharmacology/therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6985448/
919,trimethoprim,3320619,Trimethoprim-sulfamethoxazole and other sulfonamides.,"['Foltzer MA', 'Reese RE']","['Anti-Infective Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Drug Combinations/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Sulfamethoxazole/adverse effects/pharmacokinetics/*therapeutic use', 'Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use', 'Trimethoprim/adverse effects/pharmacokinetics/*therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination']",https://pubmed.ncbi.nlm.nih.gov/3320619/
920,trimethoprim,6372565,Trimethoprim-sulfamethoxazole for bacterial meningitis.,"['Levitz RE', 'Quintiliani R']","['Adolescent', 'Adult', 'Animals', 'Bacteria/drug effects', 'Child, Preschool', 'Drug Combinations/metabolism/pharmacology/therapeutic use', 'Enterobacteriaceae Infections/drug therapy', 'Female', 'Gram-Negative Bacteria', 'Gram-Positive Bacteria', 'Humans', 'Infant', 'Infant, Newborn', 'Kinetics', 'Male', 'Meningitis/*drug therapy/microbiology', 'Microbial Sensitivity Tests', 'Middle Aged', 'Sulfamethoxazole/metabolism/pharmacology/*therapeutic use', 'Trimethoprim/metabolism/pharmacology/*therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination']",https://pubmed.ncbi.nlm.nih.gov/6372565/
921,trimethoprim,12601341,Urinary tract infection: traditional pharmacologic therapies.,['Nicolle LE'],"['Adolescent', 'Adult', 'Anti-Infective Agents, Urinary/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Female', 'Humans', 'Middle Aged', 'Pyelonephritis/drug therapy', 'Risk Factors', 'Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects/*therapeutic use', 'Urinary Tract Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/12601341/
922,trimethoprim,2678767,Clinical use of trimethoprim/sulfamethoxazole during renal dysfunction.,"['Paap CM', 'Nahata MC']","['Humans', 'Kidney Diseases/*complications', 'Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2678767/
923,trimethoprim,7023899,Trimethoprim: clinical use and pharmacokinetics.,"['Friesen WT', 'Hekster YA', 'Vree TB']","['Bacterial Infections/*drug therapy', 'Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Humans', 'Kidney Diseases/metabolism', 'Kinetics', 'Metabolic Clearance Rate', 'Tissue Distribution', 'Trimethoprim/adverse effects/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7023899/
924,trimethoprim,15767239,Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.,"['Grim SA', 'Rapp RP', 'Martin CA', 'Evans ME']","['Anti-Infective Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Drug Interactions', 'Half-Life', 'Humans', 'Methicillin Resistance/drug effects', 'Staphylococcal Infections/*drug therapy/prevention & control', 'Staphylococcus aureus/*drug effects', 'Tissue Distribution', 'Trimethoprim, Sulfamethoxazole Drug Combination/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15767239/
925,trimethoprim,3325433,Adverse reactions to Bactrim--a retrospective view.,['Hell K'],"['Anti-Infective Agents/*adverse effects', 'Drug Combinations/adverse effects', 'Humans', 'Sulfamethoxazole/*adverse effects', 'Trimethoprim/*adverse effects', 'Trimethoprim, Sulfamethoxazole Drug Combination']",https://pubmed.ncbi.nlm.nih.gov/3325433/
926,trimethoprim,1443457,Hypersensitivity to trimethoprim.,"['Alonso MD', 'Marcos C', 'Davila I', 'de la Hoz B', 'Martin JA', 'Parra F', 'Diez ML']","['Adult', 'Drug Eruptions/*etiology', 'Female', 'Humans', 'Respiratory Tract Infections/drug therapy', 'Trimethoprim/administration & dosage/*adverse effects', 'Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use', 'Urticaria/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1443457/
927,trimethoprim,4613504,Antifolic combinations in the treatment of malaria.,['Conno L'],"['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Resistance', 'Drug Synergism', 'Drug Therapy, Combination', 'Erythrocytes/microbiology', '*Folic Acid Antagonists/therapeutic use', 'Humans', 'Immunity', 'Infant', 'Infant, Newborn', 'Malaria/*drug therapy', 'Middle Aged', 'Oxidoreductases/antagonists & inhibitors', 'Plasmodium falciparum/drug effects/pathogenicity', 'Pyrimethamine/adverse effects/pharmacology/therapeutic use', 'Sulfonamides/adverse effects/pharmacology/therapeutic use', 'Trimethoprim/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4613504/
928,trimethoprim,3502034,Trimethoprim associated aseptic meningitis.,"['Carlson J', 'Wiholm BE']","['Adolescent', 'Adult', 'Aged', 'Anti-Infective Agents, Urinary/*adverse effects/therapeutic use', 'Autoimmune Diseases/complications', 'Drug Combinations/adverse effects/therapeutic use', 'Female', 'Humans', 'Meningitis/*chemically induced', 'Meningitis, Aseptic/*chemically induced', 'Sulfamethoxazole/*adverse effects/therapeutic use', 'Time Factors', 'Trimethoprim/*adverse effects/therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination', 'Urinary Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3502034/
929,trimethoprim,38583518,Comparative efficacy and safety of Pneumocystis jirovecii pneumonia prophylaxis regimens for people living with HIV: a systematic review and network meta-analysis of randomized controlled trials.,"['Prosty C', 'Katergi K', 'Sorin M', 'Rjeily MB', 'Butler-Laporte G', 'McDonald EG', 'Lee TC']","['Humans', '*Pneumonia, Pneumocystis/prevention & control', '*Randomized Controlled Trials as Topic', '*Network Meta-Analysis', '*Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use/administration & dosage/adverse effects', '*Pneumocystis carinii/drug effects', '*HIV Infections/complications', 'AIDS-Related Opportunistic Infections/prevention & control/drug therapy', 'Dapsone/therapeutic use/adverse effects/administration & dosage', 'Pentamidine/therapeutic use/administration & dosage/adverse effects', 'Atovaquone/therapeutic use/adverse effects', 'Antifungal Agents/therapeutic use/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38583518/
930,trimethoprim,16739835,Uncomplicated urinary tract infection in women. Current practice and the effect of antibiotic resistance on empiric treatment.,"['Nicolle L', 'Anderson PA', 'Conly J', 'Mainprize TC', 'Meuser J', 'Nickel JC', 'Senikas VM', 'Zhanel GG']","['Anti-Infective Agents, Urinary/adverse effects/pharmacology/*therapeutic use', 'Drug Combinations', '*Drug Resistance, Bacterial', 'Female', 'Fluoroquinolones/adverse effects/pharmacology/therapeutic use', 'Humans', 'Nitrofurantoin/adverse effects/pharmacology/therapeutic use', 'Practice Guidelines as Topic', 'Sulfamethizole/adverse effects/pharmacology/therapeutic use', 'Trimethoprim/adverse effects/pharmacology/therapeutic use', 'Urinary Tract Infections/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/16739835/
931,trimethoprim,7051235,Trimethoprim alone in the treatment of urinary tract infections: eight years of experience in Finland.,"['Kasanen A', 'Sundquist H']","['Acute Disease', 'Drug Resistance, Microbial', 'Finland', 'Humans', 'Recurrence', 'Trimethoprim/pharmacology/*therapeutic use', 'Urinary Tract Infections/*drug therapy/microbiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/7051235/
932,trimethoprim,4013832,Digoxin-trimethoprim interaction.,"['Petersen P', 'Kastrup J', 'Bartram R', 'Molholm Hansen J']","['Administration, Oral', 'Adult', 'Aged', 'Digoxin/administration & dosage/*blood', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Humans', 'Infusions, Parenteral', 'Kinetics', 'Male', 'Middle Aged', 'Trimethoprim/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/4013832/
933,trimethoprim,3498863,Trimethoprim-sulfamethoxazole.,"['Cockerill FR 3rd', 'Edson RS']","['Bacterial Infections/drug therapy', 'Drug Combinations/administration & dosage/pharmacokinetics/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Sulfamethoxazole/administration & dosage/pharmacokinetics/*therapeutic use', 'Trimethoprim/administration & dosage/pharmacokinetics/*therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination']",https://pubmed.ncbi.nlm.nih.gov/3498863/
934,trimethoprim,412099,Successful chemoprophylaxis for Pneumocystis carinii pneumonitis.,"['Hughes WT', 'Kuhn S', 'Chaudhary S', 'Feldman S', 'Verzosa M', 'Aur RJ', 'Pratt C', 'George SL']","['Adolescent', 'Adult', 'Bacteria/isolation & purification', 'Child', 'Child, Preschool', 'Drug Combinations', 'Drug Evaluation', 'Female', 'Fungi/isolation & purification', 'Humans', 'Infant', 'Infection Control', 'Leukemia, Lymphoid/complications', 'Male', 'Neoplasms/complications', 'Pharynx/microbiology', 'Pneumonia, Pneumocystis/etiology/*prevention & control', 'Rectum/microbiology', 'Risk', 'Sulfamethoxazole/*administration & dosage/adverse effects/therapeutic use', 'Trimethoprim/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/412099/
935,trimethoprim,6981164,Trimethoprim-sulfamethoxazole and trimethoprim alone in the prophylaxis of childhood urinary tract infection.,"['Smellie JM', 'Gruneberg RN', 'Normand IC', 'Bantock HM']","['Child', 'Drug Combinations/adverse effects/therapeutic use', 'Drug Resistance, Microbial', 'Feces/microbiology', 'Humans', 'Recurrence', 'Sulfamethoxazole/adverse effects/*therapeutic use', 'Trimethoprim/adverse effects/*therapeutic use', 'Trimethoprim, Sulfamethoxazole Drug Combination', 'Urinary Tract Infections/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/6981164/
936,glyburide,9739505,Repaglinide.,"['Balfour JA', 'Faulds D']","['Animals', 'Carbamates/administration & dosage/pharmacokinetics/*therapeutic use', 'Diabetes Mellitus, Experimental/drug therapy', 'Diabetes Mellitus, Type 2/*drug therapy', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Islets of Langerhans/drug effects', 'Piperidines/administration & dosage/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/9739505/
937,glyburide,32654523,Glibenclamide as a neuroprotective antidementia drug.,"['Zubov A', 'Muruzheva Z', 'Tikhomirova M', 'Karpenko M']","['Humans', '*Alzheimer Disease/drug therapy', '*Diabetes Mellitus/drug therapy', 'Glyburide/pharmacology/therapeutic use', 'Hypoglycemic Agents/adverse effects', '*Neuroprotective Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32654523/
938,glyburide,9533980,Is there a concentration-effect relationship for sulphonylureas?,"['Melander A', 'Donnelly R', 'Rydberg T']","['Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Glyburide/administration & dosage/pharmacokinetics', 'Humans', 'Hypoglycemic Agents/*administration & dosage/pharmacokinetics', 'Sulfonylurea Compounds/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/9533980/
939,glyburide,19640341,The use of oral antidiabetic medications in gestational diabetes mellitus.,"['Paglia MJ', 'Coustan DR']","['Administration, Oral', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/administration & dosage/therapeutic use', 'Humans', 'Hypoglycemic Agents/*administration & dosage/*therapeutic use', 'Metformin/administration & dosage/therapeutic use', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/19640341/
940,glyburide,28665392,[Glibenclamide as a promising agent for prevention and treatment of cerebral edema].,"['Tsarenko SV', ""Dzyadz'ko AM"", 'Rybalko SS']","['Animals', 'Brain Edema/*drug therapy/prevention & control', 'Clinical Trials as Topic', 'Drug Evaluation, Preclinical', 'Glyburide/administration & dosage/*therapeutic use', 'Humans', 'Intracranial Pressure/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28665392/
941,glyburide,38191184,"Safety and efficacy of glibenclamide on cerebral oedema following aneurysmal subarachnoid haemorrhage: a randomised, double-blind, placebo-controlled clinical trial.","['Feng X', 'Zhang T', 'Wang N', 'Qu X', 'Qi M', 'Zhao H', 'Zhang H', 'Xu Y']","['Humans', '*Glyburide/adverse effects/administration & dosage/therapeutic use', 'Male', 'Middle Aged', '*Subarachnoid Hemorrhage/drug therapy/diagnosis/complications', 'Double-Blind Method', 'Female', '*TRPM Cation Channels', '*Brain Edema/drug therapy/etiology/prevention & control/diagnostic imaging/diagnosis', '*Sulfonylurea Receptors/genetics', 'Treatment Outcome', 'Time Factors', 'Aged', 'Adult', 'Neuroprotective Agents/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38191184/
942,glyburide,11390165,Glyburide and fetal safety; transplacental pharmacokinetic considerations.,['Koren G'],"['Adult', 'Female', 'Fetal Diseases/chemically induced', 'Fetus/drug effects/*metabolism', 'Glyburide/adverse effects/*pharmacokinetics', 'Humans', 'Hypoglycemic Agents/adverse effects/*pharmacokinetics', 'Ions', '*Maternal-Fetal Exchange', 'Molecular Weight', 'Placenta/drug effects/*metabolism', 'Pregnancy', 'Pregnancy Outcome', 'Protein Binding', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11390165/
943,glyburide,31805373,Found in translation: The rationale behind the early development of glibenclamide in large hemispheric infarction.,"['Jacobson SM', 'MacAllister TW', 'Geliebter DM']","['Animals', '*Brain Edema/drug therapy/etiology', '*Cerebral Infarction/complications/drug therapy', 'Disease Models, Animal', 'Glyburide/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/31805373/
944,glyburide,3923454,"Glipizide: a second-generation sulfonylurea hypoglycemic agent. Pharmacology, pharmacokinetics and clinical use.",['Lebovitz HE'],"['Animals', 'Blood Glucose/metabolism', 'Chemical Phenomena', 'Chemistry', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dogs', 'Glipizide/metabolism/pharmacology/*therapeutic use', 'Glyburide/metabolism/pharmacology', 'Half-Life', 'Humans', 'Insulin/metabolism', 'Insulin Secretion', 'Kinetics', 'Liver/metabolism', 'Mice', 'Pancreas/drug effects', 'Rats', 'Serum Albumin/metabolism', 'Sulfonylurea Compounds/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3923454/
945,glyburide,109337,Radioimmunoassay of glibenclamide.,"['Kawashima K', 'Kuzuya T', 'Matsuda A']","['Animals', 'Diabetes Mellitus/blood/drug therapy', 'Dogs', 'Glyburide/*blood/therapeutic use', 'Humans', 'Radioimmunoassay/methods']",https://pubmed.ncbi.nlm.nih.gov/109337/
946,glyburide,19366943,Use of hypoglycemic drugs during lactation.,"['Glatstein MM', 'Djokanovic N', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Administration, Oral', 'Breast Feeding', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glipizide/administration & dosage/adverse effects', 'Glyburide/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Infant, Newborn', 'Lactation/*drug effects', 'Maternal Welfare', 'Milk, Human/drug effects', 'Pregnancy', 'Pregnancy in Diabetics/drug therapy', 'Risk Assessment', 'Sulfonylurea Compounds/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19366943/
947,glyburide,8864641,Cardiovascular effects of sulphonylurea derivatives.,"['Smits P', 'Bijlstra PJ', 'Russel FG', 'Lutterman JA', 'Thien T']","['Adenosine Triphosphate/*physiology', 'Animals', 'Cardiovascular System/*drug effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Potassium Channels/*drug effects', 'Sulfonylurea Compounds/*therapeutic use', 'Tolbutamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8864641/
948,glyburide,3082015,Oral sulfonylureas for the treatment of type II diabetes: an update.,"['Shank WA Jr', 'Morrison AD']","['Administration, Oral', 'Chlorpropamide/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Hypersensitivity/etiology', 'Glipizide/administration & dosage/metabolism/therapeutic use', 'Glyburide/administration & dosage/metabolism/therapeutic use', 'Humans', 'Insulin Resistance', 'Kinetics', 'Liver/metabolism', 'Nausea/chemically induced', 'Patient Education as Topic', 'Sulfonylurea Compounds/administration & dosage/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3082015/
949,glyburide,27582151,Non-insulin pharmacological therapy in pregnancy.,['Bajaj S'],"['Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/therapeutic use', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin', 'Metformin/therapeutic use', 'Pregnancy', 'Pregnancy Outcome', '*Pregnancy in Diabetics']",https://pubmed.ncbi.nlm.nih.gov/27582151/
950,glyburide,9069698,Drug interaction: rifampicin and glibenclamide.,"['Surekha V', 'Peter JV', 'Jeyaseelan L', 'Cherian AM']","['Adult', 'Aged', 'Antibiotics, Antitubercular/administration & dosage/*pharmacology', 'Blood Glucose/drug effects', 'Diabetes Mellitus, Type 2/blood/drug therapy', 'Drug Interactions', 'Female', 'Glyburide/administration & dosage/*pharmacology', 'Humans', 'Hypoglycemic Agents/administration & dosage/*pharmacology', 'Male', 'Middle Aged', 'Rifampin/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9069698/
951,glyburide,3925246,Sulfonylureas in the treatment of diabetes mellitus--1985.,['Gerich JE'],"['Blood Glucose/metabolism', 'Body Weight', 'Diabetes Mellitus, Type 1/therapy', 'Diabetes Mellitus, Type 2/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/pharmacology', 'Glyburide/pharmacology', 'Humans', 'Hypoglycemia/etiology', 'Insulin/metabolism/therapeutic use', 'Pancreas/metabolism', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3925246/
952,glyburide,19082520,Sulphonylureas and cancer: a case-control study.,"['Monami M', 'Lamanna C', 'Balzi D', 'Marchionni N', 'Mannucci E']","['Aged', 'Case-Control Studies', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Female', 'Follow-Up Studies', 'Gliclazide/therapeutic use', 'Glyburide/adverse effects/therapeutic use', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Male', 'Metformin/therapeutic use', 'Middle Aged', 'Neoplasms/epidemiology/*etiology', 'Risk Factors', 'Sulfonylurea Compounds/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19082520/
953,glyburide,35195193,Metformin versus glyburide in treatment and control of gestational diabetes mellitus: a systematic review with meta-analysis.,"['Oliveira MM', 'Andrade KFO', 'Lima GHS', 'Rocha TC']","['Blood Glucose', '*Diabetes, Gestational/drug therapy', 'Female', 'Glyburide/adverse effects/therapeutic use', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Infant, Newborn', 'Insulin/therapeutic use', '*Metformin/adverse effects/therapeutic use', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/35195193/
954,glyburide,28847172,The care of pregestational and gestational diabetes and drug metabolism considerations.,"['Hedrington MS', 'Davis SN']","['Animals', 'Blood Glucose/drug effects', 'Diabetes, Gestational/*drug therapy', 'Female', 'Glyburide/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Hypoglycemia/chemically induced', 'Hypoglycemic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Insulin/administration & dosage/adverse effects/pharmacokinetics', 'Metformin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy', 'Pregnancy in Diabetics/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28847172/
955,glyburide,19791828,Saxagliptin.,"['Dhillon S', 'Weber J']","['Blood Glucose/analysis/drug effects', 'Diabetes Mellitus, Type 2/chemically induced/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use', 'Drug Therapy, Combination', 'Glucagon-Like Peptide 1/*therapeutic use', 'Glyburide/pharmacology/therapeutic use', 'Humans', 'Metformin/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19791828/
956,nisoldipine,25283255,Treatment for calcium channel blocker poisoning: a systematic review.,"['St-Onge M', 'Dube PA', 'Gosselin S', 'Guimont C', 'Godwin J', 'Archambault PM', 'Chauny JM', 'Frenette AJ', 'Darveau M', 'Le Sage N', 'Poitras J', 'Provencher J', 'Juurlink DN', 'Blais R']","['Animals', 'Calcium Channel Blockers/blood/*poisoning', 'Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Drug Overdose/mortality/*therapy', 'Guidelines as Topic', 'Hospitalization', 'Humans', 'Insulin/therapeutic use', 'Length of Stay', 'Observational Studies as Topic', 'Treatment Outcome', 'Vasoconstrictor Agents/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25283255/
957,nisoldipine,3154705,Calcium channel antagonists. Part V: Second-generation agents.,['Opie LH'],"['Animals', 'Calcium Channel Blockers/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/3154705/
958,nisoldipine,8429113,Nisoldipine: a new dihydropyridine calcium-channel blocker.,"['Mitchell J', 'Frishman W', 'Heiman M']","['Angina Pectoris/drug therapy/physiopathology', 'Cardiovascular Diseases/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Nisoldipine/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8429113/
959,nisoldipine,8370362,Nisoldipine in severe ischaemic left ventricular dysfunction.,"['Pouleur H', 'Rousseau MF']","['Coronary Circulation/drug effects/physiology', 'Diastole/drug effects/physiology', 'Hemodynamics/drug effects/physiology', 'Humans', 'Myocardial Ischemia/*drug therapy/physiopathology', 'Nisoldipine/adverse effects/*therapeutic use', 'Ventricular Function, Left/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/8370362/
960,nisoldipine,33944777,Permeant fluorescent probes visualize the activation of SARM1 and uncover an anti-neurodegenerative drug candidate.,"['Li WH', 'Huang K', 'Cai Y', 'Wang QW', 'Zhu WJ', 'Hou YN', 'Wang S', 'Cao S', 'Zhao ZY', 'Xie XJ', 'Du Y', 'Lee CS', 'Lee HC', 'Zhang H', 'Zhao YJ']","['Animals', 'Armadillo Domain Proteins/antagonists & inhibitors/*chemistry/genetics/*metabolism', 'Cryoelectron Microscopy', 'Cytoskeletal Proteins/antagonists & inhibitors/*chemistry/genetics/*metabolism', 'Dihydropyridines/therapeutic use', 'Drug Evaluation, Preclinical/*methods', '*Fluorescent Dyes', 'HEK293 Cells', 'Humans', 'Mice', 'Mice, Inbred C57BL', 'Neurons/physiology', 'Neuroprotection/*drug effects', 'Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/33944777/
961,nisoldipine,2457808,Calcium channels in thrombin-activated human platelet membrane.,"['Zschauer A', 'van Breemen C', 'Buhler FR', 'Nelson MT']","['Barium/blood', 'Blood Platelets/drug effects/*physiology', 'Calcium/*blood', 'Calcium Channel Blockers', 'Cations, Divalent', 'Cell Membrane/drug effects/physiology', 'Electric Conductivity', 'Humans', 'Ion Channels/drug effects/*physiology', 'Lipid Bilayers/metabolism', 'Membrane Potentials', 'Nickel/pharmacology', 'Nifedipine/analogs & derivatives/pharmacology', 'Nisoldipine', 'Sodium/blood', 'Thrombin/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2457808/
962,nisoldipine,9129871,Nisoldipine coat-core. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of ischaemic heart disease.,"['Langtry HD', 'Spencer CM']","['Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Drug Interactions', 'Food-Drug Interactions', 'Humans', 'Myocardial Ischemia/*drug therapy/metabolism', 'Nisoldipine/pharmacokinetics/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/9129871/
963,nisoldipine,2429539,Antihypertensive mechanism of action and binding sites of nitrendipine.,['Triggle DJ'],"['Animals', 'Blood Pressure/*drug effects', 'Calcium/metabolism', 'Calcium Channel Blockers/pharmacology', 'Calcium Channels', 'Heart/drug effects', 'Humans', 'Ion Channels/drug effects', 'Muscle, Smooth, Vascular/drug effects', 'Neurons/metabolism', 'Nitrendipine/metabolism/*pharmacology', 'Organ Specificity', 'Radioligand Assay', 'Receptors, Nicotinic', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/2429539/
964,nisoldipine,3154674,The pharmacology of nisoldipine.,['Knorr A'],"['Animals', 'Humans', 'Nisoldipine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3154674/
965,nisoldipine,8483021,Vascular effects of lacidipine: a review of animal and human data.,"['Mancia G', 'Ferrari AU', 'Giannattasio C', 'Trazzi S']","['Animals', 'Antihypertensive Agents/*pharmacology', 'Calcium Channel Blockers/*pharmacology', 'Dihydropyridines/*pharmacology', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8483021/
966,nisoldipine,18176062,"Relationship between lipophilicities of 1,4-dihydropyridine derivatives and pharmacokinetic interaction strengths with grapefruit juice.","['Uesawa Y', 'Mohri K']","['Antihypertensive Agents/chemistry/*pharmacokinetics', 'Calcium Channel Blockers/chemistry/*pharmacokinetics', 'Chemical Phenomena', 'Chemistry, Physical', '*Citrus paradisi', 'Dihydropyridines/chemistry/*pharmacokinetics', '*Food-Drug Interactions', 'Humans', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/18176062/
967,nisoldipine,12578880,Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes.,"['Mehler PS', 'Coll JR', 'Estacio R', 'Esler A', 'Schrier RW', 'Hiatt WR']","['Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/*prevention & control', 'Cohort Studies', 'Comorbidity', 'Death, Sudden, Cardiac/prevention & control', 'Diabetes Mellitus, Type 2/*complications', 'Enalapril/therapeutic use', 'Female', 'Follow-Up Studies', 'Humans', 'Hypertension/complications/*drug therapy', 'Male', 'Middle Aged', 'Myocardial Infarction/prevention & control', 'Nisoldipine/therapeutic use', 'Odds Ratio', 'Peripheral Vascular Diseases/*complications', 'Risk Assessment', 'Stroke/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12578880/
968,nisoldipine,31013922,Calcium Channel Blocker-Associated Chyloperitoneum in Patients Receiving Peritoneal Dialysis: A Systematic Review.,"['Kim S', 'Yu YM', 'Kwon J', 'Yoo H', 'Jung SH', 'Lee E']","['Calcium Channel Blockers/*adverse effects', 'Chylous Ascites/*chemically induced', 'Humans', '*Peritoneal Dialysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/31013922/
969,nisoldipine,17433928,Risk and predictability of drug interactions in the elderly.,"['Levy RH', 'Collins C']","['Aged', '*Aging', 'Anticonvulsants/adverse effects', 'Antidepressive Agents/adverse effects', 'Antipsychotic Agents/adverse effects', 'Cardiovascular Agents/adverse effects', 'Dementia/drug therapy', '*Drug Interactions', 'Humans', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/17433928/
970,nisoldipine,32259277,Drug treatments in patients with cardiac diseases and epilepsy.,"['Zaccara G', 'Lattanzi S', 'Cincotta M', 'Russo E']","['Animals', 'Anticonvulsants/*therapeutic use', 'Cardiovascular Agents/*therapeutic use', 'Drug Interactions', 'Epilepsy/*complications/*drug therapy', 'Heart Diseases/*complications/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/32259277/
971,nisoldipine,2994701,Effects of verapamil and nisoldipine on human platelets: in vivo and in vitro studies.,"['Jones CR', 'Pasanisi F', 'Elliott HL', 'Reid JL']","['Adult', 'Blood Platelets/*drug effects/metabolism', 'Calcium Channel Blockers/*pharmacology', 'Humans', 'In Vitro Techniques', 'Male', 'Nifedipine/*analogs & derivatives/pharmacology', 'Nisoldipine', 'Platelet Aggregation/drug effects', 'Receptors, Adrenergic, alpha/metabolism', 'Verapamil/*pharmacology', 'Yohimbine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2994701/
972,nisoldipine,9126676,Nisoldipine CC: efficacy and tolerability in hypertension and ischemic heart disease.,['Fodor JG'],"['Aging/pathology', 'Angina Pectoris/drug therapy', 'Antihypertensive Agents/administration & dosage/pharmacology/*therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/administration & dosage/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Hypertension/*drug therapy', 'Myocardial Contraction/drug effects', 'Myocardial Infarction/drug therapy', 'Myocardial Ischemia/*drug therapy', 'Nisoldipine/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9126676/
973,nisoldipine,9862440,Sulfonylureas blockade of neural and cardiac HERG channels.,"['Rosati B', 'Rocchetti M', 'Zaza A', 'Wanke E']","['Action Potentials/drug effects', 'Animals', '*Cation Transport Proteins', 'Chromans/pharmacology', '*DNA-Binding Proteins', 'Dose-Response Relationship, Drug', 'ERG1 Potassium Channel', 'Ether-A-Go-Go Potassium Channels', 'Glyburide/*pharmacology', 'Guinea Pigs', 'Humans', 'Inhibitory Concentration 50', 'Mice', 'Myocardium/cytology/*metabolism', 'Neuroblastoma', 'Neurons/drug effects/*metabolism', 'Nisoldipine/pharmacology', 'Piperidines/pharmacology', '*Potassium Channel Blockers', 'Potassium Channels/metabolism', '*Potassium Channels, Voltage-Gated', 'Pyridines/pharmacology', 'Rats', 'Sulfonamides/pharmacology', 'Sulfonylurea Compounds/*pharmacology', '*Trans-Activators', 'Transcriptional Regulator ERG', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/9862440/
974,nisoldipine,2731403,"Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly.","['van Harten J', 'Burggraaf J', 'Ligthart GJ', 'van Brummelen P', 'Breimer DD']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*metabolism/physiology', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Nisoldipine', 'Norepinephrine/blood', 'Vasodilator Agents/administration & dosage/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2731403/
975,nisoldipine,12825828,"1,4-Dihydropyridines as calcium channel ligands and privileged structures.",['Triggle DJ'],"['Animals', 'Calcium Channel Blockers/*chemistry/*pharmacokinetics', 'Calcium Channels/*drug effects/metabolism', 'Cardiovascular System/drug effects/*metabolism', 'Cell Membrane/*drug effects/metabolism', 'Dihydropyridines/*chemistry', 'Humans', 'Ligands', 'Molecular Conformation', 'Molecular Structure', 'Receptors, Cell Surface/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12825828/
976,phentermine,26868660,Management of obesity.,"['Bray GA', 'Fruhbeck G', 'Ryan DH', 'Wilding JP']","['Anti-Obesity Agents/*therapeutic use', 'Bariatric Surgery/methods', 'Diet, Reducing/methods', 'Exercise Therapy/methods', 'Humans', 'Obesity/*therapy', 'Risk Reduction Behavior', 'Treatment Outcome', 'Weight Loss/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/26868660/
977,phentermine,39037780,Medications for Obesity: A Review.,"['Gudzune KA', 'Kushner RF']","['Female', 'Humans', 'Male', '*Anti-Obesity Agents/therapeutic use/adverse effects', 'Bupropion/therapeutic use/adverse effects', 'Drug Combinations', 'Fructose/analogs & derivatives/therapeutic use/adverse effects', 'Glucagon-Like Peptides/therapeutic use/adverse effects', 'Lactones/therapeutic use/adverse effects', 'Liraglutide/therapeutic use/adverse effects', 'Naltrexone/therapeutic use/adverse effects', '*Obesity/diet therapy/drug therapy', 'Orlistat/therapeutic use', 'Phentermine/therapeutic use/adverse effects', 'Topiramate/therapeutic use/adverse effects', 'Weight Loss/drug effects', '*Diet, Healthy', 'Combined Modality Therapy/methods']",https://pubmed.ncbi.nlm.nih.gov/39037780/
978,phentermine,36273831,AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity.,"['Grunvald E', 'Shah R', 'Hernaez R', 'Chandar AK', 'Pickett-Blakely O', 'Teigen LM', 'Harindhanavudhi T', 'Sultan S', 'Singh S', 'Davitkov P']","['Adult', 'Humans', 'Orlistat/therapeutic use', '*Anti-Obesity Agents/adverse effects', 'Overweight/drug therapy', 'Liraglutide/therapeutic use', 'Bupropion/therapeutic use', 'Naltrexone/therapeutic use', 'Topiramate/therapeutic use', 'Weight Loss', 'Diethylpropion/therapeutic use', 'Phentermine/therapeutic use', 'Obesity/complications/diagnosis/therapy', 'Hydrogels/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36273831/
979,phentermine,34895470,Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.,"['Shi Q', 'Wang Y', 'Hao Q', 'Vandvik PO', 'Guyatt G', 'Li J', 'Chen Z', 'Xu S', 'Shen Y', 'Ge L', 'Sun F', 'Li L', 'Yu J', 'Nong K', 'Zou X', 'Zhu S', 'Wang C', 'Zhang S', 'Qiao Z', 'Jian Z', 'Li Y', 'Zhang X', 'Chen K', 'Qu F', 'Wu Y', 'He Y', 'Tian H', 'Li S']","['Adult', 'Anti-Obesity Agents/*administration & dosage/adverse effects', 'Humans', 'Network Meta-Analysis', 'Obesity/*drug therapy', 'Overweight/*drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34895470/
980,phentermine,9457156,Obesity.,['Aronne LJ'],"['Appetite Depressants/administration & dosage', 'Behavior', 'Body Mass Index', 'Diet, Reducing', 'Exercise', 'Female', 'Fenfluramine/administration & dosage', 'Humans', '*Obesity/epidemiology/psychology/therapy', 'Phentermine/administration & dosage', 'Risk Factors', '*Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/9457156/
981,phentermine,27299618,Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.,"['Khera R', 'Murad MH', 'Chandar AK', 'Dulai PS', 'Wang Z', 'Prokop LJ', 'Loomba R', 'Camilleri M', 'Singh S']","['Anti-Obesity Agents/*adverse effects/therapeutic use', 'Bayes Theorem', 'Benzazepines/adverse effects/therapeutic use', 'Drug Combinations', 'Female', 'Fructose/adverse effects/analogs & derivatives/therapeutic use', 'Humans', 'Lactones/adverse effects/therapeutic use', 'Liraglutide/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Naltrexone/adverse effects/therapeutic use', 'Obesity/*drug therapy', 'Orlistat', 'Phentermine/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Topiramate', '*Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/27299618/
982,phentermine,34783910,Drugs for Treating Obesity.,['Ryan DH'],"['*Anti-Obesity Agents/therapeutic use', 'Humans', 'Islet Amyloid Polypeptide', 'Obesity/drug therapy', '*Phentermine/therapeutic use', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/34783910/
983,phentermine,29993319,Combination Therapies for Obesity.,"['Camilleri M', 'Acosta A']","['Animals', 'Anti-Obesity Agents/adverse effects/*therapeutic use', 'Bariatric Surgery/adverse effects/*methods', 'Caloric Restriction', 'Combined Modality Therapy', 'Diet, Reducing/adverse effects/*methods', 'Disease Models, Animal', 'Humans', 'Obesity/diagnosis/epidemiology/physiopathology/*therapy', 'Treatment Outcome', 'Weight Gain', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/29993319/
984,phentermine,33410104,Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?,"['Tak YJ', 'Lee SY']","['Animals', 'Anti-Obesity Agents/*therapeutic use', 'Benzazepines/therapeutic use', 'Bupropion/therapeutic use', 'Humans', 'Liraglutide/therapeutic use', 'Naltrexone/therapeutic use', 'Obesity/*drug therapy', 'Orlistat/therapeutic use', 'Overweight/drug therapy', 'Phentermine/therapeutic use', 'Topiramate/therapeutic use', 'United States', 'United States Food and Drug Administration', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/33410104/
985,phentermine,33759389,Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic.,"['Acosta A', 'Camilleri M', 'Abu Dayyeh B', 'Calderon G', 'Gonzalez D', 'McRae A', 'Rossini W', 'Singh S', 'Burton D', 'Clark MM']","['Anti-Obesity Agents/*therapeutic use', 'Clinical Trials as Topic/*methods', 'Female', 'Humans', 'Male', 'Obesity/*drug therapy', 'Precision Medicine/*methods', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/33759389/
986,phentermine,33389955,Comprehensive Review of Current and Upcoming Anti-Obesity Drugs.,"['Son JW', 'Kim S']","['Anti-Obesity Agents/*therapeutic use', 'Benzazepines', 'Humans', 'Orlistat', 'Phentermine', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/33389955/
987,phentermine,24126545,Obesity drug therapy.,['Baretic M'],"['Anti-Obesity Agents/economics/pharmacology/*therapeutic use', 'Appetite/physiology', 'Combined Modality Therapy', 'Comorbidity', 'Cost-Benefit Analysis', 'Cyclobutanes/therapeutic use', 'Diabetes Mellitus, Type 2/epidemiology', 'Diet, Diabetic', 'Drug Combinations', 'Exercise Therapy', 'Fructose/administration & dosage/analogs & derivatives/therapeutic use', 'Gastrointestinal Hormones/metabolism', 'Humans', 'Incretins/physiology', 'Insulin/metabolism', 'Insulin Secretion', 'Intestines/drug effects', 'Lactones/therapeutic use', 'Leptin/physiology', 'Life Style', 'Models, Biological', 'Neuropeptides/physiology', 'Obesity/diet therapy/*drug therapy/economics/epidemiology/therapy', 'Orlistat', 'Phentermine/administration & dosage/therapeutic use', 'Phytotherapy', 'Piperidines/therapeutic use', 'Plant Preparations/therapeutic use', 'Pyrazoles/therapeutic use', 'Rimonabant', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/24126545/
988,phentermine,26382553,Anti-obesity drugs.,"['Rankin W', 'Wittert G']","['Animals', '*Anti-Obesity Agents/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Discovery', 'Humans', 'Obesity/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26382553/
989,phentermine,37368102,Narrative Review of Topiramate: Clinical Uses and Pharmacological Considerations.,"['Pearl NZ', 'Babin CP', 'Catalano NT', 'Blake JC', 'Ahmadzadeh S', 'Shekoohi S', 'Kaye AD']","['Humans', 'Topiramate/therapeutic use', 'Anticonvulsants/adverse effects', 'Fructose/pharmacology/therapeutic use', '*Epilepsy/drug therapy', '*Migraine Disorders/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37368102/
990,phentermine,29156182,Obesity Pharmacotherapy.,"['Saunders KH', 'Umashanker D', 'Igel LI', 'Kumar RB', 'Aronne LJ']","['Anti-Obesity Agents/*therapeutic use', 'Benzazepines/therapeutic use', 'Drug Combinations', 'Fructose/analogs & derivatives/therapeutic use', 'Humans', 'Lactones/therapeutic use', 'Naltrexone/therapeutic use', 'Obesity/*drug therapy/prevention & control', 'Orlistat', 'Phentermine/therapeutic use', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/29156182/
991,phentermine,37651143,Cost-Effectiveness of Pharmacotherapy for the Treatment of Obesity in Adolescents.,"['Lim F', 'Bellows BK', 'Tan SX', 'Aziz Z', 'Woo Baidal JA', 'Kelly AS', 'Hur C']","['United States', 'Adolescent', 'Humans', 'Female', 'Male', 'Cost-Benefit Analysis', '*Pediatric Obesity/drug therapy', 'Topiramate/therapeutic use', 'Liraglutide/therapeutic use', 'Phentermine']",https://pubmed.ncbi.nlm.nih.gov/37651143/
992,phentermine,38582569,Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.,"['Shi Q', 'Wang Y', 'Hao Q', 'Vandvik PO', 'Guyatt G', 'Li J', 'Chen Z', 'Xu S', 'Shen Y', 'Ge L', 'Sun F', 'Li L', 'Yu J', 'Nong K', 'Zou X', 'Zhu S', 'Wang C', 'Zhang S', 'Qiao Z', 'Jian Z', 'Li Y', 'Zhang X', 'Chen K', 'Qu F', 'Wu Y', 'He Y', 'Tian H', 'Li S']","['Adult', 'Humans', '*Overweight/drug therapy', 'Network Meta-Analysis', 'Topiramate/therapeutic use', '*Obesity/drug therapy', 'Weight Loss', 'Phentermine/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38582569/
993,phentermine,16255666,Safety of obesity drugs.,"['Greenway FL', 'Caruso MK']","['Appetite Depressants/*adverse effects/*therapeutic use', 'Central Nervous System Stimulants/*adverse effects/*therapeutic use', 'Drug Approval', 'Humans', 'Insurance Coverage', 'Obesity/*drug therapy', 'Piperidines/*adverse effects/*therapeutic use', 'Pyrazoles/*adverse effects/*therapeutic use', 'Rimonabant']",https://pubmed.ncbi.nlm.nih.gov/16255666/
994,phentermine,28192104,Practical Use of Pharmacotherapy for Obesity.,"['Igel LI', 'Kumar RB', 'Saunders KH', 'Aronne LJ']","['Androgens/*therapeutic use', 'Anti-Obesity Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents/adverse effects', 'Antihypertensive Agents/adverse effects', 'Antipsychotic Agents/adverse effects', 'Appetite Depressants/therapeutic use', 'Benzazepines/therapeutic use', 'Bupropion/administration & dosage/*therapeutic use', 'Drug Combinations', 'Fructose/analogs & derivatives/therapeutic use', 'Humans', 'Hypoglycemic Agents/adverse effects', 'Hypogonadism/complications/drug therapy', 'Lactones/therapeutic use', 'Liraglutide/therapeutic use', 'Naltrexone/administration & dosage/*therapeutic use', 'Obesity/complications/*drug therapy', 'Orlistat', 'Phentermine/therapeutic use', 'Testosterone/*therapeutic use', 'Topiramate', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/28192104/
995,phentermine,34423889,Clinical outcomes associated with anti-obesity medications in real-world practice: A systematic literature review.,"['Ahmad NN', 'Robinson S', 'Kennedy-Martin T', 'Poon JL', 'Kan H']","['Adult', '*Anti-Obesity Agents/therapeutic use', 'Humans', 'Orlistat', 'Phentermine', '*State Medicine', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/34423889/
996,propranolol,28431779,Propranolol.,"['Al-Majed AA', 'Bakheit AHH', 'Abdel Aziz HA', 'Alajmi FM', 'AlRabiah H']","['*Adrenergic beta-Antagonists/chemistry/pharmacokinetics/pharmacology/therapeutic use', 'Drug Stability', 'Humans', 'Hypertension/drug therapy', 'Molecular Structure', '*Propranolol/chemistry/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28431779/
997,propranolol,31136408,Can propranolol prevent progression of melanoma?,"['Kao J', 'Luu B']","['Adrenergic beta-Antagonists/*therapeutic use', 'Disease Progression', 'Humans', 'Melanoma/*drug therapy', 'Neoplasm Recurrence, Local/*prevention & control', 'Propranolol/*therapeutic use', 'Skin Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31136408/
998,propranolol,22874493,[News on infantile hemangioma therapy by beta-blocker].,"['Delmotte N', 'Curti C', 'Montana M', 'Crozet M', 'Vanelle P', 'Gensollen S']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/*therapeutic use', 'Child', 'Child, Preschool', 'Hemangioma/complications/*drug therapy/physiopathology', 'Humans', 'Infant', 'Propranolol/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22874493/
999,propranolol,24305730,Treatment of infantile hemangiomas with beta-blockers: a review.,"['Shah S', 'Frieden IJ']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Drug Monitoring/methods', 'Glucocorticoids/adverse effects/therapeutic use', 'Hemangioma/*drug therapy/epidemiology/pathology', 'Humans', 'Infant', 'Prevalence', 'Propranolol/administration & dosage/adverse effects/therapeutic use', 'Skin Neoplasms/*drug therapy/epidemiology/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24305730/
1000,propranolol,3894197,The use of propranolol in the treatment of anxiety disorders.,"['Fonte RJ', 'Stevenson JM']","['Anxiety/drug therapy', 'Anxiety Disorders/complications/*drug therapy', 'Double-Blind Method', 'Heart Diseases/complications', 'Humans', 'Mitral Valve Prolapse/complications', 'Panic/drug effects', 'Propranolol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3894197/
1001,propranolol,6682990,Propranolol in schizophrenia.,"['Sethi BB', 'Dube S']","['Adult', 'Humans', 'Male', 'Propranolol/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/6682990/
1002,propranolol,3503570,Propranolol for the treatment of the alcoholic hangover.,"['Bogin RM', 'Nostrant TT', 'Young MJ']","['Adult', 'Alcoholic Intoxication/*complications/physiopathology', 'Double-Blind Method', 'Female', 'Heart Rate/drug effects', 'Humans', 'Male', 'Propranolol/adverse effects/*therapeutic use', 'Random Allocation', 'Tremor/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3503570/
1003,propranolol,95728,Minoxidil in resistant hypertension.,"['Dargie HJ', 'Dollery CT', 'Daniel J']","['Blood Pressure/drug effects', 'Drug Combinations', 'Female', 'Follow-Up Studies', 'Furosemide/administration & dosage/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Minoxidil/administration & dosage/adverse effects/*therapeutic use', 'Propranolol/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/95728/
1004,propranolol,7055283,Propranolol and depression.,"['Petrie WM', 'Maffucci RJ', 'Woosley RL']","['Adult', 'Arrhythmias, Cardiac/drug therapy', 'Depressive Disorder/*chemically induced', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Propranolol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7055283/
1005,propranolol,9352395,Inverse PK/PD: estimation and differentiation of bioavailability from effect kinetics--observations with beta-adrenoceptor antagonists.,['De Mey C'],"['Adrenergic beta-Antagonists/*pharmacokinetics/*pharmacology', 'Adult', 'Binding, Competitive', 'Biological Availability', 'Carbazoles/pharmacokinetics/pharmacology', 'Carvedilol', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Models, Biological', 'Propanolamines/pharmacokinetics/pharmacology', 'Propranolol/administration & dosage/pharmacokinetics/pharmacology', 'Randomized Controlled Trials as Topic', 'Tachycardia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9352395/
1006,propranolol,32662682,beta-blocker therapy for infantile hemangioma.,"['Koh SP', 'Leadbitter P', 'Smithers F', 'Tan ST']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Animals', 'Hemangioma/*drug therapy/pathology', 'Humans', 'Infant', 'Propranolol/administration & dosage/adverse effects/pharmacology', 'Renin-Angiotensin System/drug effects', 'Skin Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/32662682/
1007,propranolol,937905,Treatment of recurrent symptomatic ventricular tachycardia.,"['Winkle RA', 'Alderman EL', 'Fitzgerald JW', 'Harrison DC']","['Adult', 'Aged', 'Anti-Arrhythmia Agents/*therapeutic use', 'Cardiomyopathies/complications', 'Coronary Disease/complications', 'Drug Evaluation', 'Female', 'Heart Aneurysm/complications/surgery', 'Hemochromatosis/complications', 'Humans', 'Male', 'Middle Aged', 'Mitral Valve Insufficiency/complications', 'Phenytoin/administration & dosage/adverse effects/therapeutic use', 'Procainamide/administration & dosage/adverse effects/therapeutic use', 'Propranolol/administration & dosage/adverse effects/therapeutic use', 'Quinidine/administration & dosage/adverse effects/therapeutic use', 'Recurrence', 'Tachycardia/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/937905/
1008,propranolol,1237822,Essential tremor: treatment with propranolol.,"['Tolosa ES', 'Loewenson RB']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Propranolol/administration & dosage/*therapeutic use', 'Tremor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1237822/
1009,propranolol,28265298,Safety and effectiveness of propranolol in severely burned patients: systematic review and meta-analysis.,"['Manzano-Nunez R', 'Garcia-Perdomo HA', 'Ferrada P', 'Ordonez Delgado CA', 'Gomez DA', 'Foianini JE']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/therapeutic use', 'Burns/*drug therapy', 'Humans', 'Patient Safety', 'Propranolol/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28265298/
1010,propranolol,33776033,Propranolol Therapy in Infantile Hemangioma: It Is Not Just About the Beta.,"['Lee JC', 'Modiri O', 'England RW', 'Shawber CJ', 'Wu JK']","['Adrenergic beta-Antagonists/*therapeutic use', 'Hemangioma, Capillary/*drug therapy', 'Humans', 'Infant', 'Propranolol/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33776033/
1011,propranolol,21622997,Propranolol for infantile haemangiomas: a review.,"['Starkey E', 'Shahidullah H']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Child, Preschool', 'Drug Administration Schedule', 'Hemangioma/*drug therapy/epidemiology', 'Humans', 'Infant', 'Infant, Newborn', 'Propranolol/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21622997/
1012,propranolol,234668,A comparison of timolol and propranolol in essential hypertension.,"['Lohmoller G', 'Frohlich ED']","['Adrenergic beta-Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Follow-Up Studies', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Morpholines/therapeutic use', 'Placebos', 'Propanolamines/*therapeutic use', 'Propranolol/administration & dosage/adverse effects/*therapeutic use', 'Thiadiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/234668/
1013,propranolol,3087677,"Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism.","['Reilly CS', 'Biollaz J', 'Koshakji RP', 'Wood AJ']","['Administration, Oral', 'Adult', 'Cimetidine/*pharmacology', 'Double-Blind Method', 'Drug Interactions', 'Enprostil', 'Humans', 'Indocyanine Green/blood', 'Injections, Intravenous', 'Kinetics', 'Liver Circulation', 'Male', 'Propranolol/administration & dosage/*metabolism', 'Prostaglandins E, Synthetic/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3087677/
1014,propranolol,2502256,Controlled trial of propranolol to prevent recurrent variceal bleeding in patients with non-cirrhotic portal fibrosis.,['Kiire CF'],"['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Esophageal and Gastric Varices/etiology/*prevention & control', 'Female', 'Follow-Up Studies', 'Gastrointestinal Hemorrhage/etiology/*prevention & control', 'Humans', 'Hypertension, Portal/complications', 'Liver Cirrhosis/*complications', 'Male', 'Middle Aged', 'Propranolol/administration & dosage/*therapeutic use', 'Pulse/drug effects', 'Random Allocation', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/2502256/
1015,propranolol,333492,The influence of propranolol on the exposure in vivo of agoraphobics.,"['Hafner J', 'Milton F']","['Adult', 'Agoraphobia/*drug therapy/psychology', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Follow-Up Studies', 'Heart Rate/drug effects', 'Humans', 'Male', 'Phobic Disorders/*drug therapy', 'Propranolol/administration & dosage/*therapeutic use', 'Psychiatric Status Rating Scales', 'Social Adjustment']",https://pubmed.ncbi.nlm.nih.gov/333492/
1016,Salbutamol,36430683,Salbutamol in the Management of Asthma: A Review.,"['Marques L', 'Vale N']","['Humans', 'Albuterol/therapeutic use', '*Asthma/drug therapy', 'Bronchi', '*Drug-Related Side Effects and Adverse Reactions', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/36430683/
1017,Salbutamol,11253864,Single-isomer beta-agonists.,['Handley DA'],"['Administration, Inhalation', 'Adrenergic beta-Agonists/chemistry/*pharmacology', 'Albuterol/adverse effects/chemistry/pharmacology', 'Asthma/*drug therapy', 'Bronchi/drug effects', 'Bronchodilator Agents/chemistry/*pharmacology', 'Ethanolamines/adverse effects/chemistry/pharmacology', 'Formoterol Fumarate', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11253864/
1018,Salbutamol,11802253,Levalbuterol hydrochloride.,"['Slattery D', 'Wong SW', 'Colin AA']","['Adrenergic beta-Agonists/adverse effects/chemistry/pharmacology/*therapeutic use', 'Albuterol/adverse effects/chemistry/pharmacology/*therapeutic use', 'Asthma/*drug therapy', 'Bronchial Provocation Tests', 'Bronchodilator Agents/adverse effects/chemistry/pharmacology/*therapeutic use', 'Eosinophils/drug effects', 'Humans', 'Mucociliary Clearance/drug effects', 'Receptors, Adrenergic, beta-2/*metabolism', 'Research', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/11802253/
1019,Salbutamol,7875287,Salmeterol-induced vertigo.,"['Lopez-Guillen A', 'Marques L', 'Lopez-Llorente MT', 'Pastor E', 'Figueras A']","['Administration, Inhalation', 'Aged', 'Albuterol/adverse effects/*analogs & derivatives/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Salmeterol Xinafoate', 'Vertigo/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7875287/
1020,Salbutamol,9877002,Pharmacokinetic and pharmacodynamic aspects of salmeterol therapy.,"['Buchwald A', 'Hochhaus G']","['Adrenergic beta-Agonists/*pharmacokinetics/*pharmacology/therapeutic use', 'Albuterol/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Asthma/drug therapy', 'Bronchodilator Agents/*pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/9877002/
1021,Salbutamol,17547854,Levalbuterol for asthma: a better treatment?,['Kelly HW'],"['Albuterol/adverse effects/*therapeutic use', 'Animals', 'Asthma/*drug therapy', 'Bronchial Hyperreactivity/chemically induced', 'Bronchodilator Agents/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/17547854/
1022,Salbutamol,12562558,Single-isomer levalbuterol: a review of the acute data.,['Nowak R'],"['Acute Disease', 'Albuterol/economics/pharmacokinetics/*pharmacology', 'Asthma/*drug therapy', 'Bronchodilator Agents/economics/pharmacokinetics/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12562558/
1023,Salbutamol,26742192,Usefulness Of Glucocorticoids In The Management Of Foreign Body Aspiration.,"['Pagan Rivera BL', 'Anselmi FJ', 'Torres Mdel M', 'Segarra A', 'Rivera JR']","['Acetaminophen/administration & dosage/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azithromycin/administration & dosage/therapeutic use', 'Bronchodilator Agents/administration & dosage/therapeutic use', 'Ceftriaxone/administration & dosage/therapeutic use', 'Cough/etiology', 'Drug Therapy, Combination', 'Dyspnea/etiology', 'Fluoroquinolones/administration & dosage/therapeutic use', 'Foreign Bodies/diagnostic imaging/*drug therapy', 'Humans', 'Levalbuterol/administration & dosage/therapeutic use', 'Male', 'Methylprednisolone/administration & dosage/*therapeutic use', 'Moxifloxacin', 'Play and Playthings', 'Pneumonia, Aspiration/*drug therapy/etiology', 'Ranitidine/administration & dosage/therapeutic use', 'Tomography, X-Ray Computed', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26742192/
1024,Salbutamol,36865421,Loeffler's Syndrome and Multifocal Cutaneous Larva Migrans: Case report of an uncommon occurrence and review of the literature.,"['Sil A', 'Bhanja DB', 'Chandra A', 'Biswas SK']","['Male', 'Humans', 'Adult', '*Larva Migrans/diagnosis/drug therapy', 'Skin', 'Albendazole/therapeutic use', 'India', 'Levalbuterol']",https://pubmed.ncbi.nlm.nih.gov/36865421/
1025,Salbutamol,10452792,Clinical experience with levalbuterol.,['Nelson HS'],"['Adrenergic beta-Agonists/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Adult', 'Albuterol/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/administration & dosage/adverse effects/chemistry/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Female', 'Humans', 'Male', 'Respiratory Hypersensitivity/drug therapy', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10452792/
1026,Salbutamol,1897692,Cyclosporin for steroid-dependent asthma.,"['Szczeklik A', 'Nizankowska E', 'Dworski R', 'Domagala B', 'Pinis G']","['Adult', 'Albuterol/administration & dosage/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/therapeutic use', 'Cyclosporins/administration & dosage/blood/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peak Expiratory Flow Rate/drug effects', 'Prednisone/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1897692/
1027,Salbutamol,39213627,beta-Adrenergic Agonist-Induced Lactic Acidosis: A Case Report.,['Blush RR 3rd'],"['Humans', '*Acidosis, Lactic/chemically induced', '*Adrenergic beta-Agonists/adverse effects', '*Albuterol/adverse effects/therapeutic use/administration & dosage', 'Asthma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39213627/
1028,Salbutamol,12493336,The long and short of beta2-agonists.,['Lotvall J'],"['Administration, Inhalation', '*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/*administration & dosage/therapeutic use', 'Albuterol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Budesonide/adverse effects/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/adverse effects/pharmacology/therapeutic use', 'Formoterol Fumarate', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/12493336/
1029,Salbutamol,12810191,Long-acting beta 2-adrenoceptor agonists or tiotropium bromide for patients with COPD: is combination therapy justified?,"['Tennant RC', 'Erin EM', 'Barnes PJ', 'Hansel TT']","['*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/administration & dosage/therapeutic use', 'Albuterol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Anti-Inflammatory Agents/administration & dosage/pharmacology/therapeutic use', 'Bronchodilator Agents/administration & dosage/pharmacology/*therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/administration & dosage/pharmacology/therapeutic use', 'Exercise Tolerance/drug effects', 'Formoterol Fumarate', 'Humans', 'Mucus/metabolism', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Quality of Life', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate', 'Scopolamine Derivatives/administration & dosage/pharmacology/*therapeutic use', 'Tiotropium Bromide']",https://pubmed.ncbi.nlm.nih.gov/12810191/
1030,Salbutamol,19671384,Levalbuterol versus albuterol.,"['Ameredes BT', 'Calhoun WJ']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/chemistry/*therapeutic use', 'Albuterol/administration & dosage/chemistry/*therapeutic use', 'Animals', 'Asthma/*drug therapy/immunology', 'Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/19671384/
1031,Salbutamol,8322251,Prolonged hypoxaemia after nebulised salbutamol.,"['Connett G', 'Lenney W']","['Acute Disease', 'Albuterol/administration & dosage/*adverse effects', 'Asthma/drug therapy', 'Child', 'Child, Preschool', 'Humans', 'Hypoxia/*chemically induced', 'Infant', 'Nebulizers and Vaporizers']",https://pubmed.ncbi.nlm.nih.gov/8322251/
1032,Salbutamol,889727,The effect of intravenous and oral salbutamol on fetus and mother in premature labour.,"['Dawson AM', 'Davies HJ']","['Administration, Oral', 'Adolescent', 'Adult', 'Albuterol/administration & dosage/*therapeutic use', 'Blood Pressure/drug effects', 'Depression, Chemical', 'Female', 'Fetal Heart/drug effects', 'Fetus/drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/889727/
1033,Salbutamol,7780253,"Acute asthma, salbutamol and hyperglycaemia.","['Dawson KP', 'Penna AC', 'Manglick P']","['Acute Disease', 'Age Factors', 'Albuterol/administration & dosage/*adverse effects/blood', 'Asthma/*drug therapy', 'Blood Glucose/analysis', 'Child', 'Child, Preschool', 'Chromatography, High Pressure Liquid', 'Fluorometry', 'Humans', 'Hyperglycemia/*chemically induced', 'Nebulizers and Vaporizers', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/7780253/
1034,Salbutamol,32051218,Rebound of Involuted Infantile Hemangioma After Administration of Salbutamol.,"['Knopfel N', 'Oesch V', 'Theiler M', 'Szello P', 'Weibel L']","['Adrenergic beta-2 Receptor Agonists/administration & dosage/*adverse effects', 'Albuterol/administration & dosage/*adverse effects', 'Bronchitis/drug therapy', 'Child, Preschool', 'Female', 'Hemangioma/drug therapy/*pathology', 'Humans', 'Infusions, Intravenous', 'Neoplasm Recurrence, Local/*chemically induced', 'Propranolol/therapeutic use', 'Skin Neoplasms/drug therapy/*pathology', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32051218/
1035,Salbutamol,10678290,Levalbuterol nebulizer solution: is it worth five times the cost of albuterol?,"['Asmus MJ', 'Hendeles L']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/*economics/*therapeutic use', 'Albuterol/administration & dosage/*economics/*therapeutic use', 'Anti-Asthmatic Agents/administration & dosage/*economics/*therapeutic use', 'Asthma/*drug therapy/*economics', 'Humans', 'Nebulizers and Vaporizers', 'Pharmaceutical Solutions', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10678290/
1036,bupropion,34823737,Tobacco Use Disorder.,"['Leone FT', 'Evers-Casey S']","['Behavior, Addictive/psychology', 'Bupropion/pharmacology/therapeutic use', 'Combined Modality Therapy', 'Counseling/methods', 'Drug Therapy/methods', 'Electronic Nicotine Delivery Systems/statistics & numerical data', 'Humans', 'Morbidity/*trends', 'Neurobiology/methods', 'Nicotine/*adverse effects', 'Nicotinic Agonists/pharmacology/therapeutic use', 'Phenotype', 'Prevalence', 'Smoking Cessation/methods', 'Smoking Cessation Agents/pharmacology/therapeutic use', 'Tobacco Use Cessation Devices/adverse effects', 'Tobacco Use Disorder/complications/*epidemiology/prevention & control/*therapy', 'United States/epidemiology', 'Varenicline/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34823737/
1037,bupropion,33497547,Bupropion and Naltrexone in Methamphetamine Use Disorder.,"['Trivedi MH', 'Walker R', 'Ling W', 'Dela Cruz A', 'Sharma G', 'Carmody T', 'Ghitza UE', 'Wahle A', 'Kim M', 'Shores-Wilson K', 'Sparenborg S', 'Coffin P', 'Schmitz J', 'Wiest K', 'Bart G', 'Sonne SC', 'Wakhlu S', 'Rush AJ', 'Nunes EV', 'Shoptaw S']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Amphetamine-Related Disorders/*drug therapy', 'Bupropion/*administration & dosage/adverse effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections', 'Male', 'Medication Adherence', '*Methamphetamine/urine', 'Middle Aged', 'Naltrexone/*administration & dosage/adverse effects', 'Narcotic Antagonists', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33497547/
1038,bupropion,26975593,Antidepressant-Induced Hyponatremia in Older Adults.,"['Viramontes TS', 'Truong H', 'Linnebur SA']","['Aged', 'Antidepressive Agents/administration & dosage/*adverse effects/pharmacology', 'Bupropion/*administration & dosage/adverse effects/pharmacology', 'Humans', 'Hyponatremia/*chemically induced/epidemiology', 'Middle Aged', 'Prevalence', 'Sodium/blood']",https://pubmed.ncbi.nlm.nih.gov/26975593/
1039,bupropion,31124380,Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects.,"['Costa R', 'Oliveira NG', 'Dinis-Oliveira RJ']","['Animals', 'Antidepressive Agents, Second-Generation/adverse effects/chemistry/pharmacokinetics/pharmacology', 'Bupropion/adverse effects/chemistry/*pharmacokinetics/*pharmacology', 'Forensic Toxicology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/31124380/
1040,bupropion,16165100,Use of bupropion in combination with serotonin reuptake inhibitors.,"['Zisook S', 'Rush AJ', 'Haight BR', 'Clines DC', 'Rockett CB']","['Bupropion/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder, Major/diagnosis/*drug therapy/psychology', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Sexual Dysfunction, Physiological/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/16165100/
1041,bupropion,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
1042,bupropion,28192104,Practical Use of Pharmacotherapy for Obesity.,"['Igel LI', 'Kumar RB', 'Saunders KH', 'Aronne LJ']","['Androgens/*therapeutic use', 'Anti-Obesity Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents/adverse effects', 'Antihypertensive Agents/adverse effects', 'Antipsychotic Agents/adverse effects', 'Appetite Depressants/therapeutic use', 'Benzazepines/therapeutic use', 'Bupropion/administration & dosage/*therapeutic use', 'Drug Combinations', 'Fructose/analogs & derivatives/therapeutic use', 'Humans', 'Hypoglycemic Agents/adverse effects', 'Hypogonadism/complications/drug therapy', 'Lactones/therapeutic use', 'Liraglutide/therapeutic use', 'Naltrexone/administration & dosage/*therapeutic use', 'Obesity/complications/*drug therapy', 'Orlistat', 'Phentermine/therapeutic use', 'Testosterone/*therapeutic use', 'Topiramate', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/28192104/
1043,bupropion,26940167,Bupropion Hydrochloride.,"['Khan SR', 'Berendt RT', 'Ellison CD', 'Ciavarella AB', 'Asafu-Adjaye E', 'Khan MA', 'Faustino PJ']","['Animals', 'Antidepressive Agents, Second-Generation/*administration & dosage/chemistry/pharmacokinetics/therapeutic use', 'Bupropion/*administration & dosage/chemistry/pharmacokinetics/therapeutic use', 'Chemistry, Pharmaceutical', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/26940167/
1044,bupropion,20202580,Pharmacologic therapies for obesity.,['Kaplan LM'],"['Anti-Obesity Agents/pharmacology/*therapeutic use', 'Appetite Depressants/administration & dosage/pharmacology/therapeutic use', 'Bariatric Surgery', 'Benzazepines/pharmacology/therapeutic use', 'Bupropion/pharmacology/therapeutic use', 'Cyclobutanes/administration & dosage/pharmacology/therapeutic use', 'Ephedrine/pharmacology/therapeutic use', 'Fenfluramine/adverse effects', 'Humans', 'Lactones/administration & dosage/pharmacology/therapeutic use', 'Naltrexone/pharmacology/therapeutic use', 'Obesity/*drug therapy', 'Orlistat', 'Phentermine/pharmacology/therapeutic use', 'Weight Gain/drug effects', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/20202580/
1045,bupropion,22860172,ACS chemical neuroscience molecule spotlight on contrave.,['Mercer SL'],"['Anti-Obesity Agents/adverse effects/pharmacology/*therapeutic use', 'Bupropion/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Double-Blind Method', 'Drug Approval', 'Drug Combinations', 'Humans', 'Naltrexone/adverse effects/pharmacology/*therapeutic use', 'Obesity/*drug therapy', 'Overweight/drug therapy', 'Randomized Controlled Trials as Topic', 'United States', 'United States Food and Drug Administration', 'Weight Loss/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22860172/
1046,bupropion,14700452,Improving antidepressant adherence.,['Nemeroff CB'],"['Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', '*Health Promotion', 'Humans', 'Paroxetine/administration & dosage/adverse effects/*therapeutic use', '*Patient Compliance', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/14700452/
1047,bupropion,1813898,Pharmacokinetics of second generation antidepressants: bupropion.,['Goodnick PJ'],"['Antidepressive Agents/*pharmacokinetics', 'Bupropion/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1813898/
1048,bupropion,26512740,Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.,"['Ali KF', 'Shukla AP', 'Aronne LJ']","['Animals', 'Anti-Obesity Agents/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Drug Approval', 'Drug Combinations', 'Humans', 'Naltrexone/administration & dosage/adverse effects/*therapeutic use', 'Obesity/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26512740/
1049,bupropion,36951340,New Combination Drug for Depression.,['Aschenbrenner DS'],"['Humans', 'Male', 'Female', 'Child', 'Young Adult', '*Depressive Disorder, Major/drug therapy', '*Dextromethorphan/adverse effects/therapeutic use', '*Bupropion/adverse effects/therapeutic use', '*Antidepressive Agents/adverse effects/therapeutic use', 'Drug Combinations']",https://pubmed.ncbi.nlm.nih.gov/36951340/
1050,bupropion,16785579,Bupropion for smoking cessation: a review.,"['Tong EK', 'Carmody TP', 'Simon JA']","['Antidepressive Agents, Second-Generation/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Nicotine/*therapeutic use', 'Secondary Prevention', 'Smoking/psychology', 'Smoking Cessation/ethnology/*methods']",https://pubmed.ncbi.nlm.nih.gov/16785579/
1051,bupropion,23408728,"A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).","['Apovian CM', 'Aronne L', 'Rubino D', 'Still C', 'Wyatt H', 'Burns C', 'Kim D', 'Dunayevich E']","['Adult', 'Anti-Obesity Agents/adverse effects/pharmacology/*therapeutic use', 'Bupropion/adverse effects/pharmacology/*therapeutic use', 'Cardiovascular Diseases/etiology/*prevention & control', 'Delayed-Action Preparations', 'Dopamine Uptake Inhibitors/adverse effects/pharmacology/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Dyslipidemias/complications', 'Feeding Behavior/drug effects', 'Female', 'Humans', 'Hypertension/complications', 'Male', 'Middle Aged', 'Naltrexone/adverse effects/pharmacology/*therapeutic use', 'Narcotic Antagonists/adverse effects/pharmacology/therapeutic use', 'Nausea/etiology', 'Obesity/complications/*drug therapy/prevention & control', 'Overweight', 'Quality of Life', 'Risk Factors', 'Weight Loss/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/23408728/
1052,bupropion,17094922,Strategies for managing antidepressant-induced sexual dysfunction: a review.,['Taylor MJ'],"['Antidepressive Agents/administration & dosage/*adverse effects', 'Bupropion/administration & dosage/adverse effects', 'Buspirone/administration & dosage/adverse effects', 'Depressive Disorder/*drug therapy', 'Erectile Dysfunction/*chemically induced/drug therapy', 'Female', 'Ginkgo biloba', 'Granisetron/administration & dosage/adverse effects', 'Humans', 'Male', 'Randomized Controlled Trials as Topic', 'Sexual Dysfunction, Physiological/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17094922/
1053,bupropion,17136226,Bupropion.,['Wilkes S'],"['Antidepressive Agents, Second-Generation/adverse effects/therapeutic use', 'Bupropion/adverse effects/*therapeutic use', 'Dizziness/chemically induced', 'Headache/chemically induced', 'Humans', 'Models, Biological', 'Nausea/chemically induced', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Smoking Cessation/methods', 'Tobacco Use Disorder/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17136226/
1054,Gatifloxacin,14743020,Pharmacologic considerations for cataract surgery.,['Tipperman R'],"['Anti-Bacterial Agents/*therapeutic use', '*Antibiotic Prophylaxis', 'Aza Compounds/pharmacology/therapeutic use', '*Cataract Extraction', 'Fluoroquinolones/pharmacology/therapeutic use', 'Gatifloxacin', 'Humans', 'Moxifloxacin', 'Ophthalmic Solutions/therapeutic use', 'Quinolines/pharmacology/therapeutic use', 'Triamcinolone Acetonide/pharmacology/therapeutic use', 'Vancomycin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14743020/
1055,Gatifloxacin,11765309,Gatifloxacin-associated acute hepatitis.,"['Henann NE', 'Zambie MF']","['Acute Disease', 'Adult', 'Anti-Infective Agents/*adverse effects', 'Chemical and Drug Induced Liver Injury/*etiology', 'Female', '*Fluoroquinolones', 'Gatifloxacin', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11765309/
1056,Gatifloxacin,17057046,Gatifloxacin-induced dysglycemia.,['Zvonar R'],"['Aged', 'Aged, 80 and over', 'Anti-Infective Agents/administration & dosage/*adverse effects/pharmacology', 'Female', 'Fluoroquinolones/administration & dosage/*adverse effects/pharmacology', 'Gatifloxacin', 'Humans', 'Hyperglycemia/*chemically induced', 'Hypoglycemia/*chemically induced', 'Male', 'United States']",https://pubmed.ncbi.nlm.nih.gov/17057046/
1057,Gatifloxacin,17304180,[Status epilepticus and gatifloxacin].,"['Koussa S', 'Hage Chahine S', 'Zoghbi A', 'Yazbeck P']","['Aged', 'Anti-Infective Agents/*adverse effects', 'Female', 'Fluoroquinolones/*adverse effects', 'Gatifloxacin', 'Humans', 'Status Epilepticus/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/17304180/
1058,Gatifloxacin,24643074,Corneal crystalline deposits associated with topically applied gatifloxacin.,"['Elia M', 'Khodadadeh S', 'Chow J']","['Administration, Topical', 'Anti-Bacterial Agents/*adverse effects', 'Cataract Extraction', 'Corneal Diseases/*chemically induced/diagnosis', 'Corneal Stroma/*drug effects/pathology', 'Crystallization', 'Endophthalmitis/prevention & control', 'Female', 'Fluoroquinolones/*adverse effects', 'Gatifloxacin', 'Humans', 'Middle Aged', 'Ophthalmic Solutions', 'Trabeculectomy']",https://pubmed.ncbi.nlm.nih.gov/24643074/
1059,Gatifloxacin,31662120,Different molecular characteristics and antimicrobial resistance profiles of Clostridium difficile in the Asia-Pacific region.,"['Luo Y', 'Cheong E', 'Bian Q', 'Collins DA', 'Ye J', 'Shin JH', 'Yam WC', 'Takata T', 'Song X', 'Wang X', 'Kamboj M', 'Gottlieb T', 'Jiang J', 'Riley TV', 'Tang YW', 'Jin D']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*pharmacology', 'Asia', 'Child', 'Child, Preschool', 'Clostridioides difficile/classification/*drug effects/genetics/isolation & purification', 'Clostridium Infections/*microbiology', 'Cross Infection/microbiology', '*Drug Resistance, Bacterial', 'Erythromycin/pharmacology', 'Female', 'Gatifloxacin/pharmacology', 'Humans', 'Infant', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', 'Phylogeny', 'Tetracycline/pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31662120/
1060,Gatifloxacin,30617959,The Role of Fluoroquinolones in the Treatment of Tuberculosis in 2019.,"['Pranger AD', 'van der Werf TS', 'Kosterink JGW', 'Alffenaar JWC']","['Antitubercular Agents/administration & dosage/adverse effects/*therapeutic use', 'Fluoroquinolones/administration & dosage/adverse effects/*therapeutic use', 'Gatifloxacin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Levofloxacin/administration & dosage/adverse effects/therapeutic use', 'Moxifloxacin/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', 'Tuberculosis, Pulmonary/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30617959/
1061,Gatifloxacin,15131460,Potential role of fluoroquinolone therapy in childhood otitis media.,"['Dagan R', 'Arguedas A', 'Schaad UB']","['Anti-Infective Agents/pharmacology/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Resistance, Microbial', 'Fluoroquinolones/pharmacology/*therapeutic use', 'Gatifloxacin', 'Haemophilus Infections/drug therapy/microbiology', 'Haemophilus influenzae/drug effects', 'Humans', 'Infant', 'Microbial Sensitivity Tests', 'Otitis Media/*drug therapy/microbiology', 'Pneumococcal Infections/drug therapy/microbiology', 'Streptococcus pneumoniae/drug effects']",https://pubmed.ncbi.nlm.nih.gov/15131460/
1062,Gatifloxacin,22873504,Moxifloxacin-induced hypoglycemia in a non-diabetic patient.,"['Mandavia DR', 'Virpariya MM', 'Patel TK', 'Tripathi CB']","['Anti-Infective Agents/*adverse effects/therapeutic use', 'Aza Compounds/*adverse effects/therapeutic use', 'Female', 'Fluoroquinolones', 'Humans', 'Hypoglycemia/*chemically induced', 'Middle Aged', 'Moxifloxacin', 'Quinolines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22873504/
1063,Gatifloxacin,11265366,What do the new antimicrobials offer? Weighing the advantages and disadvantages compared with traditional agents.,['Gleckman R'],"['Acetamides/pharmacology/*therapeutic use', 'Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Anti-Infective Agents/pharmacology/*therapeutic use', '*Aza Compounds', 'Drug Approval', 'Drug Resistance, Microbial', 'Drug Therapy, Combination/pharmacology/*therapeutic use', '*Fluoroquinolones', 'Gatifloxacin', 'Humans', 'Linezolid', 'Moxifloxacin', 'Oxazolidinones/pharmacology/*therapeutic use', 'Patient Selection', '*Quinolines', 'Treatment Outcome', 'United States', 'United States Food and Drug Administration', 'Virginiamycin/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11265366/
1064,Gatifloxacin,11405611,Microbial drug resistance and the roles of the new antibiotics.,['Longworth DL'],"['Acetamides/therapeutic use', 'Anti-Infective Agents/therapeutic use', 'Atovaquone', '*Aza Compounds', 'Drug Combinations', '*Drug Resistance, Microbial', 'Drug Therapy, Combination', 'Enterococcus/drug effects', '*Fluoroquinolones', 'Gatifloxacin', 'Humans', 'Linezolid', 'Methicillin Resistance', 'Moxifloxacin', 'Naphthoquinones/therapeutic use', 'Oxazolidinones/therapeutic use', 'Proguanil/therapeutic use', 'Pseudomonas aeruginosa/drug effects', '*Quinolines', 'Staphylococcus aureus/drug effects', 'Streptococcus pneumoniae/drug effects', 'Vancomycin/therapeutic use', 'Vancomycin Resistance', 'Virginiamycin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11405611/
1065,Gatifloxacin,10551438,Gatifloxacin.,"['Perry CM', 'Barman Balfour JA', 'Lamb HM']","['Anti-Infective Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Clinical Trials as Topic', '*Fluoroquinolones', 'Gatifloxacin', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/10551438/
1066,Gatifloxacin,15654182,Pancreatic abscess secondary to Alcaligenes faecalis.,"['Ashwath ML', 'Katner HP']","['Abscess/*microbiology/therapy', 'Adult', 'Alcaligenes faecalis/*isolation & purification', 'Anti-Bacterial Agents/therapeutic use', 'Combined Modality Therapy', 'Drainage', 'Fluoroquinolones/therapeutic use', 'Gatifloxacin', 'Gram-Negative Bacterial Infections/*microbiology/therapy', 'Humans', 'Male', 'Necrosis', 'Pancreatic Diseases/diagnosis/*microbiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/15654182/
1067,Gatifloxacin,18183859,Gatifloxacin-associated hypoglycemia.,"['Ali T', 'Greenfield RA', 'Scofield H', 'Bronze MS']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Bacterial Infections/drug therapy', 'Diabetes Mellitus, Type 2/complications', 'Fluoroquinolones/*adverse effects/therapeutic use', 'Gatifloxacin', 'Humans', 'Hypoglycemia/*chemically induced/complications', 'Male']",https://pubmed.ncbi.nlm.nih.gov/18183859/
1068,Gatifloxacin,31881243,"Profiling the interaction of Al(III)-GFLX complex, a potential pollution risk, with bovine serum albumin.","['Chen H', 'Zhu C', 'Chen F', 'Xu J', 'Jiang X', 'Wu Z', 'Ding X', 'Fan GC', 'Shen Y', 'Ye Y']","['Aluminum/chemistry/metabolism', 'Animals', 'Cattle', 'Coordination Complexes/chemistry/*metabolism', 'Environmental Pollutants/chemistry/*metabolism', 'Fluorescence', 'Gatifloxacin/*analogs & derivatives/*metabolism', 'Proof of Concept Study', 'Protein Binding', 'Protein Conformation/drug effects', 'Serum Albumin, Bovine/chemistry/*metabolism', 'Static Electricity', 'Thermodynamics']",https://pubmed.ncbi.nlm.nih.gov/31881243/
1069,Gatifloxacin,32618257,Case Report: Dynamics of Acquired Fluoroquinolone Resistance under Standardized Short-Course Treatment of Multidrug-Resistant Tuberculosis.,"['Ngabonziza JCS', 'Van Deun A', 'Migambi P', 'Niyigena EB', 'Dusabe T', 'Habimana YM', 'Ushizimpumu B', 'Mulders W', 'Decroo T', 'Affolabi D', 'Supply P', 'de Jong BC', 'Rigouts L']","['Antitubercular Agents/therapeutic use', 'Clofazimine/therapeutic use', 'Drug Resistance, Multiple, Bacterial/drug effects/genetics', 'Female', 'Fluoroquinolones/*therapeutic use', 'Gatifloxacin/therapeutic use', 'Genes, Bacterial', 'High-Throughput Nucleotide Sequencing', 'Humans', 'Kanamycin/therapeutic use', 'Microbial Sensitivity Tests', 'Middle Aged', 'Moxifloxacin/therapeutic use', 'Mycobacterium tuberculosis/*drug effects/genetics', 'Rwanda', 'Sequence Analysis, DNA', 'Tuberculosis, Multidrug-Resistant/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32618257/
1070,Gatifloxacin,16631067,Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery.,"['Moshirfar M', 'Mirzaian G', 'Feiz V', 'Kang PC']","['Adult', 'Aza Compounds/pharmacology/therapeutic use', 'Bacteria/drug effects/isolation & purification', 'Cornea/microbiology', 'Corneal Ulcer/drug therapy/*microbiology', '*Drug Resistance, Bacterial', 'Drug Therapy, Combination', 'Eye Infections, Bacterial/drug therapy/*microbiology', 'Female', 'Fluoroquinolones/pharmacology/*therapeutic use', 'Gatifloxacin', 'Humans', 'Keratomileusis, Laser In Situ', 'Keratoplasty, Penetrating', 'Lasers, Excimer', 'Microbial Sensitivity Tests', 'Moxifloxacin', 'Myopia/*surgery', 'Photorefractive Keratectomy', '*Postoperative Complications', 'Pseudomonas Infections/drug therapy/*microbiology', 'Quinolines/pharmacology/therapeutic use', 'Staphylococcal Infections/drug therapy/*microbiology']",https://pubmed.ncbi.nlm.nih.gov/16631067/
1071,Gatifloxacin,11060784,Gatifloxacin: a new fluoroquinolone.,['Blondeau JM'],"['Animals', 'Anti-Infective Agents/pharmacokinetics/*pharmacology/therapeutic use', 'Bacteria/drug effects', 'Clinical Trials as Topic', '*Fluoroquinolones', 'Gatifloxacin', 'Humans', 'Respiratory Tract Infections/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/11060784/
1072,Gatifloxacin,27142291,Human Tuberculosis. III. Current and Prospective Approaches in Anti-Tubercular Therapy.,"['Sgaragli G', 'Frosini M', 'Saponara S', 'Corelli F']","['Antitubercular Agents/chemistry/pharmacology/*therapeutic use', 'Bacterial Proteins/antagonists & inhibitors/metabolism', 'Clinical Trials as Topic', 'Fluoroquinolones/chemistry/pharmacology/therapeutic use', 'Gatifloxacin', 'Humans', 'Moxifloxacin', 'Mycobacterium tuberculosis/drug effects/metabolism', 'Prospective Studies', 'Tuberculosis/*drug therapy', 'Tuberculosis, Multidrug-Resistant/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27142291/
1073,Gatifloxacin,20409374,"Multihospital outbreak of Clostridium difficile infection, Cleveland, Ohio, USA.","['Jump RL', 'Riggs MM', 'Sethi AK', 'Pultz MJ', 'Ellis-Reid T', 'Riebel W', 'Gerding DN', 'Salata RA', 'Donskey CJ']","['Anti-Infective Agents/therapeutic use', 'Aza Compounds/therapeutic use', 'Clostridioides difficile/drug effects/genetics/*isolation & purification', 'Clostridium Infections/drug therapy/*epidemiology/microbiology', 'Cross Infection/drug therapy/*epidemiology/microbiology', '*Disease Outbreaks', 'Drug Resistance, Bacterial', 'Feces/microbiology', 'Fluoroquinolones/therapeutic use', 'Gatifloxacin', 'Genes, Bacterial', '*Hospitals', 'Humans', 'Moxifloxacin', 'Ohio/epidemiology', 'Quinolines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20409374/
1074,raloxifene,34002830,"Osteoporosis - risk factors, pharmaceutical and non-pharmaceutical treatment.","['Tanski W', 'Kosiorowska J', 'Szymanska-Chabowska A']","['Cholecalciferol/administration & dosage/therapeutic use', 'Denosumab/administration & dosage/therapeutic use', 'Dietary Supplements', 'Diphosphonates/administration & dosage/therapeutic use', '*Exercise', 'Humans', '*Kinesiology, Applied', 'Osteoporosis/*therapy', 'Raloxifene Hydrochloride/administration & dosage/therapeutic use', 'Risk Factors', 'Teriparatide/administration & dosage/therapeutic use', 'Thiophenes/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34002830/
1075,raloxifene,38251461,Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses.,"['Zhang N', 'Li Y', 'Sundquist J', 'Sundquist K', 'Ji J']","['Humans', 'Female', '*Breast Neoplasms/drug therapy/genetics', 'Case-Control Studies', 'Genome-Wide Association Study', 'Mendelian Randomization Analysis', 'Nitrofurantoin', 'Raloxifene Hydrochloride/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38251461/
1076,raloxifene,29676942,Pharmacotherapy for schizophrenia in postmenopausal women.,"['Gonzalez-Rodriguez A', 'Seeman MV']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Female', 'Humans', 'Phytoestrogens/therapeutic use', 'Postmenopause', 'Raloxifene Hydrochloride/adverse effects/therapeutic use', 'Receptors, Estrogen/metabolism', 'Schizophrenia/*drug therapy', 'Venous Thromboembolism/etiology']",https://pubmed.ncbi.nlm.nih.gov/29676942/
1077,raloxifene,25432354,Efficacy and safety of currently marketed anti-osteoporosis medications.,"['Reginster JY', 'Neuprez A', 'Dardenne N', 'Beaudart C', 'Emonts P', 'Bruyere O']","['*Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/pharmacology', '*Bone Density Conservation Agents/administration & dosage/adverse effects/pharmacology', 'Denosumab', '*Diphosphonates/administration & dosage/adverse effects/pharmacology', 'Humans', '*Indoles/administration & dosage/adverse effects/pharmacology', 'Osteoporosis/*drug therapy', '*Parathyroid Hormone/administration & dosage/adverse effects/pharmacology', '*Raloxifene Hydrochloride/administration & dosage/adverse effects/pharmacology', '*Selective Estrogen Receptor Modulators/administration & dosage/adverse effects/pharmacology', '*Thiophenes/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25432354/
1078,raloxifene,15012972,Progress in chemoprevention of breast cancer.,"['Serrano D', 'Perego E', 'Costa A', 'Decensi A']","['Aromatase Inhibitors', 'Breast Neoplasms/*drug therapy', 'Chemoprevention/methods/*trends', 'Female', 'Fenretinide/therapeutic use', 'Hormone Replacement Therapy', 'Humans', 'Raloxifene Hydrochloride/therapeutic use', 'Receptors, Estrogen/analysis', 'Tamoxifen/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15012972/
1079,raloxifene,32121307,Distinct Approaches of Raloxifene: Its Far-Reaching Beneficial Effects Implicating the HO-System.,"['Borzsei D', 'Szabo R', 'Hoffmann A', 'Veszelka M', 'Pavo I', 'Turcsan Z', 'Viczian C', 'Kupai K', 'Varga C', 'Posa A']","['Antioxidants/*metabolism', 'Female', 'Gene Expression Regulation, Enzymologic/*drug effects', 'Heme Oxygenase (Decyclizing)/*biosynthesis', 'Humans', 'Raloxifene Hydrochloride/*therapeutic use', 'Selective Estrogen Receptor Modulators/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32121307/
1080,raloxifene,11732640,Raloxifene.,['Kellen JA'],"['Breast Neoplasms/*drug therapy/prevention & control', 'Clinical Trials as Topic', 'Drugs, Investigational', 'Endometrium/drug effects', 'Female', 'Humans', 'Lipoproteins/blood/drug effects', 'Osteoporosis/prevention & control', 'Ovulation/drug effects', 'Raloxifene Hydrochloride/adverse effects/*pharmacology/therapeutic use', 'Receptors, Estrogen/metabolism', 'Selective Estrogen Receptor Modulators/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11732640/
1081,raloxifene,11795366,Raloxifene: risks and benefits.,['Barrett-Connor E'],"['Breast Neoplasms/*drug therapy/prevention & control', 'Endometrial Neoplasms/chemically induced', 'Endometrium/drug effects', 'Female', 'Hot Flashes/chemically induced', 'Humans', 'Morbidity', 'Osteoporosis, Postmenopausal/*drug therapy/epidemiology/prevention & control', 'Raloxifene Hydrochloride/adverse effects/*therapeutic use', 'Risk Assessment', 'Selective Estrogen Receptor Modulators/adverse effects/*therapeutic use', 'Thromboembolism/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11795366/
1082,raloxifene,29303860,Mandibular Osteonecrosis Associated With Raloxifene.,"['Pontes HAR', 'Souza LL', 'Uchoa DCC', 'Cerqueira JMM']","['Bone Density Conservation Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Mandibular Diseases/*chemically induced/complications', 'Middle Aged', 'Osteonecrosis/*chemically induced/complications', 'Osteoporosis/complications/drug therapy', 'Raloxifene Hydrochloride/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29303860/
1083,raloxifene,11281162,Raloxifene.,['Seeman E'],"['Animals', 'Estrogen Antagonists/adverse effects/chemistry/*pharmacology', 'Humans', 'Raloxifene Hydrochloride/adverse effects/chemistry/*pharmacology', 'Selective Estrogen Receptor Modulators/adverse effects/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11281162/
1084,raloxifene,11815274,Selective estrogen receptor modulators (SERMS) and their roles in breast cancer prevention.,"['Park WC', 'Jordan VC']","['Animals', 'Breast Neoplasms/drug therapy/*metabolism/*prevention & control', 'Clinical Trials as Topic', 'Female', 'Humans', 'Osteoporosis/prevention & control', 'Raloxifene Hydrochloride/chemistry/pharmacology/therapeutic use', 'Receptors, Estrogen/metabolism', 'Selective Estrogen Receptor Modulators/chemistry/metabolism/*pharmacology/*therapeutic use', 'Tamoxifen/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11815274/
1085,raloxifene,15050912,Selective estrogen receptor modulation: concept and consequences in cancer.,['Jordan VC'],"['Apoptosis/physiology', 'Breast Neoplasms/drug therapy/*metabolism', 'Dimerization', 'Drug Resistance', 'Endometrial Neoplasms/drug therapy/metabolism', 'Estrogen Antagonists', 'Estrogen Receptor Modulators/metabolism/*pharmacology', 'Estrogen Replacement Therapy', 'Estrogens/*metabolism', 'Female', 'Hot Flashes/chemically induced', 'Humans', 'Osteoporosis/chemically induced', 'Protein Binding', 'Protein Conformation', 'Protein Interaction Mapping', 'Raloxifene Hydrochloride/adverse effects/pharmacology', 'Receptors, Estrogen/antagonists & inhibitors/*metabolism', 'Signal Transduction', 'Tamoxifen/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15050912/
1086,raloxifene,32406536,Osteoporosis Management in the Era of COVID-19.,"['Yu EW', 'Tsourdi E', 'Clarke BL', 'Bauer DC', 'Drake MT']","['Absorptiometry, Photon', 'Biomarkers/blood', 'Bone Density', 'Bone Density Conservation Agents/administration & dosage/adverse effects/therapeutic use', 'COVID-19', 'Continuity of Patient Care', '*Coronavirus Infections/blood/complications', 'Denosumab/adverse effects/therapeutic use', 'Disease Management', 'Drug Administration Schedule', 'Estrogen Replacement Therapy/adverse effects', 'Fractures, Spontaneous/prevention & control/therapy', 'Home Care Services', 'Humans', 'Immunosuppression Therapy/adverse effects', 'Osteoporosis/blood/diagnostic imaging/drug therapy/*therapy', '*Pandemics', '*Pneumonia, Viral/blood/complications', 'Raloxifene Hydrochloride/adverse effects/therapeutic use', 'Recurrence', 'Telemedicine', 'Thrombophilia/chemically induced/etiology', 'Unnecessary Procedures']",https://pubmed.ncbi.nlm.nih.gov/32406536/
1087,raloxifene,26852151,[Hormonotherapy for breast cancer prevention: What about women with genetic predisposition to breast cancer?].,"['Senechal C', 'Reyal F', 'Callet N', 'This P', 'Nogues C', 'Stoppa-Lyonnet D', 'Fourme E']","['Anastrozole', 'Androstadienes/adverse effects/therapeutic use', 'Aromatase Inhibitors/adverse effects/therapeutic use', 'Breast Neoplasms/*genetics/*prevention & control', 'Endometrial Neoplasms/chemically induced', 'Female', '*Genes, BRCA1', '*Genes, BRCA2', 'Genetic Predisposition to Disease', 'Humans', 'Mastectomy', '*Mutation', 'Nitriles/adverse effects/therapeutic use', 'Prophylactic Surgical Procedures', 'Raloxifene Hydrochloride/adverse effects/therapeutic use', 'Tamoxifen/adverse effects/therapeutic use', 'Triazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26852151/
1088,raloxifene,10680024,Selective estrogen receptor modulators--a new age of estrogens in cardiovascular disease?,['Guzzo JA'],"['Adult', 'Cardiovascular Diseases/drug therapy/*prevention & control', 'Estrogen Replacement Therapy/adverse effects/*trends', 'Female', 'Humans', 'Raloxifene Hydrochloride/therapeutic use', 'Selective Estrogen Receptor Modulators/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10680024/
1089,raloxifene,25280036,Novel hydroxyapatite biomaterial covalently linked to raloxifene.,"['Meme L', 'Santarelli A', 'Marzo G', 'Emanuelli M', 'Nocini PF', 'Bertossi D', 'Putignano A', 'Dioguardi M', 'Lo Muzio L', 'Bambini F']","['Biocompatible Materials/*chemistry', 'Cell Survival', 'Durapatite/*chemistry', 'Humans', 'Microscopy, Electron, Scanning', 'Osteoblasts/drug effects', 'Raloxifene Hydrochloride/*chemistry/pharmacology', 'Spectroscopy, Fourier Transform Infrared']",https://pubmed.ncbi.nlm.nih.gov/25280036/
1090,raloxifene,17107283,Prevention of breast cancer: current state of the science and future opportunities.,"['Uray IP', 'Brown PH']","['Adenocarcinoma/prevention & control', 'Adult', 'Aged', 'Animals', 'Antineoplastic Agents, Hormonal/pharmacology/therapeutic use', 'Aromatase Inhibitors/pharmacology/*therapeutic use', 'Breast Neoplasms/drug therapy/*prevention & control', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use', 'Double-Blind Method', 'Drug Evaluation, Preclinical', 'Drug Therapy, Combination', 'Estrogen Receptor Modulators/pharmacology/therapeutic use', 'Estrogens/physiology', 'Female', 'Forecasting', 'Humans', 'Leuprolide/therapeutic use', 'Mammary Neoplasms, Experimental/drug therapy/prevention & control', 'Mice', 'Middle Aged', 'Ovariectomy', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Protein-Tyrosine Kinases/antagonists & inhibitors', 'Raloxifene Hydrochloride/adverse effects/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Rats', 'Retinoids/pharmacology/therapeutic use', 'Selective Estrogen Receptor Modulators/adverse effects/pharmacology/*therapeutic use', 'Tamoxifen/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17107283/
1091,raloxifene,22873502,Hypocalcemia induced by raloxifene.,"['Vu TD', 'Varadarajan S', 'Seeman E', 'Jerums G', 'MacIsaac RJ']","['Aged, 80 and over', 'Bone Density Conservation Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Hypocalcemia/*chemically induced', 'Mass Screening/methods', 'Osteoporosis, Postmenopausal/drug therapy', 'Raloxifene Hydrochloride/*adverse effects/therapeutic use', 'Vitamin D Deficiency/complications/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/22873502/
1092,raloxifene,26759040,Bone strength: more than just bone density.,['Ott SM'],"['Animals', '*Bone Density', 'Bone Density Conservation Agents/therapeutic use', 'Bone and Bones', 'Humans', 'Osteoporosis/*drug therapy', 'Raloxifene Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26759040/
1093,raloxifene,12371603,The effects of estrogen replacement therapy on neuropsychological functioning in postmenopausal women with and without dementia: a critical and theoretical review.,"['Zec RF', 'Trivedi MA']","['Aging/psychology', 'Alzheimer Disease/genetics/prevention & control/psychology', 'Apolipoprotein E4', 'Apolipoproteins E/genetics', 'Brain/drug effects/physiology', 'Cognition/*drug effects', 'Dementia/*prevention & control/psychology', '*Estrogen Replacement Therapy/adverse effects', 'Female', 'Humans', 'Memory/*drug effects', 'Neuropsychological Tests', '*Postmenopause', 'Raloxifene Hydrochloride/therapeutic use', 'Randomized Controlled Trials as Topic', 'Selective Estrogen Receptor Modulators/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12371603/
1094,celecoxib,36053397,Efficacy and Safety of NSAIDs in Infants: A Comprehensive Review of the Literature of the Past 20 Years.,"['Ziesenitz VC', 'Welzel T', 'van Dyk M', 'Saur P', 'Gorenflo M', 'van den Anker JN']","['Adolescent', 'Infant', 'Child', 'Humans', 'Meloxicam', 'Naproxen/therapeutic use', 'Celecoxib/adverse effects', 'Ibuprofen', '*Ketoprofen', 'Diclofenac', 'Ketorolac', '*Flurbiprofen', 'Niflumic Acid', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Aspirin/adverse effects', 'Anti-Inflammatory Agents', 'Chronic Disease', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36053397/
1095,celecoxib,30073924,Celecoxib in Cancer Therapy and Prevention - Review.,"['Toloczko-Iwaniuk N', 'Dziemianczyk-Pakiela D', 'Nowaszewska BK', 'Celinska-Janowicz K', 'Miltyk W']","['Animals', 'Apoptosis/drug effects', 'Celecoxib/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasms/*drug therapy/epidemiology/prevention & control', 'Precancerous Conditions/*drug therapy/enzymology', 'Treatment Outcome', 'Tumor Microenvironment/drug effects']",https://pubmed.ncbi.nlm.nih.gov/30073924/
1096,celecoxib,36106817,Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.,"['Salomon-Zimri S', 'Pushett A', 'Russek-Blum N', 'Van Eijk RPA', 'Birman N', 'Abramovich B', 'Eitan E', 'Elgrart K', 'Beaulieu D', 'Ennist DL', 'Berry JD', 'Paganoni S', 'Shefner JM', 'Drory VE']","['Humans', '*Amyotrophic Lateral Sclerosis/diagnosis/drug therapy', 'Biomarkers', 'Celecoxib/therapeutic use', '*COVID-19', 'Disease Progression', 'DNA-Binding Proteins', 'Double-Blind Method', '*Neurodegenerative Diseases', 'Ciprofloxacin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36106817/
1097,celecoxib,35655045,Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials.,"['Pandy JGP', 'Franco PIG', 'Li RK']","['Humans', '*Hand-Foot Syndrome/etiology/prevention & control/drug therapy', 'Capecitabine/adverse effects', 'Sorafenib/therapeutic use', 'Pyridoxine/therapeutic use', 'Celecoxib/therapeutic use', 'Randomized Controlled Trials as Topic', '*Neoplasms/drug therapy/complications']",https://pubmed.ncbi.nlm.nih.gov/35655045/
1098,celecoxib,34376069,Gastrointestinal and cardiovascular adverse events associated with NSAIDs.,"['Domper Arnal MJ', 'Hijos-Mallada G', 'Lanas A']","['Aged', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Celecoxib/adverse effects', '*Cyclooxygenase 2 Inhibitors/adverse effects', '*Gastrointestinal Diseases/drug therapy', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/34376069/
1099,celecoxib,35277974,Etoricoxib and celecoxib sensitive indomethacin-responsive headache disorders.,"['Farag M', 'Bahra A']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology', 'Celecoxib/adverse effects', 'Etoricoxib/therapeutic use', 'Headache/chemically induced/drug therapy', '*Headache Disorders/drug therapy', 'Humans', '*Indomethacin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35277974/
1100,celecoxib,30240679,Fixed-Dose Combination Amlodipine/Celecoxib (Consensi) for Hypertension and Osteoarthritis.,"['Smith SM', 'Cooper-DeHoff RM']","['Amlodipine/administration & dosage/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Antihypertensive Agents/administration & dosage/therapeutic use', 'Celecoxib/administration & dosage/*therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Osteoarthritis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30240679/
1101,celecoxib,32296574,COX-2 as a potential biomarker and therapeutic target in melanoma.,"['Tudor DV', 'Baldea I', 'Lupu M', 'Kacso T', 'Kutasi E', 'Hopartean A', 'Stretea R', 'Gabriela Filip A']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/pharmacology/therapeutic use', 'Biomarkers, Tumor/*analysis/metabolism', 'Celecoxib/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase 2/*analysis/metabolism', 'Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use', 'Disease Models, Animal', 'Disease Progression', 'Humans', 'Melanoma/drug therapy/immunology/*mortality/pathology', 'Molecular Targeted Therapy/methods', 'Prognosis', 'Progression-Free Survival', 'Signal Transduction/drug effects/immunology', 'Skin/immunology/pathology', 'Skin Neoplasms/drug therapy/immunology/*mortality/pathology', 'Tumor Escape/drug effects', 'Tumor Microenvironment/drug effects/immunology']",https://pubmed.ncbi.nlm.nih.gov/32296574/
1102,celecoxib,36890655,Modulation effects of different treatments on periaqueductal gray resting state functional connectivity in knee osteoarthritis knee pain patients.,"['Zhou J', 'Zeng F', 'Cheng S', 'Dong X', 'Jiang N', 'Zhang X', 'Tang C', 'He W', 'Chen Y', 'Sun N', 'Zhou Y', 'Li X', 'Hu S', 'Sun R', 'Wintermark M', 'Yang W', 'Liang F', 'Li Z']","['Humans', '*Osteoarthritis, Knee/diagnostic imaging/drug therapy', 'Periaqueductal Gray/diagnostic imaging', 'Celecoxib/pharmacology/therapeutic use', 'Capsules', 'Pain/complications', '*Acupuncture Therapy', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Magnetic Resonance Imaging']",https://pubmed.ncbi.nlm.nih.gov/36890655/
1103,celecoxib,33783231,Repurposing celecoxib analogues as leads for antibiotics.,"['Yang B', 'Mei Y', 'Li Q', 'Zhang M', 'Tang H', 'Liu T', 'Feng F', 'Fu Q', 'Jiang Y', 'Ye Q']","['Acinetobacter baumannii/*drug effects/growth & development', 'Animals', 'Anti-Bacterial Agents/chemical synthesis/chemistry/*pharmacology', 'Celecoxib/chemical synthesis/chemistry/*pharmacology', 'Cell Survival/drug effects', 'Female', 'Hep G2 Cells', 'Humans', 'Mice', 'Mice, Inbred ICR', 'Microbial Sensitivity Tests', 'Molecular Structure', 'Staphylococcus aureus/*drug effects/growth & development']",https://pubmed.ncbi.nlm.nih.gov/33783231/
1104,celecoxib,33821899,Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.,"['Meyerhardt JA', 'Shi Q', 'Fuchs CS', 'Meyer J', 'Niedzwiecki D', 'Zemla T', 'Kumthekar P', 'Guthrie KA', 'Couture F', 'Kuebler P', 'Bendell JC', 'Kumar P', 'Lewis D', 'Tan B', 'Bertagnolli M', 'Grothey A', 'Hochster HS', 'Goldberg RM', 'Venook A', 'Blanke C', ""O'Reilly EM"", 'Shields AF']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Celecoxib/adverse effects/*therapeutic use', '*Chemotherapy, Adjuvant', 'Colonic Neoplasms/*drug therapy/surgery', 'Cyclooxygenase 2 Inhibitors/adverse effects/*therapeutic use', 'Disease-Free Survival', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neoplasm Recurrence, Local/epidemiology/prevention & control', 'Neoplasm Staging', 'Patient Compliance', 'Proportional Hazards Models', 'Secondary Prevention', 'Survival Rate', 'Treatment Failure', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33821899/
1105,celecoxib,26520197,[Gastrointestinal bleeding].,['Lanas A'],"['Anemia/etiology/therapy', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Anticoagulants/adverse effects/therapeutic use', 'Aspirin/adverse effects/therapeutic use', 'Blood Transfusion', 'Celecoxib/therapeutic use', 'Drug Therapy, Combination', 'Endoscopy, Gastrointestinal', '*Gastrointestinal Hemorrhage/etiology/therapy', 'Hemorrhagic Disorders/chemically induced', 'Hemostatic Techniques', 'Humans', 'Ligation', 'Platelet Aggregation Inhibitors/adverse effects/therapeutic use', 'Proton Pump Inhibitors/therapeutic use', 'Randomized Controlled Trials as Topic', 'Recurrence', 'Thrombophilia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26520197/
1106,celecoxib,32615181,MicroRNAs in the anticancer effects of celecoxib: A systematic review.,"['Mishan MA', 'Khazeei Tabari MA', 'Zargari M', 'Bagheri A']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antineoplastic Agents/*therapeutic use', 'Celecoxib/*therapeutic use', 'Humans', '*MicroRNAs', 'Neoplasms/*drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/32615181/
1107,celecoxib,37749237,Rosmarinic acid in combination with ginsenoside Rg1 suppresses colon cancer metastasis via co-inhition of COX-2 and PD1/PD-L1 signaling axis.,"['Liu H', 'Deng R', 'Zhu CW', 'Han HK', 'Zong GF', 'Ren L', 'Cheng P', 'Wei ZH', 'Zhao Y', 'Yu SY', 'Lu Y']","['Humans', 'Animals', 'Mice', 'B7-H1 Antigen/metabolism', 'Cyclooxygenase 2/metabolism', 'Rosmarinic Acid', 'Celecoxib/pharmacology/therapeutic use', 'Cyclooxygenase 2 Inhibitors/pharmacology/therapeutic use', 'Immune Checkpoint Inhibitors/therapeutic use', 'Programmed Cell Death 1 Receptor/metabolism', 'Cell Line, Tumor', '*Colonic Neoplasms/drug therapy/metabolism', '*Lung Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37749237/
1108,celecoxib,37739445,Angioedema without urticaria after recent initiation of celecoxib.,"['Jasti VV', 'Anderson J', 'Abdujelil I']","['Humans', 'Celecoxib/adverse effects', '*Urticaria/chemically induced', '*Angioedema/chemically induced', 'Skin', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37739445/
1109,celecoxib,27524864,Celecoxib Adjunctive Treatment to Antipsychotics in Schizophrenia: A Review of Randomized Clinical Add-On Trials.,"['Marini S', 'De Berardis D', 'Vellante F', 'Santacroce R', 'Orsolini L', 'Valchera A', 'Girinelli G', 'Carano A', 'Fornaro M', 'Gambi F', 'Martinotti G', 'Di Giannantonio M']","['Antipsychotic Agents/*therapeutic use', 'Celecoxib/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27524864/
1110,celecoxib,14519044,Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.,"['West PM', 'Fernandez C']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Aspirin/administration & dosage/*adverse effects', 'Asthma/*chemically induced/drug therapy/*prevention & control', 'Celecoxib', 'Cyclooxygenase 2', 'Drug Hypersensitivity/complications/*etiology', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/administration & dosage/pharmacokinetics/therapeutic use', 'Membrane Proteins', 'Meta-Analysis as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/administration & dosage/pharmacokinetics/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/14519044/
1111,celecoxib,36964012,Quality of recovery after pericapsular nerve group (PENG) block for primary total hip arthroplasty under spinal anaesthesia: a randomised controlled observer-blinded trial.,"['Kukreja P', 'Uppal V', 'Kofskey AM', 'Feinstein J', 'Northern T', 'Davis C', 'Morgan CJ', 'Kalagara H']","['Humans', '*Anesthesia, Spinal/methods', 'Anesthetics, Local/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Acetaminophen/therapeutic use', 'Femoral Nerve', '*Arthroplasty, Replacement, Hip/adverse effects', 'Celecoxib/therapeutic use', 'Pain, Postoperative/prevention & control/etiology']",https://pubmed.ncbi.nlm.nih.gov/36964012/
1112,celecoxib,25589511,"Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib.","['Hochberg MC', 'Martel-Pelletier J', 'Monfort J', 'Moller I', 'Castillo JR', 'Arden N', 'Berenbaum F', 'Blanco FJ', 'Conaghan PG', 'Domenech G', 'Henrotin Y', 'Pap T', 'Richette P', 'Sawitzke A', 'du Souich P', 'Pelletier JP']","['Aged', 'Celecoxib/*therapeutic use', 'Chondroitin Sulfates/adverse effects/*therapeutic use', 'Cyclooxygenase 2 Inhibitors/*therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Edema/*etiology', 'Female', 'Glucosamine/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Musculoskeletal Pain/drug therapy/etiology', 'Osteoarthritis, Knee/complications/*drug therapy/physiopathology', 'Pain Measurement', 'Quality of Life', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25589511/
1113,celecoxib,28530031,Celecoxib for osteoarthritis.,"['Puljak L', 'Marin A', 'Vrdoljak D', 'Markotic F', 'Utrobicic A', 'Tugwell P']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Celecoxib/adverse effects/*therapeutic use', 'Diclofenac/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Naproxen/therapeutic use', 'Osteoarthritis, Hip/*drug therapy', 'Osteoarthritis, Knee/*drug therapy', 'Pain Measurement/methods', 'Placebos/adverse effects/therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28530031/
1114,Gefitinib,33466795,Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury.,"['Ohmori T', 'Yamaoka T', 'Ando K', 'Kusumoto S', 'Kishino Y', 'Manabe R', 'Sagara H']","['Acrylamides/adverse effects/therapeutic use', 'Afatinib/adverse effects/therapeutic use', 'Aniline Compounds/adverse effects/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'ErbB Receptors/*antagonists & inhibitors/genetics', 'Gefitinib/adverse effects/therapeutic use', 'Humans', 'Lung Diseases, Interstitial/chemically induced/*diagnosis', 'Lung Injury/chemically induced/*diagnosis', 'Lung Neoplasms/*drug therapy/genetics', 'Mutation', 'Protein Kinase Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33466795/
1115,Gefitinib,32778129,FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.,"['Sun C', 'Gao W', 'Liu J', 'Cheng H', 'Hao J']","['A549 Cells', 'Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Apoptosis/drug effects/physiology', 'Carcinoma, Non-Small-Cell Lung/drug therapy/*metabolism/pathology', 'Cell Survival/drug effects/physiology', 'Drug Resistance, Neoplasm/drug effects/*physiology', 'Fibrinogen/antagonists & inhibitors/*biosynthesis', 'Gefitinib/pharmacology/*therapeutic use', 'Humans', 'Lung Neoplasms/drug therapy/*metabolism/pathology', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Xenograft Model Antitumor Assays/methods']",https://pubmed.ncbi.nlm.nih.gov/32778129/
1116,Gefitinib,29978332,Metastatic and triple-negative breast cancer: challenges and treatment options.,"['Al-Mahmood S', 'Sapiezynski J', 'Garbuzenko OB', 'Minko T']","['Animals', 'Biomarkers, Tumor/*metabolism', 'Clinical Trials as Topic', 'Combined Modality Therapy/*methods', 'ErbB Receptors/antagonists & inhibitors', 'Female', 'Gefitinib/therapeutic use', 'Genetic Therapy', 'Humans', 'Neoplasm Metastasis', 'Prognosis', 'RNA, Small Interfering/administration & dosage', 'Triple Negative Breast Neoplasms/metabolism/*therapy']",https://pubmed.ncbi.nlm.nih.gov/29978332/
1117,Gefitinib,31411950,Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR-Mutated Lung Cancer.,"['Noronha V', 'Patil VM', 'Joshi A', 'Menon N', 'Chougule A', 'Mahajan A', 'Janu A', 'Purandare N', 'Kumar R', 'More S', 'Goud S', 'Kadam N', 'Daware N', 'Bhattacharjee A', 'Shah S', 'Yadav A', 'Trivedi V', 'Behel V', 'Dutt A', 'Banavali SD', 'Prabhash K']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics', 'ErbB Receptors/antagonists & inhibitors/genetics', 'Female', 'Gefitinib/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/enzymology/genetics', 'Male', 'Middle Aged', 'Mutation', 'Pemetrexed/administration & dosage/adverse effects', 'Progression-Free Survival', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/31411950/
1118,Gefitinib,21119248,Geftinib.,"['Gupta A', 'Raina V']","['Antineoplastic Agents/adverse effects/pharmacology/*therapeutic use', 'ErbB Receptors/genetics', 'Gefitinib', 'Humans', 'Mutation', 'Neoplasms/*drug therapy/ethnology', 'Quinazolines/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21119248/
1119,Gefitinib,35960896,Updated Analysis of NEJ009: Gefitinib-Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated EGFR.,"['Miyauchi E', 'Morita S', 'Nakamura A', 'Hosomi Y', 'Watanabe K', 'Ikeda S', 'Seike M', 'Fujita Y', 'Minato K', 'Ko R', 'Harada T', 'Hagiwara K', 'Kobayashi K', 'Nukiwa T', 'Inoue A']","['Humans', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'Gefitinib/therapeutic use', 'Pemetrexed', '*Lung Neoplasms/drug therapy/genetics', 'Protein Kinase Inhibitors/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'ErbB Receptors/genetics', 'Mutation']",https://pubmed.ncbi.nlm.nih.gov/35960896/
1120,Gefitinib,36738759,"Combination of gefitinib and methotrexate to treat tubal ectopic pregnancy (GEM3): a multicentre, randomised, double-blind, placebo-controlled trial.","['Horne AW', 'Tong S', 'Moakes CA', 'Middleton LJ', 'Duncan WC', 'Mol BW', 'Whitaker LHR', 'Jurkovic D', 'Coomarasamy A', 'Nunes N', 'Holland T', 'Clarke F', 'Doust AM', 'Daniels JP']","['Pregnancy', 'Female', 'Humans', '*Methotrexate', 'Gefitinib/therapeutic use', '*Pregnancy, Ectopic/chemically induced/drug therapy', 'Proportional Hazards Models', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/36738759/
1121,Gefitinib,24794908,Gefitinib.,"['Rahman AF', 'Korashy HM', 'Kassem MG']","['Animals', 'Antineoplastic Agents/*analysis/*chemistry/pharmacokinetics/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/drug therapy/metabolism', 'Chemistry, Pharmaceutical', 'Drug Resistance, Neoplasm', 'ErbB Receptors/antagonists & inhibitors', 'Gefitinib', 'Humans', 'Lung Neoplasms/drug therapy/metabolism', 'Quinazolines/*analysis/*chemistry/pharmacokinetics/therapeutic use', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/24794908/
1122,Gefitinib,33332190,Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial.,"['Zhong WZ', 'Wang Q', 'Mao WM', 'Xu ST', 'Wu L', 'Wei YC', 'Liu YY', 'Chen C', 'Cheng Y', 'Yin R', 'Yang F', 'Ren SX', 'Li XF', 'Li J', 'Huang C', 'Liu ZD', 'Xu S', 'Chen KN', 'Xu SD', 'Liu LX', 'Yu P', 'Wang BH', 'Ma HT', 'Yang JJ', 'Yan HH', 'Yang XN', 'Liu SY', 'Zhou Q', 'Wu YL']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics/mortality/pathology', 'Chemotherapy, Adjuvant', 'China', 'Cisplatin/adverse effects/*therapeutic use', 'Disease-Free Survival', 'ErbB Receptors/genetics', 'Female', 'Gefitinib/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/genetics/mortality/pathology', 'Male', 'Middle Aged', '*Mutation', 'Neoplasm Staging', 'Time Factors', 'Vinorelbine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33332190/
1123,Gefitinib,37392558,Elevated NOX4 promotes tumorigenesis and acquired EGFR-TKIs resistance via enhancing IL-8/PD-L1 signaling in NSCLC.,"['Liu WJ', 'Wang L', 'Zhou FM', 'Liu SW', 'Wang W', 'Zhao EJ', 'Yao QJ', 'Li W', 'Zhao YQ', 'Shi Z', 'Qiu JG', 'Jiang BH']","['Humans', 'Carcinogenesis', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm/genetics', 'ErbB Receptors', 'Gefitinib/pharmacology/therapeutic use', 'Interleukin-8/genetics', '*Lung Neoplasms/drug therapy/genetics', 'Mutation', 'NADPH Oxidase 4/genetics', '*Tyrosine Kinase Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37392558/
1124,Gefitinib,34707044,Rhabdomyolysis Caused by Gefitinib Overdose.,"['Obayashi S', 'Tomomatsu K', 'Urata M', 'Tanaka J', 'Niimi K', 'Hayama N', 'Oguma T', 'Asano K', 'Ito Y']","['*Antineoplastic Agents/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy', 'ErbB Receptors/genetics', 'Gefitinib/adverse effects', 'Humans', '*Lung Neoplasms/drug therapy', 'Mutation', 'Protein Kinase Inhibitors/therapeutic use', 'Quinazolines/adverse effects', '*Rhabdomyolysis/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34707044/
1125,Gefitinib,37463108,NAT10-mediated ac4C tRNA modification promotes EGFR mRNA translation and gefitinib resistance in cancer.,"['Wei W', 'Zhang S', 'Han H', 'Wang X', 'Zheng S', 'Wang Z', 'Yang C', 'Wang L', 'Ma J', 'Guo S', 'Wang J', 'Liu L', 'Choe J', 'Lin S']","['Animals', 'Mice', 'ErbB Receptors/genetics', 'Gefitinib/pharmacology/therapeutic use', '*Neoplasms', 'Protein Biosynthesis', '*RNA, Transfer/genetics', 'Humans', 'Cell Line, Tumor', '*N-Terminal Acetyltransferases/genetics', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/37463108/
1126,Gefitinib,37146936,Reprogramming of TAMs via the STAT3/CD47-SIRPalpha axis promotes acquired resistance to EGFR-TKIs in lung cancer.,"['Lu J', 'Li J', 'Lin Z', 'Li H', 'Lou L', 'Ding W', 'Ouyang S', 'Wu Y', 'Wen Y', 'Chen X', 'Yue P', 'Wang Y', 'Liu P', 'Lu J', 'Zhang J', 'Feng W', 'Zhang X']","['Humans', 'Gefitinib/pharmacology/therapeutic use', '*ErbB Receptors/metabolism', 'Tumor-Associated Macrophages/metabolism', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', 'Cell Line, Tumor', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Tumor Microenvironment', 'STAT3 Transcription Factor/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37146936/
1127,Gefitinib,36753281,"Gefitinib Plus Chemotherapy vs Gefitinib Alone in Untreated EGFR-Mutant Non-Small Cell Lung Cancer in Patients With Brain Metastases: The GAP BRAIN Open-Label, Randomized, Multicenter, Phase 3 Study.","['Hou X', 'Li M', 'Wu G', 'Feng W', 'Su J', 'Jiang H', 'Jiang G', 'Chen J', 'Zhang B', 'You Z', 'Liu Q', 'Chen L']","['Female', 'Humans', 'Male', 'Middle Aged', '*Brain Neoplasms/drug therapy/genetics', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'ErbB Receptors/genetics', '*Gefitinib/therapeutic use/adverse effects', '*Lung Neoplasms/drug therapy/genetics', 'Prospective Studies', 'Protein Kinase Inhibitors', 'Adult', 'Aged', 'Aged, 80 and over']",https://pubmed.ncbi.nlm.nih.gov/36753281/
1128,Gefitinib,34118816,Gefitinib-associated lichen planus pigmentosus-like eruption.,"['Chuenwipasakul D', 'Wititsuwannakul J', 'Asawanonda P', 'Rerknimitr P']","['Antineoplastic Agents/*adverse effects/therapeutic use', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'Drug Eruptions/*etiology', 'Female', 'Gefitinib/*adverse effects/therapeutic use', 'Humans', 'Hyperpigmentation/*chemically induced', 'Lichen Planus/*chemically induced', 'Lung Neoplasms/drug therapy', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/34118816/
1129,Gefitinib,30358009,Novel application of metformin combined with targeted drugs on anticancer treatment.,"['Deng J', 'Peng M', 'Wang Z', 'Zhou S', 'Xiao D', 'Deng J', 'Yang X', 'Peng J', 'Yang X']","['Administration, Intravesical', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Drug Resistance, Neoplasm/*drug effects', 'Gefitinib/administration & dosage', 'Humans', 'Metformin/administration & dosage', 'Molecular Targeted Therapy/*methods', 'Treatment Outcome', 'Urinary Bladder Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30358009/
1130,Gefitinib,12381224,Gefitinib.,"['Culy CR', 'Faulds D']","['Administration, Oral', 'Animals', 'Antineoplastic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Biological Availability', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'ErbB Receptors/*antagonists & inhibitors', 'Gefitinib', 'Humans', 'Inhibitory Concentration 50', 'Lung Neoplasms/*drug therapy/pathology', 'Quinazolines/adverse effects/pharmacokinetics/*therapeutic use', 'Signal Transduction/drug effects', 'Treatment Outcome', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/12381224/
1131,Gefitinib,33331989,Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.,"['Mok TS', 'Cheng Y', 'Zhou X', 'Lee KH', 'Nakagawa K', 'Niho S', 'Chawla A', 'Rosell R', 'Corral J', 'Migliorino MR', 'Pluzanski A', 'Noonan K', 'Tang Y', 'Pastel M', 'Wilner KD', 'Wu YL']","['Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*pharmacology', 'Carcinoma, Non-Small-Cell Lung/diagnosis/*drug therapy/metabolism', 'Dose-Response Relationship, Drug', 'ErbB Receptors/antagonists & inhibitors/genetics/metabolism', 'Female', 'Gefitinib/administration & dosage/*pharmacology', 'Humans', 'Lung Neoplasms/diagnosis/*drug therapy/metabolism', 'Male', 'Mutation', 'Protein Kinase Inhibitors/administration & dosage/*pharmacology', 'Quinazolinones/administration & dosage/*pharmacology', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/33331989/
1132,Gefitinib,16610973,Gefitinib: an adverse effects profile.,['Cersosimo RJ'],"['Aged', 'Antineoplastic Agents/administration & dosage/*adverse effects', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'Diarrhea/chemically induced', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'ErbB Receptors/*antagonists & inhibitors', 'Exanthema/chemically induced', 'Female', 'Gefitinib', 'Humans', 'Lung Diseases, Interstitial/chemically induced', 'Lung Neoplasms/drug therapy', 'Male', 'Middle Aged', 'Quinazolines/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16610973/
1133,Gefitinib,31682542,Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study.,"['Hosomi Y', 'Morita S', 'Sugawara S', 'Kato T', 'Fukuhara T', 'Gemma A', 'Takahashi K', 'Fujita Y', 'Harada T', 'Minato K', 'Takamura K', 'Hagiwara K', 'Kobayashi K', 'Nukiwa T', 'Inoue A']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/enzymology/genetics', 'ErbB Receptors/antagonists & inhibitors/genetics', 'Female', 'Gefitinib/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/enzymology/genetics', 'Male', 'Middle Aged', 'Mutation', 'Pemetrexed/administration & dosage/adverse effects', 'Progression-Free Survival', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quality of Life', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/31682542/
1134,nefazodone,10086478,Mechanism of action of antidepressant medications.,['Feighner JP'],"['Antidepressive Agents/*pharmacology/therapeutic use', 'Antidepressive Agents, Tricyclic/history/pharmacology/therapeutic use', 'Cyclohexanols/pharmacology/therapeutic use', 'Depressive Disorder/*drug therapy', 'Down-Regulation/drug effects', 'History, 20th Century', 'Humans', 'Monoamine Oxidase Inhibitors/history/pharmacology/therapeutic use', 'Receptors, Adrenergic/drug effects', 'Receptors, Adrenergic, beta/drug effects', 'Receptors, Dopamine/drug effects', 'Receptors, Glucocorticoid/drug effects', 'Receptors, Serotonin/drug effects', 'Selective Serotonin Reuptake Inhibitors/pharmacology/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/10086478/
1135,nefazodone,9090573,Pharmacology of antidepressants.,['Frazer A'],"['Antidepressive Agents/adverse effects/*pharmacology/*therapeutic use', 'Antidepressive Agents, Second-Generation/pharmacology', 'Brain/*drug effects/metabolism', 'Depressive Disorder/*drug therapy', 'Humans', 'Monoamine Oxidase Inhibitors/pharmacology', 'Norepinephrine/metabolism', 'Receptor, Serotonin, 5-HT2A', 'Receptors, Adrenergic, alpha-1/metabolism', 'Receptors, Histamine H1/metabolism', 'Receptors, Muscarinic/metabolism', 'Receptors, Serotonin/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9090573/
1136,nefazodone,36253442,Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis.,"['Kishi T', 'Ikuta T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Matsuda Y', 'Iwata N']","['Female', 'Humans', 'Adult', '*Depressive Disorder, Major/drug therapy', 'Duloxetine Hydrochloride/therapeutic use', 'Sertraline/therapeutic use', 'Citalopram/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use', 'Vortioxetine/therapeutic use', 'Fluoxetine/therapeutic use', 'Paroxetine/therapeutic use', 'Mirtazapine/therapeutic use', 'Amitriptyline/therapeutic use', 'Desvenlafaxine Succinate/therapeutic use', 'Fluvoxamine/therapeutic use', 'Reboxetine/therapeutic use', 'Network Meta-Analysis', 'Antidepressive Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36253442/
1137,nefazodone,9554321,Antidepressant-induced sexual dysfunction.,['Segraves RT'],"['Antidepressive Agents/*adverse effects', 'Antidepressive Agents, Second-Generation/adverse effects', 'Bupropion/adverse effects', 'Female', 'Humans', 'Libido/drug effects', 'Male', 'Piperazines', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Sexual Dysfunctions, Psychological/*chemically induced/drug therapy', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9554321/
1138,nefazodone,7500370,Antidepressant-induced orgasm disorder.,['Segraves RT'],"['Antidepressive Agents/*adverse effects', 'Drug Therapy, Combination', 'Ejaculation/drug effects', 'Female', 'Humans', 'Male', 'Orgasm/*drug effects', 'Prevalence', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Sexual Dysfunction, Physiological/*chemically induced/drug therapy/epidemiology/physiopathology/therapy', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/7500370/
1139,nefazodone,23914755,Liver injury associated with antidepressants.,"['Park SH', 'Ishino R']","['Animals', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/diagnosis/epidemiology/*etiology', 'Drug Interactions', 'Drug Monitoring/*methods', 'Humans', 'Liver Function Tests', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/23914755/
1140,nefazodone,10926053,Weight gain and antidepressants.,['Fava M'],"['Antidepressive Agents/*adverse effects/therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/adverse effects/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/therapeutic use', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/10926053/
1141,nefazodone,19440080,Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.,"['Serretti A', 'Chiesa A']","['Antidepressive Agents/*adverse effects', 'Arousal/drug effects', 'Female', 'Humans', 'Male', 'Orgasm/drug effects', 'Sex Factors', 'Sexual Dysfunctions, Psychological/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19440080/
1142,nefazodone,12904104,Antidepressant-induced hepatotoxicity.,"['Lucena MI', 'Carvajal A', 'Andrade RJ', 'Velasco A']","['Antidepressive Agents/*adverse effects/chemistry/therapeutic use', 'Antidepressive Agents, Second-Generation/adverse effects/chemistry/therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/chemistry/therapeutic use', 'Chemical and Drug Induced Liver Injury/*etiology/prevention & control/therapy', 'Chemical and Drug Induced Liver Injury, Chronic/etiology/prevention & control/therapy', 'Depressive Disorder/drug therapy/etiology', 'Humans', 'Monoamine Oxidase Inhibitors/adverse effects/chemistry/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12904104/
1143,nefazodone,28822709,The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review.,"['Kolla BP', 'Mansukhani MP', 'Bostwick JM']","['Antidepressive Agents/*adverse effects', '*Comorbidity', 'Cross-Sectional Studies', 'Humans', 'Prospective Studies', 'Restless Legs Syndrome/*complications', 'Sleep/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28822709/
1144,nefazodone,20726290,Best practice guide for the treatment of nightmare disorder in adults.,"['Aurora RN', 'Zak RS', 'Auerbach SH', 'Casey KR', 'Chowdhuri S', 'Karippot A', 'Maganti RK', 'Ramar K', 'Kristo DA', 'Bista SR', 'Lamm CI', 'Morgenthaler TI']","['Adult', 'Clonidine/therapeutic use', 'Cognitive Behavioral Therapy/methods', 'Dreams/drug effects/*psychology', 'Evidence-Based Medicine', 'Eye Movement Desensitization Reprocessing', 'Humans', 'Hypnosis', 'Norepinephrine/antagonists & inhibitors', 'Prazosin/therapeutic use', 'Psychotropic Drugs/therapeutic use', 'Randomized Controlled Trials as Topic', 'Relaxation Therapy', 'Stress Disorders, Post-Traumatic/diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/20726290/
1145,nefazodone,33459228,"HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.","['Balasubramanian R', 'Maideen NMP']","['ATP Binding Cassette Transporter, Subfamily B, Member 1/*metabolism', 'Anti-Infective Agents', 'Anticonvulsants', 'Antiviral Agents', 'Cardiovascular Agents', 'Colchicine', 'Contraceptives, Oral', 'Cytochrome P-450 CYP3A/*metabolism', 'Drug Interactions', 'Fibric Acids', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/blood/*pharmacology', 'Immunosuppressive Agents', 'Organic Anion Transporters/*metabolism', 'Phosphodiesterase 5 Inhibitors', 'Piperazines', 'Triazoles', 'Warfarin']",https://pubmed.ncbi.nlm.nih.gov/33459228/
1146,nefazodone,9227670,Safety and tolerability of the new antidepressants.,['Nelson JC'],"['Antidepressive Agents, Second-Generation/*adverse effects/*therapeutic use', 'Antidepressive Agents, Tricyclic/adverse effects/therapeutic use', 'Cyclohexanols/adverse effects/therapeutic use', 'Depressive Disorder/*drug therapy', 'Headache/chemically induced', 'Humans', 'Mianserin/adverse effects/analogs & derivatives/therapeutic use', 'Mirtazapine', 'Nausea/chemically induced', 'Piperazines', 'Selective Serotonin Reuptake Inhibitors/*adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Triazoles/adverse effects/therapeutic use', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9227670/
1147,nefazodone,16236049,Mirtazapine-induced arthralgia.,"['Passier A', 'van Puijenbroek E']","['Adult', 'Antidepressive Agents, Tricyclic/*adverse effects', 'Arthralgia/*chemically induced', 'Depressive Disorder/*drug therapy', 'Female', 'Humans', 'Male', 'Mianserin/adverse effects/*analogs & derivatives', 'Middle Aged', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/16236049/
1148,nefazodone,25894359,Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature.,"['Brownlow JA', 'Harb GC', 'Ross RJ']","['Antipsychotic Agents/therapeutic use', '*Cognitive Behavioral Therapy', 'Dreams', '*Eye Movement Desensitization Reprocessing', 'Fluvoxamine/therapeutic use', 'Humans', 'Piperazines', 'Prazosin/therapeutic use', 'REM Sleep Behavior Disorder/therapy', 'Restless Legs Syndrome/therapy', 'Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', 'Sleep', 'Sleep Apnea, Obstructive/therapy', 'Sleep Initiation and Maintenance Disorders/therapy', 'Sleep Wake Disorders/psychology/*therapy', 'Stress Disorders, Post-Traumatic/*psychology/therapy', 'Trazodone/therapeutic use', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25894359/
1149,nefazodone,11568979,"Depression, sleep physiology, and antidepressant drugs.","['Winokur A', 'Gary KA', 'Rodner S', 'Rae-Red C', 'Fernando AT', 'Szuba MP']","['Antidepressive Agents/*therapeutic use', 'Depressive Disorder/*drug therapy/*physiopathology', 'Humans', 'Polysomnography', 'Sleep/*drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/11568979/
1150,nefazodone,10468320,Nefazodone-induced clitoral priapism.,"['Brodie-Meijer CC', 'Diemont WL', 'Buijs PJ']","['Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Clitoris/*drug effects', 'Depressive Disorder/complications/drug therapy', 'Female', 'Humans', 'Middle Aged', 'Piperazines', 'Triazoles/*adverse effects/therapeutic use', 'Vaginal Diseases/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/10468320/
1151,nefazodone,10379419,"Metabolism of some ""second""- and ""fourth""-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.","['Rotzinger S', 'Bourin M', 'Akimoto Y', 'Coutts RT', 'Baker GB']","['Animals', 'Antidepressive Agents/*metabolism/pharmacokinetics', 'Antidepressive Agents, Second-Generation/*metabolism/pharmacokinetics', 'Clinical Trials as Topic', 'Drug Interactions/physiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/10379419/
1152,nefazodone,27091414,Antidepressants and Driving in Older Adults: A Systematic Review.,"['Cameron DH', 'Rapoport MJ']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Aging', 'Antidepressive Agents/administration & dosage/*adverse effects', '*Automobile Driving/psychology', 'Cohort Studies', 'Cross-Over Studies', 'Depression/complications/*drug therapy', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27091414/
1153,nefazodone,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
1154,Bosentan,32930508,Persistent pulmonary hypertension of the newborn.,"['Mandell E', 'Kinsella JP', 'Abman SH']","['Bosentan/therapeutic use', 'Epoprostenol/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Hypoxia', 'Infant', 'Infant, Newborn', '*Infant, Premature', 'Lung/embryology/*physiopathology', 'Milrinone/therapeutic use', 'Nitric Oxide/*administration & dosage', 'Oxygen/therapeutic use', 'Persistent Fetal Circulation Syndrome/*drug therapy', 'Pulmonary Alveoli/*abnormalities', 'Pulmonary Surfactants/therapeutic use', 'Risk', 'Sildenafil Citrate/therapeutic use', '*Vascular Resistance', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32930508/
1155,Bosentan,19470885,Tadalafil therapy for pulmonary arterial hypertension.,"['Galie N', 'Brundage BH', 'Ghofrani HA', 'Oudiz RJ', 'Simonneau G', 'Safdar Z', 'Shapiro S', 'White RJ', 'Chan M', 'Beardsworth A', 'Frumkin L', 'Barst RJ']","['Adult', 'Aged', 'Bosentan', 'Carbolines/*administration & dosage/adverse effects', 'Double-Blind Method', 'Endothelin Receptor Antagonists', 'Exercise Tolerance/drug effects', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Male', 'Middle Aged', 'Phosphodiesterase Inhibitors/therapeutic use', 'Quality of Life', 'Sulfonamides/therapeutic use', 'Tadalafil', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19470885/
1156,Bosentan,36915092,Endothelial cell-derived MMP19 promotes pulmonary fibrosis by inducing E(nd)MT and monocyte infiltration.,"['Zhao W', 'Wang L', 'Yang J', 'Chen X', 'Guo X', 'Xu K', 'Wang N', 'Zhao W', 'Xia C', 'Lian H', 'Rosas I', 'Yu G']","['Animals', 'Humans', 'Mice', 'Bleomycin/adverse effects', 'Bosentan/metabolism/therapeutic use', '*Endothelial Cells/pathology', 'Epithelial-Mesenchymal Transition', '*Idiopathic Pulmonary Fibrosis/pathology', 'Lung/metabolism', 'Monocytes', '*Matrix Metalloproteinases, Secreted/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36915092/
1157,Bosentan,16294183,[Pulmonary arterial hypertension].,"['Montani D', 'Jais X', 'Sitbon O', 'Capron F', 'Simonneau G', 'Humbert M']","['Antihypertensive Agents/therapeutic use', 'Bosentan', 'Drug Therapy, Combination', 'Electrocardiography', 'Epoprostenol/therapeutic use', 'Humans', '*Hypertension, Pulmonary/classification/diagnosis/drug therapy', 'Phosphodiesterase Inhibitors/therapeutic use', 'Sulfonamides/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16294183/
1158,Bosentan,20307226,Bosentan.,"['Mathier MA', 'Ishizawar D']","['Animals', 'Antihypertensive Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Blood Pressure/drug effects', 'Bosentan', 'Drug Interactions', '*Endothelin Receptor Antagonists', 'Endothelins/metabolism', 'Evidence-Based Medicine', 'Exercise Tolerance/drug effects', 'Humans', 'Hypertension, Pulmonary/*drug therapy/metabolism/physiopathology', 'Receptors, Endothelin/metabolism', 'Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20307226/
1159,Bosentan,14597580,Endothelin receptor blockers in cardiovascular disease.,"['Rich S', 'McLaughlin VV']","['Animals', 'Antihypertensive Agents/therapeutic use', 'Bosentan', 'Cardiovascular Diseases/*drug therapy', '*Endothelin Receptor Antagonists', 'Exercise Tolerance/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Isoxazoles/therapeutic use', 'Sulfonamides/*therapeutic use', 'Thiophenes/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14597580/
1160,Bosentan,11097125,Bosentan and the endothelin system in congestive heart failure.,"['Ellahham SH', 'Charlon V', 'Abassi Z', 'Calis KA', 'Choucair WK']","['Animals', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Bosentan', 'Controlled Clinical Trials as Topic', 'Dogs', 'Double-Blind Method', '*Endothelin Receptor Antagonists', 'Endothelin-1/physiology', 'Endothelins/physiology', 'Heart Failure/*drug therapy/physiopathology', 'Hemodynamics', 'Humans', 'Placebos', 'Rats', 'Receptors, Endothelin/physiology', 'Sulfonamides/administration & dosage/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/11097125/
1161,Bosentan,33002306,Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.,"['Kam CW', 'Ruiz FE']","['Adolescent', 'Adult', 'Bosentan/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Child', 'Child, Preschool', 'Epoprostenol/administration & dosage/analogs & derivatives', 'Familial Primary Pulmonary Hypertension/*drug therapy', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Iloprost/administration & dosage', 'Infant', 'Infant, Newborn', 'Phenotype', 'Phenylpropionates/administration & dosage', 'Phosphodiesterase 5 Inhibitors/therapeutic use', 'Prognosis', 'Pulmonary Arterial Hypertension/*drug therapy', 'Pyridazines/administration & dosage', 'Pyrimidines/administration & dosage', 'Receptors, Endothelin/metabolism', 'Sildenafil Citrate/therapeutic use', 'Sulfonamides/administration & dosage', 'Tadalafil/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33002306/
1162,Bosentan,19688101,Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.,"['Valerio CJ', 'Coghlan JG']","['Administration, Oral', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Bosentan', 'Endothelin A Receptor Antagonists', 'Exercise Tolerance/drug effects', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Quality of Life', 'Severity of Illness Index', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Time Factors', 'Treatment Outcome', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/19688101/
1163,Bosentan,15151466,Bosentan.,"['Chin K', 'Channick R']","['Administration, Oral', 'Antihypertensive Agents/administration & dosage/pharmacokinetics/*pharmacology/*therapeutic use', 'Bosentan', 'Controlled Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Interactions', '*Endothelin Receptor Antagonists', 'Epoprostenol/pharmacology/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Sulfonamides/administration & dosage/pharmacokinetics/*pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15151466/
1164,Bosentan,26201488,Novel Strategies in the Treatment of Pulmonary Arterial Hypertension.,"['Madonna R', 'Cocco N']","['Bosentan', 'Endothelin Receptor Antagonists/pharmacology/*therapeutic use', 'Humans', 'Hypertension, Pulmonary/*diagnosis/*drug therapy', 'Phenylpropionates/pharmacology/therapeutic use', 'Prognosis', 'Pulmonary Circulation/drug effects', 'Pyridazines/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Sulfonamides/pharmacology/therapeutic use', 'Treatment Outcome', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26201488/
1165,Bosentan,22884806,Endothelin receptor antagonists for the treatment of pulmonary artery hypertension.,['Rubin LJ'],"['Administration, Oral', 'Animals', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Bosentan', 'Drug Design', 'Drug Monitoring', '*Endothelin Receptor Antagonists', 'Endothelin-1/metabolism', 'Familial Primary Pulmonary Hypertension', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Phenylpropionates/administration & dosage/pharmacology/therapeutic use', 'Pyridazines/administration & dosage/pharmacology/therapeutic use', 'Sulfonamides/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22884806/
1166,Bosentan,20874675,"Review on bosentan, a dual endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.","['Serasli E', 'Michaelidis V', 'Kosmas A', 'Antoniadou M', 'Tsara V']","['Animals', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Bosentan', 'Drug Interactions', '*Endothelin Receptor Antagonists', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Randomized Controlled Trials as Topic', 'Sulfonamides/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20874675/
1167,Bosentan,25336296,[Digital ulcers in systemic scleroderma].,"['Belz D', 'Hunzelmann N', 'Moinzadeh P']","['Bosentan', 'Fingers/pathology', 'Hand Dermatoses/diagnosis/etiology/therapy', 'Humans', 'Iloprost/*therapeutic use', 'Phosphodiesterase 5 Inhibitors/*therapeutic use', 'Scleroderma, Systemic/*complications/diagnosis/*therapy', 'Skin Ulcer/diagnosis/*etiology/*therapy', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25336296/
1168,Bosentan,28606996,Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure.,"['Smith MP', 'Rowling EJ', 'Miskolczi Z', 'Ferguson J', 'Spoerri L', 'Haass NK', 'Sloss O', 'McEntegart S', 'Arozarena I', 'von Kriegsheim A', 'Rodriguez J', 'Brunton H', 'Kmarashev J', 'Levesque MP', 'Dummer R', 'Frederick DT', 'Andrews MC', 'Cooper ZA', 'Flaherty KT', 'Wargo JA', 'Wellbrock C']","['Animals', 'Antineoplastic Agents/*therapeutic use', 'Bosentan', 'Cell Line, Tumor', 'Disease Models, Animal', 'Endothelin Receptor Antagonists/*administration & dosage', 'Heterografts', 'Humans', 'Melanoma/*drug therapy/*pathology', 'Mice, Nude', 'Neoplasm Transplantation', 'Proto-Oncogene Proteins B-raf/*antagonists & inhibitors', 'Sulfonamides/*administration & dosage', 'Treatment Outcome', 'Zebrafish']",https://pubmed.ncbi.nlm.nih.gov/28606996/
1169,Bosentan,22759771,The big clinical trials in idiopathic pulmonary fibrosis.,"['Luppi F', 'Spagnolo P', 'Cerri S', 'Richeldi L']","['Bosentan', 'Humans', 'Idiopathic Pulmonary Fibrosis/*drug therapy', 'Pyridones/therapeutic use', '*Randomized Controlled Trials as Topic', 'Sulfonamides/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22759771/
1170,Bosentan,14994973,Bosentan: a novel agent for the treatment of pulmonary arterial hypertension.,"[""O'Callaghan D"", 'Gaine SP']","['Antihypertensive Agents/*administration & dosage', 'Bosentan', 'Dose-Response Relationship, Drug', 'Endothelin-1/antagonists & inhibitors', 'Female', 'Humans', 'Hypertension, Pulmonary/*drug therapy', 'Male', 'Randomized Controlled Trials as Topic', 'Sulfonamides/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/14994973/
1171,Bosentan,11790297,Endothelin antagonists and heart failure.,"['Hurlimann D', 'Enseleit F', 'Noll G', 'Luscher TF', 'Ruschitzka F']","['Atrasentan', 'Bosentan', '*Endothelin Receptor Antagonists', 'Endothelins/antagonists & inhibitors/*physiology', 'Heart Failure/drug therapy/*physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/drug therapy/*physiopathology', 'Pyrrolidines/therapeutic use', 'Receptors, Endothelin/physiology', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11790297/
1172,Bosentan,21504371,Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension.,"[""O'Callaghan DS"", 'Savale L', 'Yaici A', 'Natali D', 'Jais X', 'Parent F', 'Montani D', 'Humbert M', 'Simonneau G', 'Sitbon O']","['Animals', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Bosentan', '*Endothelin A Receptor Antagonists', '*Endothelin B Receptor Antagonists', 'Humans', 'Hypertension, Pulmonary/*drug therapy/physiopathology', 'Phenylpropionates/pharmacology/therapeutic use', 'Pyridazines/pharmacology/therapeutic use', 'Sulfonamides/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21504371/
1173,Bosentan,18690874,Current pharmacological treatment of pulmonary arterial hypertension.,"['Steiropoulos P', 'Trakada G', 'Bouros D']","['Bosentan', 'Diuretics/therapeutic use', 'Epoprostenol/therapeutic use', 'Humans', 'Hypertension, Pulmonary/*drug therapy/etiology', 'Iloprost/therapeutic use', 'Nitric Oxide/administration & dosage', 'Piperazines/therapeutic use', 'Purines/therapeutic use', 'Sildenafil Citrate', 'Sulfonamides/therapeutic use', 'Sulfones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18690874/
1174,propofol,20816571,Propofol.,"['Lundstrom S', 'Twycross R', 'Mihalyo M', 'Wilcock A']","['Anesthetics, Intravenous/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Death', 'Delirium/drug therapy/psychology', 'Drug Interactions', 'Humans', 'Propofol/administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20816571/
1175,propofol,30019172,Clinical Pharmacokinetics and Pharmacodynamics of Propofol.,"['Sahinovic MM', 'Struys MMRF', 'Absalom AR']","['Adult', 'Anesthetics, Intravenous/*administration & dosage/pharmacokinetics/pharmacology', 'Animals', 'Child', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/pharmacokinetics/pharmacology', 'Models, Biological', 'Obesity/complications', 'Propofol/*administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30019172/
1176,propofol,30732981,Clinical Practice Guideline for Emergency Department Procedural Sedation With Propofol: 2018 Update.,"['Miller KA', 'Andolfatto G', 'Miner JR', 'Burton JH', 'Krauss BS']","['Anesthetics, Intravenous/*administration & dosage/adverse effects', 'Drug Dosage Calculations', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Evidence-Based Medicine', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Practice Guidelines as Topic', 'Propofol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30732981/
1177,propofol,28566410,Postoperative drug-induced priapism.,"['Corten BJGA', 'Aarts F', 'Harms AS', 'Vogelaar J']","['Anesthetics, Intravenous/*adverse effects', 'Colonic Neoplasms/surgery', 'Diagnosis, Differential', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Male', 'Middle Aged', 'Postoperative Complications/chemically induced/diagnosis', 'Priapism/chemically induced/*diagnosis', 'Propofol/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28566410/
1178,propofol,26290263,Propofol: a review of its role in pediatric anesthesia and sedation.,"['Chidambaran V', 'Costandi A', ""D'Mello A""]","['Anesthetics, Intravenous/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Child', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Propofol/*administration & dosage/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/26290263/
1179,propofol,29661412,Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation.,"['Eleveld DJ', 'Colin P', 'Absalom AR', 'Struys MMRF']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anesthesia/*methods', 'Anesthetics, Intravenous/administration & dosage/pharmacokinetics/*pharmacology', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Models, Biological', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29661412/
1180,propofol,30501158,Propofol: Review of Potential Risks During Administration.,['Adler AC'],"['Anesthetics, Intravenous/*administration & dosage/adverse effects', '*Conscious Sedation', 'Drug Administration Schedule', 'Humans', 'Hypnotics and Sedatives/*administration & dosage/adverse effects', 'Injection Site Reaction/nursing/*prevention & control', 'Nurse Anesthetists', 'Postoperative Complications/nursing/prevention & control', 'Propofol/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30501158/
1181,propofol,33317804,Prospective clinical validation of the Eleveld propofol pharmacokinetic-pharmacodynamic model in general anaesthesia.,"['Vellinga R', 'Hannivoort LN', 'Introna M', 'Touw DJ', 'Absalom AR', 'Eleveld DJ', 'Struys MMRF']","['Adolescent', 'Adult', 'Age Factors', 'Aged', '*Anesthesia, General', 'Anesthetics, Intravenous/administration & dosage/blood/*pharmacokinetics', 'Body Weight', 'Child', 'Child, Preschool', 'Consciousness/*drug effects', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Models, Biological', 'Obesity', 'Propofol/administration & dosage/blood/*pharmacokinetics', 'Prospective Studies', 'Reproducibility of Results', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33317804/
1182,propofol,28526162,Pharmacologic Considerations of Anesthetic Agents in Pediatric Patients: A Comprehensive Review.,"['Kaye AD', 'Fox CJ', 'Padnos IW', 'Ehrhardt KP Jr', 'Diaz JH', 'Cornett EM', 'Chandler D', 'Sen S', 'Patil S']","['Age Factors', 'Analgesics, Opioid/pharmacokinetics/pharmacology', 'Anesthesiologists', 'Anesthetics, Intravenous/administration & dosage/adverse effects', 'Anesthetics, Local/pharmacokinetics/*pharmacology', 'Child', 'Drug Dosage Calculations', 'Humans', 'Neuromuscular Blocking Agents/pharmacokinetics/pharmacology', 'Propofol/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28526162/
1183,propofol,20205488,Fospropofol.,"['Garnock-Jones KP', 'Scott LJ']","['Anesthetics, Intravenous/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Bronchoscopy', '*Colonoscopy', 'Humans', 'Propofol/administration & dosage/adverse effects/*analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20205488/
1184,propofol,29847365,Challenges of bringing a new sedative to market!,['Sear JW'],"['Anesthesia/adverse effects/*methods', 'Benzodiazepines/administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Conscious Sedation/adverse effects/*methods', 'Drug Recalls', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*adverse effects', 'Pregnanediones/administration & dosage/adverse effects', 'Propofol/administration & dosage/adverse effects/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/29847365/
1185,propofol,15675608,GPI-15715 Guilford.,['Krasowski MD'],"['*Anesthetics, Intravenous/adverse effects/pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Humans', '*Prodrugs/adverse effects/pharmacology/therapeutic use', '*Propofol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15675608/
1186,propofol,15365226,Propofol-induced alpha rhythm.,"['Feshchenko VA', 'Veselis RA', 'Reinsel RA']","['Adult', 'Alpha Rhythm/*drug effects', 'Anesthetics, Intravenous/administration & dosage/pharmacokinetics/*pharmacology', 'Dose-Response Relationship, Drug', 'Frontal Lobe/drug effects/physiology', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Thiopental/administration & dosage/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15365226/
1187,propofol,18225970,Propofol-related infusion syndrome in intensive care patients.,"['Corbett SM', 'Montoya ID', 'Moore FA']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*adverse effects', 'Infant', 'Infusions, Intravenous', '*Intensive Care Units', 'Male', 'Middle Aged', 'Propofol/administration & dosage/*adverse effects', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/18225970/
1188,propofol,9415349,Propofol for sedation in the intensive care unit: essentials for the clinician.,['Marinella MA'],"['Adult', 'Aged', 'Apnea/chemically induced', 'Bradycardia/chemically induced', '*Critical Care', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Hypnosis, Anesthetic', '*Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacology', 'Hypotension/chemically induced', 'Metabolic Clearance Rate', 'Pain/chemically induced', '*Propofol/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9415349/
1189,propofol,28506099,Propofol-Based Palliative Sedation to Treat Antipsychotic-Resistant Agitated Delirium.,"['Covarrubias-Gomez A', 'Lopez Collada-Estrada M']","['Antipsychotic Agents', 'Delirium/*complications/*drug therapy', '*Drug Resistance/drug effects', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Palliative Care/*methods', 'Propofol/administration & dosage/*therapeutic use', 'Psychomotor Agitation/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28506099/
1190,propofol,28066096,Pain on propofol injection: Causes and remedies.,['Desousa KA'],"['Anesthetics, Intravenous/*administration & dosage/*adverse effects/chemistry', 'Drug Compounding', 'Humans', 'Injections, Intravenous/adverse effects', 'Pain/chemically induced/*etiology/*prevention & control', 'Propofol/*administration & dosage/*adverse effects/chemistry']",https://pubmed.ncbi.nlm.nih.gov/28066096/
1191,propofol,30898682,Sex effects on behavioral markers of emergence from propofol and isoflurane anesthesia in rats.,"['Mansouri MT', 'Fidler JA', 'Meng QC', 'Eckenhoff RG', 'Garcia PS']","['*Anesthesia', 'Anesthetics, General/administration & dosage/pharmacokinetics/*pharmacology', 'Animals', 'Behavior, Animal/*drug effects', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Isoflurane/administration & dosage/pharmacokinetics/*pharmacology', 'Male', 'Movement/*drug effects', 'Propofol/administration & dosage/pharmacokinetics/*pharmacology', 'Rats', 'Rats, Sprague-Dawley', '*Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/30898682/
1192,propofol,11983797,Efficacy and safety of venlafaxine-ECT combination in treatment-resistant depression.,"['Gonzalez-Pinto A', 'Gutierrez M', 'Gonzalez N', 'Elizagarate E', 'Perez de Heredia JL', 'Mico JA']","['Aged', 'Anesthetics, Intravenous/pharmacology/therapeutic use', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Depressive Disorder, Major/drug therapy/*therapy', 'Drug Administration Schedule', 'Electroconvulsive Therapy/*methods', 'Female', 'Heart Arrest/chemically induced/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Propofol/pharmacology/therapeutic use', 'Retrospective Studies', 'Sodium Channels/drug effects', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/11983797/
1193,propofol,7621219,Successful treatment of amoxapine-induced refractory status epilepticus with propofol (diprivan).,"['Merigian KS', 'Browning RG', 'Leeper KV']","['Adult', 'Amoxapine/*adverse effects', 'Drug Overdose', 'Female', 'Humans', 'Infusions, Intravenous', 'Propofol/administration & dosage/*therapeutic use', 'Status Epilepticus/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7621219/
1194,baclofen,33772789,Pharmacological and neurosurgical interventions for individuals with cerebral palsy and dystonia: a systematic review update and meta-analysis.,"['Bohn E', 'Goren K', 'Switzer L', 'Falck-Ytter Y', 'Fehlings D']","['Baclofen/administration & dosage/therapeutic use', 'Botulinum Toxins/adverse effects/therapeutic use', 'Cerebral Palsy/drug therapy/surgery/*therapy', 'Clonidine/adverse effects/therapeutic use', 'Deep Brain Stimulation/adverse effects', 'Dystonia/drug therapy/surgery/*therapy', 'Humans', 'Injections, Spinal/adverse effects', 'Levodopa/therapeutic use', '*Neurosurgical Procedures', 'Trihexyphenidyl/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33772789/
1195,baclofen,24491650,Major surgical procedures in children with cerebral palsy.,"['Theroux MC', 'DiCindio S']","['Anesthetics', 'Baclofen/administration & dosage/adverse effects', 'Cerebral Palsy/complications/physiopathology/*therapy', 'Child', 'Humans', 'Injections, Spinal', 'Kyphosis/surgery', 'Muscle Relaxants, Central/administration & dosage/adverse effects', 'Osteotomy', 'Plastic Surgery Procedures/methods', 'Risk', 'Scoliosis/surgery', 'Surgical Procedures, Operative/adverse effects/*methods']",https://pubmed.ncbi.nlm.nih.gov/24491650/
1196,baclofen,25479781,"Scoliosis, spinal fusion, and intrathecal baclofen pump implantation.","['Scannell B', 'Yaszay B']","['Baclofen/administration & dosage/*therapeutic use', 'Cerebral Palsy/*complications', 'Humans', '*Infusion Pumps, Implantable/adverse effects', 'Muscle Relaxants, Central/administration & dosage/*therapeutic use', 'Muscle Spasticity/*drug therapy/etiology', 'Scoliosis/etiology/rehabilitation/*surgery', '*Spinal Fusion']",https://pubmed.ncbi.nlm.nih.gov/25479781/
1197,baclofen,11727722,Intrathecal baclofen therapy for spastic hypertonia.,"['Ivanhoe CB', 'Tilton AH', 'Francisco GE']","['Baclofen/administration & dosage/*therapeutic use', 'Cerebral Palsy/complications', 'Drug Overdose', 'GABA Agonists/administration & dosage/*therapeutic use', 'Humans', 'Injections, Spinal', 'Multiple Sclerosis/complications', 'Muscle Spasticity/*drug therapy/etiology', 'Patient Selection', 'Spinal Cord Injuries/complications']",https://pubmed.ncbi.nlm.nih.gov/11727722/
1198,baclofen,7633787,Implants for spasticity.,['Teddy PJ'],"['Baclofen/*administration & dosage/adverse effects', 'Brain/physiopathology', 'Electric Stimulation Therapy/*instrumentation', 'Electrodes, Implanted', 'Equipment Design', 'Humans', '*Infusion Pumps, Implantable', 'Injections, Spinal/*instrumentation', 'Motor Neurons/physiology', 'Muscle Spasticity/etiology/physiopathology/*rehabilitation', 'Muscle Tonus/drug effects/physiology', 'Muscle, Skeletal/innervation', 'Spinal Cord/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7633787/
1199,baclofen,25672696,[Intrathecal baclofen therapy for hereditary spastic paraplegia].,"['Taira T', 'Takeda N']","['Adult', 'Aged', 'Baclofen/*administration & dosage', 'Catheters/adverse effects', 'Dose-Response Relationship, Drug', 'GABA-B Receptor Agonists/*administration & dosage', 'Humans', 'Injections, Spinal', 'Male', 'Middle Aged', 'Paraplegia/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25672696/
1200,baclofen,16722294,Management of childhood spasticity: a neurosurgical perspective.,"['Mandigo CE', 'Anderson RC']","['Baclofen/*administration & dosage/therapeutic use', '*Cerebral Palsy/classification/diagnosis/physiopathology', 'Humans', 'Infant', 'Injections, Spinal', 'Muscle Relaxants, Central/*administration & dosage/therapeutic use', '*Muscle Spasticity/etiology/surgery/therapy', 'Parasympatholytics/adverse effects/*therapeutic use', 'Peripheral Nerves/surgery', 'Physical Examination', 'Randomized Controlled Trials as Topic', 'Rhizotomy']",https://pubmed.ncbi.nlm.nih.gov/16722294/
1201,baclofen,25479782,Intrathecal baclofen bolus dosing and catheter tip placement in pediatric tone management.,"['Skalsky AJ', 'Fournier CM']","['Adolescent', 'Baclofen/*administration & dosage/adverse effects', 'Catheterization', 'Cerebral Palsy/*complications', 'Drug Administration Schedule', 'Humans', '*Infusion Pumps, Implantable', 'Injections, Spinal', 'Male', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Muscle Spasticity/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/25479782/
1202,baclofen,22015172,Intrathecal baclofen for progressive neurological disease in childhood: a systematic review of literature.,"['Bonouvrie LA', 'van Schie PE', 'Becher JG', 'van Ouwerkerk WJ', 'Vermeulen RJ']","['Adolescent', 'Adult', 'Baclofen/*administration & dosage/adverse effects', 'Brain Diseases/complications', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Injections, Spinal', 'Male', 'Muscle Relaxants, Central/*administration & dosage/adverse effects', 'Muscle Spasticity/*drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/22015172/
1203,baclofen,7852758,Baclofen as an adjuvant analgesic.,['Fromm GH'],"['Adjuvants, Pharmaceutic/*therapeutic use', 'Analgesics/*therapeutic use', 'Baclofen/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Humans', 'Trigeminal Neuralgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7852758/
1204,baclofen,17691375,Intrathecal baclofen for the treatment of spasticity.,['Dones I'],"['Baclofen/*administration & dosage/therapeutic use', 'Humans', 'Infusion Pumps, Implantable', 'Injections, Spinal/methods', 'Muscle Relaxants, Central/*administration & dosage/therapeutic use', 'Muscle Spasticity/*drug therapy', 'Patient Selection', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17691375/
1205,baclofen,8443626,Intrathecal baclofen in severe spasticity.,['McLean BN'],"['Baclofen/*administration & dosage/pharmacology/therapeutic use', 'Clinical Protocols/standards', 'Clinical Trials as Topic', 'Electric Stimulation Therapy/methods', 'Humans', 'Infusion Pumps, Implantable', 'Injections, Spinal', 'Muscle Spasticity/diagnosis/*drug therapy/surgery', 'Nerve Block/methods', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8443626/
1206,baclofen,12217208,The impact of intrathecal baclofen on gastrointestinal function.,"['Kofler M', 'Matzak H', 'Saltuari L']","['Adolescent', 'Adult', 'Baclofen/administration & dosage/*adverse effects/*pharmacology', 'Digestive System/*drug effects/*physiopathology', 'Female', 'Gastrointestinal Diseases/*chemically induced/*physiopathology', 'Humans', 'Injections, Spinal', 'Male', 'Muscle Relaxants, Central/administration & dosage/*adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12217208/
1207,baclofen,18162701,A review of the complications of intrathecal baclofen in patients with cerebral palsy.,"['Kolaski K', 'Logan LR']","['Adolescent', 'Adult', 'Baclofen/administration & dosage/*adverse effects', 'Cerebral Palsy/*complications', 'Child', 'Humans', 'Infusion Pumps, Implantable/adverse effects', 'Infusions, Parenteral', 'Injections, Spinal', 'Muscle Relaxants, Central/administration & dosage/*adverse effects', 'Muscle Spasticity/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/18162701/
1208,baclofen,9850294,An approach to switching patients from baclofen to tizanidine.,"['Brenner R', 'Hyman N', 'Knobler R', ""O'Brien M"", 'Stephan T']","['Baclofen/adverse effects/*therapeutic use', 'Clinical Competence', 'Clonidine/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Multiple Sclerosis/complications', 'Muscle Relaxants, Central/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy/etiology', 'Spinal Cord Diseases/drug therapy', 'Spinal Cord Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9850294/
1209,baclofen,14518519,Intrathecal drug delivery 2002.,['Turner MS'],"['Baclofen/administration & dosage/pharmacokinetics', 'Drug Approval', 'Humans', '*Infusion Pumps, Implantable', 'Injections, Spinal/*methods/*trends', 'Morphine/administration & dosage/pharmacokinetics', 'Movement Disorders/*drug therapy', 'Pain/*drug therapy', ""Practice Patterns, Physicians'"", 'Spinal Cord/drug effects/metabolism', 'United States']",https://pubmed.ncbi.nlm.nih.gov/14518519/
1210,baclofen,34106538,[Baclofen in the treatment of alcohol addiction : a French saga].,['Paille F'],"['*Alcoholism/drug therapy', 'Baclofen/therapeutic use', 'France', 'Humans', '*Medicine', 'Off-Label Use']",https://pubmed.ncbi.nlm.nih.gov/34106538/
1211,baclofen,329292,Baclofen (para-chlorphenyl-GABA) in schizophrenia.,"['Beckmann H', 'Frische M', 'Ruther E', 'Zimmer R']","['Adult', 'Aminobutyrates/*therapeutic use', 'Animals', 'Baclofen/administration & dosage/pharmacology/*therapeutic use', 'Blood-Brain Barrier/drug effects', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/329292/
1212,baclofen,28353527,Baclofen Pumps: Uses and Complications.,"['Woolf SM', 'Baum CR']","['Baclofen/*administration & dosage/adverse effects', 'Brain Injuries/*drug therapy', 'Dystonia/*drug therapy', 'Humans', 'Infusion Pumps, Implantable/adverse effects', 'Reoperation/statistics & numerical data', 'Spinal Cord Injuries/*drug therapy', 'Surgical Wound Infection/epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28353527/
1213,baclofen,2795085,Intrathecal baclofen and the H-reflex.,"['Macdonell RA', 'Talalla A', 'Swash M', 'Grundy D']","['Adult', 'Baclofen/administration & dosage/*therapeutic use', 'H-Reflex/*drug effects', 'Humans', 'Injections, Spinal', 'Male', 'Muscle Spasticity/*drug therapy/etiology', 'Reflex, Monosynaptic', 'Spinal Cord Injuries/complications/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/2795085/
1214,hydroxychloroquine,27927040,Hydroxychloroquine in systemic lupus erythematosus (SLE).,"['Ponticelli C', 'Moroni G']","['Animals', 'Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects/*therapeutic use', 'Lupus Erythematosus, Systemic/*drug therapy/physiopathology', 'Pregnancy', 'Retinal Diseases/chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/27927040/
1215,hydroxychloroquine,36112387,Hydroxychloroquine Dose per Ophthalmology Guidelines and the Risk of Systemic Lupus Erythematosus Flares.,"['Jorge AM', 'Mancini C', 'Zhou B', 'Ho G', 'Zhang Y', 'Costenbader K', 'Choi HK']","['*Antirheumatic Agents/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', '*Eye Diseases/chemically induced', 'Humans', '*Hydroxychloroquine/administration & dosage/adverse effects', '*Lupus Erythematosus, Systemic/drug therapy/prevention & control', '*Ophthalmology/standards', 'Practice Guidelines as Topic/standards', 'Risk', '*Symptom Flare Up']",https://pubmed.ncbi.nlm.nih.gov/36112387/
1216,hydroxychloroquine,32634079,The Role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.,"['Martinez GP', 'Zabaleta ME', 'Di Giulio C', 'Charris JE', 'Mijares MR']","['Autoimmune Diseases/drug therapy', 'Betacoronavirus', 'COVID-19', 'Chloroquine/*pharmacology/therapeutic use', 'Coronavirus Infections', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immune System/*drug effects', 'Pandemics', 'Pneumonia, Viral', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32634079/
1217,hydroxychloroquine,33775862,Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms.,"['Ferreira PMP', 'Sousa RWR', 'Ferreira JRO', 'Militao GCG', 'Bezerra DP']","['Antineoplastic Agents/pharmacology', 'Autophagy/*drug effects', 'Chloroquine/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Resistance, Neoplasm', 'Humans', 'Hydroxychloroquine/*pharmacology/therapeutic use', 'Immunomodulating Agents/pharmacology', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33775862/
1218,hydroxychloroquine,32478627,Systemic lupus erythematosus and risk of infection.,"['Barber MRW', 'Clarke AE']","['Humans', '*Hydroxychloroquine/adverse effects/therapeutic use', 'Immunosuppression Therapy/*adverse effects', '*Immunosuppressive Agents/adverse effects/therapeutic use', '*Infection Control', '*Infections/chemically induced/epidemiology/immunology', '*Lupus Erythematosus, Systemic/complications/drug therapy/epidemiology/immunology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32478627/
1219,hydroxychloroquine,32675702,Hydroxychloroquine and antiphospholipid antibody-related pregnancy morbidity: a systematic review and meta-analysis.,"['Frishman M', 'Radin M', 'Schreiber K']","['Antibodies, Antiphospholipid/immunology', 'Antiphospholipid Syndrome/*drug therapy', 'Case-Control Studies', 'Female', 'Humans', 'Hydroxychloroquine/*administration & dosage/adverse effects', 'Live Birth', 'Observational Studies as Topic', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32675702/
1220,hydroxychloroquine,32147496,Of chloroquine and COVID-19.,"['Touret F', 'de Lamballerie X']","['Antiviral Agents/adverse effects/pharmacology/standards/*therapeutic use', 'Betacoronavirus/drug effects', 'COVID-19', 'China', 'Chloroquine/adverse effects/pharmacology/standards/*therapeutic use', 'Clinical Trials as Topic/standards', 'Coronavirus Infections/*drug therapy', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacology/standards/therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/32147496/
1221,hydroxychloroquine,39981928,Hydroxychloroquine: A doubleedged sword (Review).,"['Huo R', 'Wei C', 'Yang Y', 'Lin J', 'Huang X']","['Humans', '*Hydroxychloroquine/therapeutic use/adverse effects', '*Antirheumatic Agents/therapeutic use/adverse effects/pharmacology', 'Antimalarials/therapeutic use/adverse effects/pharmacology', 'Arthritis, Rheumatoid/drug therapy', 'Autoimmune Diseases/drug therapy', ""Sjogren's Syndrome/drug therapy"", 'Lupus Erythematosus, Systemic/drug therapy', 'Rheumatic Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39981928/
1222,hydroxychloroquine,33693723,What makes (hydroxy)chloroquine ineffective against COVID-19: insights from cell biology.,"['Altulea D', 'Maassen S', 'Baranov MV', 'van den Bogaart G']","['Antiviral Agents/therapeutic use', 'COVID-19/virology', 'Cell Proliferation/drug effects', 'Chloroquine/adverse effects/*therapeutic use', 'Drug Repositioning', 'Humans', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'SARS-CoV-2/drug effects/pathogenicity', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33693723/
1223,hydroxychloroquine,32726238,Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.,"['Lebin JA', 'LeSaint KT']","['Betacoronavirus/*drug effects', 'COVID-19', 'Chloroquine/adverse effects/*therapeutic use', 'Coronavirus Infections/*drug therapy', 'Humans', 'Hydroxychloroquine/adverse effects/*therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'SARS-CoV-2', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32726238/
1224,hydroxychloroquine,28302011,The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.,"['Hu C', 'Lu L', 'Wan JP', 'Wen C']","['Animals', 'Anti-Inflammatory Agents/adverse effects/pharmacology/*therapeutic use', 'Antirheumatic Agents/adverse effects/pharmacology/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy/immunology', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacology/*therapeutic use', 'Lupus Erythematosus, Systemic/*drug therapy/immunology', 'Rheumatic Diseases/*drug therapy/immunology']",https://pubmed.ncbi.nlm.nih.gov/28302011/
1225,hydroxychloroquine,8153401,Antimalarial agents and lupus.,['Wallace DJ'],"['Antibodies, Antiphospholipid/drug effects', 'Antimalarials/adverse effects/pharmacology/*therapeutic use', 'Chloroquine/therapeutic use', 'Female', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Kidney Diseases/etiology', 'Lupus Erythematosus, Systemic/*drug therapy', 'Neuromuscular Diseases/etiology', 'Pregnancy', 'Quinacrine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8153401/
1226,hydroxychloroquine,39899183,Safety of Hydroxychloroquine: What a Dermatologist Should Know.,"['Rapparini L', 'Cedirian S', 'La Placa M', 'Piraccini BM', 'Raschi E', 'Starace M']","['*Hydroxychloroquine/adverse effects/therapeutic use', 'Humans', 'Antirheumatic Agents/adverse effects', 'COVID-19', 'Retinal Diseases/chemically induced/diagnosis', 'Skin Diseases/chemically induced', 'SARS-CoV-2', 'Dermatologists']",https://pubmed.ncbi.nlm.nih.gov/39899183/
1227,hydroxychloroquine,32425199,Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019.,"['Aggarwal G', 'Henry BM', 'Aggarwal S', 'Bangalore S']","['Adenosine Monophosphate/administration & dosage/adverse effects/analogs & derivatives', 'Alanine/administration & dosage/adverse effects/analogs & derivatives', 'Anti-Infective Agents/administration & dosage/*adverse effects', 'Azithromycin/administration & dosage/adverse effects', '*Betacoronavirus', 'COVID-19', 'Cardiovascular Diseases/*chemically induced', 'Coronavirus Infections/*drug therapy', 'Drug Combinations', 'Enzyme Inhibitors/administration & dosage/*adverse effects', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects', 'Lopinavir/therapeutic use', 'Pandemics', 'Pneumonia, Viral/*drug therapy', 'Ritonavir/therapeutic use', 'SARS-CoV-2', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/32425199/
1228,hydroxychloroquine,32316844,Current opinion on hydroxychloroquine-related retinal toxicity screening: where do we stand now?,"['Aduriz-Lorenzo PM', 'Aduriz-Llaneza P', 'Araiz-Iribarren J', 'Khamashta MA']","['Academies and Institutes', 'Antirheumatic Agents/administration & dosage/*adverse effects', 'Electroretinography', 'Humans', 'Hydroxychloroquine/administration & dosage/*adverse effects', 'Practice Guidelines as Topic', 'Retina/*drug effects', 'Retinal Diseases/*chemically induced/*diagnosis', 'Risk Assessment', 'Tomography, Optical Coherence', 'United States', 'Visual Fields']",https://pubmed.ncbi.nlm.nih.gov/32316844/
1229,hydroxychloroquine,28458440,Hydroxychloroquine-induced erythroderma.,"['Pai SB', 'Sudershan B', 'Kuruvilla M', 'Kamath A', 'Suresh PK']","['Antirheumatic Agents/administration & dosage/adverse effects', 'Biopsy', 'Dermatitis, Exfoliative/*chemically induced/diagnosis/pathology', 'Drug Eruptions/*diagnosis/etiology/pathology', 'Female', 'Humans', 'Hydroxychloroquine/administration & dosage/*adverse effects', 'Lupus Erythematosus, Systemic/drug therapy', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28458440/
1230,hydroxychloroquine,31277749,Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?,"['Schwartzman S', 'Samson CM']","['Antimalarials/adverse effects/therapeutic use', '*Chloroquine/adverse effects/therapeutic use', '*Eye Diseases/chemically induced/prevention & control', 'Humans', '*Hydroxychloroquine/adverse effects/therapeutic use', 'Patient Care Management/methods/standards', 'Rheumatic Diseases/*drug therapy', 'Risk Adjustment']",https://pubmed.ncbi.nlm.nih.gov/31277749/
1231,hydroxychloroquine,33244901,Safety of hydroxychloroquine for treatment or prevention of SARS-CoV-2 infection: A rapid systematic review and meta-analysis of randomized clinical trials.,"['Maraolo AE', 'Grossi A']","['COVID-19/*virology', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects/*therapeutic use', 'Odds Ratio', 'Randomized Controlled Trials as Topic', 'SARS-CoV-2/*drug effects', 'Treatment Outcome', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/33244901/
1232,hydroxychloroquine,17952481,Hydroxychloroquine-induced DRESS syndrome.,"['Volpe A', 'Marchetta A', 'Caramaschi P', 'Biasi D', 'Bambara LM', 'Arcaro G']","['Antirheumatic Agents/*adverse effects/therapeutic use', 'Arthritis/drug therapy', 'Eosinophilia/*chemically induced/diagnosis', 'Exanthema/*chemically induced/diagnosis', 'Fever/*chemically induced/diagnosis', 'Humans', 'Hydroxychloroquine/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/17952481/
1233,cyclobenzaprine,27377815,EULAR revised recommendations for the management of fibromyalgia.,"['Macfarlane GJ', 'Kronisch C', 'Dean LE', 'Atzeni F', 'Hauser W', 'Fluss E', 'Choy E', 'Kosek E', 'Amris K', 'Branco J', 'Dincer F', 'Leino-Arjas P', 'Longley K', 'McCarthy GM', 'Makri S', 'Perrot S', 'Sarzi-Puttini P', 'Taylor A', 'Jones GT']","['*Activities of Daily Living', 'Acupuncture Therapy', 'Amitriptyline/analogs & derivatives/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Anticonvulsants/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Biofeedback, Psychology', 'Capsaicin/therapeutic use', 'Cognitive Behavioral Therapy', 'Europe', 'Evidence-Based Medicine', 'Exercise Therapy', 'Fatigue/physiopathology/*therapy', 'Fibromyalgia/physiopathology/*therapy', 'Human Growth Hormone/therapeutic use', 'Humans', 'Hydrotherapy', 'Hypnosis', 'Manipulation, Chiropractic', 'Massage', 'Mind-Body Therapies', 'Mindfulness', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Pain/physiopathology', '*Practice Guidelines as Topic', 'S-Adenosylmethionine/therapeutic use', 'Sensory System Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Sleep', 'Societies, Medical', 'Sodium Oxybate/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27377815/
1234,cyclobenzaprine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
1235,cyclobenzaprine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
1236,cyclobenzaprine,26868680,"Maladaptive plasticity in tinnitus--triggers, mechanisms and treatment.","['Shore SE', 'Roberts LE', 'Langguth B']","['Animals', 'Auditory Cortex/pathology/physiopathology', 'Auditory Pathways/pathology/*physiopathology', 'Cochlear Nucleus/pathology/physiopathology', 'Humans', 'Neuronal Plasticity/*physiology', 'Noise/adverse effects', 'Tinnitus/*diagnosis/*physiopathology/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26868680/
1237,cyclobenzaprine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
1238,cyclobenzaprine,38355316,"""Fibromyalgia - are there any new approaches?"".","['Martinez JE', 'Guimaraes I']","['*Fibromyalgia/therapy/drug therapy', 'Humans', '*Cognitive Behavioral Therapy', 'Exercise Therapy', 'Pain Management/methods', 'Analgesics/therapeutic use', 'Patient Education as Topic', 'Combined Modality Therapy']",https://pubmed.ncbi.nlm.nih.gov/38355316/
1239,cyclobenzaprine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
1240,cyclobenzaprine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
1241,cyclobenzaprine,38621248,Rheumatology: What You May Have Missed in 2023.,"['Jalali K', 'Mandl LA']","['Humans', '*Glucocorticoids/therapeutic use/adverse effects/administration & dosage', 'Osteoporosis/drug therapy', 'Arthritis, Rheumatoid/drug therapy', 'Antirheumatic Agents/therapeutic use/adverse effects', 'Methotrexate/therapeutic use/adverse effects', 'Rheumatology/standards', 'Rheumatic Diseases/drug therapy/complications', 'Biosimilar Pharmaceuticals/therapeutic use/adverse effects', 'Polymyalgia Rheumatica/drug therapy', 'Fibromyalgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38621248/
1242,cyclobenzaprine,27649348,Compounded Topical Analgesics for Chronic Pain.,"['Cline AE', 'Turrentine JE']","['Administration, Cutaneous', 'Amines/administration & dosage', 'Amitriptyline/administration & dosage/analogs & derivatives', 'Analgesics/*administration & dosage', 'Anesthetics, Local/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Baclofen/administration & dosage', 'Capsaicin/administration & dosage', 'Chronic Pain/*drug therapy', 'Clonidine/administration & dosage', 'Cyclohexanecarboxylic Acids/administration & dosage', 'Drug Combinations', 'Drug Compounding', 'Gabapentin', 'Humans', 'Ketamine/administration & dosage', 'Lidocaine/administration & dosage', 'Muscle Relaxants, Central/administration & dosage', 'gamma-Aminobutyric Acid/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27649348/
1243,cyclobenzaprine,6620442,Cyclobenzaprine overdosage.,"['Linden CH', 'Mitchiner JC', 'Lindzon RD', 'Rumack BH']","['Adolescent', 'Adult', 'Amitriptyline/*analogs & derivatives/poisoning', 'Female', 'Humans', 'Male', 'Physostigmine/*therapeutic use', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/6620442/
1244,cyclobenzaprine,19590258,Torticollis under cyclobenzaprine.,"['Reuss R', 'Reuter I', 'Jauss M', 'Fischer F', 'Muller SC', 'Stolz E']","['Amitriptyline/adverse effects/*analogs & derivatives/therapeutic use', 'Biperiden/therapeutic use', 'Humans', 'Male', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/*adverse effects/therapeutic use', 'Myoclonus/chemically induced/drug therapy', 'Torticollis/*chemically induced/drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19590258/
1245,cyclobenzaprine,37165930,"Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled Trial.","['Lederman S', 'Arnold LM', 'Vaughn B', 'Kelley M', 'Sullivan GM']","['Humans', 'Double-Blind Method', '*Fibromyalgia/diagnosis/drug therapy/complications', 'Pain/complications', 'Pain Measurement', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37165930/
1246,cyclobenzaprine,3078905,Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience.,"['Katz WA', 'Dube J']","['Amitriptyline/*analogs & derivatives/therapeutic use', 'Humans', 'Muscle Relaxants, Central/*therapeutic use', 'Spasm/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3078905/
1247,cyclobenzaprine,2644679,Treatment of fibromyalgia syndrome.,['Goldenberg DL'],"['Amitriptyline/analogs & derivatives/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Fibromyalgia/*drug therapy/therapy', 'Humans', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/2644679/
1248,cyclobenzaprine,1861061,Post-triathalon delirium.,"['Stephen JM', 'Ghezzi KT', 'Bailey K', 'Shesser R']","['Adult', '*Akathisia, Drug-Induced', 'Amitriptyline/*analogs & derivatives/poisoning', 'Delirium/*chemically induced/diagnosis/drug therapy', 'Humans', 'Male', 'Muscle Relaxants, Central/*poisoning', 'Physostigmine/therapeutic use', 'Psychomotor Agitation/drug therapy', 'Sports']",https://pubmed.ncbi.nlm.nih.gov/1861061/
1249,cyclobenzaprine,27474822,PURLs: More isn't better with acute low back pain treatment.,"['Frazer K', 'Stevermer JJ']","['Acetaminophen/*therapeutic use', 'Amitriptyline/*analogs & derivatives/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Low Back Pain/*drug therapy', 'Male', 'Muscle Relaxants, Central/*therapeutic use', 'Naproxen/*therapeutic use', 'Oxycodone/*therapeutic use', 'Pain Measurement', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27474822/
1250,cyclobenzaprine,8187451,Fibromyalgia associated with female urethral syndrome.,['Paira SO'],"['Adult', 'Aged', 'Blood Sedimentation', 'Female', 'Fibromyalgia/*complications', 'Humans', 'Middle Aged', 'Retrospective Studies', 'Syndrome', 'Urethral Diseases/*complications/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/8187451/
1251,cyclobenzaprine,2327059,Skeletal muscle relaxant ingestion.,"['Lebby TI', 'Dugger K', 'Lipscomb JW', 'Leikin JB']","['Adolescent', 'Adult', 'Child', 'Child, Preschool', 'Drug Overdose', 'Humans', 'Infant', 'Infant, Newborn', 'Middle Aged', 'Muscle Relaxants, Central/*adverse effects', 'Muscles/*drug effects', '*Poison Control Centers', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/2327059/
1252,ketoconazole,2546775,New antifungal agents.,['Graybill JR'],"['*Aminoglycosides', 'Anti-Bacterial Agents/therapeutic use', 'Antifungal Agents/pharmacology/*therapeutic use', 'Azoles/therapeutic use', 'Echinocandins', 'Fluconazole', 'Fungi/*drug effects', 'Humans', 'Itraconazole', 'Ketoconazole/analogs & derivatives/therapeutic use', 'Mycoses/*drug therapy', 'Peptides/therapeutic use', '*Peptides, Cyclic', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2546775/
1253,ketoconazole,18038701,The role of ketoconazole in seborrheic dermatitis.,"['Borgers M', 'Degreef H']","['Administration, Topical', 'Antifungal Agents/administration & dosage/*pharmacology', 'Dermatitis, Seborrheic/*drug therapy/microbiology', 'Dermatomycoses/complications/*drug therapy', 'Gels', 'Humans', 'Ketoconazole/administration & dosage/*pharmacology', '*Malassezia']",https://pubmed.ncbi.nlm.nih.gov/18038701/
1254,ketoconazole,12956199,The use of oral antifungal agents to treat onychomycosis.,"['Gupta AK', 'Ryder JE']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Drug Interactions', 'Fluconazole/administration & dosage/adverse effects/therapeutic use', 'Griseofulvin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/adverse effects/therapeutic use', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/therapeutic use', 'Onychomycosis/diagnosis/*drug therapy/microbiology/pathology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12956199/
1255,ketoconazole,2170472,Itraconazole in tinea versicolor: a review.,['Delescluse J'],"['Antifungal Agents/adverse effects/*therapeutic use', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Tinea Versicolor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2170472/
1256,ketoconazole,19454093,Seborrhoeic dermatitis.,"['Manriquez JJ', 'Uribe P']","['Administration, Oral', 'Administration, Topical', '*Dermatitis, Seborrheic/drug therapy', 'Face', 'Humans', '*Ketoconazole/administration & dosage', 'Lithium/therapeutic use', 'Malassezia', 'Remission Induction', 'Scalp Dermatoses']",https://pubmed.ncbi.nlm.nih.gov/19454093/
1257,ketoconazole,2172333,Treatment of chromoblastomycosis.,"['Tuffanelli L', 'Milburn PB']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Chromoblastomycosis/*drug therapy', 'Drug Administration Schedule', 'Humans', 'Itraconazole', 'Ketoconazole/administration & dosage/*analogs & derivatives/therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2172333/
1258,ketoconazole,1918469,"Tinea versicolor: epidemiologic, clinical, and therapeutic aspects.","['Borelli D', 'Jacobs PH', 'Nall L']","['Adult', 'Diagnosis, Differential', 'Female', 'Humans', 'Ketoconazole/administration & dosage/adverse effects/pharmacology', 'Male', 'Recurrence', 'Terminology as Topic', '*Tinea Versicolor/drug therapy/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/1918469/
1259,ketoconazole,18793935,Medical treatments for male and female pattern hair loss.,"['Rogers NE', 'Avram MR']","['Adult', 'Alopecia/*therapy', 'Androgen Antagonists/pharmacology/therapeutic use', 'Azasteroids/pharmacology/therapeutic use', 'Drug Therapy, Combination', 'Dutasteride', 'Female', 'Finasteride/therapeutic use', 'Hair/transplantation', 'Humans', 'Hyperhidrosis/chemically induced', 'Ketoconazole/therapeutic use', 'Male', 'Minoxidil/adverse effects/pharmacology/therapeutic use', 'Phototherapy', 'Prostate/drug effects', 'Sperm Count', 'Tretinoin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/18793935/
1260,ketoconazole,4062088,Ketoconazole therapy for endemic blastomycosis.,"['Bradsher RW', 'Rice DC', 'Abernathy RS']","['Adult', 'Aged', 'Blastomycosis/*drug therapy', 'Endocrine System Diseases/chemically induced', 'Female', 'Humans', 'Ketoconazole/adverse effects/blood/*therapeutic use', 'Lung Diseases, Fungal/drug therapy', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Pneumonia/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/4062088/
1261,ketoconazole,2161523,The triazole antifungal agents: a review of itraconazole and fluconazole.,"['Bailey EM', 'Krakovsky DJ', 'Rybak MJ']","['Antifungal Agents/adverse effects/*pharmacokinetics/pharmacology', 'Aspergillus/drug effects', 'Candida albicans/drug effects', 'Chemical Phenomena', 'Chemistry', 'Clinical Trials as Topic', 'Cryptococcus neoformans/drug effects', 'Fluconazole/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Half-Life', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/2161523/
1262,ketoconazole,2670371,Systemic candidiasis.,['Ray TL'],"['Amphotericin B/administration & dosage/therapeutic use', '*Candidiasis/drug therapy/epidemiology/microbiology', 'Flucytosine/therapeutic use', 'Humans', 'Immune Tolerance', 'Ketoconazole/adverse effects/therapeutic use', 'Neoplasms/complications/drug therapy', 'Opportunistic Infections/drug therapy/epidemiology/microbiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/2670371/
1263,ketoconazole,29360892,Long-term pubic dermatitis diagnosed as white piedra.,['Landero J'],"['Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Dermatitis/*diagnosis', 'Dermoscopy/methods', 'Groin', 'Hair', 'Humans', 'Ketoconazole/administration & dosage/*therapeutic use', 'Male', 'Middle Aged', 'Piedra/*diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29360892/
1264,ketoconazole,2170477,Itraconazole treatment of phaeohyphomycosis.,"['Sharkey PK', 'Graybill JR', 'Rinaldi MG', 'Stevens DA', 'Tucker RM', 'Peterie JD', 'Hoeprich PD', 'Greer DL', 'Frenkel L', 'Counts GW', 'et al.']","['Adult', 'Aged', 'Antifungal Agents/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Administration Schedule', 'Female', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Male', 'Microbial Sensitivity Tests', 'Middle Aged', 'Mycoses/*drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/2170477/
1265,ketoconazole,2670368,Coccidioidomycosis.,['Hobbs ER'],"['Adult', 'Age Factors', 'Amphotericin B/administration & dosage/adverse effects/therapeutic use', 'Arizona', 'Biopsy', 'Child', 'Child, Preschool', '*Coccidioidomycosis/diagnosis/drug therapy/epidemiology/microbiology', 'Dermatomycoses/pathology', 'Female', 'Humans', 'Immune Tolerance', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Male', 'Pregnancy', 'Serologic Tests', 'Sex Factors', 'Skin Tests/methods']",https://pubmed.ncbi.nlm.nih.gov/2670368/
1266,ketoconazole,1926909,Ketoconazole in the treatment of pityriasis versicolor: international review of clinical trials.,"['Goodless DR', 'Ramos-Caro FA', 'Flowers FP']","['Humans', 'Ketoconazole/adverse effects/*therapeutic use', 'Tinea Versicolor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1926909/
1267,ketoconazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
1268,ketoconazole,1653679,Itraconazole in the treatment of coccidioidomycosis.,"['Diaz M', 'Puente R', 'de Hoyos LA', 'Cruz S']","['Adult', 'Antifungal Agents/adverse effects/*therapeutic use', 'Coccidioidomycosis/*drug therapy', 'Female', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/*analogs & derivatives/therapeutic use', 'Lung Diseases, Fungal/*drug therapy', 'Male', 'Prospective Studies', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1653679/
1269,ketoconazole,8362113,[Value of ketoconazole in the treatment of Cushing disease].,"['Pascal V', 'Denet S', 'Weryha G', 'Kaminski P', 'Leclere J', 'Hartemann P']","['Adult', 'Aged', 'Cushing Syndrome/*drug therapy', 'Drug Resistance', 'Female', 'Humans', 'Ketoconazole/adverse effects/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8362113/
1270,ketoconazole,32981763,The myringoplasty of the perforation with otomycosis.,['Lou Z'],"['Antifungal Agents/*administration & dosage', 'Ear Cartilage/surgery', 'Endoscopy/*methods', 'Humans', 'Intraoperative Care', 'Ketoconazole/*administration & dosage/adverse effects', 'Myringoplasty/*methods', 'Otomycosis/*drug therapy/*surgery', 'Tympanic Membrane Perforation/*surgery']",https://pubmed.ncbi.nlm.nih.gov/32981763/
1271,ketoconazole,2846299,Treatment of systemic fungal infections: recent progress and current problems.,"['Walsh TJ', 'Pizzo A']","['Amphotericin B/adverse effects/pharmacokinetics/therapeutic use', 'Antifungal Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Fluconazole', 'Flucytosine/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Itraconazole', 'Ketoconazole/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Miconazole/adverse effects/pharmacokinetics/therapeutic use', 'Mycoses/*drug therapy', 'Triazoles/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2846299/
1272,Lanicor,32464466,Digoxin: Pharmacology and toxicology-A review.,"['Patocka J', 'Nepovimova E', 'Wu W', 'Kuca K']","['Animals', 'Digoxin/*adverse effects/*pharmacology', 'Drug Interactions', 'Humans', 'Poisoning/therapy']",https://pubmed.ncbi.nlm.nih.gov/32464466/
1273,Lanicor,9296249,Digoxin-macrolide drug interaction.,"['Bizjak ED', 'Mauro VF']","['Aged', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Biological Availability', 'Digoxin/*adverse effects/pharmacokinetics', 'Drug Interactions', 'Female', 'Humans', 'Macrolides', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/9296249/
1274,Lanicor,29519345,Digoxin and Mortality in Patients With Atrial Fibrillation.,"['Lopes RD', 'Rordorf R', 'De Ferrari GM', 'Leonardi S', 'Thomas L', 'Wojdyla DM', 'Ridefelt P', 'Lawrence JH', 'De Caterina R', 'Vinereanu D', 'Hanna M', 'Flaker G', 'Al-Khatib SM', 'Hohnloser SH', 'Alexander JH', 'Granger CB', 'Wallentin L']","['Aged', 'Anti-Arrhythmia Agents/administration & dosage/adverse effects/blood/pharmacokinetics', '*Atrial Fibrillation/diagnosis/drug therapy/mortality', '*Cause of Death', 'Correlation of Data', '*Death, Sudden/epidemiology/etiology', '*Digoxin/administration & dosage/adverse effects/blood/pharmacokinetics', 'Female', '*Heart Failure/diagnosis/mortality', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Risk Assessment/methods/statistics & numerical data', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/29519345/
1275,Lanicor,26159635,Digoxin: The Art and Science.,['Ewy GA'],"['Aged', 'Cardiotonic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Digoxin/adverse effects/pharmacokinetics/*therapeutic use', 'Heart Failure, Systolic/*drug therapy', 'Humans', 'Tachycardia, Supraventricular/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26159635/
1276,Lanicor,33351042,Effect of Digoxin vs Bisoprolol for Heart Rate Control in Atrial Fibrillation on Patient-Reported Quality of Life: The RATE-AF Randomized Clinical Trial.,"['Kotecha D', 'Bunting KV', 'Gill SK', 'Mehta S', 'Stanbury M', 'Jones JC', 'Haynes S', 'Calvert MJ', 'Deeks JJ', 'Steeds RP', 'Strauss VY', 'Rahimi K', 'Camm AJ', 'Griffith M', 'Lip GYH', 'Townend JN', 'Kirchhof P']","['Adrenergic beta-1 Receptor Antagonists/therapeutic use', 'Aged', 'Aged, 80 and over', 'Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Atrial Fibrillation/complications/*drug therapy/physiopathology', 'Bisoprolol/adverse effects/pharmacology/*therapeutic use', 'Digoxin/adverse effects/pharmacology/*therapeutic use', 'Female', 'Heart Failure/complications/drug therapy', 'Heart Rate/*drug effects', 'Humans', 'Male', 'Middle Aged', '*Quality of Life', 'Single-Blind Method', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/33351042/
1277,Lanicor,31237216,Digoxin in Atrial Fibrillation: An Old Topic Revisited.,"['Ferrari F', 'Santander IRMF', 'Stein R']","['Anti-Arrhythmia Agents/*adverse effects/pharmacology/*therapeutic use', 'Atrial Fibrillation/*drug therapy', 'Cross-Sectional Studies', 'Digoxin/*adverse effects/pharmacology/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/31237216/
1278,Lanicor,6751790,Quinidine and digoxin. An important interaction.,"['Bigger JT Jr', 'Leahey EB Jr']","['Digoxin/adverse effects/*blood/pharmacology', 'Drug Interactions', 'Humans', 'Intestinal Absorption/drug effects', 'Kidney/metabolism', 'Myocardial Contraction/drug effects', 'Quinidine/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6751790/
1279,Lanicor,27696142,Contemporary Controversies in Digoxin Use in Systolic Heart Failure.,"['Albert CL', 'Kamdar F', 'Hanna M']","['Cardiotonic Agents/adverse effects/*therapeutic use', 'Digoxin/adverse effects/*therapeutic use', 'Heart Failure, Systolic/*drug therapy', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27696142/
1280,Lanicor,25944069,[A baby with digoxin toxicity].,"['Andrews LM', 'Puiman PJ', 'van der Sijs H', 'van Beynum IM']","['Antibodies/*administration & dosage', 'Cardiotonic Agents/*adverse effects/therapeutic use', 'Digoxin/*adverse effects/therapeutic use', 'Drug Overdose', 'Drug-Related Side Effects and Adverse Reactions', 'Humans', 'Hyperkalemia/chemically induced', 'Infant', 'Male', 'Medication Errors']",https://pubmed.ncbi.nlm.nih.gov/25944069/
1281,Lanicor,30209692,Is There Still a Role for Digoxin in the Management of Atrial Fibrillation?,"['Washam JB', 'Patel MR']","['Atrial Fibrillation/*drug therapy', 'Digoxin/adverse effects/*therapeutic use', 'Heart Failure/prevention & control', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30209692/
1282,Lanicor,12864722,Digoxin in heart failure and cardiac arrhythmias.,"['Campbell TJ', 'MacDonald PS']","['Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy', 'Digoxin/adverse effects/pharmacology/*therapeutic use', 'Heart Failure/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/12864722/
1283,Lanicor,21988950,Digoxin: clinical highlights: a review of digoxin and its use in contemporary medicine.,"['Ehle M', 'Patel C', 'Giugliano RP']","['Atrial Fibrillation/complications/*drug therapy/physiopathology', 'Cardiotonic Agents/administration & dosage/adverse effects/pharmacokinetics', 'Clinical Protocols', '*Digoxin/administration & dosage/adverse effects/immunology/pharmacokinetics', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Drug Monitoring/*methods', 'Drug-Related Side Effects and Adverse Reactions/etiology/*physiopathology/therapy', 'Heart Failure/complications/*drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Immunoglobulin Fab Fragments/*therapeutic use', 'Myocardial Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21988950/
1284,Lanicor,1389200,The rational pharmacology of digoxin.,"['Heerdt PM', 'Heerdt ME']","['Digoxin/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1389200/
1285,Lanicor,23008361,Digoxin--'a friend or foe'.,['Kolev KK'],"['Aged', 'Anti-Arrhythmia Agents/*adverse effects/immunology/therapeutic use', 'Atrial Fibrillation/*drug therapy/etiology', 'Cardiotonic Agents/administration & dosage/adverse effects/*therapeutic use', 'Digitalis Glycosides/administration & dosage/adverse effects/*therapeutic use', 'Digoxin/*adverse effects/immunology/therapeutic use', 'Female', 'Heart Rate/drug effects', 'Humans', 'Immunoglobulin Fab Fragments/*therapeutic use', 'Stroke/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23008361/
1286,Lanicor,7873474,Reassessment of digoxin and other low-dose positive inotropes in the treatment of chronic heart failure.,"['Tauke J', 'Han D', 'Gheorghiade M']","['Adrenergic beta-Agonists/administration & dosage/pharmacology/*therapeutic use', 'Cardiotonic Agents/administration & dosage/pharmacology/*therapeutic use', 'Digoxin/administration & dosage/pharmacology/*therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Electrophysiology', 'Heart Failure/*drug therapy/mortality', 'Hemodynamics/drug effects', 'Humans', 'Myocardial Contraction/*drug effects', 'Neurosecretory Systems/drug effects', 'Phosphodiesterase Inhibitors/administration & dosage/pharmacology/*therapeutic use', 'Pyrazines', 'Quinolines/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7873474/
1287,Lanicor,671662,Interaction between quinidine and digoxin.,"['Leahey EB Jr', 'Reiffel JA', 'Drusin RE', 'Heissenbuttel RH', 'Lovejoy WP', 'Bigger JT Jr']","['Aged', 'Anorexia/chemically induced', 'Arrhythmias, Cardiac/*drug therapy', 'Digoxin/*administration & dosage/adverse effects/blood', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Quinidine/*administration & dosage/pharmacology', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/671662/
1288,Lanicor,7037912,Digoxin use in the elderly.,['Stults BM'],"['Adult', 'Age Factors', 'Aged', 'Atrial Fibrillation/blood/drug therapy', 'Digoxin/adverse effects/blood/metabolism/*therapeutic use', 'Diuretics/therapeutic use', 'Drug Interactions', 'Half-Life', 'Heart Conduction System/physiopathology', 'Heart Failure/drug therapy', 'Heart Ventricles/physiopathology', 'Humans', 'Middle Aged', 'Monitoring, Physiologic', 'Patient Compliance', 'Quinidine/blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7037912/
1289,Lanicor,9639187,Clarithromycin induced digoxin toxicity.,"['Nordt SP', 'Williams SR', 'Manoguerra AS', 'Clark RF']","['Adult', 'Anorexia/chemically induced', 'Anti-Arrhythmia Agents/*poisoning/therapeutic use', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Clarithromycin/*adverse effects/therapeutic use', 'Digoxin/*poisoning/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Humans', 'Male', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/9639187/
1290,Lanicor,22216507,"Digoxin therapy: textbooks, theory and practice.","['Aronson JK', 'Grahame-Smith DG']","['Cardiotonic Agents/*therapeutic use', 'Digoxin/administration & dosage/pharmacokinetics/*therapeutic use', 'Drug Administration Schedule', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/22216507/
1291,Lanicor,15868358,Digitalis in heart failure! Still applicable?,"['Hoppe UC', 'Erdmann E']","['Adrenergic beta-Antagonists/adverse effects/pharmacokinetics/therapeutic use', 'Atrial Fibrillation/blood/*drug therapy/mortality', 'Digitalis Glycosides/adverse effects/pharmacokinetics/*therapeutic use', 'Digoxin/adverse effects/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Heart Failure/blood/*drug therapy/mortality', 'Humans', 'Risk Factors', 'Sex Factors', 'Survival Analysis', 'Sympathetic Nervous System/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15868358/
1292,nitrazepam,20726290,Best practice guide for the treatment of nightmare disorder in adults.,"['Aurora RN', 'Zak RS', 'Auerbach SH', 'Casey KR', 'Chowdhuri S', 'Karippot A', 'Maganti RK', 'Ramar K', 'Kristo DA', 'Bista SR', 'Lamm CI', 'Morgenthaler TI']","['Adult', 'Clonidine/therapeutic use', 'Cognitive Behavioral Therapy/methods', 'Dreams/drug effects/*psychology', 'Evidence-Based Medicine', 'Eye Movement Desensitization Reprocessing', 'Humans', 'Hypnosis', 'Norepinephrine/antagonists & inhibitors', 'Prazosin/therapeutic use', 'Psychotropic Drugs/therapeutic use', 'Randomized Controlled Trials as Topic', 'Relaxation Therapy', 'Stress Disorders, Post-Traumatic/diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/20726290/
1293,nitrazepam,4892037,Nitrazepam--a safe hypnotic.,"['Matthew H', 'Proudfoot AT', 'Aitken RC', 'Raeburn JA', 'Wright N']","['Adult', 'Aged', 'Barbiturates/therapeutic use', '*Benzazepines/poisoning/therapeutic use', 'Clinical Trials as Topic', 'Female', 'Humans', 'Hypnotics and Sedatives/*poisoning/*therapeutic use', 'Male', 'Middle Aged', 'Placebos', 'Sleep', 'Sleep Initiation and Maintenance Disorders/drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/4892037/
1294,nitrazepam,82859,One man's poison.,['Hunter A'],"['Capsules', 'Clinical Trials as Topic', 'Diphenhydramine/administration & dosage', 'Drug Combinations', 'Drug Evaluation', 'Flurazepam/administration & dosage', 'Humans', 'Methaqualone/administration & dosage', 'Nitrazepam/administration & dosage', 'Sleep/*drug effects', 'Temazepam/administration & dosage', '*Travel']",https://pubmed.ncbi.nlm.nih.gov/82859/
1295,nitrazepam,3117519,Febrile seizures.,['Rosman NP'],"['Child', 'Child, Preschool', 'Diagnosis, Differential', 'Diazepam/administration & dosage', 'Electroencephalography', 'Epilepsy/etiology', 'Female', 'Humans', 'Infant', 'Male', 'Nitrazepam/administration & dosage', 'Phenobarbital/therapeutic use', 'Risk Factors', '*Seizures, Febrile/complications/diagnosis/drug therapy/prevention & control', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3117519/
1296,nitrazepam,8692185,Genetic toxicology of four commonly used benzodiazepines: a review.,"['Giri AK', 'Banerjee S']","['Animals', 'Benzodiazepines/*toxicity', 'Chlordiazepoxide/toxicity', '*DNA Damage', 'Diazepam/toxicity', 'Humans', 'Mutagenicity Tests/*methods', 'Mutagens/*toxicity', 'Nitrazepam/toxicity', 'Oxazepam/toxicity']",https://pubmed.ncbi.nlm.nih.gov/8692185/
1297,nitrazepam,6124415,"Use of benzodiazepines during pregnancy, labour and lactation, with particular reference to pharmacokinetic considerations.",['Kanto JH'],"['Anti-Anxiety Agents/adverse effects/*metabolism', 'Chlordiazepoxide/metabolism', 'Clorazepate Dipotassium/metabolism', 'Diazepam/metabolism', 'Female', 'Flunitrazepam/metabolism', 'Humans', 'Infant, Newborn', '*Labor, Obstetric', '*Lactation', 'Lorazepam/metabolism', 'Maternal-Fetal Exchange', 'Nitrazepam/metabolism', 'Oxazepam/metabolism', '*Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/6124415/
1298,nitrazepam,2985947,Myoclonus.,['Swaiman KF'],"['Adrenocorticotropic Hormone/therapeutic use', 'Child', 'Child, Preschool', 'Clonazepam/therapeutic use', 'Diagnosis, Differential', 'Electroencephalography', 'Epilepsies, Myoclonic/diagnosis/drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Myoclonus/*classification', 'Nitrazepam/therapeutic use', 'Prednisone/therapeutic use', 'Spasms, Infantile/diagnosis/therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2985947/
1299,nitrazepam,7725291,[Insomnia and hypnotics].,['Kayed K'],"['Humans', 'Hypnotics and Sedatives/*administration & dosage', 'Sleep Initiation and Maintenance Disorders/classification/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7725291/
1300,nitrazepam,687502,Clobazam--a new hypnotic?,"['Kesson CM', 'Gray JM', 'Lawson DH']","['Adult', 'Age Factors', 'Aged', 'Benzodiazepinones/*pharmacology', 'Double-Blind Method', 'Female', 'Humans', '*Hypnotics and Sedatives', 'Male', 'Middle Aged', 'Nitrazepam/pharmacology', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/687502/
1301,nitrazepam,7572872,Two cases of lethal nitrazepam poisoning.,"['Brodsgaard I', 'Hansen AC', 'Vesterby A']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Nitrazepam/blood/*poisoning', '*Suicide, Assisted']",https://pubmed.ncbi.nlm.nih.gov/7572872/
1302,nitrazepam,6142468,Pharmacological studies on zopiclone.,"['Julou L', 'Bardone MC', 'Blanchard JC', 'Garret C', 'Stutzmann JM']","['Aggression/drug effects', 'Animals', 'Anti-Anxiety Agents/pharmacology', 'Anticonvulsants', 'Azabicyclo Compounds', 'Barbiturates/pharmacology', 'Benzodiazepines', 'Cats', 'Drug Tolerance', 'Electrophysiology', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Mice', 'Mice, Inbred Strains', 'Muscle Relaxants, Central', 'Piperazines/*pharmacology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/6142468/
1303,nitrazepam,4717418,Benzodiazepines and tricyclic antidepressant plasma levels.,"['Silverman G', 'Braithwaite RA']","['Amitriptyline/*blood', 'Benzazepines/*pharmacology', 'Chlordiazepoxide/administration & dosage/pharmacology', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations', 'Drug Interactions', 'Female', 'Humans', 'Male', 'Nitrazepam/administration & dosage/pharmacology', 'Nortriptyline/*blood', 'Oxazepam/administration & dosage/pharmacology', 'Tranquilizing Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/4717418/
1304,nitrazepam,25926432,Gut Microbiota-Mediated Drug-Antibiotic Interactions.,['Kim DH'],"['Administration, Oral', 'Animals', 'Anti-Bacterial Agents/*administration & dosage/*metabolism', 'Drug Interactions/*physiology', 'Gastrointestinal Microbiome/*drug effects/*physiology', 'Gastrointestinal Tract/drug effects/metabolism/microbiology', 'Humans', 'Pharmaceutical Preparations/administration & dosage/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25926432/
1305,nitrazepam,6135296,Triazolam as a hypnotic for geriatric patients. A double-blind cross-over comparison of nitrazepam and triazolam regarding effects on sleep and psychomotor performance.,"['Dehlin O', 'Bjornson G']","['Aged', 'Anti-Anxiety Agents/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motor Skills/*drug effects', 'Nitrazepam/adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/*drug effects', 'Triazolam/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6135296/
1306,nitrazepam,20418931,[Benzodiazepines in the treatment of epilepsy].,"['Nakken KO', 'Rytter EM', 'Brockmeier F']","['Administration, Buccal', 'Anticonvulsants/administration & dosage/*therapeutic use', 'Benzodiazepines/administration & dosage/*therapeutic use', 'Epilepsy/*drug therapy/prevention & control', 'Humans', 'Midazolam/administration & dosage', 'Status Epilepticus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20418931/
1307,nitrazepam,9022890,Benzodiazepine misuse by drug addicts.,"['Garretty DJ', 'Wolff K', 'Hay AW', 'Raistrick D']","['Alcoholism/drug therapy', 'Benzodiazepines/*therapeutic use/*urine', 'Chromatography, High Pressure Liquid/methods', 'Diazepam/therapeutic use/urine', 'Humans', 'Narcotics', 'Nitrazepam/therapeutic use/urine', 'Nordazepam/therapeutic use/urine', 'Substance-Related Disorders/drug therapy/*epidemiology', 'Temazepam/therapeutic use/urine']",https://pubmed.ncbi.nlm.nih.gov/9022890/
1308,nitrazepam,19450355,Insomnia in the elderly.,"['Montgomery P', 'Lilly J']","['Aged', 'Cognitive Behavioral Therapy', 'Flurazepam/pharmacology', 'Humans', 'Risk Factors', '*Sleep/drug effects', '*Sleep Initiation and Maintenance Disorders', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/19450355/
1309,nitrazepam,1349894,An investigation of the association of benzodiazepines and other hypnotics with the incidence of falls in the elderly.,"['Trewin VF', 'Lawrence CJ', 'Veitch GB']","['*Accidental Falls', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Benzodiazepines', 'Female', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Incidence', 'Male', 'Risk Factors', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/1349894/
1310,nitrazepam,5071698,Factors leading to dependence on hypnotic drugs.,['Clift AD'],"['Amobarbital/*adverse effects', 'Benzazepines/*adverse effects', 'Diazepam/adverse effects', 'Family Practice', 'Female', 'Glutethimide/adverse effects', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Male', 'Nitrazepam/adverse effects', 'Personality Disorders/complications', 'Sleep Initiation and Maintenance Disorders/drug therapy/etiology', 'Substance-Related Disorders/complications/*etiology']",https://pubmed.ncbi.nlm.nih.gov/5071698/
1311,nitrazepam,6669627,Effects of hypnotics on memory.,"['Fossen A', 'Godlibsen OB', 'Loyning Y', 'Dreyfus JF']","['Adult', 'Azabicyclo Compounds', 'Female', 'Flunitrazepam/pharmacology', 'Humans', 'Hypnotics and Sedatives/*pharmacology', 'Male', 'Memory/*drug effects', 'Neuropsychological Tests', 'Piperazines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6669627/
1312,Desloratadine,38470381,Allergic Rhinitis: A Review.,"['Bernstein JA', 'Bernstein JS', 'Makol R', 'Ward S']","['Humans', 'Budesonide/administration & dosage/therapeutic use', 'Cetirizine/therapeutic use', 'Fluticasone/administration & dosage/therapeutic use', 'Histamine H1 Antagonists/administration & dosage/therapeutic use', 'Immunoglobulin E/immunology', 'Mometasone Furoate/administration & dosage/therapeutic use', 'Olopatadine Hydrochloride/administration & dosage/therapeutic use', 'Pruritus/etiology', '*Rhinitis, Allergic/complications/diagnosis/immunology/therapy', 'Rhinorrhea/etiology', 'Sneezing', 'Triamcinolone/administration & dosage/therapeutic use', '*Glucocorticoids/administration & dosage/therapeutic use', 'Rhinitis/drug therapy', '*Histamine Antagonists/administration & dosage/therapeutic use', 'Administration, Intranasal']",https://pubmed.ncbi.nlm.nih.gov/38470381/
1313,Desloratadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
1314,Desloratadine,36617552,Blockade of NMT1 enzymatic activity inhibits N-myristoylation of VILIP3 protein and suppresses liver cancer progression.,"['Tan XP', 'He Y', 'Yang J', 'Wei X', 'Fan YL', 'Zhang GG', 'Zhu YD', 'Li ZQ', 'Liao HX', 'Qin DJ', 'Guan XY', 'Li B']","['Humans', '*Carcinoma, Hepatocellular/drug therapy/genetics', '*Liver Neoplasms/drug therapy/genetics', 'Myristic Acid/metabolism', 'Protein Processing, Post-Translational']",https://pubmed.ncbi.nlm.nih.gov/36617552/
1315,Desloratadine,33030434,Efficacy and Safety of Up-dosing Antihistamines in Chronic Spontaneous Urticaria: A Systematic Review of the Literature.,"['Iriarte Sotes P', 'Armisen M', 'Usero-Barcena T', 'Rodriguez Fernandez A', 'Otero Rivas MM', 'Gonzalez MT', 'Meijide Calderon A', 'Veleiro B']","['Administration, Oral', 'Animals', 'Anti-Allergic Agents/*therapeutic use', 'Chronic Urticaria/*drug therapy', 'Clinical Trials as Topic', 'Drug Dosage Calculations', 'Drug-Related Side Effects and Adverse Reactions', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33030434/
1316,Desloratadine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1317,Desloratadine,33893956,Antihistamines Modulate Functional Activity of Macrophages.,"['Plekhova NG', 'Eliseeva EV', 'Dubnyak IN']","['Animals', 'Cells, Cultured', 'Histamine Antagonists/*pharmacology', 'Humans', 'Hypersensitivity/metabolism', 'Loratadine/analogs & derivatives/pharmacology', 'Macrophages, Peritoneal/*drug effects/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/33893956/
1318,Desloratadine,22185044,Effect of bilastine upon nasal obstruction.,"['Davila I', 'Sastre J', 'Mullol J', 'Montoro J', 'Jauregui I', 'Ferrer M', 'del Cuvillo A', 'Bartra J', 'Valero A']","['Benzimidazoles/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Nasal Obstruction/*drug therapy', 'Piperidines/pharmacology/*therapeutic use', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22185044/
1319,Desloratadine,26839083,Effectiveness of allergic rhinitis treatments in real-life with a focus on MP-AzeFlu.,"['Klimek L', 'Demoly P', 'Price D']","['Adrenal Cortex Hormones/*therapeutic use', 'Fluticasone/administration & dosage/*therapeutic use', 'Histamine Antagonists/*therapeutic use', 'Humans', 'Phthalazines/administration & dosage/*therapeutic use', 'Rhinitis, Allergic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26839083/
1320,Desloratadine,38958110,Multicompartment Polyion Complex Micelles Based on Triblock Polypept(o)ides Mediate Efficient siRNA Delivery to Cancer-Associated Fibroblasts for Antistromal Therapy of Hepatocellular Carcinoma.,"['Schneider P', 'Zhang H', 'Simic L', 'Dai Z', 'Schrors B', 'Akilli-Ozturk O', 'Lin J', 'Durak F', 'Schunke J', 'Bolduan V', 'Bogaert B', 'Schwiertz D', 'Schafer G', 'Bros M', 'Grabbe S', 'Schattenberg JM', 'Raemdonck K', 'Koynov K', 'Diken M', 'Kaps L', 'Barz M']","['*Carcinoma, Hepatocellular/drug therapy/pathology/metabolism', '*RNA, Small Interfering/chemistry', '*Liver Neoplasms/drug therapy/pathology/metabolism', 'Animals', '*Micelles', 'Mice', '*Cancer-Associated Fibroblasts/metabolism/drug effects', 'Humans', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38958110/
1321,Desloratadine,14988742,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['Clinical Trials as Topic/*statistics & numerical data', 'Databases, Factual/*statistics & numerical data', 'Humans', 'Statistics as Topic']",https://pubmed.ncbi.nlm.nih.gov/14988742/
1322,Desloratadine,23967751,Treatment of recalcitrant chronic urticaria with nonsedating antihistamines: is there evidence for updosing?,"['Sanchez-Borges M', 'Caballero-Fonseca F', 'Capriles-Hulett A']","['Chronic Disease', 'Histamine H1 Antagonists, Non-Sedating/*administration & dosage', 'Humans', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23967751/
1323,Desloratadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
1324,Desloratadine,28458435,Ciprofloxacin induced acute generallised exanthematous pustulosis.,"['Foti C', 'Romita P', 'Zanframundo G', 'Mastrolonardo M', 'Angelini G', 'Calogiuri G', 'Nettis E', 'Bonamonte D']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Fever/etiology', 'Humans', 'Intertrigo/drug therapy', 'Loratadine/administration & dosage/analogs & derivatives', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28458435/
1325,Desloratadine,20480793,Second-generation antihistamines for the treatment of chronic idiopathic urticaria.,['Belsito DV'],"['Brain/metabolism', 'Chronic Disease', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Quality of Life', 'Receptors, Histamine H1/drug effects/metabolism', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20480793/
1326,Desloratadine,35725203,Effective RNAi in leukemia cells is enhanced by spermine-modified pullulan combined with desloratadine.,"['Wang T', 'Hao B', 'Xu S', 'Meng J', 'Wen T', 'Liu J', 'Xu H']","['Glucans', 'Humans', '*Leukemia/drug therapy/genetics', 'Loratadine/analogs & derivatives', 'RNA Interference', 'RNA, Small Interfering/genetics/therapeutic use', '*Spermine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35725203/
1327,Desloratadine,32579347,Asymmetric Catalysis upon Helically Chiral Loratadine Analogues Unveils Enantiomer-Dependent Antihistamine Activity.,"['Stone EA', 'Cutrona KJ', 'Miller SJ']","['Aspartic Acid/*chemistry', 'Catalysis', 'Histamine Antagonists/chemical synthesis/chemistry/*pharmacology', 'Humans', 'Loratadine/analogs & derivatives/chemistry/*pharmacology', 'Molecular Conformation', 'Molecular Docking Simulation', 'Peptides/*chemistry', 'Receptors, Histamine/*metabolism', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/32579347/
1328,Desloratadine,22686617,Bilastine: in allergic rhinitis and urticaria.,['Carter NJ'],"['Area Under Curve', 'Benzimidazoles/*therapeutic use', 'Cetirizine/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/therapeutic use', 'Piperidines/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Perennial/*drug therapy', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22686617/
1329,Desloratadine,26253363,H1-antihistamines for chronic spontaneous urticaria: an abridged Cochrane Systematic Review.,"['Sharma M', 'Bennett C', 'Carter B', 'Cohen SN']","['Chronic Disease', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Histamine Antagonists/*therapeutic use', 'Humans', 'Male', '*Quality of Life', 'Randomized Controlled Trials as Topic', 'Recurrence', 'Severity of Illness Index', 'Treatment Outcome', 'Urticaria/*diagnosis/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/26253363/
1330,Desloratadine,24673474,"Assessment of the effects of antihistamine drugs on mood, sleep quality, sleepiness, and dream anxiety.","['Ozdemir PG', 'Karadag AS', 'Selvi Y', 'Boysan M', 'Bilgili SG', 'Aydin A', 'Onder S']","['Adolescent', 'Adult', 'Affect/*drug effects', 'Anxiety/chemically induced', 'Depression/chemically induced', 'Dreams/*drug effects', 'Fatigue/chemically induced', 'Female', 'Histamine H1 Antagonists/*adverse effects/*pharmacology/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects/*pharmacology/therapeutic use', 'Humans', 'Middle Aged', 'Pruritus/drug therapy', 'Sleep/*drug effects', 'Sleep Stages/*drug effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24673474/
1331,rofecoxib,11566042,COX-1 and COX-2 inhibitors.,['Hawkey CJ'],"['Celecoxib', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects/pharmacology', 'Humans', 'Isoenzymes/*antagonists & inhibitors/metabolism', 'Lactones/*adverse effects/pharmacology', 'Membrane Proteins', 'Peptic Ulcer/chemically induced', 'Prostaglandin-Endoperoxide Synthases/metabolism', 'Pyrazoles', 'Sulfonamides/*adverse effects/pharmacology', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11566042/
1332,rofecoxib,15270001,[Etoricoxib (Arcoxia)].,"['Leclercq P', 'Malaise MG']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Gouty/*drug therapy', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2', 'Etoricoxib', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Osteoarthritis/*drug therapy', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sulfones/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15270001/
1333,rofecoxib,10892637,Cyclooxygenase-2 enzyme inhibitors: place in therapy.,"['Noble SL', 'King DS', 'Olutade JI']","['Analgesics, Non-Narcotic/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Arthritis/drug therapy', 'Bleeding Time', 'Blood Platelets/drug effects', 'Celecoxib', 'Cyclooxygenase Inhibitors/adverse effects/economics/pharmacokinetics/*therapeutic use', 'Drug Interactions', 'Duodenal Ulcer/chemically induced', 'Humans', 'Lactones/therapeutic use', 'Pyrazoles', 'Risk Factors', 'Sulfonamides/therapeutic use', 'Sulfones', 'United States']",https://pubmed.ncbi.nlm.nih.gov/10892637/
1334,rofecoxib,24393558,"Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications.","['Harirforoosh S', 'Asghar W', 'Jamali F']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use', 'Cardiovascular System/drug effects', 'Gastrointestinal Tract/drug effects', 'Humans', 'Kidney/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24393558/
1335,rofecoxib,35585779,Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials.,"['Stiller CO', 'Hjemdahl P']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Celecoxib', 'Cyclooxygenase 2', '*Cyclooxygenase 2 Inhibitors/adverse effects', '*Diclofenac/adverse effects', 'Etoricoxib', 'Fibrinolytic Agents/therapeutic use', 'Humans', 'Ibuprofen/adverse effects', 'Lactones', 'Naproxen', 'Prostaglandins', 'Prostaglandins I', 'Sulfones', 'Thromboxanes']",https://pubmed.ncbi.nlm.nih.gov/35585779/
1336,rofecoxib,10493277,Rofecoxib.,"['Scott LJ', 'Lamb HM']","['Analgesics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Lactones/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Osteoarthritis/drug therapy', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10493277/
1337,rofecoxib,32251635,Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review.,"['Arora M', 'Choudhary S', 'Singh PK', 'Sapra B', 'Silakari O']","['Cardiotoxicity/*etiology/physiopathology/prevention & control', 'Celecoxib/administration & dosage/adverse effects', 'Cyclooxygenase 2 Inhibitors/administration & dosage/*adverse effects/chemistry', 'Drug Labeling', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/32251635/
1338,rofecoxib,17003914,COX-2 inhibitors and cardiovascular risk. Inferences based on biology and clinical studies.,"['Marwali MR', 'Mehta JL']","['Animals', 'Blood Platelets/*drug effects/metabolism', 'Cardiovascular Diseases/*chemically induced/metabolism', 'Celecoxib', 'Cyclooxygenase 2/metabolism', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Diclofenac/adverse effects/analogs & derivatives', 'Drug Labeling', 'Endothelium, Vascular/*drug effects/metabolism', 'Epoprostenol/metabolism', 'Humans', 'Lactones/adverse effects', 'Platelet Aggregation', 'Product Surveillance, Postmarketing', 'Pyrazoles/adverse effects', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects', 'Thromboxane A2/metabolism']",https://pubmed.ncbi.nlm.nih.gov/17003914/
1339,rofecoxib,25956433,Elevation of cardiovascular risk by non-steroidal anti-inflammatory drugs.,"['Anwar A', 'Anwar IJ', 'Delafontaine P']","['Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Cardiovascular Diseases/enzymology/*etiology/physiopathology', 'Case-Control Studies', 'Cyclooxygenase 1/drug effects/*metabolism', 'Cyclooxygenase 2/drug effects/*metabolism', 'Female', 'Follow-Up Studies', 'Homeostasis/drug effects', 'Humans', 'Lactones/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Naproxen/adverse effects/therapeutic use', 'Prevalence', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Sulfones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25956433/
1340,rofecoxib,11087881,Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.,"['Bombardier C', 'Laine L', 'Reicin A', 'Shapiro D', 'Burgos-Vargas R', 'Davis B', 'Day R', 'Ferraz MB', 'Hawkey CJ', 'Hochberg MC', 'Kvien TK', 'Schnitzer TJ']","['Adult', 'Arthritis, Rheumatoid/*drug therapy/mortality', 'Cardiovascular Diseases/mortality', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*therapeutic use', 'Duodenal Obstruction/chemically induced', 'Female', 'Gastric Outlet Obstruction/chemically induced', 'Gastrointestinal Diseases/*chemically induced', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Membrane Proteins', 'Middle Aged', 'Naproxen/*adverse effects/therapeutic use', 'Peptic Ulcer/chemically induced', 'Proportional Hazards Models', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11087881/
1341,rofecoxib,11173045,Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors.,"['Buttgereit F', 'Burmester GR', 'Simon LS']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Anti-Ulcer Agents/therapeutic use', 'Celecoxib', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastric Mucosa/drug effects', 'Gastrointestinal Diseases/*chemically induced/epidemiology/prevention & control', 'Humans', 'Incidence', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/*adverse effects', 'Membrane Proteins', 'Patient Selection', 'Practice Guidelines as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/*adverse effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11173045/
1342,rofecoxib,14519044,Safety of COX-2 inhibitors in asthma patients with aspirin hypersensitivity.,"['West PM', 'Fernandez C']","['Anti-Inflammatory Agents, Non-Steroidal/pharmacology/therapeutic use', 'Aspirin/administration & dosage/*adverse effects', 'Asthma/*chemically induced/drug therapy/*prevention & control', 'Celecoxib', 'Cyclooxygenase 2', 'Drug Hypersensitivity/complications/*etiology', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Lactones/administration & dosage/pharmacokinetics/therapeutic use', 'Membrane Proteins', 'Meta-Analysis as Topic', 'Prostaglandin-Endoperoxide Synthases', 'Pyrazoles', 'Sulfonamides/administration & dosage/pharmacokinetics/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/14519044/
1343,rofecoxib,11249495,Rofecoxib.,"['Hillson JL', 'Furst DE']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Arthritis/drug therapy', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Approval', 'Humans', 'Isoenzymes/*drug effects', 'Lactones/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Membrane Proteins', 'Pain/drug therapy', 'Prostaglandin-Endoperoxide Synthases/*drug effects', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11249495/
1344,rofecoxib,11550988,Nephrotoxicity of selective COX-2 inhibitors.,"['Woywodt A', 'Schwarz A', 'Mengel M', 'Haller H', 'Zeidler H', 'Kohler L']","['Acute Kidney Injury/*chemically induced/therapy', 'Adult', 'Arthritis, Psoriatic/diagnosis/*drug therapy', 'Cyclooxygenase Inhibitors/*adverse effects/therapeutic use', 'Follow-Up Studies', 'Humans', 'Kidney/*drug effects', 'Kidney Function Tests', 'Kidney Transplantation', 'Lactones/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Osteoarthritis/diagnosis/*drug therapy', 'Renal Dialysis/methods', 'Risk Assessment', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11550988/
1345,rofecoxib,11953329,Cyclooxygenase inhibition: between the devil and the deep blue sea.,['Hawkey CJ'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Arthritis/drug therapy', 'Celecoxib', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastroscopy', 'Humans', 'Isoenzymes/*antagonists & inhibitors', 'Kidney/drug effects', 'Lactones/adverse effects', 'Meloxicam', 'Membrane Proteins', 'Myocardial Infarction/chemically induced', 'Prostaglandin-Endoperoxide Synthases', 'Proton Pump Inhibitors', 'Pyrazoles', 'Randomized Controlled Trials as Topic', 'Stomach Ulcer/*chemically induced', 'Sulfonamides/adverse effects', 'Sulfones', 'Thiazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11953329/
1346,rofecoxib,18457612,The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis.,"['Scanzello CR', 'Moskowitz NK', 'Gibofsky A']","['Administration, Topical', 'Analgesics/*administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dietary Supplements', 'Humans', 'Inflammation/drug therapy/physiopathology', 'Joints/drug effects/innervation/physiopathology', 'Osteoarthritis/*drug therapy/physiopathology', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18457612/
1347,rofecoxib,16184084,Essay: the political logic of regulatory error.,"['Carpenter D', 'Ting MM']","['Drug Approval/legislation & jurisprudence/*methods/statistics & numerical data', 'Humans', 'Lactones/adverse effects/therapeutic use', '*Logic', 'Observer Variation', '*Politics', 'Research Design/*statistics & numerical data', 'Sulfones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16184084/
1348,rofecoxib,11478054,Current concepts regarding pharmacologic treatment of rheumatoid and osteoarthritis.,"['Wildy KS', 'Wasko MC']","['Adjuvants, Immunologic/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Antibodies, Monoclonal/therapeutic use', 'Antirheumatic Agents/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/physiopathology', 'Celecoxib', 'Cyclooxygenase Inhibitors/therapeutic use', 'Digestive System/drug effects', 'Etanercept', 'Glucocorticoids/therapeutic use', 'Humans', 'Hydroxychloroquine/therapeutic use', 'Immunoglobulin G/therapeutic use', 'Infliximab', 'Isoxazoles/therapeutic use', 'Lactones/therapeutic use', 'Leflunomide', 'Methotrexate/therapeutic use', 'Osteoarthritis/*drug therapy', 'Pyrazoles', 'Receptors, Tumor Necrosis Factor/therapeutic use', 'Sulfasalazine/therapeutic use', 'Sulfonamides/therapeutic use', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/11478054/
1349,rofecoxib,12017748,[Pain management with herbal antirheumatic drugs].,"['Chrubasik S', 'Pollak S']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Lactones/adverse effects/therapeutic use', 'Low Back Pain/drug therapy', '*Phytotherapy', 'Plant Extracts/adverse effects/*therapeutic use', 'Sulfones', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12017748/
1350,rofecoxib,11467102,Ibuprofen to rofecoxib: what does it all mean and what do I do now?,"['Varga J', 'Dickman A']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Drug Administration Schedule', 'Drug Costs', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Ibuprofen/adverse effects/classification/economics/*therapeutic use', 'Lactones/classification/economics/*therapeutic use', 'Neoplasms/complications', 'Pain/*drug therapy/etiology/prevention & control', '*Patient Selection', 'Risk Factors', 'Sulfones', 'Terminal Care/methods']",https://pubmed.ncbi.nlm.nih.gov/11467102/
1351,Colesevelam,21342078,Statin-induced myopathy: a review and update.,"['Abd TT', 'Jacobson TA']","['Animals', 'Drug Interactions', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Muscles/drug effects', 'Muscular Diseases/*chemically induced', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/21342078/
1352,Colesevelam,29671894,Select medications that unexpectedly lower HbA1c levels.,"['Tillman F', 'Kim J']","['Blood Glucose/drug effects', 'Bromocriptine/therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Glycated Hemoglobin/*metabolism', 'Humans', 'Hypoglycemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29671894/
1353,Colesevelam,28153426,Factors Affecting Gastrointestinal Absorption of Levothyroxine: A Review.,"['Skelin M', 'Lucijanic T', 'Amidzic Klaric D', 'Resic A', 'Bakula M', 'Liberati-Cizmek AM', 'Gharib H', 'Rahelic D']","['Gastrointestinal Diseases/*physiopathology', 'Humans', '*Intestinal Absorption', 'Proton Pump Inhibitors/pharmacology', 'Thyrotropin/blood', 'Thyroxine/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28153426/
1354,Colesevelam,24410472,Advances in understanding of bile acid diarrhea.,['Camilleri M'],"['Antidiarrheals/therapeutic use', 'Bile Acids and Salts/*metabolism', 'Diarrhea/drug therapy/*metabolism/*physiopathology', 'Fibroblast Growth Factors/metabolism', 'Humans', 'Ileum/metabolism', 'Receptors, Cytoplasmic and Nuclear/agonists']",https://pubmed.ncbi.nlm.nih.gov/24410472/
1355,Colesevelam,32400758,Colesevelam in the management of type 2 diabetes.,"['Kalra S', 'Priya G', 'Aggarwal S']","['Anticholesteremic Agents/pharmacology', 'Colesevelam Hydrochloride/*pharmacology', '*Diabetes Mellitus, Type 2/drug therapy/metabolism', 'Dyslipidemias/*drug therapy/metabolism', 'Humans', 'Pharmacovigilance']",https://pubmed.ncbi.nlm.nih.gov/32400758/
1356,Colesevelam,23317402,Colesevelam: a new and improved bile acid sequestrant?,"['Tziomalos K', 'Karagiannis A', 'Mikhailidis DP', 'Athyros VG']","['Allylamine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Anticholesteremic Agents/*therapeutic use', 'Bile Acids and Salts/*metabolism', 'C-Reactive Protein/analysis', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Glycated Hemoglobin/analysis', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage', 'Hypercholesterolemia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23317402/
1357,Colesevelam,21739227,Use and indications of cholestyramine and bile acid sequestrants.,"['Scaldaferri F', 'Pizzoferrato M', 'Ponziani FR', 'Gasbarrini G', 'Gasbarrini A']","['Anticholesteremic Agents/*therapeutic use', 'Bile/metabolism', 'Cholestasis/complications/*drug therapy', 'Cholestyramine Resin/*therapeutic use', 'Humans', 'Hypercholesterolemia/complications/drug therapy', 'Sequestering Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21739227/
1358,Colesevelam,27578074,Itch Management: Treatments under Development.,"['Pereira MP', 'Stander S']","['Acrylamides/therapeutic use', 'Analgesics, Opioid/*therapeutic use', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Antipruritics/*therapeutic use', 'Carrier Proteins/antagonists & inhibitors', 'Cholestasis/complications', 'Colesevelam Hydrochloride', 'Humans', 'Lymphoma, T-Cell, Cutaneous/complications/drug therapy', 'Membrane Glycoproteins/antagonists & inhibitors', 'Nerve Growth Factor/antagonists & inhibitors', 'Neurokinin-1 Receptor Antagonists/*therapeutic use', 'Prurigo/complications/drug therapy', 'Pruritus/*drug therapy/etiology', 'Pyridines/therapeutic use', 'Receptors, Interleukin/antagonists & inhibitors', 'Receptors, Opioid, kappa/agonists', 'Sequestering Agents/*therapeutic use', 'TRPV Cation Channels/antagonists & inhibitors', 'Uremia/complications']",https://pubmed.ncbi.nlm.nih.gov/27578074/
1359,Colesevelam,14728043,Colesevelam.,"['Melian EB', 'Plosker GL']","['Allylamine/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Colesevelam Hydrochloride', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', 'Hypolipidemic Agents/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14728043/
1360,Colesevelam,16568248,Lipid-lowering drugs.,['Pahan K'],"['Alzheimer Disease/drug therapy', '*Clofibric Acid/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hyperlipidemias/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Lipids/biosynthesis', 'Neoplasms/drug therapy', 'Osteoporosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16568248/
1361,Colesevelam,25041567,Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential.,"['Bronden A', 'Hansen M', 'Sonne DP', 'Rohde U', 'Vilsboll T', 'Knop FK']","['Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology', 'Anticholesteremic Agents/pharmacokinetics/pharmacology', 'Cholesterol, LDL/blood/drug effects', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Glycated Hemoglobin/*drug effects/metabolism', 'Humans', 'Hypercholesterolemia/blood/*drug therapy', 'Hypoglycemic Agents/pharmacokinetics/*pharmacology', 'Polyamines/pharmacokinetics/*pharmacology', 'Sevelamer', 'Treatment Outcome', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/25041567/
1362,Colesevelam,20415686,Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence.,"['Fonseca VA', 'Handelsman Y', 'Staels B']","['Adult', 'Allylamine/administration & dosage/*analogs & derivatives/pharmacology', 'Anticholesteremic Agents/*administration & dosage/pharmacology', 'Blood Glucose/*drug effects/metabolism', 'Cardiovascular Diseases/*prevention & control', 'Colesevelam Hydrochloride', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Diabetic Angiopathies/*prevention & control', 'Female', 'Glycated Hemoglobin/drug effects/metabolism', 'Humans', 'Lipids/*blood', 'Male']",https://pubmed.ncbi.nlm.nih.gov/20415686/
1363,Colesevelam,25640999,Risk identification and possible countermeasures for muscle adverse effects during statin therapy.,"['Magni P', 'Macchi C', 'Morlotti B', 'Sirtori CR', 'Ruscica M']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Anticholesteremic Agents/*therapeutic use', 'Colesevelam Hydrochloride/therapeutic use', 'Creatine Kinase/blood', 'Drug Interactions', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/epidemiology', 'Ezetimibe/therapeutic use', 'Fatty Acids, Monounsaturated/adverse effects', 'Female', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects', 'Indoles/adverse effects', 'Male', 'Muscular Diseases/chemically induced/metabolism', 'Myalgia/blood/*chemically induced', 'Rhabdomyolysis/blood/*chemically induced', 'Risk Assessment', 'Risk Factors', 'Rosuvastatin Calcium/adverse effects', 'Sex Factors', 'Vitamin D Deficiency/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/25640999/
1364,Colesevelam,11383377,New therapies on the horizon.,['Brown WV'],"['Allylamine/analogs & derivatives/metabolism/therapeutic use', 'Anticholesteremic Agents/metabolism/*therapeutic use', 'Bile Acids and Salts/metabolism', 'Biological Transport', 'Cholesterol/metabolism', 'Cholestyramine Resin/metabolism/therapeutic use', 'Colesevelam Hydrochloride', 'Esterification', 'Fluorobenzenes/metabolism/therapeutic use', 'Humans', 'Intestinal Absorption', 'Lipoproteins, LDL/*blood', '*Pyrimidines', 'Rosuvastatin Calcium', '*Sulfonamides', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11383377/
1365,Colesevelam,30336707,Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes.,"['Nerild HH', 'Christensen MB', 'Knop FK', 'Bronden A']","['Animals', 'Anticholesteremic Agents/administration & dosage/adverse effects/pharmacology', 'Blood Glucose/*drug effects', 'Clinical Trials, Phase III as Topic', 'Colesevelam Hydrochloride/*administration & dosage/adverse effects/pharmacology', 'Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Drug Therapy, Combination', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology', 'Patient Selection']",https://pubmed.ncbi.nlm.nih.gov/30336707/
1366,Colesevelam,12040732,Colesevelam hydrochloride.,['Steinmetz KL'],"['*Allylamine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Cholestyramine Resin/therapeutic use', 'Colesevelam Hydrochloride', 'Colestipol/therapeutic use', 'Drug Administration Schedule', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Hypercholesterolemia/*drug therapy', '*Hypolipidemic Agents/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12040732/
1367,Colesevelam,19682080,Combined therapy in the treatment of dyslipidemia.,['Reiner Z'],"['Animals', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/physiopathology', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Hypolipidemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Practice Guidelines as Topic', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/19682080/
1368,Colesevelam,20819059,Combination of fenofibrate with non-statin drug regimens.,"['Agouridis AP', 'Filippatos TD', 'Derdemezis CS', 'Mikhailidis DP', 'Elisaf MS']","['Animals', 'Drug Therapy, Combination', 'Fenofibrate/administration & dosage/*pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hyperlipidemias/*drug therapy/physiopathology', 'Hypolipidemic Agents/administration & dosage/*pharmacology/therapeutic use', 'Lipid Metabolism/drug effects', 'Metabolic Syndrome/drug therapy/etiology/physiopathology', 'Obesity/complications']",https://pubmed.ncbi.nlm.nih.gov/20819059/
1369,Colesevelam,22142158,Is combination therapy an effective way of reaching lipid goals in type 2 diabetes mellitus?,"['Handelsman Y', 'Fonseca V', 'Rosenstock J']","['Animals', 'Anticholesteremic Agents/administration & dosage', 'Cardiovascular Diseases/blood/drug therapy', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic/methods', 'Diabetes Mellitus, Type 2/*blood/*drug therapy', 'Drug Therapy, Combination', '*Goals', 'Humans', 'Hypolipidemic Agents/administration & dosage', 'Lipid Metabolism/*drug effects/physiology', 'Lipoproteins, LDL/blood', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22142158/
1370,Colesevelam,33471721,Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm - 2020 Executive Summary.,"['Handelsman Y', 'Jellinger PS', 'Guerin CK', 'Bloomgarden ZT', 'Brinton EA', 'Budoff MJ', 'Davidson MH', 'Einhorn D', 'Fazio S', 'Fonseca VA', 'Garber AJ', 'Grunberger G', 'Krauss RM', 'Mechanick JI', 'Rosenblit PD', 'Smith DA', 'Wyne KL']","['Algorithms', '*Anticholesteremic Agents', '*Cardiovascular Diseases/epidemiology/prevention & control', 'Consensus', '*Dyslipidemias/drug therapy/epidemiology', 'Endocrinologists', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Risk Factors', 'United States']",https://pubmed.ncbi.nlm.nih.gov/33471721/
1371,aspirin,32580960,Aspirin in Primary Prevention of Cardiovascular Events.,"['Soodi D', 'VanWormer JJ', 'Rezkalla SH']","['Aspirin/*therapeutic use', 'Cardiovascular Diseases', 'Humans', '*Primary Prevention', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32580960/
1372,aspirin,17107286,Prasugrel.,"['Tantry US', 'Bliden KP', 'Gurbel PA']","['Adenosine Diphosphate/antagonists & inhibitors/pharmacology', 'Animals', 'Aspirin/administration & dosage/therapeutic use', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase III as Topic', 'Clopidogrel', 'Collagen/antagonists & inhibitors/pharmacology', 'Coronary Disease/drug therapy', 'Drug Evaluation, Preclinical', 'Drug Resistance', 'Drug Synergism', 'Drug Therapy, Combination', '*Drugs, Investigational/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Humans', '*Piperazines/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Platelet Activation/drug effects', 'Platelet Aggregation/drug effects', '*Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Prasugrel Hydrochloride', 'Prodrugs/pharmacokinetics/therapeutic use', '*Purinergic P2 Receptor Antagonists', 'Pyridines/administration & dosage/therapeutic use', 'Rats', 'Receptors, Purinergic P2Y12', '*Thiophenes/administration & dosage/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Ticlopidine/analogs & derivatives/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17107286/
1373,aspirin,38704715,[Not Available].,"['Andersen MF', 'Rode L', 'Christiansen ILR', 'Tabor A', 'Ekelund CK']","['Humans', '*Pre-Eclampsia/prevention & control', 'Pregnancy', '*Aspirin/administration & dosage/adverse effects/therapeutic use', 'Female', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38704715/
1374,aspirin,31669590,Aspirin and its pleiotropic application.,"['Hybiak J', 'Broniarek I', 'Kiryczynski G', 'Los LD', 'Rosik J', 'Machaj F', 'Slawinski H', 'Jankowska K', 'Urasinska E']","['Animals', 'Aspirin/*pharmacology/therapeutic use', 'Female', 'Humans', 'Mental Disorders/drug therapy', 'Neoplasms/drug therapy/prevention & control', 'Platelet Aggregation Inhibitors/pharmacology/therapeutic use', 'Pre-Eclampsia/prevention & control', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/31669590/
1375,aspirin,34824680,Aspirin in the Modern Era of Cardiovascular Disease Prevention.,"['Murphy E', 'Curneen JMG', 'McEvoy JW']","['Aspirin/adverse effects', '*Cardiovascular Diseases/epidemiology/prevention & control', 'Humans', '*Myocardial Infarction', '*Percutaneous Coronary Intervention', 'Platelet Aggregation Inhibitors/adverse effects', 'Purinergic P2Y Receptor Antagonists']",https://pubmed.ncbi.nlm.nih.gov/34824680/
1376,aspirin,38839268,Low-dose aspirin for the prevention of atherosclerotic cardiovascular disease.,['Patrono C'],"['Humans', '*Aspirin/administration & dosage', '*Platelet Aggregation Inhibitors/administration & dosage', '*Atherosclerosis/prevention & control', 'Cardiovascular Diseases/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/38839268/
1377,aspirin,17523700,Aspirin and Reye syndrome: a review of the evidence.,['Schror K'],"['Aspirin/administration & dosage/*adverse effects/pharmacokinetics/pharmacology', 'Child', 'Energy Metabolism', 'Humans', 'Liver/drug effects/metabolism', '*Reye Syndrome/chemically induced/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/17523700/
1378,aspirin,12638472,[Antiaggregation: aspirin].,"['Eichenberger A', 'Pontiggia L', 'Beer JH']","['Administration, Oral', 'Adult', 'Age Factors', 'Aged', 'Anticoagulants/administration & dosage/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Cardiovascular Diseases/prevention & control', 'Diabetes Complications', 'Diabetes Mellitus/drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Fibrinolytic Agents/administration & dosage/adverse effects/*therapeutic use', 'Hemorrhage/chemically induced', 'Humans', 'Male', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Primary Prevention', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12638472/
1379,aspirin,1199984,Aspirin hepatitis.,"['Zucker P', 'Daum F', 'Cohen MI']","['Adolescent', 'Anemia, Sickle Cell/complications', 'Arthritis, Juvenile/complications/*drug therapy', 'Aspartate Aminotransferases/blood', 'Aspirin/administration & dosage/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/*etiology', 'Child', 'Female', 'Humans', 'Lupus Erythematosus, Systemic/*drug therapy', 'Male', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1199984/
1380,aspirin,31300475,Are Platelets the Primary Target of Aspirin's Remarkable Anticancer Activity?,"['Lichtenberger LM', 'Vijayan KV']","['Aspirin/*pharmacology', 'Blood Platelets/*drug effects/pathology', 'Cyclooxygenase Inhibitors/pharmacology', 'Humans', 'Neoplasms/*blood/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/31300475/
1381,aspirin,22372726,Acetylsalicylic acid/esomeprazole fixed-dose combination.,"['Burness CB', 'Scott LJ']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Capsules', 'Cardiovascular Diseases/prevention & control', 'Drug Combinations', 'Esomeprazole/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Peptic Ulcer/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Prodrugs/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22372726/
1382,aspirin,20338720,[Prevention of preeclampsia].,"['Deruelle P', 'Girard JM', 'Coutty N', 'Subtil D']","['Adolescent', 'Adult', 'Anticoagulants/therapeutic use', 'Antioxidants/therapeutic use', 'Aspirin/administration & dosage/therapeutic use', 'Calcium Compounds/therapeutic use', 'Diuretics/adverse effects/therapeutic use', 'Female', 'Heparin, Low-Molecular-Weight/therapeutic use', 'Humans', 'Male', 'Malnutrition/complications', 'Nitric Oxide Donors/adverse effects/therapeutic use', 'Platelet Aggregation Inhibitors/administration & dosage/therapeutic use', 'Pre-Eclampsia/*prevention & control', 'Pregnancy', 'Risk', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20338720/
1383,aspirin,26369684,Prevention of Upper Gastrointestinal Ulcer and Complications in Low-Dose Aspirin Users.,['Sugano K'],"['Aspirin/administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', 'Gastrointestinal Hemorrhage/*chemically induced/prevention & control', 'Humans', 'Peptic Ulcer/*chemically induced/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects', 'Practice Guidelines as Topic', 'Proton Pump Inhibitors/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26369684/
1384,aspirin,30665790,[Aspirin and preeclampsia].,"['Atallah A', 'Lecarpentier E', 'Goffinet F', 'Gaucherand P', 'Doret-Dion M', 'Tsatsaris V']","['Aspirin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Chronobiology Phenomena', 'Contraindications, Drug', 'Cyclooxygenase Inhibitors/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Drug Utilization', 'Early Diagnosis', 'Female', 'Fetal Diseases/chemically induced', 'France/epidemiology', 'Humans', 'Mass Screening', 'Meta-Analysis as Topic', 'Placenta/metabolism', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Pre-Eclampsia/diagnosis/epidemiology/*prevention & control', 'Pregnancy', 'Pregnancy Complications/chemically induced', 'Pregnancy Trimester, First', 'Primary Prevention', 'Prostaglandin Antagonists/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30665790/
1385,aspirin,25577431,[Managing antithrombotic therapy in vitreoretinal surgery].,"['Gallice M', 'Rouberol F', 'Albaladejo P', 'Brillat Zaratzian E', 'Palombi K', 'Aptel F', 'Romanet JP', 'Chiquet C']","['Anesthesia, Local', 'Anticoagulants/administration & dosage/adverse effects/classification/pharmacokinetics/*therapeutic use', 'Aspirin/administration & dosage/adverse effects/therapeutic use', 'Blood Coagulation/drug effects/physiology', 'Eye Diseases/surgery', 'Fibrinolytic Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Hemorrhage/chemically induced/*prevention & control', 'Humans', 'International Normalized Ratio', 'Intraoperative Complications/prevention & control', 'Models, Biological', '*Ophthalmologic Surgical Procedures', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Postoperative Complications/prevention & control', 'Purinergic P2Y Receptor Antagonists/administration & dosage/adverse effects/therapeutic use', 'Retinal Diseases/complications/surgery', 'Risk Assessment', 'Thromboembolism/*prevention & control', 'Thrombophilia/complications/drug therapy', 'Vitreous Body/surgery']",https://pubmed.ncbi.nlm.nih.gov/25577431/
1386,aspirin,6344620,Aspirin in the treatment of juvenile arthritis.,['Baum J'],"['Arthritis, Juvenile/*drug therapy', 'Aspirin/administration & dosage/adverse effects/*therapeutic use', 'Chemical and Drug Induced Liver Injury', 'Child', 'Clinical Trials as Topic', 'Humans', 'Liver Diseases/enzymology', 'Protein Binding', 'Salicylates/administration & dosage/blood', 'Serum Albumin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6344620/
1387,aspirin,22591976,"Aspirin: a history, a love story.",['Wick JY'],"['Analgesics/*history', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/*history/therapeutic use', 'Aspirin/adverse effects/*history/therapeutic use', 'Benzyl Alcohols/chemistry', 'Cardiovascular Diseases/prevention & control', 'Drug Hypersensitivity', 'Drug Resistance', 'Glucosides/chemistry', 'History, 18th Century', 'History, 19th Century', 'History, 20th Century', 'Humans', 'Neoplasms/prevention & control', 'Salix/chemistry', 'Sex Characteristics']",https://pubmed.ncbi.nlm.nih.gov/22591976/
1388,aspirin,28342880,[For a targeted use of aspirin].,"['Madar H', 'Brun S', 'Coatleven F', 'Nithart A', 'Lecoq C', 'Gleyze M', 'Merlot B', 'Sentilhes L']","['Abnormalities, Drug-Induced/etiology', 'Antiphospholipid Syndrome/complications/drug therapy', 'Aspirin/*adverse effects/*therapeutic use', 'Female', 'Humans', 'Pre-Eclampsia/drug therapy', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Premature Birth/prevention & control', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/28342880/
1389,aspirin,24558899,[Aspirin: once or twice a day?].,"['Fontana P', 'Casini A', 'Boehlen F', 'Reny JL']","['Aspirin/*administration & dosage/metabolism', 'Blood Platelets/drug effects/physiology', 'Drug Administration Schedule', 'Hemostasis/drug effects', 'Humans', 'Individuality']",https://pubmed.ncbi.nlm.nih.gov/24558899/
1390,aspirin,26747390,The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.,"['Tamargo J', 'Castellano JM', 'Fuster V']","['Aspirin/*administration & dosage/adverse effects/therapeutic use', 'Atorvastatin/*administration & dosage/adverse effects/therapeutic use', 'Cardiovascular Agents/*administration & dosage/adverse effects/therapeutic use', 'Cardiovascular Diseases/drug therapy/economics/*prevention & control', 'Drug Combinations', 'Humans', 'Ramipril/*administration & dosage/adverse effects/therapeutic use', 'Secondary Prevention/*methods']",https://pubmed.ncbi.nlm.nih.gov/26747390/
1391,labetalol,29808264,"Neonatal hypertension: cases, causes, and clinical approach.","['Starr MC', 'Flynn JT']","['Administration, Intravenous', 'Antihypertensive Agents/*administration & dosage/adverse effects', 'Birth Weight/physiology', 'Blood Pressure/drug effects/*physiology', 'Blood Pressure Determination/instrumentation/methods', 'Clinical Decision-Making', 'Gestational Age', 'Humans', 'Hydralazine/administration & dosage/adverse effects', 'Hypertension/*diagnosis/epidemiology/etiology/therapy', 'Incidence', 'Infant, Newborn', 'Infant, Newborn, Diseases/*diagnosis/epidemiology/etiology/therapy', 'Infant, Premature/*physiology', 'Intensive Care Units, Neonatal', 'Kidney/physiopathology/surgery', 'Labetalol/administration & dosage/adverse effects', 'Neuroblastoma/complications/surgery', 'Reference Values', 'Renal Artery Obstruction/complications/surgery', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29808264/
1392,labetalol,8522630,Management of hypertensive urgencies and emergencies.,"['Abdelwahab W', 'Frishman W', 'Landau A']","['Administration, Oral', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Emergencies', 'Enalaprilat/therapeutic use', 'Female', 'Humans', 'Hydralazine/therapeutic use', 'Hypertension/classification/*drug therapy', 'Infusions, Parenteral', 'Labetalol/therapeutic use', 'Nicardipine/therapeutic use', 'Nitroglycerin/therapeutic use', 'Nitroprusside/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8522630/
1393,labetalol,18827911,Perioperative hypertension management.,"['Varon J', 'Marik PE']","['Adrenergic beta-Antagonists/pharmacology', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Enalaprilat/pharmacology/therapeutic use', 'Fenoldopam/pharmacology/therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/pharmacology/therapeutic use', 'Hypertension/*drug therapy/epidemiology', 'Incidence', 'Labetalol/administration & dosage/pharmacology', 'Nicardipine/pharmacology/therapeutic use', 'Nitroglycerin/pharmacology', 'Nitroprusside/pharmacology', 'Perioperative Care', 'Postoperative Complications/*drug therapy', 'Propanolamines/pharmacology', 'Pyridines/pharmacology/therapeutic use', '*Surgical Procedures, Operative', 'Vascular Resistance/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18827911/
1394,labetalol,26600442,Hypertensive Emergencies in Pregnancy.,"['Olson-Chen C', 'Seligman NS']","['Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Cesarean Section/standards', 'Chronic Disease', 'Congenital Abnormalities/*epidemiology/etiology', 'Emergencies', 'Esophageal Atresia/epidemiology/etiology', 'Female', 'Heart Defects, Congenital/epidemiology/etiology', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/complications/drug therapy/epidemiology/physiopathology', 'Hypertension, Pregnancy-Induced/drug therapy/epidemiology/*physiopathology', 'Hypospadias/epidemiology/etiology', 'Labetalol/administration & dosage/adverse effects/therapeutic use', 'Labor, Induced/standards', 'Male', 'Nifedipine/administration & dosage/adverse effects/therapeutic use', 'Postnatal Care', 'Pre-Eclampsia/drug therapy/epidemiology/*physiopathology', 'Pregnancy', 'Pregnancy Outcome/*epidemiology', 'Prevalence', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/26600442/
1395,labetalol,16596031,Hypertensive emergencies.,"['Moser M', 'Izzo JL Jr', 'Bisognano J']","['Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Captopril/administration & dosage/therapeutic use', 'Clonidine/administration & dosage/therapeutic use', 'Diuretics/therapeutic use', 'Emergencies', 'Emergency Medical Services', 'Humans', 'Hypertension/diagnosis/*drug therapy', 'Labetalol/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16596031/
1396,labetalol,6310529,"Labetalol: a review of its pharmacology, pharmacokinetics, clinical uses and adverse effects.","['MacCarthy EP', 'Bloomfield SS']","['Animals', 'Anti-Arrhythmia Agents/pharmacology', 'Coronary Disease/drug therapy', 'Ethanolamines/*therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/drug therapy', 'Kidney/drug effects', 'Kinetics', 'Labetalol/metabolism/pharmacology/*therapeutic use', 'Norepinephrine/metabolism', 'Receptors, Adrenergic, alpha/drug effects', 'Receptors, Adrenergic, beta/drug effects', 'Renin-Angiotensin System/drug effects', 'Respiratory System/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6310529/
1397,labetalol,36104450,"Pharmacokinetics of the most commonly used antihypertensive drugs throughout pregnancy methyldopa, labetalol, and nifedipine: a systematic review.","['van de Vusse D', 'Mian P', 'Schoenmakers S', 'Flint RB', 'Visser W', 'Allegaert K', 'Versmissen J']","['Antihypertensive Agents', 'Female', 'Humans', '*Hypertension/drug therapy', '*Hypertension, Pregnancy-Induced/drug therapy/prevention & control', '*Labetalol/therapeutic use', 'Methyldopa/therapeutic use', 'Nifedipine', 'Pregnancy', '*Pregnancy Complications, Cardiovascular/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/36104450/
1398,labetalol,791329,Double-blind trial of labetalol.,"['Kane J', 'Gregg I', 'Richards DA']","['Adult', 'Aged', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Ethanolamines/*therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Labetalol/adverse effects/pharmacology/*therapeutic use', 'Male', 'Middle Aged', 'Pulse/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/791329/
1399,labetalol,38949541,Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.,"['Sanusi AA', 'Leach J', 'Boggess K', 'Dugoff L', 'Sibai B', 'Lawrence K', 'Hughes BL', 'Bell J', 'Aagaard K', 'Edwards RK', 'Gibson KS', 'Haas DM', 'Plante L', 'Metz TD', 'Casey B', 'Esplin S', 'Longo S', 'Hoffman MK', 'Saade GR', 'Hoppe KK', 'Foroutan J', 'Tuuli M', 'Owens MY', 'Simhan HN', 'Frey H', 'Rosen T', 'Palatnik A', 'Baker S', 'August P', 'Reddy UM', 'Su EJ', 'Krishna I', 'Nguyen NA', 'Norton ME', 'Skupski D', 'El-Sayed YY', 'Ogunyemi D', 'Galis ZS', 'Harper L', 'Ambalavanan N', 'Geller NL', 'Kuo HC', 'Sinkey RG', 'Librizzi R', 'Pereira L', 'Magann EF', 'Habli M', 'Williams S', 'Mari G', 'Pridjian G', 'McKenna DS', 'Parrish M', 'Chang E', 'Osmundson S', 'Quinones J', 'Szychowski JM', 'Tita ATN']","['Humans', 'Pregnancy', 'Female', '*Labetalol/administration & dosage/adverse effects/therapeutic use', '*Nifedipine/administration & dosage/adverse effects/therapeutic use', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Adult', '*Pregnancy Outcome', '*Hypertension/drug therapy', 'Infant, Newborn', 'Pregnancy Complications, Cardiovascular/drug therapy', 'Hypertension, Pregnancy-Induced/drug therapy', 'Administration, Oral', 'Infant, Small for Gestational Age', 'Pre-Eclampsia/drug therapy', 'Chronic Disease']",https://pubmed.ncbi.nlm.nih.gov/38949541/
1400,labetalol,7684671,An overview of the pharmacodynamic properties and therapeutic potential of combined alpha- and beta-adrenoceptor antagonists.,['van Zwieten PA'],"['Adrenergic alpha-Antagonists/*pharmacology/*therapeutic use', 'Adrenergic beta-Antagonists/*pharmacology/*therapeutic use', 'Animals', 'Carbazoles/pharmacology/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Carvedilol', 'Hemodynamics/drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Propanolamines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7684671/
1401,labetalol,2179899,Dilevalol: an overview of its clinical pharmacology and therapeutic use in hypertension.,"['Lalonde RL', 'Tenero DM', 'Kazierad DJ']","['Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Animals', 'Dogs', 'Heart/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Hypertension/*drug therapy', 'Labetalol/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Lipids/blood', 'Phenylephrine/pharmacology', 'Receptors, Adrenergic/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2179899/
1402,labetalol,37016996,Cardiac medications in obstetric patients.,"['Spehar SM', 'Albert-Stone E', 'Davis MB']","['Female', 'Humans', '*Pregnancy', 'Antihypertensive Agents/therapeutic use', 'Aspirin/therapeutic use', 'Hypertension/drug therapy', 'Labetalol/therapeutic use', 'Platelet Aggregation Inhibitors/therapeutic use', 'Pre-Eclampsia/drug therapy', '*Cardiovascular Agents/adverse effects/therapeutic use', '*Hematologic Agents/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37016996/
1403,labetalol,17686376,The vasodilatory beta-blockers.,"['Pedersen ME', 'Cockcroft JR']","['Adrenergic beta-Antagonists/adverse effects/*pharmacology/*therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Antioxidants/pharmacology/therapeutic use', 'Atenolol/pharmacology/therapeutic use', 'Benzopyrans/pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiac Output/drug effects', 'Cardiovascular Diseases/physiopathology/prevention & control', 'Carvedilol', 'Endothelium, Vascular/*drug effects', 'Ethanolamines/pharmacology/therapeutic use', 'Hemodynamics/*drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Nebivolol', 'Propanolamines/pharmacology/therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilation/*drug effects', 'Ventricular Function, Left/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17686376/
1404,labetalol,31487627,Quantifying adherence to antihypertensive medication for chronic hypertension during pregnancy.,"['Webster LM', 'Reed K', 'Myers JE', 'Burns A', 'Gupta P', 'Patel P', 'Wiesender C', 'Seed PT', 'Nelson-Piercy C', 'Chappell LC']","['Adult', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Blood Pressure Determination', 'Chromatography, High Pressure Liquid', 'Cohort Studies', 'Female', 'Humans', 'Hypertension/*drug therapy/urine', 'Labetalol/administration & dosage/therapeutic use', '*Medication Adherence', 'Nifedipine/administration & dosage/therapeutic use', 'Pre-Eclampsia/*prevention & control', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', '*Prenatal Care', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31487627/
1405,labetalol,35667400,A comparative study of intravenous labetalol VS intravenous nitroglycerin in the treatment of hypertensive crises.,"['Malik MA', 'Ahmad R', 'Beg M', 'Ahmad R']","['Antihypertensive Agents/therapeutic use', 'Blood Pressure', 'Humans', '*Hypertension/drug therapy', '*Labetalol/pharmacology/therapeutic use', 'Nitroglycerin/pharmacology', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/35667400/
1406,labetalol,1994940,Oral labetalol in hypertensive urgencies.,"['Zell-Kanter M', 'Leikin JB']","['Administration, Oral', 'Adult', 'Blood Pressure/drug effects', 'Clinical Protocols/*standards', '*Emergencies', 'Emergency Service, Hospital', 'Female', 'Furosemide/administration & dosage/therapeutic use', 'Hospitals, University', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Illinois', 'Injections, Intravenous', 'Labetalol/administration & dosage/pharmacology/*therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/1994940/
1407,labetalol,15687755,[Antihypertensive management in acute cerebral stroke].,['Ziliene V'],"['Acute Disease', 'Adult', 'Antihypertensive Agents/*therapeutic use', 'Brain Injuries/*drug therapy/physiopathology', 'Cerebrovascular Circulation', 'Emergencies', 'Female', 'Fenoldopam/administration & dosage/therapeutic use', 'Humans', 'Hypertensive Encephalopathy/diagnosis/*drug therapy/physiopathology', 'Intracranial Aneurysm/drug therapy', 'Intracranial Pressure', 'Labetalol/administration & dosage/therapeutic use', 'Male', 'Models, Biological', 'Nicardipine/administration & dosage/therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use', 'Nitroprusside/administration & dosage/therapeutic use', 'Stroke/*drug therapy', 'Subarachnoid Hemorrhage/drug therapy', 'Time Factors', 'Vasodilator Agents/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15687755/
1408,labetalol,8340162,De novo hypertension after liver transplantation.,['Textor SC'],"['Adult', 'Azathioprine/therapeutic use', 'Cyclosporine/therapeutic use', 'Humans', 'Hypertension/drug therapy/*etiology', 'Immunosuppression Therapy/adverse effects', 'Labetalol/therapeutic use', '*Liver Transplantation', 'Male', 'Opportunistic Infections/etiology', 'Postoperative Care', '*Postoperative Complications', 'Prednisone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8340162/
1409,labetalol,38973651,Labetalol Dosing in Pregnancy: PBPK/PD and CYP2C19 Polymorphisms.,"['Liu XI', 'Green DJ', 'van den Anker J', 'Calderon J', 'Ahmadzia H', 'Burckart GJ', 'Dallmann A']","['Humans', 'Male', 'Female', '*Polymorphism, Genetic', '*Cytochrome P-450 CYP2C19/genetics', '*Labetalol/administration & dosage/pharmacology', 'Alleles', 'Pregnancy', 'Blood Pressure/drug effects', 'Genotype', 'Clinical Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/38973651/
1410,labetalol,6354658,Labetalol.,['Carter BL'],"['Drug Interactions', 'Ethanolamines/*therapeutic use', 'Humans', 'Hypertension/drug therapy', 'Intestinal Absorption', 'Kinetics', 'Labetalol/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/6354658/
1411,nabumetone,25650579,[Clinical review of pseudoporphyria].,"['Velander MJ', 'Thornorsteinsdottir S', 'Bygum A']","['Drug Eruptions/etiology', 'Humans', 'Porphyria Cutanea Tarda/diagnosis', 'Porphyrins/analysis', '*Skin Diseases, Vesiculobullous/diagnosis/etiology/pathology/therapy', 'Ultraviolet Rays/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25650579/
1412,nabumetone,22381180,Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats.,"['Khan SA', 'McLean MK']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*antagonists & inhibitors/metabolism/*poisoning', 'Cat Diseases/chemically induced/diagnosis/therapy', 'Cats', 'Dog Diseases/chemically induced/diagnosis/*therapy', 'Dogs', 'Incidence', 'Poison Control Centers/statistics & numerical data', 'Poisoning/diagnosis/therapy/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/22381180/
1413,nabumetone,1474539,Upper gastrointestinal safety with nabumetone.,['Roth SH'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Aspirin/adverse effects', 'Butanones/*adverse effects', 'Chromium Radioisotopes', 'Clinical Trials as Topic', 'Digestive System/*drug effects/pathology', 'Double-Blind Method', 'Endoscopy', 'Gastrointestinal Hemorrhage/chemically induced/diagnosis', 'Humans', 'Longitudinal Studies', 'Nabumetone', 'Naproxen/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1474539/
1414,nabumetone,1632009,[Pseudoporphyria].,"['Petersen CS', 'Thomsen K']","['Adult', 'Female', 'Humans', 'Ibuprofen/adverse effects', 'Male', 'Middle Aged', 'Naproxen/adverse effects', 'Porphyrias/chemically induced/etiology/*pathology', 'Quinidine/adverse effects', 'Skin Diseases/chemically induced/etiology/pathology', 'Ultraviolet Rays/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1632009/
1415,nabumetone,26414123,Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.,"['Moore RA', 'Derry S', 'Aldington D', 'Wiffen PJ']","['Acute Pain/*drug therapy', 'Administration, Oral', 'Adult', 'Analgesics/*administration & dosage/adverse effects', 'Humans', 'Pain, Postoperative/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26414123/
1416,nabumetone,10493277,Rofecoxib.,"['Scott LJ', 'Lamb HM']","['Analgesics/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Cyclooxygenase Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Drug Interactions', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Lactones/adverse effects/pharmacokinetics/*pharmacology/*therapeutic use', 'Osteoarthritis/drug therapy', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10493277/
1417,nabumetone,1474531,An overview of the clinical pharmacokinetics of nabumetone.,['Hyneck ML'],"['Adult', 'Aged', 'Aging/metabolism', 'Antacids/pharmacology', 'Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacokinetics/urine', 'Butanones/metabolism/*pharmacokinetics/urine', 'Eating', 'Humans', 'Kidney Diseases/metabolism', 'Liver Diseases/metabolism', 'Nabumetone']",https://pubmed.ncbi.nlm.nih.gov/1474531/
1418,nabumetone,9831331,Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.,['Kawai S'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Arthritis, Rheumatoid/drug therapy/enzymology', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Isoenzymes/metabolism', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9831331/
1419,nabumetone,2525273,NSAIDs: new approaches to limiting gastropathy.,"['Zeidler H', 'Munzel P']","['Adenosine Triphosphatases/antagonists & inhibitors', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Campylobacter Infections/complications/drug therapy', 'Chemistry, Pharmaceutical', 'Drug Therapy, Combination', 'Humans', 'Pepsinogens/blood', 'Prostaglandins/therapeutic use', 'Risk Factors', 'Stomach Diseases/chemically induced/complications/*prevention & control', 'Sucralfate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2525273/
1420,nabumetone,30366253,"Naphthalene, a versatile platform in medicinal chemistry: Sky-high perspective.","['Makar S', 'Saha T', 'Singh SK']","['Chemistry, Pharmaceutical', 'Dose-Response Relationship, Drug', 'Drug Discovery', 'Humans', 'Molecular Structure', 'Naphthalenes/chemistry/*pharmacology', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/30366253/
1421,nabumetone,34203324,Toward Multitasking Pharmacological COX-Targeting Agents: Non-Steroidal Anti-Inflammatory Prodrugs with Antiproliferative Effects.,"['Grande F', 'Giordano F', 'Occhiuzzi MA', 'Rocca C', 'Ioele G', 'De Luca M', 'Ragno G', 'Panno ML', 'Rizzuti B', 'Garofalo A']","['*Anti-Inflammatory Agents, Non-Steroidal/chemical synthesis/chemistry/pharmacology', 'Cell Proliferation/*drug effects', '*Cyclooxygenase Inhibitors/chemical synthesis/chemistry/pharmacology', 'Humans', 'MCF-7 Cells', '*Nabumetone/chemical synthesis/chemistry/pharmacology', 'Prodrugs/chemical synthesis/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34203324/
1422,nabumetone,11165993,Management of nonsteroidal anti-inflammatory drug-related peptic ulcer bleeding.,['Sung JJ'],"['Anti-Bacterial Agents/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Anti-Ulcer Agents/*therapeutic use', 'Aspirin/*adverse effects', 'Butanones/adverse effects', 'Helicobacter Infections/*drug therapy', '*Helicobacter pylori/drug effects', 'Humans', 'Misoprostol/therapeutic use', 'Nabumetone', 'Peptic Ulcer Hemorrhage/*chemically induced/*drug therapy/prevention & control', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/11165993/
1423,nabumetone,15456329,Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis.,"['Hedner T', 'Samulesson O', 'Wahrborg P', 'Wadenvik H', 'Ung KA', 'Ekbom A']","['Adolescent', 'Adult', 'Aged', 'Animals', '*Anti-Inflammatory Agents, Non-Steroidal/metabolism/pharmacokinetics/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', '*Butanones/metabolism/pharmacokinetics/therapeutic use', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', '*Cyclooxygenase Inhibitors/adverse effects/therapeutic use', 'Drug Interactions', 'Food-Drug Interactions', 'Humans', 'Middle Aged', 'Nabumetone', 'Osteoarthritis/*drug therapy', 'Stomach Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15456329/
1424,nabumetone,8591651,Innovative treatment approaches for rheumatoid arthritis. New cyclo-oxygenase and cytokine inhibitors.,"['Richardson CE', 'Emery P']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Butanones/adverse effects/therapeutic use', 'Cyclooxygenase Inhibitors/*therapeutic use', 'Cytokines/*antagonists & inhibitors', 'Digestive System/drug effects', 'Drug Therapy, Combination', 'Humans', 'Indoles/adverse effects/therapeutic use', 'Isoenzymes/antagonists & inhibitors', 'Meloxicam', 'Misoprostol/therapeutic use', 'Nabumetone', 'Oxindoles', 'Thiazines/adverse effects/therapeutic use', 'Thiazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8591651/
1425,nabumetone,10628595,Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition.,['Brater DC'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Butanones/adverse effects', 'Celecoxib', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Humans', 'Isoenzymes/*pharmacology', 'Kidney/*drug effects/metabolism/*physiopathology', 'Lactones/adverse effects', 'Meloxicam', 'Membrane Proteins', 'Nabumetone', 'Natriuresis/drug effects', 'Nephritis, Interstitial/chemically induced', 'Potassium/urine', 'Prostaglandin-Endoperoxide Synthases/*pharmacology', 'Pyrazoles', 'Renal Circulation/drug effects', 'Sodium/metabolism', 'Sulfonamides/adverse effects', 'Sulfones', 'Thiazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10628595/
1426,nabumetone,25372212,Hydroxychloroquine retinopathy after short-term therapy.,"['Phillips BN', 'Chun DW']","['Antirheumatic Agents/*adverse effects', 'Female', 'Humans', 'Hydroxychloroquine/*adverse effects', 'Middle Aged', 'Retinal Diseases/*chemically induced', 'Vision Disorders/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25372212/
1427,nabumetone,38203608,Dissecting CYP1A2 Activation by Arylalkanoic Acid Prodrugs toward the Development of Anti-Inflammatory Agents.,"['Occhiuzzi MA', 'Ioele G', 'De Luca M', 'Rizzuti B', 'Scordamaglia D', 'Lappano R', 'Maggiolini M', 'Garofalo A', 'Grande F']","['Humans', '*Cytochrome P-450 CYP1A2', 'Molecular Docking Simulation', 'Anti-Inflammatory Agents/pharmacology', 'Nabumetone', '*Prodrugs/pharmacology', 'Radiopharmaceuticals']",https://pubmed.ncbi.nlm.nih.gov/38203608/
1428,nabumetone,15654705,Rofecoxib for osteoarthritis.,"['Garner SE', 'Fidan DD', 'Frankish R', 'Maxwell L']","['*Anti-Inflammatory Agents, Non-Steroidal/adverse effects/therapeutic use', '*Cyclooxygenase Inhibitors/adverse effects/therapeutic use', 'Drug Approval', 'Humans', '*Lactones/adverse effects/therapeutic use', 'Osteoarthritis/*drug therapy', 'Randomized Controlled Trials as Topic', '*Sulfones/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15654705/
1429,nabumetone,8036523,Nabumetone: a clinical appraisal.,['Helfgott SM'],"['Anti-Inflammatory Agents, Non-Steroidal/adverse effects/standards/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Butanones/adverse effects/standards/*therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Nabumetone', 'Osteoarthritis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8036523/
1430,nabumetone,2730099,Photosensitizing potential of certain nonsteroidal anti-inflammatory agents.,"['Kaidbey KH', 'Mitchell FN']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Butanones/adverse effects', 'Humans', 'Hypersensitivity, Immediate', 'Male', 'Nabumetone', 'Naproxen/adverse effects', 'Photosensitivity Disorders/*etiology', 'Piroxicam/adverse effects', 'Propionates/adverse effects', 'Ultraviolet Rays/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2730099/
1431,amifostine,24130023,Radioprotectors - the evergreen topic.,"['Kuntic VS', 'Stankovic MB', 'Vujic ZB', 'Brboric JS', 'Uskokovic-Markovic SM']","['Amifostine/chemistry/therapeutic use', 'Antioxidants/chemistry/therapeutic use', 'Biological Products/chemistry/therapeutic use', 'Humans', 'Plants/chemistry/metabolism', 'Polyphenols/chemistry/therapeutic use', 'Radiation Injuries/*prevention & control', 'Radiation-Protective Agents/*chemistry/therapeutic use', 'Sulfhydryl Compounds/chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24130023/
1432,amifostine,16015537,Treatment-related esophagitis.,['Werner-Wasik M'],"['Amifostine/therapeutic use', 'Antineoplastic Agents/adverse effects', 'Dose Fractionation, Radiation', 'Esophagitis/*etiology/*prevention & control', 'Humans', 'Lung Neoplasms/drug therapy/*radiotherapy', 'Radiation Injuries/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16015537/
1433,amifostine,32443117,Prevention of Platinum-Induced Hearing Loss in Children with Cancer.,['Navarro-Ruiz NE'],"['Amifostine/standards/therapeutic use', 'Humans', 'Neoplasms/*drug therapy/nursing', 'Ototoxicity/drug therapy/nursing/*prevention & control', 'Platinum/*adverse effects/pharmacology/therapeutic use', 'Practice Guidelines as Topic', 'Thiosulfates/standards/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32443117/
1434,amifostine,30914026,Cytoprotective Agents to Avoid Chemotherapy Induced Sideeffects on Normal Cells: A Review.,"['Rohilla S', 'Dureja H', 'Chawla V']","['Amifostine/*therapeutic use', 'Antineoplastic Agents/*adverse effects', '*Cytoprotection', 'Drug-Related Side Effects and Adverse Reactions/etiology/*prevention & control', 'Humans', 'Neoplasms/*drug therapy/pathology', 'Protective Agents/*therapeutic use', 'Radiation-Protective Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30914026/
1435,amifostine,16586122,Amifostine in the management of radiation-induced and chemo-induced mucositis.,"['Bensadoun RJ', 'Schubert MM', 'Lalla RV', 'Keefe D']","['Amifostine/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Combined Modality Therapy', 'Esophagitis/drug therapy/etiology', 'Evidence-Based Medicine', 'Gastrointestinal Diseases/*drug therapy/etiology', 'Head and Neck Neoplasms/therapy', 'Hematologic Neoplasms/therapy', 'Humans', 'Lung Neoplasms/therapy', 'Mucositis/*drug therapy/etiology', 'Neoplasms/complications/*therapy', 'Pelvic Neoplasms/therapy', 'Practice Guidelines as Topic', 'Proctitis/drug therapy/etiology', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects', 'Research Design', 'Stomatitis/*drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16586122/
1436,amifostine,12868117,Cisplatin nephrotoxicity affects magnesium and calcium metabolism.,['Goren MP'],"['Adult', 'Amifostine/therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Calcium/*metabolism', 'Child', 'Cisplatin/*adverse effects', 'Clinical Trials as Topic', 'Humans', 'Kidney/*drug effects/metabolism', 'Kidney Diseases/*chemically induced/metabolism', 'Magnesium/*metabolism', 'Magnesium Deficiency', 'Oxidative Stress', 'Radiation-Protective Agents/therapeutic use', 'Water-Electrolyte Imbalance']",https://pubmed.ncbi.nlm.nih.gov/12868117/
1437,amifostine,12621500,Mucosal injury in patients undergoing hematopoietic progenitor cell transplantation: new approaches to prophylaxis and treatment.,"['Filicko J', 'Lazarus HM', 'Flomenberg N']","['Amifostine/therapeutic use', 'Humans', 'Interleukin-11/therapeutic use', 'Mucous Membrane/*pathology', 'Stem Cell Transplantation/*adverse effects', 'Transforming Growth Factor beta/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12621500/
1438,amifostine,11917288,The potential role of amifostine in the treatment of carcinoma of the uterine cervix: a review.,['Small W Jr'],"['Amifostine/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Cisplatin/administration & dosage/adverse effects', 'Combined Modality Therapy', 'Female', 'Humans', 'Lymphatic Metastasis', 'Radiation Injuries/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy Dosage', 'Uterine Cervical Neoplasms/drug therapy/pathology/*radiotherapy']",https://pubmed.ncbi.nlm.nih.gov/11917288/
1439,amifostine,18328585,Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy.,"['Valeyrie-Allanore L', 'Poulalhon N', 'Fagot JP', 'Sekula P', 'Davidovici B', 'Sidoroff A', 'Mockenhaupt M']","['Adult', 'Adverse Drug Reaction Reporting Systems', 'Aged', 'Amifostine/*adverse effects', 'Europe', 'Female', 'Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Male', 'Middle Aged', 'Prospective Studies', 'Radiation-Protective Agents/*adverse effects', 'Stevens-Johnson Syndrome/*chemically induced/*etiology']",https://pubmed.ncbi.nlm.nih.gov/18328585/
1440,amifostine,31526195,The efficacy and safety of amifostine for the acute radiation syndrome.,"['Singh VK', 'Seed TM']","['Acute Radiation Syndrome/*drug therapy', 'Amifostine/*administration & dosage/adverse effects', 'Animals', 'Drug Approval', 'Drug Design', 'Humans', 'Radiation-Protective Agents/*administration & dosage/adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/31526195/
1441,amifostine,16015536,Pulmonary toxicity associated with the treatment of non-small cell lung cancer and the effects of cytoprotective strategies.,['Gopal R'],"['Amifostine/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/*radiotherapy', 'Clinical Trials as Topic', 'Combined Modality Therapy/adverse effects', 'Esophagitis/etiology/prevention & control', 'Humans', 'Lung/drug effects/radiation effects', 'Lung Neoplasms/*drug therapy/*radiotherapy', 'Radiation Pneumonitis/*prevention & control', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16015536/
1442,amifostine,17578604,"[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].","['Kowalski T', 'Maier C', 'Reinacher-Schick A', 'Schlegel U']","['Adrenergic Uptake Inhibitors/therapeutic use', 'Amifostine/therapeutic use', 'Animals', 'Antineoplastic Agents/administration & dosage/*adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Calcium Carbonate/therapeutic use', 'Calcium Gluconate/therapeutic use', 'Colorectal Neoplasms/*drug therapy', 'Cyclohexanols/therapeutic use', 'Humans', 'Hyperalgesia/*chemically induced/drug therapy/physiopathology', 'Magnesium Chloride/therapeutic use', 'Nerve Fibers/drug effects/physiology', 'Neurotoxicity Syndromes/drug therapy/*physiopathology', 'Organoplatinum Compounds/administration & dosage/*adverse effects', 'Oxaliplatin', 'Paresthesia/*chemically induced/drug therapy/physiopathology', 'Peripheral Nerves/drug effects/physiopathology', 'Rats', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sodium Channels/drug effects/physiology', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/17578604/
1443,amifostine,18537748,Prevention and treatment of regimen-related mucosal toxicity.,['Bowen JM'],"['Amifostine/therapeutic use', 'Animals', 'Antineoplastic Agents/*adverse effects', 'Apoptosis/drug effects', 'Cell Proliferation/drug effects', 'Cytoprotection', 'Humans', 'Immunologic Factors/therapeutic use', 'Mucositis/*chemically induced/*drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/18537748/
1444,amifostine,37747899,Advances of Amifostine in Radiation Protection: Administration and Delivery.,"['Ji L', 'Cui P', 'Zhou S', 'Qiu L', 'Huang H', 'Wang C', 'Wang J']","['Humans', '*Amifostine/pharmacology/therapeutic use', '*Radiation Protection', '*Radiation-Protective Agents/pharmacology', 'Administration, Intravenous', 'Adjuvants, Immunologic', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/37747899/
1445,amifostine,25774860,Mucositis: pathobiology and management.,"['Villa A', 'Sonis ST']","['Amifostine/therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Drug-Related Side Effects and Adverse Reactions', 'Fibroblast Growth Factor 7/therapeutic use', 'Humans', 'Neoplasms/complications/*drug therapy/*radiotherapy', 'Post-Exposure Prophylaxis', 'Quality of Life', 'Radiation-Protective Agents/*therapeutic use', 'Radiotherapy/*adverse effects', 'Risk Factors', 'Stomatitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25774860/
1446,amifostine,8976823,"Amifostine (Ethyol): dosing, administration and patient management guidelines.",['Bukowski RM'],"['Amifostine/*administration & dosage/adverse effects', 'Antineoplastic Agents/*adverse effects/antagonists & inhibitors', 'Drug Administration Schedule', 'Humans', 'Hypotension/chemically induced/therapy']",https://pubmed.ncbi.nlm.nih.gov/8976823/
1447,amifostine,15726526,Randomized trials of amifostine and radiotherapy: effect on survival?,"['Bourhis J', 'Thephamongkhol K', 'Pignon JP']","['Amifostine/*therapeutic use', 'Combined Modality Therapy', 'Cytoprotection', '*Databases as Topic', 'Humans', 'Meta-Analysis as Topic', 'Neoplasms/*therapy', 'Radiation-Protective Agents/*therapeutic use', '*Randomized Controlled Trials as Topic', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/15726526/
1448,amifostine,18794784,Amifostine protection against mitomycin-induced chromosomal breakage in fanconi anaemia lymphocytes.,"['Camelo RM', 'Kehdy FS', 'Salas CE', 'Lopes MT']","['Adolescent', 'Adult', 'Amifostine/*pharmacology', 'Blood Cells', 'Case-Control Studies', 'Child', 'Chromosome Breakage/*drug effects', 'Fanconi Anemia/*drug therapy/genetics', 'Female', 'Humans', 'Lymphocytes/*drug effects', 'Male', 'Micronuclei, Chromosome-Defective/drug effects', 'Mitomycin/*adverse effects', 'Reactive Oxygen Species/metabolism']",https://pubmed.ncbi.nlm.nih.gov/18794784/
1449,amifostine,29776830,Pharmacological modulation of radiation-induced oral mucosal complications.,"['Bockel S', 'Vallard A', 'Levy A', 'Francois S', 'Bourdis M', 'Le Gallic C', 'Riccobono D', 'Annede P', 'Drouet M', 'Tao Y', 'Blanchard P', 'Deutsch E', 'Magne N', 'Chargari C']","['Amifostine/therapeutic use', 'Analgesics/therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Benzydamine/therapeutic use', 'Dietary Supplements', 'Fibroblast Growth Factor 7/therapeutic use', 'Glutamine/therapeutic use', 'Humans', 'Low-Level Light Therapy', 'Mouthwashes', 'Mucositis/*etiology/*therapy', 'Oral Hygiene', 'Radiation-Protective Agents/therapeutic use', 'Radiotherapy/*adverse effects', 'Risk Factors', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29776830/
1450,amifostine,10882182,"Supportive care in hematologic malignancies: hematopoietic growth factors, infections, transfusion therapy.","['Fetscher S', 'Mertelsmann R']","['Adult', 'Amifostine/pharmacology/therapeutic use', 'Amphotericin B/administration & dosage/therapeutic use', 'Animals', 'Antifungal Agents/administration & dosage/therapeutic use', 'Aspergillosis/prevention & control', 'Blood Transfusion/statistics & numerical data', 'Bone Marrow/drug effects/pathology', 'Clinical Trials, Phase I as Topic', 'Hematologic Neoplasms/complications/*therapy', 'Hematopoietic Cell Growth Factors/pharmacology/therapeutic use', 'Hematopoietic Stem Cells/drug effects', 'Humans', 'Infection Control', 'Neutropenia/etiology/therapy', 'Patient Care', 'Practice Guidelines as Topic', 'Radiation-Protective Agents/pharmacology/therapeutic use', 'Societies, Medical', 'Transfusion Reaction']",https://pubmed.ncbi.nlm.nih.gov/10882182/
1451,venlafaxine,36749328,Management of Menopausal Symptoms: A Review.,"['Crandall CJ', 'Mehta JM', 'Manson JE']","['Female', 'Humans', '*Estrogen Replacement Therapy/methods', 'Estrogens/therapeutic use', 'Estrogens, Conjugated (USP)/adverse effects', 'Hot Flashes/drug therapy/etiology', 'Medroxyprogesterone Acetate/therapeutic use', '*Menopause/drug effects', 'Neoplasms/drug therapy', 'Paroxetine/pharmacology', 'Venlafaxine Hydrochloride/pharmacology/therapeutic use', 'Venous Thromboembolism/drug therapy/etiology', 'Sweating', '*Female Urogenital Diseases/etiology', '*Autonomic Nervous System Diseases/etiology']",https://pubmed.ncbi.nlm.nih.gov/36749328/
1452,venlafaxine,31368838,Venlafaxine pharmacogenetics: a comprehensive review.,"['Suwala J', 'Machowska M', 'Wiela-Hojenska A']","['Antidepressive Agents/adverse effects/*therapeutic use', 'Cytochrome P-450 CYP2D6/*genetics', 'Depressive Disorder, Major/*drug therapy/genetics', 'Genotype', 'Humans', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Venlafaxine Hydrochloride/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31368838/
1453,venlafaxine,31178367,"Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.","['Furukawa TA', 'Cipriani A', 'Cowen PJ', 'Leucht S', 'Egger M', 'Salanti G']","['Depressive Disorder, Major/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Humans', 'Mirtazapine/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31178367/
1454,venlafaxine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
1455,venlafaxine,36920821,Posttraumatic Stress Disorder: Evaluation and Treatment.,"['Sartor Z', 'Kelley L', 'Laschober R']","['Humans', '*Stress Disorders, Post-Traumatic/diagnosis/therapy/psychology', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use', 'Fluoxetine/therapeutic use', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36920821/
1456,venlafaxine,24964257,Clinical drug-drug interactions: focus on venlafaxine.,"['Magalhaes P', 'Alves G', 'LLerena A', 'Falcao A']","['Antidepressive Agents, Second-Generation/pharmacokinetics/pharmacology/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Humans', 'Serotonin and Noradrenaline Reuptake Inhibitors/pharmacokinetics/pharmacology/*therapeutic use', 'Venlafaxine Hydrochloride/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24964257/
1457,venlafaxine,27929271,Hormone Therapy and Other Treatments for Symptoms of Menopause.,"['Hill DA', 'Crider M', 'Hill SR']","['Acupuncture Therapy', 'Administration, Intravaginal', 'Amines/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Atrophy', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Dietary Supplements', 'Drug Therapy, Combination', 'Dyspareunia/*therapy', 'Estrogen Replacement Therapy/*methods', 'Estrogens/therapeutic use', 'Exercise Therapy', 'Female', 'Gabapentin', 'Hot Flashes/*therapy', 'Humans', 'Hypnosis', 'Indoles/therapeutic use', '*Menopause', 'Paroxetine/therapeutic use', 'Progestins/therapeutic use', 'Selective Estrogen Receptor Modulators/therapeutic use', 'Tamoxifen/analogs & derivatives/therapeutic use', 'Vagina', 'Vaginal Diseases/*therapy', 'Vasomotor System', 'Venlafaxine Hydrochloride/therapeutic use', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27929271/
1458,venlafaxine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
1459,venlafaxine,12013367,Venlafaxine-associated vaginal bleeding.,"['Linnebur SA', 'Saseen JJ', 'Pace WD']","['Adult', 'Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Cyclohexanols/*adverse effects/therapeutic use', 'Depressive Disorder/complications/drug therapy', 'Female', 'Hemorrhage/*chemically induced', 'Humans', 'Menstruation/drug effects', 'Vaginal Diseases/*chemically induced', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/12013367/
1460,venlafaxine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
1461,venlafaxine,35630043,Impact of Venlafaxine on Platelet Count and Activity-Case Report and Narrative Review.,"['Smolarczyk-Kosowska J', 'Kosowski M', 'Kunert L', 'Filipczyk K', 'Wojciechowski M', 'Piegza M', 'Gorczyca P', 'Okopien B', 'Pudlo R']","['*Cyclohexanols/pharmacology', 'Humans', 'Platelet Count', '*Serotonin', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35630043/
1462,venlafaxine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
1463,venlafaxine,29509823,Clinical Inquiries: Does exercise relieve vasomotor menopausal symptoms?,"['Lyon C', 'Mullen R', 'Deffenbacher B', 'Reed A', 'Nashelsky J']","['Aged', 'Antidepressive Agents, Second-Generation/therapeutic use', 'Citalopram/therapeutic use', 'Estrogen Replacement Therapy', '*Exercise Therapy', 'Fatty Acids, Omega-3/therapeutic use', 'Female', 'Hot Flashes/*prevention & control', 'Humans', '*Menopause', 'Middle Aged', '*Sweating', 'Venlafaxine Hydrochloride/therapeutic use', 'Yoga']",https://pubmed.ncbi.nlm.nih.gov/29509823/
1464,venlafaxine,14700452,Improving antidepressant adherence.,['Nemeroff CB'],"['Antidepressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Bupropion/administration & dosage/adverse effects/*therapeutic use', 'Cyclohexanols/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', '*Health Promotion', 'Humans', 'Paroxetine/administration & dosage/adverse effects/*therapeutic use', '*Patient Compliance', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/14700452/
1465,venlafaxine,31637686,Mania induced by tramadol-venlafaxine combination.,"['Hefzi N', 'Grekin J', 'Ahmed A']","['Analgesics, Opioid', '*Bipolar Disorder/chemically induced', '*Depressive Disorder, Major/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/adverse effects', '*Tramadol/adverse effects/therapeutic use', '*Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31637686/
1466,venlafaxine,32345407,Evidence-based prescribing for post-traumatic stress disorder.,"['Bisson JI', 'Baker A', 'Dekker W', 'Hoskins MD']","['*Evidence-Based Medicine', 'Fluoxetine/therapeutic use', 'Humans', 'Paroxetine/therapeutic use', 'Sertraline/therapeutic use', 'Stress Disorders, Post-Traumatic/*drug therapy', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32345407/
1467,venlafaxine,37748003,Status Cataplecticus Induced by an Abrupt Duloxetine Withdrawal-A Case Report.,"['Cierny M', 'Feemster J', 'Hamid M', 'Battistini HA']","['Female', 'Humans', 'Aged', 'Duloxetine Hydrochloride/adverse effects', '*Cataplexy/drug therapy', '*Narcolepsy/drug therapy', 'Antidepressive Agents/adverse effects', 'Venlafaxine Hydrochloride/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37748003/
1468,venlafaxine,23045839,Warfarin: pharmacological profile and drug interactions with antidepressants.,"['Teles JS', 'Fukuda EY', 'Feder D']","['Administration, Oral', 'Anticoagulants/adverse effects/pharmacokinetics/*pharmacology/therapeutic use', 'Antidepressive Agents/*pharmacology', 'Biotransformation/drug effects', 'Cyclohexanols/pharmacology', 'Cytochrome P-450 Enzyme System/metabolism', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Fluoxetine/pharmacology', 'Hemorrhage/chemically induced', 'Humans', 'Paroxetine/pharmacology', 'Thiophenes/pharmacology', 'Thrombophilia/drug therapy', 'Venlafaxine Hydrochloride', 'Vitamin K/antagonists & inhibitors', 'Warfarin/adverse effects/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23045839/
1469,venlafaxine,26355986,Multiple Subungual Pyogenic Granulomas Following Levothyroxine Treatment.,"['Keles MK', 'Yosma E', 'Aydogdu IO', 'Simsek T', 'Park TH']","['Antidepressive Agents, Second-Generation/therapeutic use', 'Female', 'Follow-Up Studies', 'Granuloma, Pyogenic/*chemically induced', 'Hormone Replacement Therapy/adverse effects', 'Humans', 'Hypothyroidism/drug therapy', 'Middle Aged', 'Nail Diseases/*chemically induced', 'Recurrence', 'Thyroxine/*adverse effects', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26355986/
1470,venlafaxine,30946169,Attrition in treatment-resistant depression: predictors and clinical impact.,"['Olgiati P', 'Serretti A', 'Souery D', 'Kasper S', 'Kraus C', 'Montgomery S', 'Zohar J', 'Mendlewicz J']","['Adult', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Citalopram/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy/*epidemiology', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Dropouts/*statistics & numerical data', 'Venlafaxine Hydrochloride/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30946169/
1471,losartan,26051686,Losartan: Comprehensive Profile.,"['Al-Majed AR', 'Assiri E', 'Khalil NY', 'Abdel-Aziz HA']","['Angiotensin II Type 1 Receptor Blockers/*chemistry/pharmacokinetics/pharmacology', 'Animals', 'Antihypertensive Agents/*chemistry/pharmacokinetics/pharmacology', 'Blood Pressure/drug effects', 'Chemistry, Pharmaceutical', 'Drug Stability', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Losartan/*chemistry/pharmacokinetics/pharmacology', 'Molecular Structure', 'Technology, Pharmaceutical/methods']",https://pubmed.ncbi.nlm.nih.gov/26051686/
1472,losartan,16029066,Clinical pharmacokinetics of losartan.,"['Sica DA', 'Gehr TW', 'Ghosh S']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/*pharmacokinetics/pharmacology', 'Antihypertensive Agents/adverse effects/pharmacokinetics/pharmacology', 'Diabetic Nephropathies/prevention & control', 'Humans', 'Hypertension/drug therapy', 'Losartan/adverse effects/*pharmacokinetics/pharmacology', 'Prodrugs/adverse effects/*pharmacokinetics/pharmacology', 'Stroke/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/16029066/
1473,losartan,34580111,"Losartan Blocks Osteosarcoma-Elicited Monocyte Recruitment, and Combined With the Kinase Inhibitor Toceranib, Exerts Significant Clinical Benefit in Canine Metastatic Osteosarcoma.","['Regan DP', 'Chow L', 'Das S', 'Haines L', 'Palmer E', 'Kurihara JN', 'Coy JW', 'Mathias A', 'Thamm DH', 'Gustafson DL', 'Dow SW']","['Animals', '*Bone Neoplasms/drug therapy/veterinary', '*Dog Diseases/drug therapy', 'Dogs', 'Humans', 'Leukocytes, Mononuclear', 'Losartan/pharmacology/therapeutic use', 'Mice', 'Monocytes', '*Osteosarcoma/drug therapy/veterinary']",https://pubmed.ncbi.nlm.nih.gov/34580111/
1474,losartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
1475,losartan,34831368,Molecular Mechanisms of Hypertensive Nephropathy: Renoprotective Effect of Losartan through Hsp70.,"['Costantino VV', 'Gil Lorenzo AF', 'Bocanegra V', 'Valles PG']","['Animals', 'Epithelial-Mesenchymal Transition/drug effects', 'HSP70 Heat-Shock Proteins/*metabolism', 'Humans', 'Hypertension, Renal/*drug therapy', 'Kidney/drug effects/*pathology', 'Losartan/pharmacology/*therapeutic use', 'Nephritis/*drug therapy', 'Protective Agents/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34831368/
1476,losartan,31630573,Current Status of Angiotensin Receptor Blocker Recalls.,"['Gunasekaran PM', 'Chertow GM', 'Bhalla V', 'Byrd JB']","['Angiotensin Receptor Antagonists/pharmacology/*therapeutic use', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Carcinogens/*pharmacology', 'Drug Recalls/*legislation & jurisprudence/statistics & numerical data', 'Drug Utilization/statistics & numerical data', 'Female', 'Humans', 'Hypertension/diagnosis/*drug therapy', 'Losartan/*adverse effects/therapeutic use', 'Male', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/31630573/
1477,losartan,37965705,A Rare Case of Losartan-Induced Visceral Angioedema.,"['Rosas S', 'Fowler A', 'Stodgill E', 'Deyo-Svendsen M', 'Phillips M']","['Humans', '*Losartan/adverse effects', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Angiotensin Receptor Antagonists/therapeutic use', 'Renin-Angiotensin System', '*Angioedema/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37965705/
1478,losartan,32397766,A review of clinically significant drug-drug interactions involving angiotensin II receptor antagonists and antiepileptic drugs.,"['Rusek M', 'Czuczwar SJ']","['Angiotensin Receptor Antagonists/*administration & dosage/pharmacokinetics/pharmacology', 'Animals', 'Anticonvulsants/*administration & dosage/pharmacology', 'Drug Interactions', 'Humans', 'Losartan/administration & dosage/pharmacokinetics/pharmacology', 'Neuroprotective Agents/administration & dosage/pharmacokinetics/pharmacology', 'Renin-Angiotensin System/*drug effects', 'Seizures/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/32397766/
1479,losartan,16050407,[Renin-angiotensin system in diabetic nephropathy].,['Luno J'],"['Albuminuria/diagnosis', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use', 'Animals', 'Antihypertensive Agents/administration & dosage/therapeutic use', 'Benzimidazoles/administration & dosage/therapeutic use', 'Benzoates/administration & dosage/therapeutic use', 'Blood Glucose/analysis', 'Diabetes Mellitus, Type 2/complications', 'Diabetic Nephropathies/blood/*physiopathology/*prevention & control', 'Disease Progression', 'Drug Therapy, Combination', 'Homeostasis', 'Humans', 'Lisinopril/administration & dosage/therapeutic use', 'Losartan/administration & dosage/therapeutic use', 'Meta-Analysis as Topic', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/*drug effects/physiology', 'Risk Factors', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/16050407/
1480,losartan,38573840,Topical Losartan for Treating Corneal Haze After Ultraviolet-A/Riboflavin Collagen Cross-Linking.,"['Rodgers EG', 'Al-Mohtaseb Z', 'Chen AJ']","['Humans', '*Losartan/administration & dosage/therapeutic use', 'Male', '*Riboflavin/therapeutic use', '*Collagen/metabolism', '*Cross-Linking Reagents', 'Young Adult', '*Corneal Opacity/drug therapy/etiology', '*Ultraviolet Rays', '*Photosensitizing Agents/therapeutic use', '*Visual Acuity', 'Keratoconus/drug therapy', 'Corneal Stroma/metabolism/drug effects', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use/administration & dosage', 'Photochemotherapy/methods', 'Ophthalmic Solutions', 'Administration, Topical']",https://pubmed.ncbi.nlm.nih.gov/38573840/
1481,losartan,10772441,Angiotensin II receptor blockers in patients with ACE inhibitor-induced angioedema.,"['Warner KK', 'Visconti JA', 'Tschampel MM']","['Angioedema/chemically induced/*drug therapy', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Humans', 'Losartan/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10772441/
1482,losartan,25271811,Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.,"['Rakugi H', 'Tsuchihashi T', 'Shimada K', 'Numaguchi H', 'Nishida C', 'Yamaguchi H', 'Shirakawa M', 'Azuma K', 'Fujita KP']","['Aged', '*Amlodipine/administration & dosage/adverse effects', 'Antihypertensive Agents/administration & dosage/adverse effects', 'Blood Pressure/*drug effects', 'Drug Combinations', 'Drug Monitoring/methods', 'Essential Hypertension', 'Female', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', '*Hypertension/diagnosis/drug therapy/physiopathology', 'Japan', '*Losartan/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25271811/
1483,losartan,23093500,Losartan-induced coronary artery spasm.,"['Josefsson J', 'Frobert O']","['Antihypertensive Agents/*adverse effects', 'Coronary Vasospasm/*chemically induced/complications', 'Coronary Vessels/*drug effects', 'Female', 'Humans', 'Losartan/*adverse effects', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/23093500/
1484,losartan,30092110,Potential Usefulness of Losartan as an Antifibrotic Agent and Adjunct to Platelet-Rich Plasma Therapy to Improve Muscle Healing and Cartilage Repair and Prevent Adhesion Formation.,"['Huard J', 'Bolia I', 'Briggs K', 'Utsunomiya H', 'Lowe WR', 'Philippon MJ']","['Animals', 'Antifibrinolytic Agents/*therapeutic use', 'Cartilage/drug effects', 'Disease Models, Animal', 'Fibrosis/drug therapy', 'Humans', 'Losartan/*therapeutic use', 'Muscle, Skeletal/drug effects', 'Orthopedic Procedures/adverse effects', '*Platelet-Rich Plasma', 'Postoperative Complications/prevention & control', 'Tissue Adhesions/*prevention & control', 'Transforming Growth Factor beta/*antagonists & inhibitors', 'Transforming Growth Factor beta1', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/30092110/
1485,losartan,19092813,Inhibition of the renin-angiotensin system: is more better?,"['Anderson S', 'Komers R']","['Angiotensin II Type 1 Receptor Blockers/therapeutic use', 'Animals', 'Diabetic Nephropathies/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Kidney Glomerulus/pathology', 'Losartan/administration & dosage/therapeutic use', 'Proteinuria/drug therapy', 'Rats', 'Renin-Angiotensin System/*drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19092813/
1486,losartan,11824872,Clinical trials of angiotensin receptor blockers in heart failure: what do we know and what will we learn?,['Pitt B'],"['Angiotensin I/metabolism', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Clinical Trials as Topic', 'Forecasting', 'Heart Failure/*drug therapy', 'Humans', 'Losartan/administration & dosage/therapeutic use', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11824872/
1487,losartan,39325643,Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial.,"['Tran KC', 'Asfar P', 'Cheng M', 'Demiselle J', 'Singer J', 'Lee T', 'Sweet D', 'Boyd J', 'Walley K', 'Haljan G', 'Sharif O', 'Geri G', 'Auchabie J', 'Quenot JP', 'Lee TC', 'Tsang J', 'Meziani F', 'Lamontagne F', 'Dubee V', 'Lasocki S', 'Ovakim D', 'Wood G', 'Turgeon A', 'Cohen Y', 'Lebas E', 'Goudelin M', 'Forrest D', 'Teale A', 'Mira JP', 'Fowler R', 'Daneman N', 'Adhikari NKJ', 'Gousseff M', 'Leroy P', 'Plantefeve G', 'Rispal P', 'Courtois R', 'Winston B', 'Reynolds S', 'Birks P', 'Bienvenu B', 'Tadie JM', 'Talarmin JP', 'Ansart S', 'Russell JA']","['Humans', '*Losartan/therapeutic use/adverse effects/administration & dosage', 'Male', 'Female', 'Aged', 'Middle Aged', '*Hospitalization', '*COVID-19/mortality', '*COVID-19 Drug Treatment', 'France/epidemiology', 'Hospital Mortality', 'SARS-CoV-2/drug effects', 'Canada/epidemiology', 'Aged, 80 and over', 'Treatment Outcome', 'Hypotension/chemically induced', 'Angiotensin II Type 1 Receptor Blockers/therapeutic use/adverse effects/administration & dosage', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39325643/
1488,losartan,23250713,Additive antiproteinuric effect of enalapril and losartan in children with hemolytic uremic syndrome.,"['Caletti MG', 'Balestracci A', 'Missoni M', 'Vezzani C']","['Angiotensin II Type 1 Receptor Blockers/adverse effects/therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Diarrhea/complications/diagnosis/*drug therapy', 'Drug Therapy, Combination', 'Enalapril/adverse effects/*therapeutic use', 'Female', 'Hemolytic-Uremic Syndrome/complications/diagnosis/*drug therapy', 'Humans', 'Infant', 'Losartan/adverse effects/*therapeutic use', 'Male', 'Proteinuria/diagnosis/*drug therapy/etiology', 'Retrospective Studies', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23250713/
1489,losartan,11888349,Can angiotensin receptor antagonists be used safely in patients with previous ACE inhibitor-induced angioedema?,"['Howes LG', 'Tran D']","['Angioedema/*chemically induced', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Benzimidazoles/adverse effects/therapeutic use', 'Benzoates/adverse effects/therapeutic use', 'Biphenyl Compounds/adverse effects/therapeutic use', 'Blood Pressure/*drug effects', 'Humans', 'Irbesartan', 'Losartan/adverse effects/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11888349/
1490,losartan,36586717,The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.,"['Yamaura K', 'Nelson AL', 'Nishimura H', 'Rutledge JC', 'Ravuri SK', 'Bahney C', 'Philippon MJ', 'Huard J']","['Animals', 'Humans', 'Angiotensin II Type 2 Receptor Blockers', 'Angiotensin Receptor Antagonists', 'Cartilage', '*Losartan/pharmacology/therapeutic use', '*Osteoarthritis']",https://pubmed.ncbi.nlm.nih.gov/36586717/
1491,alfuzosin,16613526,BPH: epidemiology and comorbidities.,['McVary KT'],"['5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/therapeutic use', 'Adult', 'Age Distribution', 'Aged', 'Aged, 80 and over', 'Cardiovascular Diseases/epidemiology', 'Comorbidity', 'Diabetes Complications/epidemiology', 'Enzyme Inhibitors/therapeutic use', 'Erectile Dysfunction/epidemiology', 'Global Health', 'Humans', 'Male', 'Metabolic Syndrome/epidemiology', 'Middle Aged', 'Prevalence', 'Prostatic Hyperplasia/*epidemiology/therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/16613526/
1492,alfuzosin,33694138,[Intraoperative floppy iris syndrom (IFIS) associated with tamsulosin].,"['Bigdon E', 'Casagrande M', 'Spitzer MS', 'Hassenstein A']","['*Adrenergic alpha-1 Receptor Antagonists/adverse effects', 'Adrenergic alpha-Antagonists/adverse effects', '*Cataract/chemically induced', 'Humans', 'Intraoperative Complications/chemically induced', 'Iris Diseases/chemically induced', 'Sulfonamides/adverse effects', 'Tamsulosin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33694138/
1493,alfuzosin,11074198,Alpha blockers: are all created equal?,['Debruyne FM'],"['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11074198/
1494,alfuzosin,27127315,"A randomized, comparative, open-label study of efficacy and tolerability of alfuzosin, tamsulosin and silodosin in benign prostatic hyperplasia.","['Manjunatha R', 'Pundarikaksha HP', 'Madhusudhana HR', 'Amarkumar J', 'Hanumantharaju BK']","['Adrenergic alpha-1 Receptor Antagonists/*therapeutic use', 'Aged', 'Humans', 'Indoles/*therapeutic use', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy/physiopathology', 'Quinazolines/*therapeutic use', 'Sulfonamides/*therapeutic use', 'Tamsulosin', 'Treatment Outcome', 'Urological Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27127315/
1495,alfuzosin,19057209,Watchful waiting in benign prostatic hyperplasia.,"['Wiygul J', 'Babayan RK']","['Adrenergic alpha-Antagonists/therapeutic use', '*Disease Progression', 'Humans', 'Male', 'Prostate/pathology', 'Prostate-Specific Antigen/blood', 'Prostatic Hyperplasia/blood/*physiopathology/*therapy', 'Quinazolines/therapeutic use', 'Transurethral Resection of Prostate']",https://pubmed.ncbi.nlm.nih.gov/19057209/
1496,alfuzosin,10771467,Alfuzosin-induced hepatotoxicity.,"['Zabala S', 'Thomson C', 'Valdearcos S', 'Gascon A', 'Pina MA']","['Acute Disease', 'Antihypertensive Agents/*adverse effects', 'Chemical and Drug Induced Liver Injury/*physiopathology', 'Humans', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Quinazolines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10771467/
1497,alfuzosin,29971698,Is Tamsulosin Linked to Dementia in the Elderly?,"['Frankel JK', 'Duan Y', 'Albertsen PC']","['Adrenergic alpha-1 Receptor Antagonists/adverse effects/pharmacology/therapeutic use', 'Aged', 'Brain/drug effects', 'Cognition/drug effects/physiology', 'Dementia/*chemically induced', 'Humans', 'Lower Urinary Tract Symptoms/*drug therapy', 'Sulfonamides/*adverse effects/therapeutic use', 'Tamsulosin', 'Urological Agents/*adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29971698/
1498,alfuzosin,29334287,Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.,"['Sridharan K', 'Sivaramakrishnan G']","['Adrenal Cortex Hormones/administration & dosage', 'Adrenergic alpha-Antagonists/*administration & dosage/adverse effects', 'Adult', 'Child', 'Drug Therapy, Combination', 'Humans', 'Phosphodiesterase Inhibitors/administration & dosage', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic', 'Sulfonamides/*administration & dosage/adverse effects', 'Tamsulosin', 'Treatment Outcome', 'Ureteral Calculi/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29334287/
1499,alfuzosin,16553574,Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.,['Elhilali MM'],"['Adrenergic alpha-1 Receptor Antagonists', 'Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/complications/*drug therapy', 'Quality of Life', 'Quinazolines/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sexual Dysfunction, Physiological/etiology', 'Urodynamics/drug effects', 'Urologic Diseases/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/16553574/
1500,alfuzosin,9732825,Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.,['de Mey C'],"['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Blood Pressure/*drug effects', 'Humans', 'Male', 'Prostatic Hyperplasia/complications/*drug therapy', 'Sulfonamides/adverse effects/therapeutic use', 'Tamsulosin', 'Urinary Bladder Neck Obstruction/etiology']",https://pubmed.ncbi.nlm.nih.gov/9732825/
1501,alfuzosin,12230262,Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.,"['Pool JL', 'Kirby RS']","['Adrenergic alpha-Antagonists/pharmacokinetics/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Blood-Brain Barrier', 'Doxazosin/pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quinazolines/pharmacokinetics/*therapeutic use', 'Receptors, Adrenergic, alpha-1/*classification/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12230262/
1502,alfuzosin,33566468,Otorhinolaryngological adverse effects of urological drugs.,"['Maia NPD', 'Lopes KC', 'Gananca FF']","['Adrenergic alpha-Antagonists', 'Doxazosin', 'Humans', 'Male', '*Pharmaceutical Preparations', 'Prazosin', '*Prostatic Hyperplasia', 'Tadalafil', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/33566468/
1503,alfuzosin,12426862,[alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness].,"['Berges RR', 'Michel MC', 'Jonas U']","['*Adrenergic alpha-1 Receptor Antagonists', 'Adrenergic alpha-Antagonists/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Urinary Bladder Neck Obstruction/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12426862/
1504,alfuzosin,9248814,Using a large clinical database to assess the effectiveness of alfuzosin.,['Lukacs B'],"['Adrenergic alpha-Antagonists/pharmacology/*therapeutic use', 'Aged', 'Cost-Benefit Analysis', 'Databases, Factual', '*Decision Making, Computer-Assisted', 'Humans', 'Male', 'Middle Aged', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life', 'Quinazolines/pharmacology/*therapeutic use', 'Surveys and Questionnaires', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9248814/
1505,alfuzosin,26244843,Efficacy and Safety of Alfuzosin as Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.,"['Liu C', 'Zeng G', 'Kang R', 'Wu W', 'Li J', 'Chen K', 'Wan SP']","['Humans', 'Quinazolines/adverse effects/*therapeutic use', 'Sulfonamides/adverse effects/therapeutic use', 'Tamsulosin', 'Ureter/drug effects/pathology', 'Ureteral Calculi/*drug therapy/pathology', 'Urological Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26244843/
1506,alfuzosin,38896813,"Association of Terazosin, Doxazosin, or Alfuzosin Use and Risk of Dementia With Lewy Bodies in Men.","['Hart A', 'Aldridge G', 'Zhang Q', 'Narayanan NS', 'Simmering JE']","['Humans', 'Male', '*Doxazosin/therapeutic use', 'Aged', '*Prazosin/analogs & derivatives/therapeutic use', '*Lewy Body Disease/drug therapy', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Quinazolines/therapeutic use/adverse effects', 'Aged, 80 and over', 'Tamsulosin/therapeutic use', 'Prostatic Hyperplasia/drug therapy', 'Neuroprotective Agents/therapeutic use/pharmacology', 'Middle Aged', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38896813/
1507,alfuzosin,34184151,Intraoperative floppy iris syndrome: an updated review of literature.,"['Kumar A', 'Raj A']","['*Adrenergic alpha-1 Receptor Antagonists/adverse effects', 'Humans', '*Iris Diseases/chemically induced/diagnosis', 'Male', 'Pupil', 'Sulfonamides', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/34184151/
1508,alfuzosin,38457017,Effect of different alpha-receptor antagonists on metabolic parameters: a head-to-head comparison.,"['Castur L', 'Uzunlulu M', 'Eken E', 'Cicek M', 'Tahra A', 'Efiloglu O', 'Demirtas B', 'Yildirim A']","['Humans', 'Male', '*Doxazosin/therapeutic use', '*Tamsulosin/therapeutic use', 'Middle Aged', 'Prospective Studies', '*Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Prostatic Hyperplasia/drug therapy', 'Aged', 'Lower Urinary Tract Symptoms/drug therapy', 'Blood Glucose/metabolism/drug effects', 'Insulin Resistance', 'Glycated Hemoglobin/metabolism', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38457017/
1509,alfuzosin,19296449,Functional screening of adrenergic receptors by measuring intracellular calcium using the FlexStation scanning fluorimeter.,"['Nanda K', 'Chatterjee M', 'Gupta S', 'Singh R', 'Tiwar A', 'Gupta D', 'Ray A']","['Animals', 'Biotechnology/*methods', 'Calcium/chemistry/metabolism', 'Cell Line', 'Dose-Response Relationship, Drug', 'Fluorescent Dyes/pharmacology', 'Fluorometry/*instrumentation/methods', 'GTP-Binding Proteins/chemistry', 'Humans', 'Kinetics', 'Prazosin/analogs & derivatives/pharmacology', 'Protein Binding', 'Quinazolines/pharmacology', 'Receptors, Adrenergic/metabolism', 'Signal Transduction', 'Sulfonamides/pharmacology', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/19296449/
1510,alfuzosin,12892027,Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.,['Lee M'],"['Adrenergic alpha-Antagonists/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Drug Therapy, Combination', 'Finasteride/therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy', 'Quality of Life', 'Quinazolines/administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12892027/
1511,Cinacalcet,36382758,Medical management of primary hyperparathyroidism.,"['Bandeira F', 'de Moura Nobrega J', 'de Oliveira LB', 'Bilezikian J']","['Humans', '*Hyperparathyroidism, Primary/drug therapy/surgery', 'Parathyroidectomy', 'Cinacalcet/therapeutic use', 'Parathyroid Hormone/therapeutic use', 'Parathyroid Glands/surgery']",https://pubmed.ncbi.nlm.nih.gov/36382758/
1512,Cinacalcet,37777840,Hypocalcemia and cardiovascular mortality in cinacalcet users.,"['Goto S', 'Hamano T', 'Fujii H', 'Taniguchi M', 'Abe M', 'Nitta K', 'Nishi S']","['Humans', 'Cinacalcet', '*Hypocalcemia/chemically induced', 'Calcium', 'Prospective Studies', 'Renal Dialysis/adverse effects', 'Parathyroid Hormone', '*Hyperparathyroidism, Secondary/etiology', 'Calcimimetic Agents', '*Heart Failure/etiology']",https://pubmed.ncbi.nlm.nih.gov/37777840/
1513,Cinacalcet,35277957,Parathyroidectomy vs Cinacalcet Among Patients Undergoing Hemodialysis.,"['Komaba H', 'Hamano T', 'Fujii N', 'Moriwaki K', 'Wada A', 'Masakane I', 'Nitta K', 'Fukagawa M']","['Calcium', '*Cinacalcet/therapeutic use', 'Humans', '*Hyperparathyroidism, Secondary/drug therapy/etiology/surgery', 'Parathyroid Hormone', '*Parathyroidectomy', 'Prospective Studies', 'Renal Dialysis/mortality']",https://pubmed.ncbi.nlm.nih.gov/35277957/
1514,Cinacalcet,39298584,Large library docking identifies positive allosteric modulators of the calcium-sensing receptor.,"['Liu F', 'Wu CG', 'Tu CL', 'Glenn I', 'Meyerowitz J', 'Kaplan AL', 'Lyu J', 'Cheng Z', 'Tarkhanova OO', 'Moroz YS', 'Irwin JJ', 'Chang W', 'Shoichet BK', 'Skiniotis G']","['Animals', 'Humans', 'Mice', 'Allosteric Regulation', 'Cinacalcet/pharmacokinetics/pharmacology', '*Cryoelectron Microscopy', '*Molecular Docking Simulation', '*Parathyroid Hormone/metabolism', 'Protein Conformation', '*Receptors, Calcium-Sensing/agonists/antagonists & inhibitors/chemistry', '*Small Molecule Libraries/chemistry/pharmacology', '*Drug Discovery', '*Calcimimetic Agents/chemistry/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/39298584/
1515,Cinacalcet,34774237,Sporadic Primary Hyperparathyroidism.,"['Kim SJ', 'Shoback DM']","['Calcium', 'Cinacalcet/therapeutic use', 'Female', 'Humans', '*Hyperparathyroidism, Primary/diagnosis/surgery', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34774237/
1516,Cinacalcet,28097356,Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial.,"['Block GA', 'Bushinsky DA', 'Cheng S', 'Cunningham J', 'Dehmel B', 'Drueke TB', 'Ketteler M', 'Kewalramani R', 'Martin KJ', 'Moe SM', 'Patel UD', 'Silver J', 'Sun Y', 'Wang H', 'Chertow GM']","['Administration, Oral', 'Biomarkers/blood', 'Calcimimetic Agents/administration & dosage/adverse effects/*pharmacology', 'Calcium/administration & dosage/blood', 'Cinacalcet/administration & dosage/adverse effects/*pharmacology', 'Double-Blind Method', 'Female', 'Fibroblast Growth Factor-23', 'Fibroblast Growth Factors/blood', 'Humans', 'Hyperparathyroidism, Secondary/blood/*drug therapy/etiology', 'Infusions, Intravenous', 'Kidney Failure, Chronic/complications/therapy', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Parathyroid Hormone/*blood', 'Peptides/administration & dosage/adverse effects/*pharmacology', '*Renal Dialysis', 'Time Factors', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/28097356/
1517,Cinacalcet,38326620,Allosteric modulation and G-protein selectivity of the Ca(2+)-sensing receptor.,"['He F', 'Wu CG', 'Gao Y', 'Rahman SN', 'Zaoralova M', 'Papasergi-Scott MM', 'Gu TJ', 'Robertson MJ', 'Seven AB', 'Li L', 'Mathiesen JM', 'Skiniotis G']","['Humans', 'Allosteric Regulation/drug effects', 'Cinacalcet/pharmacology', 'Cryoelectron Microscopy', 'GTP-Binding Protein alpha Subunits, Gi-Go/metabolism', 'GTP-Binding Protein alpha Subunits, Gq-G11/metabolism', '*Heterotrimeric GTP-Binding Proteins/metabolism', 'Ligands', 'Lipids', 'Nanostructures/chemistry', 'Polyamines/metabolism', 'Protein Conformation/drug effects', '*Receptors, Calcium-Sensing/chemistry/metabolism/ultrastructure', 'Substrate Specificity', 'Tryptophan/metabolism', 'Calcium/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38326620/
1518,Cinacalcet,28992983,Primary hyperparathyroidism.,"['Munoz-Torres M', 'Garcia-Martin A']","['Biomarkers/blood', 'Calcium/blood', 'Calcium-Regulating Hormones and Agents/therapeutic use', 'Cinacalcet/therapeutic use', 'Diagnosis, Differential', 'Humans', '*Hyperparathyroidism, Primary/blood/diagnosis/etiology/therapy', 'Parathyroid Hormone/blood', 'Parathyroidectomy']",https://pubmed.ncbi.nlm.nih.gov/28992983/
1519,Cinacalcet,38040277,Impact of Parathyroidectomy Versus Oral Cinacalcet on Bone Mineral Density in Patients on Peritoneal Dialysis With Advanced Secondary Hyperparathyroidism: The PROCEED Pilot Randomized Trial.,"['Wang AY', 'Tang TK', 'Yau YY', 'Lo WK']","['Humans', 'Bone Density', 'Pilot Projects', 'Cinacalcet/therapeutic use', 'Parathyroidectomy', 'Prospective Studies', '*Osteoporosis', '*Hyperparathyroidism, Secondary/drug therapy', '*Bone Diseases, Metabolic/etiology', '*Peritoneal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/38040277/
1520,Cinacalcet,30665549,Non-surgical management of primary hyperparathyroidism.,"['Cetani F', 'Saponaro F', 'Marcocci C']","['Calcium/blood', 'Cinacalcet/therapeutic use', 'Female', 'Fluid Therapy', 'Humans', 'Hypercalcemia/etiology/therapy', 'Hyperparathyroidism, Primary/complications/*therapy', 'Parathyroid Hormone/blood', 'Parathyroidectomy', 'Pregnancy', 'Pregnancy Complications/therapy', 'Vitamin D Deficiency/etiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/30665549/
1521,Cinacalcet,25350412,[Medical treatment of children with hypophosphataemic rickets].,"['Rahbek ET', 'Nielsen LH', 'Beck-Nielsen SS', 'Christesen HT']","['Bone Density Conservation Agents/administration & dosage/adverse effects/therapeutic use', 'Child', 'Cinacalcet/administration & dosage/adverse effects/therapeutic use', 'Fibroblast Growth Factor-23', 'Fibroblast Growth Factors/antagonists & inhibitors/blood/metabolism', 'Genetic Diseases, X-Linked', 'Humans', 'Hydroxycholecalciferols/administration & dosage/adverse effects/therapeutic use', 'Oligopeptides/administration & dosage/adverse effects/therapeutic use', 'Phosphates/administration & dosage/adverse effects/blood/therapeutic use', 'Protease Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Radiography', 'Rickets, Hypophosphatemic/complications/diagnostic imaging/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/25350412/
1522,Cinacalcet,19092812,The new role of calcimimetics as vasculotropic agents.,['Al-Aly Z'],"['Aniline Compounds/therapeutic use', 'Calcinosis/complications/*drug therapy/prevention & control', 'Calcium/*agonists', 'Cardiovascular Diseases/*prevention & control', 'Cinacalcet', 'Humans', 'Naphthalenes/therapeutic use', 'Phenethylamines', 'Propylamines', 'Receptors, Calcium-Sensing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/19092812/
1523,Cinacalcet,21821309,Calciphylaxis: a systematic review of existing and emerging therapies.,"['Vedvyas C', 'Winterfield LS', 'Vleugels RA']","['Antioxidants/therapeutic use', 'Calciphylaxis/*therapy', 'Cinacalcet', 'Diphosphonates/therapeutic use', 'Humans', 'Naphthalenes/therapeutic use', 'Parathyroidectomy', 'Skin Diseases, Vascular/*therapy', 'Thiosulfates/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21821309/
1524,Cinacalcet,18220773,Recent updates on the calcium-sensing receptor as a drug target.,"['Trivedi R', 'Mithal A', 'Chattopadhyay N']","['Allosteric Regulation', 'Animals', 'Calcium/*metabolism', 'Cinacalcet', 'Clinical Trials as Topic', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy/metabolism', 'Kidney Failure, Chronic/complications', 'Naphthalenes/administration & dosage/chemistry/therapeutic use', 'Osteoporosis/*drug therapy/metabolism', 'Parathyroid Glands/drug effects/metabolism', 'Parathyroid Hormone/blood/*metabolism', 'Receptors, Calcium-Sensing/agonists/antagonists & inhibitors/chemistry/*metabolism', 'Receptors, GABA-B/metabolism']",https://pubmed.ncbi.nlm.nih.gov/18220773/
1525,Cinacalcet,15631545,Cinacalcet hydrochloride.,"['Barman Balfour JA', 'Scott LJ']","['Animals', 'Cinacalcet', 'Clinical Trials as Topic', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy/etiology', 'Kidney Failure, Chronic/complications', 'Naphthalenes/administration & dosage/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Parathyroid Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15631545/
1526,Cinacalcet,31169527,Revisiting therapeutic options for calciphylaxis.,"['Seethapathy H', 'Nigwekar SU']","['Anticoagulants/therapeutic use', 'Calciphylaxis/diagnosis/etiology/*therapy', 'Cinacalcet/therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Pain Management', 'Parathyroidectomy', 'Thiosulfates/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31169527/
1527,Cinacalcet,36848027,Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.,"['Bernardor J', 'De Mul A', 'Bacchetta J', 'Schmitt CP']","['Adult', 'Humans', 'Child', 'Cinacalcet/therapeutic use', 'Renal Dialysis', 'Calcium/therapeutic use', '*Chronic Kidney Disease-Mineral and Bone Disorder/drug therapy/complications', '*Cardiovascular Diseases', '*Hyperparathyroidism, Secondary/drug therapy/etiology', 'Calcimimetic Agents/therapeutic use', 'Parathyroid Hormone', 'Vitamin D/therapeutic use', '*Renal Insufficiency, Chronic/complications/therapy', 'Minerals', 'Phosphates/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36848027/
1528,Cinacalcet,28390776,Calciphylaxis: Beyond CKD-MBD.,"['Fernandez M', 'Morales E', 'Gutierrez E', 'Polanco N', 'Hernandez E', 'Merida E', 'Praga M']","['Adrenal Cortex Hormones/adverse effects', 'Adult', 'Aged', 'Aged, 80 and over', 'Amputation, Surgical', 'Calciphylaxis/*etiology/mortality/therapy', 'Chelation Therapy', 'Cinacalcet/therapeutic use', 'Combined Modality Therapy', 'Diphosphonates/therapeutic use', 'Female', 'Humans', 'Hypoalbuminemia/complications', 'Kaplan-Meier Estimate', 'Kidney Failure, Chronic/complications/surgery/therapy', 'Kidney Transplantation', 'Male', 'Middle Aged', 'Pentoxifylline/therapeutic use', 'Postoperative Complications/ethnology/etiology', 'Renal Dialysis', 'Retrospective Studies', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28390776/
1529,Cinacalcet,21310676,"[Calcimimetics: physiology, results of preclinical and clinical studies, and perspectives].",['Torres PU'],"['Biomarkers/blood', 'Calcimimetic Agents/*therapeutic use', 'Calcium Phosphates/blood', 'Cinacalcet', 'Evidence-Based Medicine', 'Humans', 'Hyperparathyroidism, Secondary/blood/diagnosis/*drug therapy/etiology', 'Naphthalenes/therapeutic use', 'Parathyroid Hormone/*blood', 'Receptors, Calcium-Sensing/*drug effects', 'Renal Dialysis/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21310676/
1530,Cinacalcet,21151209,Renal allograft failure in a hyperparathyroid patient following initiation of a calcimimetic.,"['Seikrit C', 'Muhlfeld A', 'Groene HJ', 'Floege J']","['Cinacalcet', 'Graft Survival/drug effects', 'Humans', 'Hyperparathyroidism, Secondary/*drug therapy', 'Kidney Failure, Chronic/*surgery', '*Kidney Transplantation', 'Male', 'Middle Aged', 'Naphthalenes/*adverse effects', 'Nephrocalcinosis/*chemically induced', 'Postoperative Complications/drug therapy', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/21151209/
1531,lansoprazole,36228734,Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.,"['Laine L', 'DeVault K', 'Katz P', 'Mitev S', 'Lowe J', 'Hunt B', 'Spechler S']","['Adult', 'Humans', 'Lansoprazole/therapeutic use', 'Pyrroles/adverse effects', 'Sulfonamides/therapeutic use', '*Esophagitis', 'Proton Pump Inhibitors/therapeutic use', '*Peptic Ulcer', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36228734/
1532,lansoprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
1533,lansoprazole,19708852,Dexlansoprazole MR.,"['Aslam N', 'Wright R']","['2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects/*pharmacokinetics', 'Acute Disease', 'Anti-Ulcer Agents/adverse effects/*pharmacokinetics', 'Delayed-Action Preparations/metabolism/pharmacokinetics', 'Dexlansoprazole', 'Esophagitis, Peptic/drug therapy', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Lansoprazole', '*Proton Pump Inhibitors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19708852/
1534,lansoprazole,35679950,Vonoprazan Triple and Dual Therapy for Helicobacter pylori Infection in the United States and Europe: Randomized Clinical Trial.,"['Chey WD', 'Megraud F', 'Laine L', 'Lopez LJ', 'Hunt BJ', 'Howden CW']","['Adult', 'Amoxicillin/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Clarithromycin/adverse effects', 'Drug Therapy, Combination', '*Helicobacter Infections/diagnosis/drug therapy', '*Helicobacter pylori', 'Humans', 'Lansoprazole/adverse effects', 'Proton Pump Inhibitors/adverse effects', 'Pyrroles', 'Sulfonamides', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/35679950/
1535,lansoprazole,37849071,Clinical pharmacokinetics of nebivolol: a systematic review.,"['Hanif N', 'Zamir A', 'Imran I', 'Saeed H', 'Majeed A', 'Rehman AU', 'Ashraf W', 'Alqahtani F', 'Rasool MF']","['Male', 'Humans', 'Nebivolol/pharmacokinetics/therapeutic use', '*Hypertension/drug therapy', 'Fluvoxamine/therapeutic use', 'Lansoprazole/therapeutic use', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/37849071/
1536,lansoprazole,37883084,"Ceftriaxone and the Risk of Ventricular Arrhythmia, Cardiac Arrest, and Death Among Patients Receiving Lansoprazole.","['Bai AD', 'Wilkinson A', 'Almufleh A', 'Rai M', 'Razak F', 'Verma AA', 'Srivastava S']","['Adult', 'Humans', 'Male', 'Aged', 'Female', 'Lansoprazole/therapeutic use', '*Ceftriaxone/adverse effects', 'Cohort Studies', 'Retrospective Studies', 'Arrhythmias, Cardiac/chemically induced/epidemiology', '*Heart Arrest/chemically induced/epidemiology', 'Proton Pump Inhibitors/adverse effects', 'Inpatients', 'Ontario/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/37883084/
1537,lansoprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
1538,lansoprazole,24414180,Lansoprazole-induced hypomagnesaemia.,"['Krupa LZ', 'Fellows IW']","['Aged', 'Female', 'Humans', 'Hypocalcemia/chemically induced', 'Lansoprazole/*adverse effects', 'Magnesium/*therapeutic use', 'Magnesium Deficiency/*chemically induced/complications', 'Proton Pump Inhibitors/*adverse effects', 'Tachycardia, Supraventricular/etiology', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/24414180/
1539,lansoprazole,38897240,Concomitant use of lansoprazole and ceftriaxone is associated with an increased risk of ventricular arrhythmias and cardiac arrest in a large Japanese hospital database.,"['Mitsuboshi S', 'Imai S', 'Kizaki H', 'Hori S']","['Humans', '*Lansoprazole/adverse effects/administration & dosage', '*Ceftriaxone/adverse effects/administration & dosage', '*Heart Arrest/chemically induced/epidemiology', 'Male', 'Japan/epidemiology', 'Female', 'Aged', 'Middle Aged', '*Proton Pump Inhibitors/adverse effects/administration & dosage', '*Arrhythmias, Cardiac/chemically induced/epidemiology', 'Anti-Bacterial Agents/adverse effects/administration & dosage', 'Databases, Factual', 'Aged, 80 and over', 'Adult', 'Retrospective Studies', 'Incidence', 'Administration, Oral', 'Risk Factors', 'Drug Therapy, Combination/adverse effects', 'East Asian People']",https://pubmed.ncbi.nlm.nih.gov/38897240/
1540,lansoprazole,21366513,Dexlansoprazole MR: a review.,"['Hershcovici T', 'Jha LK', 'Fass R']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Dexlansoprazole', 'Esophagitis/*drug therapy/physiopathology', 'Gastroesophageal Reflux/drug therapy/physiopathology', 'Humans', 'Lansoprazole', 'Mucous Membrane/pathology', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/21366513/
1541,lansoprazole,37127558,Randomised clinical trial: 3-year interim analysis results of the VISION trial to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive oesophagitis.,"['Haruma K', 'Kinoshita Y', 'Yao T', 'Kushima R', 'Akiyama J', 'Aoyama N', 'Kanoo T', 'Miyata K', 'Kusumoto N', 'Uemura N']","['Humans', 'Proton Pump Inhibitors/therapeutic use', 'Hyperplasia', '*Esophagitis', 'Lansoprazole/adverse effects', '*Peptic Ulcer', 'Treatment Outcome', '2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', '*Anti-Ulcer Agents/therapeutic use', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/37127558/
1542,lansoprazole,32701188,"Randomised clinical trial: tegoprazan, a novel potassium-competitive acid blocker, or lansoprazole in the treatment of gastric ulcer.","['Cho YK', 'Choi MG', 'Choi SC', 'Lee KM', 'Kim TO', 'Park SH', 'Moon JS', 'Lim YJ', 'Kang DH', 'Cheon GJ', 'Baik GH', 'Kim KO', 'Cho KB', 'Jang JS', 'Park JJ', 'Son BK', 'Jung HK', 'Kim BW', 'Kim SK', 'Lee ST', 'Cha JM', 'Kim AR', 'Kim EJ', 'Park HW', 'Song GS']","['Adult', 'Aged', 'Anti-Ulcer Agents/administration & dosage/adverse effects', 'Benzene Derivatives/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Imidazoles/*administration & dosage/adverse effects', 'Lansoprazole/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Potassium/metabolism', 'Proton Pump Inhibitors/administration & dosage/adverse effects', 'Republic of Korea', 'Stomach Ulcer/*drug therapy', 'Treatment Outcome', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32701188/
1543,lansoprazole,35294415,Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.,"['Laine L', 'Sharma P', 'Mulford DJ', 'Hunt B', 'Leifke E', 'Smith N', 'Howden CW']","['Adult', 'Humans', 'Hydrogen-Ion Concentration', 'Lansoprazole/pharmacology', '*Potassium', '*Proton Pump Inhibitors/pharmacology', 'Pyrroles/pharmacology', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/35294415/
1544,lansoprazole,31409606,"Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.","['Xiao Y', 'Zhang S', 'Dai N', 'Fei G', 'Goh KL', 'Chun HJ', 'Sheu BS', 'Chong CF', 'Funao N', 'Zhou W', 'Chen M']","['Adult', 'Aged', 'Double-Blind Method', 'Drug Administration Schedule', 'Esophagitis, Peptic/*drug therapy', 'Female', 'Humans', 'Lansoprazole/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Pyrroles/administration & dosage/adverse effects/*therapeutic use', 'Severity of Illness Index', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/31409606/
1545,lansoprazole,38777170,Comparison of Los Angeles Grades of Erosive Esophagitis Scored by Local Investigators vs Central Adjudicators in a Clinical Trial.,"['Spechler SJ', 'Laine L', 'DeVault KR', 'Nabulsi A', 'Hunt B', 'Katz P']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', '*Esophagitis/pathology/diagnosis/drug therapy', 'Lansoprazole/therapeutic use', 'Pyrroles/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/38777170/
1546,lansoprazole,20687622,Dexlansoprazole modified release: in erosive oesophagitis and non-erosive reflux disease.,"['Croxtall JD', 'Scott LJ']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology/*therapeutic use', 'Anti-Ulcer Agents/administration & dosage/pharmacology/*therapeutic use', 'Delayed-Action Preparations', 'Dexlansoprazole', 'Esophagitis/*drug therapy', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lansoprazole', 'Proton Pump Inhibitors/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20687622/
1547,lansoprazole,26420698,Upper gastrointestinal bleed associated with cholinesterase inhibitor use.,"['Kok KS', 'Loke Y', 'Southgate J']","['Aged, 80 and over', 'Alzheimer Disease', 'Cholinesterase Inhibitors/administration & dosage/*adverse effects', 'Donepezil', 'Duodenal Ulcer/*diagnosis/*drug therapy', 'Endoscopy/methods', 'Gastrointestinal Hemorrhage/chemically induced', 'Humans', 'Indans/administration & dosage/*adverse effects', 'Lansoprazole/*administration & dosage', 'Male', 'Piperidines/administration & dosage/*adverse effects', 'Proton Pump Inhibitors/*administration & dosage', 'Syncope/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/26420698/
1548,lansoprazole,38654422,Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.,"['Xiao Y', 'Qian J', 'Zhang S', 'Dai N', 'Chun HJ', 'Chiu C', 'Chong CF', 'Funao N', 'Sakurai Y', 'Eisner JD', 'Xie L', 'Chen M']","['Adult', 'East Asian People', '*Proton Pump Inhibitors/therapeutic use', 'Female', 'Humans', 'Aged', 'Middle Aged', 'Male', '*Sulfonamides/therapeutic use', 'Esophagitis, Peptic/drug therapy', 'Asian People', 'China', 'Esophagitis/drug therapy', 'Republic of Korea', 'Malaysia', '*Pyrroles/therapeutic use', '*Lansoprazole/therapeutic use', 'Southeast Asian People', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38654422/
1549,lansoprazole,26559637,"Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.","['Ashida K', 'Sakurai Y', 'Hori T', 'Kudou K', 'Nishimura A', 'Hiramatsu N', 'Umegaki E', 'Iwakiri K']","['Adult', 'Aged', 'Cytochrome P-450 CYP2C19/metabolism', 'Double-Blind Method', 'Esophagitis/*drug therapy', 'Female', 'Humans', 'Lansoprazole/*therapeutic use', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/*therapeutic use', 'Recurrence', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26559637/
1550,lansoprazole,8490081,Safety of lansoprazole.,['Colin-Jones DG'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Ulcer Agents/*adverse effects', 'Clinical Trials as Topic', 'Humans', 'Lansoprazole', 'Middle Aged', 'Omeprazole/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/8490081/
1551,hydroxyzine,36843057,Efficacy and safety of hydroxyzine for sleep in adults: Systematic review.,"['Burgazli CR', 'Rana KB', 'Brown JN', 'Tillman F 3rd']","['Humans', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Hypnotics and Sedatives/pharmacology', 'Hydroxyzine/adverse effects', 'Prospective Studies', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/36843057/
1552,hydroxyzine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
1553,hydroxyzine,38980829,Managing Pruritus in Advanced Chronic Disease.,"['Kaya E', 'McDonald G', 'Gallagher R']","['Humans', '*Pruritus/drug therapy/etiology', 'Chronic Disease', 'Hydroxyzine/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38980829/
1554,hydroxyzine,6627988,Follicular dermographism.,"['Shelley WB', 'Shelley ED']","['Adolescent', 'Adult', 'Female', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Middle Aged', 'Physical Stimulation', 'Pruritus/etiology', 'Urticaria/drug therapy/*etiology']",https://pubmed.ncbi.nlm.nih.gov/6627988/
1555,hydroxyzine,1979802,Recent advances in H1-receptor antagonist treatment.,['Simons FE'],"['Astemizole', 'Benzhydryl Compounds/*pharmacokinetics', 'Benzimidazoles/*pharmacokinetics', 'Cetirizine', 'Cyproheptadine/*analogs & derivatives/pharmacokinetics', 'Histamine H1 Antagonists/*pharmacokinetics', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacokinetics', 'Loratadine', 'Receptors, Histamine H1/drug effects', 'Rhinitis, Allergic, Perennial/drug therapy', 'Terfenadine', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1979802/
1556,hydroxyzine,35976065,Topical cetirizine for treating androgenetic alopecia: A systematic review.,"['Chen X', 'Xiang H', 'Yang M']","['Humans', 'Administration, Topical', '*Alopecia/drug therapy', '*Cetirizine/administration & dosage/adverse effects', 'Hair', 'Minoxidil/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35976065/
1557,hydroxyzine,1686525,Cetirizine: more than an antihistamine?,"['Bernheim J', 'Arendt C', 'de Vos C']","['Allergens/immunology', 'Animals', 'Asthma/drug therapy/immunology/physiopathology', 'Cetirizine', 'Exercise', 'Histamine Antagonists/*pharmacology', 'Histamine H1 Antagonists/pharmacology', 'Humans', 'Hydroxyzine/*analogs & derivatives/pharmacology/therapeutic use', 'Hypersensitivity/physiopathology', 'Muscle Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1686525/
1558,hydroxyzine,36613097,"The Effects of Pharmacological Treatment of Nightmares: A Systematic Literature Review and Meta-Analysis of Placebo-Controlled, Randomized Clinical Trials.","['Skeie-Larsen M', 'Stave R', 'Gronli J', 'Bjorvatn B', 'Wilhelmsen-Langeland A', 'Zandi A', 'Pallesen S']","['Humans', '*Dreams', 'Randomized Controlled Trials as Topic', 'Prazosin/therapeutic use/pharmacology', 'Adrenergic alpha-1 Receptor Antagonists/therapeutic use', '*Stress Disorders, Post-Traumatic', 'Hydroxyzine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36613097/
1559,hydroxyzine,11034010,Cetirizine-induce cholestasis.,"['Fong DG', 'Angulo P', 'Burgart LJ', 'Lindor KD']","['Adult', 'Cetirizine/*adverse effects/therapeutic use', 'Cholestasis, Intrahepatic/*chemically induced/diagnosis/pathology', 'Histamine H1 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Liver/pathology', 'Male', 'Rhinitis, Allergic, Perennial/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11034010/
1560,hydroxyzine,9852800,Oral sedation.,['Dionne R'],"['Administration, Oral', 'Algorithms', 'Anesthesia, Dental/*methods', 'Anti-Anxiety Agents/*administration & dosage', 'Chloral Hydrate/adverse effects', 'Conscious Sedation/*methods', 'Dental Anxiety/*prevention & control', 'Diazepam/administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Hydroxyzine/administration & dosage', 'Hypnotics and Sedatives/adverse effects', 'Midazolam/administration & dosage', 'Mutagens', 'Premedication', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9852800/
1561,hydroxyzine,11414551,Pharmacotherapy of generalized anxiety disorder.,['Davidson JR'],"['Anti-Anxiety Agents/therapeutic use', 'Antidepressive Agents/administration & dosage/*therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/*drug therapy/epidemiology/psychology', 'Benzodiazepines', 'Buspirone/therapeutic use', 'Comorbidity', 'Depressive Disorder/drug therapy/epidemiology', 'Heart Rate/drug effects', 'Humans', 'Hydroxyzine/therapeutic use', 'Serotonin Receptor Agonists/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11414551/
1562,hydroxyzine,1979793,H1-receptor antagonist treatment of seasonal allergic rhinitis.,['Kaiser HB'],"['Astemizole', 'Benzhydryl Compounds/pharmacokinetics/therapeutic use', 'Benzimidazoles/pharmacokinetics/therapeutic use', 'Cetirizine', 'Chlorpheniramine/pharmacokinetics/therapeutic use', 'Clemastine/pharmacokinetics/therapeutic use', 'Cyproheptadine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Histamine H1 Antagonists/pharmacokinetics/*therapeutic use', 'Humans', 'Hydroxyzine/analogs & derivatives/pharmacokinetics/therapeutic use', 'Ketotifen/pharmacokinetics/therapeutic use', 'Loratadine', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Terfenadine']",https://pubmed.ncbi.nlm.nih.gov/1979793/
1563,hydroxyzine,11772135,Cetirizine/pseudoephedrine.,"['Wellington K', 'Jarvis B']","['Administration, Oral', 'Adrenergic Agents/adverse effects/pharmacokinetics/*pharmacology', 'Anxiety/chemically induced', 'Asthenia/chemically induced', 'Biological Availability', 'Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Chemistry, Pharmaceutical', 'Drug Administration Schedule', 'Ephedrine/adverse effects/pharmacokinetics/*pharmacology', 'Headache/chemically induced', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Nasal Cavity', 'Pruritus/drug therapy', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy/pathology', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Tablets', 'Treatment Outcome', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11772135/
1564,hydroxyzine,10582736,Therapeutic index of H1-antihistamines: example of cetirizine.,['Rihoux JP'],"['Cetirizine/adverse effects/metabolism/*therapeutic use', 'Histamine H1 Antagonists/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypersensitivity, Immediate/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10582736/
1565,hydroxyzine,34818169,Urticaria and edema in a 2-year-old boy.,"['Cook JS', 'Angles A', 'Morley E']","['Amoxicillin/*adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Child, Preschool', 'Diagnosis, Differential', 'Drug Eruptions/*diagnosis/*drug therapy', 'Edema', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Otitis Media/*drug therapy', 'Triamcinolone/therapeutic use', 'Urticaria/*diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34818169/
1566,hydroxyzine,2871956,Repeat chemonucleolysis.,['Sutton JC Jr'],"['Adolescent', 'Adult', 'Anaphylaxis/etiology/*prevention & control', 'Chymopapain/adverse effects/*therapeutic use', 'Cimetidine/*therapeutic use', 'Female', 'Follow-Up Studies', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use', 'Intervertebral Disc Displacement/*drug therapy', 'Lumbar Vertebrae', 'Male', 'Middle Aged', '*Premedication', 'Recurrence', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2871956/
1567,hydroxyzine,9146011,Hydroxyzine therapy for interstitial cystitis.,"['Theoharides TC', 'Sant GR']","['Cystitis, Interstitial/*drug therapy', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Hydroxyzine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9146011/
1568,hydroxyzine,22030083,Generalised anxiety disorder.,"['Gale CK', 'Millichamp J']","['Anxiety Disorders/drug therapy', 'Benzodiazepines/therapeutic use', '*Buspirone/therapeutic use', 'Humans', '*Hydroxyzine/therapeutic use', 'Psychiatric Status Rating Scales', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Sertraline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22030083/
1569,hydroxyzine,8833171,Aquagenic urticaria.,['Medeiros M Jr'],"['Adult', 'Cetirizine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Urticaria/*diagnosis/drug therapy/*etiology', 'Water/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8833171/
1570,hydroxyzine,2188436,Potentiation of pain relief with hydroxyzine: a therapeutic myth?,['Glazier HS'],"['Drug Synergism', 'Humans', 'Hydroxyzine/adverse effects/*therapeutic use', 'Narcotics/adverse effects/*therapeutic use', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2188436/
1571,metoclopramide,1387327,Antiemetic agents.,['Bleiberg H'],"['Antiemetics/administration & dosage/economics/*therapeutic use', 'Antineoplastic Agents/adverse effects', 'Cisplatin/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Imidazoles/administration & dosage/therapeutic use', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/drug therapy', 'Ondansetron', 'Serotonin Antagonists', 'Treatment Outcome', 'Vomiting/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1387327/
1572,metoclopramide,38311315,The Management of Nausea and Vomiting in Pregnancy and Hyperemesis Gravidarum (Green-top Guideline No. 69).,"['Nelson-Piercy C', 'Dean C', 'Shehmar M', 'Gadsby R', ""O'Hara M"", 'Hodson K', 'Nana M']","['Humans', 'Female', 'Pregnancy', '*Hyperemesis Gravidarum/therapy/diagnosis', '*Antiemetics/therapeutic use/administration & dosage', '*Ondansetron/therapeutic use/administration & dosage', 'Morning Sickness/therapy', 'Nausea/etiology/therapy', 'Pyridoxine/therapeutic use/administration & dosage', 'Metoclopramide/therapeutic use/administration & dosage', 'Severity of Illness Index', 'Pregnancy Complications/drug therapy/therapy']",https://pubmed.ncbi.nlm.nih.gov/38311315/
1573,metoclopramide,3515136,Metoclopramide--a review.,"['Desmond PV', 'Watson KJ']","['Anxiety/chemically induced', 'Digestive System/drug effects', 'Dopamine Antagonists', 'Drug Interactions', 'Female', 'Gastric Emptying/drug effects', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Hyperemesis Gravidarum/drug therapy', 'Metoclopramide/adverse effects/pharmacology/*therapeutic use', 'Migraine Disorders/drug therapy', 'Muscle, Smooth/drug effects', 'Nausea/drug therapy', 'Neurons/drug effects', 'Pregnancy', 'Sleep Stages/drug effects', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3515136/
1574,metoclopramide,10473023,Intranasal metoclopramide.,"['Ormrod D', 'Goa KL']","['Administration, Intranasal', 'Antiemetics/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Metoclopramide/administration & dosage/adverse effects/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10473023/
1575,metoclopramide,19906028,Translating 5-HT receptor pharmacology.,['Sanger GJ'],"['Aged', 'Animals', 'Benzofurans/adverse effects/pharmacology/*therapeutic use', 'Dopamine Antagonists/pharmacology/therapeutic use', 'Gastrointestinal Diseases/*drug therapy/physiopathology', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Metoclopramide/pharmacology/therapeutic use', 'Receptors, G-Protein-Coupled/drug effects', 'Receptors, Serotonin, 5-HT4/*drug effects', 'Serotonin 5-HT4 Receptor Agonists', 'Serotonin Receptor Agonists/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19906028/
1576,metoclopramide,25350407,[Pharmaceutical treatment of lactation deficiency lacks evidence].,"['Axelsson PB', 'Bjerrum F', 'Lokkegaard EC']","['*Breast Feeding', 'Domperidone/therapeutic use', 'Dopamine Antagonists/adverse effects/therapeutic use', 'Evidence-Based Medicine', 'Female', 'Humans', 'Lactation/*drug effects/physiology', 'Lactation Disorders/*drug therapy', 'Metoclopramide/adverse effects/therapeutic use', 'Oxytocics/therapeutic use', 'Oxytocin/therapeutic use', 'Pregnancy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25350407/
1577,metoclopramide,234288,Some aspects of medical management of gastrointestinal disease. I.,['Badley BW'],"['Diarrhea/chemically induced', 'Disaccharides/*therapeutic use', 'Endoscopy', 'Esophagitis/drug therapy', 'Gastric Juice/metabolism', 'Gastric Mucosa/drug effects', 'Gastrointestinal Diseases/*drug therapy', 'Gastrointestinal Motility/drug effects', 'Hepatic Encephalopathy/*drug therapy', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hypokalemia/chemically induced', 'Intubation, Gastrointestinal', 'Lactulose/adverse effects/*therapeutic use', 'Metoclopramide/adverse effects/*therapeutic use', 'Peptic Ulcer/drug therapy', 'Secretory Rate/drug effects', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/234288/
1578,metoclopramide,28424994,Modulation of gastrointestinal motility beyond metoclopramide and domperidone : Pharmacological and clinical evidence for phytotherapy in functional gastrointestinal disorders.,"['Madisch A', 'Vinson BR', 'Abdel-Aziz H', 'Kelber O', 'Nieber K', 'Kraft K', 'Storr M']","['Domperidone/adverse effects/*therapeutic use', 'Gastrointestinal Diseases/*drug therapy', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Irritable Bowel Syndrome/drug therapy', 'Metoclopramide/adverse effects/*therapeutic use', '*Phytotherapy', 'Plant Extracts/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28424994/
1579,metoclopramide,1448341,[Prokinetic drugs].,['Hellstrom P'],"['Cisapride', 'Gastrointestinal Agents/*pharmacology', 'Gastrointestinal Diseases/drug therapy', 'Gastrointestinal Motility/*drug effects', 'Humans', 'Metoclopramide/pharmacokinetics/pharmacology/therapeutic use', 'Myoelectric Complex, Migrating/drug effects', 'Piperidines/pharmacokinetics/pharmacology/therapeutic use', 'Serotonin Antagonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1448341/
1580,metoclopramide,1183218,Metoclopramide in hiccup.,['Madanagopolan N'],"['Administration, Oral', 'Hiccup/*drug therapy', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1183218/
1581,metoclopramide,8879888,Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis.,['Perez EA'],"['Administration, Oral', 'Antineoplastic Agents/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Granisetron/*administration & dosage/therapeutic use', 'Humans', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Ondansetron/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8879888/
1582,metoclopramide,6421373,Tardive dyskinesia associated with metoclopramide.,"['Wiholm BE', 'Mortimer O', 'Boethius G', 'Haggstrom JE']","['Age Factors', 'Aged', 'Drug Administration Schedule', 'Dyskinesia, Drug-Induced/epidemiology/*etiology', 'Female', 'Humans', 'Metoclopramide/administration & dosage/*adverse effects', 'Sex Factors', 'Sweden']",https://pubmed.ncbi.nlm.nih.gov/6421373/
1583,metoclopramide,3898991,[Indications for primperan in pediatrics].,['Coignet J'],"['Anesthesia', 'Child, Preschool', 'Digestive System/diagnostic imaging', 'Gastric Emptying/drug effects', 'Gastroesophageal Reflux/drug therapy', 'Gastrointestinal Diseases/*drug therapy', 'Gastroscopy', 'Humans', 'Infant', 'Metoclopramide/pharmacology/*therapeutic use', 'Pneumonia, Aspiration/prevention & control', 'Radiography']",https://pubmed.ncbi.nlm.nih.gov/3898991/
1584,metoclopramide,8931828,Use of prokinetic agents in special populations.,['Horn JR'],"['Age Factors', 'Cisapride', 'Drug Interactions', 'Gastroesophageal Reflux/*drug therapy', 'Gastrointestinal Agents/*therapeutic use', 'Gastrointestinal Motility/*drug effects', 'Gastroparesis/drug therapy', 'Humans', 'Metoclopramide/adverse effects/therapeutic use', 'Piperidines/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8931828/
1585,metoclopramide,1814735,The effect of food and metoclopramide on the pharmacokinetics and side effects of bromocriptine.,"['Kopitar Z', 'Vrhovac B', 'Povsic L', 'Plavsic F', 'Francetic I', 'Urbancic J']","['Administration, Oral', 'Adult', 'Biological Availability', 'Bromocriptine/administration & dosage/adverse effects/blood/*pharmacokinetics', '*Food', 'Humans', 'Male', 'Metoclopramide/*pharmacology', 'Radioimmunoassay']",https://pubmed.ncbi.nlm.nih.gov/1814735/
1586,metoclopramide,7288971,Metoclopramide treatment of tardive dyskinesia.,"['Karp JM', 'Perkel MS', 'Hersh T', 'McKinney AS']","['Administration, Oral', 'Aged', 'Dyskinesia, Drug-Induced/*drug therapy', 'Female', 'Humans', 'Male', 'Metoclopramide/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Sleep Stages/drug effects']",https://pubmed.ncbi.nlm.nih.gov/7288971/
1587,metoclopramide,8032699,Cost-effectiveness analysis of antiemetic treatment.,"['Bleiberg H', 'Autier P', 'Michaux D']","['Antiemetics/adverse effects/*economics/*therapeutic use', 'Cost-Benefit Analysis', 'Costs and Cost Analysis', 'Dexamethasone/administration & dosage/adverse effects/economics/therapeutic use', 'Europe', 'European Union', 'Humans', 'Lorazepam/administration & dosage/adverse effects/economics/therapeutic use', 'Metoclopramide/administration & dosage/adverse effects/economics/therapeutic use', 'Ondansetron/administration & dosage/adverse effects/economics/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salvage Therapy', 'Serotonin Antagonists/adverse effects/economics/therapeutic use', 'Vomiting/economics/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8032699/
1588,metoclopramide,8527494,"Progress in identifying clinical relevance of inhibition, stimulation and measurements of poly ADP-ribosylation.","['Pero RW', 'Olsson A', 'Sheng Y', 'Hua J', 'Moller C', 'Kjellen E', 'Killander D', 'Marmor M']","['Animals', 'Antineoplastic Agents/toxicity', 'Carcinoma, Squamous Cell/drug therapy/radiotherapy', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'DNA/drug effects/radiation effects', '*DNA Damage', '*DNA Repair', 'Humans', 'Leukocytes, Mononuclear/enzymology', 'Lung Neoplasms/drug therapy/radiotherapy', 'Metoclopramide/adverse effects/*pharmacology/*therapeutic use', 'Mutagens/toxicity', '*Oxidative Stress', 'Poly Adenosine Diphosphate Ribose/analysis/*metabolism', 'Poly(ADP-ribose) Polymerase Inhibitors', 'Poly(ADP-ribose) Polymerases/analysis/*metabolism', 'Radiation-Sensitizing Agents/adverse effects/pharmacology/*therapeutic use', 'Zinc Fingers']",https://pubmed.ncbi.nlm.nih.gov/8527494/
1589,metoclopramide,31314613,Metoclopramide for the treatment of diabetic gastroparesis.,"['Shakhatreh M', 'Jehangir A', 'Malik Z', 'Parkman HP']","['Diabetes Complications/*complications', 'Dopamine D2 Receptor Antagonists/adverse effects/pharmacology/*therapeutic use', 'Gastric Emptying/*drug effects', 'Gastroparesis/*drug therapy/etiology', 'Humans', 'Metoclopramide/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome', 'Upper Gastrointestinal Tract/*drug effects/innervation']",https://pubmed.ncbi.nlm.nih.gov/31314613/
1590,metoclopramide,31050085,"Gastroparesis, metoclopramide, and tardive dyskinesia: Risk revisited.","['Al-Saffar A', 'Lennernas H', 'Hellstrom PM']","['Antiemetics/adverse effects/*pharmacology', 'Dopamine D2 Receptor Antagonists/adverse effects/*pharmacology', 'Gastroparesis/*drug therapy', 'Humans', 'Metoclopramide/adverse effects/chemistry/*pharmacology', 'Risk Factors', 'Tardive Dyskinesia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/31050085/
1591,fluvastatin,38553451,Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.,"['Bi YY', 'Chen Q', 'Yang MY', 'Xing L', 'Jiang HL']","['Humans', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics/pathology', 'Cisplatin/pharmacology/therapeutic use', 'Tumor Suppressor Protein p53/genetics/metabolism', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Drug Resistance, Neoplasm/genetics', 'Fluvastatin/therapeutic use', 'Neoplasm Recurrence, Local/drug therapy/genetics', 'Cell Line, Tumor', '*Nanoparticles', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Mutation', '*Phosphatidylethanolamines', '*Polyethylene Glycols']",https://pubmed.ncbi.nlm.nih.gov/38553451/
1592,fluvastatin,25821790,"A low-dose combination of fluvastatin and valsartan: a new ""drug"" and a new approach for decreasing the arterial age.","['Janic M', 'Lunder M', 'Sabovic M']","['Aging/drug effects/*physiology', 'Animals', 'Antioxidants/administration & dosage', 'Arteries/drug effects/*physiology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Combinations', 'Fatty Acids, Monounsaturated/*administration & dosage', 'Fluvastatin', 'Humans', 'Indoles/*administration & dosage', 'Valsartan/*administration & dosage', 'Vascular Stiffness/drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/25821790/
1593,fluvastatin,10821323,Non-lipid-related effects of statins.,"['Bellosta S', 'Ferri N', 'Bernini F', 'Paoletti R', 'Corsini A']","['Animals', 'Arteriosclerosis/drug therapy', 'Blood Coagulation/drug effects/physiology', 'Cholesterol/chemistry', 'Cholesterol, LDL/blood', 'Endothelium, Vascular/drug effects', 'Esterification', 'Fatty Acids, Monounsaturated/pharmacology', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology/therapeutic use', 'Indoles/pharmacology', 'Pravastatin/pharmacology', 'Simvastatin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10821323/
1594,fluvastatin,30716508,"Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants.","['Yebyo HG', 'Aschmann HE', 'Kaufmann M', 'Puhan MA']","['Atorvastatin/adverse effects/therapeutic use', 'Cardiovascular Diseases/mortality/*prevention & control', 'Cause of Death', 'Chemical and Drug Induced Liver Injury/etiology', 'Double-Blind Method', 'Fluvastatin/adverse effects/therapeutic use', 'Headache/chemically induced', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*therapeutic use', 'Kidney Diseases/chemically induced', 'Lovastatin/adverse effects/therapeutic use', 'Middle Aged', 'Muscular Diseases/chemically induced', 'Nausea/chemically induced', 'Neoplasms/chemically induced', '*Network Meta-Analysis', 'Placebos/therapeutic use', 'Pravastatin/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic/*statistics & numerical data', 'Risk Assessment', 'Rosuvastatin Calcium/adverse effects/therapeutic use', 'Simvastatin/adverse effects/therapeutic use', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/30716508/
1595,fluvastatin,38044042,Comparison of the anticancer effects of various statins on canine oral melanoma cells.,"['Ishikawa T', 'Irie N', 'Tashiro J', 'Osaki T', 'Warita T', 'Warita K', 'Naito M']","['Animals', 'Dogs', 'Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/therapeutic use', 'Atorvastatin/pharmacology/therapeutic use', 'Rosuvastatin Calcium', '*Melanoma/drug therapy/veterinary', 'Fluvastatin/therapeutic use', '*Mouth Neoplasms/drug therapy/veterinary', '*Dog Diseases/drug therapy', 'Simvastatin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38044042/
1596,fluvastatin,37721222,Pravastatin for lowering lipids.,"['Adams SP', 'Alaeiilkhchi N', 'Tasnim S', 'Wright JM']","['Humans', 'Infant, Newborn', 'Infant', 'Pravastatin/adverse effects', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Atorvastatin', '*Cardiovascular Diseases', 'Cholesterol, HDL', 'Cholesterol, LDL', 'Fluvastatin', 'Rosuvastatin Calcium', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/37721222/
1597,fluvastatin,16144508,Fluvastatin: efficacy and safety in reducing cardiac events.,"['Chan MY', 'Lee CH']","['Age Factors', 'Animals', 'Cardiovascular Diseases/drug therapy/*prevention & control', 'Cholesterol, LDL/blood', 'Cholinergic Antagonists/adverse effects/pharmacology/*therapeutic use', 'Fatty Acids, Monounsaturated/adverse effects/pharmacology/*therapeutic use', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Hypercholesterolemia/blood/*drug therapy', 'Indoles/adverse effects/pharmacology/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rhabdomyolysis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/16144508/
1598,fluvastatin,12394230,Acute pancreatitis induced by fluvastatin therapy.,"['Tysk C', 'Al-Eryani AY', 'Shawabkeh AA']","['Acute Disease', 'Adult', 'Fatty Acids, Monounsaturated/*adverse effects', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects', 'Indoles/*adverse effects', 'Male', 'Pancreatitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12394230/
1599,fluvastatin,31391514,Lipophilic statins inhibit Zika virus production in Vero cells.,"['Espano E', 'Nam JH', 'Song EJ', 'Song D', 'Lee CK', 'Kim JK']","['Animals', 'Chlorocebus aethiops', 'Dose-Response Relationship, Drug', 'Drug Evaluation, Preclinical', 'Fluvastatin/chemistry/pharmacology/therapeutic use', 'Humans', 'Hydrophobic and Hydrophilic Interactions', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/chemistry/*pharmacology/therapeutic use', 'Time-to-Treatment', 'Vero Cells', 'Virus Replication/*drug effects', 'Zika Virus/*drug effects/physiology', 'Zika Virus Infection/*drug therapy/virology']",https://pubmed.ncbi.nlm.nih.gov/31391514/
1600,fluvastatin,35728952,Adverse drug reactions of statin therapy in China from 1989 to 2019: a national database analysis.,"['Tsui L', 'Ye P', 'Xu S', 'Lin Y', 'Chen B', 'Chen SP', 'Cheng RY']","['Humans', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects', 'Rosuvastatin Calcium/therapeutic use', 'Pravastatin/therapeutic use', 'Fluvastatin', 'Simvastatin/therapeutic use', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/35728952/
1601,fluvastatin,29445111,Fluvastatin protects cochleae from damage by high-level noise.,"['Richter CP', 'Young H', 'Richter SV', 'Smith-Bronstein V', 'Stock SR', 'Xiao X', 'Soriano C', 'Whitlon DS']","['Animals', 'Auditory Threshold', 'Cochlea/*drug effects/metabolism', 'Evoked Potentials, Auditory, Brain Stem/drug effects', 'Female', 'Fluvastatin/metabolism/*pharmacology', 'Guinea Pigs', 'Hair Cells, Auditory, Outer', 'Hearing Loss, Noise-Induced/physiopathology/*prevention & control', 'Male', 'Noise/adverse effects', 'Organ of Corti', 'Protective Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29445111/
1602,fluvastatin,30939798,Fluvastatin Sodium Ameliorates Obesity through Brown Fat Activation.,"['Yin N', 'Zhang H', 'Ye R', 'Dong M', 'Lin J', 'Zhou H', 'Huang Y', 'Chen L', 'Jiang X', 'Nagaoka K', 'Zhang C', 'Jin W']","['Adipose Tissue, Brown/*drug effects/metabolism', 'Animals', 'Anti-Obesity Agents/pharmacology/*therapeutic use', 'Cells, Cultured', 'Energy Metabolism', 'Fluvastatin/pharmacology/*therapeutic use', 'Humans', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Obesity/*drug therapy', 'Uncoupling Protein 1/genetics/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30939798/
1603,fluvastatin,9118584,Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.,"['Desager JP', 'Horsmans Y']","['Aged', 'Cholesterol/biosynthesis/metabolism', 'Drug Interactions', 'Fatty Acids, Monounsaturated/pharmacokinetics/pharmacology', 'Female', 'Fluvastatin', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacokinetics/pharmacology', 'Indoles/pharmacokinetics/pharmacology', 'Lipoproteins/biosynthesis/metabolism', 'Lovastatin/analogs & derivatives/pharmacokinetics/pharmacology', 'Male', 'Pravastatin/pharmacokinetics/pharmacology', 'Pregnancy', 'Simvastatin']",https://pubmed.ncbi.nlm.nih.gov/9118584/
1604,fluvastatin,38821590,ERK5 Activity Prevention Improves the Antitumor Efficacy of Fluvastatin on Thymic Carcinoma.,"['Hayashi K', 'Fujita T', 'Chida M']","['*Fluvastatin/pharmacology', 'Humans', '*Thymus Neoplasms/drug therapy/pathology/metabolism', 'Cell Line, Tumor', '*Mitogen-Activated Protein Kinase 7/metabolism/antagonists & inhibitors', 'Phosphorylation/drug effects', '*Indoles/pharmacology', '*Fatty Acids, Monounsaturated/pharmacology', 'Thymoma/drug therapy/pathology', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/therapeutic use', 'Animals']",https://pubmed.ncbi.nlm.nih.gov/38821590/
1605,fluvastatin,32612149,Mesenchymal subtype neuroblastomas are addicted to TGF-betaR2/HMGCR-driven protein geranylgeranylation.,"['Stokes ME', 'Small JC', 'Vasciaveo A', 'Shimada K', 'Hirschhorn T', 'Califano A', 'Stockwell BR']","['Antineoplastic Agents/pharmacology', 'Apoptosis', 'Biomarkers, Tumor/metabolism', 'Cell Line, Tumor', 'Fluvastatin/pharmacology', 'Humans', 'Hydroxymethylglutaryl CoA Reductases/metabolism', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology', 'Lipids/chemistry', 'Lovastatin/pharmacology', 'Methotrexate/pharmacology', 'N-Myc Proto-Oncogene Protein/metabolism', 'Neuroblastoma/*metabolism', '*Protein Prenylation', 'RNA, Small Interfering/metabolism', 'Receptor, Transforming Growth Factor-beta Type II/*metabolism', '*Signal Transduction', 'Triamterene/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32612149/
1606,fluvastatin,32665698,The mevalonate pathway is an actionable vulnerability of t(4;14)-positive multiple myeloma.,"['Longo J', 'Smirnov P', 'Li Z', 'Branchard E', 'van Leeuwen JE', 'Licht JD', 'Haibe-Kains B', 'Andrews DW', 'Keats JJ', 'Pugh TJ', 'Trudel S', 'Penn LZ']","['Animals', 'Antineoplastic Agents/pharmacology', 'Apoptosis', 'Biomarkers, Tumor/genetics/metabolism', 'Bortezomib/*pharmacology', 'Cell Proliferation', 'Chromosomes, Human, Pair 14', 'Chromosomes, Human, Pair 4', 'Female', 'Fluvastatin/*pharmacology', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*pharmacology', 'Mevalonic Acid/*metabolism', 'Mice', 'Mice, Inbred NOD', 'Mice, SCID', 'Multiple Myeloma/*drug therapy/genetics/metabolism/pathology', 'Polyisoprenyl Phosphates/*pharmacology', 'Translocation, Genetic', 'Tumor Cells, Cultured', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/32665698/
1607,fluvastatin,31311976,"Identifying chemopreventive agents for obesity-associated cancers using an efficient, 3D high-throughput transformation assay.","['Benham V', 'Bullard B', 'Dexheimer TS', 'Bernard MP', 'Neubig RR', 'Liby KT', 'Bernard JJ']","['Animals', 'Antineoplastic Agents/*pharmacology', 'Cell Culture Techniques', 'Cell Proliferation/drug effects', 'Cell Transformation, Neoplastic/*drug effects', 'Drug Screening Assays, Antitumor/*methods', 'Fibroblast Growth Factor 2/*pharmacology', 'Fibroblasts/cytology/drug effects', 'Fluvastatin/pharmacology', 'High-Throughput Screening Assays', 'Humans', 'Mice', 'Models, Biological', 'Neoplasms/*prevention & control', 'Obesity/*complications/metabolism', 'Podophyllotoxin/analogs & derivatives/pharmacology', 'Skin/cytology/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31311976/
1608,fluvastatin,36129989,SARS-CoV-2 disrupts respiratory vascular barriers by suppressing Claudin-5 expression.,"['Hashimoto R', 'Takahashi J', 'Shirakura K', 'Funatsu R', 'Kosugi K', 'Deguchi S', 'Yamamoto M', 'Tsunoda Y', 'Morita M', 'Muraoka K', 'Tanaka M', 'Kanbara T', 'Tanaka S', 'Tamiya S', 'Tokunoh N', 'Kawai A', 'Ikawa M', 'Ono C', 'Tachibana K', 'Kondoh M', 'Obana M', 'Matsuura Y', 'Ohsumi A', 'Noda T', 'Yamamoto T', 'Yoshioka Y', 'Torisawa YS', 'Date H', 'Fujio Y', 'Nagao M', 'Takayama K', 'Okada Y']","['*COVID-19', 'Claudin-5/genetics/*metabolism', 'Endothelial Cells/metabolism', 'Fluvastatin/metabolism/pharmacology', 'Humans', '*SARS-CoV-2', 'Tight Junction Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36129989/
1609,fluvastatin,38361240,Statins Prevent the Deleterious Consequences of Placental Chemerin Upregulation in Preeclampsia.,"['Tan L', 'Kluivers ACM', 'Cruz-Lopez EO', 'Broekhuizen M', 'Chen Z', 'Neuman RI', 'Schoenmakers S', 'Ruijgrok L', 'van de Velde D', 'de Winter BCM', 'van den Bogaerdt AJ', 'Lu X', 'Danser AHJ', 'Verdonk K']","['Humans', 'Pregnancy', 'Female', 'Animals', 'Mice', 'Placenta/metabolism', '*Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology', 'Placenta Growth Factor', 'Pravastatin/pharmacology', 'Up-Regulation', 'Prospective Studies', '*Pre-Eclampsia/drug therapy/prevention & control', 'Fluvastatin/metabolism/pharmacology', 'Vascular Endothelial Growth Factor Receptor-1', 'Lipoproteins, LDL/metabolism/pharmacology', 'Biomarkers', 'Chemokines/metabolism', 'Intercellular Signaling Peptides and Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38361240/
1610,fluvastatin,30898664,Fluvastatin inhibits Rab5-mediated IKs internalization caused by chronic Ca(2+)-dependent PKC activation.,"['Parks XX', 'Ronzier E', 'O-Uchi J', 'Lopes CM']","['Animals', 'Calcium/*metabolism', 'Cell Membrane/drug effects/metabolism', 'Dynamins/metabolism', '*Endocytosis/drug effects', 'Enzyme Activation/drug effects', 'Female', 'Fluvastatin/*pharmacology', 'HEK293 Cells', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology', 'Intermediate-Conductance Calcium-Activated Potassium Channels/*metabolism', 'Models, Biological', 'Myocytes, Cardiac/drug effects/metabolism', 'Protein Kinase C/*metabolism', 'Rats', 'rab5 GTP-Binding Proteins/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/30898664/
1611,methadone,19074706,Methadone exposure during lactation.,"['Glatstein MM', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Lactation/*drug effects', 'Maternal Exposure/adverse effects', 'Methadone/administration & dosage/*adverse effects/pharmacokinetics', 'Milk, Human/chemistry/drug effects', 'Opioid-Related Disorders/*drug therapy/metabolism', 'Pregnancy', 'Pregnancy Complications/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19074706/
1612,methadone,1960766,Methadone and edema.,"[""O'Conor LM"", 'Woody G', 'Yeh HS', 'Manny I', 'Dhopesh V']","['Adult', 'Dose-Response Relationship, Drug', 'Edema/*chemically induced', 'Heroin Dependence/*rehabilitation', 'Humans', 'Male', 'Methadone/*adverse effects/therapeutic use', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/1960766/
1613,methadone,17182514,Equianalgesic dosing of opioids.,"['Berdine HJ', 'Nesbit SA']","['*Analgesics, Opioid', 'Dose-Response Relationship, Drug', 'Fentanyl/administration & dosage/*pharmacokinetics/therapeutic use', 'Humans', 'Hydromorphone/administration & dosage/*pharmacokinetics/therapeutic use', 'Methadone/administration & dosage/*pharmacokinetics/therapeutic use', 'Pain/*drug therapy', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/17182514/
1614,methadone,4599599,Methadone.,['Sim SK'],"['Acetates/therapeutic use', 'Administration, Oral', 'Adolescent', 'American Medical Association', 'Canada', 'Chemical Phenomena', 'Chemistry', 'Drug and Narcotic Control', 'Female', 'Heroin Dependence/*drug therapy/rehabilitation', 'Humans', 'Methadone/administration & dosage/metabolism/pharmacology/*therapeutic use', 'Pregnancy', 'Pregnancy Complications', 'Private Practice', 'Structure-Activity Relationship', 'Substance Withdrawal Syndrome/drug therapy', 'Substance-Related Disorders', 'United States']",https://pubmed.ncbi.nlm.nih.gov/4599599/
1615,methadone,15909785,Methadone for cancer pain: what have we learned from clinical studies?,['Soares LG'],"['Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Methadone/administration & dosage/adverse effects/*therapeutic use', 'Morphine/therapeutic use', 'Neoplasms/*complications', 'Pain/*drug therapy/etiology', 'Pain Measurement', 'Palliative Care/*methods', 'World Health Organization']",https://pubmed.ncbi.nlm.nih.gov/15909785/
1616,methadone,28956544,Serotonin syndrome due to co-administration of linezolid and methadone.,"['Mastroianni A', 'Ravaglia G']","['Adult', 'Anti-HIV Agents/therapeutic use', 'Drug Synergism', 'Drug Therapy, Combination', 'HIV Infections/complications', 'Humans', 'Linezolid/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Male', 'Methadone/administration & dosage/*adverse effects/pharmacokinetics/therapeutic use', 'Methicillin-Resistant Staphylococcus aureus/isolation & purification', 'Monoamine Oxidase Inhibitors/adverse effects/pharmacokinetics', 'Opiate Substitution Treatment', 'Serotonin Syndrome/*etiology', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics', 'Staphylococcal Infections/drug therapy/microbiology', 'Substance Abuse, Intravenous/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28956544/
1617,methadone,16859402,Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence.,"['Maas B', 'Kerr T', 'Fairbairn N', 'Montaner J', 'Wood E']","['Animals', 'Anti-HIV Agents/*adverse effects/*pharmacokinetics', 'Buprenorphine/adverse effects/pharmacokinetics/therapeutic use', 'Drug Interactions', 'Humans', 'Methadone/adverse effects/pharmacokinetics/therapeutic use', 'Methadyl Acetate/adverse effects/pharmacokinetics/therapeutic use', 'Narcotic Antagonists/*adverse effects/*pharmacokinetics/therapeutic use', 'Narcotics/adverse effects/pharmacokinetics/therapeutic use', 'Opioid-Related Disorders/*rehabilitation']",https://pubmed.ncbi.nlm.nih.gov/16859402/
1618,methadone,9547764,Opioid dependence during pregnancy. Effects and management.,"['Kaltenbach K', 'Berghella V', 'Finnegan L']","['Delivery, Obstetric', 'Female', 'Humans', 'Infant, Newborn', 'Methadone/pharmacology/therapeutic use', 'Narcotics/adverse effects', 'Neonatal Abstinence Syndrome/physiopathology/prevention & control', '*Opioid-Related Disorders/complications/drug therapy', 'Postnatal Care', 'Pregnancy', '*Pregnancy Complications/chemically induced/drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/9547764/
1619,methadone,7931860,Methadone treatment during pregnancy.,"['Jarvis MA', 'Schnoll SH']","['Female', 'Humans', 'Methadone/adverse effects/*therapeutic use', 'Opioid-Related Disorders/*complications/*rehabilitation', 'Pregnancy', 'Pregnancy Complications/*therapy', 'Pregnancy Outcome']",https://pubmed.ncbi.nlm.nih.gov/7931860/
1620,methadone,11911622,Treatment of neonatal abstinence syndrome with breast milk containing methadone.,['Ballard JL'],"['*Breast Feeding', 'Drug Administration Schedule', 'Female', 'Humans', 'Infant, Newborn', 'Labor, Obstetric/drug effects', 'Methadone/*administration & dosage/pharmacokinetics', '*Milk, Human', 'Morphine/therapeutic use', 'Neonatal Abstinence Syndrome/*rehabilitation', 'Opioid-Related Disorders/*rehabilitation', 'Pregnancy', 'Pregnancy Complications/*rehabilitation', 'Prenatal Care']",https://pubmed.ncbi.nlm.nih.gov/11911622/
1621,methadone,9034479,The dangers of dextropropoxyphene.,['Dore GM'],"['Adult', 'Analgesics, Opioid/administration & dosage/*adverse effects', 'Combined Modality Therapy', 'Dextropropoxyphene/*adverse effects', 'Drug Overdose', 'Female', 'Humans', 'Methadone/*therapeutic use', 'Psychotherapy', 'Substance-Related Disorders/*rehabilitation']",https://pubmed.ncbi.nlm.nih.gov/9034479/
1622,methadone,7224382,Phenytoin-induced methadone withdrawal.,"['Tong TG', 'Pond SM', 'Kreek MJ', 'Jaffery NF', 'Benowitz NL']","['Adult', 'Drug Administration Schedule', 'Drug Interactions', 'Humans', 'Male', 'Methadone/administration & dosage/*adverse effects', 'Phenytoin/*adverse effects', 'Pyrrolidines/urine', 'Substance Withdrawal Syndrome/*chemically induced/metabolism']",https://pubmed.ncbi.nlm.nih.gov/7224382/
1623,methadone,2846900,Implications of methadone maintenance for theories of narcotic addiction.,['Dole VP'],"['Drug Administration Schedule', 'Humans', 'Methadone/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Narcotic Antagonists/pharmacology', 'Narcotics/administration & dosage/pharmacology', 'Opioid-Related Disorders/metabolism/physiopathology/*rehabilitation', 'Receptors, Opioid/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2846900/
1624,methadone,12378067,Intrathecal therapy for chronic pain.,['Miles J'],"['Administration, Oral', 'Analgesics/*administration & dosage/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Chronic Disease', 'Humans', 'Infusion Pumps, Implantable', 'Infusions, Parenteral', 'Injections, Spinal', 'Ketamine/administration & dosage/pharmacology/therapeutic use', 'Methadone/administration & dosage/pharmacology/therapeutic use', 'Morphine/administration & dosage/therapeutic use', 'Narcotics/administration & dosage/therapeutic use', 'Neoplasms/complications', 'Pain/*drug therapy/etiology', 'Patient Selection', 'Receptors, N-Methyl-D-Aspartate/drug effects']",https://pubmed.ncbi.nlm.nih.gov/12378067/
1625,methadone,24956254,Pharmacogenomics of methadone maintenance treatment.,"['Somogyi AA', 'Barratt DT', 'Ali RL', 'Coller JK']","['Dose-Response Relationship, Drug', 'Humans', 'Methadone/*administration & dosage/adverse effects', 'Opiate Substitution Treatment/*methods', '*Pharmacogenetics', 'Polymorphism, Single Nucleotide', 'Receptors, Opioid, mu/*genetics']",https://pubmed.ncbi.nlm.nih.gov/24956254/
1626,methadone,8160253,Probable metabolic interaction between methadone and fluvoxamine in addict patients.,"['Bertschy G', 'Baumann P', 'Eap CB', 'Baettig D']","['Adult', 'Depressive Disorder/drug therapy/psychology', 'Drug Interactions', 'Female', 'Fluvoxamine/adverse effects/*pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Methadone/adverse effects/*pharmacokinetics/therapeutic use', 'Opioid-Related Disorders/drug therapy/*metabolism/psychology']",https://pubmed.ncbi.nlm.nih.gov/8160253/
1627,methadone,24519114,[No opiates against cannabis hyperemesis syndrome].,"['Bonnet U', 'Stratmann U', 'Isbruch K']","['Adult', 'Antiemetics/adverse effects/therapeutic use', 'Dronabinol/*adverse effects', 'Drug Administration Schedule', 'Drug Resistance', 'Drug Therapy, Combination', 'Germany', 'Humans', 'Infusions, Intravenous', 'Male', 'Marijuana Abuse/*complications/rehabilitation', 'Methadone/*administration & dosage/*adverse effects', 'Morphine/*administration & dosage/*adverse effects', 'Opioid-Related Disorders/etiology/*rehabilitation', 'Substance Abuse Treatment Centers', 'Substance Withdrawal Syndrome/etiology/*rehabilitation', 'Vomiting/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24519114/
1628,methadone,26461073,Cardiac Effects of Opioid Therapy.,"['Chen A', 'Ashburn MA']","['Analgesics, Opioid/adverse effects/*therapeutic use', 'Chronic Pain/*drug therapy', 'Heart/*drug effects', 'Humans', 'Methadone/adverse effects/therapeutic use', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/26461073/
1629,methadone,25487851,Role of Methadone in Induction and/or Exacerbation of Cluster Headache in Patients Treated for Opioid Addiction.,"['Diot C', 'Eiden C', 'Leglise Y', 'Donnadieu-Rigole H', 'Peyriere H']","['Adult', 'Cluster Headache/*chemically induced', 'Dose-Response Relationship, Drug', 'Heroin Dependence/*drug therapy', 'Humans', 'Male', 'Methadone/administration & dosage/*adverse effects', 'Opiate Substitution Treatment/adverse effects/methods']",https://pubmed.ncbi.nlm.nih.gov/25487851/
1630,methadone,31178032,[Improve the benefit/risk balance of methadone by respecting its pharmacological specificities].,"['Frauger E', 'Fouilhe Sam-Lai N', 'Mallaret M', 'Micallef J']","['Analgesics, Opioid/*administration & dosage/adverse effects/pharmacology', 'Drug Overdose', 'France', 'Humans', 'Methadone/*administration & dosage/adverse effects/pharmacology', 'Opiate Substitution Treatment/adverse effects/*methods', 'Opioid-Related Disorders/rehabilitation', 'Pharmacovigilance']",https://pubmed.ncbi.nlm.nih.gov/31178032/
1631,Carboplatinum,26780071,[Platinum antitumor complexes].,"['Bonetti A', 'Giuliani J', 'Muggia F']","['Antineoplastic Agents/*administration & dosage/adverse effects/therapeutic use', 'Carboplatin/administration & dosage/adverse effects/therapeutic use', 'Cisplatin/administration & dosage/adverse effects/therapeutic use', 'Drug Design', 'Drug Resistance, Neoplasm', 'Humans', 'Neoplasms, Germ Cell and Embryonal/*drug therapy/pathology', 'Organoplatinum Compounds/administration & dosage/*therapeutic use', 'Oxaliplatin', 'Testicular Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/26780071/
1632,Carboplatinum,25129986,Carboplatin dosing for adult Japanese patients.,"['Ando Y', 'Shimokata T', 'Yasuda Y', 'Hasegawa Y']","['Adult', 'Age Factors', 'Antineoplastic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Area Under Curve', '*Asian People', 'Biomarkers/blood/urine', 'Carboplatin/*administration & dosage/adverse effects/pharmacokinetics', 'Creatinine/blood/urine', '*Drug Dosage Calculations', 'Glomerular Filtration Rate', 'Humans', 'Japan/epidemiology', 'Metabolic Clearance Rate', '*Models, Biological', 'Neoplasms/*drug therapy/ethnology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25129986/
1633,Carboplatinum,11082722,[Carboplatin in cancer of the ovary].,"['Pujade-Lauraine E', 'Guastalla JP', 'Vincent P']","['Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Area Under Curve', 'Attitude of Health Personnel', 'Carboplatin/administration & dosage/adverse effects/*therapeutic use', 'Cisplatin/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Europe', 'Female', 'Humans', 'Meta-Analysis as Topic', 'Ovarian Neoplasms/*drug therapy', 'Paclitaxel/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Thrombocytopenia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11082722/
1634,Carboplatinum,37801303,Peripheral Blasts in a Patient Receiving Chemotherapy.,"['Kshattry S', 'Parker TL', 'Huntington SF']","['Humans', '*Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Gemcitabine/administration & dosage/adverse effects', '*Antineoplastic Agents/adverse effects/therapeutic use', '*Urinary Bladder Neoplasms/drug therapy/pathology', 'Carboplatin/administration & dosage/adverse effects', '*Granulocyte Colony-Stimulating Factor/administration & dosage/adverse effects', '*Leukopoiesis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/37801303/
1635,Carboplatinum,7992062,Cisplatin: the future.,['Comis RL'],"['Carboplatin/adverse effects/therapeutic use', 'Cisplatin/adverse effects/*therapeutic use', 'Forecasting', 'Humans', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7992062/
1636,Carboplatinum,7825958,Dose optimisation of carboplatin in adults.,['Calvert AH'],"['Adult', 'Carboplatin/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Glomerular Filtration Rate', 'Humans', 'Metabolic Clearance Rate', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7825958/
1637,Carboplatinum,10864227,Clinical pharmacokinetics and administration of established platinum drugs.,"[""O'Dwyer PJ"", 'Stevenson JP', 'Johnson SW']","['Animals', 'Antineoplastic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Carboplatin/administration & dosage/adverse effects/*pharmacokinetics', 'Cisplatin/administration & dosage/adverse effects/*pharmacokinetics', 'Humans', 'Organoplatinum Compounds/administration & dosage/adverse effects/*pharmacokinetics', 'Oxaliplatin']",https://pubmed.ncbi.nlm.nih.gov/10864227/
1638,Carboplatinum,24195728,Emerging drugs for urothelial carcinoma.,"['Gartrell BA', 'Sonpavde G']","['Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects/therapeutic use', 'Carcinoma/*drug therapy/pathology/radiotherapy/surgery', 'Cisplatin/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Disease-Free Survival', 'Drug Discovery', 'Humans', 'Molecular Targeted Therapy', 'Neoadjuvant Therapy', 'Neoplasm Invasiveness', 'Urinary Bladder Neoplasms/*drug therapy/pathology/radiotherapy/surgery', 'Urothelium/*drug effects/pathology/radiation effects/surgery']",https://pubmed.ncbi.nlm.nih.gov/24195728/
1639,Carboplatinum,38104995,Cytokine Release Syndrome More than Two Years after Pembrolizumab Introduction.,"['Nakashima K', 'Kitani K', 'Kono K', 'Yoshihara K', 'Kawakado K', 'Kobayashi M', 'Okuno T', 'Amano Y', 'Tsubata Y', 'Isobe T']","['Humans', 'Male', 'Aged', '*Antibodies, Monoclonal, Humanized/adverse effects/therapeutic use', '*Lung Neoplasms/drug therapy', '*Cytokine Release Syndrome/drug therapy/etiology', '*Adenocarcinoma of Lung/drug therapy', 'Immune Checkpoint Inhibitors/adverse effects/therapeutic use', 'Prednisolone/therapeutic use', 'Time Factors', 'Pemetrexed/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Carboplatin/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38104995/
1640,Carboplatinum,8052868,Carboplatin for small cell lung cancer: progress toward greater efficacy and reduced toxicity.,"['Raghavan D', 'Perez R', 'Creaven P', 'Takita H', 'Loewen G', 'Vaickus L']","['Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carboplatin/*administration & dosage/adverse effects/pharmacology', 'Carcinoma, Small Cell/*drug therapy', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Resistance', 'Humans', 'Lung Neoplasms/*drug therapy', 'Platinum Compounds/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8052868/
1641,Carboplatinum,18788992,Fibrin sealant for retinoblastoma: where are we?,"['Martin NE', 'Kim JW', 'Abramson DH']","['Animals', '*Antineoplastic Agents/administration & dosage/pharmacokinetics/therapeutic use', 'Biological Availability', '*Carboplatin/administration & dosage/pharmacokinetics/therapeutic use', 'Drug Delivery Systems', '*Fibrin Tissue Adhesive', 'Humans', 'Permeability', 'Retinal Neoplasms/*drug therapy', 'Retinoblastoma/*drug therapy', 'Sclera']",https://pubmed.ncbi.nlm.nih.gov/18788992/
1642,Carboplatinum,7825959,The comparative pharmacokinetics and pharmacodynamics of cisplatin and carboplatin in paediatric patients: a review.,"['Bin P', 'Boddy AV', 'English MW', 'Pearson AD', 'Price L', 'Tilby MJ', 'Newell DR']","['Adolescent', 'Carboplatin/administration & dosage/pharmacokinetics/*pharmacology', 'Child', 'Child, Preschool', 'Cisplatin/administration & dosage/pharmacokinetics/*pharmacology', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Humans', 'Metabolic Clearance Rate']",https://pubmed.ncbi.nlm.nih.gov/7825959/
1643,Carboplatinum,17355104,Chemotherapy dosing part II: alternative approaches and future prospects.,"['Kaestner SA', 'Sewell GJ']","['Animals', 'Antineoplastic Agents/*administration & dosage/pharmacokinetics', 'Carboplatin/*administration & dosage/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Monitoring', 'Humans', 'Models, Biological', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17355104/
1644,Carboplatinum,34607430,Nanoscale Coordination Polymers for Combined Chemotherapy and Photodynamic Therapy of Metastatic Cancer.,"['Li Y', 'Han W', 'He C', 'Jiang X', 'Fan Y', 'Lin W']","['Animals', '*Photochemotherapy/methods', 'Mice', '*Polymers/chemistry', '*Nanoparticles/chemistry', 'Female', '*Photosensitizing Agents/therapeutic use/pharmacology/chemistry', 'Cell Line, Tumor', 'Humans', 'Carboplatin/therapeutic use/administration & dosage/pharmacology/chemistry', 'Neoplasm Metastasis', 'Antineoplastic Agents/therapeutic use/pharmacology/chemistry', 'Triple Negative Breast Neoplasms/drug therapy/pathology', 'Mice, Inbred BALB C', 'Reactive Oxygen Species/metabolism', 'Apoptosis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/34607430/
1645,Carboplatinum,9322881,Comparative clinical pharmacology of cisplatin and carboplatin.,['Murry DJ'],"['Animals', 'Antineoplastic Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Carboplatin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Cisplatin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9322881/
1646,Carboplatinum,1323807,Carboplatin/etoposide in small cell lung cancer.,['Bishop JF'],"['Aged', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects/*therapeutic use', 'Carcinoma, Small Cell/*drug therapy', 'Drug Administration Schedule', 'Etoposide/administration & dosage/adverse effects/*therapeutic use', 'Hematopoietic Cell Growth Factors/therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1323807/
1647,Carboplatinum,27617542,OCULAR PHARMACOLOGY OF CHEMOTHERAPY FOR RETINOBLASTOMA.,"['Schaiquevich P', 'Fabius AW', 'Francis JH', 'Chantada GL', 'Abramson DH']","['Animals', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/*pharmacokinetics/therapeutic use', 'Carboplatin/administration & dosage/*pharmacokinetics/therapeutic use', 'Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Evaluation, Preclinical', 'Humans', 'Infusions, Intra-Arterial', 'Injections, Intraocular', 'Melphalan/administration & dosage/pharmacokinetics/*therapeutic use', 'Retinal Neoplasms/*drug therapy', 'Retinoblastoma/*drug therapy', 'Topotecan/administration & dosage/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27617542/
1648,Carboplatinum,34731446,Durvalumab: A Review in Extensive-Stage SCLC.,['Al-Salama ZT'],"['Adult', '*Antibodies, Monoclonal/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Carboplatin/pharmacology/therapeutic use', 'Cisplatin/therapeutic use', 'Etoposide/pharmacology/therapeutic use', 'Humans', '*Lung Neoplasms/drug therapy', '*Small Cell Lung Carcinoma/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34731446/
1649,Carboplatinum,12523468,Recurring chemotherapy-associated alopecia areata: case report and literature review.,"['Motl SE', 'Fausel C']","['Alopecia Areata/*chemically induced', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects', 'Carboplatin/administration & dosage/adverse effects', 'Female', 'Humans', 'Middle Aged', 'Paclitaxel/administration & dosage/adverse effects', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/12523468/
1650,Carboplatinum,10235026,[Paclitaxel/carboplatin in first line treatment of advanced ovarian carcinoma].,['Meerpohl HG'],"['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Female', 'Humans', 'Neoplasm Staging', 'Ovarian Neoplasms/*drug therapy/pathology', 'Paclitaxel/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10235026/
1651,isradipine,28641520,Try to Remember: Interplay between Memory and Substance Use Disorder.,"['Mohamed RMP', 'Kumar J', 'Yap E', 'Mohamed IN', 'Sidi H', 'Adam RL', 'Das S']","['Cues', 'Heterocyclic Compounds, 4 or More Rings/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacology/therapeutic use', 'Memory, Long-Term/*drug effects', 'Molecular Targeted Therapy', 'Neuronal Plasticity/drug effects', 'Substance-Related Disorders/drug therapy/*psychology']",https://pubmed.ncbi.nlm.nih.gov/28641520/
1652,isradipine,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
1653,isradipine,1830320,Isradipine.,['Schachter M'],"['Angina Pectoris/drug therapy', 'Animals', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Arteriosclerosis/prevention & control', 'Calcium Channel Blockers/pharmacokinetics/*therapeutic use', 'Humans', 'Hypertension/drug therapy', 'Isradipine', 'Pyridines/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1830320/
1654,isradipine,8097608,Role of isradipine and other antihypertensive agents in the treatment of peri- and postoperative hypertension.,['Marty J'],"['Adrenergic alpha-Antagonists/therapeutic use', 'Adrenergic beta-Antagonists/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Humans', 'Hypertension/*prevention & control', 'Intraoperative Complications/*prevention & control', 'Isradipine/*therapeutic use', 'Postoperative Complications/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8097608/
1655,isradipine,8743037,Antiatherosclerotic effects of antihypertensive drugs: recent evidence and ongoing trials.,['Zanchetti A'],"['Aged', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Antihypertensive Agents/*pharmacology', 'Arteriosclerosis/*prevention & control', 'Calcium Channel Blockers/pharmacology', 'Carotid Arteries/diagnostic imaging/drug effects', 'Carotid Artery Diseases/diagnostic imaging/etiology/prevention & control', 'Clinical Trials as Topic', 'Dihydropyridines/pharmacology', 'Humans', 'Hypertension/complications/diagnostic imaging/drug therapy', 'Isradipine/pharmacology', 'Ultrasonography', 'Verapamil/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8743037/
1656,isradipine,30758052,Calcium antagonists for acute ischemic stroke.,"['Zhang J', 'Liu J', 'Li D', 'Zhang C', 'Liu M']","['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Brain Ischemia/*drug therapy/mortality', 'Calcium/metabolism', 'Calcium Channel Blockers/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Flunarizine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Isradipine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Nimodipine/administration & dosage/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Stroke/*drug therapy', 'Vasodilator Agents/administration & dosage/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30758052/
1657,isradipine,9812220,Rational use of calcium-channel antagonists in Raynaud's phenomenon.,"['Sturgill MG', 'Seibold JR']","['Amlodipine/pharmacokinetics/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacokinetics/pharmacology/*therapeutic use', 'Diltiazem/pharmacokinetics/pharmacology/therapeutic use', 'Felodipine/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Isradipine/pharmacokinetics/pharmacology/therapeutic use', 'Nicardipine/pharmacokinetics/pharmacology/therapeutic use', 'Nifedipine/pharmacokinetics/pharmacology/therapeutic use', 'Raynaud Disease/*drug therapy/epidemiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/9812220/
1658,isradipine,36595455,Applications of isradipine in human addiction studies: A systematic literature review.,"['Natal S', 'Young CC', 'Kaur K', 'Gebhardt ES', 'Perrone A', 'Morikawa H', 'Tirado C', 'Smits JAJ']","['Adult', 'Humans', 'Isradipine/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', '*Cocaine', '*Methamphetamine', '*Substance-Related Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36595455/
1659,isradipine,1376831,Antiatherosclerotic actions of isradipine.,"['Sinzinger H', 'Fitscha P']","['Arteriosclerosis/*drug therapy', 'Calcium Channel Blockers/*therapeutic use', 'Dihydropyridines/*therapeutic use', 'Humans', 'Isradipine', 'Lipid Metabolism']",https://pubmed.ncbi.nlm.nih.gov/1376831/
1660,isradipine,9790159,Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.,"['Pazzaglia PJ', 'Post RM', 'Ketter TA', 'Callahan AM', 'Marangell LB', 'Frye MA', 'George MS', 'Kimbrell TA', 'Leverich GS', 'Cora-Locatelli G', 'Luckenbaugh D']","['Adult', 'Antimanic Agents/*administration & dosage/adverse effects', 'Bipolar Disorder/diagnosis/*drug therapy/psychology', 'Calcium Channel Blockers/*administration & dosage/adverse effects', 'Carbamazepine/*administration & dosage/adverse effects', 'Depressive Disorder/diagnosis/*drug therapy/psychology', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Nimodipine/*administration & dosage/adverse effects', 'Psychiatric Status Rating Scales', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9790159/
1661,isradipine,9600578,Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study.,"['Johnson B', 'Barron B', 'Fang B', 'Lamki L', 'Wagner L', 'Wells L', 'Kenny P', 'Overton D', 'Dhother S', 'Abramson D', 'Chen R', 'Kramer L']","['Adult', 'Brain/blood supply/diagnostic imaging/*drug effects', 'Calcium Channel Blockers/*pharmacology', 'Cerebral Arteries/diagnostic imaging/*drug effects', 'Cocaine/antagonists & inhibitors/*pharmacology', 'Female', 'Humans', 'Isradipine/*pharmacology', 'Male', 'Narcotics/*pharmacology', 'Regional Blood Flow', 'Substance-Related Disorders/diagnostic imaging', 'Tomography, Emission-Computed, Single-Photon']",https://pubmed.ncbi.nlm.nih.gov/9600578/
1662,isradipine,8827760,Hypertensive crisis in children.,['Groshong T'],"['Antihypertensive Agents/*therapeutic use', 'Emergencies', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/diagnosis/*drug therapy/etiology/physiopathology', 'Isradipine/therapeutic use', 'Labetalol/therapeutic use', 'Nicardipine/therapeutic use', 'Nitroprusside/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8827760/
1663,isradipine,8480505,Isradipine and the coronary circulation.,"['Feneck RO', 'Underwood SM', 'Walesby RK']","['Animals', 'Coronary Circulation/*drug effects/physiology', 'Hemodynamics/*drug effects/physiology', 'Humans', 'Isradipine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8480505/
1664,isradipine,8647348,Effects of calcium on the migration and recruitment of macrophages and macrophage-derived foam cells.,"['Shi H', 'Severs NJ', 'Robenek H']","['Animals', 'Arteriosclerosis/etiology', 'Calcinosis/etiology', 'Calcium/*pharmacology', 'Cell Movement/drug effects', 'Chemotaxis', 'Foam Cells/*drug effects/physiology', 'Humans', 'Isradipine/pharmacology', 'Lipoproteins/pharmacology', 'Macrophages/*drug effects/physiology', 'Male', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/8647348/
1665,isradipine,37640098,Quinpirole inhibits levodopa-induced dyskinesias at structural and behavioral levels: Efficacy negated by co-administration of isradipine.,"['Collier TJ', 'Begg L', 'Stancati JA', 'Mercado NM', 'Sellnow RC', 'Sandoval IM', 'Sortwell CE', 'Steece-Collier K']","['Animals', '*Levodopa/toxicity/adverse effects', '*Isradipine/pharmacology/therapeutic use', '*Dyskinesia, Drug-Induced/prevention & control/drug therapy', 'Rats', '*Quinpirole/pharmacology', 'Male', '*Calcium Channel Blockers/pharmacology', '*Rats, Sprague-Dawley', 'Antiparkinson Agents', 'Calcium Channels, L-Type/metabolism/drug effects', 'Dopamine Agonists/pharmacology', 'Dendritic Spines/drug effects/pathology', 'Corpus Striatum/drug effects/metabolism/pathology', 'Parkinsonian Disorders/drug therapy/chemically induced/metabolism/pathology/prevention & control', 'Calcium Channels']",https://pubmed.ncbi.nlm.nih.gov/37640098/
1666,isradipine,15610940,"Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals.","['Johnson BA', 'Javors MA', 'Lam YW', 'Wells LT', 'Tiouririne M', 'Roache JD', 'Ait-Daoud N', 'Lawson K']","['Adult', 'Area Under Curve', 'Calcium Channel Blockers/administration & dosage/*pharmacokinetics/*pharmacology', 'Chromatography, High Pressure Liquid', 'Cocaine-Related Disorders/*metabolism', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Hemodynamics/*drug effects', 'Humans', 'Isradipine/administration & dosage/*pharmacokinetics/*pharmacology', 'Male', 'Spectrophotometry, Ultraviolet']",https://pubmed.ncbi.nlm.nih.gov/15610940/
1667,isradipine,8397999,Antihypertensive medication-taking. Investigation of a simple regimen.,"['Guerrero D', 'Rudd P', 'Bryant-Kosling C', 'Middleton B', 'Middleton BF [corrected to Middleton B]']","['Adult', 'Clinical Protocols', 'Double-Blind Method', 'Drug Evaluation', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Isradipine/administration & dosage/*therapeutic use', 'Male', '*Patient Compliance', 'Research Design']",https://pubmed.ncbi.nlm.nih.gov/8397999/
1668,isradipine,34353274,Formulation and Evaluation of Isradipine Nanosuspension and Exploring its Role as a Potential Anticancer Drug by Computational Approach.,"['Mohapatra PK', 'Srivastava R', 'Varshney KK', 'Babu SH']","['*Antineoplastic Agents/pharmacology', 'Aspartic Acid', 'Biological Availability', 'Humans', 'Isradipine/chemistry', 'Metalloproteases', '*Nanoparticles/chemistry', 'Particle Size', 'Peptide Hydrolases', 'Polymers', 'Solubility', 'Suspensions']",https://pubmed.ncbi.nlm.nih.gov/34353274/
1669,isradipine,33460320,Isradipine plasma pharmacokinetics and exposure-response in early Parkinson's disease.,"['Venuto CS', 'Yang L', 'Javidnia M', 'Oakes D', 'James Surmeier D', 'Simuni T']","['Aged', 'Calcium Channel Blockers/administration & dosage/blood/*pharmacokinetics', '*Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Isradipine/administration & dosage/blood/*pharmacokinetics', 'Male', 'Middle Aged', '*Outcome Assessment, Health Care', 'Parkinson Disease/*drug therapy/physiopathology', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/33460320/
1670,VERAPAMIL,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
1671,VERAPAMIL,6340050,Verapamil: an effective calcium blocking agent for pediatric patients.,"['Porter CJ', 'Garson A Jr', 'Gillette PC']","['Administration, Oral', 'Adult', 'Aged', 'Animals', 'Arrhythmias, Cardiac/drug therapy', '*Calcium Channel Blockers', 'Cardiomyopathy, Hypertrophic/drug therapy', 'Child, Preschool', 'Drug Interactions', 'Electrophysiology', 'Female', 'Heart Conduction System/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Infant', 'Infant, Newborn', 'Infusions, Parenteral', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Pregnancy', 'Tachycardia/drug therapy', 'Verapamil/administration & dosage/adverse effects/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6340050/
1672,VERAPAMIL,6764159,Calcium-channel blocking agents.,"['Leonard RG', 'Talbert RL']","['Adolescent', 'Benzazepines/*pharmacology', 'Calcium/physiology', 'Calcium Channel Blockers/*pharmacology', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Diltiazem/adverse effects/metabolism/*pharmacology/therapeutic use', 'Double-Blind Method', 'Heart/*drug effects', 'Heart Diseases/*drug therapy', 'Humans', 'Hypertension/drug therapy', 'Infant', 'Myocardial Contraction/drug effects', 'Nifedipine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Pyridines/*pharmacology', 'Verapamil/adverse effects/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6764159/
1673,VERAPAMIL,9265278,[Calcium channel blockers in heart failure].,"['Hole T', 'Dickstein K', 'Gundersen T', 'Kjekshus J', 'Myhre ES', 'Ronnevik PK', 'Westheim AS']","['Calcium Channel Blockers/administration & dosage/*adverse effects', 'Dihydropyridines/administration & dosage/adverse effects', 'Diltiazem/administration & dosage/adverse effects', 'Heart Failure/*drug therapy/etiology/physiopathology', 'Humans', 'Ventricular Dysfunction, Left/complications/drug therapy/physiopathology', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9265278/
1674,VERAPAMIL,8524707,"Verapamil-induced ""primary"" polydipsia.","['Schwartz ID', 'Scagliotti D']","['Administration, Oral', 'Drinking/*drug effects', 'Humans', 'Infant', 'Male', 'Polyuria/chemically induced', 'Tachycardia, Supraventricular/*drug therapy', 'Thirst/drug effects', 'Verapamil/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8524707/
1675,VERAPAMIL,1862052,Supraventricular tachycardia. Changes in management.,['Caruso AC'],"['Adenosine/administration & dosage/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Education, Medical, Continuing', 'Electrocardiography', 'Electrocoagulation', 'Humans', 'Injections, Intravenous', 'Tachycardia, Supraventricular/classification/*diagnosis/therapy', 'Verapamil/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1862052/
1676,VERAPAMIL,6319840,Verapamil: full spectrum calcium channel blocking agent: an overview.,"['Guerrero JR', 'Martin SS']","['Calcium/*metabolism', 'Heart/drug effects', 'Heart Diseases/drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Ion Channels/*drug effects', 'Kinetics', 'Muscles/metabolism', 'Myocardium/metabolism', 'Verapamil/adverse effects/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6319840/
1677,VERAPAMIL,25331694,Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.,"['Gupta S', 'Tyagi S', 'Bishai WR']","['Animals', 'Antitubercular Agents/administration & dosage/pharmacology/*therapeutic use', 'Calcium Channel Blockers/administration & dosage/pharmacology/*therapeutic use', 'Diarylquinolines/administration & dosage/pharmacology/*therapeutic use', 'Disease Models, Animal', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Lung/microbiology', 'Mice', 'Mice, Inbred BALB C', 'Mycobacterium tuberculosis/*drug effects', 'Tuberculosis, Pulmonary/*drug therapy/microbiology', 'Verapamil/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25331694/
1678,VERAPAMIL,6695685,Accelerated junctional rhythms during oral verapamil therapy.,"['Schwartz JB', 'Jeang M', 'Raizner AE', 'Griffin JC', 'Wyndham CR']","['Administration, Oral', 'Arrhythmias, Cardiac/*chemically induced/diagnosis', 'Electrocardiography', 'Female', 'Heart Block/chemically induced', 'Humans', 'Male', 'Middle Aged', 'Pain/physiopathology', 'Tachycardia/drug therapy', 'Thorax', 'Verapamil/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6695685/
1679,VERAPAMIL,7004158,The clinical use of intravenous verapamil.,['Schamroth L'],"['Angina Pectoris, Variant/drug therapy', 'Arrhythmias, Cardiac/drug therapy', 'Atrial Fibrillation/drug therapy', 'Atrial Flutter/drug therapy', 'Atrioventricular Node/drug effects', 'Electrophysiology', 'Humans', 'Hypertension/drug therapy', 'Tachycardia/drug therapy', 'Vasodilation', 'Verapamil/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7004158/
1680,VERAPAMIL,31814590,Acute calcium channel blocker withdrawal-induced cardiac arrest.,"['Peeters LEJ', 'den Uil CA', 'Feyz L', 'van den Bemt PMLA', 'Daemen J', 'Versmissen J']","['Angina Pectoris/drug therapy', 'Calcium Channel Blockers/*administration & dosage/*adverse effects', 'Coronary Vasospasm/drug therapy', 'Diagnosis, Differential', 'Female', 'Heart Arrest, Induced/*methods', 'Humans', 'Middle Aged', 'Substance Withdrawal Syndrome/*drug therapy', 'Treatment Outcome', 'Verapamil/*administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31814590/
1681,VERAPAMIL,16244356,Modified release verapamil induced cardiogenic shock.,"['Nanda U', 'Ashish A', 'Why HJ']","['Anti-Arrhythmia Agents/administration & dosage/*adverse effects', 'Atrial Fibrillation/*drug therapy', 'Delayed-Action Preparations', 'Humans', 'Male', 'Middle Aged', 'Shock, Cardiogenic/*chemically induced', 'Verapamil/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16244356/
1682,VERAPAMIL,26901756,Hyaluronic acid modified mesoporous carbon nanoparticles for targeted drug delivery to CD44-overexpressing cancer cells.,"['Wan L', 'Jiao J', 'Cui Y', 'Guo J', 'Han N', 'Di D', 'Chang D', 'Wang P', 'Jiang T', 'Wang S']","['Animals', 'Cell Survival/drug effects', 'Colorectal Neoplasms/*drug therapy', 'Doxorubicin/*administration & dosage/chemistry/pharmacology', 'Drug Delivery Systems', 'HCT116 Cells', 'Humans', 'Hyaluronan Receptors/*metabolism', 'Hyaluronic Acid/*chemical synthesis', 'Mice', 'Mice, Nude', 'Nanoparticles/*administration & dosage/chemistry', 'Porosity', 'Verapamil/*administration & dosage/chemistry/pharmacology', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/26901756/
1683,VERAPAMIL,6807854,Long-term effect of verapamil in hypertrophic cardiomyopathy.,"['Hasin Y', 'Lewis BS', 'Lewis N', 'Weiss AT', 'Gotsman MS']","['Adult', 'Aged', 'Cardiomyopathy, Hypertrophic/diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Echocardiography', 'Electrocardiography', 'Female', 'Heart Murmurs', 'Heart Rate/drug effects', 'Heart Ventricles/physiopathology', 'Humans', 'Long-Term Care', 'Male', 'Middle Aged', 'Verapamil/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6807854/
1684,VERAPAMIL,1417461,Bioavailability study of two different verapamil formulations.,"['Horne C', 'Stenzhorn G', 'Blume H', 'Knauf H', 'Mutschler E']","['Adult', 'Biological Availability', 'Delayed-Action Preparations', 'Humans', 'Male', 'Tablets', 'Verapamil/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1417461/
1685,VERAPAMIL,2009180,Doxorubicin in combination with verapamil in advanced colorectal cancer. A phase II trial.,"['Dalmark M', 'Pals H', 'Johnsen AH']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Colorectal Neoplasms/*drug therapy', 'Doxorubicin/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2009180/
1686,VERAPAMIL,3065507,Verapamil SR and propranolol LA: a comparison of efficacy and side effects in the treatment of mild to moderate hypertension.,"['Bochsler JA', 'Simmons RL', 'Ward PJ', 'Chester PC', 'Latham AN']","['Adult', 'Aged', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Delayed-Action Preparations', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Propranolol/*administration & dosage/adverse effects/therapeutic use', 'Random Allocation', 'Verapamil/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3065507/
1687,VERAPAMIL,6362951,Clinical pharmacokinetics of verapamil.,"['Hamann SR', 'Blouin RA', 'McAllister RG Jr']","['Adult', 'Aged', 'Digoxin/metabolism', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Intestinal Absorption', 'Kinetics', 'Liver Diseases/metabolism', 'Middle Aged', 'Propranolol/pharmacology', 'Protein Binding', 'Verapamil/administration & dosage/*metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/6362951/
1688,VERAPAMIL,2708046,Prophylactic treatment of cluster headache with verapamil.,"['Gabai IJ', 'Spierings EL']","['Adolescent', 'Adult', 'Aged', 'Cluster Headache/*drug therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Vascular Headaches/*drug therapy', 'Verapamil/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2708046/
1689,VERAPAMIL,29962336,Coronary No-Reflow Phenomenon in Clinical Practice.,"['Scarpone M', 'Cenko E', 'Manfrini O']","['Adenosine/administration & dosage/*pharmacology', 'Coronary Vessels/*drug effects/metabolism', 'Humans', 'Microcirculation/*drug effects', 'Nitroprusside/administration & dosage/*pharmacology', 'No-Reflow Phenomenon/*drug therapy/metabolism', 'Verapamil/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29962336/
1690,letrozole,27959613,Palbociclib and Letrozole in Advanced Breast Cancer.,"['Finn RS', 'Martin M', 'Rugo HS', 'Jones S', 'Im SA', 'Gelmon K', 'Harbeck N', 'Lipatov ON', 'Walshe JM', 'Moulder S', 'Gauthier E', 'Lu DR', 'Randolph S', 'Dieras V', 'Slamon DJ']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy', 'Cyclin-Dependent Kinases/antagonists & inhibitors', 'Disease-Free Survival', 'Double-Blind Method', 'Female', 'Humans', 'Letrozole', 'Middle Aged', 'Neutropenia/chemically induced', 'Nitriles/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Postmenopause', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Pyridines/*administration & dosage/adverse effects', 'Receptors, Estrogen/analysis', 'Triazoles/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27959613/
1691,letrozole,37873987,[Not Available].,"['Dahlberg ES', 'Andersen D', 'Andersson PS', 'Birch K', 'Colmon L', 'Holt MD', 'Ingerslev K', 'Kirkegaard K', 'Lossl K', 'Poulsen LC', 'Wissing ML', 'Yde M', 'Bulow NS']","['Male', 'Female', 'Humans', 'Letrozole/therapeutic use', '*Anovulation/therapy', 'Fertility Agents, Female', 'Semen', 'Clomiphene/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37873987/
1692,letrozole,38507751,Ribociclib plus Endocrine Therapy in Early Breast Cancer.,"['Slamon D', 'Lipatov O', 'Nowecki Z', 'McAndrew N', 'Kukielka-Budny B', 'Stroyakovskiy D', 'Yardley DA', 'Huang CS', 'Fasching PA', 'Crown J', 'Bardia A', 'Chia S', 'Im SA', 'Ruiz-Borrego M', 'Loi S', 'Xu B', 'Hurvitz S', 'Barrios C', 'Untch M', 'Moroose R', 'Visco F', 'Afenjar K', 'Fresco R', 'Severin I', 'Ji Y', 'Ghaznawi F', 'Li Z', 'Zarate JP', 'Chakravartty A', 'Taran T', 'Hortobagyi G']","['Female', 'Humans', 'Aminopyridines/administration & dosage/adverse effects/therapeutic use', '*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism/mortality/pathology', '*Letrozole/administration & dosage/adverse effects/therapeutic use', 'Purines/administration & dosage/adverse effects/therapeutic use', 'Receptor, ErbB-2/metabolism', '*Aromatase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Goserelin/administration & dosage/adverse effects/therapeutic use', 'Antineoplastic Agents, Hormonal', 'Male']",https://pubmed.ncbi.nlm.nih.gov/38507751/
1693,letrozole,34220713,Letrozole for Female Infertility.,"['Yang AM', 'Cui N', 'Sun YF', 'Hao GM']","['Aromatase Inhibitors/*therapeutic use', 'Female', 'Humans', 'Infertility, Female/*drug therapy', 'Letrozole/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34220713/
1694,letrozole,36243120,"Letrozole: Pharmacology, toxicity and potential therapeutic effects.","['Mukherjee AG', 'Wanjari UR', 'Nagarajan D', 'K K V', 'V A', 'P JP', 'T TP', 'Chakraborty R', 'Renu K', 'Dey A', 'Vellingiri B', 'Gopalakrishnan AV']","['Female', 'Humans', 'Letrozole/pharmacology/therapeutic use', 'Nitriles/therapeutic use', 'Triazoles/pharmacology/therapeutic use', 'Aromatase Inhibitors/pharmacology/therapeutic use', '*Breast Neoplasms/drug therapy/metabolism', 'Estrogens/metabolism', '*Infertility, Female/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36243120/
1695,letrozole,27717303,"Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.","['Hortobagyi GN', 'Stemmer SM', 'Burris HA', 'Yap YS', 'Sonke GS', 'Paluch-Shimon S', 'Campone M', 'Blackwell KL', 'Andre F', 'Winer EP', 'Janni W', 'Verma S', 'Conte P', 'Arteaga CL', 'Cameron DA', 'Petrakova K', 'Hart LL', 'Villanueva C', 'Chan A', 'Jakobsen E', 'Nusch A', 'Burdaeva O', 'Grischke EM', 'Alba E', 'Wist E', 'Marschner N', 'Favret AM', 'Yardley D', 'Bachelot T', 'Tseng LM', 'Blau S', 'Xuan F', 'Souami F', 'Miller M', 'Germa C', 'Hirawat S', ""O'Shaughnessy J""]","['Adult', 'Aged', 'Aged, 80 and over', 'Aminopyridines/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/pathology', 'Disease-Free Survival', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Kaplan-Meier Estimate', 'Letrozole', 'Middle Aged', 'Neoplasm Staging', 'Nitriles/*administration & dosage', 'Purines/*administration & dosage', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Receptors, Progesterone', 'Triazoles/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27717303/
1696,letrozole,35263519,Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.,"['Hortobagyi GN', 'Stemmer SM', 'Burris HA', 'Yap YS', 'Sonke GS', 'Hart L', 'Campone M', 'Petrakova K', 'Winer EP', 'Janni W', 'Conte P', 'Cameron DA', 'Andre F', 'Arteaga CL', 'Zarate JP', 'Chakravartty A', 'Taran T', 'Le Gac F', 'Serra P', ""O'Shaughnessy J""]","['Aged', 'Aminopyridines/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality/pathology', 'Female', 'Humans', 'Intention to Treat Analysis', 'Letrozole/*administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Grading', 'Neutropenia/chemically induced', 'Purines/*administration & dosage/adverse effects', 'Receptor, ErbB-2', 'Receptors, Estrogen', 'Survival Analysis']",https://pubmed.ncbi.nlm.nih.gov/35263519/
1697,letrozole,38729566,"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3.","['Goetz MP', 'Toi M', 'Huober J', 'Sohn J', 'Tredan O', 'Park IH', 'Campone M', 'Chen SC', 'Manso LM', 'Paluch-Shimon S', 'Freedman OC', ""O'Shaughnessy J"", 'Pivot X', 'Tolaney SM', 'Hurvitz SA', 'Llombart-Cussac A', 'Andre V', 'Saha A', 'van Hal G', 'Shahir A', 'Iwata H', 'Johnston SRD']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Middle Aged', '*Aminopyridines/administration & dosage/therapeutic use', 'Anastrozole/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Aromatase Inhibitors/therapeutic use/administration & dosage', '*Benzimidazoles/administration & dosage/therapeutic use', '*Breast Neoplasms/drug therapy/pathology/mortality', 'Double-Blind Method', '*Letrozole/administration & dosage/therapeutic use', 'Progression-Free Survival', 'Receptor, ErbB-2/metabolism/antagonists & inhibitors', 'Receptors, Estrogen/metabolism', 'Receptors, Progesterone/metabolism']",https://pubmed.ncbi.nlm.nih.gov/38729566/
1698,letrozole,29804902,"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","['Tripathy D', 'Im SA', 'Colleoni M', 'Franke F', 'Bardia A', 'Harbeck N', 'Hurvitz SA', 'Chow L', 'Sohn J', 'Lee KS', 'Campos-Gomez S', 'Villanueva Vazquez R', 'Jung KH', 'Babu KG', 'Wheatley-Price P', 'De Laurentiis M', 'Im YH', 'Kuemmel S', 'El-Saghir N', 'Liu MC', 'Carlson G', 'Hughes G', 'Diaz-Padilla I', 'Germa C', 'Hirawat S', 'Lu YS']","['Administration, Oral', 'Adult', 'Aminopyridines/*administration & dosage', 'Antineoplastic Agents, Hormonal/*administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Breast Neoplasms/*drug therapy/*genetics/mortality/pathology', 'Disease-Free Survival', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Internationality', 'Kaplan-Meier Estimate', 'Letrozole/administration & dosage', 'Middle Aged', 'Neoplasm Invasiveness/pathology', 'Neoplasm Staging', 'Premenopause/drug effects', 'Prognosis', 'Proportional Hazards Models', 'Purines/*administration & dosage', 'Survival Analysis', 'Tamoxifen/administration & dosage', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29804902/
1699,letrozole,30470497,Pharmacology of medications used for ovarian stimulation.,"['Quaas AM', 'Legro RS']","['Clomiphene/therapeutic use', 'Female', 'Fertility Agents, Female/classification/*therapeutic use', 'Gonadotropin-Releasing Hormone/therapeutic use', 'Gonadotropins/therapeutic use', 'Humans', 'Infertility, Female/complications/drug therapy', 'Letrozole/therapeutic use', 'Ovulation/drug effects/physiology', 'Ovulation Induction/adverse effects/*methods', 'Polycystic Ovary Syndrome/complications/drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/30470497/
1700,letrozole,34617955,"Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial.","['Llombart-Cussac A', 'Perez-Garcia JM', 'Bellet M', 'Dalenc F', 'Gil-Gil M', 'Ruiz-Borrego M', 'Gavila J', 'Sampayo-Cordero M', 'Aguirre E', 'Schmid P', 'Marme F', 'Di Cosimo S', 'Gligorov J', 'Schneeweiss A', 'Albanell J', 'Zamora P', 'Wheatley D', 'Martinez-de Duenas E', 'Amillano K', 'Malfettone A', 'Cortes J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', '*Breast Neoplasms/pathology', 'Female', 'Fulvestrant', 'Humans', 'Letrozole/therapeutic use', 'Middle Aged', 'Piperazines', 'Pyridines', 'Receptor, ErbB-2']",https://pubmed.ncbi.nlm.nih.gov/34617955/
1701,letrozole,38295043,Ideal frozen embryo transfer regime.,"['Castillo J', 'Kol S']","['Humans', 'Female', '*Embryo Transfer/methods', 'Pregnancy', '*Cryopreservation/methods', 'Embryo Implantation/physiology', 'Progesterone/administration & dosage', 'Endometrium', 'Ovulation Induction/methods', 'Letrozole/therapeutic use', 'Fertilization in Vitro/methods', 'Pregnancy Rate']",https://pubmed.ncbi.nlm.nih.gov/38295043/
1702,letrozole,30632023,Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up.,"['Rugo HS', 'Finn RS', 'Dieras V', 'Ettl J', 'Lipatov O', 'Joy AA', 'Harbeck N', 'Castrellon A', 'Iyer S', 'Lu DR', 'Mori A', 'Gauthier ER', 'Bartlett CH', 'Gelmon KA', 'Slamon DJ']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Breast Neoplasms/*drug therapy/metabolism/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Letrozole/*administration & dosage/adverse effects', 'Piperazines/*administration & dosage/adverse effects', 'Postmenopause/psychology', 'Pyridines/*administration & dosage/adverse effects', 'Quality of Life/psychology', 'Receptor, ErbB-2/metabolism', 'Receptors, Estrogen/metabolism', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30632023/
1703,letrozole,32920843,Letrozole versus clomiphene citrate for ovulation induction in anovulatory women with polycystic ovarian syndrome: A randomized controlled trial.,"['Bansal S', 'Goyal M', 'Sharma C', 'Shekhar S']","['Adult', 'Clomiphene/administration & dosage/*therapeutic use', 'Female', 'Fertility Agents, Female/administration & dosage/*therapeutic use', 'Humans', '*Infertility, Female', 'Letrozole/administration & dosage/*therapeutic use', '*Ovulation Induction', '*Polycystic Ovary Syndrome', 'Pregnancy', 'Pregnancy Rate', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32920843/
1704,letrozole,39073142,"The NEOLETRIB trial: neoadjuvant treatment with Letrozole and Ribociclib in ER-positive, HER2-negative breast cancer.","['Fjermeros K', 'Ghannoum S', 'Geisler SB', 'Bhargava S', 'Tahiri A', 'Klajic J', 'Luders T', 'Fongard M', 'Nawaz MS', 'Bosnjak-Olsen T', 'Buvarp UE', 'Rosenskiold AKJ', 'Nguyen NT', 'Sletbak TT', 'Seyedzadeh M', 'Selsas K', 'Porojnicu AC', 'Skjerven HK', 'Hovda T', 'Sahlberg KK', 'Torland LA', 'Lyngra M', 'Hammarstrom CL', 'Honigsperger EB', 'Noone JC', 'Mathiassen S', 'Hurtado A', 'Goel S', 'Koff A', 'Tekpli X', 'Kristensen VN', 'Geisler J']","['Adult', 'Female', 'Humans', 'Middle Aged', '*Aminopyridines/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Breast Neoplasms/drug therapy/pathology', '*Letrozole/administration & dosage/therapeutic use', '*Neoadjuvant Therapy/methods', '*Purines/administration & dosage/therapeutic use', '*Receptor, ErbB-2/metabolism', '*Receptors, Estrogen/metabolism', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39073142/
1705,letrozole,35063278,"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.","['Slomovitz BM', 'Filiaci VL', 'Walker JL', 'Taub MC', 'Finkelstein KA', 'Moroney JW', 'Fleury AC', 'Muller CY', 'Holman LL', 'Copeland LJ', 'Miller DS', 'Coleman RL']","['*Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Drug Combinations', '*Endometrial Neoplasms/drug therapy/pathology', 'Estradiol', 'Estriol', 'Estrone', 'Everolimus/therapeutic use', 'Female', 'Humans', 'Letrozole/therapeutic use', '*Neoplasm Recurrence, Local/drug therapy/pathology', 'Phosphatidylinositol 3-Kinases']",https://pubmed.ncbi.nlm.nih.gov/35063278/
1706,letrozole,30683591,A randomized controlled trial of combination letrozole and clomiphene citrate or letrozole alone for ovulation induction in women with polycystic ovary syndrome.,"['Mejia RB', 'Summers KM', 'Kresowik JD', 'Van Voorhis BJ']","['Adolescent', 'Adult', 'Age Factors', 'Biomarkers/blood', 'Body Mass Index', 'Clomiphene/*administration & dosage/adverse effects', 'Female', 'Fertility/drug effects', 'Fertility Agents, Female/*administration & dosage/adverse effects', 'Humans', 'Infertility, Female/diagnosis/*drug therapy/physiopathology', 'Iowa', 'Letrozole/*administration & dosage/adverse effects', 'Live Birth', 'Ovulation/*drug effects', 'Ovulation Induction/adverse effects/*methods', 'Polycystic Ovary Syndrome/diagnosis/*drug therapy/physiopathology', 'Pregnancy', 'Pregnancy Rate', 'Progesterone/blood', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30683591/
1707,letrozole,37520487,Comparing efficacy and safety of stair step protocols for clomiphene citrate and letrozole in ovulation induction for women with polycystic ovary syndrome (PCOS): a randomized controlled clinical trial.,"['Al-Thuwaynee S', 'Swadi AAJ']","['Child', 'Female', 'Humans', 'Pregnancy', 'Clomiphene/therapeutic use', 'Fertility Agents, Female/therapeutic use', '*Infertility, Female/drug therapy/etiology', 'Letrozole/therapeutic use', 'Nitriles/therapeutic use', 'Ovulation Induction/methods', '*Polycystic Ovary Syndrome/drug therapy', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37520487/
1708,letrozole,31125276,"Palbociclib Plus Letrozole as First-Line Therapy in Postmenopausal Asian Women With Metastatic Breast Cancer: Results From the Phase III, Randomized PALOMA-2 Study.","['Im SA', 'Mukai H', 'Park IH', 'Masuda N', 'Shimizu C', 'Kim SB', 'Im YH', 'Ohtani S', 'Huang Bartlett C', 'Lu DR', 'Iyer S', 'Mori Y', 'Mori A', 'Gauthier E', 'Finn RS', 'Toi M']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Breast Neoplasms/*drug therapy/mortality/*pathology', 'Female', 'Humans', 'Letrozole/administration & dosage/pharmacokinetics', 'Middle Aged', 'Neoplasm Staging', 'Piperazines/administration & dosage/pharmacokinetics', 'Postmenopause', 'Prognosis', 'Pyridines/administration & dosage/pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31125276/
1709,letrozole,32221019,Letrozole in the management of advanced ovarian cancer: an old drug as a new targeted therapy.,"['Marchetti C', 'De Felice F', 'Ergasti R', 'Scambia G', 'Fagotti A']","['Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Aromatase Inhibitors/administration & dosage', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Female', 'Humans', 'Letrozole/*administration & dosage', 'Ovarian Neoplasms/*drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32221019/
1710,Imatinib,38820078,Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.,"['Hochhaus A', 'Wang J', 'Kim DW', 'Kim DDH', 'Mayer J', 'Goh YT', 'le Coutre P', 'Takahashi N', 'Kim I', 'Etienne G', 'Andorsky D', 'Issa GC', 'Larson RA', 'Bombaci F', 'Kapoor S', 'McCulloch T', 'Malek K', 'Yau L', 'Ifrah S', 'Hoch M', 'Cortes JE', 'Hughes TP']","['Adult', 'Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', '*Antineoplastic Agents/administration & dosage/adverse effects', '*Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics', '*Imatinib Mesylate/therapeutic use/adverse effects', 'Kaplan-Meier Estimate', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', 'Niacinamide/administration & dosage/adverse effects/analogs & derivatives', '*Pyrazoles/administration & dosage/adverse effects', '*Tyrosine Kinase Inhibitors/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38820078/
1711,Imatinib,34002056,Kinase drug discovery 20 years after imatinib: progress and future directions.,"['Cohen P', 'Cross D', 'Janne PA']","['Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Drug Delivery Systems', 'Drug Discovery/*trends', 'Drug Resistance, Neoplasm', 'Humans', 'Imatinib Mesylate/pharmacology/*therapeutic use', 'Protein Kinase Inhibitors/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34002056/
1712,Imatinib,38722621,Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.,"['Jabbour E', 'Kantarjian HM', 'Aldoss I', 'Montesinos P', 'Leonard JT', 'Gomez-Almaguer D', 'Baer MR', 'Gambacorti-Passerini C', 'McCloskey J', 'Minami Y', 'Papayannidis C', 'Rocha V', 'Rousselot P', 'Vachhani P', 'Wang ES', 'Wang B', 'Hennessy M', 'Vorog A', 'Patel N', 'Yeh T', 'Ribera JM']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Young Adult', '*Antineoplastic Agents/therapeutic use/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Fusion Proteins, bcr-abl/genetics', '*Imatinib Mesylate/therapeutic use/adverse effects', '*Imidazoles/therapeutic use/adverse effects/administration & dosage', 'Philadelphia Chromosome', '*Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy/genetics', 'Progression-Free Survival', 'Protein Kinase Inhibitors/therapeutic use/adverse effects', '*Pyridazines/therapeutic use/adverse effects', 'Remission Induction', 'Adolescent']",https://pubmed.ncbi.nlm.nih.gov/38722621/
1713,Imatinib,33768564,Imatinib-induced eruptive nevi.,"['Hamie L', 'Sawaya RT', 'Abbas O']","['Adolescent', 'Humans', 'Male', '*Antineoplastic Agents/adverse effects/therapeutic use', '*Imatinib Mesylate/adverse effects/therapeutic use', '*Nevus, Pigmented/chemically induced/pathology', 'Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy', 'Protein Kinase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33768564/
1714,Imatinib,30504305,The argument for using imatinib in CML.,"['Claudiani S', 'Apperley JF']","['Clinical Trials as Topic', 'Humans', 'Imatinib Mesylate/adverse effects/*therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy', '*Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/30504305/
1715,Imatinib,38884296,[IMATINIB INDUCED EDEMA].,"['Olshanskiy D', 'Ben Varon H', 'Mouallem M']","['Humans', '*Imatinib Mesylate/adverse effects/administration & dosage', '*Edema/chemically induced', '*Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy', '*Protein Kinase Inhibitors/adverse effects/administration & dosage', '*Antineoplastic Agents/adverse effects/administration & dosage', 'Male', 'Middle Aged', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38884296/
1716,Imatinib,30199910,[Chronic Myelogenous Leukemia].,"['Hochhaus A', 'Eigendorff E', 'Ernst T']","['Aniline Compounds/adverse effects/therapeutic use', 'Antineoplastic Agents/adverse effects/*therapeutic use', 'Blast Crisis/drug therapy', 'Cytogenetic Analysis', 'Dasatinib/adverse effects/therapeutic use', 'Drug Monitoring', 'Female', 'Humans', 'Imatinib Mesylate/adverse effects/therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/diagnosis/*drug therapy/genetics', 'Mutation/drug effects', 'Nitriles/adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Hematologic/*drug therapy', 'Pregnancy Complications, Neoplastic/*drug therapy', 'Prognosis', 'Protein Kinase Inhibitors/adverse effects/*therapeutic use', 'Protein-Tyrosine Kinases/antagonists & inhibitors', 'Pyrimidines/adverse effects/therapeutic use', 'Quinolines/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30199910/
1717,Imatinib,35680144,Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension.,"['Galkin A', 'Sitapara R', 'Clemons B', 'Garcia E', 'Kennedy M', 'Guimond D', 'Carter LL', 'Douthitt A', 'Osterhout R', 'Gandjeva A', 'Slee D', 'Salter-Cid L', 'Tuder RM', 'Zisman LS']","['Rats', 'Humans', 'Animals', '*Pulmonary Arterial Hypertension', 'Imatinib Mesylate/pharmacology/metabolism/therapeutic use', 'Monocrotaline', '*Hypertension, Pulmonary', 'Familial Primary Pulmonary Hypertension', 'Pulmonary Artery', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Hypoxia', '*MicroRNAs/metabolism', 'Disease Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/35680144/
1718,Imatinib,38634915,Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.,"['Jain AG', 'Gesiotto Q', 'Ball S', 'Nodzon L', 'Rodriguez A', 'Chan O', 'Padron E', 'Kuykendall A', 'Komrokji R', 'Sallman DA', 'Lancet JE', 'Pinilla-Ibarz J', 'Sweet K']","['Humans', '*Dasatinib/adverse effects/administration & dosage/therapeutic use', 'Male', 'Female', 'Middle Aged', '*Protein Kinase Inhibitors/adverse effects/therapeutic use/administration & dosage', 'Aged', '*Pleural Effusion/chemically induced/epidemiology', 'Adult', 'Incidence', 'Leukemia, Myeloid, Chronic-Phase/drug therapy', 'Aged, 80 and over', 'Quinolines/adverse effects/administration & dosage/therapeutic use', 'Nitriles/adverse effects/therapeutic use', 'Drug Substitution', 'Aniline Compounds/adverse effects/therapeutic use/administration & dosage', 'Imatinib Mesylate/adverse effects/administration & dosage/therapeutic use', 'Young Adult', 'Retrospective Studies', 'Pyrimidines/adverse effects/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38634915/
1719,Imatinib,31155535,[Toward Personalized Cancer Therapy with Oral Molecular-targeted Agents].,"['Yamaguchi H', 'Takasaki S', 'Kikuchi M', 'Kawasaki Y', 'Arai Y', 'Mano N']","['Administration, Oral', 'Antineoplastic Agents/*administration & dosage/*adverse effects/pharmacokinetics', 'Asian People', 'Carcinoma, Renal Cell/*drug therapy', 'Drug Monitoring', 'Humans', 'Imatinib Mesylate/administration & dosage/adverse effects/pharmacokinetics', 'Kidney Neoplasms/*drug therapy', '*Molecular Targeted Therapy', '*Precision Medicine/methods', 'Sunitinib/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/31155535/
1720,Imatinib,32166445,Towards point of care systems for the therapeutic drug monitoring of imatinib.,"['Pearce CM', 'Resmini M']","['Antineoplastic Agents/administration & dosage/*blood/pharmacokinetics', 'Chromatography, Liquid/methods', 'Drug Monitoring/*instrumentation', 'Electrochemical Techniques/methods', 'Enzyme-Linked Immunosorbent Assay/methods', 'Humans', 'Imatinib Mesylate/administration & dosage/*blood/pharmacokinetics', 'Limit of Detection', '*Point-of-Care Systems', 'Protein Kinase Inhibitors/administration & dosage/*blood/pharmacokinetics', 'Reproducibility of Results', 'Spectrophotometry, Ultraviolet/methods', 'Spectrum Analysis, Raman/methods', 'Tandem Mass Spectrometry/methods']",https://pubmed.ncbi.nlm.nih.gov/32166445/
1721,Imatinib,26969425,[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].,"['Jovelet C', 'Broutin S', 'Gil S', 'Mir O', 'Paci A']","['Abnormalities, Drug-Induced', 'Adult', 'Antineoplastic Agents/*adverse effects/pharmacokinetics', 'Dasatinib/adverse effects', 'Erlotinib Hydrochloride/adverse effects', 'Female', 'Fetus/*drug effects', 'Gefitinib', 'Humans', 'Imatinib Mesylate/adverse effects/pharmacokinetics', 'Lapatinib', 'Maternal Age', 'Placenta/metabolism', 'Pregnancy', 'Pregnancy Complications, Neoplastic/*drug therapy/metabolism', 'Protein Kinase Inhibitors/*adverse effects/pharmacokinetics', 'Protein-Tyrosine Kinases/*antagonists & inhibitors/pharmacokinetics', 'Pyrimidines/adverse effects', 'Quinazolines/adverse effects', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/26969425/
1722,Imatinib,15796158,Clinical pharmacokinetics of imatinib mesylate.,"['Leveque D', 'Maloisel F']","['Administration, Oral', 'Antineoplastic Agents/administration & dosage/*pharmacokinetics', 'Benzamides', 'Drug Interactions', 'Enzyme Inhibitors/*therapeutic use', 'Gastrointestinal Neoplasms/*drug therapy', 'Humans', 'Imatinib Mesylate', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Piperazines/administration & dosage/*pharmacokinetics', 'Protein-Tyrosine Kinases/*antagonists & inhibitors', 'Pyrimidines/administration & dosage/*pharmacokinetics', 'Stromal Cells/drug effects']",https://pubmed.ncbi.nlm.nih.gov/15796158/
1723,Imatinib,29463446,How to treat chronic myeloid leukemia (CML) in older adults.,"['Luskin MR', 'DeAngelo DJ']","['Aged', 'Aniline Compounds/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Humans', 'Imatinib Mesylate/*administration & dosage/adverse effects', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy/genetics', 'Nitriles/*administration & dosage/adverse effects', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Protein-Tyrosine Kinases/*antagonists & inhibitors', 'Quinolines/*administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29463446/
1724,Imatinib,27100618,Recognizing Endocrinopathies Associated With Tyrosine Kinase Inhibitor Therapy in Children With Chronic Myelogenous Leukemia.,"['Samis J', 'Lee P', 'Zimmerman D', 'Arceci RJ', 'Suttorp M', 'Hijiya N']","['Adrenal Glands/drug effects', 'Aniline Compounds/adverse effects/therapeutic use', 'Antineoplastic Agents/adverse effects/therapeutic use', 'Bone Remodeling/drug effects', 'Child', 'Dasatinib/adverse effects/therapeutic use', 'Endocrine System/*drug effects/*pathology', 'Endocrine System Diseases/*chemically induced', 'Fusion Proteins, bcr-abl/antagonists & inhibitors', 'Glucose Metabolism Disorders/chemically induced', 'Humans', 'Imatinib Mesylate/adverse effects/therapeutic use', 'Imidazoles/adverse effects/therapeutic use', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Nitriles/adverse effects/therapeutic use', 'Protein Kinase Inhibitors/*adverse effects/*therapeutic use', 'Pyridazines/adverse effects/therapeutic use', 'Pyrimidines/adverse effects/therapeutic use', 'Quinolines/adverse effects/therapeutic use', 'Thyroid Gland/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27100618/
1725,Imatinib,35473395,Lichenoid drug eruption associated with imatinib mesylate therapy.,"['Alexandris D', 'Alevizopoulos N', 'Marinos L', 'Kanellis G', 'Gakiopoulou C']","['Humans', 'Imatinib Mesylate/adverse effects', '*Lichenoid Eruptions/chemically induced/diagnosis/pathology', '*Drug Eruptions/diagnosis/etiology', '*Lichen Planus/chemically induced', 'Protein Kinase Inhibitors/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35473395/
1726,Imatinib,28589771,Imatinib mesylate in desmoplastic small round cell tumors.,"['De Sanctis R', 'Bertuzzi A', 'Bisogno G', 'Carli M', 'Ferrari A', 'Comandone A', 'Santoro A']","['Adolescent', 'Adult', 'Child', 'Desmoplastic Small Round Cell Tumor/*drug therapy/*genetics/pathology', 'Female', 'Gene Expression Regulation, Neoplastic/drug effects', 'Humans', 'Imatinib Mesylate/*administration & dosage/adverse effects', 'Italy', 'Male', 'Patient Selection', 'Proto-Oncogene Proteins c-kit/antagonists & inhibitors/genetics', 'Receptor, Platelet-Derived Growth Factor alpha/antagonists & inhibitors/genetics', 'Treatment Failure', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28589771/
1727,Imatinib,38772691,Imatinib-induced ulcerative colitis.,"['Ma Z', 'Zhao J', 'Li S', 'Gao F', 'Zhang C', 'Wu L', 'Lin Y']","['Humans', '*Imatinib Mesylate/adverse effects/therapeutic use', '*Colitis, Ulcerative/drug therapy', 'Male', 'Middle Aged', '*Gastrointestinal Stromal Tumors/drug therapy', '*Antineoplastic Agents/adverse effects/therapeutic use', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Diarrhea/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/38772691/
1728,Imatinib,39102630,Asciminib monotherapy as frontline treatment of chronic-phase chronic myeloid leukemia: results from the ASCEND study.,"['Yeung DT', 'Shanmuganathan N', 'Reynolds J', 'Branford S', 'Walia M', 'Yong ASM', 'Shortt J', 'Chee L', 'Viiala N', 'Cunningham I', 'Ross DM', ""D'Souza A"", 'Wright M', 'Harrup R', 'Forsyth C', 'Filshie R', 'Lane S', 'Browett P', 'Grove C', 'Grigg AP', 'Hughes TP']","['Humans', 'Male', 'Middle Aged', 'Female', 'Aged', 'Adult', 'Aged, 80 and over', '*Leukemia, Myeloid, Chronic-Phase/drug therapy', 'Fusion Proteins, bcr-abl/antagonists & inhibitors/genetics', 'Young Adult', 'Antineoplastic Agents/therapeutic use/adverse effects', 'Protein Kinase Inhibitors/therapeutic use/adverse effects/administration & dosage', 'Pyrimidines/therapeutic use/adverse effects/administration & dosage', 'Treatment Outcome', 'Imatinib Mesylate/therapeutic use/adverse effects/administration & dosage', 'Follow-Up Studies', 'Niacinamide/analogs & derivatives', 'Pyrazoles']",https://pubmed.ncbi.nlm.nih.gov/39102630/
1729,Imatinib,31313559,Imatinib Mesylate Induced Erythroderma.,"['Lunge S', 'Bhise R']","['Antineoplastic Agents/*adverse effects', 'Dermatitis, Exfoliative/*chemically induced', 'Exanthema', 'Female', 'Humans', 'Imatinib Mesylate/*adverse effects', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/31313559/
1730,nortriptyline,36867173,Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.,"['Lenze EJ', 'Mulsant BH', 'Roose SP', 'Lavretsky H', 'Reynolds CF 3rd', 'Blumberger DM', 'Brown PJ', 'Cristancho P', 'Flint AJ', 'Gebara MA', 'Gettinger TR', 'Lenard E', 'Miller JP', 'Nicol GE', 'Oughli HA', 'Pham VT', 'Rollman BL', 'Yang L', 'Karp JF']","['Aged', 'Humans', '*Antidepressive Agents/adverse effects/therapeutic use', '*Aripiprazole/adverse effects/therapeutic use', '*Bupropion/adverse effects/therapeutic use', 'Depression', 'Drug Therapy, Combination', '*Nortriptyline/adverse effects/therapeutic use', '*Treatment Switching', '*Lithium Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36867173/
1731,nortriptyline,37696529,Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.,"['Lindson N', 'Theodoulou A', 'Ordonez-Mena JM', 'Fanshawe TR', 'Sutton AJ', 'Livingstone-Banks J', 'Hajizadeh A', 'Zhu S', 'Aveyard P', 'Freeman SC', 'Agrawal S', 'Hartmann-Boyce J']","['Adult', 'Female', 'Humans', 'Pregnancy', 'Bupropion/therapeutic use', '*Electronic Nicotine Delivery Systems', 'Network Meta-Analysis', 'Nicotine/adverse effects', 'Nortriptyline/therapeutic use', '*Smoking Cessation', 'Varenicline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37696529/
1732,nortriptyline,1390620,Drug-induced Creutzfeldt-Jakob like syndrome.,['Finelli PF'],"['Creutzfeldt-Jakob Syndrome/*chemically induced/diagnosis', 'Dementia/chemically induced/diagnosis', 'Depressive Disorder/*drug therapy', 'Electroencephalography/drug effects', 'Humans', 'Lithium/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Neuropsychological Tests', 'Nortriptyline/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1390620/
1733,nortriptyline,32539668,Sigma-1 receptor antagonists: promising players in fighting neuropathic pain.,"['Linciano P', 'Rossino G', 'Listro R', 'Rossi D', 'Collina S']","['Analgesics, Opioid/chemistry/pharmacology/therapeutic use', 'Animals', 'Humans', 'Methadone/chemistry/pharmacology/therapeutic use', 'Narcotic Antagonists/chemistry/pharmacology/*therapeutic use', 'Neuralgia/*drug therapy/metabolism', 'Nortriptyline/chemistry/pharmacology/therapeutic use', '*Patents as Topic/legislation & jurisprudence', 'Receptors, sigma/*antagonists & inhibitors/metabolism', 'Tramadol/chemistry/pharmacology/therapeutic use', 'Sigma-1 Receptor']",https://pubmed.ncbi.nlm.nih.gov/32539668/
1734,nortriptyline,30920402,Nortriptyline Abuse: A Case Report and Review of the Literature.,"['Miller JJ', 'Whiting WL', 'Catalano G', 'Sanchez DL']","['Aged', 'Alcoholism', 'Antidepressive Agents, Tricyclic/*adverse effects', 'Cholinergic Antagonists/adverse effects', 'Depressive Disorder/drug therapy', 'Humans', 'Male', 'Nortriptyline/*adverse effects', '*Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/30920402/
1735,nortriptyline,3900052,Nortriptyline pharmacokinetics and plasma levels: implications for clinical practice.,"['Rubin EH', 'Biggs JT', 'Preskorn SH']","['Age Factors', 'Aged', 'Antidepressive Agents, Tricyclic/blood/metabolism/therapeutic use', 'Depressive Disorder/*drug therapy/metabolism', 'Half-Life', 'Humans', 'Kinetics', 'Middle Aged', 'Nortriptyline/analogs & derivatives/blood/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3900052/
1736,nortriptyline,37155164,Effectiveness of Genotype-Specific Tricyclic Antidepressant Dosing in Patients With Major Depressive Disorder: A Randomized Clinical Trial.,"['Vos CF', 'Ter Hark SE', 'Schellekens AFA', 'Spijker J', 'van der Meij A', 'Grotenhuis AJ', 'Mihaescu R', 'Kievit W', 'Donders R', 'Aarnoutse RE', 'Coenen MJH', 'Janzing JGE']","['Humans', 'Female', 'Adult', 'Male', 'Antidepressive Agents, Tricyclic/therapeutic use', '*Depressive Disorder, Major/diagnosis', 'Antidepressive Agents/therapeutic use', 'Nortriptyline/therapeutic use', '*Drug-Related Side Effects and Adverse Reactions', 'Genotype']",https://pubmed.ncbi.nlm.nih.gov/37155164/
1737,nortriptyline,4074608,CSF and plasma levels of nortriptyline and its 10-hydroxy metabolite.,"['Nordin C', 'Bertilsson L', 'Siwers B']","['Aged', 'Depression/drug therapy', 'Humans', 'Middle Aged', 'Nortriptyline/*analogs & derivatives/blood/cerebrospinal fluid/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/4074608/
1738,nortriptyline,4607336,Variability in response to drugs.,['Rawlins MD'],"['Acute Disease', 'Acylation', 'Chlorthalidone/therapeutic use', 'Chronic Disease', 'Depression/drug therapy/etiology', 'Diazoxide/therapeutic use', 'Digoxin/administration & dosage/blood', '*Dose-Response Relationship, Drug', 'Glomerulonephritis/complications', 'Humans', 'Hypertension/drug therapy', 'Nephrotic Syndrome/etiology', 'Norepinephrine/metabolism', 'Nortriptyline/blood/therapeutic use/toxicity', 'Oxidation-Reduction', 'Phenylthiourea/administration & dosage', 'Serotonin/metabolism', 'Spironolactone/therapeutic use', 'Steroids/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4607336/
1739,nortriptyline,3893842,Discrepancies between pharmacokinetic studies of amitriptyline.,"['Schulz P', 'Dick P', 'Blaschke TF', 'Hollister L']","['Amitriptyline/administration & dosage/*metabolism/therapeutic use', 'Depressive Disorder/drug therapy', 'Half-Life', 'Humans', 'Kinetics', 'Models, Biological', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/3893842/
1740,nortriptyline,7203728,Pharmacokinetics of amitriptyline in the elderly.,"['Henry JF', 'Altamura C', 'Gomeni R', 'Hervy MP', 'Forette F', 'Morselli PL']","['Aged', 'Amitriptyline/adverse effects/*metabolism/pharmacology', 'Electrocardiography', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/7203728/
1741,nortriptyline,790409,Relationship between antidepressant effect and plasma level of nortriptyline. Clinical studies.,"['Kragh-Soorensen P', 'Hansen CE', 'Baastrup PC']","['Depression/drug therapy', 'Humans', 'Nortriptyline/administration & dosage/blood/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/790409/
1742,nortriptyline,6174553,The psychopharmacological treatment of obsessive-compulsive disorder: a review.,"['Insel TR', 'Murphy DL']","['Anti-Anxiety Agents/therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Clinical Trials as Topic', 'Clomipramine/adverse effects/therapeutic use', 'Double-Blind Method', 'Humans', 'Hydroxyindoleacetic Acid/cerebrospinal fluid', 'Nortriptyline/therapeutic use', 'Obsessive-Compulsive Disorder/diagnosis/*drug therapy', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/6174553/
1743,nortriptyline,6705454,Plasma 10-hydroxynortriptyline in elderly depressed patients.,"['Young RC', 'Alexopoulos GS', 'Shamoian CA', 'Manley MW', 'Dhar AK', 'Kutt H']","['Adolescent', 'Adult', 'Aged', 'Aging', 'Creatinine/blood', 'Depressive Disorder/drug therapy/*metabolism', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nortriptyline/*analogs & derivatives/blood/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6705454/
1744,nortriptyline,3518904,Clomipramine: an antiobsessive drug.,['Ananth J'],"['Anxiety/complications', 'Behavior Therapy', 'Clinical Trials as Topic', 'Clomipramine/administration & dosage/*therapeutic use', 'Compulsive Behavior/*drug therapy', 'Depressive Disorder/complications', 'Diazepam/administration & dosage', 'Haloperidol/administration & dosage', 'Humans', 'Imipramine/therapeutic use', 'Nortriptyline/administration & dosage', 'Obsessive Behavior/*drug therapy', 'Obsessive-Compulsive Disorder/diagnosis/*drug therapy', 'Phobic Disorders/complications', 'Psychological Tests']",https://pubmed.ncbi.nlm.nih.gov/3518904/
1745,nortriptyline,401340,The role of plasma concentrations in the use of tricyclic antidepressant drugs.,['Levine RR'],"['Amitriptyline/blood/pharmacokinetics/therapeutic use', 'Antidepressive Agents, Tricyclic/*blood/pharmacokinetics/therapeutic use', 'Depressive Disorder/blood/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Nortriptyline/blood/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/401340/
1746,nortriptyline,1133723,Comparison of observed and predicted bioavailability of nortriptyline in humans following oral administration.,['Gibaldi M'],"['Administration, Oral', '*Biological Availability', '*Biopharmaceutics', 'Blood Flow Velocity', 'Dose-Response Relationship, Drug', 'Humans', 'Liver/blood supply/metabolism', 'Nortriptyline/administration & dosage/*blood/metabolism']",https://pubmed.ncbi.nlm.nih.gov/1133723/
1747,nortriptyline,6148744,Antidepressant and antipsychotic plasma levels.,"['Boyer WF', 'Friedel RO']","['Amitriptyline/blood', 'Antidepressive Agents/administration & dosage/adverse effects/*blood', 'Antipsychotic Agents/administration & dosage/adverse effects/*blood', 'Chromatography/methods', 'Dose-Response Relationship, Drug', 'Humans', 'Imipramine/blood', 'Monitoring, Physiologic', 'Nortriptyline/blood']",https://pubmed.ncbi.nlm.nih.gov/6148744/
1748,nortriptyline,3985739,Nortriptyline-induced severe hyperventilation.,"['Sunderrajan S', 'Brooks CS', 'Sunderrajan EV']","['Alkalosis, Respiratory/blood/*chemically induced', 'Blood Gas Analysis', 'Humans', 'Male', 'Middle Aged', 'Nortriptyline/*adverse effects/blood']",https://pubmed.ncbi.nlm.nih.gov/3985739/
1749,nortriptyline,8179745,Aspiration of nortriptyline.,"['Johnson DR', 'Yew D']","['Adult', 'Bronchoscopy', 'Capsules', 'Emergencies', 'Female', '*Foreign Bodies', 'Humans', 'Lung/diagnostic imaging', 'Nortriptyline/administration & dosage/analysis/*blood', 'Radiography', '*Respiratory System']",https://pubmed.ncbi.nlm.nih.gov/8179745/
1750,sevoflurane,39436171,Research progress in the clinical application of inhaled anesthetic sevoflurane.,"['Wu H', 'Wang S', 'Dai FB', 'Tang CL']","['*Sevoflurane/pharmacology/administration & dosage', 'Humans', '*Anesthetics, Inhalation/administration & dosage/pharmacology', 'Methyl Ethers/administration & dosage/pharmacology', 'Asthma/drug therapy', 'Animals']",https://pubmed.ncbi.nlm.nih.gov/39436171/
1751,sevoflurane,32596964,Effects of propofol on the development of cancer in humans.,"['Xu Y', 'Pan S', 'Jiang W', 'Xue F', 'Zhu X']","['Anesthetics, Intravenous/pharmacology', 'Animals', 'Gene Expression Regulation, Neoplastic/*drug effects', 'Humans', 'Neoplasms/*drug therapy', 'Propofol/*pharmacology', 'Sevoflurane/*pharmacology', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32596964/
1752,sevoflurane,32588067,Inhalational volatile-based sedation for COVID-19 pneumonia and ARDS.,"['Jerath A', 'Ferguson ND', 'Cuthbertson B']","['Algorithms', '*Anesthetics, Inhalation/administration & dosage/adverse effects', 'Anesthetics, Intravenous/supply & distribution', '*Betacoronavirus', 'COVID-19', 'Coronavirus Infections/*complications', 'Humans', 'Hypnotics and Sedatives/*administration & dosage', 'Isoflurane', 'Pandemics', 'Pneumonia, Viral/complications/etiology/*therapy', 'Respiratory Distress Syndrome/etiology/*therapy', 'SARS-CoV-2', 'Sevoflurane/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32588067/
1753,sevoflurane,33419036,Molecular Diversity of Anesthetic Actions Is Evident in Electroencephalogram Effects in Humans and Animals.,"['Eagleman S', 'MacIver MB']","['Anesthesia/*methods', 'Anesthetics/*administration & dosage/classification', 'Animals', 'Electroencephalography/*drug effects', 'Humans', 'Ketamine/administration & dosage', 'Monitoring, Intraoperative/*methods', 'Propofol/administration & dosage', 'Remifentanil/administration & dosage', 'Sevoflurane/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/33419036/
1754,sevoflurane,39126872,Effect of remimazolam versus propofol on hypotension after anesthetic induction in patients undergoing coronary artery bypass grafting: A randomized controlled trial.,"['Ju JW', 'Lee DJ', 'Chung J', 'Lee S', 'Cho YJ', 'Jeon Y', 'Nam K']","['Humans', '*Propofol/administration & dosage/adverse effects', 'Male', 'Female', '*Coronary Artery Bypass/adverse effects', '*Hypotension/prevention & control', 'Middle Aged', 'Aged', '*Anesthetics, Intravenous/administration & dosage/adverse effects', 'Benzodiazepines/administration & dosage/adverse effects', 'Sevoflurane/administration & dosage/adverse effects', 'Arterial Pressure/drug effects', 'Consciousness Monitors', 'Coronary Artery Disease/surgery']",https://pubmed.ncbi.nlm.nih.gov/39126872/
1755,sevoflurane,36640476,Prolonged sedation with sevoflurane in comparison to intravenous sedation in critically ill patients - A randomized controlled trial.,"['Soukup J', 'Michel P', 'Christel A', 'Schittek GA', 'Wagner NM', 'Kellner P']","['Humans', '*Propofol/adverse effects', 'Sevoflurane', 'Anesthetics, Intravenous', 'Analgesics, Opioid', 'Respiration, Artificial', 'Prospective Studies', 'Critical Illness', 'Hypnotics and Sedatives']",https://pubmed.ncbi.nlm.nih.gov/36640476/
1756,sevoflurane,31613372,[Climate footprint of halogenated inhalation anesthetics].,"['Linden-Sonderso A', 'Nielsen N', 'Bentzer P']","['*Anesthetics, Inhalation/analysis/chemistry', 'Anesthetics, Intravenous/analysis/chemistry', '*Carbon Footprint', 'Desflurane/analysis/chemistry', 'Global Warming', 'Humans', 'Isoflurane/analysis/chemistry', 'Nitrous Oxide/analysis/chemistry', 'Propofol/administration & dosage/analysis/chemistry', 'Sevoflurane/analysis/chemistry', 'Sweden']",https://pubmed.ncbi.nlm.nih.gov/31613372/
1757,sevoflurane,10774610,Sevoflurane and anesthesia for neurosurgery: a review.,"['Duffy CM', 'Matta BF']","['*Anesthesia, Inhalation', '*Anesthetics, Inhalation/pharmacokinetics', 'Humans', 'Isoflurane', '*Methyl Ethers/pharmacokinetics', '*Neurosurgical Procedures', 'Sevoflurane']",https://pubmed.ncbi.nlm.nih.gov/10774610/
1758,sevoflurane,29733898,Intravenous dexmedetomidine augments the oculocardiac reflex.,"['Arnold RW', 'Biggs RE', 'Beerle BJ']","['Adrenergic alpha-2 Receptor Agonists/*adverse effects', 'Anesthetics, Inhalation/administration & dosage', 'Child', 'Child, Preschool', 'Dexmedetomidine/*adverse effects', 'Electrocardiography', 'Female', 'Heart Rate', 'Humans', 'Injections, Intravenous', 'Male', 'Oculomotor Muscles/*surgery', '*Ophthalmologic Surgical Procedures', 'Reflex, Oculocardiac/*drug effects', 'Sevoflurane/administration & dosage', 'Strabismus/*surgery']",https://pubmed.ncbi.nlm.nih.gov/29733898/
1759,sevoflurane,27687440,Sevoflurane-induced arrhythmia in healthy adult.,"['Santos J', 'Santos V', 'Gago P', 'Cortez-Dias N']","['Adult', 'Anesthesia, Inhalation/*adverse effects', 'Anesthetics, Inhalation/administration & dosage/*adverse effects', 'Calcium/metabolism', 'Humans', 'Ion Channels/metabolism', 'Keloid/*surgery', 'Male', 'Methyl Ethers/administration & dosage/*adverse effects', 'Sevoflurane', 'Tachycardia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/27687440/
1760,sevoflurane,38195081,Effect of Volatile Anesthesia Versus Intravenous Anesthesia on Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy: A Randomized Clinical Trial.,"['Zhang YT', 'Chen Y', 'Shang KX', 'Yu H', 'Li XF', 'Yu H']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', 'Anesthesia, Inhalation/adverse effects', 'Anesthesia, Intravenous/adverse effects', '*Anesthetics, Inhalation/adverse effects/administration & dosage', '*Anesthetics, Intravenous/administration & dosage/adverse effects', '*Desflurane/administration & dosage', 'Esophageal Neoplasms/surgery', '*Esophagectomy/adverse effects', '*Lung Diseases/etiology', 'Minimally Invasive Surgical Procedures/adverse effects/methods', '*Postoperative Complications/prevention & control/etiology/epidemiology', '*Propofol/administration & dosage/adverse effects', '*Sevoflurane/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38195081/
1761,sevoflurane,33186346,Malignant hyperthermia syndrome: A rare entity.,"['Garcia-Muro C', 'Saenz-Moreno I', 'Riano-Mendez B', 'Gutierrez-Delgado JM', 'Valencia-Ramos J', 'Esteban-Zubero E']","['Adenoidectomy', '*Anesthetics, Inhalation/adverse effects', 'Child', 'Dantrolene/therapeutic use', 'Female', 'Humans', '*Malignant Hyperthermia/drug therapy/etiology', '*Sevoflurane/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33186346/
1762,sevoflurane,30366817,Pediatric Emergence Delirium: A Case Study.,"['Kamienski MC', 'McCartney MA', 'McLaughlin M', 'Pallaria T']","['Anesthetics, Inhalation/*administration & dosage/adverse effects', 'Child, Preschool', 'Emergence Delirium/*diagnosis/epidemiology/physiopathology', 'Humans', 'Male', 'Middle Ear Ventilation/methods', 'Sevoflurane/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30366817/
1763,sevoflurane,38777646,"Hypotension after general anaesthesia induction using remimazolam or propofol in geriatric patients undergoing sevoflurane anaesthesia with remifentanil: a single-centre, double-blind, randomised controlled trial.","['Takaki R', 'Yokose M', 'Mihara T', 'Saigusa Y', 'Tanaka H', 'Yamamoto N', 'Masui K', 'Goto T']","['Humans', 'Double-Blind Method', 'Female', '*Remifentanil/administration & dosage/adverse effects', 'Male', '*Propofol/adverse effects/administration & dosage', '*Hypotension/chemically induced/prevention & control/epidemiology', '*Anesthesia, General/adverse effects/methods', 'Aged, 80 and over', '*Sevoflurane/adverse effects/administration & dosage', 'Anesthetics, Inhalation/adverse effects', 'Anesthetics, Intravenous/adverse effects', 'Benzodiazepines/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38777646/
1764,sevoflurane,33956800,Machine learning of EEG spectra classifies unconsciousness during GABAergic anesthesia.,"['Abel JH', 'Badgeley MA', 'Meschede-Krasa B', 'Schamberg G', 'Garwood IC', 'Lecamwasam K', 'Chakravarty S', 'Zhou DW', 'Keating M', 'Purdon PL', 'Brown EN']","['Humans', '*Electroencephalography/methods', '*Machine Learning', '*Unconsciousness/chemically induced/physiopathology', '*Propofol/pharmacology/administration & dosage', 'Adult', 'Male', 'Female', 'Sevoflurane/pharmacology/administration & dosage', 'Middle Aged', 'Anesthetics, Intravenous/pharmacology/administration & dosage', 'Anesthesia/methods', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33956800/
1765,sevoflurane,19412157,A novel approach to reversal of neuromuscular blockade.,"['Della Rocca G', 'Pompei L']","['Adolescent', 'Adult', 'Androstanols/antagonists & inhibitors', 'Child', 'Cholinesterase Inhibitors/therapeutic use', 'Clinical Trials as Topic', 'Delayed Emergence from Anesthesia/*drug therapy', 'Humans', 'Methyl Ethers/pharmacokinetics', 'Neostigmine/therapeutic use', 'Neuromuscular Blockade/*adverse effects/methods', 'Neuromuscular Nondepolarizing Agents/adverse effects/antagonists & inhibitors/pharmacology', 'Paralysis/chemically induced/drug therapy', 'Rocuronium', 'Sevoflurane', 'Sugammadex', 'gamma-Cyclodextrins/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19412157/
1766,sevoflurane,37455474,Acute Fulminant Hepatic Failure Caused by Sevoflurane Linked to Influenza A.,"['Koker A', 'Arslan G', 'Ozden O', 'Karaarslan U', 'Koroglu T']","['Humans', 'Child, Preschool', 'Sevoflurane/adverse effects', '*Influenza, Human/complications/diagnosis/drug therapy', '*Liver Failure, Acute/chemically induced/diagnosis/surgery', '*Hepatitis', '*Chemical and Drug Induced Liver Injury']",https://pubmed.ncbi.nlm.nih.gov/37455474/
1767,sevoflurane,29745067,"Surgery for triple-negative breast cancer- does the type of anaesthesia have an influence on oxidative stress, inflammation, molecular regulators, and outcomes of disease?","['Lukoseviciene V', 'Tikuisis R', 'Dulskas A', 'Miliauskas P', 'Ostapenko V']","['Anesthesia/*adverse effects', 'Biomarkers, Tumor/genetics', 'Female', 'Humans', 'Inflammation/chemically induced/*drug therapy/genetics/pathology', 'Lymphatic Metastasis', 'Neoplasm Recurrence, Local/chemically induced/*drug therapy/genetics', 'Oxidative Stress/drug effects/genetics', 'Perioperative Period', 'Propofol/adverse effects/therapeutic use', 'Sevoflurane/adverse effects/therapeutic use', 'Treatment Outcome', 'Triple Negative Breast Neoplasms/classification/drug therapy/genetics/*surgery']",https://pubmed.ncbi.nlm.nih.gov/29745067/
1768,sevoflurane,31127152,Multi-timescale phase-amplitude couplings in transitions of anesthetic-induced unconsciousness.,"['Tsai FF', 'Fan SZ', 'Cheng HL', 'Yeh JR']","['Anesthetics, General/*adverse effects', 'Brain/*drug effects', 'Case-Control Studies', 'Electroencephalography', 'Humans', 'Sevoflurane/*adverse effects', 'Unconsciousness/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/31127152/
1769,sevoflurane,38152013,Diffuse alveolar hemorrhage following inhaled sevoflurane: A rare complication of inhalational anesthesia.,"['Baran Ketencioglu B', 'Hastekkesin M', 'Yetkin NA', 'Tutar N']","['Young Adult', 'Humans', 'Sevoflurane/adverse effects', 'Pulmonary Alveoli', 'Hemorrhage/chemically induced', '*Lung Diseases/complications', '*Anesthesia/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38152013/
1770,loxapine,6237317,Second-generation antidepressants.,"['Rudorfer MV', 'Golden RN', 'Potter WZ']","['Alprazolam', 'Amoxapine/pharmacology/therapeutic use', 'Antidepressive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzodiazepines/pharmacology', 'Bupropion', 'Citalopram', 'Clinical Trials as Topic', 'Dopamine/metabolism', 'Double-Blind Method', 'Humans', 'Maprotiline/adverse effects/analogs & derivatives/pharmacology', 'Nomifensine/pharmacology', 'Norepinephrine/metabolism', 'Propiophenones/therapeutic use', 'Propylamines/pharmacology', 'Seizures/chemically induced', 'Serotonin/metabolism', 'Trazodone/therapeutic use', 'Zimeldine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6237317/
1771,loxapine,34843030,New Antipsychotic Medications in the Last Decade.,"['Pahwa M', 'Sleem A', 'Elsayed OH', 'Good ME', 'El-Mallakh RS']","['Adult', '*Antipsychotic Agents/adverse effects', 'Humans', 'Olanzapine/therapeutic use', '*Psychotic Disorders/drug therapy', 'Risperidone/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34843030/
1772,loxapine,37581475,Improving the pharmacotherapeutic treatment of agitation associated with bipolar disorder.,"['Faden J', 'Goldberg JF', 'Citrome L']","['Humans', '*Bipolar Disorder/complications/drug therapy', '*Antipsychotic Agents', 'Psychomotor Agitation/drug therapy/etiology', '*Loxapine/therapeutic use', 'Administration, Inhalation']",https://pubmed.ncbi.nlm.nih.gov/37581475/
1773,loxapine,37062836,"KCNT2-Related Disorders: Phenotypes, Functional, and Pharmacological Properties.","['Cioclu MC', 'Mosca I', 'Ambrosino P', 'Puzo D', 'Bayat A', 'Wortmann SB', 'Koch J', 'Strehlow V', 'Shirai K', 'Matsumoto N', 'Sanders SJ', 'Michaud V', 'Legendre M', 'Riva A', 'Striano P', 'Muhle H', 'Pendziwiat M', 'Lesca G', 'Mangano GD', 'Nardello R', 'Lemke JR', 'Moller RS', 'Soldovieri MV', 'Rubboli G', 'Taglialatela M']","['Humans', 'HEK293 Cells', '*Neuroblastoma', 'Phenotype', 'Genotype', '*Intellectual Disability/drug therapy/genetics', 'Potassium Channels, Sodium-Activated/genetics']",https://pubmed.ncbi.nlm.nih.gov/37062836/
1774,loxapine,29952523,Update Psychopharmacotherapy.,['Laux G'],"['Antidepressive Agents/therapeutic use', 'Antipsychotic Agents/therapeutic use', 'Humans', 'Mental Disorders/drug therapy', 'Psychopharmacology/*trends', 'Psychotropic Drugs/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29952523/
1775,loxapine,33924111,The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review.,"['Pompili M', 'Ducci G', 'Galluzzo A', 'Rosso G', 'Palumbo C', 'De Berardis D']","['*Antipsychotic Agents/therapeutic use', '*Bipolar Disorder/drug therapy', 'Humans', '*Loxapine/therapeutic use', 'Psychomotor Agitation/drug therapy/etiology', '*Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33924111/
1776,loxapine,3345021,Amoxapine cardiotoxicity.,"['Munger MA', 'Effron BA']","['Adult', 'Amoxapine/*poisoning', 'Dibenzoxazepines/*poisoning', 'Electrocardiography', 'Emergencies', 'Female', 'Heart Arrest/*chemically induced', 'Humans', 'Tachycardia/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/3345021/
1777,loxapine,9294935,Neuroleptic-induced dysphagia.,"['Sokoloff LG', 'Pavlakovic R']","['Aged', 'Alzheimer Disease/complications', 'Antipsychotic Agents/*adverse effects', 'Deglutition Disorders/*chemically induced/complications/diagnosis', 'Fluoroscopy/methods', 'Haloperidol/*adverse effects', 'Humans', 'Male', 'Mental Disorders/drug therapy', 'Severity of Illness Index', 'Thioridazine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9294935/
1778,loxapine,3504556,Tardive myoclonus.,"['Little JT', 'Jankovic J']","['Dibenzoxazepines/*adverse effects', 'Dyskinesia, Drug-Induced/*etiology', 'Female', 'Humans', 'Loxapine/*adverse effects/therapeutic use', 'Middle Aged', 'Myoclonus/*chemically induced', 'Parkinson Disease, Secondary/chemically induced', 'Schizophrenia, Paranoid/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3504556/
1779,loxapine,25365434,Antipsychotic drugs and safety concerns for breast-feeding infants.,"['Parikh T', 'Goyal D', 'Scarff JR', 'Lippmann S']","['Antipsychotic Agents/adverse effects/metabolism/*pharmacology', '*Breast Feeding', 'Female', 'Humans', 'Milk, Human/*drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25365434/
1780,loxapine,36180017,Antipsychotic Safety in Liver Disease: A Narrative Review and Practical Guide for the Clinician.,"['Gunther M', 'Dopheide JA']","['Humans', '*Antipsychotic Agents/adverse effects', 'Risperidone/adverse effects', 'Olanzapine', '*Clozapine', '*Liver Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36180017/
1781,loxapine,21490598,Modelling schizophrenia using human induced pluripotent stem cells.,"['Brennand KJ', 'Simone A', 'Jou J', 'Gelboin-Burkhart C', 'Tran N', 'Sangar S', 'Li Y', 'Mu Y', 'Chen G', 'Yu D', 'McCarthy S', 'Sebat J', 'Gage FH']","['Adolescent', 'Adult', 'Antipsychotic Agents/pharmacology', 'Cell Differentiation', 'Cells, Cultured', 'Cellular Reprogramming/genetics', 'Child', 'Disks Large Homolog 4 Protein', 'Female', 'Fibroblasts/cytology', 'Gene Expression Profiling', '*Gene Expression Regulation/drug effects', 'Humans', 'Intracellular Signaling Peptides and Proteins/metabolism', 'Loxapine/pharmacology', 'Male', 'Membrane Proteins/metabolism', 'Models, Biological', 'Neurites', 'Neurons/*cytology/drug effects/*metabolism', 'Phenotype', 'Pluripotent Stem Cells/*cytology/*metabolism/pathology', 'Receptors, Glutamate/metabolism', 'Schizophrenia/*pathology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21490598/
1782,loxapine,28886752,Protocol for the management of psychiatric patients with psychomotor agitation.,"['Vieta E', 'Garriga M', 'Cardete L', 'Bernardo M', 'Lombrana M', 'Blanch J', 'Catalan R', 'Vazquez M', 'Soler V', 'Ortuno N', 'Martinez-Aran A']","['Aggression/psychology', 'Antipsychotic Agents/therapeutic use', '*Consensus', 'Disease Management', 'Humans', '*Practice Guidelines as Topic', 'Psychiatric Status Rating Scales', 'Psychiatry/standards', 'Psychomotor Agitation/*diagnosis/*drug therapy', 'Risk Factors', 'Spain']",https://pubmed.ncbi.nlm.nih.gov/28886752/
1783,loxapine,10340683,D2 and 5-HT2 receptor effects of antipsychotics: bridging basic and clinical findings using PET.,"['Remington G', 'Kapur S']","['Amoxapine/metabolism/pharmacology', 'Antipsychotic Agents/metabolism/*pharmacology/therapeutic use', 'Benzodiazepines', 'Dibenzothiazepines/metabolism/pharmacology', 'Dopamine Antagonists/*pharmacology', 'Haloperidol/metabolism/pharmacology', 'Humans', 'In Vitro Techniques', 'Loxapine/metabolism/pharmacology', 'Olanzapine', 'Pirenzepine/analogs & derivatives/metabolism/pharmacology', 'Quetiapine Fumarate', 'Receptors, Dopamine/*drug effects/metabolism', 'Receptors, Serotonin/*drug effects/metabolism', 'Risperidone/metabolism/pharmacology', 'Schizophrenia/drug therapy/metabolism', 'Serotonin Antagonists/*pharmacology', '*Tomography, Emission-Computed']",https://pubmed.ncbi.nlm.nih.gov/10340683/
1784,loxapine,38097097,Clinical effectiveness of pharmacological and non-pharmacological treatments for the management of anxiety in community dwelling people living with dementia: A systematic review and meta-analysis.,"['Nimmons D', 'Aker N', 'Burnand A', 'Jordan KP', 'Cooper C', 'Davies N', 'Manthorpe J', 'Chew-Graham CA', 'Kingstone T', 'Petersen I', 'Walters K']","['Humans', '*Independent Living', 'Olanzapine', 'Anxiety/therapy', 'Treatment Outcome', '*Dementia/complications/therapy']",https://pubmed.ncbi.nlm.nih.gov/38097097/
1785,loxapine,7028656,Evaluations of loxapine succinate in the ambulatory treatment of acute schizophrenic episodes.,"['Zisook S', 'Click MA Jr']","['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Ambulatory Care', 'Clinical Trials as Topic', 'Dibenzoxazepines/*therapeutic use', 'Dystonia/chemically induced', 'Female', 'Humans', 'Loxapine/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7028656/
1786,loxapine,33460070,How to treat mania.,"['Pacchiarotti I', 'Anmella G', 'Colomer L', 'Vieta E']","['*Antipsychotic Agents/therapeutic use', '*Bipolar Disorder/drug therapy', '*Clozapine/therapeutic use', 'Humans', 'Mania', 'Olanzapine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33460070/
1787,loxapine,29361326,Evidence-Based Review of Pharmacotherapy for Acute Agitation. Part 1: Onset of Efficacy.,['Zun LS'],"['Antipsychotic Agents/*pharmacology/therapeutic use', 'Aripiprazole/pharmacology/therapeutic use', 'Benzodiazepines/pharmacology/therapeutic use', 'Drug Therapy/*methods', 'Evidence-Based Practice/methods', 'Haloperidol/pharmacology/therapeutic use', 'Humans', 'Injections, Intramuscular/methods', 'Olanzapine', 'Psychomotor Agitation/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29361326/
1788,loxapine,7016801,Amoxapine: a review of literature.,"['Ban TA', 'Wilson WH', 'McEvoy JP']","['Amoxapine/metabolism/*pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Dibenzoxazepines/*pharmacology', 'Humans', 'Norepinephrine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/7016801/
1789,loxapine,29109161,Combating Multidrug-Resistant Pathogens with Host-Directed Nonantibiotic Therapeutics.,"['Andersson JA', 'Sha J', 'Kirtley ML', 'Reyes E', 'Fitts EC', 'Dann SM', 'Chopra AK']","['Acinetobacter baumannii/drug effects', 'Amoxapine/pharmacology', 'Animals', 'Anti-Bacterial Agents/*pharmacology', 'Cell Line', 'Disease Models, Animal', 'Doxapram/pharmacology', 'Drug Repositioning/methods', 'Drug Resistance, Multiple, Bacterial/*drug effects', 'Female', 'Klebsiella pneumoniae/drug effects', 'Levofloxacin/pharmacology', 'Macrophages/microbiology', 'Mice', 'Mice, Inbred C57BL', 'Plague/*drug therapy/microbiology', 'RAW 264.7 Cells', 'Trifluoperazine/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29109161/
1790,imipramine,1142523,Imipramine toxicity.,"['Rohner TJ Jr', 'Sanford EJ']","['Animals', 'Arrhythmias, Cardiac/chemically induced', 'Central Nervous System/*drug effects', 'Coma/chemically induced', 'Dogs', 'Dose-Response Relationship, Drug', 'Enuresis/*drug therapy', 'Heart/*drug effects', 'Humans', 'Imipramine/adverse effects/therapeutic use/*toxicity', 'Rats', 'Respiratory Insufficiency/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1142523/
1791,imipramine,7021449,Trazodone in depression.,['Wheatley D'],"['Adult', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/therapeutic use', 'Male', 'Middle Aged', 'Piperazines/*administration & dosage', 'Sleep Stages/drug effects', 'Trazodone/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7021449/
1792,imipramine,7002831,Viloxazine: a review of the literature.,"['Ban TA', 'McEvoy JP', 'Wilson WH']","['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Morpholines/*pharmacology', 'Viloxazine/adverse effects/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7002831/
1793,imipramine,1543251,The pharmacotherapy of minor depression.,"['Stewart JW', 'Quitkin FM', 'Klein DF']","['Antidepressive Agents, Tricyclic/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Fluoxetine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Imipramine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Monoamine Oxidase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1543251/
1794,imipramine,3930473,Treatment-emergent incontinence with lithium.,"['Rosenbaum JF', 'Pollack MH']","['Adult', 'Aged', 'Bipolar Disorder/*drug therapy', 'Female', 'Humans', 'Imipramine/therapeutic use', 'Lithium/administration & dosage/*adverse effects', 'Lithium Carbonate', 'Mandelic Acids/therapeutic use', 'Middle Aged', 'Muscle, Smooth/drug effects', 'Urinary Bladder/drug effects', 'Urinary Incontinence/*chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/3930473/
1795,imipramine,354920,Non-monoamine oxidase inhibitor antidepressants and epilepsy: a review.,['Trimble M'],"['Adult', 'Aged', 'Amines/metabolism', 'Animals', 'Anticonvulsants/administration & dosage/blood', 'Antidepressive Agents/*adverse effects', 'Antidepressive Agents, Tricyclic/adverse effects', 'Brain/drug effects/metabolism', 'Child', 'Electroencephalography', 'Epilepsy/*chemically induced/drug therapy', 'Humans', 'Imipramine/pharmacology', 'Seizures/chemically induced', 'Viloxazine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/354920/
1796,imipramine,8930024,Paroxetine shifts imipramine metabolism.,"['Albers LJ', 'Reist C', 'Helmeste D', 'Vu R', 'Tang SW']","['Adult', 'Antidepressive Agents, Tricyclic/blood/*metabolism/*therapeutic use', 'Cytochrome P-450 Enzyme System/metabolism', 'Depressive Disorder/blood/*drug therapy/psychology', 'Desipramine/metabolism', 'Drug Synergism', 'Humans', 'Imipramine/blood/*metabolism/*therapeutic use', 'Male', 'Middle Aged', 'Paroxetine/blood/pharmacokinetics/*pharmacology', 'Selective Serotonin Reuptake Inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8930024/
1797,imipramine,7908332,Combined behavioral therapy and pharmacotherapy of agoraphobia.,['Mavissakalian M'],"['Agoraphobia/psychology/*therapy', '*Behavior Therapy', 'Combined Modality Therapy', 'Desensitization, Psychologic', 'Follow-Up Studies', 'Humans', 'Imipramine/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/7908332/
1798,imipramine,6764165,Evaluation of amoxapine.,"['Kinney JL', 'Evans RL Jr']","['Amitriptyline/therapeutic use', '*Amoxapine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Animals', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', '*Dibenzoxazepines', 'Double-Blind Method', 'Humans', 'Imipramine/therapeutic use', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6764165/
1799,imipramine,6363397,Double-blind comparison of amoxapine and imipramine in the treatment of depressed patients.,"['Gelenberg AJ', 'Wojcik JD', 'Lydiard RB', 'McCormick MG', 'Falk WE', 'Hicks RH', 'Curren FC', 'Cohen BM']","['Adolescent', 'Adult', 'Ambulatory Care', 'Amoxapine/adverse effects/blood/*therapeutic use', 'Basal Ganglia Diseases/chemically induced', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Dibenzoxazepines/*therapeutic use', 'Double-Blind Method', 'Female', 'Galactorrhea/chemically induced', 'Humans', 'Imipramine/adverse effects/blood/*therapeutic use', 'Male', 'Middle Aged', 'Pregnancy', 'Prolactin/blood', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/6363397/
1800,imipramine,19882939,[Antidepressants in migraine prophylaxis].,['Nagata E'],"['Amitriptyline/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Depression/complications/drug therapy', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Migraine Disorders/complications/*prevention & control', 'Practice Guidelines as Topic', '*Premedication']",https://pubmed.ncbi.nlm.nih.gov/19882939/
1801,imipramine,7846193,Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. A controlled clinical study.,"['Lauritzen L', 'Bendsen BB', 'Vilmar T', 'Bendsen EB', 'Lunde M', 'Bech P']","['Aged', 'Cerebrovascular Disorders/*complications/psychology', 'Depressive Disorder/*drug therapy/*etiology', 'Desipramine/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Imipramine/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Mianserin/administration & dosage/adverse effects/*therapeutic use', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/7846193/
1802,imipramine,7072577,Enuresis.,['Agarwal A'],"['Adolescent', '*Behavior Therapy', 'Child', 'Child, Preschool', 'Enuresis/etiology/*therapy', 'Female', 'Humans', 'Hypnosis', 'Imipramine/adverse effects/*therapeutic use', 'Male', 'Psychotherapy', 'Sex Factors', 'Sleep Wake Disorders/complications', 'Socioeconomic Factors']",https://pubmed.ncbi.nlm.nih.gov/7072577/
1803,imipramine,1677479,The drug treatment of panic disorder.,"['Matuzas W', 'Jack E']","['Adolescent', 'Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Antidepressive Agents/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Anxiety Disorders/complications/diagnosis/*drug therapy', 'Benzodiazepines/therapeutic use', 'Child', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Imipramine/administration & dosage/adverse effects/*therapeutic use', '*Panic', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1677479/
1804,imipramine,804259,Imipramine and seizures.,"['Petti TA', 'Campbell M']","['Child, Preschool', 'Epilepsy/*chemically induced', 'Epilepsy, Absence/complications', 'Epilepsy, Tonic-Clonic/chemically induced', 'Humans', 'Imipramine/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Measles/complications', 'Schizophrenia, Childhood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/804259/
1805,imipramine,2647951,"Nocturnal enuresis: epidemiology, evaluation, and currently available treatment options.",['Rushton HG'],"['Adolescent', 'Age Factors', 'Behavior Therapy/methods', 'Child', 'Child, Preschool', 'Counseling', 'Enuresis/epidemiology/*therapy', 'Female', 'Humans', 'Imipramine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Urinary Bladder/physiology']",https://pubmed.ncbi.nlm.nih.gov/2647951/
1806,imipramine,1603294,Imipramine-induced jitteriness and decreased serum iron levels.,"['Yeragani VK', 'Pohl R', 'Balon R', 'Ramesh C', 'Weinberg P']","['Adult', '*Akathisia, Drug-Induced', 'Antidepressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Imipramine/*adverse effects/therapeutic use', 'Iron/*blood/metabolism', 'Male', 'Panic Disorder/diagnosis/drug therapy/etiology', 'Prospective Studies', 'Psychiatric Status Rating Scales', 'Psychomotor Agitation/complications/psychology']",https://pubmed.ncbi.nlm.nih.gov/1603294/
1807,imipramine,1430670,Imipramine and weight gain during the long-term treatment of recurrent depression.,"['Frank E', 'Kupfer DJ', 'Buhari A', 'McEachran AB', 'Grochocinski VJ']","['Adult', 'Body Mass Index', 'Depressive Disorder/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Imipramine/administration & dosage/*adverse effects', 'Long-Term Care', 'Male', 'Recurrence', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1430670/
1808,imipramine,8904989,Dosing issues in the pharmacotherapy of alcoholism.,['Mason BJ'],"['Administration, Oral', 'Adult', 'Alcoholism/psychology/*rehabilitation', 'Antidepressive Agents, Tricyclic/administration & dosage/adverse effects/pharmacokinetics', 'Comorbidity', 'Depressive Disorder/psychology/rehabilitation', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Imipramine/administration & dosage/adverse effects/pharmacokinetics', 'Male', 'Middle Aged', 'Naltrexone/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Narcotic Antagonists/*administration & dosage/adverse effects/pharmacokinetics', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/8904989/
1809,imipramine,23385211,Basic N-interlinked imipramines show apoptotic activity against malignant cells including Burkitt's lymphoma.,"['Bright SA', 'Brinko A', 'Larsen MT', 'Sinning S', 'Williams DC', 'Jensen HH']","['Antineoplastic Agents/*chemistry/*pharmacology', 'Apoptosis/drug effects', 'Burkitt Lymphoma/*drug therapy/metabolism/pathology', 'Cell Death/drug effects', 'Cell Line, Tumor', 'Cell Survival/drug effects', 'Humans', 'Imipramine/*analogs & derivatives/chemical synthesis/*pharmacology', 'Serotonin Plasma Membrane Transport Proteins/metabolism', 'Selective Serotonin Reuptake Inhibitors/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/23385211/
1810,temozolomide,34419533,Elucidating the mechanisms of Temozolomide resistance in gliomas and the strategies to overcome the resistance.,"['Tomar MS', 'Kumar A', 'Srivastava C', 'Shrivastava A']","['Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Drug Resistance, Neoplasm', 'Glioblastoma/*drug therapy', 'Glioma/*drug therapy', 'Humans', 'Temozolomide/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34419533/
1811,temozolomide,39079407,Framework nucleic acid-based nanoparticles enhance temozolomide sensitivity in glioblastoma.,"['Lan Y', 'Li X', 'Liu B', 'Lu J', 'Zuo B', 'Wang Y', 'Cao S', 'Fu X', 'Yue Q', 'Luo X', 'Zhong X', 'Dong Y', 'Wang Z', 'Yang T', 'Xie X', 'Zeng T', 'Zhang M', 'Wang Y', 'Shen Y', 'Zuo H', 'Zhao Y', 'Zhang C', 'Guo H']","['*Glioblastoma/drug therapy/pathology', '*Temozolomide/pharmacology/administration & dosage/therapeutic use', 'Humans', '*Brain Neoplasms/drug therapy/pathology/genetics', '*Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', '*Nanoparticles/chemistry', 'Animals', '*Blood-Brain Barrier/metabolism/drug effects', 'Drug Resistance, Neoplasm/drug effects', 'Cell Line, Tumor', 'RNA-Binding Proteins/metabolism', 'DNA Repair Enzymes/metabolism/genetics', 'DNA Modification Methylases/metabolism', 'Nucleolin', 'Phosphoproteins/metabolism', 'Tumor Suppressor Proteins/metabolism/genetics', 'RNA, Small Interfering/administration & dosage', 'Nucleic Acids', 'Peptides']",https://pubmed.ncbi.nlm.nih.gov/39079407/
1812,temozolomide,36805210,Modeling glioblastoma complexity with organoids for personalized treatments.,"['Pawlowski KD', 'Duffy JT', 'Babak MV', 'Balyasnikova IV']","['Humans', '*Glioblastoma/drug therapy', '*Brain Neoplasms/drug therapy/pathology', 'Temozolomide/pharmacology/therapeutic use', 'Cell Culture Techniques', 'Organoids/pathology', 'Cell Line, Tumor', 'Drug Resistance, Neoplasm', 'Tumor Microenvironment']",https://pubmed.ncbi.nlm.nih.gov/36805210/
1813,temozolomide,37697045,A designer peptide against the EAG2-Kvbeta2 potassium channel targets the interaction of cancer cells and neurons to treat glioblastoma.,"['Dong W', 'Fekete A', 'Chen X', 'Liu H', 'Beilhartz GL', 'Chen X', 'Bahrampour S', 'Xiong Y', 'Yang Q', 'Zhao H', 'Kong T', 'Morioka MS', 'Jung G', 'Kim JE', 'Schramek D', 'Dirks PB', 'Song Y', 'Kim TH', 'He Y', 'Wanggou S', 'Li X', 'Melnyk RA', 'Wang LY', 'Huang X']","['Humans', 'Mice', 'Animals', '*Glioblastoma/drug therapy', 'Temozolomide/pharmacology/therapeutic use', 'Ether-A-Go-Go Potassium Channels/therapeutic use', 'Disease Models, Animal', 'Peptides/therapeutic use', 'Neurons/pathology']",https://pubmed.ncbi.nlm.nih.gov/37697045/
1814,temozolomide,39461382,Novel strategies to overcome chemoresistance in human glioblastoma.,"['Tang Q', 'Ren T', 'Bai P', 'Wang X', 'Zhao L', 'Zhong R', 'Sun G']","['*Glioblastoma/drug therapy/metabolism', 'Humans', '*Drug Resistance, Neoplasm/drug effects/physiology', '*Temozolomide/pharmacology/therapeutic use', '*Brain Neoplasms/drug therapy/metabolism/pathology', 'Antineoplastic Agents, Alkylating/therapeutic use/pharmacology', 'Tumor Microenvironment/drug effects/physiology', 'Animals']",https://pubmed.ncbi.nlm.nih.gov/39461382/
1815,temozolomide,35738390,Brain Co-Delivery of Temozolomide and Cisplatin for Combinatorial Glioblastoma Chemotherapy.,"['Zou Y', 'Wang Y', 'Xu S', 'Liu Y', 'Yin J', 'Lovejoy DB', 'Zheng M', 'Liang XJ', 'Park JB', 'Efremov YM', 'Ulasov I', 'Shi B']","['Animals', 'Blood-Brain Barrier/metabolism', '*Brain Neoplasms/pathology', 'Cell Line, Tumor', 'Cisplatin/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', '*Glioblastoma/pathology', 'Mice', 'Temozolomide/pharmacology/therapeutic use', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/35738390/
1816,temozolomide,34274381,Antioxidant responses related to temozolomide resistance in glioblastoma.,"['Campos-Sandoval JA', 'Gomez-Garcia MC', 'Santos-Jimenez JL', 'Mates JM', 'Alonso FJ', 'Marquez J']","['Animals', 'Antineoplastic Agents, Alkylating/pharmacology/*therapeutic use', 'Antioxidants/*metabolism', 'Brain Neoplasms/drug therapy/*metabolism', 'Drug Resistance, Neoplasm/*drug effects/physiology', 'Glioblastoma/drug therapy/*metabolism', 'Humans', 'Neoplastic Stem Cells/drug effects/metabolism', 'Reactive Oxygen Species/antagonists & inhibitors/metabolism', 'Temozolomide/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34274381/
1817,temozolomide,38353396,Kinome-Wide Synthetic Lethal Screen Identifies PANK4 as a Modulator of Temozolomide Resistance in Glioblastoma.,"['Vella V', 'Ditsiou A', 'Chalari A', 'Eravci M', 'Wooller SK', 'Gagliano T', 'Bani C', 'Kerschbamer E', 'Karakostas C', 'Xu B', 'Zhang Y', 'Pearl FMG', 'Lopez G', 'Peng L', 'Stebbing J', 'Klinakis A', 'Giamas G']","['Humans', 'Temozolomide/pharmacology/therapeutic use', '*Glioblastoma/drug therapy/metabolism', 'Proteomics', 'Antineoplastic Agents, Alkylating/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', '*Brain Neoplasms/drug therapy/metabolism', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38353396/
1818,temozolomide,34678239,Comprehensive pharmacogenomics characterization of temozolomide response in gliomas.,"['Tong S', 'Wang Y', 'Wu J', 'Long J', 'Zhong P', 'Wang B']","['Brain Neoplasms/*drug therapy/*genetics', 'DNA Repair/genetics', 'Glioma/*drug therapy/*genetics', 'Humans', 'Pharmacogenetics', 'Polymorphism, Genetic', 'Temozolomide/*pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34678239/
1819,temozolomide,38448295,Identification of TMZ resistance-associated histone post-translational modifications in glioblastoma using multi-omics data.,"['Ye L', 'Gu L', 'Wang Y', 'Xing H', 'Li P', 'Guo X', 'Wang Y', 'Ma W']","['Humans', '*Glioblastoma/drug therapy/genetics', 'Temozolomide/pharmacology/therapeutic use', 'Histones', 'Multiomics', 'Protein Processing, Post-Translational', 'Sp1 Transcription Factor']",https://pubmed.ncbi.nlm.nih.gov/38448295/
1820,temozolomide,31984871,Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.,"['Rezaei V', 'Rabiee A', 'Khademi F']","['Antineoplastic Agents/administration & dosage/pharmacology/*therapeutic use', 'Blood-Brain Barrier/metabolism', 'Brain Neoplasms/*drug therapy/*pathology/therapy', 'Chemistry, Pharmaceutical/methods', 'Dendrimers/chemistry', 'Drug Carriers/chemistry', 'Environmental Exposure/adverse effects', 'Genetic Therapy/methods', 'Glioblastoma/*drug therapy/*pathology/therapy', 'Humans', 'Hyperthermia, Induced/methods', 'Liposomes/chemistry', 'Micelles', 'Nanotechnology', 'Neoplastic Stem Cells/pathology', 'Radiation, Ionizing', 'Risk Factors', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31984871/
1821,temozolomide,30470397,Chemotherapy Treatment and Trials in Low-Grade Gliomas.,"['Donovan LE', 'Lassman AB']","['Brain Neoplasms/*therapy', '*Chemoradiotherapy', '*Drug Therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Glioma/*therapy', 'Humans', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30470397/
1822,temozolomide,36010607,Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.,"['Drakulic D', 'Schwirtlich M', 'Petrovic I', 'Mojsin M', 'Milivojevic M', 'Kovacevic-Grujicic N', 'Stevanovic M']","['*Brain Neoplasms/metabolism', '*Glioblastoma/metabolism', 'Humans', 'Signal Transduction', 'Temozolomide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36010607/
1823,temozolomide,35200546,Efficacy of Capecitabine and Temozolomide in Small Bowel (Midgut) Neuroendocrine Tumors.,"['Al-Toubah T', 'Morse B', 'Strosberg J']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Capecitabine/therapeutic use', 'Humans', '*Neuroendocrine Tumors/drug therapy/pathology', 'Retrospective Studies', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35200546/
1824,temozolomide,30171377,Targeting autophagy for combating chemoresistance and radioresistance in glioblastoma.,"['Taylor MA', 'Das BC', 'Ray SK']","['Antineoplastic Agents/pharmacology/*therapeutic use', 'Autophagosomes/metabolism', '*Autophagy/drug effects/radiation effects', 'Brain Neoplasms/pathology/*therapy', 'Cell Death/drug effects/radiation effects', '*Drug Resistance, Neoplasm/drug effects/radiation effects', 'Glioblastoma/pathology/*therapy', 'Humans', 'Radiation-Sensitizing Agents/pharmacology/therapeutic use', 'Temozolomide/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30171377/
1825,temozolomide,32463097,Temozolomide and etoposide combination for the treatment of relapsed osteosarcoma.,"['Akazawa R', 'Umeda K', 'Saida S', 'Kato I', 'Hiramatsu H', 'Sakamoto A', 'Arakawa Y', 'Sumiyoshi S', 'Okamoto T', 'Moritake H', 'Adachi S', 'Takita J']","['Adolescent', 'Adult', 'Antineoplastic Agents, Alkylating/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bone Neoplasms/*drug therapy', 'Child', 'Etoposide/*therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasm Recurrence, Local/*drug therapy', 'Osteosarcoma/*drug therapy', 'Prognosis', 'Retrospective Studies', 'Temozolomide/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32463097/
1826,temozolomide,34214730,Progress and prospect in tumor treating fields treatment of glioblastoma.,"['Liu S', 'Shi W', 'Zhao Q', 'Zheng Z', 'Liu Z', 'Meng L', 'Dong L', 'Jiang X']","['Animals', 'Antineoplastic Agents, Alkylating/administration & dosage/therapeutic use', 'Brain Neoplasms/drug therapy/surgery/*therapy', 'Chemoradiotherapy/trends', 'Combined Modality Therapy', 'Glioblastoma/drug therapy/surgery/*therapy', 'Humans', 'Neoplasm Recurrence, Local', 'Neurosurgical Procedures', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34214730/
1827,temozolomide,32347934,"Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.","['Hanna C', 'Kurian KM', 'Williams K', 'Watts C', 'Jackson A', 'Carruthers R', 'Strathdee K', 'Cruickshank G', 'Dunn L', 'Erridge S', 'Godfrey L', 'Jefferies S', 'McBain C', 'Sleigh R', 'McCormick A', 'Pittman M', 'Halford S', 'Chalmers AJ']","['Adult', 'Animals', 'Antineoplastic Agents, Alkylating/therapeutic use', '*Glioblastoma/drug therapy', 'Humans', 'Mice', 'Phthalazines/therapeutic use', 'Piperazines', 'Rats', 'Temozolomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32347934/
1828,temozolomide,37261804,Camrelizumab Plus Apatinib and Temozolomide as First-Line Treatment in Patients With Advanced Acral Melanoma: The CAP 03 Phase 2 Nonrandomized Clinical Trial.,"['Mao L', 'Lian B', 'Li C', 'Bai X', 'Zhou L', 'Cui C', 'Chi Z', 'Sheng X', 'Wang X', 'Tang B', 'Yan X', 'Li S', 'Kong Y', 'Dai J', 'Wei X', 'Li J', 'Duan R', 'Xu H', 'Wu X', 'Yang Y', 'Cheng F', 'Zhang C', 'Xia F', 'Pang Z', 'Guo J', 'Si L']","['Male', 'Humans', 'Middle Aged', 'Temozolomide/therapeutic use', '*Vascular Endothelial Growth Factor A', '*Melanoma/pathology', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects', 'Melanoma, Cutaneous Malignant']",https://pubmed.ncbi.nlm.nih.gov/37261804/
1829,temozolomide,37866459,Mitochondrial response of glioma cells to temozolomide.,"['Lenz LS', 'Torgo D', 'Buss JH', 'Pereira LC', 'Bueno M', 'Filippi-Chiela EC', 'Lenz G']","['Humans', 'Temozolomide/pharmacology/therapeutic use', 'Dacarbazine/pharmacology/metabolism/therapeutic use', 'Apoptosis', 'Cell Line, Tumor', '*Glioma/drug therapy/metabolism', 'Mitochondria/metabolism', 'Antineoplastic Agents, Alkylating/pharmacology', '*Brain Neoplasms/drug therapy/metabolism', 'Drug Resistance, Neoplasm']",https://pubmed.ncbi.nlm.nih.gov/37866459/
1830,fluconazole,10830059,Fluconazole.,"['Agrawal PB', 'Narang A', 'Kumar P']","['Antifungal Agents/adverse effects/*therapeutic use', 'Candidiasis/*drug therapy/mortality', 'Child', 'Child, Preschool', 'Fluconazole/adverse effects/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10830059/
1831,fluconazole,21498839,Candida urinary tract infections--treatment.,"['Fisher JF', 'Sobel JD', 'Kauffman CA', 'Newman CA']","['Algorithms', 'Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Azoles/therapeutic use', 'Candida/*drug effects/growth & development/pathogenicity', 'Candidiasis/microbiology/*therapy/urine', 'Candidiasis, Invasive/*diagnosis/microbiology', 'Causality', 'Echinocandins/therapeutic use', 'Fluconazole/administration & dosage/therapeutic use', 'Flucytosine/adverse effects/therapeutic use', 'Humans', 'Urinary Tract Infections/microbiology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/21498839/
1832,fluconazole,31287594,Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.,"['Taudorf EH', 'Jemec GBE', 'Hay RJ', 'Saunte DML']","['Administration, Oral', 'Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Cutaneous/*drug therapy', 'Clotrimazole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Fluconazole/administration & dosage/*therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Miconazole/administration & dosage/*therapeutic use', 'Nystatin/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31287594/
1833,fluconazole,36688321,Off-label treatments as potential accelerators in the search for the ideal antifungal treatment of cryptococcosis.,"['Alves V', 'Araujo GR', 'Frases S']","['Animals', 'Humans', 'Antifungal Agents/adverse effects', 'Off-Label Use', 'Fluconazole/pharmacology/therapeutic use', '*Cryptococcosis/drug therapy/microbiology', 'Amphotericin B/pharmacology', '*Cryptococcus neoformans']",https://pubmed.ncbi.nlm.nih.gov/36688321/
1834,fluconazole,8118162,Fluconazole: pharmacokinetics and indications.,['Montero-Gei F'],"['Animals', 'Fluconazole/metabolism/*pharmacokinetics/*therapeutic use', 'Humans', 'Mycoses/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8118162/
1835,fluconazole,26759844,Fluconazole use during breastfeeding.,"['Kaplan YC', 'Koren G', 'Ito S', 'Bozzo P']","['Antifungal Agents/*administration & dosage/adverse effects', 'Breast Diseases/drug therapy', '*Breast Feeding', 'Candidiasis/*drug therapy', 'Female', 'Fluconazole/*administration & dosage/adverse effects', 'Humans', 'Infant', 'Nipples/*microbiology']",https://pubmed.ncbi.nlm.nih.gov/26759844/
1836,fluconazole,12956199,The use of oral antifungal agents to treat onychomycosis.,"['Gupta AK', 'Ryder JE']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Drug Interactions', 'Fluconazole/administration & dosage/adverse effects/therapeutic use', 'Griseofulvin/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/adverse effects/therapeutic use', 'Ketoconazole/administration & dosage/adverse effects/therapeutic use', 'Naphthalenes/administration & dosage/adverse effects/therapeutic use', 'Onychomycosis/diagnosis/*drug therapy/microbiology/pathology', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/12956199/
1837,fluconazole,10423506,[Antifungal drugs for pediatric use].,['Nishimoto K'],"['Adult', '*Antifungal Agents/administration & dosage/adverse effects', 'Child', 'Fluconazole/administration & dosage/adverse effects', 'Humans', 'Infant', 'Infant, Newborn', 'Itraconazole/administration & dosage/adverse effects', 'Naphthalenes/administration & dosage/adverse effects', 'Terbinafine']",https://pubmed.ncbi.nlm.nih.gov/10423506/
1838,fluconazole,29896619,Oral Fluconazole in Pregnancy and Risk of Stillbirth and Neonatal Death.,"['Pasternak B', 'Wintzell V', 'Furu K', 'Engeland A', 'Neovius M', 'Stephansson O']","['Administration, Oral', 'Antifungal Agents/administration & dosage/*adverse effects', 'Cohort Studies', 'Female', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Infant, Newborn', 'Perinatal Death/*etiology', 'Pregnancy', 'Pregnancy Complications, Infectious/drug therapy', 'Propensity Score', 'Regression Analysis', 'Stillbirth/*epidemiology']",https://pubmed.ncbi.nlm.nih.gov/29896619/
1839,fluconazole,26938747,Fluconazole-Induced Type 1 Kounis Syndrome.,['Singh Mahal H'],"['Acute Coronary Syndrome/*chemically induced', 'Adult', 'Angina Pectoris/*chemically induced', 'Antifungal Agents/*adverse effects/therapeutic use', 'Drug Hypersensitivity/etiology', 'Eczema/drug therapy', 'Female', 'Fluconazole/*adverse effects/therapeutic use', 'Humans', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/26938747/
1840,fluconazole,20463252,Traditional and emerging antifungal therapies.,"['Arnold TM', 'Dotson E', 'Sarosi GA', 'Hage CA']","['Amphotericin B/administration & dosage/adverse effects', 'Anidulafungin', 'Antifungal Agents/administration & dosage/adverse effects/classification/*pharmacology/*therapeutic use', 'Caspofungin', 'Drug Therapy, Combination', 'Echinocandins/administration & dosage/pharmacology', 'Fluconazole/therapeutic use', 'Humans', 'Itraconazole/therapeutic use', 'Lipopeptides/administration & dosage', 'Micafungin', 'Pyrimidines/adverse effects', 'Triazoles/adverse effects/pharmacokinetics/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/20463252/
1841,fluconazole,25263725,Toxic epidermal necrolysis in a neonate receiving fluconazole.,"['Islam S', 'Singer M', 'Kulhanjian JA']","['Disease Progression', 'Fatal Outcome', 'Female', 'Fluconazole/administration & dosage/*adverse effects', 'Humans', 'Infant, Newborn', '*Infant, Premature', 'Infant, Premature, Diseases/diagnosis/*drug therapy', 'Intensive Care Units, Neonatal', 'Liver Diseases/diagnosis/drug therapy', 'Multiple Organ Failure', 'Rare Diseases', 'Severity of Illness Index', 'Stevens-Johnson Syndrome/*etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/25263725/
1842,fluconazole,2191444,Prophylaxis of candidiasis in cancer patients.,"['Bodey GP', 'Samonis G', 'Rolston K']","['Adolescent', 'Adult', 'Aged', 'Candidiasis, Oral/*prevention & control', 'Double-Blind Method', 'Female', 'Fluconazole/adverse effects/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/*complications', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/2191444/
1843,fluconazole,38392866,Antifungal Resistance in Cryptococcal Infections.,"['Melhem MSC', 'Leite Junior DP', 'Takahashi JPF', 'Macioni MB', 'Oliveira L', 'de Araujo LS', 'Fava WS', 'Bonfietti LX', 'Paniago AMM', 'Venturini J', 'Espinel-Ingroff A']","['*Antifungal Agents/therapeutic use/pharmacology', 'Humans', '*Drug Resistance, Fungal', '*Cryptococcosis/drug therapy', '*Cryptococcus neoformans/drug effects/genetics', '*Microbial Sensitivity Tests', 'Cryptococcus gattii/drug effects/genetics', 'Fluconazole/therapeutic use/pharmacology', 'Virulence']",https://pubmed.ncbi.nlm.nih.gov/38392866/
1844,fluconazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
1845,fluconazole,19519193,Fabrication and design of transdermal fluconazole spray.,"['Gohel MC', 'Nagori SA']","['Administration, Cutaneous', 'Adult', 'Animals', 'Antifungal Agents/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Camphor/administration & dosage/chemistry', 'Candida albicans/drug effects', 'Cellulose/administration & dosage/analogs & derivatives/chemistry', 'Drug Delivery Systems/*instrumentation/methods', 'Drug Stability', 'Equipment Design', 'Fluconazole/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Menthol/administration & dosage/chemistry', 'Middle Aged', 'Polyethylene Glycols/administration & dosage/chemistry', 'Rats', 'Skin Absorption', 'Tinea/*drug therapy/pathology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/19519193/
1846,fluconazole,15055139,[New therapeutical options for pulmonary fungal infections in non-neutropenic ICU-patients].,['Hohl R'],"['Amphotericin B/administration & dosage/pharmacology/therapeutic use', 'Antifungal Agents/*pharmacology/*therapeutic use', 'Caspofungin', 'Echinocandins', 'Fluconazole/administration & dosage/pharmacology/therapeutic use', 'Fungi/drug effects', 'Humans', '*Intensive Care Units', 'Lipopeptides', 'Lung Diseases, Fungal/*drug therapy/epidemiology/microbiology/pathology', 'Neutropenia/*complications', 'Peptides/administration & dosage/pharmacology/therapeutic use', '*Peptides, Cyclic', 'Pyrimidines/administration & dosage/pharmacology/therapeutic use', 'Risk Factors', 'Triazoles/administration & dosage/pharmacology/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/15055139/
1847,fluconazole,27333619,[CANDIDIASIS GASTROINTESTINAL TRACT].,"['Kozlova IV', 'Lekareva LI', 'Bykova AP', 'Myalina JN', 'Ostrovskaja LJ']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Candida/genetics/*isolation & purification/pathogenicity', 'Candidiasis/*drug therapy/microbiology', 'Diagnosis, Differential', 'Drug Resistance, Fungal', 'Fluconazole/administration & dosage/*therapeutic use', 'Gastrointestinal Tract/drug effects/*microbiology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/27333619/
1848,fluconazole,23112430,Fixed drug eruption to fluconazole: a case report and review of literature.,"['Pai VV', 'Bhandari P', 'Kikkeri NN', 'Athanikar SB', 'Sori T']","['Adult', 'Antifungal Agents/*adverse effects', 'Drug Eruptions/*diagnosis/drug therapy', 'Fluconazole/*adverse effects', 'Humans', 'Male', 'Steroids/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/23112430/
1849,fluconazole,1897559,Fluconazole: a new triazole antifungal agent.,['Morrow JD'],"['Animals', '*Antifungal Agents', 'Candidiasis/drug therapy', 'Costs and Cost Analysis', 'Cryptococcosis/drug therapy', 'Fluconazole/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Meningitis/drug therapy', 'Mycoses/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1897559/
1850,enoxaparin,31673991,Safety and Efficacy of Enoxaparin in Pregnancy: A Systematic Review and Meta-Analysis.,"['Jacobson B', 'Rambiritch V', 'Paek D', 'Sayre T', 'Naidoo P', 'Shan J', 'Leisegang R']","['Anticoagulants/administration & dosage/adverse effects/*therapeutic use', 'Aspirin/therapeutic use', 'Enoxaparin/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Hemorrhage/chemically induced', 'Humans', 'Pregnancy', 'Pregnancy Complications/*epidemiology', 'Pregnancy Outcome/epidemiology', 'Venous Thromboembolism/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/31673991/
1851,enoxaparin,34297496,Abelacimab for Prevention of Venous Thromboembolism.,"['Verhamme P', 'Yi BA', 'Segers A', 'Salter J', 'Bloomfield D', 'Buller HR', 'Raskob GE', 'Weitz JI']","['Adult', 'Aged', 'Aged, 80 and over', 'Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use', 'Anticoagulants/administration & dosage/adverse effects/*therapeutic use', '*Arthroplasty, Replacement, Knee', 'Dose-Response Relationship, Drug', 'Enoxaparin/adverse effects/*therapeutic use', 'Factor XI/*antagonists & inhibitors/metabolism', 'Female', 'Hemorrhage/chemically induced', 'Humans', 'Infusions, Intravenous', 'Injections, Subcutaneous', 'Male', 'Middle Aged', 'Partial Thromboplastin Time', 'Postoperative Complications/*prevention & control', 'Venous Thromboembolism/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34297496/
1852,enoxaparin,12959635,Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice.,"['Fareed J', 'Hoppensteadt D', 'Walenga J', 'Iqbal O', 'Ma Q', 'Jeske W', 'Sheikh T']","['Age Factors', 'Anticoagulants/*pharmacokinetics/pharmacology/therapeutic use', 'Biological Availability', 'Clinical Trials as Topic', 'Enoxaparin/*pharmacokinetics/pharmacology/therapeutic use', 'Female', 'Half-Life', 'Humans', 'Obesity/metabolism', 'Pregnancy', 'Renal Insufficiency/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12959635/
1853,enoxaparin,34780683,Milvexian for the Prevention of Venous Thromboembolism.,"['Weitz JI', 'Strony J', 'Ageno W', 'Gailani D', 'Hylek EM', 'Lassen MR', 'Mahaffey KW', 'Notani RS', 'Roberts R', 'Segers A', 'Raskob GE']","['Administration, Oral', 'Aged', 'Aged, 80 and over', 'Anticoagulants/adverse effects/*therapeutic use', '*Arthroplasty, Replacement, Knee', 'Dose-Response Relationship, Drug', 'Enoxaparin/adverse effects/therapeutic use', 'Factor XIa/*antagonists & inhibitors', 'Female', 'Humans', 'Male', 'Middle Aged', 'Postoperative Complications/*prevention & control', 'Pyrimidines/administration & dosage/adverse effects/*therapeutic use', 'Triazoles/administration & dosage/adverse effects/*therapeutic use', 'Venous Thromboembolism/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/34780683/
1854,enoxaparin,38402505,A systematic review of therapeutic enoxaparin dosing in obesity.,"['Chilbert MR', 'Zammit K', 'Ahmed U', 'Devlin A', 'Radparvar S', 'Schuler A', 'Woodruff AE']","['*Enoxaparin/administration & dosage/adverse effects', 'Humans', '*Obesity/drug therapy/complications', 'Body Mass Index', 'Anticoagulants/administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Factor Xa Inhibitors/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38402505/
1855,enoxaparin,24033757,What do we learn from repeated population analyses?,"['Duffull SB', 'Wright DF']","['Enoxaparin/*pharmacokinetics', 'Humans', '*Models, Biological']",https://pubmed.ncbi.nlm.nih.gov/24033757/
1856,enoxaparin,27624773,Heparin and Lovenox: What the Oral and Maxillofacial Surgeon Needs to Know.,"['Pasquale LD', 'Ferneini EM']","['Anticoagulants/*administration & dosage/therapeutic use', 'Enoxaparin/*administration & dosage/therapeutic use', 'Hemostasis, Surgical/*methods', 'Heparin/*administration & dosage/therapeutic use', 'Humans', 'Medication Therapy Management', '*Oral Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/27624773/
1857,enoxaparin,8979142,Prolonged prophylaxis against postoperative venous thromboembolism.,['Bergqvist D'],"['Adult', 'Aged', 'Aged, 80 and over', 'Anticoagulants/administration & dosage/therapeutic use', 'Disease Susceptibility', 'Double-Blind Method', 'Drug Administration Schedule', 'Enoxaparin/administration & dosage/therapeutic use', 'Female', 'Fibrinolytic Agents/administration & dosage/*therapeutic use', 'Hip Prosthesis/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/blood/surgery', 'Postoperative Complications/*prevention & control', 'Postoperative Period', 'Pulmonary Embolism/epidemiology/*prevention & control', 'Risk Factors', 'Sweden/epidemiology', 'Thrombophlebitis/epidemiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8979142/
1858,enoxaparin,26721520,New Oral Anticoagulants in Prophylaxis of Venous Thromboembolic Disease in Major Orthopedic Surgery.,['Rostagno C'],"['Administration, Oral', 'Anticoagulants/administration & dosage/adverse effects/*therapeutic use', 'Dabigatran/administration & dosage/adverse effects/therapeutic use', 'Enoxaparin/administration & dosage/adverse effects/therapeutic use', 'Fondaparinux', 'Hemorrhage/chemically induced', 'Heparin, Low-Molecular-Weight/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Orthopedic Procedures/*adverse effects', 'Polysaccharides/administration & dosage/adverse effects/therapeutic use', 'Rivaroxaban/administration & dosage/adverse effects/therapeutic use', 'Venous Thromboembolism/*etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/26721520/
1859,enoxaparin,25811446,Enoxaparin-induced unilateral hemotympanum.,"['Aydin U', 'Asik MB', 'Gokgoz MC', 'Karakoc O']","['Anticoagulants/administration & dosage/*therapeutic use', 'Ear Diseases/*chemically induced/etiology', 'Enoxaparin/administration & dosage/*therapeutic use', 'Female', 'Hemorrhage/*chemically induced/etiology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25811446/
1860,enoxaparin,21703676,"Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial.","['Aujesky D', 'Roy PM', 'Verschuren F', 'Righini M', 'Osterwalder J', 'Egloff M', 'Renaud B', 'Verhamme P', 'Stone RA', 'Legall C', 'Sanchez O', 'Pugh NA', ""N'gako A"", 'Cornuz J', 'Hugli O', 'Beer HJ', 'Perrier A', 'Fine MJ', 'Yealy DM']","['Acute Disease', 'Administration, Oral', '*Ambulatory Care', 'Anticoagulants/administration & dosage/adverse effects', 'Enoxaparin/administration & dosage/adverse effects', 'Female', 'Health Resources/statistics & numerical data', 'Hemorrhage/chemically induced', '*Hospitalization', 'Humans', 'Injections, Subcutaneous', 'Length of Stay', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Patient Readmission', 'Patient Satisfaction', 'Pulmonary Embolism/diagnosis/*drug therapy', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/21703676/
1861,enoxaparin,19087845,[Venous thromboembolism and immobilization for medical reason].,"['Villalba JC', 'Monreal M']","['Age Factors', 'Aged', 'Anticoagulants/administration & dosage/therapeutic use', 'Dalteparin/administration & dosage/therapeutic use', 'Enoxaparin/administration & dosage/therapeutic use', 'Female', 'Fibrinolytic Agents/administration & dosage/therapeutic use', 'Fondaparinux', 'Home Care Services', '*Hospitalization', 'Humans', 'Immobilization/*adverse effects', 'Male', 'Middle Aged', 'Polysaccharides/administration & dosage/therapeutic use', 'Prevalence', 'Pulmonary Embolism/epidemiology', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Time Factors', 'Venous Thromboembolism/*epidemiology/prevention & control', 'Venous Thrombosis/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/19087845/
1862,enoxaparin,18406991,"Heparins, low-molecular-weight heparins, and pentasaccharides: use in the older patient.","['Dinwoodey DL', 'Ansell JE']","['Aged', 'Anticoagulants/administration & dosage/pharmacokinetics/*therapeutic use', 'Arginine/analogs & derivatives', 'Enoxaparin/administration & dosage/therapeutic use', 'Fondaparinux', 'Heparin/*therapeutic use', 'Heparin, Low-Molecular-Weight/therapeutic use', 'Hirudins/administration & dosage', 'Humans', 'Pipecolic Acids/administration & dosage/therapeutic use', 'Polysaccharides/administration & dosage/*therapeutic use', 'Recombinant Proteins/administration & dosage', 'Sulfonamides']",https://pubmed.ncbi.nlm.nih.gov/18406991/
1863,enoxaparin,34192360,Acute localized exanthematous pustulosis caused by enoxaparin.,"['Mozafari N', 'Farjami M', 'Jamali E', 'Rostami H', 'Ketabi Y']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Adult', 'Anticoagulants/administration & dosage/*adverse effects', 'Enoxaparin/administration & dosage/*adverse effects', 'Female', 'Humans', 'Injections, Intradermal', 'Venous Thrombosis/prevention & control', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/34192360/
1864,enoxaparin,8979124,Comparison of the relative efficacy and safety of low molecular weight heparin and unfractionated heparin for the treatment of venous thrombosis.,['Hirsh J'],"['Adult', 'Anticoagulants/*therapeutic use', 'Double-Blind Method', 'Enoxaparin/administration & dosage/adverse effects/therapeutic use', 'Fibrinolytic Agents/*therapeutic use', 'Hemorrhage/chemically induced/epidemiology', 'Heparin/administration & dosage/adverse effects/*therapeutic use', 'Heparin, Low-Molecular-Weight/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Incidence', 'Infusions, Intravenous', 'Injections, Subcutaneous', 'Nadroparin/administration & dosage/adverse effects/therapeutic use', 'Partial Thromboplastin Time', 'Randomized Controlled Trials as Topic', 'Recurrence', 'Safety', 'Thromboembolism/epidemiology/*prevention & control', '*Thrombolytic Therapy', 'Thrombophlebitis/*drug therapy/mortality', 'Warfarin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8979124/
1865,enoxaparin,24721062,A world of low molecular weight heparins (LMWHs) enoxaparin as a promising moiety--a review.,"['Ingle RG', 'Agarwal AS']","['Anticoagulants/*therapeutic use', 'Blood Coagulation/*drug effects', 'Enoxaparin/*therapeutic use', 'Heparin, Low-Molecular-Weight/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/24721062/
1866,enoxaparin,23989356,Use of enoxaparin in end-stage renal disease.,"['Lai S', 'Coppola B']","['Enoxaparin/*administration & dosage/*therapeutic use', 'Female', 'Hemorrhage/*epidemiology', 'Heparin/*administration & dosage/*therapeutic use', 'Humans', 'Kidney Failure, Chronic/*complications', 'Male', 'Venous Thromboembolism/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/23989356/
1867,enoxaparin,27680213,Update on Brazilian biosimilar enoxaparins.,"['Vilanova E', 'Glauser BF', 'Oliveira SM', 'Tovar AM', 'Mourao PA']","['Anticoagulants/chemistry/*pharmacology/*therapeutic use', '*Biosimilar Pharmaceuticals', 'Brazil', 'Cost-Benefit Analysis', 'Enoxaparin/chemistry/*pharmacology/*therapeutic use', 'Humans', 'Thromboembolism/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27680213/
1868,enoxaparin,20423535,Adequate thromboprophylaxis in critically ill patients.,['Levi M'],"['Anticoagulants/administration & dosage/pharmacology', '*Critical Illness', 'Dose-Response Relationship, Drug', 'Enoxaparin/administration & dosage/pharmacology', 'Factor Xa/drug effects', 'Humans', 'Venous Thromboembolism/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/20423535/
1869,enoxaparin,29097086,Extended outpatient chemoprophylaxis reduces venous thromboembolism after radical cystectomy.,"['Schomburg J', 'Krishna S', 'Soubra A', 'Cotter K', 'Fan Y', 'Brown G', 'Konety B']","['Aged', 'Anticoagulants/administration & dosage/therapeutic use', 'Chemoprevention/*methods', 'Cystectomy/adverse effects/*methods', 'Enoxaparin/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Injections, Subcutaneous', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care/methods/statistics & numerical data', 'Outpatients/statistics & numerical data', 'Postoperative Complications/etiology/prevention & control', 'Prospective Studies', 'Venous Thromboembolism/etiology/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/29097086/
1870,OXCARBAZEPINE,27737595,Hyponatremia induced by antiepileptic drugs in patients with epilepsy.,"['Lu X', 'Wang X']","['Anticonvulsants/*adverse effects/therapeutic use', 'Carbamazepine/adverse effects/analogs & derivatives/therapeutic use', 'Epilepsy/*drug therapy', 'Humans', 'Hyponatremia/*chemically induced/epidemiology/therapy', 'Incidence', 'Oxcarbazepine', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/27737595/
1871,OXCARBAZEPINE,32822636,"Advances in diagnosis, classification, pathophysiology, and management of trigeminal neuralgia.","['Bendtsen L', 'Zakrzewska JM', 'Heinskou TB', 'Hodaie M', 'Leal PRL', 'Nurmikko T', 'Obermann M', 'Cruccu G', 'Maarbjerg S']","['Animals', 'Anticonvulsants/pharmacology/therapeutic use', 'Carbamazepine/pharmacology/therapeutic use', 'Decompression, Surgical/methods', '*Disease Management', 'Humans', 'Neuroimaging/methods', 'Oxcarbazepine/pharmacology/therapeutic use', 'Pain Measurement/drug effects/methods', 'Trigeminal Neuralgia/classification/*diagnostic imaging/*physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/32822636/
1872,OXCARBAZEPINE,34108244,Trigeminal neuralgia: a practical guide.,"['Lambru G', 'Zakrzewska J', 'Matharu M']","['Anticonvulsants/therapeutic use', 'Carbamazepine/therapeutic use', 'Humans', 'Magnetic Resonance Imaging', 'Oxcarbazepine/therapeutic use', '*Trigeminal Neuralgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34108244/
1873,OXCARBAZEPINE,31908187,Trigeminal neuralgia: An overview from pathophysiology to pharmacological treatments.,"['Gambeta E', 'Chichorro JG', 'Zamponi GW']","['Animals', 'Anticonvulsants/*administration & dosage', 'Baclofen/administration & dosage', 'Botulinum Toxins, Type A/administration & dosage', 'Carbamazepine/administration & dosage', 'Facial Pain/*drug therapy', 'Gabapentin/administration & dosage', 'Humans', 'Lamotrigine/administration & dosage', 'Oxcarbazepine/administration & dosage', 'Pain Management/methods', 'Phenytoin/administration & dosage', 'Pregabalin/administration & dosage', 'Quality of Life', 'Trigeminal Neuralgia/*drug therapy/*physiopathology/psychology']",https://pubmed.ncbi.nlm.nih.gov/31908187/
1874,OXCARBAZEPINE,38816415,Trigeminal neuralgia.,"['Ashina S', 'Robertson CE', 'Srikiatkhachorn A', 'Di Stefano G', 'Donnet A', 'Hodaie M', 'Obermann M', 'Romero-Reyes M', 'Park YS', 'Cruccu G', 'Bendtsen L']","['*Trigeminal Neuralgia/physiopathology/diagnosis/therapy/etiology', 'Humans', 'Carbamazepine/therapeutic use', 'Quality of Life/psychology', 'Oxcarbazepine/therapeutic use', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38816415/
1875,OXCARBAZEPINE,30860637,European Academy of Neurology guideline on trigeminal neuralgia.,"['Bendtsen L', 'Zakrzewska JM', 'Abbott J', 'Braschinsky M', 'Di Stefano G', 'Donnet A', 'Eide PK', 'Leal PRL', 'Maarbjerg S', 'May A', 'Nurmikko T', 'Obermann M', 'Jensen TS', 'Cruccu G']","['Analgesics/*therapeutic use', 'Carbamazepine/therapeutic use', '*Decompression, Surgical', 'Europe', 'Gabapentin/therapeutic use', 'Humans', '*Neurology', 'Oxcarbazepine/therapeutic use', 'Phenytoin/analogs & derivatives/therapeutic use', 'Trigeminal Neuralgia/diagnosis/surgery/*therapy']",https://pubmed.ncbi.nlm.nih.gov/30860637/
1876,OXCARBAZEPINE,29680205,Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry.,"['Tomson T', 'Battino D', 'Bonizzoni E', 'Craig J', 'Lindhout D', 'Perucca E', 'Sabers A', 'Thomas SV', 'Vajda F']","['Abnormalities, Drug-Induced/*epidemiology', 'Adult', 'Anticonvulsants/*therapeutic use', 'Carbamazepine/therapeutic use', 'Dose-Response Relationship, Drug', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Logistic Models', 'Male', 'Oxcarbazepine/therapeutic use', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Topiramate/therapeutic use', 'Valproic Acid/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29680205/
1877,OXCARBAZEPINE,33334546,Current role of carbamazepine and oxcarbazepine in the management of epilepsy.,"['Beydoun A', 'DuPont S', 'Zhou D', 'Matta M', 'Nagire V', 'Lagae L']","['Anticonvulsants/*therapeutic use', 'Carbamazepine/*therapeutic use', 'Epilepsy/*drug therapy', 'Epilepsy, Generalized/drug therapy', 'Humans', 'Oxcarbazepine/*therapeutic use', 'Topiramate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33334546/
1878,OXCARBAZEPINE,38870050,An update on pharmacotherapy for trigeminal neuralgia.,"['Pergolizzi JV Jr', 'LeQuang JA', 'El-Tallawy SN', 'Wagner M', 'Ahmed RS', 'Varrassi G']","['*Trigeminal Neuralgia/drug therapy', 'Humans', '*Anticonvulsants/therapeutic use', '*Carbamazepine/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Migraine Disorders/drug therapy', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38870050/
1879,OXCARBAZEPINE,38497990,Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.,"['Battino D', 'Tomson T', 'Bonizzoni E', 'Craig J', 'Perucca E', 'Sabers A', 'Thomas S', 'Alvestad S', 'Perucca P', 'Vajda F']","['Humans', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', 'Adult', 'Pregnancy', 'Young Adult', 'Adolescent', '*Epilepsy/drug therapy/epidemiology', '*Abnormalities, Drug-Induced/epidemiology/etiology', 'Middle Aged', 'Longitudinal Studies', '*Pregnancy Complications/drug therapy/epidemiology', 'Prospective Studies', 'Valproic Acid/adverse effects/therapeutic use', 'Prenatal Exposure Delayed Effects/epidemiology/chemically induced', 'Phenytoin/adverse effects/therapeutic use', 'Lamotrigine/adverse effects/therapeutic use', 'Carbamazepine/adverse effects', 'Phenobarbital/adverse effects/therapeutic use', 'Cohort Studies', 'Oxcarbazepine/adverse effects/therapeutic use', 'Prevalence']",https://pubmed.ncbi.nlm.nih.gov/38497990/
1880,OXCARBAZEPINE,35629976,Oxcarbazepine and Hyponatremia.,"['Ciauskaite J', 'Gelziniene G', 'Jurkeviciene G']","['Anticonvulsants/adverse effects', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', '*Hyponatremia/chemically induced/epidemiology', 'Oxcarbazepine/adverse effects', 'Retrospective Studies', 'Sodium']",https://pubmed.ncbi.nlm.nih.gov/35629976/
1881,OXCARBAZEPINE,37067807,Prenatal Exposure to Antiseizure Medication and Incidence of Childhood- and Adolescence-Onset Psychiatric Disorders.,"['Dreier JW', 'Bjork MH', 'Alvestad S', 'Gissler M', 'Igland J', 'Leinonen MK', 'Sun Y', 'Zoega H', 'Cohen JM', 'Furu K', 'Tomson T', 'Christensen J']","['Pregnancy', 'Child', 'Female', 'Male', 'Adolescent', 'Humans', 'Child, Preschool', 'Valproic Acid/therapeutic use', 'Lamotrigine/therapeutic use', 'Incidence', 'Levetiracetam/therapeutic use', 'Topiramate/therapeutic use', '*Prenatal Exposure Delayed Effects/chemically induced', 'Prospective Studies', 'Anticonvulsants/therapeutic use', '*Epilepsy/drug therapy', 'Oxcarbazepine/therapeutic use', 'Carbamazepine/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/37067807/
1882,OXCARBAZEPINE,10530693,Oxcarbazepine.,['Tecoma ES'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Biological Availability', 'Biotransformation', 'Carbamazepine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Controlled Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Humans', 'Oxcarbazepine', 'Phenytoin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10530693/
1883,OXCARBAZEPINE,26844734,Antiepileptic Drugs.,['Abou-Khalil BW'],"['Adult', 'Aged', 'Anticonvulsants/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Epilepsy/*diagnosis/*drug therapy', 'Female', 'Humans', 'Lamotrigine', 'Levetiracetam', 'Oxcarbazepine', 'Phenytoin/*adverse effects', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin/therapeutic use', 'Seizures/*chemically induced/*diagnosis', 'Triazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26844734/
1884,OXCARBAZEPINE,1408017,Drugs used in the management of trigeminal neuralgia.,"['Zakrzewska JM', 'Patsalos PN']","['Anticonvulsants/*administration & dosage/*pharmacokinetics', 'Baclofen/*administration & dosage', 'Carbamazepine/administration & dosage/analogs & derivatives/pharmacokinetics', 'Clonazepam/administration & dosage/pharmacokinetics', 'Humans', 'Oxcarbazepine', 'Phenytoin/administration & dosage/pharmacokinetics', 'Trigeminal Neuralgia/*drug therapy', 'Valproic Acid/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1408017/
1885,OXCARBAZEPINE,37929429,Anti-Seizure Monotherapy and Early Abortion Under Real-World Conditions.,"['Chen Y', 'Wu J', 'Zhang H', 'Chen H', 'Tian X', 'Jing W', 'Wang X']","['Pregnancy', 'Humans', 'Female', '*Anticonvulsants/adverse effects', '*Epilepsy/drug therapy', 'Lamotrigine/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Carbamazepine/therapeutic use', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37929429/
1886,OXCARBAZEPINE,35157004,Antiseizure Medication Concentrations During Pregnancy: Results From the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Study.,"['Pennell PB', 'Karanam A', 'Meador KJ', 'Gerard E', 'Kalayjian L', 'Penovich P', 'Matthews A', 'McElrath TM', 'Birnbaum AK']","['Adult', '*Anticonvulsants/adverse effects', 'Carbamazepine/therapeutic use', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lacosamide/therapeutic use', 'Lamotrigine/therapeutic use', 'Levetiracetam/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Pregnancy', 'Prospective Studies', 'Topiramate/therapeutic use', 'Zonisamide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35157004/
1887,OXCARBAZEPINE,11772334,Oxcarbazepine.,"['Beydoun A', 'Kutluay E']","['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/*therapeutic use', 'Carbamazepine/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Child', 'Cognition/drug effects', 'Epilepsy/*drug therapy/metabolism/psychology', 'Humans', 'Oxcarbazepine', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Trigeminal Nerve Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11772334/
1888,OXCARBAZEPINE,17367259,"Safety and efficacy of anticonvulsants in elderly patients with psychiatric disorders: oxcarbazepine, topiramate and gabapentin.","['Sommer BR', 'Fenn HH', 'Ketter TA']","['Aged', '*Amines/adverse effects/pharmacokinetics/therapeutic use', '*Anticonvulsants/adverse effects/pharmacokinetics/therapeutic use', 'Carbamazepine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', '*Cyclohexanecarboxylic Acids/adverse effects/pharmacokinetics/therapeutic use', 'Fructose/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Gabapentin', 'Humans', 'Mental Disorders/*drug therapy/metabolism/*psychology', 'Oxcarbazepine', 'Topiramate', '*gamma-Aminobutyric Acid/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17367259/
1889,OXCARBAZEPINE,32207738,[Pharmacoeconomic aspects of monotherapy of focal epilepsy].,"['Mkrtchyan VR', 'Kaimovsky IL']","['Adolescent', 'Adult', 'Anticonvulsants/administration & dosage/*economics/*therapeutic use', 'Carbamazepine', '*Cost-Benefit Analysis', '*Economics, Pharmaceutical', 'Epilepsies, Partial/*drug therapy/*economics', 'Humans', 'Lacosamide', 'Lamotrigine', 'Oxcarbazepine', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32207738/
1890,ADAPALENE,33751778,"Perioral dermatitis: Diagnosis, proposed etiologies, and management.","['Searle T', 'Ali FR', 'Al-Niaimi F']","['Anti-Bacterial Agents/therapeutic use', '*Dermatitis, Perioral/diagnosis/drug therapy/etiology', '*Dermatologic Agents/therapeutic use', 'Humans', 'Isotretinoin', 'Metronidazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33751778/
1891,ADAPALENE,34812859,Management of Acne Vulgaris: A Review.,"['Eichenfield DZ', 'Sprague J', 'Eichenfield LF']","['Acne Vulgaris/*drug therapy/pathology/therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzoyl Peroxide/administration & dosage', 'Child', 'Contraceptives, Oral, Combined/therapeutic use', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Retinoids/*administration & dosage', 'Salicylic Acid/administration & dosage', 'Spironolactone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34812859/
1892,ADAPALENE,38300170,Guidelines of care for the management of acne vulgaris.,"['Reynolds RV', 'Yeung H', 'Cheng CE', 'Cook-Bolden F', 'Desai SR', 'Druby KM', 'Freeman EE', 'Keri JE', 'Stein Gold LF', 'Tan JKL', 'Tollefson MM', 'Weiss JS', 'Wu PA', 'Zaenglein AL', 'Han JM', 'Barbieri JS']","['Humans', '*Acne Vulgaris/drug therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Adrenal Cortex Hormones/administration & dosage/therapeutic use', '*Anti-Bacterial Agents/administration & dosage/therapeutic use', '*Benzoyl Peroxide/administration & dosage/therapeutic use', 'Contraceptives, Oral, Combined/administration & dosage/therapeutic use', 'Cortodoxone/analogs & derivatives', '*Dermatologic Agents/administration & dosage/therapeutic use', '*Dicarboxylic Acids/administration & dosage/therapeutic use', '*Doxycycline/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine/standards', 'Injections, Intralesional', '*Isotretinoin/administration & dosage/therapeutic use', 'Minocycline/administration & dosage/therapeutic use', 'Propionates', 'Retinoids/administration & dosage/therapeutic use', '*Salicylic Acid/administration & dosage/therapeutic use', '*Spironolactone/administration & dosage/therapeutic use', 'Tetracyclines/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38300170/
1893,ADAPALENE,38154809,Managing acne vulgaris: an update.,"['Santer M', 'Burden-Teh E', 'Ravenscroft J']","['Humans', 'Female', '*Isotretinoin', '*Acne Vulgaris/drug therapy', 'Benzoyl Peroxide', 'Anti-Bacterial Agents/adverse effects', 'Adapalene']",https://pubmed.ncbi.nlm.nih.gov/38154809/
1894,ADAPALENE,36301760,Novel and emerging treatment options for acne vulgaris.,"['Auffret N', 'Claudel JP', 'Leccia MT', 'Ballanger F', 'Dreno B']","['Humans', 'Anti-Bacterial Agents/adverse effects', '*Acne Vulgaris/drug therapy', 'Benzoyl Peroxide/adverse effects', 'Adapalene', 'Propionibacterium acnes', '*Dermatologic Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36301760/
1895,ADAPALENE,36220974,Use of Retinoids in Topical Antiaging Treatments: A Focused Review of Clinical Evidence for Conventional and Nanoformulations.,"['Milosheska D', 'Roskar R']","['Humans', 'Retinoids/therapeutic use', '*Dermatologic Agents/therapeutic use', '*Cosmeceuticals/therapeutic use', 'Adapalene', 'Tretinoin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36220974/
1896,ADAPALENE,30674002,Topical Retinoids in Acne Vulgaris: A Systematic Review.,"['Kolli SS', 'Pecone D', 'Pona A', 'Cline A', 'Feldman SR']","['Acne Vulgaris/diagnosis/*drug therapy', 'Administration, Cutaneous', 'Administration, Oral', 'Anti-Bacterial Agents/*administration & dosage', 'Benzoyl Peroxide/*administration & dosage/adverse effects', 'Clinical Trials as Topic', 'Dermatologic Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Humans', 'Retinoids/*administration & dosage/adverse effects', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30674002/
1897,ADAPALENE,38428412,Retinoic acid receptor activation reprograms senescence response and enhances anti-tumor activity of natural killer cells.,"['Colucci M', 'Zumerle S', 'Bressan S', 'Gianfanti F', 'Troiani M', 'Valdata A', ""D'Ambrosio M"", 'Pasquini E', 'Varesi A', 'Cogo F', 'Mosole S', 'Dongilli C', 'Desbats MA', 'Contu L', 'Revankdar A', 'Chen J', 'Kalathur M', 'Perciato ML', 'Basilotta R', 'Endre L', 'Schauer S', 'Othman A', 'Guccini I', 'Saponaro M', 'Maraccani L', 'Bancaro N', 'Lai P', 'Liu L', 'Pernigoni N', 'Mele F', 'Merler S', 'Trotman LC', 'Guarda G', 'Cali B', 'Montopoli M', 'Alimonti A']","['Male', 'Humans', 'Animals', 'Mice', '*Cellular Senescence', '*Prostatic Neoplasms/drug therapy', 'Receptors, Retinoic Acid', 'Killer Cells, Natural', 'Adapalene']",https://pubmed.ncbi.nlm.nih.gov/38428412/
1898,ADAPALENE,38428411,Unleashing a safe and potent pro-senescence anti-tumor strategy.,"['Chen S', 'Sun B', 'Dong Z']","['Humans', 'Cell Line, Tumor', 'Docetaxel/pharmacology', 'Adapalene', '*Cellular Senescence']",https://pubmed.ncbi.nlm.nih.gov/38428411/
1899,ADAPALENE,32356369,"Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne.","['Liu H', 'Yu H', 'Xia J', 'Liu L', 'Liu GJ', 'Sang H', 'Peinemann F']","['Acne Vulgaris/*drug therapy', 'Adapalene/adverse effects/therapeutic use', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/therapeutic use', 'Benzoyl Peroxide/therapeutic use', 'Bias', 'Child', 'Clindamycin/adverse effects/therapeutic use', 'Dermatologic Agents/adverse effects/*therapeutic use', 'Dicarboxylic Acids/adverse effects/therapeutic use', 'Erythromycin/adverse effects/therapeutic use', 'Female', 'Glycolates/therapeutic use', 'Humans', 'Keratolytic Agents/therapeutic use', 'Male', 'Mandelic Acids/therapeutic use', 'Niacinamide/adverse effects/therapeutic use', 'Patient Dropouts/statistics & numerical data', 'Pyruvic Acid/adverse effects/therapeutic use', 'Quality of Life', 'Salicylic Acid/therapeutic use', 'Sulfur/therapeutic use', 'Tretinoin/therapeutic use', 'Young Adult', 'Zinc/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32356369/
1900,ADAPALENE,37683070,Topical Treatments for Photoaged Skin.,"['Sadick N', 'Pannu S', 'Abidi Z', 'Arruda S']","['Humans', '*Keratinocytes', 'Melanocytes', 'Retinoids/adverse effects', '*Skin', 'Tretinoin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37683070/
1901,ADAPALENE,37843943,Over-the-Counter Medications in Pregnancy.,"['Powers EA', 'Tewell R', 'Bayard M']","['Pregnancy', 'Female', 'Humans', 'Histamine Antagonists', 'Vomiting', 'Nausea', '*Rhinitis, Allergic', 'Administration, Intranasal', '*Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37843943/
1902,ADAPALENE,18046911,Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety.,"['Mukherjee S', 'Date A', 'Patravale V', 'Korting HC', 'Roeder A', 'Weindl G']","['Adapalene', 'Dermatologic Agents/pharmacology/therapeutic use', 'Dermis/drug effects', 'Epidermis/drug effects', 'Humans', 'Naphthalenes/pharmacology/therapeutic use', 'Nicotinic Acids/pharmacology/therapeutic use', 'Retinaldehyde/pharmacology/therapeutic use', 'Retinoids/adverse effects/*pharmacology/*therapeutic use', 'Skin Aging/*drug effects', 'Treatment Outcome', 'Tretinoin/pharmacology/therapeutic use', 'Vitamin A Deficiency/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18046911/
1903,ADAPALENE,32175593,Topical benzoyl peroxide for acne.,"['Yang Z', 'Zhang Y', 'Lazic Mosler E', 'Hu J', 'Li H', 'Zhang Y', 'Liu J', 'Zhang Q']","['Acne Vulgaris/complications/*drug therapy', 'Adolescent', 'Adult', 'Benzoyl Peroxide/*therapeutic use', 'Cicatrix/etiology/prevention & control', 'Dermatologic Agents/*therapeutic use', 'Female', 'Humans', 'Male', 'Randomized Controlled Trials as Topic', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32175593/
1904,ADAPALENE,38118404,Single-cell transcriptomics identifies adipose tissue CD271(+) progenitors for enhanced angiogenesis in limb ischemia.,"['Inoue O', 'Goten C', 'Hashimuko D', 'Yamaguchi K', 'Takeda Y', 'Nomura A', 'Ootsuji H', 'Takashima S', 'Iino K', 'Takemura H', 'Halurkar M', 'Lim HW', 'Hwa V', 'Sanchez-Gurmaches J', 'Usui S', 'Takamura M']","['Humans', 'Adapalene', '*Angiogenesis', '*Gene Expression Profiling', 'Adipose Tissue', 'Ischemia/genetics']",https://pubmed.ncbi.nlm.nih.gov/38118404/
1905,ADAPALENE,14738100,Axillary granular parakeratosis.,"['English JC 3rd', 'Derdeyn AS', 'Wilson WM', 'Patterson JW']","['Adapalene', 'Adult', 'Axilla', 'Dermatologic Agents/*therapeutic use', 'Female', 'Humans', 'Naphthalenes/*therapeutic use', 'Parakeratosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/14738100/
1906,ADAPALENE,34841914,Therapeutic Options for the Treatment of Darier's Disease: A Comprehensive Review of the Literature.,"['Hanna N', 'Lam M', 'Fleming P', 'Lynde CW']","['Acitretin/therapeutic use', 'Adapalene', '*Darier Disease/drug therapy', 'Humans', 'Isotretinoin/therapeutic use', 'Sunscreening Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34841914/
1907,ADAPALENE,17824582,Utilizing combination therapy for ethnic skin.,['Taylor SC'],"['Acne Vulgaris/complications/*drug therapy/*ethnology', 'Adapalene', 'Black or African American', 'Anti-Bacterial Agents/pharmacology/therapeutic use', 'Asian People', 'Benzoyl Peroxide/pharmacology/therapeutic use', 'Clindamycin/pharmacology/therapeutic use', 'Dermatologic Agents/pharmacology/therapeutic use', 'Dimethylpolysiloxanes/pharmacology', 'Drug Combinations', 'Drug Therapy, Combination', 'Glycerol/pharmacology', 'Hispanic or Latino', 'Humans', 'Hyperpigmentation/*drug therapy/ethnology/etiology/*prevention & control', 'Keratolytic Agents/pharmacology/therapeutic use', 'Naphthalenes/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic', 'Skin Pigmentation/*drug effects', 'Tretinoin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17824582/
1908,ADAPALENE,37276158,Ceramide-Containing Adjunctive Skin Care for Skin Barrier Restoration During Acne Vulgaris Treatment.,"['Draelos ZD', 'Baalbaki N', 'Colon G', 'Dreno B']","['Humans', '*Dermatologic Agents', 'Drug Combinations', 'Benzoyl Peroxide', '*Acne Vulgaris/drug therapy/pathology', 'Adapalene', 'Erythema/chemically induced/drug therapy', 'Skin Care', 'Double-Blind Method', 'Inflammation/drug therapy', 'Treatment Outcome', 'Gels/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37276158/
1909,ADAPALENE,32729430,Current Insights for the Management of Acne in the Modern Era.,"['Singh N', 'Singh A', 'Pandey K', 'Nimisha']","['Acne Vulgaris/*drug therapy/epidemiology/*etiology', 'Administration, Topical', 'Anti-Infective Agents/pharmacology/therapeutic use', 'Cosmetics/administration & dosage/pharmacology', 'Dermatologic Agents/administration & dosage/*pharmacology/therapeutic use', 'Drug Delivery Systems/*methods', 'Humans', 'Patents as Topic', 'Plant Extracts/administration & dosage/pharmacology', 'Plants, Medicinal', 'Tetracyclines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32729430/
1910,quetiapine,37149344,Pharmacotherapy for Treatment-Resistant Depression: Antidepressants and Atypical Antipsychotics.,"['Vas C', 'Jain A', 'Trivedi M', 'Jha MK', 'Mathew SJ']","['Humans', '*Antipsychotic Agents/adverse effects', '*Depressive Disorder, Major/drug therapy', 'Depression/drug therapy', 'Antidepressive Agents/adverse effects', 'Quetiapine Fumarate/therapeutic use', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/37149344/
1911,quetiapine,37792613,Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression.,"['Reif A', 'Bitter I', 'Buyze J', 'Cebulla K', 'Frey R', 'Fu DJ', 'Ito T', 'Kambarov Y', 'Llorca PM', 'Oliveira-Maia AJ', 'Messer T', 'Mulhern-Haughey S', 'Rive B', 'von Holt C', 'Young AH', 'Godinov Y']","['Humans', '*Antidepressive Agents/administration & dosage/adverse effects/therapeutic use', 'Delayed-Action Preparations', 'Depression/drug therapy', 'Drug Therapy, Combination', 'Nasal Sprays', '*Quetiapine Fumarate/administration & dosage/adverse effects/therapeutic use', 'Recurrence', '*Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Single-Blind Method', 'Treatment Outcome', '*Ketamine/administration & dosage/adverse effects/therapeutic use', '*Depressive Disorder, Treatment-Resistant/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37792613/
1912,quetiapine,36427216,Weak legs.,"['Timmons P', 'Williamson A', 'Gibbs V', 'Torgersen A']","['Female', 'Humans', 'Middle Aged', '*Leg', '*Paresis', 'Muscle Weakness/etiology', 'Clopidogrel', 'Quetiapine Fumarate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36427216/
1913,quetiapine,33941603,Quetiapine for primary insomnia: Consider the risks.,"['Modesto-Lowe V', 'Harabasz AK', 'Walker SA']","['*Antipsychotic Agents/adverse effects', 'Humans', 'Quetiapine Fumarate/adverse effects', '*Sleep Initiation and Maintenance Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33941603/
1914,quetiapine,36705012,Interventions for generalized anxiety disorder.,['Byrne GJ'],"['Humans', 'Quetiapine Fumarate/therapeutic use', '*COVID-19', 'Anxiety Disorders/drug therapy', 'Antidepressive Agents/therapeutic use', '*Cognitive Behavioral Therapy']",https://pubmed.ncbi.nlm.nih.gov/36705012/
1915,quetiapine,32513237,"Drug dosing in the critically ill obese patient-a focus on sedation, analgesia, and delirium.","['Erstad BL', 'Barletta JF']","['Analgesia/methods/*standards/statistics & numerical data', 'Analgesics, Non-Narcotic/administration & dosage/therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Benzodiazepines/administration & dosage/therapeutic use', 'Critical Illness/therapy', 'Deep Sedation/methods/*standards/statistics & numerical data', 'Delirium/*etiology', 'Dexmedetomidine/administration & dosage/therapeutic use', '*Dose-Response Relationship, Drug', 'Etomidate/administration & dosage/therapeutic use', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Ketamine/administration & dosage/therapeutic use', 'Obesity/drug therapy/*physiopathology', 'Pain Management/methods', 'Quetiapine Fumarate/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32513237/
1916,quetiapine,39234895,[Not Available].,"['Norup S', 'Rosenquist SB', 'Knudsen TR', 'Thorgaard MV']","['Humans', '*Quetiapine Fumarate/adverse effects', '*Urinary Retention/chemically induced', 'Female', '*Antipsychotic Agents/adverse effects/administration & dosage', 'Young Adult', 'Dibenzothiazepines/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39234895/
1917,quetiapine,33059460,Quetiapine withdrawal: A systematic review.,"['Monahan K', 'Cuzens-Sutton J', 'Siskind D', 'Kisely S']","['Anxiety Disorders', 'Humans', 'Psychomotor Agitation', '*Psychotic Disorders', 'Quetiapine Fumarate/adverse effects', '*Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/33059460/
1918,quetiapine,36463762,Effects of quetiapine on sleep: A systematic review and meta-analysis of clinical trials.,"['Lin CY', 'Chiang CH', 'Tseng MM', 'Tam KW', 'Loh EW']","['Humans', 'Aged', 'Quetiapine Fumarate/adverse effects', '*Depressive Disorder, Major/drug therapy', '*Antipsychotic Agents/adverse effects', 'Anxiety Disorders/drug therapy', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/36463762/
1919,quetiapine,28975049,Oculogyric Crises.,"['Solberg M', 'Koht J']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Dibenzocycloheptenes', 'Dystonic Disorders/*chemically induced', 'Heterocyclic Compounds, 4 or More Rings/adverse effects/therapeutic use', 'Humans', 'Male', 'Mental Disorders/drug therapy', 'Ocular Motility Disorders/*chemically induced', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28975049/
1920,quetiapine,32036034,Quetiapine-Induced Central Hypothyroidism.,"['Zenno A', 'Leschek E']","['Humans', '*Hypothyroidism/chemically induced', 'Quetiapine Fumarate/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32036034/
1921,quetiapine,38897219,Discontinuation Rate of Lurasidone and Quetiapine Extended Release in Bipolar Depression.,"['Kishi T', 'Sakuma K', 'Hamanaka S', 'Nishii Y', 'Iwata N']","['Humans', '*Quetiapine Fumarate/adverse effects/therapeutic use', '*Lurasidone Hydrochloride/adverse effects/therapeutic use', '*Bipolar Disorder/drug therapy', 'Male', 'Female', '*Antipsychotic Agents/adverse effects/therapeutic use/administration & dosage', '*Delayed-Action Preparations', 'Retrospective Studies', 'Middle Aged', 'Adult', 'Proportional Hazards Models', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/38897219/
1922,quetiapine,29372938,Second-Generation Antipsychotic-Induced Hypoglycemia.,"['Fujita T', 'Mizoguchi Y', 'Kunitake Y', 'Tateishi H', 'Inaba T', 'Kato TA', 'Monji A']","['Antidepressive Agents/adverse effects/therapeutic use', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Bipolar Disorder/blood/complications/diagnosis/drug therapy', 'Depressive Disorder, Major/blood/complications/diagnosis/drug therapy', 'Diagnostic Errors', 'Female', 'Humans', 'Hypoglycemia/blood/diagnosis/*etiology', 'Middle Aged', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29372938/
1923,quetiapine,33975574,Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis.,"['Kadakia A', 'Dembek C', 'Heller V', 'Singh R', 'Uyei J', 'Hagi K', 'Nosaka T', 'Loebel A']","['Adult', '*Antipsychotic Agents/adverse effects', 'Bayes Theorem', '*Bipolar Disorder/drug therapy', 'Depression', 'Humans', 'Network Meta-Analysis', 'Quetiapine Fumarate/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33975574/
1924,quetiapine,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
1925,quetiapine,26635371,Quetiapine-induced cervical dystonia.,"['Tso G', 'Kolur U']","['Antipsychotic Agents/*adverse effects', 'Female', 'Humans', 'Middle Aged', 'Psychotic Disorders/*drug therapy', 'Quetiapine Fumarate/*adverse effects', 'Torticollis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/26635371/
1926,quetiapine,9855315,"Quetiapine, an atypical antipsychotic.","['Goren JL', 'Levin GM']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Dibenzothiazepines/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Quetiapine Fumarate', 'Schizophrenia/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9855315/
1927,quetiapine,15729090,Quetiapine-induced myoclonus.,"['Velayudhan L', 'Kirchner V']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Dibenzothiazepines/administration & dosage/*adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Electrocardiography', 'Humans', 'Male', 'Middle Aged', 'Myoclonus/*chemically induced/physiopathology', 'Quetiapine Fumarate', 'Schizophrenia, Paranoid/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15729090/
1928,quetiapine,36513918,Implications of Adverse Outcomes Associated with Antipsychotics in Older Patients with Dementia: A 2011-2022 Update.,"['Rogowska M', 'Thornton M', 'Creese B', 'Velayudhan L', 'Aarsland D', 'Ballard C', 'Tsamakis K', 'Stewart R', 'Mueller C']","['Humans', 'Aged', '*Antipsychotic Agents/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', '*Psychotic Disorders/drug therapy', 'Quetiapine Fumarate/therapeutic use', '*Dementia/drug therapy/psychology', 'Benzodiazepines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/36513918/
1929,quetiapine,28806160,Delirium in hospitalized patients: Risks and benefits of antipsychotics.,"['Thom RP', 'Mock CK', 'Teslyar P']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Aripiprazole/adverse effects/therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Delirium/*drug therapy', 'Haloperidol/adverse effects/therapeutic use', 'Hospitalization', 'Humans', 'Olanzapine', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28806160/
1930,zopiclone,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
1931,zopiclone,18035234,Pharmacotherapy for insomnia.,"['Tariq SH', 'Pulisetty S']","['Antidepressive Agents/therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Central Nervous System Depressants/therapeutic use', 'Eszopiclone', 'GABA Agonists/therapeutic use', '*GABA-A Receptor Antagonists', 'Humans', 'Indenes/therapeutic use', 'Melatonin/therapeutic use', 'Phytotherapy', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Valerian', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18035234/
1932,zopiclone,24614774,Hypnotic hiccups.,"['Vorona RD', 'Szklo-Coxe M', 'Ware JC']","['Azabicyclo Compounds/*adverse effects', 'Eszopiclone', 'Female', 'Hiccup/*chemically induced', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Middle Aged', 'Piperazines/*adverse effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24614774/
1933,zopiclone,21786646,[Sleep and stress].,['Strygin KN'],"['Adaptation, Psychological/drug effects/physiology', 'Animals', 'Azabicyclo Compounds/therapeutic use', '*Circadian Rhythm', 'Humans', 'Piperazines/therapeutic use', 'Polysomnography', 'Sleep/drug effects/*physiology', 'Sleep Initiation and Maintenance Disorders/drug therapy/*etiology/physiopathology', '*Stress, Physiological', '*Stress, Psychological']",https://pubmed.ncbi.nlm.nih.gov/21786646/
1934,zopiclone,11816843,(S)-Zopiclone Sepracor.,['Georgiev V'],"['Animals', 'Azabicyclo Compounds', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacology/*therapeutic use', 'Piperazines/adverse effects/pharmacology/*therapeutic use', 'Sleep Wake Disorders/*drug therapy/psychology', 'Stereoisomerism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/11816843/
1935,zopiclone,27751669,Review of Safety and Efficacy of Sleep Medicines in Older Adults.,"['Schroeck JL', 'Ford J', 'Conway EL', 'Kurtzhalts KE', 'Gee ME', 'Vollmer KA', 'Mergenhagen KA']","['Aged', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27751669/
1936,zopiclone,38551874,[Pharmacotherapies for insomnia].,"['Vecchierini MF', 'Leger D']","['Adult', 'Humans', 'Middle Aged', '*Sleep Initiation and Maintenance Disorders/drug therapy', '*Melatonin/therapeutic use/adverse effects', 'Hypnotics and Sedatives/therapeutic use', 'Benzodiazepines/therapeutic use', 'Sleep', 'Antidepressive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38551874/
1937,zopiclone,15883924,Insomnia.,['Holzinger E'],"['Azabicyclo Compounds', 'Clinical Trials as Topic', 'Humans', 'Hypnotics and Sedatives/chemistry/economics/therapeutic use', 'Molecular Structure', 'Piperazines/chemistry/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/diagnosis/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/15883924/
1938,zopiclone,32858054,"Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences.","['Himmerich H', 'Kan C', 'Au K', 'Treasure J']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Avitaminosis', 'Clinical Decision-Making/methods', 'Drug Monitoring/methods', 'Feeding and Eating Disorders/*drug therapy/*epidemiology/physiopathology/psychology', 'Humans', 'Malnutrition/*drug therapy/*epidemiology', 'Mental Disorders/drug therapy/epidemiology', 'Patient Care Planning', 'Pharmacogenomic Testing/methods', 'Sleep Wake Disorders/drug therapy/epidemiology', 'Trace Elements/deficiency', 'Water-Electrolyte Balance/physiology']",https://pubmed.ncbi.nlm.nih.gov/32858054/
1939,zopiclone,21573250,Eszopiclone: an update on its use in insomnia.,['Owen RT'],"['Adult', 'Aged', 'Animals', 'Azabicyclo Compounds/adverse effects/chemistry/economics/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Cognition/drug effects', 'Drug Approval', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/adverse effects/chemistry/pharmacology/*therapeutic use', 'Japan', 'Memory/drug effects', 'Middle Aged', 'Piperazines/adverse effects/chemistry/economics/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep Apnea, Obstructive/drug therapy', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21573250/
1940,zopiclone,30303519,Eszopiclone for insomnia.,"['Rosner S', 'Englbrecht C', 'Wehrle R', 'Hajak G', 'Soyka M']","['Adult', 'Aged', 'Aged, 80 and over', 'Eszopiclone/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30303519/
1941,zopiclone,38630476,Treatment Failure and Long-Term Prescription Risk for Guideline-Recommended Hypnotics in Japan.,"['Takeshima M', 'Yoshizawa K', 'Ogasawara M', 'Kudo M', 'Itoh Y', 'Ayabe N', 'Mishima K']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', 'Eszopiclone', 'Hypnotics and Sedatives/adverse effects', '*Indenes', 'Japan', 'Retrospective Studies', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Failure', '*Triazolam', 'Zolpidem/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38630476/
1942,zopiclone,8853211,Polysomnographic effects of hypnotic drugs. A review.,"['Parrino L', 'Terzano MG']","['Adult', 'Anti-Anxiety Agents/pharmacology/*therapeutic use', 'Azabicyclo Compounds', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/pharmacology/*therapeutic use', 'Middle Aged', 'Piperazines/pharmacology/therapeutic use', 'Polysomnography/*drug effects', 'Pyridines/pharmacology/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/8853211/
1943,zopiclone,18044182,Eszopiclone for late-life insomnia.,"['McCrae CS', 'Ross A', 'Stripling A', 'Dautovich ND']","['Adult', 'Age of Onset', 'Aged', 'Aged, 80 and over', 'Azabicyclo Compounds/adverse effects/economics/*therapeutic use', 'Chronic Disease', 'Cognitive Behavioral Therapy', 'Drug Costs', 'Drug Interactions', 'Drug Tolerance', 'Eszopiclone', 'Humans', 'Hypnotics and Sedatives/adverse effects/economics/*therapeutic use', 'Middle Aged', 'Piperazines/adverse effects/economics/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy/epidemiology', 'Substance-Related Disorders/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18044182/
1944,zopiclone,28391425,"Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with Attention-Deficit/Hyperactivity Disorder: A Systematic Review with Methodological Quality Assessment.","['Anand S', 'Tong H', 'Besag FMC', 'Chan EW', 'Cortese S', 'Wong ICK']","['Attention Deficit Disorder with Hyperactivity/complications/*drug therapy/physiopathology', 'Child', 'Clonidine/therapeutic use', 'Eszopiclone/therapeutic use', 'Glutamates/therapeutic use', 'Guanfacine/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Observational Studies as Topic', 'Pyridines/therapeutic use', 'Randomized Controlled Trials as Topic', 'Sleep Initiation and Maintenance Disorders/complications/*drug therapy/physiopathology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/28391425/
1945,zopiclone,25115782,Severe agitation in depression precipitated by dasatinib.,"['Sami MB', 'Yousaf F', 'Fialho A']","['Azabicyclo Compounds/administration & dosage', 'Dasatinib', 'Depression/*complications/diagnosis/drug therapy', 'Diagnosis, Differential', 'Dose-Response Relationship, Drug', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Piperazines/administration & dosage', 'Protein-Tyrosine Kinases/antagonists & inhibitors', 'Psychomotor Agitation/diagnosis/drug therapy/*etiology', 'Pyrimidines/*adverse effects/therapeutic use', 'Thiazoles/*adverse effects/therapeutic use', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/25115782/
1946,zopiclone,16750956,"Insomnia in the elderly: cause, approach, and treatment.","['Kamel NS', 'Gammack JK']","['Acetamides/therapeutic use', 'Aged', '*Aging', 'Antidepressive Agents/therapeutic use', 'Azabicyclo Compounds', 'Behavior Therapy', 'Benzodiazepines/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Nonprescription Drugs/therapeutic use', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Receptor, Melatonin, MT1/agonists', 'Receptor, Melatonin, MT2/agonists', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/drug therapy/*etiology/physiopathology/*therapy', 'Sleep, REM/drug effects', 'Thiophenes/therapeutic use', 'Trazodone/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16750956/
1947,zopiclone,18800955,Which medications are safe and effective for improving sleep at high altitude?,['Luks AM'],"['Acetamides/therapeutic use', 'Acetazolamide/therapeutic use', 'Altitude Sickness/*physiopathology', 'Anti-Anxiety Agents/*therapeutic use', 'Azabicyclo Compounds/therapeutic use', 'Benzodiazepines/therapeutic use', 'Diphenhydramine/therapeutic use', 'Eszopiclone', 'GABA Agonists/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', '*Mountaineering', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/drug effects', 'Temazepam/therapeutic use', 'Wakefulness/drug effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/18800955/
1948,zopiclone,16703122,Ramelteon: profile of a new sleep-promoting medication.,['Owen RT'],"['Animals', 'Drug Interactions', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Indenes/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Receptor, Melatonin, MT1/agonists/metabolism', 'Receptor, Melatonin, MT2/agonists/metabolism', 'Sleep', 'Sleep Initiation and Maintenance Disorders/*drug therapy/metabolism', 'Suprachiasmatic Nucleus/drug effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/16703122/
1949,zopiclone,18693067,Hypnotic use for insomnia management in chronic obstructive pulmonary disease.,['Roth T'],"['Humans', 'Hypnotics and Sedatives/*administration & dosage/*adverse effects', 'Pulmonary Disease, Chronic Obstructive/*complications', 'Sleep Initiation and Maintenance Disorders/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18693067/
1950,triazolam,7617794,Current benzodiazepine issues.,"['Woods JH', 'Winger G']","['Age Factors', 'Benzodiazepines/*adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Memory Disorders/chemically induced', 'Risk Factors', 'Substance Withdrawal Syndrome/etiology', 'Substance-Related Disorders/*etiology', 'Triazolam/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7617794/
1951,triazolam,9852800,Oral sedation.,['Dionne R'],"['Administration, Oral', 'Algorithms', 'Anesthesia, Dental/*methods', 'Anti-Anxiety Agents/*administration & dosage', 'Chloral Hydrate/adverse effects', 'Conscious Sedation/*methods', 'Dental Anxiety/*prevention & control', 'Diazepam/administration & dosage', 'Histamine H1 Antagonists/administration & dosage', 'Humans', 'Hydroxyzine/administration & dosage', 'Hypnotics and Sedatives/adverse effects', 'Midazolam/administration & dosage', 'Mutagens', 'Premedication', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9852800/
1952,triazolam,2071567,The beneficial and adverse effects of hypnotics.,"['Balter MB', 'Uhlenhuth EH']","['Adolescent', 'Adult', 'Aged', 'Attitude to Health', 'Benzodiazepines/adverse effects/*therapeutic use', 'Data Collection', 'Drug Prescriptions/standards', 'Evaluation Studies as Topic', 'Female', 'Flurazepam/adverse effects/therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Nonprescription Drugs/adverse effects/standards', 'Sleep Initiation and Maintenance Disorders/*drug therapy/psychology', 'Telephone', 'Temazepam/adverse effects/therapeutic use', 'Triazolam/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2071567/
1953,triazolam,9042985,The safety of ranitidine in over a decade of use.,"['Mills JG', 'Koch KM', 'Webster C', 'Sirgo MA', 'Fitzgerald K', 'Wood JR']","['Anti-Ulcer Agents/*adverse effects', 'Clinical Trials as Topic', 'Databases, Factual', 'Drug Interactions', 'Ethanol/administration & dosage', 'Heartburn/drug therapy', 'Histamine H2 Antagonists/*adverse effects', 'Humans', 'Product Surveillance, Postmarketing', 'Ranitidine/*adverse effects', 'Theophylline/administration & dosage', 'Triazolam/administration & dosage', 'Warfarin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/9042985/
1954,triazolam,8227774,Using triazolam to reduce dental anxiety.,"['Berthold CW', 'Schneider A', 'Dionne RA']","['Anesthesia, Dental/*methods', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Cognition/drug effects', 'Delirium/chemically induced', 'Dental Anxiety/*drug therapy/prevention & control', 'Humans', 'Memory/drug effects', 'Preanesthetic Medication', 'Psychomotor Performance/drug effects', 'Triazolam/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8227774/
1955,triazolam,6135296,Triazolam as a hypnotic for geriatric patients. A double-blind cross-over comparison of nitrazepam and triazolam regarding effects on sleep and psychomotor performance.,"['Dehlin O', 'Bjornson G']","['Aged', 'Anti-Anxiety Agents/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motor Skills/*drug effects', 'Nitrazepam/adverse effects/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Stages/*drug effects', 'Triazolam/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6135296/
1956,triazolam,11041533,Comparison of the effects of zolpidem and triazolam on nocturnal sleep and sleep latency in the morning: a cross-over study in healthy young volunteers.,"['Kanno O', 'Sasaki T', 'Watanabe H', 'Takazawa S', 'Nakagome K', 'Nakajima T', 'Ichikawa I', 'Akaho R', 'Suzuki M']","['Adult', 'Affect/drug effects', 'Anti-Anxiety Agents/adverse effects/*pharmacology', 'Cross-Over Studies', 'Humans', 'Hypnotics and Sedatives/adverse effects/*pharmacology', 'Male', 'Pyridines/adverse effects/*pharmacology', 'Sleep/*drug effects', 'Sleep Wake Disorders/*chemically induced', 'Triazolam/adverse effects/*pharmacology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11041533/
1957,triazolam,3567010,Population study of triazolam pharmacokinetics.,"['Friedman H', 'Greenblatt DJ', 'Burstein ES', 'Harmatz JS', 'Shader RI']","['Adult', 'Half-Life', 'Humans', 'Kinetics', 'Male', 'Metabolic Clearance Rate', 'Statistics as Topic', 'Triazolam/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/3567010/
1958,triazolam,1762703,What about Halcion?,['Greenfield DP'],"['Humans', 'Triazolam/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1762703/
1959,triazolam,11592471,Benzodiazepines as a social problem: the case of halcion.,['Gabe J'],"['Humans', 'Hypnotics and Sedatives/*adverse effects/therapeutic use', '*Social Problems', 'Triazolam/*adverse effects/therapeutic use', 'United Kingdom', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11592471/
1960,triazolam,2889723,Withdrawal and detoxification from benzodiazepine dependence: a potential role for clonazepam.,['Albeck JH'],"['Adolescent', 'Adult', 'Aged', 'Alprazolam/adverse effects', '*Anti-Anxiety Agents/adverse effects/therapeutic use', 'Clonazepam/*therapeutic use', 'Diazepam/adverse effects', 'Drug Tolerance', 'Humans', 'Male', 'Middle Aged', 'Substance Withdrawal Syndrome/drug therapy/*etiology/prevention & control', 'Substance-Related Disorders/*drug therapy/etiology/rehabilitation', 'Triazolam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2889723/
1961,triazolam,9230647,Progesterone: does it affect response to drug?,"['Kroboth PD', 'McAuley JW']","['Alprazolam/metabolism/pharmacology', 'Contraceptives, Oral/pharmacology', 'Drug Interactions', 'Female', 'Humans', 'Lorazepam/metabolism/pharmacology', 'Middle Aged', 'Progesterone/*pharmacology', 'Receptors, GABA-A/drug effects/*physiology', 'Temazepam/metabolism/pharmacology', 'Triazolam/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9230647/
1962,triazolam,1686197,Abuse liability assessment of anxiolytics/hypnotics: rationale and laboratory lore.,"['Evans SM', 'Critchfield TS', 'Griffiths RR']","['*Anti-Anxiety Agents/administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Humans', '*Hypnotics and Sedatives/administration & dosage/adverse effects', 'Pyridines/administration & dosage/adverse effects', 'Risk Factors', 'Substance-Related Disorders/*etiology', 'Triazolam/administration & dosage/adverse effects', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/1686197/
1963,triazolam,6102691,The Halcion story: trial by media.,['Lasagna L'],"['Anti-Anxiety Agents/*adverse effects', '*Drug and Narcotic Control', 'Ethics, Professional', 'Hallucinations/chemically induced', 'Hallucinogens', 'Humans', 'Netherlands', '*Newspapers as Topic', 'Propaganda', 'Psychoses, Substance-Induced', 'Public Opinion', '*Television', 'Triazolam/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6102691/
1964,triazolam,8426714,Comparison of oral triazolam and nitrous oxide with placebo and intravenous diazepam for outpatient premedication.,"['Kaufman E', 'Hargreaves KM', 'Dionne RA']","['Administration, Oral', 'Analysis of Variance', 'Anesthesia Recovery Period', 'Anesthesia, Dental/*methods', 'Anesthesia, Intravenous', 'Chi-Square Distribution', 'Cognition/drug effects', 'Conscious Sedation/*methods', 'Dental Anxiety/*prevention & control', '*Diazepam/administration & dosage/pharmacology', 'Dose-Response Relationship, Drug', 'Humans', 'Manifest Anxiety Scale', 'Memory', 'Nitrous Oxide', 'Pain Measurement', 'Preanesthetic Medication', 'Psychomotor Performance/drug effects', 'Regression Analysis', '*Triazolam/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8426714/
1965,triazolam,2859217,Effects of repeated RO 15-1788 administration in benzodiazepine-dependent baboons.,"['Lamb RJ', 'Griffiths RR']","['Animals', 'Anti-Anxiety Agents/*pharmacology', 'Benzodiazepinones/adverse effects/*pharmacology', 'Convulsants/adverse effects/*pharmacology', 'Diazepam/pharmacology', 'Drug Tolerance', 'Flumazenil', 'Humans', 'Male', 'Papio', 'Posture', 'Substance Withdrawal Syndrome', '*Substance-Related Disorders', 'Tremor/chemically induced', 'Triazolam/pharmacology', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2859217/
1966,triazolam,2183493,"Triazolam--an ""abused drug"" by the lay press?","['Schneider PJ', 'Perry PJ']","['Amnesia/etiology/psychology', '*Communication', 'Humans', '*Mass Media', 'Psychoses, Substance-Induced/psychology', 'Substance Withdrawal Syndrome/psychology', 'Triazolam/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2183493/
1967,triazolam,9161660,Zolpidem: distinct from triazolam?,"['Lobo BL', 'Greene WL']","['Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/*therapeutic use', 'Pyridines/adverse effects/pharmacokinetics/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy/psychology', 'Triazolam/adverse effects/pharmacokinetics/*therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/9161660/
1968,triazolam,684426,Rebound insomnia: a new clinical syndrome.,"['Kales A', 'Scharf MB', 'Kales JD']","['Benzodiazepines/*adverse effects/metabolism', 'Brain/metabolism', 'Flunitrazepam/adverse effects/metabolism', 'Humans', 'Hypnotics and Sedatives/*adverse effects/metabolism', 'Nitrazepam/adverse effects/metabolism', 'Receptors, Drug/drug effects/metabolism', 'Sleep Initiation and Maintenance Disorders/*etiology/metabolism', '*Substance Withdrawal Syndrome/metabolism', 'Syndrome', 'Time Factors', 'Triazolam/adverse effects/metabolism']",https://pubmed.ncbi.nlm.nih.gov/684426/
1969,triazolam,11243489,Acute dose-effects of scopolamine on false recognition.,"['Mintzer MZ', 'Griffiths RR']","['Adult', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'GABA Modulators/pharmacology', 'Humans', 'Male', 'Middle Aged', 'Muscarinic Antagonists/administration & dosage/*pharmacology', 'Psychomotor Performance/drug effects', 'Recognition, Psychology/*drug effects', 'Scopolamine/administration & dosage/*pharmacology', 'Triazolam/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11243489/
1970,lamotrigine,33573557,"Use of Phenytoin, Phenobarbital Carbamazepine, Levetiracetam Lamotrigine and Valproate in Pregnancy and Breastfeeding: Risk of Major Malformations, Dose-dependency, Monotherapy vs Polytherapy, Pharmacokinetics and Clinical Implications.","['Kaplan YC', 'Demir O']","['Anticonvulsants/adverse effects', 'Breast Feeding', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Female', 'Humans', 'Lamotrigine/adverse effects', 'Levetiracetam/adverse effects', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', '*Pregnancy Complications/drug therapy', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33573557/
1971,lamotrigine,38507750,"Risk of Autism after Prenatal Topiramate, Valproate, or Lamotrigine Exposure.","['Hernandez-Diaz S', 'Straub L', 'Bateman BT', 'Zhu Y', 'Mogun H', 'Wisner KL', 'Gray KJ', 'Lester B', 'McDougle CJ', 'DiCesare E', 'Pennell PB', 'Huybrechts KF']","['Child', 'Female', 'Humans', 'Pregnancy', '*Anticonvulsants/adverse effects/therapeutic use', '*Autism Spectrum Disorder/chemically induced/epidemiology/etiology', 'Autistic Disorder/chemically induced/epidemiology/etiology', '*Lamotrigine/adverse effects/therapeutic use', '*Prenatal Exposure Delayed Effects/epidemiology/chemically induced/drug therapy', '*Topiramate/adverse effects/therapeutic use', '*Valproic Acid/adverse effects/therapeutic use', 'Epilepsy/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38507750/
1972,lamotrigine,30734897,A Practical Guide to Treatment of Childhood Absence Epilepsy.,"['Kessler SK', 'McGinnis E']","['Anticonvulsants/therapeutic use', 'Child', 'Child, Preschool', 'Drug-Related Side Effects and Adverse Reactions', 'Electroencephalography', 'Epilepsy, Absence/diagnosis/*drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Lamotrigine/therapeutic use', 'Male', 'Practice Guidelines as Topic', 'Seizures/drug therapy', 'Treatment Outcome', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30734897/
1973,lamotrigine,35523739,Individualizing doses of antiepileptic drugs.,"['Liparoti G', 'Burchiani B', 'Mencaroni E', 'Tripodi D', 'Di Cara G', 'Verrotti A']","['*Anticonvulsants/adverse effects', '*Carbamazepine/therapeutic use', 'Humans', 'Lamotrigine', 'Levetiracetam', 'Topiramate']",https://pubmed.ncbi.nlm.nih.gov/35523739/
1974,lamotrigine,39548057,Antiseizure medication use during pregnancy and children's neurodevelopmental outcomes.,"['Madley-Dowd P', 'Ahlqvist VH', 'Forbes H', 'Rast JE', 'Martin FZ', 'Zhong C', 'Barry CS', 'Berglind D', 'Lundberg M', 'Lyall K', 'Newschaffer CJ', 'Tomson T', 'Davies NM', 'Magnusson C', 'Rai D', 'Lee BK']","['Humans', 'Pregnancy', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', '*Prenatal Exposure Delayed Effects/chemically induced/epidemiology', 'Child', '*Intellectual Disability/epidemiology', '*Valproic Acid/adverse effects/therapeutic use', '*Carbamazepine/adverse effects/therapeutic use', 'Sweden/epidemiology', 'Pregnancy Complications/drug therapy', 'Lamotrigine/adverse effects/therapeutic use', 'Male', 'United Kingdom/epidemiology', 'Child, Preschool', 'Registries', 'Topiramate/adverse effects/therapeutic use', 'Autistic Disorder/drug therapy/chemically induced', 'Adult', 'Attention Deficit Disorder with Hyperactivity/drug therapy/epidemiology', 'Neurodevelopmental Disorders/chemically induced/epidemiology', 'Epilepsy/drug therapy', 'Cohort Studies', 'Adolescent', 'Infant']",https://pubmed.ncbi.nlm.nih.gov/39548057/
1975,lamotrigine,34523118,Lamotrigine in the maintenance treatment of bipolar disorder.,"['Hashimoto Y', 'Kotake K', 'Watanabe N', 'Fujiwara T', 'Sakamoto S']","['Adult', 'Anticonvulsants/therapeutic use', '*Bipolar Disorder/drug therapy', 'Humans', 'Lamotrigine/adverse effects', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34523118/
1976,lamotrigine,28862044,Acute lamotrigine overdose: a systematic review of published adult and pediatric cases.,"['Alyahya B', 'Friesen M', 'Nauche B', 'Laliberte M']","['Adult', 'Anticonvulsants/blood/*poisoning', 'Child', 'Drug Overdose/blood/*therapy', 'Humans', 'Lamotrigine/blood/*poisoning', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/28862044/
1977,lamotrigine,37047022,Understanding Lamotrigine's Role in the CNS and Possible Future Evolution.,"['Costa B', 'Vale N']","['Humans', 'Lamotrigine/therapeutic use', '*Depressive Disorder, Major/drug therapy', 'Anticonvulsants/pharmacology/therapeutic use', '*Epilepsy/drug therapy', 'Central Nervous System', 'Glutamic Acid', 'Ion Channels', 'Triazines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37047022/
1978,lamotrigine,38497990,Risk of Major Congenital Malformations and Exposure to Antiseizure Medication Monotherapy.,"['Battino D', 'Tomson T', 'Bonizzoni E', 'Craig J', 'Perucca E', 'Sabers A', 'Thomas S', 'Alvestad S', 'Perucca P', 'Vajda F']","['Humans', 'Female', '*Anticonvulsants/adverse effects/therapeutic use', 'Adult', 'Pregnancy', 'Young Adult', 'Adolescent', '*Epilepsy/drug therapy/epidemiology', '*Abnormalities, Drug-Induced/epidemiology/etiology', 'Middle Aged', 'Longitudinal Studies', '*Pregnancy Complications/drug therapy/epidemiology', 'Prospective Studies', 'Valproic Acid/adverse effects/therapeutic use', 'Prenatal Exposure Delayed Effects/epidemiology/chemically induced', 'Phenytoin/adverse effects/therapeutic use', 'Lamotrigine/adverse effects/therapeutic use', 'Carbamazepine/adverse effects', 'Phenobarbital/adverse effects/therapeutic use', 'Cohort Studies', 'Oxcarbazepine/adverse effects/therapeutic use', 'Prevalence']",https://pubmed.ncbi.nlm.nih.gov/38497990/
1979,lamotrigine,38345991,Lamotrigine-Induced Hemophagocytic Lymphohistiocytosis with DRESS.,"['Wang H', 'Peng J', 'Zeng W', 'Pan X']","['Adult', 'Humans', 'Lamotrigine/adverse effects', '*Lymphohistiocytosis, Hemophagocytic/chemically induced/diagnosis/drug therapy', 'Anticonvulsants/adverse effects', '*Rheumatic Diseases', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/38345991/
1980,lamotrigine,30092918,Treatment of Peripartum Bipolar Disorder.,"['Clark CT', 'Wisner KL']","['Bipolar Disorder/*drug therapy/physiopathology', 'Electroconvulsive Therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Peripartum Period/*drug effects', 'Phototherapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy/psychology', 'Pregnancy Outcome', 'Pregnant People', 'Recurrence', 'Triazines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30092918/
1981,lamotrigine,37782485,Levetiracetam vs Lamotrigine as First-Line Antiseizure Medication in Female Patients With Idiopathic Generalized Epilepsy.,"['Cerulli Irelli E', 'Cocchi E', 'Morano A', 'Gesche J', 'Caraballo RH', 'Lattanzi S', 'Strigaro G', 'Catania C', 'Ferlazzo E', 'Pascarella A', 'Casciato S', 'Quarato P', 'Pizzanelli C', 'Pulitano P', 'Giuliano L', 'Viola V', 'Mostacci B', 'Fortunato F', 'Marini C', 'Di Gennaro G', 'Gambardella A', 'Labate A', 'Operto FF', 'Giallonardo AT', 'Baykan B', 'Beier CP', 'Di Bonaventura C']","['*Epilepsy/drug therapy', 'Retrospective Studies', 'Lamotrigine/therapeutic use', 'Cohort Studies', '*Anticonvulsants/adverse effects', 'Child', 'Humans', 'Immunoglobulin E/therapeutic use', 'Adult', 'Epilepsy, Generalized', 'Levetiracetam/therapeutic use', 'Female']",https://pubmed.ncbi.nlm.nih.gov/37782485/
1982,lamotrigine,11785058,[Epilepsy and pregnancy].,"['Dominguez M', 'Diaz Obregon MC', 'Bhathal H', 'Santiago R']","['Abnormalities, Drug-Induced', 'Adult', 'Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Epilepsy/*drug therapy/physiopathology', 'Female', 'Fetus/*drug effects/physiology', 'Humans', 'Lamotrigine', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Triazines/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11785058/
1983,lamotrigine,10417037,Lamotrigine-induced blepharospasm.,"['Verma A', 'Miller P', 'Carwile ST', 'Husain AM', 'Radtke RA']","['Anticonvulsants/*adverse effects/therapeutic use', 'Blepharospasm/*chemically induced', 'Humans', 'Lamotrigine', 'Male', 'Middle Aged', 'Seizures/drug therapy', 'Triazines/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10417037/
1984,lamotrigine,33838757,"The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial.","['Marson A', 'Burnside G', 'Appleton R', 'Smith D', 'Leach JP', 'Sills G', 'Tudur-Smith C', 'Plumpton C', 'Hughes DA', 'Williamson P', 'Baker GA', 'Balabanova S', 'Taylor C', 'Brown R', 'Hindley D', 'Howell S', 'Maguire M', 'Mohanraj R', 'Smith PE']","['Administration, Oral', 'Adolescent', 'Adult', 'Aged', 'Anticonvulsants/*adverse effects', 'Child', '*Cost-Benefit Analysis', 'Epilepsies, Partial/*drug therapy', 'Female', 'Humans', 'Lamotrigine/*therapeutic use', 'Levetiracetam/*therapeutic use', 'Male', 'Middle Aged', '*Treatment Outcome', 'Young Adult', 'Zonisamide/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33838757/
1985,lamotrigine,35534674,Avoidance of cutaneous adverse drug reactions induced by antiepileptic drugs based on pharmacogenomics.,['Mushiroda T'],"['Humans', '*Anticonvulsants/adverse effects', 'Pharmacogenetics', 'Lamotrigine', 'Carbamazepine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/35534674/
1986,lamotrigine,33774428,The effects of antiepileptic drugs on bone health: A systematic review.,"['Griepp DW', 'Kim DJ', 'Ganz M', 'Dolphin EJ', 'Sotudeh N', 'Burekhovich SA', 'Naziri Q']","['*Anticonvulsants/adverse effects', 'Bone Density', 'Carbamazepine/adverse effects', '*Epilepsy/drug therapy', 'Humans', 'Lamotrigine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33774428/
1987,lamotrigine,34710770,Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review.,"['Liguori C', 'Toledo M', 'Kothare S']","['Anticonvulsants/pharmacology/therapeutic use', '*Disorders of Excessive Somnolence/drug therapy', '*Epilepsy/complications/drug therapy', 'Humans', 'Lamotrigine/pharmacology/therapeutic use', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/34710770/
1988,lamotrigine,15744223,Lamotrigine in psychiatry: pharmacology and therapeutics.,['Jefferson JW'],"['Antidepressive Agents/adverse effects/*therapeutic use', 'Bipolar Disorder/diagnosis/*drug therapy/psychology', 'Controlled Clinical Trials as Topic', 'Drug Therapy, Combination', 'Humans', 'Lamotrigine', 'Treatment Outcome', 'Triazines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15744223/
1989,lamotrigine,23036173,"Lamotrigine in epilepsy, pregnancy and psychiatry--a drug for all seasons?","['Vajda FJ', 'Dodd S', 'Horgan D']","['Abnormalities, Drug-Induced/etiology', 'Anticonvulsants/*therapeutic use', 'Antipsychotic Agents/*therapeutic use', 'Epilepsy/complications/*drug therapy', 'Female', 'Humans', 'Lamotrigine', 'Mood Disorders/complications/*drug therapy', '*Pregnancy', 'Triazines/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23036173/
1990,risperidone,33341539,Antipsychotics and hemodialysis: A systematic review.,"['Sutar R', 'Atlani MK', 'Chaudhary P']","['*Antipsychotic Agents/adverse effects', 'Benzodiazepines', 'Humans', 'Olanzapine', 'Renal Dialysis', 'Risperidone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33341539/
1991,risperidone,24794100,Role of atypical antipsychotics in the treatment of generalized anxiety disorder.,"['Hershenberg R', 'Gros DF', 'Brawman-Mintzer O']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Anxiety Disorders/*drug therapy/psychology', 'Aripiprazole', 'Benzodiazepines/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dibenzothiazepines/administration & dosage/adverse effects/therapeutic use', 'Generalization, Psychological/*drug effects', 'Humans', 'Olanzapine', 'Piperazines/administration & dosage/adverse effects/therapeutic use', 'Quetiapine Fumarate', 'Quinolones/administration & dosage/adverse effects/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24794100/
1992,risperidone,12151468,Risperidone in children with autism and serious behavioral problems.,"['McCracken JT', 'McGough J', 'Shah B', 'Cronin P', 'Hong D', 'Aman MG', 'Arnold LE', 'Lindsay R', 'Nash P', 'Hollway J', 'McDougle CJ', 'Posey D', 'Swiezy N', 'Kohn A', 'Scahill L', 'Martin A', 'Koenig K', 'Volkmar F', 'Carroll D', 'Lancor A', 'Tierney E', 'Ghuman J', 'Gonzalez NM', 'Grados M', 'Vitiello B', 'Ritz L', 'Davies M', 'Robinson J', 'McMahon D']","['Adolescent', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Autistic Disorder/*drug therapy/psychology', 'Child', 'Child Behavior/drug effects', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Risperidone/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12151468/
1993,risperidone,11869410,Drug-induced extrapyramidal reactions.,"['Teoh L', 'Allen H', 'Kowalenko N']","['Antipsychotic Agents/administration & dosage/*adverse effects', 'Attention Deficit Disorder with Hyperactivity/complications/*drug therapy', 'Basal Ganglia Diseases/*chemically induced', 'Child', 'Drug Therapy, Combination', 'Humans', 'Male', 'New South Wales', 'Risperidone/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11869410/
1994,risperidone,21294670,Aripiprazole for the treatment of irritability associated with autism.,"['Farmer CA', 'Aman MG']","['Antipsychotic Agents/adverse effects/pharmacokinetics/therapeutic use', 'Aripiprazole', 'Autistic Disorder/*drug therapy', 'Humans', 'Irritable Mood/*drug effects', 'Piperazines/adverse effects/pharmacokinetics/*therapeutic use', 'Quinolones/adverse effects/pharmacokinetics/*therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21294670/
1995,risperidone,11584985,Long-term safety of risperidone.,['Davidson M'],"['Aged', 'Antipsychotic Agents/*adverse effects/pharmacokinetics/therapeutic use', 'Basal Ganglia Diseases/chemically induced/epidemiology', 'Cholinesterase Inhibitors/adverse effects/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Dementia/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Dyskinesia, Drug-Induced/epidemiology/etiology', 'Humans', 'Incidence', 'Receptors, Dopamine/drug effects/metabolism', 'Receptors, Histamine/drug effects/metabolism', 'Receptors, Muscarinic/drug effects/metabolism', 'Risperidone/*adverse effects/pharmacokinetics/therapeutic use', 'Treatment Outcome', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/11584985/
1996,risperidone,8948000,Use of novel antipsychotic drugs.,['Raleigh F'],"['Antipsychotic Agents/*administration & dosage/adverse effects', 'Basal Ganglia Diseases/*chemically induced/drug therapy/prevention & control', 'Clozapine/*administration & dosage/adverse effects', 'Humans', 'Risperidone/*administration & dosage/adverse effects', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8948000/
1997,risperidone,8690833,Pharmacokinetics of clozapine and risperidone: a review of recent literature.,"['Byerly MJ', 'DeVane CL']","['Antipsychotic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Clozapine/administration & dosage/adverse effects/*pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Metabolic Clearance Rate/physiology', 'Risperidone/administration & dosage/adverse effects/*pharmacokinetics', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8690833/
1998,risperidone,22964442,Does a normalizing electroencephalogram in benign childhood epilepsy with centrotemporal spikes abort attention deficit hyperactivity disorder?,"['Schneebaum-Sender N', 'Goldberg-Stern H', 'Fattal-Valevski A', 'Kramer U']","['Age of Onset', 'Anticonvulsants/adverse effects/*therapeutic use', 'Attention/drug effects', 'Attention Deficit Disorder with Hyperactivity/drug therapy/etiology/genetics/*prevention & control', 'Central Nervous System Stimulants/*therapeutic use', 'Child', 'Child, Preschool', 'Drug Evaluation', 'Drug Therapy, Combination', '*Electroencephalography/drug effects', 'Epilepsy/complications', 'Epilepsy, Rolandic/drug therapy/*physiopathology', 'Female', 'Humans', 'Infant', 'Male', 'Methylphenidate/administration & dosage/*therapeutic use', 'Retrospective Studies', 'Risperidone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22964442/
1999,risperidone,18281731,Paliperidone for schizophrenia.,"['Dolder C', 'Nelson M', 'Deyo Z']","['Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Controlled Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects/pharmacokinetics', 'Paliperidone Palmitate', 'Pyrimidines/*administration & dosage/adverse effects/pharmacokinetics', 'Risperidone/metabolism/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18281731/
2000,risperidone,16822092,Risks versus benefits of different types of long-acting injectable antipsychotics.,['McEvoy JP'],"['Administration, Oral', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Fluphenazine/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Haloperidol/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Health Care Costs', 'Humans', 'Injections, Intramuscular', 'Microspheres', 'Quality of Life', 'Risk Assessment', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention', '*Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/16822092/
2001,risperidone,15522979,Long-acting injectable risperidone.,"['Ehret MJ', 'Fuller MA']","['*Antipsychotic Agents/adverse effects/pharmacology/therapeutic use', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Humans', 'Injections, Intramuscular', 'Randomized Controlled Trials as Topic', '*Risperidone/adverse effects/pharmacology/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15522979/
2002,risperidone,29695153,Classics in Chemical Neuroscience: Risperidone.,"['Chopko TC', 'Lindsley CW']","['Animals', 'Humans', 'Mental Disorders/drug therapy', 'Risperidone/adverse effects/chemistry/pharmacology/*therapeutic use', 'Serotonin Antagonists/adverse effects/chemistry/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29695153/
2003,risperidone,9562211,Risperidone-induced tardive dyskinesia.,['Silberbauer C'],"['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Dyskinesia, Drug-Induced/*physiopathology', 'Humans', 'Male', 'Risperidone/*adverse effects/therapeutic use', 'Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9562211/
2004,risperidone,10724129,"Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality.",['Glazer WM'],"['Antipsychotic Agents/*adverse effects/pharmacology/therapeutic use', 'Basal Ganglia Diseases/*chemically induced', 'Benzodiazepines', 'Brain/drug effects', 'Clozapine/adverse effects/pharmacology/therapeutic use', 'Dibenzothiazepines/adverse effects/pharmacology/therapeutic use', 'Humans', 'Movement Disorders/*etiology', 'Olanzapine', 'Pirenzepine/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Quetiapine Fumarate', 'Receptors, Dopamine/drug effects', 'Receptors, Serotonin/drug effects', 'Risk Factors', 'Risperidone/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10724129/
2005,risperidone,19102665,"Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.",['Keith S'],"['Antipsychotic Agents/*administration & dosage/adverse effects/economics', 'Bipolar Disorder/drug therapy/economics', 'Clinical Trials as Topic', 'Cost-Benefit Analysis', 'Delayed-Action Preparations/economics/*therapeutic use', 'Humans', 'Medication Adherence', 'Risperidone/*administration & dosage/adverse effects/economics', 'Schizophrenia/*drug therapy/economics']",https://pubmed.ncbi.nlm.nih.gov/19102665/
2006,risperidone,9448664,The treatment of psychosis in late life.,"['Zayas EM', 'Grossberg GT']","['Age Factors', 'Aged', 'Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Clozapine/adverse effects/pharmacokinetics/therapeutic use', 'Decision Trees', 'Delirium/diagnosis/drug therapy', 'Diagnosis, Differential', 'Drug Administration Schedule', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Nursing Homes/legislation & jurisprudence', 'Psychotic Disorders/diagnosis/*drug therapy/epidemiology', 'Risk Factors', 'Risperidone/adverse effects/pharmacokinetics/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/9448664/
2007,risperidone,11232752,Weight change and atypical antipsychotic treatment in patients with schizophrenia.,"['Jones B', 'Basson BR', 'Walker DJ', 'Crawford AM', 'Kinon BJ']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Behavior Therapy/methods', 'Benzodiazepines', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/therapeutic use', 'Health Behavior', 'Humans', 'Obesity/chemically induced/prevention & control', 'Olanzapine', 'Pirenzepine/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Schizophrenia/*drug therapy', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11232752/
2008,risperidone,33074724,CYP2D6 and Antipsychotic Treatment Outcomes in Children and Youth: A Systematic Review.,"['Maruf AA', 'Stein K', 'Arnold PD', 'Aitchison KJ', 'Muller DJ', 'Bousman C']","['Adolescent', 'Antipsychotic Agents/*therapeutic use', 'Child', 'Cytochrome P-450 CYP2D6/*genetics', '*Drug-Related Side Effects and Adverse Reactions', 'Humans', '*Pharmacogenetics', '*Risperidone/pharmacokinetics/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33074724/
2009,risperidone,8749887,Risperidone: efficacy and safety.,"['Umbricht D', 'Kane JM']","['Acute Disease', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Double-Blind Method', 'Humans', 'Randomized Controlled Trials as Topic', 'Risperidone/adverse effects/*therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/8749887/
2010,Paliperidone,35486616,Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.,"['Lian L', 'Kim DD', 'Procyshyn RM', 'Cazares D', 'Honer WG', 'Barr AM']","['*Antipsychotic Agents/adverse effects', 'Cohort Studies', 'Delayed-Action Preparations', 'Humans', 'Paliperidone Palmitate', '*Psychotic Disorders/drug therapy', 'Risperidone']",https://pubmed.ncbi.nlm.nih.gov/35486616/
2011,Paliperidone,24556260,Paliperidone-associated motor tics.,"['Hsieh MH', 'Chiu NY']","['Antipsychotic Agents/administration & dosage/*adverse effects', 'Blinking/*drug effects', 'Humans', 'Isoxazoles/administration & dosage/*adverse effects', 'Male', 'Paliperidone Palmitate', 'Pyrimidines/administration & dosage/*adverse effects', 'Schizophrenia/*drug therapy', 'Tics/*chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24556260/
2012,Paliperidone,38301289,A comparison of recurrence rates after discontinuation of second-generation antipsychotic long-acting injectable versus corresponding oral antipsychotic in the maintenance treatment of bipolar disorder: A systematic review.,"['Kishi T', 'Citrome L', 'Sakuma K', 'Iwata N']","['Humans', '*Antipsychotic Agents/administration & dosage/therapeutic use', 'Aripiprazole/administration & dosage/therapeutic use', '*Bipolar Disorder/drug therapy/chemically induced', 'Delayed-Action Preparations/administration & dosage/therapeutic use', 'Paliperidone Palmitate/administration & dosage/therapeutic use', '*Schizophrenia/drug therapy', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/38301289/
2013,Paliperidone,35777418,"Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.","['Lopez-Morinigo JD', 'Leucht S', 'Arango C']","['Adolescent', '*Antipsychotic Agents/therapeutic use', 'Aripiprazole/therapeutic use', 'Benzodiazepines/therapeutic use', '*Clozapine/therapeutic use', 'Haloperidol/therapeutic use', 'Humans', 'Lurasidone Hydrochloride/therapeutic use', 'Molindone/therapeutic use', 'Olanzapine', 'Paliperidone Palmitate/therapeutic use', 'Quality of Life', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy', 'Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/35777418/
2014,Paliperidone,29389211,Hypersexuality associated with paliperidone.,"['Caykoylu A', 'Karslioglu EH', 'Ozer I', 'Koksal AG']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/pharmacokinetics', 'Delayed-Action Preparations', 'Diagnostic and Statistical Manual of Mental Disorders', 'Female', 'Humans', 'Male', '*Paliperidone Palmitate/administration & dosage/adverse effects/pharmacokinetics', 'Peripheral Nervous System Agents', 'Schizophrenia/diagnosis/*drug therapy', 'Sexual Behavior/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/29389211/
2015,Paliperidone,36165513,Aripiprazole: examining the clinical implications of D2 affinity.,"['Anam A', 'Lynch S', 'Mosharraf N', 'Soukas C', 'Gekhman D']","['Humans', 'Aripiprazole/therapeutic use', '*Antipsychotic Agents/therapeutic use', 'Paliperidone Palmitate/therapeutic use', 'Risperidone/therapeutic use', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36165513/
2016,Paliperidone,30244607,The current data on the 3-month paliperidone palmitate formulation for the treatment of schizophrenia.,"['Bioque M', 'Bernardo M']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Cost-Benefit Analysis', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Paliperidone Palmitate/adverse effects/pharmacokinetics/*therapeutic use', 'Schizophrenia/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/30244607/
2017,Paliperidone,37350486,Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.,"['Wang D', 'Schneider-Thoma J', 'Siafis S', 'Burschinski A', 'Dong S', 'Wu H', 'Zhu Y', 'Davis JM', 'Priller J', 'Leucht S']","['Humans', '*Antipsychotic Agents/adverse effects', 'Paliperidone Palmitate/adverse effects', 'Aripiprazole/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', 'Delayed-Action Preparations/therapeutic use', '*Schizophrenia/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37350486/
2018,Paliperidone,35307578,Eosinophilic Pleural Effusion Induced by Paliperidone Palmitate: Case Report and Literature Review.,"['de Ghellinck L', 'Frusch N', 'Duysinx B']","['*Eosinophilia/chemically induced/complications', 'Exudates and Transudates', 'Humans', 'Leukocyte Count', 'Paliperidone Palmitate/adverse effects', '*Pleural Effusion/chemically induced/complications/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/35307578/
2019,Paliperidone,33242202,[Rhabdomyolysis induced by paliperidone palmitate].,"['Klein B', 'Silberbauer C']","['*Antipsychotic Agents/adverse effects', 'Humans', 'Male', 'Middle Aged', 'Paliperidone Palmitate/adverse effects', '*Rhabdomyolysis/chemically induced/diagnosis/drug therapy', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/33242202/
2020,Paliperidone,28699847,A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone.,"['Schoretsanitis G', 'Spina E', 'Hiemke C', 'de Leon J']","['Administration, Oral', 'Animals', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics', 'Delayed-Action Preparations', 'Drug Monitoring/*methods', 'Humans', 'Injections', 'Microspheres', 'Paliperidone Palmitate/pharmacokinetics', 'Risperidone/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28699847/
2021,Paliperidone,20406162,Paliperidone use in the elderly.,"['Madhusoodanan S', 'Zaveri D']","['Age Factors', 'Aged', 'Clinical Trials as Topic/methods', 'Dyskinesia, Drug-Induced/diagnosis/metabolism', 'Humans', 'Isoxazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Nervous System Diseases/chemically induced/diagnosis/metabolism', 'Paliperidone Palmitate', 'Pyrimidines/adverse effects/pharmacokinetics/*therapeutic use', 'Schizophrenia/*drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/20406162/
2022,Paliperidone,34791283,"A Randomized, Double-Blind, Multicenter, Noninferiority Study Comparing Paliperidone Palmitate 6-Month Versus the 3-Month Long-Acting Injectable in Patients With Schizophrenia.","['Najarian D', 'Sanga P', 'Wang S', 'Lim P', 'Singh A', 'Robertson MJ', 'Cohen K', 'Schotte A', 'Milz R', 'Venkatasubramanian R', ""T'Jollyn H"", 'Walling DP', 'Galderisi S', 'Gopal S']","['Adult', '*Antipsychotic Agents/adverse effects', 'Double-Blind Method', 'Humans', 'Paliperidone Palmitate/adverse effects', 'Recurrence', '*Schizophrenia/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34791283/
2023,Paliperidone,36834095,Effectiveness of Paliperidone Palmitate in Reducing Acute Psychiatric Service Use for Patients Suffering from Psychosis-A Retrospective Mirror-Image Study.,"['Chan CT', 'Verma S', 'Subramaniam M', 'Abdin E', 'Tay J']","['Humans', 'Paliperidone Palmitate/therapeutic use', 'Retrospective Studies', '*Antipsychotic Agents/therapeutic use', '*Psychotic Disorders/drug therapy', 'Hospitalization', '*Mental Health Services']",https://pubmed.ncbi.nlm.nih.gov/36834095/
2024,Paliperidone,29968279,Paliperidone palmitate once-every-3-months in adults with early illness schizophrenia.,"['Bell Lynum KS', 'Turkoz I', 'Kim E']","['Adolescent', 'Adult', 'Antipsychotic Agents/therapeutic use', 'Double-Blind Method', 'Drug Administration Schedule', 'Early Medical Intervention', 'Female', 'Humans', 'Male', 'Middle Aged', 'Paliperidone Palmitate/*administration & dosage/adverse effects', 'Psychiatric Status Rating Scales', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/29968279/
2025,Paliperidone,34212530,Outcomes of patients with schizophrenia who discontinued long-acting injectable antipsychotic therapy due to adverse events: A chart review.,"['Kishi T', 'Sakuma K', 'Okuya M', 'Hatano M', 'Iwata N']","['*Antipsychotic Agents/adverse effects', 'Aripiprazole/adverse effects', 'Delayed-Action Preparations/therapeutic use', 'Humans', 'Paliperidone Palmitate/adverse effects', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34212530/
2026,Paliperidone,18281731,Paliperidone for schizophrenia.,"['Dolder C', 'Nelson M', 'Deyo Z']","['Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Controlled Clinical Trials as Topic', 'Delayed-Action Preparations', 'Drug Interactions', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects/pharmacokinetics', 'Paliperidone Palmitate', 'Pyrimidines/*administration & dosage/adverse effects/pharmacokinetics', 'Risperidone/metabolism/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18281731/
2027,Paliperidone,35093701,Comparing 1-year effectiveness and acceptability of once-monthly paliperidone palmitate and aripiprazole monohydrate for schizophrenia spectrum disorders: Findings from the STAR Network Depot Study.,"['Bartoli F', 'Cavaleri D', 'Callovini T', 'Riboldi I', 'Crocamo C', ""D'Agostino A"", 'Martinotti G', 'Bertolini F', 'Ostuzzi G', 'Barbui C', 'Carra G']","['*Antipsychotic Agents/pharmacology/therapeutic use', 'Aripiprazole/pharmacology/therapeutic use', 'Humans', 'Paliperidone Palmitate/therapeutic use', 'Prospective Studies', '*Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35093701/
2028,Paliperidone,26230268,Effectiveness of long-acting paliperidone palmitate in borderline personality disorder.,"['Palomares N', 'Montes A', 'Diaz-Marsa M', 'Carrasco JL']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Borderline Personality Disorder/*drug therapy', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Interpersonal Relations', 'Male', 'Middle Aged', 'Paliperidone Palmitate/administration & dosage/adverse effects/*therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26230268/
2029,Paliperidone,28005578,Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.,"['Bossie CA', 'Turkoz I', 'Alphs L', 'Mahalchick L', 'Fu DJ']","['Adult', 'Aged', 'Antipsychotic Agents/administration & dosage/*pharmacology', 'Chronic Disease', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', '*Outcome Assessment, Health Care', 'Paliperidone Palmitate/administration & dosage/*pharmacology', 'Psychotic Disorders/*drug therapy', 'Recurrence', 'Secondary Prevention/*methods', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28005578/
2030,gabapentin,39163072,Gabapentin-induced Multifocal Myoclonus.,"['Priya L', 'Alamanda VA', 'Javali M', 'Acharya P', 'Rangaiah P', 'Nagabushana D']","['Humans', '*Gabapentin/adverse effects', 'Male', '*Myoclonus/chemically induced', '*Analgesics/adverse effects', 'Neuralgia/drug therapy', 'Aged', 'gamma-Aminobutyric Acid/adverse effects', 'Amines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39163072/
2031,gabapentin,29023146,Is there a role for combined use of gabapentin and pregabalin in pain control? Too good to be true?,"['Senderovich H', 'Jeyapragasan G']","['Analgesics/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Gabapentin/*administration & dosage', 'Humans', 'Neuralgia/*drug therapy', 'Pregabalin/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29023146/
2032,gabapentin,37493871,"Therapeutic Strategies for Postherpetic Neuralgia: Mechanisms, Treatments, and Perspectives.","['Tang J', 'Zhang Y', 'Liu C', 'Zeng A', 'Song L']","['Humans', 'Aged', '*Neuralgia, Postherpetic/therapy', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Lidocaine', 'Analgesics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37493871/
2033,gabapentin,33215352,Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update.,"['Evoy KE', 'Sadrameli S', 'Contreras J', 'Covvey JR', 'Peckham AM', 'Morrison MD']","['Animals', 'Drug Overdose', 'Gabapentin/*adverse effects', 'Humans', 'Pregabalin/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33215352/
2034,gabapentin,37208596,The comparative effectiveness of migraine preventive drugs: a systematic review and network meta-analysis.,"['Lampl C', 'MaassenVanDenBrink A', 'Deligianni CI', 'Gil-Gouveia R', 'Jassal T', 'Sanchez-Del-Rio M', 'Reuter U', 'Uluduz D', 'Versijpt J', 'Zeraatkar D', 'Sacco S']","['Adult', 'Humans', 'Topiramate/adverse effects', '*Valproic Acid/therapeutic use', 'Gabapentin/therapeutic use', 'Calcitonin Gene-Related Peptide/therapeutic use', 'Network Meta-Analysis', 'Amitriptyline/therapeutic use', 'Antibodies, Monoclonal/therapeutic use', '*Migraine Disorders/drug therapy/prevention & control/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37208596/
2035,gabapentin,36195376,Effectiveness of mirror therapy in phantom limb pain: a literature review.,"['Campo-Prieto P', 'Rodriguez-Fuentes G']","['Amitriptyline', 'Antidepressive Agents, Tricyclic', 'Gabapentin/therapeutic use', 'Humans', 'Mirror Movement Therapy', '*Phantom Limb/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36195376/
2036,gabapentin,37138086,Glioblastoma remodelling of human neural circuits decreases survival.,"['Krishna S', 'Choudhury A', 'Keough MB', 'Seo K', 'Ni L', 'Kakaizada S', 'Lee A', 'Aabedi A', 'Popova G', 'Lipkin B', 'Cao C', 'Nava Gonzales C', 'Sudharshan R', 'Egladyous A', 'Almeida N', 'Zhang Y', 'Molinaro AM', 'Venkatesh HS', 'Daniel AGS', 'Shamardani K', 'Hyer J', 'Chang EF', 'Findlay A', 'Phillips JJ', 'Nagarajan S', 'Raleigh DR', 'Brang D', 'Monje M', 'Hervey-Jumper SL']","['Humans', 'Brain/drug effects/metabolism/pathology', '*Brain Neoplasms/drug therapy/metabolism/pathology', '*Glioblastoma/drug therapy/metabolism/pathology', '*Neural Pathways', 'Thrombospondin 1/antagonists & inhibitors', 'Gabapentin/pharmacology/therapeutic use', 'Disease Progression', 'Cognition', 'Survival Rate', 'Wakefulness', 'Biopsy', 'Cell Proliferation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/37138086/
2037,gabapentin,35716275,Evidence-Based Treatment of Painful Diabetic Neuropathy: a Systematic Review.,"[""D'Souza RS"", 'Barman R', 'Joseph A', 'Abd-Elsayed A']","['*Diabetes Mellitus', '*Diabetic Neuropathies/therapy', 'Gabapentin/therapeutic use', 'Humans', '*Insulins/therapeutic use', 'Pregabalin/therapeutic use', '*Spinal Cord Stimulation']",https://pubmed.ncbi.nlm.nih.gov/35716275/
2038,gabapentin,31036121,Myocardial Ischemia Presenting with Hiccups.,['Yuan SM'],"['Baclofen/*therapeutic use', 'Electrocardiography', 'GABA-B Receptor Agonists/*therapeutic use', 'Gabapentin/*therapeutic use', 'Hiccup/diagnosis/*drug therapy/etiology/*physiopathology', 'Humans', 'Myocardial Infarction/*complications', 'Myocardial Ischemia/*complications', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31036121/
2039,gabapentin,34637958,A systematic review and meta-analysis of the effectiveness and adverse events of gabapentin and pregabalin for sciatica pain.,"['Gimenez-Campos MS', 'Pimenta-Fermisson-Ramos P', 'Diaz-Cambronero JI', 'Carbonell-Sanchis R', 'Lopez-Briz E', 'Ruiz-Garcia V']","['Adolescent', 'Adult', 'Analgesics/adverse effects', 'Gabapentin/adverse effects', 'Humans', '*Low Back Pain', 'Pregabalin/adverse effects', '*Sciatica/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34637958/
2040,gabapentin,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
2041,gabapentin,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
2042,gabapentin,31473025,[HTA and non-hormonal menopause treatment].,['Boivin JM'],"['Acupuncture Therapy', 'Clonidine/adverse effects/therapeutic use', 'Complementary Therapies', 'Female', 'Gabapentin/adverse effects/therapeutic use', 'Hot Flashes/drug therapy', 'Humans', 'Hypertension/*etiology', '*Menopause/drug effects', 'Panax', 'Phytoestrogens/adverse effects/*therapeutic use', 'Pregabalin/adverse effects/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Vasomotor System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31473025/
2043,gabapentin,36890758,[Medical Treatment of Chronic Pain].,['Nodera H'],"['Humans', 'Analgesics/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/chemically induced', 'Pregabalin/therapeutic use', 'Gabapentin/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890758/
2044,gabapentin,38574212,Diabetic Peripheral Neuropathy: Prevention and Treatment.,"['Bragg S', 'Marrison ST', 'Haley S']","['Humans', '*Diabetic Neuropathies/diagnosis/prevention & control', 'Duloxetine Hydrochloride/therapeutic use', 'Capsaicin/therapeutic use', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Pain/drug therapy', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38574212/
2045,gabapentin,34232226,[Hepatotoxicity probably associated with gabapentin].,"['Contreras-Mota M', 'Rosales-Cortes V']","['Amines/adverse effects', 'Analgesics', '*Chemical and Drug Induced Liver Injury/diagnosis/etiology', '*Cyclohexanecarboxylic Acids/adverse effects', 'Gabapentin/adverse effects', 'Humans', 'Male', 'Middle Aged', 'gamma-Aminobutyric Acid/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34232226/
2046,gabapentin,39978848,Treatment of Vasomotor Symptoms.,"['Atwell K', 'White M', 'Kuphal G', 'Williams M', 'Schrager S']","['Humans', '*Hot Flashes/drug therapy', 'Female', '*Menopause/physiology', 'Vasomotor System/drug effects/physiopathology', 'Quality of Life', 'Estrogen Replacement Therapy/methods', 'Complementary Therapies/methods', 'Gabapentin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39978848/
2047,gabapentin,30326006,Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial.,"['Robertson K', 'Marshman LAG', 'Plummer D', 'Downs E']","['Adult', 'Aged', 'Analgesics/administration & dosage/adverse effects/*pharmacology', 'Chronic Pain/*drug therapy', 'Cross-Over Studies', 'Double-Blind Method', 'Female', 'Gabapentin/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Middle Aged', 'Outcome Assessment, Health Care', 'Pregabalin/administration & dosage/adverse effects/*pharmacology', 'Sciatica/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30326006/
2048,gabapentin,39088823,Mirogabalin: a novel gabapentinoid or another false dawn?,"['Craig TJ', 'Farquhar-Smith P']","['Humans', '*Neuralgia/drug therapy', '*Analgesics/therapeutic use', '*Bridged Bicyclo Compounds/therapeutic use/pharmacology', 'Gabapentin/therapeutic use', 'Calcium Channels/drug effects', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39088823/
2049,gabapentin,30383545,"Psychology of Chronic Pelvic Pain: Prevalence, Neurobiological Vulnerabilities, and Treatment.","['Till SR', 'As-Sanie S', 'Schrepf A']","['Antidepressive Agents, Tricyclic/pharmacology', 'Anxiety/*complications', 'Catastrophization/*complications', 'Chronic Pain/complications/drug therapy/*psychology/therapy', 'Cognitive Behavioral Therapy', 'Depression/*complications', 'Female', 'Gabapentin/pharmacology/therapeutic use', 'Humans', 'Off-Label Use', 'Pelvic Pain/complications/drug therapy/*psychology/therapy', 'Prevalence', 'Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology/therapeutic use', 'Twin Studies as Topic']",https://pubmed.ncbi.nlm.nih.gov/30383545/
2050,aminophylline,38059379,Aminophylline in pain and migraine.,"['Phillips BL', 'Phillips MC']","['Humans', '*Aminophylline/administration & dosage/adverse effects', '*Migraine Disorders/drug therapy', '*Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38059379/
2051,aminophylline,12389450,[Cold-induced urticaria].,"['Delorme N', 'Drouet M', 'Thibaudeau A', 'Verret JL']","['Acetates/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Cold Temperature/*adverse effects', 'Cyclopropanes', 'Doxepin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Genes, Dominant', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hypotension/etiology', 'Male', 'Quinolines/therapeutic use', 'Stanozolol/therapeutic use', 'Sulfides', 'Terbutaline/administration & dosage/therapeutic use', 'Urticaria/diagnosis/drug therapy/*etiology/genetics/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12389450/
2052,aminophylline,3543827,Aminophylline toxicity.,['Albert S'],"['Adolescent', 'Aminophylline/*adverse effects/metabolism/therapeutic use', 'Cardiovascular Diseases/chemically induced', 'Child', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Kinetics', 'Nervous System Diseases/chemically induced', 'Theophylline/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3543827/
2053,aminophylline,7254994,Steam vaporizer injuries.,"['Colombo JL', 'Hopkins RL', 'Waring WW']","['Aminophylline/therapeutic use', 'Burns/*etiology', 'Child, Preschool', 'Dexamethasone/therapeutic use', 'Drug Therapy, Combination', 'Facial Injuries/*etiology', 'Female', 'Humans', 'Infant', 'Isoproterenol/therapeutic use', 'Male', '*Neck Injuries', 'Respiratory Tract Infections/drug therapy/therapy', 'Theophylline/therapeutic use', 'Volatilization/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7254994/
2054,aminophylline,32767571,Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews.,"['Craig SS', 'Dalziel SR', 'Powell CV', 'Graudins A', 'Babl FE', 'Lunny C']","['Acute Disease', 'Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Aminophylline/administration & dosage/adverse effects', 'Anti-Asthmatic Agents/administration & dosage/*therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Asthma/drug therapy/*therapy', 'Bias', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Child', 'Child, Preschool', 'Cholinergic Antagonists/therapeutic use', '*Disease Progression', 'Helium', 'Humans', 'Infant', 'Length of Stay', 'Leukotriene Antagonists/therapeutic use', 'Magnesium Sulfate/administration & dosage/adverse effects/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Oxygen/administration & dosage', 'Positive-Pressure Respiration', 'Randomized Controlled Trials as Topic', '*Systematic Reviews as Topic', 'Vomiting/chemically induced', 'Work of Breathing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32767571/
2055,aminophylline,3297523,Favorable cardiovascular effects of theophylline in COPD.,['Matthay RA'],"['Administration, Oral', 'Aminophylline/administration & dosage/pharmacology', 'Blood Pressure/drug effects', 'Cardiovascular System/*drug effects', 'Delayed-Action Preparations', 'Heart/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Humans', 'Injections, Intravenous', 'Lung Diseases, Obstructive/*drug therapy/physiopathology', 'Myocardial Contraction/drug effects', 'Pulmonary Heart Disease/etiology/physiopathology', 'Theophylline/blood/*pharmacology', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/3297523/
2056,aminophylline,15889197,Aminophylline: exploring cardiovascular benefits versus medical malcontent.,['Rudusky BM'],"['Aminophylline/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Cardiotonic Agents/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Humans', 'Lung Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15889197/
2057,aminophylline,3970454,Aminophylline and its influence on ventilatory endurance in humans.,"['Belman MJ', 'Sieck GC', 'Mazar A']","['Adult', 'Aminophylline/*pharmacology/therapeutic use', 'Diaphragm/*drug effects/physiology', 'Humans', 'Lung Diseases, Obstructive/drug therapy/*physiopathology', 'Lung Volume Measurements', 'Maximal Voluntary Ventilation', 'Middle Aged', 'Muscle Contraction/*drug effects', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3970454/
2058,aminophylline,1897692,Cyclosporin for steroid-dependent asthma.,"['Szczeklik A', 'Nizankowska E', 'Dworski R', 'Domagala B', 'Pinis G']","['Adult', 'Albuterol/administration & dosage/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Beclomethasone/administration & dosage/therapeutic use', 'Cyclosporins/administration & dosage/blood/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peak Expiratory Flow Rate/drug effects', 'Prednisone/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1897692/
2059,aminophylline,8169027,Treatment of cold urticaria.,"['Husz S', 'Toth-Kasa I', 'Kiss M', 'Dobozy A']","['Adolescent', 'Adult', 'Aminophylline/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Cold Temperature/*adverse effects', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Remission Induction', 'Terbutaline/administration & dosage/adverse effects/*therapeutic use', 'Time Factors', 'Urticaria/*drug therapy/*etiology', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/8169027/
2060,aminophylline,7049586,"Clenbuterol (""Spiropent'): a long-acting bronchodilator.",['Wheatley D'],"['Adolescent', 'Adult', 'Aged', 'Aminophylline/adverse effects/therapeutic use', 'Asthma/*drug therapy', 'Clenbuterol/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Ethanolamines/*therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7049586/
2061,aminophylline,2743738,"Coffee, catecholamines and cardiac arrhythmia.","['Wennmalm A', 'Wennmalm M']","['Aminophylline/therapeutic use', 'Arrhythmias, Cardiac/*etiology', 'Biomechanical Phenomena', 'Brain/physiology', 'Catecholamines/*metabolism', 'Coffee/*adverse effects', 'Coronary Disease/complications', 'Humans', 'Peripheral Nerves/physiology', 'Xanthines/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2743738/
2062,aminophylline,31473373,Caffeine not associated with irritable behaviour in very low-birth-weight infants.,"['Maeda T', 'Sekiguchi K', 'Wasada R', 'Ihara K']","['Aminophylline/administration & dosage/adverse effects/therapeutic use', 'Apnea/drug therapy', 'Bronchodilator Agents/administration & dosage/adverse effects/therapeutic use', 'Caffeine/administration & dosage/*adverse effects/therapeutic use', 'Central Nervous System Stimulants/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', '*Infant Behavior', 'Infant, Newborn', 'Infant, Premature, Diseases/drug therapy', 'Infant, Very Low Birth Weight/*physiology', '*Irritable Mood', 'Male', 'Movement']",https://pubmed.ncbi.nlm.nih.gov/31473373/
2063,aminophylline,3970566,Rectal aminophylline in the management of apnoea of prematurity.,"['Lyon AJ', 'McIntosh N']","['Aminophylline/*administration & dosage/therapeutic use', 'Apnea/blood/*drug therapy', 'Humans', 'Infant, Newborn', 'Infant, Premature, Diseases/blood/*drug therapy', 'Recurrence', 'Suppositories', 'Theophylline/blood']",https://pubmed.ncbi.nlm.nih.gov/3970566/
2064,aminophylline,31526835,A comparative insight into the oxidative damage and cell death potential of photoilluminated aminophylline - riboflavin system in normal and cancer lung cells of swiss albino mice.,"['Khan S', 'Naseem I']","['Aminophylline/pharmacology/radiation effects', 'Animals', 'Catalysis', 'Cell Death/drug effects', 'Cell Line', 'Cell Survival/drug effects', 'DNA Damage', '*Light', 'Lung', 'Lung Neoplasms/*drug therapy', 'Mice', 'Oxidative Stress/drug effects', 'Photochemical Processes', 'Photochemotherapy', 'Reactive Oxygen Species/metabolism', 'Riboflavin/pharmacology/*radiation effects']",https://pubmed.ncbi.nlm.nih.gov/31526835/
2065,aminophylline,3429693,Inhibition of theophylline elimination by diltiazem therapy.,"['Nafziger AN', 'May JJ', 'Bertino JS Jr']","['Adult', 'Aminophylline/administration & dosage/blood/pharmacokinetics', 'Diltiazem/*pharmacokinetics', 'Drug Interactions', 'Humans', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Smoking/blood', 'Theophylline/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3429693/
2066,aminophylline,3533398,Respiratory pharmacology. Methylxanthines.,"['Miech RP', 'Stein M']","['Administration, Oral', 'Aminophylline/administration & dosage', 'Asthma/*drug therapy', 'Drug Interactions', 'Humans', 'Injections, Intravenous', 'Kinetics', 'Theophylline/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3533398/
2067,aminophylline,6668100,Comparison of aminophylline and theophylline sustained-release formulations by their bioavailability and steady-state serum levels.,"['Steinijans VW', 'Zech K', 'Fischer R']","['Adult', 'Aminophylline/administration & dosage/blood/*metabolism', 'Biological Availability', 'Delayed-Action Preparations', 'Drug Tolerance', 'Humans', 'Kinetics', 'Male', 'Middle Aged', 'Theophylline/administration & dosage/blood/*metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6668100/
2068,aminophylline,3297524,Effect of theophylline on diaphragmatic muscle function.,['Aubier M'],"['Aminophylline/pharmacology', 'Animals', 'Diaphragm/*drug effects/physiology/physiopathology', 'Electromyography', 'Humans', 'Lung Diseases, Obstructive/drug therapy/physiopathology', 'Muscle Contraction/drug effects', 'Rats', 'Theophylline/administration & dosage/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3297524/
2069,aminophylline,1797890,Theophylline and ethylenediamine pharmacokinetics following administration of aminophylline to septic patients with multiorgan failure.,"['Toft P', 'Heslet L', 'Hansen M', 'Klitgaard NA']","['Adult', 'Aged', 'Aminophylline/*administration & dosage', 'Anti-Bacterial Agents/therapeutic use', 'Ethylenediamines/blood/*pharmacokinetics', 'Female', 'Half-Life', 'Humans', 'Infusions, Intravenous', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Multiple Organ Failure/*complications/drug therapy/metabolism', 'Sepsis/*complications/drug therapy/metabolism', 'Theophylline/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1797890/
2070,guaifenesin,12099787,Herbal antitussives.,['Ziment I'],"['Antitussive Agents/*therapeutic use', 'Cough/*drug therapy', 'Humans', '*Phytotherapy']",https://pubmed.ncbi.nlm.nih.gov/12099787/
2071,guaifenesin,17594730,"Mucolytics, expectorants, and mucokinetic medications.",['Rubin BK'],"['Expectorants/administration & dosage/classification/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Treatment Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/17594730/
2072,guaifenesin,22964341,Nebulized lidocaine in the treatment of intractable cough.,"['Truesdale K', 'Jurdi A']","['Administration, Inhalation', 'Anesthetics, Local/administration & dosage/*therapeutic use', 'Cough/*drug therapy/etiology', 'Humans', 'Lidocaine/administration & dosage/*therapeutic use', 'Lung Neoplasms/complications', 'Nebulizers and Vaporizers', 'Neoplasms/complications']",https://pubmed.ncbi.nlm.nih.gov/22964341/
2073,guaifenesin,25420096,Over-the-counter (OTC) medications for acute cough in children and adults in community settings.,"['Smith SM', 'Schroeder K', 'Fahey T']","['Acute Disease', 'Administration, Oral', 'Adult', 'Ambulatory Care', 'Antitussive Agents/*administration & dosage/adverse effects', 'Child', 'Cough/*drug therapy', 'Drug Therapy, Combination/methods', 'Expectorants/*administration & dosage/adverse effects/therapeutic use', 'Histamine H1 Antagonists/*administration & dosage', 'Humans', 'Nonprescription Drugs/*administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/25420096/
2074,guaifenesin,19210898,Guaifenesin in rhinitis.,"['Storms W', 'Farrar JR']","['Cough/*drug therapy', 'Expectorants/administration & dosage/*therapeutic use', 'Guaifenesin/administration & dosage/*therapeutic use', 'Humans', 'Mucus/chemistry/*drug effects/physiology', 'Respiratory Mucosa/physiology', 'Respiratory System/pathology', 'Respiratory Tract Infections/*drug therapy', 'Rhinitis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19210898/
2075,guaifenesin,18049062,How to try this: detecting delirium.,['Waszynski CM'],"['Algorithms', 'Analgesics, Opioid/*adverse effects', '*Auditory Perceptual Disorders', '*Confusion', 'Delirium/chemically induced/*diagnosis/nursing', 'Humans', 'Hydromorphone/*adverse effects', 'Male', 'Methocarbamol/*adverse effects', 'Muscle Relaxants, Central/adverse effects', '*Psychomotor Agitation', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/18049062/
2076,guaifenesin,20877172,Case report: anaphylactic reaction to guaifenesin.,"['Ray M', 'Faltay B', 'Haller NA']","['Allergens', 'Anaphylaxis/*chemically induced/diagnosis', 'Drug Hypersensitivity/blood/*diagnosis/etiology', 'Expectorants/administration & dosage/*adverse effects', 'Guaifenesin/administration & dosage/*adverse effects', 'Humans', 'Immunoglobulin E/*blood', 'Male', 'Patch Tests/methods', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20877172/
2077,guaifenesin,28737047,The role of mucoactive agents in the mechanically ventilated patient: a review of the literature.,"['Icard BL', 'Rubio E']","['Acetylcysteine/therapeutic use', 'Ambroxol/therapeutic use', 'Critical Care', 'Critical Illness', 'Deoxyribonuclease I/therapeutic use', 'Expectorants/*therapeutic use', 'Guaifenesin/therapeutic use', 'Humans', 'Intensive Care Units', 'Mannitol/therapeutic use', '*Mucociliary Clearance', 'Potassium Dichromate/therapeutic use', 'Recombinant Proteins/therapeutic use', '*Respiration, Artificial', 'Saline Solution, Hypertonic/therapeutic use', 'Sodium Bicarbonate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28737047/
2078,guaifenesin,38804670,Guaifenesin: The Ubiquitous Orphan.,"['Eyassu DG', 'McCoul ED']","['Humans', '*Guaifenesin/therapeutic use', '*Expectorants/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38804670/
2079,guaifenesin,837639,Hemolytic potential of methocarbamol.,"['Scott RB', 'Tisdale SA Jr', 'Cummings WB']","['Adult', 'Haptoglobins/metabolism', 'Hemoglobinometry', 'Hemolysis/*drug effects', 'Humans', 'Methocarbamol/*pharmacology', 'Plasma/analysis', 'Polyethylene Glycols/pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/837639/
2080,guaifenesin,15673990,Ephedrine- and guaifenesin-induced nephrolithiasis.,"['Bennett S', 'Hoffman N', 'Monga M']","['Antitussive Agents/adverse effects', 'Bronchodilator Agents/adverse effects', 'Ephedrine/*adverse effects', 'Expectorants/adverse effects', 'Guaifenesin/*adverse effects', 'Humans', 'Kidney/*drug effects', 'Kidney Calculi/*chemically induced/drug therapy', 'Nonprescription Drugs/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/15673990/
2081,guaifenesin,23758573,Guaifenesin derivatives promote neurite outgrowth and protect diabetic mice from neuropathy.,"['Hadimani MB', 'Purohit MK', 'Vanampally C', 'Van der Ploeg R', 'Arballo V', 'Morrow D', 'Frizzi KE', 'Calcutt NA', 'Fernyhough P', 'Kotra LP']","['Animals', 'Diabetic Neuropathies/*pathology/*prevention & control', 'Female', 'Guaifenesin/*analogs & derivatives/metabolism/pharmacokinetics/*pharmacology', 'Humans', 'Male', 'Mice', 'Microsomes, Liver/metabolism', 'Neurites/*drug effects/*metabolism', 'Permeability', 'Rats', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/23758573/
2082,guaifenesin,461786,Urticaria of the colon.,"['Yousefzadeh DK', 'Teplick JG']","['Cecal Diseases/*complications', 'Colonic Diseases/chemically induced/complications/*diagnostic imaging', 'Drug Hypersensitivity/complications', 'Humans', 'Intestinal Obstruction/*complications/diagnostic imaging', 'Male', 'Methocarbamol/adverse effects', 'Middle Aged', 'Radiography', 'Thioridazine/adverse effects', 'Urticaria/chemically induced/complications/*diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/461786/
2083,guaifenesin,37481407,Impact of methocarbamol on opioid use after ventral incisional hernia repair.,"['Desai S', 'Carbonell C', 'Hoffman K', 'Hammond B', 'Crosier C', 'Blackhurst D', 'Carbonell AM', 'Love MW', 'Cobb WS', 'Warren JA']","['Humans', 'Analgesics, Opioid/therapeutic use', '*Methocarbamol/therapeutic use', '*Incisional Hernia/surgery', ""Practice Patterns, Physicians'"", '*Hernia, Ventral/surgery', '*Opioid-Related Disorders/prevention & control', 'Pain, Postoperative/drug therapy/surgery', 'Herniorrhaphy', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/37481407/
2084,guaifenesin,7097192,A fatal methocarbamol intoxication.,"['Kemal M', 'Imami R', 'Poklis A']","['Adult', 'Alcoholic Intoxication', 'Chromatography, Gas', 'Chromatography, High Pressure Liquid', 'Chromatography, Thin Layer', 'Ethanol/blood', 'Female', 'Humans', 'Methocarbamol/*poisoning', 'Spectrophotometry, Ultraviolet', 'Toxicology/methods']",https://pubmed.ncbi.nlm.nih.gov/7097192/
2085,guaifenesin,24535583,Urological complications of illicit drug use.,"['Skeldon SC', 'Goldenberg SL']","['Fournier Gangrene/chemically induced/diagnosis/therapy', 'Humans', 'Illicit Drugs/*adverse effects', 'Lower Urinary Tract Symptoms/chemically induced/diagnosis/therapy', 'Male', 'Prostatic Neoplasms/chemically induced/diagnosis/therapy', 'Substance-Related Disorders/*complications/diagnosis/therapy', 'Urinary Bladder Neoplasms/chemically induced/diagnosis/therapy', 'Urologic Diseases/*chemically induced/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/24535583/
2086,guaifenesin,13618740,Use of methocarbamol in orthopedics.,['LEWIS WB'],"['*Cardiovascular Agents', '*Disease', 'Humans', '*Methocarbamol', 'Muscle Relaxants, Central/*therapeutic use', '*Muscles', '*Muscular Diseases', '*Nervous System Diseases', '*Orthopedics', '*Spasm']",https://pubmed.ncbi.nlm.nih.gov/13618740/
2087,guaifenesin,14751382,Bilateral guaifenesin ureteral calculi.,"['Whelan C', 'Schwartz BF']","['Adult', 'Drug Combinations', 'Ephedrine/administration & dosage/adverse effects', 'Guaifenesin/administration & dosage/*adverse effects/analysis', 'Hematuria/etiology', 'Humans', 'Hydronephrosis/etiology', 'Male', 'Spectrophotometry, Infrared', 'Substance-Related Disorders/complications', 'Ureteral Calculi/*chemically induced/chemistry/complications/surgery', 'Ureteroscopy']",https://pubmed.ncbi.nlm.nih.gov/14751382/
2088,haloperidol,27023437,Possible biomarkers modulating haloperidol efficacy and/or tolerability.,"['Porcelli S', 'Crisafulli C', 'Calabro M', 'Serretti A', 'Rujescu D']","['Antipsychotic Agents/adverse effects/pharmacology/*therapeutic use', 'Biomarkers/analysis', 'Epigenesis, Genetic', 'Gene Expression Profiling', 'Genetic Markers', 'Genotype', 'Haloperidol/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Organ Specificity', 'Psychotic Disorders/*drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/27023437/
2089,haloperidol,7504573,Pharmacological profile of risperidone.,"['Ereshefsky L', 'Lacombe S']","['Antipsychotic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Brain/drug effects/metabolism', 'Dose-Response Relationship, Drug', 'Haloperidol/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Isoxazoles/administration & dosage/adverse effects/*pharmacokinetics', 'Metabolic Clearance Rate/physiology', 'Piperidines/administration & dosage/adverse effects/*pharmacokinetics', 'Receptors, Dopamine D2/drug effects/metabolism', 'Receptors, Serotonin/drug effects/metabolism', 'Risperidone', 'Schizophrenia/*blood/drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/7504573/
2090,haloperidol,2259358,Tardive eating dystonia.,"['Achiron A', 'Melamed E']","['Aged', 'Aggression/*drug effects', 'Blepharospasm/chemically induced', 'Deglutition Disorders/chemically induced', 'Dyskinesia, Drug-Induced/*etiology', 'Feeding and Eating Disorders/*chemically induced', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Male', 'Neurologic Examination', 'Substance Withdrawal Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/2259358/
2091,haloperidol,11044761,Rational antipsychotic polypharmacy.,"['Kennedy NB', 'Procyshyn RM']","['Antipsychotic Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Clozapine/administration & dosage/pharmacokinetics/*therapeutic use', 'Cytochrome P-450 Enzyme System/drug effects', 'Drug Interactions', 'Haloperidol/administration & dosage/pharmacokinetics/*therapeutic use', 'Humans', 'Isoenzymes/drug effects', 'Polypharmacy', 'Psychotic Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11044761/
2092,haloperidol,26561842,[The neurotoxicity of pyridinium metabolites of haloperidol].,"['Gorska A', 'Marszall M', 'Sloderbach A']","['Antipsychotic Agents/*pharmacology', '*Biotransformation', 'Brain/*drug effects', 'Delirium/drug therapy', 'Haloperidol/*adverse effects/metabolism/pharmacology', 'Humans', 'Nausea/drug therapy', 'Neurodegenerative Diseases/*chemically induced', '*Neurotoxicity Syndromes', 'Schizophrenia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26561842/
2093,haloperidol,1933763,Haloperidol-induced bronchospasm.,"['Sethna R', 'Notkin R']","['Administration, Oral', 'Adult', 'Bronchial Spasm/*chemically induced', 'Female', 'Haloperidol/administration & dosage/*adverse effects', '*Hospitalization', 'Humans', 'Psychotic Disorders/*drug therapy/psychology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1933763/
2094,haloperidol,12522522,Torsade de pointes associated with the administration of intravenous haloperidol.,"['Hassaballa HA', 'Balk RA']","['Administration, Oral', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Injections, Intravenous', 'Torsades de Pointes/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12522522/
2095,haloperidol,30337420,BET 1: Haloperidol in cannabinoid hyperemesis syndrome.,"['Dida J', 'Walji N']","['Adult', 'Antiemetics/pharmacology/therapeutic use', 'Cannabinoids/*adverse effects/therapeutic use', 'Haloperidol/*pharmacology/therapeutic use', 'Humans', 'Male', 'Vomiting/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30337420/
2096,haloperidol,16822092,Risks versus benefits of different types of long-acting injectable antipsychotics.,['McEvoy JP'],"['Administration, Oral', 'Antipsychotic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Fluphenazine/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Haloperidol/administration & dosage/analogs & derivatives/pharmacokinetics/therapeutic use', 'Health Care Costs', 'Humans', 'Injections, Intramuscular', 'Microspheres', 'Quality of Life', 'Risk Assessment', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Secondary Prevention', '*Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/16822092/
2097,haloperidol,15888517,Antipsychotic drug-induced acute laryngeal dystonia: two case reports and a mini review.,"['Christodoulou C', 'Kalaitzi C']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Diagnosis, Differential', 'Dystonia/*chemically induced/diagnosis', 'Female', 'Haloperidol/adverse effects/therapeutic use', 'Humans', 'Laryngeal Diseases/*chemically induced/diagnosis', 'Male', 'Psychotic Disorders/complications/drug therapy', 'Risk Factors', 'Schizophrenia/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15888517/
2098,haloperidol,2689040,Pharmacokinetics of haloperidol.,"['Froemming JS', 'Lam YW', 'Jann MW', 'Davis CM']","['Drug Interactions', 'Haloperidol/adverse effects/analogs & derivatives/metabolism/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/2689040/
2099,haloperidol,11305682,Neuroleptic malignant syndrome in children and adolescents.,"['Ty EB', 'Rothner AD']","['Adolescent', 'Adult', 'Antipsychotic Agents/*adverse effects', 'Child', 'Depressive Disorder, Major/*drug therapy', 'Female', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Neuroleptic Malignant Syndrome/*diagnosis/etiology', 'Psychotic Disorders/*drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11305682/
2100,haloperidol,1937339,[30 years experience with haloperidol].,"['Bandelow B', 'Muller P', 'Ruther E']","['Brain/drug effects', 'Dopamine Antagonists', 'Dyskinesia, Drug-Induced/blood/*etiology', 'Haloperidol/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Psychotic Disorders/blood/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1937339/
2101,haloperidol,8830064,Haloperidol dose and blood level variability: toxicity and interindividual and intraindividual variability in the nonresponder patient in the clinical practice setting.,"['Darby JK', 'Pasta DJ', 'Dabiri L', 'Clark L', 'Mosbacher D']","['Administration, Oral', 'Adult', 'Antipsychotic Agents/administration & dosage/*adverse effects/pharmacokinetics', 'Biological Availability', 'Chronic Disease', 'Dose-Response Relationship, Drug', 'Female', 'Haloperidol/administration & dosage/*adverse effects/pharmacokinetics', 'Humans', 'Long-Term Care', 'Male', 'Metabolic Clearance Rate/physiology', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Psychoses, Substance-Induced/blood/diagnosis/psychology', 'Schizophrenia/blood/*drug therapy', '*Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/8830064/
2102,haloperidol,16915578,Pharmacokinetic parameters of bromperidol in Korean subjects.,"['Lee SY', 'Kim YG', 'Kim HG', 'Kim JW']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/blood/*pharmacokinetics', 'Basal Ganglia Diseases/chemically induced', 'Cytochrome P-450 CYP2D6/genetics/metabolism', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/genetics/metabolism', 'Dose-Response Relationship, Drug', 'Dystonia/chemically induced', 'Female', 'Genotype', 'Haloperidol/administration & dosage/adverse effects/*analogs & derivatives/blood/pharmacokinetics', 'Humans', 'Korea', 'Male', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/16915578/
2103,haloperidol,2544823,Haloperidol and cognitive shifting.,"['Berger HJ', 'van Hoof JJ', 'van Spaendonck KP', 'Horstink MW', 'van den Bercken JH', 'Jaspers R', 'Cools AR']","['Attention/drug effects', 'Basal Ganglia/drug effects', 'Cognition Disorders/*chemically induced', 'Female', 'Frontal Lobe/drug effects', 'Haloperidol/administration & dosage/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Neuropsychological Tests', 'Pattern Recognition, Visual/drug effects', 'Psychomotor Performance/drug effects', 'Receptors, Dopamine/drug effects', 'Synaptic Transmission/drug effects', 'Torticollis/*drug therapy', 'Verbal Behavior/drug effects', 'Verbal Learning/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2544823/
2104,haloperidol,8220668,Management of delirium associated with use of the intra-aortic balloon pump.,"['Sanders KM', 'Stern TA']","['Administration, Oral', 'Adult', 'Aged', 'Clinical Protocols', 'Coronary Disease/therapy', 'Delirium/diagnosis/*drug therapy/*etiology/nursing', 'Diagnosis, Differential', 'Female', 'Haloperidol/administration & dosage/*therapeutic use', 'Humans', 'Injections, Intravenous', 'Intensive Care Units', 'Intra-Aortic Balloon Pumping/*adverse effects', 'Male', 'Middle Aged', 'Referral and Consultation']",https://pubmed.ncbi.nlm.nih.gov/8220668/
2105,haloperidol,33068931,Haloperidol in palliative care: Indications and risks.,"['Zaporowska-Stachowiak I', 'Stachowiak-Szymczak K', 'Oduah MT', 'Sopata M']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Haloperidol/adverse effects/*therapeutic use', 'Humans', 'Palliative Care/*methods', 'Quality of Life', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/33068931/
2106,haloperidol,11232752,Weight change and atypical antipsychotic treatment in patients with schizophrenia.,"['Jones B', 'Basson BR', 'Walker DJ', 'Crawford AM', 'Kinon BJ']","['Antipsychotic Agents/administration & dosage/*adverse effects/therapeutic use', 'Behavior Therapy/methods', 'Benzodiazepines', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/therapeutic use', 'Health Behavior', 'Humans', 'Obesity/chemically induced/prevention & control', 'Olanzapine', 'Pirenzepine/administration & dosage/*adverse effects/*analogs & derivatives/therapeutic use', 'Risperidone/administration & dosage/adverse effects/therapeutic use', 'Schizophrenia/*drug therapy', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/11232752/
2107,haloperidol,16127964,Treatment response to olanzapine and haloperidol and its association with dopamine D receptor occupancy in first-episode psychosis.,"['Zipursky RB', 'Christensen BK', 'Daskalakis Z', 'Epstein I', 'Roy P', 'Furimsky I', 'Sanger T', 'Kapur S']","['Acute Disease', 'Adolescent', 'Adult', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Corpus Striatum/diagnostic imaging/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Female', 'Haloperidol/*administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Male', 'Olanzapine', '*Positron-Emission Tomography', 'Psychotic Disorders/diagnostic imaging/*drug therapy/psychology', 'Raclopride', 'Receptors, Dopamine D2/*drug effects', 'Schizophrenia/diagnostic imaging/*drug therapy', 'Schizophrenic Psychology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16127964/
2108,chlorpromazine,3046553,Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.,"['Kane J', 'Honigfeld G', 'Singer J', 'Meltzer H']","['Adult', 'Chlorpromazine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Clozapine/adverse effects/*therapeutic use', 'Dibenzazepines/*therapeutic use', 'Double-Blind Method', 'Female', 'Haloperidol/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Random Allocation', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3046553/
2109,chlorpromazine,1679251,Neuroleptic plasma levels.,"['Van Putten T', 'Marder SR', 'Wirshing WC', 'Aravagiri M', 'Chabert N']","['Antipsychotic Agents/administration & dosage/adverse effects/*blood/pharmacokinetics/therapeutic use', 'Biological Availability', 'Chlorpromazine/administration & dosage/blood', 'Fluphenazine/administration & dosage/analogs & derivatives/blood', 'Haloperidol/administration & dosage/blood', 'Humans', 'Perphenazine/administration & dosage/blood', 'Schizophrenia/blood/drug therapy', 'Thiothixene/administration & dosage/blood']",https://pubmed.ncbi.nlm.nih.gov/1679251/
2110,chlorpromazine,29079070,Pharmacologic Interventions for Intractable and Persistent Hiccups: A Systematic Review.,"['Polito NB', 'Fellows SE']","['Adrenergic Uptake Inhibitors/pharmacology/therapeutic use', 'Chlorpromazine/pharmacology/therapeutic use', 'Dopamine Antagonists/pharmacology/therapeutic use', 'Dopamine D2 Receptor Antagonists/pharmacology/therapeutic use', 'Emergency Service, Hospital/organization & administration', 'GABA-B Receptor Agonists/pharmacology/therapeutic use', 'Hiccup/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/29079070/
2111,chlorpromazine,342230,Drug-induced agranulocytosis.,['Pisciotta V'],"['Agranulocytosis/*chemically induced/immunology/pathology', 'Aminopyrine/adverse effects', 'Antibodies', 'Antibodies, Antinuclear', 'Bone Marrow/drug effects/pathology', 'Chlorpromazine/adverse effects/pharmacology', 'Humans', 'Leukocytes/immunology']",https://pubmed.ncbi.nlm.nih.gov/342230/
2112,chlorpromazine,16358614,[Hiccups].,['ten Holter JB'],"['Baclofen/therapeutic use', 'Chlorpromazine/adverse effects/therapeutic use', 'Hiccup/*drug therapy/*etiology', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Piracetam/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16358614/
2113,chlorpromazine,36847737,Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life.,"['Tiefenthaler CM', 'Hirst JM', 'Edmonds KP', 'Atayee RS']","['Humans', 'Chlorpromazine/therapeutic use', 'Psychomotor Agitation/drug therapy/complications/prevention & control', '*Delirium/drug therapy', '*Neoplasms/complications', 'Death', 'Palliative Care']",https://pubmed.ncbi.nlm.nih.gov/36847737/
2114,chlorpromazine,9682944,Hypogammaglobulinemia during antipsychotic therapy.,"['Abe S', 'Suzuki T', 'Hori T', 'Baba A', 'Shiraishi H']","['Adult', 'Agammaglobulinemia/*chemically induced/immunology', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Chlorpromazine/administration & dosage/adverse effects', 'Drug Therapy, Combination', 'Female', 'Humans', 'Immunoglobulin A/blood', 'Immunoglobulin G/blood', 'Immunoglobulin M/blood']",https://pubmed.ncbi.nlm.nih.gov/9682944/
2115,chlorpromazine,32327675,Photomutagenicity of chlorpromazine and its N-demethylated metabolites assessed by NGS.,"['Agundez JAG', 'Garcia-Martin E', 'Garcia-Lainez G', 'Miranda MA', 'Andreu I']","['Cell Line', 'Chlorpromazine/chemistry/*toxicity', '*Demethylation/drug effects', 'Genetic Variation', '*High-Throughput Nucleotide Sequencing', 'Humans', '*Metabolome', 'Mutagenesis/*genetics']",https://pubmed.ncbi.nlm.nih.gov/32327675/
2116,chlorpromazine,790414,Monitoring plasma concentrations of neuroleptics.,['Lader M'],"['Administration, Oral', 'Chlorpromazine/administration & dosage/*blood/therapeutic use', 'Drug Interactions', 'Enzyme Induction', 'Humans', 'Microsomes, Liver/metabolism', 'Protein Binding', 'Psychotropic Drugs/therapeutic use', 'Pupil/drug effects', 'Remission, Spontaneous']",https://pubmed.ncbi.nlm.nih.gov/790414/
2117,chlorpromazine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
2118,chlorpromazine,2021,Maintenance antipsychotic therapy: is the cure worse than the disease?,"['Gardos G', 'Cole JO']","['Antipsychotic Agents/*administration & dosage/adverse effects', 'Basal Ganglia Diseases/chemically induced', 'Chlorpromazine/administration & dosage', 'Chronic Disease', 'Clinical Trials as Topic', 'Female', 'Humans', 'Movement Disorders/chemically induced', 'Promazine/administration & dosage', 'Recurrence', 'Schizophrenia/*drug therapy', 'Trifluoperazine/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2021/
2119,chlorpromazine,3909565,Cancer therapy: phenothiazines in an unexpected role.,['Jones GR'],"['Animals', 'Chlorpromazine/pharmacology/therapeutic use', 'Hospitals, Psychiatric', 'Humans', 'Neoplasms/*drug therapy/mortality', 'Neoplasms, Experimental/drug therapy', 'Oxidative Phosphorylation/drug effects', 'Phenothiazines/pharmacology/*therapeutic use', 'Rodentia']",https://pubmed.ncbi.nlm.nih.gov/3909565/
2120,chlorpromazine,4305078,Hallucinogen-tranquilizer interaction: its nature.,"['Halasz MF', 'Formanek J', 'Marrazzi AS']","['Animals', 'Brain/*drug effects', 'Cats', 'Chlorpromazine/administration & dosage/*pharmacology', 'Conditioning, Psychological/drug effects', 'Depression, Chemical', 'Drug Synergism', 'Haplorhini', 'Humans', 'Lysergic Acid Diethylamide/administration & dosage/*pharmacology', 'Psychoses, Substance-Induced', 'Receptors, Drug', 'Synapses/*drug effects', 'Synaptic Transmission/drug effects']",https://pubmed.ncbi.nlm.nih.gov/4305078/
2121,chlorpromazine,2568378,Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics.,"['Rey MJ', 'Schulz P', 'Costa C', 'Dick P', 'Tissot R']","['Antipsychotic Agents/*administration & dosage', 'Chlorpromazine/*administration & dosage', 'Dose-Response Relationship, Drug', 'Humans', 'Psychotic Disorders/*drug therapy', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/2568378/
2122,chlorpromazine,1970485,Neuroleptic-associated autoantibodies. A prevalence study.,"['Canoso RT', 'de Oliveira RM', 'Nixon RA']","['Adult', 'Aged', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Autoantibodies/*analysis', 'Autoimmune Diseases/*chemically induced', 'Chlorpromazine/*adverse effects/therapeutic use', 'Chronic Disease', 'Humans', 'Male', 'Middle Aged', 'Psychotic Disorders/*drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1970485/
2123,chlorpromazine,661049,Fatal drug-induced heat stroke.,['Forester D'],"['Adult', 'Benztropine/*adverse effects/therapeutic use', 'Chlorpromazine/*adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Heat Exhaustion/*chemically induced/therapy', 'Humans', 'Male', 'Schizophrenia, Paranoid/drug therapy', 'Tropanes/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/661049/
2124,chlorpromazine,12003252,Butyrylcholinesterase and cognitive function.,"['Darvesh S', 'MacKnight C', 'Rockwood K']","['Adult', 'Brain/drug effects/physiopathology', 'Butyrylcholinesterase/*physiology', 'Chlorpromazine/*adverse effects/therapeutic use', 'Cholinergic Antagonists/*adverse effects/therapeutic use', 'Cognition Disorders/chemically induced/*physiopathology', 'Dose-Response Relationship, Drug', 'Dyskinesia, Drug-Induced/*drug therapy', 'Humans', 'Male', 'Neurons/drug effects/physiology', 'Phenothiazines/*adverse effects/therapeutic use', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12003252/
2125,chlorpromazine,1974283,Neuroleptic malignant syndrome.,"['Srinivasan AV', 'Murugappan M', 'Krishnamurthy SG', 'Sayeed ZA']","['Adult', 'Affective Disorders, Psychotic/*drug therapy', 'Antipsychotic Agents/administration & dosage/*adverse effects', 'Butyrophenones', 'Chlorpromazine/adverse effects', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Neuroleptic Malignant Syndrome/*etiology', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1974283/
2126,chlorpromazine,10746,Generic and trade-name antipsychotic drugs: clinical equivalence.,"['Chien CP', 'Labrie R', 'Park CG', 'Cole JO', 'Werner WM']","['Adult', 'Brief Psychiatric Rating Scale', 'Chlorpromazine/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Humans', 'Middle Aged', 'Psychiatric Status Rating Scales', 'Psychotropic Drugs/*therapeutic use', '*Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/10746/
2127,chlorpromazine,2568377,Guidelines for the dosage of neuroleptics. II: Changing from daily oral to long acting injectable neuroleptics.,"['Schulz P', 'Rey MJ', 'Dick P', 'Tissot R']","['Administration, Oral', 'Antipsychotic Agents/*administration & dosage', 'Chlorpromazine/*administration & dosage', 'Delayed-Action Preparations', 'Dose-Response Relationship, Drug', 'Humans', 'Psychotic Disorders/*drug therapy', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/2568377/
2128,memantine,31638686,Diagnosis and Management of Dementia: Review.,"['Arvanitakis Z', 'Shah RC', 'Bennett DA']","['Alzheimer Disease/diagnosis/therapy', 'Cholinesterase Inhibitors/adverse effects/therapeutic use', 'Dementia/*diagnosis/*therapy', 'Excitatory Amino Acid Antagonists/adverse effects/therapeutic use', 'Humans', 'Memantine/adverse effects/therapeutic use', 'Neuroimaging', 'Neuropsychological Tests']",https://pubmed.ncbi.nlm.nih.gov/31638686/
2129,memantine,34856086,Cholinesterase inhibitors and memantine for the treatment of Alzheimer and non-Alzheimer dementias.,"['Balazs N', 'Bereczki D', 'Kovacs T']","['*Alzheimer Disease/drug therapy', 'Caregivers', 'Cholinesterase Inhibitors/therapeutic use', 'Humans', '*Memantine/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/34856086/
2130,memantine,37762203,Treatment of Alzheimer's Disease: Beyond Symptomatic Therapies.,"['Buccellato FR', ""D'Anca M"", 'Tartaglia GM', 'Del Fabbro M', 'Scarpini E', 'Galimberti D']","['United States', 'Humans', 'Aged', '*Alzheimer Disease/metabolism', 'Acetylcholinesterase', 'Amyloid beta-Peptides/metabolism', 'Memantine/therapeutic use/pharmacology', 'Antibodies, Monoclonal/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37762203/
2131,memantine,16368266,Mechanism of action of memantine.,"['Johnson JW', 'Kotermanski SE']","['Alzheimer Disease/drug therapy/metabolism', 'Animals', 'Brain/drug effects/metabolism', 'Excitatory Amino Acid Antagonists/*pharmacology/therapeutic use', 'Humans', 'Ion Channel Gating', 'Ketamine/pharmacology', 'Magnesium/metabolism', 'Memantine/*pharmacology/therapeutic use', 'Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors/metabolism']",https://pubmed.ncbi.nlm.nih.gov/16368266/
2132,memantine,30222469,The efficacy and safety of memantine for the treatment of Alzheimer's disease.,"['Matsunaga S', 'Kishi T', 'Nomura I', 'Sakuma K', 'Okuya M', 'Ikuta T', 'Iwata N']","['Alzheimer Disease/*drug therapy/physiopathology', 'Cholinesterase Inhibitors/administration & dosage/adverse effects', 'Cognition/drug effects', 'Donepezil', 'Drug Therapy, Combination', 'Excitatory Amino Acid Antagonists/*administration & dosage/adverse effects', 'Humans', 'Indans/administration & dosage/adverse effects', 'Memantine/*administration & dosage/adverse effects', 'Piperidines/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30222469/
2133,memantine,34461125,"Memantine and its benefits for cancer, cardiovascular and neurological disorders.","['Shafiei-Irannejad V', 'Abbaszadeh S', 'Janssen PML', 'Soraya H']","['Animals', 'Cardiovascular Diseases/*drug therapy/metabolism', 'Excitatory Amino Acid Antagonists/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Inflammation/drug therapy/metabolism', 'Memantine/pharmacokinetics/*pharmacology/therapeutic use', 'Neoplasms/*drug therapy/metabolism', 'Nervous System Diseases/*drug therapy/metabolism', 'Oxidative Stress/drug effects', 'Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors/metabolism', 'Retinal Diseases/drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34461125/
2134,memantine,12672860,Memantine in moderate-to-severe Alzheimer's disease.,"['Reisberg B', 'Doody R', 'Stoffler A', 'Schmitt F', 'Ferris S', 'Mobius HJ']","['Activities of Daily Living', 'Aged', 'Alzheimer Disease/classification/*drug therapy/psychology', 'Behavior', 'Cognition', 'Disease Progression', 'Excitatory Amino Acid Antagonists/adverse effects/*therapeutic use', 'Female', 'Humans', 'Male', 'Memantine/adverse effects/*therapeutic use', 'Middle Aged', 'N-Methylaspartate/*antagonists & inhibitors', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/12672860/
2135,memantine,28922160,Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.,"['Kishi T', 'Matsunaga S', 'Oya K', 'Nomura I', 'Ikuta T', 'Iwata N']","['Alzheimer Disease/*drug therapy', 'Excitatory Amino Acid Antagonists/*therapeutic use', 'Humans', 'Memantine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28922160/
2136,memantine,30891742,Memantine for dementia.,"['McShane R', 'Westby MJ', 'Roberts E', 'Minakaran N', 'Schneider L', 'Farrimond LE', 'Maayan N', 'Ware J', 'Debarros J']","['Activities of Daily Living', 'Aged', 'Aged, 80 and over', 'Akathisia, Drug-Induced/etiology', 'Alzheimer Disease/drug therapy', 'Cognition Disorders/drug therapy', 'Dementia/*drug therapy', 'Dementia, Vascular/drug therapy', 'Excitatory Amino Acid Antagonists/adverse effects/*therapeutic use', 'Humans', 'Memantine/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/30891742/
2137,memantine,30349215,Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.,"['Zhang N', 'Gordon ML']","['Alzheimer Disease/*drug therapy', 'China', 'Cholinesterase Inhibitors/adverse effects/*therapeutic use', 'Cognitive Dysfunction/*drug therapy', 'Donepezil/adverse effects/*therapeutic use', 'Humans', 'Memantine/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30349215/
2138,memantine,30028898,The use of memantine in neuropsychiatric disorders: An overview.,"['Lu S', 'Nasrallah HA']","['Attention Deficit Disorder with Hyperactivity/drug therapy', 'Autism Spectrum Disorder/drug therapy', 'Binge-Eating Disorder/drug therapy', '*Drug Therapy, Combination', 'Humans', 'Memantine/pharmacology/*therapeutic use', 'Mood Disorders/drug therapy', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30028898/
2139,memantine,34851866,Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.,"['Bago Rozankovic P', 'Rozankovic M', 'Badzak J', 'Stojic M', 'Susak Sporis I']","['*Alzheimer Disease/complications/drug therapy', 'Behavioral Symptoms/drug therapy', 'Donepezil/therapeutic use', 'Humans', 'Indans/therapeutic use', '*Memantine/therapeutic use', 'Piperidines/therapeutic use', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34851866/
2140,memantine,35473731,Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.,"['Veroniki AA', 'Ashoor HM', 'Rios P', 'Seitidis G', 'Stewart L', 'Clarke M', 'Tudur-Smith C', 'Mavridis D', 'Hemmelgarn BR', 'Holroyd-Leduc J', 'Straus SE', 'Tricco AC']","['Adult', '*Alzheimer Disease/drug therapy', 'Donepezil/therapeutic use', 'Galantamine/therapeutic use', 'Humans', 'Memantine/therapeutic use', 'Network Meta-Analysis', '*Nootropic Agents/adverse effects', 'Rivastigmine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35473731/
2141,memantine,24662102,"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.","['Tan CC', 'Yu JT', 'Wang HF', 'Tan MS', 'Meng XF', 'Wang C', 'Jiang T', 'Zhu XC', 'Tan L']","['Alzheimer Disease/*drug therapy', 'Cholinesterase Inhibitors/administration & dosage', 'Donepezil', 'Galantamine/adverse effects/*therapeutic use', 'Humans', 'Indans/adverse effects/*therapeutic use', 'Memantine/adverse effects/*therapeutic use', 'Nootropic Agents/adverse effects/*therapeutic use', 'Phenylcarbamates/adverse effects/*therapeutic use', 'Piperidines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rivastigmine']",https://pubmed.ncbi.nlm.nih.gov/24662102/
2142,memantine,12710865,Memantine.,"['Jarvis B', 'Figgitt DP']","['Alzheimer Disease/drug therapy', 'Animals', 'Clinical Trials as Topic', 'Dementia/*drug therapy', 'Humans', 'Memantine/pharmacokinetics/*pharmacology/*therapeutic use', 'Receptors, N-Methyl-D-Aspartate/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/12710865/
2143,memantine,21726471,Dementia.,"['Warner JP', 'Butler R', 'Gupta S']","['*Alzheimer Disease/drug therapy', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Cholinesterase Inhibitors/administration & dosage', '*Dementia/drug therapy', 'Galantamine/therapeutic use', 'Humans', 'Memantine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21726471/
2144,memantine,19196860,Memantine (Namenda) for neuropathic pain.,"['Rogers M', 'Rasheed A', 'Moradimehr A', 'Baumrucker SJ']","['Clinical Trials as Topic', 'Humans', 'Memantine/*therapeutic use', 'Neuroprotective Agents/*therapeutic use', 'Pain/*drug therapy', 'Pain Measurement', 'Pain Threshold/drug effects', '*Palliative Care', 'Receptors, N-Methyl-D-Aspartate/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19196860/
2145,memantine,36890259,Esmethadone-HCl (REL-1017): a promising rapid antidepressant.,"['Fava M', 'Stahl SM', 'De Martin S', 'Mattarei A', 'Bettini E', 'Comai S', 'Alimonti A', 'Bifari F', 'Pani L', 'Folli F', 'Guidetti C', 'Furlan A', 'Sgrignani J', 'Locatelli P', 'Cavalli A', ""O'Gorman C"", 'Traversa S', 'Inturrisi CE', 'Pappagallo M', 'Manfredi PL']","['Humans', 'Excitatory Amino Acid Antagonists/pharmacology', '*Depressive Disorder, Major/drug therapy', 'Memantine/pharmacology/therapeutic use', 'Antidepressive Agents/pharmacology/therapeutic use', '*Alzheimer Disease/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890259/
2146,memantine,27822591,[Memantine as add-on medication to acetylcholinesterase inhibitor therapy for Alzheimer dementia].,"['Haussmann R', 'Donix M']","['Alzheimer Disease/diagnosis/*drug therapy', 'Cholinesterase Inhibitors/administration & dosage', 'Drug Administration Schedule', 'Drug Monitoring/standards', 'Drug Therapy, Combination/standards', 'Evidence-Based Medicine', 'Germany', 'Humans', 'Memantine/*administration & dosage', '*Practice Guidelines as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27822591/
2147,memantine,37248422,Synthesis and Biological Evaluation of a Library of Sulfonamide Analogs of Memantine to Target Glioblastoma.,"['Philo JE', 'Caudle JD', 'Moussa RN', 'Kampmeyer PM', 'Hasin TR', 'Seo DK', 'Sheaff RJ', 'Lamar AA']","['Animals', 'Humans', '*Glioblastoma/drug therapy', 'Memantine/pharmacology/therapeutic use', 'Sulfonamides', 'Blood-Brain Barrier', 'Biological Transport', 'Structure-Activity Relationship', '*Antineoplastic Agents', 'Mammals']",https://pubmed.ncbi.nlm.nih.gov/37248422/
2148,acebutolol,16640500,Transdermal delivery of beta-blockers.,"['Aqil M', 'Sultana Y', 'Ali A']","['Administration, Cutaneous', 'Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics', 'Animals', 'Drug Delivery Systems/*methods', 'Humans', 'Propanolamines/administration & dosage/pharmacokinetics', 'Sotalol/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16640500/
2149,acebutolol,25075,Beta-blockers and asthma.,"['Decalmer PB', 'Chatterjee SS', 'Cruickshank JM', 'Benson MK', 'Sterling GM']","['Adolescent', 'Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Adult', 'Aged', 'Asthma/*drug therapy', 'Clinical Trials as Topic', 'Female', 'Forced Expiratory Volume', 'Heart Rate/drug effects', 'Humans', 'Isoproterenol/antagonists & inhibitors', 'Male', 'Middle Aged', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25075/
2150,acebutolol,21498145,Infantile haemangioma and beta-blockers in otolaryngology.,"['Leboulanger N', 'Cox A', 'Garabedian EN', 'Denoyelle F']","['Acebutolol/pharmacology/therapeutic use', 'Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Hemangioma/*drug therapy', 'Humans', 'Infant', 'Laryngeal Neoplasms/*drug therapy', 'Laryngoscopy', 'Propranolol/pharmacology/therapeutic use', 'Tracheal Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21498145/
2151,acebutolol,19882938,[Beta blockers in migraine prophylaxis].,['Shimizu T'],"['Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics/pharmacology', 'Drug Administration Schedule', 'Humans', 'Metoprolol/administration & dosage/pharmacokinetics/pharmacology', 'Migraine Disorders/*prevention & control', 'Nadolol/administration & dosage/pharmacokinetics/pharmacology', '*Premedication', 'Propranolol/*administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19882938/
2152,acebutolol,6114739,Adrenergic hypersensitivity after beta-blocker withdrawal.,"['Ross PJ', 'Lewis MJ', 'Sheridan DJ', 'Henderson AH']","['Adrenergic beta-Antagonists/*adverse effects/therapeutic use', 'Angina Pectoris/drug therapy/physiopathology', 'Heart Rate/drug effects', 'Humans', 'Hyperthyroidism/drug therapy/physiopathology', 'Male', 'Nitroglycerin/pharmacology', 'Substance Withdrawal Syndrome/*physiopathology', 'Sympathetic Nervous System/*physiopathology', 'Valsalva Maneuver']",https://pubmed.ncbi.nlm.nih.gov/6114739/
2153,acebutolol,1977302,Relevance of intrinsic sympathomimetic activity for beta blockers.,['Jaillon P'],"['Acebutolol/pharmacology/therapeutic use', 'Adrenergic beta-Antagonists/classification/*pharmacology/therapeutic use', 'Animals', 'Blood Circulation/drug effects', 'Cardiac Output/drug effects', 'Catecholamines/*antagonists & inhibitors', 'Drug Evaluation', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy', 'Lipoproteins/blood', 'Myocardial Infarction/prevention & control', 'Rats', 'Receptors, Adrenergic, beta/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1977302/
2154,acebutolol,32662682,beta-blocker therapy for infantile hemangioma.,"['Koh SP', 'Leadbitter P', 'Smithers F', 'Tan ST']","['Adrenergic beta-Antagonists/*administration & dosage/adverse effects/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Animals', 'Hemangioma/*drug therapy/pathology', 'Humans', 'Infant', 'Propranolol/administration & dosage/adverse effects/pharmacology', 'Renin-Angiotensin System/drug effects', 'Skin Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/32662682/
2155,acebutolol,6147077,Single-agent and combination therapy of essential hypertension.,"['Weber MA', 'Drayer JI']","['Acebutolol/administration & dosage', 'Adrenergic beta-Antagonists/*administration & dosage/therapeutic use', 'Adult', 'Aldosterone/metabolism', 'Blood Pressure/drug effects', 'Diuretics/*administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/administration & dosage', 'Hypertension/*drug therapy/metabolism/physiopathology', 'Male', 'Metoprolol/administration & dosage', 'Middle Aged', 'Propranolol/administration & dosage', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6147077/
2156,acebutolol,20557953,Management of infantile subglottic hemangioma: acebutolol or propranolol?,"['Blanchet C', 'Nicollas R', 'Bigorre M', 'Amedro P', 'Mondain M']","['Acebutolol/*administration & dosage', 'Adrenergic beta-Antagonists/administration & dosage', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Glottis/pathology', 'Hemangioma/congenital/*drug therapy', 'Humans', 'Laryngeal Neoplasms/congenital/*drug therapy/surgery', 'Laryngoscopy/methods', 'Laryngostenosis/diagnosis/etiology', 'Neoplasm Recurrence, Local/pathology/*surgery', 'Propranolol/*administration & dosage', 'Sampling Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20557953/
2157,acebutolol,6794766,Neonatal effects of maternal administration of acebutolol.,"['Dumez Y', 'Tchobroutsky C', 'Hornych H', 'Amiel-Tison C']","['Acebutolol/*adverse effects/therapeutic use', 'Blood Glucose/analysis', 'Blood Pressure/drug effects', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy', 'Infant, Newborn', '*Maternal-Fetal Exchange', 'Methyldopa/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/drug therapy', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/6794766/
2158,acebutolol,19067419,Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol.,"['Kato Y', 'Miyazaki T', 'Kano T', 'Sugiura T', 'Kubo Y', 'Tsuji A']","['ATP Binding Cassette Transporter, Subfamily B, Member 1/genetics/*metabolism', 'Administration, Oral', 'Adrenergic beta-Antagonists/blood/metabolism/*pharmacokinetics', 'Animals', 'Celiprolol/blood/metabolism/*pharmacokinetics', 'Humans', '*Intestinal Absorption/drug effects', 'Intestine, Small/drug effects/*metabolism', 'Male', 'Mice', 'Mice, Knockout', 'Oocytes/metabolism', 'Organic Anion Transporters/antagonists & inhibitors/genetics/*metabolism', 'Sulfobromophthalein/pharmacology', 'Transfection', 'Xenopus laevis']",https://pubmed.ncbi.nlm.nih.gov/19067419/
2159,acebutolol,1293408,Toxicological findings in a fatal case of acebutolol self-poisoning.,"['Tracqui A', 'Kintz P', 'Wendling P', 'Ritter-Lohner S', 'Mangin P', 'Jaeger A']","['Acebutolol/analysis/*poisoning', 'Adolescent', 'Chromatography, High Pressure Liquid', 'Female', 'Humans', 'Suicide']",https://pubmed.ncbi.nlm.nih.gov/1293408/
2160,acebutolol,6146344,Beta-adrenoceptor blocker pharmacokinetics and the oral contraceptive pill.,"['Kendall MJ', 'Jack DB', 'Quarterman CP', 'Smith SR', 'Zaman R']","['Acebutolol/metabolism', 'Adrenergic beta-Antagonists/*metabolism', 'Contraceptives, Oral/*pharmacology', 'Contraceptives, Oral, Hormonal/*pharmacology', 'Drug Interactions', 'Female', 'Humans', 'Kinetics', 'Metoprolol/metabolism', 'Oxprenolol/metabolism', 'Propranolol/metabolism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6146344/
2161,acebutolol,7950612,Randomised controlled trial of enalapril and beta blockers in non-diabetic chronic renal failure.,"['Hannedouche T', 'Landais P', 'Goldfarb B', 'el Esper N', 'Fournier A', 'Godin M', 'Durand D', 'Chanard J', 'Mignon F', 'Suo JM', 'et al.']","['Acebutolol/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Aged', 'Atenolol/adverse effects/*therapeutic use', 'Blood Pressure', 'Body Weight', 'Enalapril/adverse effects/*therapeutic use', 'Female', 'Humans', 'Hypertension/complications', 'Kidney Failure, Chronic/*drug therapy/mortality/physiopathology', 'Male', 'Middle Aged', 'Potassium/blood', 'Proteinuria/etiology']",https://pubmed.ncbi.nlm.nih.gov/7950612/
2162,acebutolol,8187,"Comparison of propranolol, metoprolol, and acebutolol on insulin-induced hypoglycaemia.",['Newman RJ'],"['Acebutolol/*pharmacology', 'Adrenergic beta-Antagonists/*pharmacology', 'Adult', '*Blood Glucose/analysis', 'Depression, Chemical', 'Drug Synergism', 'Heart Rate/drug effects', 'Humans', 'Hypoglycemia/chemically induced/*metabolism', 'Insulin', 'Male', 'Propanolamines/*pharmacology', 'Propranolol/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8187/
2163,acebutolol,3013766,Is low-dose hydrochlorothiazide effective?,"['Magee PF', 'Freis ED']","['Acebutolol/administration & dosage', 'Aged', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Enalapril/administration & dosage', 'Humans', 'Hydrochlorothiazide/*administration & dosage/adverse effects', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nadolol', 'Potassium/blood', 'Propanolamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/3013766/
2164,acebutolol,32888198,Time course for blood pressure lowering of beta-blockers with partial agonist activity.,"['Zhang XY', 'Soufi S', 'Dormuth C', 'Musini VM']","['Acebutolol/therapeutic use', 'Adrenergic beta-Agonists/therapeutic use', 'Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Antihypertensive Agents/*therapeutic use', 'Bias', 'Blood Pressure/*drug effects/physiology', 'Circadian Rhythm/*physiology', 'Controlled Clinical Trials as Topic', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Pindolol/analogs & derivatives/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/32888198/
2165,acebutolol,12458371,The effect of selective beta1-blockade on EMG signal characteristics during progressive endurance exercise.,"['Hunter AM', 'St Clair Gibson A', 'Derman WE', 'Lambert M', 'Dennis SC', 'Noakes TD']","['Acebutolol/*pharmacology', 'Adrenergic beta-Antagonists/*pharmacology', 'Adult', 'Electromyography', 'Exercise/*physiology', 'Humans', 'Male', 'Muscle, Skeletal/*drug effects/*physiology', 'Neuromuscular Junction/drug effects/physiology', 'Physical Endurance/*physiology', 'Recruitment, Neurophysiological/drug effects/physiology', 'Sympathetic Nervous System/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/12458371/
2166,acebutolol,10729673,Acebutolol overdose resulting in fatalities.,['Love JN'],"['Acebutolol/*poisoning', 'Adolescent', 'Adrenergic beta-Antagonists/*poisoning', 'Adult', 'Drug Overdose/diagnosis/drug therapy', 'Drug Therapy, Combination', 'Electrocardiography', 'Emergency Service, Hospital', 'Fatal Outcome', 'Female', 'Humans', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/10729673/
2167,acebutolol,9114777,Effectiveness of digitalis with or without acebutolol in preventing atrial arrhythmias after coronary artery surgery.,"['Kowey PR', 'Dalessandro DA', 'Herbertson R', 'Briggs B', 'Wertan MA', 'Rials SJ', 'Filart RA', 'Marinchak RA']","['Acebutolol/*therapeutic use', 'Aged', 'Anti-Arrhythmia Agents/*therapeutic use', 'Atrial Fibrillation/etiology/*prevention & control', 'Atrial Flutter/etiology/*prevention & control', 'Coronary Artery Bypass/*adverse effects', 'Digoxin/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Single-Blind Method', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9114777/
2168,primidone,38553256,Essential Tremor: Update of Therapeutic Strategies.,"['Gironell A', 'Marin-Lahoz J', 'Poveda S']","['*Essential Tremor/therapy/drug therapy', 'Humans', 'Propranolol/therapeutic use', 'Primidone/therapeutic use', 'High-Intensity Focused Ultrasound Ablation', 'Anticonvulsants/therapeutic use', 'Thalamus', 'Adrenergic beta-Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38553256/
2169,primidone,12869807,Tremor.,['Sethi KD'],"['Acetates/therapeutic use', '*Amines', 'Anticonvulsants/therapeutic use', 'Antiparkinson Agents/therapeutic use', '*Cyclohexanecarboxylic Acids', 'Diagnosis, Differential', 'Electromyography', 'Essential Tremor/diagnosis/drug therapy/physiopathology', 'Fructose/*analogs & derivatives/therapeutic use', 'Gabapentin', 'Humans', 'Levodopa/therapeutic use', 'Motor Cortex/physiopathology', 'Muscle, Skeletal/physiopathology', 'Parkinson Disease/diagnosis/drug therapy/*physiopathology', 'Posture', 'Primidone/therapeutic use', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index', 'Somatosensory Cortex/physiopathology', 'Topiramate', 'Tremor/diagnosis/drug therapy/*physiopathology', '*gamma-Aminobutyric Acid']",https://pubmed.ncbi.nlm.nih.gov/12869807/
2170,primidone,25515681,"Interactions between antiepileptic drugs, and between antiepileptic drugs and other drugs.","['Zaccara G', 'Perucca E']","['Anticonvulsants/*adverse effects/*pharmacokinetics', '*Drug Interactions', 'Epilepsy/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25515681/
2171,primidone,30704686,Essential Tremor.,['Reich SG'],"['Adrenergic beta-Antagonists/therapeutic use', 'Aged', 'Deep Brain Stimulation', 'Diagnosis, Differential', 'Essential Tremor/*diagnosis/*therapy', 'Female', 'Humans', 'Parkinson Disease/diagnosis', 'Primidone/therapeutic use', 'Propranolol/therapeutic use', 'Ultrasonic Therapy']",https://pubmed.ncbi.nlm.nih.gov/30704686/
2172,primidone,3504257,Essential tongue tremor.,"['Biary N', 'Koller WC']","['Adolescent', 'Adult', 'Aged', 'Clonazepam/therapeutic use', 'Coxsackievirus Infections/*physiopathology', 'Electroencephalography', 'Ethanol/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Primidone/therapeutic use', 'Propranolol/therapeutic use', 'Tongue Diseases/drug therapy/*physiopathology', 'Tremor/drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/3504257/
2173,primidone,19067999,Postural induced-tremor in psychiatry.,"['Arbaizar B', 'Gomez-Acebo I', 'Llorca J']","['Biomechanical Phenomena', 'Humans', 'Mental Disorders/complications/drug therapy', 'Muscle, Skeletal/physiopathology', 'Parkinson Disease/complications', 'Psychotropic Drugs/*adverse effects/therapeutic use', 'Tremor/*chemically induced/classification/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/19067999/
2174,primidone,30102491,Phenytoin induced dystonia.,"['Acar T', 'Alkan G', 'Caksen H', 'Ertekin B', 'Ergin M', 'Kocak S', 'Cander B']","['Anticonvulsants/*adverse effects/therapeutic use', 'Child, Preschool', 'Dystonia/*chemically induced', 'Epilepsy/*drug therapy', 'Humans', 'Male', 'Phenytoin/*adverse effects', 'Primidone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30102491/
2175,primidone,9203243,Established antiepileptic drugs.,"['Brodie MJ', 'Dichter MA']","['Anticonvulsants/adverse effects/pharmacology/*therapeutic use', 'Drug Monitoring', 'Drug Therapy, Combination', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9203243/
2176,primidone,1914921,[Orthostatic tremor].,"['Willeit J', 'Deisenhammer F', 'Ransmayr G', 'Gerstenbrand F']","['Aged', 'Chronic Disease', 'Dose-Response Relationship, Drug', 'Electromyography', 'Humans', 'Male', 'Middle Aged', 'Neurologic Examination', '*Posture/physiology', 'Primidone/administration & dosage', 'Tremor/*diagnosis/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1914921/
2177,primidone,14524643,Essential tremor: diagnosis and treatment.,"['Chen JJ', 'Swope DM']","['Acetates/therapeutic use', '*Amines', '*Cyclohexanecarboxylic Acids', 'Diagnosis, Differential', 'Essential Tremor/classification/*diagnosis/*therapy', 'Gabapentin', 'Humans', 'Parkinson Disease/diagnosis/drug therapy', 'Primidone/therapeutic use', 'Propranolol/therapeutic use', '*gamma-Aminobutyric Acid']",https://pubmed.ncbi.nlm.nih.gov/14524643/
2178,primidone,29404647,[Essential tremor: state of the art].,"['Deuschl G', 'Berg D']","['Age Factors', 'Deep Brain Stimulation', 'Diagnosis, Differential', 'Essential Tremor/classification/*diagnosis/physiopathology/therapy', 'Genetic Predisposition to Disease', 'Humans', 'Nerve Net/physiopathology', 'Primidone/therapeutic use', 'Prognosis', 'Propranolol/therapeutic use', 'Risk Factors', 'Syndrome', 'Ventral Thalamic Nuclei/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/29404647/
2179,primidone,1678770,Tremor.,['Gillespie MM'],"['Adrenergic beta-Antagonists/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Patient Care Planning', 'Primidone/administration & dosage/adverse effects/therapeutic use', 'Tremor/*classification/drug therapy/nursing']",https://pubmed.ncbi.nlm.nih.gov/1678770/
2180,primidone,31976837,Current and Future Neuropharmacological Options for the Treatment of Essential Tremor.,"['Alonso-Navarro H', 'Garcia-Martin E', 'Agundez JAG', 'Jimenez-Jimenez FJ']","['Adrenergic beta-Antagonists/therapeutic use', 'Animals', 'Anticonvulsants/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Electrical Synapses/drug effects', 'Essential Tremor/*drug therapy', 'Humans', 'Neuropharmacology', 'Primidone/therapeutic use', 'Propranolol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31976837/
2181,primidone,19454072,Essential tremor.,"['Ferreira JJ', 'Sampaio C']","['*Double-Blind Method', '*Essential Tremor/drug therapy', 'Humans', 'Primidone/therapeutic use', 'Propranolol/therapeutic use', 'Tremor/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19454072/
2182,primidone,15794733,Pharmacological treatment of disabling tremor.,"['Schadt CR', 'Duffis EI', 'Charles PD']","['Botulinum Toxins, Type A/therapeutic use', 'Dystonia/*drug therapy', 'Essential Tremor/*drug therapy', 'Humans', 'Parkinson Disease/*drug therapy', 'Primidone/therapeutic use', 'Propranolol/therapeutic use', 'Tremor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15794733/
2183,primidone,6407960,Diagnosis and treatment of epilepsy.,['Rowan AJ'],"['Automatism/etiology', 'Benzodiazepines/therapeutic use', 'Carbamazepine/therapeutic use', 'Electroencephalography/methods', 'Epilepsies, Partial/diagnosis/etiology', 'Epilepsy/*diagnosis/drug therapy/physiopathology', 'Epilepsy, Temporal Lobe/complications', 'Ethosuximide/therapeutic use', 'Humans', 'Muscle Tonus', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Primidone/therapeutic use', 'Telemetry/methods', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6407960/
2184,primidone,16736,Interactions with antiepileptic drugs.,['Richens A'],"['Acetaminophen/pharmacology', 'Acetazolamide/pharmacology', 'Anti-Anxiety Agents/pharmacology', 'Anticoagulants/pharmacology', 'Anticonvulsants/blood/*pharmacology', 'Carbamazepine/pharmacology', 'Diazepam/pharmacology', 'Drug Interactions', 'Furosemide/pharmacology', 'Gonadal Steroid Hormones/pharmacology', 'Griseofulvin/pharmacology', 'Humans', 'Phenobarbital/pharmacology', 'Phenytoin/blood', 'Primidone/pharmacology', 'Thiazines/pharmacology', 'Urea/analogs & derivatives/pharmacology', 'Valproic Acid/pharmacology', 'Vitamin D/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16736/
2185,primidone,241674,Behavioural effects of anti-epileptic drugs.,['Stores G'],"['Anti-Anxiety Agents/adverse effects', 'Anticonvulsants/*adverse effects/therapeutic use', 'Benzodiazepines', 'Carbamazepine/therapeutic use', 'Confusion/chemically induced', 'Disorders of Excessive Somnolence/chemically induced', 'Epilepsy/*drug therapy', 'Ethosuximide/adverse effects', 'Humans', 'Hyperkinesis/chemically induced', 'Learning Disabilities/chemically induced', 'Mental Disorders/*chemically induced', 'Phenobarbital/adverse effects', 'Phenytoin/adverse effects', 'Primidone/adverse effects', 'Psychoses, Substance-Induced/etiology', 'Psychotropic Drugs/pharmacology', 'Thiazines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/241674/
2186,primidone,9375547,Nonconvulsive status epilepticus.,"['Thibodeau LG', 'Ferrera PC']","['Anticonvulsants/therapeutic use', 'Dizziness/diagnosis', 'Electroencephalography', 'Emergency Service, Hospital', 'Epilepsy, Tonic-Clonic/prevention & control', 'Humans', 'Lorazepam/therapeutic use', 'Male', 'Middle Aged', 'Neurologic Examination', 'Phenobarbital/therapeutic use', 'Primidone/therapeutic use', 'Status Epilepticus/*diagnosis', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9375547/
2187,primidone,18540790,Essential tremor: symptoms and treatment.,"['Wick JY', 'Zanni GR']","['Adolescent', 'Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Aged', 'Anticonvulsants/therapeutic use', 'Essential Tremor/classification/diagnosis/*drug therapy/etiology', 'Humans', 'Middle Aged', 'Parkinson Disease/diagnosis', 'Primidone/*therapeutic use', 'Propranolol/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18540790/
2188,Ziprasidone,12973403,Antipsychotic medication and seizures: a review.,"['Hedges D', 'Jeppson K', 'Whitehead P']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Aripiprazole', 'Benzodiazepines', 'Clinical Trials as Topic', 'Clozapine/pharmacology/therapeutic use', 'Dibenzothiazepines/pharmacology/therapeutic use', 'Humans', 'Imidazoles/pharmacology/therapeutic use', 'Indoles/pharmacology/therapeutic use', 'Olanzapine', 'Piperazines/pharmacology/therapeutic use', 'Pirenzepine/*analogs & derivatives/pharmacology/therapeutic use', 'Quetiapine Fumarate', 'Quinolones/pharmacology/therapeutic use', 'Risperidone/pharmacology/therapeutic use', 'Seizures/*chemically induced', 'Thiazoles/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12973403/
2189,Ziprasidone,30346242,Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness.,"['Girard TD', 'Exline MC', 'Carson SS', 'Hough CL', 'Rock P', 'Gong MN', 'Douglas IS', 'Malhotra A', 'Owens RL', 'Feinstein DJ', 'Khan B', 'Pisani MA', 'Hyzy RC', 'Schmidt GA', 'Schweickert WD', 'Hite RD', 'Bowton DL', 'Masica AL', 'Thompson JL', 'Chandrasekhar R', 'Pun BT', 'Strength C', 'Boehm LM', 'Jackson JC', 'Pandharipande PP', 'Brummel NE', 'Hughes CG', 'Patel MB', 'Stollings JL', 'Bernard GR', 'Dittus RS', 'Ely EW']","['Aged', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Critical Illness/mortality/*psychology/therapy', 'Delirium/*drug therapy', 'Dopamine Antagonists/*therapeutic use', 'Double-Blind Method', 'Female', 'Haloperidol/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Piperazines/administration & dosage/adverse effects/*therapeutic use', 'Respiratory Insufficiency/psychology', 'Shock/psychology', 'Thiazoles/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/30346242/
2190,Ziprasidone,33341539,Antipsychotics and hemodialysis: A systematic review.,"['Sutar R', 'Atlani MK', 'Chaudhary P']","['*Antipsychotic Agents/adverse effects', 'Benzodiazepines', 'Humans', 'Olanzapine', 'Renal Dialysis', 'Risperidone/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33341539/
2191,Ziprasidone,29915922,Clinical Pharmacokinetics of Atypical Antipsychotics: An Update.,"['Mauri MC', 'Paletta S', 'Di Pace C', 'Reggiori A', 'Cirnigliaro G', 'Valli I', 'Altamura AC']","['Animals', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Monitoring/*methods', 'Humans', 'Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/29915922/
2192,Ziprasidone,16172203,Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.,"['Lieberman JA', 'Stroup TS', 'McEvoy JP', 'Swartz MS', 'Rosenheck RA', 'Perkins DO', 'Keefe RS', 'Davis SM', 'Davis CE', 'Lebowitz BD', 'Severe J', 'Hsiao JK']","['Adult', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Chronic Disease', 'Dibenzothiazepines/adverse effects/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Lipids/blood', 'Male', 'Olanzapine', 'Patient Compliance', 'Perphenazine/adverse effects/therapeutic use', 'Piperazines/adverse effects/therapeutic use', 'Proportional Hazards Models', 'Quetiapine Fumarate', 'Risperidone/adverse effects/therapeutic use', 'Schizophrenia/blood/*drug therapy', 'Thiazoles/adverse effects/therapeutic use', 'Treatment Outcome', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/16172203/
2193,Ziprasidone,27919473,Kounis syndrome and ziprasidone.,"['Hamera L', 'Khishfe BF']","['Acute Coronary Syndrome/*chemically induced/*immunology', 'Adult', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Bipolar Disorder/*drug therapy', 'Drug Hypersensitivity/*complications', 'Emergency Service, Hospital', 'Humans', 'Male', 'Piperazines/*adverse effects/therapeutic use', '*Suicidal Ideation', 'Syndrome', 'Thiazoles/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27919473/
2194,Ziprasidone,29885904,"Intramuscular Midazolam, Olanzapine, Ziprasidone, or Haloperidol for Treating Acute Agitation in the Emergency Department.","['Klein LR', 'Driver BE', 'Miner JR', 'Martel ML', 'Hessel M', 'Collins JD', 'Horton GB', 'Fagerstrom E', 'Satpathy R', 'Cole JB']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Antipsychotic Agents/administration & dosage/*therapeutic use', 'Cohort Studies', 'Emergency Medical Services', 'Female', 'Haloperidol/administration & dosage/therapeutic use', 'Humans', 'Injections, Intramuscular', 'Male', 'Mental Status and Dementia Tests', 'Midazolam/administration & dosage/therapeutic use', 'Middle Aged', 'Olanzapine/administration & dosage/therapeutic use', 'Piperazines/administration & dosage/therapeutic use', 'Prospective Studies', 'Psychomotor Agitation/*drug therapy', 'Thiazoles/administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29885904/
2195,Ziprasidone,31974576,"Antipsychotic Treatment Effectiveness in First Episode of Psychosis: PAFIP 3-Year Follow-Up Randomized Clinical Trials Comparing Haloperidol, Olanzapine, Risperidone, Aripiprazole, Quetiapine, and Ziprasidone.","['Gomez-Revuelta M', 'Pelayo-Teran JM', 'Juncal-Ruiz M', 'Vazquez-Bourgon J', 'Suarez-Pinilla P', 'Romero-Jimenez R', 'Setien Suero E', 'Ayesa-Arriola R', 'Crespo-Facorro B']","['Adolescent', 'Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*pharmacology', 'Aripiprazole/administration & dosage/adverse effects/*pharmacology', 'Female', 'Follow-Up Studies', 'Haloperidol/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Male', 'Olanzapine/administration & dosage/adverse effects/*pharmacology', '*Outcome Assessment, Health Care', 'Piperazines/administration & dosage/adverse effects/*pharmacology', 'Psychotic Disorders/*drug therapy', 'Quetiapine Fumarate/administration & dosage/adverse effects/*pharmacology', 'Risperidone/administration & dosage/adverse effects/*pharmacology', 'Schizophrenia/*drug therapy', 'Thiazoles/administration & dosage/adverse effects/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31974576/
2196,Ziprasidone,23859663,Atypical antipsychotics in the treatment of delirium.,"['Wang HR', 'Woo YS', 'Bahk WM']","['Amisulpride', 'Antipsychotic Agents/adverse effects/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Delirium/*drug therapy', 'Dibenzothiazepines/therapeutic use', 'Humans', 'Olanzapine', 'Piperazines/therapeutic use', 'Quetiapine Fumarate', 'Randomized Controlled Trials as Topic', 'Risperidone/therapeutic use', 'Sulpiride/analogs & derivatives/therapeutic use', 'Thiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23859663/
2197,Ziprasidone,38701817,"Long-term outcomes after treatment of delirium during critical illness with antipsychotics (MIND-USA): a randomised, placebo-controlled, phase 3 trial.","['Mart MF', 'Boehm LM', 'Kiehl AL', 'Gong MN', 'Malhotra A', 'Owens RL', 'Khan BA', 'Pisani MA', 'Schmidt GA', 'Hite RD', 'Exline MC', 'Carson SS', 'Hough CL', 'Rock P', 'Douglas IS', 'Feinstein DJ', 'Hyzy RC', 'Schweickert WD', 'Bowton DL', 'Masica A', 'Orun OM', 'Raman R', 'Pun BT', 'Strength C', 'Rolfsen ML', 'Pandharipande PP', 'Brummel NE', 'Hughes CG', 'Patel MB', 'Stollings JL', 'Ely EW', 'Jackson JC', 'Girard TD']","['Humans', '*Antipsychotic Agents/therapeutic use/adverse effects', '*Delirium/drug therapy', 'Male', '*Critical Illness/psychology/therapy', 'Female', 'Middle Aged', 'Double-Blind Method', 'Aged', '*Quality of Life', 'Haloperidol/therapeutic use', 'Treatment Outcome', 'Piperazines/therapeutic use/adverse effects', 'Adult', 'Thiazoles/therapeutic use/adverse effects/administration & dosage', 'Follow-Up Studies', 'Intensive Care Units']",https://pubmed.ncbi.nlm.nih.gov/38701817/
2198,Ziprasidone,26033792,Rational Use of Second-Generation Antipsychotics for the Treatment of ICU Delirium.,"['Mo Y', 'Yam FK']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Cytochrome P-450 Enzyme System/genetics', 'Delirium/diagnosis/*drug therapy', 'Humans', '*Intensive Care Units', 'Synaptic Transmission/drug effects']",https://pubmed.ncbi.nlm.nih.gov/26033792/
2199,Ziprasidone,15468580,[Psychotropics and weight gain].,"['Sahli Ch', 'Bryois Ch']","['Adolescent', 'Adult', 'Amisulpride', 'Antidepressive Agents/administration & dosage/adverse effects', 'Antimanic Agents/administration & dosage/adverse effects', 'Antipsychotic Agents/administration & dosage/adverse effects', 'Aripiprazole', 'Benzodiazepines/administration & dosage/adverse effects', 'Body Mass Index', 'Child', 'Clozapine/administration & dosage/adverse effects', 'Dibenzothiazepines/administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Fructose/administration & dosage/adverse effects/*analogs & derivatives', 'Haloperidol/administration & dosage/adverse effects', 'Humans', 'Imidazoles/administration & dosage/adverse effects', 'Indoles/administration & dosage/adverse effects', 'Male', 'Obesity/*chemically induced', 'Olanzapine', 'Piperazines/administration & dosage/adverse effects', 'Placebos', 'Psychotropic Drugs/administration & dosage/*adverse effects', 'Quetiapine Fumarate', 'Quinolones/administration & dosage/adverse effects', 'Randomized Controlled Trials as Topic', 'Risperidone/administration & dosage/adverse effects', 'Socioeconomic Factors', 'Sulpiride/administration & dosage/adverse effects/*analogs & derivatives', 'Thiazoles/administration & dosage/adverse effects', 'Time Factors', 'Topiramate', 'Valproic Acid/administration & dosage/adverse effects', '*Weight Gain']",https://pubmed.ncbi.nlm.nih.gov/15468580/
2200,Ziprasidone,10340682,Receptor pharmacology of neuroleptics: relation to clinical effects.,['Richelson E'],"['Adrenergic alpha-Antagonists/pharmacology', 'Animals', 'Antipsychotic Agents/*pharmacology/therapeutic use', 'Dopamine Antagonists/pharmacology', 'Drug Interactions', 'Humans', 'Muscarinic Antagonists/pharmacology', 'Receptors, Dopamine/drug effects', 'Receptors, Muscarinic/drug effects', 'Receptors, Neurotransmitter/*drug effects', 'Receptors, Serotonin/drug effects', 'Serotonin Antagonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/10340682/
2201,Ziprasidone,33763203,Case Report: Ziprasidone induced neuroleptic malignant syndrome.,"['Sedhai YR', 'Atreya A', 'Phuyal P', 'Basnyat S', 'Pokhrel S']","['*Antipsychotic Agents/adverse effects', 'Humans', '*Neuroleptic Malignant Syndrome/etiology', 'Piperazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33763203/
2202,Ziprasidone,16487905,A systematic review of the efficacy and safety of second generation antipsychotics in the treatment of mania.,"['Jones RM', 'Thompson C', 'Bitter I']","['Antipsychotic Agents/*adverse effects/therapeutic use', 'Benzodiazepines/adverse effects', 'Bipolar Disorder/*drug therapy', 'Clozapine/adverse effects', 'Dibenzothiazepines/adverse effects', 'Humans', 'Olanzapine', 'Piperazines/adverse effects', 'Quetiapine Fumarate', 'Risperidone/adverse effects', 'Thiazoles/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/16487905/
2203,Ziprasidone,15517848,Aripiprazole: review of its pharmacology and therapeutic use in psychiatric disorders.,"['Gupta S', 'Masand P']","['Antipsychotic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Aripiprazole', 'Basal Ganglia Diseases/chemically induced', 'Bipolar Disorder/*drug therapy', 'Body Weight/drug effects', 'Cognition/drug effects', 'Dyskinesia, Drug-Induced/etiology', 'Electrocardiography/drug effects', 'Humans', 'Lipoproteins/drug effects', 'Piperazines/adverse effects/pharmacokinetics/*therapeutic use', 'Quinolones/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15517848/
2204,Ziprasidone,19164500,Ziprasidone-induced spontaneous orgasm.,"['Boora K', 'Chiappone K', 'Dubovsky S', 'Xu J']","['Antipsychotic Agents/adverse effects/therapeutic use', 'Bipolar Disorder/*drug therapy', 'Female', 'Humans', 'Middle Aged', '*Orgasm', 'Piperazines/*adverse effects/therapeutic use', 'Sexual Dysfunctions, Psychological/*chemically induced', 'Thiazoles/*adverse effects/therapeutic use', 'Torticollis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19164500/
2205,Ziprasidone,15222776,Dose response and atypical antipsychotics in schizophrenia.,"['Kinon BJ', 'Ahl J', 'Stauffer VL', 'Hill AL', 'Buckley PF']","['Antipsychotic Agents/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Humans', 'Schizophrenia/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15222776/
2206,Ziprasidone,25351397,[Sparse evidence of antipsychotic drugs for the treatment of delirium].,"['Andersen CU', 'Hoimark L', 'Dabrowski K', 'Hansen KB', 'Saedder E']","['Amisulpride', 'Antipsychotic Agents/*therapeutic use', 'Benzodiazepines/therapeutic use', 'Delirium/*drug therapy', 'Evidence-Based Medicine', 'Humans', 'Olanzapine', 'Piperazines/therapeutic use', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/therapeutic use', 'Sulpiride/analogs & derivatives/therapeutic use', 'Thiazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25351397/
2207,Ziprasidone,21448108,Antipsychotic treatment--side-effect and/or metabolic syndrome.,"['Dadic-Hero E', 'Ruzic K', 'Grahovac T', 'Palijan TZ', 'Petranovic D', 'Sepic-Grahovac D']","['Adult', 'Antipsychotic Agents/*adverse effects/therapeutic use', 'Benzodiazepines/*adverse effects/*therapeutic use', 'Combined Modality Therapy', 'Drug Substitution/psychology', 'Female', 'Humans', 'Metabolic Syndrome/*chemically induced/*diagnosis/psychology', 'Olanzapine', 'Piperazines/adverse effects/therapeutic use', 'Psychotherapy', 'Schizophrenia/diagnosis/*drug therapy', '*Schizophrenic Psychology', 'Social Adjustment', 'Thiazoles/adverse effects/therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21448108/
2208,glipizide,26204670,HYPOGLYCEMIA INDUCED BY ANTIDIABETIC SULFONYLUREAS.,"['Confederat L', 'Constantin S', 'Lupascu F', 'Panzariu A', 'Hancianu M', 'Profire L']","['Chlorpropamide/adverse effects', '*Diabetes Mellitus, Type 2/drug therapy', 'Gliclazide/adverse effects', 'Glipizide/adverse effects', 'Glyburide/adverse effects', 'Humans', 'Hypoglycemia/*chemically induced', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Risk Factors', 'Sulfonylurea Compounds/administration & dosage/*adverse effects', 'Tolbutamide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26204670/
2209,glipizide,37714605,The Patient Faints in the Waiting Area with a Suspected Hypoglycemic Event.,"['Chmieliauskaite M', 'Grosh MD', 'Syed A', 'Pinto A']","['Female', 'Humans', 'Aged', '*Hypoglycemic Agents/adverse effects', '*Hypoglycemia/chemically induced', 'Sulfonylurea Compounds/adverse effects', 'Glipizide']",https://pubmed.ncbi.nlm.nih.gov/37714605/
2210,glipizide,34721294,Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.,"['Zhang YS', 'Zheng YD', 'Yuan Y', 'Chen SC', 'Xie BC']","['Diabetes Mellitus, Type 2/*drug therapy', 'Fractures, Bone/*etiology', 'Humans', 'Hypoglycemic Agents/*adverse effects/therapeutic use', 'Network Meta-Analysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/34721294/
2211,glipizide,30246878,Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.,"['Lo C', 'Toyama T', 'Wang Y', 'Lin J', 'Hirakawa Y', 'Jun M', 'Cass A', 'Hawley CM', 'Pilmore H', 'Badve SV', 'Perkovic V', 'Zoungas S']","['Cause of Death', 'Diabetes Mellitus/blood/*drug therapy/mortality', 'Diabetic Nephropathies/blood/*drug therapy/mortality', 'Dipeptidyl-Peptidase IV Inhibitors/therapeutic use', 'Glipizide/adverse effects/therapeutic use', 'Glucagon-Like Peptide 1/agonists', 'Glycated Hemoglobin/drug effects', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Renal Insufficiency, Chronic/blood/*drug therapy/mortality', 'Sitagliptin Phosphate/adverse effects/therapeutic use', 'Sodium-Glucose Transporter 2', 'Sodium-Glucose Transporter 2 Inhibitors', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30246878/
2212,glipizide,16596036,Antihypertensive pharmacobezoar.,"['Prisant LM', 'Spaulding VC']","['Antihypertensive Agents/*administration & dosage/*adverse effects', 'Bezoars/*etiology', 'Calcium Channel Blockers/administration & dosage', 'Drug Delivery Systems/*adverse effects', 'Gastrointestinal Diseases/*etiology', 'Humans', 'Isradipine/administration & dosage/adverse effects', 'Nifedipine/administration & dosage', 'Postoperative Complications/etiology', 'Tablets', 'Verapamil/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16596036/
2213,glipizide,15200348,The role of sulphonylureas in the management of type 2 diabetes mellitus.,['Rendell M'],"['Benzamides/therapeutic use', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/15200348/
2214,glipizide,27796819,Sulfonylurea Poisoning in a Healthy Toddler.,"['Kumar S', 'Choudhary A', 'Ali M', 'Gupta V', 'Muralidharan J', 'Singhi SC']","['Gastrointestinal Agents/therapeutic use', 'Glipizide/*poisoning', 'Glucose/therapeutic use', 'Humans', 'Hypoglycemic Agents/*poisoning', 'Infant', 'Male', 'Octreotide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27796819/
2215,glipizide,19366943,Use of hypoglycemic drugs during lactation.,"['Glatstein MM', 'Djokanovic N', 'Garcia-Bournissen F', 'Finkelstein Y', 'Koren G']","['Administration, Oral', 'Breast Feeding', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glipizide/administration & dosage/adverse effects', 'Glyburide/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Infant, Newborn', 'Lactation/*drug effects', 'Maternal Welfare', 'Milk, Human/drug effects', 'Pregnancy', 'Pregnancy in Diabetics/drug therapy', 'Risk Assessment', 'Sulfonylurea Compounds/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19366943/
2216,glipizide,3931464,Pharmacokinetics of glyburide.,['Pearson JG'],"['Acute Kidney Injury/metabolism', 'Blood Glucose/analysis', 'Dose-Response Relationship, Drug', 'Fasting', 'Glipizide/metabolism', 'Glyburide/*metabolism/urine', 'Humans', 'Kidney/metabolism', 'Kinetics', 'Liver/metabolism']",https://pubmed.ncbi.nlm.nih.gov/3931464/
2217,glipizide,389600,Glipizide: a review of its pharmacological properties and therapeutic use.,"['Brogden RN', 'Heel RC', 'Pakes GE', 'Speight TM', 'Avery GS']","['Animals', 'Diabetes Mellitus/drug therapy', 'Fatty Acids/blood', 'Glipizide/administration & dosage/adverse effects/metabolism/*pharmacology/therapeutic use', 'Glucagon/blood', 'Humans', 'Hypoglycemic Agents', 'Kinetics', 'Sulfonylurea Compounds/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/389600/
2218,glipizide,30471177,Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?,"['Cordiner RLM', 'Pearson ER']","['Diabetes Mellitus/drug therapy/genetics/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/therapeutic use', 'Dose-Response Relationship, Drug', 'Gliclazide/therapeutic use', 'Glipizide/therapeutic use', 'Glyburide/therapeutic use', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Hypoglycemic Agents/*therapeutic use', 'Insulin Secretion', 'Insulin-Secreting Cells/drug effects/metabolism', 'Metformin/therapeutic use', 'Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Sulfonylurea Compounds/history/pharmacology/*therapeutic use', 'Treatment Failure', 'Glucagon-Like Peptide-1 Receptor Agonists']",https://pubmed.ncbi.nlm.nih.gov/30471177/
2219,glipizide,27292155,Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis.,"['Qi C', 'Bin Li', 'Yang Y', 'Yang Y', 'Li J', 'Zhou Q', 'Wen Y', 'Zeng C', 'Zheng L', 'Zhang Q', 'Li J', 'He X', 'Zhou J', 'Shao C', 'Wang L']","['Angiogenesis Inhibitors/*pharmacology/therapeutic use', 'Animals', 'Antigens, Polyomavirus Transforming/*genetics', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Disease Progression', 'Down-Regulation/drug effects', 'Glipizide/*pharmacology/therapeutic use', 'Human Umbilical Vein Endothelial Cells', 'Humans', 'Liver Neoplasms/pathology/prevention & control/secondary', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Mice, Transgenic', 'Models, Animal', 'Neovascularization, Physiologic/*drug effects', 'Prostatic Neoplasms/drug therapy/metabolism/pathology', 'Rats', 'Rats, Sprague-Dawley', 'Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27292155/
2220,glipizide,3082015,Oral sulfonylureas for the treatment of type II diabetes: an update.,"['Shank WA Jr', 'Morrison AD']","['Administration, Oral', 'Chlorpropamide/adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Hypersensitivity/etiology', 'Glipizide/administration & dosage/metabolism/therapeutic use', 'Glyburide/administration & dosage/metabolism/therapeutic use', 'Humans', 'Insulin Resistance', 'Kinetics', 'Liver/metabolism', 'Nausea/chemically induced', 'Patient Education as Topic', 'Sulfonylurea Compounds/administration & dosage/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3082015/
2221,glipizide,6656850,Drug-induced reversal of early diabetic microangiopathy.,"['Camerini-Davalos RA', 'Velasco C', 'Glasser M', 'Bloodworth JM Jr']","['Adult', 'Basement Membrane/ultrastructure', 'Blood Glucose/metabolism', 'Capillaries/ultrastructure', 'Diabetic Angiopathies/*drug therapy/pathology', 'Female', 'Glipizide/*therapeutic use', 'Glucose Tolerance Test', 'Humans', 'Male', 'Middle Aged', 'Muscles/blood supply', 'Prediabetic State/*drug therapy/pathology', 'Sulfonylurea Compounds/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6656850/
2222,glipizide,3925246,Sulfonylureas in the treatment of diabetes mellitus--1985.,['Gerich JE'],"['Blood Glucose/metabolism', 'Body Weight', 'Diabetes Mellitus, Type 1/therapy', 'Diabetes Mellitus, Type 2/diet therapy/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/pharmacology', 'Glyburide/pharmacology', 'Humans', 'Hypoglycemia/etiology', 'Insulin/metabolism/therapeutic use', 'Pancreas/metabolism', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3925246/
2223,glipizide,15979893,Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening.,"['Srinivasan K', 'Viswanad B', 'Asrat L', 'Kaul CL', 'Ramarao P']","['Animals', 'Blood Glucose/analysis', 'Cholesterol/blood', 'Diabetes Mellitus, Experimental/*chemically induced/drug therapy/*etiology', 'Dietary Fats/*administration & dosage', 'Glipizide/pharmacology', 'Glucose Tolerance Test', 'Hypoglycemic Agents/*pharmacology', 'Insulin/blood', 'Male', 'Pioglitazone', 'Rats', 'Rats, Sprague-Dawley', 'Streptozocin', 'Thiazolidinediones/pharmacology', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/15979893/
2224,glipizide,8992534,[Glipizide--a short-acting sulphonylurea derivative].,['Ogonowski J'],"['Aged', 'Diabetes Mellitus/*drug therapy', 'Drug Therapy, Combination', 'Glipizide/*pharmacology', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Insulin/administration & dosage', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/8992534/
2225,glipizide,6369969,Long-term safety and efficacy of glipizide.,"['Feinglos MN', 'Lebovitz HE']","['Blood Glucose/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Female', 'Glipizide/adverse effects/*therapeutic use', 'Glucose Tolerance Test', 'Humans', 'Insulin/metabolism', 'Insulin Resistance', 'Male', 'Middle Aged', 'Sulfonylurea Compounds/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6369969/
2226,glipizide,12517365,"Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs.","['Rogers JF', 'Nafziger AN', 'Bertino JS Jr']","['Anti-Arrhythmia Agents/metabolism', 'Antidepressive Agents, Tricyclic/metabolism', 'Aryl Hydrocarbon Hydroxylases/metabolism', 'Codeine/metabolism', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2C9', 'Cytochrome P-450 CYP2D6/metabolism', 'Cytochrome P-450 Enzyme System/*metabolism', 'Diazepam/metabolism', 'Genotype', 'Glipizide/metabolism', 'Humans', 'Mixed Function Oxygenases/metabolism', 'Omeprazole/metabolism', 'Pharmacogenetics', 'Phenotype', 'Phenytoin/metabolism', 'Warfarin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12517365/
2227,phenytoin,15347487,Topical phenytoin for wound healing.,"['Bhatia A', 'Prakash S']","['Abscess/drug therapy', 'Administration, Topical', 'Burns/drug therapy', 'Collagenases/biosynthesis', 'Connective Tissue/drug effects', 'Diabetic Foot/drug therapy', 'Drug Evaluation', 'Enzyme Induction/drug effects', 'Fibroblasts/drug effects', 'Granulation Tissue/drug effects', 'Humans', 'Keratinocytes/drug effects', 'Phenytoin/administration & dosage/pharmacology/*therapeutic use', 'Powders', 'Skin Ulcer/drug therapy', 'Wound Healing/*drug effects', 'Wounds, Penetrating/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15347487/
2228,phenytoin,17075669,Phenytoin-induced parkinsonism.,"['Ertan S', 'Ulu MO', 'Hanimoglu H', 'Tanriverdi T', 'Kafadar AM', 'Acar ZU', 'Kiziltan G']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects', 'Cerebellar Ataxia/*chemically induced', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Parkinsonian Disorders/*chemically induced', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/17075669/
2229,phenytoin,10530693,Oxcarbazepine.,['Tecoma ES'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Biological Availability', 'Biotransformation', 'Carbamazepine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Controlled Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Humans', 'Oxcarbazepine', 'Phenytoin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10530693/
2230,phenytoin,3150279,Phenytoin-induced thrombocytopenia.,"['Brown JJ', 'Chun RW']","['Adolescent', 'Epilepsy, Tonic-Clonic/*drug therapy', 'Humans', 'Male', 'Phenytoin/*adverse effects/therapeutic use', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3150279/
2231,phenytoin,1925719,Phenytoin intoxication.,"['Murphy JM', 'Motiwala R', 'Devinsky O']","['Adult', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Liver Function Tests', 'Male', 'Middle Aged', 'Nervous System Diseases/chemically induced', 'Phenytoin/administration & dosage/blood/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/1925719/
2232,phenytoin,9952260,Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.,"['Walton NY', 'Uthman BM', 'El Yafi K', 'Kim JM', 'Treiman DM']","['Animals', 'Anticonvulsants/*administration & dosage/*pharmacokinetics', 'Blood-Brain Barrier/drug effects', 'Brain/*metabolism', 'Brain Chemistry/drug effects', 'Dose-Response Relationship, Drug', 'Femoral Vein', 'Humans', 'Infusions, Intravenous', 'Injections, Intravenous', 'Male', 'Phenytoin/*administration & dosage/*analogs & derivatives/analysis/*pharmacokinetics', 'Rats', 'Rats, Sprague-Dawley']",https://pubmed.ncbi.nlm.nih.gov/9952260/
2233,phenytoin,7207767,Phenytoin: pharmacokinetics and clinical therapeutics.,"['Olanow CW', 'Finn AL']","['Abnormalities, Drug-Induced/etiology', 'Biological Availability', 'Drug Interactions', 'Humans', 'Kidney Diseases/etiology', 'Liver Diseases/etiology', '*Phenytoin/adverse effects/blood/metabolism/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Vitamin D Deficiency/etiology']",https://pubmed.ncbi.nlm.nih.gov/7207767/
2234,phenytoin,7990791,Eclampsia.,"['Kaplan PW', 'Repke JT']","['Diagnosis, Differential', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics', 'Eclampsia/diagnosis/*etiology/therapy', 'Female', 'Humans', 'Infant, Newborn', 'Magnesium Sulfate/administration & dosage/adverse effects/pharmacokinetics', 'Neurologic Examination/drug effects', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7990791/
2235,phenytoin,405624,Carbamazepine--a double-blind comparison with phenytoin.,"['Troupin A', 'Ojemann LM', 'Halpern L', 'Dodrill C', 'Wilkus R', 'Friel P', 'Feigl P']","['Adult', 'Ataxia/chemically induced', 'Carbamazepine/adverse effects/blood/*therapeutic use', 'Clinical Trials as Topic', 'Drug Evaluation', 'Epilepsies, Partial/*drug therapy', 'Hematocrit', 'Humans', 'Leukocyte Count', 'Phenytoin/adverse effects/blood/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/405624/
2236,phenytoin,563669,Anticonvulsant-induced osteomalacia.,"['Palmer KT', 'Smith AE', 'Taylor BB']","['Animals', 'Chick Embryo', 'Dose-Response Relationship, Drug', 'Female', 'Fractures, Bone/etiology', 'Humans', 'Osteomalacia/*chemically induced/complications', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/563669/
2237,phenytoin,27938813,Acral manifestations of systemic diseases: Drug-induced and infectious diseases.,"['Caccavale S', 'Ruocco E']","['Acrodermatitis/diagnosis/*microbiology', 'Administration, Intravenous', 'Antineoplastic Agents/*adverse effects', 'Drug Eruptions/*etiology/prevention & control', 'Erythema Multiforme/chemically induced/complications', 'Foot Dermatoses/*etiology', 'Hand Dermatoses/*etiology', 'Hand, Foot and Mouth Disease/*complications', 'Humans', 'Phenytoin/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27938813/
2238,phenytoin,8520091,Phenytoin-folic acid interaction.,"['Lewis DP', 'Van Dyke DC', 'Willhite LA', 'Stumbo PJ', 'Berg MJ']","['Anticonvulsants/pharmacokinetics/*pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Epilepsy/drug therapy', 'Folic Acid/*pharmacology', 'Folic Acid Deficiency/drug therapy', 'Food, Fortified', '*Food-Drug Interactions', 'Humans', 'Phenytoin/pharmacokinetics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8520091/
2239,phenytoin,10687229,A clinical review of drug-induced gingival overgrowths.,"['Marshall RI', 'Bartold PM']","['Anticonvulsants/administration & dosage/adverse effects', 'Australia', 'Calcium Channel Blockers/adverse effects', 'Cyclosporine/administration & dosage/adverse effects', 'Drug Interactions', 'Gingival Overgrowth/*chemically induced/therapy', 'Humans', 'Immunosuppressive Agents/adverse effects', 'Oral Hygiene', 'Phenytoin/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10687229/
2240,phenytoin,3986867,Status epilepticus.,['Leppik IE'],"['Adult', 'Aged', 'Anticonvulsants/*therapeutic use', 'Diazepam/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenobarbital/therapeutic use', 'Phenytoin/administration & dosage/adverse effects/therapeutic use', 'Status Epilepticus/mortality/*therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3986867/
2241,phenytoin,1683079,Differences in phenytoin biotransformation and susceptibility to congenital malformations: a review.,"['Van Dyke DC', 'Berg MJ', 'Olson CH']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Biotransformation', 'Cytochrome P-450 Enzyme System/metabolism', 'Disease Susceptibility', 'Epoxide Hydrolases/metabolism', 'Female', 'Fetus/abnormalities/drug effects', 'Glutathione Transferase/metabolism', 'Humans', 'Hydantoins/metabolism', 'Phenytoin/adverse effects/*pharmacokinetics/pharmacology', 'Polymorphism, Restriction Fragment Length', 'Pregnancy', 'Tetrahydrofolate Dehydrogenase/metabolism']",https://pubmed.ncbi.nlm.nih.gov/1683079/
2242,phenytoin,4006880,Zonisamide in epilepsy: a pilot study.,"['Wilensky AJ', 'Friel PN', 'Ojemann LM', 'Dodrill CB', 'McCormick KB', 'Levy RH']","['Adolescent', 'Adult', 'Anticonvulsants/administration & dosage/adverse effects/blood/metabolism/*therapeutic use', 'Carbamazepine/blood/therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Isoxazoles/adverse effects/blood/metabolism/*therapeutic use', 'Male', 'Middle Aged', 'Oxazoles/*therapeutic use', 'Phenytoin/blood/therapeutic use', 'Time Factors', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/4006880/
2243,phenytoin,25044856,Angiopep-conjugated electro-responsive hydrogel nanoparticles: therapeutic potential for epilepsy.,"['Ying X', 'Wang Y', 'Liang J', 'Yue J', 'Xu C', 'Lu L', 'Xu Z', 'Gao J', 'Du Y', 'Chen Z']","['Amygdala/drug effects/physiopathology', 'Animals', 'Anticonvulsants/*administration & dosage/pharmacokinetics/therapeutic use', 'Blood-Brain Barrier/metabolism', 'Cell Line', 'Drug Delivery Systems', 'Electricity', 'Epilepsy/*drug therapy/physiopathology', 'Humans', 'Hydrogel, Polyethylene Glycol Dimethacrylate/*chemistry', 'Mice', 'Nanoparticles/*chemistry', 'Peptides/*chemistry', 'Phenytoin/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25044856/
2244,phenytoin,2185438,The pharmacokinetics of agents used to treat status epilepticus.,['Browne TR'],"['Anticonvulsants/*pharmacokinetics/therapeutic use', 'Diazepam/administration & dosage/blood/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Injections, Intramuscular', 'Lipid Metabolism', 'Phenobarbital/administration & dosage/pharmacokinetics', 'Phenytoin/administration & dosage/blood/pharmacokinetics', 'Solubility', 'Status Epilepticus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185438/
2245,phenytoin,21675930,EMPACT syndrome.,"['Bilgili SG', 'Calka O', 'Karadag AS', 'Burakgazi AZ']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects/therapeutic use', 'Brain Neoplasms/complications/radiotherapy/secondary', 'Cranial Irradiation/*adverse effects', 'Erythema Multiforme/*chemically induced/diagnosis/drug therapy/etiology', 'Fatal Outcome', 'Female', 'Glucocorticoids/administration & dosage/therapeutic use', 'Humans', 'Phenytoin/administration & dosage/*adverse effects/therapeutic use', 'Prednisolone/administration & dosage/therapeutic use', 'Seizures/prevention & control', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/21675930/
2246,phenytoin,7294047,Phenytoin-induced hyperglycemia.,"['Carter BL', 'Small RE', 'Mandel MD', 'Starkman MT']","['Acidosis/etiology', 'Diabetes Complications', 'Female', 'Humans', 'Hyperglycemia/*chemically induced', 'Middle Aged', 'Phenytoin/*adverse effects/therapeutic use', 'Seizures/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7294047/
2247,Salmeterol,26051688,Salmeterol Xinafoate.,"['Anwar MM', 'El-Haggar RS', 'Zaghary WA']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists/administration & dosage/*chemistry/pharmacokinetics/pharmacology', 'Albuterol/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics', 'Animals', 'Asthma/drug therapy/physiopathology', 'Biotransformation', 'Bronchodilator Agents/administration & dosage/*chemistry/pharmacokinetics', 'Chemistry, Pharmaceutical', 'Drug Stability', 'Humans', 'Molecular Structure', 'Salmeterol Xinafoate', 'Technology, Pharmaceutical/methods']",https://pubmed.ncbi.nlm.nih.gov/26051688/
2248,Salmeterol,35857184,Comparative Efficacy of Umeclidinium/Vilanterol Versus Other Bronchodilators for the Treatment of Chronic Obstructive Pulmonary Disease: A Network Meta-Analysis.,"['Ismaila AS', 'Haeussler K', 'Czira A', 'Tongbram V', 'Malmenas M', 'Agarwal J', 'Nassim M', 'Zivkovic-Gojovic M', 'Shen Y', 'Dong X', 'Duarte M', 'Compton C', 'Vogelmeier CF', 'Halpin DMG']","['Administration, Inhalation', 'Adrenergic beta-2 Receptor Agonists', 'Adult', 'Benzyl Alcohols', '*Bronchodilator Agents', 'Chlorobenzenes', 'Drug Combinations', 'Dyspnea/drug therapy', 'Forced Expiratory Volume', 'Glycopyrrolate/therapeutic use', 'Humans', 'Muscarinic Antagonists', 'Network Meta-Analysis', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Quinuclidines', 'Salmeterol Xinafoate/pharmacology/therapeutic use', 'Tiotropium Bromide', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35857184/
2249,Salmeterol,7875287,Salmeterol-induced vertigo.,"['Lopez-Guillen A', 'Marques L', 'Lopez-Llorente MT', 'Pastor E', 'Figueras A']","['Administration, Inhalation', 'Aged', 'Albuterol/adverse effects/*analogs & derivatives/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Salmeterol Xinafoate', 'Vertigo/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7875287/
2250,Salmeterol,15256389,Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study.,"['Bateman ED', 'Boushey HA', 'Bousquet J', 'Busse WW', 'Clark TJ', 'Pauwels RA', 'Pedersen SE']","['Adrenal Cortex Hormones/administration & dosage/therapeutic use', 'Adult', 'Albuterol/administration & dosage/adverse effects/*analogs & derivatives/*therapeutic use', 'Androstadienes/administration & dosage/adverse effects/*therapeutic use', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/therapeutic use', 'Asthma/drug therapy/*prevention & control', 'Bronchodilator Agents/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Fluticasone', 'Forced Expiratory Volume/drug effects', 'Humans', 'Male', 'Practice Guidelines as Topic', 'Prospective Studies', 'Quality of Life', 'Salmeterol Xinafoate', 'Surveys and Questionnaires', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15256389/
2251,Salmeterol,26866910,WITHDRAWN: Inhaled bronchodilators for cystic fibrosis.,"['Halfhide C', 'Evans HJ', 'Couriel J']","['Adrenergic beta-Agonists/*therapeutic use', 'Adult', 'Albuterol/analogs & derivatives/therapeutic use', 'Bronchial Hyperreactivity/*drug therapy/etiology', 'Bronchodilator Agents/*therapeutic use', 'Child', 'Cystic Fibrosis/*complications', 'Humans', 'Ipratropium/therapeutic use', 'Randomized Controlled Trials as Topic', 'Salmeterol Xinafoate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26866910/
2252,Salmeterol,32168461,Evaluation of fluticasone propionate/salmeterol for the treatment of COPD: a systematic review.,"['Calzetta L', 'Ritondo BL', 'Matera MG', 'Cazzola M', 'Rogliani P']","['Administration, Inhalation', 'Adult', 'Aged', 'Aged, 80 and over', 'Bronchodilator Agents/administration & dosage/*therapeutic use', 'Clinical Trials, Phase IV as Topic', 'Drug Therapy, Combination', 'Female', 'Fluticasone/administration & dosage/*therapeutic use', 'Fluticasone-Salmeterol Drug Combination/administration & dosage/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32168461/
2253,Salmeterol,12493336,The long and short of beta2-agonists.,['Lotvall J'],"['Administration, Inhalation', '*Adrenergic beta-2 Receptor Agonists', 'Adrenergic beta-Agonists/*administration & dosage/therapeutic use', 'Albuterol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Animals', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Asthma/*drug therapy', 'Bronchodilator Agents/*administration & dosage/therapeutic use', 'Budesonide/adverse effects/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Ethanolamines/adverse effects/pharmacology/therapeutic use', 'Formoterol Fumarate', 'Humans', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/12493336/
2254,Salmeterol,26677916,Budesonide/salmeterol in fixed-dose combination for the treatment of asthma.,"['Popov TA', 'De Niet S', 'Vanderbist F']","['Adrenergic beta-2 Receptor Agonists/*administration & dosage/pharmacokinetics', 'Asthma/*drug therapy', 'Budesonide/*administration & dosage/pharmacokinetics', 'Clinical Trials as Topic', 'Drug Combinations', 'Drug Evaluation, Preclinical', 'Glucocorticoids/*administration & dosage/pharmacokinetics', 'Humans', 'Nebulizers and Vaporizers', 'Salmeterol Xinafoate/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26677916/
2255,Salmeterol,31666084,Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.,"['Maltais F', 'Bjermer L', 'Kerwin EM', 'Jones PW', 'Watkins ML', 'Tombs L', 'Naya IP', 'Boucot IH', 'Lipson DA', 'Compton C', 'Vahdati-Bolouri M', 'Vogelmeier CF']","['Administration, Inhalation', '*Adrenal Cortex Hormones/administration & dosage', 'Aged', 'Benzyl Alcohols/*administration & dosage', 'Bronchodilator Agents/*therapeutic use', 'Chlorobenzenes/*administration & dosage', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Forced Expiratory Volume/drug effects/physiology', 'Humans', 'Male', 'Middle Aged', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Quinuclidines/*administration & dosage', 'Salmeterol Xinafoate/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31666084/
2256,Salmeterol,27515731,Concerns with beta2-agonists in pediatric asthma - a clinical perspective.,"['Kersten ET', 'Koppelman GH', 'Thio BJ']","['Adrenergic beta-2 Receptor Agonists/*adverse effects', 'Asthma/*drug therapy/mortality', 'Child', 'Child, Preschool', 'Down-Regulation', 'Drug Labeling', 'Hospitalization/*statistics & numerical data', 'Humans', 'Intubation, Intratracheal/*statistics & numerical data', 'Mortality', 'Pharmacogenomic Variants', 'Receptors, Adrenergic, beta-2/genetics', 'Salmeterol Xinafoate/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27515731/
2257,Salmeterol,1978163,Protection against allergen-induced asthma by salmeterol.,"['Twentyman OP', 'Finnerty JP', 'Harris A', 'Palmer J', 'Holgate ST']","['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/pharmacology/*therapeutic use', 'Adult', 'Albuterol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Analysis of Variance', 'Asthma/physiopathology/*prevention & control', 'Bronchial Provocation Tests/methods', 'Bronchoconstriction/drug effects', 'Female', 'Forced Expiratory Volume/drug effects/physiology', 'Histamine/administration & dosage/pharmacology', 'Humans', 'Male', 'Salmeterol Xinafoate', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1978163/
2258,Salmeterol,27879340,G Protein-Coupled Receptor Endocytosis Confers Uniformity in Responses to Chemically Distinct Ligands.,"['Tsvetanova NG', 'Trester-Zedlitz M', 'Newton BW', 'Riordan DP', 'Sundaram AB', 'Johnson JR', 'Krogan NJ', 'von Zastrow M']","['*Endocytosis', 'Endosomes/drug effects/metabolism', 'HEK293 Cells', 'Humans', 'Isoproterenol/pharmacology', 'Ligands', 'Mass Spectrometry', 'Models, Biological', 'Oligonucleotide Array Sequence Analysis', 'Phosphoproteins/metabolism', 'Phosphorylation/drug effects', 'Proteome/metabolism', 'Proteomics', 'Receptors, Adrenergic, beta-2/metabolism', 'Receptors, G-Protein-Coupled/*metabolism', 'Salmeterol Xinafoate/pharmacology', 'Signal Transduction/drug effects', 'Transcription, Genetic/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27879340/
2259,Salmeterol,1974666,The current place of beta 2-agonists in the management of asthma.,['Svedmyr N'],"['Administration, Inhalation', 'Adrenergic beta-Agonists/*administration & dosage/adverse effects', 'Airway Resistance/drug effects', 'Albuterol/administration & dosage/analogs & derivatives', 'Asthma/*drug therapy', 'Bronchial Provocation Tests', 'Humans', 'Respiratory Hypersensitivity/drug therapy', 'Salmeterol Xinafoate']",https://pubmed.ncbi.nlm.nih.gov/1974666/
2260,Salmeterol,29301922,Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma.,"['Jorup C', 'Lythgoe D', 'Bisgaard H']","['Adolescent', 'Asthma/*drug therapy/pathology', 'Budesonide/*administration & dosage', 'Child', 'Double-Blind Method', 'Female', 'Fluticasone/administration & dosage', 'Forced Expiratory Volume', 'Formoterol Fumarate/*administration & dosage', 'Humans', 'Male', 'Peak Expiratory Flow Rate', 'Salmeterol Xinafoate/administration & dosage', 'Surveys and Questionnaires', 'Terbutaline/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/29301922/
2261,Salmeterol,35057598,Salmeterol-Fluticasone: The Role Revisited.,"['Vora A', 'Dhar R', 'Pinto L', 'Koul P', 'Gaonkar P']","['*Asthma/drug therapy', 'Fluticasone', 'Fluticasone-Salmeterol Drug Combination', 'Humans', '*Pulmonary Disease, Chronic Obstructive/drug therapy/epidemiology', 'Salmeterol Xinafoate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35057598/
2262,Salmeterol,17128539,The controversy over long-acting beta agonists: examining the evidence.,['Lang DM'],"['Administration, Inhalation', 'Adrenergic beta-Agonists/administration & dosage/*adverse effects', 'Black or African American/statistics & numerical data', 'Albuterol/administration & dosage/adverse effects/*analogs & derivatives', 'Asthma/*drug therapy/mortality', 'Bronchodilator Agents/*administration & dosage/adverse effects', 'Drug Therapy, Combination', '*Drug-Related Side Effects and Adverse Reactions', 'Ethanolamines/administration & dosage/*adverse effects', 'Evidence-Based Medicine', 'Formoterol Fumarate', 'Glucocorticoids/administration & dosage', 'Humans', 'Salmeterol Xinafoate', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/17128539/
2263,Salmeterol,25552883,Three-month treatment response and exacerbation in chronic obstructive pulmonary disease.,"['Lee JS', 'Rhee CK', 'Yoo KH', 'Lee JH', 'Yoon HI', 'Kim TH', 'Kim WJ', 'Lee J', 'Lim SY', 'Park TS', 'Lee JS', 'Lee SW', 'Lee SD', 'Oh YM']","['Adrenal Cortex Hormones/*therapeutic use', 'Adrenergic beta-2 Receptor Agonists/*therapeutic use', 'Bronchodilator Agents/*therapeutic use', 'Budesonide/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Fluticasone/therapeutic use', 'Forced Expiratory Volume/drug effects/*physiology', 'Formoterol Fumarate/therapeutic use', 'Humans', 'Male', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/physiopathology', 'Recurrence', 'Republic of Korea', 'Salmeterol Xinafoate/therapeutic use', 'Smoking', 'Spirometry', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25552883/
2264,Salmeterol,26750624,[Mountain sickness].,['Bultas J'],"['Acetazolamide/therapeutic use', 'Acute Disease', 'Adaptation, Physiological/physiology', 'Altitude', 'Altitude Sickness/*diagnosis/physiopathology/*therapy', 'Brain Edema', 'Calcium Channel Blockers/therapeutic use', 'Combined Modality Therapy', 'Dexamethasone/therapeutic use', 'Humans', 'Hypertension, Pulmonary/complications/*diagnosis/physiopathology/*therapy', 'Oxygen/blood', 'Oxygen Inhalation Therapy', 'Salmeterol Xinafoate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26750624/
2265,Salmeterol,39688267,G-Protein-Coupled Receptor Surface Creates a Favorable Pathway for Membrane Permeation of Drug Molecules.,"['Gil Herrero C', 'Thallmair S']","['*Molecular Dynamics Simulation', '*Receptors, Adrenergic, beta-2/metabolism/chemistry', '*Salmeterol Xinafoate/chemistry/metabolism', '*Albuterol/chemistry/metabolism', 'Cell Membrane Permeability', 'Humans', 'Cell Membrane/metabolism/chemistry', 'Receptors, G-Protein-Coupled/metabolism/chemistry', 'Protein Kinase Inhibitors/chemistry/pharmacology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39688267/
2266,Salmeterol,31299468,Genetic effects on efficacy to fluticasone propionate/salmeterol treatment in COPD.,"['Condreay LD', 'Qu XA', 'Anderson J', 'Compton C', 'Ghosh S']","['Chromosomes, Human, Pair 20/genetics', 'Fluticasone/*administration & dosage', 'Forced Expiratory Volume', 'Gene Frequency', '*Genetic Association Studies', 'Humans', 'Pulmonary Disease, Chronic Obstructive/*drug therapy/*genetics/physiopathology', 'Salmeterol Xinafoate/*administration & dosage', 'Surveys and Questionnaires', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31299468/
2267,clonazepam,18625105,Burning mouth syndrome.,"['Speciali JG', 'Stuginski-Barbosa J']","['Administration, Oral', 'Burning Mouth Syndrome/*diagnosis/epidemiology/*therapy', 'Clonazepam/administration & dosage', 'Dopamine Agonists/administration & dosage', 'Female', 'Humans', 'Male', 'Mouth Mucosa/drug effects/pathology', 'Postmenopause/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/18625105/
2268,clonazepam,561907,Spinal myoclonus.,"['Hoehn MM', 'Cherington M']","['Clonazepam/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Myoclonus/drug therapy/*etiology', 'Spinal Cord Diseases/*complications', 'Tetrabenazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/561907/
2269,clonazepam,4082246,Phenytoin/clonazepam interaction.,"['Saavedra IN', 'Aguilera LI', 'Faure E', 'Galdames DG']","['Adult', 'Benzodiazepinones/*pharmacology', 'Clonazepam/administration & dosage/blood/*pharmacology/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Epilepsy/blood/drug therapy', 'Humans', 'Male', 'Phenytoin/administration & dosage/*blood/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/4082246/
2270,clonazepam,35971024,"Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability.","['Kienitz R', 'Kay L', 'Beuchat I', 'Gelhard S', 'von Brauchitsch S', 'Mann C', 'Lucaciu A', 'Schafer JH', 'Siebenbrodt K', 'Zollner JP', 'Schubert-Bast S', 'Rosenow F', 'Strzelczyk A', 'Willems LM']","['Anticonvulsants/adverse effects', '*Benzodiazepines/adverse effects', 'Clonazepam/therapeutic use', 'Diazepam/therapeutic use', 'Humans', 'Lorazepam/therapeutic use', 'Midazolam', 'Seizures/drug therapy', '*Status Epilepticus/drug therapy', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35971024/
2271,clonazepam,20473065,Tapering clonazepam in patients with panic disorder after at least 3 years of treatment.,"['Nardi AE', 'Freire RC', 'Valenca AM', 'Amrein R', 'de Cerqueira AC', 'Lopes FL', 'Nascimento I', 'Mezzasalma MA', 'Veras AB', 'Sardinha A', 'de Carvalho MR', 'da Costa RT', 'Levitan MN', 'de-Melo-Neto VL', 'Soares-Filho GL', 'Versiani M']","['Adolescent', 'Adult', 'Aged', 'Clonazepam/*administration & dosage/adverse effects', 'Female', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Panic Disorder/*drug therapy/*psychology', 'Prospective Studies', 'Psychiatric Status Rating Scales/standards', 'Substance Withdrawal Syndrome/etiology/*prevention & control/*psychology', 'Time Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20473065/
2272,clonazepam,1408017,Drugs used in the management of trigeminal neuralgia.,"['Zakrzewska JM', 'Patsalos PN']","['Anticonvulsants/*administration & dosage/*pharmacokinetics', 'Baclofen/*administration & dosage', 'Carbamazepine/administration & dosage/analogs & derivatives/pharmacokinetics', 'Clonazepam/administration & dosage/pharmacokinetics', 'Humans', 'Oxcarbazepine', 'Phenytoin/administration & dosage/pharmacokinetics', 'Trigeminal Neuralgia/*drug therapy', 'Valproic Acid/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1408017/
2273,clonazepam,1422166,Anticonvulsants in the treatment of bipolar disorder.,"['Keck PE Jr', 'McElroy SL', 'Nemeroff CB']","['Anticonvulsants/adverse effects/*therapeutic use', 'Bipolar Disorder/*drug therapy/psychology', 'Carbamazepine/adverse effects/therapeutic use', 'Clonazepam/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Electroconvulsive Therapy', 'Humans', 'Psychiatric Status Rating Scales', 'Recurrence', 'Valproic Acid/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1422166/
2274,clonazepam,14700107,Clonazepam associated retinopathy.,"['Gatzonis S', 'Karadimas P', 'Gatzonis S', 'Bouzas EA']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects', 'Clonazepam/administration & dosage/*adverse effects', 'Female', 'Fluorescein Angiography', 'Fundus Oculi', 'Humans', 'Retinal Diseases/*chemically induced/diagnosis/therapy', 'Vision Disorders/chemically induced/diagnosis/therapy', 'Visual Acuity']",https://pubmed.ncbi.nlm.nih.gov/14700107/
2275,clonazepam,1469409,"""Isolated"" postinfectious myoclonus.","['Bhatia K', 'Thompson PD', 'Marsden CD']","['Adolescent', 'Clonazepam/therapeutic use', 'Evoked Potentials, Somatosensory', 'Female', 'Humans', 'Infections/*complications', 'Myoclonus/diagnosis/drug therapy/*etiology', 'Prognosis', 'Valproic Acid/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1469409/
2276,clonazepam,1486834,Antiepileptic drugs and their psychotropic effects.,['Fenwick PB'],"['Affect/drug effects', 'Anticonvulsants/*pharmacology/therapeutic use', 'Brain/drug effects/growth & development', 'Carbamazepine/therapeutic use', 'Clonazepam/therapeutic use', 'Epilepsy/drug therapy', 'Humans', 'Mental Disorders/drug therapy', '*Psychotropic Drugs', 'Valproic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1486834/
2277,clonazepam,121641,The pharmacological treatment of epilepsy.,['Aucamp AK'],"['Anticonvulsants/adverse effects/*therapeutic use', 'Carbamazepine/therapeutic use', 'Child, Preschool', 'Clonazepam/therapeutic use', 'Drug Therapy, Combination', 'Epilepsies, Myoclonic/drug therapy', 'Epilepsy/classification/*drug therapy/pathology', 'Epilepsy, Absence/drug therapy', 'Epilepsy, Temporal Lobe/drug therapy', 'Ethosuximide/therapeutic use', 'Female', 'Humans', 'Infant', 'Phenobarbital/therapeutic use', 'Phenytoin/therapeutic use', 'Pregnancy', 'Primidone/therapeutic use', 'Spasms, Infantile/drug therapy', 'Status Epilepticus/drug therapy', 'Thyroid Gland/drug effects']",https://pubmed.ncbi.nlm.nih.gov/121641/
2278,clonazepam,34536833,Ultrasound-assisted electromembrane extraction of clonazepam from plasma and determination using capillary electrophoresis.,"['Seyfinejad B', 'Ozkan SA', 'Jouyban A']","['Clonazepam/*blood/chemistry/isolation & purification/pharmacokinetics', 'Electrophoresis, Capillary/*methods', 'Humans', 'Limit of Detection', 'Linear Models', 'Reproducibility of Results', 'Research Design', 'Sonication']",https://pubmed.ncbi.nlm.nih.gov/34536833/
2279,clonazepam,1360697,The treatment of the restless leg syndrome with or without periodic leg movements in sleep.,"['Montplaisir J', 'Lapierre O', 'Warnes H', 'Pelletier G']","['Anti-Anxiety Agents/adverse effects/therapeutic use', 'Clonazepam/adverse effects/therapeutic use', 'Dextropropoxyphene/adverse effects/therapeutic use', 'Dopamine Agents/adverse effects/therapeutic use', 'Humans', 'Levodopa/adverse effects/therapeutic use', 'Narcotics/adverse effects/therapeutic use', 'Polysomnography', 'Restless Legs Syndrome/*drug therapy/physiopathology', 'Sleep Stages/drug effects/physiology', 'Sleep Wake Disorders/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/1360697/
2280,clonazepam,2889724,Clonazepam: new uses and potential problems.,"['Cohen LS', 'Rosenbaum JF']","['Adult', 'Antipsychotic Agents/therapeutic use', 'Clonazepam/adverse effects/*therapeutic use', 'Depressive Disorder/chemically induced', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Psychotic Disorders/drug therapy', 'Sexual Dysfunctions, Psychological/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/2889724/
2281,clonazepam,21418666,Burning mouth syndrome.,"['Buchanan JA', 'Zakrzewska JM']","['Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', '*Burning Mouth Syndrome/drug therapy', '*Clonazepam/therapeutic use', 'Cognitive Behavioral Therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21418666/
2282,clonazepam,27449005,Pramipexole in the treatment of REM sleep behaviour disorder: A critical review.,"['Tan SM', 'Wan YM']","['Benzothiazoles/pharmacology/*therapeutic use', 'Clonazepam/pharmacology/therapeutic use', 'Dopamine Agonists/pharmacology/*therapeutic use', 'Humans', 'Observational Studies as Topic/methods', 'Polysomnography/drug effects', 'Pramipexole', 'REM Sleep Behavior Disorder/diagnosis/*drug therapy/physiopathology', 'Sleep, REM/drug effects/physiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27449005/
2283,clonazepam,19450321,Burning mouth syndrome.,"['Buchanan J', 'Zakrzewska J']","['Antidepressive Agents/therapeutic use', 'Benzodiazepines/therapeutic use', '*Burning Mouth Syndrome/drug therapy', '*Clonazepam/therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/19450321/
2284,clonazepam,37287278,Post-hypoxic myoclonus; what we know and gaps in knowledge.,['Ahmed HS'],"['Humans', '*Myoclonus/diagnosis/drug therapy/etiology', 'Hypoxia/complications/therapy', 'Clonazepam/therapeutic use', '*Cardiopulmonary Resuscitation/adverse effects', 'Valproic Acid/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/37287278/
2285,clonazepam,28138205,Opium Withdrawal Delirium: Two Case Reports.,"['Sharma RC', 'Kumar R', 'Sharma DD', 'Kanwar P']","['Adult', 'Analgesics, Opioid/therapeutic use', 'Anticonvulsants/therapeutic use', 'Clonazepam/therapeutic use', 'Delirium/*etiology', 'Humans', 'Male', 'Middle Aged', 'Opioid-Related Disorders/*complications', 'Opium/*adverse effects', 'Opium Dependence/drug therapy', 'Substance Withdrawal Syndrome/*complications/drug therapy/etiology', 'Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28138205/
2286,clonazepam,38043794,The anthelmintic meclonazepam activates a schistosome transient receptor potential channel.,"['Park SK', 'Sprague DJ', 'Rohr CM', 'Chulkov EG', 'Petrow I', 'Kumar S', 'Marchant JS']","['Animals', 'Humans', '*Anthelmintics/pharmacology', 'Benzodiazepines/pharmacology', 'Benzodiazepinones/pharmacology', '*Clonazepam/analogs & derivatives/pharmacology', 'Praziquantel/pharmacology', 'Schistosoma mansoni/drug effects/metabolism', '*Schistosomiasis mansoni/drug therapy', '*TRPM Cation Channels/agonists']",https://pubmed.ncbi.nlm.nih.gov/38043794/
2287,Eletriptan,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
2288,Eletriptan,26178694,Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis.,"['Cameron C', 'Kelly S', 'Hsieh SC', 'Murphy M', 'Chen L', 'Kotb A', 'Peterson J', 'Coyle D', 'Skidmore B', 'Gomes T', 'Clifford T', 'Wells G']","['Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Drug Administration Schedule', 'Humans', 'Migraine Disorders/diagnosis/*drug therapy/*epidemiology', 'Oxazolidinones/therapeutic use', 'Randomized Controlled Trials as Topic/methods', 'Serotonin 5-HT1 Receptor Agonists/therapeutic use', 'Treatment Outcome', 'Tryptamines/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26178694/
2289,Eletriptan,18223456,Triptans in pregnancy.,"['Soldin OP', 'Dahlin J', ""O'Mara DM""]","['Animals', 'Female', 'Humans', 'Migraine Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', '*Prenatal Exposure Delayed Effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18223456/
2290,Eletriptan,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
2291,Eletriptan,39293828,Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.,"['Karlsson WK', 'Ostinelli EG', 'Zhuang ZA', 'Kokoti L', 'Christensen RH', 'Al-Khazali HM', 'Deligianni CI', 'Tomlinson A', 'Ashina H', 'Ruiz de la Torre E', 'Diener HC', 'Cipriani A', 'Ashina M']","['Adult', 'Humans', '*Migraine Disorders/diagnosis/drug therapy', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Tryptamines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39293828/
2292,Eletriptan,19929447,Eletriptan.,"['Sandrini G', 'Perrotta A', 'Tassorelli C', 'Nappi G']","['Animals', 'Controlled Clinical Trials as Topic', 'Humans', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/economics/metabolism/pharmacokinetics/*therapeutic use', 'Receptor, Serotonin, 5-HT1B/metabolism', 'Receptor, Serotonin, 5-HT1D/metabolism', '*Serotonin 5-HT1 Receptor Agonists', 'Serotonin Receptor Agonists/economics/metabolism/pharmacokinetics/*therapeutic use', 'Tryptamines/economics/metabolism/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19929447/
2293,Eletriptan,38030397,Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users' Self-Reported Records From a Smartphone Application.,"['Chiang CC', 'Fang X', 'Horvath Z', 'Cadiou F', 'Urani A', 'Poh W', 'Narimatsu H', 'Cheng Y', 'Dodick DW']","['Humans', 'Ibuprofen/therapeutic use', 'Acetaminophen/therapeutic use', '*Antiemetics/therapeutic use', 'Self Report', 'Retrospective Studies', 'Smartphone', '*Migraine Disorders/drug therapy/epidemiology', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Tryptamines/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Aspirin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38030397/
2294,Eletriptan,14988742,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['Clinical Trials as Topic/*statistics & numerical data', 'Databases, Factual/*statistics & numerical data', 'Humans', 'Statistics as Topic']",https://pubmed.ncbi.nlm.nih.gov/14988742/
2295,Eletriptan,12463280,Eletriptan: pharmacological differences and clinical results.,['Giffin N'],"['Humans', 'Indoles/*pharmacology/therapeutic use', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/*pharmacology/therapeutic use', 'Serotonin Receptor Agonists/*pharmacology/therapeutic use', 'Sumatriptan/*pharmacology/therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12463280/
2296,Eletriptan,10463349,Antimigraine drugs.,"['Diener HC', 'Kaube H', 'Limmroth V']","['Analgesics/*therapeutic use', 'Antiemetics/*therapeutic use', 'Ergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/therapeutic use', 'Vasoconstrictor Agents/*therapeutic use', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/10463349/
2297,Eletriptan,25155004,Myocardial infarction after taking eletriptan.,"['Dias A', 'Franco E', 'Hebert K', 'Mercedes A']","['Humans', 'Male', 'Middle Aged', 'Myocardial Infarction/*chemically induced', 'Pyrrolidines/*adverse effects', 'Serotonin Receptor Agonists/*adverse effects', 'Tryptamines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25155004/
2298,Eletriptan,26252584,Acute Migraine Treatment.,['Becker WJ'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Dihydroergotamine/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Tryptamines/*therapeutic use', 'Vasoconstrictor Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26252584/
2299,Eletriptan,12117355,Mechanisms of action of the 5-HT1B/1D receptor agonists.,"['Tepper SJ', 'Rapoport AM', 'Sheftell FD']","['Carbazoles/pharmacology', 'Humans', 'Indoles/pharmacology', 'Migraine Disorders/*drug therapy/*metabolism', 'Oxazolidinones/pharmacology', 'Piperidines/pharmacology', 'Pyrrolidines/pharmacology', 'Receptor, Serotonin, 5-HT1B', 'Receptor, Serotonin, 5-HT1D', 'Receptors, Serotonin/*drug effects', 'Serotonin Receptor Agonists/*pharmacology', 'Sumatriptan/pharmacology', 'Triazoles/pharmacology', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/12117355/
2300,Eletriptan,15096220,Double-blind clinical trials of oral triptans vs other classes of acute migraine medication - a review.,"['Lipton RB', 'Bigal ME', 'Goadsby PJ']","['Administration, Oral', 'Analgesics/*therapeutic use', 'Double-Blind Method', 'Humans', 'Indoles/*administration & dosage', 'Migraine Disorders/*drug therapy', 'Oxazolidinones/*administration & dosage', 'Pyrrolidines/*administration & dosage', 'Randomized Controlled Trials as Topic', 'Sumatriptan/*administration & dosage', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15096220/
2301,Eletriptan,11772292,Eletriptan.,"['Gawel MJ', 'Grujich NN']","['Clinical Trials as Topic', 'Humans', 'Indoles/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Serotonin Receptor Agonists/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/11772292/
2302,Eletriptan,15853473,Eletriptan in migraine.,['Diener HC'],"['Analgesics/therapeutic use', 'Drug Interactions', 'Economics, Pharmaceutical', 'Expert Testimony', 'Humans', 'Migraine Disorders/*drug therapy', 'Pyrrolidines/chemistry/metabolism/pharmacology/*therapeutic use', 'Serotonin Receptor Agonists/chemistry/metabolism/pharmacology/*therapeutic use', 'Tryptamines/chemistry/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15853473/
2303,Eletriptan,31389059,Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.,"['Tfelt-Hansen P', 'Messlinger K']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*pharmacokinetics', 'Arteries/drug effects/innervation', 'Calcitonin Gene-Related Peptide Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Migraine Disorders/*drug therapy/physiopathology', 'Nociception/drug effects/physiology', '*Randomized Controlled Trials as Topic', 'Serotonin 5-HT1 Receptor Agonists/administration & dosage/*pharmacokinetics', 'Thalamus/drug effects/physiopathology', 'Time Factors', 'Treatment Outcome', 'Trigeminal Ganglion/drug effects/physiopathology', 'Vasoconstriction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31389059/
2304,Eletriptan,15934888,Eletriptan review.,"['Farkkila M', 'Kallela M']","['Clinical Trials as Topic/statistics & numerical data', 'Dose-Response Relationship, Drug', 'Humans', 'Migraine Disorders/*drug therapy/metabolism', 'Pyrrolidines/metabolism/*therapeutic use', 'Serotonin Receptor Agonists/metabolism/*therapeutic use', 'Tryptamines/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934888/
2305,Eletriptan,15109360,Eletriptan for the short-term prophylaxis of cluster headache.,"['Zebenholzer K', 'Wober C', 'Vigl M', 'Wessely P']","['Adult', 'Cluster Headache/*prevention & control', 'Female', 'Humans', 'Indoles/*therapeutic use', 'Male', 'Middle Aged', 'Pilot Projects', 'Pyrrolidines/*therapeutic use', 'Serotonin Receptor Agonists/*therapeutic use', 'Time Factors', 'Treatment Outcome', 'Tryptamines']",https://pubmed.ncbi.nlm.nih.gov/15109360/
2306,norgestrel,2113816,Levonorgestrel-releasing intrauterine device.,"['Luukkainen T', 'Lahteenmaki P', 'Toivonen J']","['Contraceptive Agents, Female/*administration & dosage/adverse effects', 'Female', 'Humans', '*Intrauterine Devices, Medicated/adverse effects', 'Levonorgestrel', 'Menorrhagia/*prevention & control', 'Norgestrel/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2113816/
2307,norgestrel,8616980,Norgestimate.,['Corson SL'],"['Carbohydrate Metabolism', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Clinical Trials as Topic', 'Contraceptives, Oral/adverse effects/chemistry/*pharmacology', 'Endometrium/drug effects', 'Female', 'Humans', 'Norgestrel/adverse effects/*analogs & derivatives/chemistry/pharmacology', 'Progestins/adverse effects/chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8616980/
2308,norgestrel,9174757,Implantable contraception.,['Bardin CW'],"['Contraceptive Agents, Female/*administration & dosage/adverse effects/pharmacology', '*Drug Implants', 'Humans', 'Levonorgestrel/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9174757/
2309,norgestrel,2124088,Pharmacologic and pharmacokinetic characteristics of norgestimate and its metabolites.,"['McGuire JL', 'Phillips A', 'Hahn DW', 'Tolman EL', 'Flor S', 'Kafrissen ME']","['Animals', 'Biotransformation', '*Contraceptives, Oral/chemistry/metabolism/pharmacokinetics/pharmacology', 'Drug Combinations', 'Female', 'Humans', 'Levonorgestrel', 'Molecular Structure', 'Norgestrel/*analogs & derivatives/chemistry/metabolism/pharmacokinetics/pharmacology', 'Oximes']",https://pubmed.ncbi.nlm.nih.gov/2124088/
2310,norgestrel,33464138,The paradigm of norgestimate: a third-generation testosterone-derivative progestin with a peripheral anti-androgenic activity and the lowest risk of venous thromboembolism.,"['Grandi G', 'Del Savio MC', 'Facchinetti F']","['Animals', 'Contraceptive Agents, Hormonal/*administration & dosage/adverse effects/pharmacology', 'Female', 'Humans', 'Levonorgestrel/administration & dosage/adverse effects/pharmacology', 'Norgestrel/administration & dosage/adverse effects/*analogs & derivatives/pharmacology', 'Risk', 'Venous Thromboembolism/*chemically induced/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/33464138/
2311,norgestrel,2966138,[Impetigo herpetiformis].,"['Winzer M', 'Wolff HH']","['Adult', 'Biopsy', 'Contraceptives, Oral, Combined/adverse effects', 'Cysts/pathology', 'Dermatitis Herpetiformis/drug therapy/*pathology', 'Drug Eruptions/pathology', 'Ethinyl Estradiol/adverse effects', 'Etretinate/administration & dosage', 'Female', 'HLA Antigens/genetics', '*HLA-C Antigens', 'Humans', 'Impetigo/*pathology', 'Levonorgestrel', 'Norgestrel/adverse effects', 'Prednisolone/administration & dosage', 'Pregnancy', 'Pregnancy Complications, Infectious/pathology', 'Skin/pathology', 'Splenic Rupture/pathology']",https://pubmed.ncbi.nlm.nih.gov/2966138/
2312,norgestrel,17030284,Advances in hormonal contraception.,['Gupta N'],"['Administration, Cutaneous', 'Administration, Intravaginal', '*Contraceptive Agents, Female/administration & dosage/adverse effects', 'Contraceptives, Postcoital', 'Delayed-Action Preparations', 'Drug Combinations', 'Ethinyl Estradiol/adverse effects/therapeutic use', 'Female', 'Humans', 'Injections, Subcutaneous', 'Intrauterine Devices', 'Levonorgestrel/adverse effects/therapeutic use', 'Medroxyprogesterone Acetate/adverse effects/therapeutic use', 'Norgestrel/adverse effects/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17030284/
2313,norgestrel,14748201,[Medication of the month. Evra: first contraceptive transdermal patch].,['Gaspard U'],"['Administration, Cutaneous', 'Adult', 'Contraception/*methods', 'Contraceptives, Oral', 'Contraceptives, Oral, Combined/*administration & dosage/adverse effects/*pharmacokinetics/pharmacology', 'Drug Combinations', 'Ethisterone/analogs & derivatives', 'Female', 'Glucose/metabolism', 'Humans', 'Lipid Metabolism', 'Menstrual Cycle/*drug effects', 'Nausea/chemically induced', 'Norgestrel/analogs & derivatives', 'Oximes', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/14748201/
2314,norgestrel,11521121,Combined oral hormone replacement therapy formulations.,"['Mattox JH', 'Shulman LP']","['Chemistry, Pharmaceutical', '*Contraceptives, Oral, Combined', 'Estradiol/*administration & dosage', 'Female', 'Humans', 'Norgestrel/*administration & dosage/*analogs & derivatives', 'Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/11521121/
2315,norgestrel,19445984,Mirena (Levonorgestrel intrauterine system): a successful novel drug delivery option in contraception.,"['Rose S', 'Chaudhari A', 'Peterson CM']","['Administration, Intravaginal', '*Contraception', 'Contraceptive Agents, Female/*administration & dosage/adverse effects/therapeutic use', 'Drug Administration Schedule', '*Drug Delivery Systems', 'Female', 'Genital Diseases, Female/drug therapy', 'Humans', '*Intrauterine Devices, Medicated', 'Levonorgestrel/*administration & dosage/adverse effects/therapeutic use', 'Menstruation Disturbances/drug therapy', 'Patient Satisfaction']",https://pubmed.ncbi.nlm.nih.gov/19445984/
2316,norgestrel,18328481,Contraception in hereditary angioedema.,['Sanhueza PI'],"['Administration, Cutaneous', 'Angioedemas, Hereditary/chemically induced/*etiology/immunology', 'Contraceptives, Oral, Hormonal/*adverse effects', 'Drug Combinations', 'Ethinyl Estradiol/*administration & dosage', 'Female', 'Humans', 'Norgestrel/administration & dosage/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/18328481/
2317,norgestrel,1804093,Norplant.,['Cooper M'],"['Drug Implants', 'Female', 'Humans', '*Levonorgestrel/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1804093/
2318,norgestrel,6804163,Fertility after discontinuation of levonorgestrel-releasing intrauterine devices.,['Nilsson CG'],"['Adult', 'Female', 'Fertility/*drug effects', 'Humans', '*Intrauterine Devices, Medicated', 'Levonorgestrel', 'Norgestrel/*administration & dosage/pharmacology', 'Pregnancy', 'Stereoisomerism', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6804163/
2319,norgestrel,28285154,The pharmacokinetics of 12-week continuous contraceptive patch use.,"['Lavelanet AF', 'Rybin D', 'White KO']","['Administration, Cutaneous', 'Adult', 'Body Mass Index', 'Contraceptives, Oral, Combined/administration & dosage/*pharmacokinetics', 'Drug Combinations', 'Ethinyl Estradiol/adverse effects/blood/*pharmacokinetics', 'Female', 'Humans', 'Norgestrel/adverse effects/*analogs & derivatives/blood/pharmacokinetics', 'Oximes/adverse effects/blood/pharmacokinetics', 'Time Factors', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/28285154/
2320,norgestrel,17689623,Transdermal hormonal contraception: benefits and risks.,['Burkman RT'],"['Adhesiveness', 'Administration, Cutaneous', 'Contraceptive Agents, Female/*administration & dosage', 'Contraceptives, Oral/administration & dosage', 'Drug Combinations', 'Ethinyl Estradiol/*administration & dosage/adverse effects/pharmacokinetics', 'Female', 'Humans', 'Norgestrel/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Patient Compliance', 'Patient Satisfaction', 'Venous Thrombosis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/17689623/
2321,norgestrel,6793299,Intracervical release of levonorgestrel for contraception.,"['Kurunmaki H', 'Toivonen J', 'Lahteenmaki P', 'Luukkainen T']","['Adult', 'Estradiol/blood', 'Female', 'Humans', '*Intrauterine Devices, Medicated/adverse effects', 'Levonorgestrel', 'Norgestrel/*administration & dosage/blood', 'Ovulation/drug effects', 'Progesterone/blood', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/6793299/
2322,norgestrel,2125544,Clinical experience with the progestogen-only pill.,"['Broome M', 'Fotherby K']","['Adult', '*Contraception', 'Contraceptives, Oral, Combined/administration & dosage/adverse effects', 'Ethynodiol Diacetate/administration & dosage/adverse effects/analogs & derivatives', 'Female', 'Humans', 'Levonorgestrel', 'Menstrual Cycle/drug effects', 'Middle Aged', 'Norethindrone/administration & dosage/adverse effects', 'Norgestrel/administration & dosage/adverse effects', 'Patient Dropouts', 'Progestins/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2125544/
2323,norgestrel,11134831,"Clinical evidence supporting the rationale for constant oestrogen, intermittent progestogen hormone replacement therapy.",['Rozenberg S'],"['Animals', 'Endometrial Neoplasms/chemically induced/prevention & control', 'Estradiol/administration & dosage', 'Estrogen Replacement Therapy', 'Estrogens/*administration & dosage/adverse effects', 'Female', '*Hormone Replacement Therapy', 'Humans', '*Menopause', 'Norgestrel/administration & dosage/*analogs & derivatives', 'Progestins/*administration & dosage/adverse effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11134831/
2324,norgestrel,892044,Ethinylestradiol and dl-norgestrel as a postcoital contraceptive.,"['Yuzpe AA', 'Lancee WJ']","['Adolescent', 'Adult', 'Contraception Behavior', 'Contraceptives, Postcoital/*pharmacology', 'Drug Administration Schedule', 'Ethinyl Estradiol/administration & dosage/adverse effects/*pharmacology', 'Female', 'Fertilization/drug effects', 'Humans', 'Menstruation', 'Nausea/chemically induced', 'Norgestrel/administration & dosage/adverse effects/*pharmacology', 'Pregnancy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/892044/
2325,norgestrel,16813747,Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial.,"['Anderson FD', 'Gibbons W', 'Portman D']","['Adult', 'Contraceptives, Oral, Combined/*administration & dosage/adverse effects', 'Ethinyl Estradiol-Norgestrel Combination/*administration & dosage/adverse effects', 'Female', 'Humans', 'Menstruation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/16813747/
2326,glimepiride,30265743,Novel therapeutic approaches to xeroderma pigmentosum.,"['Weon JL', 'Glass DA 2nd']","['Acetohexamide/pharmacology/therapeutic use', 'Administration, Cutaneous', 'Animals', 'Caloric Restriction', 'DNA Damage/*drug effects/radiation effects', 'DNA Repair/*drug effects', 'Dermatology/methods/trends', 'Disease Models, Animal', 'Humans', 'Niacinamide/pharmacology/therapeutic use', 'Protective Clothing', 'Randomized Controlled Trials as Topic', 'Sulfonylurea Compounds/pharmacology/*therapeutic use', 'Sunlight/adverse effects', 'Sunscreening Agents/*administration & dosage', 'Treatment Outcome', 'Ultraviolet Rays/adverse effects', 'Xeroderma Pigmentosum/genetics/*therapy']",https://pubmed.ncbi.nlm.nih.gov/30265743/
2327,glimepiride,36129997,Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.,"['Nathan DM', 'Lachin JM', 'Bebu I', 'Burch HB', 'Buse JB', 'Cherrington AL', 'Fortmann SP', 'Green JB', 'Kahn SE', 'Kirkman MS', 'Krause-Steinrauf H', 'Larkin ME', 'Phillips LS', 'Pop-Busui R', 'Steffes M', 'Tiktin M', 'Tripputi M', 'Wexler DJ', 'Younes N']","['Albuminuria/etiology/prevention & control', 'Blood Glucose/analysis', '*Cardiovascular Diseases/etiology/prevention & control', 'Comparative Effectiveness Research', '*Diabetes Complications/etiology/prevention & control', '*Diabetes Mellitus, Type 2/complications/drug therapy', 'Diabetic Neuropathies/diagnosis/etiology/prevention & control', 'Drug Therapy, Combination', 'Dyslipidemias/etiology/prevention & control', 'Glomerular Filtration Rate', '*Glycated Hemoglobin/analysis', 'Heart Failure/etiology/prevention & control', 'Humans', 'Hypertension/etiology/prevention & control', '*Hypoglycemic Agents/adverse effects/therapeutic use', 'Insulin Glargine/adverse effects/therapeutic use', 'Liraglutide/adverse effects/therapeutic use', '*Metformin/adverse effects/therapeutic use', 'Microvessels/drug effects', 'Sitagliptin Phosphate/adverse effects/therapeutic use', 'Sulfonylurea Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36129997/
2328,glimepiride,36300277,Evaluating gliclazide for the treatment of type 2 diabetes mellitus.,"['Tomlinson B', 'Li YH', 'Chan P']","['Humans', '*Gliclazide/adverse effects', '*Diabetes Mellitus, Type 2/drug therapy', 'Sulfonylurea Compounds/therapeutic use', 'Hypoglycemic Agents/adverse effects', 'Blood Glucose']",https://pubmed.ncbi.nlm.nih.gov/36300277/
2329,glimepiride,17076998,Are sulfonylureas passe?,"['Green JB', 'Feinglos MN']","['Diabetes Mellitus, Type 2/*drug therapy/physiopathology', 'Humans', 'Hypoglycemic Agents/adverse effects/therapeutic use', 'Sulfonylurea Compounds/adverse effects/*therapeutic use', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17076998/
2330,glimepiride,24948511,"Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.","['Ridderstrale M', 'Andersen KR', 'Zeller C', 'Kim G', 'Woerle HJ', 'Broedl UC']","['Adult', 'Benzhydryl Compounds/*administration & dosage', 'Blood Glucose/drug effects/metabolism', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Glucosides/*administration & dosage', 'Glycated Hemoglobin/drug effects/metabolism', 'Humans', 'Hypoglycemic Agents/*administration & dosage', 'Male', 'Metformin/*administration & dosage', 'Middle Aged', 'Sodium-Glucose Transporter 2', '*Sodium-Glucose Transporter 2 Inhibitors', 'Sulfonylurea Compounds/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24948511/
2331,glimepiride,15200348,The role of sulphonylureas in the management of type 2 diabetes mellitus.,['Rendell M'],"['Benzamides/therapeutic use', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects/*therapeutic use', 'Insulin/therapeutic use', 'Sulfonylurea Compounds/administration & dosage/adverse effects/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/15200348/
2332,glimepiride,37909653,Drug-induced hypoglycemia: a disproportionality analysis of the FAERS database.,"['Li J', 'Wang Y', 'Yang X', 'Zhu H', 'Jiang Z']","['*Hypoglycemia/chemically induced/epidemiology', 'Humans', '*Databases, Factual', '*Adverse Drug Reaction Reporting Systems/statistics & numerical data', '*Pharmacovigilance', 'United States/epidemiology', '*United States Food and Drug Administration', '*Hypoglycemic Agents/adverse effects/administration & dosage', 'Male', 'Adult', 'Middle Aged', 'Female', 'Drug Labeling', 'Aged', 'Child', 'Young Adult', 'Adolescent', 'Child, Preschool']",https://pubmed.ncbi.nlm.nih.gov/37909653/
2333,glimepiride,32861392,Modern sulphonylureas and cardiovascular adverse effects: Will CAROLINA put an end to the controversy?,"['John M', 'Kalra S', 'Nair T']","['Cardiovascular Diseases/etiology/*prevention & control', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Sulfonylurea Compounds/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32861392/
2334,glimepiride,33754231,Development of anti-acanthamoebic approaches.,"['Mungroo MR', 'Tong T', 'Khan NA', 'Anuar TS', 'Maciver SK', 'Siddiqui R']","['Acanthamoeba Keratitis/*drug therapy/*parasitology', 'Acanthamoeba castellanii/*drug effects', 'Acarbose/pharmacology', 'Antiprotozoal Agents/*pharmacology', 'Carbamates/pharmacology', 'Cell Line', 'Contact Lens Solutions/pharmacology', 'Contact Lenses/adverse effects/*parasitology', 'HaCaT Cells', 'Humans', 'Indenes/pharmacology', 'Inositol/pharmacology', 'Nanoparticles', 'Piperidines/pharmacology', 'Sulfonylurea Compounds/pharmacology', 'Triazines/pharmacology', 'Vildagliptin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33754231/
2335,glimepiride,22247979,A case of hypoglycemic hemiparesis and literature review.,"['Yoshino T', 'Meguro S', 'Soeda Y', 'Itoh A', 'Kawai T', 'Itoh H']","['Aged', 'Aged, 80 and over', 'Blood Glucose/analysis', 'Diabetes Mellitus/drug therapy', 'Humans', 'Hypoglycemia/*complications', 'Male', 'Metformin/administration & dosage/therapeutic use', 'Paresis/*diagnosis/etiology', 'Sulfonylurea Compounds/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22247979/
2336,glimepiride,36592466,"In type 2 diabetes, liraglutide reduced CV events at 5 y vs. glargine, glimepiride, or sitagliptin.","['Brown K', 'Donato AA']","['Humans', '*Diabetes Mellitus, Type 2/complications/drug therapy', 'Insulin Glargine/therapeutic use', 'Liraglutide/therapeutic use', 'Sitagliptin Phosphate/therapeutic use', 'Hypoglycemic Agents/therapeutic use', 'Drug Therapy, Combination', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36592466/
2337,glimepiride,38853720,"Efficacy and tolerability of initial triple combination therapy with metformin, dapagliflozin and saxagliptin compared with stepwise add-on therapy in drug-naive patients with type 2 diabetes (TRIPLE-AXEL study): A multicentre, randomized, 104-week, open-label, active-controlled trial.","['Kim NH', 'Moon JS', 'Lee YH', 'Cho HC', 'Kwak SH', 'Lim S', 'Moon MK', 'Kim DL', 'Kim TH', 'Ko E', 'Lee J', 'Kim SG']","['Humans', '*Diabetes Mellitus, Type 2/drug therapy/blood', '*Metformin/therapeutic use/administration & dosage/adverse effects', '*Glucosides/administration & dosage/adverse effects/therapeutic use', 'Male', 'Female', '*Benzhydryl Compounds/therapeutic use/administration & dosage/adverse effects', 'Middle Aged', '*Drug Therapy, Combination', '*Dipeptides/adverse effects/administration & dosage/therapeutic use', '*Adamantane/analogs & derivatives/administration & dosage/adverse effects/therapeutic use', '*Hypoglycemic Agents/administration & dosage/therapeutic use/adverse effects', '*Glycated Hemoglobin/analysis/metabolism', 'Aged', 'Treatment Outcome', 'Hypoglycemia/chemically induced', 'Sulfonylurea Compounds/therapeutic use/administration & dosage/adverse effects', 'Blood Glucose/drug effects/metabolism', 'Adult', 'Weight Gain/drug effects', 'Sitagliptin Phosphate/therapeutic use/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38853720/
2338,glimepiride,17728849,Pioglitazone hydrochloride/glimepiride.,['Blake EW'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', '*Sulfonylurea Compounds/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728849/
2339,glimepiride,39546502,Glycemia reduction in type 2 diabetes-Hypoglycemia outcomes: A randomized clinical trial.,"['Seaquist ER', 'Phillips LS', 'Ghosh A', 'Baker C', 'Bergenstal RM', 'Crandall JP', 'Goland RS', 'Gramzinski MR', 'Hox SH', 'Hsia DS', 'Johnson ML', 'Lachin JM', 'Raskin P', 'Valencia WM', 'Waltje AH', 'Younes N']","['Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Blood Glucose/drug effects/analysis', '*Diabetes Mellitus, Type 2/drug therapy/blood', 'Glycated Hemoglobin/analysis/metabolism', '*Hypoglycemia/chemically induced', '*Hypoglycemic Agents/therapeutic use/adverse effects', 'Insulin Glargine/therapeutic use/adverse effects/administration & dosage', 'Liraglutide/therapeutic use/adverse effects', 'Metformin/therapeutic use/adverse effects', 'Sitagliptin Phosphate/therapeutic use/adverse effects', 'Sulfonylurea Compounds/therapeutic use/adverse effects', 'Treatment Outcome', '*Glycemic Control']",https://pubmed.ncbi.nlm.nih.gov/39546502/
2340,glimepiride,21240619,Pneumatosis cystoides intestinalis in neuropsychiatric systemic lupus erythematosus with diabetes mellitus: case report and literature review.,"['Shimojima Y', 'Ishii W', 'Matsuda M', 'Tojo K', 'Watanabe R', 'Ikeda S']","['Diabetes Complications/*drug therapy', 'Drug Therapy, Combination', 'Glucocorticoids/administration & dosage/adverse effects', 'Humans', 'Hypoglycemic Agents/administration & dosage/adverse effects', 'Inositol/administration & dosage/adverse effects/*analogs & derivatives', 'Lupus Vasculitis, Central Nervous System/*drug therapy', 'Male', 'Middle Aged', 'Pneumatosis Cystoides Intestinalis/*chemically induced/diagnostic imaging', 'Prednisolone/administration & dosage/*adverse effects', 'Sulfonylurea Compounds/administration & dosage/*adverse effects', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/21240619/
2341,glimepiride,8864639,Clinical profile of the novel sulphonylurea glimepiride.,"['Rosskamp R', 'Wernicke-Panten K', 'Draeger E']","['Blood Glucose/metabolism', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Sulfonylurea Compounds/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8864639/
2342,glimepiride,8911978,"Combined therapy with a sulfonylurea plus evening insulin: safe, reliable, and becoming routine.",['Riddle MC'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Hypoglycemic Agents/administration & dosage/therapeutic use', 'Insulin/administration & dosage/*therapeutic use', 'Sulfonylurea Compounds/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8911978/
2343,glimepiride,23521323,Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA(1)c < 7% with no hypoglycaemia and no weight gain over 2 years.,"['Gallwitz B', 'Rosenstock J', 'Emser A', 'von Eynatten M', 'Woerle HJ']","['Analysis of Variance', 'Diabetes Mellitus, Type 2/blood/*drug therapy', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Glycated Hemoglobin/*metabolism', 'Humans', 'Hypoglycemia/prevention & control', 'Hypoglycemic Agents/*administration & dosage', 'Linagliptin', 'Male', 'Middle Aged', 'Purines/*administration & dosage', 'Quinazolines/*administration & dosage', 'Sulfonylurea Compounds/*administration & dosage', 'Treatment Outcome', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/23521323/
2344,Celestone,39575914,[Not Available].,"['Kofoed K', 'Skov L', 'Zachariae C']","['Humans', '*Psoriasis/drug therapy', '*Dermatologic Agents/administration & dosage/therapeutic use', '*Betamethasone/administration & dosage/therapeutic use', '*Calcitriol/analogs & derivatives/administration & dosage/therapeutic use', 'Calcineurin Inhibitors/therapeutic use/administration & dosage', 'Administration, Cutaneous', 'Administration, Topical', 'Drug Combinations', 'Adrenal Cortex Hormones/administration & dosage/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39575914/
2345,Celestone,2186003,Penicillamine-induced pemphigus erythematosus.,"['Willemsen MJ', 'De Coninck AL', 'De Raeve LE', 'Roseeuw DI']","['Administration, Cutaneous', 'Arthritis, Rheumatoid/drug therapy', 'Betamethasone/administration & dosage/therapeutic use', 'Fluorescent Antibody Technique', 'Humans', 'Immunoglobulin M/analysis', 'Male', 'Middle Aged', 'Pemphigus/*chemically induced/immunology', 'Penicillamine/administration & dosage/adverse effects/therapeutic use', 'Skin/immunology/pathology']",https://pubmed.ncbi.nlm.nih.gov/2186003/
2346,Celestone,38656759,Neurodevelopmental Outcomes After Late Preterm Antenatal Corticosteroids: The ALPS Follow-Up Study.,"['Gyamfi-Bannerman C', 'Clifton RG', 'Tita ATN', 'Blackwell SC', 'Longo M', 'de Voest JA', ""O'Shea TM"", 'Bousleiman SZ', 'Ortiz F', 'Rouse DJ', 'Metz TD', 'Saade GR', 'Rood KM', 'Heyborne KD', 'Thorp JM Jr', 'Swamy GK', 'Grobman WA', 'Gibson KS', 'El-Sayed YY', 'Macones GA']","['Child', 'Female', 'Humans', 'Infant, Newborn', 'Male', 'Pregnancy', '*Betamethasone/administration & dosage/adverse effects/therapeutic use', 'Child Development/drug effects', 'Follow-Up Studies', '*Glucocorticoids/administration & dosage/adverse effects/therapeutic use', 'Infant, Premature', '*Neurodevelopmental Disorders/chemically induced/epidemiology', 'Premature Birth/prevention & control', 'Prenatal Care', '*Prenatal Exposure Delayed Effects/chemically induced', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/38656759/
2347,Celestone,17521858,[Paclitaxel-induced lupus].,"['Lortholary A', 'Cary-Ten Have Dallinga M', 'El Kouri C', 'Morineau N', 'Ramee JF']","['Aged', 'Anti-Inflammatory Agents/administration & dosage/therapeutic use', 'Antibodies, Antinuclear/analysis', 'Antineoplastic Agents, Phytogenic/*adverse effects/therapeutic use', 'Betamethasone/administration & dosage/analogs & derivatives/therapeutic use', 'Biopsy', 'Drug Therapy, Combination', 'Erythropoietin/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lupus Erythematosus, Cutaneous/*chemically induced/diagnosis/drug therapy/immunology/pathology', 'Ovarian Neoplasms/drug therapy', 'Paclitaxel/*adverse effects', 'Recombinant Proteins', 'Recurrence', 'Skin/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17521858/
2348,Celestone,16402537,[The calcipotriol-betamethasone dipropionate association].,"['Henry F', 'Flagothier C', 'Delvoye P', 'Pierard-Franchimont C', 'Pierard GE']","['Administration, Topical', 'Betamethasone/administration & dosage/*analogs & derivatives/therapeutic use', 'Calcitriol/administration & dosage/*analogs & derivatives/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Inflammation', 'Psoriasis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16402537/
2349,Celestone,29895522,Repeat Antenatal Betamethasone and Cardiometabolic Outcomes.,"['Cartwright RD', 'Harding JE', 'Crowther CA', 'Cutfield WS', 'Battin MR', 'Dalziel SR', 'McKinlay CJD']","['Absorptiometry, Photon', 'Anthropometry', 'Australia', 'Betamethasone/administration & dosage/*adverse effects', 'Blood Pressure Monitoring, Ambulatory', 'Child', 'Child Development/drug effects', 'Child, Preschool', 'Double-Blind Method', 'Female', 'Fetal Growth Retardation/*drug therapy/physiopathology', 'Glucocorticoids/administration & dosage/*adverse effects', 'Glucose Tolerance Test', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'New Zealand', 'Pregnancy', 'Prenatal Exposure Delayed Effects/*epidemiology', 'Risk Factors', 'Spirometry']",https://pubmed.ncbi.nlm.nih.gov/29895522/
2350,Celestone,15606220,Effects of glucocorticoids on fetal and neonatal lung development.,"['Grier DG', 'Halliday HL']","['Betamethasone/administration & dosage/pharmacology/therapeutic use', 'Female', '*Fetal Organ Maturity', 'Glucocorticoids/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Infant, Newborn', 'Lung/drug effects/*embryology', 'Pregnancy', 'Respiratory Distress Syndrome, Newborn/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/15606220/
2351,Celestone,28659016,Calcipotriene betamethasone dipropionate aerosol foam in the treatment of plaque psoriasis: a review of the literature.,"['Frieder J', 'Kivelevitch D', 'Menter A']","['Betamethasone/administration & dosage/*analogs & derivatives/therapeutic use', 'Calcitriol/administration & dosage/*analogs & derivatives/therapeutic use', 'Dermatologic Agents/*administration & dosage/therapeutic use', 'Drug Combinations', 'Humans', 'Psoriasis/*drug therapy', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/28659016/
2352,Celestone,8075276,Intraocular blastomycosis: case report and review.,"['Lopez R', 'Mason JO', 'Parker JS', 'Pappas PG']","['Amphotericin B/administration & dosage/therapeutic use', 'Betamethasone/adverse effects/therapeutic use', '*Blastomycosis/diagnosis/drug therapy', 'Dermatomycoses/complications/diagnosis/microbiology', 'Drug Therapy, Combination', 'Humans', 'Iritis/diagnosis/drug therapy/*microbiology', 'Lung Diseases, Fungal/chemically induced/complications/diagnosis', 'Male', 'Miconazole/administration & dosage/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8075276/
2353,Celestone,24529761,[Prenatal corticosteroids: short-term and long-term effects of multiple courses. Literature review in 2013].,"['Fuchs F', 'Audibert F', 'Senat MV']","['Adrenal Cortex Hormones/administration & dosage/*pharmacology', 'Betamethasone/administration & dosage/*pharmacology', 'Birth Weight/drug effects', 'Body Height/drug effects', 'Dexamethasone/administration & dosage/*pharmacology', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Evidence-Based Medicine', 'Female', 'Fetal Development/drug effects', 'Humans', 'Infant, Premature, Diseases/prevention & control', 'Pregnancy', 'Premature Birth/*prevention & control', '*Prenatal Care/methods', 'Respiratory Distress Syndrome, Newborn/*prevention & control', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/24529761/
2354,Celestone,16038572,The role of topical corticosteroids in bullous pemphigoid in the elderly.,"['Joly P', 'Fontaine J', 'Roujeau JC']","['Administration, Topical', 'Adrenal Cortex Hormones/*administration & dosage/adverse effects/*therapeutic use', 'Aged', 'Clobetasol/administration & dosage/analogs & derivatives/therapeutic use', 'Humans', 'Pemphigoid, Bullous/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16038572/
2355,Celestone,15968261,A novel foam vehicle for delivery of topical corticosteroids.,"['Huang X', 'Tanojo H', 'Lenn J', 'Deng CH', 'Krochmal L']","['Administration, Cutaneous', 'Administration, Topical', 'Adrenal Cortex Hormones/*administration & dosage/pharmacokinetics/therapeutic use', 'Anti-Inflammatory Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Betamethasone/administration & dosage/pharmacokinetics', 'Body Water', 'Calcitriol/administration & dosage/analogs & derivatives/pharmacokinetics', 'Clindamycin/administration & dosage/pharmacokinetics', 'Clobetasol/administration & dosage/analogs & derivatives/pharmacokinetics', 'Dermatologic Agents/*administration & dosage/pharmacokinetics/therapeutic use', 'Dosage Forms', 'Hot Temperature', 'Humans', 'Ketoconazole/administration & dosage/pharmacokinetics', 'Ointments', 'Pharmaceutical Vehicles', 'Skin/drug effects/metabolism', 'Skin Absorption']",https://pubmed.ncbi.nlm.nih.gov/15968261/
2356,Celestone,9691827,[Allergic rhinoconjunctivitis treated with intramuscular injection of glucocorticoid].,"['Dahl M', 'Laursen LC']","['Betamethasone/administration & dosage/adverse effects', 'Delayed-Action Preparations', 'Glucocorticoids/*administration & dosage/adverse effects', 'Humans', 'Injections, Intramuscular', 'Methylprednisolone/administration & dosage/adverse effects', 'Prednisolone/administration & dosage/adverse effects', 'Rhinitis, Allergic, Seasonal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9691827/
2357,Celestone,21575796,Potential risks and benefits of antenatal corticosteroid therapy prior to preterm birth in pregnancies complicated by severe fetal growth restriction.,"['Vidaeff AC', 'Blackwell SC']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/therapeutic use', 'Adult', 'Betamethasone/administration & dosage/adverse effects/therapeutic use', 'Dexamethasone/administration & dosage/adverse effects/therapeutic use', 'Female', 'Fetal Growth Retardation/*drug therapy', 'Humans', 'Infant, Newborn', 'Pregnancy', '*Pregnancy Complications', '*Premature Birth', 'Prenatal Care', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/21575796/
2358,Celestone,30261718,Calcipotriene plus betamethasone dipropionate in aerosol foam formulation: will this effective treatment for mild-to-moderate psoriasis change clinical practice?,"['Giovene GL', 'Giacomelli L']","['Administration, Cutaneous', 'Aerosols', 'Betamethasone/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Biological Availability', 'Calcitriol/administration & dosage/adverse effects/*analogs & derivatives/pharmacokinetics', 'Dermatologic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Drug Combinations', 'Humans', 'Italy', 'Psoriasis/*drug therapy/pathology', 'Skin Absorption', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30261718/
2359,Celestone,31272782,Long-Term Evaluation of Low-Dose Betamethasone for Ataxia Telangiectasia.,"['Hasegawa S', 'Kumada S', 'Tanuma N', 'Tsuji-Hosokawa A', 'Kashimada A', 'Mizuno T', 'Moriyama K', 'Sugawara Y', 'Shirai I', 'Miyata Y', 'Nishida H', 'Mashimo H', 'Hasegawa T', 'Hosokawa T', 'Hisakawa H', 'Uematsu M', 'Fujine A', 'Miyata R', 'Sakuma H', 'Kashimada K', 'Imai K', 'Morio T', 'Hayashi M', 'Mizutani S', 'Takagi M']","['Adolescent', 'Adrenal Gland Diseases/chemically induced', 'Ataxia Telangiectasia/*drug therapy', 'Betamethasone/administration & dosage/adverse effects/*pharmacology', 'Child', '*Drug-Related Side Effects and Adverse Reactions', 'Female', 'Glucocorticoids/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Longitudinal Studies', 'Male', '*Outcome Assessment, Health Care', 'Peripheral Nervous System Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/31272782/
2360,Celestone,14714924,Antenatal corticosteroids for fetal maturation in women at risk for preterm delivery.,"['Vidaeff AC', 'Doyle NM', 'Gilstrap LC 3rd']","['Adrenal Cortex Hormones/*administration & dosage/*pharmacology', 'Betamethasone/administration & dosage/pharmacology', 'Consensus Development Conferences, NIH as Topic', 'Dexamethasone/administration & dosage/pharmacology', 'Female', 'Fetal Membranes, Premature Rupture/*complications', 'Fetal Organ Maturity/*drug effects', 'Gestational Age', 'Humans', 'Obstetric Labor, Premature/*etiology/*prevention & control', 'Pregnancy', 'Pregnancy Outcome', 'United States']",https://pubmed.ncbi.nlm.nih.gov/14714924/
2361,Celestone,15035454,Antenatal corticosteroid therapy: benefits and risks.,['Baud O'],"['Adrenal Cortex Hormones/adverse effects/*therapeutic use', 'Animals', 'Betamethasone/adverse effects/therapeutic use', 'Cerebral Palsy/prevention & control', 'Dexamethasone/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Embryonic and Fetal Development/drug effects', 'Female', 'Humans', 'Infant, Newborn', 'Pregnancy', 'Pregnancy Complications/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15035454/
2362,Celestone,2396837,Penile verrucous carcinoma.,"['Yeager JK', 'Findlay RF', 'McAleer IM']","['Administration, Topical', 'Aged', 'Betamethasone/*analogs & derivatives', 'Carcinoma, Papillary/*pathology', 'Child', 'Clobetasol/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Middle Aged', 'Penile Neoplasms/*pathology', 'Photosensitivity Disorders/*drug therapy', 'Prurigo/*drug therapy/etiology', 'Skin/*pathology', 'Sunlight/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2396837/
2363,Celestone,12454632,[Corticosteroid for fetal lung maturation: indication and treatment protocols].,['Senat MV'],"['Betamethasone/adverse effects/*therapeutic use', 'Female', 'Fetal Organ Maturity/drug effects', 'Fetus', 'France', 'Glucocorticoids/adverse effects/*therapeutic use', 'Humans', 'Infant, Newborn', 'Lung/*embryology', '*Practice Guidelines as Topic', 'Pregnancy', 'Pregnancy Trimester, Second', 'Pregnancy Trimester, Third', 'Randomized Controlled Trials as Topic', 'Respiratory Distress Syndrome, Newborn/*prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12454632/
2364,nifedipine,8061479,Sublingual nifedipine: the continuing controversy.,['Oliver S'],"['Administration, Oral', 'Administration, Sublingual', 'Clinical Trials as Topic', 'Humans', 'Nifedipine/*administration & dosage/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8061479/
2365,nifedipine,38949541,Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.,"['Sanusi AA', 'Leach J', 'Boggess K', 'Dugoff L', 'Sibai B', 'Lawrence K', 'Hughes BL', 'Bell J', 'Aagaard K', 'Edwards RK', 'Gibson KS', 'Haas DM', 'Plante L', 'Metz TD', 'Casey B', 'Esplin S', 'Longo S', 'Hoffman MK', 'Saade GR', 'Hoppe KK', 'Foroutan J', 'Tuuli M', 'Owens MY', 'Simhan HN', 'Frey H', 'Rosen T', 'Palatnik A', 'Baker S', 'August P', 'Reddy UM', 'Su EJ', 'Krishna I', 'Nguyen NA', 'Norton ME', 'Skupski D', 'El-Sayed YY', 'Ogunyemi D', 'Galis ZS', 'Harper L', 'Ambalavanan N', 'Geller NL', 'Kuo HC', 'Sinkey RG', 'Librizzi R', 'Pereira L', 'Magann EF', 'Habli M', 'Williams S', 'Mari G', 'Pridjian G', 'McKenna DS', 'Parrish M', 'Chang E', 'Osmundson S', 'Quinones J', 'Szychowski JM', 'Tita ATN']","['Humans', 'Pregnancy', 'Female', '*Labetalol/administration & dosage/adverse effects/therapeutic use', '*Nifedipine/administration & dosage/adverse effects/therapeutic use', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Adult', '*Pregnancy Outcome', '*Hypertension/drug therapy', 'Infant, Newborn', 'Pregnancy Complications, Cardiovascular/drug therapy', 'Hypertension, Pregnancy-Induced/drug therapy', 'Administration, Oral', 'Infant, Small for Gestational Age', 'Pre-Eclampsia/drug therapy', 'Chronic Disease']",https://pubmed.ncbi.nlm.nih.gov/38949541/
2366,nifedipine,1834848,Amlodipine: an effective once-daily antihypertensive agent.,['Tyler HM'],"['Amlodipine', '*Antihypertensive Agents/administration & dosage/therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Longitudinal Studies', 'Nifedipine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1834848/
2367,nifedipine,3912182,Felodipine in hypertension.,"['Mace PJ', 'Stallard TJ', 'Littler WA']","['Adult', 'Antihypertensive Agents/administration & dosage/blood/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Felodipine', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*analogs & derivatives/blood/therapeutic use', 'Norepinephrine/blood', 'Posture', 'Renin/blood', 'Time Factors', 'Vasodilator Agents/administration & dosage/blood/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3912182/
2368,nifedipine,3551600,"Sodium intake, high blood pressure, and calcium channel blockers.","['MacGregor GA', 'Cappuccio FP', 'Markandu ND']","['Animals', 'Blood Pressure/drug effects', 'Calcium/physiology', 'Calcium Channel Blockers/pharmacology/*therapeutic use', 'Humans', 'Hypertension/*chemically induced/drug therapy/physiopathology', 'Kidney/physiopathology', 'Nifedipine/pharmacology/therapeutic use', 'Sodium/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3551600/
2369,nifedipine,25728783,[Calcium channel blockers pharmacology and their use as tocolytics].,"['Bejan-Angoulvant T', 'Crochet J', 'Jonville-Bera AP']","['Adult', '*Calcium Channel Blockers/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Female', 'Humans', '*Nicardipine/administration & dosage/adverse effects/pharmacokinetics/pharmacology', '*Nifedipine/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Obstetric Labor, Premature/*drug therapy', 'Pregnancy', '*Tocolytic Agents/administration & dosage/adverse effects/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25728783/
2370,nifedipine,11434453,Barnidipine.,"['Malhotra HS', 'Plosker GL']","['Aged', 'Animals', 'Area Under Curve', 'Biological Availability', '*Calcium Channel Blockers/metabolism/pharmacokinetics/pharmacology/therapeutic use', 'Hemodynamics/drug effects', 'Humans', '*Hypertension/*drug therapy', 'Intestinal Absorption', 'Multicenter Studies as Topic', '*Nifedipine/*analogs & derivatives/metabolism/pharmacokinetics/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11434453/
2371,nifedipine,2212122,Chilblains (perniosis).,['Goette DK'],"['Adult', 'Aged', 'Aged, 80 and over', 'Chilblains/etiology/*pathology/therapy', 'Child', 'Diagnosis, Differential', 'Female', 'Humans', 'Lymphocytes/pathology', 'Male', 'Nifedipine/administration & dosage/adverse effects/therapeutic use', 'San Francisco', 'Skin/pathology']",https://pubmed.ncbi.nlm.nih.gov/2212122/
2372,nifedipine,6764159,Calcium-channel blocking agents.,"['Leonard RG', 'Talbert RL']","['Adolescent', 'Benzazepines/*pharmacology', 'Calcium/physiology', 'Calcium Channel Blockers/*pharmacology', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Diltiazem/adverse effects/metabolism/*pharmacology/therapeutic use', 'Double-Blind Method', 'Heart/*drug effects', 'Heart Diseases/*drug therapy', 'Humans', 'Hypertension/drug therapy', 'Infant', 'Myocardial Contraction/drug effects', 'Nifedipine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Pyridines/*pharmacology', 'Verapamil/adverse effects/metabolism/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6764159/
2373,nifedipine,1836870,"The clinical consequences of the absorption, distribution, metabolism and excretion of amlodipine.","['Elliott HL', 'Meredith PA']","['Amlodipine', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/adverse effects/metabolism/*pharmacokinetics/pharmacology', 'Humans', 'Hypertension/drug therapy', 'Nifedipine/adverse effects/*analogs & derivatives/metabolism/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1836870/
2374,nifedipine,3288468,"Efficacy and tolerability of atenolol, nifedipine and their combination in the management of hypertension.","['Stanley NN', 'Thirkettle JL', 'Varma MP', 'Larkin H', 'Heath ID']","['Adult', 'Aged', 'Atenolol/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Creatinine/blood', 'Double-Blind Method', 'Drug Therapy, Combination', 'Drug Tolerance', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use', 'Potassium/blood', 'Random Allocation', 'Uric Acid/blood']",https://pubmed.ncbi.nlm.nih.gov/3288468/
2375,nifedipine,3234257,Subcutaneous administration of nifedipine.,"['Krichbaum DW', 'Malone PM']","['Aged', 'Emergencies', 'Female', 'Humans', 'Hypertension/drug therapy', 'Injections, Subcutaneous', 'Nifedipine/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3234257/
2376,nifedipine,6712894,Treatment of severe pregnancy-associated hypertension with the calcium antagonist nifedipine.,"['Walters BN', 'Redman CW']","['Adolescent', 'Adult', 'Blood Pressure/drug effects', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Nifedipine/adverse effects/*therapeutic use', 'Pilot Projects', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Puerperal Disorders/drug therapy', 'Pulse/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6712894/
2377,nifedipine,28233944,Therapeutic Differences in 24-h Ambulatory Blood Pressures in Patients Switched Between Bioequivalent Nifedipine Osmotic Systems With Differing Delivery Technologies.,"['Pollak PT', 'Herman RJ', 'Feldman RD']","['Aged', 'Blood Pressure/*drug effects', '*Blood Pressure Monitoring, Ambulatory', 'Demography', '*Drug Delivery Systems', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/*administration & dosage/pharmacokinetics/pharmacology/*therapeutic use', 'Osmosis', 'Systole/drug effects', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/28233944/
2378,nifedipine,3987547,"Antihypertensive and water and sodium balance effects of felodipine, a new vasodilating calcium antagonist, in hypertensive patients.","['Leonetti G', 'Fruscio M', 'Terzoli L', 'Rupoli L', 'Gradnik R', 'Sampieri L', 'Cuspidi C', 'Boselli L', 'Bolla G', 'Zanchetti A']","['Adult', 'Antihypertensive Agents/adverse effects/*pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Calcium Channel Blockers/*pharmacology', 'Creatinine/blood', 'Felodipine', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy/metabolism/*physiopathology', 'Male', 'Nifedipine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Sodium/*metabolism', 'Vasodilator Agents/*pharmacology', 'Water-Electrolyte Balance/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/3987547/
2379,nifedipine,2731403,"Single- and multiple-dose nisoldipine kinetics and effects in the young, the middle-aged, and the elderly.","['van Harten J', 'Burggraaf J', 'Ligthart GJ', 'van Brummelen P', 'Breimer DD']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aging/*metabolism/physiology', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/administration & dosage/*analogs & derivatives/pharmacokinetics/pharmacology', 'Nisoldipine', 'Norepinephrine/blood', 'Vasodilator Agents/administration & dosage/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2731403/
2380,nifedipine,14959468,[Assessment of the efficacy and tolerance of delayed-action nifedipine as the monotherapy or in combination with metoprolol in patients with arterial hypertension].,"['Isaikina OIu', 'Gorbunov VM', 'Andreeva GF', 'Dmitrieva NA', 'Martsevich SIu']","['Blood Pressure/drug effects', 'Blood Pressure Monitoring, Ambulatory', 'Cross-Over Studies', 'Delayed-Action Preparations', 'Drug Therapy, Combination', 'Electrocardiography', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Metoprolol/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Nifedipine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14959468/
2381,nifedipine,3331321,Innovative drug delivery systems in cardiovascular medicine: nifedipine-GITS and clonidine-TTS.,"['Frishman WH', 'Sherman D', 'Feinfeld DA']","['Administration, Cutaneous', 'Angina Pectoris/*drug therapy', 'Clinical Trials as Topic', 'Clonidine/*administration & dosage/pharmacokinetics/therapeutic use', 'Delayed-Action Preparations', 'Humans', 'Hypertension/*drug therapy', 'Nifedipine/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3331321/
2382,nifedipine,3689628,The trans-hepatic extraction of nifedipine.,"['Challenor VF', 'Waller DG', 'Renwick AG', 'Gruchy BS', 'George CF']","['Adult', 'Aged', 'Humans', 'Indocyanine Green', 'Injections, Intravenous', 'Liver/*metabolism', 'Male', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Nifedipine/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3689628/
2383,nifedipine,18203344,[Antihypertensive effects of nifedipine and changing for modified-release formula].,['Kuwajima I'],"['Antihypertensive Agents/*administration & dosage/*pharmacology', 'Delayed-Action Preparations', 'Humans', 'Nifedipine/*administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18203344/
2384,metoprolol,38619832,Serious Bleeding in Patients With Atrial Fibrillation Using Diltiazem With Apixaban or Rivaroxaban.,"['Ray WA', 'Chung CP', 'Stein CM', 'Smalley W', 'Zimmerman E', 'Dupont WD', 'Hung AM', 'Daugherty JR', 'Dickson A', 'Murray KT']","['Aged', 'Aged, 80 and over', 'Female', 'Humans', 'Male', '*Atrial Fibrillation/drug therapy/complications', '*Diltiazem/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Embolism/prevention & control', '*Factor Xa Inhibitors/adverse effects/therapeutic use', '*Hemorrhage/chemically induced', 'Hospitalization/statistics & numerical data', 'Medicare', 'Metoprolol/adverse effects/therapeutic use/administration & dosage', 'Pyrazoles/adverse effects/therapeutic use', 'Pyridones/adverse effects/therapeutic use/administration & dosage', 'Retrospective Studies', '*Rivaroxaban/adverse effects/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/38619832/
2385,metoprolol,35764772,Clinical Pharmacokinetics of Metoprolol: A Systematic Review.,"['Zamir A', 'Hussain I', 'Ur Rehman A', 'Ashraf W', 'Imran I', 'Saeed H', 'Majeed A', 'Alqahtani F', 'Rasool MF']","['Administration, Oral', 'Area Under Curve', 'Female', 'Food-Drug Interactions', 'Humans', '*Liver', '*Metoprolol/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35764772/
2386,metoprolol,34781150,Intravenous diltiazem versus metoprolol for atrial fibrillation with rapid ventricular rate: A meta-analysis.,"['Lan Q', 'Wu F', 'Han B', 'Ma L', 'Han J', 'Yao Y']","['Administration, Intravenous', 'Atrial Fibrillation/*drug therapy', 'Blood Pressure/drug effects', 'Diltiazem/administration & dosage/*therapeutic use', 'Heart Rate/*drug effects', 'Humans', 'Metoprolol/administration & dosage/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34781150/
2387,metoprolol,2668307,"Metoprolol-controlled release, zero order kinetics.",['Kendall MJ'],"['Delayed-Action Preparations', 'Humans', 'Metoprolol/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2668307/
2388,metoprolol,18479744,Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.,"['Devereaux PJ', 'Yang H', 'Yusuf S', 'Guyatt G', 'Leslie K', 'Villar JC', 'Xavier D', 'Chrolavicius S', 'Greenspan L', 'Pogue J', 'Pais P', 'Liu L', 'Xu S', 'Malaga G', 'Avezum A', 'Chan M', 'Montori VM', 'Jacka M', 'Choi P']","['Adrenergic beta-Antagonists/adverse effects/pharmacology/*therapeutic use', 'Aged', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/mortality/*prevention & control', 'Delayed-Action Preparations', 'Female', 'Humans', 'Intraoperative Complications/*prevention & control', 'Male', 'Metoprolol/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Middle Aged', 'Perioperative Care/*methods', 'Preoperative Care/*methods', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/18479744/
2389,metoprolol,2871805,Use of beta adrenoceptor blockade during and after acute myocardial infarction.,['Sleight P'],"['Adrenergic beta-Antagonists/*therapeutic use', 'Arrhythmias, Cardiac/drug therapy', 'Atenolol/administration & dosage/therapeutic use', 'Cardiotonic Agents/therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Fibrinolytic Agents/administration & dosage', 'Heart Rupture/prevention & control', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/therapeutic use', 'Myocardial Infarction/*drug therapy/mortality/prevention & control', 'Random Allocation', 'Retrospective Studies', 'Risk', 'Streptokinase/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2871805/
2390,metoprolol,2723107,Obesity and beta-blockers: influence of body fat on their kinetics and cardiovascular effects.,"['Galletti F', 'Fasano ML', 'Ferrara LA', 'Groppi A', 'Montagna M', 'Mancini M']","['Adipose Tissue/*metabolism', 'Atenolol/blood/*pharmacokinetics/therapeutic use', 'Blood Pressure/drug effects', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hypertension/*complications/drug therapy/metabolism', 'Kinetics', 'Male', 'Metoprolol/blood/*pharmacokinetics/therapeutic use', 'Middle Aged', 'Obesity/complications/*metabolism', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2723107/
2391,metoprolol,21547667,Pulsatile multiparticulate drug delivery system for metoprolol succinate.,"['Jagdale SC', 'Chede SM', 'Gulwady R', 'Kuchekar BS', 'Lokhande PD', 'Shah TP', 'Chabukswar AR']","['Adrenergic beta-Antagonists/*administration & dosage/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Chemistry, Pharmaceutical', 'Delayed-Action Preparations', 'Drug Carriers/*chemistry', 'Drug Chronotherapy', 'Drug Compounding/methods', 'Drug Stability', 'Humans', 'Metoprolol/administration & dosage/*analogs & derivatives/therapeutic use', 'Solubility']",https://pubmed.ncbi.nlm.nih.gov/21547667/
2392,metoprolol,7059440,Comparison of the pharmacodynamic and pharmacokinetic profiles of single and multiple doses of a commercial slow-release metoprolol formulation with a new Oros delivery system.,"['Kendall MJ', 'Jack DB', 'Woods KL', 'Laugher SJ', 'Quarterman CP', 'John VA']","['Adult', 'Blood Pressure/drug effects', 'Delayed-Action Preparations', 'Double-Blind Method', 'Heart Rate/drug effects', 'Hemodynamics/*drug effects', 'Humans', 'Kinetics', 'Male', 'Metoprolol/*administration & dosage/metabolism/pharmacology', 'Physical Exertion', 'Propanolamines/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/7059440/
2393,metoprolol,2715675,Aqueous humor concentration of metoprolol after oral administration.,"['Calissendorff B', 'Savvaides I']","['Administration, Oral', 'Adult', 'Aged', 'Aged, 80 and over', 'Aqueous Humor/*metabolism', 'Female', 'Half-Life', 'Humans', 'Male', 'Metoprolol/administration & dosage/*pharmacokinetics', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2715675/
2394,metoprolol,409024,Metoprolol and the peripheral platelet count.,"['Kutti J', 'Bergstrom AL', 'Lundborg P']","['Administration, Oral', 'Adolescent', 'Adult', 'Blood Cell Count', 'Blood Platelets/*drug effects', 'Female', 'Humans', 'Male', 'Metoprolol/administration & dosage/*pharmacology', 'Middle Aged', 'Propanolamines/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/409024/
2395,metoprolol,12784773,"Tolerability of beta-blockers in heart failure: reassurance needed, reassurance provided.",['Krum H'],"['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Heart Failure/*drug therapy', 'Humans', 'Metoprolol/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12784773/
2396,metoprolol,2280237,"Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.","['Lundgren H', 'Bengtsson C', 'Lapidus L', 'Bengtsson L']","['Aged', 'Blood Glucose/*drug effects', 'Diabetes Mellitus/*chemically induced', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2280237/
2397,metoprolol,3829948,[Can beta-receptor blockers trigger coronary spasm?].,"['Cieslinski G', 'Hopf R', 'Kober G', 'Kaltenbach M']","['Cardiac Catheterization', 'Coronary Vasospasm/*chemically induced/diagnosis', 'Exercise Test', 'Female', 'Humans', 'Hypertension/drug therapy', 'Male', 'Metoprolol/*adverse effects/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/3829948/
2398,metoprolol,32420783,"The comparison of side effects of methyldopa, amlodipine, and metoprolol in pregnant women with chronic hypertension.","['Ghafarzadeh M', 'Shakarami A', 'Yari F', 'Namdari P']","['Adult', 'Amlodipine/administration & dosage/*adverse effects', 'Antihypertensive Agents/administration & dosage/*adverse effects', 'Blood Pressure/drug effects', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Incidence', 'Methyldopa/administration & dosage/*adverse effects', 'Metoprolol/administration & dosage/*adverse effects', 'Obstetric Labor, Premature/chemically induced/*epidemiology', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy', 'Prevalence', 'Retrospective Studies', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/32420783/
2399,metoprolol,39764905,Metoprolol vs diltiazem for atrial fibrillation with rapid ventricular rate: Systematic review and meta-analysis of adverse events.,"['Hintze TD', 'Downing JV', 'Acquisto NM', 'Downton Mslis K', 'Yardi I', 'Moran M', 'Sharma A', 'Pourmand A', 'Tran QK']","['*Diltiazem/therapeutic use/adverse effects', 'Humans', '*Metoprolol/therapeutic use/adverse effects', '*Atrial Fibrillation/drug therapy', 'Anti-Arrhythmia Agents/adverse effects/therapeutic use', 'Bradycardia/chemically induced', 'Hypotension/chemically induced', 'Calcium Channel Blockers/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39764905/
2400,metoprolol,7038656,Once-daily metoprolol for hypertension.,"['Ward MJ', 'Roland JM', 'Banks DC']","['Antihypertensive Agents', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Hypertension/*drug therapy', 'Metoprolol/administration & dosage/*therapeutic use', 'Patient Compliance', 'Propanolamines/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/7038656/
2401,metoprolol,18174771,"Treatment with metoprolol succinate, a selective beta adrenergic blocker, lowers blood pressure without altering insulin sensitivity in diabetic patients.","['Falkner B', 'Kushner H']","['Adrenergic beta-Antagonists/administration & dosage/*pharmacology/therapeutic use', 'Adult', 'Aged', 'Blood Pressure/*drug effects', 'Diabetes Mellitus, Type 2/*physiopathology', 'Diabetic Angiopathies/drug therapy', 'Female', 'Glucose Clamp Technique', 'Humans', 'Hypertension/drug therapy', 'Insulin/metabolism', '*Insulin Resistance', 'Male', 'Metoprolol/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/18174771/
2402,metoprolol,6973256,Intravenous metoprolol for the treatment of acute supraventricular tachyarrhythmias.,"['Stroobandt R', 'Kesteloot H']","['Aged', 'Atrial Fibrillation/drug therapy', 'Atrial Flutter/drug therapy', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/*administration & dosage/adverse effects', 'Middle Aged', 'Propanolamines/*administration & dosage', 'Tachycardia/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6973256/
2403,metoprolol,453778,Metoprolol in the treatment of supraventricular tachyarrhythmias.,"['Moller B', 'Ringqvist C']","['Adult', 'Aged', 'Atrial Fibrillation/*drug therapy', 'Atrial Flutter/*drug therapy', 'Blood Pressure/drug effects', 'Drug Evaluation', 'Female', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Male', 'Metoprolol/administration & dosage/adverse effects/*therapeutic use', 'Middle Aged', 'Myocardial Contraction/drug effects', 'Propanolamines/*therapeutic use', 'Tachycardia, Paroxysmal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/453778/
2404,hydroxyurea,26366626,Hydroxyurea therapy for sickle cell anemia.,"['McGann PT', 'Ware RE']","['Administration, Oral', 'Anemia, Sickle Cell/*drug therapy', 'Animals', 'Antisickling Agents/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Hydroxyurea/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26366626/
2405,hydroxyurea,34356112,"Hydroxyurea-The Good, the Bad and the Ugly.","['Musialek MW', 'Rybaczek D']","['Animals', 'DNA Replication/drug effects', 'Humans', 'Hydroxyurea/*metabolism/*pharmacology/*therapeutic use', 'Ribonucleotide Reductases/antagonists & inhibitors/metabolism', 'S Phase/drug effects']",https://pubmed.ncbi.nlm.nih.gov/34356112/
2406,hydroxyurea,15280852,Hydroxyurea-associated squamous dysplasia.,"['Sanchez-Palacios C', 'Guitart J']","['Aged', 'Carcinoma, Squamous Cell/chemically induced', 'Humans', 'Hydroxyurea/administration & dosage/*adverse effects', 'Keratosis/chemically induced', 'Male', 'Precancerous Conditions/chemically induced', 'Skin Diseases/*chemically induced', 'Skin Neoplasms/chemically induced', 'Skin Ulcer/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15280852/
2407,hydroxyurea,32941305,Managing patients with sickle cell disease in primary care.,['Hehre RJ'],"['Administration, Oral', 'Anemia, Sickle Cell/*diagnosis/epidemiology/etiology/*therapy', 'Antibodies, Monoclonal, Humanized/administration & dosage', 'Antisickling Agents/*administration & dosage', 'Blood Transfusion', 'Evidence-Based Medicine', 'Female', 'Glutamine/administration & dosage', 'Hematopoietic Stem Cell Transplantation', 'Humans', 'Hydroxyurea/*administration & dosage/adverse effects/pharmacology', 'Iodine Isotopes/administration & dosage', 'Maintenance Chemotherapy', 'Male', 'Monitoring, Physiologic', 'Practice Guidelines as Topic', '*Primary Health Care']",https://pubmed.ncbi.nlm.nih.gov/32941305/
2408,hydroxyurea,10233638,Use of hydroxyurea in psoriasis.,['Smith CH'],"['Humans', 'Hydroxyurea/adverse effects/*therapeutic use', 'Nucleic Acid Synthesis Inhibitors/adverse effects/*therapeutic use', 'Psoriasis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10233638/
2409,hydroxyurea,1918491,Hydroxyurea therapy.,"['Boyd AS', 'Neldner KH']","['Humans', 'Hydroxyurea/adverse effects/*therapeutic use', 'Psoriasis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1918491/
2410,hydroxyurea,25155936,Individualizing fetal hemoglobin augmenting therapy for beta-type hemoglobinopathies patients.,"['Gravia A', 'Chondrou V', 'Sgourou A', 'Papantoni I', 'Borg J', 'Katsila T', 'Papachatzopoulou A', 'Patrinos GP']","['Anemia, Sickle Cell/*genetics/pathology', 'Fetal Hemoglobin/*genetics', 'Humans', 'Hydroxyurea/administration & dosage/*adverse effects/therapeutic use', 'Pharmacogenetics', 'Polymorphism, Single Nucleotide', 'Precision Medicine', 'beta-Thalassemia/drug therapy/*genetics/pathology']",https://pubmed.ncbi.nlm.nih.gov/25155936/
2411,hydroxyurea,20425334,Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.,"['Dingli D', 'Tefferi A']","['Aged', 'Agranulocytosis/chemically induced', 'Alkylating Agents/therapeutic use', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Disease Progression', 'Evidence-Based Medicine', 'Hemorrhage/etiology', 'Humans', 'Hydroxyurea/adverse effects/pharmacokinetics/*therapeutic use', 'Leukemia, Myeloid, Acute/etiology/prevention & control', 'Middle Aged', 'Phlebotomy', 'Phosphorus Radioisotopes/therapeutic use', 'Polycythemia Vera/*drug therapy/radiotherapy/therapy', 'Thrombocythemia, Essential/complications/*drug therapy/radiotherapy', 'Thrombophilia/etiology']",https://pubmed.ncbi.nlm.nih.gov/20425334/
2412,hydroxyurea,21417854,Hydroxycarbamide: a user's guide for chronic myeloproliferative disorders.,"['Spivak JL', 'Hasselbalch H']","['Antineoplastic Agents/adverse effects/*therapeutic use', 'Chronic Disease', 'Female', 'Fertility/drug effects', 'Humans', 'Hydroxyurea/adverse effects/*therapeutic use', 'Male', 'Myeloproliferative Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21417854/
2413,hydroxyurea,10088642,Long-term hydroxyurea treatment in young sickle cell patients.,"['Maier-Redelsperger M', 'Labie D', 'Elion J']","['Adolescent', 'Adult', 'Anemia, Sickle Cell/*drug therapy', 'Antisickling Agents/adverse effects/*therapeutic use', 'Child', 'Child, Preschool', 'Double-Blind Method', 'Humans', 'Hydroxyurea/adverse effects/*therapeutic use', 'Longitudinal Studies', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10088642/
2414,hydroxyurea,27667542,Sickle cell disease: Its molecular mechanism and the one drug that treats it.,['Ferrone FA'],"['Anemia, Sickle Cell/*drug therapy/metabolism', 'Hemoglobins/chemistry', 'Humans', 'Hydroxyurea/pharmacology/therapeutic use', 'Protein Multimerization/drug effects', 'Protein Structure, Secondary']",https://pubmed.ncbi.nlm.nih.gov/27667542/
2415,hydroxyurea,23643402,Hydroxycarbamide: clinical aspects.,['Ware RE'],"['Agranulocytosis/chemically induced', 'Anemia, Sickle Cell/*drug therapy', 'Antisickling Agents/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Developing Countries', 'Forecasting', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Hydroxyurea/administration & dosage/adverse effects/*therapeutic use', 'Hyperpigmentation/chemically induced', 'Maximum Tolerated Dose', 'Multicenter Studies as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23643402/
2416,hydroxyurea,36803179,Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular level.,"['Gibson JS', 'Rees DC']","['Adult', 'Humans', '*Anemia, Sickle Cell/drug therapy', 'Hydroxyurea/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36803179/
2417,hydroxyurea,16019501,A critical review of anagrelide therapy in essential thrombocythemia and related disorders.,"['Dingli D', 'Tefferi A']","['Clinical Trials as Topic', 'Humans', 'Hydroxyurea/adverse effects/therapeutic use', 'Quinazolines/adverse effects/pharmacology/*therapeutic use', 'Thrombocythemia, Essential/*drug therapy', 'Thrombocytosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16019501/
2418,hydroxyurea,35776113,Resveratrol plus low-dose hydroxyurea compared to high-dose hydroxyurea alone is more effective in gamma-globin gene expression and ROS reduction in K562 cells.,"['Alipour M', 'Nasiri N', 'Kazemi F', 'Zare F', 'Sharifzadeh S']","['Humans', '*Hydroxyurea/pharmacology/therapeutic use', '*gamma-Globins/genetics/metabolism', 'K562 Cells', 'Resveratrol/pharmacology', 'Reactive Oxygen Species', 'Reproducibility of Results', 'Gene Expression']",https://pubmed.ncbi.nlm.nih.gov/35776113/
2419,hydroxyurea,3790210,Volumetric erythrocyte macrocytosis induced by hydroxyurea.,"['Burns ER', 'Reed LJ', 'Wenz B']","['Blood Viscosity/drug effects', 'Erythrocyte Deformability/drug effects', 'Erythrocyte Indices/drug effects', 'Erythrocytes, Abnormal/*drug effects/ultrastructure', 'Humans', 'Hydroxyurea/*adverse effects/therapeutic use', 'Microscopy, Electron, Scanning']",https://pubmed.ncbi.nlm.nih.gov/3790210/
2420,hydroxyurea,30865915,Impact of Hydroxyurea on Survival and Risk of Thrombosis Among Older Patients With Essential Thrombocythemia.,"['Podoltsev NA', 'Zhu M', 'Zeidan AM', 'Wang R', 'Wang X', 'Davidoff AJ', 'Huntington SF', 'Giri S', 'Gore SD', 'Ma X']","['Aged', 'Aged, 80 and over', 'Female', 'Health Care Surveys', 'Humans', 'Hydroxyurea/administration & dosage/*adverse effects/*therapeutic use', 'Kaplan-Meier Estimate', 'Male', 'Prognosis', 'Risk Assessment', 'Risk Factors', 'SEER Program', 'Thrombocythemia, Essential/*complications/*drug therapy/epidemiology/mortality', 'Thrombosis/diagnosis/epidemiology/*etiology/*mortality', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30865915/
2421,hydroxyurea,12642122,The role of hydroxyurea in the management of sickle cell disease.,"['Davies SC', 'Gilmore A']","['Anemia, Sickle Cell/blood/*drug therapy', 'Animals', 'Antisickling Agents/administration & dosage/*therapeutic use', 'Dose-Response Relationship, Drug', 'Follow-Up Studies', 'Hematocrit', 'Hemoglobins/metabolism', 'Humans', 'Hydroxyurea/administration & dosage/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12642122/
2422,hydroxyurea,20001623,Hydroxyurea in the management of thalassemia intermedia.,['Karimi M'],"['Antineoplastic Agents', 'Hemoglobins/analysis', 'Humans', 'Hydroxyurea/adverse effects/*therapeutic use', 'Treatment Outcome', 'beta-Thalassemia/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20001623/
2423,hydroxyurea,38970408,Hydroxyurea in Sickle Cell Disease and Invasive Bacterial Infections: A Case-Control Study.,"['Pascault A', 'Koehl B', 'Brousse V', 'Benkerrou M', 'Gaschignard J']","['Humans', '*Anemia, Sickle Cell/complications/drug therapy', '*Hydroxyurea/therapeutic use/adverse effects', 'Case-Control Studies', 'Child', 'Female', 'Male', '*Antisickling Agents/therapeutic use/adverse effects', 'Adolescent', '*Bacterial Infections/drug therapy', 'Child, Preschool']",https://pubmed.ncbi.nlm.nih.gov/38970408/
2424,clotrimazole,392476,Dermatophyte infections.,['Clayton YM'],"['Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Clotrimazole/therapeutic use', 'Dermatomycoses/*drug therapy', 'Drug Resistance, Microbial', 'Griseofulvin/therapeutic use', 'Humans', 'Miconazole/therapeutic use', 'Phenyl Ethers/therapeutic use', 'Tolnaftate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/392476/
2425,clotrimazole,31287594,Cutaneous candidiasis - an evidence-based review of topical and systemic treatments to inform clinical practice.,"['Taudorf EH', 'Jemec GBE', 'Hay RJ', 'Saunte DML']","['Administration, Oral', 'Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Cutaneous/*drug therapy', 'Clotrimazole/administration & dosage/*therapeutic use', 'Drug Therapy, Combination', 'Evidence-Based Medicine', 'Fluconazole/administration & dosage/*therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Miconazole/administration & dosage/*therapeutic use', 'Nystatin/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31287594/
2426,clotrimazole,30818309,Therapeutic tools for oral candidiasis: Current and new antifungal drugs.,"['Quindos G', 'Gil-Alonso S', 'Marcos-Arias C', 'Sevillano E', 'Mateo E', 'Jauregizar N', 'Eraso E']","['Administration, Intravenous', 'Administration, Oral', 'Administration, Topical', 'Amphotericin B/therapeutic use', 'Anidulafungin/therapeutic use', 'Antifungal Agents/*administration & dosage/*pharmacology/*therapeutic use', 'Azoles/therapeutic use', 'Candidiasis, Oral/*drug therapy', 'Caspofungin/therapeutic use', 'Clotrimazole/therapeutic use', 'Databases, Factual', 'Drug Interactions', 'Echinocandins/therapeutic use', 'Fluconazole/therapeutic use', 'Humans', 'Miconazole/therapeutic use', 'Nitriles/therapeutic use', 'Nystatin/therapeutic use', 'Pyridines/therapeutic use', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30818309/
2427,clotrimazole,36762958,Clotrimazole-Based Modulators of the TRPM3 Ion Channel Reveal Narrow Structure-Activity Relationship.,"['Kahler JP', 'Aloi VD', 'Miedes Aliaga J', 'Kerselaers S', 'Voets T', 'Vriens J', 'Verhelst SHL', 'Barniol-Xicota M']","['Humans', '*Clotrimazole/pharmacology', '*TRPM Cation Channels/metabolism', 'Pain', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/36762958/
2428,clotrimazole,6859904,White piedra.,"['Benson PM', 'Lapins NA', 'Odom RB']","['Adult', 'Clotrimazole/therapeutic use', 'Dermatomycoses/*diagnosis/drug therapy', 'Genitalia, Male', 'Humans', 'Male', 'Mycoses/*diagnosis', 'Piedra/*diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6859904/
2429,clotrimazole,21696646,Athlete's foot.,['Crawford F'],"['Administration, Oral', '*Administration, Topical', 'Clotrimazole/therapeutic use', 'Drug Administration Schedule', 'Econazole/therapeutic use', 'Evidence-Based Medicine', 'Humans', 'Hygiene', 'Miconazole/therapeutic use', '*Tinea Pedis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/21696646/
2430,clotrimazole,22430336,Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review.,"['Viswanatha B', 'Sumatha D', 'Vijayashree MS']","['Adolescent', 'Adult', 'Aged', 'Antifungal Agents/therapeutic use', 'Aspergillus', 'Candida albicans', 'Clotrimazole/therapeutic use', 'Female', 'Humans', '*Immunocompetence', '*Immunocompromised Host', 'Male', 'Middle Aged', 'Otomycosis/drug therapy/*immunology/microbiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22430336/
2431,clotrimazole,22678642,[Drug therapy of otitis externa and otitis media].,"['Okovityi SV', 'Ivkin DIu', 'Malygin SV']","['Administration, Topical', 'Anesthetics, Local/*administration & dosage', 'Anti-Bacterial Agents/*administration & dosage', 'Anti-Inflammatory Agents/*administration & dosage', 'Antifungal Agents/*administration & dosage', 'Beclomethasone/*administration & dosage', 'Chloramphenicol/*administration & dosage', 'Clotrimazole/*administration & dosage', 'Drug Combinations', 'Humans', 'Lidocaine/*administration & dosage', 'Otitis Externa/*drug therapy', 'Otitis Media/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22678642/
2432,clotrimazole,38753333,Clotrimazole-Betamethasone Dipropionate Prescribing for Nonfungal Skin Conditions.,"['Gold JAW', 'Caplan AS', 'Benedict K', 'Lipner SR', 'Smith DJ']","['Humans', '*Betamethasone/therapeutic use/analogs & derivatives', '*Clotrimazole/therapeutic use', 'Skin Diseases/drug therapy', 'Male', 'Female', 'Antifungal Agents/therapeutic use', ""Practice Patterns, Physicians'/statistics & numerical data"", 'Drug Combinations', 'Middle Aged', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38753333/
2433,clotrimazole,7002065,Clotrimazole in rheumatoid arthritis.,"['Wojtulewski JA', 'Gow PJ', 'Walter J', 'Grahame R', 'Gibson T', 'Panayi GS', 'Mason J']","['Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Clotrimazole/adverse effects/*therapeutic use', 'Double-Blind Method', 'Humans', 'Imidazoles/*therapeutic use', 'Ketoprofen/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7002065/
2434,clotrimazole,9372064,Treatment of sickling disorders.,['Charache S'],"['Anemia, Sickle Cell/mortality/*therapy', 'Antisickling Agents/therapeutic use', 'Blood Component Removal/methods', 'Blood Transfusion', 'Butyrates/therapeutic use', 'Clotrimazole/therapeutic use', 'Erythrocytes', 'Fetal Hemoglobin/drug effects', 'Humans', 'Hydroxyurea/therapeutic use', 'Survival Rate', 'beta-Thalassemia/mortality/*therapy']",https://pubmed.ncbi.nlm.nih.gov/9372064/
2435,clotrimazole,2275233,Drugs for treatment of vulvovaginal candidiasis: comparative efficacy of agents and regimens.,"['Doering PL', 'Santiago TM']","['Antifungal Agents/administration & dosage/*therapeutic use', 'Candidiasis, Vulvovaginal/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Costs and Cost Analysis', 'Female', 'Humans', 'Imidazoles/administration & dosage/*therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Triazoles/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2275233/
2436,clotrimazole,11218451,Antimycotic agents in oral candidosis: an overview: 2. Treatment of oral candidosis.,"['Ellepola AN', 'Samaranayake LP']","['Amphotericin B/administration & dosage/therapeutic use', 'Antifungal Agents/administration & dosage/adverse effects/classification/*therapeutic use', 'Candida/drug effects/growth & development/pathogenicity', 'Candidiasis, Oral/*drug therapy', 'Clotrimazole/administration & dosage/therapeutic use', 'Drug Interactions', 'Drug Resistance, Microbial', 'Fluconazole/administration & dosage/therapeutic use', 'Humans', 'Itraconazole/administration & dosage/therapeutic use', 'Ketoconazole/administration & dosage/therapeutic use', 'Miconazole/administration & dosage/therapeutic use', 'Nystatin/administration & dosage/therapeutic use', 'Virulence/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11218451/
2437,clotrimazole,4067613,Prophylaxis of oropharyngeal candidiasis with clotrimazole.,"['Yeo E', 'Alvarado T', 'Fainstein V', 'Bodey GP']","['Adolescent', 'Adult', 'Aged', 'Antineoplastic Agents/adverse effects', 'Candidiasis/microbiology/*prevention & control', 'Candidiasis, Oral/prevention & control', 'Clotrimazole/*therapeutic use', 'Disease Susceptibility', 'Female', 'Hospitalization', 'Humans', 'Imidazoles/*therapeutic use', 'Lymphoma/drug therapy', 'Male', 'Middle Aged', 'Neoplasms/drug therapy', 'Oropharynx/microbiology', 'Pharyngeal Diseases/*prevention & control', 'Random Allocation', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/4067613/
2438,clotrimazole,523357,Pharmacokinetics of imidazole antimycotics.,['Plempel M'],"['Adult', 'Animals', 'Antifungal Agents/*metabolism/pharmacology', 'Child', 'Clotrimazole/metabolism', 'Econazole/metabolism', 'Fungi/drug effects', 'Guinea Pigs', 'Humans', 'Imidazoles/*metabolism/pharmacology', 'Kinetics', 'Mice', 'Miconazole/metabolism', 'Rabbits', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/523357/
2439,clotrimazole,9154392,Tinea pedis: clinical experience and efficacy of short treatment.,['Evans EG'],"['Administration, Topical', 'Antifungal Agents/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Clotrimazole/administration & dosage/*therapeutic use', 'Drug Administration Schedule', 'Humans', 'Naphthalenes/administration & dosage/*therapeutic use', 'Terbinafine', 'Tinea Pedis/diagnosis/*drug therapy/epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9154392/
2440,clotrimazole,12673842,Prevention of red cell dehydration: a possible new treatment for sickle cell disease.,"['Mueller BU', 'Brugnara C']","['Adult', 'Anemia, Sickle Cell/blood/*therapy', 'Animals', 'Body Water', 'Child', 'Clotrimazole/pharmacology/therapeutic use', 'Dehydration', 'Disease Models, Animal', 'Erythrocytes, Abnormal/*chemistry/drug effects', 'Hemoglobin, Sickle/chemistry', 'Humans', 'Ion Transport/drug effects', 'Magnesium/pharmacology/therapeutic use', 'Mice', 'Mice, Transgenic', 'Oxidative Stress', 'Potassium Channels, Calcium-Activated/blood/drug effects', 'Sodium-Potassium-Exchanging ATPase/blood/drug effects', 'Solubility', 'Symporters/blood/drug effects', 'K Cl- Cotransporters']",https://pubmed.ncbi.nlm.nih.gov/12673842/
2441,clotrimazole,3204180,Radiation port dermatophytosis.,"['Rosen T', 'Dupuy J', 'Maor M', 'Altman A']","['Adult', 'Carcinoma, Squamous Cell/*radiotherapy/surgery', 'Clotrimazole/therapeutic use', 'Cobalt Radioisotopes/adverse effects', 'Combined Modality Therapy', 'Dermatomycoses/drug therapy/*etiology', 'Diagnosis, Differential', 'Humans', 'Laryngeal Neoplasms/*radiotherapy/surgery', 'Male', 'Middle Aged', 'Neurofibroma/*radiotherapy/surgery', 'Radiodermatitis/*diagnosis']",https://pubmed.ncbi.nlm.nih.gov/3204180/
2442,clotrimazole,870143,Three-day clotrimazole treatment in candidal vulvovaginitis.,"['Masterton G', 'Napier IR', 'Henderson JN', 'Roberts JE']","['Candidiasis/*drug therapy', 'Clotrimazole/*administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Female', 'Humans', 'Imidazoles/*administration & dosage', 'Patient Compliance', 'Vulvovaginitis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/870143/
2443,clotrimazole,3768930,Treatment of vaginal candidiasis in pregnant women.,['Weisberg M'],"['Adult', 'Antifungal Agents/therapeutic use', 'Candidiasis, Vulvovaginal/*drug therapy', 'Clotrimazole/therapeutic use', 'Female', 'Humans', 'Imidazoles/therapeutic use', 'Miconazole/adverse effects/*therapeutic use', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3768930/
2444,isoniazid,26773235,Mechanism of isoniazid-induced hepatotoxicity: then and now.,"['Metushi I', 'Uetrecht J', 'Phillips E']","['Antitubercular Agents/adverse effects/pharmacokinetics', 'Biotransformation', '*Chemical and Drug Induced Liver Injury', 'Humans', 'Isoniazid/*adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26773235/
2445,isoniazid,14689075,[Tuberculosis-current therapeutic principles].,"['Greinert U', 'Zabel P']","['Animals', 'Antitubercular Agents/administration & dosage/*classification/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Drug Therapy, Combination', 'Humans', 'Isoniazid/administration & dosage/*therapeutic use', ""Practice Patterns, Physicians'"", 'Rifampin/administration & dosage/*therapeutic use', 'Tuberculosis/*drug therapy/*prevention & control', 'Tuberculosis, Multidrug-Resistant/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/14689075/
2446,isoniazid,4622757,Rifampin.,"['Schonell M', 'Dorken E', 'Grzybowski S']","['Adult', 'Aged', 'Animals', 'Drug Combinations', 'Ethambutol/administration & dosage/therapeutic use', 'Female', 'Humans', 'Isoniazid/administration & dosage/therapeutic use', 'Jaundice/chemically induced', 'Male', 'Mice', 'Middle Aged', 'Mycobacterium tuberculosis/drug effects', 'Pregnancy', 'Rifampin/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Thrombocytopenia/chemically induced', 'Tuberculosis, Pulmonary/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/4622757/
2447,isoniazid,40023825,Evaluation of High-Dose Isoniazid in Multidrug-Resistant Tuberculosis Treatment.,"['Gerussi V', 'Petersen T', 'Bonnet I', 'Aubry A', 'Bachir M', 'Gyde E', 'Morel F', 'Poignon C', 'Rached B', 'Pourcher V', 'Rioux C', 'Vallois D', 'Veziris N', 'Robert J', 'Guglielmetti L']","['*Isoniazid/therapeutic use/administration & dosage', 'Humans', '*Tuberculosis, Multidrug-Resistant/drug therapy', '*Antitubercular Agents/therapeutic use/administration & dosage', '*Mycobacterium tuberculosis/drug effects/genetics', 'Adult', 'Microbial Sensitivity Tests', 'Male', 'Female', 'Middle Aged', 'Drug Resistance, Multiple, Bacterial', 'France/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/40023825/
2448,isoniazid,34973508,Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.,"['Perveen S', 'Kumari D', 'Singh K', 'Sharma R']","['Antitubercular Agents/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Diarylquinolines/pharmacology/standards', 'Drug Therapy, Combination', 'Ethambutol/chemistry/pharmacology', 'Extensively Drug-Resistant Tuberculosis/*drug therapy', 'Humans', 'Isoniazid/chemistry/pharmacology', 'Mycobacterium tuberculosis/*drug effects', 'Nitroimidazoles/pharmacology/standards', 'Oxazoles/pharmacology/standards', 'Pyrazinamide/chemistry/pharmacology', 'Rifampin/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34973508/
2449,isoniazid,6338464,Clinical pharmacology of antitubercular drugs.,"['Reed MD', 'Blumer JL']","['*Antitubercular Agents/metabolism/pharmacology/therapeutic use', 'Child', 'Child, Preschool', 'Ethambutol/adverse effects/metabolism', 'Humans', 'Infant', 'Isoniazid/adverse effects/metabolism/therapeutic use', 'Rifampin/adverse effects/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6338464/
2450,isoniazid,34770817,Microencapsulated Isoniazid-Loaded Metal-Organic Frameworks for Pulmonary Administration of Antituberculosis Drugs.,"['Fernandez-Paz C', 'Fernandez-Paz E', 'Salcedo-Abraira P', 'Rojas S', 'Barrios-Esteban S', 'Csaba N', 'Horcajada P', 'Remunan-Lopez C']","['A549 Cells', 'Administration, Inhalation', 'Antitubercular Agents/administration & dosage/chemistry/*pharmacology', 'Capsules/administration & dosage/chemistry/pharmacology', 'Cell Survival/drug effects', 'Dose-Response Relationship, Drug', 'Humans', 'Isoniazid/administration & dosage/chemistry/*pharmacology', 'Metal-Organic Frameworks/administration & dosage/chemistry/*pharmacology', 'Particle Size', 'Tuberculosis, Pulmonary/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34770817/
2451,isoniazid,3682957,Antituberculous agents.,"['Van Scoy RE', 'Wilkowske CJ']","['*Antitubercular Agents/adverse effects/pharmacology/therapeutic use', 'Ethambutol/adverse effects/pharmacology/therapeutic use', 'Humans', 'Isoniazid/adverse effects/pharmacology/therapeutic use', 'Pyrazinamide/therapeutic use', 'Rifampin/adverse effects/pharmacology/therapeutic use', 'Streptomycin/adverse effects/therapeutic use', 'Tuberculosis/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/3682957/
2452,isoniazid,29748305,3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.,"['Assefa Y', 'Assefa Y', 'Woldeyohannes S', 'Hamada Y', 'Getahun H']","['Adolescent', 'Antitubercular Agents/*administration & dosage/adverse effects', 'Child', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Humans', 'Isoniazid/*administration & dosage/adverse effects', 'Latent Tuberculosis/*drug therapy', 'Rifampin/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29748305/
2453,isoniazid,12751276,Isoniazid-induced anaphylaxis.,['Crook MJ'],"['Adult', 'Anaphylaxis/*chemically induced/pathology/physiopathology', 'Antitubercular Agents/*adverse effects/therapeutic use', 'Humans', 'Isoniazid/*adverse effects/therapeutic use', 'Male', 'Prisoners', 'Skin Tests', 'Tuberculosis, Pulmonary/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12751276/
2454,isoniazid,3890202,Isoniazid interactions.,"['Baciewicz AM', 'Self TH']","['Animals', 'Antacids/pharmacology', 'Anticoagulants/pharmacology', 'Biological Availability', 'Carbamazepine/pharmacology/poisoning', 'Drug Interactions', 'Food/adverse effects', 'Humans', 'Intestinal Absorption/drug effects', 'Isoniazid/adverse effects/metabolism/*pharmacology', 'Phenytoin/metabolism/pharmacology/poisoning']",https://pubmed.ncbi.nlm.nih.gov/3890202/
2455,isoniazid,21517721,Isoniazid-induced pellagra.,"['Bilgili SG', 'Karadag AS', 'Calka O', 'Altun F']","['Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use', 'Child', 'Drug Therapy, Combination', 'Humans', 'Isoniazid/administration & dosage/*adverse effects/therapeutic use', 'Male', 'Niacinamide/administration & dosage/therapeutic use', 'Pellagra/*chemically induced/complications/diagnosis/drug therapy', 'Treatment Outcome', 'Tuberculosis, Pulmonary/complications/drug therapy', 'Vitamin B Complex/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21517721/
2456,isoniazid,14745341,[Isoniazid-induced pleuro-pericarditis].,"['Jouneau S', 'Volatron AC', 'Brinchault G', 'Morel V', 'Belleguic C', 'Delaval P']","['Antitubercular Agents/*adverse effects/therapeutic use', 'Humans', 'Isoniazid/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Pericarditis/*chemically induced', 'Pleural Diseases/*chemically induced', 'Tuberculosis, Pulmonary/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/14745341/
2457,isoniazid,21873403,Isoniazid-induced recurrent acute pancreatitis.,"['Pandey AS', 'Surana A']","['Acute Disease', 'Antitubercular Agents/*adverse effects/therapeutic use', 'Female', 'Humans', 'Isoniazid/*adverse effects/therapeutic use', 'Pancreatitis/*chemically induced/drug therapy', 'Recurrence', 'Tuberculosis, Lymph Node/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21873403/
2458,isoniazid,24903787,Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.,"['Amlabu V', 'Mulligan C', 'Jele N', 'Evans A', 'Gray D', 'Zar HJ', 'McIlleron H', 'Smith P']","['Age Factors', 'Antitubercular Agents/administration & dosage/pharmacokinetics/*urine', 'Biomarkers/urine', 'Biotransformation', 'Child', 'Chromatography, High Pressure Liquid', '*Coinfection', 'Colorimetry', 'Drug Monitoring/*methods', 'HIV Infections/*complications/diagnosis', 'Humans', 'Isoniazid/administration & dosage/*analogs & derivatives/pharmacokinetics/urine', '*Medication Adherence', 'Predictive Value of Tests', 'Primary Prevention/*methods', 'Reproducibility of Results', 'South Africa', 'Tandem Mass Spectrometry', 'Tuberculosis/complications/diagnosis/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24903787/
2459,isoniazid,38568956,Twice-Daily Dolutegravir-Based Antiretroviral Therapy With 1 Month of Daily Rifapentine and Isoniazid for Tuberculosis Prevention.,"['Podany AT', 'Cramer Y', 'Imperial M', 'Rosenkranz SL', 'Avihingsanon A', 'Arduino R', 'Samaneka W', 'Gelmanova I', 'Savic R', 'Swindells S', 'Dawson R', 'Luetkemeyer AF']","['Humans', '*Pyridones', '*Heterocyclic Compounds, 3-Ring/administration & dosage/pharmacokinetics/therapeutic use/adverse effects', '*Piperazines', '*Oxazines', 'Female', 'Adult', 'Male', '*Rifampin/analogs & derivatives/administration & dosage/pharmacokinetics/therapeutic use', '*Isoniazid/administration & dosage/pharmacokinetics/therapeutic use', '*HIV Infections/drug therapy/prevention & control', 'Middle Aged', '*Tuberculosis/prevention & control/drug therapy', 'Antitubercular Agents/pharmacokinetics/administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Anti-HIV Agents/administration & dosage/pharmacokinetics/therapeutic use', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38568956/
2460,isoniazid,22542415,[Treatment of latent tuberculosis infection].,['Fraisse P'],"['Antitubercular Agents/administration & dosage/adverse effects/economics', 'Cost of Illness', 'Drug Combinations', 'Humans', 'Incidence', 'Isoniazid/administration & dosage/adverse effects/economics', 'Latent Tuberculosis/economics/epidemiology/*therapy/transmission', 'Rifampin/administration & dosage/adverse effects/economics', 'Treatment Outcome', 'Assessment of Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/22542415/
2461,isoniazid,3221901,Isoniazid therapy in Parkinson's disease.,"['Gershanik OS', 'Luquin MR', 'Scipioni O', 'Obeso JA']","['Aged', 'Dyskinesia, Drug-Induced/cerebrospinal fluid/*drug therapy/etiology', 'Female', 'Humans', 'Isoniazid/cerebrospinal fluid/pharmacokinetics/*therapeutic use', 'Levodopa/*adverse effects', 'Male', 'Middle Aged', 'Parkinson Disease/*complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3221901/
2462,isoniazid,27088582,Safety and Adherence for 12 Weekly Doses of Isoniazid and Rifapentine for Pediatric Tuberculosis Infection.,"['Cruz AT', 'Starke JR']","['Adolescent', 'Antibiotics, Antitubercular/*administration & dosage/*adverse effects', 'Antitubercular Agents/therapeutic use', 'Child', 'Child, Preschool', 'Drug Administration Schedule', 'Female', 'Humans', 'Isoniazid/*administration & dosage/*adverse effects', 'Male', 'Medication Adherence', 'Rifampin/administration & dosage/adverse effects/*analogs & derivatives', 'Skin Tests', 'Treatment Outcome', 'Tuberculosis/diagnosis/*drug therapy/epidemiology', 'Tuberculosis, Pulmonary/drug therapy/epidemiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27088582/
2463,isoniazid,26332072,Isoniazid@Fe2 O3 Nanocontainers and Their Antibacterial Effect on Tuberculosis Mycobacteria.,"['Leidinger P', 'Treptow J', 'Hagens K', 'Eich J', 'Zehethofer N', 'Schwudke D', 'Oehlmann W', 'Lunsdorf H', 'Goldmann O', 'Schaible UE', 'Dittmar KE', 'Feldmann C']","['Animals', 'Antitubercular Agents/*administration & dosage/*pharmacology', 'Cells, Cultured', 'Ferric Compounds/*chemistry', 'Humans', 'Isoniazid/*administration & dosage/*pharmacology', 'Macrophages/microbiology', 'Mice', 'Mycobacterium tuberculosis/*drug effects', 'Nanospheres/*chemistry/ultrastructure', 'Tuberculosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26332072/
2464,RANOLAZINE,32270509,Guidelines on clinical presentation and management of nondystrophic myotonias.,"['Stunnenberg BC', 'LoRusso S', 'Arnold WD', 'Barohn RJ', 'Cannon SC', 'Fontaine B', 'Griggs RC', 'Hanna MG', 'Matthews E', 'Meola G', 'Sansone VA', 'Trivedi JR', 'van Engelen BGM', 'Vicart S', 'Statland JM']","['Acetazolamide/therapeutic use', 'Age of Onset', 'Carbonic Anhydrase Inhibitors/therapeutic use', 'Chloride Channels/genetics', 'Electrodiagnosis', 'Electromyography', 'Fatigue/*physiopathology', 'Genetic Testing', 'Humans', 'Lamotrigine/therapeutic use', 'Mexiletine/therapeutic use', 'Muscle Weakness/*physiopathology', 'Muscle, Skeletal/*physiopathology', 'Myalgia/*physiopathology', 'Myotonia Congenita/drug therapy/genetics/physiopathology', 'Myotonic Disorders/genetics/*physiopathology', 'NAV1.4 Voltage-Gated Sodium Channel/genetics', 'Practice Guidelines as Topic', 'Ranolazine/therapeutic use', 'Sodium Channel Blockers/therapeutic use', 'Voltage-Gated Sodium Channel Blockers/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32270509/
2465,RANOLAZINE,30609105,Review of primary and secondary erythromelalgia.,"['Mann N', 'King T', 'Murphy R']","['Capsaicin/therapeutic use', 'Erythromelalgia/complications/*diagnosis/genetics/therapy', 'Humans', 'Mass Screening', 'Mexiletine/therapeutic use', 'Myeloproliferative Disorders/complications/diagnosis', 'NAV1.7 Voltage-Gated Sodium Channel/genetics', 'Ranolazine/therapeutic use', 'Sensory System Agents/therapeutic use', 'Sodium Channel Blockers/therapeutic use', 'Sympathectomy']",https://pubmed.ncbi.nlm.nih.gov/30609105/
2466,RANOLAZINE,29874661,Treatment of Angina: Where Are We?,"['Balla C', 'Pavasini R', 'Ferrari R']","['Adrenergic beta-Antagonists/therapeutic use', 'Angina, Stable/*drug therapy/*physiopathology', 'Calcium Channel Blockers/therapeutic use', 'Cardiovascular Agents/adverse effects/*therapeutic use', 'Chest Pain/*etiology', 'Humans', 'Ivabradine', 'Nicorandil', 'Patient Selection', 'Practice Guidelines as Topic', 'Ranolazine', 'Treatment Outcome', 'Trimetazidine']",https://pubmed.ncbi.nlm.nih.gov/29874661/
2467,RANOLAZINE,26072257,Ranolazine overdose-induced seizures.,"['Akil N', 'Bottei E', 'Kamath S']","['Adolescent', 'Cardiovascular Agents/*poisoning', 'Drug Overdose', 'Glasgow Coma Scale', 'Humans', 'Male', 'Ranolazine/*poisoning', 'Seizures/*chemically induced', 'Suicide, Attempted']",https://pubmed.ncbi.nlm.nih.gov/26072257/
2468,RANOLAZINE,24838374,Stable angina pectoris.,"['Valgimigli M', 'Biscaglia S']","['Acetanilides/therapeutic use', 'Angina, Stable/diagnosis/etiology/*therapy', 'Benzazepines/therapeutic use', '*Coronary Artery Bypass', 'Coronary Artery Disease/complications/diagnosis/*therapy', 'Coronary Vasospasm/complications/diagnosis/*therapy', 'Echocardiography, Stress', 'Exercise Test', 'Humans', 'Ivabradine', 'Microvessels', 'Nicorandil/therapeutic use', 'Nitrates/therapeutic use', '*Percutaneous Coronary Intervention', 'Piperazines/therapeutic use', 'Ranolazine', '*Smoking Cessation', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24838374/
2469,RANOLAZINE,34498453,Through the heart and beyond: a review on ranolazine.,['Uran C'],"['*Acetanilides/therapeutic use', 'Heart', 'Humans', '*Piperazines/pharmacology/therapeutic use', 'Ranolazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34498453/
2470,RANOLAZINE,25989429,Pharmacologic management of chronic stable angina.,"['Dixit D', 'Kimborowicz K']","['Adrenergic beta-Antagonists/*therapeutic use', 'Angina, Stable/*drug therapy', 'Benzazepines/therapeutic use', 'Calcium Channel Blockers/*therapeutic use', 'Cardiovascular Agents/*therapeutic use', 'Humans', 'Isosorbide Dinitrate/analogs & derivatives/therapeutic use', 'Ivabradine', 'Nicorandil/therapeutic use', 'Nitroglycerin/therapeutic use', 'Ranolazine/therapeutic use', 'Sodium Channel Blockers/*therapeutic use', 'Vasodilator Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25989429/
2471,RANOLAZINE,22492919,A focus on antiarrhythmic properties of ranolazine.,"['Vizzardi E', ""D'Aloia A"", 'Quinzani F', 'Bonadei I', 'Rovetta R', 'Bontempi L', 'Curnis A', 'Dei Cas L']","['Acetanilides/pharmacology/*therapeutic use', 'Action Potentials', 'Angina Pectoris/drug therapy/metabolism', 'Animals', 'Anti-Arrhythmia Agents/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy/metabolism', 'Heart Atria/drug effects/metabolism', 'Heart Ventricles/drug effects/metabolism', 'Humans', 'Ion Channels/antagonists & inhibitors/metabolism', 'Membrane Transport Modulators/pharmacology/therapeutic use', 'Piperazines/pharmacology/*therapeutic use', 'Ranolazine']",https://pubmed.ncbi.nlm.nih.gov/22492919/
2472,RANOLAZINE,22707076,Pharmacology of myocardial calcium-handling.,"['Vogler J', 'Eckardt L']","['Acetanilides/*pharmacology', 'Adrenergic beta-Antagonists/*pharmacology', 'Amiodarone/analogs & derivatives/pharmacology', 'Anti-Arrhythmia Agents/*pharmacology', 'Calcium/*metabolism', 'Calcium Channel Blockers/*pharmacology', 'Cardiomegaly/drug therapy/*physiopathology', 'Cardiotonic Agents/*pharmacology', 'Digitalis Glycosides/*pharmacology', 'Dronedarone', 'Electrocardiography/drug effects', 'Heart Failure/drug therapy/*physiopathology', 'Humans', 'Ion Channels/drug effects/physiology', 'Myocardial Contraction/drug effects/physiology', 'Piperazines/*pharmacology', 'Ranolazine', 'Signal Transduction/drug effects/physiology', 'Tachycardia/drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/22707076/
2473,RANOLAZINE,33144165,"""Pill in the Pocket"" Antiarrhythmic Drugs for Orally Administered Pharmacologic Cardioversion of Atrial Fibrillation.","['Reiffel JA', 'Capucci A']","['Administration, Oral', 'Anti-Arrhythmia Agents/administration & dosage', 'Atrial Fibrillation/*drug therapy', 'Dose-Response Relationship, Drug', 'Heart Rate/*drug effects', 'Humans', 'Quinidine/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33144165/
2474,RANOLAZINE,26459200,Ranolazine in Cardiac Arrhythmia.,"['Saad M', 'Mahmoud A', 'Elgendy IY', 'Richard Conti C']","['Action Potentials', 'Animals', 'Anti-Arrhythmia Agents/adverse effects/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy/metabolism/physiopathology', 'Heart Conduction System/*drug effects/metabolism/physiopathology', 'Heart Rate/*drug effects', 'Humans', 'Kinetics', 'Ranolazine/adverse effects/*therapeutic use', 'Sodium Channel Blockers/adverse effects/*therapeutic use', 'Sodium Channels/*drug effects/metabolism', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26459200/
2475,RANOLAZINE,19737166,Chronic angina and the treatment with ranolazine: facts and recommendations.,"['Milne HC', 'Vallerand AH']","['Acetanilides/pharmacology/*therapeutic use', 'Angina Pectoris/*drug therapy/genetics', 'Chronic Disease', 'Enzyme Inhibitors/pharmacology/*therapeutic use', 'Humans', 'Piperazines/pharmacology/*therapeutic use', 'Ranolazine']",https://pubmed.ncbi.nlm.nih.gov/19737166/
2476,RANOLAZINE,7904560,Metabolic management of ischaemic heart disease.,"['Chierchia SL', 'Fragasso G']","['Acetanilides', 'Adrenergic beta-Antagonists/*therapeutic use', 'Angina Pectoris/*drug therapy', 'Calcium Channel Blockers/*therapeutic use', 'Carnitine/therapeutic use', 'Energy Metabolism/drug effects', 'Humans', 'Myocardium/*metabolism', 'Nitroglycerin/*therapeutic use', 'Piperazines/therapeutic use', 'Ranolazine', 'Trimetazidine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7904560/
2477,RANOLAZINE,27813339,Metabolic support for the heart: complementary therapy for heart failure?,"['Heggermont WA', 'Papageorgiou AP', 'Heymans S', 'van Bilsen M']","['Acetyl-CoA C-Acyltransferase/antagonists & inhibitors', 'Cardiovascular Agents/therapeutic use', 'Carnitine/analogs & derivatives/therapeutic use', 'Carnitine O-Palmitoyltransferase/antagonists & inhibitors', 'Dichloroacetic Acid/therapeutic use', 'Energy Metabolism', 'Enzyme Inhibitors/therapeutic use', 'Epoxy Compounds/therapeutic use', 'Fatty Acids/metabolism', 'Glucose/metabolism', 'Heart Failure/drug therapy/*metabolism/physiopathology', 'Humans', 'Myocardium/*metabolism', 'Myocytes, Cardiac/*metabolism', 'Oxidation-Reduction', 'Perhexiline/therapeutic use', 'Ranolazine/therapeutic use', 'Stroke Volume', 'Trimetazidine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27813339/
2478,RANOLAZINE,30447715,Lifestyle Modification and Medical Management of Hypertrophic Cardiomyopathy.,"['Heitner SB', 'Fischer KL']","['Adrenergic beta-Antagonists/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Cardiomyopathy, Hypertrophic/*therapy', 'Cardiotonic Agents/therapeutic use', 'Diet, Healthy', 'Disopyramide/therapeutic use', 'Exercise Therapy/methods', 'Health Status', '*Healthy Lifestyle', 'Humans', 'Obesity/prevention & control', 'Ranolazine/therapeutic use', '*Risk Reduction Behavior', 'Sleep Apnea Syndromes/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/30447715/
2479,RANOLAZINE,28455610,Inhibition of Late Sodium Current as an Innovative Antiarrhythmic Strategy.,"['Bengel P', 'Ahmad S', 'Sossalla S']","['Anti-Arrhythmia Agents/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy/etiology', 'Heart Failure/drug therapy/metabolism', 'Humans', 'Long QT Syndrome/metabolism', 'Ranolazine/*therapeutic use', 'Sodium Channel Blockers/*therapeutic use', 'Sodium Channels/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/28455610/
2480,RANOLAZINE,16448320,Evolving treatment strategies for chronic refractory angina.,"['Yang EH', 'Barsness GW']","['Acetanilides/therapeutic use', 'Angina Pectoris/*drug therapy/therapy', 'Arginine/therapeutic use', 'Benzazepines/therapeutic use', 'Cardiovascular Agents/*therapeutic use', 'Chronic Disease', 'Combined Modality Therapy/*trends', 'Counterpulsation', 'Electric Stimulation Therapy', 'Humans', 'Ivabradine', 'Myocardial Revascularization', 'Piperazines/therapeutic use', 'Randomized Controlled Trials as Topic', 'Ranolazine', 'Spinal Cord']",https://pubmed.ncbi.nlm.nih.gov/16448320/
2481,RANOLAZINE,15346837,Ischemic heart disease: metabolic approaches to management.,"['Pauly DF', 'Pepine CJ']","['Acetanilides', 'Cardiovascular Agents/*therapeutic use', 'Carnitine/therapeutic use', 'Dichloroacetic Acid/therapeutic use', '*Energy Metabolism', 'Humans', 'Myocardial Ischemia/*drug therapy/metabolism', 'Oxidation-Reduction/drug effects', 'Piperazines/therapeutic use', 'Ranolazine', 'Ribose/therapeutic use', 'Trimetazidine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15346837/
2482,RANOLAZINE,28826858,Automated JTpeak analysis by BRAVO.,"['Badilini F', 'Libretti G', 'Vaglio M']","['*Algorithms', '*Diagnosis, Computer-Assisted', 'Electrocardiography, Ambulatory/*methods', 'Heart Conduction System/*drug effects', 'Humans', 'Phenethylamines/pharmacology', 'Potassium Channel Blockers/*pharmacology', 'Quinidine/pharmacology', 'Randomized Controlled Trials as Topic', 'Ranolazine/pharmacology', 'Sodium Channel Blockers/*pharmacology', 'Software', 'Sulfonamides/pharmacology', 'Verapamil/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28826858/
2483,RANOLAZINE,20393344,Metabolic modulation: a new therapeutic target in treatment of heart failure.,"['Palaniswamy C', 'Mellana WM', 'Selvaraj DR', 'Mohan D']","['Acetanilides/therapeutic use', 'Carnitine O-Palmitoyltransferase/antagonists & inhibitors', 'Enzyme Inhibitors/therapeutic use', 'Epoxy Compounds/therapeutic use', 'Fatty Acids/metabolism', 'Glucose/metabolism', 'Heart Failure/*drug therapy/*metabolism', 'Humans', 'Mitochondria, Heart/drug effects/metabolism', 'Myocytes, Cardiac/drug effects/metabolism', 'Perhexiline/therapeutic use', 'Piperazines/therapeutic use', 'Ranolazine', 'Trimetazidine/therapeutic use', 'Vasodilator Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20393344/
2484,iopromide,28233565,"Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): a prospective, randomised, phase 3, controlled, open-label, non-inferiority trial.","['Nijssen EC', 'Rennenberg RJ', 'Nelemans PJ', 'Essers BA', 'Janssen MM', 'Vermeeren MA', 'Ommen VV', 'Wildberger JE']","['Aged', 'Contrast Media/*adverse effects', 'Costs and Cost Analysis', 'Creatinine/blood', 'Female', '*Fluid Therapy/economics/methods', 'Glomerular Filtration Rate', 'Humans', 'Infusions, Intravenous', 'Iohexol/adverse effects/*analogs & derivatives', 'Kidney Diseases/chemically induced/*prevention & control', 'Male', 'Prospective Studies', 'Risk Factors', 'Sodium Chloride/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28233565/
2485,iopromide,19859861,Risk of extravasation after power injection of contrast media via the proximal port of multilumen central venous catheters: case report and review of the literature.,"['Schummer C', 'Sakr Y', 'Steenbeck J', 'Gugel M', 'Reinhart K', 'Schummer W']","['Adult', 'Catheterization, Central Venous/instrumentation/*methods', 'Contrast Media/*administration & dosage', 'Extravasation of Diagnostic and Therapeutic Materials/*diagnostic imaging', 'Female', 'Humans', 'Injections, Intravenous/instrumentation', 'Intensive Care Units', 'Iohexol/adverse effects/*analogs & derivatives', 'Liver Abscess/*diagnostic imaging', 'Lung Diseases/*diagnostic imaging', 'Mediastinum/diagnostic imaging', 'Neck/diagnostic imaging', 'Obesity/complications', 'Quality Assurance, Health Care', 'Shock, Septic/*diagnostic imaging', 'Shoulder/diagnostic imaging', 'Subclavian Vein', '*Tomography, Spiral Computed', 'Vena Cava, Superior']",https://pubmed.ncbi.nlm.nih.gov/19859861/
2486,iopromide,2205329,Comparison of iopromide and iopamidol in left ventricular angiography and in coronary angiography.,"['Dyet JF', 'Carter EC', 'Hartley WC']","['Adult', 'Aged', '*Contrast Media/adverse effects', '*Coronary Angiography', 'Double-Blind Method', 'Female', 'Heart Ventricles/*diagnostic imaging', 'Humans', '*Iohexol/adverse effects', '*Iopamidol/adverse effects', 'Male', 'Middle Aged', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/2205329/
2487,iopromide,8600965,Influence of a non-ionic radiography contrast medium on the microcirculation.,"['Bach R', 'Jung F', 'Scheller B', 'Hummel B', 'Ozbek C', 'Spitzer S', 'Schieffer H']","['Adult', 'Aged', 'Capillaries/drug effects', 'Contrast Media/*adverse effects', 'Female', 'Humans', 'Iohexol/adverse effects/*analogs & derivatives', 'Male', 'Microcirculation/*drug effects', 'Middle Aged', 'Prospective Studies', 'Skin/blood supply']",https://pubmed.ncbi.nlm.nih.gov/8600965/
2488,iopromide,22696011,Incompatibility of contrast medium and trisodium citrate.,"['Delcour C', 'Bruninx G']","['Catheterization, Central Venous/adverse effects/methods', 'Citrates/adverse effects/*pharmacology', 'Contrast Media/adverse effects/*pharmacology', '*Drug Incompatibility', 'Humans', 'Iohexol/adverse effects/analogs & derivatives/pharmacology', 'Iopamidol/adverse effects/analogs & derivatives/pharmacology', 'Ioxaglic Acid/adverse effects/pharmacology', 'Materials Testing/methods', 'Risk Factors', 'Safety Management', 'Triiodobenzoic Acids/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/22696011/
2489,iopromide,38043998,"Acute Adverse Events After Iodinated Contrast Agent Administration of 359,977 Injections: A Single-Center Retrospective Study.","['McDonald JS', 'Larson NB', 'Schmitz JJ', 'Kolbe AB', 'Hunt CH', 'Hartman RP', 'Hagan JB', 'Kallmes DF', 'McDonald RJ']","['Humans', 'Female', '*Contrast Media/adverse effects', 'Iohexol/adverse effects', 'Retrospective Studies', 'Risk Factors', '*Drug Hypersensitivity/diagnosis/epidemiology/etiology']",https://pubmed.ncbi.nlm.nih.gov/38043998/
2490,iopromide,28777405,Bursting pressure of triple-lumen central venous catheters under static and dynamic loads.,"['Beckingham T', 'Roberts A', 'St John A', ""O'Callaghan G""]","['Administration, Intravenous', 'Catheterization, Central Venous/*instrumentation', '*Central Venous Catheters', 'Computed Tomography Angiography', 'Contrast Media/administration & dosage', 'Device Removal', 'Equipment Design', 'Equipment Failure', 'Humans', 'Iohexol/administration & dosage/analogs & derivatives', 'Iopamidol/administration & dosage', 'Materials Testing', 'Pressure']",https://pubmed.ncbi.nlm.nih.gov/28777405/
2491,iopromide,33496800,Combined rare anatomic variants: persistent primitive olfactory artery and azygos pericallosal artery.,"['Radoi PM', 'Rusu MC', 'Dinca D', 'Toader C']","['Aged', '*Anatomic Variation', 'Anterior Cerebral Artery/*abnormalities/diagnostic imaging', 'Cerebral Angiography', 'Computed Tomography Angiography', 'Contrast Media/administration & dosage', 'Humans', 'Iohexol/administration & dosage/analogs & derivatives', 'Male']",https://pubmed.ncbi.nlm.nih.gov/33496800/
2492,iopromide,23354966,Fluoroscopically guided balloon dilation for postintubation tracheal stenosis.,"['Lee WH', 'Kim JH', 'Park JH']","['Adult', 'Aged', 'Catheterization/*methods', 'Contrast Media', 'Female', 'Fluoroscopy', 'Follow-Up Studies', 'Humans', 'Imaging, Three-Dimensional/methods', 'Intubation, Intratracheal/*adverse effects', 'Iohexol/analogs & derivatives', 'Male', 'Middle Aged', 'Radiographic Image Enhancement/methods', 'Radiography, Interventional/*methods', 'Retrospective Studies', 'Tomography, X-Ray Computed/methods', 'Tracheal Stenosis/*diagnostic imaging/etiology/*therapy', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23354966/
2493,iopromide,22492012,Long-term effect of radiocontrast-enhanced computed tomography on the renal function of chronic kidney disease patients.,"['Kim IY', 'Lee SB', 'Lee DW', 'Song SH', 'Seong EY', 'Kwak IS']","['Aged', 'Contrast Media/*adverse effects', 'Female', 'Glomerular Filtration Rate', 'Humans', 'Iohexol/adverse effects/analogs & derivatives', 'Kidney/drug effects/physiology', 'Kidney Failure, Chronic/physiopathology', 'Male', 'Middle Aged', 'Nephrogenic Fibrosing Dermopathy/chemically induced', 'Renal Insufficiency, Chronic/*diagnostic imaging', 'Retrospective Studies', 'Time', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/22492012/
2494,iopromide,16950712,A simple technique for shoulder arthrography.,"['Berna-Serna JD', 'Redondo MV', 'Martinez F', 'Reus M', 'Alonso J', 'Parrilla A', 'Campos PA']","['Adult', 'Aged', 'Arthrography/*methods', 'Contrast Media/administration & dosage', 'Female', 'Gadolinium DTPA/administration & dosage', 'Humans', 'Iohexol/administration & dosage/analogs & derivatives', 'Male', 'Middle Aged', 'Pain Measurement', 'Punctures', 'Shoulder Joint/*diagnostic imaging']",https://pubmed.ncbi.nlm.nih.gov/16950712/
2495,iopromide,2568810,Tolerance of iopromide in angiography: a multicenter study.,"['Langer M', 'Behrends B', 'Langer R', 'Eichstadt H', 'Janicke UA']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', '*Angiography', 'Aortography', 'Cerebral Angiography', 'Child', 'Child, Preschool', 'Clinical Trials as Topic', 'Contrast Media/*adverse effects', 'Female', 'Humans', 'Iohexol/adverse effects/*analogs & derivatives', 'Male', 'Middle Aged', 'Prospective Studies', 'Subtraction Technique']",https://pubmed.ncbi.nlm.nih.gov/2568810/
2496,iopromide,29718868,Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI.,"['Zhang J', 'Jiang Y', 'Rui Q', 'Chen M', 'Zhang N', 'Yang H', 'Zhou Y']","['Contrast Media/*adverse effects', 'Coronary Angiography/*methods', 'Creatinine/blood', 'Humans', 'Iohexol/adverse effects/*analogs & derivatives', 'Kidney Diseases/blood/*chemically induced', '*Percutaneous Coronary Intervention', 'Renal Insufficiency/*complications', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29718868/
2497,iopromide,25654667,Intravenous Iodinated Contrast Agents Amplify DNA Radiation Damage at CT.,"['Piechowiak EI', 'Peter JF', 'Kleb B', 'Klose KJ', 'Heverhagen JT']","['Adult', 'Aged', 'Aged, 80 and over', 'Contrast Media/*administration & dosage/*adverse effects', 'DNA Damage/*radiation effects', 'Female', 'Humans', 'Injections, Intravenous', 'Iohexol/administration & dosage/adverse effects/*analogs & derivatives', 'Male', 'Middle Aged', 'Prospective Studies', 'Tomography, X-Ray Computed/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25654667/
2498,iopromide,22951623,Pathophysiology of the contrast media-induced nephropathy (CIN) in patients undergoing coronary interventions.,"['Franke RP', 'Jung F']","['Animals', 'Contrast Media/*adverse effects', 'Coronary Angiography/*adverse effects', 'Humans', 'Iohexol/adverse effects/analogs & derivatives', 'Kidney/physiopathology', 'Kidney Diseases/*chemically induced/physiopathology', 'Kidney Failure, Chronic/chemically induced/complications', 'Microcirculation/*drug effects', 'Oxygen/blood', 'Triiodobenzoic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/22951623/
2499,iopromide,8136474,[Gadolinium-DTPA (Magnevist) as contrast medium for arterial DSA].,"['Schild HH', 'Weber W', 'Boeck E', 'Mildenberger P', 'Strunk H', 'Duber C', 'Grebe P', 'Schadmand-Fischer S', 'Thelen M']","['Angiography, Digital Subtraction/*methods', '*Contrast Media/administration & dosage/adverse effects', 'Drug Evaluation', '*Gadolinium/administration & dosage/adverse effects', 'Gadolinium DTPA', 'Humans', 'Injections, Intra-Arterial', 'Iohexol/analogs & derivatives', 'Iopamidol', '*Organometallic Compounds/administration & dosage/adverse effects', 'Pentetic Acid/administration & dosage/adverse effects/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/8136474/
2500,iopromide,25227190,"Effect of radiographic contrast media (Iodixanol, Iopromide) on hemolysis.","['Gerk U', 'Kruger A', 'Franke RP', 'Jung F']","['Aged', 'Contrast Media/*chemistry', 'Coronary Angiography', 'Erythrocyte Membrane', 'Erythrocytes/drug effects', 'Female', 'Glomerular Filtration Rate', 'Hemoglobins/chemistry', 'Hemolysis/*drug effects', 'Humans', 'Iohexol/*analogs & derivatives/chemistry', 'Male', 'Middle Aged', '*Radiography', 'Triiodobenzoic Acids/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/25227190/
2501,iopromide,6475563,Iopromide. A new non-ionic contrast medium.,"['Dawson P', 'Bradshaw A', 'Hill C']","['Animals', 'Blood Coagulation/drug effects', 'Chemical Phenomena', 'Chemistry', 'Cholinesterase Inhibitors', 'Contrast Media/blood/*toxicity', 'Humans', 'Iodobenzoates/*toxicity', '*Iohexol/*analogs & derivatives', 'Iopamidol', 'Iothalamic Acid/analogs & derivatives/pharmacology', 'Ioxaglic Acid', 'Lethal Dose 50', 'Mice', 'Protein Binding', 'Thrombin Time', 'Triiodobenzoic Acids/blood/pharmacology/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/6475563/
2502,iopromide,14760933,Influence of ionic and non-ionic radiographic contrast media on leukocyte adhesion molecules.,"['Vermeiren GL', 'Willems R', 'Claeys MJ', 'Vrints C', 'Slegers H', 'Jorens PG']","['Aged', 'Cell Adhesion/*drug effects/immunology', 'Cell Adhesion Molecules/immunology', 'Contrast Media/*administration & dosage', 'Coronary Angiography', 'Female', 'Granulocytes/*cytology/*drug effects', 'Humans', 'Iohexol/*administration & dosage/*analogs & derivatives', 'Male', 'Middle Aged', 'Monocytes/cytology/drug effects', 'Myocardial Ischemia/diagnosis/immunology', 'Osmolar Concentration']",https://pubmed.ncbi.nlm.nih.gov/14760933/
2503,iopromide,20921088,Iopromide-induced encephalopathy following coronary angioplasty.,"['Kocabay G', 'Karabay CY']","['Aged', '*Angioplasty, Balloon, Coronary', 'Contrast Media/*adverse effects', 'Humans', 'Iohexol/adverse effects/*analogs & derivatives', 'Male', 'Middle Aged', 'Myocardial Infarction/surgery', 'Neurotoxicity Syndromes/diagnosis/*etiology']",https://pubmed.ncbi.nlm.nih.gov/20921088/
2504,oxaprozin,1603605,Oxaprozin: a new NSAID.,"['al-Faks MA', 'Pugh MC']","['Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Double-Blind Method', 'Half-Life', 'Humans', 'Osteoarthritis/*drug therapy', 'Oxaprozin', 'Propionates/adverse effects/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/1603605/
2505,oxaprozin,38959933,A rare case of meloxicam-induced pseudoporphyria.,"['Benandi K', 'Sieving D', 'Wolf K']","['Humans', '*Meloxicam/adverse effects', 'Female', 'Middle Aged', '*Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Thiazoles/adverse effects', 'Porphyrias/chemically induced', 'Foot Dermatoses/chemically induced/pathology', 'Thiazines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38959933/
2506,oxaprozin,9831331,Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.,['Kawai S'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Arthritis, Rheumatoid/drug therapy/enzymology', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Isoenzymes/metabolism', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9831331/
2507,oxaprozin,9884815,Clinical pharmacokinetics of oxaprozin.,['Davies NM'],"['Age Factors', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Heart Failure/*metabolism', 'Humans', 'Kidney Diseases/metabolism', 'Liver Diseases/metabolism', 'Oxaprozin', 'Propionates/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9884815/
2508,oxaprozin,24075938,Drug/drug interaction of common NSAIDs with antiplatelet effect of aspirin in human platelets.,"['Saxena A', 'Balaramnavar VM', 'Hohlfeld T', 'Saxena AK']","['Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology', 'Aspirin/*pharmacology', 'Blood Platelets/*drug effects/physiology', 'Catalytic Domain', 'Cyclooxygenase 1/chemistry/metabolism', 'Drug Interactions', 'Humans', 'Molecular Docking Simulation', 'Platelet Aggregation Inhibitors/*pharmacology', 'Platelet Function Tests']",https://pubmed.ncbi.nlm.nih.gov/24075938/
2509,oxaprozin,3220091,Pharmacokinetics of oxaprozin in women receiving conjugated estrogen.,"['Scavone JM', 'Ochs HR', 'Greenblatt DJ', 'Matlis R']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics', 'Drug Interactions', 'Estrogens/*adverse effects', 'Female', 'Half-Life', 'Humans', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3220091/
2510,oxaprozin,15934904,A review of the emerging profile of the anti-inflammatory drug oxaprozin.,"['Dallegri F', 'Bertolotto M', 'Ottonello L']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy/metabolism', 'Drug Industry/*trends', 'Humans', 'Oxaprozin', 'Propionates/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15934904/
2511,oxaprozin,6340971,Oxaprozin and sulindac in rheumatoid arthritis: a double-blind comparative trial.,"['Zuccollo R', 'Mackinnon MJ', 'Fraser KM', 'Hall SM', 'Palmer DG']","['Adult', 'Aged', 'Anti-Inflammatory Agents/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Humans', 'Indenes/*therapeutic use', 'Male', 'Middle Aged', 'Oxaprozin', 'Propionates/adverse effects/*therapeutic use', 'Sulindac/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6340971/
2512,oxaprozin,1617910,Oxaprozin: a once-daily nonsteroidal anti-inflammatory drug.,['Miller LG'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacokinetics/*therapeutic use', 'Drug Interactions', 'Humans', 'Oxaprozin', 'Propionates/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1617910/
2513,oxaprozin,3536423,"Oxaprozin. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.","['Todd PA', 'Brogden RN']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects/metabolism/pharmacology/*therapeutic use', 'Biological Availability', 'Drug Interactions', 'Humans', 'Joint Diseases/*drug therapy', 'Kinetics', 'Oxaprozin', 'Propionates/adverse effects/metabolism/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3536423/
2514,oxaprozin,8154406,A review of selected newer nonsteroidal anti-inflammatory drugs.,"['Cummings DM', 'Amadio P Jr']","['*Anti-Inflammatory Agents, Non-Steroidal/classification/economics/pharmacology/therapeutic use', 'Arthritis, Rheumatoid/drug therapy', '*Butanones/economics/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Drug Costs', '*Etodolac/economics/pharmacology/therapeutic use', 'Gastrointestinal Diseases/chemically induced/epidemiology', 'Humans', 'Incidence', 'Ketorolac', 'Nabumetone', 'Osteoarthritis/drug therapy', 'Oxaprozin', '*Propionates/economics/pharmacology/therapeutic use', 'Tolmetin/*analogs & derivatives/economics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8154406/
2515,oxaprozin,39081058,Structural Optimization of Oxaprozin for Selective Inverse Nurr1 Agonism.,"['Willems S', 'Busch R', 'Nawa F', 'Ballarotto M', 'Lillich FF', 'Kasch T', 'Lopez-Garcia U', 'Marschner JA', 'Ruger LA', 'Renelt B', 'Ohrndorf J', 'Arifi S', 'Zaienne D', 'Proschak E', 'Pabel J', 'Merk D']","['*Nuclear Receptor Subfamily 4, Group A, Member 2/agonists/metabolism/chemistry', 'Structure-Activity Relationship', 'Humans', 'Animals', 'Molecular Structure', 'Drug Inverse Agonism']",https://pubmed.ncbi.nlm.nih.gov/39081058/
2516,oxaprozin,3365912,Hepatic safety of two analgesics used over the counter: ibuprofen and aspirin.,"['Freeland GR', 'Northington RS', 'Hedrich DA', 'Walker BR']","['Alanine Transaminase/blood', 'Aspirin/*adverse effects', 'Humans', 'Ibuprofen/*adverse effects', 'Liver/*drug effects', 'Oxaprozin', 'Propionates/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3365912/
2517,oxaprozin,15324530,Oxaprozin: kinetic and dynamic profile in the treatment of pain.,['Kean WF'],"['Anti-Inflammatory Agents, Non-Steroidal/*pharmacokinetics/therapeutic use', 'Antirheumatic Agents/pharmacokinetics/therapeutic use', 'Diclofenac/*pharmacokinetics/therapeutic use', 'Humans', 'Oxaprozin', 'Periarthritis/complications/*drug therapy', 'Propionates/*pharmacokinetics/therapeutic use', 'Shoulder Joint', 'Shoulder Pain/drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15324530/
2518,oxaprozin,38451034,Drug-induced liver injury (DILI) ascribed to non-steroidal anti-inflammatory drugs (NSAIDs) in the USA-Update with genetic correlations.,"['Bonkovsky HL', 'Ghabril M', 'Nicoletti P', 'Dellinger A', 'Fontana RJ', 'Barnhart H', 'Gu J', 'Daly AK', 'Aithal GP', 'Phillips EJ', 'Kleiner DE']","['Humans', '*Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Female', 'Middle Aged', 'Adult', 'Aged', 'Male', '*Chemical and Drug Induced Liver Injury/genetics/etiology', 'United States/epidemiology', 'Aged, 80 and over', 'Case-Control Studies', 'Young Adult', '*Diclofenac/adverse effects', 'Risk Factors', 'Celecoxib/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38451034/
2519,oxaprozin,36356292,Two Binding Sites of SARS-CoV-2 Macrodomain 3 Probed by Oxaprozin and Meclomen.,"['Li J', 'Zhong F', 'Li M', 'Liu Y', 'Wang L', 'Liu M', 'Li F', 'Zhang J', 'Wu J', 'Shi Y', 'Zhang Z', 'Tu X', 'Ruan K', 'Gao J']","['Humans', 'Binding Sites', 'Meclofenamic Acid', 'Oxaprozin', '*SARS-CoV-2', 'Viral Nonstructural Proteins/metabolism', '*Coronavirus Papain-Like Proteases/chemistry', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/36356292/
2520,oxaprozin,20206429,"Analgesic and anti-inflammatory effects of oxaprozin and naproxen sodium after removal of impacted lower third molars: a randomized, double-blind, placebo-controlled crossover study.","['Kara IM', 'Polat S', 'Inci MF', 'Gumus C']","['Adolescent', 'Anti-Inflammatory Agents/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Cross-Over Studies', 'Double-Blind Method', 'Edema/prevention & control', 'Face', 'Female', 'Humans', 'Male', 'Mandible/physiopathology', 'Molar, Third/*surgery', 'Naproxen/*therapeutic use', 'Oxaprozin', 'Pain, Postoperative/prevention & control', 'Placebos', 'Propionates/*therapeutic use', 'Prospective Studies', 'Range of Motion, Articular/physiology', 'Tooth, Impacted/*surgery', 'Trismus/prevention & control', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/20206429/
2521,oxaprozin,26350105,Oxaprozin-Loaded Lipid Nanoparticles towards Overcoming NSAIDs Side-Effects.,"['Lopes-de-Araujo J', 'Neves AR', 'Gouveia VM', 'Moura CC', 'Nunes C', 'Reis S']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*administration & dosage/adverse effects/*pharmacokinetics', 'Caco-2 Cells', 'Cell Line', 'Drug Carriers/*chemistry', 'Folic Acid/chemistry', 'Humans', 'Mice', 'Nanoparticles/*chemistry', 'Oxaprozin', 'Permeability', 'Phosphatidylethanolamines/*chemistry', 'Polyethylene Glycols/*chemistry', 'Propionates/*administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/26350105/
2522,oxaprozin,33793232,Oxaprozin Analogues as Selective RXR Agonists with Superior Properties and Pharmacokinetics.,"['Schierle S', 'Chaikuad A', 'Lillich FF', 'Ni X', 'Woltersdorf S', 'Schallmayer E', 'Renelt B', 'Ronchetti R', 'Knapp S', 'Proschak E', 'Merk D']","['Animals', 'Binding Sites', 'Cell Survival/drug effects', 'Crystallography, X-Ray', 'Half-Life', 'Humans', 'Ligands', 'Mice', 'Microsomes/metabolism', 'Molecular Dynamics Simulation', 'Oxaprozin/*analogs & derivatives/metabolism/pharmacology', 'Protein Isoforms/agonists/genetics/metabolism', 'Pyrazoles/chemistry/metabolism/pharmacology', 'Rats', 'Retinoid X Receptors/*agonists/genetics/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/33793232/
2523,gemfibrozil,1888257,Gemfibrozil-induced myopathy.,"['Magarian GJ', 'Lucas LM', 'Colley C']","['Clofibrate/adverse effects', 'Drug Therapy, Combination', 'Gemfibrozil/*adverse effects/therapeutic use', 'Humans', 'Hypertriglyceridemia/drug therapy', 'Lovastatin/adverse effects', 'Male', 'Middle Aged', 'Muscular Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1888257/
2524,gemfibrozil,39273674,"Hypertriglyceridemia Therapy: Past, Present and Future Perspectives.","['Canfora I', 'Pierno S']","['Humans', '*Hypertriglyceridemia/drug therapy', '*Hypolipidemic Agents/therapeutic use', 'Fibric Acids/therapeutic use', 'PPAR alpha/metabolism', 'Animals', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Cardiovascular Diseases/drug therapy/prevention & control', 'Gemfibrozil/therapeutic use', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/39273674/
2525,gemfibrozil,20211755,The nasty surprise of a complex drug-drug interaction.,['Bode C'],"['Carbamates/*adverse effects/pharmacokinetics', 'Drug Approval', 'Drug Evaluation, Preclinical/*methods', 'Drug Industry/methods', '*Drug Interactions', 'Drug Therapy, Combination/*adverse effects', 'Gemfibrozil/*adverse effects/pharmacokinetics', 'Humans', 'Itraconazole/*adverse effects/pharmacokinetics', 'Models, Biological', 'Piperidines/*adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/20211755/
2526,gemfibrozil,31577610,SPPARM alpha: the Lazarus effect.,"['Fruchart JC', 'Santos RD']","['Animals', '*Atherosclerosis/drug therapy/metabolism/pathology', 'Benzoxazoles/adverse effects/*therapeutic use', 'Butyrates/adverse effects/*therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/metabolism/pathology', '*Dyslipidemias/drug therapy/metabolism/pathology', 'Fenofibrate/adverse effects/therapeutic use', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'PPAR alpha/*agonists/metabolism']",https://pubmed.ncbi.nlm.nih.gov/31577610/
2527,gemfibrozil,18042221,Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.,"['Bouhlel MA', 'Staels B', 'Chinetti-Gbaguidi G']","['*Atherosclerosis/drug therapy/metabolism/prevention & control', 'Cardiovascular Diseases/*drug therapy', 'Cholesterol/*metabolism', 'Clinical Trials as Topic', 'Fenofibrate/adverse effects/therapeutic use', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'Hypolipidemic Agents/*therapeutic use', 'Macrophages/*drug effects/metabolism', '*Peroxisome Proliferator-Activated Receptors/agonists/drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/18042221/
2528,gemfibrozil,12762976,Combination lipid-lowering therapy in diabetes.,['Davidson MH'],"['Diabetes Mellitus/*blood', 'Drug Therapy, Combination', 'Fenofibrate/pharmacokinetics/therapeutic use', 'Gemfibrozil/pharmacokinetics/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/pharmacokinetics/*therapeutic use', 'Lipoproteins, HDL/blood', 'Lipoproteins, LDL/blood', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/12762976/
2529,gemfibrozil,1498281,Hyperlipidemia and transplantation: etiologic factors and therapy.,"['Pirsch JD', ""D'Alessandro AM"", 'Sollinger HW', 'Knechtle SJ', 'Reed A', 'Kalayoglu M', 'Belzer FO']","['Adrenal Cortex Hormones/adverse effects', 'Antihypertensive Agents/adverse effects', 'Coronary Disease/etiology/prevention & control', 'Diuretics/adverse effects', 'Gemfibrozil/therapeutic use', 'Humans', 'Hyperlipidemias/diet therapy/drug therapy/*etiology', 'Immunosuppressive Agents/adverse effects', 'Kidney Failure, Chronic/blood/*surgery', '*Kidney Transplantation', 'Lipid Metabolism', 'Lipoprotein Lipase/deficiency', 'Lovastatin/therapeutic use', 'Postoperative Complications/*etiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1498281/
2530,gemfibrozil,32155958,The Peroxisome Proliferator-Activated Receptor alpha- Agonist Gemfibrozil Promotes Defense Against Mycobacterium abscessus Infections.,"['Kim YS', 'Kim JK', 'Hanh BTB', 'Kim SY', 'Kim HJ', 'Kim YJ', 'Jeon SM', 'Park CR', 'Oh GT', 'Park JW', 'Kim JM', 'Jang J', 'Jo EK']","['Animals', 'Gemfibrozil/pharmacology/*therapeutic use', 'Humans', 'Hypolipidemic Agents/pharmacology/*therapeutic use', 'Male', 'Mice', 'Mycobacterium Infections, Nontuberculous/*drug therapy', 'PPAR alpha/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32155958/
2531,gemfibrozil,12044585,Postprandial lipemia--effect of lipid-lowering drugs.,['Karpe F'],"['Clinical Trials as Topic', 'Coronary Disease/etiology', 'Drug Therapy, Combination', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use', 'Hyperlipidemias/complications/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', '*Lipid Metabolism', 'Postprandial Period', 'Simvastatin/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12044585/
2532,gemfibrozil,15198967,Safety of statins: focus on clinical pharmacokinetics and drug interactions.,"['Bellosta S', 'Paoletti R', 'Corsini A']","['Binding, Competitive', 'Biological Availability', 'Calcium Channel Blockers/pharmacokinetics', 'Chemical and Drug Induced Liver Injury', 'Citrus', 'Cytochrome P-450 CYP2D6/genetics', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme Inhibitors', 'Cytochrome P-450 Enzyme System/physiology', 'Drug Interactions', 'Fenofibrate/pharmacokinetics', 'Gemfibrozil/pharmacokinetics', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/pharmacokinetics', 'Liver Function Tests', 'Polymorphism, Genetic', 'Polymyositis/chemically induced', 'Rhabdomyolysis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15198967/
2533,gemfibrozil,28735742,Genotoxicity of gemfibrozil in the gilthead seabream (Sparus aurata).,"['Barreto A', 'Luis LG', 'Soares AMVM', 'Paiga P', 'Santos LHMLM', 'Delerue-Matos C', 'Hylland K', 'Loureiro S', 'Oliveira M']","['Animals', 'Comet Assay', '*DNA Breaks', 'Dose-Response Relationship, Drug', 'Erythrocytes/*drug effects/pathology', 'Gemfibrozil/*toxicity', 'Micronuclei, Chromosome-Defective/*chemically induced', 'Micronucleus Tests', 'Sea Bream/blood/*genetics', 'Water Pollutants, Chemical/*toxicity']",https://pubmed.ncbi.nlm.nih.gov/28735742/
2534,gemfibrozil,2385552,Lovastatin-induced acute rhabdomyolysis.,"['Kogan AD', 'Orenstein S']","['Acute Disease', 'Age Factors', 'Aged', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/adverse effects', 'Humans', 'Kidney Failure, Chronic/complications/drug therapy', 'Lovastatin/*adverse effects/therapeutic use', 'Muscles/pathology', 'Rhabdomyolysis/*chemically induced/pathology']",https://pubmed.ncbi.nlm.nih.gov/2385552/
2535,gemfibrozil,2123013,Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.,"['Schulman KA', 'Kinosian B', 'Jacobson TA', 'Glick H', 'Willian MK', 'Koffer H', 'Eisenberg JM']","['Anticholesteremic Agents/*therapeutic use', 'Cholestyramine Resin/therapeutic use', 'Clinical Trials as Topic', 'Colestipol/therapeutic use', 'Cost-Benefit Analysis', 'Drug Therapy, Combination', 'Gemfibrozil/therapeutic use', 'Humans', 'Hypercholesterolemia/drug therapy/*economics', 'Lovastatin/therapeutic use', 'Niacin/therapeutic use', 'Probucol/therapeutic use', 'Sensitivity and Specificity']",https://pubmed.ncbi.nlm.nih.gov/2123013/
2536,gemfibrozil,21192242,Statin-associated rhabdomyolysis with acute renal failure complicated by intradialytic NSTEMI: a review of lipid management considerations.,"['Kar S', 'Chockalingam A']","['Acute Kidney Injury/diagnosis/*etiology/therapy', 'Aged, 80 and over', 'Coronary Artery Disease/*drug therapy', 'Drug Therapy, Combination', 'Gemfibrozil/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*adverse effects/therapeutic use', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'Male', 'Myocardial Infarction/diagnosis/*etiology', 'Renal Dialysis/*adverse effects', 'Rhabdomyolysis/*chemically induced/complications/diagnosis', 'Simvastatin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21192242/
2537,gemfibrozil,10357573,Role of fibrates in the management of hypertriglyceridemia.,"['Rader DJ', 'Haffner SM']","['Anticholesteremic Agents/therapeutic use', 'Cardiovascular Diseases/etiology/prevention & control', 'Drug Therapy, Combination', 'Female', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypertriglyceridemia/complications/*drug therapy', 'Hypolipidemic Agents/*therapeutic use', 'Lovastatin/therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/10357573/
2538,gemfibrozil,27548563,Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters.,"['Tornio A', 'Neuvonen PJ', 'Niemi M', 'Backman JT']","['Cytochrome P-450 CYP2C8/drug effects', 'Cytochrome P-450 CYP2C8 Inhibitors/metabolism/*pharmacology', 'Drug Interactions', 'Gemfibrozil/analogs & derivatives/metabolism/*pharmacology', 'Glucuronates/metabolism/pharmacology', 'Humans', 'Hypolipidemic Agents/metabolism/pharmacology', 'Membrane Transport Proteins/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/27548563/
2539,gemfibrozil,11570656,Smoking diminishes the beneficial effect of statins: observations from the landmark trials.,"['Milionis HJ', 'Rizos E', 'Mikhailidis DP']","['Anticholesteremic Agents/*therapeutic use', 'Clinical Trials as Topic', 'Gemfibrozil/therapeutic use', 'Humans', 'Lovastatin/*therapeutic use', 'Myocardial Ischemia/*prevention & control', 'Pravastatin/*therapeutic use', 'Risk Factors', 'Simvastatin/*therapeutic use', 'Smoking/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11570656/
2540,gemfibrozil,2192877,Drug treatment of dyslipoproteinemia.,['Hunninghake DB'],"['Bile Acids and Salts/metabolism', 'Clofibrate/therapeutic use', 'Coronary Disease/prevention & control', 'Drug Therapy, Combination', 'Gemfibrozil/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors', 'Hyperlipoproteinemias/*drug therapy', 'Hypolipoproteinemias/*drug therapy', 'Niacin/metabolism', 'Probucol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2192877/
2541,gemfibrozil,26932225,Gemfibrozil in Combination with Statins-Is It Really Contraindicated?,"['Wiggins BS', 'Saseen JJ', 'Morris PB']","['Cardiovascular Diseases/drug therapy', 'Drug Combinations', 'Gemfibrozil/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use', 'Hypolipidemic Agents/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/26932225/
2542,gemfibrozil,27642087,Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?,"['Templeton IE', 'Chen Y', 'Mao J', 'Lin J', 'Yu H', 'Peters S', 'Shebley M', 'Varma MV']","['Amiodarone/*pharmacokinetics', 'Animals', 'Area Under Curve', 'Drug Discovery', 'Drug Interactions', 'Gemfibrozil/*pharmacokinetics', 'Humans', 'Models, Biological', 'Sertraline/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/27642087/
2543,famotidine,25750443,Urticaria pigmentosa-like disease in a dog.,"['Pariser MS', 'Gram DW']","['Animals', 'Anti-Allergic Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/therapeutic use', 'Cetirizine/administration & dosage/therapeutic use', 'Diphenhydramine/administration & dosage/therapeutic use', 'Dog Diseases/diagnosis/*pathology', 'Dogs', 'Famotidine/administration & dosage/therapeutic use', 'Male', 'Urticaria Pigmentosa/diagnosis/drug therapy/pathology/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/25750443/
2544,famotidine,28153970,A Rare Case of Famotidine-Induced Delirium in a Peritoneal Dialysis Patient.,"['Chan GC', 'Lee KM', 'Kwan LP', 'Mok MM', 'Ma MK', 'Yap DY', 'Tang SC']","['Acute Disease', 'Delirium/*chemically induced/physiopathology', 'Dyspepsia/diagnosis/*drug therapy', 'Famotidine/*adverse effects/therapeutic use', 'Follow-Up Studies', 'Humans', 'Kidney Failure, Chronic/diagnosis/*therapy', 'Male', 'Middle Aged', 'Peritoneal Dialysis/*adverse effects/methods', 'Risk Assessment', 'Treatment Outcome', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/28153970/
2545,famotidine,32912894,"Angioedema, ACE inhibitor and COVID-19.","['Grewal E', 'Sutarjono B', 'Mohammed I']","['Angioedema/*chemically induced/*complications/drug therapy', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects', 'Anti-Allergic Agents/therapeutic use', 'Benzazepines/*adverse effects', '*Betacoronavirus', 'COVID-19', 'Coronavirus Infections/*complications', 'Diagnosis, Differential', 'Diphenhydramine/therapeutic use', 'Famotidine/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Pandemics', 'Pneumonia, Viral/*complications', 'SARS-CoV-2', 'Tranexamic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32912894/
2546,famotidine,24267478,The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.,"['Tuskey A', 'Peura D']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Anti-Ulcer Agents/therapeutic use', 'Drug Therapy, Combination', 'Famotidine/therapeutic use', 'Gastrointestinal Diseases/chemically induced/*drug therapy/prevention & control', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ibuprofen/adverse effects/therapeutic use', 'Intestinal Mucosa/*drug effects/pathology', 'Stomach Ulcer/chemically induced/drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24267478/
2547,famotidine,24532249,WITHDRAWN: Pharmacological interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood.,"['Huertas-Ceballos AA', 'Logan S', 'Bennett C', 'Macarthur C', 'Martin AE']","['Abdominal Pain/*drug therapy', 'Adolescent', 'Analgesics, Non-Narcotic/*therapeutic use', 'Child', 'Child, Preschool', 'Famotidine/therapeutic use', 'Humans', 'Irritable Bowel Syndrome/*drug therapy', 'Mentha piperita', 'Pizotyline/therapeutic use', 'Plant Oils/therapeutic use', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/24532249/
2548,famotidine,10410190,Famotidine in the management of schizophrenia.,['Martinez MC'],"['Clinical Trials as Topic', 'Famotidine/*therapeutic use', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10410190/
2549,famotidine,28867258,Risk factors for suboptimal drug concentration of posaconazole oral suspension in patients with hematologic malignancy.,"['Kim EJ', 'Yu KS', 'Na SH', 'Nam EY', 'Oh HS', 'Kim M', 'Yoon SH', 'Lee JO', 'Koh Y', 'Song KH', 'Choe PG', 'Cho JY', 'Song SH', 'Kim ES', 'Kim HB', 'Bang SM', 'Kim NJ', 'Oh MD', 'Kim I', 'Park WB']","['Administration, Oral', 'Adult', 'Aged', 'Antifungal Agents/*pharmacokinetics', 'Famotidine/therapeutic use', 'Female', 'Hematologic Neoplasms/*drug therapy', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Mycoses/prevention & control', '*Pre-Exposure Prophylaxis', 'Prospective Studies', 'Risk Factors', 'Triazoles/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28867258/
2550,famotidine,11967601,H(2) antagonist-induced thrombocytopenia: is this a real phenomenon?,"['Wade EE', 'Rebuck JA', 'Healey MA', 'Rogers FB']","['Cimetidine/adverse effects', 'Critical Care', 'Famotidine/adverse effects', 'Histamine H2 Antagonists/*adverse effects/therapeutic use', 'Humans', 'Peptic Ulcer/*prevention & control', 'Ranitidine/adverse effects', 'Risk Factors', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11967601/
2551,famotidine,37722599,Oral famotidine reduces the plasma level of soluble P-selectin in children with sickle cell disease.,"['Allali S', 'Marquant F', 'Rignault-Bricard R', 'Taylor M', 'Brice J', 'de Montalembert M', 'Maciel TT', 'Elie C', 'Hermine O']","['Child', 'Humans', '*Famotidine/therapeutic use', 'P-Selectin/metabolism', 'Histamine', 'Prospective Studies', '*Anemia, Sickle Cell']",https://pubmed.ncbi.nlm.nih.gov/37722599/
2552,famotidine,33135390,Effect of gastric acid-reducing agents on the pharmacokinetics and efficacy of lemborexant.,"['Landry I', 'Aluri J', 'Hall N', 'Kumar D', 'Dayal S', 'Moline M', 'Reyderman L']","['Adult', 'Double-Blind Method', 'Drug Interactions/physiology', 'Famotidine/administration & dosage/*pharmacokinetics', 'Female', 'Gastric Acid/*metabolism', 'Histamine H2 Antagonists/administration & dosage/*pharmacokinetics', 'Humans', 'Male', 'Orexin Receptor Antagonists/administration & dosage/*pharmacokinetics', 'Pyridines/administration & dosage/*pharmacokinetics', 'Pyrimidines/administration & dosage/*pharmacokinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33135390/
2553,famotidine,25318791,Iron-deficiency anemia caused by a proton pump inhibitor.,"['Hashimoto R', 'Matsuda T', 'Chonan A']","['Anemia, Iron-Deficiency/*chemically induced', 'Famotidine/therapeutic use', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects/therapeutic use', 'Rabeprazole/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25318791/
2554,famotidine,7914403,Intestinal clearance of H2-antagonists.,"['Hui YF', 'Kolars J', 'Hu Z', 'Fleisher D']","[""4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid/administration & dosage"", 'Animals', 'Cimetidine/analogs & derivatives/analysis/pharmacokinetics', 'Famotidine/pharmacokinetics', 'Histamine H2 Antagonists/*pharmacokinetics', 'Humans', 'Intestinal Mucosa/*metabolism', 'Jejunum/*metabolism', 'Methionine/administration & dosage', 'Perfusion', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/7914403/
2555,famotidine,24550598,Stevens-Johnson syndrome following use of metronidazole in a dental patient.,"['Mazumdar G', 'Shome K']","['*Dental Health Services', 'Dibenzoxepins/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Erythromycin/administration & dosage/therapeutic use', 'Famotidine/administration & dosage/therapeutic use', 'Humans', 'Lichen Planus, Oral/drug therapy', 'Male', 'Methylprednisolone/administration & dosage/therapeutic use', 'Metronidazole/administration & dosage/*adverse effects', 'Middle Aged', 'Olopatadine Hydrochloride', 'Stevens-Johnson Syndrome/drug therapy/*etiology', 'Triamcinolone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/24550598/
2556,famotidine,2979247,Dose--response effect of famotidine on patterns of gastro-oesophageal reflux.,"['Orr WC', 'Robinson MG', 'Humphries TJ', 'Antonello J', 'Cagliola A']","['Adult', 'Aged', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Famotidine/administration & dosage/*therapeutic use', 'Gastric Acidity Determination', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2979247/
2557,famotidine,22419335,Histamine H2-receptor antagonists for urticaria.,"['Fedorowicz Z', 'van Zuuren EJ', 'Hu N']","['Cimetidine/adverse effects/therapeutic use', 'Diphenhydramine/adverse effects/therapeutic use', 'Drug Therapy, Combination/methods', 'Famotidine/adverse effects/therapeutic use', 'Histamine H1 Antagonists', 'Histamine H2 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Ranitidine/adverse effects/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22419335/
2558,famotidine,34609001,The association between famotidine and in-hospital mortality of patients with COVID-19.,"['Kuno T', 'So M', 'Takahashi M', 'Egorova NN']","['Famotidine/therapeutic use', 'Hospital Mortality', 'Humans', 'Retrospective Studies', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34609001/
2559,famotidine,11027567,Ghrelin stimulates gastric acid secretion and motility in rats.,"['Masuda Y', 'Tanaka T', 'Inomata N', 'Ohnuma N', 'Tanaka S', 'Itoh Z', 'Hosoda H', 'Kojima M', 'Kangawa K']","['Animals', 'Atropine/pharmacology', 'Dose-Response Relationship, Drug', 'Famotidine/pharmacology', 'Gastric Acid/*metabolism', 'Gastric Mucosa/metabolism', 'Ghrelin', 'Histamine/pharmacology', 'Histamine H2 Antagonists/pharmacology', 'Male', '*Peptide Hormones', 'Peptides/administration & dosage/antagonists & inhibitors/*pharmacology', 'Peristalsis/*drug effects', 'Rats', 'Rats, Sprague-Dawley', 'Stomach/*drug effects/innervation/physiology', 'Vagotomy']",https://pubmed.ncbi.nlm.nih.gov/11027567/
2560,famotidine,1625532,The clinical use of histamine-2 receptor antagonists.,"['Michocki RJ', 'Richardson JP']","['Cimetidine/administration & dosage/*therapeutic use', 'Drug Evaluation', 'Famotidine/administration & dosage/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Nizatidine/administration & dosage/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Ranitidine/administration & dosage/*therapeutic use', 'Recurrence', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1625532/
2561,famotidine,8305790,Risk for adverse events among patients receiving intravenous histamine2-receptor antagonists.,"['Ben-Joseph R', 'Segal R', 'Russell WL']","['Age Factors', 'Cimetidine/administration & dosage/*adverse effects', 'Drug Interactions', 'Famotidine/administration & dosage/*adverse effects', 'Female', 'Humans', 'Injections, Intravenous', 'Kidney Diseases/chemically induced', 'Male', 'Ranitidine/administration & dosage/*adverse effects', 'Regression Analysis', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/8305790/
2562,cyclophosphamide,19786984,Cyclophosphamide and cancer: golden anniversary.,"['Emadi A', 'Jones RJ', 'Brodsky RA']","['Aldehyde Dehydrogenase/metabolism', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Bone Marrow Transplantation', 'Cyclophosphamide/metabolism/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Immunosuppressive Agents/pharmacology/*therapeutic use', 'Neoplasms/*drug therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/19786984/
2563,cyclophosphamide,3511372,Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.,"['Austin HA 3rd', 'Klippel JH', 'Balow JE', 'le Riche NG', 'Steinberg AD', 'Plotz PH', 'Decker JL']","['Administration, Oral', 'Adult', 'Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Biopsy', 'Clinical Trials as Topic', 'Creatinine/blood', 'Cyclophosphamide/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerulonephritis/*drug therapy/etiology/physiopathology', 'Humans', 'Injections, Intravenous', 'Kidney/pathology', 'Kidney Failure, Chronic/etiology', 'Lupus Erythematosus, Systemic/*complications', 'Male', 'Prednisone/administration & dosage/adverse effects/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3511372/
2564,cyclophosphamide,27646791,The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy.,"['Ahlmann M', 'Hempel G']","['Antineoplastic Agents, Alkylating/adverse effects/*pharmacology/therapeutic use', 'Cyclophosphamide/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Immune System/*drug effects', 'Immunologic Factors/pharmacology', 'Immunosuppressive Agents', 'Neoplasms/*drug therapy/*immunology']",https://pubmed.ncbi.nlm.nih.gov/27646791/
2565,cyclophosphamide,1804803,Ifosfamide pharmacokinetics.,['Lewis LD'],"['Administration, Oral', 'Aging/metabolism', 'Brain Diseases/chemically induced', 'Dose-Response Relationship, Drug', 'Humans', 'Ifosfamide/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1804803/
2566,cyclophosphamide,6997053,Cyclophosphamide cardiotoxicity.,"['von Bernuth G', 'Adam D', 'Hofstetter R', 'Lang D', 'Mohr W', 'Kohne E', 'Niethammer D']","['Anemia, Aplastic/drug therapy/therapy', 'Bone Marrow Transplantation', 'Child', 'Cyclophosphamide/administration & dosage/*adverse effects/therapeutic use', 'Heart Failure/*chemically induced', 'Humans', 'Male', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/6997053/
2567,cyclophosphamide,26937514,Chemotherapy and pelvic radiotherapy-induced bladder injury.,['Cetinel B'],"['Antineoplastic Agents, Alkylating/*adverse effects', 'Cyclophosphamide/administration & dosage/*adverse effects', 'Cystitis/*etiology', 'Humans', 'Pelvis', 'Radiation Injuries/*etiology', 'Radiotherapy/adverse effects', 'Urinary Bladder/*drug effects/*radiation effects']",https://pubmed.ncbi.nlm.nih.gov/26937514/
2568,cyclophosphamide,856438,Adriamycin cardiomyopathy--risk factors.,"['Minow RA', 'Benjamin RS', 'Lee ET', 'Gottlieb JA']","['Adolescent', 'Adult', 'Aged', 'Cyclophosphamide/adverse effects/therapeutic use', 'Doxorubicin/administration & dosage/*adverse effects/therapeutic use', 'Drug Interactions', 'Drug Therapy, Combination', 'Electrocardiography', 'Female', 'Heart Failure/*chemically induced/physiopathology', 'Humans', 'Male', 'Middle Aged', 'Neoplasms/drug therapy', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/856438/
2569,cyclophosphamide,20087683,High-dose cyclophosphamide for autoimmunity and alloimmunity.,['Brodsky RA'],"['Autoimmune Diseases/*drug therapy/immunology', 'Bone Marrow Transplantation', 'Clinical Trials as Topic', 'Cyclophosphamide/*administration & dosage/therapeutic use', 'Graft vs Host Disease/immunology/*prevention & control', 'Hematopoietic Stem Cells/drug effects/immunology', 'Humans', 'Immunosuppressive Agents/*administration & dosage/therapeutic use', 'Lymphocytes/drug effects/immunology', 'Transplantation, Homologous/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20087683/
2570,cyclophosphamide,38969879,Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial.,"['Mo H', 'Yu Y', 'Sun X', 'Ge H', 'Yu L', 'Guan X', 'Zhai J', 'Zhu A', 'Wei Y', 'Wang J', 'Yan X', 'Qian H', 'Xu B', 'Ma F']","['Humans', 'Female', '*Breast Neoplasms/drug therapy/pathology', '*Administration, Metronomic', 'Middle Aged', '*Bayes Theorem', '*Programmed Cell Death 1 Receptor/antagonists & inhibitors', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/administration & dosage', 'Adult', 'Aged', '*Neoplasm Metastasis', 'Cyclophosphamide/administration & dosage/therapeutic use/adverse effects', 'Immune Checkpoint Inhibitors/administration & dosage/therapeutic use/adverse effects', 'Vinorelbine/administration & dosage/therapeutic use', 'Bevacizumab/administration & dosage/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38969879/
2571,cyclophosphamide,22761338,Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.,"['Le DT', 'Jaffee EM']","['Administration, Metronomic', 'Administration, Oral', 'Cancer Vaccines/*administration & dosage', 'Combined Modality Therapy', 'Cyclophosphamide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Neoplasms/immunology/*therapy', 'T-Lymphocytes, Regulatory/drug effects/*immunology']",https://pubmed.ncbi.nlm.nih.gov/22761338/
2572,cyclophosphamide,27196429,"Old-School Chemotherapy in Immunotherapeutic Combination in Cancer, A Low-cost Drug Repurposed.","['Abu Eid R', 'Razavi GS', 'Mkrtichyan M', 'Janik J', 'Khleif SN']","['Antineoplastic Agents, Alkylating/administration & dosage/pharmacology/*therapeutic use', 'Cyclophosphamide/administration & dosage/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Repositioning/methods', 'Humans', 'Immunologic Factors/administration & dosage/pharmacology/*therapeutic use', 'Immunotherapy/*methods', 'Neoplasms/*drug therapy/immunology', 'T-Lymphocyte Subsets/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27196429/
2573,cyclophosphamide,38688830,Sigle Agent of Posttransplant Cyclophosphamide Without Calcineurin Inhibitor Controls Severity of Experimental Chronic GVHD.,"['Saeki K', 'Fujiwara H', 'Seike K', 'Kuroi T', 'Nishimori H', 'Tanaka T', 'Matsuoka KI', 'Fujii N', 'Maeda Y']","['*Graft vs Host Disease/prevention & control/drug therapy', 'Animals', '*Cyclophosphamide/therapeutic use/administration & dosage', '*Hematopoietic Stem Cell Transplantation/adverse effects', 'Mice', 'Chronic Disease', 'Immunosuppressive Agents/therapeutic use', 'Calcineurin Inhibitors/therapeutic use', 'Female', 'Mice, Inbred BALB C', 'Mice, Inbred C57BL', 'Cyclosporine/therapeutic use', 'Disease Models, Animal']",https://pubmed.ncbi.nlm.nih.gov/38688830/
2574,cyclophosphamide,21674420,"Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring.","['Wang T', 'Weigt SS', 'Belperio JA', 'Lynch JP 3rd']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/pharmacology/therapeutic use', '*Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy', 'Azathioprine/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Cyclophosphamide/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Humans', '*Immunosuppressive Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Methotrexate/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Mycophenolic Acid/administration & dosage/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/21674420/
2575,cyclophosphamide,7850923,Cyclocreatine in cancer chemotherapy.,"['Teicher BA', 'Menon K', 'Northey D', 'Liu J', 'Kufe DW', 'Kaddurah-Daouk R']","['Adenocarcinoma/*drug therapy', 'Animals', 'Antineoplastic Agents/administration & dosage/*therapeutic use/toxicity', 'Carcinoma, Small Cell/*drug therapy', 'Carmustine/administration & dosage/therapeutic use/toxicity', 'Cell Division/drug effects', 'Cell Survival/drug effects', 'Cisplatin/administration & dosage/therapeutic use/toxicity', 'Creatinine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use/toxicity', 'Cyclophosphamide/administration & dosage/analogs & derivatives/therapeutic use/toxicity', 'Disease Models, Animal', 'Drug Synergism', 'Drug Therapy, Combination', 'Female', 'Humans', 'Injections, Intraperitoneal', 'Injections, Intravenous', 'Lung Neoplasms/*drug therapy', 'Mammary Neoplasms, Experimental/*drug therapy', 'Melphalan/administration & dosage/therapeutic use/toxicity', 'Rats', 'Rats, Inbred F344', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/7850923/
2576,cyclophosphamide,4103984,Cyclophosphamide and human organ transplantation.,"['Starzl TE', 'Halgrimson CG', 'Penn I', 'Martineau G', 'Schroter G', 'Amemiya H', 'Putnam CW', 'Groth CG']","['Administration, Oral', 'Adolescent', 'Adult', 'Animals', 'Antilymphocyte Serum/administration & dosage', 'Azathioprine/administration & dosage/adverse effects', 'Cadaver', 'Consanguinity', 'Cyclophosphamide/administration & dosage/*therapeutic use', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Graft Rejection', 'Histocompatibility', 'Horses', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Injections, Intramuscular', '*Kidney Transplantation', '*Liver Transplantation', 'Male', 'Middle Aged', 'Postoperative Complications', 'Prednisone/administration & dosage', 'Time Factors', 'Transplantation Immunology', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/4103984/
2577,cyclophosphamide,3855382,High-dose ifosfamide in advanced osteosarcoma.,"['Marti C', 'Kroner T', 'Remagen W', 'Berchtold W', 'Cserhati M', 'Varini M']","['Alopecia/chemically induced', 'Bone Marrow/drug effects', 'Cyclophosphamide/*analogs & derivatives', 'Humans', 'Ifosfamide/administration & dosage/adverse effects/*therapeutic use', 'Nausea/chemically induced', 'Osteosarcoma/*drug therapy/pathology', 'Prospective Studies', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3855382/
2578,cyclophosphamide,2361797,Dexamethasone-cyclophosphamide pulse therapy in pemphigus.,"['Kaur S', 'Kanwar AJ']","['Adolescent', 'Adult', 'Age Factors', 'Cyclophosphamide/administration & dosage/*therapeutic use', 'Dexamethasone/administration & dosage/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Female', 'Hospitalization', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Pemphigus/diagnosis/*drug therapy/mortality', 'Prednisolone/administration & dosage/adverse effects', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/2361797/
2579,cyclophosphamide,4097649,Evaluation of cyclophosphamide dosage schedules in breast cancer.,['Stoll BA'],"['Adrenal Cortex Hormones/therapeutic use', 'Alkylating Agents/administration & dosage', 'Alopecia/chemically induced', 'Androgens/therapeutic use', 'Animals', 'Bone Marrow/drug effects', 'Breast Neoplasms/*drug therapy', 'Cyclophosphamide/*administration & dosage/adverse effects', 'Female', 'Humans', 'Nausea/chemically induced', 'Neoplasm Metastasis', 'Palliative Care', 'Rats', 'Sarcoma, Yoshida/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/4097649/
2580,cyclophosphamide,32827162,"Justification for a Fixed Dose of Eflapegrastim, a Long-Acting G-CSF, in Patients Receiving Docetaxel-Cyclophosphamide Chemotherapy.","['Barrett JA', 'Greene D', 'Lakshmikanthan S', 'Kolli P', 'Chawla S', 'Lebel F']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Area Under Curve', 'Breast Neoplasms/*drug therapy', 'Cyclophosphamide/adverse effects/therapeutic use', 'Docetaxel/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Filgrastim/administration & dosage', 'Granulocyte Colony-Stimulating Factor/*administration & dosage', 'Half-Life', 'Hematologic Agents/*administration & dosage', 'Humans', 'Immunoglobulin Fc Fragments/*administration & dosage', 'Metabolic Clearance Rate', 'Middle Aged', 'Neutropenia/*chemically induced/*prevention & control', 'Neutrophils/drug effects', 'Polyethylene Glycols/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32827162/
2581,cyclophosphamide,28019118,The mechanisms of cyclophosphamide-induced testicular toxicity and the protective agents.,"['Ghobadi E', 'Moloudizargari M', 'Asghari MH', 'Abdollahi M']","['Animals', 'Antineoplastic Agents, Alkylating/administration & dosage/*adverse effects', 'Antioxidants/pharmacology', 'Cyclophosphamide/administration & dosage/*adverse effects', 'Gene Expression Regulation/drug effects', 'Humans', 'Male', 'Mice', 'Oxidative Stress/drug effects', 'Protective Agents/pharmacology', 'Rats', 'Spermatocytes/drug effects', 'Testicular Diseases/*chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/28019118/
2582,Vecuronium,24636599,The concept behind sugammadex.,"['Epemolu O', 'Bom A']","['Acetylcholine/metabolism/physiology', 'Androstanols/administration & dosage/*antagonists & inhibitors/blood', 'Binding, Competitive', 'Delayed Emergence from Anesthesia/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Neuromuscular Nondepolarizing Agents/administration & dosage/*antagonists & inhibitors/blood', 'Osmolar Concentration', 'Receptors, Nicotinic/drug effects/physiology', 'Rocuronium', 'Sugammadex', 'Vecuronium Bromide/administration & dosage/*antagonists & inhibitors/blood', 'gamma-Cyclodextrins/administration & dosage/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24636599/
2583,Vecuronium,11235463,Rapacuronium bromide.,['Stump L'],"['Humans', 'Neuromuscular Nondepolarizing Agents/*therapeutic use', 'Postanesthesia Nursing', 'Vecuronium Bromide/*analogs & derivatives/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11235463/
2584,Vecuronium,20489603,Sugammadex: a selective relaxant-binding agent providing rapid reversal.,"['Rex C', 'Bergner UA', 'Puhringer FK']","['Androstanols/antagonists & inhibitors', '*Anesthesia', 'Animals', 'Drug Interactions', 'Emergency Medical Services', 'Humans', 'Muscle Relaxants, Central/*antagonists & inhibitors', 'Neuromuscular Nondepolarizing Agents/antagonists & inhibitors', 'Rocuronium', 'Sugammadex', 'Vecuronium Bromide/antagonists & inhibitors', 'gamma-Cyclodextrins/administration & dosage/adverse effects/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/20489603/
2585,Vecuronium,19887279,[Indications and clinical use of sugammadex].,"['Debaene B', 'Meistelman C']","['Algorithms', 'Androstanols/adverse effects/antagonists & inhibitors/chemistry/pharmacology', 'Anesthesia Recovery Period', 'Clinical Trials, Phase III as Topic', 'Contraindications', 'Electrodiagnosis', 'Humans', 'Kidney Failure, Chronic/complications', 'Muscle Relaxation/drug effects', 'Neostigmine/therapeutic use', 'Neuromuscular Blockade/*adverse effects', 'Neuromuscular Nondepolarizing Agents/adverse effects/*antagonists & inhibitors/chemistry/pharmacology', 'Postoperative Complications/chemically induced/diagnosis/*drug therapy', 'Randomized Controlled Trials as Topic', 'Respiratory Paralysis/chemically induced/diagnosis/*drug therapy', 'Rocuronium', 'Sugammadex', 'Vecuronium Bromide/antagonists & inhibitors/chemistry/pharmacology', 'gamma-Cyclodextrins/administration & dosage/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19887279/
2586,Vecuronium,11766252,Rapacuronium: clinical pharmacology.,"['Mirakhur RK', 'McCourt KC']","['Animals', 'Humans', '*Intubation, Intratracheal', '*Neuromuscular Nondepolarizing Agents/adverse effects/antagonists & inhibitors/pharmacokinetics/pharmacology', '*Vecuronium Bromide/adverse effects/*analogs & derivatives/antagonists & inhibitors/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11766252/
2587,Vecuronium,7904430,Resistance to vecuronium.,['Norman J'],"['Adult', 'Carbamazepine/therapeutic use', 'Drug Resistance', 'Electroencephalography', 'Epilepsy/prevention & control', 'Female', 'Humans', 'Neostigmine/pharmacology', 'Vecuronium Bromide/antagonists & inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7904430/
2588,Vecuronium,7743572,Nondepolarizing neuromuscular blocking drugs and train-of-four fade.,"['McCoy EP', 'Connolly FM', 'Mirakhur RK', 'Loan PB', 'Paxton LD']","['Adult', 'Androstanols/administration & dosage/pharmacology', 'Anesthesia Recovery Period', 'Anesthesia, Intravenous', 'Atracurium/administration & dosage/pharmacology', 'Electric Stimulation', 'Female', 'Humans', 'Isoquinolines/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Mivacurium', 'Muscle Contraction/drug effects', 'Neural Conduction/drug effects', 'Neuromuscular Junction/*drug effects', 'Neuromuscular Nondepolarizing Agents/administration & dosage/*pharmacology', 'Rocuronium', 'Ulnar Nerve/drug effects/physiology', 'Vecuronium Bromide/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7743572/
2589,Vecuronium,8740751,Neuromuscular blocking agents in the emergency department.,"['Rubin MA', 'Sadovnikoff N']","['Androstanols/therapeutic use', 'Atracurium/therapeutic use', 'Drug Utilization', '*Emergency Service, Hospital', 'Humans', 'Isoquinolines/therapeutic use', 'Mivacurium', 'Neuromuscular Depolarizing Agents/pharmacology/*therapeutic use', 'Neuromuscular Nondepolarizing Agents/pharmacology/*therapeutic use', 'Pancuronium/therapeutic use', 'Rocuronium', 'Succinylcholine/therapeutic use', 'Vecuronium Bromide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8740751/
2590,Vecuronium,20337001,"[Sugammadex, a novel drug for neuromuscular blockade reversal].","['Fernandez Mere LA', 'Alvarez-Blanco M']","['Androstanols/adverse effects/*antagonists & inhibitors/blood', 'Anesthesia Recovery Period', 'Chelating Agents/administration & dosage/pharmacology/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Drug Approval', 'Europe', 'Humans', 'Neuromuscular Blockade/*adverse effects', 'Neuromuscular Junction/drug effects', 'Neuromuscular Nondepolarizing Agents/adverse effects/*antagonists & inhibitors/blood', 'Postoperative Complications/chemically induced/*drug therapy', 'Receptors, Cholinergic/drug effects', 'Rocuronium', 'Sensation Disorders/chemically induced', 'Sugammadex', 'Vecuronium Bromide/adverse effects/*antagonists & inhibitors/blood', 'Vomiting/chemically induced', 'gamma-Cyclodextrins/administration & dosage/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20337001/
2591,Vecuronium,2888476,"Electrical and mechanical responses after neuromuscular blockade with vecuronium, and subsequent antagonism with neostigmine or edrophonium.","['Astley BA', 'Katz RL', 'Payne JP']","['Adult', 'Aged', 'Edrophonium/pharmacology', 'Electromyography', 'Humans', 'Middle Aged', 'Muscle Contraction/drug effects', 'Neostigmine/pharmacology', 'Neuromuscular Junction/*drug effects', 'Time Factors', 'Vecuronium Bromide/antagonists & inhibitors/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2888476/
2592,Vecuronium,2894106,The influence of alfentanil on the intubating conditions after priming with vecuronium.,"['Helbo-Hansen S', 'Ravlo O', 'Trap-Andersen S']","['Adult', 'Alfentanil', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Fentanyl/administration & dosage/*analogs & derivatives/pharmacology', 'Humans', 'Intubation, Intratracheal/*methods', 'Male', 'Middle Aged', 'Neuromuscular Blocking Agents/administration & dosage/*pharmacology', 'Random Allocation', 'Vecuronium Bromide/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/2894106/
2593,Vecuronium,1684201,A clinical study of intubating conditions under vecuronium bromide.,"['Betal S', 'Bose SM', 'Biswas N', 'Mitra H']","['Adult', 'Humans', 'Injections, Intravenous', '*Intubation, Intratracheal', 'Premedication', 'Time Factors', 'Vecuronium Bromide/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/1684201/
2594,Vecuronium,11094016,Accidental epidural injection of vecuronium.,"['Kostopanagiotou G', 'Mylona M', 'Massoura L', 'Siafaka I']","['Adult', '*Anesthesia, Epidural', 'Female', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Medication Errors', 'Neuromuscular Nondepolarizing Agents/administration & dosage/*adverse effects', 'Vecuronium Bromide/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11094016/
2595,Vecuronium,2877591,Bronchospasm following the use of vecuronium.,"[""O'Callaghan AC"", 'Scadding G', 'Watkins J']","['Aged', 'Bronchial Spasm/*chemically induced', 'Drug Hypersensitivity/etiology', 'Humans', 'Intradermal Tests', 'Intraoperative Complications/etiology', 'Male', 'Neuromuscular Blocking Agents/*adverse effects', 'Vecuronium Bromide/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2877591/
2596,Vecuronium,32323660,Anaphylactic Bronchospasm during Induction of General Anaesthesia: A Case Report.,"['Gautam B', 'Shakya R']","['Adult', 'Anaphylaxis/*chemically induced/drug therapy', 'Anesthesia, General/*adverse effects/methods', 'Bronchial Spasm/*chemically induced/drug therapy', 'Bronchodilator Agents/administration & dosage', 'Humans', 'Male', 'Vecuronium Bromide/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32323660/
2597,Vecuronium,8858758,Should ICU patients receive muscle relaxants?,['Coakley J'],"['Atracurium/therapeutic use', 'Critical Care/*methods', 'Humans', 'Intensive Care Units', 'Muscle Weakness/chemically induced', 'Neuromuscular Blocking Agents/adverse effects/*therapeutic use', 'Neuromuscular Nondepolarizing Agents/therapeutic use', 'Vecuronium Bromide/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8858758/
2598,Vecuronium,11682407,Precurarization and priming: a theoretical analysis of safety and timing.,"['Kopman AF', 'Khan NA', 'Neuman GG']","['Androstanols/administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Computer Simulation', 'Dose-Response Relationship, Drug', 'Humans', 'Individuality', 'Models, Biological', 'Neuromuscular Blockade/*methods', 'Neuromuscular Nondepolarizing Agents/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Rocuronium', 'Vecuronium Bromide/administration & dosage/adverse effects/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11682407/
2599,Vecuronium,8533549,Spontaneous recovery or evoked reversal of neuromuscular block.,['Mirakhur RK'],"['*Anesthesia Recovery Period', 'Atracurium/antagonists & inhibitors/metabolism', 'Cholinesterase Inhibitors/administration & dosage/pharmacology', 'Edrophonium/administration & dosage/pharmacology', 'Humans', 'Isoquinolines/antagonists & inhibitors/metabolism', 'Mivacurium', 'Neostigmine/administration & dosage/pharmacology', 'Neuromuscular Junction/*drug effects', 'Neuromuscular Nondepolarizing Agents/administration & dosage/*antagonists & inhibitors/*metabolism', 'Pyridostigmine Bromide/administration & dosage/pharmacology', 'Time Factors', 'Vecuronium Bromide/antagonists & inhibitors/metabolism']",https://pubmed.ncbi.nlm.nih.gov/8533549/
2600,Vecuronium,2891365,Use of neostigmine in the antagonism of residual neuromuscular blockade produced by vecuronium.,"['Jones JE', 'Hunter JM', 'Utting JE']","['Adult', 'Female', 'Humans', 'Male', 'Neostigmine/administration & dosage/*pharmacology', 'Neuromuscular Junction/*physiology', 'Synaptic Transmission/*drug effects', 'Time Factors', 'Vecuronium Bromide/*antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/2891365/
2601,Vecuronium,1974395,Rapid-sequence orotracheal intubation: a comparison of three techniques.,"['Silverman SM', 'Culling RD', 'Middaugh RE']","['Abdomen/physiology', 'Adolescent', 'Adult', 'Aged', 'Cough', 'Electric Stimulation', 'Humans', 'Intubation, Intratracheal/adverse effects/*methods', 'Midazolam', 'Middle Aged', 'Muscles/drug effects/physiology', 'Preanesthetic Medication', 'Random Allocation', 'Single-Blind Method', 'Succinylcholine/*administration & dosage', 'Thiopental/administration & dosage', 'Time Factors', 'Vecuronium Bromide/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1974395/
2602,fenofibrate,38905569,Effect of Fenofibrate on Progression of Diabetic Retinopathy.,"['Preiss D', 'Logue J', 'Sammons E', 'Zayed M', 'Emberson J', 'Wade R', 'Wallendszus K', 'Stevens W', 'Cretney R', 'Harding S', 'Leese G', 'Currie G', 'Armitage J']","['Humans', '*Fenofibrate/therapeutic use/pharmacology', '*Diabetic Retinopathy/drug therapy', 'Male', 'Female', 'Middle Aged', '*Disease Progression', '*Hypolipidemic Agents/therapeutic use/administration & dosage', 'Aged', 'Adult', 'Double-Blind Method']",https://pubmed.ncbi.nlm.nih.gov/38905569/
2603,fenofibrate,33137654,Fenofibrate treatment for severe hypertriglyceridemia in dogs.,"['Miceli DD', 'Vidal VP', 'Blatter MFC', 'Pignataro OP', 'Castillo VA']","['Animals', 'Diet, Fat-Restricted/*veterinary', 'Dog Diseases/blood/*drug therapy', 'Dogs', 'Fenofibrate/adverse effects/*therapeutic use', 'Gene Expression Regulation/drug effects', 'Glucose Transporter Type 4/genetics/metabolism', 'Hypertriglyceridemia/drug therapy/*veterinary', 'Hypolipidemic Agents/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33137654/
2604,fenofibrate,25043542,[Efficacy studies].,"['Pedro-Botet J', 'Flores-Le Roux JA']","['Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol, HDL/blood', 'Drug Combinations', 'Dyslipidemias/complications/*drug therapy', 'Fenofibrate/administration & dosage/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypertriglyceridemia/complications/drug therapy', 'Hypolipidemic Agents/administration & dosage/therapeutic use', 'Lipids/blood', 'Pravastatin/administration & dosage/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/25043542/
2605,fenofibrate,38114295,5-Fluorouracil-associated severe hypertriglyceridaemia with positive rechallenge.,"['Giacomuzzi Moore B', 'Durigova A', 'Lamine F', 'Chtioui H', 'Salati E']","['Humans', 'Fenofibrate/therapeutic use', '*Fluorouracil/adverse effects', '*Hypertriglyceridemia/chemically induced/drug therapy', 'Pancreatitis/etiology']",https://pubmed.ncbi.nlm.nih.gov/38114295/
2606,fenofibrate,29110023,[Modern treatment of primary biliary cholangitis].,['Strassburg CP'],"['Bezafibrate/adverse effects/therapeutic use', 'Budesonide/adverse effects/therapeutic use', 'Chenodeoxycholic Acid/adverse effects/*analogs & derivatives/therapeutic use', 'Cohort Studies', 'Female', 'Fenofibrate/adverse effects/therapeutic use', 'Humans', 'Liver Cirrhosis, Biliary/diagnosis/*drug therapy', 'Liver Transplantation', 'Male', 'Multicenter Studies as Topic', 'PPAR alpha/agonists', 'Pregnancy', 'Prognosis', 'Quality of Life', 'Receptors, Cytoplasmic and Nuclear/drug effects', 'Risk Assessment', 'Treatment Outcome', 'Ursodeoxycholic Acid/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29110023/
2607,fenofibrate,16310551,Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.,"['Keech A', 'Simes RJ', 'Barter P', 'Best J', 'Scott R', 'Taskinen MR', 'Forder P', 'Pillai A', 'Davis T', 'Glasziou P', 'Drury P', 'Kesaniemi YA', 'Sullivan D', 'Hunt D', 'Colman P', ""d'Emden M"", 'Whiting M', 'Ehnholm C', 'Laakso M']","['Aged', 'Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol/*blood', 'Coronary Disease/mortality/prevention & control', 'Diabetes Mellitus, Type 2/blood/*complications', 'Double-Blind Method', 'Dyslipidemias/complications/*drug therapy', 'Female', 'Fenofibrate/adverse effects/*therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Triglycerides/*blood']",https://pubmed.ncbi.nlm.nih.gov/16310551/
2608,fenofibrate,25432393,Combination therapy with statins: who benefits?,"['Singh A', 'Davidson M']","['Cardiovascular Diseases/*drug therapy', 'Drug Therapy, Combination/adverse effects/*standards', 'Fenofibrate/adverse effects/*pharmacology', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/*pharmacology', 'Hypolipidemic Agents/adverse effects/*pharmacology', 'Niacin/adverse effects/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/25432393/
2609,fenofibrate,28243111,"Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.","['Tarantino N', 'Santoro F', 'De Gennaro L', 'Correale M', 'Guastafierro F', 'Gaglione A', 'Di Biase M', 'Brunetti ND']","['Animals', 'Biomarkers/blood', 'Drug Combinations', 'Dyslipidemias/blood/diagnosis/*drug therapy', 'Fenofibrate/*administration & dosage/adverse effects', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects', 'Lipoproteins, HDL/*blood', 'Simvastatin/*administration & dosage/adverse effects', 'Treatment Outcome', 'Triglycerides/*blood']",https://pubmed.ncbi.nlm.nih.gov/28243111/
2610,fenofibrate,32170673,The Novel Role of PPAR Alpha in the Brain: Promising Target in Therapy of Alzheimer's Disease and Other Neurodegenerative Disorders.,"['Wojtowicz S', 'Strosznajder AK', 'Jezyna M', 'Strosznajder JB']","['Alzheimer Disease/drug therapy/*metabolism', 'Animals', 'Brain/drug effects/*metabolism', 'Drug Delivery Systems/*trends', 'Fenofibrate/administration & dosage/metabolism', 'Humans', 'Neurodegenerative Diseases/drug therapy/metabolism', 'PPAR alpha/agonists/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/32170673/
2611,fenofibrate,31974794,"Pemafibrate, a New Selective PPARalpha Modulator: Drug Concept and Its Clinical Applications for Dyslipidemia and Metabolic Diseases.","['Yamashita S', 'Masuda D', 'Matsuzawa Y']","['Animals', 'Atherosclerosis/*drug therapy/metabolism', 'Benzoxazoles/adverse effects/metabolism/*pharmacokinetics/*therapeutic use', 'Butyrates/adverse effects/metabolism/*pharmacokinetics/*therapeutic use', 'Cholesterol, HDL/blood', 'Diabetes Mellitus, Type 2/*drug therapy/metabolism', 'Drug Therapy, Combination', 'Dyslipidemias/*drug therapy/metabolism', 'Fenofibrate/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'PPAR alpha/*metabolism', 'Treatment Outcome', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/31974794/
2612,fenofibrate,8318433,Phenofibrate-induced lichenoid photodermatitis.,"['Gardeazabal J', 'Gonzalez M', 'Izu R', 'Gil N', 'Aguirre A', 'Diaz-Perez JL']","['Dermatitis, Photoallergic/*etiology/pathology', 'Female', 'Fenofibrate/*adverse effects', 'Humans', 'Middle Aged', 'Skin/pathology']",https://pubmed.ncbi.nlm.nih.gov/8318433/
2613,fenofibrate,25227751,Protective factors in diabetic retinopathy: focus on blood-retinal barrier.,"['Zhang C', 'Wang H', 'Nie J', 'Wang F']","['Animals', 'Blood-Retinal Barrier/drug effects/pathology/*physiopathology', 'Diabetic Retinopathy/etiology/*physiopathology/*prevention & control', 'Erythropoietin/pharmacology', 'Fenofibrate/analogs & derivatives/pharmacology', 'Humans', 'Insulin-Like Growth Factor Binding Protein 3/physiology', 'Macular Edema/complications/pathology/physiopathology', 'Protective Factors', 'Pyrazines/pharmacology', 'Sitagliptin Phosphate', 'Triazoles/pharmacology', 'Vascular Endothelial Growth Factor A/antagonists & inhibitors']",https://pubmed.ncbi.nlm.nih.gov/25227751/
2614,fenofibrate,12481201,Update on fenofibrate.,['Guay DR'],"['Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', '*Fenofibrate/economics/pharmacology/therapeutic use', 'Humans', 'Hyperlipidemias/*drug therapy', '*Hypolipidemic Agents/economics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12481201/
2615,fenofibrate,38336772,Role of fenofibrate in multiple sclerosis.,"['Abulaban AA', 'Al-Kuraishy HM', 'Al-Gareeb AI', 'Elekhnawy E', 'Alanazi A', 'Alexiou A', 'Papadakis M', 'Batiha GE']","['Humans', '*Multiple Sclerosis/drug therapy/pathology', '*Fenofibrate/pharmacology/therapeutic use', 'Central Nervous System', 'Neurons/pathology', 'Inflammation/pathology']",https://pubmed.ncbi.nlm.nih.gov/38336772/
2616,fenofibrate,15269493,Fenofibrate-induced myopathy.,"['Ghosh B', 'Sengupta S', 'Bhattacharjee B', 'Majumder A', 'Sarkar SB']","['Fenofibrate/*adverse effects/therapeutic use', 'Humans', 'Hyperlipidemias/drug therapy', 'Hypolipidemic Agents/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Muscular Diseases/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/15269493/
2617,fenofibrate,15638786,Fenofibrate: metabolic and pleiotropic effects.,"['Tsimihodimos V', 'Miltiadous G', 'Daskalopoulou SS', 'Mikhailidis DP', 'Elisaf MS']","['Anti-Inflammatory Agents/metabolism/pharmacology', 'Antifibrinolytic Agents/metabolism/pharmacology', 'Antioxidants/metabolism/pharmacology/therapeutic use', 'Endothelium, Vascular/drug effects', 'Fenofibrate/*metabolism/pharmacology/*therapeutic use', 'Fibrinolytic Agents/pharmacology', 'Humans', 'PPAR alpha/drug effects/metabolism/therapeutic use', 'Prodrugs/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15638786/
2618,fenofibrate,31928604,[Severe Thrombocitopenia Induced by Fenofibrate].,"['Clara A', 'Martins T', 'Martins A', 'Baptista A', 'Lazaro M']","['Aged', 'Fenofibrate/*adverse effects', 'Glucocorticoids/therapeutic use', 'Humans', 'Hypolipidemic Agents/*adverse effects', 'Male', 'Methylprednisolone/therapeutic use', 'Purpura, Thrombocytopenic/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31928604/
2619,fenofibrate,25989912,Non-traditional systemic treatments for diabetic retinopathy: an evidence-based review.,"['Simo R', 'Ballarini S', 'Cunha-Vaz J', 'Ji L', 'Haller H', 'Zimmet P', 'Wong TY']","['Animals', 'Calcium Dobesilate/therapeutic use', 'Diabetic Retinopathy/*drug therapy', 'Fenofibrate/therapeutic use', 'Humans', 'Renin-Angiotensin System/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25989912/
2620,fenofibrate,21736529,Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.,"['Filippatos TD', 'Elisaf MS']","['Adult', 'Cardiovascular Diseases/epidemiology', 'Diabetes Complications/blood/drug therapy/metabolism', 'Drug Combinations', 'Drug Monitoring', 'Dyslipidemias/blood/*drug therapy/metabolism', 'Fenofibrate/*administration & dosage/adverse effects/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/*administration & dosage/adverse effects/therapeutic use', 'Hypertriglyceridemia/blood/drug therapy/metabolism', 'Hypolipidemic Agents/*administration & dosage/adverse effects/therapeutic use', 'Lipoproteins/blood', 'Risk Factors', 'Simvastatin/*administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21736529/
2621,fenofibrate,26959124,Lipids and Diabetic Retinopathy.,"['Modjtahedi BS', 'Bose N', 'Papakostas TD', 'Morse L', 'Vavvas DG', 'Kishan AU']","['Diabetic Retinopathy/*physiopathology', 'Fenofibrate/analogs & derivatives/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hyperlipidemias/drug therapy/*physiopathology', 'Lipids/*physiology']",https://pubmed.ncbi.nlm.nih.gov/26959124/
2622,meperidine,9564390,Intrathecal pethidine: pharmacology and clinical applications.,['Ngan Kee WD'],"['Adjuvants, Anesthesia/administration & dosage/*pharmacology', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Spinal', 'Humans', 'Injections, Spinal', 'Meperidine/administration & dosage/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/9564390/
2623,meperidine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
2624,meperidine,16114176,Nonpharmacological treatment options for epilepsy.,"['Sheth RD', 'Stafstrom CE', 'Hsu D']","['Allylamine/administration & dosage/analogs & derivatives', 'Biofeedback, Psychology/*methods', 'Diet Therapy/*methods', 'Drug Combinations', 'Electric Stimulation/*methods', 'Electroencephalography/methods', 'Epilepsy/classification/*therapy', 'Humans', 'Meperidine/administration & dosage/analogs & derivatives', 'Neurosurgery/*methods', 'Pyridoxine/therapeutic use', 'Vagus Nerve/physiopathology/radiation effects']",https://pubmed.ncbi.nlm.nih.gov/16114176/
2625,meperidine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
2626,meperidine,1585886,Lethal effects of normeperidine.,['Jiraki K'],"['Adult', 'Cholinesterase Inhibitors/pharmacokinetics/*poisoning', 'Half-Life', 'Humans', 'Kidney Failure, Chronic/*complications/etiology', 'Male', 'Meperidine/administration & dosage/*analogs & derivatives/*pharmacokinetics/poisoning', 'Substance-Related Disorders/*complications']",https://pubmed.ncbi.nlm.nih.gov/1585886/
2627,meperidine,12819163,Naloxone for narcotic exposed newborn infants: systematic review.,"['McGuire W', 'Fowlie PW']","['Analgesia, Obstetrical/*adverse effects', 'Analgesics, Opioid/*adverse effects/therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Intensive Care, Neonatal', 'Meperidine/*adverse effects/therapeutic use', 'Naloxone/*therapeutic use', 'Narcotic Antagonists/*therapeutic use', 'Pregnancy', '*Prenatal Exposure Delayed Effects', 'Randomized Controlled Trials as Topic', 'Respiration, Artificial']",https://pubmed.ncbi.nlm.nih.gov/12819163/
2628,meperidine,11574125,Effect of epidural analgesia on the fetal heart rate.,['Capogna G'],"['Analgesics, Opioid/administration & dosage/therapeutic use', 'Anesthesia, Epidural/*adverse effects', 'Clinical Trials as Topic', 'Female', 'Heart Rate, Fetal/*drug effects', 'Humans', 'Hypotension/physiopathology', 'Meperidine/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/physiopathology', 'Sufentanil/administration & dosage/therapeutic use', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11574125/
2629,meperidine,8239638,Postoperative narcotic analgesic administration.,['McDonald DD'],"['Adolescent', 'Adult', '*Appendectomy', 'Drug Utilization', 'Female', 'Humans', 'Length of Stay/statistics & numerical data', 'Male', 'Meperidine/administration & dosage/therapeutic use', 'Middle Aged', 'Narcotics/administration & dosage/*therapeutic use', 'Pain, Postoperative/*drug therapy/nursing', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/8239638/
2630,meperidine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
2631,meperidine,9619217,Epidural pethidine: pharmacology and clinical experience.,['Ngan Kee WD'],"['Analgesia, Obstetrical', 'Analgesia, Patient-Controlled', 'Analgesics, Opioid/administration & dosage/*pharmacology', '*Anesthesia, Epidural', 'Female', 'Humans', 'Injections, Epidural', 'Meperidine/administration & dosage/*pharmacology', 'Pain, Postoperative/drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/9619217/
2632,meperidine,2354093,Analgesic efficacy of perioperative buccal morphine.,"['Manara AR', 'Bodenham AR', 'Park GR']","['Administration, Buccal', 'Adult', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Meperidine/administration & dosage', 'Morphine/administration & dosage/adverse effects/*therapeutic use', 'Pain Measurement', 'Pain, Postoperative/*drug therapy', 'Patient Acceptance of Health Care', 'Random Allocation', 'Taste/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2354093/
2633,meperidine,3605428,Meperidine-induced delirium.,"['Eisendrath SJ', 'Goldman B', 'Douglas J', 'Dimatteo L', 'Van Dyke C']","['Adult', 'Aged', 'Delirium/*chemically induced', 'Drug Interactions', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Meperidine/*adverse effects/pharmacology', 'Middle Aged', 'Parasympatholytics/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3605428/
2634,meperidine,3355732,Patient-controlled analgesia with extradural morphine or pethidine.,"['Sjostrom S', 'Hartvig D', 'Tamsen A']","['Adult', 'Female', 'Humans', 'Injections, Epidural', 'Male', 'Meperidine/*administration & dosage/blood/therapeutic use', 'Middle Aged', 'Morphine/*administration & dosage/blood/therapeutic use', 'Pain, Postoperative/*drug therapy', 'Self Administration', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3355732/
2635,meperidine,2568289,Pharmacokinetics of meperidine in pregnancy.,"['Todd EL', 'Stafford DT', 'Bucovaz ET', 'Morrison JC']","['Female', 'Fetal Distress/chemically induced', 'Fetus/metabolism', 'Humans', 'Injections, Intravenous', 'Meperidine/administration & dosage/adverse effects/*pharmacokinetics', 'Pregnancy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2568289/
2636,meperidine,337983,Comparison of nefopam and pethidine in postoperative pain.,"['Tigerstedt I', 'Sipponen J', 'Tammisto T', 'Turunen M']","['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Meperidine/administration & dosage/*therapeutic use', 'Nefopam/administration & dosage/*therapeutic use', 'Oxazocines/*therapeutic use', 'Pain, Postoperative/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/337983/
2637,meperidine,8007042,Meperidine neurotoxicity after organ transplantation.,"['Adair JC', 'Gilmore RL']","['Adult', 'Central Nervous System/*drug effects', 'Humans', '*Kidney Transplantation', 'Male', 'Meperidine/*adverse effects/blood', '*Pancreas Transplantation', 'Pancreatitis/drug therapy', 'Postoperative Complications/*chemically induced/drug therapy/physiopathology', 'Seizures/chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/8007042/
2638,meperidine,1609533,[Effectiveness and tolerance of tramadol with or without an antiemetic and pethidine in obstetric analgesia].,"['Kainz C', 'Joura E', 'Obwegeser R', 'Plockinger B', 'Gruber W']","['Adult', 'Analgesia, Obstetrical/*methods', 'Cardiotocography/drug effects', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', 'Meperidine/*administration & dosage/adverse effects', 'Oxytocin/administration & dosage', 'Pain Measurement', 'Pregnancy', 'Prospective Studies', 'Tramadol/*administration & dosage/adverse effects', 'Triflupromazine/*administration & dosage/adverse effects', 'Uterine Contraction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1609533/
2639,meperidine,11782820,Meperidine: a critical review.,"['Latta KS', 'Ginsberg B', 'Barkin RL']","['*Adjuvants, Anesthesia/pharmacokinetics/pharmacology/therapeutic use', '*Analgesics, Opioid/pharmacokinetics/pharmacology/therapeutic use', 'Animals', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Humans', '*Meperidine/pharmacokinetics/pharmacology/therapeutic use', 'Muscle, Smooth/drug effects', 'Pain/drug therapy', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/11782820/
2640,meperidine,2719235,Epidural pethidine or fentanyl during caesarean section: a double-blind comparison.,['Paech MJ'],"['Adult', '*Anesthesia, Obstetrical', '*Cesarean Section', 'Double-Blind Method', 'Female', 'Fentanyl/*administration & dosage/adverse effects', 'Humans', 'Injections, Epidural', 'Meperidine/*administration & dosage/adverse effects', 'Pain, Postoperative/*prevention & control', 'Pregnancy', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2719235/
2641,meperidine,4913784,Comparison of pentazocine and pethidine in labour.,"['Mowat J', 'Garrey MM']","['Adolescent', 'Adult', '*Anesthesia, Obstetrical', 'Clinical Trials as Topic', 'Female', 'Humans', 'Infant, Newborn', 'Injections, Intramuscular', '*Labor, Obstetric', 'Meperidine/*administration & dosage/adverse effects', 'Pentazocine/*administration & dosage/adverse effects', 'Physical Examination', 'Pre-Eclampsia', 'Pregnancy', 'Statistics as Topic', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/4913784/
2642,Cytosar,2329025,Psoriasis without neutrophils.,['Paslin D'],"['Cytarabine/administration & dosage/therapeutic use', 'Daunorubicin/administration & dosage/therapeutic use', 'Drug Administration Schedule', 'Drug Therapy, Combination', 'Evaluation Studies as Topic', 'Humans', 'Leukemia, Myeloid, Acute/*blood/complications', 'Leukocyte Count/drug effects', 'Male', 'Middle Aged', '*Neutrophils/drug effects', 'Psoriasis/*blood/complications/drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/2329025/
2643,Cytosar,2081008,Cytarabine.,"['Betcher DL', 'Burnham N']","['Adult', 'Child', 'Cytarabine/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', 'Leukemia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2081008/
2644,Cytosar,29870791,Advances in treatment formulations for acute myeloid leukemia.,"['Briot T', 'Roger E', 'Thepot S', 'Lagarce F']","['Animals', 'Anthracyclines/adverse effects/therapeutic use', 'Cytarabine/adverse effects/therapeutic use', 'Drug Delivery Systems/methods', 'Humans', 'Leukemia, Myeloid, Acute/*drug therapy', 'Pharmaceutical Preparations/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/29870791/
2645,Cytosar,3287015,High dose cytarabine: a review.,"['Bolwell BJ', 'Cassileth PA', 'Gale RP']","['Amsacrine/administration & dosage', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/therapeutic use', 'Asparaginase/therapeutic use', 'Cytarabine/*administration & dosage/adverse effects/therapeutic use', 'Daunorubicin/administration & dosage', 'Humans', 'Leukemia, Lymphoid/*drug therapy', 'Leukemia, Myeloid/drug therapy', 'Leukemia, Myeloid, Acute/*drug therapy', 'Pancytopenia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/3287015/
2646,Cytosar,38703055,Efficacy and safety of venetoclax-based combination therapy for previously untreated acute myeloid leukemia: a meta-analysis.,"['He H', 'Wen X', 'Zheng H']","['Humans', '*Bridged Bicyclo Compounds, Heterocyclic/therapeutic use/adverse effects/administration & dosage', '*Sulfonamides/therapeutic use/administration & dosage/adverse effects', '*Leukemia, Myeloid, Acute/drug therapy', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Azacitidine/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', 'Aged', 'Cytarabine/administration & dosage/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/38703055/
2647,Cytosar,30504411,Liposomal Cytarabine-Daunorubicin (CPX-351) Extravasation: Case Report and Literature Review.,"['Howell G', 'Oliai C', 'Schiller G']","['Adult', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Chest Tubes', 'Cytarabine/*administration & dosage/adverse effects', 'Daunorubicin/*administration & dosage/adverse effects', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/*drug therapy', 'Liposomes', 'Vascular Access Devices']",https://pubmed.ncbi.nlm.nih.gov/30504411/
2648,Cytosar,23287624,Sense and nonsense of high-dose cytarabine for acute myeloid leukemia.,['Lowenberg B'],"['Adult', 'Antimetabolites, Antineoplastic/*administration & dosage/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Consolidation Chemotherapy', 'Cytarabine/*administration & dosage/adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Induction Chemotherapy', 'Infusions, Intravenous', 'Leukemia, Myeloid, Acute/*drug therapy/pathology', 'Multicenter Studies as Topic/statistics & numerical data', 'Patient Selection', 'Randomized Controlled Trials as Topic/statistics & numerical data', 'Retrospective Studies', 'Risk', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23287624/
2649,Cytosar,39535303,"Methotrexate and cytarabine in adult LCH: High risk, high reward and maintenance free?","['Abeykoon JP', 'Go RS', 'Azoulay LD', 'Haroche J']","['Humans', '*Methotrexate/therapeutic use/adverse effects', '*Cytarabine/therapeutic use/administration & dosage', '*Histiocytosis, Langerhans-Cell/drug therapy', 'Adult', 'Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Male', 'Female', 'Follow-Up Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39535303/
2650,Cytosar,30892988,Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study.,"['Wei AH', 'Strickland SA Jr', 'Hou JZ', 'Fiedler W', 'Lin TL', 'Walter RB', 'Enjeti A', 'Tiong IS', 'Savona M', 'Lee S', 'Chyla B', 'Popovic R', 'Salem AH', 'Agarwal S', 'Xu T', 'Fakouhi KM', 'Humerickhouse R', 'Hong WJ', 'Hayslip J', 'Roboz GJ']","['Age Factors', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/pharmacokinetics', 'Bridged Bicyclo Compounds, Heterocyclic/administration & dosage/adverse effects/pharmacokinetics', 'Cytarabine/administration & dosage/adverse effects/pharmacokinetics', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/*drug therapy/genetics/metabolism', 'Male', 'Middle Aged', 'Mutation', 'Sulfonamides/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/30892988/
2651,Cytosar,12210815,Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature.,"['Truica CI', 'Frankel SR']","['Acute Disease', 'Acute Kidney Injury/etiology', 'Apoptosis/drug effects', 'Cytarabine/administration & dosage/*adverse effects', 'Humans', 'Leukemia, Myelomonocytic, Acute/complications/*drug therapy', 'Male', 'Middle Aged', 'Pancreatitis/etiology', 'Respiratory Insufficiency/etiology', 'Rhabdomyolysis/*chemically induced/drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12210815/
2652,Cytosar,11054987,Clinical pharmacology of encapsulated sustained-release cytarabine.,"['Murry DJ', 'Blaney SM']","['Animals', 'Antimetabolites, Antineoplastic/administration & dosage/*pharmacology/therapeutic use', 'Cytarabine/administration & dosage/*pharmacology/therapeutic use', 'Delayed-Action Preparations', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11054987/
2653,Cytosar,21178637,High-dose cytosine arabinoside-induced symptomatic bradycardia.,"['Wayangankar SA', 'Patel BC', 'Parekh HD', 'Holter JL', 'Lazzara R']","['Antimetabolites, Antineoplastic/*adverse effects', 'Bradycardia/*chemically induced/*diagnosis/physiopathology', 'Cytarabine/administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', '*Electrocardiography', 'Female', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/21178637/
2654,Cytosar,24687088,"Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML.","['Lancet JE', 'Cortes JE', 'Hogge DE', 'Tallman MS', 'Kovacsovics TJ', 'Damon LE', 'Komrokji R', 'Solomon SR', 'Kolitz JE', 'Cooper M', 'Yeager AM', 'Louie AC', 'Feldman EJ']","['Aged', 'Antibiotics, Antineoplastic/administration & dosage/adverse effects/*therapeutic use', 'Antimetabolites, Antineoplastic/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/*therapeutic use', 'Cytarabine/administration & dosage/adverse effects/*therapeutic use', 'Daunorubicin/administration & dosage/adverse effects/therapeutic use', 'Disease-Free Survival', 'Female', 'Humans', 'Leukemia, Myeloid, Acute/drug therapy', 'Liposomes', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/24687088/
2655,Cytosar,3925558,Cellular and clinical pharmacology of low-dose ara-C.,"['Kufe DW', 'Griffin JD', 'Spriggs DR']","['Adult', 'Aged', 'Aphidicolin', 'Bone Marrow/pathology', 'Cell Differentiation/drug effects', 'Cell Division/drug effects', 'Cell Line', 'Cytarabine/administration & dosage/adverse effects/metabolism/pharmacology/*therapeutic use', 'DNA/biosynthesis', 'DNA Replication/drug effects', 'Diterpenes/pharmacology', 'Dose-Response Relationship, Drug', 'Female', 'Hemoglobins/biosynthesis', 'Humans', 'Karyotyping', 'Kinetics', 'Leukemia/*drug therapy/pathology', 'Male', 'Middle Aged', 'Preleukemia/drug therapy/genetics/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/3925558/
2656,Cytosar,20425342,Is cytarabine required in the treatment of acute promyelocytic leukemia?,"['Ades L', 'Fenaux P']","['Adult', 'Anthracyclines/administration & dosage/adverse effects', 'Antimetabolites, Antineoplastic/administration & dosage/adverse effects/therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Cytarabine/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Leukemia, Promyelocytic, Acute/*drug therapy', 'Middle Aged', 'Multicenter Studies as Topic', 'Randomized Controlled Trials as Topic', 'Remission Induction', 'Treatment Outcome', 'Tretinoin/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20425342/
2657,Cytosar,8078551,Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B.,"['Mayer RJ', 'Davis RB', 'Schiffer CA', 'Berg DT', 'Powell BL', 'Schulman P', 'Omura GA', 'Moore JO', 'McIntyre OR', 'Frei E 3rd']","['Acute Disease', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Cytarabine/administration & dosage/adverse effects/*therapeutic use', 'Daunorubicin/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Humans', 'Infusions, Intravenous', 'Leukemia, Myeloid/*drug therapy/mortality', 'Male', 'Middle Aged', 'Remission Induction', 'Survival Rate']",https://pubmed.ncbi.nlm.nih.gov/8078551/
2658,Cytosar,23373775,Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.,"['Keane N', 'Freeman C', 'Swords R', 'Giles FJ']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage', 'Cytarabine/administration & dosage/adverse effects/*analogs & derivatives', 'Drug Delivery Systems/methods', 'Drug Discovery', 'Humans', 'Leukemia, Myeloid, Acute/*drug therapy', 'Molecular Targeted Therapy']",https://pubmed.ncbi.nlm.nih.gov/23373775/
2659,Cytosar,38526002,BEAM versus pharmacokinetics-directed BuCyVP16 conditioning for patients with peripheral T-cell lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation.,"['Stuver R', 'Mian A', 'Brown S', 'Devlin S', 'Caimi PF', 'Chinapen S', 'Dahi P', 'Dean R', 'Epstein-Peterson ZD', 'Hill B', 'Horwitz SM', 'Lahoud O', 'Lin R', 'Moskowitz AJ', 'Sauter C', 'Shah G', 'Winter A', 'Jagadeesh D', 'Scordo M']","['Humans', '*Hematopoietic Stem Cell Transplantation/methods', '*Lymphoma, T-Cell, Peripheral/therapy', '*Transplantation Conditioning/methods', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/administration & dosage/pharmacokinetics', 'Male', 'Middle Aged', 'Female', '*Transplantation, Autologous', 'Cytarabine/administration & dosage/pharmacokinetics/therapeutic use', 'Carmustine/administration & dosage/pharmacokinetics/therapeutic use', 'Adult', 'Melphalan/administration & dosage/therapeutic use/pharmacokinetics', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38526002/
2660,Cytosar,38532078,A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.,"['Usuki K', 'Miyamoto T', 'Yamauchi T', 'Ando K', 'Ogawa Y', 'Onozawa M', 'Yamauchi T', 'Kiyoi H', 'Yokota A', 'Ikezoe T', 'Katsuoka Y', 'Takada S', 'Aotsuka N', 'Morita Y', 'Ishikawa T', 'Asada N', 'Ota S', 'Dohi A', 'Morimoto K', 'Imai S', 'Kishimoto U', 'Akashi K', 'Miyazaki Y']","['Humans', '*Daunorubicin/administration & dosage/pharmacokinetics', '*Cytarabine/administration & dosage/pharmacokinetics', '*Leukemia, Myeloid, Acute/drug therapy', 'Middle Aged', 'Aged', '*Liposomes', 'Male', 'Female', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects/pharmacokinetics/administration & dosage', 'Japan', 'Treatment Outcome', 'Asian People', 'East Asian People']",https://pubmed.ncbi.nlm.nih.gov/38532078/
2661,Cytosar,10862474,[The action in vitro of a permanent and an alternating magnetic field and of cytosar on the colony- and cluster-forming properties of bone marrow cells from hematologic patients].,"[""Bessmel'tsev SS"", 'Balashova VA']","['Antimetabolites, Antineoplastic/*pharmacology/therapeutic use', 'Bone Marrow Cells/cytology/*drug effects', 'Colony-Forming Units Assay/methods/statistics & numerical data', 'Cytarabine/*pharmacology/therapeutic use', 'Hematologic Neoplasms/*pathology/therapy', 'Humans', '*Magnetics/therapeutic use', 'Time Factors', 'Tumor Cells, Cultured']",https://pubmed.ncbi.nlm.nih.gov/10862474/
2662,omeprazole,35787720,An update on drug-drug interactions associated with proton pump inhibitors.,"['Ben Ghezala I', 'Luu M', 'Bardou M']","['2-Pyridinylmethylsulfinylbenzimidazoles/pharmacology', 'Drug Interactions', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Esomeprazole/pharmacology', 'Humans', '*Omeprazole/pharmacokinetics', 'Prospective Studies', '*Proton Pump Inhibitors/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/35787720/
2663,omeprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
2664,omeprazole,38594198,Severe DRESS with myocarditis secondary to naproxen/esomeprazole.,"[""O'Mahony S"", 'Tobin AM', 'Donnelly TM']","['Humans', 'Male', '*Drug Hypersensitivity Syndrome/diagnosis', '*Eosinophilia/complications', 'Esomeprazole/adverse effects', '*Myocarditis/complications', 'Naproxen/adverse effects', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38594198/
2665,omeprazole,26329348,Comparative effectiveness and tolerability of esomeprazole and omeprazole in gastro-esophageal reflux disease: A systematic review and meta-analysis.,"['Qi Q', 'Wang R', 'Liu L', 'Zhao F', 'Wang S']","['Esomeprazole/adverse effects/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Omeprazole/adverse effects/*therapeutic use', 'Proton Pump Inhibitors/*therapeutic use', 'Publication Bias']",https://pubmed.ncbi.nlm.nih.gov/26329348/
2666,omeprazole,22372726,Acetylsalicylic acid/esomeprazole fixed-dose combination.,"['Burness CB', 'Scott LJ']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Aspirin/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Capsules', 'Cardiovascular Diseases/prevention & control', 'Drug Combinations', 'Esomeprazole/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Humans', 'Peptic Ulcer/prevention & control', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use', 'Prodrugs/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22372726/
2667,omeprazole,16520709,Intravenous proton pump inhibitors.,['Baker DE'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage/pharmacokinetics', 'Benzimidazoles/*administration & dosage/pharmacokinetics', 'Biological Availability', 'Drug Interactions', 'Esomeprazole/*administration & dosage/*analogs & derivatives/pharmacokinetics', 'Humans', 'Hydrogen-Ion Concentration', 'Injections, Intravenous', 'Lansoprazole', 'Pantoprazole', '*Proton Pump Inhibitors', 'Stomach/chemistry', 'Sulfoxides/*administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16520709/
2668,omeprazole,20739778,Esomeprazole-induced photoallergic dermatitis.,"['Shukla A', 'Mahapatra A', 'Gogtay N', 'Khopkar U']","['Anti-Ulcer Agents/*adverse effects', 'Dermatitis, Photoallergic/*etiology', 'Esomeprazole/*adverse effects', 'Female', 'Heartburn/diagnosis/*drug therapy', 'Humans', 'Middle Aged', 'Ranitidine/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20739778/
2669,omeprazole,17472543,Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.,"['Morgner A', 'Miehlke S', 'Labenz J']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Anti-Ulcer Agents/adverse effects/*therapeutic use', 'Dyspepsia/drug therapy', 'Esomeprazole/adverse effects/*therapeutic use', 'Humans', '*Proton Pump Inhibitors', 'Stomach Ulcer/chemically induced/*drug therapy/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/17472543/
2670,omeprazole,19210109,Esomeprazole: a proton pump inhibitor.,"['Vachhani R', 'Olds G', 'Velanovich V']","['Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Drug Costs', 'Esomeprazole/adverse effects/economics/*therapeutic use', 'Gastroesophageal Reflux/*drug therapy', 'Helicobacter Infections/drug therapy', 'Humans', 'Proton Pump Inhibitors/adverse effects/economics/*therapeutic use', 'Stomach Ulcer/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19210109/
2671,omeprazole,32935346,"Pharmacologic treatment of GERD: Where we are now, and where are we going?","['Scarpignato C', 'Hongo M', 'Wu JCY', 'Lottrup C', 'Lazarescu A', 'Stein E', 'Hunt RH']","['Cimetidine/therapeutic use', 'Esomeprazole/therapeutic use', 'Esophageal Mucosa/*pathology', 'Gastroesophageal Reflux/diagnosis/*drug therapy', 'Humans', 'Lansoprazole/therapeutic use', 'Omeprazole/therapeutic use', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/therapeutic use', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32935346/
2672,omeprazole,10983736,Esomeprazole.,"['Spencer CM', 'Faulds D']","['Animals', 'Anti-Ulcer Agents/*therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Enzyme Inhibitors/*therapeutic use', 'Esomeprazole', 'Gastroesophageal Reflux/drug therapy', 'Helicobacter pylori/drug effects', 'Humans', 'Omeprazole/pharmacokinetics/pharmacology/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/10983736/
2673,omeprazole,16335854,"What is potent acid inhibition, and how can it be achieved?","['Calvet X', 'Gomollon F']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/*administration & dosage', 'Benzimidazoles/administration & dosage', 'Clinical Trials as Topic', 'Esomeprazole', 'Gastric Acid/*metabolism', 'Humans', 'Lansoprazole', 'Omeprazole/administration & dosage/analogs & derivatives', 'Pantoprazole', 'Peptic Ulcer/*drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole', 'Sulfoxides/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/16335854/
2674,omeprazole,39023173,Efficacy and Safety of Postbiotic Contained Inactivated Lactobacillus reuteri ( Limosilactobacillus reuteri ) DSM 17648 as Adjuvant Therapy in the Eradication of Helicobacter pylori in Adults With Functional Dyspepsia: A Randomized Double-Blind Placebo-Controlled Trial.,"['Ivashkin V', 'Maev I', 'Poluektova E', 'Sinitsa A', 'Avalueva E', 'Mnatsakanyan M', 'Simanenkov V', 'Karpeeva J', 'Kopylova D', 'Kuprina I', 'Kucheryavyy Y', 'Lapina T', 'Solovyeva O', 'Soom M', 'Cheremushkina N', 'Maevskaya E', 'Maslennikov R']","['Humans', 'Double-Blind Method', '*Limosilactobacillus reuteri', '*Dyspepsia/microbiology/diagnosis/drug therapy/therapy', 'Male', 'Female', '*Helicobacter Infections/drug therapy/diagnosis/therapy/microbiology', 'Adult', '*Helicobacter pylori/isolation & purification', '*Probiotics/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', '*Amoxicillin/administration & dosage/adverse effects/therapeutic use', '*Clarithromycin/administration & dosage/therapeutic use/adverse effects', '*Drug Therapy, Combination', 'Treatment Outcome', '*Anti-Bacterial Agents/adverse effects/administration & dosage/therapeutic use', '*Quality of Life', 'Esomeprazole/administration & dosage/adverse effects/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/39023173/
2675,omeprazole,26661629,Esomeprazole induced galactorrhea: a novel side effect.,"['Pipaliya N', 'Solanke D', 'Rathi C', 'Patel R', 'Ingle M', 'Sawant P']","['Adult', 'Amenorrhea/*chemically induced', 'Esomeprazole/*adverse effects/therapeutic use', 'Female', 'Galactorrhea/*chemically induced', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Proton Pump Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26661629/
2676,omeprazole,36657136,Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.,"['Abdo-Francis JM', 'Cabrera-Alvarez G', 'Martinez-Torres H', 'Remes-Troche JM']","['Humans', '*Esomeprazole/adverse effects', 'Rabeprazole/therapeutic use', 'Prospective Studies', 'Treatment Outcome', '*Gastroesophageal Reflux/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36657136/
2677,omeprazole,29186640,[Esomeprazol-induced cutaneous lupus erythematosus].,"['Gliem N', 'Broekaert SMC', 'Seitz CS', 'Schon MP', 'Ellenrieder V']","['Aged', 'Biopsy', 'Esomeprazole/*adverse effects/therapeutic use', 'Female', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lupus Erythematosus, Cutaneous/*chemically induced/pathology', 'Proton Pump Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29186640/
2678,omeprazole,39097924,"Tetracycline Three Times Daily Versus Four Times Daily in Bismuth-Containing Quadruple Therapy as the First-Line Treatment of Helicobacter pylori Infection: A Multicenter, Noninferiority, Randomized Controlled Trial.","['Ding YM', 'Zhang QM', 'Li RL', 'Han ZX', 'Zhao Q', 'Xu LD', 'Wang KY', 'Nan XP', 'Duan M', 'Zeng SY', 'Kong QZ', 'Wang H', 'Wu XQ', 'Zhang N', 'Li YQ', 'Zuo XL', 'Li YY']","['Humans', '*Helicobacter Infections/drug therapy', '*Tetracycline/therapeutic use/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Female', '*Bismuth/therapeutic use/adverse effects', '*Anti-Bacterial Agents/therapeutic use/administration & dosage/adverse effects', 'Adult', '*Drug Therapy, Combination', '*Helicobacter pylori/drug effects', 'Treatment Outcome', 'China', 'Amoxicillin/therapeutic use/administration & dosage', 'Drug Administration Schedule', 'Esomeprazole/therapeutic use/administration & dosage', 'Aged', 'Young Adult', 'Breath Tests', 'Proton Pump Inhibitors/therapeutic use/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39097924/
2679,omeprazole,25019289,Pharmacokinetic evaluation of esomeprazole for the treatment of gastroesophageal reflux disease.,"['Goirand F', 'Le Ray I', 'Bardou M']","['Esomeprazole/adverse effects/*pharmacokinetics/therapeutic use', 'Esophagitis/drug therapy/pathology', 'Gastroesophageal Reflux/*drug therapy/epidemiology', 'Humans', 'Incidence', 'Proton Pump Inhibitors/adverse effects/*pharmacokinetics/therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/25019289/
2680,omeprazole,22122397,Hypomagnesaemia/hypokalemia associated with the use of esomeprazole.,"['Negri AL', 'Valle EE']","['Anti-Ulcer Agents/adverse effects/therapeutic use', 'Esomeprazole/*adverse effects/therapeutic use', 'Humans', 'Hypokalemia/*chemically induced', 'Magnesium/*blood/metabolism', 'Magnesium Deficiency/chemically induced', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/22122397/
2681,omeprazole,12120118,Esomeprazole magnesium (Nexium).,['Baker DE'],"['Anti-Ulcer Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Esomeprazole', 'Esophagitis/drug therapy', 'Gastroesophageal Reflux/drug therapy', 'Helicobacter Infections/drug therapy', 'Humans', 'Omeprazole/analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12120118/
2682,Erlotinib,28295308,"Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.","['Yang Z', 'Hackshaw A', 'Feng Q', 'Fu X', 'Zhang Y', 'Mao C', 'Tang J']","['Afatinib', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'Diarrhea/chemically induced', 'Disease-Free Survival', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/adverse effects/*therapeutic use', 'Exanthema/chemically induced', 'Gefitinib', 'Humans', 'Lung Neoplasms/*drug therapy/genetics', 'Mutation', 'Outcome Assessment, Health Care/methods/statistics & numerical data', 'Proportional Hazards Models', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Quinazolines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/28295308/
2683,Erlotinib,25979753,EGFR and NF-kappaB: partners in cancer.,"['Shostak K', 'Chariot A']","['Animals', 'Drug Resistance, Neoplasm', 'ErbB Receptors/*antagonists & inhibitors/*immunology', 'Erlotinib Hydrochloride/pharmacology/therapeutic use', 'Gefitinib', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Hyaluronoglucosaminidase', 'NF-kappa B/antagonists & inhibitors/*immunology', 'Neoplasms/*drug therapy/genetics/*immunology/pathology', 'Protein Kinase Inhibitors/pharmacology/*therapeutic use', 'Proteins/immunology', 'Quinazolines/pharmacology/therapeutic use', '*Signal Transduction/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25979753/
2684,Erlotinib,28268137,Synthesis and biological assay of erlotinib analogues and BSA-conjugated erlotinib analogue.,"['Boobalan R', 'Liu KK', 'Chao JI', 'Chen C']","['Animals', 'Antineoplastic Agents/chemical synthesis/*chemistry/*pharmacology', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology', 'Cattle', 'Cell Line, Tumor', 'Cell Survival/drug effects', 'Erlotinib Hydrochloride/*analogs & derivatives/chemical synthesis/*pharmacology', 'Humans', 'Lung/drug effects/pathology', 'Lung Neoplasms/*drug therapy/pathology', 'Models, Molecular', 'Serum Albumin, Bovine/chemical synthesis/*chemistry/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/28268137/
2685,Erlotinib,30418766,Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.,"['Luan Y', 'Li J', 'Bernatchez JA', 'Li R']","['Binding Sites', 'Catalytic Domain', 'Drug Design', 'Erlotinib Hydrochloride/chemistry/metabolism/therapeutic use', 'Histone Deacetylase Inhibitors/chemistry/metabolism/therapeutic use', 'Histone Deacetylases/*chemistry/metabolism', 'Humans', 'Neoplasms/drug therapy', 'Protein Kinase Inhibitors/*chemistry/metabolism/therapeutic use', 'Protein Kinases/*chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30418766/
2686,Erlotinib,34388377,"Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study.","['Zhou Q', 'Xu CR', 'Cheng Y', 'Liu YP', 'Chen GY', 'Cui JW', 'Yang N', 'Song Y', 'Li XL', 'Lu S', 'Zhou JY', 'Ma ZY', 'Yu SY', 'Huang C', 'Shu YQ', 'Wang Z', 'Yang JJ', 'Tu HY', 'Zhong WZ', 'Wu YL']","['Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Bevacizumab/*administration & dosage/adverse effects', 'Brain Neoplasms/*drug therapy/genetics/*secondary', 'Carcinoma, Non-Small-Cell Lung/*drug therapy/genetics', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Humans', 'Lung Neoplasms/*drug therapy/genetics', 'Male', 'Middle Aged', 'Mutation', 'Random Allocation', 'Survival Analysis', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34388377/
2687,Erlotinib,23535946,[Erlotinib-induced acneiform eruption].,"['Wahl RU', 'Megahed M']","['Acneiform Eruptions/*chemically induced/*drug therapy/pathology', 'Adenocarcinoma/complications/drug therapy', 'Aged', 'Anti-Bacterial Agents/administration & dosage', 'Anti-Inflammatory Agents/administration & dosage', 'Ciprofloxacin/*administration & dosage', 'Doxycycline/*administration & dosage', 'Drug Therapy, Combination/methods', 'Erlotinib Hydrochloride', 'Fluoroquinolones/*administration & dosage', 'Humans', 'Lung Neoplasms/complications/drug therapy', 'Male', 'Methylprednisolone/*administration & dosage', 'Quinazolines/*adverse effects/therapeutic use', 'Quinolizines/*administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23535946/
2688,Erlotinib,29174651,Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib.,['Efferth T'],"['Antineoplastic Combined Chemotherapy Protocols/*pharmacology', 'Artemisinins/administration & dosage/*pharmacology', 'Artesunate', 'ErbB Receptors/*antagonists & inhibitors/metabolism', 'Erlotinib Hydrochloride/administration & dosage/pharmacology', 'Humans', 'Molecular Targeted Therapy', 'Protein Kinase Inhibitors/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29174651/
2689,Erlotinib,38346461,The role of angiogenesis inhibitors associated with tyrosine kinase inhibitors in the first-line treatment for EGFR-mutated advanced lung cancer.,"['Motta-Guerrero R', 'Recondo G', 'Cardona A', 'Corrales L', 'Arnao V', 'Failoc-Rojas VE', 'Aliaga C']","['Humans', 'Angiogenesis', 'Angiogenesis Inhibitors/adverse effects/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/drug therapy/genetics', 'ErbB Receptors', 'Erlotinib Hydrochloride/adverse effects', '*Lung Neoplasms/drug therapy/genetics', 'Mutation', 'Protein Kinase Inhibitors/adverse effects/therapeutic use', 'Tyrosine Kinase Inhibitors']",https://pubmed.ncbi.nlm.nih.gov/38346461/
2690,Erlotinib,37863665,BPTF Drives Gastric Cancer Resistance to EGFR Inhibitor by Epigenetically Regulating the C-MYC/PLCG1/Perk Axis.,"['Li F', 'Yu J', 'Pan T', 'Feng H', 'Li J', 'Yu B', 'Fan Z', 'Sang Q', 'Chen M', 'Zang M', 'Hou J', 'Wu X', 'Yu Y', 'Li YY', 'Yan C', 'Zhu Z', 'Su L', 'Liu B']","['Humans', 'Erlotinib Hydrochloride/pharmacology/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/genetics', '*Lung Neoplasms/genetics', 'ErbB Receptors/genetics', '*Stomach Neoplasms/drug therapy/genetics', 'Drug Resistance, Neoplasm/genetics', 'Cell Line, Tumor', 'Phospholipase C gamma/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37863665/
2691,Erlotinib,26043220,Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.,"['Huang Z', 'Wu Y', 'Zhou X', 'Qian J', 'Zhu W', 'Shu Y', 'Liu P']","['Antibodies, Monoclonal/administration & dosage', 'Antibodies, Monoclonal, Humanized', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Bevacizumab/administration & dosage', 'Clinical Trials as Topic', 'Docetaxel', 'Erlotinib Hydrochloride/administration & dosage', 'Everolimus/administration & dosage', 'Gefitinib', 'Humans', 'Imatinib Mesylate/administration & dosage', 'Neoplasms/*drug therapy/pathology', 'Protein Kinase Inhibitors/*administration & dosage/adverse effects', 'Quinazolines/administration & dosage', 'Signal Transduction/drug effects', 'Sirolimus/administration & dosage/analogs & derivatives', 'TOR Serine-Threonine Kinases/*antagonists & inhibitors', 'Taxoids/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/26043220/
2692,Erlotinib,39048364,Successful Treatment with Ramucirumab Plus Erlotinib following Osimertinib-induced Interstitial Lung Disease.,"['Fujimoto S', 'Katsurada N', 'Hazama D', 'Yamamoto M', 'Nagano T', 'Tachihara M']","['Humans', '*Ramucirumab', 'Female', '*Acrylamides/administration & dosage/adverse effects/therapeutic use', '*Aniline Compounds/adverse effects/administration & dosage/therapeutic use', '*Erlotinib Hydrochloride/adverse effects/administration & dosage', '*Antibodies, Monoclonal, Humanized/adverse effects/administration & dosage/therapeutic use', '*Lung Diseases, Interstitial/chemically induced/drug therapy/diagnosis', 'Aged, 80 and over', '*Lung Neoplasms/drug therapy', 'ErbB Receptors/antagonists & inhibitors/genetics', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/administration & dosage/therapeutic use', 'Adenocarcinoma of Lung/drug therapy', 'Treatment Outcome', 'Antibodies, Monoclonal/adverse effects/administration & dosage/therapeutic use', 'Protein Kinase Inhibitors/adverse effects/administration & dosage', 'Mutation', 'Adenocarcinoma/drug therapy', 'Carcinoma, Non-Small-Cell Lung/drug therapy', 'Indoles', 'Pyrimidines']",https://pubmed.ncbi.nlm.nih.gov/39048364/
2693,Erlotinib,31985516,Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.,"['Abrams RA', 'Winter KA', 'Safran H', 'Goodman KA', 'Regine WF', 'Berger AC', 'Gillin MT', 'Philip PA', 'Lowy AM', 'Wu A', 'DiPetrillo TA', 'Corn BW', 'Seaward SA', 'Haddock MG', 'Song S', 'Jiang Y', 'Fisher BJ', 'Katz AW', 'Mehta S', 'Willett CG', 'Crane CH']","['Adenocarcinoma/*drug therapy/mortality', 'Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Combined Chemotherapy Protocols/*therapeutic use', 'Chemotherapy, Adjuvant/*methods/mortality', 'Deoxycytidine/administration & dosage/adverse effects/analogs & derivatives', 'Erlotinib Hydrochloride/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pancreatic Neoplasms/*drug therapy/mortality', 'Gemcitabine']",https://pubmed.ncbi.nlm.nih.gov/31985516/
2694,Erlotinib,31887927,Erlotinib-loaded carboxymethyl temarind gum semi-interpenetrating nanocomposites.,"['Bera H', 'Abbasi YF', 'Lee Ping L', 'Marbaniang D', 'Mazumder B', 'Kumar P', 'Tambe P', 'Gajbhiye V', 'Cun D', 'Yang M']","['A549 Cells', 'Drug Carriers/*chemistry/therapeutic use', 'Drug Liberation', 'Erlotinib Hydrochloride/*administration & dosage', 'Humans', 'Lung Neoplasms/drug therapy', 'Nanocomposites/*chemistry/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31887927/
2695,Erlotinib,37211067,A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.,"['Caban M', 'Koblmueller B', 'Groza D', 'Schueffl HH', 'Terenzi A', 'Tolios A', 'Mohr T', 'Mathuber M', 'Kryeziu K', 'Jaunecker C', 'Pirker C', 'Keppler BK', 'Berger W', 'Kowol CR', 'Heffeter P']","['Humans', '*Prodrugs/pharmacology/therapeutic use', 'ErbB Receptors/metabolism', 'Protein Kinase Inhibitors/therapeutic use', 'Erlotinib Hydrochloride/pharmacology', '*Lung Neoplasms/metabolism', 'Cell Proliferation', 'Hypoxia/metabolism', 'Cell Line, Tumor', '*Antineoplastic Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37211067/
2696,Erlotinib,33686255,Extracellular vesicle drug occupancy enables real-time monitoring of targeted cancer therapy.,"['Pan S', 'Zhang Y', 'Natalia A', 'Lim CZJ', 'Ho NRY', 'Chowbay B', 'Loh TP', 'Tam JKC', 'Shao H']","['Antineoplastic Agents/pharmacokinetics/*pharmacology', 'Biomarkers, Tumor/blood', 'Biosensing Techniques/instrumentation/methods', 'Case-Control Studies', 'Cell Line, Tumor', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/blood/therapeutic use', 'Extracellular Vesicles/chemistry/*drug effects', 'Feasibility Studies', 'Humans', 'Lung Neoplasms/blood/*drug therapy', 'Molecular Targeted Therapy/*methods', 'Signal-To-Noise Ratio']",https://pubmed.ncbi.nlm.nih.gov/33686255/
2697,Erlotinib,38183413,Self-Assembly of Erlotinib-Platinum(II) Complexes for Epidermal Growth Factor Receptor-Targeted Photodynamic Therapy.,"['Wang H', 'Lai Y', 'Li D', 'Karges J', 'Zhang P', 'Huang H']","['Humans', 'Erlotinib Hydrochloride/pharmacology/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/drug therapy', 'Platinum/pharmacology', '*Antineoplastic Agents/pharmacology/therapeutic use', '*Lung Neoplasms/pathology', 'ErbB Receptors/metabolism', 'Mutation', '*Photochemotherapy', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'Drug Resistance, Neoplasm', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/38183413/
2698,Erlotinib,37837329,First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation.,"['Ishibashi N', 'Tabata T', 'Nonomura R', 'Oshima Y', 'Sasaki T', 'Mitomo H', 'Sugawara T', 'Sagawa M']","['Aged', 'Female', 'Humans', '*Carcinoma, Non-Small-Cell Lung/pathology', 'ErbB Receptors/genetics', 'Erlotinib Hydrochloride/pharmacology/therapeutic use', 'Lung/pathology', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Mutation', 'Protein Kinase Inhibitors/therapeutic use', 'Ramucirumab']",https://pubmed.ncbi.nlm.nih.gov/37837329/
2699,Erlotinib,31521491,Continued exposure of anti-cancer drugs to human iPS cell-derived cardiomyocytes can unmask their cardiotoxic effects.,"['Sakamoto K', 'Sakatoku K', 'Sugimoto S', 'Iwasaki N', 'Sano Y', 'Yamaguchi M', 'Kurokawa J']","['Antineoplastic Agents/*adverse effects/*pharmacology', 'Cardiotoxicity/*etiology', 'Cells, Cultured', 'Doxorubicin/adverse effects/pharmacology', 'Erlotinib Hydrochloride/adverse effects/pharmacology', 'Humans', 'Induced Pluripotent Stem Cells/*drug effects', 'Myocardial Contraction/drug effects', 'Myocytes, Cardiac/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/31521491/
2700,Erlotinib,30025479,Role of osteopontin as a predictive biomarker for anti-EGFR therapy in triple-negative breast cancer.,"['Anborgh PH', 'Lee DJ', 'Stam PF', 'Tuck AB', 'Chambers AF']","['Antineoplastic Agents/administration & dosage/pharmacology', 'Biomarkers, Tumor/metabolism', 'Cell Line, Tumor', 'ErbB Receptors/antagonists & inhibitors', 'Erlotinib Hydrochloride/*administration & dosage/pharmacology', 'Female', 'Humans', 'Molecular Targeted Therapy', 'Osteopontin/*metabolism', 'Phosphorylation/drug effects', 'Protein Kinase Inhibitors/administration & dosage/pharmacology', 'Signal Transduction/drug effects', 'Triple Negative Breast Neoplasms/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/30025479/
2701,Erlotinib,39434878,"Erlotinib regulates short-term memory, tau/Abeta pathology, and astrogliosis in mouse models of AD.","['Lee HJ', 'Hwang JW', 'Kim J', 'Jo AR', 'Park JH', 'Jeong YJ', 'Jang JY', 'Kim SJ', 'Song JH', 'Hoe HS']","['Animals', 'Humans', 'Male', 'Mice', '*Alzheimer Disease/drug therapy/metabolism/pathology', 'Amyloid beta-Peptides/metabolism', 'Astrocytes/metabolism/drug effects', 'Disease Models, Animal', '*Erlotinib Hydrochloride/pharmacology/therapeutic use', '*Gliosis/drug therapy', '*Memory, Short-Term/drug effects', 'Mice, Transgenic', 'Protein Kinase Inhibitors/pharmacology/therapeutic use', 'tau Proteins/metabolism']",https://pubmed.ncbi.nlm.nih.gov/39434878/
2702,prochlorperazine,32142680,Endocytosis Inhibition in Humans to Improve Responses to ADCC-Mediating Antibodies.,"['Chew HY', 'De Lima PO', 'Gonzalez Cruz JL', 'Banushi B', 'Echejoh G', 'Hu L', 'Joseph SR', 'Lum B', 'Rae J', ""O'Donnell JS"", 'Merida de Long L', 'Okano S', 'King B', 'Barry R', 'Moi D', 'Mazzieri R', 'Thomas R', 'Souza-Fonseca-Guimaraes F', 'Foote M', 'McCluskey A', 'Robinson PJ', 'Frazer IH', 'Saunders NA', 'Parton RG', 'Dolcetti R', 'Cuff K', 'Martin JH', 'Panizza B', 'Walpole E', 'Wells JW', 'Simpson F']","['Animals', 'Antibodies, Monoclonal/pharmacology', 'Antibodies, Monoclonal, Humanized/pharmacology', 'Antibody-Dependent Cell Cytotoxicity/*drug effects/immunology', 'Antigen Presentation/drug effects', 'Biopsy', 'Cetuximab/pharmacology', 'Drug Delivery Systems/methods', 'Drug Resistance, Neoplasm/genetics/*immunology', 'Endocytosis/drug effects/immunology', 'Heterografts', 'Humans', 'Immunoglobulin G/genetics/immunology', 'Killer Cells, Natural/drug effects/immunology', 'MCF-7 Cells', 'Membrane Proteins/genetics/immunology', 'Mice', 'Neoplasms/*drug therapy/genetics/immunology', 'Prochlorperazine/*pharmacology', 'Signal Transduction/drug effects/immunology', 'Trastuzumab/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/32142680/
2703,prochlorperazine,25877672,Acute Migraine Treatment in Adults.,['Becker WJ'],"['Adult', 'Analgesics, Opioid/administration & dosage', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage', 'Caffeine/administration & dosage', 'Dihydroergotamine/administration & dosage', 'Drug Administration Schedule', 'Female', 'Humans', 'Male', 'Migraine Disorders/*diagnosis/*drug therapy', 'Pain Management/*methods', 'Serotonin Receptor Agonists/administration & dosage', 'Treatment Outcome', 'Tryptamines/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/25877672/
2704,prochlorperazine,25600718,The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies.,"['Marmura MJ', 'Silberstein SD', 'Schwedt TJ']","['Adult', 'Anti-Inflammatory Agents/*therapeutic use', 'Humans', 'Migraine Disorders/*drug therapy', 'Serotonin Receptor Agonists/*therapeutic use', 'Societies, Medical/standards/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/25600718/
2705,prochlorperazine,12463273,Anti-emetics.,['MacGregor EA'],"['Antiemetics/*therapeutic use', 'Domperidone/therapeutic use', 'Dopamine Antagonists/*therapeutic use', 'Humans', 'Metoclopramide/therapeutic use', 'Migraine Disorders/*complications/physiopathology', 'Nausea/*drug therapy/etiology', 'Prochlorperazine/therapeutic use', 'Vomiting/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/12463273/
2706,prochlorperazine,3428161,Spironolactone-induced agranulocytosis.,"['Jivraj KT', 'Noseworthy TW', 'Friesen EG', 'Shustack AS', 'Konopad EM', 'Johnston RG']","['Agranulocytosis/blood/*chemically induced', 'Humans', 'Leukocyte Count/drug effects', 'Male', 'Middle Aged', 'Spironolactone/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3428161/
2707,prochlorperazine,22488022,Evolving treatment paradigms for chemotherapy-induced nausea and vomiting.,['Wickham R'],"['Antiemetics/*therapeutic use', 'Antineoplastic Agents/*adverse effects', 'Humans', 'Metoclopramide/*therapeutic use', 'Nausea/*chemically induced/*drug therapy', 'Prochlorperazine/*therapeutic use', 'Vomiting/*chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/22488022/
2708,prochlorperazine,3392386,Prochlorperazine-induced chronic cholestasis.,"['Lok AS', 'Ng IO']","['Aged', 'Alanine Transaminase/blood', 'Alkaline Phosphatase/blood', 'Bilirubin/blood', 'Biopsy', 'Cholestasis/*chemically induced/pathology', 'Cholesterol/blood', 'Humans', 'Liver/pathology', 'Male', 'Prochlorperazine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3392386/
2709,prochlorperazine,30189270,Orally inhaled migraine therapy: Where are we now?,['Stapleton KW'],"['Administration, Inhalation', 'Administration, Oral', 'Humans', 'Migraine Disorders/*drug therapy', 'Peptides/administration & dosage/*therapeutic use', '*Respiratory Therapy']",https://pubmed.ncbi.nlm.nih.gov/30189270/
2710,prochlorperazine,532925,Pseudotetanus.,['Stoddart JC'],"['Adolescent', 'Adult', 'Child', 'Diagnosis, Differential', 'Drug Hypersensitivity/diagnosis', 'Female', 'Humans', 'Male', 'Meningitis, Viral/diagnosis', 'Metoclopramide/adverse effects', 'Middle Aged', 'Muscle Hypertonia/*diagnosis', 'Prochlorperazine/adverse effects', 'Tetanus/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/532925/
2711,prochlorperazine,1666930,Recent clinical experience with dronabinol.,"['Plasse TF', 'Gorter RW', 'Krasnow SH', 'Lane M', 'Shepard KV', 'Wadleigh RG']","['Antineoplastic Agents/*adverse effects', 'Appetite/drug effects', 'Dronabinol/*therapeutic use', 'HIV Infections/complications/psychology', 'Humans', 'Vomiting/chemically induced/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1666930/
2712,prochlorperazine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
2713,prochlorperazine,38409683,Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis.,"['Ismail S', 'Funk MJ', 'Flythe JE']","['Humans', '*Renal Dialysis/adverse effects', '*Death, Sudden, Cardiac/etiology', '*Ondansetron/therapeutic use/adverse effects', 'Male', 'Female', 'Middle Aged', 'Kidney Failure, Chronic/therapy/complications/mortality', 'Antiemetics/adverse effects/therapeutic use', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38409683/
2714,prochlorperazine,7014918,Compazine complications: a review.,"['Baker FM', 'Cook P']","['Adolescent', 'Adult', 'Antiemetics/*adverse effects', 'Basal Ganglia Diseases/chemically induced', 'Dyskinesia, Drug-Induced/etiology', 'Dystonia/chemically induced', 'Female', 'Humans', 'Male', 'Parkinson Disease, Secondary/chemically induced', 'Prochlorperazine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7014918/
2715,prochlorperazine,12486841,Medical management of Meniere's disease.,['Sajjadi H'],"['Adrenal Cortex Hormones/administration & dosage/therapeutic use', 'Amitriptyline/administration & dosage/therapeutic use', 'Antidepressive Agents, Tricyclic/administration & dosage/therapeutic use', 'Antiemetics/administration & dosage/therapeutic use', 'Azathioprine/therapeutic use', 'Depression/drug therapy/etiology', 'Diet', 'Diuretics/therapeutic use', 'Glycopyrrolate/administration & dosage/therapeutic use', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Immunotherapy', 'Life Style', 'Meniere Disease/diagnosis/drug therapy/immunology/psychology/rehabilitation/*therapy', 'Muscarinic Antagonists/administration & dosage/therapeutic use', 'Physical Therapy Modalities', 'Prochlorperazine/administration & dosage/therapeutic use', 'Scopolamine/administration & dosage/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/12486841/
2716,prochlorperazine,30059368,Emergency Department Use of Intravenous Prochlorperazine for Acute Migraine.,"['Cook C', 'Newberry B']","['Acute Disease', 'Administration, Intravenous', 'Adult', 'Analgesics, Opioid/administration & dosage/*therapeutic use', 'Diphenhydramine/administration & dosage/*therapeutic use', 'Dopamine Antagonists/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Emergency Service, Hospital', 'Female', 'Humans', 'Hydromorphone/administration & dosage/*therapeutic use', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Male', 'Migraine Disorders/*drug therapy', 'Pain Measurement', 'Prochlorperazine/administration & dosage/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30059368/
2717,prochlorperazine,32358422,Ketamine for Migraine in the Emergency Department.,"['Bilhimer MH', 'Groth ME', 'Holmes AK']","['Analgesics/*administration & dosage', '*Emergency Service, Hospital', 'Humans', 'Ketamine/*administration & dosage', 'Migraine Disorders/*drug therapy', 'Pain Management', 'Pain Measurement']",https://pubmed.ncbi.nlm.nih.gov/32358422/
2718,prochlorperazine,9058397,Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.,['Mathew NT'],"['Acute Disease', 'Analgesics, Non-Narcotic/therapeutic use', 'Cluster Headache/drug therapy', 'Dihydroergotamine/therapeutic use', 'Drug Interactions', 'Humans', 'Migraine Disorders/complications/*drug therapy/etiology', 'Recurrence', 'Serotonin Receptor Agonists/adverse effects/*therapeutic use', 'Sumatriptan/adverse effects/therapeutic use', 'Treatment Outcome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9058397/
2719,prochlorperazine,8879888,Comparative efficacy of oral and intravenous granisetron for the prevention of acute chemotherapy-induced emesis.,['Perez EA'],"['Administration, Oral', 'Antineoplastic Agents/adverse effects', 'Dexamethasone/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Granisetron/*administration & dosage/therapeutic use', 'Humans', 'Injections, Intravenous', 'Metoclopramide/administration & dosage/therapeutic use', 'Nausea/chemically induced/prevention & control', 'Ondansetron/therapeutic use', 'Serotonin Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8879888/
2720,prochlorperazine,20021339,Neuroleptics and migraine.,"['Dusitanond P', 'Young WB']","['Antipsychotic Agents/adverse effects', 'Benzodiazepines/pharmacology', 'Brain/drug effects', 'Caffeine/pharmacology', 'Dibenzothiazepines/pharmacology', 'Dopamine', 'Dopamine Antagonists/*adverse effects', '*Dopamine D2 Receptor Antagonists', 'Drug Interactions', 'Female', 'Humans', 'Hyperprolactinemia/chemically induced', 'Indomethacin/pharmacology', 'Male', 'Migraine Disorders', 'Neural Pathways/drug effects', 'Olanzapine', 'Prochlorperazine/pharmacology', 'Quetiapine Fumarate', 'Randomized Controlled Trials as Topic', '*Serotonin 5-HT2 Receptor Antagonists', 'Serotonin Receptor Agonists/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20021339/
2721,prochlorperazine,18451718,Acute migraine therapy: recent evidence from randomized comparative trials.,"['Mett A', 'Tfelt-Hansen P']","['Acute Disease', 'Analgesics/classification/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Antiemetics/therapeutic use', 'Caffeine/therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Drug Therapy, Combination', 'Ergotamine/therapeutic use', 'Humans', 'Indomethacin/therapeutic use', 'Migraine Disorders/*therapy', 'Prochlorperazine/therapeutic use', 'Randomized Controlled Trials as Topic', 'Serotonin Receptor Agonists/classification/*therapeutic use', 'Treatment Outcome', 'Tryptamines/classification/therapeutic use', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18451718/
2722,etodolac,35453005,"Non-steroidal anti-inflammatory drugs (NSAIDs), pain and aging: Adjusting prescription to patient features.","['Ribeiro H', 'Rodrigues I', 'Napoleao L', 'Lira L', 'Marques D', 'Verissimo M', 'Andrade JP', 'Dourado M']","['Aged', 'Aging', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', '*Cyclooxygenase 2 Inhibitors/therapeutic use', '*Diclofenac/therapeutic use', 'Etoricoxib', 'Humans', 'Pain/drug therapy', 'Prescriptions']",https://pubmed.ncbi.nlm.nih.gov/35453005/
2723,etodolac,22381180,Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats.,"['Khan SA', 'McLean MK']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/*antagonists & inhibitors/metabolism/*poisoning', 'Cat Diseases/chemically induced/diagnosis/therapy', 'Cats', 'Dog Diseases/chemically induced/diagnosis/*therapy', 'Dogs', 'Incidence', 'Poison Control Centers/statistics & numerical data', 'Poisoning/diagnosis/therapy/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/22381180/
2724,etodolac,16868333,Poststreptococcal reactive arthritis.,"['Logan D', 'McKee PJ']","['Acute Disease', 'Adrenal Cortex Hormones/*therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use', 'Arthritis, Reactive/diagnosis/drug therapy/*etiology', 'Etodolac/*therapeutic use', 'Humans', 'Lower Extremity', 'Male', 'Middle Aged', 'Penicillin V/therapeutic use', 'Streptococcal Infections/*complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16868333/
2725,etodolac,32286125,Nonsteroidal Anti-Inflammatory Drugs and Opioids in Postsurgical Dental Pain.,"['Hersh EV', 'Moore PA', 'Grosser T', 'Polomano RC', 'Farrar JT', 'Saraghi M', 'Juska SA', 'Mitchell CH', 'Theken KN']","['*Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/adverse effects', 'Diclofenac', 'Humans', 'Pain, Postoperative/*drug therapy', '*Pharmaceutical Preparations']",https://pubmed.ncbi.nlm.nih.gov/32286125/
2726,etodolac,35319403,Etodolac Enhances the Radiosensitivity of Irradiated HT-29 Human Colorectal Cancer Cells.,"['Shaghaghi Z', 'Polgardani NZ', 'Abbasi S', 'Albooyeh H', 'Dastranj L', 'Farzipour S', 'Alvandi M']","['Apoptosis/radiation effects', 'Cell Line, Tumor', '*Colorectal Neoplasms/drug therapy/metabolism/radiotherapy', 'Etodolac/pharmacology/therapeutic use', 'HT29 Cells', 'Humans', 'Radiation Tolerance/radiation effects', '*Radiation-Sensitizing Agents/pharmacology', 'Radiopharmaceuticals/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35319403/
2727,etodolac,2525273,NSAIDs: new approaches to limiting gastropathy.,"['Zeidler H', 'Munzel P']","['Adenosine Triphosphatases/antagonists & inhibitors', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/therapeutic use', 'Campylobacter Infections/complications/drug therapy', 'Chemistry, Pharmaceutical', 'Drug Therapy, Combination', 'Humans', 'Pepsinogens/blood', 'Prostaglandins/therapeutic use', 'Risk Factors', 'Stomach Diseases/chemically induced/complications/*prevention & control', 'Sucralfate/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2525273/
2728,etodolac,25563511,"Recent advances bioactive 1,2,4-triazole-3-thiones.","['Kucukguzel SG', 'Cikla-Suzgun P']","['Animals', 'Drug Discovery/*methods', 'Humans', 'Thiones/*chemistry/*pharmacology', 'Triazoles/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/25563511/
2729,etodolac,2525986,A global safety evaluation of etodolac.,['Karbowski A'],"['Adolescent', 'Adult', 'Aged', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Arthritis, Rheumatoid/*drug therapy', 'Clinical Trials as Topic', 'Diclofenac/adverse effects', 'Double-Blind Method', 'Etodolac', 'Female', 'Humans', 'Indoleacetic Acids/*adverse effects', 'Male', 'Middle Aged', 'Naproxen/adverse effects', 'Osteoarthritis/*drug therapy', 'Piroxicam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2525986/
2730,etodolac,8403735,Protein binding and stereoselectivity of nonsteroidal anti-inflammatory drugs.,"['Lapicque F', 'Muller N', 'Payan E', 'Dubois N', 'Netter P']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/blood/*pharmacokinetics/pharmacology', 'Blood Proteins/metabolism', 'Humans', 'Protein Binding', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/8403735/
2731,etodolac,19602986,Variability in the response to cyclooxygenase inhibitors: toward the individualization of nonsteroidal anti-inflammatory drug therapy.,['Grosser T'],"['Cardiovascular Diseases/*chemically induced', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Humans', 'Risk Assessment', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19602986/
2732,etodolac,9831331,Cyclooxygenase selectivity and the risk of gastro-intestinal complications of various non-steroidal anti-inflammatory drugs: a clinical consideration.,['Kawai S'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Arthritis, Rheumatoid/drug therapy/enzymology', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Isoenzymes/metabolism', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/9831331/
2733,etodolac,2937024,A review of selected investigational nonsteroidal antiinflammatory drugs of the 1980s.,"['Marsh CC', 'Schuna AA', 'Sundstrom WR']","['Acetates/administration & dosage/adverse effects/metabolism/therapeutic use', 'Anti-Inflammatory Agents/metabolism/*pharmacology/therapeutic use', 'Diclofenac/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Drug Interactions', 'Etodolac', 'Flurbiprofen/administration & dosage/adverse effects/metabolism/therapeutic use', 'Humans', 'Kinetics', 'Phenylacetates/administration & dosage/adverse effects/metabolism/therapeutic use', '*Phenylbutyrates', 'Propionates/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Quinazolines/administration & dosage/adverse effects/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2937024/
2734,etodolac,34872472,A Comprehensive Review on Pyranoindole-containing Agents.,"['Catalano A', 'Iacopetta D', 'Ceramella J', 'Saturnino C', 'Sinicropi MS']","['Anti-Inflammatory Agents/pharmacology/therapeutic use', '*Biological Products/chemistry/pharmacology', 'Etodolac', '*Heterocyclic Compounds', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/34872472/
2735,etodolac,8013160,Etodolac clinical pharmacokinetics.,"['Brocks DR', 'Jamali F']","['Aging/*metabolism', 'Animals', 'Drug Interactions', 'Etodolac/chemistry/*pharmacokinetics/therapeutic use', 'Humans', 'Intestinal Absorption', 'Kidney Diseases/metabolism', 'Liver Cirrhosis/metabolism', 'Osteoarthritis/drug therapy/metabolism', 'Postoperative Period', 'Protein Binding', 'Stereoisomerism', 'Synovial Fluid/metabolism', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/8013160/
2736,etodolac,31726891,Systemic drugs with impact on osteoarthritis.,"['Apostu D', 'Lucaciu O', 'Mester A', 'Oltean-Dan D', 'Baciut M', 'Baciut G', 'Bran S', 'Onisor F', 'Piciu A', 'Pasca RD', 'Maxim A', 'Benea H']","['Acetaminophen/therapeutic use', 'Analgesics, Non-Narcotic/therapeutic use', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Capsaicin/therapeutic use', 'Cartilage, Articular/drug effects/metabolism/pathology', 'Cyclooxygenase 2 Inhibitors/therapeutic use', 'Dietary Supplements', 'Humans', 'Osteoarthritis/*drug therapy/metabolism/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/31726891/
2737,etodolac,10628589,"Distribution and expression of cyclooxygenase (COX) isoenzymes, their physiological roles, and the categorization of nonsteroidal anti-inflammatory drugs (NSAIDs).",['Wallace JL'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Celecoxib', 'Controlled Clinical Trials as Topic', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/*adverse effects', 'Etodolac/adverse effects', 'Gene Expression', 'Humans', 'Ibuprofen/adverse effects', 'Indomethacin/adverse effects', 'Isoenzymes/antagonists & inhibitors/metabolism/pharmacology', 'Meloxicam', 'Membrane Proteins', 'Naproxen/adverse effects', 'Nitrobenzenes/adverse effects', 'Prostaglandin-Endoperoxide Synthases/biosynthesis/*metabolism/pharmacology', 'Pyrazoles', 'Sulfonamides/adverse effects', 'Thiazines/adverse effects', 'Thiazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/10628589/
2738,etodolac,25676325,"Anti-cancer and anti-hepatitis C virus NS5B polymerase activity of etodolac 1,2,4-triazoles.","['Cikla-Suzgun P', 'Kaushik-Basu N', 'Basu A', 'Arora P', 'Talele TT', 'Durmaz I', 'Cetin-Atalay R', 'Kucukguzel SG']","['Antineoplastic Agents/chemical synthesis/chemistry/*pharmacology', 'Antiviral Agents/chemical synthesis/chemistry/*pharmacology', 'Cell Line, Tumor', 'Cell Proliferation/drug effects', 'Dose-Response Relationship, Drug', 'Drug Screening Assays, Antitumor', 'Enzyme Inhibitors/chemical synthesis/chemistry/*pharmacology', 'Etodolac/*analogs & derivatives/chemical synthesis/chemistry/pharmacology', 'Hepacivirus/*drug effects/enzymology', 'Humans', 'Molecular Structure', 'Structure-Activity Relationship', 'Triazoles/chemical synthesis/chemistry/*pharmacology', 'Viral Nonstructural Proteins/*antagonists & inhibitors/metabolism']",https://pubmed.ncbi.nlm.nih.gov/25676325/
2739,etodolac,32238633,[Vascular Remodeling Induced by Biological Stresses].,['Hasegawa H'],"['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/pharmacology', 'Blood Vessels/*immunology/*physiopathology', 'Humans', 'Mice', 'Prostaglandins/metabolism/physiology', 'Stress, Physiological/*immunology/physiology', 'Stress, Psychological/*immunology', 'T-Lymphocytes/immunology', 'Thymus Gland/*immunology/pathology', '*Vascular Remodeling/drug effects']",https://pubmed.ncbi.nlm.nih.gov/32238633/
2740,etodolac,33015819,Remdesivir-COVID-19: drug interactions in dentistry.,['Gomez-Moreno G'],"['Adenosine Monophosphate/adverse effects/*analogs & derivatives/therapeutic use', 'Alanine/adverse effects/*analogs & derivatives/therapeutic use', 'Antiviral Agents/adverse effects/therapeutic use', 'Betacoronavirus', 'COVID-19', '*Coronavirus Infections/drug therapy', '*Dentistry', '*Drug Interactions', 'Humans', '*Pandemics', '*Pneumonia, Viral/drug therapy', 'SARS-CoV-2']",https://pubmed.ncbi.nlm.nih.gov/33015819/
2741,ofloxacin,31350743,[Legionella and Legionellosis].,"['Kolditz M', 'Luck C']","['*Anti-Bacterial Agents/pharmacology/therapeutic use', 'Drug Resistance, Bacterial', 'Humans', 'Legionella/*drug effects', '*Legionellosis/diagnosis/drug therapy/microbiology', 'Levofloxacin/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31350743/
2742,ofloxacin,39019103,Ciprofloxacin versus levofloxacin prophylaxis in hematopoietic stem cell transplantation: A randomized trial.,"['Farhan S', 'Mazur I', 'Hartzell S', 'Xie P', 'Neme K', 'German A', 'Mikulandric N', 'Patel K', 'Wu M', 'Kortam N', 'Yaseen A', 'Sweidan A', 'Latack K', 'Emole J', 'Peres E', 'Abidi MH', 'Ramesh M']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', '*Antibiotic Prophylaxis/methods', 'Bacteremia/prevention & control/epidemiology', '*Ciprofloxacin/therapeutic use/administration & dosage', '*Hematopoietic Stem Cell Transplantation/adverse effects', '*Levofloxacin/therapeutic use/administration & dosage', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/39019103/
2743,ofloxacin,11249554,Levofloxacin.,['Norrby SR'],"['Animals', 'Anti-Infective Agents/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy/microbiology', 'Clinical Trials as Topic', 'Humans', '*Levofloxacin', 'Ofloxacin/adverse effects/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11249554/
2744,ofloxacin,33964616,Levofloxacin in veterinary medicine: a literature review.,"['Sitovs A', 'Sartini I', 'Giorgi M']","['Animals', 'Anti-Infective Agents/*therapeutic use', 'Humans', 'Levofloxacin/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33964616/
2745,ofloxacin,19702070,Levofloxacin-induced severe thrombocytopenia.,"['Polprasert C', 'Prayongratana K']","['Aged', 'Anti-Bacterial Agents/*adverse effects', 'Hemoptysis/*chemically induced', 'Humans', '*Levofloxacin', 'Male', 'Ofloxacin/*adverse effects', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19702070/
2746,ofloxacin,25629432,On two-sample McNemar test.,['Xiang JX'],"['Anti-Bacterial Agents/administration & dosage/therapeutic use', '*Clinical Trials as Topic/methods/statistics & numerical data', 'Computer Simulation', 'Cross-Over Studies', 'Data Interpretation, Statistical', 'Dose-Response Relationship, Drug', 'Fever/drug therapy', 'Humans', 'Levofloxacin/administration & dosage/therapeutic use', '*Matched-Pair Analysis', '*Models, Statistical', 'Research Design/*statistics & numerical data', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25629432/
2747,ofloxacin,32496110,Acute pancreatitis associated with levofloxacin.,"['Jimenez Moreno MA', 'Hontoria Bautista G', 'Pereda Garcia R']","['Acute Disease', 'Humans', '*Levofloxacin/adverse effects', '*Pancreatitis/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/32496110/
2748,ofloxacin,23176385,MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.,"['Azoicai D', 'Antoniu SA']","['Administration, Inhalation', 'Anti-Bacterial Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic', 'Drug Discovery', 'Drug Resistance, Bacterial/drug effects', 'Humans', '*Levofloxacin', 'Ofloxacin/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Pseudomonas Infections/*drug therapy/microbiology', 'Pseudomonas aeruginosa/*drug effects', 'Respiratory Tract Infections/*drug therapy/microbiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23176385/
2749,ofloxacin,20424532,[PK/PD profile and post-marketing surveillance of levofloxacin].,['Pea F'],"['Animals', 'Anti-Bacterial Agents/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Area Under Curve', 'Cohort Studies', 'Drug Resistance, Multiple, Bacterial', 'Drug Therapy, Combination', 'Female', 'Gram-Negative Bacterial Infections/drug therapy', 'Humans', 'Kidney/physiopathology', '*Levofloxacin', 'Male', 'Metabolic Clearance Rate', 'Microbial Sensitivity Tests', 'Ofloxacin/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Product Surveillance, Postmarketing', 'Respiratory Tract Infections/drug therapy', 'Spondylitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20424532/
2750,ofloxacin,30713304,Levofloxacin-associated Encephalopathy with Severe Hyperventilation.,"['Sugiura M', 'Shibata K', 'Saito S', 'Nishimura Y', 'Sakura H']","['Anti-Infective Agents, Urinary/*adverse effects/*therapeutic use', 'Brain Diseases/*chemically induced', 'Cystitis/*drug therapy', 'Female', 'Humans', 'Hyperventilation/*chemically induced', 'Levofloxacin/*adverse effects/*therapeutic use', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30713304/
2751,ofloxacin,37154772,In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.,"['Shah S', 'Clarke LG', 'Adams KK']","['Humans', 'Fluoroquinolones/adverse effects', 'Moxifloxacin/adverse effects', 'Levofloxacin/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Ciprofloxacin', '*Hypersensitivity/drug therapy', '*Quinolines/adverse effects', '*Aza Compounds', 'Ofloxacin']",https://pubmed.ncbi.nlm.nih.gov/37154772/
2752,ofloxacin,26238129,DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test.,"['Charfi O', 'Lakhoua G', 'Sahnoun R', 'Badri T', 'Daghfous R', 'El Aidli S', 'Kastalli S', 'Zaiem A']","['Acetaminophen/therapeutic use', 'Adult', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Drug Hypersensitivity Syndrome/diagnosis/*etiology', 'Drug Therapy, Combination', 'Epstein-Barr Virus Infections/drug therapy', 'Fluoroquinolones/adverse effects', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Liver Function Tests', 'Male', 'Metronidazole/administration & dosage/therapeutic use', '*Patch Tests', 'Phenols/therapeutic use', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26238129/
2753,ofloxacin,11130225,Anaphylactoid reaction to levofloxacin.,"['Smythe MA', 'Cappelletty DM']","['Anaphylaxis/*chemically induced', 'Anti-Infective Agents/*adverse effects/therapeutic use', 'Drug Hypersensitivity/*etiology', 'Female', 'Humans', '*Levofloxacin', 'Middle Aged', 'Ofloxacin/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11130225/
2754,ofloxacin,19534690,Efficacy of fluoroquinolones against pathogenic oral bacteria.,"['Nunez Otero V', 'Limeres Posse J', 'Carmona IT', 'Diz Dios P']","['Aza Compounds/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Bacteria/drug effects', 'Bacterial Infections/*drug therapy', 'Ciprofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Fluoroquinolones/chemistry/pharmacokinetics/pharmacology/*therapeutic use', 'Humans', '*Levofloxacin', 'Mouth Diseases/*drug therapy', 'Moxifloxacin', 'Ofloxacin/chemistry/pharmacokinetics/pharmacology/*therapeutic use', '*Oral Medicine', 'Quinolines/chemistry/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19534690/
2755,ofloxacin,24550337,Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children.,"['Thee S', 'Garcia-Prats AJ', 'McIlleron HM', 'Wiesner L', 'Castel S', 'Norman J', 'Draper HR', 'van der Merwe PL', 'Hesseling AC', 'Schaaf HS']","['Adolescent', 'Antitubercular Agents/*pharmacokinetics/*therapeutic use', 'Child', 'Child, Preschool', 'Female', 'Humans', 'Infant', 'Levofloxacin/*pharmacokinetics/*therapeutic use', 'Male', 'Ofloxacin/*pharmacokinetics/*therapeutic use', 'Prospective Studies', 'Tuberculosis, Multidrug-Resistant/blood/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24550337/
2756,ofloxacin,31636067,DAV131A Protects Hamsters from Lethal Clostridioides difficile Infection Induced by Fluoroquinolones.,"['Saint-Lu N', 'Burdet C', 'Sablier-Gallis F', 'Corbel T', 'Neviere A', 'Sayah-Jeanne S', 'Pulse M', 'Weiss W', 'Ferreira S', 'Andremont A', 'Mentre F', 'de Gunzburg J']","['Administration, Oral', 'Adsorption', 'Animals', 'Anti-Bacterial Agents/adverse effects/pharmacokinetics', 'Charcoal/*administration & dosage', 'Ciprofloxacin/adverse effects/pharmacokinetics', '*Clostridioides difficile/pathogenicity', 'Clostridium Infections/*prevention & control', 'Disease Models, Animal', 'Dysbiosis/chemically induced/metabolism/prevention & control', 'Fluoroquinolones/adverse effects/pharmacokinetics', 'Gastrointestinal Microbiome/drug effects', 'Levofloxacin/adverse effects/pharmacokinetics', 'Male', 'Mesocricetus']",https://pubmed.ncbi.nlm.nih.gov/31636067/
2757,ofloxacin,38848797,Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment.,"['Paul PK', 'Nakpheng T', 'Paliwal H', 'Prem Ananth K', 'Srichana T']","['*Levofloxacin/administration & dosage/chemistry/pharmacology', '*Nanoparticles/chemistry', 'Administration, Inhalation', 'Humans', '*Dry Powder Inhalers', '*Antitubercular Agents/administration & dosage/chemistry/pharmacology/pharmacokinetics', '*Tuberculosis/drug therapy', '*Particle Size', 'Lipids/chemistry', 'Mycobacterium bovis/drug effects', 'Cell Line', 'Aerosols', 'A549 Cells', 'Animals', 'Spray Drying', 'Microbial Sensitivity Tests', 'Drug Carriers/chemistry', 'Polyethylene Glycols/chemistry', 'Anti-Bacterial Agents/administration & dosage/chemistry/pharmacology', 'Liposomes']",https://pubmed.ncbi.nlm.nih.gov/38848797/
2758,ofloxacin,27557756,Levofloxacin-induced rhabdomyolysis: a case report.,"['John F', 'Oluronbi R', 'Pitchumoni CS']","['Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Creatine Kinase/blood/metabolism', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Muscle Fatigue', 'Respiratory Tract Infections/drug therapy', 'Rhabdomyolysis/*chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27557756/
2759,ofloxacin,16669931,Levofloxacin in the treatment of ventilator-associated pneumonia.,"['Alvarez-Lerma F', 'Grau S', 'Alvarez-Beltran M']","['Anti-Infective Agents/pharmacokinetics/*therapeutic use', 'Cross Infection/*drug therapy/microbiology', 'Gram-Negative Bacterial Infections/drug therapy/etiology', 'Humans', '*Levofloxacin', 'Ofloxacin/pharmacokinetics/*therapeutic use', 'Pneumonia, Bacterial/*drug therapy/etiology', 'Respiration, Artificial/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16669931/
2760,Fosamprenavir,19061617,Doxorubicin-induced hyperpigmentation.,"['Abbasi NR', 'Wang N']","['Acquired Immunodeficiency Syndrome/complications', 'Adult', 'Anti-HIV Agents/therapeutic use', 'Antineoplastic Agents/*adverse effects/therapeutic use', 'Antiretroviral Therapy, Highly Active', 'Carbamates/therapeutic use', 'Doxorubicin/*adverse effects/therapeutic use', 'Drug Combinations', 'Furans', 'Humans', 'Lamivudine/therapeutic use', 'Lip Diseases/*chemically induced', 'Male', 'Melanosis/*chemically induced', 'Nails, Malformed/*chemically induced', 'Organophosphates/therapeutic use', 'Ritonavir/therapeutic use', 'Sarcoma, Kaposi/complications/*drug therapy', 'Sulfonamides/therapeutic use', 'Tongue Diseases/*chemically induced', 'Zidovudine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19061617/
2761,Fosamprenavir,23344266,Review of drug interactions with telaprevir and antiretrovirals.,"['van Heeswijk RP', 'Beumont M', 'Kauffman RS', 'Garg V']","['Adult', 'Antiviral Agents/*therapeutic use', 'Coinfection', 'Drug Interactions', 'Drug Therapy, Combination', 'HIV Infections/drug therapy/virology', 'Hepacivirus/drug effects', 'Hepatitis C, Chronic/*drug therapy/virology', 'Humans', 'Male', 'Oligopeptides/*therapeutic use', 'Protease Inhibitors/*therapeutic use', 'Reverse Transcriptase Inhibitors/*therapeutic use', 'Ritonavir/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23344266/
2762,Fosamprenavir,20116625,[Etravirine drug interactions].,"['Perez VE', 'Sanchez-Parra C', 'Serrano Villar S']","['Analgesics/pharmacology', 'Anesthetics/pharmacology', 'Anti-HIV Agents/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Anti-Infective Agents/pharmacology', 'Anticonvulsants/pharmacology', 'Antiretroviral Therapy, Highly Active', 'Aryl Hydrocarbon Hydroxylases/*antagonists & inhibitors', 'Biotransformation/*drug effects', 'Contraceptives, Oral, Hormonal/pharmacology', 'Contraindications', 'Cytochrome P-450 CYP2C19', 'Cytochrome P-450 CYP2C9', 'Cytochrome P-450 CYP3A/*biosynthesis/genetics', 'Drug Interactions', 'Drug Therapy, Combination', 'Enzyme Induction/drug effects', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/administration & dosage/pharmacokinetics/pharmacology', 'HIV Reverse Transcriptase/*antagonists & inhibitors', 'HIV-1/drug effects', 'Humans', 'Microsomes, Liver/*drug effects/enzymology', 'Nitriles', 'Piperazines/administration & dosage/pharmacology', 'Purines/administration & dosage/pharmacology', 'Pyridazines/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Pyrimidines', 'Reverse Transcriptase Inhibitors/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Sildenafil Citrate', 'Sulfones/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/20116625/
2763,Fosamprenavir,15934866,Emerging anti-HIV drugs.,['De Clercq E'],"['Animals', 'Anti-HIV Agents/chemistry/pharmacology/*therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Drug Industry/*trends', 'Drug Therapy, Combination', 'Drugs, Investigational/chemistry/pharmacology/*therapeutic use', 'HIV Infections/*drug therapy/metabolism', 'HIV-1/*drug effects/metabolism', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/15934866/
2764,Fosamprenavir,22362299,Protease inhibitor monotherapy: what is its role?,"['Estebanez M', 'Arribas JR']","['Adipose Tissue/drug effects', 'Bone Density/drug effects', 'Carbamates/therapeutic use', 'Drug Combinations', 'Drug Resistance, Viral/drug effects', 'Furans', 'HIV Infections/*drug therapy/virology', 'Humans', 'Lopinavir/therapeutic use', 'Organophosphates/therapeutic use', 'Protease Inhibitors/adverse effects/*therapeutic use', 'Ritonavir/therapeutic use', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22362299/
2765,Fosamprenavir,19275497,"Etravirine, a next-generation nonnucleoside reverse-transcriptase inhibitor.","['Johnson LB', 'Saravolatz LD']","['*Anti-HIV Agents/administration & dosage/adverse effects/pharmacology', 'Clinical Trials as Topic', 'Drug Interactions', 'HIV Infections/*drug therapy', 'Humans', 'Nitriles', '*Pyridazines/administration & dosage/adverse effects/pharmacology', 'Pyrimidines', '*Reverse Transcriptase Inhibitors/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19275497/
2766,Fosamprenavir,15193140,Peptidomimetic inhibitors of HIV protease.,"['Randolph JT', 'DeGoey DA']","['Anti-HIV Agents/chemistry/pharmacology/*therapeutic use', 'Atazanavir Sulfate', 'Carbamates', 'Clinical Trials as Topic', 'Dipeptides/chemistry/pharmacology', 'Furans', 'HIV/drug effects', 'HIV Infections/drug therapy', 'HIV Protease Inhibitors/chemistry/pharmacology/*therapeutic use', 'Humans', 'Indinavir/pharmacology/therapeutic use', 'Lopinavir', 'Models, Molecular', 'Molecular Mimicry', 'Molecular Structure', 'Nelfinavir/pharmacology/therapeutic use', 'Oligopeptides/chemistry/pharmacology/therapeutic use', 'Organophosphates/chemistry/pharmacology/therapeutic use', 'Peptides/chemistry/pharmacology/*therapeutic use', 'Phenylbutyrates/chemistry/pharmacology', 'Pyridines/chemistry/pharmacology/therapeutic use', 'Pyrimidinones/chemistry/pharmacology/therapeutic use', 'Ritonavir/chemistry/pharmacology/therapeutic use', 'Saquinavir/chemistry/pharmacology/therapeutic use', 'Sulfonamides/chemistry/pharmacology/therapeutic use', 'Urethane/*analogs & derivatives/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15193140/
2767,Fosamprenavir,15060437,"Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers.","['Wire MB', 'Ballow C', 'Preston SL', 'Hendrix CW', 'Piliero PJ', 'Lou Y', 'Stein DS']","['Adult', 'Alkynes', 'Anti-HIV Agents/blood', 'Area Under Curve', 'Benzoxazines', 'Carbamates', 'Cholesterol/blood', 'Cyclopropanes', 'Drug Administration Schedule', 'Drug Interactions', 'Female', 'Furans', 'Humans', 'Linear Models', 'Male', 'Middle Aged', 'Organophosphates/adverse effects/blood/*pharmacokinetics', 'Oxazines/adverse effects/*pharmacokinetics', 'Prodrugs/adverse effects/analysis/*pharmacokinetics', 'Ritonavir/*pharmacokinetics', 'Sulfonamides/adverse effects/blood/*pharmacokinetics', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/15060437/
2768,Fosamprenavir,17550060,Anti-HIV drugs.,['De Clercq E'],"['Anti-HIV Agents/adverse effects/*classification/*therapeutic use', 'Antiretroviral Therapy, Highly Active/*methods', 'Drug Interactions', '*Drug Resistance, Viral', 'Drug Synergism', 'Drug Therapy, Combination', 'HIV Infections/*drug therapy', 'Humans', 'Safety', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17550060/
2769,Fosamprenavir,16179960,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/16179960/
2770,Fosamprenavir,23314414,"Steady-state pharmacokinetics, cord blood concentrations, and safety of ritonavir-boosted fosamprenavir in pregnancy.","['Cespedes MS', 'Castor D', 'Ford SL', 'Lee D', 'Lou Y', 'Pakes GE', 'Aberg JA']","['Adult', 'Area Under Curve', 'Carbamates/administration & dosage/*pharmacokinetics', 'Disease Transmission, Infectious/prevention & control', 'Female', 'Fetal Blood', 'Furans', 'HIV/isolation & purification', 'HIV Infections/drug therapy/*metabolism/prevention & control/virology', 'HIV Protease Inhibitors/administration & dosage/*pharmacokinetics', 'Humans', 'Infant, Newborn', 'Organophosphates/administration & dosage/*pharmacokinetics', 'Postpartum Period/blood/metabolism', 'Pregnancy', 'Pregnancy Complications, Infectious/blood/*drug therapy/*metabolism/virology', 'Ritonavir/administration & dosage/*pharmacokinetics', 'Sulfonamides/administration & dosage/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23314414/
2771,Fosamprenavir,12054084,Fosamprenavir. Vertex Pharmaceuticals/GlaxoSmithKline.,"['Corbett AH', 'Kashuba AD']","['Anti-HIV Agents/chemical synthesis/metabolism/*pharmacology/therapeutic use/toxicity', 'Carbamates', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Furans', 'HIV Infections/*drug therapy/virology', 'Humans', 'Organophosphates/chemical synthesis/metabolism/*pharmacology/therapeutic use/toxicity', 'Structure-Activity Relationship', 'Sulfonamides/chemical synthesis/metabolism/*pharmacology/therapeutic use/toxicity']",https://pubmed.ncbi.nlm.nih.gov/12054084/
2772,Fosamprenavir,16757678,Fosamprenavir: drug development for adherence.,"['Hester EK', 'Chandler HV', 'Sims KM']","['Carbamates/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Drug Interactions', 'Drug Resistance, Viral', 'Furans', 'HIV Infections/*drug therapy/metabolism/virology', 'HIV Protease Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Organophosphates/adverse effects/pharmacokinetics/*therapeutic use', 'Patient Compliance', 'Sulfonamides/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16757678/
2773,Fosamprenavir,15538546,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['Cardiovascular Diseases/*drug therapy', 'Communicable Diseases/*drug therapy', 'Double-Blind Method', 'Humans', 'Liver Diseases/*drug therapy', 'Metabolic Diseases/*drug therapy', 'Neoplasms/*drug therapy', '*Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/15538546/
2774,Fosamprenavir,32015036,Fosamprenavir with Ritonavir Pharmacokinetics during Pregnancy.,"['Eke AC', 'Wang J', 'Amin K', 'Shapiro DE', 'Stek A', 'Smith E', 'Chakhtoura N', 'Basar M', 'George K', 'Knapp KM', 'Joao EC', 'Rungruengthanakit K', 'Capparelli E', 'Burchett S', 'Mirochnick M', 'Best BM']","['Adult', 'Area Under Curve', 'Carbamates/adverse effects/*pharmacokinetics', 'Female', 'Furans/adverse effects/*pharmacokinetics', 'HIV Infections/*drug therapy', 'HIV Protease Inhibitors/adverse effects/*pharmacokinetics', 'Humans', 'Maternal Age', 'Pregnancy', 'Pregnancy Complications, Infectious/*drug therapy', 'Pregnancy Trimesters', 'RNA, Viral/blood', 'Ritonavir/adverse effects/*pharmacokinetics', 'Sulfonamides/adverse effects/*pharmacokinetics', 'Viral Load']",https://pubmed.ncbi.nlm.nih.gov/32015036/
2775,Fosamprenavir,33629924,Severe hyperkalaemia due to a potential drug-drug interaction between eplerenone and antiretrovirals in a HIV-positive patient after a myocardial infarction.,"['Cordova E', 'Garibaldi F', 'Bono L', 'Rodriguez C']","['Drug Interactions', 'Eplerenone/therapeutic use', '*HIV Infections/complications/drug therapy', '*HIV Protease Inhibitors/adverse effects', 'Humans', '*Hyperkalemia/chemically induced/drug therapy', 'Male', 'Middle Aged', '*Myocardial Infarction/drug therapy', '*Pharmaceutical Preparations', 'Ritonavir/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33629924/
2776,Fosamprenavir,21531048,[Characteristics of antiretroviral drugs].,"['Ribera E', 'Tuset M', 'Martin M', 'del Cacho E']","['Anti-Retroviral Agents/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/21531048/
2777,Fosamprenavir,36863666,Validation of an LC-MS/MS method for quantitation of fostemsavir in plasma.,"['Lolla S', 'Gubbiyappa KS', 'Cheruku S', 'Bhikshapathi DVRN']","['Animals', 'Humans', 'Rabbits', 'Chromatography, Liquid/methods', '*Tandem Mass Spectrometry/methods', '*Piperazines', 'Plasma', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/36863666/
2778,Fosamprenavir,22100576,Interactions between buprenorphine and the protease inhibitors darunavir-ritonavir and fosamprenavir-ritonavir.,"['Gruber VA', 'Rainey PM', 'Moody DE', 'Morse GD', 'Ma Q', 'Prathikanti S', 'Pade PA', 'Alvanzo AA', 'McCance-Katz EF']","['Anti-HIV Agents/administration & dosage/blood/pharmacokinetics', 'Area Under Curve', 'Buprenorphine/administration & dosage/analogs & derivatives/blood/*pharmacokinetics', 'Carbamates/administration & dosage/blood/*pharmacokinetics', 'Darunavir', 'Drug Interactions', 'Female', 'Furans', 'Half-Life', 'History, 16th Century', 'History, 17th Century', 'Humans', 'Male', 'Naloxone/pharmacology', 'Narcotic Antagonists/administration & dosage/pharmacokinetics', 'Opiate Substitution Treatment', 'Organophosphates/administration & dosage/blood/*pharmacokinetics', 'Protease Inhibitors/administration & dosage/blood/pharmacokinetics', 'Ritonavir/administration & dosage/blood/*pharmacokinetics', 'Sulfonamides/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/22100576/
2779,Solgol,1353872,[Beta-blockers and migraine].,"['Massiou H', 'Bousser MG']","['Adrenergic beta-Antagonists/pharmacology/therapeutic use', 'Atenolol/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Dilatation, Pathologic/drug therapy', 'Evoked Potentials, Visual/drug effects', 'Humans', 'Metoprolol/pharmacology/*therapeutic use', 'Migraine Disorders/*drug therapy', 'Nadolol/pharmacology/therapeutic use', 'Platelet Aggregation/drug effects', 'Propranolol/pharmacology/*therapeutic use', 'Receptors, Serotonin/drug effects', 'Timolol/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1353872/
2780,Solgol,28685702,A Focus on Pharmacological Management of Catecholaminergic Polymorphic Ventricular Tachycardia.,"['Claudio B', 'Alice M', 'Daniel S']","['Adrenergic beta-Antagonists/*therapeutic use', 'Anti-Arrhythmia Agents/*therapeutic use', 'Calcium Channel Blockers/*therapeutic use', 'Death, Sudden, Cardiac/etiology', 'Defibrillators, Implantable', 'Electrocardiography', 'Humans', 'Sodium Channel Blockers/*therapeutic use', 'Tachycardia, Ventricular/complications/diagnosis/*drug therapy/physiopathology', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/28685702/
2781,Solgol,34747977,Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma: A Randomized Clinical Trial.,"['Pope E', 'Lara-Corrales I', 'Sibbald C', 'Liy-Wong C', 'Kanigsberg N', 'Drolet B', 'Ma J']","['Administration, Oral', 'Adrenergic beta-Antagonists/adverse effects/pharmacology/standards', 'Double-Blind Method', 'Equivalence Trials as Topic', 'Female', 'Hemangioma, Capillary/*drug therapy/physiopathology', 'Humans', 'Infant', 'Male', 'Nadolol/adverse effects/pharmacology/*standards', 'Neoplastic Syndromes, Hereditary/*drug therapy/physiopathology', 'Ontario', 'Propranolol/adverse effects/pharmacology/*standards', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34747977/
2782,Solgol,6407348,New antiarrhythmic drugs.,"['Scheinman MM', 'Hess DS']","['Amiodarone/therapeutic use', 'Angina Pectoris/drug therapy', 'Anti-Arrhythmia Agents/pharmacology/*therapeutic use', 'Blood Circulation', 'Bradycardia/chemically induced', 'Diltiazem/therapeutic use', 'Half-Life', 'Humans', 'Hypertension/drug therapy', 'Lidocaine/analogs & derivatives/therapeutic use', 'Metoprolol/therapeutic use', 'Nadolol', 'Nifedipine/therapeutic use', 'Propanolamines/therapeutic use', 'Propranolol/therapeutic use', 'Tocainide', 'Verapamil/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6407348/
2783,Solgol,30372514,"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","['Zacharias AP', 'Jeyaraj R', 'Hobolth L', 'Bendtsen F', 'Gluud LL', 'Morgan MY']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Adult', 'Carvedilol/adverse effects/*therapeutic use', 'Esophageal and Gastric Varices/complications/*drug therapy/mortality', 'Gastrointestinal Hemorrhage/mortality/*prevention & control', 'Humans', 'Liver Cirrhosis/complications/*drug therapy/mortality', 'Nadolol/adverse effects/*therapeutic use', 'Primary Prevention', 'Propranolol/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30372514/
2784,Solgol,11153162,Beta blockers and lactation: an update.,"['Shannon ME', 'Malecha SE', 'Cha AJ']","['Adrenergic beta-Antagonists/*adverse effects/*pharmacokinetics', 'Adult', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Infant', 'Milk, Human/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/11153162/
2785,Solgol,35353122,Outcomes of Patients With Catecholaminergic Polymorphic Ventricular Tachycardia Treated With beta-Blockers.,"['Mazzanti A', 'Kukavica D', 'Trancuccio A', 'Memmi M', 'Bloise R', 'Gambelli P', 'Marino M', 'Ortiz-Genga M', 'Morini M', 'Monteforte N', 'Giordano U', 'Keegan R', 'Tomasi L', 'Anastasakis A', 'Davis AM', 'Shimizu W', 'Blom NA', 'Santiago DJ', 'Napolitano C', 'Monserrat L', 'Priori SG']","['Adolescent', 'Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Child', 'Cohort Studies', 'Electrocardiography', 'Female', 'Humans', 'Male', '*Nadolol/therapeutic use', 'Prospective Studies', 'Ryanodine Receptor Calcium Release Channel/genetics', 'Syncope', '*Tachycardia, Ventricular/diagnosis', 'Young Adult', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/35353122/
2786,Solgol,6145385,Antiadrenergic antihypertensive drugs: their effect on renal function.,"['Bernstein KN', ""O'Connor DT""]","['Administration, Oral', 'Adrenergic alpha-Agonists/pharmacology', 'Adrenergic alpha-Antagonists/pharmacology', 'Adrenergic beta-Antagonists/administration & dosage/pharmacology', 'Animals', 'Antihypertensive Agents/*pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Injections', 'Kallikreins/physiology', 'Kidney/*drug effects', 'Plasma Volume/drug effects', 'Renal Circulation/drug effects', 'Renin/physiology', 'Renin-Angiotensin System/drug effects', 'Sympatholytics/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6145385/
2787,Solgol,26436966,Beta blocker treatment for infantile hemangiomas.,"['Rouhana HF', 'Fruge JH', 'Massengale WT']","['Administration, Oral', 'Adrenergic beta-Antagonists/*therapeutic use', 'Atenolol/therapeutic use', 'Child', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Follow-Up Studies', 'Hemangioma, Capillary/diagnosis/*drug therapy', 'Humans', 'Infant', 'Male', 'Nadolol/therapeutic use', 'Propranolol/*therapeutic use', 'Skin Neoplasms/diagnosis/*drug therapy', 'Timolol/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/26436966/
2788,Solgol,19882938,[Beta blockers in migraine prophylaxis].,['Shimizu T'],"['Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics/pharmacology', 'Drug Administration Schedule', 'Humans', 'Metoprolol/administration & dosage/pharmacokinetics/pharmacology', 'Migraine Disorders/*prevention & control', 'Nadolol/administration & dosage/pharmacokinetics/pharmacology', '*Premedication', 'Propranolol/*administration & dosage/pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19882938/
2789,Solgol,30660822,Interaction of herbal products with prescribed medications: A systematic review and meta-analysis.,"['Awortwe C', 'Bruckmueller H', 'Cascorbi I']","['Animals', 'Biological Transport/drug effects', 'Cytochrome P-450 Enzyme System/metabolism', 'Echinacea/chemistry', '*Herb-Drug Interactions', 'Humans', 'Hypericum/chemistry', 'Hypnotics and Sedatives/metabolism/pharmacokinetics', 'Midazolam/metabolism/pharmacokinetics', 'Oximes/metabolism/pharmacokinetics', 'Plant Preparations/chemistry/*pharmacology', 'Tea/chemistry']",https://pubmed.ncbi.nlm.nih.gov/30660822/
2790,Solgol,6124267,Nadolol in thyrotoxicosis.,"['Peden NR', 'Isles TE', 'Stevenson IH', 'Crooks J']","['Adrenergic beta-Antagonists/*therapeutic use', 'Adult', 'Female', 'Heart Rate/drug effects', 'Humans', 'Hyperthyroidism/*drug therapy/physiopathology', 'Male', 'Middle Aged', 'Nadolol', 'Peak Expiratory Flow Rate', 'Physical Exertion', 'Propanolamines/*therapeutic use', 'Thyroid Hormones/blood', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6124267/
2791,Solgol,27798055,Exercise-induced syncope in a 22-year-old man.,"['Yeo C', 'Tan VH', 'Wong KC']","['Action Potentials', 'Anti-Arrhythmia Agents/therapeutic use', 'DNA Mutational Analysis', 'Electrocardiography', '*Exercise', 'Exercise Test', 'Genetic Predisposition to Disease', 'Heart Conduction System/drug effects/*physiopathology', '*Heart Rate/drug effects', 'Humans', 'Male', '*Mutation, Missense', 'Nadolol/therapeutic use', 'Phenotype', 'Ryanodine Receptor Calcium Release Channel/*genetics', 'Syncope/*etiology', 'Tachycardia, Ventricular/diagnosis/drug therapy/*genetics/physiopathology', 'Time Factors', 'Young Adult', 'Polymorphic Catecholaminergic Ventricular Tachycardia']",https://pubmed.ncbi.nlm.nih.gov/27798055/
2792,Solgol,2883876,Clinical significance of beta 1-selectivity and intrinsic sympathomimetic activity in a beta-adrenergic blocking drug.,['Frishman WH'],"['Adrenergic beta-Agonists/pharmacology', 'Adrenergic beta-Antagonists/*metabolism/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Chemical Phenomena', 'Chemistry', 'Glucose/metabolism', 'Humans', 'Lipids/blood', 'Lipoproteins/blood', 'Lung/drug effects', 'Receptors, Adrenergic, beta/*classification/metabolism', 'Sympathomimetics/*therapeutic use', 'Vascular Resistance/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2883876/
2793,Solgol,33010357,beta-Blocker Use and Risk of Mortality in Heart Failure Patients Initiating Maintenance Dialysis.,"['Zhou H', 'Sim JJ', 'Shi J', 'Shaw SF', 'Lee MS', 'Neyer JR', 'Kovesdy CP', 'Kalantar-Zadeh K', 'Jacobsen SJ']","['Adrenergic beta-Antagonists/metabolism/*therapeutic use', 'Aged', 'Aged, 80 and over', 'Atenolol/metabolism/therapeutic use', 'Bisoprolol/metabolism/therapeutic use', 'Carvedilol/metabolism/therapeutic use', 'Cause of Death', 'Cohort Studies', 'Female', 'Heart Failure/complications/*drug therapy', 'Hospitalization/*statistics & numerical data', 'Humans', 'Kidney Failure, Chronic/complications/*therapy', 'Labetalol/metabolism/therapeutic use', 'Logistic Models', 'Male', 'Metoprolol/metabolism/therapeutic use', 'Middle Aged', '*Mortality', 'Nadolol/metabolism/therapeutic use', 'Proportional Hazards Models', 'Propranolol/metabolism/therapeutic use', 'Protective Factors', '*Renal Dialysis', 'Retrospective Studies', 'Risk', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/33010357/
2794,Solgol,8310973,Usefulness of amlodipine for angina pectoris.,['Taylor SH'],"['Amlodipine/administration & dosage/*therapeutic use', 'Angina Pectoris/*drug therapy/etiology/physiopathology', 'Angina Pectoris, Variant/drug therapy', 'Cardiac Output', 'Clinical Trials as Topic', 'Diltiazem/administration & dosage', 'Double-Blind Method', 'Drug Administration Schedule', 'Electrocardiography', 'Exercise', 'Humans', 'Male', 'Myocardial Ischemia/physiopathology', 'Nadolol/administration & dosage', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/8310973/
2795,Solgol,6348587,Nadolol in essential tremor.,['Koller WC'],"['Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Male', 'Middle Aged', 'Nadolol', 'Placebos', 'Propanolamines/*administration & dosage/therapeutic use', 'Propranolol/therapeutic use', 'Tremor/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6348587/
2796,Solgol,12499857,Central beta-adrenergic modulation of cognitive flexibility.,"['Beversdorf DQ', 'White DM', 'Chever DC', 'Hughes JD', 'Bornstein RA']","['Adrenergic beta-Agonists/administration & dosage', 'Adrenergic beta-Antagonists/administration & dosage', 'Adult', 'Cognition/drug effects/*physiology', 'Ephedrine/administration & dosage', 'Female', 'Humans', 'Male', 'Nadolol/administration & dosage', 'Norepinephrine/physiology', 'Problem Solving/drug effects', 'Propranolol/administration & dosage', 'Receptors, Adrenergic, beta/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/12499857/
2797,Solgol,1672603,Required beta blocker profile in the elderly.,['Opie LH'],"['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Aged', 'Aging/*physiology', 'Hemodynamics/physiology', 'Humans', 'Kidney/physiology', 'Quality of Life', 'Renin/metabolism', 'Respiration/physiology', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/1672603/
2798,Solgol,6125096,Therapeutic trials of pindolol in hypertension: comparison and combination with other drugs.,['Fanchamps A'],"['Adrenergic beta-Antagonists/therapeutic use', 'Adult', 'Aged', 'Antihypertensive Agents/*therapeutic use', 'Clinical Trials as Topic', 'Diuretics/therapeutic use', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pindolol/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6125096/
2799,ceftazidime,29671219,Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections.,['Shirley M'],"['Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Azabicyclo Compounds/administration & dosage/adverse effects/*therapeutic use', 'Ceftazidime/administration & dosage/adverse effects/*therapeutic use', 'Cephalosporins/therapeutic use', 'Drug Approval', 'Drug Combinations', 'Drug Resistance, Multiple, Bacterial/drug effects', 'Europe', 'Gram-Negative Bacterial Infections/*drug therapy', 'Humans', 'United States', 'beta-Lactamase Inhibitors/therapeutic use', 'beta-Lactamases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/29671219/
2800,ceftazidime,27107460,"Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study.","['Carmeli Y', 'Armstrong J', 'Laud PJ', 'Newell P', 'Stone G', 'Wardman A', 'Gasink LB']","['Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/therapeutic use', 'Azabicyclo Compounds/*administration & dosage/adverse effects', 'Carbapenems/therapeutic use', 'Ceftazidime/*administration & dosage/adverse effects', 'Drug Combinations', '*Drug Resistance, Multiple, Bacterial', 'Enterobacteriaceae/*drug effects', 'Female', 'Gram-Negative Bacteria/drug effects', 'Humans', 'Intraabdominal Infections/*drug therapy/microbiology', 'Male', 'Middle Aged', 'Pseudomonas aeruginosa/*drug effects', 'Urinary Tract Infections/*drug therapy/microbiology', 'beta-Lactamase Inhibitors/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27107460/
2801,ceftazidime,27716499,Empowering Older Antibiotics.,['Wright GD'],"['*Anti-Bacterial Agents/chemistry/pharmacology/therapeutic use', '*Azabicyclo Compounds/chemistry/pharmacology/therapeutic use', 'Bacteria/*drug effects', '*Ceftazidime/chemistry/pharmacology/therapeutic use', 'Cell Wall/drug effects', 'Drug Combinations', 'Drug Resistance, Bacterial', 'Humans', 'Penicillin-Binding Proteins/*antagonists & inhibitors', 'Urinary Tract Infections/drug therapy', '*beta-Lactamase Inhibitors/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27716499/
2802,ceftazidime,27758148,Ceftazidime-avibactam for the treatment of complicated intra-abdominal infections.,"['Buckman SA', 'Krekel T', 'Muller AE', 'Mazuski JE']","['Azabicyclo Compounds/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Bacterial Proteins/antagonists & inhibitors', 'Ceftazidime/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Drug Combinations', 'Enterobacteriaceae/drug effects/enzymology', 'Gram-Negative Bacterial Infections/*drug therapy/microbiology', 'Humans', 'Intraabdominal Infections/*drug therapy/microbiology', 'Klebsiella pneumoniae/drug effects/enzymology', 'Metronidazole/therapeutic use', 'beta-Lactamase Inhibitors/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'beta-Lactamases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27758148/
2803,ceftazidime,38739208,Ceftazidime-avibactam combination therapy versus monotherapy for treating carbapenem-resistant gram-negative infection: a systemic review and meta-analysis.,"['Hsu W', 'Chuang MH', 'Tsai WW', 'Lai CC', 'Lai HY', 'Tang HJ']","['Humans', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', '*Azabicyclo Compounds/therapeutic use', '*Carbapenems/therapeutic use', '*Ceftazidime/therapeutic use', 'Drug Combinations', 'Drug Therapy, Combination', 'Gram-Negative Bacteria/drug effects', '*Gram-Negative Bacterial Infections/drug therapy/mortality']",https://pubmed.ncbi.nlm.nih.gov/38739208/
2804,ceftazidime,26962078,"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.","['Mazuski JE', 'Gasink LB', 'Armstrong J', 'Broadhurst H', 'Stone GG', 'Rank D', 'Llorens L', 'Newell P', 'Pachl J']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Azabicyclo Compounds/administration & dosage/adverse effects/therapeutic use', '*Ceftazidime/administration & dosage/adverse effects/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Intraabdominal Infections/*drug therapy/epidemiology', 'Male', 'Meropenem', '*Metronidazole/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', '*Thienamycins/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26962078/
2805,ceftazidime,22963144,Desensitization to antibiotics in children.,['Cernadas JR'],"['Adult', 'Anti-Bacterial Agents/*administration & dosage/adverse effects/immunology', 'Ceftazidime/administration & dosage/adverse effects/immunology', 'Child', 'Child, Preschool', 'Desensitization, Immunologic/*methods', 'Drug Administration Schedule', 'Drug Hypersensitivity/epidemiology/*prevention & control', 'Female', 'Humans', 'Immune Tolerance/immunology', 'Immunoglobulin E/blood', 'Male', 'Penicillins/administration & dosage/adverse effects/immunology', 'Rifampin/administration & dosage/adverse effects/immunology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22963144/
2806,ceftazidime,27313268,"Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program.","['Wagenlehner FM', 'Sobel JD', 'Newell P', 'Armstrong J', 'Huang X', 'Stone GG', 'Yates K', 'Gasink LB']","['Adult', 'Aged', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Azabicyclo Compounds/administration & dosage/adverse effects/*therapeutic use', 'Carbapenems/administration & dosage/adverse effects/*therapeutic use', 'Ceftazidime/administration & dosage/adverse effects/*therapeutic use', 'Doripenem', 'Drug Combinations', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pyelonephritis/complications/*drug therapy', 'Urinary Tract Infections/complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27313268/
2807,ceftazidime,29659836,Efficacy and safety of ceftazidime/avibactam: a systematic review and meta-analysis.,"['Sternbach N', 'Leibovici Weissman Y', 'Avni T', 'Yahav D']","['Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Azabicyclo Compounds/adverse effects/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Ceftazidime/adverse effects/*therapeutic use', 'Drug Combinations', 'Drug Resistance, Multiple, Bacterial', 'Enterobacteriaceae/*drug effects', 'Humans', 'Mortality', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29659836/
2808,ceftazidime,1565167,[Intraventricular antibiotic therapy].,"['Thilmann AF', 'Mobius E', 'Podoll K']","['Aged', 'Ceftazidime/*administration & dosage/adverse effects', 'Cerebrospinal Fluid Shunts', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination/therapeutic use', 'Humans', 'Hydrocephalus/surgery', 'Injections, Intraventricular', 'Long-Term Care', 'Magnetic Resonance Imaging', 'Male', 'Meningitis, Bacterial/*drug therapy', 'Pseudomonas Infections/*drug therapy', 'Pseudomonas aeruginosa/*drug effects', 'Recurrence', 'Staphylococcal Infections/*drug therapy', 'Surgical Wound Infection/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1565167/
2809,ceftazidime,15829812,Recurrent Alcaligenes xylosoxidans keratitis.,"['Huang ZL', 'Chen YF', 'Chang SW', 'Lin KK', 'Hsiao CH']","['Abscess/surgery', 'Administration, Topical', 'Adult', '*Alcaligenes', 'Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Ceftazidime/administration & dosage/therapeutic use', 'Corneal Transplantation/*adverse effects', 'Gram-Negative Bacterial Infections/drug therapy/*etiology/surgery', 'Humans', 'Keratitis/*microbiology/pathology', 'Male', 'Piperacillin/administration & dosage/therapeutic use', 'Recurrence', 'Reoperation']",https://pubmed.ncbi.nlm.nih.gov/15829812/
2810,ceftazidime,39159014,An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients.,"['Cojutti PG', 'Pai MP', 'Gatti M', 'Rinaldi M', 'Ambretti S', 'Viale P', 'Pea F']","['Humans', '*Ceftazidime/pharmacokinetics/administration & dosage/pharmacology', '*Azabicyclo Compounds/pharmacokinetics/administration & dosage/pharmacology', '*Drug Combinations', 'Middle Aged', '*Critical Illness', 'Female', 'Male', 'Retrospective Studies', '*Anti-Bacterial Agents/pharmacokinetics/administration & dosage/pharmacology', 'Aged', '*Enterobacteriaceae Infections/drug therapy', 'Adult', 'Microbial Sensitivity Tests', 'Drug Monitoring', 'beta-Lactamases/metabolism', 'Enterobacteriaceae/drug effects', 'Infusions, Intravenous', 'Bacterial Proteins', 'Aged, 80 and over', 'Monte Carlo Method']",https://pubmed.ncbi.nlm.nih.gov/39159014/
2811,ceftazidime,38546808,Ceftazidime/avibactam serum concentration in patients on ECMO.,"['Curtiaud A', 'Petit M', 'Chommeloux J', 'Pineton de Chambrun M', 'Hekimian G', 'Schmidt M', 'Combes A', 'Luyt CE']","['Humans', '*Ceftazidime/pharmacokinetics/administration & dosage/therapeutic use/blood', '*Azabicyclo Compounds/pharmacokinetics/administration & dosage/therapeutic use/blood', 'Male', 'Female', 'Retrospective Studies', 'Middle Aged', '*Drug Combinations', '*Anti-Bacterial Agents/pharmacokinetics/administration & dosage/therapeutic use/blood', '*Extracorporeal Membrane Oxygenation', 'Adult', 'Aged', 'Pseudomonas aeruginosa/drug effects', 'Microbial Sensitivity Tests', 'Enterobacteriaceae/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38546808/
2812,ceftazidime,3279907,Pharmacokinetics and serum bactericidal activity of vancomycin alone and in combination with ceftazidime in healthy volunteers.,"['Boeckh M', 'Lode H', 'Borner K', 'Hoffken G', 'Wagner J', 'Koeppe P']","['Adult', 'Bacteria/*drug effects', 'Ceftazidime/administration & dosage/blood/*pharmacokinetics/pharmacology', 'Drug Combinations', 'Female', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', 'Vancomycin/administration & dosage/blood/*pharmacokinetics/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/3279907/
2813,ceftazidime,8783345,Teicoplanin pharmacokinetics in pediatric patients.,"['Dufort G', 'Ventura C', 'Olive T', 'Ortega JJ']","['Adolescent', 'Anti-Bacterial Agents/*administration & dosage/blood/*pharmacokinetics', 'Aztreonam/pharmacology', 'Bone Marrow Transplantation/*adverse effects', 'Ceftazidime/pharmacology', 'Cephalosporins/pharmacology', 'Child', 'Child, Preschool', 'Drug Therapy, Combination', 'Gram-Positive Bacteria/drug effects', 'Gram-Positive Bacterial Infections/*drug therapy', 'Humans', 'Infant', 'Microbial Sensitivity Tests', 'Monobactams/pharmacology', 'Teicoplanin/*administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/8783345/
2814,ceftazidime,37301439,Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients.,"['Al Jalali V', 'Matzneller P', 'Pham AD', 'van Os W', 'Wolfl-Duchek M', 'Sanz-Codina M', 'Vychytil A', 'Reiter B', 'Stimpfl T', 'Zeitlinger M']","['Humans', '*Ceftazidime', 'Anti-Bacterial Agents/therapeutic use', 'Prospective Studies', 'Drug Combinations', 'Microbial Sensitivity Tests', '*Peritoneal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/37301439/
2815,ceftazidime,26289307,The beta-Lactams Strike Back: Ceftazidime-Avibactam.,"['Zasowski EJ', 'Rybak JM', 'Rybak MJ']","['Anti-Bacterial Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Azabicyclo Compounds/pharmacokinetics/pharmacology/*therapeutic use', 'Ceftazidime/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials, Phase II as Topic', 'Drug Combinations', '*Drug Resistance, Multiple, Bacterial', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Randomized Controlled Trials as Topic', 'beta-Lactamase Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26289307/
2816,ceftazidime,21431580,A Monte Carlo analysis of peritoneal antimicrobial pharmacokinetics.,"['Hota S', 'Crooke P', 'Hotchkiss J']","['Anti-Infective Agents/administration & dosage/*pharmacokinetics', 'Area Under Curve', 'Ascitic Fluid/metabolism', 'Cefazolin/administration & dosage/pharmacokinetics', 'Ceftazidime/administration & dosage/pharmacokinetics', 'Clinical Trials as Topic', 'Computational Biology', 'Computer Simulation', 'Dialysis Solutions', 'Humans', 'Microbial Sensitivity Tests', 'Models, Biological', 'Monte Carlo Method', 'Peritoneal Dialysis/adverse effects', 'Peritonitis/*drug therapy/etiology/*metabolism', 'User-Computer Interface']",https://pubmed.ncbi.nlm.nih.gov/21431580/
2817,ceftazidime,2656929,Ciprofloxacin versus ceftazidime in skin and soft tissue infections.,"['Thadepalli H', 'Mathai D', 'Chuah SK', 'Bansal MB']","['Administration, Oral', 'Bacterial Infections/*drug therapy', 'Ceftazidime/adverse effects/*therapeutic use', 'Ciprofloxacin/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Connective Tissue Diseases/*drug therapy', 'Humans', 'Infusions, Intravenous', 'Prospective Studies', 'Random Allocation', 'Skin Diseases, Infectious/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2656929/
2818,ceftazidime,19803002,Trial of ceftazidime efficacy in respiratory infections at two dose levels.,"['Feist H', 'Vetter N', 'Muhar F', 'Williams KJ', 'Brandstetter HJ', 'Ho I']","['Adult', 'Aged', 'Anti-Bacterial Agents/administration & dosage/*therapeutic use', 'Bronchitis/complications', 'Ceftazidime/administration & dosage/*therapeutic use', 'Chronic Disease', 'Humans', 'Male', 'Middle Aged', 'Respiratory Tract Infections/*drug therapy/microbiology', 'Sputum/microbiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/19803002/
2819,hydralazine,29808264,"Neonatal hypertension: cases, causes, and clinical approach.","['Starr MC', 'Flynn JT']","['Administration, Intravenous', 'Antihypertensive Agents/*administration & dosage/adverse effects', 'Birth Weight/physiology', 'Blood Pressure/drug effects/*physiology', 'Blood Pressure Determination/instrumentation/methods', 'Clinical Decision-Making', 'Gestational Age', 'Humans', 'Hydralazine/administration & dosage/adverse effects', 'Hypertension/*diagnosis/epidemiology/etiology/therapy', 'Incidence', 'Infant, Newborn', 'Infant, Newborn, Diseases/*diagnosis/epidemiology/etiology/therapy', 'Infant, Premature/*physiology', 'Intensive Care Units, Neonatal', 'Kidney/physiopathology/surgery', 'Labetalol/administration & dosage/adverse effects', 'Neuroblastoma/complications/surgery', 'Reference Values', 'Renal Artery Obstruction/complications/surgery', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29808264/
2820,hydralazine,8522630,Management of hypertensive urgencies and emergencies.,"['Abdelwahab W', 'Frishman W', 'Landau A']","['Administration, Oral', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Emergencies', 'Enalaprilat/therapeutic use', 'Female', 'Humans', 'Hydralazine/therapeutic use', 'Hypertension/classification/*drug therapy', 'Infusions, Parenteral', 'Labetalol/therapeutic use', 'Nicardipine/therapeutic use', 'Nitroglycerin/therapeutic use', 'Nitroprusside/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8522630/
2821,hydralazine,18827911,Perioperative hypertension management.,"['Varon J', 'Marik PE']","['Adrenergic beta-Antagonists/pharmacology', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Enalaprilat/pharmacology/therapeutic use', 'Fenoldopam/pharmacology/therapeutic use', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/pharmacology/therapeutic use', 'Hypertension/*drug therapy/epidemiology', 'Incidence', 'Labetalol/administration & dosage/pharmacology', 'Nicardipine/pharmacology/therapeutic use', 'Nitroglycerin/pharmacology', 'Nitroprusside/pharmacology', 'Perioperative Care', 'Postoperative Complications/*drug therapy', 'Propanolamines/pharmacology', 'Pyridines/pharmacology/therapeutic use', '*Surgical Procedures, Operative', 'Vascular Resistance/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/18827911/
2822,hydralazine,26600442,Hypertensive Emergencies in Pregnancy.,"['Olson-Chen C', 'Seligman NS']","['Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Cesarean Section/standards', 'Chronic Disease', 'Congenital Abnormalities/*epidemiology/etiology', 'Emergencies', 'Esophageal Atresia/epidemiology/etiology', 'Female', 'Heart Defects, Congenital/epidemiology/etiology', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/complications/drug therapy/epidemiology/physiopathology', 'Hypertension, Pregnancy-Induced/drug therapy/epidemiology/*physiopathology', 'Hypospadias/epidemiology/etiology', 'Labetalol/administration & dosage/adverse effects/therapeutic use', 'Labor, Induced/standards', 'Male', 'Nifedipine/administration & dosage/adverse effects/therapeutic use', 'Postnatal Care', 'Pre-Eclampsia/drug therapy/epidemiology/*physiopathology', 'Pregnancy', 'Pregnancy Outcome/*epidemiology', 'Prevalence', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/26600442/
2823,hydralazine,32927458,Genotype-Guided Hydralazine Therapy.,"['Collins KS', 'Raviele ALJ', 'Elchynski AL', 'Woodcock AM', 'Zhao Y', 'Cooper-DeHoff RM', 'Eadon MT']","['Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Arylamine N-Acetyltransferase/*genetics/metabolism', 'Dose-Response Relationship, Drug', 'Drug Resistance/genetics', 'Humans', 'Hydralazine/pharmacokinetics/*therapeutic use', 'Hypertension/*drug therapy/genetics', 'Nephrology/methods/standards', 'Pharmacogenomic Testing/standards', 'Pharmacogenomic Variants', 'Practice Guidelines as Topic', 'Precision Medicine/*methods/standards', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32927458/
2824,hydralazine,9543400,Parenteral hydralazine revisited.,"['Powers DR', 'Papadakos PJ', 'Wallin JD']","['Emergencies', 'Female', 'Humans', 'Hydralazine/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Infusions, Parenteral', 'Pre-Eclampsia/drug therapy', 'Pregnancy', 'Vasodilator Agents/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9543400/
2825,hydralazine,21896152,Direct-acting vasodilators.,"['Cohn JN', 'McInnes GT', 'Shepherd AM']","['Antihypertensive Agents/adverse effects/*therapeutic use', 'Hirsutism/chemically induced', 'Humans', 'Hydralazine/adverse effects/therapeutic use', 'Hypertension/*drug therapy', 'Minoxidil/adverse effects/therapeutic use', 'Tachycardia/chemically induced', 'Treatment Outcome', 'Vasodilator Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21896152/
2826,hydralazine,2196888,Severe preeclampsia: is vasodilation therapy with hydralazine dangerous for the preterm fetus?,"['Derham RJ', 'Robinson J']","['Female', 'Fetus/*drug effects', 'Humans', 'Hydralazine/*adverse effects', 'Hypotension/*chemically induced', 'Pre-Eclampsia/*drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/2196888/
2827,hydralazine,8710038,Hydralazine-induced constrictive pericarditis.,"['Franssen CF', 'el Gamal MI', 'Gans RO', 'Hoorntje SJ']","['Antibodies, Antineutrophil Cytoplasmic', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Autoantibodies/*analysis', 'Autoimmune Diseases/*chemically induced/physiopathology', 'Humans', 'Hydralazine/*adverse effects/therapeutic use', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Pericarditis, Constrictive/*chemically induced/diagnosis', 'Peroxidase/immunology', 'Thoracotomy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8710038/
2828,hydralazine,18473924,Carbonyl-scavenging drugs & protection against carbonyl stress-associated cell injury.,"['Burcham PC', 'Kaminskas LM', 'Tan D', 'Pyke SM']","['Acrolein/*antagonists & inhibitors/toxicity', 'Alzheimer Disease/chemically induced/drug therapy', 'Animals', 'Atherosclerosis/chemically induced/drug therapy', 'Cell Death/drug effects', 'Free Radical Scavengers/chemistry/*pharmacology/therapeutic use', 'Humans', 'Hydralazine/analogs & derivatives/chemistry/*pharmacology', 'Liver Diseases, Alcoholic/drug therapy', 'Oxidative Stress/drug effects', 'Protective Agents/chemistry/*pharmacology/therapeutic use', 'Spinal Cord Injuries/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18473924/
2829,hydralazine,6349967,Vasodilator therapy in chronic congestive heart failure.,"['Schwartz AB', 'Chatterjee K']","['Captopril/therapeutic use', 'Chronic Disease', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/therapeutic use', 'Minoxidil/therapeutic use', 'Nitrates/therapeutic use', 'Piperazines/therapeutic use', 'Vasodilator Agents/classification/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6349967/
2830,hydralazine,36150895,A review on the clinical pharmacokinetics of hydralazine.,"['Shahzad Qamar A', 'Zamir A', 'Khalid S', 'Ashraf W', 'Imran I', 'Hussain I', 'Rehman AU', 'Saeed H', 'Majeed A', 'Alqahtani F', 'Rasool MF']","['Pregnancy', 'Female', 'Humans', 'Hydralazine/pharmacokinetics/therapeutic use', 'Vasodilator Agents', '*Hypertension/drug therapy', '*Heart Failure/drug therapy', '*Drug-Related Side Effects and Adverse Reactions', 'Pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/36150895/
2831,hydralazine,3511697,Vasodilator therapy.,['Sutton FJ'],"['Administration, Oral', 'Captopril/administration & dosage', 'Cardiac Output/drug effects', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Heart Failure/*drug therapy', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/administration & dosage', 'Nitrates/administration & dosage', 'Physical Exertion/drug effects', 'Prazosin/administration & dosage', 'Random Allocation', 'Stroke Volume/drug effects', 'Time Factors', 'Vasodilator Agents/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3511697/
2832,hydralazine,6519160,Hydralazine-induced lupus: is there a toxic metabolic pathway?,"['Timbrell JA', 'Facchini V', 'Harland SJ', 'Mansilla-Tinoco R']","['Acetylation', 'Biotransformation', 'Creatinine/urine', 'Female', 'Humans', 'Hydralazine/*adverse effects/metabolism', 'Kinetics', 'Lupus Vulgaris/*chemically induced', 'Male', 'Phenotype', 'Sulfamethazine']",https://pubmed.ncbi.nlm.nih.gov/6519160/
2833,hydralazine,37989321,In vivo ameliorative effects of vitamin E against hydralazine-induced lupus.,"['Githaiga FM', 'Omwenga GI', 'Ngugi MP']","['Humans', 'Animals', 'Mice', '*Vitamin E/pharmacology/therapeutic use', '*Lupus Erythematosus, Systemic/chemically induced/drug therapy', 'Hydralazine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37989321/
2834,hydralazine,24673554,Biomimetic microfluidic device for in vitro antihypertensive drug evaluation.,"['Li L', 'Lv X', 'Ostrovidov S', 'Shi X', 'Zhang N', 'Liu J']","['Antihypertensive Agents/chemistry/*pharmacology', 'Biomimetic Materials/chemistry/*pharmacology', 'Biomimetics/*methods', 'Blood Vessels/drug effects', 'Cells, Cultured', 'Dimethylpolysiloxanes/chemistry', 'Drug Evaluation/methods', 'Endothelial Cells/drug effects', 'Human Umbilical Vein Endothelial Cells', 'Humans', 'Hydralazine/chemistry/pharmacology', 'In Vitro Techniques/methods', 'Lab-On-A-Chip Devices/*methods', 'Microfluidics/methods', 'Nylons/chemistry', 'Pressure', 'Shear Strength/drug effects', 'Stress, Mechanical']",https://pubmed.ncbi.nlm.nih.gov/24673554/
2835,hydralazine,3884988,Vasodilator drugs in the treatment of hypertension.,['Kincaid-Smith P'],"['Calcium Channel Blockers/therapeutic use', 'Captopril/administration & dosage/therapeutic use', 'Cardiac Output/drug effects', 'Diazoxide/adverse effects/therapeutic use', 'Diuretics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Hemodynamics/drug effects', 'Humans', 'Hydralazine/administration & dosage/adverse effects/therapeutic use', 'Hypertension/*drug therapy', 'Infusions, Parenteral', 'Minoxidil/administration & dosage/adverse effects/therapeutic use', 'Prazosin/therapeutic use', 'Renal Circulation/drug effects', 'Vasodilator Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3884988/
2836,hydralazine,38542088,Beyond Quadruple Therapy and Current Therapeutic Strategies in Heart Failure with Reduced Ejection Fraction: Medical Therapies with Potential to Become Part of the Therapeutic Armamentarium.,"['Kourek C', 'Briasoulis A', 'Papamichail A', 'Xanthopoulos A', 'Tsougos E', 'Farmakis D', 'Paraskevaidis I']","['Humans', '*Heart Failure', 'Stroke Volume', 'Hydralazine/pharmacology/therapeutic use', 'Isosorbide Dinitrate/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/pharmacology', 'Multicenter Studies as Topic', 'Urea/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38542088/
2837,hydralazine,32044579,The flipside of hydralazine in pregnancy: A systematic review and meta-analysis.,"['Antza C', 'Dimou C', 'Doundoulakis I', 'Akrivos E', 'Stabouli S', 'Haidich AB', 'Goulis DG', 'Kotsis V']","['Antihypertensive Agents/*therapeutic use', 'Birth Weight', 'Female', 'Heart Rate', 'Humans', 'Hydralazine/*therapeutic use', 'Hypertension/*drug therapy', 'Hypertension, Pregnancy-Induced/*drug therapy', 'Infant, Newborn', 'Pregnancy', 'Pregnancy Complications, Cardiovascular/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32044579/
2838,hydralazine,2666324,Bullous systemic lupus erythematosus.,"['Fleming MG', 'Bergfeld WF', 'Tomecki KJ', 'Tuthill RJ', 'Norris M', 'Benedetto EA', 'Weber LA']","['Adult', 'Aged', 'Dapsone/therapeutic use', 'Female', 'Fluorescent Antibody Technique', 'Humans', 'Hydralazine/*adverse effects', 'Lupus Erythematosus, Systemic/chemically induced/*complications/pathology', 'Skin Diseases, Vesiculobullous/chemically induced/*complications/immunology/pathology']",https://pubmed.ncbi.nlm.nih.gov/2666324/
2839,alprazolam,28777203,"A Review of Alprazolam Use, Misuse, and Withdrawal.","['Ait-Daoud N', 'Hamby AS', 'Sharma S', 'Blevins D']","['Alprazolam/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/*adverse effects/therapeutic use', 'Female', 'Humans', 'Panic Disorder/drug therapy', 'Pregnancy', '*Prescription Drug Misuse', 'Substance Withdrawal Syndrome/*therapy']",https://pubmed.ncbi.nlm.nih.gov/28777203/
2840,alprazolam,2185302,Oxazepam: update 1989.,['Ayd FJ Jr'],"['Aged', 'Alcoholism/drug therapy', 'Alprazolam/adverse effects/pharmacology/therapeutic use', 'Female', 'Humans', '*Oxazepam/adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Seizures/chemically induced', 'Substance Withdrawal Syndrome', 'Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/2185302/
2841,alprazolam,1980694,Efficacy of benzodiazepines in panic disorder and agoraphobia.,['Ballenger JC'],"['Agoraphobia/*drug therapy/psychology', 'Alprazolam/therapeutic use', 'Anti-Anxiety Agents/*therapeutic use', 'Anxiety Disorders/*drug therapy/psychology', 'Arousal/drug effects', 'Humans', 'Panic/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1980694/
2842,alprazolam,16858890,Hypersensitivity to paroxetine.,"['Mera MT', 'Perez BV', 'Fernandez RO', 'Iglesias JF']","['Alprazolam/administration & dosage/therapeutic use', 'Depressive Disorder/drug therapy', 'Drug Eruptions/diagnosis/*etiology', 'Exanthema/*chemically induced/diagnosis', 'Female', 'Humans', 'Middle Aged', 'Paroxetine/*adverse effects/therapeutic use', 'Patch Tests', 'Selective Serotonin Reuptake Inhibitors/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16858890/
2843,alprazolam,3536383,A review of alprazolam withdrawal.,"['Browne JL', 'Hauge KJ']","['Alprazolam/*adverse effects', 'Humans', 'Substance Withdrawal Syndrome/*etiology']",https://pubmed.ncbi.nlm.nih.gov/3536383/
2844,alprazolam,1684083,Snorting benzodiazepines.,"['Sheehan MF', 'Sheehan DV', 'Torres A', 'Coppola A', 'Francis E']","['Administration, Intranasal', 'Adult', 'Alprazolam/administration & dosage', '*Anti-Anxiety Agents/administration & dosage/adverse effects', 'Arousal/drug effects', 'Bipolar Disorder/psychology', 'Diazepam/administration & dosage', 'Female', 'Humans', 'Male', 'Personality Disorders/psychology', 'Substance Withdrawal Syndrome/diagnosis/psychology', 'Substance-Related Disorders/*psychology']",https://pubmed.ncbi.nlm.nih.gov/1684083/
2845,alprazolam,8262887,Medication discontinuation in panic disorder.,"['Ballenger JC', 'Pecknold J', 'Rickels K', 'Sellers EM']","['Alprazolam/*administration & dosage/therapeutic use', 'Benzodiazepines/*administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Panic Disorder/*drug therapy/psychology', 'Patient Compliance', 'Patient Education as Topic', 'Recurrence', 'Substance Withdrawal Syndrome/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/8262887/
2846,alprazolam,22275853,Experimental panic provocation in healthy man-a translational role in anti-panic drug development?,['Kellner M'],"['Alprazolam/*administration & dosage', 'Anti-Anxiety Agents/administration & dosage', 'Clinical Trials as Topic/trends', 'Drug Design', 'Humans', 'Panic Disorder/*chemically induced/*drug therapy', 'Tetragastrin/*adverse effects', 'Translational Research, Biomedical/*trends']",https://pubmed.ncbi.nlm.nih.gov/22275853/
2847,alprazolam,2823537,Pharmacology of the benzodiazepines; with special emphasis on alprazolam.,['Soderpalm B'],"['Alprazolam/pharmacology', 'Animals', 'Anxiety Disorders/drug therapy', 'Benzodiazepines/pharmacokinetics/*pharmacology', 'Drug Tolerance', 'Humans', 'Rats', 'Receptors, GABA-A/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2823537/
2848,alprazolam,2187582,Problems in the treatment of premenstrual syndrome.,"['Robinson GE', 'Garfinkel PE']","['Alprazolam/therapeutic use', 'Combined Modality Therapy', 'Female', 'Humans', 'Premenstrual Syndrome/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/2187582/
2849,alprazolam,16296788,Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.,"['Alberti I', 'Grenier A', 'Kraus H', 'Carrara DN']","['*Administration, Cutaneous', 'Alprazolam/administration & dosage/therapeutic use', 'Animals', 'Anti-Anxiety Agents/administration & dosage/therapeutic use', '*Drug Delivery Systems', 'Estradiol/administration & dosage/therapeutic use', 'Female', '*Gels', 'Humans', 'Hypogonadism/drug therapy', 'Male', 'Mandelic Acids/administration & dosage/therapeutic use', 'Norethindrone/administration & dosage/therapeutic use', 'Parasympatholytics/administration & dosage/therapeutic use', 'Progesterone Congeners/administration & dosage/therapeutic use', 'Testosterone/administration & dosage/therapeutic use', 'Urinary Bladder, Neurogenic/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16296788/
2850,alprazolam,6135693,Pharmacokinetics of alprazolam.,"['Abernethy DR', 'Greenblatt DJ', 'Divoll M', 'Shader RI']","['Age Factors', 'Alprazolam', 'Anti-Anxiety Agents/*metabolism', 'Benzodiazepines/*metabolism', 'Biotransformation/drug effects', 'Body Weight', 'Cimetidine/pharmacology', 'Female', 'Humans', 'Kinetics', 'Male', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/6135693/
2851,alprazolam,2890266,Brain neurotransmission in panic disorder.,['Eriksson E'],"['Alprazolam/pharmacology', 'Antidepressive Agents/pharmacology', 'Anxiety Disorders/drug therapy/*physiopathology', 'Brain Chemistry', 'Fear/*physiology', 'Humans', 'Neurotransmitter Agents/*physiology', 'Panic/drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/2890266/
2852,alprazolam,9617514,Alprazolam withdrawal delirium: a case report.,"['Zalsman G', 'Hermesh H', 'Munitz H']","['Aged', 'Alprazolam/*adverse effects', 'Anti-Anxiety Agents/*adverse effects', 'Delirium/*chemically induced', 'Humans', 'Male', 'Substance Withdrawal Syndrome/*complications']",https://pubmed.ncbi.nlm.nih.gov/9617514/
2853,alprazolam,23070072,Oral alprazolam acutely increases nucleus accumbens perfusion.,"['Wolf DH', 'Pinkham AE', 'Satterthwaite TD', 'Ruparel K', 'Elliott MA', 'Valdez J', 'Smith MA', 'Detre JA', 'Gur RC', 'Gur RE']","['Administration, Oral', 'Alprazolam/*administration & dosage', 'Anti-Anxiety Agents/*administration & dosage', 'Anxiety/drug therapy', 'Benzodiazepines/therapeutic use', 'Cerebrovascular Circulation/drug effects', 'Cross-Sectional Studies', 'Double-Blind Method', 'Female', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Nucleus Accumbens/diagnostic imaging/*drug effects', 'Positron-Emission Tomography']",https://pubmed.ncbi.nlm.nih.gov/23070072/
2854,alprazolam,1362662,Mode of action of the triazolobenzodiazepines in the treatment of panic attacks: a hypothesis.,"['Van Gool D', 'Igodt P', 'De Cuyper H']","['Alprazolam/chemistry/*therapeutic use', 'Anti-Anxiety Agents/chemistry/*therapeutic use', 'Humans', 'Panic Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1362662/
2855,alprazolam,37040158,"Alprazolam: Good for Some, Not Good for All!","['Mamtani H', 'Chaturvedi SK']","['Humans', 'Alprazolam/adverse effects', 'Benzodiazepines/adverse effects', '*Panic Disorder/drug therapy', 'Anxiety Disorders/drug therapy', 'Antisocial Personality Disorder/chemically induced/drug therapy', '*Anti-Anxiety Agents/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37040158/
2856,alprazolam,27369688,[Duloxetine-Induced Hypertension: A Case Report].,"['Mermi O', 'Atmaca M']","['Alprazolam/administration & dosage', 'Anti-Anxiety Agents/administration & dosage', 'Depressive Disorder/*drug therapy', 'Diagnosis, Differential', 'Drug Therapy, Combination', 'Duloxetine Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Humans', 'Hypertension/chemically induced/*diagnosis', 'Middle Aged', 'Selective Serotonin Reuptake Inhibitors/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27369688/
2857,alprazolam,7932278,Hypercapneic ventilatory response in patients with panic disorder before and after alprazolam treatment and in pre- and postmenstrual women.,"['Fishman SM', 'Carr DB', 'Beckett A', 'Rosenbaum JF']","['Adult', 'Alprazolam/*therapeutic use', 'Arousal/drug effects/physiology', '*Carbon Dioxide/blood', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Menstrual Cycle/drug effects/*physiology', 'Panic Disorder/diagnosis/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7932278/
2858,alprazolam,3655003,Alprazolam: effects on sleep and withdrawal phenomena.,"['Kales A', 'Bixler EO', 'Vela-Bueno A', 'Soldatos CR', 'Manfredi RL']","['Adult', 'Alprazolam/adverse effects/*therapeutic use', 'Electroencephalography', 'Humans', 'Middle Aged', 'Sleep Stages/drug effects', 'Sleep Wake Disorders/*drug therapy', 'Substance Withdrawal Syndrome/*psychology']",https://pubmed.ncbi.nlm.nih.gov/3655003/
2859,temazepam,22929751,[Choosing the correct benzodiazepine: mechanism of action and pharmacokinetics].,"['Vinkers CH', 'Tijdink JK', 'Luykx JJ', 'Vis R']","['Anti-Anxiety Agents/*pharmacokinetics', 'Anxiety/*drug therapy', 'Area Under Curve', 'Benzodiazepines/*pharmacokinetics', 'Half-Life', 'Humans', 'Kinetics', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22929751/
2860,temazepam,82859,One man's poison.,['Hunter A'],"['Capsules', 'Clinical Trials as Topic', 'Diphenhydramine/administration & dosage', 'Drug Combinations', 'Drug Evaluation', 'Flurazepam/administration & dosage', 'Humans', 'Methaqualone/administration & dosage', 'Nitrazepam/administration & dosage', 'Sleep/*drug effects', 'Temazepam/administration & dosage', '*Travel']",https://pubmed.ncbi.nlm.nih.gov/82859/
2861,temazepam,27751669,Review of Safety and Efficacy of Sleep Medicines in Older Adults.,"['Schroeck JL', 'Ford J', 'Conway EL', 'Kurtzhalts KE', 'Gee ME', 'Vollmer KA', 'Mergenhagen KA']","['Aged', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27751669/
2862,temazepam,21963855,Checkpoint control and cancer.,"['Medema RH', 'Macurek L']","['Apoptosis', 'Cell Cycle', 'Cell Cycle Checkpoints/drug effects/*physiology', '*DNA Damage', '*DNA Repair', 'Humans', 'Neoplasms/*genetics', 'Protein Kinases/metabolism', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/21963855/
2863,temazepam,17384366,Serotonin syndrome.,"['Evans CE', 'Sebastian J']","['Adult', 'Diphenhydramine/*poisoning', 'Drug Overdose', 'Female', 'Glasgow Coma Scale', 'Humans', 'Paroxetine/*poisoning', 'Serotonin Syndrome/*chemically induced', 'Temazepam/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/17384366/
2864,temazepam,9022890,Benzodiazepine misuse by drug addicts.,"['Garretty DJ', 'Wolff K', 'Hay AW', 'Raistrick D']","['Alcoholism/drug therapy', 'Benzodiazepines/*therapeutic use/*urine', 'Chromatography, High Pressure Liquid/methods', 'Diazepam/therapeutic use/urine', 'Humans', 'Narcotics', 'Nitrazepam/therapeutic use/urine', 'Nordazepam/therapeutic use/urine', 'Substance-Related Disorders/drug therapy/*epidemiology', 'Temazepam/therapeutic use/urine']",https://pubmed.ncbi.nlm.nih.gov/9022890/
2865,temazepam,6142469,Pharmacokinetics of benzodiazepine hypnotics.,"['Greenblatt DJ', 'Divoll M', 'Abernethy DR', 'Locniskar A', 'Shader RI']","['Anti-Anxiety Agents/*metabolism', 'Biotransformation', 'Drug Utilization', 'Flurazepam/metabolism', 'Humans', 'Kinetics', 'Temazepam/metabolism', 'Triazolam/metabolism', 'United States']",https://pubmed.ncbi.nlm.nih.gov/6142469/
2866,temazepam,1354722,Oral benzodiazepines and conscious sedation: a review.,['Loeffler PM'],"['Administration, Oral', 'Alprazolam/administration & dosage', 'Ambulatory Surgical Procedures', 'Anti-Anxiety Agents/*administration & dosage/pharmacology', 'Conscious Sedation/*methods', 'Diazepam/administration & dosage', 'Flurazepam/administration & dosage', 'Humans', 'Lorazepam/administration & dosage', 'Midazolam/administration & dosage', 'Oxazepam/administration & dosage', 'Premedication', 'Receptors, GABA-A/physiology', 'Temazepam/administration & dosage', 'Triazolam/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/1354722/
2867,temazepam,2071567,The beneficial and adverse effects of hypnotics.,"['Balter MB', 'Uhlenhuth EH']","['Adolescent', 'Adult', 'Aged', 'Attitude to Health', 'Benzodiazepines/adverse effects/*therapeutic use', 'Data Collection', 'Drug Prescriptions/standards', 'Evaluation Studies as Topic', 'Female', 'Flurazepam/adverse effects/therapeutic use', 'Humans', 'Hypnotics and Sedatives/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Nonprescription Drugs/adverse effects/standards', 'Sleep Initiation and Maintenance Disorders/*drug therapy/psychology', 'Telephone', 'Temazepam/adverse effects/therapeutic use', 'Triazolam/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2071567/
2868,temazepam,1680124,A review of the safety profiles of benzodiazepine hypnotics.,"['Roth T', 'Roehrs TA']","['Aged', 'Anti-Anxiety Agents/*adverse effects', 'Benzodiazepines/adverse effects', 'Central Nervous System/drug effects', 'Flurazepam/adverse effects', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/*adverse effects', 'Middle Aged', 'Psychomotor Performance/drug effects', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/chemically induced/drug therapy', 'Temazepam/adverse effects', 'Triazolam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/1680124/
2869,temazepam,19450355,Insomnia in the elderly.,"['Montgomery P', 'Lilly J']","['Aged', 'Cognitive Behavioral Therapy', 'Flurazepam/pharmacology', 'Humans', 'Risk Factors', '*Sleep/drug effects', '*Sleep Initiation and Maintenance Disorders', 'Temazepam']",https://pubmed.ncbi.nlm.nih.gov/19450355/
2870,temazepam,2904371,Pharmacokinetics of a new sublingual formulation of temazepam.,"['Russell WJ', 'Badcock NR', 'Frewin DB', 'Sansom LN']","['Administration, Oral', 'Administration, Sublingual', 'Adolescent', 'Adult', 'Anti-Anxiety Agents/*pharmacokinetics', 'Half-Life', 'Humans', 'Male', 'Metabolic Clearance Rate', 'Middle Aged', 'Random Allocation', 'Temazepam/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/2904371/
2871,temazepam,7791648,Sleep problems.,['Flamer HE'],"['Aged', 'Anti-Anxiety Agents/therapeutic use', 'Benzodiazepines', 'Humans', 'Hypnotics and Sedatives/administration & dosage/therapeutic use', 'Movement Disorders/diagnosis', 'Sleep Apnea Syndromes/diagnosis', 'Sleep Wake Disorders/diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7791648/
2872,temazepam,2071884,A comparison of the hypnotic effects of temazepam capsules and temazepam elixir.,"['Patel AG', 'Gura R', 'Kurian T', 'Lambert MT', 'Steinert J', 'Priest RG']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Dosage Forms', 'Double-Blind Method', 'Female', 'Humans', '*Hypnotics and Sedatives', 'Male', 'Middle Aged', 'Sleep/drug effects', 'Temazepam/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/2071884/
2873,temazepam,11975400,[Adverse renal effects of legal and illicit drugs].,['Orth SR'],"['Acute Kidney Injury/chemically induced', 'Adolescent', 'Adult', 'Alcoholism/complications', 'Amphetamines/adverse effects', 'Anti-Anxiety Agents/adverse effects', 'Benzodiazepines/adverse effects', 'Cocaine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions', 'Hallucinogens/adverse effects', 'Heroin/adverse effects', 'Humans', 'Illicit Drugs/*adverse effects', 'Kidney/*drug effects', 'Kidney Diseases/*chemically induced', 'Kidney Failure, Chronic/chemically induced', 'Male', 'N-Methyl-3,4-methylenedioxyamphetamine/adverse effects', 'Narcotics/adverse effects', 'Nephrotic Syndrome/chemically induced', 'Odds Ratio', 'Risk Factors', 'Smoking/adverse effects', 'Smoking Cessation', 'Substance-Related Disorders/*complications', 'Temazepam/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11975400/
2874,temazepam,2876901,Pharmacokinetics of temazepam in geriatric patients.,"['Klem K', 'Murray GR', 'Laake K']","['Aged', 'Aged, 80 and over', 'Anti-Anxiety Agents/*metabolism', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Kinetics', 'Male', 'Temazepam/blood/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/2876901/
2875,temazepam,6106488,Pharmacokinetics of benzodiazepines. Short-acting versus long-acting.,"['Breimer DD', 'Jochemsen R', 'von Albert HH']","['Anti-Anxiety Agents/administration & dosage/*metabolism/pharmacology', 'Benzodiazepines', 'Biotransformation', 'Half-Life', 'Humans', 'Kinetics']",https://pubmed.ncbi.nlm.nih.gov/6106488/
2876,temazepam,1539877,Pneumocephalus following nasotracheal intubation.,"['Conetta R', 'Nierman DM']","['Aged', 'Cerebral Hemorrhage/etiology', 'Drug Overdose', 'Female', 'Humans', 'Intubation, Intratracheal/*adverse effects', 'Nose', 'Pneumocephalus/complications/diagnostic imaging/*etiology', 'Poisoning/therapy', 'Suicide, Attempted', 'Temazepam/poisoning', 'Tomography, X-Ray Computed']",https://pubmed.ncbi.nlm.nih.gov/1539877/
2877,temazepam,23674942,Nocturnal temazepam in the treatment of narcolepsy.,"['Kansagra S', 'Walter R', 'Vaughn B']","['Adolescent', 'Adult', 'Aged', 'Child', 'Drug Administration Schedule', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', 'Middle Aged', 'Narcolepsy/*drug therapy', 'Polysomnography/methods', 'Retrospective Studies', 'Temazepam/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/23674942/
2878,temazepam,2183493,"Triazolam--an ""abused drug"" by the lay press?","['Schneider PJ', 'Perry PJ']","['Amnesia/etiology/psychology', '*Communication', 'Humans', '*Mass Media', 'Psychoses, Substance-Induced/psychology', 'Substance Withdrawal Syndrome/psychology', 'Triazolam/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2183493/
2879,loratadine,35396016,Loratadine.,"['AlMasoud N', 'Bakheit AH', 'Alshammari MFM', 'Abdel-Aziz HA', 'AlRabiah H']","['Humans', '*Hypersensitivity', '*Loratadine/chemistry/pharmacology/therapeutic use', 'Mass Spectrometry', 'Solubility', 'X-Ray Diffraction']",https://pubmed.ncbi.nlm.nih.gov/35396016/
2880,loratadine,25397904,H1-antihistamines for chronic spontaneous urticaria.,"['Sharma M', 'Bennett C', 'Cohen SN', 'Carter B']","['Cetirizine/therapeutic use', 'Cyproheptadine/analogs & derivatives/therapeutic use', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Loratadine/analogs & derivatives/therapeutic use', 'Randomized Controlled Trials as Topic', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25397904/
2881,loratadine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
2882,loratadine,12549956,Desloratadine: a nonsedating antihistamine.,"['Limon L', 'Kockler DR']","['Adult', 'Area Under Curve', 'Child', 'Female', 'Half-Life', '*Histamine H1 Antagonists, Non-Sedating/blood/pharmacokinetics/therapeutic use', 'Humans', '*Loratadine/analogs & derivatives/blood/pharmacokinetics/therapeutic use', 'Male', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12549956/
2883,loratadine,33893956,Antihistamines Modulate Functional Activity of Macrophages.,"['Plekhova NG', 'Eliseeva EV', 'Dubnyak IN']","['Animals', 'Cells, Cultured', 'Histamine Antagonists/*pharmacology', 'Humans', 'Hypersensitivity/metabolism', 'Loratadine/analogs & derivatives/pharmacology', 'Macrophages, Peritoneal/*drug effects/*metabolism', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/33893956/
2884,loratadine,38368709,Discovery of the novel and potent histamine H1 receptor antagonists for treatment of allergic diseases.,"['Chu Z', 'Cen L', 'Xu Q', 'Lin G', 'Mo J', 'Shao L', 'Zhao Y', 'Li J', 'Ye W', 'Fang T', 'Ren W', 'Zhu Q', 'He G', 'Xu Y']","['Humans', '*Histamine H1 Antagonists/pharmacology/therapeutic use', 'Receptors, Histamine H1/therapeutic use', 'Loratadine/pharmacology/therapeutic use/*analogs & derivatives', '*Hypersensitivity/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38368709/
2885,loratadine,9152563,Loratadine in the treatment of urticaria.,['Monroe EW'],"['Arrhythmias, Cardiac/chemically induced', 'Histamine H1 Antagonists/adverse effects/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*therapeutic use', 'Urticaria/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/9152563/
2886,loratadine,11964751,Are antihistamines useful in managing asthma?,['Wilson AM'],"['Acetates/agonists/metabolism', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Asthma/*drug therapy/prevention & control', 'Bronchospirometry/methods', 'Cetirizine/pharmacology', 'Cyclopropanes', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/metabolism/pharmacology/*therapeutic use', 'Humans', 'Loratadine/agonists/analogs & derivatives/*metabolism/pharmacology', 'Mannitol/administration & dosage/*metabolism', 'Quinolines/agonists/metabolism', 'Rhinitis/metabolism', 'Sulfides', 'Terfenadine/*analogs & derivatives/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11964751/
2887,loratadine,11583068,Triamcinolone: new and old indications.,['Doggrell SA'],"['Administration, Intranasal', 'Adult', 'Aerosols', 'Androstadienes/therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Astemizole/therapeutic use', 'Asthma/drug therapy', 'Child', 'Clinical Trials as Topic', 'Conjunctivitis, Allergic/drug therapy', 'Dose-Response Relationship, Drug', 'Fluticasone', 'Humans', 'Injections, Intramuscular', 'Loratadine/therapeutic use', 'Lung Diseases, Obstructive/drug therapy', 'Macular Degeneration/drug therapy', 'Molecular Structure', 'Nasal Mucosa/drug effects', 'Rhinitis, Allergic, Perennial/etiology', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Structure-Activity Relationship', 'Triamcinolone/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11583068/
2888,loratadine,11243502,Desloratadine in the treatment of chronic idiopathic urticaria.,"['Ring J', 'Hein R', 'Gauger A']","['Cholinergic Antagonists/pharmacology/*therapeutic use', 'Chronic Disease', 'Cytokines/drug effects', 'Histamine H1 Antagonists/pharmacology/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacology/*therapeutic use', 'Severity of Illness Index', 'Time Factors', 'Treatment Outcome', 'Urticaria/*drug therapy/etiology/immunology']",https://pubmed.ncbi.nlm.nih.gov/11243502/
2889,loratadine,11398910,Desloratadine.,"['McClellan K', 'Jarvis B']","['Asthma/drug therapy', 'Clinical Trials as Topic', 'Drug Interactions', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Loratadine/analogs & derivatives/pharmacokinetics/pharmacology/*therapeutic use', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11398910/
2890,loratadine,10444237,Cardiovascular profile of loratadine.,"['Hey JA', 'Affrime M', 'Cobert B', 'Kreutner W', 'Cuss FM']","['Animals', 'Cardiovascular System/*drug effects', '*Cation Transport Proteins', '*DNA-Binding Proteins', 'Drug Interactions', 'ERG1 Potassium Channel', 'Electrocardiography/drug effects', 'Ether-A-Go-Go Potassium Channels', 'Histamine H1 Antagonists/*adverse effects', 'Humans', 'Loratadine/*adverse effects', 'Potassium Channels/drug effects', '*Potassium Channels, Voltage-Gated', '*Trans-Activators', 'Transcriptional Regulator ERG']",https://pubmed.ncbi.nlm.nih.gov/10444237/
2891,loratadine,28458435,Ciprofloxacin induced acute generallised exanthematous pustulosis.,"['Foti C', 'Romita P', 'Zanframundo G', 'Mastrolonardo M', 'Angelini G', 'Calogiuri G', 'Nettis E', 'Bonamonte D']","['Acute Generalized Exanthematous Pustulosis/*etiology/pathology', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Ciprofloxacin/administration & dosage/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Female', 'Fever/etiology', 'Humans', 'Intertrigo/drug therapy', 'Loratadine/administration & dosage/analogs & derivatives', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/28458435/
2892,loratadine,15245363,Antihistamines: do they work? Further well-controlled trials involving larger samples are needed.,"['Fumagalli F', 'Baiardini I', 'Pasquali M', 'Compalati E', 'Guerra L', 'Massacane P', 'Canonica GW']","['Anti-Allergic Agents/*therapeutic use', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Histamine H1 Antagonists/*therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hypersensitivity/*drug therapy', 'Loratadine/*analogs & derivatives/therapeutic use', 'Piperazines/therapeutic use', 'Quality of Life']",https://pubmed.ncbi.nlm.nih.gov/15245363/
2893,loratadine,19473112,Desloratadine and pseudoephedrine combination therapy as a comprehensive treatment for allergic rhinitis and nasal congestion.,['Anolik R'],"['Clinical Trials as Topic', 'Drug Combinations', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Nasal Decongestants/pharmacology/*therapeutic use', 'Nasal Obstruction/*drug therapy', 'Pseudoephedrine/pharmacology/*therapeutic use', 'Quality of Life', 'Rhinitis, Allergic, Perennial/*drug therapy', 'Rhinitis, Allergic, Seasonal/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19473112/
2894,loratadine,38163866,Loratidine is associated with improved prognosis and exerts antineoplastic effects via apoptotic and pyroptotic crosstalk in lung cancer.,"['Liu X', 'Zhong R', 'Huang J', 'Chen Z', 'Xu H', 'Lin L', 'Cai Q', 'He M', 'Lao S', 'Deng H', 'Li C', 'Li J', 'Zheng Y', 'Liu X', 'Zeng R', 'He J', 'Liang W']","['Animals', 'Humans', '*Lung Neoplasms/drug therapy/genetics/pathology', 'Loratadine/pharmacology/therapeutic use', 'Retrospective Studies', 'Caspase 8', '*Antineoplastic Agents/pharmacology/therapeutic use', 'Apoptosis', 'Prognosis']",https://pubmed.ncbi.nlm.nih.gov/38163866/
2895,loratadine,17176780,Effect of desloratadine on the control of morning symptoms in patients with seasonal and perennial allergic rhinitis.,['Schenkel EJ'],"['Animals', 'Circadian Rhythm/*drug effects/physiology', 'Histamine H1 Antagonists, Non-Sedating/pharmacology/*therapeutic use', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Rhinitis, Allergic, Perennial/*drug therapy/*physiopathology', 'Rhinitis, Allergic, Seasonal/*drug therapy/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/17176780/
2896,loratadine,25752982,Loratadine analogues as MAGL inhibitors.,"['Patel JZ', 'Ahenkorah S', 'Vaara M', 'Staszewski M', 'Adams Y', 'Laitinen T', 'Navia-Paldanius D', 'Parkkari T', 'Savinainen JR', 'Walczynski K', 'Laitinen JT', 'Nevalainen TJ']","['Amidohydrolases/antagonists & inhibitors/metabolism', 'Dose-Response Relationship, Drug', 'Enzyme Inhibitors/chemical synthesis/chemistry/*pharmacology', 'Humans', 'Loratadine/chemical synthesis/chemistry/*pharmacology', 'Models, Molecular', 'Molecular Structure', 'Monoacylglycerol Lipases/*antagonists & inhibitors/metabolism', 'Recombinant Proteins/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/25752982/
2897,loratadine,32043642,Desloratadine inhibits heterotopic ossification by suppression of BMP2-Smad1/5/8 signaling.,"['Kusano T', 'Nakatani M', 'Ishiguro N', 'Ohno K', 'Yamamoto N', 'Morita M', 'Yamada H', 'Uezumi A', 'Tsuchida K']","['Animals', 'Bone Morphogenetic Protein 2/*physiology', 'Cell Differentiation/drug effects', 'Loratadine/*analogs & derivatives/pharmacology/therapeutic use', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Ossification, Heterotopic/*prevention & control', 'Osteogenesis/drug effects', 'Receptor, Platelet-Derived Growth Factor alpha/analysis', 'Signal Transduction/drug effects', 'Smad Proteins/*physiology']",https://pubmed.ncbi.nlm.nih.gov/32043642/
2898,loratadine,29380864,The treatment outcomes and dose de-escalation of desloratadine up-dosing in chronic spontaneous urticaria.,"['Choonhakarn C', 'Chaowattanapanit S', 'Julanon N']","['Adult', 'Chronic Disease', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*administration & dosage/adverse effects', 'Humans', 'Loratadine/administration & dosage/adverse effects/*analogs & derivatives', 'Maintenance Chemotherapy/methods', 'Male', 'Middle Aged', 'Recurrence', 'Remission Induction/methods', 'Retreatment', 'Retrospective Studies', 'Treatment Outcome', 'Urticaria/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29380864/
2899,donepezil,33035532,Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.,"['Marucci G', 'Buccioni M', 'Ben DD', 'Lambertucci C', 'Volpini R', 'Amenta F']","['Alzheimer Disease/*drug therapy', 'Antioxidants/therapeutic use', 'Cholinesterase Inhibitors/*therapeutic use', 'Donepezil/therapeutic use', 'Drug Therapy, Combination', 'Excitatory Amino Acid Antagonists/therapeutic use', 'Galantamine/therapeutic use', 'Humans', 'Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors', 'Rivastigmine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33035532/
2900,donepezil,38484213,Lecanemab Questions.,['Nadeau SE'],"['Humans', '*Alzheimer Disease/diagnostic imaging/drug therapy/psychology', 'Antibodies, Monoclonal, Humanized/therapeutic use', 'Cognition', 'Donepezil/pharmacology/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38484213/
2901,donepezil,37479527,Lecanemab: Looking Before We Leap.,"['Burke JF', 'Kerber KA', 'Langa KM', 'Albin RL', 'Kotagal V']","['Aged', 'Humans', '*Alzheimer Disease/drug therapy/epidemiology', '*Dementia', 'Donepezil/therapeutic use', 'Medicare', 'United States', '*Antibodies, Monoclonal, Humanized/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37479527/
2902,donepezil,30349215,Clinical efficacy and safety of donepezil in the treatment of Alzheimer's disease in Chinese patients.,"['Zhang N', 'Gordon ML']","['Alzheimer Disease/*drug therapy', 'China', 'Cholinesterase Inhibitors/adverse effects/*therapeutic use', 'Cognitive Dysfunction/*drug therapy', 'Donepezil/adverse effects/*therapeutic use', 'Humans', 'Memantine/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30349215/
2903,donepezil,34924395,The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.,"['Fan F', 'Liu H', 'Shi X', 'Ai Y', 'Liu Q', 'Cheng Y']","['Activities of Daily Living/*psychology', 'Alzheimer Disease/*drug therapy', 'Amino Acids/therapeutic use', 'Cholinesterase Inhibitors/*therapeutic use', 'Cognition/drug effects', 'Donepezil/therapeutic use', 'Galantamine/therapeutic use', 'Ginkgo biloba', 'Humans', 'Nootropic Agents/*therapeutic use', '*Patient Safety', 'Plant Extracts/therapeutic use', 'Rivastigmine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34924395/
2904,donepezil,37381137,A Novel Formulation: Donepezil Patch.,"['Adelman M', 'Louis L']","['Humans', '*Acetylcholinesterase', 'Donepezil/therapeutic use', '*Drug-Related Side Effects and Adverse Reactions', 'Rivastigmine/therapeutic use', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/37381137/
2905,donepezil,34851866,Impact of Donepezil and Memantine on Behavioral and Psychological Symptoms of Alzheimer Disease: Six-month Open-label Study.,"['Bago Rozankovic P', 'Rozankovic M', 'Badzak J', 'Stojic M', 'Susak Sporis I']","['*Alzheimer Disease/complications/drug therapy', 'Behavioral Symptoms/drug therapy', 'Donepezil/therapeutic use', 'Humans', 'Indans/therapeutic use', '*Memantine/therapeutic use', 'Piperidines/therapeutic use', 'Prospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34851866/
2906,donepezil,35473731,Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.,"['Veroniki AA', 'Ashoor HM', 'Rios P', 'Seitidis G', 'Stewart L', 'Clarke M', 'Tudur-Smith C', 'Mavridis D', 'Hemmelgarn BR', 'Holroyd-Leduc J', 'Straus SE', 'Tricco AC']","['Adult', '*Alzheimer Disease/drug therapy', 'Donepezil/therapeutic use', 'Galantamine/therapeutic use', 'Humans', 'Memantine/therapeutic use', 'Network Meta-Analysis', '*Nootropic Agents/adverse effects', 'Rivastigmine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35473731/
2907,donepezil,24662102,"Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.","['Tan CC', 'Yu JT', 'Wang HF', 'Tan MS', 'Meng XF', 'Wang C', 'Jiang T', 'Zhu XC', 'Tan L']","['Alzheimer Disease/*drug therapy', 'Cholinesterase Inhibitors/administration & dosage', 'Donepezil', 'Galantamine/adverse effects/*therapeutic use', 'Humans', 'Indans/adverse effects/*therapeutic use', 'Memantine/adverse effects/*therapeutic use', 'Nootropic Agents/adverse effects/*therapeutic use', 'Phenylcarbamates/adverse effects/*therapeutic use', 'Piperidines/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rivastigmine']",https://pubmed.ncbi.nlm.nih.gov/24662102/
2908,donepezil,34602041,Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.,"['Sivaraman B', 'Raji V', 'Velmurugan BA', 'Natarajan R']","['Acetylcholinesterase', '*Alzheimer Disease/drug therapy', '*Cholinesterase Inhibitors/pharmacology/therapeutic use', 'Donepezil/therapeutic use', 'Humans', 'Rivastigmine/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34602041/
2909,donepezil,34137271,Multitarget therapeutic approaches for Alzheimer's and Parkinson's diseases: an opportunity or an illusion?,['Matos MJ'],"['Alzheimer Disease/*drug therapy/pathology', 'Donepezil/chemistry/pharmacology/therapeutic use', 'Drug Synergism', 'Humans', 'Indans/chemistry/pharmacology/therapeutic use', 'Neuroprotective Agents/chemistry/pharmacology/*therapeutic use', 'Parkinson Disease/*drug therapy/pathology', 'Protein Aggregates/drug effects', 'Small Molecule Libraries/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34137271/
2910,donepezil,33704781,Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta-analysis.,"['Battle CE', 'Abdul-Rahim AH', 'Shenkin SD', 'Hewitt J', 'Quinn TJ']","['Activities of Daily Living', 'Bias', 'Cholinesterase Inhibitors/*administration & dosage/adverse effects', 'Cognition/drug effects', 'Dementia, Vascular/*drug therapy', 'Donepezil/*administration & dosage/adverse effects', 'Galantamine/*administration & dosage/adverse effects', 'Humans', '*Network Meta-Analysis', 'Nootropic Agents/administration & dosage/adverse effects', 'Physical Functional Performance', 'Placebos/therapeutic use', 'Randomized Controlled Trials as Topic', 'Rivastigmine/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33704781/
2911,donepezil,38640313,Evaluating the efficacy and safety of Alzheimer's disease drugs: A meta-analysis and systematic review.,"['Chen Y', 'Lai M', 'Tao M']","['Humans', '*Alzheimer Disease/drug therapy/chemically induced', 'Donepezil/therapeutic use', 'Galantamine/therapeutic use', 'Memantine/therapeutic use', 'Molecular Docking Simulation', 'Cholinesterase Inhibitors/therapeutic use', 'Rivastigmine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38640313/
2912,donepezil,32457075,Cholinergic Modulation of Binocular Vision.,"['Sheynin Y', 'Rosa-Neto P', 'Hess RF', 'Vaucher E']","['Acetylcholine/pharmacology', 'Adult', 'Cholinergic Agents/pharmacology', 'Cholinesterase Inhibitors/pharmacology', 'Cross-Over Studies', 'Donepezil/pharmacology', 'Female', 'Functional Laterality/drug effects', 'Humans', 'Male', 'Parasympathetic Nervous System/drug effects/*physiology', 'Photic Stimulation', 'Psychomotor Performance/drug effects', 'Vision Disparity', 'Vision, Binocular/drug effects/*physiology', 'Young Adult', 'gamma-Aminobutyric Acid/physiology']",https://pubmed.ncbi.nlm.nih.gov/32457075/
2913,donepezil,17939763,Donepezil for Alzheimer's disease.,"['Benjamin B', 'Burns A']","['Alzheimer Disease/*drug therapy/enzymology/physiopathology', 'Animals', 'Cholinesterase Inhibitors/adverse effects/pharmacology/therapeutic use', 'Donepezil', 'Humans', 'Indans/adverse effects/pharmacology/*therapeutic use', 'Nootropic Agents/adverse effects/pharmacology/therapeutic use', 'Piperidines/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17939763/
2914,donepezil,29772289,Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.,"['Agrawal M', 'Saraf S', 'Saraf S', 'Antimisiaris SG', 'Chougule MB', 'Shoyele SA', 'Alexander A']","['Administration, Intranasal', 'Alzheimer Disease/*drug therapy', 'Animals', 'Biological Availability', 'Blood-Brain Barrier/*metabolism', '*Brain', 'Deferoxamine/administration & dosage/pharmacokinetics/therapeutic use', 'Donepezil/administration & dosage/pharmacokinetics/therapeutic use', 'Drug Carriers/administration & dosage/*pharmacokinetics/therapeutic use', 'Drug Liberation', 'Galantamine/administration & dosage/pharmacokinetics/therapeutic use', 'Humans', 'Mucociliary Clearance', 'Nanoparticles/*chemistry', 'Nasal Mucosa/metabolism', '*Nose', 'Olfactory Bulb/metabolism', 'Risperidone/administration & dosage/pharmacokinetics/therapeutic use', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/29772289/
2915,donepezil,11893059,Donepezil hydrochloride: a treatment drug for Alzheimer's disease.,['Sugimoto H'],"['Alzheimer Disease/*drug therapy', 'Cholinesterase Inhibitors/*chemistry/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Donepezil', 'Humans', 'Indans/*chemistry/pharmacology/therapeutic use', 'Nootropic Agents/chemistry/pharmacology/therapeutic use', 'Piperidines/*chemistry/pharmacology/therapeutic use', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/11893059/
2916,donepezil,39598703,New Insights into the Development of Donepezil-Based Hybrid and Natural Molecules as Multi-Target Drug Agents for Alzheimer's Disease Treatment.,"['Angelova VT', 'Stoyanov BP', 'Simeonova R']","['*Alzheimer Disease/drug therapy/metabolism', 'Humans', '*Donepezil/therapeutic use/pharmacology/chemistry', '*Biological Products/chemistry/therapeutic use/pharmacology', 'Animals', 'Cholinesterase Inhibitors/chemistry/pharmacology/therapeutic use', 'Drug Development', 'Drug Design']",https://pubmed.ncbi.nlm.nih.gov/39598703/
2917,donepezil,30372021,Classics in Chemical Neuroscience: Donepezil.,"['Brewster JT 2nd', ""Dell'Acqua S"", 'Thach DQ', 'Sessler JL']","['Acetylcholinesterase/metabolism', 'Alzheimer Disease/drug therapy/metabolism', 'Animals', 'Cholinesterase Inhibitors/*chemistry/pharmacology/*therapeutic use', 'Donepezil/*chemistry/pharmacology/*therapeutic use', 'Humans', 'Nerve Degeneration/drug therapy/metabolism', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/30372021/
2918,donepezil,39545607,Metabolic Activation and Cytotoxicity of Donepezil Induced by CYP3A4.,"['Zheng J', 'Zhao G', 'Hu Z', 'Jia C', 'Li W', 'Peng Y', 'Zheng J']","['*Donepezil/metabolism/pharmacology/chemistry', 'Animals', '*Cytochrome P-450 CYP3A/metabolism', 'Rats', 'Humans', '*Hepatocytes/drug effects/metabolism', '*Piperidines/pharmacology/chemistry/metabolism', 'Male', '*Rats, Sprague-Dawley', '*Indans/chemistry/toxicity/pharmacology', 'Cholinesterase Inhibitors/toxicity/chemistry/metabolism', 'Microsomes, Liver/metabolism', 'Activation, Metabolic', 'Glutathione/metabolism', 'Ketoconazole/pharmacology', 'Cytochrome P-450 CYP3A Inhibitors/pharmacology/chemistry', 'Tandem Mass Spectrometry']",https://pubmed.ncbi.nlm.nih.gov/39545607/
2919,terazosin,31524631,Enhancing glycolysis attenuates Parkinson's disease progression in models and clinical databases.,"['Cai R', 'Zhang Y', 'Simmering JE', 'Schultz JL', 'Li Y', 'Fernandez-Carasa I', 'Consiglio A', 'Raya A', 'Polgreen PM', 'Narayanan NS', 'Yuan Y', 'Chen Z', 'Su W', 'Han Y', 'Zhao C', 'Gao L', 'Ji X', 'Welsh MJ', 'Liu L']","['Adenosine Triphosphate/metabolism', 'Aged', 'Aged, 80 and over', 'Animals', 'Brain/drug effects/metabolism', 'Disease Progression', 'Dopamine/metabolism', 'Drosophila melanogaster/drug effects/metabolism', 'Female', 'Glycolysis/*drug effects', 'Humans', 'Induced Pluripotent Stem Cells/drug effects/metabolism', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Nerve Degeneration/drug therapy', 'Parkinson Disease/*drug therapy/*metabolism', 'Parkinsonian Disorders/drug therapy/metabolism', 'Phosphoglycerate Kinase/metabolism', 'Prazosin/*analogs & derivatives/pharmacology', 'Rats']",https://pubmed.ncbi.nlm.nih.gov/31524631/
2920,terazosin,16613526,BPH: epidemiology and comorbidities.,['McVary KT'],"['5-alpha Reductase Inhibitors', 'Adrenergic alpha-Antagonists/therapeutic use', 'Adult', 'Age Distribution', 'Aged', 'Aged, 80 and over', 'Cardiovascular Diseases/epidemiology', 'Comorbidity', 'Diabetes Complications/epidemiology', 'Enzyme Inhibitors/therapeutic use', 'Erectile Dysfunction/epidemiology', 'Global Health', 'Humans', 'Male', 'Metabolic Syndrome/epidemiology', 'Middle Aged', 'Prevalence', 'Prostatic Hyperplasia/*epidemiology/therapy', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/16613526/
2921,terazosin,11074198,Alpha blockers: are all created equal?,['Debruyne FM'],"['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Humans', 'Male', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11074198/
2922,terazosin,27476127,"alpha-Blockers, 5-alpha-Reductase Inhibitors, Acetylcholine, beta3 Agonists, and Phosphodiesterase-5s in Medical Management of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia: How Much Do the Different Formulations Actually Matter in the Classes?","['Chughtai B', 'Thomas D', 'Kaplan S']","['5-alpha Reductase Inhibitors/*therapeutic use', 'Acetylcholine/*therapeutic use', 'Adrenergic beta-3 Receptor Agonists/*therapeutic use', 'Cholinergic Agonists/therapeutic use', 'Cyclic Nucleotide Phosphodiesterases, Type 5/*therapeutic use', 'Humans', 'Lower Urinary Tract Symptoms/*drug therapy/etiology/physiopathology', 'Male', 'Muscarinic Antagonists/*therapeutic use', 'Prostatic Hyperplasia/*complications/drug therapy', 'Urodynamics/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27476127/
2923,terazosin,8094084,Antihypertensive therapy in the geriatric patient: II. A review of the alpha1-adrenergic blocking agents.,"['Studer JA', 'Piepho RW']","['Adrenergic alpha-Antagonists/pharmacokinetics/pharmacology/*therapeutic use', 'Age Factors', 'Aged', 'Antihypertensive Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Heart Failure/complications/drug therapy', 'Humans', 'Hypertension/*drug therapy', 'Hypertrophy, Left Ventricular/complications/drug therapy', 'Male']",https://pubmed.ncbi.nlm.nih.gov/8094084/
2924,terazosin,9160069,Side effects of terazosin in the treatment of symptomatic benign prostatic hyperplasia.,"['McKiernan JM', 'Lowe FC']","['Adrenergic alpha-Antagonists/administration & dosage/*adverse effects/therapeutic use', 'Aged', 'Aged, 80 and over', 'Clinical Trials as Topic', 'Dizziness/chemically induced', 'Humans', 'Hypotension/etiology', 'Male', 'Prazosin/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Prospective Studies', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9160069/
2925,terazosin,11750252,"Terazosin, doxazosin, and prazosin: current clinical experience.","['Akduman B', 'Crawford ED']","['Adrenergic alpha-Antagonists/adverse effects/pharmacokinetics/*therapeutic use', 'Adult', 'Aged', 'Doxazosin/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Prazosin/adverse effects/*analogs & derivatives/pharmacokinetics/*therapeutic use', 'Prostatic Hyperplasia/complications/*drug therapy', 'Randomized Controlled Trials as Topic', 'Receptors, Adrenergic, alpha/classification']",https://pubmed.ncbi.nlm.nih.gov/11750252/
2926,terazosin,2883273,"Terazosin: a new alpha 1-blocker for the treatment of hypertension: a review of randomized, controlled clinical trials of once-daily administration as monotherapy.","['Luther RR', 'Glassman HN', 'Sperzel WD', 'Steinberg FJ', 'Horton JK', 'Jordan DC']","['Adrenergic alpha-Antagonists/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Hypertension/*drug therapy', 'Prazosin/*analogs & derivatives/therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/2883273/
2927,terazosin,29334287,Efficacy and safety of alpha blockers in medical expulsive therapy for ureteral stones: a mixed treatment network meta-analysis and trial sequential analysis of randomized controlled clinical trials.,"['Sridharan K', 'Sivaramakrishnan G']","['Adrenal Cortex Hormones/administration & dosage', 'Adrenergic alpha-Antagonists/*administration & dosage/adverse effects', 'Adult', 'Child', 'Drug Therapy, Combination', 'Humans', 'Phosphodiesterase Inhibitors/administration & dosage', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic', 'Sulfonamides/*administration & dosage/adverse effects', 'Tamsulosin', 'Treatment Outcome', 'Ureteral Calculi/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29334287/
2928,terazosin,22080875,alpha-Blockers for benign prostatic hyperplasia: the new era.,"['Lepor H', 'Kazzazi A', 'Djavan B']","['Adrenergic alpha-1 Receptor Antagonists/adverse effects/chemistry/*therapeutic use', 'Animals', 'Drug Design', 'Humans', 'Lower Urinary Tract Symptoms/drug therapy/etiology', 'Male', 'Prostatic Hyperplasia/complications/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22080875/
2929,terazosin,9732825,Cardiovascular effects of alpha-blockers used for the treatment of symptomatic BPH: impact on safety and well-being.,['de Mey C'],"['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Blood Pressure/*drug effects', 'Humans', 'Male', 'Prostatic Hyperplasia/complications/*drug therapy', 'Sulfonamides/adverse effects/therapeutic use', 'Tamsulosin', 'Urinary Bladder Neck Obstruction/etiology']",https://pubmed.ncbi.nlm.nih.gov/9732825/
2930,terazosin,9021791,"Measures of Proscar, Hytrin, and Cardura side effects.",['Frankel S'],"['Adrenergic alpha-Antagonists/adverse effects', 'Doxazosin/*adverse effects', 'Finasteride/*adverse effects', 'Humans', 'Male', 'Prazosin/adverse effects/*analogs & derivatives', 'Prostatic Hyperplasia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9021791/
2931,terazosin,26245042,Role of Alpha Blockers in Hypertension with Benign Prostatic Hyperplasia.,"['Mathur RP', 'Nayak S', 'Sivaramakrishnan R', 'Jain V']","['Adrenergic alpha-Antagonists/adverse effects/*therapeutic use', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Autonomic Nervous System/physiopathology', 'Humans', 'Hypertension/*complications/*drug therapy/epidemiology/physiopathology', 'Male', 'Prostatic Hyperplasia/*complications/epidemiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/26245042/
2932,terazosin,29971698,Is Tamsulosin Linked to Dementia in the Elderly?,"['Frankel JK', 'Duan Y', 'Albertsen PC']","['Adrenergic alpha-1 Receptor Antagonists/adverse effects/pharmacology/therapeutic use', 'Aged', 'Brain/drug effects', 'Cognition/drug effects/physiology', 'Dementia/*chemically induced', 'Humans', 'Lower Urinary Tract Symptoms/*drug therapy', 'Sulfonamides/*adverse effects/therapeutic use', 'Tamsulosin', 'Urological Agents/*adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29971698/
2933,terazosin,15155119,Combination of finasteride and doxazosin for the treatment of benign prostatic hyperplasia.,['Doggrell SA'],"['Clinical Trials as Topic', 'Doxazosin/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Drug Synergism', '*Drug Therapy, Combination', 'Finasteride/*therapeutic use', 'Follow-Up Studies', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prostatic Hyperplasia/*drug therapy', 'Sulfonamides/therapeutic use', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/15155119/
2934,terazosin,9061268,Treatment of benign prostatic hyperplasia. A pharmacoeconomic perspective.,"['Eri LM', 'Tveter KJ']","['Adrenergic alpha-Antagonists/adverse effects/economics/*therapeutic use', 'Aged', 'Enzyme Inhibitors/adverse effects/economics/*therapeutic use', 'Finasteride/adverse effects/economics/*therapeutic use', 'Humans', 'Male', 'Middle Aged', ""Practice Patterns, Physicians'"", 'Prazosin/adverse effects/*analogs & derivatives/economics/therapeutic use', 'Prevalence', 'Prostatectomy/*economics', 'Prostatic Hyperplasia/*drug therapy/*economics/epidemiology/surgery', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9061268/
2935,terazosin,15549140,Unresolved priapism secondary to tamsulosin.,"['Pahuja A', 'Bashir J', 'Williamson EM', 'Barber N']","['Adrenergic alpha-Antagonists/*adverse effects', 'Blood Flow Velocity', 'Humans', 'Male', 'Middle Aged', 'Penis/blood supply/diagnostic imaging', 'Priapism/*chemically induced', 'Prostatic Hyperplasia/drug therapy', 'Sulfonamides/*adverse effects', 'Tamsulosin', 'Ultrasonography']",https://pubmed.ncbi.nlm.nih.gov/15549140/
2936,terazosin,10750258,The role of alpha 1-blockers in combination therapy for hypertension.,['Zusman RM'],"['Adrenergic alpha-Antagonists/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Diabetes Mellitus, Type 2/drug therapy', 'Doxazosin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hyperlipidemias/drug therapy', 'Hypertension/*drug therapy', 'Male', 'Prazosin/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10750258/
2937,terazosin,30395035,Factors Affecting Urinary Retention in Critically Ill Trauma Patients.,"['Fowler S', 'Urban S', 'Taggart H']","['Adult', 'Catheters, Indwelling/*adverse effects', 'Cohort Studies', 'Critical Illness/*therapy', 'Female', 'Humans', 'Male', 'Middle Aged', 'Prazosin/*analogs & derivatives/therapeutic use', 'Prognosis', 'Retrospective Studies', 'Risk Factors', 'Spinal Injuries/complications', 'Tamsulosin/*therapeutic use', 'Trauma Centers', 'Treatment Outcome', 'Urinary Catheterization/adverse effects/methods', 'Urinary Retention/*drug therapy/etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/30395035/
2938,terazosin,33566468,Otorhinolaryngological adverse effects of urological drugs.,"['Maia NPD', 'Lopes KC', 'Gananca FF']","['Adrenergic alpha-Antagonists', 'Doxazosin', 'Humans', 'Male', '*Pharmaceutical Preparations', 'Prazosin', '*Prostatic Hyperplasia', 'Tadalafil', 'Tamsulosin']",https://pubmed.ncbi.nlm.nih.gov/33566468/
2939,zaleplon,37549414,Insomnia Management: A Review and Update.,['Shaha DP'],"['Humans', '*Sleep Initiation and Maintenance Disorders/diagnosis/drug therapy', 'Sleep', 'Zolpidem', 'Doxepin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37549414/
2940,zaleplon,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
2941,zaleplon,36701954,Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis.,"['Yue JL', 'Chang XW', 'Zheng JW', 'Shi L', 'Xiang YJ', 'Que JY', 'Yuan K', 'Deng JH', 'Teng T', 'Li YY', 'Sun W', 'Sun HQ', 'Vitiello MV', 'Tang XD', 'Zhou XY', 'Bao YP', 'Shi J', 'Lu L']","['Humans', 'Adult', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Network Meta-Analysis', 'Sleep', 'Hypnotics and Sedatives/adverse effects', 'Wakefulness', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36701954/
2942,zaleplon,29487083,"Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.","['Atkin T', 'Comai S', 'Gobbi G']","['Benzodiazepines/adverse effects/pharmacology/*therapeutic use', 'Drug Discovery/*methods', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacology/*therapeutic use', 'Pharmacology, Clinical/*methods', 'Precision Medicine', 'Sleep Aids, Pharmaceutical/adverse effects/pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29487083/
2943,zaleplon,28671376,Insomnia: Pharmacologic Therapy.,"['Matheson E', 'Hainer BL']","['Benzodiazepines/administration & dosage/therapeutic use', 'Doxepin/administration & dosage/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage/therapeutic use', 'Melatonin/administration & dosage/agonists/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28671376/
2944,zaleplon,27998379,Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline.,"['Sateia MJ', 'Buysse DJ', 'Krystal AD', 'Neubauer DN', 'Heald JL']","['Academies and Institutes', 'Adult', 'Central Nervous System Depressants/*therapeutic use', 'Chronic Disease', 'GABA Modulators/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Sleep Aids, Pharmaceutical/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy', 'Sleep Medicine Specialty', 'United States']",https://pubmed.ncbi.nlm.nih.gov/27998379/
2945,zaleplon,11716908,Pyrazolopyrimidines.,['George CF'],"['*Acetamides/metabolism/pharmacokinetics/therapeutic use', 'Aged', 'Biological Availability', 'Child', 'Half-Life', 'Humans', '*Hypnotics and Sedatives/metabolism/pharmacokinetics/therapeutic use', 'Psychomotor Performance/drug effects', '*Pyrimidines/metabolism/pharmacokinetics/therapeutic use', 'Receptors, GABA/*drug effects/metabolism', 'Sleep/drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11716908/
2946,zaleplon,20945020,[The newer sedative-hypnotics].,"['Sukys-Claudino L', 'Moraes WA', 'Tufik S', 'Poyares D']","['Antidepressive Agents/*therapeutic use', 'GABA Agonists/*therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Receptor, Melatonin, MT1/*agonists', 'Receptor, Melatonin, MT2/*agonists', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20945020/
2947,zaleplon,27751669,Review of Safety and Efficacy of Sleep Medicines in Older Adults.,"['Schroeck JL', 'Ford J', 'Conway EL', 'Kurtzhalts KE', 'Gee ME', 'Vollmer KA', 'Mergenhagen KA']","['Aged', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27751669/
2948,zaleplon,34121443,Comparative efficacy of lemborexant and other insomnia treatments: a network meta-analysis.,"['McElroy H', ""O'Leary B"", 'Adena M', 'Campbell R', 'Monfared AAT', 'Meier G']","['Humans', '*Orexin Receptor Antagonists/therapeutic use', '*Pyridines/therapeutic use', '*Pyrimidines/therapeutic use', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Treatment Outcome', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/34121443/
2949,zaleplon,21459634,Serotonin control of sleep-wake behavior.,['Monti JM'],"['Animals', 'Brain/physiology', 'Humans', 'Mice', 'Raphe Nuclei/physiology', 'Rats', 'Receptors, Serotonin/physiology', 'Serotonin/*physiology', 'Sleep/*physiology', 'Sleep Wake Disorders/physiopathology', 'Sleep, REM/physiology', 'Wakefulness/*physiology']",https://pubmed.ncbi.nlm.nih.gov/21459634/
2950,zaleplon,28845958,Sleep Disorders: Insomnia.,['Burman D'],"['Cognitive Behavioral Therapy/*methods', 'GABA-A Receptor Agonists/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Medical History Taking', 'Relaxation Therapy/methods', 'Sleep', 'Sleep Initiation and Maintenance Disorders/*diagnosis/drug therapy/*therapy']",https://pubmed.ncbi.nlm.nih.gov/28845958/
2951,zaleplon,11388587,A psychiatric perspective on insomnia.,['McCall WV'],"['Acetamides/therapeutic use', 'Benzodiazepines/therapeutic use', 'Comorbidity', 'Depressive Disorder/diagnosis/drug therapy/psychology', 'Diagnosis, Differential', 'GABA-A Receptor Agonists', 'Humans', 'Hypnotics and Sedatives/therapeutic use', 'Mental Disorders/*diagnosis/drug therapy/epidemiology', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*diagnosis/drug therapy/epidemiology', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11388587/
2952,zaleplon,18693067,Hypnotic use for insomnia management in chronic obstructive pulmonary disease.,['Roth T'],"['Humans', 'Hypnotics and Sedatives/*administration & dosage/*adverse effects', 'Pulmonary Disease, Chronic Obstructive/*complications', 'Sleep Initiation and Maintenance Disorders/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18693067/
2953,zaleplon,31152244,Drug Interactions in Space: a Cause for Concern?,"['Berman E', 'Eyal S']","['Computational Biology', 'Databases, Pharmaceutical', '*Drug Interactions', 'Drug-Related Side Effects and Adverse Reactions/*metabolism', 'Humans', 'Pharmacokinetics', 'Prescription Drugs/*metabolism', 'Severity of Illness Index', '*Space Flight']",https://pubmed.ncbi.nlm.nih.gov/31152244/
2954,zaleplon,10755806,Perspectives on the management of insomnia in patients with chronic respiratory disorders.,['George CF'],"['Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Lung Diseases, Obstructive/*complications', 'Sleep Apnea, Obstructive/*complications', 'Sleep Initiation and Maintenance Disorders/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10755806/
2955,zaleplon,16750956,"Insomnia in the elderly: cause, approach, and treatment.","['Kamel NS', 'Gammack JK']","['Acetamides/therapeutic use', 'Aged', '*Aging', 'Antidepressive Agents/therapeutic use', 'Azabicyclo Compounds', 'Behavior Therapy', 'Benzodiazepines/therapeutic use', 'Humans', 'Hypnotics and Sedatives/*therapeutic use', 'Nonprescription Drugs/therapeutic use', 'Piperazines/therapeutic use', 'Pyridines/therapeutic use', 'Pyrimidines/therapeutic use', 'Receptor, Melatonin, MT1/agonists', 'Receptor, Melatonin, MT2/agonists', 'Sleep/*drug effects', 'Sleep Initiation and Maintenance Disorders/drug therapy/*etiology/physiopathology/*therapy', 'Sleep, REM/drug effects', 'Thiophenes/therapeutic use', 'Trazodone/therapeutic use', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/16750956/
2956,zaleplon,11388589,Consequences of insomnia and its therapies.,['Benca RM'],"['Acetamides/adverse effects/pharmacokinetics/therapeutic use', 'Circadian Rhythm/physiology', 'Comorbidity', 'Half-Life', 'Health Status Indicators', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacokinetics/therapeutic use', 'Mental Disorders/diagnosis/epidemiology', 'Pyridines/adverse effects/pharmacokinetics/therapeutic use', 'Pyrimidines/adverse effects/pharmacokinetics/therapeutic use', 'Quality of Life', 'Sleep/physiology', 'Sleep Deprivation', 'Sleep Initiation and Maintenance Disorders/diagnosis/*drug therapy/*epidemiology', 'Treatment Outcome', 'Zolpidem']",https://pubmed.ncbi.nlm.nih.gov/11388589/
2957,zaleplon,17988972,[Insomnia and cerebral hypoperfusion].,"['Kaposzta Z', 'Racz K']","['*Cerebrovascular Circulation/drug effects', 'GABA-A Receptor Agonists', 'Humans', 'Hungary/epidemiology', 'Hypoxia, Brain/*complications/drug therapy/physiopathology', 'Sleep Initiation and Maintenance Disorders/drug therapy/epidemiology/*etiology/*physiopathology']",https://pubmed.ncbi.nlm.nih.gov/17988972/
2958,meclizine,33075160,Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.,"['Weibel S', 'Rucker G', 'Eberhart LH', 'Pace NL', 'Hartl HM', 'Jordan OL', 'Mayer D', 'Riemer M', 'Schaefer MS', 'Raj D', 'Backhaus I', 'Helf A', 'Schlesinger T', 'Kienbaum P', 'Kranke P']","['Adult', 'Anesthesia, General/*adverse effects', 'Antiemetics/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', '*Network Meta-Analysis', 'Placebos/therapeutic use', 'Postoperative Nausea and Vomiting/*prevention & control', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33075160/
2959,meclizine,27170253,Meniere's disease.,"['Nakashima T', 'Pyykko I', 'Arroll MA', 'Casselbrant ML', 'Foster CA', 'Manzoor NF', 'Megerian CA', 'Naganawa S', 'Young YH']","['Antiemetics/pharmacology/therapeutic use', 'Audiometry/methods', 'Benzodiazepines/pharmacology/therapeutic use', 'Catheter Ablation/methods', 'Dimenhydrinate/pharmacology/therapeutic use', 'Ear, Inner/pathology/physiopathology', 'Endolymph/metabolism', 'Ganglia, Sensory/abnormalities/injuries', 'Hearing Loss/etiology', 'Humans', 'Magnetic Resonance Imaging/methods', 'Meclizine/pharmacology/therapeutic use', 'Meniere Disease/*complications/epidemiology/*physiopathology', 'Promethazine/pharmacology/therapeutic use', 'Quality of Life/psychology', 'Tinnitus/etiology', 'Vertigo/etiology']",https://pubmed.ncbi.nlm.nih.gov/27170253/
2960,meclizine,10367916,Mal de debarquement.,"['Hain TC', 'Hanna PA', 'Rheinberger MA']","['Adult', 'Aged', 'Chronic Disease', 'Disability Evaluation', 'Female', 'Humans', 'Male', 'Middle Aged', 'Motion Perception', 'Motion Sickness/*diagnosis/etiology/therapy', 'Risk Factors', 'Surveys and Questionnaires', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/10367916/
2961,meclizine,26684019,C-Type Natriuretic Peptide Analog as Therapy for Achondroplasia.,['Legeai-Mallet L'],"['Achondroplasia/*drug therapy/genetics', 'Animals', 'Humans', 'Natriuretic Peptide, C-Type/*analogs & derivatives/pharmacology', 'Receptor, Fibroblast Growth Factor, Type 3/*genetics']",https://pubmed.ncbi.nlm.nih.gov/26684019/
2962,meclizine,38569854,Promising horizons in achondroplasia along with the development of new drugs.,"['Ozono K', 'Kubota T', 'Michigami T']","['*Achondroplasia/drug therapy', 'Humans', '*Receptor, Fibroblast Growth Factor, Type 3/genetics', 'Drug Development', 'Natriuretic Peptide, C-Type/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38569854/
2963,meclizine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
2964,meclizine,31887753,Vestibular Migraine: Treatment and Prognosis.,"['von Brevern M', 'Lempert T']","['Humans', 'Migraine Disorders/*diagnosis/*therapy', 'Prognosis', 'Vertigo/*diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/31887753/
2965,meclizine,9450266,Psychophysiological aspects of motion sickness.,['Murray JB'],"['Administration, Cutaneous', 'Dextroamphetamine/therapeutic use', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Meclizine/therapeutic use', 'Motion Sickness/diagnosis/drug therapy/*physiopathology', 'Promethazine/therapeutic use', 'Psychophysiology', 'Scopolamine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9450266/
2966,meclizine,12160366,Emergency contraception.,"['Grimes DA', 'Raymond EG']","['Age Factors', 'Contraceptives, Postcoital/adverse effects/*therapeutic use', 'Contraceptives, Postcoital, Hormonal/adverse effects/therapeutic use', 'Contraindications', 'Drug Combinations', 'Drug Interactions', 'Drug Prescriptions', 'Emergencies', 'Female', 'Fetus/drug effects', 'Humans', 'Intrauterine Devices', 'Jurisprudence', 'Mifepristone/therapeutic use', 'Nausea/prevention & control', 'Pregnancy', 'Pregnancy Tests', 'Pregnancy, Unwanted', 'Smoking/adverse effects', 'Time Factors', 'Vomiting/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12160366/
2967,meclizine,35033871,Meclozine ameliorates skeletal muscle pathology and increases muscle forces in mdx mice.,"['Kawamura Y', 'Hida T', 'Ohkawara B', 'Matsushita M', 'Kobayashi T', 'Ishizuka S', 'Hiraiwa H', 'Tanaka S', 'Tsushima M', 'Nakashima H', 'Ito K', 'Imagama S', 'Ito M', 'Masuda A', 'Ishiguro N', 'Ohno K']","['Animals', 'Cell Differentiation/drug effects', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Extracellular Signal-Regulated MAP Kinases/metabolism', 'Humans', 'Male', 'Meclizine/*pharmacology/therapeutic use', 'Mice, Inbred C57BL', 'Mice, Inbred mdx', 'Motor Activity/drug effects', 'Muscle Development/drug effects', 'Muscle Strength/drug effects/*physiology', 'Muscle, Skeletal/*pathology/*physiopathology', 'Muscular Dystrophy, Duchenne/drug therapy/pathology/physiopathology', 'Phosphorylation/drug effects', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/35033871/
2968,meclizine,25450422,Use of ondansetron during pregnancy and congenital malformations in the infant.,"['Danielsson B', 'Wikner BN', 'Kallen B']","['Abnormalities, Drug-Induced/*etiology', 'Antiemetics/*adverse effects', 'Female', 'Heart Septal Defects/chemically induced', 'Humans', 'Infant, Newborn', 'Male', 'Ondansetron/*adverse effects', 'Pregnancy', 'Serotonin Antagonists/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25450422/
2969,meclizine,18523693,Vertigo - part 2 - management in general practice.,"['Kuo CH', 'Pang L', 'Chang R']","['Acute Disease', 'Antiemetics/administration & dosage', 'Automobile Driving', 'Brain Stem/physiology', 'Chronic Disease', '*Family Practice', 'Humans', 'Meclizine/administration & dosage/adverse effects', 'Methylprednisolone/administration & dosage', 'Patient Education as Topic', 'Physical Therapy Modalities', 'Posture', 'Vertigo/*etiology/rehabilitation/*therapy']",https://pubmed.ncbi.nlm.nih.gov/18523693/
2970,meclizine,20977989,Meclizine is neuroprotective in models of Huntington's disease.,"['Gohil VM', 'Offner N', 'Walker JA', 'Sheth SA', 'Fossale E', 'Gusella JF', 'MacDonald ME', 'Neri C', 'Mootha VK']","['Animals', 'Apoptosis/drug effects', 'Caenorhabditis elegans/drug effects', 'Cell Respiration/drug effects', 'Disease Models, Animal', 'Drosophila melanogaster/drug effects', 'Humans', 'Huntingtin Protein', 'Huntington Disease/*drug therapy/metabolism', 'Meclizine/*pharmacology/*therapeutic use', 'Mice', 'Nerve Tissue Proteins/genetics/metabolism', 'Neurons/drug effects/metabolism', 'Neuroprotective Agents/pharmacology/therapeutic use', 'Nuclear Proteins/genetics/metabolism', 'Peptides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20977989/
2971,meclizine,773181,An evaluation of the teratogenicity of certain antinauseant drugs.,"['Milkovich L', 'van den Berg BJ']","['Abnormalities, Drug-Induced/epidemiology/mortality', 'Antiemetics/*adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Cyclizine/adverse effects', 'Dicyclomine/adverse effects', 'Doxylamine/adverse effects', 'Drug Combinations', 'Drug Evaluation', 'Female', 'Fetal Death/epidemiology', 'Humans', 'Hyperemesis Gravidarum/*drug therapy', 'Meclizine/adverse effects', 'Patient Compliance', 'Phenothiazines/adverse effects', 'Pregnancy', 'Prochlorperazine/adverse effects', 'Prospective Studies', 'Pyridoxine/adverse effects', '*Teratogens']",https://pubmed.ncbi.nlm.nih.gov/773181/
2972,meclizine,17484344,Airsickness prevention in helicopter passengers.,"['Estrada A', 'LeDuc PA', 'Curry IP', 'Phelps SE', 'Fuller DR']","['Acoustic Stimulation', 'Adolescent', 'Adult', '*Aircraft', 'Antiemetics/*therapeutic use', 'Health Surveys', 'Humans', 'Male', 'Meclizine/*therapeutic use', '*Military Medicine', '*Military Personnel', 'Motion Sickness/*prevention & control', 'Muscarinic Antagonists/therapeutic use', 'Promethazine/*therapeutic use', 'Scopolamine/*therapeutic use', 'Surveys and Questionnaires']",https://pubmed.ncbi.nlm.nih.gov/17484344/
2973,meclizine,31760071,The phosphatidylethanolamine biosynthesis pathway provides a new target for cancer chemotherapy.,"['Guan Y', 'Chen X', 'Wu M', 'Zhu W', 'Arslan A', 'Takeda S', 'Nguyen MH', 'Majeti R', 'Thomas D', 'Zheng M', 'Peltz G']","['Adult', 'Aged', 'Animals', 'Carcinoma, Hepatocellular/*drug therapy/*metabolism/pathology', 'Cell Survival/drug effects', 'Drug Therapy, Combination/methods', 'Female', 'Gene Knockout Techniques', 'Glycolysis/drug effects', 'Hep G2 Cells', 'Humans', 'Induced Pluripotent Stem Cells/drug effects/metabolism', 'Leukemia, Myeloid, Acute/*blood', 'Liver/embryology/growth & development/metabolism', 'Liver Neoplasms/*drug therapy/*metabolism/pathology', 'Male', 'Meclizine/*administration & dosage', 'Mice', 'Middle Aged', 'Organogenesis/drug effects/genetics', 'Organoids/drug effects/metabolism', 'Phosphatidylethanolamines/*antagonists & inhibitors/*biosynthesis', 'Pyridines/*administration & dosage', 'Quinolines/*administration & dosage', 'RNA Nucleotidyltransferases/deficiency/genetics', 'Retrospective Studies', 'Treatment Outcome', 'Xenograft Model Antitumor Assays']",https://pubmed.ncbi.nlm.nih.gov/31760071/
2974,meclizine,26443596,Advances in treatment of achondroplasia and osteoarthritis.,"['Klag KA', 'Horton WA']","['Achondroplasia/*therapy', 'Animals', 'Genetic Therapy', 'Humans', 'Mice', 'Osteoarthritis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/26443596/
2975,meclizine,37796301,Virtual reality as a countermeasure for astronaut motion sickness during simulated post-flight water landings.,"['Lonner TL', 'Allred AR', 'Bonarrigo L', 'Gopinath A', 'Smith K', 'Kravets V', 'Groen EL', 'Oman C', 'DiZio P', 'Lawson BD', 'Clark TK']","['Humans', 'Astronauts', '*Space Flight', 'Space Motion Sickness/drug therapy', '*Motion Sickness', 'Nausea/etiology', '*Virtual Reality']",https://pubmed.ncbi.nlm.nih.gov/37796301/
2976,meclizine,1855348,No causal relationship between transdermal scopolamine and seizures: methodologic lessons for pharmacoepidemiology.,"['Strom BL', 'Carson JL', 'Schinnar R', 'Snyder ES', 'Shaw M', 'Waiter SL']","['Administration, Cutaneous', 'Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Child, Preschool', 'Cohort Studies', 'Female', 'Florida', 'Humans', 'Infant', 'Insurance Claim Reporting', 'Male', 'Medicaid', 'Medical Records', 'Michigan', 'Middle Aged', 'Retrospective Studies', 'Scopolamine/administration & dosage/*adverse effects', 'Seizures/*chemically induced/epidemiology', 'United States']",https://pubmed.ncbi.nlm.nih.gov/1855348/
2977,meclizine,6734040,"Transdermal scopolamine, oral meclizine, and placebo in motion sickness.","['Dahl E', 'Offer-Ohlsen D', 'Lillevold PE', 'Sandvik L']","['Administration, Oral', 'Adult', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Meclizine/adverse effects/*therapeutic use', 'Motion Sickness/*prevention & control', 'Scopolamine/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6734040/
2978,megestrol,23543530,Megestrol acetate for treatment of anorexia-cachexia syndrome.,"['Ruiz Garcia V', 'Lopez-Briz E', 'Carbonell Sanchis R', 'Gonzalvez Perales JL', 'Bort-Marti S']","['Acquired Immunodeficiency Syndrome/complications', 'Anorexia/*drug therapy/etiology', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/23543530/
2979,megestrol,30229678,Efficacy and Safety of Appetite-Stimulating Medications in the Inpatient Setting.,"['Howard ML', 'Hossaini R', 'Tolar C', 'Gaviola ML']","['Adult', 'Appetite/*drug effects', 'Appetite Regulation/*drug effects', 'Appetite Stimulants/administration & dosage/*therapeutic use', 'Dronabinol/administration & dosage/therapeutic use', 'Eating/drug effects', 'Female', 'Humans', 'Inpatients', 'Male', 'Megestrol/administration & dosage/therapeutic use', 'Middle Aged', 'Mirtazapine/administration & dosage/therapeutic use', 'Retrospective Studies', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30229678/
2980,megestrol,26512437,An update on new orally administered contraceptives for women.,['Nelson AL'],"['Clinical Trials as Topic', 'Contraceptives, Oral/*administration & dosage/adverse effects', 'Estradiol/administration & dosage/adverse effects/analogs & derivatives', 'Estrogens/administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Female', 'Humans', 'Megestrol/administration & dosage/adverse effects', 'Nandrolone/administration & dosage/adverse effects/analogs & derivatives', 'Norpregnadienes/administration & dosage/adverse effects', 'Progestins/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26512437/
2981,megestrol,7773579,Management of cancer anorexia/cachexia.,['Loprinzi CL'],"['Anorexia/*drug therapy/etiology', 'Cachexia/*drug therapy/etiology', 'Controlled Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Megestrol/*analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Multicenter Studies as Topic', 'Neoplasms/complications', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/7773579/
2982,megestrol,24333799,"The ""newer"" progestogens and postmenopausal hormone therapy (HRT).",['Schindler AE'],"['Androstenes/*therapeutic use', 'Estradiol/administration & dosage/therapeutic use', 'Female', 'Humans', 'Megestrol/*therapeutic use', 'Nandrolone/*analogs & derivatives/therapeutic use', 'Norpregnadienes/*therapeutic use', 'Postmenopause', 'Progestins/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24333799/
2983,megestrol,11727176,Implant contraception.,"['Meckstroth KR', 'Darney PD']","['Cervix Mucus/drug effects', 'Clinical Trials as Topic', 'Contraceptive Agents, Female/*administration & dosage/economics/pharmacology', 'Counseling', '*Desogestrel', 'Drug Implants/*administration & dosage', 'Endometrium/drug effects', 'Female', 'Humans', 'Levonorgestrel/administration & dosage/pharmacology', 'Megestrol/administration & dosage/*analogs & derivatives/pharmacology', 'Norprogesterones/administration & dosage/pharmacology', 'Ovulation/drug effects', 'Patient Satisfaction', 'Pregnancy', 'Progesterone Congeners/*administration & dosage/economics/pharmacology', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Vinyl Compounds/administration & dosage/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/11727176/
2984,megestrol,19749678,[Nomegestrol acetate: clinical pharmacology].,['Lello S'],"['Biological Availability', 'Breast Diseases/drug therapy', 'Drug Therapy, Combination', 'Estradiol/administration & dosage/analogs & derivatives', 'Female', 'Hormone Replacement Therapy', 'Humans', 'Hypothalamo-Hypophyseal System/drug effects', 'Inactivation, Metabolic', 'Megestrol/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Menopause', 'Menstruation Disturbances/drug therapy', 'Molecular Structure', 'Norpregnadienes/adverse effects/chemistry/pharmacokinetics/*pharmacology/therapeutic use', 'Ovulation Inhibition/drug effects', 'Protein Binding']",https://pubmed.ncbi.nlm.nih.gov/19749678/
2985,megestrol,17722275,Megestrol acetate in cachexia and anorexia.,"['Yeh SS', 'Schuster MW']","['Anorexia/*drug therapy', 'Cachexia/*drug therapy', 'Clinical Trials as Topic/*trends', 'Drug Carriers/chemistry', 'Humans', 'Megestrol Acetate/adverse effects/*chemistry/*therapeutic use', 'Nanoparticles/chemistry']",https://pubmed.ncbi.nlm.nih.gov/17722275/
2986,megestrol,7889638,Megestrol-induced Cushing's syndrome.,"['Steer KA', 'Kurtz AB', 'Honour JW']","['Adenocarcinoma/drug therapy', 'Adult', 'Cushing Syndrome/*chemically induced', 'Diabetes Mellitus, Type 1/complications', 'Female', 'Humans', 'Megestrol/*adverse effects', 'Uterine Neoplasms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7889638/
2987,megestrol,27187588,Metabolic impact of combined hormonal contraceptives containing estradiol.,"['Grandi G', 'Napolitano A', 'Cagnacci A']","['Blood Pressure/drug effects', 'Contraceptives, Oral, Combined/*administration & dosage/adverse effects', 'Contraceptives, Oral, Hormonal/*administration & dosage/adverse effects', 'Estradiol/*administration & dosage/adverse effects', 'Ethinyl Estradiol/administration & dosage/adverse effects', 'Hemostasis/drug effects', 'Humans', 'Lipid Metabolism/drug effects', 'Megestrol/administration & dosage', 'Nandrolone/administration & dosage/analogs & derivatives', 'Norpregnadienes/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/27187588/
2988,megestrol,17619035,Pharmacological treatment of geriatric cachexia: evidence and safety in perspective.,"['Yeh SS', 'Lovitt S', 'Schuster MW']","['Aged', 'Anabolic Agents/adverse effects/*therapeutic use', 'Appetite Stimulants/adverse effects/*therapeutic use', 'Cachexia/*drug therapy/etiology/physiopathology', 'Dronabinol/adverse effects/therapeutic use', '*Geriatrics', 'Humans', 'Megestrol Acetate/adverse effects/*therapeutic use', 'Parenteral Nutrition']",https://pubmed.ncbi.nlm.nih.gov/17619035/
2989,megestrol,14751131,Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study.,"['Fiorica JV', 'Brunetto VL', 'Hanjani P', 'Lentz SS', 'Mannel R', 'Andersen W']","['Adult', 'Aged', 'Aged, 80 and over', 'Antineoplastic Agents, Hormonal/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Apoptosis/drug effects', 'Carcinoma, Endometrioid/drug therapy/pathology', 'Cell Differentiation/drug effects', 'Down-Regulation/drug effects', 'Drug Administration Schedule', 'Endometrial Neoplasms/*drug therapy/metabolism/pathology', 'Female', 'Humans', 'Megestrol Acetate/administration & dosage/adverse effects', 'Middle Aged', 'Receptors, Progesterone/metabolism', 'Tamoxifen/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/14751131/
2990,megestrol,22611833,"[Zoely, a combined oral contraceptive, monophasic pill containing estradiol and nomegestrol acetate].","['Pintiaux A', 'Gaspard U', 'Nisolle M']","['Animals', 'Contraception/adverse effects/methods', 'Contraceptives, Oral, Combined/adverse effects/chemistry/*therapeutic use', 'Drug Design', 'Estradiol/*administration & dosage/adverse effects', 'Humans', 'Megestrol/*administration & dosage/adverse effects', 'Norpregnadienes/*administration & dosage/adverse effects', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/22611833/
2991,megestrol,25076331,Quality of life in patients with pancreatic cancer.,"['Kiagia M', 'Syrigos KN', 'Saif MW']","['Cachexia/*drug therapy/etiology', 'Dronabinol/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Megestrol Acetate/adverse effects/therapeutic use', 'Pancreatectomy/adverse effects/methods', 'Pancreatic Neoplasms/*complications/surgery', '*Quality of Life', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/25076331/
2992,megestrol,7360074,Hounding the pill.,['Smibert J'],"['Animals', 'Australia', 'Breast Neoplasms/*chemically induced', 'Dogs', 'Drug and Narcotic Control', 'Female', 'Humans', 'Mammary Neoplasms, Experimental/chemically induced', 'Megestrol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7360074/
2993,megestrol,1721521,Management of anorexia-cachexia associated with cancer and HIV infection.,['Gorter R'],"['Anorexia/*drug therapy', 'Antineoplastic Agents/therapeutic use', 'Cachexia/*drug therapy', 'Dronabinol/therapeutic use', 'HIV Infections/*physiopathology', 'Humans', 'Hydrazines/therapeutic use', 'Megestrol/analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Metoclopramide/therapeutic use', 'Neoplasms/*physiopathology', 'Palliative Care/methods']",https://pubmed.ncbi.nlm.nih.gov/1721521/
2994,megestrol,27218795,Pharmacy Report: Megestrol Acetate-Induced Adrenal Insufficiency.,"['Nanjappa S', 'Thai C', 'Shah S', 'Snyder M']","['Adrenal Insufficiency/*etiology', 'Aged', 'Humans', 'Male', 'Megestrol Acetate/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/27218795/
2995,megestrol,11014096,[What's new in hormone replacement therapy for postmenopausal women? I. Advantages of hormone replacement therapy (HRT)].,"['Martin-Du Pan RC', 'Luzuy F']","['Aged', 'Alzheimer Disease/drug therapy', 'Cardiovascular Diseases/prevention & control', 'Cholesterol, HDL/blood', 'Depression/drug therapy', 'Dyspareunia/drug therapy', '*Estrogen Replacement Therapy', 'Female', 'Humans', 'Male', 'Megestrol/analogs & derivatives/therapeutic use', 'Middle Aged', 'Norpregnenes/therapeutic use', 'Osteoporosis/drug therapy', 'Postmenopause/*drug effects/physiology', 'Progesterone Congeners/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11014096/
2996,megestrol,16144501,Review of cost-effectiveness analyses in hormonal therapies in advanced breast cancer.,"['Benedict A', 'Brown RE']","['Antineoplastic Agents, Hormonal/*economics/therapeutic use', 'Aromatase Inhibitors/economics', 'Breast Neoplasms/drug therapy/*economics/metabolism', 'Cost-Benefit Analysis', 'Decision Making', 'Female', 'Health Care Rationing', 'Health Expenditures', 'Humans', 'Megestrol/economics/therapeutic use', 'Models, Economic', 'Randomized Controlled Trials as Topic', 'Receptors, Estrogen/metabolism', 'Tamoxifen/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16144501/
2997,megestrol,9644944,[Pharmacological modulation of the appetite].,"['Cuerda Compes M', 'Breton Lesmes I', 'Camblor Alvarez M', 'Garcia Peris P']","['Adipose Tissue', 'Appetite Depressants/pharmacology/*therapeutic use', 'Appetite Stimulants/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Dronabinol/pharmacology/therapeutic use', 'Feeding and Eating Disorders/*drug therapy', 'Humans', 'Hypothalamus/drug effects', 'Leptin', 'Megestrol Acetate/pharmacology/therapeutic use', 'Obesity/*drug therapy', 'Proteins/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9644944/
2998,irbesartan,37467498,"Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension.","['Desai AS', 'Webb DJ', 'Taubel J', 'Casey S', 'Cheng Y', 'Robbie GJ', 'Foster D', 'Huang SA', 'Rhyee S', 'Sweetser MT', 'Bakris GL']","['Humans', '*Angiotensinogen/blood/metabolism', '*Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Blood Pressure/drug effects/physiology', 'Blood Pressure Monitoring, Ambulatory', 'Double-Blind Method', '*Hypertension/blood/drug therapy/etiology/metabolism', 'Irbesartan/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'RNA Interference', 'Tetrazoles', 'Diet', 'Injections, Subcutaneous']",https://pubmed.ncbi.nlm.nih.gov/37467498/
2999,irbesartan,37931634,"Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.","['Rovin BH', 'Barratt J', 'Heerspink HJL', 'Alpers CE', 'Bieler S', 'Chae DW', 'Diva UA', 'Floege J', 'Gesualdo L', 'Inrig JK', 'Kohan DE', 'Komers R', 'Kooienga LA', 'Lafayette R', 'Maes B', 'Malecki R', 'Mercer A', 'Noronha IL', 'Oh SW', 'Peh CA', 'Praga M', 'Preciado P', 'Radhakrishnan J', 'Rheault MN', 'Rote WE', 'Tang SCW', 'Tesar V', 'Trachtman H', 'Trimarchi H', 'Tumlin JA', 'Wong MG', 'Perkovic V']","['Female', 'Humans', 'Male', 'Angiotensin Receptor Antagonists/adverse effects', 'Double-Blind Method', '*Glomerulonephritis, IGA/drug therapy', 'Irbesartan/adverse effects', '*Kidney Failure, Chronic', 'Proteinuria/drug therapy', 'Treatment Outcome', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/37931634/
3000,irbesartan,37015244,"Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial.","['Heerspink HJL', 'Radhakrishnan J', 'Alpers CE', 'Barratt J', 'Bieler S', 'Diva U', 'Inrig J', 'Komers R', 'Mercer A', 'Noronha IL', 'Rheault MN', 'Rote W', 'Rovin B', 'Trachtman H', 'Trimarchi H', 'Wong MG', 'Perkovic V']","['Adult', 'Humans', 'Adolescent', 'Irbesartan/therapeutic use', '*Glomerulonephritis, IGA/drug therapy', 'Creatinine/urine', 'Proteinuria/drug therapy', 'Double-Blind Method', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37015244/
3001,irbesartan,37921461,Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.,"['Rheault MN', 'Alpers CE', 'Barratt J', 'Bieler S', 'Canetta P', 'Chae DW', 'Coppock G', 'Diva U', 'Gesualdo L', 'Heerspink HJL', 'Inrig JK', 'Kirsztajn GM', 'Kohan D', 'Komers R', 'Kooienga LA', 'Lieberman K', 'Mercer A', 'Noronha IL', 'Perkovic V', 'Radhakrishnan J', 'Rote W', 'Rovin B', 'Tesar V', 'Trimarchi H', 'Tumlin J', 'Wong MG', 'Trachtman H']","['Humans', 'Biomarkers', 'Creatinine', 'Glomerular Filtration Rate', '*Glomerulosclerosis, Focal Segmental/complications/drug therapy/physiopathology', '*Irbesartan/administration & dosage/adverse effects/therapeutic use', '*Proteinuria/drug therapy/etiology', 'Child', 'Adolescent', 'Young Adult', 'Adult', 'Middle Aged', 'Aged', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/37921461/
3002,irbesartan,37432701,Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.,"['Xie M', 'Tang T', 'Liang H']","['Humans', '*Antihypertensive Agents/therapeutic use', 'Losartan/pharmacology/therapeutic use', '*Hypertension/diagnosis/drug therapy', 'Telmisartan/pharmacology/therapeutic use', 'Irbesartan/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/therapeutic use', 'Network Meta-Analysis', 'Hydrochlorothiazide/adverse effects', 'Valine/adverse effects', 'Drug Therapy, Combination', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Amlodipine/therapeutic use', 'Valsartan/therapeutic use', 'Tetrazoles/therapeutic use', 'Blood Pressure', 'Essential Hypertension/diagnosis/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37432701/
3003,irbesartan,10914449,Angiotensin receptor antagonists.,"['Wong W', 'Howes L']","['Angiotensin II/antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/therapeutic use', 'Antihypertensive Agents/adverse effects/pharmacology/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/therapeutic use', 'Benzoates/adverse effects/pharmacology/therapeutic use', 'Biphenyl Compounds/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/adverse effects/pharmacology/therapeutic use', 'Telmisartan', 'Tetrazoles/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10914449/
3004,irbesartan,30361325,DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS.,"['Trachtman H', 'Nelson P', 'Adler S', 'Campbell KN', 'Chaudhuri A', 'Derebail VK', 'Gambaro G', 'Gesualdo L', 'Gipson DS', 'Hogan J', 'Lieberman K', 'Marder B', 'Meyers KE', 'Mustafa E', 'Radhakrishnan J', 'Srivastava T', 'Stepanians M', 'Tesar V', 'Zhdanova O', 'Komers R']","['Adolescent', 'Adult', 'Aged', 'Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Creatinine/urine', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Endothelin A Receptor Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Glomerulosclerosis, Focal Segmental/*drug therapy/urine', 'Humans', 'Irbesartan/administration & dosage/adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Proteinuria/drug therapy/urine', 'Spiro Compounds/administration & dosage/adverse effects/*therapeutic use', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30361325/
3005,irbesartan,30002098,Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.,"['Haynes R', 'Judge PK', 'Staplin N', 'Herrington WG', 'Storey BC', 'Bethel A', 'Bowman L', 'Brunskill N', 'Cockwell P', 'Hill M', 'Kalra PA', 'McMurray JJV', 'Taal M', 'Wheeler DC', 'Landray MJ', 'Baigent C']","['Aged', 'Aminobutyrates/adverse effects/*therapeutic use', 'Angiotensin II Type 1 Receptor Blockers/adverse effects/*therapeutic use', 'Biphenyl Compounds', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Glomerular Filtration Rate/*drug effects', 'Heart Failure/diagnosis/*drug therapy/mortality/physiopathology', 'Humans', 'Irbesartan/adverse effects/*therapeutic use', 'Kidney/*drug effects/physiopathology', 'Male', 'Middle Aged', 'Renal Insufficiency, Chronic/diagnosis/mortality/*physiopathology', 'Stroke Volume/*drug effects', 'Tetrazoles/adverse effects/*therapeutic use', 'Time Factors', 'Treatment Outcome', 'United Kingdom', 'Valsartan', 'Ventricular Function, Left/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/30002098/
3006,irbesartan,11565517,Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.,"['Lewis EJ', 'Hunsicker LG', 'Clarke WR', 'Berl T', 'Pohl MA', 'Lewis JB', 'Ritz E', 'Atkins RC', 'Rohde R', 'Raz I']","['Adult', 'Aged', 'Amlodipine/adverse effects/therapeutic use', '*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Biphenyl Compounds/adverse effects/*therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Creatinine/blood', 'Diabetes Mellitus, Type 2/*complications', 'Diabetic Nephropathies/complications/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/complications/drug therapy', 'Irbesartan', 'Kidney Failure, Chronic/prevention & control', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Tetrazoles/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11565517/
3007,irbesartan,11588406,"Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension.","['Oparil S', 'Williams D', 'Chrysant SG', 'Marbury TC', 'Neutel J']","['Analysis of Variance', 'Antihypertensive Agents/adverse effects/*therapeutic use', 'Biphenyl Compounds/therapeutic use', 'Chi-Square Distribution', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Male', 'Middle Aged', 'Tetrazoles/therapeutic use', 'Valine/*analogs & derivatives/therapeutic use', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/11588406/
3008,irbesartan,11565519,The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.,"['Parving HH', 'Lehnert H', 'Brochner-Mortensen J', 'Gomis R', 'Andersen S', 'Arner P']","['Adult', 'Aged', 'Albuminuria/drug therapy/etiology', '*Angiotensin Receptor Antagonists', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Biphenyl Compounds/administration & dosage/adverse effects/*therapeutic use', 'Creatinine/blood', 'Diabetes Mellitus, Type 2/*complications', 'Diabetic Nephropathies/etiology/*prevention & control', 'Disease Progression', 'Double-Blind Method', 'Female', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Tetrazoles/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11565519/
3009,irbesartan,37143164,Irbesartan overcomes gemcitabine resistance in pancreatic cancer by suppressing stemness and iron metabolism via inhibition of the Hippo/YAP1/c-Jun axis.,"['Zhou T', 'Xie Y', 'Hou X', 'Bai W', 'Li X', 'Liu Z', 'Man Q', 'Sun J', 'Fu D', 'Yan J', 'Zhang Z', 'Wang Y', 'Wang H', 'Jiang W', 'Gao S', 'Zhao T', 'Chang A', 'Wang X', 'Sun H', 'Zhang X', 'Yang S', 'Huang C', 'Hao J', 'Liu J']","['Mice', 'Animals', 'Humans', 'Gemcitabine', 'Irbesartan/therapeutic use', 'Retrospective Studies', '*Pancreatic Neoplasms/metabolism', '*Carcinoma, Pancreatic Ductal/pathology', 'Disease Models, Animal', 'Cell Line, Tumor']",https://pubmed.ncbi.nlm.nih.gov/37143164/
3010,irbesartan,26896240,Does this patient have hypertensive encephalopathy?,"['Christopoulou F', 'Rizos EC', 'Kosta P', 'Argyropoulou MI', 'Elisaf M']","['Amlodipine/administration & dosage/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Biphenyl Compounds/administration & dosage/adverse effects/therapeutic use', 'Brain/*diagnostic imaging', 'Carbazoles/administration & dosage/therapeutic use', 'Carvedilol', 'Computed Tomography Angiography', 'Confusion/etiology', 'Creatinine/blood', 'Electrocardiography', 'Glomerular Filtration Rate', 'Hallucinations/etiology', 'Headache/etiology', 'Heart/diagnostic imaging', 'Humans', 'Hydrochlorothiazide/administration & dosage/therapeutic use', 'Hypertension/*complications/*drug therapy', 'Hypertensive Encephalopathy/complications/*diagnosis', 'Irbesartan', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Propanolamines/administration & dosage/therapeutic use', 'Renal Artery Obstruction/blood/*chemically induced', 'Spironolactone/administration & dosage/therapeutic use', 'Tetrazoles/administration & dosage/adverse effects/therapeutic use', 'Ultrasonography']",https://pubmed.ncbi.nlm.nih.gov/26896240/
3011,irbesartan,9793599,ACE inhibitor- versus angiotensin II blocker-induced cough and angioedema.,['Pylypchuk GB'],"['Angioedema/*chemically induced', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*adverse effects/therapeutic use', 'Antihypertensive Agents/*adverse effects/therapeutic use', 'Biphenyl Compounds/adverse effects/therapeutic use', 'Cough/*chemically induced', 'Humans', 'Irbesartan', 'Losartan/adverse effects/therapeutic use', 'Tetrazoles/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9793599/
3012,irbesartan,10392595,Angiotensin-II receptor antagonists: their place in therapy.,['Kirk JK'],"['Angiotensin II/*metabolism', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/pharmacology', 'Benzoates/pharmacology', 'Biphenyl Compounds/pharmacology', 'Clinical Trials as Topic', 'Drug Administration Schedule', 'Drug Interactions', 'Heart Failure/drug therapy', 'Humans', 'Hypertension/*drug therapy/metabolism', 'Irbesartan', 'Losartan/pharmacology', 'Renin-Angiotensin System/*drug effects', 'Telmisartan', 'Tetrazoles/pharmacology', 'Valine/analogs & derivatives/pharmacology', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/10392595/
3013,irbesartan,14605589,The antihypertensive response to irbesartan treatment from a pharmacogenetic perspective.,['Kurland L'],"['Antihypertensive Agents/*therapeutic use', 'Biphenyl Compounds/*therapeutic use', 'Cytochrome P-450 CYP2D6/genetics', 'Humans', 'Hypertension/*drug therapy/genetics', 'Irbesartan', '*Pharmacogenetics', 'Pharmacokinetics', 'Polymorphism, Genetic', 'Renin-Angiotensin System/genetics', 'Tetrazoles/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14605589/
3014,irbesartan,9850301,Irbesartan treatment in hypertension.,['Brown MJ'],"['Angiotensin-Converting Enzyme Inhibitors/adverse effects', 'Antihypertensive Agents/pharmacokinetics/*therapeutic use', 'Atenolol/therapeutic use', 'Biphenyl Compounds/pharmacokinetics/*therapeutic use', 'Enalapril/therapeutic use', 'Humans', 'Hypertension/complications/*drug therapy', 'Irbesartan', 'Losartan/therapeutic use', 'Renin-Angiotensin System/drug effects', 'Tetrazoles/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9850301/
3015,irbesartan,25703678,The cost-effectiveness of irbesartan for hypertension.,"['Borghi C', 'Urso R', 'Cicero AF']","['Adult', 'Aged', 'Angiotensin II Type 1 Receptor Blockers/economics/therapeutic use', 'Antihypertensive Agents/economics/*therapeutic use', 'Biphenyl Compounds/economics/*therapeutic use', 'Cost-Benefit Analysis', 'Humans', 'Hypertension/*drug therapy/economics/epidemiology', 'Irbesartan', 'Tetrazoles/economics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25703678/
3016,irbesartan,10806906,[Use of angiotensin II receptor blockaders in heart failure].,"['Bonarjee VV', 'Dickstein K']","['Angiotensin II/*antagonists & inhibitors', '*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/*administration & dosage/pharmacokinetics', 'Anti-Arrhythmia Agents/administration & dosage/pharmacokinetics', 'Antihypertensive Agents/administration & dosage/pharmacokinetics', 'Benzimidazoles/administration & dosage/pharmacokinetics', 'Biphenyl Compounds/administration & dosage/pharmacokinetics', 'Drug Therapy, Combination', 'Heart Failure/complications/*drug therapy/mortality', 'Humans', 'Irbesartan', 'Randomized Controlled Trials as Topic', 'Tetrazoles/administration & dosage/pharmacokinetics', 'Valine/administration & dosage/analogs & derivatives/pharmacokinetics', 'Valsartan']",https://pubmed.ncbi.nlm.nih.gov/10806906/
3017,irbesartan,33461698,Irbesartan (a comprehensive profile).,"['Darwish IA', 'Darwish HW', 'Bakheit AH', 'Al-Kahtani HM', 'Alanazi Z']","['Angiotensin Receptor Antagonists/*pharmacology/therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Diabetes Mellitus, Type 2', 'Diabetic Nephropathies/*drug therapy', 'Humans', '*Hypertension/drug therapy', 'Irbesartan/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33461698/
3018,ioversol,37948499,Contrast Media Ioversol Interferes with Urinalysis.,"['Tan Y', 'Cai X']","['Humans', '*Contrast Media/adverse effects', '*Urinalysis/methods', 'Triiodobenzoic Acids', 'Erythrocytes']",https://pubmed.ncbi.nlm.nih.gov/37948499/
3019,ioversol,19528424,Ioversol-induced acute generalized exanthematous pustulosis: a case report.,"['Hammerbeck AA', 'Daniels NH', 'Callen JP']","['Aged, 80 and over', 'Biopsy, Needle', 'Contrast Media/*adverse effects', 'Drug Eruptions/pathology/*radiotherapy/therapy', 'Follow-Up Studies', 'Humans', 'Immunohistochemistry', 'Male', 'Risk Assessment', 'Severity of Illness Index', 'Skin Diseases, Papulosquamous/*chemically induced/pathology/therapy', 'Triiodobenzoic Acids/*adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/19528424/
3020,ioversol,18460711,Iodinated contrast media and contrast-induced nephropathy: is there a preferred cost-effective agent?,['Sharma SK'],"['Cardiovascular Diseases/*diagnosis', 'Contrast Media/*adverse effects/*economics', 'Humans', 'Kidney Diseases/*chemically induced', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18460711/
3021,ioversol,1296489,[Pharmacotoxicological profile of a non-ionic LOCM at high hydrophilicity: ioversol].,"['Doucet D', 'Idee JM']","['Animals', 'Contrast Media/administration & dosage/*adverse effects/pharmacology', 'Dogs', 'Hemodynamics/drug effects', 'Hypothermia, Induced', 'Injections, Intravenous', 'Mice', 'Nervous System Diseases/chemically induced', 'Radiography/*methods', 'Rats', 'Triiodobenzoic Acids/administration & dosage/*adverse effects/pharmacology', 'Vomiting/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1296489/
3022,ioversol,8169099,Induction of micronuclei in lymphocytes of patients undergoing excretory urography with ioversol.,"['Cochran ST', 'Norman A']","['Adult', 'Aged', 'Contrast Media/*adverse effects', 'Female', 'Humans', 'Lymphocytes/*drug effects/ultrastructure', 'Male', '*Micronucleus Tests', 'Middle Aged', 'Triiodobenzoic Acids/*adverse effects', 'Urography/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8169099/
3023,ioversol,22778575,Acute severe thrombocytopenia following non-ionic low-osmolarity intravenous contrast medium injection.,"['Bata P', 'Tarnoki AD', 'Tarnoki DL', 'Horvath E', 'Berczi V', 'Szalay F']","['Aged', 'Comorbidity', 'Contrast Media/*administration & dosage/*adverse effects/chemistry', 'Diagnosis, Differential', 'Humans', 'Injections, Intravenous', 'Kidney Diseases/diagnostic imaging', 'Male', 'Osmolar Concentration', 'Thrombocytopenia/*chemically induced', 'Tomography, X-Ray Computed', 'Triiodobenzoic Acids/*administration & dosage/*adverse effects/chemistry']",https://pubmed.ncbi.nlm.nih.gov/22778575/
3024,ioversol,24327762,Accuracy of computed tomography findings in acute pericarditis.,"['Hammer MM', 'Raptis CA', 'Javidan-Nejad C', 'Bhalla S']","['Acute Disease', 'Adult', 'Aged', 'Aged, 80 and over', 'Chest Pain/etiology', 'Contrast Media', 'Diagnosis, Differential', 'Female', 'Humans', 'Male', 'Middle Aged', 'Observer Variation', 'Pericarditis/complications/*diagnostic imaging', 'Pericardium/diagnostic imaging', 'Radiographic Image Enhancement/methods', 'Reproducibility of Results', 'Retrospective Studies', 'Sensitivity and Specificity', 'Tomography, X-Ray Computed/*methods', 'Triiodobenzoic Acids', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/24327762/
3025,ioversol,9462198,Iodine and hypothyroidism in neonates with congenital heart disease.,"['Linder N', 'Sela B', 'German B', 'Davidovitch N', 'Kuint J', 'Hegesh J', 'Lubin D', 'Sack J']","['Anti-Infective Agents, Local/adverse effects', 'Cardiac Catheterization', 'Contrast Media/adverse effects', 'Heart Defects, Congenital/*therapy', 'Humans', 'Hypothyroidism/blood/*chemically induced', 'Infant, Newborn', 'Iodine/administration & dosage/*adverse effects', 'Povidone-Iodine/adverse effects', 'Prospective Studies', 'Thyrotropin/blood', 'Thyroxine/blood', 'Triiodobenzoic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/9462198/
3026,ioversol,33078180,Synthesis of heteronanostructures for multimodality molecular imaging-guided photothermal therapy.,"['Xu F', 'Li X', 'Chen H', 'Jian M', 'Sun Y', 'Liu G', 'Ma L', 'Wang Z']","['Animals', 'Cell Survival/drug effects/physiology', 'Dose-Response Relationship, Drug', 'Ferric Compounds/administration & dosage/*chemical synthesis/metabolism', 'Gold/administration & dosage/*chemistry/metabolism', 'Human Umbilical Vein Endothelial Cells/drug effects/metabolism', 'Humans', 'Metal Nanoparticles/administration & dosage/*chemistry', 'Mice', 'Mice, Inbred BALB C', 'Mice, Nude', 'Multimodal Imaging/*methods', 'Nanostructures/administration & dosage/*chemistry', 'Photothermal Therapy/*methods', 'Xenograft Model Antitumor Assays/methods']",https://pubmed.ncbi.nlm.nih.gov/33078180/
3027,ioversol,29668410,Case 253: Thrombosed Umbilical Venous Varix in an Infant.,"['Sandberg JK', 'Hulett-Bowling R', 'Khanna G']","['Amoxicillin/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Female', 'Fever', 'Humans', 'Infant', 'Treatment Outcome', 'Ultrasonography, Doppler', 'Umbilical Veins/*diagnostic imaging/physiopathology', 'Varicose Veins/*diagnostic imaging/physiopathology', 'Venous Thrombosis/*diagnostic imaging/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/29668410/
3028,ioversol,2692266,"Ionic versus nonionic contrast media: safety, tolerance, and rationale for use.",['McClennan BL'],"['*Contrast Media/adverse effects', 'Drug Tolerance', 'Humans', 'Ions', 'Osmolar Concentration', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/2692266/
3029,ioversol,35312790,"A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol in more than 57,000 patients: part 1-intravenous administration.","['van der Molen AJ', 'Dekkers IA', 'Bedioune I', 'Darmon-Kern E']","['*Acute Kidney Injury/chemically induced/epidemiology', 'Administration, Intravenous', 'Adult', 'Child', 'Contrast Media/adverse effects', '*Drug-Related Side Effects and Adverse Reactions/epidemiology', 'Humans', 'Incidence', '*Iodine Compounds', 'Triiodobenzoic Acids']",https://pubmed.ncbi.nlm.nih.gov/35312790/
3030,ioversol,11296788,Cortical blindness following coronary angiography.,"['Kwok BW', 'Lim TT']","['Acute Disease', 'Blindness, Cortical/*chemically induced/diagnosis', 'Contrast Media/*adverse effects', 'Coronary Angiography/*adverse effects', 'Coronary Disease/diagnostic imaging', 'Follow-Up Studies', 'Humans', 'Magnetic Resonance Imaging', 'Male', 'Middle Aged', 'Tomography, X-Ray Computed', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/11296788/
3031,ioversol,25753449,The risk of acute kidney injury with transjugular intrahepatic portosystemic shunts.,"['Danziger J', 'Thummalakunta L', 'Nelson R', 'Faintuch S']","['Acute Kidney Injury/blood/*chemically induced', 'Administration, Intravenous', 'Aged', 'Contrast Media/*administration & dosage/*adverse effects', 'Creatinine/blood', 'Female', 'Humans', 'Male', 'Middle Aged', 'Portasystemic Shunt, Transjugular Intrahepatic/*adverse effects', 'Retrospective Studies', 'Risk Factors', 'Triiodobenzoic Acids/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25753449/
3032,ioversol,24280147,Predictive factors for failure of percutaneous drainage of postoperative abscess after abdominal surgery.,"['Kassi F', 'Dohan A', 'Soyer P', 'Vicaut E', 'Boudiaf M', 'Valleur P', 'Pocard M']","['Abdominal Abscess/*surgery', 'Adult', 'Aged', 'Aged, 80 and over', 'Contrast Media', '*Digestive System Surgical Procedures', 'Drainage/*methods', 'Female', 'Humans', 'Iopamidol/analogs & derivatives', 'Male', 'Middle Aged', 'Postoperative Complications/*surgery', 'Predictive Value of Tests', '*Radiography, Interventional', 'Retrospective Studies', 'Risk Factors', '*Tomography, X-Ray Computed', 'Treatment Failure', 'Triiodobenzoic Acids']",https://pubmed.ncbi.nlm.nih.gov/24280147/
3033,ioversol,17557212,Fatal anaphylactoid reaction following ioversol administration.,"['Jansman FG', 'Kieft H', 'Harting JW']","['Anaphylaxis/*chemically induced', 'Contrast Media/*adverse effects', 'Fatal Outcome', 'Humans', 'Male', 'Middle Aged', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/17557212/
3034,ioversol,35312791,A systematic review of the incidence of hypersensitivity reactions and post-contrast acute kidney injury after ioversol: part 2-intra-arterial administration.,"['van der Molen AJ', 'Dekkers IA', 'Bedioune I', 'Darmon-Kern E']","['*Acute Kidney Injury/chemically induced/epidemiology', 'Child', 'Contrast Media/adverse effects', 'Humans', 'Incidence', '*Iodine Compounds', '*Renal Insufficiency, Chronic', 'Risk Factors', 'Triiodobenzoic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35312791/
3035,ioversol,16681576,Drug eruptions to contrast media in Japan.,"['Nakada T', 'Akiyama M', 'Iijima M', 'Kato A', 'Maibach HI']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Aldehyde Dehydrogenase/deficiency/genetics', 'Aldehyde Dehydrogenase, Mitochondrial', 'Case-Control Studies', 'Contrast Media/*adverse effects', 'Drug Eruptions/*etiology', 'Female', 'Gene Deletion', 'Humans', 'Hypersensitivity, Delayed/*chemically induced', 'Iohexol/adverse effects', 'Iopamidol/adverse effects/analogs & derivatives', 'Japan', 'Male', 'Middle Aged', 'Skin Tests', 'Triiodobenzoic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16681576/
3036,ioversol,30998567,Acute Adverse Reactions to Nonionic Iodinated Contrast Media: A Meta-Analysis.,"['Suh YJ', 'Yoon SH', 'Hong H', 'Hahn S', 'Kang DY', 'Kang HR', 'Choi YH', 'Lee W']","['Contrast Media/*adverse effects', 'Female', 'Humans', 'Incidence', 'Iohexol/*adverse effects', 'Iopamidol/adverse effects/*analogs & derivatives', 'Male', 'Middle Aged', 'Triiodobenzoic Acids/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30998567/
3037,Aripiprazole,36867173,Antidepressant Augmentation versus Switch in Treatment-Resistant Geriatric Depression.,"['Lenze EJ', 'Mulsant BH', 'Roose SP', 'Lavretsky H', 'Reynolds CF 3rd', 'Blumberger DM', 'Brown PJ', 'Cristancho P', 'Flint AJ', 'Gebara MA', 'Gettinger TR', 'Lenard E', 'Miller JP', 'Nicol GE', 'Oughli HA', 'Pham VT', 'Rollman BL', 'Yang L', 'Karp JF']","['Aged', 'Humans', '*Antidepressive Agents/adverse effects/therapeutic use', '*Aripiprazole/adverse effects/therapeutic use', '*Bupropion/adverse effects/therapeutic use', 'Depression', 'Drug Therapy, Combination', '*Nortriptyline/adverse effects/therapeutic use', '*Treatment Switching', '*Lithium Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36867173/
3038,Aripiprazole,38226593,Cannabinoid treatment for the symptoms of autism spectrum disorder.,"['Aran A', 'Cayam Rand D']","['Child', 'Humans', 'Aripiprazole/adverse effects', '*Autism Spectrum Disorder/drug therapy', 'Cannabidiol/therapeutic use', '*Cannabinoids/therapeutic use', 'Irritable Mood', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/38226593/
3039,Aripiprazole,33064050,A safety evaluation of aripiprazole in the treatment of schizophrenia.,"['Preda A', 'Shapiro BB']","['Adult', 'Antipsychotic Agents/*administration & dosage/adverse effects/pharmacology', 'Aripiprazole/*administration & dosage/pharmacology', 'Delayed-Action Preparations', 'Drug Administration Schedule', 'Humans', 'Medication Adherence', 'Prolactin/blood', 'Schizophrenia/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/33064050/
3040,Aripiprazole,37566261,Efficacy and Safety of Aripiprazole in Borderline Personality Disorder: A Systematic Review.,"['Valdivieso-Jimenez G', 'Pino-Zavaleta DA', 'Campos-Rodriguez SK', 'Ortiz-Saavedra B', 'Fernandez MF', 'Benites-Zapata VA']","['Adult', 'Female', 'Humans', 'Male', 'Aripiprazole/adverse effects', '*Borderline Personality Disorder/drug therapy', '*Antipsychotic Agents/adverse effects', 'Olanzapine/therapeutic use', 'Anxiety Disorders']",https://pubmed.ncbi.nlm.nih.gov/37566261/
3041,Aripiprazole,35904579,Cannabidiol for the treatment of autism spectrum disorder: hope or hype?,"['Pedrazzi JFC', 'Ferreira FR', 'Silva-Amaral D', 'Lima DA', 'Hallak JEC', 'Zuardi AW', 'Del-Bel EA', 'Guimaraes FS', 'Costa KCM', 'Campos AC', 'Crippa ACS', 'Crippa JAS']","['Aripiprazole/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', '*Autism Spectrum Disorder/drug therapy', '*Cannabidiol/pharmacology/therapeutic use', 'Child, Preschool', 'Endocannabinoids', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35904579/
3042,Aripiprazole,26589880,Aripiprazole.,['Prommer E'],"['Alzheimer Disease/drug therapy', 'Antipsychotic Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Aripiprazole/pharmacokinetics/pharmacology/*therapeutic use', 'Delirium/*drug therapy', 'Humans', 'Psychotic Disorders/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26589880/
3043,Aripiprazole,29788886,Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.,"['Pakri Mohamed RM', 'Kumar J', 'Ahmad SU', 'Mohamed IN']","['Alcohol Deterrents/adverse effects/*therapeutic use', 'Alcoholism/*drug therapy', 'Animals', 'Aripiprazole/adverse effects/therapeutic use', 'Baclofen/adverse effects/therapeutic use', 'Cyclopentanes/adverse effects/therapeutic use', 'Gabapentin/adverse effects/therapeutic use', 'Humans', 'Naltrexone/adverse effects/analogs & derivatives/therapeutic use', 'Quetiapine Fumarate/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29788886/
3044,Aripiprazole,38465894,Long-acting second-generation injectable antipsychotics for the maintenance treatment of bipolar disorder: a narrative review.,"['Belge JB', 'Sabbe BGCC']","['Humans', '*Bipolar Disorder/drug therapy', '*Antipsychotic Agents/administration & dosage/therapeutic use', '*Delayed-Action Preparations', '*Medication Adherence', '*Injections', 'Randomized Controlled Trials as Topic', 'Hospitalization', 'Adult', 'Aripiprazole/therapeutic use/administration & dosage', 'Risperidone/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38465894/
3045,Aripiprazole,32930009,Antipsychotic polypharmacy in schizophrenia: evolving evidence and rationale.,"['Azorin JM', 'Simon N']","['Antipsychotic Agents/*administration & dosage/adverse effects', 'Aripiprazole/administration & dosage', 'Clozapine/administration & dosage', 'Drug Therapy, Combination', 'Humans', 'Models, Theoretical', 'Polypharmacy', 'Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic', 'Schizophrenia/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32930009/
3046,Aripiprazole,28806160,Delirium in hospitalized patients: Risks and benefits of antipsychotics.,"['Thom RP', 'Mock CK', 'Teslyar P']","['Antipsychotic Agents/adverse effects/*therapeutic use', 'Aripiprazole/adverse effects/therapeutic use', 'Benzodiazepines/adverse effects/therapeutic use', 'Delirium/*drug therapy', 'Haloperidol/adverse effects/therapeutic use', 'Hospitalization', 'Humans', 'Olanzapine', 'Quetiapine Fumarate/adverse effects/therapeutic use', 'Risperidone/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28806160/
3047,Aripiprazole,39079887,"Efficacy, acceptability and tolerability of second-generation antipsychotics for behavioural and psychological symptoms of dementia: a systematic review and network meta-analysis.","['Lu W', 'Liu F', 'Zhang Y', 'He X', 'Hu Y', 'Xu H', 'Yang X', 'Li J', 'Kuang W']","['Humans', '*Antipsychotic Agents/therapeutic use/adverse effects', '*Dementia/drug therapy', '*Network Meta-Analysis', 'Randomized Controlled Trials as Topic', 'Treatment Outcome', 'Olanzapine/therapeutic use/adverse effects', 'Aripiprazole/therapeutic use/adverse effects', 'Behavioral Symptoms/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39079887/
3048,Aripiprazole,35777418,"Pharmacological Treatment of Early-Onset Schizophrenia: A Critical Review, Evidence-Based Clinical Guidance and Unmet Needs.","['Lopez-Morinigo JD', 'Leucht S', 'Arango C']","['Adolescent', '*Antipsychotic Agents/therapeutic use', 'Aripiprazole/therapeutic use', 'Benzodiazepines/therapeutic use', '*Clozapine/therapeutic use', 'Haloperidol/therapeutic use', 'Humans', 'Lurasidone Hydrochloride/therapeutic use', 'Molindone/therapeutic use', 'Olanzapine', 'Paliperidone Palmitate/therapeutic use', 'Quality of Life', 'Quetiapine Fumarate/therapeutic use', 'Risperidone/adverse effects', '*Schizophrenia/drug therapy', 'Systematic Reviews as Topic']",https://pubmed.ncbi.nlm.nih.gov/35777418/
3049,Aripiprazole,31063671,Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.,"['DeVane CL', 'Charles JM', 'Abramson RK', 'Williams JE', 'Carpenter LA', 'Raven S', 'Gwynette F', 'Stuck CA', 'Geesey ME', 'Bradley C', 'Donovan JL', 'Hall AG', 'Sherk ST', 'Powers NR', 'Spratt E', 'Kinsman A', 'Kruesi MJ', 'Bragg JE Jr']","['Adolescent', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Aripiprazole/adverse effects/*therapeutic use', 'Autism Spectrum Disorder/*drug therapy', 'Child', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Risperidone/adverse effects/*therapeutic use', 'Treatment Outcome', 'Weight Gain/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31063671/
3050,Aripiprazole,36825499,"Aripiprazole, brexpiprazole, and cariprazine can affect milk supply: Advice to breastfeeding mothers.","['Naughton S', ""O'Hara K"", 'Nelson J', 'Keightley P']","['Animals', 'Female', 'Humans', 'Aripiprazole/adverse effects', '*Milk', '*Breast Feeding', 'Mothers', 'Dopamine Agonists/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/36825499/
3051,Aripiprazole,29498507,Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents.,"['Mogwitz S', 'Buse J', 'Wolff N', 'Roessner V']","['Animals', 'Antipsychotic Agents/*therapeutic use', 'Aripiprazole/*therapeutic use', 'Dopamine Agents/*therapeutic use', 'Dopamine Antagonists/*therapeutic use', 'Humans', 'Tics/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29498507/
3052,Aripiprazole,29341822,Aripiprazole Long-Acting Injectable for Maintenance Treatment of Bipolar I Disorder in Adults.,"['Aggarwal A', 'Schrimpf L', 'Lauriello J']","['Adult', 'Antipsychotic Agents/administration & dosage/adverse effects/*pharmacology', 'Aripiprazole/administration & dosage/adverse effects/*pharmacology', 'Bipolar Disorder/*drug therapy', 'Delayed-Action Preparations', 'Humans', 'Injections']",https://pubmed.ncbi.nlm.nih.gov/29341822/
3053,Aripiprazole,30785608,Association of Antipsychotic Polypharmacy vs Monotherapy With Psychiatric Rehospitalization Among Adults With Schizophrenia.,"['Tiihonen J', 'Taipale H', 'Mehtala J', 'Vattulainen P', 'Correll CU', 'Tanskanen A']","['Adult', 'Antipsychotic Agents/*administration & dosage/therapeutic use', 'Aripiprazole/administration & dosage/therapeutic use', 'Clozapine/administration & dosage/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Patient Readmission/*statistics & numerical data', 'Polypharmacy', 'Schizophrenia/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30785608/
3054,Aripiprazole,37949235,"Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.","['Terao I', 'Tsuge T', 'Endo K', 'Kodama W']","['Adult', 'Humans', '*Ketamine/adverse effects', 'Aripiprazole/adverse effects', 'Antidepressive Agents/adverse effects', 'Lithium/therapeutic use', 'Network Meta-Analysis', '*Depressive Disorder/drug therapy', '*Depressive Disorder, Treatment-Resistant/drug therapy', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37949235/
3055,Aripiprazole,33954421,Guidance on the treatment of antipsychotic-induced hyperprolactinemia when switching the antipsychotic is not an option.,"['Rusgis MM', 'Alabbasi AY', 'Nelson LA']","['*Antipsychotic Agents/adverse effects', 'Aripiprazole/adverse effects', 'Humans', '*Hyperprolactinemia/chemically induced/diagnosis/drug therapy', '*Mental Disorders/drug therapy', 'Prolactin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33954421/
3056,Aripiprazole,37350486,Long-Acting Injectable Second-Generation Antipsychotics vs Placebo and Their Oral Formulations in Acute Schizophrenia: A Systematic Review and Meta-Analysis of Randomized-Controlled-Trials.,"['Wang D', 'Schneider-Thoma J', 'Siafis S', 'Burschinski A', 'Dong S', 'Wu H', 'Zhu Y', 'Davis JM', 'Priller J', 'Leucht S']","['Humans', '*Antipsychotic Agents/adverse effects', 'Paliperidone Palmitate/adverse effects', 'Aripiprazole/adverse effects', 'Olanzapine/therapeutic use', 'Risperidone/adverse effects', 'Delayed-Action Preparations/therapeutic use', '*Schizophrenia/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37350486/
3057,DESMOPRESSIN,22433947,Diabetes insipidus--diagnosis and management.,"['Di Iorgi N', 'Napoli F', 'Allegri AE', 'Olivieri I', 'Bertelli E', 'Gallizia A', 'Rossi A', 'Maghnie M']","['Adult', 'Age Factors', 'Animals', 'Antidiuretic Agents/administration & dosage/adverse effects/therapeutic use', 'Child', 'Deamino Arginine Vasopressin/administration & dosage/adverse effects/therapeutic use', 'Diabetes Insipidus/*diagnosis/etiology/genetics/*therapy', 'Diabetes Insipidus, Nephrogenic/diagnosis/etiology/genetics/therapy', 'Diabetes Insipidus, Neurogenic/diagnosis/etiology/genetics/therapy', 'Drug Monitoring', 'Fluid Therapy', 'Humans', 'Infant']",https://pubmed.ncbi.nlm.nih.gov/22433947/
3058,DESMOPRESSIN,34508830,Hypertonic Saline for Hyponatremia: Meeting Goals and Avoiding Harm.,"['Rondon-Berrios H', 'Sterns RH']","['Deamino Arginine Vasopressin/therapeutic use', 'Goals', 'Humans', '*Hyponatremia', 'Saline Solution, Hypertonic/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34508830/
3059,DESMOPRESSIN,12439045,Pancytopenia induced by hypothermia.,"['Lo L', 'Singer ST', 'Vichinsky E']","['Adrenal Insufficiency/etiology', 'Blood Cell Count', 'Cerebral Infarction/complications', 'Child', 'Chronic Disease', 'Consciousness Disorders/etiology', 'Craniopharyngioma/complications/*surgery', 'Deamino Arginine Vasopressin/administration & dosage/adverse effects/therapeutic use', 'Dehydration/etiology', 'Diabetes Insipidus/etiology', 'Female', 'Frontal Lobe/blood supply', 'Humans', 'Hyponatremia/etiology', '*Hypophysectomy/adverse effects', 'Hypopituitarism/etiology', 'Hypothalamus/injuries/*physiopathology', 'Hypothermia/*complications/physiopathology', 'Hypothyroidism/etiology', 'Pancreatitis/complications', 'Pancytopenia/*etiology/physiopathology', 'Pituitary Neoplasms/complications/*surgery', 'Postoperative Complications/*physiopathology', 'Seizures/etiology', 'Sleep Stages']",https://pubmed.ncbi.nlm.nih.gov/12439045/
3060,DESMOPRESSIN,2507558,Clinical use of vasopressin analogues.,"['Robertson GL', 'Harris A']","['Blood Platelet Disorders/drug therapy', 'Cardiac Surgical Procedures', 'Deamino Arginine Vasopressin/adverse effects/*therapeutic use', 'Diabetes Insipidus/drug therapy/physiopathology', 'Hemophilia A/drug therapy', 'Humans', 'Liver Cirrhosis/drug therapy', 'Uremia/drug therapy', 'von Willebrand Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2507558/
3061,DESMOPRESSIN,35327581,Desmopressin Stimulates Nitric Oxide Production in Human Lung Microvascular Endothelial Cells.,"['Rotoli BM', 'Visigalli R', 'Ferrari F', 'Ranieri M', 'Tamma G', ""Dall'Asta V"", 'Barilli A']","['*Deamino Arginine Vasopressin/metabolism/pharmacology', 'Endothelial Cells', 'Endothelium, Vascular/metabolism', 'Humans', 'Lung/metabolism', '*Nitric Oxide/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35327581/
3062,DESMOPRESSIN,16456490,Vasopressin and desmopressin in central diabetes insipidus: adverse effects and clinical considerations.,"['Kim RJ', 'Malattia C', 'Allen M', 'Moshang T Jr', 'Maghnie M']","['Antidiuretic Agents/administration & dosage/*adverse effects', 'Child', 'Deamino Arginine Vasopressin/administration & dosage/*adverse effects', 'Diabetes Insipidus, Neurogenic/*drug therapy', 'Humans', 'Vasopressins/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16456490/
3063,DESMOPRESSIN,3893256,Desmopressin.,"['Richardson DW', 'Robinson AG']","['Anemia, Sickle Cell/drug therapy', 'Animals', '*Arginine Vasopressin/analogs & derivatives/metabolism/pharmacology/therapeutic use', '*Deamino Arginine Vasopressin/adverse effects/metabolism/pharmacology/therapeutic use', 'Diabetes Insipidus/drug therapy', 'Drug Synergism', 'Enuresis/drug therapy', 'Hemophilia A/drug therapy', 'Humans', 'Kidney Concentrating Ability/drug effects', 'Learning/drug effects', 'Memory Disorders/drug therapy', 'Structure-Activity Relationship', 'Urinary Incontinence/drug therapy', 'von Willebrand Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3893256/
3064,DESMOPRESSIN,11996629,Vasopressin in cardiovascular patients: therapeutic implications.,"['Zimmerman MA', 'Albright TN', 'Raeburn CD', 'Selzman CH']","['Cardiopulmonary Resuscitation', 'Cardiovascular Diseases/*drug therapy/surgery', '*Deamino Arginine Vasopressin/administration & dosage/therapeutic use', 'Hemostatics/*therapeutic use', 'Humans', 'Postoperative Period', '*Vasopressins/physiology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11996629/
3065,DESMOPRESSIN,35604340,Impact of activity-based recovery training and desmopressin on spinal cord injury-induced polyuria in Wistar rats.,"['Hubscher CH', 'Gumbel JH', 'Armstrong JE', 'Montgomery LR']","['Humans', 'Child', 'Male', 'Rats', 'Animals', '*Deamino Arginine Vasopressin/pharmacology/therapeutic use', 'Polyuria/drug therapy/etiology', 'Rats, Wistar', '*Spinal Cord Injuries/complications/drug therapy', 'Urination']",https://pubmed.ncbi.nlm.nih.gov/35604340/
3066,DESMOPRESSIN,9599739,Therapy concept in enuretic children.,"['Etele-Hainz A', 'Artens E', 'Marberger M']","['Adolescent', 'Austria', 'Child', 'Deamino Arginine Vasopressin/administration & dosage/*therapeutic use', 'Enuresis/diagnosis/psychology/*therapy', 'Humans', 'Renal Agents/administration & dosage/*therapeutic use', 'Retrospective Studies', 'Syndrome', '*Toilet Training', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9599739/
3067,DESMOPRESSIN,8202769,"Desmopressin acetate in cardiac surgery: a double-blind, randomized study.","['Temeck BK', 'Bachenheimer LC', 'Katz NM', 'Coughlin SS', 'Wallace RB']","['Blood Loss, Surgical/prevention & control', 'Blood Transfusion', '*Cardiac Surgical Procedures', 'Cardiopulmonary Bypass', 'Chest Tubes', 'Deamino Arginine Vasopressin/administration & dosage/*therapeutic use', 'Double-Blind Method', 'Drainage', 'Female', 'Hemostatics/administration & dosage/*therapeutic use', 'Humans', 'Male', 'Partial Thromboplastin Time', 'Placebos', 'Platelet Aggregation Inhibitors/therapeutic use', 'Prospective Studies', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/8202769/
3068,DESMOPRESSIN,17344569,How do you treat bleeding disorders with desmopressin?,"['Ozgonenel B', 'Rajpurkar M', 'Lusher JM']","['Deamino Arginine Vasopressin/*administration & dosage/adverse effects/pharmacology', 'Drug Administration Routes', 'Hemorrhagic Disorders/*drug therapy', 'Hemostatics/administration & dosage/adverse effects/pharmacology', 'Humans', 'von Willebrand Factor/physiology']",https://pubmed.ncbi.nlm.nih.gov/17344569/
3069,DESMOPRESSIN,2220513,"Desmopressin for diabetes insipidus, hemostatic disorders and enuresis.","['Shulman LH', 'Miller JL', 'Rose LI']","['Deamino Arginine Vasopressin/adverse effects/therapeutic use', 'Diabetes Insipidus/*drug therapy', 'Enuresis/*drug therapy', 'Gastrointestinal Hemorrhage/*drug therapy', 'Hemorrhagic Disorders/*drug therapy', 'Humans', 'Vasopressins/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2220513/
3070,DESMOPRESSIN,23109357,The use of DDAVP in children with bleeding disorders.,"['Ben-Ami T', 'Revel-Vilk S']","['Blood Coagulation Disorders, Inherited/*drug therapy', 'Blood Platelets/drug effects', 'Child', 'Child, Preschool', 'Deamino Arginine Vasopressin/*therapeutic use', 'Hemophilia A/*drug therapy', 'Hemostasis', 'Humans', 'Platelet Function Tests', 'von Willebrand Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/23109357/
3071,DESMOPRESSIN,8495145,Nocturnal enuresis. Treatment options.,['Steele BT'],"['Administration, Intranasal', 'Age Factors', 'Causality', 'Child', 'Deamino Arginine Vasopressin/administration & dosage/therapeutic use', 'Diagnosis, Differential', 'Enuresis/diagnosis/etiology/*therapy', 'Family Practice/*methods', 'Humans', 'Imipramine/therapeutic use', 'Mandelic Acids/therapeutic use', 'Medical History Taking', 'Monitoring, Physiologic', 'Motivation', 'Parasympatholytics/therapeutic use', 'Sleep', 'Time Factors', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/8495145/
3072,DESMOPRESSIN,16517412,Desmopressin and other synthetic vasopressin analogues in cancer treatment.,"['Gomez DE', 'Ripoll GV', 'Giron S', 'Alonso DF']","['Animals', 'Deamino Arginine Vasopressin/*therapeutic use', 'Hemostatics/*therapeutic use', 'Humans', 'Neoplasm Invasiveness', 'Neoplasms/*drug therapy/pathology', 'Vasopressins/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/16517412/
3073,DESMOPRESSIN,38778788,Safety and efficacy of desmopressin (DDAVP) in preventing hematoma expansion in intracranial hemorrhage associated with antiplatelet drugs use: A systematic review and metaanalysis.,"['Shahzad F', 'Ahmed U', 'Muhammad A', 'Shahzad F', 'Naufil SI', 'Sukkari MW', 'Kamran AB', 'Murtaza S', 'Khalid MB', 'Shabbir H', 'Saeed S']","['*Deamino Arginine Vasopressin/adverse effects/administration & dosage', 'Humans', '*Platelet Aggregation Inhibitors/adverse effects/administration & dosage', '*Intracranial Hemorrhages/chemically induced', '*Hematoma/chemically induced', 'Hemostatics/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38778788/
3074,DESMOPRESSIN,35199198,Desmopressin therapy in children and adults: pharmacological considerations and clinical implications.,"['Chin X', 'Teo SW', 'Lim ST', 'Ng YH', 'Han HC', 'Yap F']","['Administration, Intranasal', 'Administration, Oral', 'Adult', '*Antidiuretic Agents/adverse effects', 'Child', 'Deamino Arginine Vasopressin/adverse effects', 'Humans', '*Hyponatremia/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35199198/
3075,DESMOPRESSIN,34487771,Variability in Oral Desmopressin Dose Requirements in Children with Central Diabetes Insipidus.,"['Almutlaq N', 'Eugster EA']","['Administration, Oral', 'Adolescent', 'Antidiuretic Agents/*administration & dosage/therapeutic use', 'Child', 'Child, Preschool', 'Deamino Arginine Vasopressin/*administration & dosage/therapeutic use', 'Diabetes Insipidus, Neurogenic/diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Female', 'Humans', 'Infant', 'Male', 'Retrospective Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34487771/
3076,DESMOPRESSIN,8936928,Partial central diabetes insipidus complicating nonketotic hyperglycemic hyperosmolar coma.,"['Amundson CD', 'Olsen CJ', 'Wade CD']","['Aged', 'Deamino Arginine Vasopressin/administration & dosage/*therapeutic use', 'Diabetes Insipidus/*complications', 'Female', 'Humans', '*Hyperglycemic Hyperosmolar Nonketotic Coma/drug therapy/etiology', 'Hypoglycemic Agents/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8936928/
3077,Telmisartan,37432701,Efficacy of single-pill combination in uncontrolled essential hypertension: A systematic review and network meta-analysis.,"['Xie M', 'Tang T', 'Liang H']","['Humans', '*Antihypertensive Agents/therapeutic use', 'Losartan/pharmacology/therapeutic use', '*Hypertension/diagnosis/drug therapy', 'Telmisartan/pharmacology/therapeutic use', 'Irbesartan/pharmacology/therapeutic use', 'Angiotensin Receptor Antagonists/therapeutic use', 'Network Meta-Analysis', 'Hydrochlorothiazide/adverse effects', 'Valine/adverse effects', 'Drug Therapy, Combination', 'Angiotensin-Converting Enzyme Inhibitors/therapeutic use', 'Amlodipine/therapeutic use', 'Valsartan/therapeutic use', 'Tetrazoles/therapeutic use', 'Blood Pressure', 'Essential Hypertension/diagnosis/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37432701/
3078,Telmisartan,32937023,Efficacy and safety of co-administered telmisartan/amlodipine and rosuvastatin in subjects with hypertension and dyslipidemia.,"['Jin X', 'Kim MH', 'Han KH', 'Hong SJ', 'Ahn JC', 'Sung JH', 'Cho JM', 'Lee HC', 'Choi SY', 'Lee K', 'Kim WS', 'Rhee MY', 'Kim JH', 'Hong SP', 'Yoo BS', 'Cho EJ', 'Lee JH', 'Kim PJ', 'Park CG', 'Hyon MS', 'Shin JH', 'Lee SH', 'Sung KC', 'Hwang J', 'Kwon K', 'Chae IH', 'Seo JS', 'Kim H', 'Lee H', 'Cho Y', 'Kim HS']","['Aged', 'Amlodipine/*administration & dosage/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', 'Drug Therapy, Combination', '*Dyslipidemias/drug therapy', 'Female', 'Humans', '*Hypertension/drug therapy', 'Male', 'Middle Aged', 'Rosuvastatin Calcium/*administration & dosage/therapeutic use', 'Telmisartan/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32937023/
3079,Telmisartan,30471331,Therapy resistance mediated by cancer stem cells.,"['Steinbichler TB', 'Dudas J', 'Skvortsov S', 'Ganswindt U', 'Riechelmann H', 'Skvortsova II']","['ATP-Binding Cassette Transporters/antagonists & inhibitors/genetics/metabolism', 'Chemoradiotherapy', 'DNA Repair/genetics', 'Drug Resistance, Neoplasm/drug effects/*genetics', 'Gene Expression Regulation, Neoplastic/drug effects/radiation effects', 'Humans', 'Neoplasms/*genetics/metabolism/therapy', 'Neoplastic Stem Cells/drug effects/*metabolism/radiation effects', 'Radiation Tolerance/drug effects/*genetics', 'Telmisartan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30471331/
3080,Telmisartan,26051689,Telmisartan.,"['Bakheit AH', 'Abd-Elgalil AA', 'Mustafa B', 'Haque A', 'Wani TA']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Animals', 'Antihypertensive Agents/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Benzimidazoles/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Benzoates/administration & dosage/adverse effects/*chemistry/pharmacokinetics', 'Blood Pressure/drug effects', 'Chemistry, Pharmaceutical', 'Drug Interactions', 'Drug Stability', 'Humans', 'Hypertension/drug therapy/physiopathology', 'Molecular Structure', 'Technology, Pharmaceutical/methods', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/26051689/
3081,Telmisartan,38228033,Effects of telmisartan on metabolic syndrome components: a comprehensive review.,"['Imenshahidi M', 'Roohbakhsh A', 'Hosseinzadeh H']","['Humans', 'Telmisartan/pharmacology', 'Angiotensin Receptor Antagonists/pharmacology', '*Metabolic Syndrome/drug therapy', 'PPAR gamma/pharmacology', 'Prospective Studies', 'Angiotensin II Type 1 Receptor Blockers/pharmacology', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology', 'Benzimidazoles/pharmacology', '*Hypertension/drug therapy', 'Antihypertensive Agents/pharmacology', 'Blood Pressure', 'Benzoates/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38228033/
3082,Telmisartan,38573089,Telmisartan-Induced Myotoxicity in Patients with Essential Hypertension.,"['Kara SC', 'Canpolat U']","['Humans', '*Myotoxicity', 'Telmisartan/adverse effects', 'Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors', 'Essential Hypertension/drug therapy', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/38573089/
3083,Telmisartan,38319595,"Efficacy and safety of combination therapy with telmisartan, rosuvastatin, and ezetimibe in patients with dyslipidemia and hypertension: A randomized, double-blind, multicenter, therapeutic confirmatory, phase III clinical trial.","['Lee CJ', 'Kang WC', 'Ihm SH', 'Sohn IS', 'Woo JS', 'Kim JW', 'Hong SJ', 'Choi JH', 'Suh JW', 'Seo JB', 'Doh JH', 'Son JW', 'Park JH', 'Lee JH', 'Hong YJ', 'Heo JH', 'Shin J', 'Kang SM']","['Humans', 'Anticholesteremic Agents/therapeutic use', 'Cholesterol, LDL', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', '*Dyslipidemias/drug therapy', '*Ezetimibe/therapeutic use', '*Hypertension/drug therapy', '*Rosuvastatin Calcium/therapeutic use', '*Telmisartan/therapeutic use', 'Treatment Outcome', 'Antihypertensive Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38319595/
3084,Telmisartan,9878991,Telmisartan.,"['McClellan KJ', 'Markham A']","['*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Animals', 'Antihypertensive Agents/pharmacokinetics/therapeutic use', 'Benzimidazoles/adverse effects/pharmacology/*therapeutic use', 'Benzoates/adverse effects/pharmacology/*therapeutic use', 'Biotransformation', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Half-Life', 'Humans', 'Hypertension/*drug therapy', 'Intestinal Absorption', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/9878991/
3085,Telmisartan,33578449,An insight into the role of telmisartan as PPAR-gamma/alpha dual activator in the management of nonalcoholic fatty liver disease.,"['Devan AR', 'Nair B', 'Kumar AR', 'Nath LR']","['Humans', 'Liver', '*Non-alcoholic Fatty Liver Disease/drug therapy/etiology/metabolism', 'PPAR alpha/agonists/metabolism', 'PPAR gamma/agonists/metabolism', 'Telmisartan/metabolism/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33578449/
3086,Telmisartan,39426836,"Efficacy and safety of a novel low-dose triple single-pill combination of telmisartan, amlodipine and indapamide, compared with dual combinations for treatment of hypertension: a randomised, double-blind, active-controlled, international clinical trial.","['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee DE', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Lakshman P', 'Uluwattage W', 'Hay P', 'Pereira T', 'Amarasena N', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Gnanenthiran SR', 'Whelton PK']","['Adult', 'Aged', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Double-Blind Method', 'Drug Combinations', '*Hypertension/drug therapy', '*Indapamide/administration & dosage/adverse effects/therapeutic use', '*Telmisartan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39426836/
3087,Telmisartan,31965140,"Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.","['Dehghan M', 'Mente A', 'Rangarajan S', 'Mohan V', 'Lear S', 'Swaminathan S', 'Wielgosz A', 'Seron P', 'Avezum A', 'Lopez-Jaramillo P', 'Turbide G', 'Chifamba J', 'AlHabib KF', 'Mohammadifard N', 'Szuba A', 'Khatib R', 'Altuntas Y', 'Liu X', 'Iqbal R', 'Rosengren A', 'Yusuf R', 'Smuts M', 'Yusufali A', 'Li N', 'Diaz R', 'Yusoff K', 'Kaur M', 'Soman B', 'Ismail N', 'Gupta R', 'Dans A', 'Sheridan P', 'Teo K', 'Anand SS', 'Yusuf S']","['Adult', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage', 'Cardiovascular Diseases/blood/drug therapy/*metabolism/*mortality', 'Eggs/*analysis', 'Female', 'Humans', 'Lipids/*blood', 'Male', 'Middle Aged', 'Proportional Hazards Models', 'Prospective Studies', 'Ramipril/administration & dosage', 'Telmisartan/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31965140/
3088,Telmisartan,17666193,Prevention of stroke in patients with hypertension.,['Dahlof B'],"['Angiotensin II Type 1 Receptor Blockers/administration & dosage/*therapeutic use', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Europe/epidemiology', 'Humans', 'Hypertension/*complications', 'Stroke/complications/mortality/*prevention & control', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/17666193/
3089,Telmisartan,27715071,[Current position of a fixed combination telmisartan with amlodipine in treatment of essential arterial hypertension].,['Sliva J'],"['Amlodipine/administration & dosage/*therapeutic use', 'Antihypertensive Agents/*therapeutic use', 'Benzimidazoles/administration & dosage/*therapeutic use', 'Benzoates/administration & dosage/*therapeutic use', 'Drug Combinations', 'Essential Hypertension', 'Humans', 'Hypertension/*drug therapy', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/27715071/
3090,Telmisartan,39217570,Efficacy and Safety of a Novel Low-Dose Triple Single-Pill Combination Compared With Placebo for Initial Treatment of Hypertension.,"['Rodgers A', 'Salam A', 'Schutte AE', 'Cushman WC', 'de Silva HA', 'Di Tanna GL', 'Grobbee D', 'Narkiewicz K', 'Ojji DB', 'Poulter NR', 'Schlaich MP', 'Oparil S', 'Spiering W', 'Williams B', 'Wright JT Jr', 'Gutierez A', 'Sanni A', 'Lakshman P', 'McMullen D', 'Ranasinghe G', 'Gianacas C', 'Shanthakumar M', 'Liu X', 'Wang N', 'Whelton P']","['Humans', '*Hypertension/drug therapy', 'Male', 'Female', 'Middle Aged', 'Double-Blind Method', '*Amlodipine/administration & dosage/adverse effects', '*Indapamide/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects', '*Telmisartan/administration & dosage', '*Drug Combinations', 'Treatment Outcome', 'Aged', 'Blood Pressure/drug effects', 'Dose-Response Relationship, Drug', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39217570/
3091,Telmisartan,39215620,Low-Dose Triple-Pill vs Standard-Care Protocols for Hypertension Treatment in Nigeria: A Randomized Clinical Trial.,"['Ojji DB', 'Salam A', 'Sani MU', 'Ogah OS', 'Schutte AE', 'Huffman MD', 'Pant R', 'Ghosh A', 'Dhurjati R', 'Lakshmi JK', 'Ripiye NR', 'Orji IA', 'Kana SA', 'Abdussalam T', 'Olawumi AL', 'Alfa IM', 'Orimolade OA', 'Ajayi MO', 'Rodgers A']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', '*Amlodipine/administration & dosage/adverse effects', '*Antihypertensive Agents/administration & dosage/adverse effects', 'Black People', '*Blood Pressure/drug effects', 'Drug Combinations', '*Hypertension/diagnosis/drug therapy/epidemiology', '*Indapamide/administration & dosage/adverse effects', 'Nigeria/epidemiology', '*Telmisartan/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39215620/
3092,Telmisartan,17703634,Is the fixed-dose combination of telmisartan and hydrochlorothiazide a good approach to treat hypertension?,"['Maillard MP', 'Burnier M']","['Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/*pharmacology/therapeutic use', 'Benzoates/*pharmacology/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/*pharmacology/therapeutic use', 'Hypertension/*drug therapy', 'Randomized Controlled Trials as Topic', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/17703634/
3093,Telmisartan,18221077,"Telmisartan, its potential therapeutic implications in cardiometabolic disorders.","['Yamagishi S', 'Nakamura K']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Animals', 'Benzimidazoles/*therapeutic use', 'Benzoates/*therapeutic use', 'Cardiovascular Diseases/*prevention & control', 'Diabetic Retinopathy/*drug therapy', 'Humans', '*Insulin Resistance', 'PPAR gamma/drug effects', 'Receptor for Advanced Glycation End Products', 'Receptors, Immunologic/drug effects', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/18221077/
3094,Telmisartan,30993607,The Possible Role of the Angiotensin System in the Pathophysiology of Schizophrenia: Implications for Pharmacotherapy.,"['Oh SJ', 'Fan X']","['Angiotensin II Type 1 Receptor Blockers/*therapeutic use', 'Cytokines/blood', 'Humans', 'Neurotransmitter Agents/*metabolism', 'Renin-Angiotensin System/*drug effects/immunology', 'Schizophrenia/*drug therapy/etiology/immunology/metabolism', 'Telmisartan/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30993607/
3095,Telmisartan,15868116,Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.,"['Kintscher U', 'Unger T']","['Angiotensin II Type 1 Receptor Blockers/*pharmacology/therapeutic use', 'Antihypertensive Agents/*pharmacology/therapeutic use', 'Benzimidazoles/pharmacology/therapeutic use', 'Benzoates/pharmacology/therapeutic use', 'Diabetes Mellitus, Type 2/*complications/*drug therapy', 'Diabetic Angiopathies/*prevention & control', 'Humans', 'Insulin Resistance/physiology', 'PPAR gamma/physiology', 'Renin-Angiotensin System/drug effects', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/15868116/
3096,Telmisartan,35851888,"RP-HPLC method development and validation for simultaneous estimation of telmisartan, rosuvastatin calcium, and amlodipine besylate in combination.","['Mistry RP', 'Shah C', 'Jat R']","['*Amlodipine/therapeutic use', 'Antihypertensive Agents/therapeutic use', 'Chromatography, High Pressure Liquid', 'Humans', '*Hypertension/drug therapy', 'Rosuvastatin Calcium/therapeutic use', 'Telmisartan/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35851888/
3097,AMPHETAMINE,23539642,"Amphetamine, past and present--a pharmacological and clinical perspective.","['Heal DJ', 'Smith SL', 'Gosden J', 'Nutt DJ']","['Adolescent', 'Adult', 'Amphetamine/adverse effects/*pharmacology/therapeutic use', 'Amphetamine-Related Disorders/*epidemiology/prevention & control', 'Animals', 'Attention Deficit Disorder with Hyperactivity/drug therapy', 'Central Nervous System Stimulants/adverse effects/*pharmacology/therapeutic use', 'Child', 'Dextroamphetamine/adverse effects/pharmacology/therapeutic use', 'Drug Design', 'Humans', 'Lisdexamfetamine Dimesylate', 'Narcolepsy/drug therapy', 'Prodrugs']",https://pubmed.ncbi.nlm.nih.gov/23539642/
3098,AMPHETAMINE,33085721,Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.,"['Elliott J', 'Johnston A', 'Husereau D', 'Kelly SE', 'Eagles C', 'Charach A', 'Hsieh SC', 'Bai Z', 'Hossain A', 'Skidmore B', 'Tsakonas E', 'Chojecki D', 'Mamdani M', 'Wells GA']","['Adult', 'Amphetamine/adverse effects/therapeutic use', 'Atomoxetine Hydrochloride/adverse effects/therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/epidemiology/pathology', 'Bayes Theorem', 'Bupropion/adverse effects/therapeutic use', 'Central Nervous System Stimulants/*adverse effects', 'Dextroamphetamine/adverse effects/therapeutic use', 'Drug-Related Side Effects and Adverse Reactions/classification/*epidemiology/pathology', 'Female', 'Guanfacine/adverse effects/therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate/adverse effects/therapeutic use', 'Male', 'Methylphenidate/adverse effects/therapeutic use', 'Modafinil/adverse effects/therapeutic use', 'Network Meta-Analysis', 'Quality of Life', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33085721/
3099,AMPHETAMINE,24788672,A systematic review of the safety of lisdexamfetamine dimesylate.,"['Coghill DR', 'Caballero B', 'Sorooshian S', 'Civil R']","['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/administration & dosage/*adverse effects/therapeutic use', 'Clinical Trials, Phase III as Topic', 'Dextroamphetamine/administration & dosage/*adverse effects/therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Lisdexamfetamine Dimesylate', 'Prodrugs/administration & dosage/*adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/24788672/
3100,AMPHETAMINE,39024047,Comparative pharmacology and abuse potential of oral dexamphetamine and lisdexamfetamine-A literature review.,['Kammerer W'],"['Animals', 'Humans', 'Administration, Oral', 'Attention Deficit Disorder with Hyperactivity/drug therapy', '*Central Nervous System Stimulants/administration & dosage/adverse effects/pharmacokinetics', '*Dextroamphetamine/administration & dosage/adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', '*Lisdexamfetamine Dimesylate/administration & dosage/adverse effects/pharmacokinetics', 'Prodrugs/administration & dosage/adverse effects/pharmacokinetics', 'Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/39024047/
3101,AMPHETAMINE,21194370,"The ugly side of amphetamines: short- and long-term toxicity of 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine.","['Steinkellner T', 'Freissmuth M', 'Sitte HH', 'Montgomery T']","['Amphetamines/*toxicity', 'Animals', 'Dextroamphetamine/*toxicity', 'Humans', 'Methamphetamine/*toxicity', 'Mitochondria/drug effects', 'Molecular Structure', 'N-Methyl-3,4-methylenedioxyamphetamine/toxicity', 'Psychoses, Substance-Induced/physiopathology', 'Substance-Related Disorders/mortality/physiopathology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/21194370/
3102,AMPHETAMINE,31931669,Amphetamine-Dextroamphetamine and Pregnancy: Neonatal Outcomes After Prenatal Prescription Mixed Amphetamine Exposure.,"['Rose SJ', 'Hathcock MA', 'White WM', 'Borowski K', 'Rivera-Chiauzzi EY']","['*Amphetamine', '*Attention Deficit Disorder with Hyperactivity/drug therapy/epidemiology', 'Dextroamphetamine/adverse effects', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Pregnancy', 'Prescriptions', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/31931669/
3103,AMPHETAMINE,30091808,Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults.,"['Castells X', 'Blanco-Silvente L', 'Cunill R']","['Adult', 'Amphetamines/*therapeutic use', 'Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/*therapeutic use', 'Dextroamphetamine/therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30091808/
3104,AMPHETAMINE,10975688,Psychostimulants in supportive care.,"['Homsi J', 'Walsh D', 'Nelson KA']","['Adult', 'Caffeine/adverse effects/pharmacology/therapeutic use', 'Central Nervous System Stimulants/adverse effects/pharmacology/*therapeutic use', 'Child', 'Dextroamphetamine/adverse effects/pharmacology/*therapeutic use', 'Ephedrine/adverse effects/pharmacology/therapeutic use', 'Humans', 'Mental Disorders/drug therapy/etiology', 'Methylphenidate/adverse effects/pharmacology/*therapeutic use', 'Neoplasms/*complications/*psychology', 'Pemoline/adverse effects/pharmacology/*therapeutic use', 'Substance-Related Disorders']",https://pubmed.ncbi.nlm.nih.gov/10975688/
3105,AMPHETAMINE,29134566,Lisdexamfetamine: A Review in Binge Eating Disorder.,"['Heo YA', 'Duggan ST']","['Administration, Oral', 'Binge-Eating Disorder/*drug therapy', 'Central Nervous System Stimulants/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Humans', 'Lisdexamfetamine Dimesylate/adverse effects/pharmacokinetics/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29134566/
3106,AMPHETAMINE,18777964,Lisdexamfetamine: a prodrug stimulant for ADHD.,['Howland RH'],"['Attention Deficit Disorder with Hyperactivity/*drug therapy/nursing', 'Cross-Over Studies', 'Dextroamphetamine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Administration Schedule', 'Humans', 'Lisdexamfetamine Dimesylate', ""Nurse's Role"", 'Placebos', 'Prodrugs/adverse effects/*therapeutic use', 'Psychiatric Nursing/organization & administration', 'Substance-Related Disorders/etiology/prevention & control', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18777964/
3107,AMPHETAMINE,7580171,Neuroendocrine responses to methylphenidate and d-amphetamine: applications to attention-deficit disorder.,"['Lurie S', ""O'Quinn A""]","['Adolescent', 'Adult', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/psychology', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Child', 'Dextroamphetamine/adverse effects/*therapeutic use', 'Growth Disorders/chemically induced', 'Humans', 'Methylphenidate/adverse effects/*therapeutic use', 'Neurosecretory Systems/*drug effects/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7580171/
3108,AMPHETAMINE,17407369,Lisdexamfetamine.,"['Blick SK', 'Keating GM']","['Attention Deficit Disorder with Hyperactivity/*drug therapy', 'Central Nervous System Stimulants/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Dextroamphetamine/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Lisdexamfetamine Dimesylate']",https://pubmed.ncbi.nlm.nih.gov/17407369/
3109,AMPHETAMINE,15006715,Evaluation of risks associated with short- and long-term psychostimulant therapy for treatment of ADHD in children.,"['Kociancic T', 'Reed MD', 'Findling RL']","['Appetite/drug effects', 'Attention Deficit Disorder with Hyperactivity/*drug therapy/physiopathology', 'Central Nervous System Stimulants/*adverse effects/pharmacology/therapeutic use', 'Child', 'Dextroamphetamine/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Methylphenidate/*adverse effects/pharmacology/therapeutic use', 'Sleep/drug effects', 'Tic Disorders/*etiology']",https://pubmed.ncbi.nlm.nih.gov/15006715/
3110,AMPHETAMINE,7580168,Psychostimulants in post-stroke depression.,"['Masand P', 'Murray GB', 'Pickett P']","['Aged', 'Aged, 80 and over', 'Central Nervous System Stimulants/adverse effects/*therapeutic use', 'Cerebrovascular Disorders/*complications', 'Depressive Disorder/*drug therapy/etiology/psychology', 'Dextroamphetamine/adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Methylphenidate/adverse effects/therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7580168/
3111,AMPHETAMINE,1480344,Effects of d-amphetamine on arousal.,['Chee SJ'],"['Animals', 'Arousal/*drug effects', 'Dextroamphetamine/*pharmacology', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1480344/
3112,AMPHETAMINE,33797985,Open-label pilot study of lisdexamfetamine for cocaine use disorder.,"['Mariani JJ', 'Choi CJ', 'Pavlicova M', 'Mahony AL', 'Brooks DJ', 'Grabowski J', 'Levin FR']","['Adolescent', 'Adult', 'Central Nervous System Stimulants/*administration & dosage/therapeutic use', 'Cocaine', 'Cocaine-Related Disorders/*drug therapy', 'Female', 'Humans', 'Lisdexamfetamine Dimesylate/*administration & dosage/therapeutic use', 'Male', 'Middle Aged', 'Pilot Projects', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33797985/
3113,AMPHETAMINE,3294284,Dextro-amphetamine diminishes negative symptoms in schizophrenia.,"['van Kammen DP', 'Boronow JJ']","['Adolescent', 'Adult', 'Clinical Trials as Topic', 'Depression/drug therapy/etiology', 'Dextroamphetamine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Emotions/drug effects', 'Female', 'Humans', 'Male', 'Pimozide/therapeutic use', 'Psychiatric Status Rating Scales', 'Random Allocation', 'Schizophrenia/*drug therapy', 'Schizophrenic Psychology']",https://pubmed.ncbi.nlm.nih.gov/3294284/
3114,AMPHETAMINE,38412018,[Not Available].,"['Martindale DM', 'Haraschak JL', 'Thiel AJ', 'Samuelson JP', 'Buchweitz JP']","['Humans', 'Female', 'Dogs', 'Animals', 'Lisdexamfetamine Dimesylate/therapeutic use', '*Central Nervous System Stimulants/therapeutic use', 'Dextroamphetamine/therapeutic use', '*Attention Deficit Disorder with Hyperactivity/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38412018/
3115,AMPHETAMINE,7296174,Amphetamine-induced dysphoria in postmenopausal women.,"['Halbreich U', 'Asnis G', 'Ross D', 'Endicott J']","['Adult', 'Affective Symptoms/*chemically induced', 'Age Factors', 'Dextroamphetamine/administration & dosage/*adverse effects', 'Female', 'Humans', 'Injections, Intravenous', 'Male', '*Menopause', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7296174/
3116,AMPHETAMINE,794087,Predicting the response of hyperkinetic children to stimulant drugs: a review.,['Barkley RA'],"['Amphetamine/therapeutic use', 'Amphetamines/*therapeutic use', 'Child', 'Clinical Trials as Topic', 'Dextroamphetamine/therapeutic use', 'Electroencephalography', 'Evoked Potentials/drug effects', 'Family', 'Galvanic Skin Response/drug effects', 'Humans', 'Hyperkinesis/diagnosis/*drug therapy', 'Methylphenidate/*therapeutic use', 'Neurologic Examination', 'Prognosis', 'Psychiatric Status Rating Scales', 'Reflex, Pupillary/drug effects', 'Socioeconomic Factors']",https://pubmed.ncbi.nlm.nih.gov/794087/
3117,Valdecoxib,15270001,[Etoricoxib (Arcoxia)].,"['Leclercq P', 'Malaise MG']","['Administration, Oral', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Gouty/*drug therapy', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2', 'Etoricoxib', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Osteoarthritis/*drug therapy', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Sulfones/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15270001/
3118,Valdecoxib,18182814,Etoricoxib-induced erythema-multiforme-like eruption.,"['Thirion L', 'Nikkels AF', 'Pierard GE']","['Aged', 'Arthritis/drug therapy', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Drug Eruptions/*etiology/pathology', 'Erythema Multiforme/*chemically induced/pathology', 'Etoricoxib', 'Humans', 'Male', 'Pyridines/*adverse effects', 'Skin/pathology', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18182814/
3119,Valdecoxib,27697053,Nitric Oxide-NASIDS Donor Prodrugs as Hybrid Safe Anti-inflammatory Agents.,"['Abdellatif KR', 'Abdelall EK', 'Bakr RB']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/chemistry/*therapeutic use', 'Humans', 'Inflammation/*drug therapy', 'Molecular Structure', 'Nitric Oxide/chemistry/*therapeutic use', 'Prodrugs/chemistry/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27697053/
3120,Valdecoxib,27150366,Medicinal Chemistry Perspective of Fused Isoxazole Derivatives.,"['Barmade MA', 'Murumkar PR', 'Sharma MK', 'Yadav MR']","['Antineoplastic Agents/chemistry/therapeutic use', 'Cardiovascular Diseases/drug therapy', 'Central Nervous System Diseases/drug therapy', '*Chemistry, Pharmaceutical', 'Humans', 'Hypoglycemic Agents/chemistry/therapeutic use', 'Isoxazoles/*chemistry/pharmacology/therapeutic use', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/27150366/
3121,Valdecoxib,19667717,COX-2 selective inhibitors and heart health.,"['Simon LS', 'White WB']","['Adult', 'Cardiovascular Diseases/*chemically induced', 'Celecoxib', 'Child', 'Cyclooxygenase 2 Inhibitors/*adverse effects', 'Humans', 'Hypertension/chemically induced', 'Isoxazoles/adverse effects', 'Lactones/*adverse effects', 'Meta-Analysis as Topic', 'Prospective Studies', 'Pyrazoles/adverse effects', 'Randomized Controlled Trials as Topic', 'Sulfonamides/adverse effects', 'Sulfones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19667717/
3122,Valdecoxib,12269850,Valdecoxib.,"['Ormrod D', 'Wellington K', 'Wagstaff AJ']","['Arthritis/drug therapy/metabolism', 'Clinical Trials as Topic/statistics & numerical data', 'Dysmenorrhea/drug therapy/metabolism', 'Female', 'Humans', 'Isoxazoles/chemistry/pharmacokinetics/*therapeutic use', 'Pain/*drug therapy/metabolism', 'Sulfonamides/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12269850/
3123,Valdecoxib,12852704,Valdecoxib: a review.,"['Chavez ML', 'DeKorte CJ']","['Adult', 'Anti-Inflammatory Agents, Non-Steroidal/*pharmacology/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Clinical Trials as Topic', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/pharmacology/therapeutic use', 'Female', 'Humans', 'Isoxazoles/*pharmacology/*therapeutic use', 'Male', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Sulfonamides/*pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12852704/
3124,Valdecoxib,12466002,Etoricoxib.,"['Cochrane DJ', 'Jarvis B', 'Keating GM']","['Administration, Oral', 'Arthritis/drug therapy', 'Back Pain/drug therapy', 'Clinical Trials as Topic', 'Cyclooxygenase 1', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Etoricoxib', 'Gout/drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Pyridines/adverse effects/pharmacology/*therapeutic use', 'Sulfones/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12466002/
3125,Valdecoxib,15182039,[Valdecoxib (Bextra)].,"['Scheen AJ', 'Malaise M']","['Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/*therapeutic use', 'Arthritis, Rheumatoid/drug therapy', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Dysmenorrhea/drug therapy', 'Enzyme Inhibitors/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Infusions, Intravenous', 'Injections, Intramuscular', 'Isoxazoles/administration & dosage/*therapeutic use', 'Osteoarthritis/drug therapy', 'Pain, Postoperative/drug therapy', 'Prodrugs', 'Sulfonamides/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15182039/
3126,Valdecoxib,27710942,Crystal structure of rofecoxib bound to human cyclooxygenase-2.,"['Orlando BJ', 'Malkowski MG']","['Amino Acid Motifs', 'Binding Sites', 'Celecoxib/*chemistry', 'Crystallography, X-Ray', 'Cyclooxygenase 2/*chemistry/genetics/metabolism', 'Cyclooxygenase 2 Inhibitors/*chemistry', 'Gene Expression', 'Humans', 'Kinetics', 'Lactones/*chemistry', 'Models, Molecular', 'Protein Binding', 'Protein Conformation, alpha-Helical', 'Protein Conformation, beta-Strand', 'Protein Interaction Domains and Motifs', 'Recombinant Proteins/chemistry/genetics/metabolism', 'Safety-Based Drug Withdrawals', 'Substrate Specificity', 'Sulfones/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/27710942/
3127,Valdecoxib,12198983,Selecting new drugs for pain control: evidence-based decisions or clinical impressions?,['Jeske AH'],"['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/therapeutic use', 'Chronic Disease', 'Clinical Trials as Topic/standards', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/administration & dosage/*therapeutic use', 'Evidence-Based Medicine', 'Facial Pain/*drug therapy', 'Humans', 'Isoenzymes/antagonists & inhibitors', 'Lactones/administration & dosage/*therapeutic use', 'Membrane Proteins', 'Oral Surgical Procedures/adverse effects', 'Pain, Postoperative/*drug therapy/etiology', 'Prostaglandin-Endoperoxide Synthases', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/12198983/
3128,Valdecoxib,15335413,Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.,"['Lazzaroni M', 'Bianchi Porro G']","['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Cyclooxygenase Inhibitors/*adverse effects', 'Gastrointestinal Diseases/*chemically induced', 'Humans', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/15335413/
3129,Valdecoxib,12911075,Meloxicam and selective COX-2 inhibitors in the management of pain in the palliative care population.,"['Smith HS', 'Baird W']","['Analgesics, Non-Narcotic/pharmacology/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Cyclooxygenase Inhibitors/pharmacology/*therapeutic use', 'Diclofenac/analogs & derivatives', 'Dose-Response Relationship, Drug', 'Etoricoxib', 'Humans', 'Isoxazoles/therapeutic use', 'Meloxicam', 'Organic Chemicals/therapeutic use', 'Pain/*drug therapy/physiopathology', 'Palliative Care/*methods', 'Pyridines/therapeutic use', 'Sulfonamides/therapeutic use', 'Sulfones/therapeutic use', 'Thiazines/pharmacology/*therapeutic use', 'Thiazoles/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12911075/
3130,Valdecoxib,16082427,Gateways to clinical trials.,"['Bayes M', 'Rabasseda X', 'Prous JR']","['*Clinical Trials as Topic', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/16082427/
3131,Valdecoxib,16202197,"Nonsteroidal anti-inflammatory drugs: confusion, controversy and dental implications.","['Klasser GD', 'Epstein J']","['Acute Disease', 'Anti-Inflammatory Agents, Non-Steroidal/*adverse effects', 'Celecoxib', 'Chronic Disease', 'Clinical Trials as Topic', 'Cyclooxygenase 2 Inhibitors/adverse effects', 'Humans', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Myocardial Infarction/*chemically induced', 'Peptic Ulcer/chemically induced', 'Pyrazoles/adverse effects', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects', 'Toothache/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/16202197/
3132,Valdecoxib,15279595,The second generation of COX-2 inhibitors: clinical pharmacological point of view.,['Stichtenoth DO'],"['Arthritis/chemically induced', 'Cardiovascular Diseases/chemically induced', 'Cyclooxygenase 2', 'Cyclooxygenase 2 Inhibitors', 'Cyclooxygenase Inhibitors/adverse effects/pharmacokinetics/*pharmacology', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Isoenzymes/*antagonists & inhibitors/chemistry', 'Membrane Proteins', 'Prostaglandin-Endoperoxide Synthases/chemistry']",https://pubmed.ncbi.nlm.nih.gov/15279595/
3133,Valdecoxib,20524091,Do the blood pressure effects of nonsteroidal antiinflammatory drugs influence cardiovascular morbidity and mortality?,['Elliott WJ'],"['Anti-Inflammatory Agents, Non-Steroidal/*adverse effects/pharmacology/therapeutic use', 'Blood Pressure/*drug effects', 'Celecoxib', 'Cyclooxygenase 2 Inhibitors/*adverse effects/pharmacology/therapeutic use', 'Diclofenac/adverse effects/analogs & derivatives', 'Etoricoxib', 'Humans', 'Hypertension/*chemically induced', 'Isoxazoles/adverse effects', 'Lactones/adverse effects', 'Pyrazoles/adverse effects', 'Pyridines/adverse effects/pharmacology/therapeutic use', 'Risk', 'Risk Factors', 'Sulfonamides/adverse effects', 'Sulfones/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20524091/
3134,Valdecoxib,23517091,Valdecoxib : the rise and fall of a COX-2 inhibitor.,"['Atukorala I', 'Hunter DJ']","['Animals', 'Arthritis, Rheumatoid/*drug therapy', 'Cyclooxygenase 2 Inhibitors/*administration & dosage/adverse effects', 'Humans', 'Isoxazoles/*administration & dosage/adverse effects', 'Osteoarthritis/*drug therapy', 'Sulfonamides/*administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23517091/
3135,Valdecoxib,37254803,Pharmacological inhibition of TRPV2 attenuates phagocytosis and lipopolysaccharide-induced migration of primary macrophages.,"['Raudszus R', 'Paulig A', 'Urban N', 'Deckers A', 'Grassle S', 'Vanderheiden S', 'Jung N', 'Brase S', 'Schaefer M', 'Hill K']","['Humans', 'Rats', 'Animals', '*Lipopolysaccharides/pharmacology', 'HEK293 Cells', '*Macrophages', 'Phagocytosis', 'Gene Expression', 'TRPV Cation Channels/genetics']",https://pubmed.ncbi.nlm.nih.gov/37254803/
3136,Varenicline,35133411,Treatment of Tobacco Smoking: A Review.,"['Rigotti NA', 'Kruse GR', 'Livingstone-Banks J', 'Hartmann-Boyce J']","['Behavior Therapy', 'Bupropion/therapeutic use', 'Drug Therapy, Combination', 'Electronic Nicotine Delivery Systems', 'Humans', 'Smoking Cessation/*methods', 'Smoking Cessation Agents/adverse effects/*therapeutic use', 'Tobacco Smoking/drug therapy/physiopathology/*therapy', '*Tobacco Use Cessation Devices', 'Varenicline/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35133411/
3137,Varenicline,34823737,Tobacco Use Disorder.,"['Leone FT', 'Evers-Casey S']","['Behavior, Addictive/psychology', 'Bupropion/pharmacology/therapeutic use', 'Combined Modality Therapy', 'Counseling/methods', 'Drug Therapy/methods', 'Electronic Nicotine Delivery Systems/statistics & numerical data', 'Humans', 'Morbidity/*trends', 'Neurobiology/methods', 'Nicotine/*adverse effects', 'Nicotinic Agonists/pharmacology/therapeutic use', 'Phenotype', 'Prevalence', 'Smoking Cessation/methods', 'Smoking Cessation Agents/pharmacology/therapeutic use', 'Tobacco Use Cessation Devices/adverse effects', 'Tobacco Use Disorder/complications/*epidemiology/prevention & control/*therapy', 'United States/epidemiology', 'Varenicline/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34823737/
3138,Varenicline,30810545,SMOKING CESSATION TREATMENTS: CURRENT PSYCHOLOGICAL AND PHARMACOLOGICAL OPTIONS.,"['Garcia-Gomez L', 'Hernandez-Perez A', 'Noe-Diaz V', 'Riesco-Miranda JA', 'Jimenez-Ruiz C']","['Bupropion/administration & dosage', 'Cognitive Behavioral Therapy/methods', 'Humans', 'Mexico', 'Motivational Interviewing/methods', '*Practice Guidelines as Topic', 'Randomized Controlled Trials as Topic', 'Smoking/adverse effects/epidemiology', 'Smoking Cessation/*methods/psychology', 'Smoking Cessation Agents/administration & dosage', '*Tobacco Use Cessation Devices', 'Varenicline/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/30810545/
3139,Varenicline,27116918,"Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial.","['Anthenelli RM', 'Benowitz NL', 'West R', 'St Aubin L', 'McRae T', 'Lawrence D', 'Ascher J', 'Russ C', 'Krishen A', 'Evins AE']","['Adolescent', 'Adult', 'Aged', 'Bupropion/*administration & dosage/adverse effects', 'Dopamine Uptake Inhibitors/*administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Mental Disorders/complications', 'Middle Aged', 'Nicotinic Agonists/*administration & dosage/adverse effects', 'Smoking/psychology', 'Smoking Cessation/methods/psychology', '*Smoking Prevention', '*Tobacco Use Cessation Devices', 'Treatment Outcome', 'Varenicline/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27116918/
3140,Varenicline,37696529,Pharmacological and electronic cigarette interventions for smoking cessation in adults: component network meta-analyses.,"['Lindson N', 'Theodoulou A', 'Ordonez-Mena JM', 'Fanshawe TR', 'Sutton AJ', 'Livingstone-Banks J', 'Hajizadeh A', 'Zhu S', 'Aveyard P', 'Freeman SC', 'Agrawal S', 'Hartmann-Boyce J']","['Adult', 'Female', 'Humans', 'Pregnancy', 'Bupropion/therapeutic use', '*Electronic Nicotine Delivery Systems', 'Network Meta-Analysis', 'Nicotine/adverse effects', 'Nortriptyline/therapeutic use', '*Smoking Cessation', 'Varenicline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37696529/
3141,Varenicline,37142273,Nicotine receptor partial agonists for smoking cessation.,"['Livingstone-Banks J', 'Fanshawe TR', 'Thomas KH', 'Theodoulou A', 'Hajizadeh A', 'Hartman L', 'Lindson N']","['Humans', '*Smoking Cessation/methods', 'Nicotine/adverse effects', 'Varenicline/adverse effects', 'Bupropion/adverse effects', '*Electronic Nicotine Delivery Systems', 'Tobacco Use Cessation Devices', 'Nicotinic Agonists/adverse effects', '*Alkaloids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37142273/
3142,Varenicline,37403047,"Varenicline and counseling for vaping cessation: a double-blind, randomized, parallel-group, placebo-controlled trial.","['Caponnetto P', 'Campagna D', 'Ahluwalia JS', 'Russell C', 'Maglia M', 'Riela PM', 'Longo CF', 'Busa B', 'Polosa R']","['Humans', 'Varenicline/adverse effects', 'Nicotinic Agonists/adverse effects', '*Vaping/adverse effects', '*Electronic Nicotine Delivery Systems', 'Benzazepines/adverse effects', 'Quinoxalines/therapeutic use', 'Double-Blind Method', 'Counseling', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37403047/
3143,Varenicline,34228066,Effect of Cytisine vs Varenicline on Smoking Cessation: A Randomized Clinical Trial.,"['Courtney RJ', 'McRobbie H', 'Tutka P', 'Weaver NA', 'Petrie D', 'Mendelsohn CP', 'Shakeshaft A', 'Talukder S', 'Macdonald C', 'Thomas D', 'Kwan BCH', 'Walker N', 'Gartner C', 'Mattick RP', 'Paul C', 'Ferguson SG', 'Zwar NA', 'Richmond RL', 'Doran CM', 'Boland VC', 'Hall W', 'West R', 'Farrell M']","['Adult', 'Alkaloids/adverse effects/*therapeutic use', 'Azocines/adverse effects/therapeutic use', 'Dreams', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nausea/chemically induced', 'Quinolizines/adverse effects/therapeutic use', 'Smoking Cessation/*methods', 'Smoking Cessation Agents/adverse effects/*therapeutic use', 'Treatment Outcome', 'Varenicline/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34228066/
3144,Varenicline,32578165,Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice.,"['Giulietti F', 'Filipponi A', 'Rosettani G', 'Giordano P', 'Iacoacci C', 'Spannella F', 'Sarzani R']","['Alkaloids/adverse effects/*therapeutic use', 'Azocines/adverse effects/therapeutic use', 'Bupropion/adverse effects/*therapeutic use', 'Clinical Decision-Making', 'Electronic Nicotine Delivery Systems', 'Humans', 'Quinolizines/adverse effects/therapeutic use', 'Recurrence', 'Risk Factors', 'Smoking/*adverse effects', '*Smoking Cessation', 'Smoking Cessation Agents/adverse effects/*therapeutic use', 'Tobacco Use Cessation Devices', 'Tobacco Use Disorder/diagnosis/*drug therapy/physiopathology/psychology', 'Treatment Outcome', 'Varenicline/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32578165/
3145,Varenicline,37567792,Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on Pharmacological Treatment of Tobacco Dependence 2023.,"['Rabade-Castedo C', 'de Granda-Orive JI', 'Riesco-Miranda JA', 'De Higes-Martinez E', 'Ramos-Pinedo A', 'Cabrera-Cesar E', 'Signes-Costa Minana J', 'Garcia Rueda M', 'Pastor-Espla E', 'Jimenez-Ruiz CA']","['Pregnancy', 'Female', 'Humans', 'Adolescent', '*Tobacco Use Disorder/drug therapy', 'Varenicline/therapeutic use', '*Smoking Cessation', 'Nicotinic Agonists/therapeutic use', '*Thoracic Surgery', '*Pulmonary Medicine', 'Tobacco Use Cessation Devices', 'Bupropion/therapeutic use', '*Alcoholism']",https://pubmed.ncbi.nlm.nih.gov/37567792/
3146,Varenicline,34716990,The Structured Process to Identify Fit-For-Purpose Data: A Data Feasibility Assessment Framework.,"['Gatto NM', 'Campbell UB', 'Rubinstein E', 'Jaksa A', 'Mattox P', 'Mo J', 'Reynolds RF']","['*Data Collection', 'Decision Making', '*Feasibility Studies', 'Humans', 'Research Design', 'Varenicline/adverse effects', 'COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/34716990/
3147,Varenicline,37678096,Cytisine for smoking cessation: A systematic review and meta-analysis.,"['Ofori S', 'Lu C', 'Olasupo OO', 'Dennis BB', 'Fairbairn N', 'Devereaux PJ', 'Mbuagbaw L']","['Adult', 'Humans', 'Varenicline/adverse effects', '*Smoking Cessation', 'Nicotinic Agonists/therapeutic use', 'Nicotine', 'Bupropion/therapeutic use', 'Benzazepines', '*Alkaloids/therapeutic use', 'Azocines/adverse effects', 'Quinolizines/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37678096/
3148,Varenicline,33372557,Pharmacological strategies for smoking cessation in patients with chronic obstructive pulmonary disease: a pragmatic review.,"['Antoniu SA', 'Buculei I', 'Mihaltan F', 'Crisan Dabija R', 'Trofor AC']","['Benzazepines', 'Bupropion/therapeutic use', 'Humans', 'Nicotine', '*Pulmonary Disease, Chronic Obstructive/drug therapy', 'Quinoxalines', '*Smoking Cessation', 'Tobacco Use Cessation Devices', 'Varenicline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33372557/
3149,Varenicline,34665204,Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.,"['Baker TB', 'Piper ME', 'Smith SS', 'Bolt DM', 'Stein JH', 'Fiore MC']","['Carbon Monoxide/analysis', 'Combined Modality Therapy/adverse effects/methods', 'Confidence Intervals', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nausea/epidemiology', 'Nicotinic Agonists/*therapeutic use', 'Odds Ratio', 'Placebos/therapeutic use', 'Self Report', 'Sleep Initiation and Maintenance Disorders/epidemiology', 'Smoking Cessation/*methods', 'Temperance', 'Time Factors', '*Tobacco Use Cessation Devices', 'Varenicline/*therapeutic use', 'Wisconsin']",https://pubmed.ncbi.nlm.nih.gov/34665204/
3150,Varenicline,38564922,Sleep-related adverse events of smoking cessation drugs: A network meta-analysis of randomized controlled trials.,"['Song Y', 'Park YA', 'Lee DH', 'Yee J', 'Gwak HS']","['Humans', '*Smoking Cessation/psychology', 'Bupropion/adverse effects', 'Varenicline/therapeutic use', 'Smoking/psychology', 'Network Meta-Analysis', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Sleepiness', 'Tobacco Use Cessation Devices/adverse effects', 'Randomized Controlled Trials as Topic', 'Nicotinic Agonists/adverse effects', 'Sleep']",https://pubmed.ncbi.nlm.nih.gov/38564922/
3151,Varenicline,36206617,Effects of different interventions on smoking cessation in chronic obstructive pulmonary disease patients: A systematic review and network meta-analysis.,"['Wei X', 'Guo K', 'Shang X', 'Wang S', 'Yang C', 'Li J', 'Li Y', 'Yang K', 'Li X', 'Zhang X']","['Humans', '*Smoking Cessation/methods', 'Nicotinic Agonists/therapeutic use', 'Network Meta-Analysis', 'Varenicline/therapeutic use', '*Pulmonary Disease, Chronic Obstructive/therapy']",https://pubmed.ncbi.nlm.nih.gov/36206617/
3152,Varenicline,37040914,Varenicline-induced drug eruption: case and review of the literature.,"['Correia C', 'Fernandes S', 'Correia T', 'Soares-de-Almeida L', 'Filipe P']","['Humans', 'Varenicline/adverse effects', 'Nicotinic Agonists/adverse effects', 'Benzazepines/adverse effects', 'Quinoxalines/adverse effects', '*Acute Generalized Exanthematous Pustulosis', '*Drug-Related Side Effects and Adverse Reactions/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37040914/
3153,Varenicline,28593623,[Smoking cessation and schizophrenia].,"['Muller DP', 'de Haan L']","['Antidepressive Agents, Second-Generation/therapeutic use', 'Bupropion/therapeutic use', 'Cognitive Behavioral Therapy', 'Combined Modality Therapy', 'Humans', 'Nicotinic Agonists/therapeutic use', '*Schizophrenia', 'Smoking Cessation/*methods/*psychology', 'Varenicline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28593623/
3154,Varenicline,36379496,Smoking Cessation Interventions.,"['Gaddey HL', 'Dakkak M', 'Jackson NM']","['Adult', 'Adolescent', 'Child', 'Humans', 'Young Adult', 'Varenicline/therapeutic use', 'Tobacco Use Cessation Devices', '*Smoking Cessation', 'Bupropion/therapeutic use', '*Electronic Nicotine Delivery Systems', 'Early Detection of Cancer', '*Lung Neoplasms', 'Neoplasm Recurrence, Local']",https://pubmed.ncbi.nlm.nih.gov/36379496/
3155,sulfadiazine,28700086,Antiseptics for burns.,"['Norman G', 'Christie J', 'Liu Z', 'Westby MJ', 'Jefferies JM', 'Hudson T', 'Edwards J', 'Mohapatra DP', 'Hassan IA', 'Dumville JC']","['Adult', 'Anti-Bacterial Agents/therapeutic use', 'Anti-Infective Agents, Local/adverse effects/*therapeutic use', 'Apitherapy/*methods', 'Bacterial Infections/etiology/*therapy', 'Bandages', 'Burns/*complications/*therapy', 'Chlorhexidine/therapeutic use', 'Disinfectants/therapeutic use', 'Honey', 'Humans', 'Merbromin/therapeutic use', 'Plant Preparations/therapeutic use', 'Povidone-Iodine/therapeutic use', 'Randomized Controlled Trials as Topic', 'Silver Sulfadiazine/therapeutic use', 'Sodium Hypochlorite/therapeutic use', 'Sulfadiazine/therapeutic use', '*Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/28700086/
3156,sulfadiazine,16766878,Silver in health care: antimicrobial effects and safety in use.,['Lansdown AB'],"['Administration, Cutaneous', 'Anti-Infective Agents/*administration & dosage/adverse effects', 'Humans', 'Silver/*administration & dosage/adverse effects/toxicity', 'Silver Nitrate/administration & dosage', 'Skin/*injuries', 'Skin Care', 'Sulfadiazine/administration & dosage', '*Textiles', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/16766878/
3157,sulfadiazine,35404714,Wound healing in second-degree burns in rats treated with silver sulfadiazine: a systematic review and meta-analysis.,"['Devi MV', 'Poornima V', 'Sivagnanam UT']","['Animals', '*Anti-Infective Agents, Local/pharmacology/therapeutic use', '*Burns/drug therapy', 'Humans', 'Ointments', 'Rats', 'Silver Sulfadiazine/pharmacology/therapeutic use', '*Soft Tissue Injuries', 'Wound Healing']",https://pubmed.ncbi.nlm.nih.gov/35404714/
3158,sulfadiazine,21718576,Burns (minor thermal).,"['Wasiak J', 'Cleland H']","['Bandages', 'Bandages, Hydrocolloid', '*Burns/drug therapy', 'Humans', 'Hydrogel, Polyethylene Glycol Dimethacrylate/pharmacology', 'Incidence', '*Silver Sulfadiazine/pharmacology', 'Sulfadiazine/pharmacology', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21718576/
3159,sulfadiazine,15114822,How safe is silver in wound care?,"['Lansdown AB', 'Williams A']","['Anti-Infective Agents, Local/pharmacokinetics/*therapeutic use', 'Bandages', 'Burns/drug therapy/nursing', 'Humans', 'Silver Nitrate/pharmacokinetics/*therapeutic use', 'Silver Sulfadiazine/pharmacokinetics/*therapeutic use', 'Skin/drug effects/metabolism', 'Skin Absorption', 'Tissue Distribution', 'Wound Healing/drug effects', 'Wounds and Injuries/*drug therapy/nursing']",https://pubmed.ncbi.nlm.nih.gov/15114822/
3160,sulfadiazine,15126971,A review of the use of silver in wound care: facts and fallacies.,['Lansdown AB'],"['Anti-Infective Agents, Local/adverse effects/pharmacology/*therapeutic use', 'Bandages', 'Humans', 'Silver/adverse effects/pharmacology/*therapeutic use', 'Silver Nitrate/pharmacology/therapeutic use', 'Silver Sulfadiazine/pharmacology/therapeutic use', 'Wound Healing/drug effects', 'Wounds and Injuries/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15126971/
3161,sulfadiazine,38861260,Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial.,"['Wei Y', 'Li Y', 'Li X', 'Zhao Y', 'Xu J', 'Wang H', 'Rong X', 'Xiong J', 'Chen X', 'Luo G', 'Lv G', 'Lin C', 'Han C', 'Yu H', 'Zhang Y', 'Tang S', 'Fan Y', 'Tu J', 'Xia C', 'Zu H', 'Liu W', 'Liu C', 'Liu J', 'Zhang B', 'Nong Q', 'Li T', 'Wang L', 'Song G', 'Su Y', 'Chen Z', 'Lai W', 'Fu Y', 'Yu J', 'Zhang P', 'Yang W', 'Yao G', 'Zhang H', 'Fan K', 'Dong H', 'Chen Y', 'Wu J']","['Humans', 'Male', 'Female', 'Middle Aged', 'Adult', '*Wound Infection/drug therapy', 'Anti-Infective Agents, Local/therapeutic use/administration & dosage', 'China', 'Silver Sulfadiazine/therapeutic use/administration & dosage', 'Treatment Outcome', 'Aged', 'Anti-Bacterial Agents/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38861260/
3162,sulfadiazine,6281592,Current management of fungal enteritis.,"['Chretien JH', 'Garagusi VF']","['Amphotericin B/therapeutic use', 'Antifungal Agents/therapeutic use', 'Candidiasis/diagnosis/drug therapy', 'Diarrhea/etiology', 'Enteritis/drug therapy/*etiology', 'Histoplasmosis/diagnosis/drug therapy', 'Humans', 'Imidazoles/therapeutic use', 'Immunosuppression Therapy/adverse effects', 'Ketoconazole', 'Miconazole/therapeutic use', 'Mycoses/*diagnosis', 'Neoplasms/complications', 'Nystatin/therapeutic use', 'Paracoccidioidomycosis/diagnosis/drug therapy', 'Piperazines/therapeutic use', 'Sulfadiazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6281592/
3163,sulfadiazine,12755974,Bromoderma.,"['Anzai S', 'Fujiwara S', 'Inuzuka M']","['Anti-Infective Agents, Local/therapeutic use', 'Anticonvulsants/administration & dosage/*adverse effects', 'Bromides/administration & dosage/*adverse effects', 'Child, Preschool', 'Dose-Response Relationship, Drug', 'Drug Eruptions/drug therapy/*etiology', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Potassium Compounds/administration & dosage/*adverse effects', 'Silver Sulfadiazine/therapeutic use', 'Skin Diseases, Vesiculobullous/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/12755974/
3164,sulfadiazine,154920,Drugs causing fixed eruptions.,['Pasricha JS'],"['Antipyrine/adverse effects/*analogs & derivatives', 'Caffeine/*adverse effects', 'Cross Reactions', 'Drug Combinations', 'Drug Eruptions/*etiology', 'Humans', 'Penicillin G/adverse effects', 'Phenacetin/*adverse effects', 'Phenobarbital/adverse effects', 'Pyridones/*adverse effects', 'Sulfadiazine/adverse effects', 'Sulfanilamides/*adverse effects', 'Tetracycline/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/154920/
3165,sulfadiazine,30447857,"Types of antiseptics, presentations and rules of use.","['Del Rio-Carbajo L', 'Vidal-Cortes P']","['Alcohols/adverse effects/*pharmacology', 'Anti-Infective Agents, Local/adverse effects/classification/*pharmacology', 'Cations/adverse effects/pharmacology', 'Chlorhexidine/adverse effects/pharmacology', 'Drug Interactions', 'Ethanol/adverse effects/pharmacology', 'Humans', 'Hydrogen Peroxide/adverse effects/therapeutic use', 'Intensive Care Units', 'Iodine/adverse effects/pharmacology', 'Iodine Compounds/adverse effects/*pharmacology', 'Iodophors/adverse effects/pharmacology', 'Mercury Compounds/pharmacology', 'Propranolol/adverse effects/pharmacology', 'Sulfadiazine/adverse effects/pharmacology', 'Triclosan/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30447857/
3166,sulfadiazine,8726163,Toxicological aspects of topical silver pharmaceuticals.,['Hollinger MA'],"['Administration, Topical', 'Animals', 'Anti-Infective Agents, Local/administration & dosage/therapeutic use/*toxicity', 'Burns/drug therapy/metabolism', 'Drug Combinations', 'Electrodes/adverse effects', 'Humans', 'Immunity, Cellular/drug effects', 'Iontophoresis', 'Silver/administration & dosage/therapeutic use/*toxicity', 'Skin Absorption', 'Sulfadiazine/adverse effects', 'Wound Healing/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/8726163/
3167,sulfadiazine,38959345,Effects of topical insulin on second-degree burn wound healing: brief report.,"['da Silveira VF Jr', 'Gomes Silva JL', 'Lima MHM', 'Saad MJA']","['Humans', '*Burns/drug therapy/physiopathology', '*Wound Healing/drug effects', '*Insulin/therapeutic use/administration & dosage/pharmacology', 'Female', 'Male', '*Administration, Topical', 'Adult', 'Middle Aged', 'Silver Sulfadiazine/therapeutic use/pharmacology/administration & dosage', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/38959345/
3168,sulfadiazine,17130603,Best evidence topic report. Silver sulphadiazine cream in burns.,"['Hussain S', 'Ferguson C']","['Administration, Cutaneous', 'Adult', 'Anti-Infective Agents, Local/*therapeutic use', 'Burns/complications/*drug therapy', 'Emergencies', 'Evidence-Based Medicine', 'Female', 'Humans', 'Silver Sulfadiazine/*therapeutic use', 'Wound Infection/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/17130603/
3169,sulfadiazine,7662136,Serious silver sulphadiazine and mafenide acetate dermatitis.,"['McKenna SR', 'Latenser BA', 'Jones LM', 'Barrette RR', 'Sherman HF', 'Varcelotti JR']","['Adult', 'Burns/complications/*drug therapy', 'Drug Eruptions/diagnosis/*etiology', 'Humans', 'Mafenide/*adverse effects', 'Male', 'Silver Sulfadiazine/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7662136/
3170,sulfadiazine,1836573,[Usefulness of folinic acid in cytopenia induced by antiparasitic drugs in AIDS patients].,"['Niyongabo T', 'Leport C', 'Vilde JL']","['Acquired Immunodeficiency Syndrome/*complications', 'Drug Therapy, Combination', 'Folic Acid/metabolism', 'Hematologic Diseases/chemically induced/complications/*prevention & control', 'Humans', 'Leucovorin/pharmacokinetics/*therapeutic use', 'Opportunistic Infections/complications/drug therapy/metabolism', 'Pneumonia, Pneumocystis/complications/*drug therapy/metabolism', 'Pyrimethamine/adverse effects/therapeutic use', 'Sulfadiazine/therapeutic use', 'Toxoplasmosis, Cerebral/complications/drug therapy/metabolism', 'Trimethoprim, Sulfamethoxazole Drug Combination/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1836573/
3171,sulfadiazine,30059387,Full-Thickness Chemical Burn From Trifluoroacetic Acid: A Case Report and Review of the Literature.,"['Rochlin DH', 'Rajasingh CM', 'Karanas YL', 'Davis DJ']","['Burns, Chemical/*therapy', 'Compression Bandages', 'Female', 'Humans', 'Occupational Exposure/*adverse effects', 'Silver Sulfadiazine/administration & dosage', 'Skin Transplantation', '*Trifluoroacetic Acid', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30059387/
3172,sulfadiazine,3979042,Patch testing with silver sulfadiazine cream.,"['Degreef H', 'Dooms-Goossens A']","['Cross Reactions', 'Dermatitis, Contact/*etiology', 'Fatty Alcohols/toxicity', 'Humans', 'Pharmaceutical Vehicles', 'Propylene Glycols/toxicity', 'Silver Sulfadiazine/*toxicity', 'Skin Tests', 'Sulfadiazine/*toxicity', 'Sulfonamides/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3979042/
3173,sulfadiazine,1409466,[Toxoplasmosis in AIDS].,"['Leport C', 'Remington JS']","['AIDS-Related Opportunistic Infections/diagnosis/etiology/therapy', 'Acquired Immunodeficiency Syndrome/*complications', 'Anti-Bacterial Agents/therapeutic use', 'Clindamycin/administration & dosage/therapeutic use', 'Humans', 'Lung Diseases, Parasitic/complications/diagnosis/therapy', 'Pyrimethamine/administration & dosage/therapeutic use', 'Recurrence', 'Sulfadiazine/administration & dosage/therapeutic use', 'Toxoplasmosis/diagnosis/*etiology/therapy', 'Toxoplasmosis, Cerebral/diagnosis/etiology/therapy', 'Toxoplasmosis, Ocular/diagnosis/etiology/therapy']",https://pubmed.ncbi.nlm.nih.gov/1409466/
3174,sulfadiazine,32155122,Acute Radiation Therapy-related Dermatitis.,['Bolton L'],"['Adrenal Cortex Hormones/administration & dosage/therapeutic use', 'Dermatologic Agents/administration & dosage/*therapeutic use', 'Humans', 'Radiodermatitis/*drug therapy/prevention & control', 'Silver Sulfadiazine/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32155122/
3175,fentanyl,15907648,Fentanyl.,['Stanley TH'],"['Analgesics, Opioid/administration & dosage/*history', 'Anesthetics, Intravenous/*history', 'Animals', 'Drug Delivery Systems/history', 'Europe', 'Fentanyl/administration & dosage/*history', 'History, 20th Century', 'Humans', 'United States']",https://pubmed.ncbi.nlm.nih.gov/15907648/
3176,fentanyl,32435865,Treating Fentanyl Withdrawal.,"['Neimark G', 'Tjoa C']","['Analgesics, Opioid/*administration & dosage/*adverse effects', 'Buprenorphine/*therapeutic use', 'Fentanyl/*administration & dosage/*adverse effects', 'Humans', 'Narcotic Antagonists/*therapeutic use', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32435865/
3177,fentanyl,29902699,Abuse of fentanyl: An emerging problem to face.,"['Kuczynska K', 'Grzonkowski P', 'Kacprzak L', 'Zawilska JB']","['Analgesics, Opioid/*adverse effects', 'Dosage Forms', 'Drug Contamination', 'Drug Overdose/drug therapy', 'Drug Trafficking/trends', 'Fentanyl/*adverse effects', 'Humans', 'Illicit Drugs/adverse effects', 'Naloxone/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Opioid-Related Disorders/*epidemiology', 'Transdermal Patch']",https://pubmed.ncbi.nlm.nih.gov/29902699/
3178,fentanyl,25441689,The fentanyl story.,['Stanley TH'],"['Analgesics, Opioid/*administration & dosage/adverse effects/chemistry', 'Fentanyl/*administration & dosage/adverse effects/chemistry', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/25441689/
3179,fentanyl,16802493,Mixed opioid--mixed message?,"['Lake AP', 'Coates OL']","['Aged', 'Analgesics, Opioid/administration & dosage/*adverse effects', 'Anesthesia Recovery Period', '*Anesthesia, General', 'Anesthetics, Intravenous', 'Female', 'Fentanyl/administration & dosage/*adverse effects', 'Humans', 'Morphine/administration & dosage/*adverse effects', 'Naloxone/therapeutic use', 'Narcotic Antagonists/therapeutic use', 'Propofol', 'Receptors, Opioid, mu/drug effects']",https://pubmed.ncbi.nlm.nih.gov/16802493/
3180,fentanyl,23801512,Sufentanil in anaesthesiology and intensive therapy.,['Maciejewski D'],"['Analgesics, Opioid/adverse effects/pharmacology/*therapeutic use', 'Anesthetics, Intravenous/adverse effects/pharmacology/*therapeutic use', 'Critical Care/methods', 'Fentanyl/administration & dosage/therapeutic use', 'Humans', 'Off-Label Use', 'Sufentanil/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/23801512/
3181,fentanyl,1477447,Transdermal fentanyl.,"['Yee LY', 'Lopez JR']","['Administration, Cutaneous', 'Aged', 'Chemistry, Pharmaceutical', 'Chronic Disease', 'Clinical Trials as Topic', 'Fentanyl/administration & dosage/pharmacokinetics/*pharmacology/therapeutic use', 'Humans', 'Infant', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1477447/
3182,fentanyl,34787646,Insights Into Mixing Fentanyl and Benzodiazepines From Canadian Drug Seizures.,['Pardo B'],"['Benzodiazepines/*administration & dosage/adverse effects', 'Canada/epidemiology', 'Criminal Law/methods/trends', '*Drug Combinations', 'Drug Trafficking/statistics & numerical data/trends', 'Fentanyl/*administration & dosage/adverse effects', 'Humans', 'Substance-Related Disorders/*complications/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/34787646/
3183,fentanyl,23613597,Fast-acting fentanyl preparations and pain management.,"['McWilliams K', 'Fallon M']","['Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use', 'Breakthrough Pain/*drug therapy', 'Drug Dosage Calculations', 'Fentanyl/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Neoplasms/complications/drug therapy', 'Pain Management/methods']",https://pubmed.ncbi.nlm.nih.gov/23613597/
3184,fentanyl,1387674,Clinical use of sufentanil as an anesthetic.,['Isaacson IJ'],"['Anesthetics/administration & dosage/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Fentanyl/administration & dosage/*analogs & derivatives/pharmacology/therapeutic use', 'Humans', 'Sufentanil']",https://pubmed.ncbi.nlm.nih.gov/1387674/
3185,fentanyl,12054098,E-TRANS fentanyl. ALZA.,['Mystakidou K'],"['Analgesics, Opioid/*administration & dosage/adverse effects/metabolism/pharmacology/*therapeutic use/toxicity', 'Animals', 'Clinical Trials, Phase I as Topic', 'Clinical Trials, Phase II as Topic', 'Contraindications', 'Drug Delivery Systems', 'Fentanyl/*administration & dosage/adverse effects/metabolism/pharmacology/*therapeutic use/toxicity', 'Humans', 'Pain/*drug therapy', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/12054098/
3186,fentanyl,27020837,Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl.,"['Alberts DS', 'Smith CC', 'Parikh N', 'Rauck RL']","['Administration, Cutaneous', 'Administration, Sublingual', 'Adult', 'Aged', 'Aged, 80 and over', 'Analgesics, Opioid/*administration & dosage/adverse effects/*therapeutic use', 'Breakthrough Pain/*drug therapy', 'Cancer Pain/*drug therapy', 'Female', 'Fentanyl/*administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/27020837/
3187,fentanyl,28068563,A review: Fentanyl and non-pharmaceutical fentanyls.,"['Suzuki J', 'El-Haddad S']","['Analgesics, Opioid/*administration & dosage/adverse effects', 'Drug Overdose/diagnosis/*epidemiology/prevention & control', 'Fentanyl/*administration & dosage/adverse effects', 'Heroin/administration & dosage/adverse effects', 'Humans', 'Opioid-Related Disorders/diagnosis/*epidemiology/prevention & control', 'United States/epidemiology']",https://pubmed.ncbi.nlm.nih.gov/28068563/
3188,fentanyl,38300830,Not Carfentanil-A Case of Unexpected Xylazine Detection.,"['Zheng JX', 'Randall S', 'Grimsrud K', 'Bainbridge S', 'Tran NK']","['Humans', 'Male', 'Analgesics, Opioid/analysis', 'Drug Contamination', 'Drug Overdose/diagnosis', '*Fentanyl/analogs & derivatives/analysis/administration & dosage', 'Gas Chromatography-Mass Spectrometry', 'Tandem Mass Spectrometry/methods', '*Xylazine/adverse effects', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38300830/
3189,fentanyl,17315410,Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.,"['Mystakidou K', 'Katsouda E', 'Parpa E', 'Tsiatas ML', 'Vlahos L']","['Administration, Oral', '*Analgesics, Opioid/administration & dosage/pharmacokinetics/pharmacology/therapeutic use', 'Clinical Trials as Topic', '*Fentanyl/administration & dosage/pharmacokinetics/pharmacology/therapeutic use', 'Humans', 'Mouth Mucosa/*metabolism', '*Neoplasms', 'Pain/*drug therapy/etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/17315410/
3190,fentanyl,24129218,Lessons learned from hospice care.,['Martin CM'],"['Aged', 'Aged, 80 and over', 'Amitriptyline/administration & dosage/adverse effects/therapeutic use', 'Analgesics, Opioid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Drug Monitoring/methods/standards', 'Fentanyl/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', '*Health Services for the Aged/organization & administration/standards/trends', '*Hospice Care/organization & administration/standards/trends', 'Humans', 'Nausea/drug therapy', 'Pruritus/drug therapy', 'Transdermal Patch', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24129218/
3191,fentanyl,20862908,Applying partially occluded fentanyl transdermal patches to manage pain in pediatric patients.,"['Mitchell A', 'Smith HS']","['Adhesiveness', 'Administration, Cutaneous', 'Analgesics, Opioid/*administration & dosage/adverse effects/pharmacokinetics', 'Child', 'Dosage Forms', 'Fentanyl/*administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Pain/*drug therapy', 'Risk Assessment', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/20862908/
3192,fentanyl,15909786,Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: an overview of its pharmacological and clinical characteristics.,"['Mystakidou K', 'Katsouda E', 'Parpa E', 'Tsiatas ML', 'Vlahos L']","['Administration, Oral', 'Analgesics, Opioid/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Dose-Response Relationship, Drug', 'Fentanyl/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Humans', 'Neoplasms/*complications', 'Pain Measurement', 'Pain, Intractable/*drug therapy/etiology', 'Palliative Care/standards', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15909786/
3193,fentanyl,28287363,Nebulized Fentanyl for Dyspnea in a Hospice Patient with True Allergy to Morphine and Hydromorphone.,"['Wahler RG Jr', 'Smith DB', 'Mulcahy KB']","['Administration, Inhalation', 'Aged, 80 and over', '*Drug Hypersensitivity', 'Dyspnea/*drug therapy', 'Female', 'Fentanyl/administration & dosage/*therapeutic use', '*Hospice Care', 'Humans', 'Hydromorphone/adverse effects', 'Morphine/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/28287363/
3194,fentanyl,24413475,The fentanyl 'lozenge' story: from books to battlefield.,"['Aldington D', 'Jagdish S']","['Administration, Buccal', '*Analgesics, Opioid/administration & dosage/pharmacokinetics/therapeutic use', '*Fentanyl/administration & dosage/pharmacokinetics/therapeutic use', 'History, 20th Century', 'History, 21st Century', 'Humans', '*Military Medicine/history/methods/organization & administration', 'Military Personnel', 'Pain Management/*history/*methods', 'Warfare']",https://pubmed.ncbi.nlm.nih.gov/24413475/
3195,brimonidine,34347259,"Rosacea: An Update in Diagnosis, Classification and Management.","['Kang CN', 'Shah M', 'Tan J']","['Brimonidine Tartrate', '*Dermatologic Agents/therapeutic use', 'Doxycycline/therapeutic use', 'Humans', 'Metronidazole', '*Rosacea/diagnosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34347259/
3196,brimonidine,35076997,Post-acne erythema treatment: A systematic review of the literature.,"['Kalantari Y', 'Dadkhahfar S', 'Etesami I']","['*Acne Vulgaris/etiology', 'Brimonidine Tartrate', 'Erythema/drug therapy/etiology', 'Humans', '*Lasers, Dye/therapeutic use', '*Lasers, Solid-State/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/35076997/
3197,brimonidine,34391325,Treatment of rosacea during pregnancy.,"['Gomolin T', 'Cline A', 'Pereira F']","['Adult', '*Algorithms', 'Animals', 'Anti-Bacterial Agents/adverse effects/therapeutic use', 'Azithromycin/adverse effects/therapeutic use', 'Brimonidine Tartrate/therapeutic use', 'Dermatologic Agents/therapeutic use', 'Dicarboxylic Acids/therapeutic use', 'Doxycycline/adverse effects/therapeutic use', 'Female', 'Humans', 'Isotretinoin/adverse effects/therapeutic use', 'Ivermectin/adverse effects/therapeutic use', 'Metronidazole/therapeutic use', 'Mice', 'Minocycline/adverse effects/therapeutic use', 'Phototherapy/adverse effects/methods', 'Pregnancy', 'Pregnancy Complications/*therapy', 'Randomized Controlled Trials as Topic', 'Rosacea/*therapy', 'Tetracyclines/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/34391325/
3198,brimonidine,37276164,Neurogenic Rosacea Treatment: A Literature Review.,"['Ivanic MG', 'Oulee A', 'Norden A', 'Javadi SS', 'Gold MH', 'Wu JJ']","['Humans', '*Rosacea/diagnosis/drug therapy', 'Erythema/drug therapy', 'Metronidazole/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', 'Brimonidine Tartrate']",https://pubmed.ncbi.nlm.nih.gov/37276164/
3199,brimonidine,27416316,What's new in acne and rosacea?,['Keri J'],"['Acne Vulgaris/*drug therapy', 'Brimonidine Tartrate/*administration & dosage', 'Dapsone/*administration & dosage', 'Dermatologic Agents/*administration & dosage', 'Dermatology/*trends', 'Gels/administration & dosage', 'Humans', 'Isotretinoin/*administration & dosage', 'Ivermectin/administration & dosage', 'Rosacea/*drug therapy', 'Skin Cream/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27416316/
3200,brimonidine,30585305,Interventions for rosacea based on the phenotype approach: an updated systematic review including GRADE assessments.,"['van Zuuren EJ', 'Fedorowicz Z', 'Tan J', 'van der Linden MMD', 'Arents BWM', 'Carter B', 'Charland L']","['Administration, Cutaneous', 'Administration, Oral', 'Anti-Bacterial Agents/administration & dosage', 'Brimonidine Tartrate/administration & dosage', 'Combined Modality Therapy/methods', 'Dermatologic Agents/administration & dosage', 'Dermatology/*methods', 'Drug Therapy, Combination/methods', 'Evidence-Based Medicine/*methods', 'Facial Dermatoses/classification/diagnosis/*therapy', 'Humans', 'Intense Pulsed Light Therapy/methods', 'Low-Level Light Therapy/methods', 'Oxymetazoline/administration & dosage', 'Randomized Controlled Trials as Topic', 'Rosacea/classification/diagnosis/*therapy', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30585305/
3201,brimonidine,25154627,Rosacea: new and emerging treatments.,"['Moustafa FA', 'Sandoval LF', 'Feldman SR']","['Administration, Cutaneous', 'Brimonidine Tartrate', 'Dermatologic Agents/administration & dosage/*therapeutic use', '*Drug Design', 'Humans', 'Ivermectin/administration & dosage/therapeutic use', 'Oxymetazoline/administration & dosage/therapeutic use', 'Quality of Life', 'Quinoxalines/administration & dosage/therapeutic use', 'Randomized Controlled Trials as Topic', 'Rosacea/*drug therapy/etiology/pathology']",https://pubmed.ncbi.nlm.nih.gov/25154627/
3202,brimonidine,28472572,Rosacea.,"['Maor D', 'Chong AH']","['Anti-Bacterial Agents/pharmacology/therapeutic use', 'Brimonidine Tartrate/pharmacology/therapeutic use', 'Diagnosis, Differential', 'Doxycycline/pharmacology/therapeutic use', 'Humans', 'Isotretinoin/pharmacology/therapeutic use', 'Ivermectin/pharmacology/therapeutic use', 'Laser Therapy/methods', 'Metronidazole/pharmacology/therapeutic use', 'Rosacea/*diagnosis/*physiopathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/28472572/
3203,brimonidine,29499798,Medical Management of Facial Redness in Rosacea.,"['Cline A', 'McGregor SP', 'Feldman SR']","['Administration, Cutaneous', 'Adrenergic alpha-Agonists/*therapeutic use', 'Antihypertensive Agents/administration & dosage/*therapeutic use', 'Brimonidine Tartrate/adverse effects/*therapeutic use', 'Calcineurin Inhibitors/therapeutic use', 'Erythema/*drug therapy/*etiology', 'Face', 'Humans', 'Off-Label Use', 'Oxymetazoline/*therapeutic use', 'Retinoids/administration & dosage', 'Rosacea/*complications', 'Tetracyclines/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29499798/
3204,brimonidine,32929988,Prophylaxis of Post-Inflammatory Hyperpigmentation From Energy-Based Device Treatments: A Review [Formula: see text].,"['Wong ITY', 'Richer V']","['Adrenal Cortex Hormones/therapeutic use', 'Adrenergic alpha-2 Receptor Agonists/therapeutic use', 'Antifibrinolytic Agents/therapeutic use', 'Antioxidants/therapeutic use', 'Brimonidine Tartrate/therapeutic use', 'Glycolates/therapeutic use', 'Humans', 'Hydroquinones/therapeutic use', 'Hyperpigmentation/diagnosis/etiology/*prevention & control', 'Inflammation/etiology', 'Keratolytic Agents/therapeutic use', 'Laser Therapy/*adverse effects', 'Retinoids/therapeutic use', 'Sunscreening Agents/therapeutic use', 'Tranexamic Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32929988/
3205,brimonidine,37061271,Brimonidine.,"['Bakheit AH', 'Alomar AM', 'Darwish H', 'Alkahtani HM']","['Humans', 'Brimonidine Tartrate/pharmacology/therapeutic use', '*Glaucoma, Open-Angle/drug therapy', 'Adrenergic alpha-Agonists/pharmacology/therapeutic use', 'Quinoxalines/pharmacology/therapeutic use', 'Ophthalmic Solutions/therapeutic use', '*Glaucoma/drug therapy', 'Antihypertensive Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37061271/
3206,brimonidine,27416312,Topical and oral therapeutic approach to rosacea.,"['Helfrich YR', 'Maier LM']","['Administration, Cutaneous', 'Administration, Oral', 'Brimonidine Tartrate/administration & dosage', 'Dermatologic Agents/*administration & dosage', 'Dicarboxylic Acids/administration & dosage', 'Doxycycline/administration & dosage', 'Evidence-Based Medicine', 'Humans', 'Ivermectin/administration & dosage', 'Metronidazole/administration & dosage', 'Rosacea/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27416312/
3207,brimonidine,8970244,The role of brimonidine in the treatment of open-angle glaucoma.,['Wilensky JT'],"['Adrenergic alpha-Agonists/*therapeutic use', 'Aqueous Humor/drug effects', 'Brimonidine Tartrate', 'Carbonic Anhydrase Inhibitors/therapeutic use', 'Glaucoma, Open-Angle/*drug therapy', 'Humans', 'Intraocular Pressure/drug effects', 'Prostaglandins/therapeutic use', 'Quinoxalines/*therapeutic use', 'Sympathomimetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8970244/
3208,brimonidine,26396117,New and Emerging Treatments for Rosacea.,"['Gold LM', 'Draelos ZD']","['Administration, Topical', 'Brimonidine Tartrate/therapeutic use', 'Clinical Trials, Phase III as Topic', 'Dermatologic Agents/*pharmacology/therapeutic use', 'Dicarboxylic Acids/therapeutic use', 'Drug Approval/*statistics & numerical data', 'Female', 'Follow-Up Studies', 'Forecasting', 'Humans', 'Ivermectin/therapeutic use', 'Male', 'Oxymetazoline/therapeutic use', 'Patient Satisfaction/statistics & numerical data', 'Rosacea/diagnosis/*drug therapy/epidemiology', 'Severity of Illness Index', 'Treatment Outcome', 'United States', '*United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/26396117/
3209,brimonidine,36306423,Inflammatory Cells and Lipid Deposits Detected by in Vivo Confocal Microscopy in Brimonidine Tartrate Ophthalmic Solution-Related Corneal Disorders: A Case Series.,"['Chikama T', 'Shinji K', 'Yokota C', 'Hayashi K', 'Kiuchi Y']","['Humans', '*Corneal Diseases', 'Brimonidine Tartrate/therapeutic use', 'Ophthalmic Solutions', 'Microscopy, Confocal', 'Lipids']",https://pubmed.ncbi.nlm.nih.gov/36306423/
3210,brimonidine,25091290,Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.,"['Tong LX', 'Moore AY']","['Adrenergic alpha-2 Receptor Agonists/adverse effects/pharmacology/therapeutic use', 'Animals', 'Brimonidine Tartrate', 'Erythema/*drug therapy', 'Humans', 'Quality of Life', 'Quinoxalines/adverse effects/pharmacology/*therapeutic use', 'Rosacea/*drug therapy/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25091290/
3211,brimonidine,10180510,Selectivity of site of action and systemic effects of topical alpha agonists.,"['Robin AL', 'Burnstein Y']","['Administration, Topical', 'Adrenergic alpha-Agonists/administration & dosage/adverse effects/*pharmacology', 'Animals', 'Brimonidine Tartrate', 'Clonidine/administration & dosage/adverse effects/analogs & derivatives/pharmacology', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Ophthalmic Solutions', 'Optic Nerve/drug effects', 'Quinoxalines/administration & dosage/adverse effects/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10180510/
3212,brimonidine,38000334,Novel frontiers in neuroprotective therapies in glaucoma: Molecular and clinical aspects.,"['Boccaccini A', 'Cavaterra D', 'Carnevale C', 'Tanga L', 'Marini S', 'Bocedi A', 'Lacal PM', 'Manni G', 'Graziani G', 'Sbardella D', 'Tundo GR']","['Humans', '*Neurodegenerative Diseases/pathology', 'Retinal Ganglion Cells/pathology/physiology', '*Glaucoma/drug therapy/pathology', 'Brimonidine Tartrate/therapeutic use', 'Retina', '*Retinal Diseases']",https://pubmed.ncbi.nlm.nih.gov/38000334/
3213,metolazone,37210742,Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics.,"['Yeoh SE', 'Osmanska J', 'Petrie MC', 'Brooksbank KJM', 'Clark AL', 'Docherty KF', 'Foley PWX', 'Guha K', 'Halliday CA', 'Jhund PS', 'Kalra PR', 'McKinley G', 'Lang NN', 'Lee MMY', 'McConnachie A', 'McDermott JJ', 'Platz E', 'Sartipy P', 'Seed A', 'Stanley B', 'Weir RAP', 'Welsh P', 'McMurray JJV', 'Campbell RT']","['Humans', '*Metolazone/therapeutic use/adverse effects', 'Sodium Potassium Chloride Symporter Inhibitors/therapeutic use', 'Furosemide/therapeutic use', '*Heart Failure/drug therapy/chemically induced', 'Diuretics/therapeutic use', 'Sodium']",https://pubmed.ncbi.nlm.nih.gov/37210742/
3214,metolazone,31838029,Diuretic Strategies for Loop Diuretic Resistance in Acute Heart Failure: The 3T Trial.,"['Cox ZL', 'Hung R', 'Lenihan DJ', 'Testani JM']","['Administration, Oral', 'Aged', 'Chlorothiazide/*administration & dosage', 'Diuretics/administration & dosage', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Follow-Up Studies', 'Furosemide/*administration & dosage', 'Heart Failure/*drug therapy', 'Humans', 'Infusions, Intravenous', 'Male', 'Metolazone/*administration & dosage', 'Middle Aged', 'Prospective Studies', 'Retrospective Studies', 'Tolvaptan/administration & dosage', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31838029/
3215,metolazone,32094236,BRASH syndrome.,"['Srivastava S', 'Kemnic T', 'Hildebrandt KR']","['Antihypertensive Agents/adverse effects', '*Atrioventricular Block', '*Bradycardia', 'Bumetanide/adverse effects', 'Carvedilol/adverse effects', 'Female', 'Humans', '*Hyperkalemia', 'Metolazone/adverse effects', 'Middle Aged', '*Renal Insufficiency', '*Shock', 'Syndrome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32094236/
3216,metolazone,25749608,Thiazide Diuretics in Chronic Kidney Disease.,"['Sinha AD', 'Agarwal R']","['Animals', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Humans', 'Hypertension/*drug therapy', 'Practice Guidelines as Topic', 'Renal Insufficiency, Chronic/*drug therapy/etiology', 'Sodium Chloride Symporter Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25749608/
3217,metolazone,33877660,Comparison of diuretic strategies in diuretic-resistant acute heart failure: a systematic review and network meta-analysis.,"['Orso D', 'Tavazzi G', 'Corradi F', 'Mearelli F', 'Federici N', 'Peric D', ""D'Andrea N"", 'Santori G', 'Mojoli F', 'Forfori F', 'Vetrugno L', 'Bove T']","['Acute Disease', 'Carbonic Anhydrase Inhibitors/*therapeutic use', 'Diuretics/*therapeutic use', 'Drug Resistance/drug effects', 'Heart Failure/*drug therapy', 'Humans', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/33877660/
3218,metolazone,8403815,Drug-induced pancreatitis.,"['Underwood TW', 'Frye CB']","['Acute Disease', '*Drug-Related Side Effects and Adverse Reactions', 'Humans', 'Pancreatitis/*chemically induced/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/8403815/
3219,metolazone,19454075,Premenstrual syndrome.,"['Kwan I', 'Onwude JL']","['Administration, Oral', 'Contraceptives, Oral/therapeutic use', 'Dietary Carbohydrates/therapeutic use', 'Dietary Supplements', 'Evidence-Based Medicine', 'Female', 'Humans', 'Life Style', 'Magnesium/therapeutic use', 'Phytotherapy', '*Premenstrual Syndrome/drug therapy', '*Pyridoxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19454075/
3220,metolazone,38739124,Diuresis Efficacy in Ambulatory Congested Heart Failure Patients: Intrapatient Comparison of 3 Diuretic Regimens (DEA-HF).,"['Abbo AR', 'Gruber A', 'Volis I', 'Aronson D', 'Girerd N', 'Lund Kristensen S', 'Zukermann R', 'Alberkant N', 'Sitnitsky E', 'Kruger A', 'Khasis P', 'Bravo E', 'Elad B', 'Helmer Levin L', 'Caspi O']","['Humans', '*Heart Failure/drug therapy/physiopathology', '*Furosemide/administration & dosage/therapeutic use', 'Male', 'Female', '*Diuretics/administration & dosage/therapeutic use', '*Acetazolamide/administration & dosage/therapeutic use', '*Metolazone/administration & dosage', 'Aged', 'Prospective Studies', '*Cross-Over Studies', 'Middle Aged', 'Drug Therapy, Combination', 'Diuresis/drug effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38739124/
3221,metolazone,2650875,Diuretics in congestive heart failure.,"['Sica DA', 'Gehr T']","['Diuresis/drug effects', 'Diuretics/*therapeutic use', 'Drug Therapy, Combination', 'Heart Failure/*drug therapy', 'Humans', 'Sodium/blood']",https://pubmed.ncbi.nlm.nih.gov/2650875/
3222,metolazone,31606239,Thiazide-Associated Hyponatremia: Clinical Manifestations and Pathophysiology.,"['Filippone EJ', 'Ruzieh M', 'Foy A']","['Biomarkers/blood', 'Humans', 'Hypertension/drug therapy', 'Hyponatremia/blood/*chemically induced/diagnosis', 'Sodium/*blood', 'Thiazides/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31606239/
3223,metolazone,5082545,High dosage metolazone in chronic renal failure.,"['Dargie HJ', 'Allison ME', 'Kennedy AC', 'Gray MJ']","['Adolescent', 'Adult', 'Aged', 'Animals', 'Creatinine/metabolism', 'Diuretics/*administration & dosage/therapeutic use', 'Female', 'Glomerulonephritis/drug therapy', 'Humans', 'Ketones/therapeutic use', 'Kidney Failure, Chronic/*drug therapy', 'Male', 'Middle Aged', 'Osmolar Concentration', 'Polycystic Kidney Diseases/drug therapy', 'Potassium/urine', 'Pyelonephritis/drug therapy', 'Quinazolines/*administration & dosage/therapeutic use', 'Sodium/urine', 'Sulfonamides/*administration & dosage/therapeutic use', 'Urination/drug effects']",https://pubmed.ncbi.nlm.nih.gov/5082545/
3224,metolazone,2676316,Management of cirrhotic ascites.,['Alaniz C'],"['Ascites/diagnosis/etiology/*therapy', 'Diagnosis, Differential', 'Diet, Sodium-Restricted', 'Humans', 'Liver Cirrhosis/*complications', 'Peritoneovenous Shunt']",https://pubmed.ncbi.nlm.nih.gov/2676316/
3225,metolazone,12671341,Metolazone and its role in edema management.,['Sica DA'],"['Diuresis/drug effects', 'Diuretics/*therapeutic use', 'Edema, Cardiac/complications/*drug therapy/physiopathology', 'Furosemide/therapeutic use', 'Heart Failure/complications/drug therapy/physiopathology', 'Humans', 'Metolazone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12671341/
3226,metolazone,334435,Do diuretics have antihypertensive properties independent of natriuresis?,"['Bennett WM', 'McDonald WJ', 'Kuehnel E', 'Hartnett MN', 'Porter GA']","['Adult', '*Antihypertensive Agents', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Diuretics/*pharmacology', 'Double-Blind Method', 'Humans', 'Hydrochlorothiazide/pharmacology', 'Kidney Failure, Chronic/physiopathology', 'Male', 'Metolazone/pharmacology', 'Middle Aged', '*Natriuresis', 'Placebos', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/334435/
3227,metolazone,16717105,Beneficial effects of metolazone in a rat model of preeclampsia.,"['Pridjian G', 'Pridjian C', 'Danchuk S', 'Ianosi-Irimie M', 'Vu HV', 'Puschett JB']","['Animals', 'Antihypertensive Agents/*therapeutic use', 'Blood Pressure/drug effects', 'Disease Models, Animal', 'Female', 'Metolazone/*therapeutic use', 'Nitric Oxide/blood/urine', 'Pre-Eclampsia/*drug therapy', 'Pregnancy', 'Rats', 'Rats, Sprague-Dawley']",https://pubmed.ncbi.nlm.nih.gov/16717105/
3228,metolazone,32639593,A Systematic Review and Meta-Analysis of Metolazone Compared to Chlorothiazide for Treatment of Acute Decompensated Heart Failure.,"['Steuber TD', 'Janzen KM', 'Howard ML']","['Chlorothiazide/administration & dosage/*therapeutic use', 'Diuretics/administration & dosage/*therapeutic use', 'Heart Failure/*drug therapy', 'Humans', 'Metolazone/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32639593/
3229,metolazone,27823694,Design and rationale for the Acute Congestive Heart Failure Urgent Care Evaluation: The ACUTE Study.,"['Lee DS', 'Lee JS', 'Schull MJ', 'Grimshaw JM', 'Austin PC', 'Tu JV']","['Age Factors', '*Algorithms', 'Ambulances/statistics & numerical data', 'Antihypertensive Agents/therapeutic use', 'Blood Pressure', 'Comorbidity', 'Creatinine/blood', 'Emergency Medical Services/statistics & numerical data', '*Emergency Service, Hospital', 'Heart Failure/diagnosis/*mortality', 'Heart Rate', 'Hospitalization', 'Humans', 'Metolazone/therapeutic use', 'Mortality', 'Neoplasms/epidemiology', 'Oximetry', 'Potassium/blood', 'Prognosis', 'Prospective Studies', 'Risk Assessment/*methods', 'Troponin/blood']",https://pubmed.ncbi.nlm.nih.gov/27823694/
3230,metolazone,25414321,Editor's Choice-Recent therapeutic trials on fluid removal and vasodilation in acute heart failure.,"['Ennezat PV', 'Stewart M', 'Samson R', 'Bouabdallaoui N', 'Marechaux S', 'Banfi C', 'Bouvaist H', 'Le Jemtel TH']","['Diuretics/therapeutic use', 'Furosemide/therapeutic use', 'Heart Failure/physiopathology/*therapy', 'Humans', 'Randomized Controlled Trials as Topic', 'Recombinant Proteins/therapeutic use', 'Relaxin/therapeutic use', 'Therapeutic Human Experimentation', 'Ultrafiltration/methods', 'Vasodilation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/25414321/
3231,promethazine,25233954,Pink urine.,"['Verhoeven E', 'Capron A', 'Hantson P']","['Alcoholism/pathology', 'Crystallization', 'Ethanol/blood', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Pentanoic Acids/urine', 'Promethazine/blood/therapeutic use/urine', 'Tablets/administration & dosage/poisoning', 'Uric Acid/urine', 'Valerian/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/25233954/
3232,promethazine,27170253,Meniere's disease.,"['Nakashima T', 'Pyykko I', 'Arroll MA', 'Casselbrant ML', 'Foster CA', 'Manzoor NF', 'Megerian CA', 'Naganawa S', 'Young YH']","['Antiemetics/pharmacology/therapeutic use', 'Audiometry/methods', 'Benzodiazepines/pharmacology/therapeutic use', 'Catheter Ablation/methods', 'Dimenhydrinate/pharmacology/therapeutic use', 'Ear, Inner/pathology/physiopathology', 'Endolymph/metabolism', 'Ganglia, Sensory/abnormalities/injuries', 'Hearing Loss/etiology', 'Humans', 'Magnetic Resonance Imaging/methods', 'Meclizine/pharmacology/therapeutic use', 'Meniere Disease/*complications/epidemiology/*physiopathology', 'Promethazine/pharmacology/therapeutic use', 'Quality of Life/psychology', 'Tinnitus/etiology', 'Vertigo/etiology']",https://pubmed.ncbi.nlm.nih.gov/27170253/
3233,promethazine,6928910,Intramuscular sedation technique.,"['Jensen ST', 'Coke JM', 'Cohen L']","['Anesthesia, Dental/*methods', 'Anesthesia, General/*methods', 'Buttocks', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Injections, Intramuscular/methods', 'Meperidine/administration & dosage/pharmacology', 'Promethazine/administration & dosage', 'Respiration/drug effects']",https://pubmed.ncbi.nlm.nih.gov/6928910/
3234,promethazine,3615241,Promethazine-induced dystonic reaction.,"['DeGrandi T', 'Simon JE']","['Acute Disease', 'Adolescent', 'Dystonia/*chemically induced/drug therapy', 'Female', 'Gastroenteritis/complications', 'Humans', 'Promethazine/*adverse effects/therapeutic use', 'Suppositories', 'Vomiting/drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/3615241/
3235,promethazine,7874402,Approach to the dizzy patient.,['Baloh RW'],"['Anxiety Disorders/*complications/psychology', 'Brain Diseases/*complications/physiopathology', 'Diazepam/administration & dosage/therapeutic use', 'Dizziness/*etiology/physiopathology', 'Heart Diseases/*complications/physiopathology', 'Humans', 'Meclizine/administration & dosage/therapeutic use', 'Meniere Disease/*complications', 'Migraine Disorders/*complications', 'Prochlorperazine/administration & dosage/therapeutic use', 'Promethazine/administration & dosage/therapeutic use', 'Proprioception', 'Scopolamine/administration & dosage/therapeutic use', 'Substance-Related Disorders/*complications/physiopathology', 'Time Factors', 'Vertebrobasilar Insufficiency/*complications', 'Vertigo/drug therapy/*etiology', 'Vestibular Diseases/*complications/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7874402/
3236,promethazine,27725018,Angio-oedema associated with colistin.,"['Abulfathi AA', 'Greyling T', 'Makiwane M', 'Esser M', 'Decloedt E']","['Acinetobacter baumannii/isolation & purification', '*Angioedema/chemically induced/diagnosis/physiopathology/therapy', 'Anti-Allergic Agents/administration & dosage', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Colistin/administration & dosage/*adverse effects', 'Diagnosis, Differential', 'Female', 'Humans', 'Hydrocortisone/*administration & dosage', 'Middle Aged', 'Promethazine/*administration & dosage', 'Sepsis/diagnosis/*drug therapy/etiology', 'Treatment Outcome', 'Urinary Tract Infections/*complications/microbiology', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/27725018/
3237,promethazine,11764306,Standard treatment: the role of antihistamines.,['Merk HF'],"['Cyclizine/therapeutic use', 'Cytochrome P-450 Enzyme System/biosynthesis', 'Diphenhydramine/therapeutic use', 'Electrocardiography/adverse effects', 'Histamine H1 Antagonists/*therapeutic use', 'Humans', 'Promethazine/therapeutic use', 'Pyrilamine/therapeutic use', 'Urticaria/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11764306/
3238,promethazine,8443849,Nasal ketamine for paediatric premedication.,"['Weksler N', 'Ovadia L', 'Muati G', 'Stav A']","['Administration, Intranasal', 'Anesthesia Recovery Period', 'Anesthesia, Inhalation', 'Child, Preschool', '*Conscious Sedation', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intramuscular', 'Ketamine/administration & dosage/*therapeutic use', 'Male', 'Meperidine/administration & dosage/therapeutic use', '*Preanesthetic Medication', 'Promethazine/administration & dosage/therapeutic use', 'Salivation/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/8443849/
3239,promethazine,36183207,Use of tracking drugs for the search of intra-hospital adverse reactions: a pharmacovigilance study.,"['Correa Benedet Baesso K', 'Zapelini do Nascimento D', 'De Sa Soares A', 'Schuelter-Trevisol F']","['Adverse Drug Reaction Reporting Systems', 'Cross-Sectional Studies', 'Diphenhydramine/adverse effects', '*Drug-Related Side Effects and Adverse Reactions/epidemiology', 'Flumazenil', 'Hospitals', 'Humans', 'Loperamide', 'Naloxone', '*Pharmacovigilance', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/36183207/
3240,promethazine,37122169,"Promethazine inhibits efflux, enhances antifungal susceptibility and disrupts biofilm structure and functioning in Trichosporon.","['Aguiar ALR', 'Silva BND', 'Fiallos NM', 'Pereira LMG', 'Silva ML', 'Souza PFSM', 'Portela FVM', 'Sidrim JJC', 'Rocha MFG', 'Castelo-Branco DSCM', 'Cordeiro RA']","['Microbial Sensitivity Tests', 'Basidiomycota', 'Promethazine/pharmacology/metabolism', '*Trichosporon', 'Plankton', '*Antifungal Agents/pharmacology/metabolism', 'Biofilms', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/37122169/
3241,promethazine,39699316,Injectable promethazine in clinics and hospitals: What's the alternative?,"['Overholser A', 'Sizemore M', 'Czech E']","['Humans', '*Promethazine/administration & dosage', 'Injections', 'Injections, Subcutaneous']",https://pubmed.ncbi.nlm.nih.gov/39699316/
3242,promethazine,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
3243,promethazine,24350243,Topical promethazine side effects: our experience and review of the literature.,"['Cantisani C', 'Ricci S', 'Grieco T', 'Paolino G', 'Faina V', 'Silvestri E', 'Calvieri S']","['Epidermis/*drug effects/*metabolism', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Inflammation/drug therapy', 'Promethazine/*adverse effects/*therapeutic use', 'Skin Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24350243/
3244,promethazine,11543005,Pharmacotherapeutics in space.,['Putcha L'],"['Acetaminophen/administration & dosage/pharmacokinetics', '*Aerospace Medicine', 'Analgesics, Non-Narcotic/administration & dosage/pharmacokinetics', 'Headache/drug therapy', 'Histamine H1 Antagonists/administration & dosage/pharmacokinetics', 'Humans', 'Muscarinic Antagonists/pharmacokinetics', '*Pharmacology, Clinical', 'Promethazine/administration & dosage/pharmacokinetics', 'Saliva/*metabolism', 'Scopolamine/administration & dosage/pharmacokinetics', '*Space Flight', 'Space Motion Sickness/drug therapy', '*Weightlessness']",https://pubmed.ncbi.nlm.nih.gov/11543005/
3245,promethazine,3675502,Mechanisms of antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Redetzki HM']","['Adult', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Motion Sickness/*prevention & control', 'Placebos', 'Promethazine/*therapeutic use', 'Scopolamine/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3675502/
3246,promethazine,33351859,Targeting bioenergetics is key to counteracting the drug-tolerant state of biofilm-grown bacteria.,"['Donnert M', 'Elsheikh S', 'Arce-Rodriguez A', 'Pawar V', 'Braubach P', 'Jonigk D', 'Haverich A', 'Weiss S', 'Musken M', 'Haussler S']","['Animals', 'Biofilms/*drug effects', 'Drug Tolerance/physiology', 'Energy Metabolism/*drug effects', 'Humans', 'Mice', 'Mice, Inbred BALB C', 'Promethazine/*pharmacology', 'Pseudomonas Infections', 'Pseudomonas aeruginosa/*drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/33351859/
3247,promethazine,39947973,Promethazine: A Review of Therapeutic Uses and Toxicity.,"['Le CK', 'Stevens CA', 'Park JH', 'Clark RF']","['*Promethazine/therapeutic use', 'Humans', '*Vomiting/drug therapy', '*Antiemetics/therapeutic use/pharmacology/adverse effects', '*Nausea/drug therapy/chemically induced', 'Emergency Service, Hospital/organization & administration', 'Histamine H1 Antagonists/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39947973/
3248,promethazine,8746124,Successful cancer therapy with promethazine: the rationale.,['Jones GR'],"['Antineoplastic Agents/adverse effects/*therapeutic use', 'Breast Neoplasms/drug therapy', 'Chlorpromazine/therapeutic use', 'Cyclophosphamide/therapeutic use', 'Female', 'Humans', 'Male', 'Neoplasms/*drug therapy/pathology', 'Pancreatic Neoplasms/drug therapy', 'Phenothiazines/therapeutic use', 'Promethazine/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8746124/
3249,promethazine,404894,Intraarterial analgesia in peripheral arteriography.,"['Guthaner DF', 'Silverman JF', 'Hayden WG', 'Wexler L']","['*Analgesia', '*Angiography', 'Diazepam', 'Humans', 'Injections, Intra-Arterial', 'Lidocaine/*administration & dosage', 'Meperidine', 'Premedication', 'Promethazine']",https://pubmed.ncbi.nlm.nih.gov/404894/
3250,promethazine,11538042,Comparison of efficacy of ginger with various antimotion sickness drugs.,"['Wood CD', 'Manno JE', 'Wood MJ', 'Manno BR', 'Mims ME']","['Administration, Oral', 'Adolescent', 'Adult', 'Antiemetics/administration & dosage/*therapeutic use', 'Dextroamphetamine/*therapeutic use', 'Dimenhydrinate/administration & dosage/therapeutic use', 'Female', 'Humans', 'Male', 'Motion Sickness/drug therapy/*prevention & control', 'Plants, Medicinal/*metabolism', 'Promethazine/administration & dosage/therapeutic use', 'Rotation', 'Scopolamine/administration & dosage/therapeutic use', 'Spices']",https://pubmed.ncbi.nlm.nih.gov/11538042/
3251,methimazole,6387489,Antithyroid drugs.,['Cooper DS'],"['Adult', 'Agranulocytosis/chemically induced', 'Autoimmune Diseases/chemically induced', 'Chemical and Drug Induced Liver Injury/etiology', 'Child', 'Female', 'Fetus/drug effects', 'Graves Disease/drug therapy', 'Humans', 'Hyperthyroidism/drug therapy', 'Immunity/drug effects', 'Immunoglobulins/analysis', 'Infant, Newborn', 'Insulin Antibodies', 'Leukopenia/chemically induced', 'Lupus Vulgaris/chemically induced', 'Methimazole/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Milk, Human/analysis', 'Pregnancy', 'Pregnancy Complications/drug therapy', 'Propylthiouracil/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Vascular Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6387489/
3252,methimazole,22820213,The propylthiouracil dilemma.,"['Glinoer D', 'Cooper DS']","['Adult', 'Age Factors', 'Antithyroid Agents/administration & dosage/*adverse effects', 'Child', 'Drug Administration Schedule', 'Female', 'Graves Disease/drug therapy', 'Humans', 'Hyperthyroidism/*drug therapy', 'Liver Failure/*chemically induced', 'Male', 'Methimazole/*administration & dosage', 'Patient Selection', 'Pregnancy', 'Pregnancy Complications/*chemically induced', 'Propylthiouracil/administration & dosage/*adverse effects', 'United States/epidemiology', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/22820213/
3253,methimazole,3755286,Which anti-thyroid drug?,['Cooper DS'],"['Drug Administration Schedule', 'Female', 'Graves Disease/*drug therapy', 'Humans', 'Metabolic Clearance Rate', 'Methimazole/adverse effects/metabolism/*therapeutic use', 'Pregnancy', 'Propylthiouracil/adverse effects/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3755286/
3254,methimazole,28242803,Antithyroid arthritis syndrome.,"['Modi A', 'Amin H', 'Morgan F']","['Antithyroid Agents/*adverse effects', 'Arthralgia/*etiology', 'Arthritis/*etiology', 'Drug Eruptions/*etiology', 'Female', 'Fever/*etiology', 'Humans', 'Hyperthyroidism/drug therapy', 'Methimazole/*adverse effects', 'Middle Aged', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/28242803/
3255,methimazole,37205692,Comparison of the safety between propylthiouracil and methimazole with hyperthyroidism in pregnancy: A systematic review and meta-analysis.,"['Liu Y', 'Li Q', 'Xu Y', 'Chen Y', 'Men Y']","['Female', 'Pregnancy', 'Humans', 'Methimazole/adverse effects', 'Propylthiouracil/adverse effects', 'Antithyroid Agents/adverse effects', '*Hyperthyroidism/drug therapy', '*Abortion, Spontaneous', '*Pregnancy Complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37205692/
3256,methimazole,27561657,Antithyroid drugs during breastfeeding.,"['Hudzik B', 'Zubelewicz-Szkodzinska B']","['Adult', 'Antithyroid Agents/adverse effects/*therapeutic use', 'Breast Feeding/*adverse effects', 'Drug Hypersensitivity', 'Female', 'Humans', 'Hyperthyroidism/*drug therapy', 'Infant, Newborn', 'Methimazole/administration & dosage/immunology/therapeutic use', 'Mothers', 'Propylthiouracil/toxicity']",https://pubmed.ncbi.nlm.nih.gov/27561657/
3257,methimazole,31652102,SIDE EFFECTS OF PTU AND MMI IN THE TREATMENT OF HYPERTHYROIDISM: A SYSTEMATIC REVIEW AND META-ANALYSIS.,"['Yu W', 'Wu N', 'Li L', 'Wang J', 'OuYang H', 'Shen H']","['Aged', 'Antithyroid Agents', 'Child', 'Female', 'Humans', '*Hyperthyroidism/drug therapy', 'Iodine Radioisotopes', 'Methimazole/*therapeutic use', 'Pregnancy', 'Propylthiouracil/*therapeutic use', 'Retrospective Studies', '*Thyroid Neoplasms']",https://pubmed.ncbi.nlm.nih.gov/31652102/
3258,methimazole,35440398,Long-term thionamide antithyroid treatment of Graves' disease.,"['Azizi F', 'Abdi H', 'Amouzegar A', 'Habibi Moeini AS']","['Adult', 'Child', 'Humans', 'Methimazole/adverse effects', 'Iodine Radioisotopes/therapeutic use', 'Treatment Outcome', '*Thyroid Neoplasms/drug therapy', 'Neoplasm Recurrence, Local', '*Graves Disease/drug therapy/radiotherapy', 'Antithyroid Agents/adverse effects', '*Hyperthyroidism/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/35440398/
3259,methimazole,34788025,Role of CYP2A6 in Methimazole Bioactivation and Hepatotoxicity.,"['Li J', 'Hussain Z', 'Zhu J', 'Lei S', 'Lu J', 'Ma X']","['Animals', 'Cytochrome P-450 CYP2A6/antagonists & inhibitors/*metabolism', 'Cytochrome P-450 Enzyme Inhibitors/chemistry/pharmacology', 'Humans', 'Liver/*drug effects/metabolism/pathology', 'Male', 'Methimazole/*adverse effects/chemistry/metabolism', 'Mice', 'Molecular Structure', 'Recombinant Proteins/metabolism', 'Thiourea/*analogs & derivatives/chemistry/metabolism', 'Tranylcypromine/chemistry/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34788025/
3260,methimazole,34644794,[Graves' Disease].,"['Allelein S', 'Schott M']","['Antithyroid Agents/adverse effects/therapeutic use', 'COVID-19/*complications', 'Carbimazole/therapeutic use', 'Causality', 'Diagnosis, Differential', 'Female', 'Graves Disease/complications/*diagnosis/diagnostic imaging/*therapy', 'Humans', 'Methimazole/therapeutic use', 'Pregnancy', 'Pregnancy Complications/diagnosis/drug therapy', 'Propylthiouracil/adverse effects/therapeutic use', 'Thyroid Hormones/analysis', 'Thyrotropin/analysis', 'Ultrasonography']",https://pubmed.ncbi.nlm.nih.gov/34644794/
3261,methimazole,1915644,Methimazole and agranulocytosis--clinical study.,"['Tuschy U', 'Muhlan J']","['Adult', 'Aged', 'Agranulocytosis/*chemically induced', 'Humans', 'Methimazole/*adverse effects/therapeutic use', 'Middle Aged', 'Thyrotoxicosis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1915644/
3262,methimazole,26486479,[Management of hypothyroidism and hyperthyroidism].,['Jiskra J'],"['Female', 'Humans', 'Hyperthyroidism/diagnosis/etiology/*therapy', 'Hypothyroidism/diagnosis/etiology/*therapy', 'Iodine Radioisotopes/adverse effects/therapeutic use', 'Methimazole/adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications/diagnosis/etiology/therapy', 'Propylthiouracil/adverse effects/therapeutic use', 'Thyroid Function Tests', 'Thyroidectomy', 'Thyroxine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26486479/
3263,methimazole,3528517,Propylthiouracil-induced cholestatic jaundice.,"['Seidman DS', 'Livni E', 'Ilie B', 'Blum I']","['Adult', 'Cholestasis/*chemically induced', 'Female', 'Humans', 'Liver/drug effects', 'Macrophage Migration-Inhibitory Factors/analysis', 'Methimazole/toxicity', 'Propylthiouracil/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3528517/
3264,methimazole,12615754,Diagnosis and management of Graves' disease.,['Ginsberg J'],"['Adult', 'Aged', 'Antithyroid Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Female', '*Graves Disease/diagnosis/drug therapy/etiology', 'Half-Life', 'Humans', 'Iodine Radioisotopes/*therapeutic use', 'Male', 'Methimazole/adverse effects/pharmacokinetics/*therapeutic use', 'Thyroid Function Tests']",https://pubmed.ncbi.nlm.nih.gov/12615754/
3265,methimazole,1287750,[Hyperthyroidism during pregnancy].,"['Castelli V', 'Moscogiuri D']","['Adolescent', 'Adult', 'Embryonic and Fetal Development', 'Female', 'Humans', 'Hyperthyroidism/*diagnosis/therapy', 'Maternal-Fetal Exchange', 'Methimazole/administration & dosage/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*diagnosis/therapy', 'Propylthiouracil/administration & dosage/therapeutic use', 'Thyrotoxicosis/diagnosis/therapy', 'Thyrotropin/analysis']",https://pubmed.ncbi.nlm.nih.gov/1287750/
3266,methimazole,37926548,Glomerular Microangiopathy-like Nephropathy Caused by Hyperthyroidism.,"['Katayama Y', 'Sawa N', 'Kurihara S', 'Ikuma D', 'Oba Y', 'Sekine A', 'Yamanouchi M', 'Hasegawa E', 'Suwabe T', 'Wada T', 'Kono K', 'Kinowaki K', 'Ohashi K', 'Tsuchiya Y', 'Ubara Y']","['Humans', 'Female', 'Middle Aged', '*Hyperthyroidism/complications/diagnosis', '*Thrombotic Microangiopathies/etiology/diagnosis', 'Methimazole/therapeutic use', 'Kidney Glomerulus/pathology', 'COVID-19/complications', 'Antithyroid Agents/therapeutic use', 'COVID-19 Vaccines/adverse effects', 'Hematuria/etiology', 'Kidney Diseases/etiology/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/37926548/
3267,methimazole,17154097,[Childhood Graves' disease].,"['Sasaki N', 'Sato K']","['Antithyroid Agents/administration & dosage/adverse effects', 'Autoantibodies/analysis', 'Biomarkers/analysis', 'Child', 'Combined Modality Therapy', 'Graves Disease/diagnosis/*therapy', 'Humans', 'Immunoglobulins, Thyroid-Stimulating', 'Methimazole/administration & dosage/adverse effects', 'Propylthiouracil/administration & dosage/adverse effects', 'Radiotherapy', 'Thyroidectomy']",https://pubmed.ncbi.nlm.nih.gov/17154097/
3268,methimazole,12192550,Radioiodine therapy and thyrostatic drugs and iodine.,"['Moka D', 'Dietlein M', 'Schicha H']","['Antithyroid Agents/adverse effects/pharmacology/*therapeutic use', 'Carbimazole/therapeutic use', 'Combined Modality Therapy', 'Dose-Response Relationship, Drug', 'Dose-Response Relationship, Radiation', 'Drug Interactions', 'Graves Disease/drug therapy/radiotherapy', 'Half-Life', 'Humans', 'Hyperthyroidism/drug therapy/*radiotherapy', 'Iodine/pharmacokinetics/*therapeutic use', 'Iodine Radioisotopes/pharmacokinetics/*therapeutic use', 'Methimazole/therapeutic use', 'Propylthiouracil/therapeutic use', 'Radiation-Protective Agents/pharmacology', 'Radiopharmaceuticals/pharmacokinetics/*therapeutic use', 'Radiotherapy Dosage']",https://pubmed.ncbi.nlm.nih.gov/12192550/
3269,methimazole,23214070,[Management of Graves' disease and hypothyroidism in pregnancy].,"['Momotani N', 'Iwama S']","['Female', 'Graves Disease/complications/*drug therapy', 'Humans', '*Hypothyroidism/chemically induced', 'Methimazole/adverse effects/*therapeutic use', 'Pregnancy', '*Pregnancy Complications/chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/23214070/
3270,methimazole,38165576,Risk of recurrence at the time of withdrawal of short- or long-term methimazole therapy in patients with Graves' hyperthyroidism: a randomized trial and a risk-scoring model.,"['Azizi F', 'Amouzegar A', 'Khalili D', 'Abdi H', 'Tohidi M', 'Hedayati M', 'Cheraghi L', 'Mehrabi Y', 'Takyar M']","['Humans', '*Methimazole/therapeutic use/adverse effects', '*Graves Disease/drug therapy/blood', 'Female', 'Male', '*Antithyroid Agents/therapeutic use', 'Adult', 'Middle Aged', '*Recurrence', 'Risk Assessment', 'Withholding Treatment', 'Time Factors', 'Drug Administration Schedule']",https://pubmed.ncbi.nlm.nih.gov/38165576/
3271,IMIQUIMOD,34936223,Allosteric inhibition of SHP2 uncovers aberrant TLR7 trafficking in aggravating psoriasis.,"['Zhu Y', 'Wu Z', 'Yan W', 'Shao F', 'Ke B', 'Jiang X', 'Gao J', 'Guo W', 'Lai Y', 'Ma H', 'Chen D', 'Xu Q', 'Sun Y']","['Animals', 'Disease Models, Animal', 'Humans', 'Imiquimod/adverse effects/metabolism', 'Mice', '*Psoriasis', 'Skin', '*Toll-Like Receptor 7/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34936223/
3272,IMIQUIMOD,36454335,Treatment of actinic keratosis: a systematic review.,"['Worley B', 'Harikumar V', 'Reynolds K', 'Dirr MA', 'Christensen RE', 'Anvery N', 'Yi MD', 'Poon E', 'Alam M']","['Humans', '*Keratosis, Actinic/drug therapy', 'Imiquimod/therapeutic use', '*Photochemotherapy/methods', 'Treatment Outcome', '*Skin Neoplasms/drug therapy', 'Fluorouracil']",https://pubmed.ncbi.nlm.nih.gov/36454335/
3273,IMIQUIMOD,33093288,Management of Condyloma Acuminata in Pregnancy: A Review.,"['Sugai S', 'Nishijima K', 'Enomoto T']","['*Condylomata Acuminata/drug therapy', 'Female', 'Humans', 'Imiquimod/therapeutic use', 'Papillomaviridae', '*Photochemotherapy', 'Pregnancy', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/33093288/
3274,IMIQUIMOD,33450859,Topical Application of Mesenchymal Stem Cell Exosomes Alleviates the Imiquimod Induced Psoriasis-Like Inflammation.,"['Zhang B', 'Lai RC', 'Sim WK', 'Choo ABH', 'Lane EB', 'Lim SK']","['Administration, Topical', 'Animals', 'Biomarkers', 'Biopsy', 'Disease Models, Animal', 'Exosomes/*metabolism', 'Imiquimod/*adverse effects', 'Mesenchymal Stem Cells/*metabolism', 'Mice', 'Permeability', 'Phenotype', 'Psoriasis/*etiology/*pathology/therapy', 'Skin/drug effects/metabolism/pathology', 'Skin Absorption']",https://pubmed.ncbi.nlm.nih.gov/33450859/
3275,IMIQUIMOD,31705912,Topical treatments for skin cancer.,"['Cullen JK', 'Simmons JL', 'Parsons PG', 'Boyle GM']","['Administration, Cutaneous', 'Antineoplastic Agents/administration & dosage/*therapeutic use', 'Carcinoma, Basal Cell/drug therapy/pathology', 'Clinical Trials as Topic', 'Diterpenes/pharmacology/therapeutic use', 'Drug Delivery Systems/*methods', 'Fluorouracil/pharmacology/therapeutic use', 'Humans', ""Hutchinson's Melanotic Freckle/drug therapy/pathology"", 'Imiquimod/pharmacology/therapeutic use', 'Keratosis, Actinic/drug therapy/pathology', 'Melanoma/drug therapy/pathology', 'Neoplasms, Squamous Cell/drug therapy/pathology', 'Photochemotherapy/adverse effects/methods', 'Retinoids/pharmacology/therapeutic use', 'Skin/physiopathology', 'Skin Neoplasms/*drug therapy/*pathology', 'Ultraviolet Rays/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31705912/
3276,IMIQUIMOD,33081840,Daphnetin inhibits proliferation and inflammatory response in human HaCaT keratinocytes and ameliorates imiquimod-induced psoriasis-like skin lesion in mice.,"['Gao J', 'Chen F', 'Fang H', 'Mi J', 'Qi Q', 'Yang M']","['*Adjuvants, Immunologic/adverse effects', 'Animals', '*Anti-Inflammatory Agents/pharmacology', 'Cell Proliferation', 'Humans', '*Imiquimod/adverse effects', '*Inflammation/drug therapy', 'Keratinocytes', 'Mice', 'Mice, Inbred BALB C', '*Psoriasis/chemically induced/drug therapy', 'Rabbits', '*Umbelliferones/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/33081840/
3277,IMIQUIMOD,12171687,Topical imiquimod.,"['Pearson GW', 'Langley RG']","['Adjuvants, Immunologic/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Administration, Topical', 'Aminoquinolines/administration & dosage/adverse effects/*pharmacology/*therapeutic use', 'Condylomata Acuminata/*drug therapy', 'Humans', 'Imiquimod', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/12171687/
3278,IMIQUIMOD,36902419,Pharmacological Agents Used in the Prevention and Treatment of Actinic Keratosis: A Review.,"['Arcuri D', 'Ramchatesingh B', 'Lagace F', 'Iannattone L', 'Netchiporouk E', 'Lefrancois P', 'Litvinov IV']","['Humans', '*Keratosis, Actinic/pathology', 'Aminolevulinic Acid', 'Diclofenac', 'Imiquimod/therapeutic use', '*Photochemotherapy/adverse effects', 'Fluorouracil/therapeutic use', 'Photosensitizing Agents/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/36902419/
3279,IMIQUIMOD,28433227,Nonsurgical Therapies for Basal Cell Carcinoma: A Review.,"['Ariza S', 'Espinosa S', 'Naranjo M']","['Administration, Cutaneous', 'Aminoquinolines/administration & dosage/therapeutic use', 'Anilides/adverse effects/therapeutic use', 'Antineoplastic Agents/administration & dosage/therapeutic use', 'Biphenyl Compounds/adverse effects/therapeutic use', 'Carcinoma, Basal Cell/*drug therapy/etiology/pathology', 'Clinical Trials as Topic', 'Fluorouracil/administration & dosage/therapeutic use', 'Humans', 'Imiquimod', 'Interferons/therapeutic use', 'Meta-Analysis as Topic', 'Molecular Targeted Therapy', 'Neoplasm Invasiveness', 'Photochemotherapy', 'Pyridines/adverse effects/therapeutic use', 'Randomized Controlled Trials as Topic', 'Risk Assessment', 'Skin Neoplasms/*drug therapy/etiology/pathology']",https://pubmed.ncbi.nlm.nih.gov/28433227/
3280,IMIQUIMOD,33820677,Guidelines of care for the management of actinic keratosis.,"['Eisen DB', 'Asgari MM', 'Bennett DD', 'Connolly SM', 'Dellavalle RP', 'Freeman EE', 'Goldenberg G', 'Leffell DJ', 'Peschin S', 'Sligh JE', 'Wu PA', 'Frazer-Green L', 'Malik S', 'Schlesinger TE']","['Diclofenac/therapeutic use', 'Fluorouracil/therapeutic use', 'Humans', 'Imiquimod/therapeutic use', '*Keratosis, Actinic/drug therapy', '*Photochemotherapy']",https://pubmed.ncbi.nlm.nih.gov/33820677/
3281,IMIQUIMOD,34460100,The STING antagonist H-151 ameliorates psoriasis via suppression of STING/NF-kappaB-mediated inflammation.,"['Pan Y', 'You Y', 'Sun L', 'Sui Q', 'Liu L', 'Yuan H', 'Chen C', 'Liu J', 'Wen X', 'Dai L', 'Sun H']","['Animals', 'Cytokines/metabolism', 'Disease Models, Animal', 'Humans', 'Imiquimod/adverse effects', 'Inflammation/pathology', 'Keratinocytes', 'Mice', 'Mice, Inbred BALB C', '*NF-kappa B/metabolism', '*Psoriasis/drug therapy/pathology', 'Skin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/34460100/
3282,IMIQUIMOD,37446011,Imiquimod as Local Immunotherapy in the Management of Premalignant Cutaneous Conditions and Skin Cancer.,"['Garcia-Mouronte E', 'Berna-Rico E', 'de Nicolas-Ruanes B', 'Azcarraga-Llobet C', 'Alonso-Martinez de Salinas L', 'Bea-Ardebol S']","['Humans', 'Imiquimod/therapeutic use', '*Skin Neoplasms/drug therapy/epidemiology', 'Adjuvants, Immunologic/therapeutic use', 'Skin/pathology', '*Precancerous Conditions/drug therapy', 'Administration, Cutaneous', 'Immunotherapy', 'Aminoquinolines/pharmacology/therapeutic use', '*Antineoplastic Agents/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37446011/
3283,IMIQUIMOD,36693922,FXYD3 enhances IL-17A signaling to promote psoriasis by competitively binding TRAF3 in keratinocytes.,"['Yang W', 'He R', 'Qu H', 'Lian W', 'Xue Y', 'Wang T', 'Lin W', 'Zhu P', 'Xia M', 'Lai L', 'Wang Q']","['Animals', 'Humans', 'Mice', 'Cytokines/metabolism', 'Disease Models, Animal', 'Imiquimod/adverse effects/metabolism', 'Interleukin-17/metabolism', 'Keratinocytes', '*Membrane Proteins/metabolism', '*Neoplasm Proteins/metabolism', '*Psoriasis/pathology', 'Skin/pathology', '*TNF Receptor-Associated Factor 3/metabolism']",https://pubmed.ncbi.nlm.nih.gov/36693922/
3284,IMIQUIMOD,39560337,Keloid management: a review of treatment modalities.,"['Luo PM', 'Glass Ii DA 2nd']","['*Keloid/therapy', 'Humans', '*Imiquimod/therapeutic use', 'Cryotherapy/methods', 'Laser Therapy/methods', 'Pentoxifylline/therapeutic use', 'Injections, Intralesional', 'Antibodies, Monoclonal, Humanized/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39560337/
3285,IMIQUIMOD,36741386,Dual targeting of mTOR/IL-17A and autophagy by fisetin alleviates psoriasis-like skin inflammation.,"['Roy T', 'Banang-Mbeumi S', 'Boateng ST', 'Ruiz EM', 'Chamcheu RN', 'Kang L', 'King JA', 'Walker AL', 'Nagalo BM', 'Kousoulas KG', 'Esnault S', 'Huang S', 'Chamcheu JC']","['Humans', 'Animals', 'Mice', 'Interleukin-17/metabolism', 'Proto-Oncogene Proteins c-akt/metabolism', 'Phosphatidylinositol 3-Kinases/metabolism', '*Psoriasis', '*Dermatitis', 'TOR Serine-Threonine Kinases/metabolism', 'Inflammation/metabolism', 'Imiquimod/adverse effects', 'Cytokines/metabolism', 'Disease Models, Animal', 'Autophagy', 'Sirolimus/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36741386/
3286,IMIQUIMOD,35589416,Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions.,"['Adachi A', 'Honda T', 'Egawa G', 'Kanameishi S', 'Takimoto R', 'Miyake T', 'Hossain MR', 'Komine M', 'Ohtsuki M', 'Gunzer M', 'Ikuta K', 'Kabashima K']","['Animals', 'Disease Models, Animal', 'Estradiol/pharmacology/therapeutic use', 'Imiquimod/adverse effects', 'Inflammation/pathology', '*Interleukin-17', 'Interleukin-23', 'Macrophages', 'Mice', 'Mice, Knockout', 'Neutrophils', '*Psoriasis', 'Receptors, Estrogen', 'Skin']",https://pubmed.ncbi.nlm.nih.gov/35589416/
3287,IMIQUIMOD,15620626,Imiquimod for the treatment of skin cancer.,"['Burns CA', 'Brown MD']","['Administration, Cutaneous', 'Aminoquinolines/*administration & dosage', 'Antineoplastic Agents/*administration & dosage', 'Clinical Trials as Topic', 'Humans', 'Imiquimod', 'Skin Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/15620626/
3288,IMIQUIMOD,32828871,Paget's disease of the vulva: A challenge for the gynaecologist.,"['Carton I', 'Lebreton M', 'Tesson C', 'Henno S', 'Lavoue V', 'Leveque J', 'Nyangoh-Timoh K']","['Administration, Topical', 'Antineoplastic Agents/therapeutic use', 'Diagnosis, Differential', 'Female', 'Humans', 'Imiquimod/therapeutic use', 'Lasers, Gas/therapeutic use', 'Neoplasm Invasiveness', 'Neoplasm Recurrence, Local', 'Paget Disease, Extramammary/pathology/*therapy', 'Photochemotherapy', 'Prognosis', 'Radiotherapy Dosage', 'Vulvar Neoplasms/pathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/32828871/
3289,IMIQUIMOD,32386432,Mesenchymal stem cells for the treatment of psoriasis: a comprehensive review.,"['Paganelli A', 'Tarentini E', 'Benassi L', 'Kaleci S', 'Magnoni C']","['Adjuvants, Immunologic/administration & dosage/adverse effects', 'Adult', 'Animals', 'Cell Proliferation/drug effects', 'Clinical Trials as Topic', 'Cytokines/immunology/metabolism', 'Female', 'Fetal Blood/cytology/*transplantation', 'Humans', 'Imiquimod/administration & dosage/*adverse effects', 'Immunomodulation/immunology', 'Infusions, Intravenous', 'Keratinocytes/pathology', 'Male', 'Mesenchymal Stem Cell Transplantation/*adverse effects/methods', 'Mesenchymal Stem Cells/*immunology/pathology', 'Mice', 'Middle Aged', 'Models, Animal', 'Psoriasis/immunology/pathology/*therapy', 'T-Lymphocytes/drug effects/immunology/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32386432/
3290,IMIQUIMOD,30142710,Reviewing the use of imiquimod for molluscum contagiosum.,"['DiBiagio JR', 'Pyle T', 'Green JJ']","['Adjuvants, Immunologic/adverse effects/*therapeutic use', 'Cheilitis/*chemically induced/etiology', 'Child', 'Humans', 'Imiquimod/adverse effects/*therapeutic use', 'Male', 'Molluscum Contagiosum/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/30142710/
3291,Carnitine,21561431,L-carnitine--metabolic functions and meaning in humans life.,"['Pekala J', 'Patkowska-Sokola B', 'Bodkowski R', 'Jamroz D', 'Nowakowski P', 'Lochynski S', 'Librowski T']","['Animals', 'Carnitine/*metabolism/*pharmacology/therapeutic use', 'Dietary Supplements', 'Heart Failure/drug therapy/metabolism', 'Humans', 'Lipid Metabolism/drug effects/physiology', 'Metabolic Networks and Pathways/drug effects/physiology', 'Oxidative Stress/drug effects/*physiology']",https://pubmed.ncbi.nlm.nih.gov/21561431/
3292,Carnitine,31906370,Carnitine in Human Muscle Bioenergetics: Can Carnitine Supplementation Improve Physical Exercise?,"['Gnoni A', 'Longo S', 'Gnoni GV', 'Giudetti AM']","['Carnitine/administration & dosage/*analogs & derivatives/biosynthesis/chemistry/*metabolism/pharmacology', 'Carnitine O-Palmitoyltransferase/metabolism', 'Dietary Supplements/adverse effects', 'Energy Metabolism/*drug effects', 'Exercise/physiology', 'Fatty Acids/*metabolism', 'Humans', 'Methylamines/metabolism', 'Mitochondria/*metabolism', 'Muscle, Skeletal/drug effects/*metabolism', 'Oxidation-Reduction']",https://pubmed.ncbi.nlm.nih.gov/31906370/
3293,Carnitine,35710135,"Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials.","['Dambrova M', 'Makrecka-Kuka M', 'Kuka J', 'Vilskersts R', 'Nordberg D', 'Attwood MM', 'Smesny S', 'Sen ZD', 'Guo AC', 'Oler E', 'Tian S', 'Zheng J', 'Wishart DS', 'Liepinsh E', 'Schioth HB']","['Biomarkers', '*Carnitine/analogs & derivatives/chemistry/metabolism/therapeutic use', 'Fatty Acids/metabolism', 'Humans', '*Insulin Resistance/physiology']",https://pubmed.ncbi.nlm.nih.gov/35710135/
3294,Carnitine,34959912,Effect of Acute and Chronic Oral l-Carnitine Supplementation on Exercise Performance Based on the Exercise Intensity: A Systematic Review.,"['Mielgo-Ayuso J', 'Pietrantonio L', 'Viribay A', 'Calleja-Gonzalez J', 'Gonzalez-Bernal J', 'Fernandez-Lazaro D']","['Administration, Oral', 'Athletic Performance/*physiology', 'Carnitine/*administration & dosage/*pharmacology', '*Dietary Supplements', 'Exercise/*physiology', 'Female', 'Humans', 'Male', 'Sports Nutritional Physiological Phenomena/*physiology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/34959912/
3295,Carnitine,32958033,The bright and the dark sides of L-carnitine supplementation: a systematic review.,"['Sawicka AK', 'Renzi G', 'Olek RA']","['Age Factors', 'Body Composition', 'Carnitine/*administration & dosage/*adverse effects', 'Cognition/physiology', 'Dietary Carbohydrates/administration & dosage', 'Dietary Supplements/*adverse effects', '*Energy Metabolism', 'Exercise/*physiology', 'Exercise Tolerance/physiology', 'Humans', 'Lipid Metabolism', 'Methylamines/blood', 'Muscle Proteins/metabolism', 'Muscle Strength', 'Muscle, Skeletal/anatomy & histology/*metabolism', 'Obesity/metabolism', 'Oxidation-Reduction', 'Physical Conditioning, Human/physiology', 'Sarcopenia/metabolism']",https://pubmed.ncbi.nlm.nih.gov/32958033/
3296,Carnitine,34639120,Neuroendocrine Effects of Carnitines on Reproductive Impairments.,"['Petrillo T', 'Battipaglia C', 'Virmani MA', 'Genazzani AR', 'Genazzani AD']","['Carnitine/*therapeutic use', 'Female', 'Humans', 'Infertility, Female/*drug therapy', 'Infertility, Male/*drug therapy', 'Male', 'Protective Agents/*therapeutic use', '*Reproduction']",https://pubmed.ncbi.nlm.nih.gov/34639120/
3297,Carnitine,25428533,Gut microorganisms and cardiovascular disease: carnitine is the answer.,"['Ginter E', 'Simko V']","['Cardiovascular Diseases/*microbiology', 'Carnitine/administration & dosage/biosynthesis/*metabolism', 'Gastrointestinal Tract/microbiology', 'Humans', 'Intestinal Mucosa/*metabolism', 'Intestines/*microbiology', 'Metabolic Diseases/microbiology', 'Microbiota']",https://pubmed.ncbi.nlm.nih.gov/25428533/
3298,Carnitine,16893411,Dialysis-related carnitine disorder.,['Hedayati SS'],"['Anemia/etiology', 'Carnitine/administration & dosage/*deficiency/metabolism', 'Humans', 'Kidney/*metabolism', 'Kidney Failure, Chronic/*metabolism/therapy', 'Muscular Diseases/etiology', 'Renal Dialysis/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/16893411/
3299,Carnitine,22943123,Intravenous lipid administration for drug-induced toxicity: a critical review of the existing data.,['Waring WS'],"['Anesthetics, Local/poisoning', 'Animals', 'Antidotes/administration & dosage/adverse effects/*therapeutic use', 'Carnitine/metabolism', 'Fat Emulsions, Intravenous/administration & dosage/adverse effects/*therapeutic use', 'Fatty Acids/metabolism', 'Humans', 'Poisoning/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/22943123/
3300,Carnitine,23321261,A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication.,"['Brass EP', 'Koster D', 'Hiatt WR', 'Amato A']","['Carnitine/*analogs & derivatives/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Exercise Test/drug effects', 'Humans', 'Intermittent Claudication/*drug therapy/physiopathology', '*Walking']",https://pubmed.ncbi.nlm.nih.gov/23321261/
3301,Carnitine,38594107,"The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials.","['Mirrafiei A', 'Jayedi A', 'Shab-Bidar S']","['Humans', '*Blood Glucose/drug effects/metabolism', 'Cardiovascular Diseases/prevention & control/etiology', '*Carnitine/administration & dosage/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/blood/complications', '*Dietary Supplements', 'Dose-Response Relationship, Drug', 'Glycated Hemoglobin/metabolism', '*Glycemic Control', 'Heart Disease Risk Factors', 'Randomized Controlled Trials as Topic', '*Weight Loss/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38594107/
3302,Carnitine,12666074,Practice recommendations for the use of L-carnitine in dialysis-related carnitine disorder. National Kidney Foundation Carnitine Consensus Conference.,"['Eknoyan G', 'Latos DL', 'Lindberg J']","['Anemia/drug therapy/etiology', 'Carnitine/administration & dosage/deficiency/physiology/*therapeutic use', 'Fatigue/drug therapy/etiology', 'Homeostasis', 'Humans', 'Hypotension/drug therapy/etiology', 'Kidney/metabolism', 'Kidney Failure, Chronic/metabolism/therapy', 'Renal Dialysis/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/12666074/
3303,Carnitine,34812127,Serum metabolite profiling yields insights into health promoting effect of A. muciniphila in human volunteers with a metabolic syndrome.,"['Depommier C', 'Everard A', 'Druart C', 'Maiter D', 'Thissen JP', 'Loumaye A', 'Hermans MP', 'Delzenne NM', 'de Vos WM', 'Cani PD']","['Adolescent', 'Adult', 'Aged', 'Akkermansia/physiology', 'Amino Acids/metabolism', 'Carnitine/analogs & derivatives/metabolism', 'Glycolysis/drug effects', 'Humans', 'Insulin Resistance', 'Ketone Bodies/metabolism', 'Lipid Metabolism/drug effects', 'Liver/drug effects/metabolism', 'Metabolic Syndrome/blood/*diet therapy', 'Metabolome/*drug effects', 'Middle Aged', 'Probiotics/administration & dosage/*pharmacology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/34812127/
3304,Carnitine,12908852,Pharmacokinetics of L-carnitine.,"['Evans AM', 'Fornasini G']","['Administration, Oral', 'Carnitine/administration & dosage/biosynthesis/*pharmacokinetics', 'Humans', 'Injections, Intravenous', 'Metabolic Clearance Rate/physiology']",https://pubmed.ncbi.nlm.nih.gov/12908852/
3305,Carnitine,8847154,L-carnitine in dialysed patients: the choice of dosage regimen.,"['Berard E', 'Iordache A', 'Barrillon D', 'Bayle J']","['Carnitine/administration & dosage/metabolism/*therapeutic use', 'Humans', 'Kidney Failure, Chronic/*complications/therapy', 'Renal Dialysis/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8847154/
3306,Carnitine,27931027,Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.,['Armenian SH'],"['Anthracyclines/*adverse effects/therapeutic use', 'Antineoplastic Agents/*adverse effects/therapeutic use', 'Cardiomyopathies/*chemically induced/diet therapy/metabolism/prevention & control', 'Cardiotoxicity/diet therapy/*metabolism/physiopathology/prevention & control', 'Carnitine/deficiency/metabolism/therapeutic use', 'Child', 'Deficiency Diseases/chemically induced/diet therapy/metabolism/prevention & control', 'Dietary Supplements', 'Heart/*drug effects/physiopathology', 'Humans', 'Myocardium/metabolism', 'Neoplasms/drug therapy/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27931027/
3307,Carnitine,17641989,[Therapeutic approach to epilepsy from the nutritional view: current status of dietary treatment].,"['Vicente-Hernandez M', 'Garcia-Garcia P', 'Gil-Nagel A', 'Lopez-Munoz F', 'Alamo C']","['Anticonvulsants/pharmacology/therapeutic use', 'Brain/metabolism', 'Carnitine/administration & dosage/therapeutic use', 'Child', 'Clinical Trials as Topic', 'Diet, Carbohydrate-Restricted', 'Dietary Fats/administration & dosage/pharmacology/*therapeutic use', 'Drug Resistance', 'Energy Intake', 'Energy Metabolism', 'Epilepsy/*diet therapy/drug therapy/physiopathology', 'Fasting', 'Fatty Acids, Omega-3/administration & dosage/therapeutic use', 'Glucose/adverse effects/metabolism', 'Humans', 'Ketone Bodies/*metabolism', 'Treatment Outcome', 'Triglycerides/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17641989/
3308,Carnitine,28805348,Levocarnitine Decreases Intradialytic Hypotension Episodes: A Randomized Controlled Trial.,"['Ibarra-Sifuentes HR', 'Del Cueto-Aguilera A', 'Gallegos-Arguijo DA', 'Castillo-Torres SA', 'Vera-Pineda R', 'Martinez-Granados RJ', 'Atilano-Diaz A', 'Cuellar-Monterrubio JE', 'Pezina-Cantu CO', 'Martinez-Guevara EJ', 'Ortiz-Trevino JF', 'Delgado-Garcia GR', 'Martinez-Jimenez JG', 'Cruz-Valdez J', 'Sanchez-Martinez C']","['Adult', 'Carnitine/*administration & dosage/deficiency', 'Double-Blind Method', 'Female', 'Humans', 'Hypotension/epidemiology/etiology/*prevention & control', 'Kidney Failure, Chronic/*therapy', 'Male', 'Middle Aged', 'Prospective Studies', 'Renal Dialysis/adverse effects/*methods', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28805348/
3309,Carnitine,26863801,[L-carnitine: properties and perspectives for use in sports practice].,"['Radzhabkadiev RM', 'Korosteleva MM', 'Evstratova VS', 'Nikityuk DB', 'Khanferyan RA']","['Carnitine/*pharmacokinetics/*therapeutic use', 'Humans', '*Sports', '*Sports Medicine']",https://pubmed.ncbi.nlm.nih.gov/26863801/
3310,hydrochlorothiazide,36856614,Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence.,"['Dhayat NA', 'Bonny O', 'Roth B', 'Christe A', 'Ritter A', 'Mohebbi N', 'Faller N', 'Pellegrini L', 'Bedino G', 'Venzin RM', 'Grosse P', 'Husler C', 'Koneth I', 'Bucher C', 'Del Giorno R', 'Gabutti L', 'Mayr M', 'Odermatt U', 'Buchkremer F', 'Ernandez T', 'Stoermann-Chopard C', 'Teta D', 'Vogt B', 'Roumet M', 'Tamo L', 'Cereghetti GM', 'Trelle S', 'Fuster DG']","['Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects/therapeutic use', 'Kidney/diagnostic imaging', '*Kidney Calculi/diagnostic imaging/prevention & control', 'Sodium Chloride Symporter Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Recurrence', 'Double-Blind Method', 'Dose-Response Relationship, Drug', '*Diuretics/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36856614/
3311,hydrochlorothiazide,32139213,Hydrochlorothiazide-induced systemic capillary leak.,['Vadas P'],"['Capillary Leak Syndrome/complications/*etiology', 'Heart Arrest/drug therapy/etiology', 'Humans', 'Hydrochlorothiazide/*adverse effects/therapeutic use', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/32139213/
3312,hydrochlorothiazide,6385697,Advantages of diuretics.,['Freis ED'],"['Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Hypokalemia/chemically induced', 'Male', 'Propranolol/*therapeutic use', 'Random Allocation', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6385697/
3313,hydrochlorothiazide,23750676,An update on telmisartan/hydrochlorothiazide combinations for the management of hypertensive patients with additional cardiovascular risk factors.,"['Kjeldsen S', 'Mancia G', 'Schmieder R', 'Mattheus M', 'Unger T']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/therapeutic use', 'Benzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Benzoates/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Cardiovascular Diseases/etiology/prevention & control', 'Drug Combinations', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'International Cooperation', 'Practice Guidelines as Topic', 'Risk Factors', 'Severity of Illness Index', 'Telmisartan']",https://pubmed.ncbi.nlm.nih.gov/23750676/
3314,hydrochlorothiazide,9001823,The angiotensin II type 1 receptor blocker losartan in clinical practice: a review.,"['Gavras HP', 'Salerno CM']","['*Angiotensin Receptor Antagonists', 'Angiotensin-Converting Enzyme Inhibitors/administration & dosage/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Biphenyl Compounds/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/administration & dosage/therapeutic use', 'Hypertension/*drug therapy/metabolism', 'Imidazoles/administration & dosage/adverse effects/*therapeutic use', 'Losartan', 'Receptor, Angiotensin, Type 1', 'Receptor, Angiotensin, Type 2', 'Safety', 'Tetrazoles/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9001823/
3315,hydrochlorothiazide,328540,The efficacy and safety of furosemide and a combination of spironolactone and hydrochlorothiazide in congestive heart failure.,['Levy B'],"['Adult', 'Aged', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Drug Evaluation', 'Electrolytes/blood/urine', 'Female', 'Furosemide/adverse effects/*therapeutic use', 'Heart Failure/blood/*drug therapy/urine', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Spironolactone/administration & dosage/adverse effects/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/328540/
3316,hydrochlorothiazide,25271811,Efficacy and safety of fixed-dose losartan/hydrochlorothiazide/amlodipine combination versus losartan/hydrochlorothiazide combination in Japanese patients with essential hypertension.,"['Rakugi H', 'Tsuchihashi T', 'Shimada K', 'Numaguchi H', 'Nishida C', 'Yamaguchi H', 'Shirakawa M', 'Azuma K', 'Fujita KP']","['Aged', '*Amlodipine/administration & dosage/adverse effects', 'Antihypertensive Agents/administration & dosage/adverse effects', 'Blood Pressure/*drug effects', 'Drug Combinations', 'Drug Monitoring/methods', 'Essential Hypertension', 'Female', 'Humans', '*Hydrochlorothiazide/administration & dosage/adverse effects', '*Hypertension/diagnosis/drug therapy/physiopathology', 'Japan', '*Losartan/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25271811/
3317,hydrochlorothiazide,19761411,Clinical experience in treating hypertension with fixed-dose combination therapy: angiotensin II receptor blocker losartan plus hydrochlorothiazide.,"['Abe M', 'Okada K', 'Matsumoto K']","['Angiotensin II Type 1 Receptor Blockers/administration & dosage/adverse effects/therapeutic use', 'Antihypertensive Agents/administration & dosage/adverse effects/*therapeutic use', 'Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Drug Combinations', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/therapeutic use', 'Hypertension/complications/*drug therapy', 'Losartan/administration & dosage/adverse effects/therapeutic use', 'Medication Adherence']",https://pubmed.ncbi.nlm.nih.gov/19761411/
3318,hydrochlorothiazide,2766837,Hydrochlorothiazide-associated pulmonary edema.,"['Anderson TJ', 'Berthiaume Y', 'Matheson D', 'Boiteau P']","['Antihypertensive Agents/therapeutic use', 'Drug Combinations/therapeutic use', 'Female', 'Humans', 'Hydrochlorothiazide/*adverse effects/therapeutic use', 'Hypoxia/chemically induced', 'Middle Aged', 'Pulmonary Edema/*chemically induced', 'Pulmonary Gas Exchange', 'Shock/chemically induced', 'Triamterene/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2766837/
3319,hydrochlorothiazide,357764,Furosemide compared with hydrochlorothiazide. Long-term treatment of hypertension.,"['Araoye MA', 'Chang MY', 'Khatri IM', 'Freis ED']","['Blood Pressure/*drug effects', 'Body Weight/drug effects', 'Clinical Trials as Topic', 'Furosemide/administration & dosage/pharmacology/*therapeutic use', 'Humans', 'Hydrochlorothiazide/administration & dosage/pharmacology/*therapeutic use', 'Hypertension/*drug therapy', 'Systole/drug effects']",https://pubmed.ncbi.nlm.nih.gov/357764/
3320,hydrochlorothiazide,8004839,Double-blind comparison of amlodipine and hydrochlorothiazide in patients with mild to moderate hypertension.,"['Ram CV', 'Ames RP', 'Applegate WB', 'Burris JF', 'Davidov ME', 'Mroczek WJ']","['Adolescent', 'Adult', 'Aged', 'Amlodipine/administration & dosage/adverse effects/*therapeutic use', 'Atenolol/administration & dosage/adverse effects/therapeutic use', 'Blood Pressure/drug effects', 'Cholesterol/blood', 'Cholesterol, HDL/blood', 'Cholesterol, LDL/blood', 'Cholesterol, VLDL/blood', 'Double-Blind Method', 'Drug Combinations', 'Electrocardiography/drug effects', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Pulse/drug effects', 'Safety', 'Single-Blind Method', 'Triglycerides/blood']",https://pubmed.ncbi.nlm.nih.gov/8004839/
3321,hydrochlorothiazide,15013933,Antihypertensive efficacy of olmesartan medoxomil alone and in combination with hydrochlorothiazide.,"['Chrysant SG', 'Chrysant GS']","['Angiotensin II Type 2 Receptor Blockers', 'Antihypertensive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Diuretics', 'Drug Therapy, Combination', 'Humans', 'Hydrochlorothiazide/administration & dosage/*therapeutic use', 'Hypertension/*drug therapy', 'Imidazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Olmesartan Medoxomil', 'Randomized Controlled Trials as Topic', 'Sodium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use', 'Tetrazoles/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15013933/
3322,hydrochlorothiazide,2280237,"Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes.","['Lundgren H', 'Bengtsson C', 'Lapidus L', 'Bengtsson L']","['Aged', 'Blood Glucose/*drug effects', 'Diabetes Mellitus/*chemically induced', 'Double-Blind Method', 'Felodipine/adverse effects/*therapeutic use', 'Female', 'Glucose Tolerance Test', 'Humans', 'Hydrochlorothiazide/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Metoprolol/adverse effects/*therapeutic use', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/2280237/
3323,hydrochlorothiazide,19885788,[When do combinations of diuretics make sense?].,['Fuster D'],"['Chlorthalidone/administration & dosage/therapeutic use', 'Diuretics/*administration & dosage/adverse effects/pharmacokinetics/pharmacology', 'Drug Therapy, Combination', 'Furosemide/administration & dosage/*therapeutic use', 'Glomerular Filtration Rate', 'Humans', 'Hydrochlorothiazide/administration & dosage/therapeutic use', 'Kidney/drug effects', 'Sodium Potassium Chloride Symporter Inhibitors/administration & dosage/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/19885788/
3324,hydrochlorothiazide,38853071,Diuretics use in the management of hypertension.,['Morales-Olivas FJ'],"['Humans', '*Hypertension/drug therapy', '*Diuretics/adverse effects/administration & dosage/therapeutic use/pharmacology', '*Antihypertensive Agents/adverse effects/administration & dosage/pharmacology/therapeutic use', 'Sodium Chloride Symporter Inhibitors/adverse effects/therapeutic use/administration & dosage/pharmacology', 'Hydrochlorothiazide/adverse effects/administration & dosage/therapeutic use', 'Chlorthalidone/administration & dosage/therapeutic use/adverse effects', 'Female', 'Male', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38853071/
3325,hydrochlorothiazide,470775,Severe hyperkalaemia with Moduretic.,"['Whiting GF', 'McLaran CJ', 'Bochner F']","['Aged', 'Amiloride/administration & dosage/*adverse effects', 'Arrhythmias, Cardiac/etiology', 'Drug Combinations', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/*adverse effects', 'Hyperkalemia/*chemically induced/complications', 'Male', 'Middle Aged', 'Pyrazines/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/470775/
3326,hydrochlorothiazide,6702628,Comparative efficacy and safety of lofexidine and clonidine in mild to moderately severe systemic hypertension.,"['Lopez LM', 'Mehta JL']","['Adolescent', 'Adult', 'Aged', 'Antihypertensive Agents/*therapeutic use', 'Clonidine/administration & dosage/*analogs & derivatives/*therapeutic use', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Heart Rate/drug effects', 'Humans', 'Hydrochlorothiazide/therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'Male', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6702628/
3327,hydrochlorothiazide,3908125,Single and divided daily dose piretanide in the treatment of uncomplicated essential hypertension: a double-blind comparison with a combination of hydrochlorothiazide and amiloride.,"['Verho M', 'Rangoonwala B', 'Dols W']","['Adult', 'Aged', 'Amiloride/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Therapy, Combination', 'Female', 'Humans', 'Hydrochlorothiazide/administration & dosage/adverse effects/*therapeutic use', 'Hypertension/*drug therapy', 'Male', 'Middle Aged', 'Posture', 'Potassium/blood', 'Random Allocation', 'Sodium/blood', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3908125/
3328,hydrochlorothiazide,18578561,Irbesartan/Hydrochlorothiazide : in moderate to severe hypertension.,"['Croxtall JD', 'Keating GM']","['Antihypertensive Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Biphenyl Compounds/*administration & dosage/pharmacokinetics/therapeutic use', 'Clinical Trials as Topic', 'Drug Combinations', 'Humans', 'Hydrochlorothiazide/*administration & dosage/adverse effects/pharmacokinetics', 'Hypertension/*drug therapy', 'Irbesartan', 'Severity of Illness Index', 'Tetrazoles/*administration & dosage/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18578561/
3329,zafirlukast,9232368,Antileukotriene agents.,"['Tan RA', 'Spector SL']","['Anti-Asthmatic Agents/*therapeutic use', 'Asthma/*drug therapy', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Indoles', '*Leukotriene Antagonists', 'Leukotrienes/*physiology', 'Lipoxygenase Inhibitors/*therapeutic use', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9232368/
3330,zafirlukast,12879996,Leukotriene antagonists.,"['Davern TJ', 'Bass NM']","['Adult', 'Aged', 'Anti-Asthmatic Agents/*adverse effects/therapeutic use', 'Asthma/drug therapy', 'Chemical and Drug Induced Liver Injury/*etiology', 'Female', 'Humans', 'Indoles', 'Leukotriene Antagonists/*adverse effects/therapeutic use', 'Male', 'Middle Aged', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12879996/
3331,zafirlukast,10023966,Leukotriene-receptor antagonists.,['Lipworth BJ'],"['Acetates/administration & dosage/adverse effects/*therapeutic use', 'Adolescent', 'Adult', 'Anti-Asthmatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Asthma/*drug therapy', 'Child', 'Cyclopropanes', 'Drug Administration Schedule', 'Humans', 'Indoles', 'Leukotriene Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Phenylcarbamates', 'Quinolines/administration & dosage/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Perennial/drug therapy/physiopathology', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/10023966/
3332,zafirlukast,20886028,The employment of leukotriene antagonists in cutaneous diseases belonging to allergological field.,"['Nettis E', ""D'Erasmo M"", 'Di Leo E', 'Calogiuri G', 'Montinaro V', 'Ferrannini A', 'Vacca A']","['Acetates/therapeutic use', 'Animals', 'Cyclopropanes', 'Humans', 'Hypersensitivity/*drug therapy', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Skin Diseases/*drug therapy', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20886028/
3333,zafirlukast,20880074,Silicone and autoimmunity.,"['Hajdu SD', 'Agmon-Levin N', 'Shoenfeld Y']","['Autoimmune Diseases/*chemically induced', 'Breast Implants/*adverse effects', 'Breast Neoplasms/*chemically induced', 'Female', 'Humans', 'Mastectomy/*methods', 'Plastic Surgery Procedures/*adverse effects', 'Risk Factors', 'Silicones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20880074/
3334,zafirlukast,17383148,[Antileukotrienes and Churg-Strauss syndrome].,"['Guilpain P', 'Pagnoux C', 'Lhote F', 'Mouthon L', 'Guillevin L']","['Acetates/adverse effects/therapeutic use', 'Adult', 'Anti-Asthmatic Agents/adverse effects/*therapeutic use', 'Antibodies, Antineutrophil Cytoplasmic', 'Asthma/complications/*drug therapy/etiology', 'Chromones/adverse effects/therapeutic use', 'Churg-Strauss Syndrome/chemically induced/complications/*diagnosis/epidemiology/etiology', 'Cohort Studies', 'Cyclopropanes', 'Humans', 'Incidence', 'Indoles', 'Leukotriene Antagonists/adverse effects/*therapeutic use', 'Leukotrienes/biosynthesis/metabolism', 'Phenylcarbamates', 'Quinolines/adverse effects/therapeutic use', 'Retrospective Studies', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17383148/
3335,zafirlukast,17225706,Leukotriene inhibitors in the treatment of allergy and asthma.,"['Scow DT', 'Luttermoser GK', 'Dickerson KS']","['Acetates/therapeutic use', 'Anti-Asthmatic Agents/therapeutic use', 'Asthma/*drug therapy', 'Asthma, Exercise-Induced/drug therapy', 'Cyclopropanes', 'Dermatitis, Atopic/drug therapy', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Hypersensitivity/*drug therapy', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17225706/
3336,zafirlukast,8885816,Leukotrienes in asthma. The potential therapeutic role of antileukotriene agents.,['Smith LJ'],"['Animals', 'Anti-Asthmatic Agents/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Asthma/*drug therapy/*physiopathology', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Indoles', 'Inflammation', 'Inflammation Mediators/physiology', '*Leukotriene Antagonists', 'Leukotrienes/*physiology', 'Lipoxygenase Inhibitors/therapeutic use', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8885816/
3337,zafirlukast,29878767,Boosting Anti-Inflammatory Potency of Zafirlukast by Designed Polypharmacology.,"['Schierle S', 'Flauaus C', 'Heitel P', 'Willems S', 'Schmidt J', 'Kaiser A', 'Weizel L', 'Goebel T', 'Kahnt AS', 'Geisslinger G', 'Steinhilber D', 'Wurglics M', 'Rovati GE', 'Schmidtko A', 'Proschak E', 'Merk D']","['3T3 Cells', 'Animals', 'Anti-Inflammatory Agents, Non-Steroidal/metabolism/*pharmacology', 'Catalytic Domain', '*Drug Design', 'Epoxide Hydrolases/chemistry/metabolism', 'Hep G2 Cells', 'Humans', 'Indoles', 'Mice', 'Molecular Docking Simulation', 'PPAR gamma/chemistry/metabolism', 'Phenylcarbamates', '*Polypharmacology', 'Sulfonamides', 'Tosyl Compounds/metabolism/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29878767/
3338,zafirlukast,10212622,Newer therapeutic agents for asthma.,"['Deykin A', 'Israel E']","['Adrenergic beta-Agonists/pharmacology/*therapeutic use', 'Albuterol/analogs & derivatives/therapeutic use', 'Androstadienes/therapeutic use', 'Anti-Asthmatic Agents/pharmacology/*therapeutic use', 'Asthma/*drug therapy/physiopathology', 'Bronchodilator Agents/pharmacology/*therapeutic use', 'Cyclosporine/therapeutic use', 'Fluticasone', 'Forced Expiratory Volume/drug effects', 'Humans', 'Immunoglobulins, Intravenous/therapeutic use', 'Immunosuppressive Agents/pharmacology/*therapeutic use', 'Indoles', 'Leukotriene Antagonists/pharmacology/*therapeutic use', 'Lidocaine/therapeutic use', 'Methotrexate/therapeutic use', 'Phenylcarbamates', 'Salmeterol Xinafoate', 'Sulfonamides', 'Tosyl Compounds/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10212622/
3339,zafirlukast,9742908,Anti-inflammatory drugs for controlling asthma.,"['Volcheck GW', ""O'Connell EJ""]","['Adult', 'Anti-Asthmatic Agents/*therapeutic use', 'Anti-Inflammatory Agents/*therapeutic use', 'Asthma/classification/*drug therapy/physiopathology', 'Child', 'Cromolyn Sodium/therapeutic use', 'Glucocorticoids/therapeutic use', 'Humans', 'Indoles', 'Inflammation/etiology', 'Phenylcarbamates', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9742908/
3340,zafirlukast,38852861,Leukotriene receptor antagonists as add-on therapy to antihistamines for urticaria: Systematic review and meta-analysis of randomized clinical trials.,"['Rayner DG', 'Liu M', 'Chu AWL', 'Chu X', 'Guyatt GH', 'Oykhman P', 'Cao DJ', 'Moellman J', 'Ben-Shoshan M', 'Baker DR', 'Waserman S', 'Lang D', 'Sheikh J', 'Mathur SK', 'Beck LA', 'Khan DA', 'Oliver ET', 'Asiniwasis RN', 'Cole EF', 'Wheeler KE', 'Runyon L', 'Chan J', 'Trayes KP', 'Eftekhari S', 'Gardner DD', 'Winders T', 'Saini SS', 'Bernstein JA', 'Chu DK']","['Humans', 'Drug Therapy, Combination', 'Histamine Antagonists/therapeutic use', 'Histamine H1 Antagonists/therapeutic use', '*Leukotriene Antagonists/therapeutic use', 'Quality of Life', 'Randomized Controlled Trials as Topic', '*Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38852861/
3341,zafirlukast,17437683,Leukotriene synthesis inhibitors versus antagonists: the pros and cons.,"['Steinke JW', 'Culp JA']","['Acetates/therapeutic use', 'Animals', 'Anti-Asthmatic Agents/pharmacology/therapeutic use', 'Arachidonate 5-Lipoxygenase/physiology', 'Asthma/*drug therapy/physiopathology', 'Chromones/therapeutic use', 'Cyclopropanes', 'Humans', 'Hypersensitivity/*drug therapy/physiopathology', 'Indoles', 'Inflammation Mediators/antagonists & inhibitors/physiology', 'Leukotriene Antagonists/*pharmacology/therapeutic use', 'Leukotrienes/*biosynthesis/physiology', 'Lipoxygenase Inhibitors/pharmacology/therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Receptors, Leukotriene/*physiology', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17437683/
3342,zafirlukast,38663558,Leukotriene-modifying agents may increase the risk of depression: A cross-sectional study.,"['Yan J', 'Sun H', 'Xin X', 'Huang T', 'Shen J']","['Humans', 'Cross-Sectional Studies', 'Male', 'Female', 'Middle Aged', 'Adult', '*Depression/epidemiology/chemically induced', '*Nutrition Surveys', 'United States/epidemiology', 'Leukotriene Antagonists/pharmacology/adverse effects', 'Prevalence', 'Risk Factors', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38663558/
3343,zafirlukast,26980339,Antileukotrienes in adenotonsillar hypertrophy: a review of the literature.,"['Kar M', 'Altintoprak N', 'Muluk NB', 'Ulusoy S', 'Bafaqeeh SA', 'Cingi C']","['Adenoids/metabolism/*pathology', 'Humans', 'Hypertrophy/drug therapy', 'Inflammation/drug therapy', 'Leukotriene Antagonists/*therapeutic use', 'Palatine Tonsil/metabolism/*pathology', 'Receptors, Leukotriene/metabolism']",https://pubmed.ncbi.nlm.nih.gov/26980339/
3344,zafirlukast,27826703,Leukotriene Receptor Antagonists and Antiallergy Drugs.,"['Tamada T', 'Ichinose M']","['Adrenal Cortex Hormones/administration & dosage', 'Adrenergic beta-2 Receptor Agonists/therapeutic use', 'Animals', 'Anti-Allergic Agents/pharmacology/*therapeutic use', 'Asthma/*drug therapy', 'Cytokines/antagonists & inhibitors', 'Drug Therapy, Combination', 'Humans', 'Leukotriene Antagonists/pharmacology/*therapeutic use', 'Receptors, Leukotriene/physiology', 'Th2 Cells/immunology']",https://pubmed.ncbi.nlm.nih.gov/27826703/
3345,zafirlukast,31544544,Asthma pharmacotherapy: an update on leukotriene treatments.,"['Trinh HKT', 'Lee SH', 'Cao TBT', 'Park HS']","['Acetates/therapeutic use', 'Asthma/*drug therapy', 'Asthma, Aspirin-Induced/drug therapy', 'Chromones/therapeutic use', 'Cyclopropanes', 'Cysteine/*therapeutic use', 'Humans', 'Indoles', 'Leukotriene Antagonists/*therapeutic use', 'Leukotrienes/*therapeutic use', 'Phenylcarbamates', 'Quinolines/therapeutic use', 'Sulfides', 'Sulfonamides', 'Tosyl Compounds/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31544544/
3346,zafirlukast,20525510,Systemic therapies in managing sinonasal inflammation.,"['DeMarcantonio MA', 'Han JK']","['Anti-Inflammatory Agents/therapeutic use', 'Combined Modality Therapy', 'Drug Therapy/*methods', 'Eosinophils', 'Histamine Antagonists/therapeutic use', 'Humans', 'Hydroxyurea/analogs & derivatives/therapeutic use', 'Immunologic Factors/therapeutic use', 'Indoles', 'Leukotriene Antagonists/therapeutic use', 'Otorhinolaryngologic Surgical Procedures/*methods', 'Phenylcarbamates', 'Rhinitis/*complications/*drug therapy/surgery', 'Sinusitis/*complications/*drug therapy/surgery', 'Sulfonamides', 'Tosyl Compounds/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20525510/
3347,medroxyprogesterone,7090370,The menopause.,['Brenner PF'],"['Adult', 'Aging/drug effects', 'Arteriosclerosis/prevention & control', 'Calcium/therapeutic use', 'Climacteric/drug effects', 'Estrogens/adverse effects/therapeutic use', 'Female', 'Humans', 'Medroxyprogesterone/therapeutic use', '*Menopause/drug effects', 'Middle Aged', 'Osteoporosis/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/7090370/
3348,medroxyprogesterone,1827623,The treatment of precocious puberty.,"['Wheeler MD', 'Styne DM']","['Androgen Antagonists/therapeutic use', 'Delayed-Action Preparations', 'Female', 'Gonadotropin-Releasing Hormone/administration & dosage/analogs & derivatives/therapeutic use', 'Humans', 'Ketoconazole/therapeutic use', 'Male', 'Medroxyprogesterone/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Puberty, Precocious/*drug therapy/psychology', 'Testolactone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/1827623/
3349,medroxyprogesterone,22587648,Contraception and antiepileptic drugs.,"['Guillemette T', 'Yount SM']","['Anticonvulsants/*adverse effects/therapeutic use', 'Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Drug Interactions', 'Epilepsy/drug therapy', 'Female', 'Health Knowledge, Attitudes, Practice', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/22587648/
3350,medroxyprogesterone,20352562,Injectable contraception.,['Roy G'],"['Bone Density/drug effects', 'Contraceptive Agents, Female/*administration & dosage/adverse effects/*therapeutic use', 'Contraindications', 'Delayed-Action Preparations/administration & dosage/adverse effects/therapeutic use', 'Female', 'Humans', 'Injections', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/therapeutic use', 'Risk Assessment']",https://pubmed.ncbi.nlm.nih.gov/20352562/
3351,medroxyprogesterone,2934522,Endometriosis.,"['Garner CH', 'Webster BW']","['Abortion, Spontaneous/etiology', 'Adult', 'Danazol/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Diethylstilbestrol/adverse effects/therapeutic use', 'Dinoprost', '*Endometriosis/complications/diagnosis/etiology/nursing/pathology/physiopathology/psychology/surgery/therapy', 'Endometrium/pathology', 'Female', 'Humans', 'Infertility, Female/etiology', 'Male', 'Medroxyprogesterone/adverse effects/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Methyltestosterone/adverse effects/therapeutic use', 'Pain/drug therapy', 'Patient Education as Topic', 'Peritoneum/pathology', 'Phagocytosis', 'Pregnancy', 'Prostaglandins F/physiology', 'Spermatozoa']",https://pubmed.ncbi.nlm.nih.gov/2934522/
3352,medroxyprogesterone,3158512,"Epilepsy, sex hormones, and antiepileptic drugs.","['Mattson RH', 'Cramer JA']","['Anovulation/physiopathology', 'Anticonvulsants/adverse effects/metabolism/*pharmacology', 'Contraceptives, Oral/pharmacology', 'Drug Interactions', 'Epilepsy/drug therapy/metabolism/*physiopathology', 'Erectile Dysfunction/chemically induced/physiopathology', 'Feedback', 'Female', 'Gonadal Steroid Hormones/metabolism/*physiology', 'Humans', 'Hypothalamo-Hypophyseal System/physiopathology', 'Kinetics', 'Libido/drug effects/physiology', 'Limbic System/physiopathology', 'Male', 'Medroxyprogesterone/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Menstruation', 'Pregnancy', 'Progesterone/blood']",https://pubmed.ncbi.nlm.nih.gov/3158512/
3353,medroxyprogesterone,12380408,Hormones and weight change.,['Pelkman C'],"['Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Delayed-Action Preparations/adverse effects', 'Double-Blind Method', 'Energy Intake/drug effects', 'Energy Metabolism/drug effects', 'Female', 'Humans', 'Injections, Intramuscular', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Randomized Controlled Trials as Topic', 'United States', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/12380408/
3354,medroxyprogesterone,20601618,Menstrual manipulation: options for suppressing the cycle.,"['Hicks CW', 'Rome ES']","['Administration, Intravaginal', 'Contraceptive Agents, Female/administration & dosage/adverse effects/therapeutic use', 'Contraceptive Devices, Female', 'Contraceptives, Oral, Hormonal/administration & dosage/adverse effects/*therapeutic use', 'Desogestrel/administration & dosage/adverse effects/therapeutic use', 'Female', 'Humans', 'Intrauterine Devices', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/therapeutic use', 'Menstruation/*drug effects', 'Menstruation Disturbances/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20601618/
3355,medroxyprogesterone,10986575,"Protocols for the use of cyproterone, medroxyprogesterone, and leuprolide in the treatment of paraphilia.","['Reilly DR', 'Delva NJ', 'Hudson RW']","['Administration, Oral', 'Androgen Antagonists/*administration & dosage/adverse effects', 'Cyproterone Acetate/*administration & dosage/adverse effects', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Injections, Intramuscular', 'Leuprolide/*administration & dosage/adverse effects', 'Male', 'Medroxyprogesterone/*administration & dosage/adverse effects', 'Paraphilic Disorders/diagnosis/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/10986575/
3356,medroxyprogesterone,5508511,"Medroxyprogesterone acetate and carbohydrate metabolism: measurement of glucose, insulin, and growth hormone during 6 months' time.","['Spellacy WN', 'McLeod AG', 'Buhi WC', 'Birk SA', 'McCreary SA']","['Adolescent', 'Adult', 'Age Factors', 'Blood Glucose/*analysis', 'Body Weight', '*Carbohydrate Metabolism', 'Contraceptive Agents/administration & dosage/*pharmacology', 'Female', 'Glucose Tolerance Test', 'Growth Hormone/*blood', 'Humans', 'Injections, Intramuscular', 'Insulin/*blood', 'Medroxyprogesterone/administration & dosage/*pharmacology', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/5508511/
3357,medroxyprogesterone,6451987,Depo-Provera: a critical analysis.,['Minkin S'],"['Abnormalities, Drug-Induced/etiology', 'Animals', 'Breast Feeding', 'Contraceptive Agents, Female/*adverse effects', 'Dogs', 'Female', 'Haplorhini', 'Humans', 'Medroxyprogesterone/adverse effects/*analogs & derivatives', 'Medroxyprogesterone Acetate', 'Milk, Human/*drug effects', 'Neoplasms/*chemically induced', 'Pregnancy', 'United States', 'United States Food and Drug Administration', 'Uterine Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6451987/
3358,medroxyprogesterone,11723414,Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy.,"['Figueroa-Casas PR', 'Ettinger B', 'Delgado E', 'Javkin A', 'Vieder C']","['Clinical Trials as Topic', 'Drug Administration Schedule', 'Endometrial Hyperplasia/*chemically induced/*drug therapy', 'Estrogen Replacement Therapy/*adverse effects', 'Female', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*therapeutic use', 'Progesterone Congeners/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11723414/
3359,medroxyprogesterone,29172413,Contraception Update: Progestin-Only Implants and Injections.,"['Deshmukh P', 'Antell K', 'Brown EJ']","['Contraceptive Agents, Female/administration & dosage/adverse effects/*therapeutic use', 'Device Removal', '*Drug Implants', 'Drug Interactions', '*Family Planning Services', '*Family Practice', 'Female', 'Humans', 'Injections', 'Medroxyprogesterone Acetate/administration & dosage/adverse effects/*therapeutic use', '*Progestins', 'Weight Gain']",https://pubmed.ncbi.nlm.nih.gov/29172413/
3360,medroxyprogesterone,2148027,Current status of high-dose progestins in breast cancer.,"['Abrams JS', 'Parnes H', 'Aisner J']","['Antineoplastic Agents/administration & dosage/therapeutic use', 'Breast Neoplasms/*drug therapy', 'Female', 'Humans', 'Medroxyprogesterone/administration & dosage/analogs & derivatives/therapeutic use', 'Medroxyprogesterone Acetate', 'Megestrol/administration & dosage/adverse effects/analogs & derivatives/therapeutic use', 'Megestrol Acetate', 'Progesterone Congeners/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2148027/
3361,medroxyprogesterone,9609206,Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.,['Kaunitz AM'],"['Adolescent', 'Adult', 'Bone Density/drug effects', 'Carbamazepine/pharmacology', 'Clinical Trials as Topic', 'Contraception/*methods', 'Contraceptive Agents, Female/*administration & dosage/adverse effects', 'Contraindications', 'Delayed-Action Preparations', 'Drug Interactions', 'Female', 'Fertility/drug effects', 'Humans', 'Injections, Intramuscular', 'Lactation/drug effects', 'Libido/drug effects', 'Medroxyprogesterone Acetate/*administration & dosage/adverse effects', 'Menstruation Disturbances/chemically induced', 'Premenopause', 'Risk Factors', 'Smoking/adverse effects', 'Thromboembolism/chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9609206/
3362,medroxyprogesterone,31436540,Postpartum hormonal contraception in breastfeeding women.,"['Stanton TA', 'Blumenthal PD']","['*Breast Feeding', 'Contraception/*methods', 'Contraceptive Agents/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Female', 'Gynecology/standards/trends', '*Health Knowledge, Attitudes, Practice', 'Hormonal Contraception', 'Humans', 'Infant', 'Infant, Newborn', 'Intrauterine Devices/adverse effects', 'Lactation/drug effects', 'Levonorgestrel/administration & dosage', 'Medroxyprogesterone Acetate/adverse effects/therapeutic use', 'Milk, Human/drug effects', 'Postpartum Period', 'Practice Guidelines as Topic', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/31436540/
3363,medroxyprogesterone,2525977,Injectable contraception.,['Kaunitz AM'],"['Contraceptive Agents, Female/*administration & dosage', 'Delayed-Action Preparations', 'Female', 'Humans', 'Injections, Intramuscular', 'Medroxyprogesterone/administration & dosage/analogs & derivatives', 'Medroxyprogesterone Acetate', 'Norethindrone/administration & dosage/analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/2525977/
3364,medroxyprogesterone,2946605,Assessment of the potency of orally administered progestins in women.,"['King RJ', 'Whitehead MI']","['Administration, Oral', 'Adult', 'Age Factors', 'DNA/biosynthesis', 'Dose-Response Relationship, Drug', 'Drug Evaluation', 'Dydrogesterone/pharmacology', 'Endometrium/*drug effects/enzymology/metabolism', 'Estradiol Dehydrogenases/analysis', 'Female', 'Glycogen/metabolism', 'Humans', 'Isocitrate Dehydrogenase/analysis', 'Medroxyprogesterone/analogs & derivatives/pharmacology', 'Medroxyprogesterone Acetate', 'Menopause', 'Menstrual Cycle/drug effects', 'Middle Aged', 'Norethindrone/pharmacology', 'Norgestrel/pharmacology', 'Progesterone/pharmacology', 'Progesterone Congeners/administration & dosage/*pharmacology', 'Reference Values']",https://pubmed.ncbi.nlm.nih.gov/2946605/
3365,medroxyprogesterone,31935387,An exploratory study of depot-medroxyprogesterone acetate and bone mineral density in adolescent and young adult women with cerebral palsy.,"['Roden RC', 'Noritz G', 'McKnight ER', 'Bonny AE']","['Adolescent', 'Bone Density/*drug effects', 'Case-Control Studies', 'Cerebral Palsy/*complications', 'Child, Preschool', 'Cohort Studies', 'Contraceptive Agents, Female/administration & dosage/*adverse effects', 'Cross-Sectional Studies', 'Female', 'Humans', 'Medroxyprogesterone Acetate/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31935387/
3366,medroxyprogesterone,2896429,Treatment of sex offenders with imaginal desensitization and/or medroxyprogesterone.,"['McConaghy N', 'Blaszczynski A', 'Kidson W']","['Adolescent', 'Adult', '*Behavior Therapy', 'Combined Modality Therapy', '*Desensitization, Psychologic', 'Humans', 'Imagination', 'Male', 'Medroxyprogesterone/adverse effects/*therapeutic use', 'Middle Aged', 'Paraphilic Disorders/drug therapy/*therapy', 'Recurrence', '*Sex Offenses', 'Testosterone/blood']",https://pubmed.ncbi.nlm.nih.gov/2896429/
3367,duloxetine,36791450,Fibromyalgia: Diagnosis and Management.,"['Winslow BT', 'Vandal C', 'Dang L']","['Humans', 'Female', '*Fibromyalgia/diagnosis/therapy', '*Chronic Pain/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36791450/
3368,duloxetine,37670573,Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy.,"['Jang HN', 'Oh TJ']","['United States', 'Humans', '*Diabetic Neuropathies/complications/drug therapy', 'Capsaicin/therapeutic use', 'Quality of Life', 'Duloxetine Hydrochloride/therapeutic use', '*Neuralgia/drug therapy/etiology', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/37670573/
3369,duloxetine,21366359,Duloxetine: clinical pharmacokinetics and drug interactions.,"['Knadler MP', 'Lobo E', 'Chappell J', 'Bergstrom R']","['Adrenergic Uptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Adult', 'Aged', 'Animals', 'Drug Interactions', 'Duloxetine Hydrochloride', 'Female', 'Humans', 'Male', 'Middle Aged', 'Pharmacogenetics', 'Risk Assessment', 'Risk Factors', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/*pharmacokinetics', 'Thiophenes/administration & dosage/adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21366359/
3370,duloxetine,25952601,Burning mouth syndrome: a review and update.,"['Silvestre FJ', 'Silvestre-Rangil J', 'Lopez-Jornet P']","['Adult', 'Age Distribution', 'Aged', 'Algorithms', 'Amisulpride', 'Antidepressive Agents/therapeutic use', '*Burning Mouth Syndrome/diagnosis/epidemiology/physiopathology/psychology/therapy', 'Clonazepam/therapeutic use', 'Deficiency Diseases/complications', 'Dentures/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Male', 'Menopause', 'Middle Aged', 'Mood Disorders/epidemiology', 'Nerve Fibers, Unmyelinated/physiology', 'Orthodontic Appliances', 'Sex Distribution', 'Sulpiride/analogs & derivatives/therapeutic use', 'Tongue Habits']",https://pubmed.ncbi.nlm.nih.gov/25952601/
3371,duloxetine,37183813,Pharmacological Treatment of Generalised Anxiety Disorder: Current Practice and Future Directions.,"['Fagan HA', 'Baldwin DS']","['Humans', '*Anti-Anxiety Agents/therapeutic use', 'Anxiety Disorders/drug therapy/psychology', 'Duloxetine Hydrochloride/therapeutic use', 'Pregabalin/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37183813/
3372,duloxetine,37085164,Combination therapy for painful diabetic neuropathy is safe and effective.,"['Saul H', 'Deeney B', 'Imison C', 'Tesfaye S']","['Humans', '*Diabetic Neuropathies/drug therapy', 'Pregabalin/therapeutic use', 'Analgesics/therapeutic use', 'Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Treatment Outcome', 'Double-Blind Method', '*Diabetes Mellitus']",https://pubmed.ncbi.nlm.nih.gov/37085164/
3373,duloxetine,30016772,Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review.,"['Fava GA', 'Benasi G', 'Lucente M', 'Offidani E', 'Cosci F', 'Guidi J']","['Adrenergic Uptake Inhibitors/*adverse effects/therapeutic use', 'Desvenlafaxine Succinate/adverse effects/therapeutic use', 'Duloxetine Hydrochloride/adverse effects/therapeutic use', 'Humans', 'Mood Disorders/drug therapy', '*Randomized Controlled Trials as Topic', 'Substance Withdrawal Syndrome/*diagnosis', 'Venlafaxine Hydrochloride/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30016772/
3374,duloxetine,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
3375,duloxetine,30838456,Serotonin and Norepinephrine Reuptake Inhibitors.,['Shelton RC'],"['Antidepressive Agents/chemistry/*pharmacology', 'Desvenlafaxine Succinate/*chemistry', 'Duloxetine Hydrochloride/chemistry/*pharmacology', 'Humans', '*Serotonin/pharmacology', '*Serotonin and Noradrenaline Reuptake Inhibitors/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/30838456/
3376,duloxetine,37461044,Duloxetine for fibromyalgia syndrome: a systematic review and meta-analysis.,"['Migliorini F', 'Maffulli N', 'Eschweiler J', 'Baroncini A', 'Bell A', 'Colarossi G']","['Humans', 'Female', 'Adult', 'Middle Aged', 'Male', 'Duloxetine Hydrochloride/therapeutic use', '*Fibromyalgia/drug therapy/chemically induced', 'Thiophenes/adverse effects', 'Treatment Outcome', 'Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37461044/
3377,duloxetine,28293734,[Chemotherapy-induced peripheral neuropathy and neuropathic pain].,"['Schuler U', 'Heller S']","['Antineoplastic Agents/*adverse effects', 'Cryotherapy', 'Duloxetine Hydrochloride/therapeutic use', 'Humans', 'Neuralgia/*chemically induced/prevention & control/therapy', 'Peripheral Nervous System Diseases/*chemically induced/prevention & control/therapy', 'Physical Therapy Modalities', 'Randomized Controlled Trials as Topic', 'Venlafaxine Hydrochloride/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28293734/
3378,duloxetine,35522835,Duloxetine-Associated Photodistributed Erythema Multiforme.,"['Gay P', 'Niezen S', 'Saenz-Davila B', 'Arellano-Mendoza I', 'Mercadillo P', 'Tirado-Sanchez A']","['Duloxetine Hydrochloride/adverse effects', '*Erythema Multiforme/chemically induced/diagnosis', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/35522835/
3379,duloxetine,34497420,Bioaccumulation of therapeutic drugs by human gut bacteria.,"['Klunemann M', 'Andrejev S', 'Blasche S', 'Mateus A', 'Phapale P', 'Devendran S', 'Vappiani J', 'Simon B', 'Scott TA', 'Kafkia E', 'Konstantinidis D', 'Zirngibl K', 'Mastrorilli E', 'Banzhaf M', 'Mackmull MT', 'Hovelmann F', 'Nesme L', 'Brochado AR', 'Maier L', 'Bock T', 'Periwal V', 'Kumar M', 'Kim Y', 'Tramontano M', 'Schultz C', 'Beck M', 'Hennig J', 'Zimmermann M', 'Sevin DC', 'Cabreiro F', 'Savitski MM', 'Bork P', 'Typas A', 'Patil KR']","['Animals', 'Antidepressive Agents/metabolism/pharmacokinetics', 'Bacteria/*metabolism', '*Bioaccumulation', 'Caenorhabditis elegans/metabolism', 'Cells/metabolism', 'Click Chemistry', 'Duloxetine Hydrochloride/adverse effects/*metabolism/pharmacokinetics', 'Gastrointestinal Microbiome/*physiology', 'Humans', 'Metabolomics', 'Models, Animal', 'Proteomics', 'Reproducibility of Results']",https://pubmed.ncbi.nlm.nih.gov/34497420/
3380,duloxetine,35587348,Comparison of Amitriptyline and US Food and Drug Administration-Approved Treatments for Fibromyalgia: A Systematic Review and Network Meta-analysis.,"['Farag HM', 'Yunusa I', 'Goswami H', 'Sultan I', 'Doucette JA', 'Eguale T']","['Amitriptyline/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', 'Fatigue/drug therapy', 'Female', '*Fibromyalgia/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Milnacipran/therapeutic use', 'Network Meta-Analysis', 'Pain/drug therapy', 'Pregabalin/therapeutic use', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/35587348/
3381,duloxetine,36890758,[Medical Treatment of Chronic Pain].,['Nodera H'],"['Humans', 'Analgesics/therapeutic use/adverse effects', '*Chronic Pain/drug therapy/chemically induced', 'Pregabalin/therapeutic use', 'Gabapentin/therapeutic use', 'Duloxetine Hydrochloride/therapeutic use', '*Diabetic Neuropathies/chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36890758/
3382,duloxetine,29279555,Pharmacotherapy for Neuropathic Pain in Japan.,"['Masuda R', 'Ajimi J', 'Murata T']","['Aged', 'Algorithms', 'Amines/*administration & dosage/adverse effects', 'Analgesics, Opioid/*administration & dosage/adverse effects', 'Anticonvulsants/*administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/adverse effects', 'Cyclohexanecarboxylic Acids/*administration & dosage/adverse effects', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/adverse effects', 'Female', 'Gabapentin', 'Humans', 'Japan', 'Neuralgia/classification/*drug therapy', 'Pain Management', 'Pregabalin/*administration & dosage/adverse effects', 'gamma-Aminobutyric Acid/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/29279555/
3383,duloxetine,38574212,Diabetic Peripheral Neuropathy: Prevention and Treatment.,"['Bragg S', 'Marrison ST', 'Haley S']","['Humans', '*Diabetic Neuropathies/diagnosis/prevention & control', 'Duloxetine Hydrochloride/therapeutic use', 'Capsaicin/therapeutic use', 'Gabapentin/therapeutic use', 'Pregabalin/therapeutic use', 'Pain/drug therapy', '*Diabetes Mellitus/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38574212/
3384,duloxetine,31290965,"Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1).","['Fedgchin M', 'Trivedi M', 'Daly EJ', 'Melkote R', 'Lane R', 'Lim P', 'Vitagliano D', 'Blier P', 'Fava M', 'Liebowitz M', 'Ravindran A', 'Gaillard R', 'Ameele HVD', 'Preskorn S', 'Manji H', 'Hough D', 'Drevets WC', 'Singh JB']","['Administration, Intranasal', 'Administration, Oral', 'Adolescent', 'Adult', 'Antidepressive Agents/administration & dosage/*adverse effects/*therapeutic use', 'Citalopram/therapeutic use', 'Delayed-Action Preparations/therapeutic use', 'Depressive Disorder, Treatment-Resistant/*drug therapy', 'Double-Blind Method', 'Drug Therapy, Combination/adverse effects', 'Duloxetine Hydrochloride/therapeutic use', 'Female', 'Humans', 'Ketamine/administration & dosage/*adverse effects/*therapeutic use', 'Male', 'Middle Aged', 'Sertraline/therapeutic use', 'Treatment Outcome', 'Venlafaxine Hydrochloride/therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/31290965/
3385,duloxetine,30877484,Comparing duloxetine and pregabalin for treatment of pain and depression in women with fibromyalgia: an open-label randomized clinical trial.,"['Bidari A', 'Moazen-Zadeh E', 'Ghavidel-Parsa B', 'Rahmani S', 'Hosseini S', 'Hassankhani A']","['Adult', 'Chronic Pain/*drug therapy', 'Depression/*drug therapy', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/*administration & dosage/therapeutic use', 'Female', 'Fibromyalgia/complications/*drug therapy', 'Humans', 'Medication Adherence', 'Middle Aged', 'Pregabalin/*administration & dosage/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30877484/
3386,duloxetine,27289172,Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.,"['Cipriani A', 'Zhou X', 'Del Giovane C', 'Hetrick SE', 'Qin B', 'Whittington C', 'Coghill D', 'Zhang Y', 'Hazell P', 'Leucht S', 'Cuijpers P', 'Pu J', 'Cohen D', 'Ravindran AV', 'Liu Y', 'Michael KD', 'Yang L', 'Liu L', 'Xie P']","['Adolescent', 'Amitriptyline/administration & dosage/adverse effects', 'Antidepressive Agents/*administration & dosage/*adverse effects', 'Bayes Theorem', 'Child', 'Citalopram/administration & dosage/adverse effects', 'Clomipramine/administration & dosage/adverse effects', 'Confounding Factors, Epidemiologic', 'Depressive Disorder, Major/*drug therapy', 'Desipramine/administration & dosage/adverse effects', 'Double-Blind Method', 'Drug Administration Schedule', 'Duloxetine Hydrochloride/administration & dosage/adverse effects', 'Evidence-Based Medicine', 'Fluoxetine/administration & dosage/adverse effects', 'Humans', 'Imipramine/administration & dosage/adverse effects', 'Mianserin/administration & dosage/adverse effects/analogs & derivatives', 'Mirtazapine', 'Nortriptyline/administration & dosage/adverse effects', 'Paroxetine/administration & dosage/adverse effects', 'Piperazines', 'Randomized Controlled Trials as Topic', 'Research Design', 'Sertraline/administration & dosage/adverse effects', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects', 'Venlafaxine Hydrochloride/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27289172/
3387,Pioglitazone,32942898,[Pioglitazone].,['Karasek D'],"['*Cardiovascular Diseases/drug therapy', '*Diabetes Mellitus, Type 2/drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects', 'Pioglitazone', '*Thiazolidinediones/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32942898/
3388,Pioglitazone,31776781,Thiazolidinediones: the Forgotten Diabetes Medications.,['Lebovitz HE'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/therapeutic use', 'Rosiglitazone/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31776781/
3389,Pioglitazone,32296231,Oncocrinology.,"['Kalra S', 'Priya G', 'Bhattacharya S', 'Sahay R']","['Antineoplastic Agents/adverse effects', 'Antineoplastic Agents, Hormonal/adverse effects/therapeutic use', 'Biomarkers, Tumor/metabolism', 'Breast Neoplasms/etiology', 'Endocrine Gland Neoplasms/complications/etiology/metabolism/therapy', 'Endocrine System Diseases/complications/etiology/metabolism/therapy', '*Endocrinology', 'Estrogen Replacement Therapy/adverse effects', 'Humans', 'Hypoglycemic Agents/adverse effects', '*Medical Oncology', 'Neoplasms/complications/etiology/metabolism/therapy', 'Obesity/complications/metabolism', 'Paraneoplastic Syndromes/etiology/metabolism', 'Pioglitazone/adverse effects', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/32296231/
3390,Pioglitazone,30706731,"Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes.","['DeFronzo RA', 'Inzucchi S', 'Abdul-Ghani M', 'Nissen SE']","['Animals', 'Biomarkers/blood', 'Blood Glucose/*drug effects/metabolism', 'Cardiovascular Diseases/economics/epidemiology/*prevention & control', 'Cost-Benefit Analysis', 'Diabetes Mellitus, Type 2/blood/*drug therapy/economics/epidemiology', 'Drug Costs', 'Glycated Hemoglobin/metabolism', 'Humans', 'Hypoglycemic Agents/adverse effects/economics/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/economics/*therapeutic use', 'Risk Assessment', 'Risk Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30706731/
3391,Pioglitazone,30411635,Present and emerging pharmacotherapies for non-alcoholic steatohepatitis in adults.,"['Ogawa Y', 'Yoneda M', 'Kobayashi T', 'Honda Y', 'Kessoku T', 'Imajo K', 'Saito S', 'Nakajima A']","['Adult', 'Diet', 'Disease Progression', 'Drug Development/*methods', 'Humans', 'Life Style', 'Non-alcoholic Fatty Liver Disease/*drug therapy', 'Pioglitazone/therapeutic use', 'Vitamin E/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30411635/
3392,Pioglitazone,38117497,Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Retinopathy in Patients With Type 2 Diabetes.,"['Yen FS', 'Wei JC', 'Yu TS', 'Hung YT', 'Hsu CC', 'Hwu CM']","['Adult', 'Humans', 'Male', 'Middle Aged', 'Cohort Studies', '*Diabetes Mellitus, Type 2/complications/drug therapy', '*Diabetic Retinopathy/chemically induced/epidemiology', 'Pioglitazone/adverse effects', '*Retinal Diseases', 'Sulfonylurea Compounds/adverse effects', '*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Aged', 'Female']",https://pubmed.ncbi.nlm.nih.gov/38117497/
3393,Pioglitazone,17728845,Pioglitazone and metformin.,"['Hill NR', 'Matthews DR']","['Animals', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Combinations', 'Humans', '*Hypoglycemic Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', '*Metformin/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Pioglitazone', 'Therapeutic Equivalency', '*Thiazolidinediones/administration & dosage/adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17728845/
3394,Pioglitazone,31255176,Dietary fructose-induced gut dysbiosis promotes mouse hippocampal neuroinflammation: a benefit of short-chain fatty acids.,"['Li JM', 'Yu R', 'Zhang LP', 'Wen SY', 'Wang SJ', 'Zhang XY', 'Xu Q', 'Kong LD']","['Animals', 'Doublecortin Protein', 'Dysbiosis/*chemically induced', 'Fatty Acids, Volatile/*administration & dosage', 'Fructose/*adverse effects', 'Gastrointestinal Microbiome', 'Hippocampus/*drug effects/pathology', 'Inflammasomes', 'Inflammation/*chemically induced', 'Intestinal Mucosa/drug effects/microbiology', 'Male', 'Mice', 'Mice, Inbred C57BL', 'Neuroimmunomodulation/drug effects', 'Pioglitazone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/31255176/
3395,Pioglitazone,31149341,A structured literature review of interventions used in the management of nonalcoholic steatohepatitis (NASH).,"['Povsic M', 'Oliver L', 'Jiandani NR', 'Perry R', 'Bottomley J']","['Clinical Trials, Phase II as Topic', 'Clinical Trials, Phase III as Topic', 'Guidelines as Topic', 'Humans', 'Life Style', 'Non-alcoholic Fatty Liver Disease/*drug therapy/prevention & control', 'Pioglitazone/*therapeutic use', 'Vitamin E/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31149341/
3396,Pioglitazone,37869901,"Diabetes, antidiabetic medications and risk of dementia: A systematic umbrella review and meta-analysis.","['Kuate Defo A', 'Bakula V', 'Pisaturo A', 'Labos C', 'Wing SS', 'Daskalopoulou SS']","['Humans', '*Dementia/epidemiology/prevention & control', '*Diabetes Mellitus, Type 2/complications/drug therapy/epidemiology', '*Dipeptidyl-Peptidase IV Inhibitors/adverse effects', 'Dipeptidyl-Peptidases and Tripeptidyl-Peptidases/therapeutic use', 'Glycoside Hydrolase Inhibitors', 'Hypoglycemic Agents/adverse effects', 'Insulin/therapeutic use', '*Metformin/adverse effects', 'Pioglitazone/therapeutic use', '*Sodium-Glucose Transporter 2 Inhibitors/therapeutic use', 'Sulfonylurea Compounds/adverse effects', 'Systematic Reviews as Topic', '*Thiazolidinediones/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37869901/
3397,Pioglitazone,32237916,Current and new pharmacotherapy options for non-alcoholic steatohepatitis.,"['Sumida Y', 'Yoneda M', 'Ogawa Y', 'Yoneda M', 'Okanoue T', 'Nakajima A']","['Chenodeoxycholic Acid/administration & dosage/*analogs & derivatives/therapeutic use', 'Clinical Trials as Topic', 'Fibroblast Growth Factors/agonists', 'Glucagon-Like Peptides/administration & dosage/*therapeutic use', 'Humans', 'Liver Cirrhosis/*drug therapy/metabolism/pathology', 'Non-alcoholic Fatty Liver Disease/*drug therapy/metabolism/pathology', 'Peroxisome Proliferator-Activated Receptors/agonists', 'Pioglitazone/administration & dosage/*therapeutic use', 'Receptors, Cytoplasmic and Nuclear/agonists', 'Treatment Outcome', 'Vitamin E/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32237916/
3398,Pioglitazone,34020670,Exosomes derived from pioglitazone-pretreated MSCs accelerate diabetic wound healing through enhancing angiogenesis.,"['Hu Y', 'Tao R', 'Chen L', 'Xiong Y', 'Xue H', 'Hu L', 'Yan C', 'Xie X', 'Lin Z', 'Panayi AC', 'Mi B', 'Liu G']","['Angiogenesis Inducing Agents/pharmacology', 'Animals', 'Cell Movement/drug effects', 'Cell Proliferation/drug effects', 'Cell Survival/drug effects', 'Collagen/metabolism', 'Diabetes Mellitus/*metabolism', 'Diabetes Mellitus, Experimental', 'Exosomes/*metabolism', 'Human Umbilical Vein Endothelial Cells/drug effects', 'Humans', 'Male', 'Mesenchymal Stem Cells/*metabolism', 'Phosphatidylinositol 3-Kinases/metabolism', 'Pioglitazone/*metabolism/*pharmacology', 'Rats', 'Rats, Sprague-Dawley', 'Skin/drug effects', 'Wound Healing/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/34020670/
3399,Pioglitazone,37923895,A gut microbial metabolite of linoleic acid ameliorates liver fibrosis by inhibiting TGF-beta signaling in hepatic stellate cells.,"['Kasahara N', 'Imi Y', 'Amano R', 'Shinohara M', 'Okada K', 'Hosokawa Y', 'Imamori M', 'Tomimoto C', 'Kunisawa J', 'Kishino S', 'Ogawa J', 'Ogawa W', 'Hosooka T']","['Mice', 'Humans', 'Animals', '*Non-alcoholic Fatty Liver Disease/pathology', 'Pioglitazone/pharmacology', 'Linoleic Acid/metabolism', 'Hepatic Stellate Cells/metabolism', '*Gastrointestinal Microbiome', 'Mice, Inbred C57BL', 'Liver/metabolism', 'Liver Cirrhosis/pathology', 'Fibrosis', 'Diet, High-Fat/adverse effects', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37923895/
3400,Pioglitazone,26690770,Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.,"['Stojanovic M', 'Prostran M', 'Radenkovic M']","['Animals', 'Endothelium, Vascular/drug effects', 'Humans', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology/*therapeutic use', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26690770/
3401,Pioglitazone,37393546,[Rediscovery of pioglitazone].,"['Pokoly B', 'Somogyi A']","['Humans', 'Pioglitazone/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/complications', 'Hypoglycemic Agents/therapeutic use', 'Prospective Studies', '*Thiazolidinediones/therapeutic use', '*Cardiovascular Diseases/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/37393546/
3402,Pioglitazone,29695452,PPARgamma agonist pioglitazone reverses pulmonary hypertension and prevents right heart failure via fatty acid oxidation.,"['Legchenko E', 'Chouvarine P', 'Borchert P', 'Fernandez-Gonzalez A', 'Snay E', 'Meier M', 'Maegel L', 'Mitsialis SA', 'Rog-Zielinska EA', 'Kourembanas S', 'Jonigk D', 'Hansmann G']","['Fatty Acids/*metabolism', 'Female', 'Heart Failure/*drug therapy/*metabolism', 'Hemodynamics/drug effects', 'Humans', 'Hypertension, Pulmonary/*drug therapy/*metabolism', 'Male', 'Oxidation-Reduction/drug effects', 'PPAR gamma/agonists/*metabolism', 'Pioglitazone/*therapeutic use', 'Ventricular Dysfunction, Right/*drug therapy/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/29695452/
3403,Pioglitazone,36401449,Pioglitazone on nonalcoholic steatohepatitis: A systematic review and meta-analysis of 15 RCTs.,"['Zhao Y', 'Zhao W', 'Wang H', 'Zhao Y', 'Bu H', 'Takahashi H']","['Humans', 'United States', '*Non-alcoholic Fatty Liver Disease/drug therapy', 'Pioglitazone/therapeutic use', '*Insulin Resistance', 'Insulin', 'Glycated Hemoglobin']",https://pubmed.ncbi.nlm.nih.gov/36401449/
3404,Pioglitazone,30472322,Diabetes Care for Patients Experiencing Homelessness: Beyond Metformin and Sulfonylureas.,"['Brooks LK', 'Kalyanaraman N', 'Malek R']","['Diabetes Mellitus, Type 2/*drug therapy', 'Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use', 'Glucagon-Like Peptide 1/agonists', '*Ill-Housed Persons', 'Humans', 'Hypoglycemic Agents/pharmacology/*therapeutic use', 'PPAR gamma/agonists', 'Pioglitazone/pharmacology/therapeutic use', 'Sodium-Glucose Transporter 2 Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30472322/
3405,Pioglitazone,37974258,Comparative effectiveness of multiple different treatment regimens for nonalcoholic fatty liver disease with type 2 diabetes mellitus: a systematic review and Bayesian network meta-analysis of randomised controlled trials.,"['Deng M', 'Wen Y', 'Yan J', 'Fan Y', 'Wang Z', 'Zhang R', 'Ren L', 'Ba Y', 'Wang H', 'Lu Q', 'Fan H']","['Humans', '*Diabetes Mellitus, Type 2/drug therapy', 'Exenatide/therapeutic use', 'Hypoglycemic Agents/pharmacology', 'Liraglutide/therapeutic use', '*Non-alcoholic Fatty Liver Disease/drug therapy', 'Network Meta-Analysis', 'Pioglitazone/therapeutic use', '*Insulin Resistance', 'Bayes Theorem']",https://pubmed.ncbi.nlm.nih.gov/37974258/
3406,Pioglitazone,38425186,"A multicentre, double-blind, placebo-controlled, randomized, parallel comparison, phase 3 trial to evaluate the efficacy and safety of pioglitazone add-on therapy in type 2 diabetic patients treated with metformin and dapagliflozin.","['Lim S', 'Lee SH', 'Min KW', 'Lee CB', 'Kim SY', 'Yoo HJ', 'Kim NH', 'Kim JH', 'Oh S', 'Won JC', 'Kwon HS', 'Kim MK', 'Park JH', 'Jeong IK', 'Kim S']","['Humans', '*Glucosides/therapeutic use/adverse effects/administration & dosage', '*Pioglitazone/therapeutic use', '*Diabetes Mellitus, Type 2/drug therapy/blood', '*Metformin/therapeutic use/adverse effects', '*Benzhydryl Compounds/therapeutic use/adverse effects', 'Double-Blind Method', 'Male', 'Female', 'Middle Aged', '*Hypoglycemic Agents/therapeutic use/adverse effects', '*Glycated Hemoglobin/analysis/drug effects/metabolism', '*Drug Therapy, Combination', 'Treatment Outcome', 'Thiazolidinediones/therapeutic use/adverse effects', 'Aged', 'Insulin Resistance', 'Sodium-Glucose Transporter 2 Inhibitors/therapeutic use/adverse effects', 'Blood Glucose/drug effects/metabolism', 'Waist Circumference/drug effects', 'Republic of Korea', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/38425186/
3407,cefdinir,31524361,Otitis Media: Rapid Evidence Review.,"['Gaddey HL', 'Wright MT', 'Nelson TN']","['Acute Disease/therapy', 'Adult', 'Amoxicillin/administration & dosage', 'Anti-Bacterial Agents/administration & dosage', 'Child', 'Child, Preschool', 'Evidence-Based Medicine', 'Family Practice/standards', 'Female', 'Humans', 'Infant', 'Male', 'Middle Ear Ventilation/methods', 'Otitis Media/diagnosis/prevention & control/*therapy', 'Pain Management/methods', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/31524361/
3408,cefdinir,29932038,Community-Acquired Pneumonia in Children.,"['Leung AKC', 'Wong AHC', 'Hon KL']","['Anti-Bacterial Agents/therapeutic use', 'Child', 'Community-Acquired Infections/*diagnosis/therapy', 'Diagnosis, Differential', 'Humans', 'Patents as Topic', 'Pneumococcal Infections/*diagnosis/therapy', 'Pneumonia/*diagnosis/therapy', 'Respiratory Syncytial Virus Infections/*diagnosis/therapy', 'Respiratory Syncytial Viruses/*physiology', 'Streptococcus pneumoniae/*immunology']",https://pubmed.ncbi.nlm.nih.gov/29932038/
3409,cefdinir,23481107,Otitis media.,['Pichichero ME'],"['Age Factors', 'Amoxicillin/administration & dosage/*therapeutic use', 'Amoxicillin-Potassium Clavulanate Combination/therapeutic use', 'Anti-Bacterial Agents/administration & dosage/*therapeutic use', 'Bacterial Infections/complications/*diagnosis/*drug therapy/microbiology', 'Cefdinir', 'Ceftizoxime/analogs & derivatives/therapeutic use', 'Cefuroxime/therapeutic use', 'Cephalosporins/therapeutic use', 'Child', 'Child, Preschool', 'Haemophilus influenzae/isolation & purification', 'Humans', 'Infant', 'Microbial Sensitivity Tests', 'Moraxella catarrhalis/isolation & purification', 'Otitis Media/complications/*diagnosis/*drug therapy/microbiology', 'Otitis Media with Effusion/diagnosis/drug therapy', 'Otoscopy', 'Streptococcus pneumoniae/isolation & purification', 'Time Factors', '*Tympanic Membrane/pathology/physiopathology', 'Cefpodoxime Proxetil']",https://pubmed.ncbi.nlm.nih.gov/23481107/
3410,cefdinir,22010614,Diagnosis and treatment of acute uncomplicated cystitis.,"['Colgan R', 'Williams M']","['Anti-Bacterial Agents/therapeutic use', 'Cystitis/complications/*diagnosis/drug therapy/urine', 'Dysuria/etiology', 'Female', 'Humans', 'Urinalysis']",https://pubmed.ncbi.nlm.nih.gov/22010614/
3411,cefdinir,35944719,Amoxicillin Versus Other Antibiotic Agents for the Treatment of Acute Otitis Media in Children.,"['Frost HM', 'Bizune D', 'Gerber JS', 'Hersh AL', 'Hicks LA', 'Tsay SV']","['Child', 'Humans', 'Infant', '*Amoxicillin/therapeutic use', 'Azithromycin/therapeutic use', 'Cefdinir', 'Retrospective Studies', 'Acute Disease', 'Treatment Outcome', 'Anti-Bacterial Agents/therapeutic use', '*Otitis Media/drug therapy/microbiology', 'Amoxicillin-Potassium Clavulanate Combination/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35944719/
3412,cefdinir,24794905,Cefdinir.,"['Al-Badr AA', 'Alasseiri FA']","['Animals', 'Anti-Bacterial Agents/adverse effects/*analysis/*chemistry/therapeutic use', 'Cefdinir', 'Cephalosporins/adverse effects/*analysis/*chemistry/therapeutic use', 'Chemistry, Pharmaceutical', 'Drug Interactions', 'Drug Resistance, Bacterial', 'Drug Stability', 'Humans', 'Molecular Structure']",https://pubmed.ncbi.nlm.nih.gov/24794905/
3413,cefdinir,37395955,Efficacy of antimicrobials or placebo compared to amoxicillin-clavulanate in children with acute otitis media: a systematic review.,"['Tsergouli K', 'Karampatakis N', 'Karampatakis T']","['Child', 'Humans', 'Infant', 'Acute Disease', 'Amoxicillin/therapeutic use', 'Amoxicillin-Potassium Clavulanate Combination/therapeutic use', 'Anti-Bacterial Agents/therapeutic use', '*Anti-Infective Agents/therapeutic use', 'Azithromycin/therapeutic use', 'Cefaclor/therapeutic use', 'Cefdinir/therapeutic use', '*Otitis Media/drug therapy/microbiology', 'Penicillin V/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/37395955/
3414,cefdinir,14726904,Antimicrobial treatment guidelines for acute bacterial rhinosinusitis.,"['Anon JB', 'Jacobs MR', 'Poole MD', 'Ambrose PG', 'Benninger MS', 'Hadley JA', 'Craig WA']","['Acute Disease', 'Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Drug Resistance, Bacterial', 'Drug Therapy, Combination/therapeutic use', 'Fluoroquinolones/pharmacology/therapeutic use', 'Haemophilus influenzae/drug effects', 'Humans', 'Lactams/therapeutic use', 'Macrolides/pharmacology/therapeutic use', 'Microbial Sensitivity Tests', 'Monte Carlo Method', 'Moraxella catarrhalis/drug effects', 'Nasopharynx/microbiology', 'Otitis Media/drug therapy', 'Rhinitis/*drug therapy/microbiology/physiopathology', 'Sinusitis/*drug therapy/microbiology/physiopathology', 'Streptococcus pneumoniae/drug effects/isolation & purification']",https://pubmed.ncbi.nlm.nih.gov/14726904/
3415,cefdinir,33634465,Interventions for bacterial folliculitis and boils (furuncles and carbuncles).,"['Lin HS', 'Lin PT', 'Tsai YS', 'Wang SH', 'Chi CC']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*therapeutic use', 'Anti-Infective Agents, Local/therapeutic use', 'Bias', 'Carbuncle/drug therapy', 'Child', 'Child, Preschool', 'Female', 'Furunculosis/*drug therapy', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Middle Aged', 'Randomized Controlled Trials as Topic', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33634465/
3416,cefdinir,38349523,Cefdinir vs cephalexin for the treatment of urinary tract infections: A retrospective evaluation.,"['Lloyd A', 'Grey J', 'Fronczek C', 'Durkin H', 'Marr K']","['*Cephalexin/therapeutic use', '*Cefdinir', 'Humans', 'Retrospective Studies', '*Anti-Bacterial Agents/therapeutic use/pharmacokinetics', 'Female', '*Urinary Tract Infections/drug therapy', 'Middle Aged', 'Male', 'Aged', 'Adult', 'Treatment Failure', 'Cephalosporins/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38349523/
3417,cefdinir,17493094,Guidelines on the treatment of ABRS in adults.,['Benninger M'],"['Acute Disease', 'Adult', 'Anti-Bacterial Agents/*therapeutic use', 'Bacterial Infections/*drug therapy', 'Cephalosporins/*therapeutic use', 'Drug Hypersensitivity/etiology', 'Humans', 'Penicillins/adverse effects', '*Practice Guidelines as Topic', 'Sinusitis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17493094/
3418,cefdinir,11060674,Novel oral cephalosporins.,['Cazzola M'],"['Administration, Oral', 'Cephalosporins/administration & dosage/classification/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', '*Drugs, Investigational', 'Gram-Negative Bacterial Infections/drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/11060674/
3419,cefdinir,31822897,Cefdinir Use in the Kentucky Medicaid Population: A Priority for Outpatient Antimicrobial Stewardship.,"['Wattles B', 'Vidwan N', 'Ghosal S', 'Feygin Y', 'Creel L', 'Myers J', 'Woods C', 'Smith M']","['Anti-Bacterial Agents/therapeutic use', '*Antimicrobial Stewardship', 'Cefdinir', 'Child', 'Humans', 'Kentucky', 'Medicaid', 'Outpatients', ""Practice Patterns, Physicians'"", '*Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31822897/
3420,cefdinir,33460959,Surrogate testing of oral third-generation cephalosporin susceptibility to common uropathogens.,"['Watson JR', 'Burch C', 'Leber AL']","['Anti-Bacterial Agents/pharmacology', 'Cephalosporins/*classification/*pharmacology', 'Drug Resistance, Bacterial', 'Escherichia coli/*drug effects', 'Humans', 'Klebsiella pneumoniae/*drug effects', 'Microbial Sensitivity Tests', 'Proteus mirabilis/*drug effects', 'Urinary Tract Infections/*microbiology']",https://pubmed.ncbi.nlm.nih.gov/33460959/
3421,cefdinir,38837394,Case Commentary: Dual beta-lactam as part of regimen to treat Mycobacterium abscessus lung disease.,"['Lippincott CK', 'Lamichhane G']","['*Mycobacterium abscessus/drug effects', 'Humans', '*Mycobacterium Infections, Nontuberculous/drug therapy/microbiology', '*Anti-Bacterial Agents/therapeutic use', '*beta-Lactams/therapeutic use', '*Lung Diseases/drug therapy/microbiology', 'Drug Therapy, Combination', 'Child']",https://pubmed.ncbi.nlm.nih.gov/38837394/
3422,cefdinir,34006862,The effect of generic market entry on antibiotic prescriptions in the United States.,"['Kallberg C', 'Hudson J', 'Salvesen Blix H', 'Ardal C', 'Klein E', 'Lindbaek M', 'Outterson K', 'Rottingen JA', 'Laxminarayan R']","['Anti-Bacterial Agents/classification/economics/*therapeutic use', 'Aztreonam/economics/therapeutic use', 'Cefdinir/economics/therapeutic use', 'Cephalosporins/economics/therapeutic use', 'Costs and Cost Analysis', 'Databases, Pharmaceutical/statistics & numerical data', 'Drug Costs/*statistics & numerical data', 'Drug Industry/economics/*statistics & numerical data/trends', 'Drug Prescriptions/*statistics & numerical data', 'Drugs, Generic/classification/economics/*therapeutic use', 'Humans', 'United States', 'Cefprozil']",https://pubmed.ncbi.nlm.nih.gov/34006862/
3423,cefdinir,39745384,How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?,"['Claeys KC', 'Simner PJ', 'Tekle T', 'Harris AD', 'Jacobs E', 'Cosgrove SE', 'Tamma PD']","['*Anti-Bacterial Agents/pharmacology', '*Ceftriaxone/pharmacology', '*Cephalosporins/pharmacology', 'Humans', '*Microbial Sensitivity Tests', '*Klebsiella pneumoniae/drug effects/genetics/isolation & purification', 'Cefixime/pharmacology', 'Cefpodoxime', 'Cefuroxime/pharmacology', 'Cefdinir', 'Escherichia coli/drug effects/isolation & purification', 'Enterobacteriaceae/drug effects/genetics', 'Proteus mirabilis/drug effects/isolation & purification', 'Klebsiella oxytoca/drug effects/genetics', 'Enterobacteriaceae Infections/microbiology/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39745384/
3424,cefdinir,37414282,Cephalosporins for the treatment of uncomplicated pyelonephritis: A systematic review.,"['Zimmerman DE', 'Tomas M', 'Miller D', 'Tomcsanyi L', 'Signorella C', 'Montepara CA', 'Covvey JR', 'Guarascio AJ']","['Humans', 'Anti-Bacterial Agents/therapeutic use/pharmacology', 'Cephalosporins/therapeutic use', '*Communicable Diseases/drug therapy', '*Pyelonephritis/drug therapy/microbiology', 'Trimethoprim, Sulfamethoxazole Drug Combination/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37414282/
3425,cefdinir,15833221,Acute otitis media: making sense of recent guidelines on antimicrobial treatment.,"['Pichichero ME', 'Casey JR']","['Acute Disease', 'Amoxicillin/*administration & dosage', 'Anti-Bacterial Agents/*administration & dosage', 'Bacterial Typing Techniques', 'Diagnosis, Differential', 'Drug Therapy, Combination/administration & dosage', 'Humans', 'Otitis Media/diagnosis/*drug therapy/microbiology', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/15833221/
3426,diazepam,28101764,Diazepam in the Treatment of Moderate to Severe Alcohol Withdrawal.,['Weintraub SJ'],"['Alcohol Withdrawal Delirium/*drug therapy', 'Alcohol Withdrawal Seizures/*drug therapy', 'Benzodiazepines/administration & dosage/adverse effects/pharmacokinetics', 'Diazepam/*administration & dosage/adverse effects/pharmacokinetics', 'Half-Life', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects/pharmacokinetics', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/28101764/
3427,diazepam,24552479,Classics in chemical neuroscience: diazepam (valium).,"['Calcaterra NE', 'Barrow JC']","['Anxiety Disorders/*drug therapy', 'Diazepam/*administration & dosage/*adverse effects', 'Dose-Response Relationship, Drug', 'Drug Design', 'Drug Overdose/*etiology/prevention & control', 'Humans', 'Respiration Disorders/*chemically induced/prevention & control', 'Seizures/*chemically induced/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/24552479/
3428,diazepam,1505149,"Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time.","['Friedman H', 'Greenblatt DJ', 'Peters GR', 'Metzler CM', 'Charlton MD', 'Harmatz JS', 'Antal EJ', 'Sanborn EC', 'Francom SF']","['Administration, Oral', 'Adult', 'Conscious Sedation', 'Diazepam/blood/*pharmacokinetics/pharmacology', 'Dose-Response Relationship, Drug', 'Electroencephalography/drug effects', 'Female', 'Humans', 'Male', 'Motor Activity/drug effects', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/1505149/
3429,diazepam,11963349,Diazepam use during pregnancy: a review of the literature.,"['Iqbal MM', 'Sobhan T', 'Aftab SR', 'Mahmud SZ']","['Animals', 'Anti-Anxiety Agents/administration & dosage/*adverse effects', 'Anxiety/*drug therapy', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Infant, Newborn, Diseases/*chemically induced', 'Lactation/*drug effects', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Rats', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/11963349/
3430,diazepam,2292778,Diazepam (Valium): its dependency liability.,['Murray JB'],"['Arousal/drug effects', '*Diazepam/adverse effects/pharmacokinetics', 'Drug Tolerance', 'Humans', 'Substance Withdrawal Syndrome/psychology', 'Substance-Related Disorders/*psychology']",https://pubmed.ncbi.nlm.nih.gov/2292778/
3431,diazepam,7990791,Eclampsia.,"['Kaplan PW', 'Repke JT']","['Diagnosis, Differential', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics', 'Eclampsia/diagnosis/*etiology/therapy', 'Female', 'Humans', 'Infant, Newborn', 'Magnesium Sulfate/administration & dosage/adverse effects/pharmacokinetics', 'Neurologic Examination/drug effects', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/7990791/
3432,diazepam,6120393,Diazepam and the risk of breast cancer.,"['Kaufman DW', 'Shapiro S', 'Slone D', 'Rosenberg L', 'Helmrich SP', 'Miettinen OS', 'Stolley PD', 'Levy M', 'Schottenfeld D']","['Adult', 'Animals', 'Breast Neoplasms/*chemically induced', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Female', 'Humans', 'Menopause', 'Middle Aged', 'Rats', 'Risk', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6120393/
3433,diazepam,27731571,Local Anesthetics Systemic Toxicity.,"['Jayanthi R', 'Nasser K', 'Monica K']","['Administration, Intravenous', 'Adult', 'Anesthetics, Local/administration & dosage/*adverse effects', 'Diazepam/administration & dosage/therapeutic use', 'Female', 'Humans', 'Lidocaine/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Seizures/*chemically induced/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27731571/
3434,diazepam,19519511,The plastic phenomenon underlying the associative processes in the addictive properties of diazepam and other psychoactive drugs.,"['Ramirez OA', 'Perez MF']","['Animals', 'Behavior, Addictive/*chemically induced', 'Brain/drug effects/physiopathology', 'Diazepam/administration & dosage/*adverse effects/chemistry', 'Drug Tolerance', 'Humans', 'Psychotropic Drugs/administration & dosage/*adverse effects/chemistry', 'Substance-Related Disorders/etiology']",https://pubmed.ncbi.nlm.nih.gov/19519511/
3435,diazepam,2677941,"Lytic/""DPT"" cocktail: time for rational and safe alternatives.","['Snodgrass WR', 'Dodge WF']","['Child', 'Child, Preschool', 'Chlorpromazine/administration & dosage/adverse effects', 'Diazepam/administration & dosage/pharmacology', 'Drug Combinations/*adverse effects', 'Humans', 'Infant', 'Meperidine/administration & dosage/adverse effects', 'Midazolam/administration & dosage/pharmacology', 'Morphine/administration & dosage/pharmacology', 'Preanesthetic Medication/*adverse effects', 'Promethazine/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2677941/
3436,diazepam,2185438,The pharmacokinetics of agents used to treat status epilepticus.,['Browne TR'],"['Anticonvulsants/*pharmacokinetics/therapeutic use', 'Diazepam/administration & dosage/blood/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Injections, Intramuscular', 'Lipid Metabolism', 'Phenobarbital/administration & dosage/pharmacokinetics', 'Phenytoin/administration & dosage/blood/pharmacokinetics', 'Solubility', 'Status Epilepticus/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2185438/
3437,diazepam,25538342,A case of etizolam dependence.,"['Gupta S', 'Garg B']","['Adult', 'Anti-Anxiety Agents/*adverse effects/therapeutic use', 'Anxiety Disorders/drug therapy', 'Diazepam/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Male', 'Substance-Related Disorders/*etiology', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25538342/
3438,diazepam,1547766,Intrarectal diazepam in epileptic adults.,"['Remy C', 'Jourdil N', 'Villemain D', 'Favel P', 'Genton P']","['Administration, Rectal', 'Adult', 'Diazepam/*administration & dosage/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Electroencephalography', 'Epilepsies, Partial/drug therapy/physiopathology', 'Epilepsy/*drug therapy/physiopathology', 'Female', 'Humans', 'Male', 'Status Epilepticus/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/1547766/
3439,diazepam,9448787,Use of inhalational and intravenous sedation in dentistry.,['Rodrigo MR'],"['Accidents', '*Anesthesia, Dental', '*Anesthesia, Inhalation', '*Anesthesia, Intravenous', 'Anesthesia, Local', 'Anesthetics, Inhalation/administration & dosage', 'Anesthetics, Intravenous/administration & dosage', 'Anti-Anxiety Agents/administration & dosage/adverse effects/antagonists & inhibitors', 'Antidotes/therapeutic use', 'Cause of Death', 'Computers', '*Conscious Sedation', 'Dental Care', 'Diazepam/administration & dosage/adverse effects/antagonists & inhibitors', 'Drug Overdose', 'Emergencies', 'Flumazenil/therapeutic use', 'GABA Modulators/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage', 'Iatrogenic Disease', 'Infusion Pumps', 'Isoflurane/administration & dosage', 'Midazolam/administration & dosage', 'Nitrous Oxide/administration & dosage', 'Oxygen/administration & dosage', 'Practice Guidelines as Topic', 'Propofol/administration & dosage', 'United Kingdom']",https://pubmed.ncbi.nlm.nih.gov/9448787/
3440,diazepam,25030,Pain and clinical thrombophlebitis following intravenous diazepam and lorazepam.,"['Graham CW', 'Pagano RR', 'Conner JT']","['Adolescent', 'Adult', 'Aged', 'Anti-Anxiety Agents/*adverse effects', 'Clinical Trials as Topic', 'Diazepam/administration & dosage/*adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Injections, Intravenous', 'Lorazepam/administration & dosage/*adverse effects', 'Male', 'Middle Aged', 'Pain/*chemically induced', 'Thrombophlebitis/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/25030/
3441,diazepam,9097367,New drug therapy for acute seizure management.,"['Morton LD', 'Rizkallah E', 'Pellock JM']","['Acute Disease', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Child', 'Diazepam/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Epilepsy/*drug therapy', 'Humans', 'Phenytoin/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Prodrugs/adverse effects/pharmacokinetics/therapeutic use', 'Seizures/*drug therapy', 'Valproic Acid/administration & dosage/adverse effects/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9097367/
3442,diazepam,1454506,Influence of diazepam on prospective time estimation.,"['Unrug-Neervoort A', 'Kaiser J', 'Coenen A']","['Adult', 'Attention/drug effects', 'Diazepam/adverse effects/*pharmacology', 'Double-Blind Method', 'Humans', 'Placebos', 'Psychomotor Performance/*drug effects', 'Random Allocation', 'Time Perception/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1454506/
3443,diazepam,329424,Selection among benzodiazepines for alcohol withdrawal.,"['Keeler MH', 'Miller WC']","['Administration, Oral', 'Benzodiazepines/administration & dosage/pharmacology/*therapeutic use', 'Central Nervous System/drug effects', 'Chlordiazepoxide/administration & dosage/pharmacology/therapeutic use', 'Clorazepate Dipotassium/administration & dosage/pharmacology/therapeutic use', 'Depression, Chemical', 'Diazepam/administration & dosage/pharmacology/therapeutic use', 'Drug Synergism', '*Ethanol', 'Half-Life', 'Humans', 'Oxazepam/administration & dosage/pharmacology/therapeutic use', 'Seizures/drug therapy', 'Substance Withdrawal Syndrome/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/329424/
3444,diazepam,1068178,Human cardiorespiratory and analgesic effects of intravenous diazepam and local anesthesia.,"['Allen GD', 'Everett GB', 'Butler LA']","['*Analgesics', '*Anesthesia, Dental', '*Anesthesia, Local', 'Cardiac Output/drug effects', 'Diazepam/administration & dosage/*pharmacology', 'Female', 'Heart/*drug effects', 'Heart Rate/drug effects', 'Humans', 'Injections, Intravenous', 'Lidocaine', 'Male', 'Mandibular Nerve', 'Nerve Block', 'Respiration/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/1068178/
3445,diazepam,34954745,Oxazepam Detected in Urine 79 Days After Withdrawal of Diazepam: A Case Report.,"['Serkland TT', 'Dale GH', 'Kaldestad IC', 'Berg JA', 'Methlie CB']","['Adult', 'Benzodiazepines/adverse effects', 'Diazepam/adverse effects/pharmacokinetics', 'Female', 'Humans', 'Oxazepam/adverse effects', '*Substance Withdrawal Syndrome/diagnosis/etiology', '*Substance-Related Disorders/complications']",https://pubmed.ncbi.nlm.nih.gov/34954745/
3446,cimetidine,6312110,Ranitidine.,['Strum WB'],"['Aged', 'Animals', 'Chemical Phenomena', 'Chemistry', 'Cimetidine/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Duodenal Ulcer/drug therapy', 'Humans', 'Male', 'Mice', 'Ranitidine/adverse effects/metabolism/*therapeutic use', 'Rats', 'Stomach Ulcer/drug therapy', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6312110/
3447,cimetidine,86721,Cimetidine and gastric cancer.,"['Elder JB', 'Ganguli PC', 'Gillespie IE']","['Adenocarcinoma/*chemically induced', 'Adult', 'Aged', 'Cimetidine/*adverse effects/analogs & derivatives/metabolism/therapeutic use', 'Female', 'Guanidines/*adverse effects', 'Humans', 'Male', 'Middle Aged', 'Nitroso Compounds/metabolism', 'Peptic Ulcer/drug therapy', 'Stomach Neoplasms/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/86721/
3448,cimetidine,6375965,Cimetidine for stress-ulcer prophylaxis.,"['Greene WL', 'Bollinger RR']","['Antacids/adverse effects/therapeutic use', 'Cimetidine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Gastric Juice/drug effects/metabolism', 'Gastric Mucosa/drug effects/metabolism', 'Humans', 'Peptic Ulcer/physiopathology/*prevention & control', 'Random Allocation', 'Stress, Physiological/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/6375965/
3449,cimetidine,2874464,Actions of cimetidine and ranitidine at some cholinergic sites: implications in toxicology and anesthesia.,"['Gwee MC', 'Cheah LS']","['*Anesthesia', 'Animals', 'Antihypertensive Agents/adverse effects', 'Bradycardia/chemically induced', 'Cholinesterase Inhibitors/pharmacology', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Confusion/chemically induced', 'Cytochrome P-450 Enzyme System/pharmacology', 'Diarrhea/chemically induced', 'Drug Interactions', 'Erectile Dysfunction/chemically induced', 'Ganglionic Blockers/pharmacology', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Mixed Function Oxygenases/antagonists & inhibitors', 'Neuromuscular Blocking Agents/pharmacology', 'Peptic Ulcer/drug therapy', 'Ranitidine/*adverse effects/pharmacology/therapeutic use', 'Receptors, Cholinergic/*drug effects/physiology', 'Receptors, Histamine H2/drug effects', 'Zollinger-Ellison Syndrome/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/2874464/
3450,cimetidine,6146287,Medical management of gastric ulcer.,['LaBrooy SJ'],"['Aged', 'Animals', 'Antacids/*therapeutic use', 'Carbenoxolone/administration & dosage/*therapeutic use', 'Cimetidine/administration & dosage/therapeutic use', 'Clinical Trials as Topic', 'Dogs', 'Double-Blind Method', 'Gastric Acid/metabolism', 'Glycyrrhetinic Acid/*analogs & derivatives', 'Histamine H2 Antagonists/*therapeutic use', 'Humans', 'Ranitidine/therapeutic use', 'Recurrence', 'Stomach Ulcer/*drug therapy/etiology/metabolism']",https://pubmed.ncbi.nlm.nih.gov/6146287/
3451,cimetidine,11243017,[About paracetamol again].,"['Hazai E', 'Monostory K', 'Bakos A', 'Zacher G', 'Vereczkey L']","['Acetaminophen/administration & dosage/*adverse effects/pharmacokinetics', 'Acetylcysteine/therapeutic use', 'Analgesics, Non-Narcotic/administration & dosage/*adverse effects/pharmacokinetics', 'Antidotes/therapeutic use', 'Cimetidine/therapeutic use', 'Drug Overdose', 'Humans', 'Liver/*drug effects', 'Liver Failure, Acute/*chemically induced/drug therapy/metabolism/prevention & control/*therapy']",https://pubmed.ncbi.nlm.nih.gov/11243017/
3452,cimetidine,6733633,Cimetidine-induced fever.,"['Landolfo K', 'Low DE', 'Rogers AG']","['Administration, Oral', 'Aged', 'Cimetidine/administration & dosage/*adverse effects', 'Duodenal Ulcer/drug therapy', 'Female', 'Fever/*chemically induced', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6733633/
3453,cimetidine,620916,Safety of cimetidine.,"['Kruss DM', 'Littman A']","['Aspartate Aminotransferases/blood', 'Cimetidine/*adverse effects/pharmacology/therapeutic use', 'Creatinine/blood', 'Drug Interactions', 'Guanidines/*adverse effects', 'Humans', 'Liver/enzymology', 'Risk', 'Substance Withdrawal Syndrome']",https://pubmed.ncbi.nlm.nih.gov/620916/
3454,cimetidine,7751419,Clinical aspects of cardiovascular effects of H2-receptor antagonists.,"['Hinrichsen H', 'Halabi A', 'Kirch W']","['Animals', 'Atrioventricular Node/drug effects', 'Blood Pressure/drug effects', 'Bradycardia/chemically induced', 'Cardiovascular System/*drug effects', 'Cimetidine/adverse effects/pharmacology', 'Electrocardiography/drug effects', 'Heart Rate/drug effects', 'Hemodynamics/drug effects', 'Histamine H2 Antagonists/chemistry/*pharmacology', 'Humans', 'Ranitidine/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7751419/
3455,cimetidine,387498,"Clinical effects of trithiozine, a newer gastric anti-secretory agent.",['Pellegrini R'],"['Anti-Ulcer Agents/administration & dosage/adverse effects/*therapeutic use', 'Cimetidine/therapeutic use', 'Clinical Trials as Topic', 'Depression, Chemical', 'Double-Blind Method', 'Gastric Juice/*metabolism', 'Humans', 'Morpholines/administration & dosage/adverse effects/*therapeutic use', 'Peptic Ulcer/*drug therapy', 'Placebos', 'Propantheline/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/387498/
3456,cimetidine,6990675,Cimetidine in the prevention of acid aspiration during anesthesia.,"['Kirkegaard P', 'Sorensen O', 'Kirkegaard P']","['Adult', 'Anesthesia, General/*adverse effects', 'Anesthesia, Inhalation/adverse effects', 'Cimetidine/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Gastric Juice/analysis/drug effects', 'Guanidines/*therapeutic use', 'Humans', 'Hydrogen-Ion Concentration', 'Middle Aged', 'Placebos', 'Pneumonia, Aspiration/*prevention & control', 'Premedication', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6990675/
3457,cimetidine,388168,Cimetidine and gastric ulcer healing: a double-blind controlled trial.,"['Landecker KD', 'Crawford J', 'Hunt JH', 'Gillespie P', 'Piper DW']","['Chronic Disease', 'Cimetidine/administration & dosage/*therapeutic use', 'Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Guanidines/*therapeutic use', 'Humans', 'Male', 'Outpatients', 'Random Allocation', 'Stomach Ulcer/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/388168/
3458,cimetidine,4057034,"Cimetidine as pre-anesthetic agent for cesarean section: perinatal effects on the infant, the placental transfer of cimetidine and its elimination in the infants.","['Qvist N', 'Storm K', 'Holmskov A']","['*Cesarean Section', 'Cimetidine/adverse effects/*blood/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', '*Infant, Newborn', '*Maternal-Fetal Exchange', '*Preanesthetic Medication', 'Pregnancy', 'Prospective Studies', 'Umbilical Veins']",https://pubmed.ncbi.nlm.nih.gov/4057034/
3459,cimetidine,2979221,Review: post-marketing surveillance of the safety of cimetidine--the problems of data interpretation.,"['Jones DG', 'Langman MJ', 'Lawson DH', 'Vessey MP']","['Adult', 'Cimetidine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', '*Product Surveillance, Postmarketing', 'Safety']",https://pubmed.ncbi.nlm.nih.gov/2979221/
3460,cimetidine,1289197,[Cimetidine hepatitis].,"['Zaidenstein R', 'Cohen N', 'Golik A']","['Acute Disease', 'Adult', 'Arthritis, Rheumatoid/complications', 'Chemical and Drug Induced Liver Injury/*etiology', 'Cimetidine/*adverse effects/therapeutic use', 'Duodenal Ulcer/complications/drug therapy', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/1289197/
3461,cimetidine,2271376,The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.,"['Coleman MD', 'Scott AK', 'Breckenridge AM', 'Park BK']","['Adult', 'Cimetidine/administration & dosage/*pharmacology', 'Dapsone/administration & dosage/*metabolism/pharmacokinetics', 'Humans', 'Hydroxylation/drug effects', 'Male', 'Methemoglobinemia/blood']",https://pubmed.ncbi.nlm.nih.gov/2271376/
3462,cimetidine,3570585,Treatment of female androgenetic alopecia with cimetidine.,['Aram H'],"['Adult', 'Alopecia/*drug therapy/etiology', 'Androgen Antagonists/therapeutic use', 'Androgens/physiology', 'Cimetidine/administration & dosage/pharmacology/*therapeutic use', 'Drug Evaluation', 'Female', 'Follow-Up Studies', 'Humans', 'Middle Aged', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3570585/
3463,cimetidine,8844752,Treatment of molluscum contagiosum with oral cimetidine: clinical experience in 13 patients.,"['Dohil M', 'Prendiville JS']","['Administration, Oral', 'Child', 'Child, Preschool', 'Cimetidine/administration & dosage/*therapeutic use', 'Facial Dermatoses/drug therapy/virology', 'Female', 'Histamine H2 Antagonists/administration & dosage/*therapeutic use', 'Humans', 'Immunocompetence', 'Infant', 'Male', 'Molluscum Contagiosum/*drug therapy', 'Remission Induction', 'Treatment Refusal']",https://pubmed.ncbi.nlm.nih.gov/8844752/
3464,cimetidine,2277761,Ascorbic acid prevents cimetidine-induced decrease of serum hydrocortisone concentrations.,"['Boidin MP', 'Stuurman A', 'Erdmann W']","['Abdomen/surgery', 'Aged', 'Ascorbic Acid/*pharmacology', 'Cimetidine/*adverse effects/therapeutic use', 'Humans', 'Hydrocortisone/*blood', 'Middle Aged', 'Prospective Studies', 'Vascular Surgical Procedures']",https://pubmed.ncbi.nlm.nih.gov/2277761/
3465,cimetidine,3859910,The risk of gastric dysplasia in medical long-term treatment of peptic ulcer disease.,"['Di Mario F', 'Farinati F', 'Cardin F']","['Adult', 'Aged', 'Anti-Ulcer Agents/administration & dosage/*adverse effects', 'Benzodiazepinones/administration & dosage/adverse effects', 'Cimetidine/administration & dosage/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', 'Peptic Ulcer/*drug therapy', 'Pirenzepine', 'Ranitidine/administration & dosage/adverse effects', 'Risk', 'Stomach/*drug effects/pathology', 'Stomach Neoplasms/*chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/3859910/
3466,tizanidine,32563380,New directions in the treatment of opioid withdrawal.,"['Srivastava AB', 'Mariani JJ', 'Levin FR']","['Adrenergic alpha-2 Receptor Agonists/administration & dosage/adverse effects', 'Analgesics, Opioid/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Humans', 'Narcotic Antagonists/administration & dosage/adverse effects', 'Opiate Substitution Treatment/*methods', 'Opioid-Related Disorders/*drug therapy', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/32563380/
3467,tizanidine,38394496,"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment.","['Haki M', 'Al-Biati HA', 'Al-Tameemi ZS', 'Ali IS', 'Al-Hussaniy HA']","['Humans', '*Multiple Sclerosis/epidemiology/etiology/therapy', 'Treatment Outcome', 'Chronic Disease', 'Muscle Spasticity/etiology']",https://pubmed.ncbi.nlm.nih.gov/38394496/
3468,tizanidine,22976059,"Spasticity: pathophysiology, evaluation and management.","['Kheder A', 'Nair KP']","['Humans', '*Motor Neuron Disease/diagnosis/physiopathology/therapy', '*Quadriplegia/diagnosis/physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/22976059/
3469,tizanidine,18225966,Skeletal muscle relaxants.,"['See S', 'Ginzburg R']","['Drug Interactions', 'Humans', 'Muscle Relaxants, Central/adverse effects/classification/*therapeutic use', 'Musculoskeletal Diseases/drug therapy', 'Nervous System Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18225966/
3470,tizanidine,37059468,Therapies in Stiff-Person Syndrome: Advances and Future Prospects Based on Disease Pathophysiology.,['Dalakas MC'],"['Child', 'Humans', 'Female', 'Aged', '*Stiff-Person Syndrome/therapy/drug therapy', 'Autoantibodies', 'Autoimmunity', 'Baclofen/therapeutic use', 'Spasm']",https://pubmed.ncbi.nlm.nih.gov/37059468/
3471,tizanidine,18711953,Choosing a skeletal muscle relaxant.,"['See S', 'Ginzburg R']","['Back Pain/drug therapy', 'Fibromyalgia/drug therapy', 'Humans', 'Neck Pain/drug therapy', 'Neuromuscular Agents/adverse effects/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18711953/
3472,tizanidine,15276195,Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.,"['Chou R', 'Peterson K', 'Helfand M']","['Clinical Trials as Topic', 'Comorbidity', 'Evidence-Based Medicine/methods', 'Humans', 'Motor Neuron Disease/classification/*drug therapy/*epidemiology', 'Muscle Spasticity/classification/*drug therapy/*epidemiology', 'Musculoskeletal Diseases/classification/drug therapy/epidemiology', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/classification/*drug therapy/*epidemiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15276195/
3473,tizanidine,29165784,Interventions for managing skeletal muscle spasticity following traumatic brain injury.,"['Synnot A', 'Chau M', 'Pitt V', ""O'Connor D"", 'Gruen RL', 'Wasiak J', 'Clavisi O', 'Pattuwage L', 'Phillips K']","['Baclofen/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Brain Injuries, Traumatic/*complications', 'Casts, Surgical', 'Electric Stimulation Therapy', 'Head-Down Tilt', 'Humans', 'Muscle Relaxants, Central/therapeutic use', 'Muscle Spasticity/etiology/*therapy', 'Neuromuscular Agents/therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/29165784/
3474,tizanidine,25347760,Dystonia.,"['Snaith A', 'Wade D']","['Analgesics/therapeutic use', 'Anticonvulsants/therapeutic use', 'Dystonia/drug therapy/surgery/*therapy', 'Humans', 'Physical Therapy Modalities', 'Speech Therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25347760/
3475,tizanidine,35754070,Pharmacotherapy for Spine-Related Pain in Older Adults.,"['Fu JL', 'Perloff MD']","['Acetaminophen/therapeutic use', 'Aged', 'Analgesics, Opioid/adverse effects', 'Anti-Inflammatory Agents, Non-Steroidal/therapeutic use', 'Gabapentin/therapeutic use', 'Humans', '*Neuralgia/drug therapy', 'Pregabalin/adverse effects', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*Serotonin and Noradrenaline Reuptake Inhibitors/therapeutic use', '*Tramadol/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35754070/
3476,tizanidine,39298168,Long-Term Use of Muscle Relaxant Medications for Chronic Pain: A Systematic Review.,"['Oldfield BJ', 'Gleeson B', 'Morford KL', 'Adams Z', 'Funaro MC', 'Becker WC', 'Merlin JS']","['Humans', '*Chronic Pain/drug therapy', 'Muscle Relaxants, Central/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39298168/
3477,tizanidine,38870050,An update on pharmacotherapy for trigeminal neuralgia.,"['Pergolizzi JV Jr', 'LeQuang JA', 'El-Tallawy SN', 'Wagner M', 'Ahmed RS', 'Varrassi G']","['*Trigeminal Neuralgia/drug therapy', 'Humans', '*Anticonvulsants/therapeutic use', '*Carbamazepine/therapeutic use', 'Oxcarbazepine/therapeutic use', 'Migraine Disorders/drug therapy', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38870050/
3478,tizanidine,36948512,Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis.,"['Wewege MA', 'Bagg MK', 'Jones MD', 'Ferraro MC', 'Cashin AG', 'Rizzo RR', 'Leake HB', 'Hagstrom AD', 'Sharma S', 'McLachlan AJ', 'Maher CG', 'Day R', 'Wand BM', ""O'Connell NE"", 'Nikolakopolou A', 'Schabrun S', 'Gustin SM', 'McAuley JH']","['Humans', 'Adult', 'Female', 'Male', 'Acetaminophen/adverse effects', '*Low Back Pain/drug therapy', '*Tramadol/therapeutic use', 'Network Meta-Analysis', 'Analgesics/adverse effects', '*Acute Pain/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36948512/
3479,tizanidine,19445753,Trigeminal neuralgia.,"['Zakrzewska JM', 'Linskey ME']","['Humans', 'Ophthalmic Solutions/therapeutic use', '*Pain/surgery', 'Pain Measurement', 'Phenytoin/therapeutic use', 'Radiosurgery', 'Trigeminal Ganglion', '*Trigeminal Neuralgia/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19445753/
3480,tizanidine,20927006,Managing spasticity with drugs.,"['Simon O', 'Yelnik AP']","['Administration, Oral', 'Baclofen/adverse effects/*therapeutic use', 'Botulinum Toxins, Type A/adverse effects/*therapeutic use', 'Clonidine/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Injections, Spinal', 'Muscle Relaxants, Central/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy', 'Neuromuscular Agents/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20927006/
3481,tizanidine,35020700,Management of Xylazine Withdrawal in a Hospitalized Patient: A Case Report.,"['Ehrman-Dupre R', 'Kaigh C', 'Salzman M', 'Haroz R', 'Peterson LK', 'Schmidt R']","['Adrenergic Agonists/therapeutic use', 'Analgesics, Opioid/therapeutic use', 'Animals', '*Buprenorphine/therapeutic use', 'Clonidine', '*Dexmedetomidine/therapeutic use', 'Female', 'Gabapentin/therapeutic use', 'Humans', '*Opioid-Related Disorders/drug therapy', 'Phenobarbital/therapeutic use', '*Substance Withdrawal Syndrome/drug therapy', 'Xylazine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35020700/
3482,tizanidine,9850294,An approach to switching patients from baclofen to tizanidine.,"['Brenner R', 'Hyman N', 'Knobler R', ""O'Brien M"", 'Stephan T']","['Baclofen/adverse effects/*therapeutic use', 'Clinical Competence', 'Clonidine/adverse effects/*analogs & derivatives/therapeutic use', 'Humans', 'Multiple Sclerosis/complications', 'Muscle Relaxants, Central/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy/etiology', 'Spinal Cord Diseases/drug therapy', 'Spinal Cord Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9850294/
3483,tizanidine,16272661,Pharmacologic interventions for reducing spasticity in cerebral palsy.,"['Patel DR', 'Soyode O']","['Administration, Oral', 'Adrenergic alpha-Agonists/administration & dosage/*therapeutic use', 'Age Factors', 'Anti-Infective Agents, Local/administration & dosage/therapeutic use', 'Baclofen/administration & dosage/adverse effects/*therapeutic use', 'Botulinum Toxins/administration & dosage/*therapeutic use', 'Cerebral Palsy/*drug therapy/physiopathology', 'Child', 'Child, Preschool', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Dantrolene/administration & dosage/adverse effects/*therapeutic use', '*Diazepam/administration & dosage/adverse effects/therapeutic use', 'Ethanol/administration & dosage/therapeutic use', 'Humans', 'Infant', 'Injections, Intramuscular', 'Injections, Spinal', 'Muscle Relaxants, Central/administration & dosage/adverse effects/*therapeutic use', 'Muscle Spasticity/*drug therapy/physiopathology', 'Neuromuscular Agents/administration & dosage/therapeutic use', 'Phenol/administration & dosage/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/16272661/
3484,tizanidine,7970008,Pharmacokinetics and pharmacodynamics of tizanidine.,"['Roberts RC', 'Part NJ', 'Pokorny R', 'Muir C', 'Leslie GC', 'Emre M']","['Clonidine/administration & dosage/*analogs & derivatives/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Humans', 'Muscle Relaxants, Central/*administration & dosage/*pharmacokinetics', 'Muscle Spasticity/blood/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/7970008/
3485,tizanidine,38421578,Pharmacological and Non-pharmacological Approaches for the Management of Neuropathic Pain in Multiple Sclerosis.,"['Shkodina AD', 'Bardhan M', 'Chopra H', 'Anyagwa OE', 'Pinchuk VA', 'Hryn KV', 'Kryvchun AM', 'Boiko DI', 'Suresh V', 'Verma A', 'Delva MY']","['Humans', '*Multiple Sclerosis/therapy/drug therapy', '*Trigeminal Neuralgia/complications/drug therapy', '*Acceptance and Commitment Therapy', '*Neuralgia/drug therapy/etiology', 'Antidepressive Agents/therapeutic use', 'Anticonvulsants/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38421578/
3486,clonidine,12126186,Clonidine toxicity revisited.,['Seger DL'],"['Adolescent', '*Adrenergic alpha-Agonists/pharmacokinetics/poisoning', 'Adult', '*Clonidine/antagonists & inhibitors/pharmacokinetics/poisoning', 'Drug Overdose', 'Female', 'Humans', 'Hypertension/chemically induced', 'Infant', 'Male', 'Middle Aged', 'Naloxone/adverse effects/*therapeutic use', 'Narcotic Antagonists/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12126186/
3487,clonidine,2869681,Alpha-adrenergic receptors and blood pressure control.,['Reid JL'],"['Adrenergic alpha-Agonists/adverse effects/*pharmacology', 'Adrenergic alpha-Antagonists/*pharmacology', 'Animals', 'Blood Pressure/*drug effects', 'Clonidine/adverse effects/pharmacology/therapeutic use', 'Drug Evaluation', 'Guanfacine', 'Guanidines/adverse effects/pharmacology/therapeutic use', 'Half-Life', 'Heart Rate/drug effects', 'Humans', 'Hypertension/drug therapy', 'Phenylacetates/adverse effects/pharmacology/therapeutic use', 'Prazosin/therapeutic use', 'Receptors, Adrenergic, alpha/*drug effects/physiology']",https://pubmed.ncbi.nlm.nih.gov/2869681/
3488,clonidine,2668350,Clinical pharmacology of centrally acting antihypertensive agents.,['Weber MA'],"['Antihypertensive Agents/administration & dosage/pharmacokinetics/*therapeutic use', 'Blood Pressure/drug effects', 'Clonidine/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Dose-Response Relationship, Drug', 'Guanfacine', 'Guanidines/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Humans', 'Hypertension/*drug therapy/physiopathology', 'Methyldopa/administration & dosage/therapeutic use', 'Phenylacetates/administration & dosage/adverse effects/pharmacokinetics/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/2668350/
3489,clonidine,7046065,Clonidine hydrochloride.,['Houston MC'],"['Antihypertensive Agents', 'Clonidine/adverse effects/metabolism/*pharmacology/therapeutic use', 'Diuretics/pharmacology', 'Drug Interactions', 'Drug Therapy, Combination', 'Hemodynamics/drug effects', 'Humans', 'Kinetics', 'Methyldopa/pharmacology', 'Prazosin/pharmacology', 'Propranolol/pharmacology', 'Renin-Angiotensin System/drug effects', 'Vasodilator Agents/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/7046065/
3490,clonidine,28833346,"Repurposing Valproate, Enteral Clonidine, and Phenobarbital for Comfort in Adult ICU Patients: A Literature Review with Practical Considerations.","['Gagnon DJ', 'Fontaine GV', 'Riker RR', 'Fraser GL']","['Administration, Oral', 'Administration, Sublingual', 'Adult', 'Clonidine/administration & dosage/*therapeutic use', 'Critical Illness', '*Drug Repositioning', 'Humans', 'Hypnotics and Sedatives/administration & dosage/*therapeutic use', '*Intensive Care Units', 'Patient Comfort', 'Phenobarbital/administration & dosage/*therapeutic use', 'Valproic Acid/administration & dosage/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28833346/
3491,clonidine,24195803,Oral clonidine in the management of acquired opioid dependency.,['Beaulieu MJ'],"['Administration, Oral', 'Adult', 'Analgesics/administration & dosage/*therapeutic use', 'Analgesics, Opioid/*adverse effects', 'Child', 'Clonidine/administration & dosage/*therapeutic use', 'Female', 'Humans', 'Infant, Newborn', 'Neonatal Abstinence Syndrome/*drug therapy', 'Opioid-Related Disorders/*drug therapy', 'Pregnancy', 'Prenatal Exposure Delayed Effects/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/24195803/
3492,clonidine,10180510,Selectivity of site of action and systemic effects of topical alpha agonists.,"['Robin AL', 'Burnstein Y']","['Administration, Topical', 'Adrenergic alpha-Agonists/administration & dosage/adverse effects/*pharmacology', 'Animals', 'Brimonidine Tartrate', 'Clonidine/administration & dosage/adverse effects/analogs & derivatives/pharmacology', 'Glaucoma, Open-Angle/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Ophthalmic Solutions', 'Optic Nerve/drug effects', 'Quinoxalines/administration & dosage/adverse effects/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10180510/
3493,clonidine,490793,Abrupt discontinuation of clonidine therapy.,"['Ram CV', 'Engelman K']","['Adult', 'Blood Pressure/*drug effects', 'Clonidine/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Hypertension/drug therapy', 'Male', 'Middle Aged', 'Substance Withdrawal Syndrome/*etiology/prevention & control']",https://pubmed.ncbi.nlm.nih.gov/490793/
3494,clonidine,6641092,Alinidine in angina.,"['Meinertz T', 'Kasper W', 'Meier R', 'Wiegand U', 'Bechtold H', 'Forster I', 'Pop T', 'Jahnchen E']","['Adult', 'Angina Pectoris/*drug therapy', 'Blood Pressure/drug effects', 'Clonidine/*analogs & derivatives/pharmacology/therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Electrocardiography', 'Exercise Test', 'Heart Rate/drug effects', 'Humans', 'Male', 'Middle Aged', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/6641092/
3495,clonidine,17233517,The pharmacological management of spasticity.,"['Saulino M', 'Jacobs BW']","['Baclofen/adverse effects/pharmacology/*therapeutic use', 'Clonidine/adverse effects/*analogs & derivatives/pharmacology/therapeutic use', 'Dantrolene/adverse effects/pharmacology/*therapeutic use', 'Humans', 'Muscle Relaxants, Central/adverse effects/pharmacology/*therapeutic use', 'Muscle Spasticity/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17233517/
3496,clonidine,3966758,Treatment of diabetic diarrhea with clonidine.,"['Fedorak RN', 'Field M', 'Chang EB']","['Chronic Disease', 'Clonidine/adverse effects/*therapeutic use', 'Diabetes Mellitus, Type 1/*complications', 'Diarrhea/*drug therapy/etiology', 'Feces/drug effects', 'Humans', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/3966758/
3497,clonidine,9327348,Clinical experience with apraclonidine 0.5%.,"['Gross RL', 'Pinyero A', 'Orengo-Nania S']","['Adolescent', 'Adrenergic alpha-Agonists/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Chronic Disease', 'Clonidine/administration & dosage/*analogs & derivatives/immunology/therapeutic use', 'Drug Hypersensitivity/immunology', 'Eye/immunology', 'Female', 'Glaucoma/*drug therapy/physiopathology', 'Humans', 'Intraocular Pressure/drug effects', 'Male', 'Middle Aged', 'Osmolar Concentration', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/9327348/
3498,clonidine,21353141,"A case of delirium, motor disturbances, and autonomic dysfunction due to baclofen and tizanidine withdrawal: a review of the literature.","['Karol DE', 'Muzyk AJ', ""Preud'homme XA""]","['Akathisia, Drug-Induced/*etiology', 'Anticonvulsants/administration & dosage/*adverse effects', 'Autonomic Nervous System Diseases/*chemically induced', 'Baclofen/administration & dosage/*adverse effects', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives', 'Delirium/*chemically induced', 'Humans', 'Male', 'Middle Aged', 'Substance Withdrawal Syndrome/etiology']",https://pubmed.ncbi.nlm.nih.gov/21353141/
3499,clonidine,11723871,Intrathecal clonidine for controlling spastic hypertonia.,"['Remy-Neris O', 'Denys P', 'Bussel B']","['Adrenergic alpha-Agonists/administration & dosage/*pharmacology/therapeutic use', 'Animals', 'Clonidine/administration & dosage/*pharmacology/therapeutic use', 'Humans', 'Injections, Spinal', 'Muscle Spasticity/*drug therapy/etiology', 'Reflex, Stretch/drug effects', 'Spinal Cord Injuries/complications']",https://pubmed.ncbi.nlm.nih.gov/11723871/
3500,clonidine,27779775,Clonidine for Sedation and Analgesia and Withdrawal in Critically Ill Infants and Children.,"['Capino AC', 'Miller JL', 'Johnson PN']","['Adrenergic alpha-2 Receptor Agonists/*administration & dosage/adverse effects', 'Analgesics/administration & dosage/adverse effects', 'Child', 'Clonidine/*administration & dosage/adverse effects', 'Critical Illness', 'Dose-Response Relationship, Drug', 'Humans', 'Hypnotics and Sedatives/administration & dosage/adverse effects', 'Infant', 'Substance Withdrawal Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27779775/
3501,clonidine,7561715,Clonidine-induced bradycardia.,"['Golusinski LL Jr', 'Blount BW']","['Antihypertensive Agents/*adverse effects/pharmacology/therapeutic use', 'Bradycardia/*chemically induced', 'Clonidine/*adverse effects/pharmacology/therapeutic use', 'Humans', 'Hypertension/*drug therapy', 'Male', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/7561715/
3502,clonidine,6822133,Pharmacokinetics and pharmacodynamics of clonidine in varying states of renal function.,"['Lowenthal DT', 'Affrime MB', 'Meyer A', 'Kim KE', 'Falkner B', 'Sharif K']","['Adult', 'Clonidine/administration & dosage/*metabolism/therapeutic use', 'Female', 'Humans', 'Hypertension/*drug therapy', 'Kidney Failure, Chronic/*metabolism', 'Kinetics', 'Male', 'Middle Aged', 'Renal Dialysis']",https://pubmed.ncbi.nlm.nih.gov/6822133/
3503,clonidine,8270972,Transdermal clonidine for ameliorating tamoxifen-induced hot flashes.,"['Goldberg RM', 'Loprinzi CL', ""O'Fallon JR"", 'Veeder MH', 'Miser AW', 'Mailliard JA', 'Michalak JC', 'Dose AM', 'Rowland KM Jr', 'Burnham NL']","['Administration, Cutaneous', 'Breast Neoplasms/drug therapy', 'Climacteric/*drug effects/physiology', 'Clonidine/administration & dosage/adverse effects/*therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Middle Aged', 'Prospective Studies', 'Tamoxifen/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8270972/
3504,clonidine,1347973,Reformulation and drop size of apraclonidine hydrochloride.,"['Vocci MJ', 'Robin AL', 'Wahl JC', 'Mayer P', 'Graves A', 'York B', 'Enger C', 'Sutton J']","['Adrenergic alpha-Agonists/*administration & dosage/adverse effects', 'Adult', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives', 'Double-Blind Method', 'Female', 'Formularies as Topic', 'Humans', 'Hypromellose Derivatives', 'Intraocular Pressure/*drug effects', 'Lysophosphatidylcholines/administration & dosage/adverse effects', 'Male', 'Methylcellulose/administration & dosage/adverse effects/analogs & derivatives', 'Middle Aged', 'Placebos', 'Prospective Studies', 'Vision Disorders/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/1347973/
3505,clonidine,6751834,Tizanidine in the treatment of spasticity.,"['Newman PM', 'Nogues M', 'Newman PK', 'Weightman D', 'Hudgson P']","['Adult', 'Baclofen/therapeutic use', 'Clinical Trials as Topic', 'Clonidine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Middle Aged', 'Muscle Spasticity/*drug therapy', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/6751834/
3506,citalopram,17375980,The clinical pharmacokinetics of escitalopram.,['Rao N'],"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Anxiety Disorders/*drug therapy', 'Child', 'Citalopram/administration & dosage/*pharmacokinetics', 'Depression/*drug therapy', 'Drug Interactions', 'Humans', 'Liver Diseases', 'Renal Insufficiency', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/*pharmacokinetics', 'Sex Factors']",https://pubmed.ncbi.nlm.nih.gov/17375980/
3507,citalopram,38950403,Medication-Induced Weight Change Across Common Antidepressant Treatments : A Target Trial Emulation Study.,"['Petimar J', 'Young JG', 'Yu H', 'Rifas-Shiman SL', 'Daley MF', 'Heerman WJ', 'Janicke DM', 'Jones WS', 'Lewis KH', 'Lin PD', 'Prentice C', 'Merriman JW', 'Toh S', 'Block JP']","['Humans', '*Antidepressive Agents/therapeutic use/adverse effects', 'Female', 'Male', '*Weight Gain/drug effects', 'Middle Aged', 'Adult', 'Bupropion/therapeutic use/adverse effects', 'Citalopram/therapeutic use/adverse effects', 'Duloxetine Hydrochloride/therapeutic use/adverse effects', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38950403/
3508,citalopram,24424469,"A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?","['Sanchez C', 'Reines EH', 'Montgomery SA']","['Allosteric Site', 'Animals', 'Antidepressive Agents, Second-Generation/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Citalopram/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Depression/drug therapy/metabolism', 'Depressive Disorder, Major/drug therapy/metabolism', 'Drug Interactions', '*Evidence-Based Medicine', 'Humans', '*Models, Biological', 'Nerve Tissue Proteins/antagonists & inhibitors/chemistry/metabolism', 'Paroxetine/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Serotonin Plasma Membrane Transport Proteins/chemistry/metabolism', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Sertraline/adverse effects/pharmacokinetics/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/24424469/
3509,citalopram,39382900,Mindfulness Meditation vs Escitalopram for Treatment of Anxiety Disorders: Secondary Analysis of a Randomized Clinical Trial.,"['Hu H', 'Mete M', 'Rustgi NK', 'Washington CI', 'Sanghavi K', 'Dutton MA', 'Simon NM', 'Baker AW', 'Bui E', 'Hoge EA']","['Humans', '*Mindfulness/methods', '*Anxiety Disorders/drug therapy/therapy', 'Female', 'Male', 'Adult', '*Meditation/methods', '*Escitalopram/therapeutic use', 'Middle Aged', 'Treatment Outcome', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', 'Citalopram/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39382900/
3510,citalopram,38520045,Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.,"['Erritzoe D', 'Barba T', 'Spriggs MJ', 'Rosas FE', 'Nutt DJ', 'Carhart-Harris R']","['Humans', '*Psilocybin/administration & dosage/pharmacology/adverse effects', '*Depressive Disorder, Major/drug therapy', 'Adult', 'Male', '*Selective Serotonin Reuptake Inhibitors/administration & dosage/adverse effects/pharmacology', 'Female', '*Hallucinogens/administration & dosage/adverse effects/pharmacology', '*Escitalopram/administration & dosage/pharmacology', 'Middle Aged', 'Treatment Outcome', 'Drug Therapy, Combination']",https://pubmed.ncbi.nlm.nih.gov/38520045/
3511,citalopram,24625921,The non-antidepressant effects of citalopram: a clinician's perspective.,"['Richter T', 'Paluch Z', 'Alusik S']","['Citalopram/administration & dosage/adverse effects/*pharmacology', 'Humans', 'Hyponatremia/*chemically induced', 'Osteoporosis/*chemically induced', 'Platelet Aggregation Inhibitors/administration & dosage/adverse effects/*pharmacology', 'Romano-Ward Syndrome/*chemically induced', 'Serotonin Antagonists/administration & dosage/adverse effects/*pharmacology', 'Serotonin Syndrome/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24625921/
3512,citalopram,11336616,Citalopram: a comprehensive review.,['Pollock BG'],"['Alcoholism/drug therapy', 'Antidepressive Agents, Second-Generation/*therapeutic use', 'Anxiety Disorders/drug therapy', 'Citalopram/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Dementia/drug therapy', 'Depression/drug therapy', 'Drug Interactions', 'Female', 'Humans', 'Premenstrual Syndrome/drug therapy', 'Selective Serotonin Reuptake Inhibitors/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/11336616/
3513,citalopram,38001423,Escitalopram versus other antidepressive agents for major depressive disorder: a systematic review and meta-analysis.,"['Yin J', 'Song X', 'Wang C', 'Lin X', 'Miao M']","['Humans', '*Depressive Disorder, Major/drug therapy', 'Escitalopram', 'Citalopram/therapeutic use', 'Antidepressive Agents/therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38001423/
3514,citalopram,39533789,[Expectancies and SSRI treatment of social anxiety disorder].,"['Wahlstedt K', 'Furmark T']","['Humans', '*Selective Serotonin Reuptake Inhibitors/therapeutic use/pharmacology', '*Phobia, Social/drug therapy', 'Treatment Outcome', 'Escitalopram/therapeutic use/pharmacology', 'Cognitive Behavioral Therapy', 'Citalopram/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39533789/
3515,citalopram,34743319,"Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects.","['Becker AM', 'Holze F', 'Grandinetti T', 'Klaiber A', 'Toedtli VE', 'Kolaczynska KE', 'Duthaler U', 'Varghese N', 'Eckert A', 'Grunblatt E', 'Liechti ME']","['Antidepressive Agents/adverse effects', '*Brain-Derived Neurotrophic Factor/genetics', 'Citalopram/adverse effects', 'Cross-Over Studies', 'Double-Blind Method', '*Escitalopram', 'Healthy Volunteers', 'Humans', 'Psilocybin/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34743319/
3516,citalopram,38851804,Modulation of serotonin transporter expression by escitalopram under inflammation.,"['Mena S', 'Cruikshank A', 'Best J', 'Nijhout HF', 'Reed MC', 'Hashemi P']","['*Serotonin Plasma Membrane Transport Proteins/metabolism', 'Animals', '*Selective Serotonin Reuptake Inhibitors/pharmacology', 'Mice', '*Inflammation/drug therapy/metabolism', '*Escitalopram/pharmacology', 'Hippocampus/metabolism/drug effects', 'Serotonin/metabolism', 'Humans', 'Citalopram/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/38851804/
3517,citalopram,18345966,Escitalopram in the treatment of obsessive-compulsive disorder.,['Zohar J'],"['Citalopram/adverse effects/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Double-Blind Method', 'Drug Approval', 'Humans', 'Obsessive-Compulsive Disorder/diagnosis/*drug therapy/psychology', 'Randomized Controlled Trials as Topic', 'Secondary Prevention', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/18345966/
3518,citalopram,15045034,Escitalopram.,"['Aronson S', 'Delgado P']","['Antidepressive Agents, Second-Generation/adverse effects/pharmacokinetics/*therapeutic use', 'Citalopram/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder, Major/*drug therapy', 'Humans', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/15045034/
3519,citalopram,39163659,A large-scale observational comparison of antidepressants and their effects.,"['Heinz MV', 'Yom-Tov E', 'Mackin DM', 'Matsumura R', 'Jacobson NC']","['Humans', '*Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacology', '*Fluvoxamine/adverse effects/pharmacology', '*Citalopram/adverse effects', 'Male', 'Adult', 'Female', 'Antidepressive Agents/adverse effects', 'Fluoxetine/adverse effects', 'Proportional Hazards Models', 'Paroxetine/adverse effects', 'Escitalopram/pharmacology/administration & dosage', 'Sertraline/adverse effects', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39163659/
3520,citalopram,38326352,"Functional brain responses to emotional faces after three to five weeks of intake of escitalopram in healthy individuals: a double-blind, placebo-controlled randomised study.","['Armand S', 'Langley C', 'Johansen A', 'Ozenne B', 'Overgaard-Hansen O', 'Larsen K', 'Jensen PS', 'Knudsen GM', 'Sahakian BJ', 'Stenbaek DS', 'Fisher PM']","['Humans', '*Escitalopram', '*Citalopram/therapeutic use', 'Emotions/physiology', 'Selective Serotonin Reuptake Inhibitors/pharmacology', 'Brain/diagnostic imaging', 'Magnetic Resonance Imaging', 'Double-Blind Method', 'Facial Expression']",https://pubmed.ncbi.nlm.nih.gov/38326352/
3521,citalopram,32112511,Escitalopram for recurrent isolated sleep paralysis.,"['Hintze JP', 'Gault D']","['Adult', 'Citalopram/pharmacology/*therapeutic use', 'Female', 'Humans', 'Male', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use', 'Sleep Paralysis/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32112511/
3522,citalopram,12474611,Escitalopram: efficacy and tolerability in the treatment of depression.,['Baldwin DS'],"['Antidepressive Agents, Second-Generation/adverse effects/*therapeutic use', 'Anxiety Disorders/drug therapy', 'Citalopram/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy', 'Humans', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/12474611/
3523,citalopram,17934195,Serotonergic anti-depressants and ethanol withdrawal syndrome: a review.,['Uzbay IT'],"['Alcohol Drinking/adverse effects/psychology', 'Animals', 'Antidepressive Agents/*therapeutic use', 'Citalopram/therapeutic use', 'Ethanol/administration & dosage/*adverse effects', 'Fluoxetine/therapeutic use', 'Humans', 'Hypericum', 'Motor Activity/drug effects', 'Plant Extracts/therapeutic use', 'Rats', 'Rats, Wistar', 'Serotonin Agents/*therapeutic use', 'Serotonin Antagonists/therapeutic use', 'Substance Withdrawal Syndrome/*drug therapy/*metabolism/psychology']",https://pubmed.ncbi.nlm.nih.gov/17934195/
3524,citalopram,38247730,Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.,"['Szigeti B', 'Weiss B', 'Rosas FE', 'Erritzoe D', 'Nutt D', 'Carhart-Harris R']","['Humans', '*Psilocybin/pharmacology/administration & dosage/therapeutic use', 'Male', 'Adult', 'Female', '*Depressive Disorder, Major/drug therapy', '*Suggestion', 'Double-Blind Method', 'Middle Aged', '*Escitalopram/pharmacology', 'Hallucinogens/pharmacology/administration & dosage', 'Anticipation, Psychological/drug effects', 'Treatment Outcome', 'Citalopram/therapeutic use/pharmacology/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38247730/
3525,citalopram,37962835,Atypical extrapyramidal manifestation of a typical antipsychotic with serotonergic antidepressant.,"['Singh R', 'Chakrabarti SS', 'Kaur U']","['Humans', '*Antipsychotic Agents/adverse effects', 'Citalopram/adverse effects', 'Dyskinesia, Drug-Induced/etiology', 'Escitalopram/adverse effects', 'Haloperidol/adverse effects', 'Selective Serotonin Reuptake Inhibitors/adverse effects/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/37962835/
3526,fluvoxamine,37849071,Clinical pharmacokinetics of nebivolol: a systematic review.,"['Hanif N', 'Zamir A', 'Imran I', 'Saeed H', 'Majeed A', 'Rehman AU', 'Ashraf W', 'Alqahtani F', 'Rasool MF']","['Male', 'Humans', 'Nebivolol/pharmacokinetics/therapeutic use', '*Hypertension/drug therapy', 'Fluvoxamine/therapeutic use', 'Lansoprazole/therapeutic use', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/37849071/
3527,fluvoxamine,35118917,"Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19a meta-analysis.","['Wen W', 'Chen C', 'Tang J', 'Wang C', 'Zhou M', 'Cheng Y', 'Zhou X', 'Wu Q', 'Zhang X', 'Feng Z', 'Wang M', 'Mao Q']","['Antiviral Agents/adverse effects', 'Cytidine/analogs & derivatives', 'Drug Combinations', '*Fluvoxamine/adverse effects', 'Humans', 'Hydroxylamines', 'Lactams', 'Leucine', 'Nitriles', 'Proline', 'Ritonavir', 'SARS-CoV-2', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/35118917/
3528,fluvoxamine,8698677,Functional neuroanatomy of obsessive-compulsive disorder.,['Trivedi MH'],"['Adult', 'Brain/diagnostic imaging/metabolism/*physiopathology', 'Cerebrovascular Circulation/drug effects', 'Deoxyglucose/analogs & derivatives', 'Female', 'Fluorodeoxyglucose F18', 'Fluvoxamine/pharmacology/therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Neuropsychological Tests', 'Obsessive-Compulsive Disorder/*diagnosis/metabolism/physiopathology', 'Organotechnetium Compounds', 'Oximes', 'Pilot Projects', 'Psychosurgery', 'Technetium Tc 99m Exametazime', 'Tomography, Emission-Computed', 'Tomography, Emission-Computed, Single-Photon', 'Tomography, X-Ray Computed', 'Xenon Radioisotopes']",https://pubmed.ncbi.nlm.nih.gov/8698677/
3529,fluvoxamine,11584871,The role of selective serotonin reuptake inhibitors in reducing alcohol consumption.,"['Naranjo CA', 'Knoke DM']","['Alcohol Drinking/*drug therapy/psychology', 'Alcoholism/*drug therapy/psychology', 'Animals', 'Behavior, Addictive/drug therapy/psychology', 'Behavior, Animal/drug effects', 'Citalopram/pharmacology/therapeutic use', 'Clinical Trials as Topic/statistics & numerical data', 'Comorbidity', 'Drinking Behavior/drug effects', 'Drug Evaluation, Preclinical/statistics & numerical data', 'Fluoxetine/therapeutic use', 'Fluvoxamine/pharmacology/therapeutic use', 'Humans', 'Mice', 'Rats', 'Selective Serotonin Reuptake Inhibitors/pharmacology/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11584871/
3530,fluvoxamine,39163659,A large-scale observational comparison of antidepressants and their effects.,"['Heinz MV', 'Yom-Tov E', 'Mackin DM', 'Matsumura R', 'Jacobson NC']","['Humans', '*Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacology', '*Fluvoxamine/adverse effects/pharmacology', '*Citalopram/adverse effects', 'Male', 'Adult', 'Female', 'Antidepressive Agents/adverse effects', 'Fluoxetine/adverse effects', 'Proportional Hazards Models', 'Paroxetine/adverse effects', 'Escitalopram/pharmacology/administration & dosage', 'Sertraline/adverse effects', 'Depression/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/39163659/
3531,fluvoxamine,15292500,Treating functional impairment of autism with selective serotonin-reuptake inhibitors.,"['Moore ML', 'Eichner SF', 'Jones JR']","['Autistic Disorder/*drug therapy', 'Citalopram/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/therapeutic use', 'Humans', 'Paroxetine/adverse effects/therapeutic use', 'Retrospective Studies', 'Selective Serotonin Reuptake Inhibitors/adverse effects/*therapeutic use', 'Sertraline/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15292500/
3532,fluvoxamine,1806635,Obsessive-compulsive disorder.,['George MS'],"['Clomipramine/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1806635/
3533,fluvoxamine,7949503,Fluvoxamine-associated sexual dysfunction.,"['Dorevitch A', 'Davis H']","['Adult', 'Depressive Disorder/drug therapy', 'Erectile Dysfunction/chemically induced', 'Female', 'Fluvoxamine/*adverse effects', 'Hospitals, University', 'Humans', 'Israel', 'Male', 'Middle Aged', 'Sexual Dysfunction, Physiological/*chemically induced', 'Sexual Dysfunctions, Psychological/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/7949503/
3534,fluvoxamine,31778417,RECURRENT SLEEP PARALYSIS - FEAR OF SLEEPING.,"['Ramos DF', 'Magalhaes J', 'Santos P', 'Vale J', 'Santos MI']","['Academic Performance/psychology', 'Administration, Oral', 'Adolescent', 'Anxiety/etiology/psychology', 'Diagnosis, Differential', 'Fear/*psychology', 'Female', 'Fluvoxamine/administration & dosage/therapeutic use', 'Hallucinations/etiology/psychology', 'Humans', 'Recurrence', 'Selective Serotonin Reuptake Inhibitors/administration & dosage/therapeutic use', 'Sleep Paralysis/*complications/diagnosis/drug therapy/*psychology', 'Sleep Wake Disorders/*diagnosis/etiology', 'Social Change', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/31778417/
3535,fluvoxamine,9720479,Pharmacokinetic interactions of antidepressants.,['Richelson E'],"['Antidepressive Agents/adverse effects/*pharmacokinetics', 'Cyclohexanols/adverse effects/pharmacokinetics', 'Cytochrome P-450 CYP1A2/drug effects', 'Cytochrome P-450 CYP2D6/drug effects', 'Cytochrome P-450 CYP3A', 'Cytochrome P-450 Enzyme System/drug effects', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Fluoxetine/adverse effects/pharmacokinetics', 'Fluvoxamine/adverse effects/pharmacokinetics', 'Humans', 'Mixed Function Oxygenases/drug effects', 'Piperazines', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics', 'Triazoles/adverse effects/pharmacokinetics', 'Venlafaxine Hydrochloride']",https://pubmed.ncbi.nlm.nih.gov/9720479/
3536,fluvoxamine,9184623,Fluvoxamine: a review of the controlled trials in depression.,['Ware MR'],"['Antidepressive Agents/therapeutic use', 'Controlled Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Drug Administration Schedule', 'Fluvoxamine/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Placebos', 'Randomized Controlled Trials as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9184623/
3537,fluvoxamine,38597272,"Fluoxetine, fluvoxamine, and hearing loss or tinnitus after cisplatin treatment: A retrospective cohort study.","['Magagnoli J', 'Cummings TH', 'Hardin JW', 'Sutton SS', 'Ambati J']","['Humans', '*Cisplatin/adverse effects', '*Hearing Loss/chemically induced', 'Retrospective Studies', 'Male', '*Tinnitus/chemically induced', 'Female', '*Fluoxetine/adverse effects/therapeutic use', 'Middle Aged', '*Fluvoxamine/adverse effects/therapeutic use', 'Aged']",https://pubmed.ncbi.nlm.nih.gov/38597272/
3538,fluvoxamine,38317106,Fluvoxamine inhibits Th1 and Th17 polarization and function by repressing glycolysis to attenuate autoimmune progression in type 1 diabetes.,"['Zou Y', 'Zhang J', 'Sun F', 'Xu Q', 'Chen L', 'Luo X', 'Wang T', 'Zhou Q', 'Zhang S', 'Xiong F', 'Kong W', 'Yang P', 'Yu Q', 'Liu S', 'Wang CY']","['Mice', 'Humans', 'Animals', '*Diabetes Mellitus, Type 1/drug therapy', 'Mice, Inbred NOD', 'Fluvoxamine/pharmacology/therapeutic use', 'Th17 Cells', 'Phosphatidylinositol 3-Kinases', '*Autoimmune Diseases', 'Th1 Cells']",https://pubmed.ncbi.nlm.nih.gov/38317106/
3539,fluvoxamine,29676327,Fluvoxamine-induced intracranial hypertension in a 10-year-old boy.,"['Samant H', 'Samant P']","['Anti-Anxiety Agents/adverse effects/therapeutic use', 'Child', 'Fluvoxamine/*adverse effects/therapeutic use', 'Humans', 'Intracranial Hypertension/*chemically induced/diagnosis/physiopathology', 'Intracranial Pressure', 'Magnetic Resonance Angiography', 'Male', 'Obsessive-Compulsive Disorder/drug therapy', 'Papilledema/diagnosis/*etiology/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/29676327/
3540,fluvoxamine,8333005,Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects.,"['Spina E', 'Pollicino AM', 'Avenoso A', 'Campo GM', 'Perucca E', 'Caputi AP']","['Adult', 'Desipramine/adverse effects/blood/*pharmacokinetics', 'Drug Interactions', 'Fluvoxamine/adverse effects/*pharmacology', 'Humans', 'Imipramine/adverse effects/blood/*pharmacokinetics', 'Male']",https://pubmed.ncbi.nlm.nih.gov/8333005/
3541,fluvoxamine,16351675,Clinical effects of pharmacological variations in selective serotonin reuptake inhibitors: an overview.,"['Carrasco JL', 'Sandner C']","['Antidepressive Agents, Second-Generation/*pharmacology', 'Citalopram/pharmacology', 'Fluoxetine/pharmacology', 'Fluvoxamine/pharmacology', 'Humans', 'Mood Disorders/*drug therapy', 'Paroxetine/pharmacology', 'Selective Serotonin Reuptake Inhibitors/*pharmacology', 'Sertraline/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/16351675/
3542,fluvoxamine,8160253,Probable metabolic interaction between methadone and fluvoxamine in addict patients.,"['Bertschy G', 'Baumann P', 'Eap CB', 'Baettig D']","['Adult', 'Depressive Disorder/drug therapy/psychology', 'Drug Interactions', 'Female', 'Fluvoxamine/adverse effects/*pharmacokinetics/therapeutic use', 'Humans', 'Male', 'Methadone/adverse effects/*pharmacokinetics/therapeutic use', 'Opioid-Related Disorders/drug therapy/*metabolism/psychology']",https://pubmed.ncbi.nlm.nih.gov/8160253/
3543,fluvoxamine,38703743,Off-label higher doses of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: Safety and tolerability.,"['Levy DM', 'Arush OB', 'Carmi L', 'Wetzler AJ', 'Zohar J']","['Humans', '*Obsessive-Compulsive Disorder/drug therapy', '*Selective Serotonin Reuptake Inhibitors/therapeutic use/administration & dosage/adverse effects', 'Female', 'Adult', 'Male', 'Retrospective Studies', '*Off-Label Use', '*Fluvoxamine/therapeutic use/administration & dosage/adverse effects', '*Sertraline/therapeutic use/administration & dosage/adverse effects', 'Middle Aged', 'Longitudinal Studies', 'Fluoxetine/therapeutic use/administration & dosage/adverse effects', 'Escitalopram/therapeutic use/administration & dosage', 'Young Adult', 'Treatment Outcome', 'Dose-Response Relationship, Drug']",https://pubmed.ncbi.nlm.nih.gov/38703743/
3544,fluvoxamine,36103313,Fluvoxamine for the treatment of COVID-19.,"['Nyirenda JL', 'Sofroniou M', 'Toews I', 'Mikolajewska A', 'Lehane C', 'Monsef I', 'Abu-Taha A', 'Maun A', 'Stegemann M', 'Schmucker C']","['*Clinical Deterioration', 'Fluvoxamine/pharmacology/therapeutic use', 'Humans', 'Randomized Controlled Trials as Topic', 'Selective Serotonin Reuptake Inhibitors/therapeutic use', '*COVID-19 Drug Treatment']",https://pubmed.ncbi.nlm.nih.gov/36103313/
3545,Voriconazole,26684607,"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.","['Maertens JA', 'Raad II', 'Marr KA', 'Patterson TF', 'Kontoyiannis DP', 'Cornely OA', 'Bow EJ', 'Rahav G', 'Neofytos D', 'Aoun M', 'Baddley JW', 'Giladi M', 'Heinz WJ', 'Herbrecht R', 'Hope W', 'Karthaus M', 'Lee DG', 'Lortholary O', 'Morrison VA', 'Oren I', 'Selleslag D', 'Shoham S', 'Thompson GR 3rd', 'Lee M', 'Maher RM', 'Schmitt-Hoffmann AH', 'Zeiher B', 'Ullmann AJ']","['Administration, Oral', 'Adult', 'Aged', 'Antifungal Agents/administration & dosage/adverse effects/*therapeutic use', 'Aspergillosis/drug therapy/mortality', 'Double-Blind Method', 'Drug Administration Schedule', 'Female', 'Humans', 'Injections, Intravenous', 'Male', 'Middle Aged', 'Mycoses/*drug therapy/mortality', 'Nitriles/administration & dosage/adverse effects/*therapeutic use', 'Pyridines/administration & dosage/adverse effects/*therapeutic use', 'Treatment Outcome', 'Triazoles/administration & dosage/adverse effects/*therapeutic use', 'Voriconazole/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26684607/
3546,Voriconazole,35969068,New Perspectives on Antimicrobial Agents: Isavuconazole.,"['Lewis JS 2nd', 'Wiederhold NP', 'Hakki M', 'Thompson GR 3rd']","['Antifungal Agents/pharmacokinetics/therapeutic use', '*Candidiasis, Invasive/drug therapy', 'Caspofungin/therapeutic use', 'Fungi', 'Humans', '*Invasive Fungal Infections/drug therapy', 'Nitriles/pharmacokinetics/therapeutic use', 'Pyridines', 'Triazoles/pharmacokinetics/therapeutic use', 'Voriconazole/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35969068/
3547,Voriconazole,16802848,Pharmacokinetic/pharmacodynamic profile of voriconazole.,"['Theuretzbacher U', 'Ihle F', 'Derendorf H']","['Animals', 'Antifungal Agents/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Biotransformation', 'Drug Interactions', 'Fungi/drug effects', 'Half-Life', 'Humans', 'Mycoses/*drug therapy/microbiology', 'Protein Binding', 'Pyrimidines/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Tissue Distribution', 'Triazoles/administration & dosage/adverse effects/*pharmacokinetics/*therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/16802848/
3548,Voriconazole,25599346,Combination antifungal therapy for invasive aspergillosis: a randomized trial.,"['Marr KA', 'Schlamm HT', 'Herbrecht R', 'Rottinghaus ST', 'Bow EJ', 'Cornely OA', 'Heinz WJ', 'Jagannatha S', 'Koh LP', 'Kontoyiannis DP', 'Lee DG', 'Nucci M', 'Pappas PG', 'Slavin MA', 'Queiroz-Telles F', 'Selleslag D', 'Walsh TJ', 'Wingard JR', 'Maertens JA']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Anidulafungin', 'Antifungal Agents/adverse effects/*therapeutic use', 'Aspergillosis/complications/diagnosis/*drug therapy/mortality', 'Double-Blind Method', 'Drug Therapy, Combination', 'Echinocandins/adverse effects/*therapeutic use', 'Female', 'Galactose/analogs & derivatives', 'Hematologic Neoplasms/*complications/therapy', '*Hematopoietic Stem Cell Transplantation', 'Humans', 'Karnofsky Performance Status', 'Male', 'Mannans/blood', 'Middle Aged', 'Platelet Count', 'Treatment Outcome', 'Voriconazole/adverse effects/*therapeutic use', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/25599346/
3549,Voriconazole,33549194,"Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a phase 3, randomised, controlled, non-inferiority trial.","['Maertens JA', 'Rahav G', 'Lee DG', 'Ponce-de-Leon A', 'Ramirez Sanchez IC', 'Klimko N', 'Sonet A', 'Haider S', 'Diego Velez J', 'Raad I', 'Koh LP', 'Karthaus M', 'Zhou J', 'Ben-Ami R', 'Motyl MR', 'Han S', 'Grandhi A', 'Waskin H']","['Administration, Intravenous', 'Administration, Oral', 'Adolescent', 'Adult', 'Antifungal Agents/*administration & dosage/adverse effects', 'Double-Blind Method', 'Female', 'Humans', 'Invasive Pulmonary Aspergillosis/*drug therapy/mortality', 'Male', 'Middle Aged', 'Prospective Studies', 'Triazoles/*administration & dosage/adverse effects', 'Voriconazole/*administration & dosage/adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33549194/
3550,Voriconazole,36622029,Optimization of Antimicrobial Stewardship Programs Using Therapeutic Drug Monitoring and Pharmacokinetics-Pharmacodynamics Protocols: A Cost-Benefit Review.,"['Telles JP', 'Morales R Jr', 'Yamada CH', 'Marins TA', ""D'Amaro Juodinis V"", 'Sztajnbok J', 'Silva M Jr', 'Bassetti BR', 'Albiero J', 'Tuon FF']","['Humans', 'Aminoglycosides', 'Anti-Bacterial Agents/therapeutic use', '*Antimicrobial Stewardship', 'Ceftazidime', 'Cost-Benefit Analysis', 'Drug Monitoring', '*Vancomycin/therapeutic use', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/36622029/
3551,Voriconazole,33084474,Dementia-Like Symptoms Associated With Posaconazole.,"['Corallo CE', 'Ivulich SP', 'Kotecha DS', 'Morrissey O']","['*Antifungal Agents/adverse effects', '*Dementia/drug therapy', 'Humans', 'Triazoles/adverse effects', 'Voriconazole/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/33084474/
3552,Voriconazole,37300337,A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.,"['Kato H', 'Hagihara M', 'Asai N', 'Umemura T', 'Hirai J', 'Mori N', 'Yamagishi Y', 'Iwamoto T', 'Mikamo H']","['Humans', '*Antifungal Agents/adverse effects', '*Invasive Fungal Infections/drug therapy/prevention & control', 'Voriconazole/therapeutic use', 'Triazoles/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37300337/
3553,Voriconazole,21668526,Anidulafungin: when and how? The clinician's view.,"['George J', 'Reboli AC']","['Anidulafungin', 'Antifungal Agents/therapeutic use', 'Aspergillosis/drug therapy/microbiology', 'Aspergillus/drug effects/pathogenicity', 'Candida/*drug effects/pathogenicity', 'Candidiasis/*drug therapy/microbiology', 'Drug Resistance, Fungal', 'Drug Synergism', 'Drug-Related Side Effects and Adverse Reactions', 'Echinocandins/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Itraconazole/administration & dosage/pharmacology', 'Microbial Sensitivity Tests', 'Pyrimidines/administration & dosage/pharmacology', 'Triazoles/administration & dosage/pharmacology', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/21668526/
3554,Voriconazole,36424314,Clinical Practice Guideline for the Therapeutic Drug Monitoring of Voriconazole in Non-Asian and Asian Adult Patients: Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.,"['Takesue Y', 'Hanai Y', 'Oda K', 'Hamada Y', 'Ueda T', 'Mayumi T', 'Matsumoto K', 'Fujii S', 'Takahashi Y', 'Miyazaki Y', 'Kimura T']","['Humans', 'Adult', 'Voriconazole/adverse effects', 'Drug Monitoring', 'Consensus', 'East Asian People', 'Antifungal Agents/therapeutic use', '*Drug-Related Side Effects and Adverse Reactions', '*Chemical and Drug Induced Liver Injury/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36424314/
3555,Voriconazole,34494173,Broad-spectrum azoles and flucloxacillin: a dangerous match.,"['Vangheluwe T', 'Van Hoecke F', 'Dumoulin A', 'Vogelaers D']","['Aged', 'Anti-Bacterial Agents/*therapeutic use', 'Antifungal Agents/*therapeutic use', 'Aspergillosis/*drug therapy/microbiology', 'Aspergillus fumigatus/drug effects', 'Azoles', '*Drug Interactions', 'Drug Therapy, Combination/adverse effects', 'Female', 'Floxacillin/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Nitriles/*therapeutic use', 'Pyridines/*therapeutic use', 'Staphylococcal Infections/*drug therapy/microbiology', 'Staphylococcus aureus/drug effects', 'Triazoles/*therapeutic use', 'Voriconazole/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/34494173/
3556,Voriconazole,38752732,Breakthrough Invasive Fungal Infections in Patients With High-Risk Hematological Disorders Receiving Voriconazole and Posaconazole Prophylaxis: A Systematic Review.,"['Boutin CA', 'Durocher F', 'Beauchemin S', 'Ziegler D', 'Abou Chakra CN', 'Dufresne SF']","['Humans', '*Antifungal Agents/therapeutic use', '*Invasive Fungal Infections/prevention & control/drug therapy', '*Voriconazole/therapeutic use', '*Hematologic Diseases/complications', '*Triazoles/therapeutic use', 'Drug Resistance, Fungal', 'Aspergillus/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38752732/
3557,Voriconazole,38161768,Isavuconazole for Treating Invasive Mould Disease in Solid Organ Transplant Recipients.,"['Silva JT', 'Husain S', 'Aguado JM']","['Humans', 'Antifungal Agents/therapeutic use/pharmacology', '*Aspergillosis/drug therapy/chemically induced', 'Nitriles/therapeutic use/pharmacology', '*Organ Transplantation/adverse effects', 'Transplant Recipients', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/38161768/
3558,Voriconazole,34637660,Fusarium Causing Recalcitrant Post-operative endophthalmitis-Report of a Case with Review of Literature.,"['Agarwal M', 'Shah S', 'Garg A', 'Gandhi A', 'Kumar B']","['Adult', 'Antifungal Agents/therapeutic use', '*Endophthalmitis/diagnosis/drug therapy', '*Eye Infections, Fungal/diagnosis/drug therapy', '*Fusarium', 'Humans', 'Male', 'Postoperative Complications/drug therapy', 'Vitrectomy/adverse effects', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/34637660/
3559,Voriconazole,28835093,Voriconazole-refractory invasive aspergillosis.,"['Park SY', 'Yoon JA', 'Kim SH']","['Antifungal Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Aspergillus/*drug effects/pathogenicity', 'Biopsy', 'Coinfection', 'Cytochrome P-450 CYP2C19/genetics/metabolism', 'Diagnosis, Differential', 'Diagnostic Errors', 'Drug Monitoring', '*Drug Resistance, Fungal', 'Female', 'Humans', 'Immunocompromised Host', 'Invasive Pulmonary Aspergillosis/diagnosis/*drug therapy/immunology/microbiology', 'Male', 'Middle Aged', 'Pharmacogenetics', 'Pharmacogenomic Variants', 'Predictive Value of Tests', 'Tomography, X-Ray Computed', 'Voriconazole/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28835093/
3560,Voriconazole,36642232,"Therapeutic drug monitoring-guided treatment versus standard dosing of voriconazole for invasive aspergillosis in haematological patients: a multicentre, prospective, cluster randomised, crossover clinical trial.","['Veringa A', 'Bruggemann RJ', 'Span LFR', 'Biemond BJ', 'de Boer MGJ', 'van den Heuvel ER', 'Klein SK', 'Kraemer D', 'Minnema MC', 'Prakken NHJ', 'Rijnders BJA', 'Swen JJ', 'Verweij PE', 'Wondergem MJ', 'Ypma PF', 'Blijlevens N', 'Kosterink JGW', 'van der Werf TS', 'Alffenaar JC']","['Humans', 'Adolescent', 'Adult', 'Voriconazole/adverse effects', 'Prospective Studies', 'Antifungal Agents/adverse effects', 'Drug Monitoring', 'Retrospective Studies', '*Aspergillosis/drug therapy', '*Invasive Fungal Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36642232/
3561,Voriconazole,29477782,[Not Available].,"['Simon L', 'Gastaud L', 'Martiano D', 'Bailleux C', 'Hasseine L', 'Gari-Toussaint M']","['Aged', 'Amphotericin B/therapeutic use', 'Anti-Bacterial Agents/administration & dosage', 'Antifungal Agents/therapeutic use', 'Endophthalmitis/diagnosis/*drug therapy/*microbiology', 'Eye/microbiology/pathology', 'Female', 'Fusarium/*isolation & purification', 'Humans', 'Hyphae/drug effects/isolation & purification', 'Immunocompromised Host', 'Leukemia, Myeloid, Acute/complications/*drug therapy/microbiology', 'Treatment Outcome', 'Triazoles/administration & dosage', 'Vitrectomy', 'Voriconazole/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29477782/
3562,Voriconazole,36929539,Invasive aspergillosis in liver transplant recipients.,"['Melenotte C', 'Aimanianda V', 'Slavin M', 'Aguado JM', 'Armstrong-James D', 'Chen YC', 'Husain S', 'Van Delden C', 'Saliba F', 'Lefort A', 'Botterel F', 'Lortholary O']","['Humans', 'Antifungal Agents/therapeutic use', '*Liver Transplantation/adverse effects', '*Aspergillosis/drug therapy/epidemiology/diagnosis', 'Voriconazole/therapeutic use', 'Aspergillus', '*Invasive Fungal Infections/drug therapy/epidemiology/complications', 'Transplant Recipients']",https://pubmed.ncbi.nlm.nih.gov/36929539/
3563,Voriconazole,27147607,Adrenal Insufficiency With Voriconazole and Inhaled/Intranasal Corticosteroids: Case Report and Systematic Review.,"['Duman AK', 'Fulco PP']","['Administration, Inhalation', 'Adrenal Cortex Hormones/administration & dosage/*adverse effects/blood', 'Adrenal Insufficiency/blood/*chemically induced/*diagnosis', 'Antifungal Agents/administration & dosage/*adverse effects/blood', 'Cushing Syndrome/blood/chemically induced/diagnosis', 'Cytochrome P-450 CYP3A Inhibitors/administration & dosage/adverse effects/blood', 'Drug Interactions/physiology', 'Female', 'Humans', 'Middle Aged', 'Voriconazole/administration & dosage/*adverse effects/blood']",https://pubmed.ncbi.nlm.nih.gov/27147607/
3564,Voriconazole,12525928,Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.,"['Fournier S', 'Pavageau W', 'Feuillhade M', 'Deplus S', 'Zagdanski AM', 'Verola O', 'Dombret H', 'Molina JM']","['Antifungal Agents/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Leukemia, Myeloid/*complications', 'Male', 'Middle Aged', 'Mycoses/*complications/*drug therapy/microbiology/pathology', 'Neutropenia/complications', 'Pyrimidines/administration & dosage/adverse effects/*therapeutic use', 'Risk Factors', 'Triazoles/administration & dosage/adverse effects/*therapeutic use', 'Trichosporon/drug effects/*physiology', 'Voriconazole']",https://pubmed.ncbi.nlm.nih.gov/12525928/
3565,nicotinate,25828829,Ethionamide-induced Pellagra.,"['Gupta Y', 'Shah I']","['Adolescent', 'Antitubercular Agents/administration & dosage/*adverse effects/therapeutic use', 'Diagnosis, Differential', 'Ethionamide/*adverse effects', 'Female', 'Humans', 'Niacin/therapeutic use', 'Pellagra/*chemically induced/diagnosis/*drug therapy', 'Treatment Outcome', 'Tuberculosis, Pulmonary/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/25828829/
3566,nicotinate,38051244,A Second Look at Niacin.,['Epstein H'],"['Humans', '*Niacin/therapeutic use/physiology', 'Niacinamide/therapeutic use', 'Skin', '*Skin Diseases', '*COVID-19']",https://pubmed.ncbi.nlm.nih.gov/38051244/
3567,nicotinate,29477227,Niacin.,"['Kirkland JB', 'Meyer-Ficca ML']","['Aging/drug effects', 'Humans', 'Neoplasms', 'Niacin/*administration & dosage/metabolism/*pharmacology', 'Pellagra/*prevention & control', 'Risk Factors', 'Vitamins/administration & dosage/metabolism/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/29477227/
3568,nicotinate,24854407,"HDL-targeted therapies: progress, failures and future.","['Kingwell BA', 'Chapman MJ', 'Kontush A', 'Miller NE']","['Animals', 'Apolipoprotein A-I/agonists/genetics/metabolism', 'Cardiovascular Diseases/blood/metabolism/*prevention & control', 'Cholesterol Ester Transfer Proteins/antagonists & inhibitors/metabolism', '*Clinical Trials as Topic', 'Drugs, Investigational/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypolipidemic Agents/adverse effects/metabolism/*therapeutic use', 'Lipoproteins, HDL/*agonists/blood/metabolism/therapeutic use', '*Models, Biological', '*Molecular Targeted Therapy/adverse effects', 'Niacin/adverse effects/metabolism/therapeutic use', 'Phosphatidylcholine-Sterol O-Acyltransferase/adverse effects/genetics/metabolism/therapeutic use', 'Recombinant Proteins/adverse effects/metabolism/therapeutic use', 'Up-Regulation/drug effects']",https://pubmed.ncbi.nlm.nih.gov/24854407/
3569,nicotinate,21418500,Future of GPR109A agonists in the treatment of dyslipidaemia.,"['Wanders D', 'Judd RL']","['Adipocytes/drug effects', 'Cardiovascular Diseases/*drug therapy', 'Dyslipidemias/*drug therapy', 'Hepatocytes/drug effects', 'Humans', 'Niacin/*pharmacology', 'Nicotinic Agonists/*pharmacology', 'Receptors, G-Protein-Coupled/*agonists/*therapeutic use', 'Receptors, Nicotinic/*drug effects/physiology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21418500/
3570,nicotinate,30813414,Niacin in the Central Nervous System: An Update of Biological Aspects and Clinical Applications.,"['Gasperi V', 'Sibilano M', 'Savini I', 'Catani MV']","['Animals', 'Central Nervous System/*metabolism', '*Clinical Trials as Topic', 'Humans', 'Nervous System Diseases/drug therapy/metabolism', 'Niacin/chemistry/deficiency/*metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/30813414/
3571,nicotinate,22116693,Niacin: vitamin and antidyslipidemic drug.,"['Jacobson EL', 'Kim H', 'Kim M', 'Jacobson MK']","['Animals', 'Clinical Trials as Topic', 'Dyslipidemias/drug therapy', 'Humans', 'Hypolipidemic Agents/*therapeutic use', 'Lipid Metabolism/drug effects', 'Lipids/blood', 'Niacin/deficiency/*metabolism/*therapeutic use', 'Pellagra/blood/drug therapy/etiology', 'Vitamins/*metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22116693/
3572,nicotinate,31617441,Activation of HCAR2 by niacin: benefits beyond lipid lowering.,['Tuteja S'],"['Cholesterol, HDL/genetics', 'Coronary Disease/*drug therapy/genetics/pathology', 'Genotype', 'Humans', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Lipids/antagonists & inhibitors/genetics', 'Niacin/adverse effects/*pharmacology', 'Polymorphism, Single Nucleotide', 'Receptors, G-Protein-Coupled/*genetics']",https://pubmed.ncbi.nlm.nih.gov/31617441/
3573,nicotinate,22138132,Niacin requirements for genomic stability.,['Kirkland JB'],"['Animals', 'DNA Damage/*drug effects', 'DNA Repair/drug effects', 'Dietary Supplements', '*Genomic Instability', 'Humans', 'Models, Animal', 'Neoplasms/epidemiology', 'Niacin/administration & dosage/deficiency/*pharmacology', 'Skin/drug effects']",https://pubmed.ncbi.nlm.nih.gov/22138132/
3574,nicotinate,22133050,Safety and tolerability of extended-release niacin with laropiprant.,"['Yadav R', 'Kwok S', 'Ammori BJ', 'Issa B', 'Soran H']","['Animals', 'Delayed-Action Preparations', 'Drug Combinations', 'Dyslipidemias/drug therapy', 'Flushing/chemically induced/prevention & control', 'Humans', 'Hypolipidemic Agents/administration & dosage/*adverse effects/therapeutic use', 'Indoles/administration & dosage/*pharmacology', 'Niacin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22133050/
3575,nicotinate,27749252,Pleiotropic effects of niacin: Current possibilities for its clinical use.,"['Zeman M', 'Vecka M', 'Perlik F', 'Stankova B', 'Hromadka R', 'Tvrzicka E', 'Sirc J', 'Hrib J', 'Zak A']","['Animals', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/pharmacology/therapeutic use', 'Antioxidants/adverse effects/therapeutic use', 'Atherosclerosis/chemically induced/etiology/metabolism/prevention & control', 'Disease Progression', 'Drug Therapy, Combination/adverse effects', 'Fibrinolytic Agents/adverse effects/pharmacology/therapeutic use', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects/therapeutic use', 'Hyperlipidemias/*drug therapy/metabolism/physiopathology', 'Hypolipidemic Agents/adverse effects/pharmacology/*therapeutic use', '*Models, Biological', 'Niacin/adverse effects/pharmacology/*therapeutic use', 'Receptors, G-Protein-Coupled/*antagonists & inhibitors/metabolism', 'Receptors, Nicotinic/metabolism', 'Vasodilator Agents/adverse effects/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27749252/
3576,nicotinate,19878384,Mechanisms of flushing due to niacin and abolition of these effects.,"['Sood A', 'Arora R']","['Aspirin/therapeutic use', 'Dose-Response Relationship, Drug', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/adverse effects/therapeutic use', 'Indoles/therapeutic use', 'Niacin/*adverse effects/*therapeutic use', 'Pruritus/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/19878384/
3577,nicotinate,21314634,What restricts the clinical use of nicotinic acid?,"['Kei A', 'Liberopoulos EN', 'Elisaf MS']","['Animals', 'Cardiovascular Diseases/*drug therapy/physiopathology', 'Cholesterol, HDL/blood', 'Clinical Trials as Topic', 'Humans', 'Hypolipidemic Agents/*adverse effects/pharmacology/therapeutic use', 'Lipids/blood', 'Lipoprotein(a)/blood', 'Niacin/*adverse effects/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21314634/
3578,nicotinate,26073392,Is HPS2-THRIVE the death knell for niacin?,"['Toth PP', 'Murthy AM', 'Sidhu MS', 'Boden WE']","['Clinical Trials as Topic', 'Humans', 'Hypolipidemic Agents/*administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Myocardial Infarction/*blood/*drug therapy', 'Niacin/*administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/26073392/
3579,nicotinate,23357134,Nicotinic acid as a lipid-modifying drug--a review.,"['Julius U', 'Fischer S']","['Animals', 'Biomarkers/blood', 'Chemistry, Pharmaceutical', 'Humans', 'Hyperlipidemias/blood/*drug therapy', 'Hypolipidemic Agents/adverse effects/chemistry/*therapeutic use', 'Lipids/*blood', 'Niacin/adverse effects/chemistry/*therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/23357134/
3580,nicotinate,16760691,Dietary and nutraceutical options for managing the hypertriglyceridemic patient.,"['Pins JJ', 'Keenan JM']","['Dietary Carbohydrates/*administration & dosage/adverse effects', 'Energy Intake', 'Evidence-Based Medicine', 'Exercise', 'Fasting', 'Fish Oils/*therapeutic use', 'Humans', 'Hypertriglyceridemia/blood/etiology/*prevention & control', 'Metabolic Syndrome/complications', 'Niacin/*therapeutic use', 'Obesity/complications', 'Pantetheine/*analogs & derivatives/therapeutic use', 'Practice Guidelines as Topic', 'Risk Factors', 'Risk Reduction Behavior', 'Severity of Illness Index', 'Triglycerides/blood', 'Weight Loss']",https://pubmed.ncbi.nlm.nih.gov/16760691/
3581,nicotinate,23948546,"Niacin, an old drug with a new twist.","['Song WL', 'FitzGerald GA']","['Animals', 'Dyslipidemias/*drug therapy', 'Humans', 'Hypolipidemic Agents/adverse effects/*therapeutic use', 'Lipoproteins, HDL/blood', 'Lipoproteins, LDL/blood', 'Niacin/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/23948546/
3582,nicotinate,21893559,The facts behind niacin.,"['Hochholzer W', 'Berg DD', 'Giugliano RP']","['Biomarkers/metabolism', 'Cardiovascular Diseases/etiology/*prevention & control', 'Cholesterol, HDL/blood/drug effects', 'Cholesterol, LDL/blood/drug effects', 'Drug Therapy, Combination', 'Dyslipidemias/complications/drug therapy', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/administration & dosage/therapeutic use', 'Hypolipidemic Agents/administration & dosage/pharmacology/*therapeutic use', 'Niacin/administration & dosage/pharmacology/*therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/21893559/
3583,nicotinate,11374857,Evaluating niacin in its various forms.,['Knopp RH'],"['*Chemistry, Pharmaceutical', 'Cholesterol/*blood', 'Coronary Disease/*prevention & control', 'Delayed-Action Preparations', 'Dietary Fats/administration & dosage/metabolism', 'Dose-Response Relationship, Drug', 'Humans', 'Intestinal Absorption', 'Niacin/administration & dosage/pharmacokinetics/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/11374857/
3584,Docetaxol,33186519,Senescence Reprogramming by TIMP1 Deficiency Promotes Prostate Cancer Metastasis.,"['Guccini I', 'Revandkar A', ""D'Ambrosio M"", 'Colucci M', 'Pasquini E', 'Mosole S', 'Troiani M', 'Brina D', 'Sheibani-Tezerji R', 'Elia AR', 'Rinaldi A', 'Pernigoni N', 'Ruschoff JH', 'Dettwiler S', 'De Marzo AM', 'Antonarakis ES', 'Borrelli C', 'Moor AE', 'Garcia-Escudero R', 'Alajati A', 'Attanasio G', 'Losa M', 'Moch H', 'Wild P', 'Egger G', 'Alimonti A']","['Animals', 'Cellular Senescence/drug effects', 'Docetaxel/*administration & dosage/pharmacology', '*Gene Deletion', 'Gene Expression Regulation, Neoplastic', 'Humans', 'Male', 'Matrix Metalloproteinases/metabolism', 'Mice', 'Neoplasm Metastasis', 'Neoplasm Transplantation', 'PC-3 Cells', 'PTEN Phosphohydrolase/*genetics', 'Prostatic Neoplasms/drug therapy/genetics/metabolism/*pathology', 'Tissue Inhibitor of Metalloproteinase-1/*genetics']",https://pubmed.ncbi.nlm.nih.gov/33186519/
3585,Docetaxol,29384722,Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.,"['Kyriakopoulos CE', 'Chen YH', 'Carducci MA', 'Liu G', 'Jarrard DF', 'Hahn NM', 'Shevrin DH', 'Dreicer R', 'Hussain M', 'Eisenberger M', 'Kohli M', 'Plimack ER', 'Vogelzang NJ', 'Picus J', 'Cooney MM', 'Garcia JA', 'DiPaola RS', 'Sweeney CJ']","['Androgen Antagonists/*administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Docetaxel/*administration & dosage/adverse effects', 'Humans', 'Male', 'Neoplasm Metastasis', 'Neoplasms, Hormone-Dependent/*drug therapy/mortality/pathology', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29384722/
3586,Docetaxol,38722620,Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review.,"['Hussain M', 'Fizazi K', 'Shore ND', 'Heidegger I', 'Smith MR', 'Tombal B', 'Saad F']","['Humans', 'Male', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology/mortality', 'Treatment Outcome', 'Neoplasm Metastasis', 'Androgen Receptor Antagonists/therapeutic use', 'Docetaxel/therapeutic use/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/38722620/
3587,Docetaxol,30509740,"Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.","['Cohen EEW', 'Soulieres D', 'Le Tourneau C', 'Dinis J', 'Licitra L', 'Ahn MJ', 'Soria A', 'Machiels JP', 'Mach N', 'Mehra R', 'Burtness B', 'Zhang P', 'Cheng J', 'Swaby RF', 'Harrington KJ']","['Aged', 'Antibodies, Monoclonal, Humanized/administration & dosage/adverse effects/*therapeutic use', 'Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects/therapeutic use', 'Cetuximab/administration & dosage/adverse effects/therapeutic use', 'Disease Progression', 'Docetaxel/administration & dosage/adverse effects', 'Drug Administration Schedule', 'Female', 'Head and Neck Neoplasms/*drug therapy/pathology', 'Humans', 'Kaplan-Meier Estimate', 'Male', 'Methotrexate/administration & dosage/adverse effects', 'Middle Aged', 'Neoplasm Recurrence, Local/*drug therapy', 'Squamous Cell Carcinoma of Head and Neck/*drug therapy/pathology/secondary']",https://pubmed.ncbi.nlm.nih.gov/30509740/
3588,Docetaxol,36184068,"Tislelizumab Versus Docetaxel in Patients With Previously Treated Advanced NSCLC (RATIONALE-303): A Phase 3, Open-Label, Randomized Controlled Trial.","['Zhou C', 'Huang D', 'Fan Y', 'Yu X', 'Liu Y', 'Shu Y', 'Ma Z', 'Wang Z', 'Cheng Y', 'Wang J', 'Hu S', 'Liu Z', 'Poddubskaya E', 'Disel U', 'Akopov A', 'Dvorkin M', 'Zheng W', 'Ma Y', 'Wang Y', 'Li S', 'Yu C', 'Rivalland G']","['Humans', 'Docetaxel/pharmacology/therapeutic use', 'B7-H1 Antigen/metabolism', '*Lung Neoplasms/pathology', '*Antineoplastic Agents/therapeutic use', '*Carcinoma, Non-Small-Cell Lung/pathology', 'Biomarkers']",https://pubmed.ncbi.nlm.nih.gov/36184068/
3589,Docetaxol,38767468,Treatment of metastatic hormone-sensitive prostate cancer: from doublet therapy to triplet therapy.,"['Ye SJ', 'Huang RD', 'Fei X', 'Tao ZL', 'Liu WH', 'Ma Q']","['Humans', 'Male', '*Androgen Antagonists/therapeutic use', '*Prostatic Neoplasms/drug therapy/pathology', '*Docetaxel/therapeutic use/administration & dosage', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Quality of Life', 'Antineoplastic Agents, Hormonal/therapeutic use/administration & dosage', 'Neoplasm Metastasis']",https://pubmed.ncbi.nlm.nih.gov/38767468/
3590,Docetaxol,31345386,Induction chemotherapy in head and neck cancers: Results and controversies.,"['Gau M', 'Karabajakian A', 'Reverdy T', 'Neidhardt EM', 'Fayette J']","['Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'Cetuximab/administration & dosage/adverse effects', 'Chemoradiotherapy/adverse effects/*methods', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Fluorouracil/administration & dosage/adverse effects', 'Head and Neck Neoplasms/pathology/*therapy', 'Humans', 'Induction Chemotherapy/adverse effects/*methods', 'Laryngectomy/adverse effects', 'Larynx/drug effects/pathology/radiation effects/surgery', 'Neoplasm Staging', 'Organ Sparing Treatments/adverse effects/*methods', 'Progression-Free Survival', 'Randomized Controlled Trials as Topic', 'Squamous Cell Carcinoma of Head and Neck/pathology/*therapy']",https://pubmed.ncbi.nlm.nih.gov/31345386/
3591,Docetaxol,38729054,Capivasertib in combination with enzalutamide for metastatic castration resistant prostate cancer after docetaxel and abiraterone: Results from the randomized phase II RE-AKT trial.,"['Rescigno P', 'Porta N', 'Finneran L', 'Riisnaes R', 'Figueiredo I', 'Carreira S', 'Flohr P', 'Miranda S', 'Bertan C', 'Ferreira A', 'Crespo M', 'Rodrigues DN', 'Gurel B', 'Nobes J', 'Crabb S', 'Malik Z', 'Ralph C', 'McGovern U', 'Hoskin P', 'Jones RJ', 'Birtle A', 'Gale J', 'Sankey P', 'Jain S', 'McLaren D', 'Chadwick E', 'Espinasse A', 'Hall E', 'de Bono J']","['Humans', 'Male', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', '*Phenylthiohydantoin/administration & dosage/therapeutic use/adverse effects', '*Benzamides', '*Docetaxel/administration & dosage/therapeutic use', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', 'Middle Aged', '*Nitriles', 'Double-Blind Method', '*Pyrimidines/therapeutic use/administration & dosage/adverse effects', 'Androstenes/therapeutic use/administration & dosage', 'Aged, 80 and over', 'Pyrroles']",https://pubmed.ncbi.nlm.nih.gov/38729054/
3592,Docetaxol,32749138,Current Development of Oral Taxane Formulations: A Review.,"['Chowdhury N', 'Singh M']","['Administration, Oral', 'Animals', 'Antineoplastic Agents/administration & dosage/chemistry/pharmacokinetics', 'Antineoplastic Agents, Phytogenic/administration & dosage/chemistry/pharmacokinetics', 'Clinical Trials as Topic', 'Docetaxel/*administration & dosage/chemistry/pharmacokinetics', 'Drug Carriers/administration & dosage/chemistry', 'Drug Compounding', 'Drug Delivery Systems', 'Humans', 'Lipids/administration & dosage/chemistry', 'Micelles', 'Nanoparticles/administration & dosage/chemistry', 'Paclitaxel/*administration & dosage/chemistry/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/32749138/
3593,Docetaxol,31977388,Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape.,"['Kinsey EN', 'Zhang T', 'Armstrong AJ']","['Androgen Antagonists/administration & dosage/adverse effects/economics', 'Androstenes/administration & dosage/adverse effects/economics', 'Antineoplastic Agents, Hormonal/*administration & dosage/adverse effects/economics', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects/economics', 'Benzamides', 'Chemoradiotherapy/economics/*methods/trends', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects/economics', 'Drug Administration Schedule', 'Drug Costs', 'Humans', 'Male', 'Medical Oncology/economics/*methods/trends', 'Nitriles', 'Phenylthiohydantoin/administration & dosage/adverse effects/analogs & derivatives/economics', 'Prostatic Neoplasms/mortality/pathology/*therapy', 'Randomized Controlled Trials as Topic', 'Thiohydantoins/administration & dosage/adverse effects/economics', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/31977388/
3594,Docetaxol,39223303,Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis.,"['Wang T', 'Wang X', 'Ding G', 'Liu H', 'Ma X', 'Ma J', 'Cui Y', 'Wu J']","['Humans', 'Male', '*Androgen Antagonists/administration & dosage/adverse effects', '*Antineoplastic Combined Chemotherapy Protocols/administration & dosage/adverse effects', 'Benzamides', 'Docetaxel/administration & dosage/therapeutic use', 'Neoplasm Metastasis', 'Network Meta-Analysis', 'Nitriles/therapeutic use/administration & dosage', 'Phenylthiohydantoin/therapeutic use/administration & dosage/adverse effects', 'Progression-Free Survival', '*Prostatic Neoplasms, Castration-Resistant/drug therapy/mortality/pathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/39223303/
3595,Docetaxol,32701855,The evolving options in metastatic castration-sensitive prostate cancer.,['Hamilou Z'],"['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/therapeutic use', 'Antineoplastic Agents/administration & dosage/adverse effects/*therapeutic use', 'Benzamides/therapeutic use', 'Docetaxel/therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Nitriles/therapeutic use', 'Phenylthiohydantoin/therapeutic use', 'Prostatic Neoplasms/*drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/32701855/
3596,Docetaxol,30015691,Treatment of hormone-naive metastatic prostate cancer.,"['Hamilou Z', 'Saad F', 'Fizazi K']","['Androgen Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Androstenes/administration & dosage/adverse effects/*therapeutic use', 'Clinical Trials, Phase III as Topic', 'Docetaxel/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Humans', 'Male', 'Neoplasm Metastasis', 'Prospective Studies', 'Prostatic Neoplasms/*drug therapy/mortality/pathology', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/30015691/
3597,Docetaxol,29722038,Long-term abiraterone withdrawal syndrome.,"['Marin S', 'Querol R', 'Campins L', 'Miarons M', 'Font A', 'Lianes P']","['Abiraterone Acetate/administration & dosage/adverse effects', 'Antineoplastic Combined Chemotherapy Protocols/*adverse effects/therapeutic use', 'Docetaxel/administration & dosage/adverse effects', 'Humans', 'Male', 'Prednisone/administration & dosage/adverse effects', 'Prostate-Specific Antigen/metabolism', 'Prostatic Neoplasms, Castration-Resistant/drug therapy/metabolism', 'Substance Withdrawal Syndrome/*etiology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29722038/
3598,Docetaxol,39250535,"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.","['Ahn MJ', 'Tanaka K', 'Paz-Ares L', 'Cornelissen R', 'Girard N', 'Pons-Tostivint E', 'Vicente Baz D', 'Sugawara S', 'Cobo M', 'Perol M', 'Mascaux C', 'Poddubskaya E', 'Kitazono S', 'Hayashi H', 'Hong MH', 'Felip E', 'Hall R', 'Juan-Vidal O', 'Brungs D', 'Lu S', 'Garassino M', 'Chargualaf M', 'Zhang Y', 'Howarth P', 'Uema D', 'Lisberg A', 'Sands J']","['Humans', '*Docetaxel/therapeutic use/administration & dosage/adverse effects', '*Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality', '*Lung Neoplasms/drug therapy/pathology/mortality', 'Male', 'Middle Aged', 'Female', 'Aged', 'Adult', 'Aged, 80 and over', 'Progression-Free Survival', 'Immunoconjugates/therapeutic use/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/39250535/
3599,Docetaxol,30382284,Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells.,"['Mikula-Pietrasik J', 'Witucka A', 'Pakula M', 'Uruski P', 'Begier-Krasinska B', 'Niklas A', 'Tykarski A', 'Ksiazek K']","['Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use', 'Carboplatin/administration & dosage/adverse effects', 'Cell Physiological Phenomena/*drug effects/genetics/physiology', 'Cisplatin/administration & dosage/adverse effects', 'Docetaxel/administration & dosage/adverse effects', 'Female', 'Humans', 'Models, Biological', 'Ovarian Neoplasms/*drug therapy/genetics/metabolism', 'Paclitaxel/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/30382284/
3600,Docetaxol,38629735,Overcoming the Blood-Brain Tumor Barrier with Docetaxel-Loaded Mesoporous Silica Nanoparticles for Treatment of Temozolomide-Resistant Glioblastoma.,"['Hsu TI', 'Chen YP', 'Zhang RL', 'Chen ZA', 'Wu CH', 'Chang WC', 'Mou CY', 'Chan HW', 'Wu SH']","['*Temozolomide/chemistry/pharmacology/therapeutic use/pharmacokinetics', '*Glioblastoma/drug therapy/pathology/metabolism', '*Docetaxel/chemistry/pharmacology/pharmacokinetics/therapeutic use', '*Silicon Dioxide/chemistry', '*Blood-Brain Barrier/drug effects/metabolism', 'Animals', '*Nanoparticles/chemistry', 'Humans', 'Mice', '*Drug Resistance, Neoplasm/drug effects', 'Brain Neoplasms/drug therapy/pathology/metabolism', 'Cell Line, Tumor', 'Porosity', 'Drug Carriers/chemistry', 'Mice, Nude', 'Antineoplastic Agents/chemistry/pharmacology', 'Apoptosis/drug effects']",https://pubmed.ncbi.nlm.nih.gov/38629735/
3601,Docetaxol,38565395,All-stage targeted red blood cell membrane-coated docetaxel nanocrystals for glioma treatment.,"['Ding Y', 'Xu Q', 'Chai Z', 'Wu S', 'Xu W', 'Wang J', 'Zhou J', 'Luo Z', 'Liu Y', 'Xie C', 'Lu L', 'Lu W']","['*Docetaxel/administration & dosage/pharmacokinetics/chemistry', '*Glioma/drug therapy', 'Animals', '*Nanoparticles/chemistry', '*Antineoplastic Agents/administration & dosage/pharmacokinetics/chemistry/therapeutic use', '*Erythrocyte Membrane/drug effects/chemistry', 'Cell Line, Tumor', '*Brain Neoplasms/drug therapy', 'Male', 'Drug Delivery Systems', 'Avidin/administration & dosage/chemistry', 'Humans', 'Biotin/chemistry/administration & dosage', 'Rats, Sprague-Dawley', 'Blood-Brain Barrier/metabolism', 'Mice, Inbred BALB C', 'Mice, Nude']",https://pubmed.ncbi.nlm.nih.gov/38565395/
3602,Docetaxol,34969724,Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma.,"['Quesada S', 'Samalin E', 'Thezenas S', 'Khellaf L', 'Mourregot A', 'Portales F', 'Mazard T', 'Ychou M', 'Adenis A']","['Adenocarcinoma/blood/*drug therapy/pathology', 'Adult', 'Aged', 'Antineoplastic Combined Chemotherapy Protocols/*administration & dosage/adverse effects', 'CA-19-9 Antigen/blood', 'Carcinoembryonic Antigen/blood', 'Disease-Free Survival', 'Docetaxel/administration & dosage/adverse effects', 'Esophagogastric Junction/drug effects/pathology', 'Female', 'Fluorouracil/administration & dosage/adverse effects', 'Humans', 'Leucovorin/administration & dosage/adverse effects', 'Male', 'Middle Aged', 'Neoadjuvant Therapy', 'Organoplatinum Compounds/administration & dosage/adverse effects', 'Oxaliplatin/administration & dosage/adverse effects', 'Perioperative Period', 'Proportional Hazards Models', 'Stomach Neoplasms/blood/*drug therapy/pathology']",https://pubmed.ncbi.nlm.nih.gov/34969724/
3603,Docetaxol,38552197,CONTACT-01: A Randomized Phase III Trial of Atezolizumab + Cabozantinib Versus Docetaxel for Metastatic Non-Small Cell Lung Cancer After a Checkpoint Inhibitor and Chemotherapy.,"['Neal J', 'Pavlakis N', 'Kim SW', 'Goto Y', 'Lim SM', 'Mountzios G', 'Fountzilas E', 'Mochalova A', 'Christoph DC', 'Bearz A', 'Quantin X', 'Palmero R', 'Antic V', 'Chun E', 'Edubilli TR', 'Lin YC', 'Huseni M', 'Ballinger M', 'Graupner V', 'Curran D', 'Vervaet P', 'Newsom-Davis T']","['Humans', '*Carcinoma, Non-Small-Cell Lung/drug therapy/pathology/mortality', '*Docetaxel/therapeutic use/administration & dosage/adverse effects', '*Antibodies, Monoclonal, Humanized/therapeutic use/adverse effects/administration & dosage', '*Lung Neoplasms/drug therapy/pathology/mortality', '*Pyridines/therapeutic use/administration & dosage/adverse effects', 'Male', 'Female', '*Anilides/therapeutic use/administration & dosage/adverse effects', 'Middle Aged', 'Aged', '*Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse effects', '*Immune Checkpoint Inhibitors/therapeutic use/adverse effects', 'Adult', 'Aged, 80 and over', 'Progression-Free Survival']",https://pubmed.ncbi.nlm.nih.gov/38552197/
3604,Amethopterin,30243154,Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review.,"['Wang W', 'Zhou H', 'Liu L']","['Animals', 'Antirheumatic Agents/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Gastrointestinal Diseases/chemically induced', 'Humans', 'Methotrexate/*adverse effects/pharmacokinetics/pharmacology/therapeutic use', 'Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/30243154/
3605,Amethopterin,39433528,Methotrexate-Induced Epidermal Necrosis.,"['Loesch AJ', 'Jin A', 'Huang S', 'Motaparthi K', 'Lee JB', 'Hsu S']","['Humans', '*Methotrexate/adverse effects/therapeutic use/administration & dosage', 'Female', 'Aged', '*Necrosis/chemically induced', '*Psoriasis/drug therapy/chemically induced/pathology', 'Dermatologic Agents/adverse effects/therapeutic use', 'Epidermis/pathology', 'Drug Eruptions/etiology/pathology/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/39433528/
3606,Amethopterin,7011005,Intrathecal methotrexate-induced neurotoxicities.,"['Nelson RW', 'Frank JT']","['Humans', 'Injections', 'Injections, Spinal', 'Lumbosacral Region', 'Methotrexate/administration & dosage/*adverse effects/cerebrospinal fluid', 'Nervous System Diseases/*chemically induced/prevention & control', 'Risk']",https://pubmed.ncbi.nlm.nih.gov/7011005/
3607,Amethopterin,29975207,Folate Supplementation for Methotrexate Therapy in Patients With Rheumatoid Arthritis: A Systematic Review.,"['Liu L', 'Liu S', 'Wang C', 'Guan W', 'Zhang Y', 'Hu W', 'Zhang L', 'He Y', 'Lu J', 'Li T', 'Liu X', 'Xuan Y', 'Wang P']","['Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Folic Acid/*therapeutic use', 'Humans', 'Leucovorin/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29975207/
3608,Amethopterin,32066146,Adverse Effects of Low-Dose Methotrexate: A Randomized Trial.,"['Solomon DH', 'Glynn RJ', 'Karlson EW', 'Lu F', 'Corrigan C', 'Colls J', 'Xu C', 'MacFadyen J', 'Barbhaiya M', 'Berliner N', 'Dellaripa PF', 'Everett BM', 'Pradhan AD', 'Hammond SP', 'Murray M', 'Rao DA', 'Ritter SY', 'Rutherford A', 'Sparks JA', 'Stratton J', 'Suh DH', 'Tedeschi SK', 'Vanni KMM', 'Paynter NP', 'Ridker PM']","['Aged', 'Antirheumatic Agents/*administration & dosage/*adverse effects', 'Cardiovascular Diseases/*drug therapy', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Methotrexate/*administration & dosage/*adverse effects', 'Middle Aged', 'Placebos', 'Prospective Studies']",https://pubmed.ncbi.nlm.nih.gov/32066146/
3609,Amethopterin,3913771,Drug interactions with methotrexate.,"['Evans WE', 'Christensen ML']","['Absorption', 'Anti-Bacterial Agents/pharmacology', 'Arthritis, Rheumatoid/drug therapy', 'Aspirin/pharmacology', 'Biological Transport/drug effects', 'Cell Membrane/metabolism', 'Cisplatin/pharmacology', 'Dose-Response Relationship, Drug', '*Drug Interactions', 'Folic Acid/pharmacology', 'Humans', 'Kidney Tubules/drug effects/metabolism', 'Methotrexate/administration & dosage/adverse effects/*metabolism/therapeutic use', 'Probenecid/pharmacology', 'Protein Binding/drug effects', 'Salicylates/pharmacology', 'Serum Albumin/metabolism', 'Sulfamethoxazole/pharmacology', 'Sulfonamides/pharmacology', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/3913771/
3610,Amethopterin,27993660,Much more than you expected: The non-DHFR-mediated effects of methotrexate.,"['Sramek M', 'Neradil J', 'Veselska R']","['Animals', 'Folic Acid/*metabolism', 'Folic Acid Antagonists/pharmacology/therapeutic use', 'Humans', 'Methotrexate/*pharmacology/*therapeutic use', 'Signal Transduction/*drug effects', 'Tetrahydrofolate Dehydrogenase/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/27993660/
3611,Amethopterin,39392455,Methotrexate polyglutamates.,"['Yang Z', 'Mo J', 'Li W', 'Zhao Z', 'Mei S']","['*Methotrexate/analogs & derivatives/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Humans', '*Polyglutamic Acid/analogs & derivatives/pharmacology', 'Animals', 'Antirheumatic Agents/adverse effects/administration & dosage/pharmacology/pharmacokinetics', 'Precision Medicine']",https://pubmed.ncbi.nlm.nih.gov/39392455/
3612,Amethopterin,31276602,Optimising low-dose methotrexate for rheumatoid arthritis-A review.,"['Lucas CJ', 'Dimmitt SB', 'Martin JH']","['Administration, Oral', 'Antirheumatic Agents/*administration & dosage/adverse effects/pharmacokinetics', 'Arthritis, Rheumatoid/*drug therapy', 'Dose-Response Relationship, Drug', 'Humans', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', 'Polyglutamic Acid/metabolism', ""Practice Patterns, Physicians'""]",https://pubmed.ncbi.nlm.nih.gov/31276602/
3613,Amethopterin,1918470,The pharmacology of methotrexate.,['Olsen EA'],"['Bone Marrow/drug effects', 'Central Nervous System/drug effects', 'Digestive System/drug effects', 'Drug Therapy, Combination', 'Humans', 'Kidney/drug effects', 'Leucovorin/administration & dosage/metabolism/pharmacology', 'Lung/drug effects', 'Methotrexate/administration & dosage/adverse effects/pharmacokinetics/*pharmacology', 'Skin/drug effects']",https://pubmed.ncbi.nlm.nih.gov/1918470/
3614,Amethopterin,21044430,Methotrexate bioavailability.,"['van Roon EN', 'van de Laar MA']","['Antirheumatic Agents/administration & dosage/adverse effects/*pharmacokinetics', 'Biological Availability', 'Drug Administration Routes', 'Drug Administration Schedule', 'Drug Dosage Calculations', 'Drug Interactions', 'Humans', 'Intestinal Absorption', 'Methotrexate/administration & dosage/adverse effects/analogs & derivatives/*pharmacokinetics', 'Polyglutamic Acid/analogs & derivatives/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/21044430/
3615,Amethopterin,300460,High-dose methotrexate therapy.,"['Bell R', 'Sullivan JR', 'Moon WJ', 'Hurley TH']","['Adult', 'Carcinoma, Squamous Cell/drug therapy', 'Drug Therapy, Combination', 'Head and Neck Neoplasms/drug therapy', 'Humans', 'Leucovorin/therapeutic use', 'Lymphoma/drug therapy', 'Methotrexate/*administration & dosage/adverse effects/therapeutic use', 'Neoplasms/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/300460/
3616,Amethopterin,26349496,Microemulsions for Colorectal Cancer Treatments. General Considerations and Formulation of Methotrexate.,"['Flores SE', 'Rial-Hermida MI', 'Ramirez JC', 'Pazos A', 'Concheiro A', 'Alvarez-Lorenzo C', 'Peralta RD']","['Animals', 'Antimetabolites, Antineoplastic/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Chemistry, Pharmaceutical/methods', 'Colon/drug effects/pathology', 'Colorectal Neoplasms/*drug therapy/pathology', 'Drug Delivery Systems/methods', 'Emulsions/adverse effects/*chemistry', 'Humans', 'Methotrexate/*administration & dosage/chemistry/pharmacology/therapeutic use', 'Oils, Volatile/adverse effects/*chemistry', 'Pharmaceutical Vehicles/adverse effects/*chemistry', 'Surface-Active Agents/adverse effects/*chemistry']",https://pubmed.ncbi.nlm.nih.gov/26349496/
3617,Amethopterin,9544409,Methotrexate therapy.,['Schep GN'],"['Antimetabolites, Antineoplastic/*therapeutic use', 'Antirheumatic Agents/*therapeutic use', 'Dermatologic Agents/*therapeutic use', 'Folic Acid Antagonists/*therapeutic use', 'Humans', 'Immunosuppressive Agents/*therapeutic use', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9544409/
3618,Amethopterin,39356310,"A European consensus recommendation on the management of delayed methotrexate elimination: supportive measures, leucovorin rescue and glucarpidase treatment.","['Bielack SS', 'Soussain C', 'Fox CP', 'Houillier C', 'Murciano T', 'Osborne W', 'Zinzani PL', 'Rizzari C', 'Schwartz S']","['Humans', '*Methotrexate/therapeutic use/administration & dosage/adverse effects', '*gamma-Glutamyl Hydrolase/therapeutic use', '*Leucovorin/administration & dosage/therapeutic use', 'Antimetabolites, Antineoplastic/adverse effects/therapeutic use/administration & dosage', 'Consensus', 'Europe', 'Neoplasms/drug therapy', 'Recombinant Proteins/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/39356310/
3619,Amethopterin,25340735,Genetic polymorphisms in low-dose methotrexate transporters: current relevance as methotrexate therapeutic outcome biomarkers.,"['Lima A', 'Sousa H', 'Monteiro J', 'Azevedo R', 'Medeiros R', 'Seabra V']","['ATP-Binding Cassette Transporters/*genetics', 'Dose-Response Relationship, Drug', 'Drug-Related Side Effects and Adverse Reactions/genetics', 'Humans', 'Membrane Transport Proteins/*genetics', 'Methotrexate/*administration & dosage/adverse effects/pharmacokinetics', '*Pharmacogenetics', 'Polymorphism, Single Nucleotide']",https://pubmed.ncbi.nlm.nih.gov/25340735/
3620,Amethopterin,2679014,Methotrexate in the treatment of rheumatoid arthritis.,"['Korn S', 'Dehoratius RJ']","['Arthritis, Rheumatoid/*drug therapy', 'Humans', 'Methotrexate/adverse effects/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2679014/
3621,Amethopterin,12222556,Methotrexate-induced toxic leukoencephalopathy.,"['Gowan GM', 'Herrington JD', 'Simonetta AB']","['Aged', 'Antimetabolites, Antineoplastic/administration & dosage/*adverse effects/therapeutic use', 'Dementia, Vascular/*chemically induced', 'Fatal Outcome', 'Female', 'Humans', 'Injections, Intraventricular', 'Leukemia, Lymphocytic, Chronic, B-Cell/complications/drug therapy/radiotherapy', 'Magnetic Resonance Imaging', 'Methotrexate/administration & dosage/*adverse effects/therapeutic use', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/12222556/
3622,Amethopterin,9608316,Disease-modifying antirheumatic drugs.,"['Li E', 'Brooks P', 'Conaghan PG']","['Antimalarials/adverse effects/therapeutic use', 'Antirheumatic Agents/administration & dosage/adverse effects/*therapeutic use', 'Arthritis, Rheumatoid/*drug therapy', 'Drug Therapy, Combination', 'Humans', 'Liver/drug effects', 'Lung/drug effects', 'Methotrexate/adverse effects/therapeutic use', 'Organogold Compounds', 'Penicillamine/adverse effects/therapeutic use', 'Sulfasalazine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9608316/
3623,Amethopterin,17377896,Medical therapy for ectopic pregnancy.,['Lipscomb GH'],"['Abortifacient Agents, Nonsteroidal/administration & dosage/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Female', 'Humans', 'Methotrexate/administration & dosage/adverse effects/*therapeutic use', 'Pregnancy', 'Pregnancy, Ectopic/*drug therapy/surgery']",https://pubmed.ncbi.nlm.nih.gov/17377896/
3624,dicyclomine,31515515,Nausea and vomiting of pregnancy and hyperemesis gravidarum.,"['Fejzo MS', 'Trovik J', 'Grooten IJ', 'Sridharan K', 'Roseboom TJ', 'Vikanes A', 'Painter RC', 'Mullin PM']","['Antiemetics/therapeutic use', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Combinations', 'Female', 'Growth Differentiation Factor 15/analysis', 'Humans', 'Hyperemesis Gravidarum/*diagnosis/epidemiology', 'Mass Screening/methods', 'Nausea/etiology', 'Pregnancy', 'Pyridoxine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31515515/
3625,dicyclomine,29941700,Infantile Colic: An Update.,"['Sarasu JM', 'Narang M', 'Shah D']","['Behavior Therapy/methods', 'Colic/*diagnosis/etiology/therapy', 'Counseling/methods', 'Crying', 'Diet Therapy/methods', 'Humans', 'Infant', 'Infant, Newborn', 'Parasympatholytics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/29941700/
3626,dicyclomine,15160628,Infantile colic.,['Kanabar D'],"['Antifoaming Agents/therapeutic use', 'Anxiety/etiology', '*Colic/diagnosis/therapy', 'Controlled Clinical Trials as Topic', 'Crying', 'Dicyclomine/therapeutic use', 'Evidence-Based Medicine', 'Humans', '*Infant Welfare', 'Infant, Newborn', '*Lactose Intolerance/diagnosis/drug therapy', 'Parent-Child Relations', 'Simethicone/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15160628/
3627,dicyclomine,30306546,Dietary modifications for infantile colic.,"['Gordon M', 'Biagioli E', 'Sorrenti M', 'Lingua C', 'Moja L', 'Banks SS', 'Ceratto S', 'Savino F']","['Allergens', 'Colic/*diet therapy', 'Crying', 'Diet Therapy/methods', 'Female', 'Humans', 'Infant', '*Infant Formula', 'Lactase/administration & dosage', 'Male', 'Randomized Controlled Trials as Topic', 'Soybean Proteins/administration & dosage', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/30306546/
3628,dicyclomine,26447441,Infantile Colic: Recognition and Treatment.,"['Johnson JD', 'Cocker K', 'Chang E']","['Colic/*diagnosis/*diet therapy/*drug therapy', 'Education, Medical, Continuing', 'Female', 'Gastrointestinal Agents/*therapeutic use', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Pediatrics/*standards', '*Practice Guidelines as Topic', 'Probiotics/*therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/26447441/
3629,dicyclomine,27038970,The Link Between Infantile Colic and Migraine.,"['Qubty W', 'Gelfand AA']","['Colic/complications/diagnosis/*drug therapy', 'Dicyclomine/*therapeutic use', '*Diet Therapy', 'Humans', 'Migraine Disorders/complications/diagnosis/*drug therapy', 'Proton Pump Inhibitors/*therapeutic use', 'Simethicone/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27038970/
3630,dicyclomine,3777291,Drugs and stillbirth.,"['Porter JB', 'Hunter-Mitchell J', 'Jick H', 'Walker AM']","['Abnormalities, Drug-Induced', 'Adult', 'Anti-Bacterial Agents/*adverse effects', 'Contraceptives, Oral/*adverse effects', 'Dicyclomine', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Fetal Death/*chemically induced', 'Health Surveys', 'Humans', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Spermatocidal Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/3777291/
3631,dicyclomine,33993133,Antispasmodics for Chronic Abdominal Pain: Analysis of North American Treatment Options.,"['Brenner DM', 'Lacy BE']","['Abdominal Pain/*drug therapy', 'Chronic Pain/*drug therapy', 'Humans', 'North America', 'Parasympatholytics/*supply & distribution/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/33993133/
3632,dicyclomine,24548499,A new pharmacologic treatment for nausea and vomiting of pregnancy.,['Fantasia HC'],"['Abnormalities, Drug-Induced/prevention & control', 'Antiemetics/administration & dosage/adverse effects/*therapeutic use', 'Delayed-Action Preparations', 'Dicyclomine/administration & dosage/adverse effects/*therapeutic use', 'Doxylamine/administration & dosage/adverse effects/*therapeutic use', 'Drug Administration Schedule', 'Drug Combinations', 'Drug Information Services', 'Female', 'Humans', 'Hyperemesis Gravidarum/*drug therapy/etiology', 'Morning Sickness/*drug therapy/etiology', 'Obstetric Nursing/standards', 'Pregnancy', 'Pyridoxine/administration & dosage/adverse effects/*therapeutic use', 'Therapeutic Equivalency']",https://pubmed.ncbi.nlm.nih.gov/24548499/
3633,dicyclomine,6384676,Effects of drugs and chemicals on the fetus and newborn (1).,"['Hill LM', 'Kleinberg F']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/adverse effects', 'Behavior/drug effects', 'Caffeine/adverse effects', 'Dicyclomine', 'Doxylamine/adverse effects', 'Drug Combinations/adverse effects', 'Embryo, Mammalian/drug effects', 'Female', 'Ferrous Compounds/adverse effects', 'Fetus/*drug effects', 'Humans', 'Infant, Newborn', 'Male', 'Maternal-Fetal Exchange', 'Nervous System/drug effects', 'Nonprescription Drugs/adverse effects', 'Oocytes/drug effects', 'Pregnancy', 'Prenatal Exposure Delayed Effects', 'Pyridoxine/adverse effects', 'Reproduction/drug effects', 'Spermatozoa/drug effects', 'Vitamins/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/6384676/
3634,dicyclomine,14994923,[Hyperemesis gravidarum--etiology and treatment].,"['Imperato F', 'Canova I', 'Basili R', 'Iuele T', 'Mossa B']","['Adrenal Cortex Hormones/administration & dosage/adverse effects/therapeutic use', 'Antiemetics/administration & dosage/adverse effects/therapeutic use', 'Clinical Trials as Topic', 'Dicyclomine', 'Doxylamine/administration & dosage/therapeutic use', 'Drug Combinations', 'Enteral Nutrition', 'Female', 'Histamine Antagonists/administration & dosage/therapeutic use', 'Humans', '*Hyperemesis Gravidarum/complications/drug therapy/etiology/psychology/therapy', 'Odds Ratio', 'Parenteral Nutrition', 'Placebos', 'Pregnancy', 'Pyridoxine/administration & dosage/therapeutic use', 'Risk Factors', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/14994923/
3635,dicyclomine,16822454,Clinical inquiries. What is the best treatment for infants with colic?,"['Crotteau CA', 'Wright ST', 'Eglash A']","['Breast Feeding', 'Colic/diet therapy/drug therapy/*therapy', 'Food Hypersensitivity/complications', 'Humans', 'Infant', '*Infant Formula']",https://pubmed.ncbi.nlm.nih.gov/16822454/
3636,dicyclomine,22436257,Epidemiological evidence in forensic pharmacovigilance.,"['Persaud N', 'Healy D']","['Abnormalities, Drug-Induced/epidemiology', 'Antiemetics/adverse effects/toxicity', 'Breast Implantation/adverse effects/statistics & numerical data', '*Causality', 'Connective Tissue Diseases/epidemiology', 'Dicyclomine/adverse effects/toxicity', 'Doxylamine/adverse effects/toxicity', 'Drug Combinations', 'Female', 'Forensic Sciences/*legislation & jurisprudence/organization & administration', 'Humans', 'Pharmacoepidemiology/*legislation & jurisprudence/organization & administration', 'Pharmacology/legislation & jurisprudence/methods', '*Pharmacovigilance', 'Pregnancy', 'Pyridoxine/adverse effects/toxicity']",https://pubmed.ncbi.nlm.nih.gov/22436257/
3637,dicyclomine,24798673,Should doxylamine-pyridoxine be used for nausea and vomiting of pregnancy?,"['Persaud N', 'Chin J', 'Walker M']","['Abnormalities, Drug-Induced', 'Antiemetics/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Doxylamine/*therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Morning Sickness/*drug therapy', 'Neoplasms/chemically induced', 'Practice Guidelines as Topic', 'Pregnancy', 'Pyloric Stenosis/chemically induced', 'Pyridoxine/*therapeutic use', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/24798673/
3638,dicyclomine,3927122,"The creation of therapeutic orphans--or, what have we learnt from the Debendox fiasco?","['Sheffield LJ', 'Batagol R']","['Abnormalities, Drug-Induced/*etiology', 'Animals', 'Antiemetics/*adverse effects', 'Australia', 'Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*adverse effects', 'Dicyclomine/*adverse effects', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Haplorhini', 'Humans', 'Infant, Newborn', 'Macaca fascicularis', 'Pregnancy', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Rabbits', 'Random Allocation', 'Rats', 'Risk', '*Teratogens', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/3927122/
3639,dicyclomine,8486081,Preliminary note: dangerous use of anticholinergic drugs in Brazil.,['Carlini EA'],"['Adolescent', 'Adult', 'Brazil/epidemiology', 'Child', 'Cross-Sectional Studies', '*Developing Countries', 'Humans', 'Incidence', 'Parasympatholytics/*adverse effects', 'Substance-Related Disorders/epidemiology/*etiology']",https://pubmed.ncbi.nlm.nih.gov/8486081/
3640,dicyclomine,32737240,Protection Versus Progress: The Challenge of Research on Cannabis Use During Pregnancy.,"['MacDuffie KE', 'Kleinhans NM', 'Stout K', 'Wilfond BS']","['Antiemetics/adverse effects', 'Dicyclomine/therapeutic use', 'Doxylamine/therapeutic use', 'Drug Approval', 'Drug Combinations', '*Ethics, Research', 'Female', 'Humans', 'Medical Marijuana/adverse effects/*therapeutic use', 'Morning Sickness/*therapy', 'Ondansetron/therapeutic use', 'Pediatrics/*ethics', 'Pregnancy', '*Pregnant People', 'Pyridoxine/therapeutic use', '*Research Subjects', 'Teratogens', 'Thalidomide/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/32737240/
3641,dicyclomine,329860,Treatment of pregnancy sickness.,['Wheatley D'],"['Clinical Trials as Topic', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/*therapeutic use', 'Double-Blind Method', 'Doxylamine/therapeutic use', 'Female', 'Humans', 'Nausea/*drug therapy', 'Placebos', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Trimester, First', 'Pyridoxine/*therapeutic use', 'Vomiting/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/329860/
3642,dicyclomine,6734920,Comparison of dicyclomine with antacid and without antacid in dyspepsia.,"['Kagan G', 'Huddlestone L', 'Wolstencroft P']","['Antacids/adverse effects/*therapeutic use', 'Cyclohexanecarboxylic Acids/*therapeutic use', 'Dicyclomine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Drug Evaluation', 'Drug Therapy, Combination', 'Dyspepsia/*drug therapy', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/6734920/
3643,dicyclomine,2772850,Bendectin and human congenital malformations.,"['Shiono PH', 'Klebanoff MA']","['Abnormalities, Drug-Induced/*etiology', 'Central Nervous System/abnormalities', 'Dicyclomine', 'Digestive System Abnormalities', 'Doxylamine/*adverse effects', 'Drug Combinations/adverse effects', 'Female', 'Head/abnormalities', 'Heart Defects, Congenital/chemically induced', 'Humans', 'Lung/abnormalities', 'Pregnancy', 'Pregnancy Trimester, First', 'Prospective Studies', 'Pyridines/*adverse effects', 'Pyridoxine/*adverse effects', 'Urogenital Abnormalities', 'Vomiting']",https://pubmed.ncbi.nlm.nih.gov/2772850/
3644,sotalol,16640500,Transdermal delivery of beta-blockers.,"['Aqil M', 'Sultana Y', 'Ali A']","['Administration, Cutaneous', 'Adrenergic beta-Antagonists/*administration & dosage/pharmacokinetics', 'Animals', 'Drug Delivery Systems/*methods', 'Humans', 'Propanolamines/administration & dosage/pharmacokinetics', 'Sotalol/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/16640500/
3645,sotalol,39555820,Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.,"['Sapp JL', 'Tang ASL', 'Parkash R', 'Stevenson WG', 'Healey JS', 'Gula LJ', 'Nair GM', 'Essebag V', 'Rivard L', 'Roux JF', 'Nery PB', 'Sarrazin JF', 'Amit G', 'Raymond JM', 'Deyell M', 'Lane C', 'Sacher F', 'de Chillou C', 'Kuriachan V', 'AbdelWahab A', 'Nault I', 'Dyrda K', 'Wilton S', 'Jolly U', 'Kanagasundram A', 'Wells GA']","['Humans', '*Tachycardia, Ventricular/drug therapy', '*Anti-Arrhythmia Agents/therapeutic use/adverse effects', '*Catheter Ablation/adverse effects', 'Male', 'Female', 'Middle Aged', 'Aged', '*Amiodarone/therapeutic use/adverse effects', '*Defibrillators, Implantable', '*Sotalol/therapeutic use/adverse effects', 'Myocardial Infarction', 'Kaplan-Meier Estimate', 'Follow-Up Studies', 'Cardiomyopathies']",https://pubmed.ncbi.nlm.nih.gov/39555820/
3646,sotalol,2403736,Sotalol for paroxysmal supraventricular tachycardias.,"['Camm AJ', 'Paul V']","['Double-Blind Method', 'Humans', 'Randomized Controlled Trials as Topic', 'Sotalol/administration & dosage/*therapeutic use', 'Tachycardia, Paroxysmal/*drug therapy/physiopathology', 'Tachycardia, Supraventricular/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/2403736/
3647,sotalol,14994845,Antiarrhythmic drug therapy of atrial fibrillation.,"['VerNooy RA', 'Mounsey JP']","['Amiodarone/therapeutic use', 'Anti-Arrhythmia Agents/*therapeutic use', 'Atrial Fibrillation/*drug therapy', 'Disopyramide/therapeutic use', 'Flecainide/therapeutic use', 'Humans', 'Phenethylamines/therapeutic use', 'Sotalol/therapeutic use', 'Sulfonamides/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/14994845/
3648,sotalol,9354408,Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.,"['Kowey PR', 'Marinchak RA', 'Rials SJ', 'Bharucha D']","['Amiodarone/pharmacokinetics/therapeutic use', 'Anti-Arrhythmia Agents/pharmacokinetics/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/*drug therapy', 'Bretylium Compounds/pharmacokinetics/therapeutic use', 'Humans', 'Phenethylamines/pharmacokinetics/therapeutic use', 'Sotalol/pharmacokinetics/therapeutic use', 'Sulfonamides/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9354408/
3649,sotalol,7777671,Sotalol: a new beta-adrenergic blocker for ventricular arrhythmias.,"['Cavusoglu E', 'Frishman WH']","['Arrhythmias, Cardiac/*drug therapy/physiopathology', 'Clinical Trials as Topic', 'Electrophysiology', 'Heart Ventricles', 'Humans', 'Sotalol/chemistry/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7777671/
3650,sotalol,8202100,Sotalol.,"['Hohnloser SH', 'Woosley RL']","['Action Potentials/drug effects', 'Animals', 'Electrocardiography/drug effects', 'Electrophysiology', 'Humans', 'Myocardial Contraction/drug effects', 'Myocardial Infarction/drug therapy', 'Sotalol/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Tachycardia, Supraventricular/drug therapy', 'Tachycardia, Ventricular/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8202100/
3651,sotalol,11050274,Pharmacologic management of arrhythmias.,['Bink-Boelkens MT'],"['Adenosine/pharmacology/therapeutic use', 'Amiodarone/pharmacology/therapeutic use', 'Anti-Arrhythmia Agents/adverse effects/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/classification/*drug therapy', 'Atrial Flutter/drug therapy', 'Child', 'Drug Interactions', 'Humans', 'Propafenone/pharmacology/therapeutic use', 'Sotalol/pharmacology/therapeutic use', 'Sulfonamides/pharmacology/therapeutic use', 'Tachycardia, Ventricular/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11050274/
3652,sotalol,7904937,"Inotropic and haemodynamic effects of d- and d,l-sotalol: comparison with other antiarrhythmics.","['Seipel L', 'Hoffmeister HM']","['Adrenergic beta-Antagonists/pharmacology', 'Animals', 'Anti-Arrhythmia Agents/classification/*pharmacology', 'Depression, Chemical', 'Hemodynamics/*drug effects', 'Humans', 'Male', 'Myocardial Contraction/*drug effects', 'Rats', 'Rats, Wistar', 'Sotalol/chemistry/*pharmacology', 'Stereoisomerism']",https://pubmed.ncbi.nlm.nih.gov/7904937/
3653,sotalol,15500415,A benefit-risk assessment of class III antiarrhythmic agents.,"['Elming H', 'Brendorp B', 'Pehrson S', 'Pedersen OD', 'Kober L', 'Torp-Petersen C']","['Amiodarone/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Anti-Arrhythmia Agents/adverse effects/classification/pharmacology/*therapeutic use', 'Arrhythmias, Cardiac/chemically induced/drug therapy/mortality/physiopathology/therapy', 'Clinical Trials as Topic', 'Combined Modality Therapy', 'Defibrillators, Implantable', 'Dronedarone', 'Heart Conduction System/drug effects/physiopathology', 'Humans', 'Hydantoins', 'Imidazolidines/adverse effects/pharmacology/therapeutic use', 'Ion Transport/drug effects', 'Life Tables', 'Membrane Potentials/drug effects', 'Meta-Analysis as Topic', 'Phenethylamines/adverse effects/pharmacology/therapeutic use', 'Piperazines/adverse effects/pharmacology/therapeutic use', 'Risk Assessment', 'Sotalol/adverse effects/pharmacology/therapeutic use', 'Sulfonamides/adverse effects/pharmacology/therapeutic use', 'Survival Analysis', 'Torsades de Pointes/chemically induced', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/15500415/
3654,sotalol,1279308,The utility of serum drug level monitoring during therapy with class III antiarrhythmic agents.,['Follath F'],"['Administration, Oral', 'Amiodarone/adverse effects/blood/pharmacokinetics', 'Anti-Arrhythmia Agents/*blood/therapeutic use', 'Arrhythmias, Cardiac/*drug therapy', 'Humans', 'Sotalol/adverse effects/blood/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1279308/
3655,sotalol,21635829,Granuloma annulare of the palms.,"['Stewart LR', 'George S', 'Hamacher KL', 'Hsu S']","['Aged', 'Amlodipine/adverse effects/therapeutic use', 'Comorbidity', 'Female', 'Granuloma Annulare/*diagnosis/pathology', 'Hand Dermatoses/*diagnosis/pathology', 'Humans', 'Polypharmacy', 'Sotalol/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/21635829/
3656,sotalol,37040036,The Dependence of the Electrophysiological Effects of Class III Antiarrhythmic Drug Refralon on the Frequency of Myocardium Activation.,"['Abramochkin DV', 'Pustovit OB', 'Mironov NY', 'Filatova TS', 'Kuzmin VS']","['Animals', 'Rabbits', '*Anti-Arrhythmia Agents/pharmacology', '*Potassium Channels/metabolism', 'Myocardium/metabolism', 'Sotalol/metabolism/pharmacology', 'Heart Ventricles', 'Action Potentials']",https://pubmed.ncbi.nlm.nih.gov/37040036/
3657,sotalol,3578041,Arrhythmogenesis--a European perspective.,['Campbell RW'],"['Amiodarone/therapeutic use', 'Anti-Arrhythmia Agents/*adverse effects/therapeutic use', 'Arrhythmias, Cardiac/*chemically induced', 'Drug Utilization', 'Europe', 'Humans', 'Mexiletine/therapeutic use', 'Sotalol/therapeutic use', 'United States']",https://pubmed.ncbi.nlm.nih.gov/3578041/
3658,sotalol,37229640,The Arrhythmogenicity of Sotalol and its Role in Heart Failure: A Literature Review.,"['Augustin N', 'Alvarez C', 'Kluger J']","['Humans', 'Female', 'Sotalol/adverse effects', 'Anti-Arrhythmia Agents/adverse effects', 'Adrenergic beta-Antagonists/therapeutic use', '*Heart Failure/diagnosis/drug therapy/chemically induced', '*Atrial Fibrillation/diagnosis/drug therapy/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/37229640/
3659,sotalol,28900864,Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate.,"['AbdelWahab A', 'Sapp J']","['Amiodarone/administration & dosage/*therapeutic use', 'Anti-Arrhythmia Agents/administration & dosage/*therapeutic use', 'Catheter Ablation/*methods', '*Defibrillators, Implantable', 'Electric Countershock/*adverse effects', 'Humans', 'Randomized Controlled Trials as Topic', 'Sotalol/therapeutic use', 'Tachycardia, Ventricular/*drug therapy/*surgery/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28900864/
3660,sotalol,7787496,Sotalol-induced bradycardia reversed by glucagon.,"['Fernandes CM', 'Daya MR']","['Aged', 'Aged, 80 and over', 'Bradycardia/chemically induced/diagnosis/*drug therapy', 'Electrocardiography', 'Female', 'Glucagon/pharmacology/*therapeutic use', 'Humans', 'Sotalol/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/7787496/
3661,sotalol,8287239,Sotalol.,['Ruffy R'],"['Arrhythmias, Cardiac/drug therapy', 'Dose-Response Relationship, Drug', 'Humans', '*Sotalol/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8287239/
3662,sotalol,6374931,Reserpine plus hydrochlorothiazide and sotalol plus hydrochlorothiazide in Black and Indian hypertensive patients.,"['Seedat YK', 'Hoosen S', 'Bhigjee AI']","['Blood Pressure/drug effects', 'Clinical Trials as Topic', 'Double-Blind Method', 'Drug Combinations', 'Humans', 'Hydrochlorothiazide/*administration & dosage/therapeutic use', 'Hypertension/*drug therapy/physiopathology', 'Random Allocation', 'Reserpine/*administration & dosage/therapeutic use', 'Sotalol/*administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/6374931/
3663,sotalol,19563362,Sotalol and a broken heart.,"['Friedman PL', 'Montgomery S', 'Matas N']","['Aged, 80 and over', 'Anti-Arrhythmia Agents/adverse effects/therapeutic use', 'Atrial Fibrillation/complications/*prevention & control', 'Female', 'Humans', 'Long QT Syndrome/*chemically induced/diagnosis', 'Sotalol/*adverse effects/*therapeutic use', 'Takotsubo Cardiomyopathy/*chemically induced/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/19563362/
3664,carvedilol,36897563,Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension.,"['Turco L', 'Reiberger T', 'Vitale G', 'La Mura V']","['Humans', 'Carvedilol/therapeutic use', 'Propranolol', '*Esophageal and Gastric Varices/etiology/complications', 'Ascites/etiology/complications', 'Gastrointestinal Hemorrhage/drug therapy/etiology', 'Adrenergic beta-Antagonists/therapeutic use', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis']",https://pubmed.ncbi.nlm.nih.gov/36897563/
3665,carvedilol,35661713,Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis.,"['Villanueva C', 'Torres F', 'Sarin SK', 'Shah HA', 'Tripathi D', 'Brujats A', 'Rodrigues SG', 'Bhardwaj A', 'Azam Z', 'Hayes PC', 'Jindal A', 'Abid S', 'Alvarado E', 'Bosch J']","['Adrenergic beta-Antagonists/therapeutic use', 'Ascites/complications', 'Carvedilol/therapeutic use', '*Esophageal and Gastric Varices/complications/prevention & control', 'Humans', '*Hypertension, Portal/complications/drug therapy', 'Liver Cirrhosis/complications/drug therapy', 'Portal Pressure', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/35661713/
3666,carvedilol,11356434,Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.,['Dargie HJ'],"['Adrenergic beta-Antagonists/administration & dosage/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Carbazoles/administration & dosage/*therapeutic use', 'Carvedilol', 'Drug Administration Schedule', 'Endpoint Determination', 'Female', 'Humans', 'Male', 'Middle Aged', 'Myocardial Infarction/complications/*drug therapy/mortality', 'Propanolamines/administration & dosage/*therapeutic use', 'Treatment Outcome', 'Ventricular Dysfunction, Left/*complications']",https://pubmed.ncbi.nlm.nih.gov/11356434/
3667,carvedilol,32094236,BRASH syndrome.,"['Srivastava S', 'Kemnic T', 'Hildebrandt KR']","['Antihypertensive Agents/adverse effects', '*Atrioventricular Block', '*Bradycardia', 'Bumetanide/adverse effects', 'Carvedilol/adverse effects', 'Female', 'Humans', '*Hyperkalemia', 'Metolazone/adverse effects', 'Middle Aged', '*Renal Insufficiency', '*Shock', 'Syndrome', 'Vasoconstrictor Agents/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32094236/
3668,carvedilol,30372514,"Carvedilol versus traditional, non-selective beta-blockers for adults with cirrhosis and gastroesophageal varices.","['Zacharias AP', 'Jeyaraj R', 'Hobolth L', 'Bendtsen F', 'Gluud LL', 'Morgan MY']","['Adrenergic beta-Antagonists/adverse effects/*therapeutic use', 'Adult', 'Carvedilol/adverse effects/*therapeutic use', 'Esophageal and Gastric Varices/complications/*drug therapy/mortality', 'Gastrointestinal Hemorrhage/mortality/*prevention & control', 'Humans', 'Liver Cirrhosis/complications/*drug therapy/mortality', 'Nadolol/adverse effects/*therapeutic use', 'Primary Prevention', 'Propranolol/adverse effects/*therapeutic use', 'Randomized Controlled Trials as Topic', 'Secondary Prevention']",https://pubmed.ncbi.nlm.nih.gov/30372514/
3669,carvedilol,30372864,Carvedilol attenuates liver fibrosis by suppressing autophagy and promoting apoptosis in hepatic stellate cells.,"['Meng D', 'Li Z', 'Wang G', 'Ling L', 'Wu Y', 'Zhang C']","['Antioxidants/pharmacology/*therapeutic use', 'Apoptosis/*drug effects/physiology', 'Autophagy/*drug effects/physiology', 'Carvedilol/pharmacology/*therapeutic use', 'Cell Line', 'Dose-Response Relationship, Drug', 'Hepatic Stellate Cells/*drug effects/metabolism', 'Humans', 'Liver Cirrhosis/*drug therapy/metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/30372864/
3670,carvedilol,35842118,Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis.,"['Jachs M', 'Hartl L', 'Simbrunner B', 'Bauer D', 'Paternostro R', 'Balcar L', 'Hofer B', 'Pfisterer N', 'Schwarz M', 'Scheiner B', 'Stattermayer AF', 'Pinter M', 'Trauner M', 'Mandorfer M', 'Reiberger T']","['Humans', 'Propranolol/therapeutic use', 'Carvedilol/therapeutic use', '*Esophageal and Gastric Varices/complications', 'Retrospective Studies', 'Gastrointestinal Hemorrhage/prevention & control/etiology', 'Adrenergic beta-Antagonists/therapeutic use', 'Hemodynamics', 'Liver Cirrhosis/complications', '*Varicose Veins/complications']",https://pubmed.ncbi.nlm.nih.gov/35842118/
3671,carvedilol,30153268,Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.,"['Watanabe H', 'Ozasa N', 'Morimoto T', 'Shiomi H', 'Bingyuan B', 'Suwa S', 'Nakagawa Y', 'Izumi C', 'Kadota K', 'Ikeguchi S', 'Hibi K', 'Furukawa Y', 'Kaji S', 'Suzuki T', 'Akao M', 'Inada T', 'Hayashi Y', 'Nanasato M', 'Okutsu M', 'Kametani R', 'Sone T', 'Sugimura Y', 'Kawai K', 'Abe M', 'Kaneko H', 'Nakamura S', 'Kimura T']","['Aged', 'Carvedilol/*therapeutic use', 'Combined Modality Therapy', 'Female', 'Humans', 'Male', 'Middle Aged', '*Percutaneous Coronary Intervention', 'ST Elevation Myocardial Infarction/*drug therapy/*surgery', 'Time Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30153268/
3672,carvedilol,37850394,Improved Cardiac Performance and Decreased Arrhythmia in Hypertrophic Cardiomyopathy With Non-beta-Blocking R-Enantiomer Carvedilol.,"['Seo K', 'Yamamoto Y', 'Kirillova A', 'Kawana M', 'Yadav S', 'Huang Y', 'Wang Q', 'Lane KV', 'Pruitt BL', 'Perez MV', 'Bernstein D', 'Wu JC', 'Wheeler MT', 'Parikh VN', 'Ashley EA']","['Humans', 'Mice', 'Animals', 'Carvedilol/pharmacology/therapeutic use', '*Metoprolol/therapeutic use', 'Ryanodine Receptor Calcium Release Channel/metabolism', '*Cardiomyopathy, Hypertrophic/complications/drug therapy', 'Arrhythmias, Cardiac/drug therapy/metabolism', 'Adrenergic beta-Antagonists/pharmacology/therapeutic use', 'Myocytes, Cardiac/metabolism', 'Verapamil/therapeutic use', 'Receptors, Adrenergic/metabolism']",https://pubmed.ncbi.nlm.nih.gov/37850394/
3673,carvedilol,20206876,Cocaine and beta-blockers: the paradigm.,['Damodaran S'],"['Acute Coronary Syndrome/chemically induced/drug therapy', 'Adrenergic beta-Antagonists/pharmacology/*therapeutic use', 'Brain/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiovascular System/drug effects', 'Carvedilol', 'Cocaine/*adverse effects/antagonists & inhibitors', 'Cocaine-Related Disorders/complications', 'Humans', 'Propanolamines/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20206876/
3674,carvedilol,33243993,beta-arrestin 2 as an activator of cGAS-STING signaling and target of viral immune evasion.,"['Zhang Y', 'Li M', 'Li L', 'Qian G', 'Wang Y', 'Chen Z', 'Liu J', 'Fang C', 'Huang F', 'Guo D', 'Zou Q', 'Chu Y', 'Yan D']","['Animals', 'Carvedilol/*pharmacology/therapeutic use', 'Disease Models, Animal', 'Drug Repositioning', 'HEK293 Cells', 'Herpesvirus 1, Human/immunology', 'Humans', 'Immune Evasion/drug effects/*immunology', 'Interferon-beta/metabolism', 'Macrophages, Peritoneal/immunology/metabolism', 'Male', 'Membrane Proteins/*metabolism', 'Mice', 'Nucleotidyltransferases/*metabolism', 'Primary Cell Culture', 'Proteolysis/drug effects', 'RAW 264.7 Cells', 'RNA-Seq', 'Sendai virus/immunology', 'Signal Transduction/drug effects/immunology', 'Vesiculovirus/immunology', 'Virus Diseases/drug therapy/*immunology/virology', 'beta-Arrestin 2/agonists/genetics/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33243993/
3675,carvedilol,39067870,Combination of carvedilol with variceal band ligation in prevention of first variceal bleed in Child-Turcotte-Pugh B and C cirrhosis with high-risk oesophageal varices: the 'CAVARLY TRIAL'.,"['Tevethia HV', 'Pande A', 'Vijayaraghavan R', 'Kumar G', 'Sarin SK']","['Humans', '*Esophageal and Gastric Varices/etiology', '*Carvedilol/therapeutic use', 'Male', 'Female', 'Ligation/methods', 'Middle Aged', '*Gastrointestinal Hemorrhage/prevention & control/etiology', '*Liver Cirrhosis/complications', 'Prospective Studies', '*Adrenergic beta-Antagonists/therapeutic use', 'Combined Modality Therapy', '*Propanolamines/therapeutic use', 'Carbazoles/therapeutic use', 'Treatment Outcome', 'Adult']",https://pubmed.ncbi.nlm.nih.gov/39067870/
3676,carvedilol,17686376,The vasodilatory beta-blockers.,"['Pedersen ME', 'Cockcroft JR']","['Adrenergic beta-Antagonists/adverse effects/*pharmacology/*therapeutic use', 'Antihypertensive Agents/pharmacology/therapeutic use', 'Antioxidants/pharmacology/therapeutic use', 'Atenolol/pharmacology/therapeutic use', 'Benzopyrans/pharmacology/therapeutic use', 'Blood Pressure/drug effects', 'Carbazoles/pharmacology/therapeutic use', 'Cardiac Output/drug effects', 'Cardiovascular Diseases/physiopathology/prevention & control', 'Carvedilol', 'Endothelium, Vascular/*drug effects', 'Ethanolamines/pharmacology/therapeutic use', 'Hemodynamics/*drug effects', 'Humans', 'Labetalol/pharmacology/therapeutic use', 'Nebivolol', 'Propanolamines/pharmacology/therapeutic use', 'Vascular Resistance/drug effects', 'Vasodilation/*drug effects', 'Ventricular Function, Left/drug effects']",https://pubmed.ncbi.nlm.nih.gov/17686376/
3677,carvedilol,30673046,Anthracycline-associated cardiotoxicity in adults: systematic review on the cardioprotective role of beta-blockers.,"['Barbosa RR', 'Bourguignon TB', 'Torres LD', 'Arruda LS', 'Jacques TM', 'Serpa RG', 'Calil OA', 'Barbosa LFM']","['Adrenergic beta-Antagonists/*pharmacology/therapeutic use', 'Adult', 'Anthracyclines/*adverse effects', 'Cardiotonic Agents/*pharmacology/therapeutic use', 'Cardiotoxicity/prevention & control', 'Carvedilol/pharmacology/therapeutic use', 'Heart Diseases/*chemically induced/*prevention & control', 'Humans', 'Reproducibility of Results', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/30673046/
3678,carvedilol,38432893,Successful Management of a Pregnant Patient with Danon Cardiomyopathy.,"['Inoue W', 'Motoki H', 'Yoshie K', 'Kuwahara K']","['Female', 'Pregnancy', 'Humans', 'Adult', 'Cesarean Section', '*Cardiomyopathies/complications/drug therapy', '*Heart Failure/drug therapy/etiology', 'Carvedilol/therapeutic use', '*Ventricular Dysfunction, Left']",https://pubmed.ncbi.nlm.nih.gov/38432893/
3679,carvedilol,37746692,"Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial.","['Henriksen PA', 'Hall P', 'MacPherson IR', 'Joshi SS', 'Singh T', 'Maclean M', 'Lewis S', 'Rodriguez A', 'Fletcher A', 'Everett RJ', 'Stavert H', 'Broom A', 'Eddie L', 'Primrose L', 'McVicars H', 'McKay P', 'Borley A', 'Rowntree C', 'Lord S', 'Collins G', 'Radford J', 'Guppy A', 'Williams MC', 'Japp A', 'Payne JR', 'Newby DE', 'Mills NL', 'Oikonomidou O', 'Lang NN']","['Humans', 'Female', 'Middle Aged', 'Male', '*Anthracyclines/adverse effects', 'Troponin I', 'Stroke Volume', 'Carvedilol/therapeutic use', 'Cardiotoxicity/etiology', 'Ventricular Function, Left', 'Prospective Studies', 'Antibiotics, Antineoplastic/pharmacology', '*Breast Neoplasms/drug therapy', 'Adrenergic beta-Antagonists/therapeutic use/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37746692/
3680,carvedilol,18488879,Carvedilol in the treatment of elderly patients with chronic heart failure.,"['Witte KK', 'Clark AL']","['Adrenergic beta-Antagonists/administration & dosage/pharmacology/*therapeutic use', 'Aged', 'Angiotensin-Converting Enzyme Inhibitors/pharmacology/therapeutic use', 'Arrhythmias, Cardiac/prevention & control', 'Carbazoles/pharmacology/*therapeutic use', 'Carvedilol', 'Chronic Disease', 'Comorbidity', 'Digoxin/pharmacology/therapeutic use', 'Heart Failure/drug therapy/epidemiology/*prevention & control', 'Humans', 'Propanolamines/pharmacology/*therapeutic use', 'Ventricular Dysfunction, Left/epidemiology', 'Ventricular Remodeling/drug effects']",https://pubmed.ncbi.nlm.nih.gov/18488879/
3681,carvedilol,36402762,How Carvedilol activates beta(2)-adrenoceptors.,"['Benkel T', 'Zimmermann M', 'Zeiner J', 'Bravo S', 'Merten N', 'Lim VJY', 'Matthees ESF', 'Drube J', 'Miess-Tanneberg E', 'Malan D', 'Szpakowska M', 'Monteleone S', 'Grimes J', 'Koszegi Z', 'Lanoiselee Y', ""O'Brien S"", 'Pavlaki N', 'Dobberstein N', 'Inoue A', 'Nikolaev V', 'Calebiro D', 'Chevigne A', 'Sasse P', 'Schulz S', 'Hoffmann C', 'Kolb P', 'Waldhoer M', 'Simon K', 'Gomeza J', 'Kostenis E']","['Humans', 'Carvedilol/pharmacology', '*Adrenergic beta-Antagonists/pharmacology', 'Receptors, Adrenergic, beta-2/genetics', '*Myocardial Infarction/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36402762/
3682,carvedilol,15144930,beta-Blockers in hypertension: is carvedilol different?,"['Messerli FH', 'Grossman E']","['Adrenergic beta-Antagonists/*pharmacology', 'Antihypertensive Agents/*pharmacology', 'Carbazoles/*pharmacology', 'Carvedilol', 'Hemodynamics/drug effects', 'Humans', 'Hypertension/*drug therapy', 'Propanolamines/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/15144930/
3683,oxybutynin,33938689,Management of Primary Focal Hyperhidrosis: An Algorithmic Approach.,"['Liu V', 'Farshchian M', 'Potts GA']","['Antiperspirants', 'Botulinum Toxins, Type A/administration & dosage/adverse effects', 'Cholinergic Antagonists/administration & dosage/adverse effects', 'Combined Modality Therapy/methods', 'Dermatology/*methods/standards', 'Humans', 'Hyperhidrosis/diagnosis/etiology/psychology/*therapy', 'Iontophoresis/methods', 'Laser Therapy/methods', 'Practice Guidelines as Topic', 'Quality of Life', 'Radiofrequency Therapy/adverse effects/instrumentation/methods', 'Severity of Illness Index', 'Sweat Glands/drug effects/*physiopathology/radiation effects', 'Sympathectomy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/33938689/
3684,oxybutynin,25697587,[Management of hyperhidrosis].,"['Maillard H', 'Lecouflet M']","['Algorithms', 'Antiperspirants/therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Cholinergic Antagonists/therapeutic use', 'Decision Trees', 'Disease Management', 'Humans', 'Hyperhidrosis/diagnosis/physiopathology/*therapy', 'Iontophoresis', 'Severity of Illness Index', 'Staining and Labeling', 'Sweat Glands/physiopathology', 'Sympathectomy']",https://pubmed.ncbi.nlm.nih.gov/25697587/
3685,oxybutynin,18086433,Oxybutynin-associated esotropia.,"['Wong EY', 'Harding A', 'Kowal L']","['Accommodation, Ocular/drug effects', 'Child, Preschool', 'Convergence, Ocular/drug effects', 'Enuresis/drug therapy', 'Esotropia/*chemically induced', 'Female', 'Humans', 'Mandelic Acids/*adverse effects', 'Muscarinic Antagonists/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18086433/
3686,oxybutynin,12431028,(S)-oxybutynin (Sepracor).,['Dmochowski RR'],"['Animals', 'Clinical Trials as Topic', 'Humans', 'Mandelic Acids/metabolism/pharmacology/*therapeutic use', 'Muscarinic Antagonists/*therapeutic use', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/12431028/
3687,oxybutynin,26455059,Use of Systemic Therapies to Manage Focal Hyperhidrosis.,"['Glaser DA', 'Glaser K']","['Adrenergic beta-Antagonists/therapeutic use', 'Benzodiazepines/therapeutic use', 'Cholinergic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Disease Management', 'Drug Therapy, Combination', 'Glycopyrrolate/therapeutic use', 'Humans', 'Hyperhidrosis/*drug therapy', 'Mandelic Acids/therapeutic use', 'Patient Selection']",https://pubmed.ncbi.nlm.nih.gov/26455059/
3688,oxybutynin,10767456,Intravesical treatment of overactive bladder.,['Fowler CJ'],"['Administration, Intravesical', 'Anesthetics, Local/administration & dosage', 'Atropine/administration & dosage', 'Capsaicin/administration & dosage', 'Cholinergic Antagonists/administration & dosage', 'Diterpenes/administration & dosage', 'Humans', 'Mandelic Acids/administration & dosage', 'Neurons, Afferent/drug effects', 'Neurotoxins/administration & dosage', 'Urinary Bladder Diseases/*complications/*drug therapy', 'Urinary Incontinence/*complications/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10767456/
3689,oxybutynin,21781635,Cutaneous reactions to transdermal therapeutic systems.,"['Bershow A', 'Warshaw E']","['Administration, Cutaneous', 'Buprenorphine/administration & dosage/adverse effects', 'Dermatitis, Allergic Contact/*etiology', 'Dermatitis, Irritant/*etiology', 'Diclofenac/administration & dosage/adverse effects', 'Exanthema/*chemically induced', 'Female', 'Humans', 'Lidocaine/administration & dosage/adverse effects', 'Male', 'Mandelic Acids/administration & dosage/adverse effects', 'Methylphenidate/administration & dosage/adverse effects', 'Nicardipine/administration & dosage/adverse effects', 'Phenylcarbamates/administration & dosage/adverse effects', 'Rivastigmine', 'Teriparatide/administration & dosage/adverse effects', 'Tetrahydronaphthalenes/administration & dosage/adverse effects', 'Thiophenes/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/21781635/
3690,oxybutynin,11392625,Clinical experiences with tolterodine.,['Nilvebrant L'],"['Animals', 'Benzhydryl Compounds/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Cresols/adverse effects/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Mandelic Acids/therapeutic use', 'Muscarinic Antagonists/adverse effects/*therapeutic use', '*Phenylpropanolamine', 'Quality of Life', 'Tolterodine Tartrate', 'Urinary Bladder/*drug effects', 'Urinary Bladder Diseases/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/11392625/
3691,oxybutynin,37506033,Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.,"['He W', 'Huang G', 'Cui W', 'Tian Y', 'Sun Q', 'Zhao X', 'Zhao Y', 'Li D', 'Liu X']","['Humans', '*Urinary Bladder, Overactive/drug therapy', 'Solifenacin Succinate/adverse effects', 'Tolterodine Tartrate/therapeutic use', 'Network Meta-Analysis', 'Double-Blind Method', 'Constipation/drug therapy', '*Xerostomia/drug therapy', 'Treatment Outcome', 'Muscarinic Antagonists/adverse effects', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/37506033/
3692,oxybutynin,19275276,Transdermal oxybutynin.,"['Baldwin CM', 'Keating GM']","['Administration, Cutaneous', 'Humans', '*Mandelic Acids/economics/pharmacokinetics/pharmacology/therapeutic use', '*Muscarinic Antagonists/economics/pharmacokinetics/pharmacology/therapeutic use', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19275276/
3693,oxybutynin,35987891,The Differential Risk of Mortality Among Users of Overactive Bladder Anticholinergic Medications and beta3 Agonists.,['Welk B'],"['Humans', 'Aged', '*Urinary Bladder, Overactive/drug therapy', 'Cholinergic Antagonists/adverse effects', 'Mandelic Acids/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/35987891/
3694,oxybutynin,9617596,Tolterodine.,"['Hills CJ', 'Winter SA', 'Balfour JA']","['Animals', 'Benzhydryl Compounds/administration & dosage/pharmacokinetics/*therapeutic use', 'Cholinergic Antagonists/administration & dosage/pharmacokinetics/therapeutic use', 'Controlled Clinical Trials as Topic', 'Cresols/administration & dosage/pharmacokinetics/*therapeutic use', 'Half-Life', 'Humans', 'In Vitro Techniques', 'Mandelic Acids/administration & dosage/pharmacokinetics/therapeutic use', 'Muscarinic Antagonists/administration & dosage/pharmacokinetics/*therapeutic use', '*Phenylpropanolamine', 'Tolterodine Tartrate', 'Urinary Bladder/*drug effects/metabolism', 'Urinary Incontinence/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/9617596/
3695,oxybutynin,2360335,Oxybutynin-induced reflux esophagitis.,"['Lee M', 'Sharifi R']","['Adult', 'Cerebral Palsy/complications', 'Esophagitis, Peptic/*chemically induced/complications/physiopathology', 'Female', 'Humans', 'Mandelic Acids/*adverse effects', 'Parasympatholytics/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/2360335/
3696,oxybutynin,11114562,Advancements in pharmacologic management of the overactive bladder.,"['Dmochowski RR', 'Appell RA']","['Adrenergic alpha-Antagonists/therapeutic use', 'Aged', 'Animals', 'Antidepressive Agents, Tricyclic/therapeutic use', 'Benzhydryl Compounds/therapeutic use', 'Benzilates', 'Benzofurans/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Cholinergic Antagonists/therapeutic use', 'Cresols/therapeutic use', 'Delayed-Action Preparations', 'Drug Administration Routes', 'Female', 'Humans', 'Mandelic Acids/administration & dosage', 'Middle Aged', 'Muscarinic Antagonists/therapeutic use', 'Muscle Relaxants, Central/therapeutic use', 'Nortropanes/administration & dosage', '*Phenylpropanolamine', 'Pyrrolidines/therapeutic use', 'Tolterodine Tartrate', 'Urinary Incontinence/*drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/11114562/
3697,oxybutynin,22749555,[Catheter-related bladder discomfort in post-anaesthesia care unit].,"['Tauzin-Fin P', 'Stecken L', 'Sztark F']","['Amines/therapeutic use', 'Anesthesia Recovery Period', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Dysuria/drug therapy/*etiology/physiopathology', 'Female', 'Gabapentin', 'Humans', 'Ketamine/therapeutic use', 'Male', 'Mandelic Acids/therapeutic use', 'Muscarinic Antagonists/therapeutic use', 'Pain, Postoperative/drug therapy/*etiology/physiopathology', 'Receptors, Muscarinic/drug effects/physiology', '*Recovery Room', 'Risk Factors', 'Severity of Illness Index', 'Symptom Assessment', 'Syndrome', 'Tramadol/therapeutic use', 'Urinary Catheterization/*adverse effects', 'Urothelium/injuries/physiopathology', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22749555/
3698,oxybutynin,18044184,Pharmacologic management of overactive bladder.,"['Lam S', 'Hilas O']","['Benzhydryl Compounds/therapeutic use', 'Benzofurans/therapeutic use', 'Cresols/therapeutic use', 'Humans', 'Mandelic Acids/therapeutic use', 'Muscarinic Antagonists/administration & dosage/adverse effects/*therapeutic use', 'Nortropanes/therapeutic use', 'Phenylpropanolamine/therapeutic use', 'Pyrrolidines/therapeutic use', 'Quinuclidines/therapeutic use', 'Solifenacin Succinate', 'Tetrahydroisoquinolines/therapeutic use', 'Tolterodine Tartrate', 'Treatment Outcome', 'Urinary Bladder, Overactive/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18044184/
3699,oxybutynin,19901914,Intravesical oxybutynin in the pediatric neurogenic bladder.,['Lazarus J'],"['Administration, Intravesical', 'Child', 'Humans', 'Mandelic Acids/*administration & dosage', 'Muscarinic Antagonists/*administration & dosage', 'Urinary Bladder, Neurogenic/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/19901914/
3700,oxybutynin,16516613,Hallucinations after hypospadias repair.,"['Swana HS', 'Youmans SL', 'Kogan BA', 'Bogetz MS']","['Child, Preschool', 'Drug Overdose', 'Hallucinations/*chemically induced', 'Humans', 'Hypospadias/*surgery', 'Male', 'Mandelic Acids/*adverse effects/therapeutic use', 'Muscarinic Antagonists/*adverse effects/therapeutic use', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/16516613/
3701,oxybutynin,28538882,Oxybutynin as an alternative treatment for hyperhidrosis.,"['Delort S', 'Marchi E', 'Correa MA']","['Humans', 'Hyperhidrosis/*drug therapy', 'Mandelic Acids/adverse effects/*therapeutic use', 'Muscarinic Antagonists/adverse effects/*therapeutic use', 'Sweat Glands/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28538882/
3702,oxybutynin,3191355,Oxybutynin: is it safe?,"['Baigrie RJ', 'Kelleher JP', 'Fawcett DP', 'Pengelly AW']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', 'Child', 'Female', 'Humans', 'Male', 'Mandelic Acids/*adverse effects/therapeutic use', 'Middle Aged', 'Parasympatholytics/*adverse effects/therapeutic use', 'Retrospective Studies', 'Urinary Bladder Diseases/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3191355/
3703,doxepin,37549414,Insomnia Management: A Review and Update.,['Shaha DP'],"['Humans', '*Sleep Initiation and Maintenance Disorders/diagnosis/drug therapy', 'Sleep', 'Zolpidem', 'Doxepin/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/37549414/
3704,doxepin,35843245,Comparative effects of pharmacological interventions for the acute and long-term management of insomnia disorder in adults: a systematic review and network meta-analysis.,"['De Crescenzo F', ""D'Alo GL"", 'Ostinelli EG', 'Ciabattini M', 'Di Franco V', 'Watanabe N', 'Kurtulmus A', 'Tomlinson A', 'Mitrova Z', 'Foti F', 'Del Giovane C', 'Quested DJ', 'Cowen PJ', 'Barbui C', 'Amato L', 'Efthimiou O', 'Cipriani A']","['Adult', 'Benzodiazepines/therapeutic use', 'Doxepin/therapeutic use', 'Eszopiclone/therapeutic use', 'Humans', 'Melatonin/therapeutic use', 'Network Meta-Analysis', 'Randomized Controlled Trials as Topic', '*Sleep Initiation and Maintenance Disorders/drug therapy', 'Zolpidem/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/35843245/
3705,doxepin,28671376,Insomnia: Pharmacologic Therapy.,"['Matheson E', 'Hainer BL']","['Benzodiazepines/administration & dosage/therapeutic use', 'Doxepin/administration & dosage/therapeutic use', 'Humans', 'Hypnotics and Sedatives/administration & dosage/therapeutic use', 'Melatonin/administration & dosage/agonists/therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/28671376/
3706,doxepin,29487083,"Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery.","['Atkin T', 'Comai S', 'Gobbi G']","['Benzodiazepines/adverse effects/pharmacology/*therapeutic use', 'Drug Discovery/*methods', 'Humans', 'Hypnotics and Sedatives/adverse effects/pharmacology/*therapeutic use', 'Pharmacology, Clinical/*methods', 'Precision Medicine', 'Sleep Aids, Pharmaceutical/adverse effects/pharmacology/*therapeutic use', 'Sleep Initiation and Maintenance Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29487083/
3707,doxepin,28791566,Effects of Antidepressants on Sleep.,"['Wichniak A', 'Wierzbicka A', 'Walecka M', 'Jernajczyk W']","['Antidepressive Agents/administration & dosage/*adverse effects', 'Depressive Disorder/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Humans', 'Sleep/*drug effects', 'Sleep Wake Disorders/*chemically induced', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/28791566/
3708,doxepin,1361426,Urticaria and angioedema.,"['Davidson AE', 'Miller SD', 'Settipane G', 'Klein D']","['Acute Disease', 'Adrenal Cortex Hormones/therapeutic use', 'Angioedema/etiology/*physiopathology/therapy', 'Chronic Disease', 'Doxepin/therapeutic use', 'Drug Therapy, Combination', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H2 Antagonists/therapeutic use', 'Humans', 'Urticaria/etiology/*physiopathology/therapy']",https://pubmed.ncbi.nlm.nih.gov/1361426/
3709,doxepin,29562618,Transdermal and Topical Drug Administration in the Treatment of Pain.,"['Leppert W', 'Malec-Milewska M', 'Zajaczkowska R', 'Wordliczek J']","['Administration, Cutaneous', 'Administration, Topical', 'Analgesics/*administration & dosage/*therapeutic use', 'Analgesics, Opioid/administration & dosage/therapeutic use', 'Animals', 'Humans', 'Pain/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/29562618/
3710,doxepin,12389450,[Cold-induced urticaria].,"['Delorme N', 'Drouet M', 'Thibaudeau A', 'Verret JL']","['Acetates/therapeutic use', 'Adrenal Cortex Hormones/therapeutic use', 'Aminophylline/administration & dosage/therapeutic use', 'Cold Temperature/*adverse effects', 'Cyclopropanes', 'Doxepin/therapeutic use', 'Drug Therapy, Combination', 'Female', 'Genes, Dominant', 'Histamine H1 Antagonists/therapeutic use', 'Humans', 'Hypotension/etiology', 'Male', 'Quinolines/therapeutic use', 'Stanozolol/therapeutic use', 'Sulfides', 'Terbutaline/administration & dosage/therapeutic use', 'Urticaria/diagnosis/drug therapy/*etiology/genetics/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/12389450/
3711,doxepin,27826702,Structural Analysis of the Histamine H(1) Receptor.,"['Shiroishi M', 'Kobayashi T']","['Animals', 'Binding Sites/physiology', 'Doxepin/chemistry/pharmacology', 'Histamine/chemistry/metabolism', 'Histamine Antagonists/chemistry/pharmacology', 'Histamine H1 Antagonists/chemistry/metabolism', 'Humans', 'Protein Binding/drug effects', 'Receptors, Histamine H1/*chemistry/metabolism']",https://pubmed.ncbi.nlm.nih.gov/27826702/
3712,doxepin,37821573,Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials.,"['Fornaro M', 'Caiazza C', 'Solini N', 'De Prisco M', 'Billeci M', 'Vannini M', 'Shorr R', 'Caiolo S', 'Lussignoli M', 'Siskind D', 'Pigato G', 'Barone A', 'Sambataro F', 'de Bartolomeis A', 'Correll CU', 'Solmi M']","['Adult', 'Humans', '*Antipsychotic Agents/adverse effects', '*Clozapine/therapeutic use', 'Sulpiride/adverse effects', 'Amisulpride/adverse effects', '*Sialorrhea/chemically induced/drug therapy', 'Doxepin/adverse effects', 'Amitriptyline/adverse effects', 'Network Meta-Analysis', 'Propantheline/adverse effects', 'Trihexyphenidyl/adverse effects', 'Metoclopramide/adverse effects', 'Chlorpheniramine/adverse effects', 'Astemizole/adverse effects', 'Randomized Controlled Trials as Topic', 'Cyproheptadine/adverse effects', 'Diphenhydramine/adverse effects', 'Ipratropium/adverse effects', 'Atropine Derivatives/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/37821573/
3713,doxepin,39746731,Insomnia in older adults: A review of treatment options.,"['Leon-Barriera R', 'Chaplin MM', 'Kaur J', 'Modesto-Lowe V']","['Humans', '*Sleep Initiation and Maintenance Disorders/therapy/etiology', 'Aged', '*Hypnotics and Sedatives/therapeutic use/adverse effects', '*Cognitive Behavioral Therapy/methods', 'Melatonin/therapeutic use', 'Indenes/therapeutic use', 'Orexin Receptor Antagonists/therapeutic use/adverse effects', 'Doxepin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/39746731/
3714,doxepin,30990550,Effect of Doxepin Mouthwash or Diphenhydramine-Lidocaine-Antacid Mouthwash vs Placebo on Radiotherapy-Related Oral Mucositis Pain: The Alliance A221304 Randomized Clinical Trial.,"['Sio TT', 'Le-Rademacher JG', 'Leenstra JL', 'Loprinzi CL', 'Rine G', 'Curtis A', 'Singh AK', 'Martenson JA Jr', 'Novotny PJ', 'Tan AD', 'Qin R', 'Ko SJ', 'Reiter PL', 'Miller RC']","['Administration, Topical', 'Adult', 'Aged', 'Aged, 80 and over', 'Antacids/*therapeutic use', 'Diphenhydramine/adverse effects/*therapeutic use', 'Double-Blind Method', 'Doxepin/adverse effects/*therapeutic use', 'Fatigue/chemically induced', 'Female', 'Head and Neck Neoplasms/*radiotherapy', 'Humans', 'Lidocaine/adverse effects/*therapeutic use', 'Linear Models', 'Male', 'Middle Aged', '*Mouthwashes', 'Pain/drug therapy', 'Radiation Injuries/*drug therapy', 'Stomatitis/*drug therapy/etiology']",https://pubmed.ncbi.nlm.nih.gov/30990550/
3715,doxepin,6612411,Doxepin and tinnitus.,"['Golden RN', 'Evans DL', 'Nau CH Jr']","['Aged', 'Depressive Disorder/drug therapy', 'Doxepin/*adverse effects', 'Female', 'Humans', 'Tinnitus/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/6612411/
3716,doxepin,2878798,"Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.","['Benfield P', 'Heel RC', 'Lewis SP']","['Animals', 'Cardiovascular System/drug effects', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Endocrine Glands/drug effects', '*Fluoxetine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Humans', 'Kinetics', 'Neurotransmitter Agents/metabolism', '*Propylamines/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Receptors, Neurotransmitter/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2878798/
3717,doxepin,27578080,Neurologic Itch Management.,['Savk E'],"['Acupuncture Therapy', 'Amines/therapeutic use', 'Anesthetics, Local/*therapeutic use', 'Anticonvulsants/*therapeutic use', 'Antipruritics/*therapeutic use', 'Botulinum Toxins, Type A/therapeutic use', 'Calcineurin Inhibitors/therapeutic use', 'Cannabinoid Receptor Agonists/therapeutic use', 'Capsaicin/therapeutic use', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Doxepin/therapeutic use', 'Gabapentin', 'Humans', 'Neuromuscular Agents/*therapeutic use', 'Peripheral Nervous System Diseases/complications/*therapy', 'Phototherapy', 'Physical Therapy Modalities', 'Pregabalin/therapeutic use', 'Pruritus/etiology/*therapy', 'Tacrolimus/therapeutic use', 'Transcranial Magnetic Stimulation', 'Transcutaneous Electric Nerve Stimulation', 'gamma-Aminobutyric Acid/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27578080/
3718,doxepin,8517180,Death due to overdose of antidepressants: experiences from Norway.,['Retterstol N'],"['Adolescent', 'Adult', 'Aged', 'Amitriptyline/poisoning', 'Antidepressive Agents/*poisoning', 'Doxepin/poisoning', 'Drug Overdose/mortality', 'Female', 'Humans', 'Male', 'Middle Aged', 'Norway/epidemiology', 'Suicide/*statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/8517180/
3719,doxepin,9437474,"Mirtazapine, an antidepressant.",['Puzantian T'],"['Animals', 'Antidepressive Agents, Tricyclic/pharmacokinetics/pharmacology/*therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Humans', 'Mianserin/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Mirtazapine']",https://pubmed.ncbi.nlm.nih.gov/9437474/
3720,doxepin,15359567,The role of metabolites in bioequivalence.,"['Midha KK', 'Rawson MJ', 'Hubbard JW']","['Area Under Curve', 'Biotransformation', 'Clinical Trials as Topic', 'Doxepin/*analogs & derivatives/pharmacokinetics', 'Guidelines as Topic', 'Humans', 'Liver/metabolism', 'Nortriptyline/*analogs & derivatives/pharmacokinetics', 'Pharmaceutical Preparations/*metabolism', '*Pharmacokinetics', 'Therapeutic Equivalency', 'United States', 'United States Food and Drug Administration/legislation & jurisprudence']",https://pubmed.ncbi.nlm.nih.gov/15359567/
3721,doxepin,12469964,Topical tacrolimus: a new therapy for atopic dermatitis.,['Russell JJ'],"['Administration, Cutaneous', 'Clinical Trials as Topic', 'Dermatitis, Atopic/*drug therapy', 'Dermatologic Agents/*administration & dosage/adverse effects/pharmacology', 'Humans', 'Immunosuppressive Agents/*administration & dosage/adverse effects/pharmacology', 'Tacrolimus/*administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/12469964/
3722,cefepime,37837651,Cefepime vs Piperacillin-Tazobactam in Adults Hospitalized With Acute Infection: The ACORN Randomized Clinical Trial.,"['Qian ET', 'Casey JD', 'Wright A', 'Wang L', 'Shotwell MS', 'Siemann JK', 'Dear ML', 'Stollings JL', 'Lloyd BD', 'Marvi TK', 'Seitz KP', 'Nelson GE', 'Wright PW', 'Siew ED', 'Dennis BM', 'Wrenn JO', 'Andereck JW', 'Han JH', 'Self WH', 'Semler MW', 'Rice TW']","['Humans', 'Adult', 'Female', 'Middle Aged', 'Male', 'Anti-Bacterial Agents/adverse effects', 'Cefepime/adverse effects', 'Coma', 'Piperacillin/adverse effects', 'Drug Therapy, Combination', 'Retrospective Studies', 'Piperacillin, Tazobactam Drug Combination/adverse effects', '*Sepsis/complications', '*Acute Kidney Injury/etiology', 'Kidney', '*Delirium']",https://pubmed.ncbi.nlm.nih.gov/37837651/
3723,cefepime,38739397,Mortality of Patients With Sepsis Administered Piperacillin-Tazobactam vs Cefepime.,"['Chanderraj R', 'Admon AJ', 'He Y', 'Nuppnau M', 'Albin OR', 'Prescott HC', 'Dickson RP', 'Sjoding MW']","['Humans', '*Cefepime/administration & dosage/therapeutic use', '*Piperacillin, Tazobactam Drug Combination/administration & dosage/therapeutic use', 'Male', '*Anti-Bacterial Agents/administration & dosage/therapeutic use', 'Female', '*Sepsis/drug therapy/mortality', 'Retrospective Studies', 'Aged', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/38739397/
3724,cefepime,36194218,Effect of Cefepime/Enmetazobactam vs Piperacillin/Tazobactam on Clinical Cure and Microbiological Eradication in Patients With Complicated Urinary Tract Infection or Acute Pyelonephritis: A Randomized Clinical Trial.,"['Kaye KS', 'Belley A', 'Barth P', 'Lahlou O', 'Knechtle P', 'Motta P', 'Velicitat P']","['Acute Disease', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Cefepime/administration & dosage/adverse effects/therapeutic use', 'Double-Blind Method', 'Drug Combinations', 'Female', 'Gram-Negative Bacterial Infections/drug therapy', 'Humans', 'Infusions, Intravenous', 'Male', 'Middle Aged', '*Piperacillin, Tazobactam Drug Combination/administration & dosage/adverse effects/therapeutic use', '*Pyelonephritis/drug therapy/microbiology', '*Urinary Tract Infections/complications/drug therapy/microbiology', '*beta-Lactamase Inhibitors/administration & dosage/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36194218/
3725,cefepime,38354140,Cefepime-Taniborbactam in Complicated Urinary Tract Infection.,"['Wagenlehner FM', 'Gasink LB', 'McGovern PC', 'Moeck G', 'McLeroth P', 'Dorr M', 'Dane A', 'Henkel T']","['Adult', 'Aged', 'Humans', 'Middle Aged', 'Administration, Intravenous', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', 'Bacteremia/drug therapy/microbiology', 'beta-Lactamases/administration & dosage/adverse effects/therapeutic use', '*Borinic Acids/administration & dosage/adverse effects/therapeutic use', '*Carboxylic Acids/administration & dosage/adverse effects/therapeutic use', '*Cefepime/administration & dosage/adverse effects/therapeutic use', 'Drug Therapy, Combination', 'Hospitalization', '*Meropenem/administration & dosage/adverse effects/therapeutic use', 'Microbial Sensitivity Tests', 'Pyelonephritis/drug therapy/microbiology', '*Urinary Tract Infections/drug therapy/microbiology', 'Drug Resistance, Bacterial']",https://pubmed.ncbi.nlm.nih.gov/38354140/
3726,cefepime,29137682,Cefepime-induced neurotoxicity: a systematic review.,"['Payne LE', 'Gagnon DJ', 'Riker RR', 'Seder DB', 'Glisic EK', 'Morris JG', 'Fraser GL']","['Anti-Bacterial Agents/adverse effects/therapeutic use', 'Cefepime', 'Cephalosporins/*adverse effects/therapeutic use', 'Consciousness Disorders/chemically induced', 'Drug-Related Side Effects and Adverse Reactions/diagnosis', 'Humans', 'Neurotoxicity Syndromes/complications/*etiology/physiopathology', 'Seizures/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/29137682/
3727,cefepime,35764774,Clinical Pharmacokinetics and Pharmacodynamics of Cefepime.,"['Pais GM', 'Chang J', 'Barreto EF', 'Stitt G', 'Downes KJ', 'Alshaer MH', 'Lesnicki E', 'Panchal V', 'Bruzzone M', 'Bumanglag AV', 'Burke SN', 'Scheetz MH']","['Adult', '*Anti-Bacterial Agents/pharmacokinetics', 'Cefepime/pharmacology', '*Cephalosporins/pharmacology/therapeutic use', 'Critical Illness', 'Humans', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/35764774/
3728,cefepime,31778052,[Cefepime-induced encephalopathy].,"['Muradbegovic J', 'Leidi A', 'Serratrice J']","['Anti-Bacterial Agents/adverse effects/supply & distribution/therapeutic use', 'Brain Diseases/blood/*chemically induced/diagnosis', 'Cefepime/administration & dosage/*adverse effects/blood/therapeutic use', 'Humans', 'Renal Insufficiency/blood/complications/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/31778052/
3729,cefepime,35971666,Cefepime-induced neurotoxicity: systematic review.,"['Maan G', 'Keitoku K', 'Kimura N', 'Sawada H', 'Pham A', 'Yeo J', 'Hagiya H', 'Nishimura Y']","['Humans', 'Cefepime/adverse effects', 'Cephalosporins/adverse effects', 'Anti-Bacterial Agents/adverse effects', '*Neurotoxicity Syndromes/etiology', '*Brain Diseases/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/35971666/
3730,cefepime,37846592,Antibiotic therapy for nonfermenting Gram-negative bacilli infections: future perspectives.,"['Bassetti M', 'Castaldo N', 'Fantin A', 'Giacobbe DR', 'Vena A']","['Humans', 'Cefepime/pharmacology/therapeutic use', '*Gram-Negative Bacterial Infections/drug therapy/microbiology', 'Anti-Bacterial Agents/pharmacology/therapeutic use', 'Gram-Negative Bacteria', 'Cephalosporins/therapeutic use', 'Microbial Sensitivity Tests']",https://pubmed.ncbi.nlm.nih.gov/37846592/
3731,cefepime,30882137,Antibiotic Therapy for Pseudomonas aeruginosa Bloodstream Infections: How Long Is Long Enough?,"['Fabre V', 'Amoah J', 'Cosgrove SE', 'Tamma PD']","['Aged', 'Bacteremia/*drug therapy/*microbiology', 'Cefepime/therapeutic use', 'Female', 'Humans', 'Male', 'Middle Aged', 'Piperacillin, Tazobactam Drug Combination/*therapeutic use', 'Pseudomonas aeruginosa/*drug effects/*pathogenicity']",https://pubmed.ncbi.nlm.nih.gov/30882137/
3732,cefepime,36374566,Subcutaneously administered antibiotics: a review.,"['Jumpertz M', 'Guilhaumou R', 'Million M', 'Parola P', 'Lagier JC', 'Brouqui P', 'Cassir N']","['Humans', '*Anti-Bacterial Agents/adverse effects', 'Ertapenem', '*Ceftriaxone', 'Teicoplanin', 'Cefepime']",https://pubmed.ncbi.nlm.nih.gov/36374566/
3733,cefepime,36745895,"In complicated UTI or pyelonephritis, cefepime-enmetazobactam increased success vs. piperacillin-tazobactam at 14 d.",['Maki DG'],"['Humans', 'Anti-Bacterial Agents/therapeutic use', 'Cefepime/therapeutic use', 'Piperacillin, Tazobactam Drug Combination/therapeutic use', '*Pyelonephritis/drug therapy', '*Urinary Tract Infections/drug therapy', 'Randomized Controlled Trials as Topic']",https://pubmed.ncbi.nlm.nih.gov/36745895/
3734,cefepime,35904000,"Activity of cefiderocol, imipenem/relebactam, cefepime/taniborbactam and cefepime/zidebactam against ceftolozane/tazobactam- and ceftazidime/avibactam-resistant Pseudomonas aeruginosa.","['Lasarte-Monterrubio C', 'Fraile-Ribot PA', 'Vazquez-Ucha JC', 'Cabot G', 'Guijarro-Sanchez P', 'Alonso-Garcia I', 'Rumbo-Feal S', 'Galan-Sanchez F', 'Beceiro A', 'Arca-Suarez J', 'Oliver A', 'Bou G']","['Anti-Bacterial Agents/pharmacology/therapeutic use', 'Azabicyclo Compounds/pharmacology/therapeutic use', 'Borinic Acids', 'Carboxylic Acids', 'Cefepime/pharmacology/therapeutic use', '*Ceftazidime/pharmacology/therapeutic use', 'Cephalosporins/pharmacology/therapeutic use', 'Cyclooctanes', 'Humans', 'Imipenem/pharmacology/therapeutic use', 'Piperidines', '*Pseudomonas Infections/drug therapy', 'Pseudomonas aeruginosa/genetics', 'Tazobactam/pharmacology/therapeutic use', 'beta-Lactamases/genetics', 'Cefiderocol']",https://pubmed.ncbi.nlm.nih.gov/35904000/
3735,cefepime,38761353,Cefepime/Enmetazobactam: First Approval.,['Keam SJ'],"['Humans', '*Anti-Bacterial Agents/pharmacology/therapeutic use/administration & dosage', 'beta-Lactamase Inhibitors/pharmacology/therapeutic use/administration & dosage', '*Cefepime/pharmacology/therapeutic use', 'Cephalosporins/therapeutic use/pharmacology', '*Drug Approval', 'Drug Combinations', 'Drug Resistance, Multiple, Bacterial/drug effects', 'Gram-Negative Bacteria/drug effects', 'Gram-Negative Bacterial Infections/drug therapy', 'Pyelonephritis/drug therapy/microbiology', 'United States', '*Urinary Tract Infections/drug therapy/microbiology']",https://pubmed.ncbi.nlm.nih.gov/38761353/
3736,cefepime,23127270,Pediatric cefepime neurotoxicity.,"['Landgrave LC', 'Lock JL', 'Whitmore JM', 'Belcher CE']","['Acute Kidney Injury/*chemically induced', 'Adolescent', 'Anti-Bacterial Agents/*adverse effects', 'Cefepime', 'Cephalosporins/*adverse effects', 'Female', 'Humans', 'Neurotoxicity Syndromes/*diagnosis']",https://pubmed.ncbi.nlm.nih.gov/23127270/
3737,cefepime,34729808,A Case of Cefepime-Induced Immune Thrombocytopenia.,"['Bystrom R', 'Wungwattana M', 'Tchekmedyian V']","['Adult', 'Blood Platelets', 'Cefepime/adverse effects', 'Humans', 'Male', '*Purpura, Thrombocytopenic, Idiopathic/chemically induced/diagnosis', '*Thrombocytopenia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/34729808/
3738,cefepime,37993680,Cefepime versus carbapenems for treatment of AmpC beta-lactamase-producing Enterobacterales bloodstream infections.,"['Herrmann J', 'Burgener-Gasser AV', 'Goldenberger D', 'Roth J', 'Weisser M', 'Tamma PD', 'Tschudin-Sutter S']","['Humans', 'Cefepime/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Carbapenems/adverse effects', 'Cephalosporins/adverse effects', 'Retrospective Studies', 'Hospital Mortality', '*Enterobacteriaceae Infections/drug therapy/microbiology', 'beta-Lactamases', '*Sepsis/drug therapy', '*Gammaproteobacteria', 'Microbial Sensitivity Tests', '*Bacterial Proteins']",https://pubmed.ncbi.nlm.nih.gov/37993680/
3739,cefepime,37028731,Effectiveness of third-generation cephalosporins or piperacillin compared with cefepime or carbapenems for severe infections caused by wild-type AmpC beta-lactamase-producing Enterobacterales: A multi-centre retrospective propensity-weighted study.,"['Maillard A', 'Delory T', 'Bernier J', 'Villa A', 'Chaibi K', 'Escaut L', 'Contejean A', 'Bercot B', 'Robert J', 'El Alaoui F', 'Tankovic J', 'Poupet H', 'Cuzon G', 'Lafaurie M', 'Surgers L', 'Joseph A', 'Paccoud O', 'Molina JM', 'Bleibtreu A']","['Humans', 'Cefepime/therapeutic use', '*Piperacillin/therapeutic use', '*Carbapenems/therapeutic use', 'Retrospective Studies', 'Anti-Bacterial Agents/therapeutic use', 'beta-Lactamases', 'Piperacillin, Tazobactam Drug Combination/therapeutic use', 'Cephalosporins/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/37028731/
3740,cefepime,30968302,Cefepime challenge after piperacillin/tazobactam-induced thrombocytopenia.,"['Beaulieu C', 'Kurczewski L', 'Yajnik V']","['Adult', 'Anti-Bacterial Agents/pharmacology', 'Cefepime/pharmacology/*therapeutic use', 'Female', 'Humans', '*Immunity, Humoral', 'Male', 'Piperacillin/adverse effects', 'Piperacillin, Tazobactam Drug Combination/adverse effects', 'Pneumonia, Aspiration/drug therapy', 'Tazobactam/adverse effects', 'Thrombocytopenia/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/30968302/
3741,cefepime,38733970,Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?,"['Bassetti M', 'Giacobbe DR']","['*Cefepime/therapeutic use/pharmacology', 'Humans', '*Anti-Bacterial Agents/therapeutic use/pharmacology', '*Carbapenems/therapeutic use/pharmacology', '*Urinary Tract Infections/drug therapy/microbiology', 'Cephalosporins/therapeutic use/pharmacology', 'Pyelonephritis/drug therapy/microbiology', 'Drug Combinations', 'Gram-Negative Bacterial Infections/drug therapy', 'Meropenem/therapeutic use/pharmacology', 'Borinic Acids', 'Carboxylic Acids']",https://pubmed.ncbi.nlm.nih.gov/38733970/
3742,metronidazole,3280909,Metronidazole.,['Scully BE'],"['Bacteria, Anaerobic', 'Bacterial Infections/*drug therapy', 'Humans', '*Metronidazole/adverse effects/therapeutic use', 'Protozoan Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/3280909/
3743,metronidazole,29077920,"Metronidazole: an update on metabolism, structure-cytotoxicity and resistance mechanisms.","['Dingsdag SA', 'Hunter N']","['Animals', 'Anti-Infective Agents/adverse effects/chemistry/metabolism/*pharmacology', '*Drug Resistance, Bacterial', 'Humans', 'Metronidazole/adverse effects/chemistry/metabolism/*pharmacology', 'Mice']",https://pubmed.ncbi.nlm.nih.gov/29077920/
3744,metronidazole,24267604,Clostridium difficile infection in the elderly.,"['Keller JM', 'Surawicz CM']","['Aged', '*Anti-Bacterial Agents/administration & dosage/adverse effects', '*Clostridioides difficile/drug effects/isolation & purification/pathogenicity', '*Clostridium Infections/epidemiology/etiology/physiopathology/therapy', 'Cross Infection', 'Diarrhea/physiopathology', 'Disease Management', 'Humans', '*Metronidazole/administration & dosage/adverse effects', 'Outcome Assessment, Health Care', 'Prevalence', 'Risk Factors', 'Severity of Illness Index', '*Vancomycin/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/24267604/
3745,metronidazole,26962078,"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program.","['Mazuski JE', 'Gasink LB', 'Armstrong J', 'Broadhurst H', 'Stone GG', 'Rank D', 'Llorens L', 'Newell P', 'Pachl J']","['Adolescent', 'Adult', 'Aged', 'Aged, 80 and over', '*Anti-Bacterial Agents/administration & dosage/adverse effects/therapeutic use', '*Azabicyclo Compounds/administration & dosage/adverse effects/therapeutic use', '*Ceftazidime/administration & dosage/adverse effects/therapeutic use', 'Drug Combinations', 'Female', 'Humans', 'Intraabdominal Infections/*drug therapy/epidemiology', 'Male', 'Meropenem', '*Metronidazole/administration & dosage/adverse effects/therapeutic use', 'Middle Aged', '*Thienamycins/administration & dosage/adverse effects/therapeutic use', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/26962078/
3746,metronidazole,2568163,Inflammatory bowel disease.,['Van Rosendaal GM'],"['Administration, Oral', 'Adrenal Cortex Hormones/adverse effects/therapeutic use', 'Aminosalicylic Acids/administration & dosage/adverse effects/therapeutic use', 'Delayed-Action Preparations', 'Drug Evaluation', 'Forecasting', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy/therapy', 'Mesalamine', 'Metronidazole/adverse effects/therapeutic use', 'Sulfasalazine/adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2568163/
3747,metronidazole,58258,Treatment of rosacea by metronidazole.,"['Pye RJ', 'Burton JL']","['Administration, Oral', 'Adult', 'Aged', 'Clinical Trials as Topic', 'Drug Evaluation', 'Humans', 'Metronidazole/administration & dosage/*therapeutic use', 'Middle Aged', 'Placebos', 'Rosacea/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/58258/
3748,metronidazole,20510762,Innovative use of topical metronidazole.,['Zip CM'],"['Acute Generalized Exanthematous Pustulosis/drug therapy', 'Administration, Cutaneous', 'Adult', 'Anti-Infective Agents/administration & dosage/adverse effects/*therapeutic use', 'Anti-Inflammatory Agents, Non-Steroidal/administration & dosage/adverse effects/*therapeutic use', 'Child', 'Dermatitis, Perioral/drug therapy', 'Dermatitis, Seborrheic/drug therapy', 'Double-Blind Method', 'Drug Eruptions/diagnosis/etiology', 'ErbB Receptors/antagonists & inhibitors', 'Female', 'Humans', 'Male', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Multicenter Studies as Topic', 'Off-Label Use', 'Randomized Controlled Trials as Topic', 'Rosacea/*drug therapy', '*Therapies, Investigational', 'Wounds and Injuries/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/20510762/
3749,metronidazole,7791427,Clindamycin and metronidazole.,"['Falagas ME', 'Gorbach SL']","['Animals', 'Bacterial Infections/*drug therapy', 'Clindamycin/adverse effects/chemistry/*therapeutic use', 'Drug Resistance, Microbial', 'Humans', 'Metronidazole/adverse effects/metabolism/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/7791427/
3750,metronidazole,9509270,Clostridium difficile infection.,"['Kelly CP', 'LaMont JT']","['Administration, Oral', 'Anti-Bacterial Agents/administration & dosage/adverse effects/economics/therapeutic use', 'Bacterial Toxins/analysis/metabolism', '*Clostridioides difficile/metabolism', 'Colon/microbiology', 'Diarrhea/microbiology', 'Drug Costs', 'Drug Resistance, Microbial', 'Enterocolitis, Pseudomembranous/drug therapy/*microbiology', 'Exotoxins/analysis/metabolism', 'Feces/chemistry', 'Hospitalization', 'Humans', 'Intestinal Mucosa/microbiology', 'Metronidazole/administration & dosage/economics/therapeutic use', 'Recurrence', 'Time Factors', 'Vancomycin/administration & dosage/economics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9509270/
3751,metronidazole,12052431,Is metronidazole carcinogenic?,"['Bendesky A', 'Menendez D', 'Ostrosky-Wegman P']","['Animals', 'Anti-Infective Agents/adverse effects/chemistry/metabolism/pharmacokinetics', 'Carcinogenicity Tests', '*Carcinogens/metabolism', 'DNA Damage', 'Humans', 'Metronidazole/*adverse effects/chemistry/metabolism/pharmacokinetics', 'Molecular Structure', 'Mutagenicity Tests', 'Mutagens/metabolism']",https://pubmed.ncbi.nlm.nih.gov/12052431/
3752,metronidazole,26238129,DRESS Syndrome Following Levofloxacin Exposure With Positive Patch-test.,"['Charfi O', 'Lakhoua G', 'Sahnoun R', 'Badri T', 'Daghfous R', 'El Aidli S', 'Kastalli S', 'Zaiem A']","['Acetaminophen/therapeutic use', 'Adult', 'Anti-Bacterial Agents/administration & dosage/*adverse effects', 'Drug Hypersensitivity Syndrome/diagnosis/*etiology', 'Drug Therapy, Combination', 'Epstein-Barr Virus Infections/drug therapy', 'Fluoroquinolones/adverse effects', 'Humans', 'Levofloxacin/administration & dosage/*adverse effects', 'Liver Function Tests', 'Male', 'Metronidazole/administration & dosage/therapeutic use', '*Patch Tests', 'Phenols/therapeutic use', 'Respiratory Tract Infections/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/26238129/
3753,metronidazole,8426284,The role of metronidazole in the treatment of periodontal diseases.,['Greenstein G'],"['Animals', 'Bacteria, Anaerobic/drug effects', 'Carcinogenicity Tests', 'Drug Interactions', 'Humans', 'Metronidazole/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Molecular Structure', 'Mutagenicity Tests', 'Periodontal Diseases/*drug therapy', 'Periodontitis/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8426284/
3754,metronidazole,29327947,Secnidazole: next-generation antimicrobial agent for bacterial vaginosis treatment.,"['Nyirjesy P', 'Schwebke JR']","['Administration, Oral', 'Adolescent', 'Adult', 'Anti-Bacterial Agents/administration & dosage/chemistry/pharmacokinetics/*therapeutic use', 'Controlled Clinical Trials as Topic', 'Double-Blind Method', 'Female', 'Gram-Negative Bacteria/drug effects', 'Gram-Positive Bacteria/drug effects', 'Humans', 'Metronidazole/administration & dosage/*analogs & derivatives/chemistry/pharmacokinetics/therapeutic use', 'Middle Aged', 'Multicenter Studies as Topic', 'Trichomonas Vaginitis/drug therapy', 'Trichomonas vaginalis/drug effects', 'United States', 'Vaginosis, Bacterial/*drug therapy', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29327947/
3755,metronidazole,7067925,Single dose treatment of trichomoniasis.,"['Gabriel G', 'Robertson E', 'Thin RN']","['Female', 'Humans', 'Metronidazole/*administration & dosage/therapeutic use', 'Nitroimidazoles/*administration & dosage', 'Tinidazole/*administration & dosage/therapeutic use', 'Trichomonas Vaginitis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7067925/
3756,metronidazole,28279442,Low efficacy of metronidazole in the eradication of Blastocystis hominis in symptomatic patients: Case series and systematic literature review.,"['Batista L', 'Perez Jove J', 'Rosinach M', 'Gonzalo V', 'Sainz E', 'Loras C', 'Forne M', 'Esteve M', 'Fernandez-Banares F']","['Aged', 'Antiprotozoal Agents/pharmacology/*therapeutic use', 'Blastocystis Infections/*drug therapy/parasitology', 'Blastocystis hominis/*drug effects/isolation & purification', 'Diarrhea/*drug therapy/parasitology', 'Drug Resistance', 'Drug Substitution', 'Dyspepsia/drug therapy/parasitology', 'Feces/parasitology', 'Female', 'Humans', 'Male', 'Metronidazole/pharmacology/*therapeutic use', 'Middle Aged', 'Retrospective Studies', 'Sampling Studies', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/28279442/
3757,metronidazole,3053871,The use of metronidazole (Flagyl) in Crohn's disease.,['Babb RR'],"['Clinical Trials as Topic', 'Crohn Disease/*drug therapy', 'Humans', 'Metronidazole/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3053871/
3758,metronidazole,22407994,Meeting the challenge of recurrent Clostridium difficile infection.,['Johnson S'],"['Aged, 80 and over', 'Anti-Bacterial Agents/administration & dosage/adverse effects/*therapeutic use', 'Clostridioides difficile/isolation & purification/pathogenicity', 'Enterocolitis, Pseudomembranous/diagnosis/*drug therapy/prevention & control', 'Female', 'Fluid Therapy', 'Humans', 'Hygiene/education/standards', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Risk Factors', 'Secondary Prevention', 'Severity of Illness Index', 'Vancomycin/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/22407994/
3759,metronidazole,7436193,Metronidazole.,['Finegold SM'],"['Animals', 'Dysentery, Amebic/*drug therapy', 'Female', 'Giardiasis/drug therapy', 'Humans', 'Liver Abscess, Amebic/*drug therapy', 'Metronidazole/administration & dosage/adverse effects/*therapeutic use', 'Mice', 'Mutation', 'Neoplasms, Experimental/chemically induced', 'Rats', 'Trichomonas Infections/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7436193/
3760,metronidazole,28758800,Dosing antibiotics in neonates: review of the pharmacokinetic data.,"['Rivera-Chaparro ND', 'Cohen-Wolkowiez M', 'Greenberg RG']","['Adult', 'Aminoglycosides/administration & dosage/adverse effects/pharmacokinetics', 'Anti-Bacterial Agents/*administration & dosage/adverse effects/*pharmacokinetics', 'Birth Weight/drug effects', 'Body Size/drug effects', 'Cephalosporins/administration & dosage', 'Child', 'Clindamycin/administration & dosage/adverse effects/pharmacokinetics', 'Glycopeptides/administration & dosage/adverse effects/pharmacokinetics', 'Humans', 'Infant', 'Infant, Newborn/*physiology', 'Medication Reconciliation', 'Meropenem', 'Metronidazole/administration & dosage/adverse effects/pharmacokinetics', 'Penicillanic Acid/administration & dosage/analogs & derivatives', 'Piperacillin/administration & dosage', 'Piperacillin, Tazobactam Drug Combination', 'Thienamycins/administration & dosage/adverse effects/pharmacokinetics', 'beta-Lactams/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/28758800/
3761,metronidazole,8193418,Metronidazole hypersensitivity.,"['Knowles S', 'Choudhury T', 'Shear NH']","['Adult', 'Biological Availability', 'Candidiasis, Vulvovaginal/*drug therapy', '*Drug Hypersensitivity', 'Drug Therapy, Combination', 'Female', 'Humans', 'Metronidazole/*adverse effects/pharmacokinetics', 'Nystatin/therapeutic use', 'Recurrence', 'Vaginosis, Bacterial/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/8193418/
3762,nitroglycerin,3120566,Nitrate tolerance.,['Parker JO'],"['Dosage Forms', 'Drug Tolerance', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/administration & dosage/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3120566/
3763,nitroglycerin,19267787,Nitroglycerin headache and nitroglycerin-induced primary headaches from 1846 and onwards: a historical overview and an update.,"['Tfelt-Hansen PC', 'Tfelt-Hansen J']","['Headache Disorders, Primary/*chemically induced/*history', 'History, 19th Century', 'History, 20th Century', 'History, 21st Century', 'Humans', 'Nitroglycerin/*adverse effects', 'Vasodilator Agents/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/19267787/
3764,nitroglycerin,4207612,Instability of nitroglycerin tablets.,['Mayer GA'],"['Angina Pectoris/drug therapy', '*Drug Stability', 'Headache/chemically induced', 'Humans', 'Middle Aged', 'Nitroglycerin/*administration & dosage/adverse effects/therapeutic use', 'Refrigeration', 'Tablets']",https://pubmed.ncbi.nlm.nih.gov/4207612/
3765,nitroglycerin,18658016,Recent advances in the pharmacotherapy of chronic anal fissure: an update.,"['Medhi B', 'Rao RS', 'Prakash A', 'Prakash O', 'Kaman L', 'Pandhi P']","['Administration, Topical', 'Adrenergic alpha-Antagonists/administration & dosage', 'Anal Canal', 'Botulinum Toxins/*administration & dosage', 'Calcium Channel Blockers/administration & dosage', 'Chronic Disease/*drug therapy', 'Clinical Trials as Topic', 'Diltiazem/administration & dosage', 'Fissure in Ano/*drug therapy', 'Headache/chemically induced', 'Humans', 'Indoramin/administration & dosage', 'Injections, Intralesional', 'Lidocaine/administration & dosage', 'Nifedipine/administration & dosage', 'Nitroglycerin/*administration & dosage/adverse effects', 'Ointments']",https://pubmed.ncbi.nlm.nih.gov/18658016/
3766,nitroglycerin,11723312,Progress in the understanding and treatment of chronic anal fissure.,"['McCallion K', 'Gardiner KR']","['Administration, Topical', 'Anal Canal/drug effects/surgery', 'Botulinum Toxins/therapeutic use', 'Calcium Channel Blockers/therapeutic use', 'Chronic Disease', 'Dilatation/methods', 'Fissure in Ano/etiology/*therapy', 'Humans', 'Nitric Oxide Donors/therapeutic use', 'Nitroglycerin/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/11723312/
3767,nitroglycerin,121456,Glyceryl trinitrate ointment in angina pectoris.,"['Salem HH', 'Singh SP']","['Adult', 'Angina Pectoris/*drug therapy', 'Clinical Trials as Topic', 'Exercise Test', 'Female', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*therapeutic use', 'Ointments', 'Placebos', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/121456/
3768,nitroglycerin,21212965,A literature review on the role of chemical sphincterotomy after Milligan-Morgan hemorrhoidectomy.,"['Siddiqui MR', 'Abraham-Igwe C', 'Shangumanandan A', 'Grassi V', 'Swift I', 'Abulafi AM']","['Anal Canal/drug effects/*surgery', 'Analgesia', 'Botulinum Toxins/pharmacology/therapeutic use', 'Calcium Channel Blockers/pharmacology/therapeutic use', 'Digestive System Surgical Procedures/adverse effects/*methods', 'Health Planning Guidelines', 'Hemorrhoids/drug therapy/*surgery', 'Humans', 'Nitroglycerin/pharmacology/therapeutic use', 'Pain Measurement', 'Postoperative Complications/etiology', 'Randomized Controlled Trials as Topic', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/21212965/
3769,nitroglycerin,3137070,Pharmacokinetics of organic nitrates in man: an overview.,['Bogaert MG'],"['Absorption', 'Administration, Cutaneous', 'Administration, Sublingual', 'Humans', 'Injections, Intravenous', 'Isosorbide Dinitrate/administration & dosage/analogs & derivatives/blood/*pharmacokinetics', 'Nitroglycerin/administration & dosage/blood/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/3137070/
3770,nitroglycerin,8154634,Contact dermatitis from nitroglycerin.,"['de la Fuente Prieto R', 'Armentia Medina A', 'Diez Perez JM']","['Administration, Topical', 'Aged', 'Angina Pectoris/drug therapy', 'Dermatitis, Allergic Contact/*etiology', 'Humans', 'Male', 'Middle Aged', 'Nitroglycerin/administration & dosage/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8154634/
3771,nitroglycerin,27213950,RNA Sequencing of Trigeminal Ganglia in Rattus Norvegicus after Glyceryl Trinitrate Infusion with Relevance to Migraine.,"['Hougaard Pedersen S', 'Maretty L', 'Ramachandran R', 'Sibbesen JA', 'Yakimov V', 'Elgaard-Christensen R', 'Hansen TF', 'Krogh A', 'Olesen J', 'Jansen-Olesen I']","['Animals', 'Disease Models, Animal', 'Gene Expression Profiling', 'Gene Expression Regulation/drug effects', 'Infusions, Intraventricular', 'Male', 'Migraine Disorders/*chemically induced/*genetics/metabolism', 'Nitroglycerin/administration & dosage/*adverse effects', 'Rats', 'Rats, Sprague-Dawley', 'Sequence Analysis, RNA', 'Trigeminal Ganglion/*drug effects/*metabolism', 'Vasodilator Agents/administration & dosage/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/27213950/
3772,nitroglycerin,3113911,Treatment of acute anginal attacks with nitrates.,['Nyberg G'],"['Administration, Oral', 'Angina Pectoris/*drug therapy', 'Humans', 'Nitrates/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3113911/
3773,nitroglycerin,26027641,Use of nitrates in ischemic heart disease.,"['Giuseppe C', 'Paul J', 'Hans-Ulrich I']","['Angina Pectoris/drug therapy', 'Coronary Artery Disease/chemically induced/drug therapy', 'Delayed-Action Preparations', 'Drug Tolerance', 'Humans', 'Myocardial Ischemia/*drug therapy', 'Nitrates/administration & dosage/adverse effects/*therapeutic use', 'Nitroglycerin']",https://pubmed.ncbi.nlm.nih.gov/26027641/
3774,nitroglycerin,3129802,Nitroglycerine-induced volume loading.,"['Bunt TJ', 'Manczuk M', 'Varley KV']","['Aorta, Abdominal', 'Aortic Aneurysm/*surgery', 'Coronary Disease/complications', 'Drug Evaluation', 'Heart Ventricles/physiopathology', 'Hemodynamics/drug effects', 'Humans', 'Intraoperative Care', 'Intraoperative Complications/*prevention & control', 'Myocardial Infarction/*prevention & control', 'Nitroglycerin/*administration & dosage/pharmacology/therapeutic use', '*Premedication', 'Risk', 'Stroke Volume']",https://pubmed.ncbi.nlm.nih.gov/3129802/
3775,nitroglycerin,10584234,[Pharmacological profiles of sildenafil (VIAGRA) in the treatment of erectile dysfunction: efficacy and drug interaction with nitrate].,['Omote M'],"['Animals', 'Blood Pressure/drug effects', 'Cyclic GMP/metabolism', 'Dogs', 'Drug Interactions', 'Erectile Dysfunction/*drug therapy', 'Humans', 'Male', 'Nitric Oxide/metabolism/physiology', 'Nitric Oxide Donors/pharmacology', 'Nitroglycerin/*pharmacology', 'Penile Erection/drug effects', 'Penis/metabolism', 'Phosphodiesterase Inhibitors/*pharmacology/therapeutic use', 'Piperazines/*pharmacology/therapeutic use', 'Purines', 'Rabbits', 'Sildenafil Citrate', 'Sulfones']",https://pubmed.ncbi.nlm.nih.gov/10584234/
3776,nitroglycerin,10696937,Cut or paste? The use of glyceryl trinitrate paste in the treatment of acute and chronic anal fissure.,"['Ward DI', 'Miller BJ', 'Schache DJ', 'Cohen JR', 'Theile DE']","['Acute Disease', 'Chronic Disease', 'Combined Modality Therapy', 'Fissure in Ano/*drug therapy/surgery', 'Humans', 'Nitroglycerin/*administration & dosage', 'Ointments', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/10696937/
3777,nitroglycerin,1576038,Nitrates.,['Kuhn M'],"['Cardiovascular Diseases/*drug therapy', 'Coronary Disease/drug therapy/nursing', 'Drug Interactions', 'Hemodynamics/drug effects', 'Humans', 'Isosorbide Dinitrate/therapeutic use', 'Nitrates/adverse effects/pharmacology/*therapeutic use', 'Nitroglycerin/administration & dosage/therapeutic use', 'Patient Education as Topic']",https://pubmed.ncbi.nlm.nih.gov/1576038/
3778,nitroglycerin,10524660,Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura.,"['Christiansen I', 'Thomsen LL', 'Daugaard D', 'Ulrich V', 'Olesen J']","['Adult', 'Analgesics/therapeutic use', 'Female', 'Hemodynamics/drug effects', 'Humans', 'Male', 'Migraine with Aura/*complications/metabolism', 'Migraine without Aura/*chemically induced/complications/drug therapy/metabolism', 'Nitric Oxide/*physiology', 'Nitroglycerin/*adverse effects', 'Pain Measurement', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/10524660/
3779,nitroglycerin,28598453,Effectiveness of 0.2% Glyceryl Trinitrate and 0.5% Nifedipine in the Treatment of Chronic Anal Fissure.,"['Shrestha SK', 'Thapa PB', 'Maharjan DK', 'Tamang TY']","['Drug Therapy, Combination', 'Female', 'Fissure in Ano/*drug therapy', 'Humans', 'Male', 'Middle Aged', 'Nifedipine/*therapeutic use', 'Nitroglycerin/*therapeutic use', 'Prospective Studies', 'Treatment Outcome', 'Vasodilator Agents/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/28598453/
3780,nitroglycerin,17443133,Inhibition of PKC beta by ruboxistaurin does not enhance the acute blood pressure response to nitroglycerin.,"['Benson C', 'Seger M', 'Voelker J']","['Administration, Oral', 'Adrenergic beta-Antagonists/therapeutic use', 'Aged', 'Angina Pectoris/drug therapy/physiopathology', 'Blood Pressure/*drug effects', 'Chronic Disease', 'Cross-Over Studies', 'Dose-Response Relationship, Drug', 'Double-Blind Method', 'Drug Administration Schedule', 'Drug Interactions', 'Enzyme Inhibitors/administration & dosage/adverse effects/pharmacology', 'Female', 'Humans', 'Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use', 'Hypotension, Orthostatic/chemically induced', 'Indoles/administration & dosage/adverse effects/*pharmacology', 'Infusions, Intravenous', 'Male', 'Maleimides/administration & dosage/adverse effects/*pharmacology', 'Middle Aged', 'Nitroglycerin/administration & dosage/adverse effects/*pharmacology', 'Protein Kinase C/*antagonists & inhibitors', 'Protein Kinase C beta', 'Treatment Outcome', 'Vasodilator Agents/administration & dosage/adverse effects/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/17443133/
3781,nitroglycerin,32778123,Efficacy of Glyceryl trinitrate (GTN) to facilitate the rewarming process during cardiopulmonary bypass.,"['Mullane D', 'Lenihan M', 'Hanley C', 'Wall T', 'Bukowska I', 'Griffin M', 'Flood G']","['Aged', 'Body Temperature/drug effects', 'Cardiopulmonary Bypass/adverse effects/*methods', 'Humans', 'Hypothermia, Induced/methods', 'Infusions, Intravenous', 'Lactic Acid/blood', 'Middle Aged', 'Nitroglycerin/*administration & dosage', 'Prospective Studies', '*Rewarming', 'Time Factors', 'Vasodilator Agents/*administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/32778123/
3782,cetirizine,34474941,Unintentional cetirizine overdose causing anticholinergic syndrome.,"['Renko A', 'Cortese T', 'Karagiannis P', 'Salzman M']","['Anti-Allergic Agents/administration & dosage/*poisoning', 'Anticholinergic Syndrome/*etiology', 'Cetirizine/administration & dosage/*poisoning', 'Child', 'Drug Overdose/complications', 'Humans', 'Male']",https://pubmed.ncbi.nlm.nih.gov/34474941/
3783,cetirizine,18336052,"Clinical pharmacokinetics and pharmacodynamics of desloratadine, fexofenadine and levocetirizine : a comparative review.","['Devillier P', 'Roche N', 'Faisy C']","['Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Drug Interactions', 'Histamine H1 Antagonists, Non-Sedating/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Loratadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Rhinitis, Allergic, Perennial/drug therapy', 'Rhinitis, Allergic, Seasonal/drug therapy', 'Terfenadine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/18336052/
3784,cetirizine,12371532,Urticaria to cetirizine.,"['Tella R', 'Gaig P', 'Bartra J', 'Garcia-Ortega P']","['Adult', 'Cetirizine/*adverse effects', 'Drug Hypersensitivity/etiology', 'Female', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects', 'Humans', 'Urticaria/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/12371532/
3785,cetirizine,33909554,"Efficacy of Cetirizine 1% Versus Minoxidil 5% Topical Solution in the Treatment of Male Alopecia: A Randomized, Single-blind Controlled Study.","['Hossein Mostafa D', 'Samadi A', 'Niknam S', 'Nasrollahi SA', 'Guishard A', 'Firooz A']","['Administration, Topical', 'Adult', 'Alopecia/*drug therapy', 'Cetirizine/*therapeutic use', 'Histamine Antagonists/*therapeutic use', 'Humans', 'Male', 'Minoxidil/adverse effects/*therapeutic use', 'Single-Blind Method', 'Solutions', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/33909554/
3786,cetirizine,17017922,Levocetirizine: an update.,['Walsh GM'],"['Anti-Inflammatory Agents/pharmacology/therapeutic use', 'Cetirizine/*pharmacology/therapeutic use', 'Histamine H1 Antagonists/pharmacology/therapeutic use', 'Humans', 'Piperazines/*pharmacology/therapeutic use', 'Rhinitis/drug therapy', 'Urticaria/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/17017922/
3787,cetirizine,25750443,Urticaria pigmentosa-like disease in a dog.,"['Pariser MS', 'Gram DW']","['Animals', 'Anti-Allergic Agents/administration & dosage/therapeutic use', 'Anti-Ulcer Agents/administration & dosage/therapeutic use', 'Cetirizine/administration & dosage/therapeutic use', 'Diphenhydramine/administration & dosage/therapeutic use', 'Dog Diseases/diagnosis/*pathology', 'Dogs', 'Famotidine/administration & dosage/therapeutic use', 'Male', 'Urticaria Pigmentosa/diagnosis/drug therapy/pathology/*veterinary']",https://pubmed.ncbi.nlm.nih.gov/25750443/
3788,cetirizine,32558665,The allergic eye: recommendations about pharmacotherapy and recent therapeutic agents.,"['Kimchi N', 'Bielory L']","['Administration, Ophthalmic', 'Anti-Allergic Agents/*administration & dosage', 'Cetirizine/therapeutic use', 'Conjunctivitis, Allergic/*drug therapy/immunology', 'Drug Delivery Systems/methods/standards', 'Drug Repositioning', 'Histamine Antagonists/*administration & dosage', 'Humans', 'Immunotherapy/*methods/standards', 'Ophthalmic Solutions/*administration & dosage', 'Practice Guidelines as Topic', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/32558665/
3789,cetirizine,9188955,Antihistamines in the treatment of asthma.,"['Malick A', 'Grant JA']","['Asthma/*drug therapy/immunology', 'Cetirizine/therapeutic use', 'Clinical Trials as Topic', 'Histamine/immunology', 'Histamine H1 Antagonists/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/9188955/
3790,cetirizine,11772135,Cetirizine/pseudoephedrine.,"['Wellington K', 'Jarvis B']","['Administration, Oral', 'Adrenergic Agents/adverse effects/pharmacokinetics/*pharmacology', 'Anxiety/chemically induced', 'Asthenia/chemically induced', 'Biological Availability', 'Cetirizine/adverse effects/pharmacokinetics/*pharmacology', 'Chemistry, Pharmaceutical', 'Drug Administration Schedule', 'Ephedrine/adverse effects/pharmacokinetics/*pharmacology', 'Headache/chemically induced', 'Histamine H1 Antagonists/adverse effects/pharmacokinetics/*pharmacology', 'Humans', 'Nasal Cavity', 'Pruritus/drug therapy', 'Randomized Controlled Trials as Topic', 'Rhinitis, Allergic, Seasonal/*drug therapy/pathology', 'Sleep Initiation and Maintenance Disorders/chemically induced', 'Tablets', 'Treatment Outcome', 'Xerostomia/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/11772135/
3791,cetirizine,19076532,Pharmacotherapy of allergic rhinitis: a pharmaco-economic approach.,"['Simoens S', 'Laekeman G']","['Cetirizine/economics/therapeutic use', 'Costs and Cost Analysis', 'Economics, Pharmaceutical', 'Humans', 'Rhinitis, Allergic, Perennial/*drug therapy/*economics']",https://pubmed.ncbi.nlm.nih.gov/19076532/
3792,cetirizine,29182459,Recurrent pityriasis rosea: A case report.,"['Li A', 'Li P', 'Li Y', 'Li W']","['Adult', 'Cetirizine/therapeutic use', 'Humans', 'Influenza A Virus, H1N1 Subtype/immunology', 'Influenza Vaccines/*adverse effects/immunology', 'Influenza, Human/immunology', 'Male', 'Pityriasis Rosea/*chemically induced/drug therapy/*immunology', 'Recurrence']",https://pubmed.ncbi.nlm.nih.gov/29182459/
3793,cetirizine,10582736,Therapeutic index of H1-antihistamines: example of cetirizine.,['Rihoux JP'],"['Cetirizine/adverse effects/metabolism/*therapeutic use', 'Histamine H1 Antagonists/adverse effects/metabolism/*therapeutic use', 'Humans', 'Hypersensitivity, Immediate/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/10582736/
3794,cetirizine,36571611,"Comparison between topical cetirizine with minoxidil versus topical placebo with minoxidil in female androgenetic alopecia: a randomized, double-blind, placebo-controlled study.","['Bassiouny EA', 'El-Samanoudy SI', 'Abbassi MM', 'Nada HR', 'Farid SF']","['Female', 'Humans', '*Minoxidil', 'Cetirizine/pharmacology/therapeutic use', 'Administration, Topical', 'Alopecia/drug therapy', 'Hair', '*Drug-Related Side Effects and Adverse Reactions']",https://pubmed.ncbi.nlm.nih.gov/36571611/
3795,cetirizine,34818169,Urticaria and edema in a 2-year-old boy.,"['Cook JS', 'Angles A', 'Morley E']","['Amoxicillin/*adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Anti-Inflammatory Agents/therapeutic use', 'Cetirizine/therapeutic use', 'Child, Preschool', 'Diagnosis, Differential', 'Drug Eruptions/*diagnosis/*drug therapy', 'Edema', 'Histamine H1 Antagonists/therapeutic use', 'Histamine H1 Antagonists, Non-Sedating/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Otitis Media/*drug therapy', 'Triamcinolone/therapeutic use', 'Urticaria/*diagnosis/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/34818169/
3796,cetirizine,22334929,[The approaches to diagnostics and therapy of allergic rhinitis].,['Zaitseva OV'],"['Administration, Oral', 'Adrenal Cortex Hormones/therapeutic use', '*Cetirizine/administration & dosage/adverse effects', 'Combined Modality Therapy', '*Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Immunotherapy', 'Rhinitis, Allergic, Perennial/classification/*diagnosis/*drug therapy', 'Rhinitis, Allergic, Seasonal/classification/*diagnosis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22334929/
3797,cetirizine,29953057,[Allergic rhinitis: the modern aspects of therapy].,"['Yanov YK', 'Ryazantsev SV', 'Artyushkin SA', 'Fanta IV', 'Pavlova SS']","['*Cetirizine/administration & dosage/adverse effects', 'Histamine H1 Antagonists, Non-Sedating/administration & dosage/adverse effects', 'Humans', 'Immunologic Tests/methods', '*Nasal Obstruction/physiopathology/therapy', 'Patient Care Management/methods', '*Rhinitis, Allergic/classification/epidemiology/immunology/therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29953057/
3798,cetirizine,8833171,Aquagenic urticaria.,['Medeiros M Jr'],"['Adult', 'Cetirizine/adverse effects/therapeutic use', 'Diagnosis, Differential', 'Histamine H1 Antagonists/adverse effects/therapeutic use', 'Humans', 'Hydroxyzine/therapeutic use', 'Male', 'Urticaria/*diagnosis/drug therapy/*etiology', 'Water/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/8833171/
3799,cetirizine,30811151,Vesiculobullous Darier Disease Symptomatically Responsive to Cetirizine.,"['Wang JF', 'Lederhandler MH', 'Brinster N', 'Soter NA']","['Anti-Allergic Agents/pharmacology/*therapeutic use', 'Cetirizine/pharmacology/*therapeutic use', 'Darier Disease/complications/diagnosis/*drug therapy', 'Dose-Response Relationship, Drug', 'Eosinophils/drug effects', 'Female', 'Humans', 'Middle Aged', 'Skin Diseases, Vesiculobullous/complications/diagnosis/*drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/30811151/
3800,cetirizine,28081586,A case of levocetirizine-induced liver injury.,"['Jung MC', 'Kim JK', 'Cho JY', 'Song JW', 'Lee B', 'Park JW', 'Seo J', 'Kim SE']","['Cetirizine/*adverse effects/therapeutic use', 'Chemical and Drug Induced Liver Injury/*diagnosis/pathology', 'Histamine H1 Antagonists, Non-Sedating/*adverse effects/therapeutic use', 'Humans', 'Hypersensitivity/drug therapy', 'Jaundice/etiology', 'Liver/pathology', 'Male', 'Middle Aged', 'Pruritus/etiology']",https://pubmed.ncbi.nlm.nih.gov/28081586/
3801,cetirizine,37928871,Efficacy of levocetirizine in isolated rat tracheal smooth muscle.,"['Chou YL', 'Wang YT', 'Cheng LH', 'Liu SC', 'Wang HW']","['Rats', 'Humans', 'Animals', 'Methacholine Chloride/pharmacology', '*Menthol/pharmacology', '*Cetirizine/pharmacology/therapeutic use', 'Muscle, Smooth/physiology', 'Muscle Contraction', 'Trachea/physiology']",https://pubmed.ncbi.nlm.nih.gov/37928871/
3802,rabeprazole,36142643,Proton Pump Inhibitors and Bone Health: An Update Narrative Review.,"['Lespessailles E', 'Toumi H']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Adenosine Triphosphatases', 'Antacids', 'Bone Density', 'Dexlansoprazole', 'Esomeprazole', 'Humans', 'Lansoprazole', 'Omeprazole/pharmacology', '*Osteoporotic Fractures/drug therapy', 'Pantoprazole', '*Proton Pump Inhibitors/adverse effects', 'Rabeprazole', 'United States']",https://pubmed.ncbi.nlm.nih.gov/36142643/
3803,rabeprazole,32711578,"Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Ochoa D', 'Roman M', 'Cabaleiro T', 'Saiz-Rodriguez M', 'Mejia G', 'Abad-Santos F']","['Adult', 'Anti-Ulcer Agents/blood/*pharmacokinetics', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/genetics', 'Dietary Fats/*administration & dosage', 'Fasting/metabolism', 'Female', '*Food-Drug Interactions', 'Genotype', 'Humans', 'Male', 'Omeprazole/blood/*pharmacokinetics', 'Pantoprazole/blood/*pharmacokinetics', 'Proton Pump Inhibitors/blood/*pharmacokinetics', 'Rabeprazole/blood/*pharmacokinetics', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/32711578/
3804,rabeprazole,27782887,"Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastric pH in extensive metabolizer patients with gastroesophageal reflux disease.","['Celebi A', 'Aydin D', 'Kocaman O', 'Konduk BT', 'Senturk O', 'Hulagu S']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/pharmacology', 'Adult', 'Cross-Over Studies', 'Cytochrome P-450 CYP2C19/*metabolism', 'Double-Blind Method', 'Esomeprazole/administration & dosage/pharmacology', 'Female', 'Gastric Acid/*chemistry', 'Gastroesophageal Reflux/*drug therapy/genetics', 'Genotype', 'Humans', 'Hydrogen-Ion Concentration/*drug effects', 'Lansoprazole/administration & dosage/pharmacology', 'Male', 'Middle Aged', 'Pantoprazole', 'Proton Pump Inhibitors/administration & dosage/*pharmacology', 'Rabeprazole/administration & dosage/pharmacology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/27782887/
3805,rabeprazole,28294690,Stereoselective and nonstereoselective pharmacokinetics of rabeprazole - an overview.,"['Dash RP', 'Rais R', 'Srinivas NR']","['Animals', 'Drug Interactions', 'Gastroesophageal Reflux/*drug therapy/*metabolism', 'Humans', 'Peptic Ulcer/*drug therapy/*metabolism', 'Proton Pump Inhibitors/*pharmacokinetics/therapeutic use', 'Rabeprazole/*pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28294690/
3806,rabeprazole,9506245,Rabeprazole.,"['Prakash A', 'Faulds D']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/pharmacokinetics/*therapeutic use', 'Benzimidazoles/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Enzyme Inhibitors/pharmacokinetics/*therapeutic use', 'Helicobacter Infections/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', 'Peptic Ulcer/*drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/9506245/
3807,rabeprazole,23111465,Do proton pump inhibitors protect against cancer progression in GERD?,"['Miyashita T', 'Shah FA', 'Harmon JW', 'Marti GP', 'Matsui D', 'Okamoto K', 'Makino I', 'Hayashi H', 'Oyama K', 'Nakagawara H', 'Tajima H', 'Fujita H', 'Takamura H', 'Murakami M', 'Ninomiya I', 'Kitagawa H', 'Fushida S', 'Fujimura T', 'Ohta T']","['Adenocarcinoma/etiology/*prevention & control', 'Animals', 'Anti-Inflammatory Agents', '*Antineoplastic Agents', 'Antioxidants', 'Barrett Esophagus/complications/drug therapy', '*Disease Progression', 'Esophageal Neoplasms/etiology/*prevention & control', 'Gastroesophageal Reflux/*complications/drug therapy', 'Humans', 'Immunologic Factors', 'Lansoprazole', 'Neutrophils/immunology', 'Omeprazole', 'Proton Pump Inhibitors/adverse effects/*pharmacology/*therapeutic use', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/23111465/
3808,rabeprazole,36657136,Efficacy and safety comparative study of dexrabeprazole vs. esomeprazole for the treatment of gastroesophageal reflux disease.,"['Abdo-Francis JM', 'Cabrera-Alvarez G', 'Martinez-Torres H', 'Remes-Troche JM']","['Humans', '*Esomeprazole/adverse effects', 'Rabeprazole/therapeutic use', 'Prospective Studies', 'Treatment Outcome', '*Gastroesophageal Reflux/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/36657136/
3809,rabeprazole,26193978,Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study.,"['Sakurai Y', 'Mori Y', 'Okamoto H', 'Nishimura A', 'Komura E', 'Araki T', 'Shiramoto M']","['Adult', 'Cross-Over Studies', 'Esomeprazole/administration & dosage/adverse effects/*therapeutic use', 'Gastric Acid', 'Humans', 'Hydrogen-Ion Concentration', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/administration & dosage/adverse effects/*therapeutic use', 'Rabeprazole/administration & dosage/adverse effects/*therapeutic use', 'Research Design', 'Sulfonamides/administration & dosage/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/26193978/
3810,rabeprazole,12152963,Proton pump inhibitors: an update.,"['Vanderhoff BT', 'Tahboub RM']","['2-Pyridinylmethylsulfinylbenzimidazoles', 'Benzimidazoles/pharmacokinetics/pharmacology/therapeutic use', 'Drug Interactions', 'Esomeprazole', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Lansoprazole', 'Omeprazole/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Pantoprazole', 'Peptic Ulcer/drug therapy', '*Proton Pump Inhibitors', 'Rabeprazole', 'Sulfoxides/pharmacokinetics/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/12152963/
3811,rabeprazole,38454589,Fixed drug combination (levosulpiride and rabeprazole)-induced atypical Parkinsonian's disorders with associated anxiety and low-lying depression.,"['Tandon VR', 'Ismail SH', 'Singh A']","['Humans', '*Tremor/chemically induced', 'Rabeprazole/adverse effects', '*Depression/chemically induced/drug therapy', 'Anxiety', 'Drug Combinations', 'Sulpiride/*analogs & derivatives']",https://pubmed.ncbi.nlm.nih.gov/38454589/
3812,rabeprazole,14680443,Review of rabeprazole in the treatment of gastro-oesophageal reflux disease.,['Thjodleifsson B'],"['2-Pyridinylmethylsulfinylbenzimidazoles', 'Anti-Ulcer Agents/adverse effects/pharmacokinetics/*therapeutic use', 'Benzimidazoles/adverse effects/pharmacokinetics/*therapeutic use', 'Clinical Trials as Topic', 'Cost-Benefit Analysis', 'Drug Interactions', 'Gastric Acid/metabolism', 'Gastroesophageal Reflux/*drug therapy', 'Humans', 'Omeprazole/analogs & derivatives', '*Proton Pump Inhibitors', 'Rabeprazole']",https://pubmed.ncbi.nlm.nih.gov/14680443/
3813,rabeprazole,39188111,Efficacy and safety of tegoprazan- and rabeprazole-based concomitant therapies for Helicobacter pylori infection: Real-world evidence.,"['Jung BW', 'Park CH', 'Jung YS']","['*Helicobacter Infections/drug therapy', '*Rabeprazole/administration & dosage/adverse effects', 'Humans', '*Helicobacter pylori/drug effects', 'Male', 'Female', 'Retrospective Studies', 'Middle Aged', '*Drug Therapy, Combination', 'Treatment Outcome', '*Proton Pump Inhibitors/administration & dosage/adverse effects', '*Sulfonamides/administration & dosage/adverse effects', 'Aged', 'Adult', 'Anti-Bacterial Agents/administration & dosage/adverse effects', 'Pyrroles']",https://pubmed.ncbi.nlm.nih.gov/39188111/
3814,rabeprazole,32270780,Multiple widespread fixed drug eruption caused by rabeprazole.,"['Gupta S', 'Gupta S', 'Mahendra A', 'Yadav A']","['Adult', 'Adverse Drug Reaction Reporting Systems', 'Drug Eruptions/*diagnosis', 'Drug-Related Side Effects and Adverse Reactions/*diagnosis', 'Gastritis/diagnosis/*drug therapy', 'Humans', 'Male', 'Rabeprazole/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32270780/
3815,rabeprazole,21528060,Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy.,"['Sugimoto M', 'Nishino M', 'Kodaira C', 'Yamade M', 'Uotani T', 'Ikuma M', 'Umemura K', 'Furuta T']","['2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', 'Adolescent', 'Adult', 'Anti-Ulcer Agents/therapeutic use', '*Drug Resistance', 'Gastroesophageal Reflux/diagnosis/*therapy', 'Humans', 'Hydrogen-Ion Concentration', 'Proton Pump Inhibitors/*therapeutic use', 'Rabeprazole', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/21528060/
3816,rabeprazole,18451374,Recognizing doxycycline-induced esophageal ulcers in dental practice: a case report and review.,"['Segelnick SL', 'Weinberg MA']","['2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use', 'Adult', 'Anti-Bacterial Agents/*adverse effects', 'Anti-Ulcer Agents/therapeutic use', 'Collagen', 'Diet Therapy', 'Doxycycline/*adverse effects', 'Esophageal Diseases/*chemically induced/diagnosis/therapy', 'Female', 'Gingival Recession/*surgery', 'Humans', 'Patient Education as Topic', 'Postoperative Care', 'Proton Pump Inhibitors/therapeutic use', 'Rabeprazole', 'Skin, Artificial', 'Ulcer/*chemically induced/diagnosis/therapy']",https://pubmed.ncbi.nlm.nih.gov/18451374/
3817,rabeprazole,25495411,"Evaluation of the relationship between polymorphisms in CYP2C19 and the pharmacokinetics of omeprazole, pantoprazole and rabeprazole.","['Roman M', 'Ochoa D', 'Sanchez-Rojas SD', 'Talegon M', 'Prieto-Perez R', 'Rivas A', 'Abad-Santos F', 'Cabaleiro T']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/*pharmacokinetics', 'Adult', 'Cytochrome P-450 CYP2C19/*genetics', 'Female', 'Genetic Association Studies', 'Genotype', 'Humans', 'Inactivation, Metabolic/genetics', 'Male', 'Omeprazole/administration & dosage/*pharmacokinetics', 'Pantoprazole', 'Polymorphism, Genetic', 'Rabeprazole/administration & dosage/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/25495411/
3818,rabeprazole,27299490,[Switching to a generic drugA blessing or a curse?].,"['Ebbelaar CF', 'Lammers HA', 'Schobben AF']","['2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use', 'Anti-Ulcer Agents/*therapeutic use', 'Drugs, Generic/*therapeutic use', 'Esomeprazole/*therapeutic use', 'Humans', 'Pantoprazole', 'Rabeprazole/*therapeutic use', 'Treatment Outcome', 'Zollinger-Ellison Syndrome/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/27299490/
3819,rabeprazole,27464849,Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.,"['Kagawa T', 'Iwamuro M', 'Ishikawa S', 'Ishida M', 'Kuraoka S', 'Sasaki K', 'Sakakihara I', 'Izumikawa K', 'Yamamoto K', 'Takahashi S', 'Tanaka S', 'Matsuura M', 'Hasui T', 'Wato M', 'Inaba T']","['Adenoma/surgery', 'Aged', 'Aged, 80 and over', 'Endoscopic Mucosal Resection/*adverse effects', 'Female', 'Gastrointestinal Hemorrhage/etiology/*prevention & control', 'Humans', 'Male', 'Middle Aged', 'Postoperative Complications/*drug therapy', 'Proton Pump Inhibitors/*therapeutic use', 'Pyrroles/*therapeutic use', 'Rabeprazole/therapeutic use', 'Stomach Neoplasms/surgery', 'Stomach Ulcer/*drug therapy/*etiology', 'Sulfonamides/*therapeutic use', 'Wound Healing/drug effects']",https://pubmed.ncbi.nlm.nih.gov/27464849/
3820,rabeprazole,25318791,Iron-deficiency anemia caused by a proton pump inhibitor.,"['Hashimoto R', 'Matsuda T', 'Chonan A']","['Anemia, Iron-Deficiency/*chemically induced', 'Famotidine/therapeutic use', 'Gastroesophageal Reflux/drug therapy', 'Humans', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/*adverse effects/therapeutic use', 'Rabeprazole/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/25318791/
3821,rabeprazole,22081052,"Rikkunshito improves symptoms in PPI-refractory GERD patients: a prospective, randomized, multicenter trial in Japan.","['Tominaga K', 'Iwakiri R', 'Fujimoto K', 'Fujiwara Y', 'Tanaka M', 'Shimoyama Y', 'Umegaki E', 'Higuchi K', 'Kusano M', 'Arakawa T']","['2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage/adverse effects/*therapeutic use', 'Adult', 'Aged', 'Aged, 80 and over', 'Body Mass Index', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Drugs, Chinese Herbal/administration & dosage/adverse effects/*therapeutic use', 'Female', 'Gastroesophageal Reflux/*drug therapy/physiopathology', 'Humans', 'Japan', 'Male', 'Middle Aged', 'Proton Pump Inhibitors/administration & dosage/adverse effects/*therapeutic use', 'Rabeprazole', 'Sex Factors', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/22081052/
3822,carbamazepine,29898616,Carbamazepine adverse drug reactions.,"['Fricke-Galindo I', 'LLerena A', 'Jung-Cook H', 'Lopez-Lopez M']","['Anticonvulsants/administration & dosage/*adverse effects/pharmacokinetics', 'Biomarkers/metabolism', 'Carbamazepine/administration & dosage/*adverse effects/pharmacokinetics', 'Dose-Response Relationship, Drug', 'Drug Monitoring/methods', 'Epilepsy/drug therapy', 'Humans', 'Pharmacogenetics/methods', '*Quality of Life', 'Research Design']",https://pubmed.ncbi.nlm.nih.gov/29898616/
3823,carbamazepine,17922625,Oxcarbazepine in neuropathic pain.,"['Nasreddine W', 'Beydoun A']","['Analgesics, Non-Narcotic/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Animals', 'Anticonvulsants/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Carbamazepine/adverse effects/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Diabetic Neuropathies/drug therapy', 'Humans', 'Neuralgia/*drug therapy', 'Oxcarbazepine']",https://pubmed.ncbi.nlm.nih.gov/17922625/
3824,carbamazepine,10530693,Oxcarbazepine.,['Tecoma ES'],"['Adult', 'Animals', 'Anticonvulsants/pharmacokinetics/pharmacology/*therapeutic use', 'Biological Availability', 'Biotransformation', 'Carbamazepine/*analogs & derivatives/pharmacokinetics/pharmacology/therapeutic use', 'Controlled Clinical Trials as Topic', 'Disease Models, Animal', 'Drug Administration Schedule', 'Drug Interactions', 'Epilepsy/*drug therapy', 'Humans', 'Oxcarbazepine', 'Phenytoin/adverse effects/therapeutic use', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/10530693/
3825,carbamazepine,8773289,Carbamazepine clinical pharmacology: a review.,"['Albani F', 'Riva R', 'Baruzzi A']","['Anticonvulsants/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Carbamazepine/adverse effects/pharmacokinetics/pharmacology/*therapeutic use', 'Epilepsy/drug therapy', 'Female', 'Humans', 'Mental Disorders/*drug therapy', 'Pregnancy']",https://pubmed.ncbi.nlm.nih.gov/8773289/
3826,carbamazepine,7845850,Pediatric carbamazepine overdoses.,"['Bridge TA', 'Norton RL', 'Robertson WO']","['Adolescent', 'Carbamazepine/*administration & dosage/*adverse effects/therapeutic use', 'Child', 'Child, Preschool', '*Dose-Response Relationship, Drug', '*Drug Overdose', 'Epilepsy/drug therapy', 'Female', 'Humans', 'Infant', 'Infant, Newborn', 'Male', 'Retrospective Studies']",https://pubmed.ncbi.nlm.nih.gov/7845850/
3827,carbamazepine,17030393,Novel anticonvulsant drugs.,"['Stefan H', 'Feuerstein TJ']","['Amines/therapeutic use', 'Animals', 'Anticonvulsants/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Carbamazepine/analogs & derivatives/therapeutic use', 'Cyclohexanecarboxylic Acids/therapeutic use', 'Epilepsy/*drug therapy', 'Fructose/analogs & derivatives/therapeutic use', 'Gabapentin', 'Humans', 'Isoxazoles/therapeutic use', 'Lamotrigine', 'Levetiracetam', 'Nipecotic Acids/therapeutic use', 'Piracetam/analogs & derivatives/therapeutic use', 'Pregabalin', 'Tiagabine', 'Topiramate', 'Treatment Outcome', 'Triazines/therapeutic use', 'Zonisamide', 'gamma-Aminobutyric Acid/analogs & derivatives/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17030393/
3828,carbamazepine,2680897,Hyponatraemia during oxcarbazepine therapy.,"['Pendlebury SC', 'Moses DK', 'Eadie MJ']","['Adult', 'Anticonvulsants/*adverse effects/pharmacokinetics/therapeutic use', 'Carbamazepine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Epilepsy/drug therapy', 'Female', 'Humans', 'Hyponatremia/blood/*chemically induced/physiopathology', 'Male', 'Multicenter Studies as Topic', 'Oxcarbazepine', 'Sodium/blood']",https://pubmed.ncbi.nlm.nih.gov/2680897/
3829,carbamazepine,4006880,Zonisamide in epilepsy: a pilot study.,"['Wilensky AJ', 'Friel PN', 'Ojemann LM', 'Dodrill CB', 'McCormick KB', 'Levy RH']","['Adolescent', 'Adult', 'Anticonvulsants/administration & dosage/adverse effects/blood/metabolism/*therapeutic use', 'Carbamazepine/blood/therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Isoxazoles/adverse effects/blood/metabolism/*therapeutic use', 'Male', 'Middle Aged', 'Oxazoles/*therapeutic use', 'Phenytoin/blood/therapeutic use', 'Time Factors', 'Zonisamide']",https://pubmed.ncbi.nlm.nih.gov/4006880/
3830,carbamazepine,2856430,The clinical uses and pharmacology of carbamazepine in psychiatry.,['Elphick M'],"['Animals', 'Brain/drug effects', 'Carbamazepine/adverse effects/pharmacokinetics/*therapeutic use', 'Dose-Response Relationship, Drug', 'Humans', 'Psychotic Disorders/blood/*drug therapy/psychology', 'Second Messenger Systems/drug effects', 'Sodium Channels/drug effects', 'Sodium-Potassium-Exchanging ATPase/metabolism', 'Synaptic Transmission/drug effects', 'Synaptosomes/drug effects']",https://pubmed.ncbi.nlm.nih.gov/2856430/
3831,carbamazepine,12136070,Carbamazepine- induced hypertension.,"['Jette N', 'Veregin T', 'Guberman A']","['Adult', 'Anticonvulsants/administration & dosage/*adverse effects', 'Carbamazepine/administration & dosage/*adverse effects', 'Epilepsy, Complex Partial/drug therapy', 'Humans', 'Hypertension/*chemically induced', 'Male']",https://pubmed.ncbi.nlm.nih.gov/12136070/
3832,carbamazepine,1893404,Carbamazepine-induced Diabetes mellitus.,['Obembe A'],"['Adult', 'Carbamazepine/administration & dosage/*adverse effects', 'Diabetes Mellitus/blood/*chemically induced', 'Female', 'Humans', 'Seizures/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/1893404/
3833,carbamazepine,3319541,Problems and management of the pregnant woman with epilepsy.,['Yerby MS'],"['Abnormalities, Drug-Induced/etiology', 'Anticonvulsants/adverse effects/pharmacokinetics/*therapeutic use', 'Carbamazepine/pharmacokinetics/therapeutic use', 'Epilepsy/*drug therapy', 'Female', 'Humans', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', 'Protein Binding', 'Risk Factors']",https://pubmed.ncbi.nlm.nih.gov/3319541/
3834,carbamazepine,8719501,Quantitative pharmaco-EEG of carbamazepine in volunteers and epileptics.,"['Wu X', 'Xiao CH']","['Adult', 'Anticonvulsants/*administration & dosage/adverse effects/pharmacokinetics', 'Brain Mapping', 'Carbamazepine/*administration & dosage/adverse effects/pharmacokinetics', 'Cerebral Cortex/drug effects/physiopathology', 'Electroencephalography/*drug effects', 'Epilepsy/*drug therapy/physiopathology', 'Evoked Potentials/drug effects/physiology', 'Female', 'Humans', 'Male', 'Metabolic Clearance Rate/physiology', '*Signal Processing, Computer-Assisted']",https://pubmed.ncbi.nlm.nih.gov/8719501/
3835,carbamazepine,1425492,Metabolism of antiepileptic medication: newborn to elderly.,['Leppik IE'],"['Adolescent', 'Adult', 'Age Factors', 'Aged', 'Anticonvulsants/administration & dosage/adverse effects/*pharmacokinetics', 'Carbamazepine/administration & dosage/adverse effects/pharmacokinetics', 'Child', 'Dose-Response Relationship, Drug', 'Drug Administration Schedule', 'Epilepsy/*drug therapy/metabolism', 'Female', 'Half-Life', 'Humans', 'Infant, Newborn', 'Male', 'Middle Aged', 'Phenytoin/administration & dosage/adverse effects/pharmacokinetics', 'Valproic Acid/administration & dosage/adverse effects/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1425492/
3836,carbamazepine,37092337,Pharmacogenomics of oxcarbazepine in the treatment of epilepsy.,"['Yuan Y', 'Zhang S', 'Yuan Y', 'Yan X', 'Zhang L', 'Ran YW']","['Humans', 'Oxcarbazepine/therapeutic use', '*Anticonvulsants/therapeutic use/pharmacokinetics', 'Carbamazepine/adverse effects/pharmacokinetics', 'Pharmacogenetics', '*Epilepsy/drug therapy/genetics']",https://pubmed.ncbi.nlm.nih.gov/37092337/
3837,carbamazepine,8156977,Practical aspects of oxcarbazepine treatment.,['Dam M'],"['Adult', 'Anticonvulsants/administration & dosage/adverse effects/*therapeutic use', 'Carbamazepine/administration & dosage/adverse effects/*analogs & derivatives/therapeutic use', 'Clinical Trials as Topic', 'Drug Eruptions/etiology', 'Epilepsy/*drug therapy', 'Humans', 'Multicenter Studies as Topic', 'Oxcarbazepine']",https://pubmed.ncbi.nlm.nih.gov/8156977/
3838,carbamazepine,18324882,Antiepileptic drugs as human teratogens.,['Eadie MJ'],"['Abnormalities, Drug-Induced/*epidemiology/etiology', 'Anticonvulsants/administration & dosage/*adverse effects', 'Carbamazepine/administration & dosage/adverse effects', 'Epilepsy/*drug therapy/epidemiology', 'Female', 'Humans', 'Phenobarbital/administration & dosage/adverse effects', 'Phenytoin/administration & dosage/adverse effects', 'Pregnancy', 'Pregnancy Complications/*drug therapy/epidemiology', 'Valproic Acid/administration & dosage/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/18324882/
3839,carbamazepine,555583,Pharmacokinetics of Carbamazepine in man: a review.,['Pynnonen S'],"['Animals', 'Biological Availability', 'Blood Proteins/metabolism', 'Carbamazepine/administration & dosage/blood/*metabolism', 'Child', 'Chromatography, Gas/methods', 'Dose-Response Relationship, Drug', 'Drug Interactions', 'Half-Life', 'Humans', 'Intestinal Absorption', 'Kinetics', 'Protein Binding', 'Tissue Distribution']",https://pubmed.ncbi.nlm.nih.gov/555583/
3840,carbamazepine,1382007,Psychosis and idiopathic precocious puberty in two 7-year-old boys.,"['Rosenberg DR', 'Crowner S', 'Thomas C', 'Gourash L']","['Attention Deficit Disorder with Hyperactivity/drug therapy', 'Body Height', 'Carbamazepine/administration & dosage/therapeutic use', 'Child', 'Developmental Disabilities/complications/drug therapy', 'Humans', 'Lithium/administration & dosage/adverse effects/therapeutic use', 'Male', 'Methylphenidate/administration & dosage/therapeutic use', 'Psychiatric Status Rating Scales', 'Psychotic Disorders/*complications/drug therapy', 'Puberty, Precocious/*complications/diagnosis']",https://pubmed.ncbi.nlm.nih.gov/1382007/
3841,carbamazepine,6769289,Organic convergence spasm.,"['Guiloff RJ', 'Whiteley A', 'Kelly RE']","['Adolescent', 'Alpha Rhythm', 'Brain/*drug effects', 'Carbamazepine/blood/therapeutic use', 'Dose-Response Relationship, Drug', 'Electroencephalography', 'Epilepsy, Tonic-Clonic/*drug therapy', 'Eye Movements/*drug effects', 'Female', 'Humans', 'Neurologic Examination', 'Phenobarbital/therapeutic use', 'Phenytoin/administration & dosage/*adverse effects/therapeutic use', 'Spasm/*chemically induced', 'Theta Rhythm']",https://pubmed.ncbi.nlm.nih.gov/6769289/
3842,fluoxetine,24738878,Fluoxetine: a case history of its discovery and preclinical development.,"['Perez-Caballero L', 'Torres-Sanchez S', 'Bravo L', 'Mico JA', 'Berrocoso E']","['Animals', 'Antidepressive Agents, Second-Generation/chemistry/*pharmacokinetics/*pharmacology', 'Drug Discovery/*history', 'Drug Evaluation, Preclinical/history', 'Fluoxetine/chemistry/*pharmacokinetics/*pharmacology', 'History, 20th Century', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/24738878/
3843,fluoxetine,2878798,"Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness.","['Benfield P', 'Heel RC', 'Lewis SP']","['Animals', 'Cardiovascular System/drug effects', 'Central Nervous System/drug effects', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Drug Interactions', 'Endocrine Glands/drug effects', '*Fluoxetine/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Humans', 'Kinetics', 'Neurotransmitter Agents/metabolism', '*Propylamines/administration & dosage/adverse effects/metabolism/pharmacology/therapeutic use', 'Receptors, Neurotransmitter/metabolism', 'Serotonin/metabolism']",https://pubmed.ncbi.nlm.nih.gov/2878798/
3844,fluoxetine,7794331,The perils of Prozac.,['Manolis DC'],"['Depressive Disorder/*drug therapy/psychology', 'Family Practice', 'Fluoxetine/adverse effects/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/7794331/
3845,fluoxetine,9297715,Serotonin syndrome.,"['Ivanusa Z', 'Hecimovic H', 'Demarin V']","['Fluoxetine/adverse effects/therapeutic use', 'Humans', 'Monoamine Oxidase Inhibitors/administration & dosage/*adverse effects', 'Nervous System Diseases/*chemically induced/diagnosis/physiopathology', 'Receptors, Serotonin/*drug effects/physiology', 'Serotonin/*physiology', 'Serotonin Agents/administration & dosage/*adverse effects', 'Substance-Related Disorders/*diagnosis/physiopathology', 'Synaptic Transmission/*drug effects/physiology', 'Syndrome']",https://pubmed.ncbi.nlm.nih.gov/9297715/
3846,fluoxetine,1813897,Pharmacokinetics of second generation antidepressants: fluoxetine.,['Goodnick PJ'],"['Antidepressive Agents/*pharmacokinetics', 'Fluoxetine/*pharmacokinetics', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/1813897/
3847,fluoxetine,7960421,Psychotropic drugs in pregnancy and lactation.,['Goldberg HL'],"['Clozapine/therapeutic use', 'Embryonic and Fetal Development/drug effects', 'Female', 'Fluoxetine/therapeutic use', 'Humans', '*Lactation/drug effects', 'Lithium/therapeutic use', 'Mental Disorders/*drug therapy', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Prenatal Exposure Delayed Effects', 'Psychotropic Drugs/adverse effects/*therapeutic use', 'Puerperal Disorders/*drug therapy']",https://pubmed.ncbi.nlm.nih.gov/7960421/
3848,fluoxetine,11772132,Once-weekly fluoxetine.,"['Wagstaff AJ', 'Goa KL']","['Administration, Oral', 'Antidepressive Agents, Second-Generation/*administration & dosage/pharmacokinetics/pharmacology', 'Delayed-Action Preparations', 'Depressive Disorder/*drug therapy', 'Drug Administration Schedule', 'Fluoxetine/*administration & dosage/pharmacokinetics/pharmacology', 'Half-Life', 'Humans', 'Patient Compliance', 'Randomized Controlled Trials as Topic', 'Severity of Illness Index', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/11772132/
3849,fluoxetine,8730028,Fluoxetin-induced pulmonary granulomatosis.,"['de Kerviler E', 'Tredaniel J', 'Revlon G', 'Groussard O', 'Zalcman G', 'Ortoli JM', 'Espie M', 'Hirsch A', 'Frija J']","['Antidepressive Agents, Second-Generation/*adverse effects/therapeutic use', 'Depressive Disorder/drug therapy', 'Diagnosis, Differential', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Granuloma, Giant Cell/*chemically induced/diagnosis/physiopathology', 'Humans', 'Lung Diseases/*chemically induced/diagnosis/physiopathology', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/8730028/
3850,fluoxetine,7993290,Fluoxetine induced dyskinesia.,"['Mander A', 'McCausland M', 'Workman B', 'Flamer H', 'Christophidis N']","['Aged', 'Depressive Disorder/*drug therapy', '*Dyskinesia, Drug-Induced', 'Female', 'Fluoxetine/*adverse effects/*therapeutic use', 'Humans']",https://pubmed.ncbi.nlm.nih.gov/7993290/
3851,fluoxetine,8984742,Prozac: panacea or puzzle?,['Stanford SC'],"['Animals', 'Brain Chemistry/drug effects', 'Catecholamines/metabolism', 'Fluoxetine/pharmacokinetics/*pharmacology', 'Humans', 'Selective Serotonin Reuptake Inhibitors/pharmacokinetics/*pharmacology']",https://pubmed.ncbi.nlm.nih.gov/8984742/
3852,fluoxetine,1543251,The pharmacotherapy of minor depression.,"['Stewart JW', 'Quitkin FM', 'Klein DF']","['Antidepressive Agents, Tricyclic/*therapeutic use', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy', 'Double-Blind Method', 'Female', 'Fluoxetine/administration & dosage/adverse effects/therapeutic use', 'Humans', 'Imipramine/administration & dosage/adverse effects/therapeutic use', 'Male', 'Monoamine Oxidase Inhibitors/administration & dosage/adverse effects/therapeutic use', 'Placebos']",https://pubmed.ncbi.nlm.nih.gov/1543251/
3853,fluoxetine,8863755,Depression: making the diagnosis and using SSRIs in the older patient.,['Reynolds CF 3rd'],"['1-Naphthylamine/adverse effects/*analogs & derivatives/pharmacokinetics/therapeutic use', 'Adult', 'Aged', 'Alzheimer Disease/diagnosis/psychology', 'Depressive Disorder/*diagnosis/*drug therapy/psychology', 'Diagnosis, Differential', 'Dose-Response Relationship, Drug', 'Fluoxetine/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Paroxetine/adverse effects/pharmacokinetics/*therapeutic use', 'Selective Serotonin Reuptake Inhibitors/adverse effects/pharmacokinetics/*therapeutic use', 'Sertraline']",https://pubmed.ncbi.nlm.nih.gov/8863755/
3854,fluoxetine,29691274,Negative myoclonus secondary to paroxetine intake.,"['Correia P', 'Ribeiro JA', 'Bento C', 'Sales F']","['Aged', 'Electroencephalography/methods', 'Fluoxetine/administration & dosage/therapeutic use', 'Humans', 'Male', 'Medical Errors/*adverse effects', 'Myoclonus/*chemically induced/diagnosis', 'Paroxetine/*adverse effects', 'Seizures/*chemically induced/diagnosis', 'Selective Serotonin Reuptake Inhibitors/adverse effects', 'Somatosensory Cortex/physiopathology', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/29691274/
3855,fluoxetine,1806635,Obsessive-compulsive disorder.,['George MS'],"['Clomipramine/adverse effects/therapeutic use', 'Fluoxetine/adverse effects/therapeutic use', 'Fluvoxamine/adverse effects/*therapeutic use', 'Humans', 'Obsessive-Compulsive Disorder/*drug therapy/psychology']",https://pubmed.ncbi.nlm.nih.gov/1806635/
3856,fluoxetine,8162401,Seizures associated with fluoxetine therapy.,['Prasher VP'],"['Adult', 'Depressive Disorder/*drug therapy/psychology', 'Epilepsy, Tonic-Clonic/drug therapy', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Humans', 'Psychotic Disorders/*drug therapy/psychology', 'Seizures/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/8162401/
3857,fluoxetine,8930062,Ring chromosome 22 and mood disorders.,"['Sovner R', 'Stone A', 'Fox C']","['Adult', 'Anticonvulsants/administration & dosage/therapeutic use', 'Antidepressive Agents/administration & dosage/therapeutic use', 'Child', '*Chromosomes, Human, Pair 22', 'Drug Therapy, Combination', 'Female', 'Fluoxetine/administration & dosage/therapeutic use', 'Humans', 'Intellectual Disability/complications', 'Male', 'Middle Aged', 'Mood Disorders/complications/drug therapy/*genetics', '*Ring Chromosomes', 'Valproic Acid/administration & dosage/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/8930062/
3858,fluoxetine,1960381,A comparison of fluoxetine and amitriptyline in the treatment of major depression.,"['Keegan D', 'Bowen RC', 'Blackshaw S', 'Saleh S', 'Dayal N', 'Remillard F', 'Shrikhande S', 'Cebrian Perez S', 'Boulton A']","['Adolescent', 'Adult', 'Aged', 'Amitriptyline/adverse effects/*therapeutic use', 'Depressive Disorder/*drug therapy/psychology', 'Female', 'Fluoxetine/adverse effects/*therapeutic use', 'Humans', 'Male', 'Middle Aged', 'Psychiatric Status Rating Scales']",https://pubmed.ncbi.nlm.nih.gov/1960381/
3859,fluoxetine,2274996,A report of trazodone-associated laboratory abnormalities.,"['Perry PJ', 'Garvey MJ', 'Dunner DL', 'Rush AJ', 'Kyhl J']","['Double-Blind Method', 'Erythrocyte Count/drug effects', 'Female', 'Fluoxetine/*adverse effects/therapeutic use', 'Hematocrit/standards', 'Hemoglobins/*drug effects', 'Humans', 'Male', 'Reference Values', 'Trazodone/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/2274996/
3860,fluoxetine,15890403,Recent advances in animal models of chronic antidepressant effects: the novelty-induced hypophagia test.,"['Dulawa SC', 'Hen R']","['Analysis of Variance', 'Animals', 'Antidepressive Agents/*adverse effects/pharmacology', 'Behavior, Animal/physiology', 'Depression/*physiopathology', '*Disease Models, Animal', 'Dose-Response Relationship, Drug', 'Drinking/drug effects/*physiology', 'Drug Administration Schedule', 'Exploratory Behavior/*drug effects/physiology', 'Fluoxetine/administration & dosage/blood', 'Humans', 'Male', 'Mice', 'Mice, Inbred BALB C', 'Predictive Value of Tests', 'Reaction Time/drug effects', 'Reproducibility of Results', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/15890403/
3861,fluoxetine,8063517,Fluoxetine and suicidal ideation--a review of the literature.,['Crundwell JK'],"['Depressive Disorder/*drug therapy/psychology', 'Fluoxetine/*adverse effects/therapeutic use', 'Humans', 'Suicide/*psychology/statistics & numerical data']",https://pubmed.ncbi.nlm.nih.gov/8063517/
3862,rosiglitazone,31776781,Thiazolidinediones: the Forgotten Diabetes Medications.,['Lebovitz HE'],"['Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Insulin Resistance', 'Pioglitazone/adverse effects/therapeutic use', 'Rosiglitazone/adverse effects/therapeutic use', 'Thiazolidinediones/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/31776781/
3863,rosiglitazone,35180475,ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury.,"['Wang Y', 'Zhang M', 'Bi R', 'Su Y', 'Quan F', 'Lin Y', 'Yue C', 'Cui X', 'Zhao Q', 'Liu S', 'Yang Y', 'Zhang D', 'Cao Q', 'Gao X']","['*Acute Kidney Injury/metabolism', 'Animals', 'Coenzyme A Ligases/genetics', 'Female', '*Ferroptosis/genetics', 'Humans', 'Male', 'Mice', 'Rosiglitazone/pharmacology']",https://pubmed.ncbi.nlm.nih.gov/35180475/
3864,rosiglitazone,30645973,Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis.,"['Ishay-Ronen D', 'Diepenbruck M', 'Kalathur RKR', 'Sugiyama N', 'Tiede S', 'Ivanek R', 'Bantug G', 'Morini MF', 'Wang J', 'Hess C', 'Christofori G']","['3T3-L1 Cells', 'Adipocytes/*cytology', 'Adipogenesis', 'Animals', 'Breast Neoplasms/*drug therapy/metabolism', 'Cell Line, Tumor', 'Cell Movement', 'Cell Transdifferentiation/*drug effects', 'Epithelial-Mesenchymal Transition/drug effects', 'Female', 'Flavonoids/*administration & dosage/pharmacology', 'Humans', 'Mice', 'Neoplasm Metastasis/*drug therapy', 'Neoplasm Transplantation', 'Proto-Oncogene Proteins c-met/metabolism', 'Rosiglitazone/*administration & dosage/therapeutic use', 'Signal Transduction/drug effects', 'Transforming Growth Factor beta/metabolism']",https://pubmed.ncbi.nlm.nih.gov/30645973/
3865,rosiglitazone,38594496,PPARgamma alleviates preeclampsia development by regulating lipid metabolism and ferroptosis.,"['Lai W', 'Yu L', 'Deng Y']","['Humans', 'Female', 'Pregnancy', 'Rats', 'Animals', 'Rosiglitazone/pharmacology/metabolism', 'PPAR gamma/metabolism', 'Lipid Metabolism', 'Placenta/metabolism', '*Pre-Eclampsia/drug therapy/prevention & control/metabolism', 'NF-E2-Related Factor 2/metabolism', '*Ferroptosis', 'Hypoxia/metabolism', 'Lipids']",https://pubmed.ncbi.nlm.nih.gov/38594496/
3866,rosiglitazone,24563375,Systematic reviews to ascertain the safety of diabetes medications.,"['Gionfriddo MR', 'Morey-Vargas OL', 'Brito JP', 'Leppin AL', 'Murad MH', 'Montori VM']","['Acidosis, Lactic/chemically induced', 'Blood Glucose/*drug effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Evidence-Based Medicine', 'Female', 'Fractures, Bone/chemically induced', 'Glycated Hemoglobin/*drug effects', 'Glycine/administration & dosage/adverse effects/analogs & derivatives', 'Humans', 'Hypoglycemic Agents/*administration & dosage/adverse effects', 'Male', 'Meta-Analysis as Topic', 'Metformin/administration & dosage/adverse effects', 'Oxazoles/administration & dosage/adverse effects', 'Pancreatic Neoplasms/chemically induced', 'Risk Assessment', 'Rosiglitazone', 'Thiazolidinediones/administration & dosage/adverse effects', 'Urinary Bladder Neoplasms/chemically induced']",https://pubmed.ncbi.nlm.nih.gov/24563375/
3867,rosiglitazone,33674341,"ESE3/EHF, a promising target of rosiglitazone, suppresses pancreatic cancer stemness by downregulating CXCR4.","['Zhou T', 'Liu J', 'Xie Y', 'Yuan S', 'Guo Y', 'Bai W', 'Zhao K', 'Jiang W', 'Wang H', 'Wang H', 'Zhao T', 'Huang C', 'Gao S', 'Wang X', 'Yang S', 'Hao J']","['Animals', 'Cohort Studies', 'Disease Models, Animal', 'Humans', 'Hypoglycemic Agents/pharmacology', 'Mice', 'Mice, Inbred BALB C', 'Neoplastic Stem Cells/*drug effects/metabolism', 'Pancreatic Neoplasms/metabolism/*pathology', 'Pancreatic Stellate Cells/*drug effects/metabolism', 'Receptors, CXCR4/*metabolism', 'Rosiglitazone/*pharmacology', 'Transcription Factors/*metabolism']",https://pubmed.ncbi.nlm.nih.gov/33674341/
3868,rosiglitazone,26690770,Thiazolidinediones improve flow-mediated dilation: a meta-analysis of randomized clinical trials.,"['Stojanovic M', 'Prostran M', 'Radenkovic M']","['Animals', 'Endothelium, Vascular/drug effects', 'Humans', 'Pioglitazone', 'Randomized Controlled Trials as Topic', 'Rosiglitazone', 'Thiazolidinediones/*pharmacology/*therapeutic use', 'Vasodilation/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/26690770/
3869,rosiglitazone,38605183,Adipose tissue macrophages secrete small extracellular vesicles that mediate rosiglitazone-induced insulin sensitization.,"['Rohm TV', 'Castellani Gomes Dos Reis F', 'Isaac R', 'Murphy C', 'Cunha E Rocha K', 'Bandyopadhyay G', 'Gao H', 'Libster AM', 'Zapata RC', 'Lee YS', 'Ying W', 'Miciano C', 'Wang A', 'Olefsky JM']","['Animals', '*Rosiglitazone/pharmacology', '*Extracellular Vesicles/metabolism/drug effects', 'Mice', '*Insulin Resistance', '*Macrophages/metabolism/drug effects', '*Adipose Tissue/metabolism/drug effects', 'Male', 'Humans', 'MicroRNAs/genetics/metabolism', 'Obesity/metabolism', 'Insulin/metabolism', 'Adipocytes/metabolism/drug effects', 'Mice, Inbred C57BL']",https://pubmed.ncbi.nlm.nih.gov/38605183/
3870,rosiglitazone,10400405,Rosiglitazone.,"['Balfour JA', 'Plosker GL']","['Animals', 'Blood Glucose/*drug effects', 'Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Interactions', 'Humans', 'Hypoglycemic Agents/*pharmacology', 'Insulin/*metabolism', 'Islets of Langerhans/*drug effects', 'Polypharmacy', 'Rosiglitazone', 'Thiazoles/adverse effects/pharmacology/*therapeutic use', '*Thiazolidinediones']",https://pubmed.ncbi.nlm.nih.gov/10400405/
3871,rosiglitazone,20977573,Cardiovascular risk and thiazolidinediones--what do meta-analyses really tell us?,"['Schernthaner G', 'Chilton RJ']","['Cardiovascular Diseases/*chemically induced', 'Diabetes Mellitus, Type 2/complications/*drug therapy', 'Diabetic Angiopathies/*chemically induced', 'Female', 'Humans', 'Male', '*Meta-Analysis as Topic', 'Randomized Controlled Trials as Topic', 'Risk Factors', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects']",https://pubmed.ncbi.nlm.nih.gov/20977573/
3872,rosiglitazone,11410214,Lessons from the glitazones: a story of drug development.,['Gale EA'],"['Adverse Drug Reaction Reporting Systems', 'Chemical and Drug Induced Liver Injury/etiology', 'Chromans/administration & dosage/*adverse effects', 'Diabetes Mellitus, Type 2/*drug therapy', 'Drug Approval/*legislation & jurisprudence', 'Drug Therapy, Combination', 'Europe', 'Humans', 'Hypoglycemic Agents/administration & dosage/*adverse effects', 'Liver Failure/chemically induced', 'Pioglitazone', 'Rosiglitazone', 'Thiazoles/administration & dosage/*adverse effects', '*Thiazolidinediones', 'Troglitazone', 'United States']",https://pubmed.ncbi.nlm.nih.gov/11410214/
3873,rosiglitazone,32353383,LINCS dataset-based repositioning of rosiglitazone as a potential anti-human adenovirus drug.,"['Wang X', 'He S', 'Zhou Z', 'Bo X', 'Qi D', 'Fu X', 'Wang Z', 'Yang J', 'Wang S']","['A549 Cells', 'Adenovirus Infections, Human/drug therapy/virology', 'Adenoviruses, Human/*drug effects/physiology', 'Algorithms', 'Animals', 'Antiviral Agents/pharmacology/*therapeutic use', '*Databases, Pharmaceutical', '*Drug Repositioning', 'Epithelial Cells/drug effects/virology', 'Female', 'Humans', 'Immunocompromised Host', 'Mice', 'Mice, SCID', 'Rosiglitazone/pharmacology/*therapeutic use', 'Virus Replication/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/32353383/
3874,rosiglitazone,37864473,Decellularization-Based Modification Strategy for Bioactive Xenografts Promoting Tendon Repair.,"['Jin H', 'Kang Y', 'Gao H', 'Lin Z', 'Huang D', 'Zheng Z', 'Zhao J', 'Wang L', 'Jiang J']","['Humans', 'Rats', 'Animals', 'Heterografts', 'Rosiglitazone/pharmacology', '*Extracellular Matrix', '*Inflammation', 'Collagen', 'Tendons', 'Tissue Engineering', 'Tissue Scaffolds']",https://pubmed.ncbi.nlm.nih.gov/37864473/
3875,rosiglitazone,38131378,PPARgamma agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRalpha+ mesenchymal cells.,"['Chen Z', 'Ghavimi SAA', 'Wu M', 'McNamara J', 'Barreiro O', 'Maridas D', 'Kratchmarov R', 'Siegel A', 'Djeddi S', 'Gutierrez-Arcelus M', 'Brennan PJ', 'Padera TP', 'von Andrian U', 'Mehrara B', 'Greene AK', 'Kahn CR', 'Orgill DP', 'Sinha I', 'Rosen V', 'Agarwal S']","['Male', 'Female', 'Humans', 'Mice', 'Animals', '*Receptor, Platelet-Derived Growth Factor alpha', 'PPAR gamma', 'Rosiglitazone/pharmacology/therapeutic use', '*Lymphedema/drug therapy', 'Fibrosis']",https://pubmed.ncbi.nlm.nih.gov/38131378/
3876,rosiglitazone,15163284,Rosiglitazone plus metformin: combination therapy for Type 2 diabetes.,"['Del Prato S', 'Volpe L']","['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Dose-Response Relationship, Drug', 'Drug Combinations', 'Humans', 'Hypoglycemic Agents/administration & dosage/pharmacology/*therapeutic use', 'Metformin/administration & dosage/pharmacology/*therapeutic use', 'Rosiglitazone', 'Thiazoles/administration & dosage/pharmacology/*therapeutic use', 'Thiazolidinediones/administration & dosage/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15163284/
3877,rosiglitazone,30142096,Glucagon-like peptide-1 receptor agonists and cardiovascular protection in type 2 diabetes: a pathophysiology-based review of clinical implications.,"['Bajaj HS', 'Al-Jabri B', 'Verma S']","['Biomarkers/blood', 'Blood Glucose/drug effects/metabolism', 'Blood Pressure/drug effects/*physiology', '*Cardiovascular Diseases/etiology/physiopathology/prevention & control', 'Diabetes Mellitus, Type 2/blood/complications/*drug therapy', 'Humans', 'Hypoglycemic Agents/therapeutic use', 'Lipids/blood', 'Prognosis', 'Rosiglitazone/*therapeutic use', '*Glucagon-Like Peptide-1 Receptor Agonists']",https://pubmed.ncbi.nlm.nih.gov/30142096/
3878,rosiglitazone,17975488,"Peroxisome proliferator-activated receptor-gamma in lung cancer: defining specific versus ""off-target"" effectors.",['Nemenoff RA'],"['Animals', 'Antineoplastic Agents/*therapeutic use', 'Humans', 'Lung Neoplasms/*drug therapy/metabolism', 'PPAR gamma/*metabolism', 'Pioglitazone', 'Rosiglitazone', 'Signal Transduction/*drug effects', 'Thiazolidinediones/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17975488/
3879,rosiglitazone,19162510,Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer.,"['Inamoto T', 'Shah JB', 'Kamat AM']","['Adjuvants, Immunologic/administration & dosage/therapeutic use', 'Animals', 'Antineoplastic Agents/pharmacology/*therapeutic use', 'Apoptosis/drug effects', 'BCG Vaccine/administration & dosage/therapeutic use', 'Disease Progression', 'Humans', 'Neoplasm Invasiveness', 'PPAR gamma/*agonists/*metabolism', 'Rosiglitazone', 'Thiazolidinediones/pharmacology/*therapeutic use', 'Urinary Bladder Neoplasms/*drug therapy/*metabolism/pathology']",https://pubmed.ncbi.nlm.nih.gov/19162510/
3880,rosiglitazone,17569897,Rosiglitazone and implications for pharmacovigilance.,['Kazi D'],"['Clinical Trials as Topic', 'Diabetes Mellitus, Type 2/*drug therapy', 'Humans', 'Hypoglycemic Agents/*adverse effects', 'Meta-Analysis as Topic', 'Product Surveillance, Postmarketing', 'Rosiglitazone', 'Thiazolidinediones/*adverse effects', 'United States', 'United States Food and Drug Administration']",https://pubmed.ncbi.nlm.nih.gov/17569897/
3881,rosiglitazone,21102545,Therapy: The second time as farce: rosiglitazone and the regulators.,['Gale EA'],"['Chromans/adverse effects/therapeutic use', 'Diabetes Mellitus/drug therapy', 'Humans', 'Hypoglycemic Agents/adverse effects/*therapeutic use', 'Rosiglitazone', 'Thiazolidinediones/adverse effects/*therapeutic use', 'Troglitazone']",https://pubmed.ncbi.nlm.nih.gov/21102545/
3882,Phenelzine,6384959,Atypical depression.,"['Silberman EK', 'Sullivan JL']","['Alprazolam', 'Anxiety Disorders/psychology', 'Benzodiazepines/therapeutic use', 'Bipolar Disorder/diagnosis', 'Character', 'Chronic Disease', 'Clinical Trials as Topic', 'Depressive Disorder/*drug therapy/psychology', 'Double-Blind Method', 'Electroconvulsive Therapy', 'Humans', 'Monoamine Oxidase Inhibitors/*therapeutic use', 'Pain/psychology', 'Phenelzine/therapeutic use', 'Rejection, Psychology']",https://pubmed.ncbi.nlm.nih.gov/6384959/
3883,Phenelzine,15916450,Herb-drug interactions: a literature review.,"['Hu Z', 'Yang X', 'Ho PC', 'Chan SY', 'Heng PW', 'Chan E', 'Duan W', 'Koh HL', 'Zhou S']","['Animals', '*Herb-Drug Interactions', 'Humans', 'Phytotherapy/*adverse effects', 'Plant Preparations/*adverse effects/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/15916450/
3884,Phenelzine,3197020,Drug-induced catatonia.,"['Herrmann N', 'Lieff SJ']","['Aged', 'Aged, 80 and over', 'Catatonia/*chemically induced', 'Dementia/*drug therapy', 'Depressive Disorder/*drug therapy', 'Drug Therapy, Combination', 'Female', 'Haloperidol/*adverse effects/therapeutic use', 'Humans', 'Phenelzine/*adverse effects/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3197020/
3885,Phenelzine,32546134,Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.,"['Revet A', 'Montastruc F', 'Roussin A', 'Raynaud JP', 'Lapeyre-Mestre M', 'Nguyen TTH']","['Adult', 'Aged', 'Antidepressive Agents/adverse effects', 'Female', 'Humans', 'Male', 'Middle Aged', '*Movement Disorders/epidemiology/etiology', '*Pharmacovigilance', 'Selective Serotonin Reuptake Inhibitors', 'Sertraline']",https://pubmed.ncbi.nlm.nih.gov/32546134/
3886,Phenelzine,35721816,The Prescriber's Guide to the MAOI Diet-Thinking Through Tyramine Troubles.,"['Van den Eynde V', 'Gillman PK', 'Blackwell BB']","['Diet', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/pharmacology', '*Phenelzine', 'Tranylcypromine', '*Tyramine/metabolism']",https://pubmed.ncbi.nlm.nih.gov/35721816/
3887,Phenelzine,11888352,Effects of psychotropic drugs on seizure threshold.,"['Pisani F', 'Oteri G', 'Costa C', 'Di Raimondo G', 'Di Perri R']","['Animals', 'Anticonvulsants/*adverse effects/therapeutic use', 'Antidepressive Agents/adverse effects/therapeutic use', 'Antipsychotic Agents/adverse effects/therapeutic use', 'Electroencephalography/drug effects', 'Epilepsy/chemically induced/drug therapy/physiopathology', 'Humans', 'Psychotropic Drugs/*adverse effects/therapeutic use', 'Risk Factors', 'Seizures/*chemically induced/drug therapy/physiopathology']",https://pubmed.ncbi.nlm.nih.gov/11888352/
3888,Phenelzine,19440080,Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis.,"['Serretti A', 'Chiesa A']","['Antidepressive Agents/*adverse effects', 'Arousal/drug effects', 'Female', 'Humans', 'Male', 'Orgasm/drug effects', 'Sex Factors', 'Sexual Dysfunctions, Psychological/*chemically induced']",https://pubmed.ncbi.nlm.nih.gov/19440080/
3889,Phenelzine,7092486,Atypical depression.,"['Davidson JR', 'Miller RD', 'Turnbull CD', 'Sullivan JL']","['Adult', 'Age Factors', 'Amitriptyline/therapeutic use', 'Anxiety/psychology', 'Bipolar Disorder/classification/psychology', 'Depressive Disorder/*classification/drug therapy/psychology', 'Double-Blind Method', 'Female', 'Humans', 'Male', 'Monoamine Oxidase Inhibitors/therapeutic use', 'Personality', 'Phenelzine/therapeutic use', 'Psychomotor Agitation/psychology', 'Sex Factors', 'Terminology as Topic']",https://pubmed.ncbi.nlm.nih.gov/7092486/
3890,Phenelzine,2868672,Phenelzine poisoning.,"['Breheny FX', 'Dobb GJ', 'Clarke GM']","['Adrenergic alpha-Antagonists/therapeutic use', 'Catecholamines/metabolism', '*Critical Care', 'Female', 'Fluid Therapy', 'Hemodynamics', 'Humans', 'Middle Aged', 'Monitoring, Physiologic', 'Phenelzine/*poisoning']",https://pubmed.ncbi.nlm.nih.gov/2868672/
3891,Phenelzine,20726290,Best practice guide for the treatment of nightmare disorder in adults.,"['Aurora RN', 'Zak RS', 'Auerbach SH', 'Casey KR', 'Chowdhuri S', 'Karippot A', 'Maganti RK', 'Ramar K', 'Kristo DA', 'Bista SR', 'Lamm CI', 'Morgenthaler TI']","['Adult', 'Clonidine/therapeutic use', 'Cognitive Behavioral Therapy/methods', 'Dreams/drug effects/*psychology', 'Evidence-Based Medicine', 'Eye Movement Desensitization Reprocessing', 'Humans', 'Hypnosis', 'Norepinephrine/antagonists & inhibitors', 'Prazosin/therapeutic use', 'Psychotropic Drugs/therapeutic use', 'Randomized Controlled Trials as Topic', 'Relaxation Therapy', 'Stress Disorders, Post-Traumatic/diagnosis/*therapy']",https://pubmed.ncbi.nlm.nih.gov/20726290/
3892,Phenelzine,1813896,Pharmacokinetics of monoamine oxidase inhibitors.,"['Mallinger AG', 'Smith E']","['Humans', 'Monoamine Oxidase Inhibitors/*pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/1813896/
3893,Phenelzine,25884531,Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.,"['Thomas SJ', 'Shin M', 'McInnis MG', 'Bostwick JR']","['Antidepressive Agents/*therapeutic use', 'Central Nervous System Stimulants/*therapeutic use', 'Contraindications', 'Depression/*drug therapy', 'Depressive Disorder, Major/*drug therapy', 'Drug Interactions', 'Drug Therapy, Combination', 'Humans', 'Monoamine Oxidase Inhibitors/*therapeutic use', 'Treatment Failure']",https://pubmed.ncbi.nlm.nih.gov/25884531/
3894,Phenelzine,35837681,"The prescriber's guide to classic MAO inhibitors (phenelzine, tranylcypromine, isocarboxazid) for treatment-resistant depression.","['Van den Eynde V', 'Abdelmoemin WR', 'Abraham MM', 'Amsterdam JD', 'Anderson IM', 'Andrade C', 'Baker GB', 'Beekman ATF', 'Berk M', 'Birkenhager TK', 'Blackwell BB', 'Blier P', 'Blom MBJ', 'Bodkin AJ', 'Cattaneo CI', 'Dantz B', 'Davidson J', 'Dunlop BW', 'Estevez RF', 'Feinberg SS', 'Finberg JPM', 'Fochtmann LJ', 'Gotlib D', 'Holt A', 'Insel TR', 'Larsen JK', 'Mago R', 'Menkes DB', 'Meyer JM', 'Nutt DJ', 'Parker G', 'Rego MD', 'Richelson E', 'Ruhe HG', 'Saiz-Ruiz J', 'Stahl SM', 'Steele T', 'Thase ME', 'Ulrich S', 'van Balkom AJLM', 'Vieta E', 'Whyte I', 'Young AH', 'Gillman PK']","['Humans', '*Monoamine Oxidase Inhibitors/therapeutic use/adverse effects/pharmacology', '*Depressive Disorder, Treatment-Resistant/drug therapy', '*Tranylcypromine/therapeutic use/adverse effects/pharmacology', '*Phenelzine/therapeutic use', 'Antidepressive Agents/therapeutic use/adverse effects', 'Drug Interactions']",https://pubmed.ncbi.nlm.nih.gov/35837681/
3895,Phenelzine,6470198,Phenelzine-induced pyridoxine deficiency.,"['Stewart JW', 'Harrison W', 'Quitkin F', 'Liebowitz MR']","['Adult', 'Female', 'Humans', 'Male', 'Middle Aged', 'Phenelzine/*adverse effects', 'Pyridoxine/therapeutic use', 'Vitamin B 6 Deficiency/*chemically induced/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/6470198/
3896,Phenelzine,9074307,Continuation and maintenance treatments in major depression: the neglected role of monoamine oxidase inhibitors.,['Kennedy SH'],"['Antidepressive Agents/*administration & dosage/adverse effects', 'Depressive Disorder/diagnosis/*drug therapy/psychology', 'Dose-Response Relationship, Drug', 'Humans', 'Long-Term Care', 'Monoamine Oxidase Inhibitors/*administration & dosage/adverse effects', 'Phenelzine/administration & dosage/adverse effects', 'Tranylcypromine/administration & dosage/adverse effects', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/9074307/
3897,Phenelzine,17348764,Treating depression with atypical features.,['Stewart JW'],"['Antidepressive Agents, Tricyclic/*therapeutic use', 'Cognitive Behavioral Therapy', 'Depressive Disorder/*drug therapy/history/*psychology', 'History, 20th Century', 'Humans', 'Monoamine Oxidase Inhibitors/*therapeutic use', 'Selective Serotonin Reuptake Inhibitors/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17348764/
3898,Phenelzine,3114597,The current status of monoamine oxidase and its inhibitors.,"['Jarrott B', 'Vajda FJ']","['Allylamine/analogs & derivatives/pharmacology/therapeutic use', 'Benzamides/pharmacology/therapeutic use', 'Clinical Trials as Topic', 'Humans', 'Moclobemide', 'Monoamine Oxidase/classification/*metabolism', 'Monoamine Oxidase Inhibitors/pharmacology/*therapeutic use', 'Oxazoles/pharmacology/therapeutic use', '*Oxazolidinones', 'Selegiline/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/3114597/
3899,Phenelzine,32339131,Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: A systematic review and network meta-analysis.,"['Bahji A', 'Ermacora D', 'Stephenson C', 'Hawken ER', 'Vazquez G']","['*Antipsychotic Agents/adverse effects', '*Bipolar Disorder/drug therapy', 'Humans', 'Lurasidone Hydrochloride/therapeutic use', 'Network Meta-Analysis', 'Olanzapine/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/32339131/
3900,Phenelzine,3068037,Monoamine oxidase inhibitors and weight gain.,"['Cantu TG', 'Korek JS']","['Humans', 'Monoamine Oxidase Inhibitors/*adverse effects', 'Weight Gain/*drug effects']",https://pubmed.ncbi.nlm.nih.gov/3068037/
3901,Phenelzine,6391305,Monoamine oxidase inhibitor overdose.,"['Linden CH', 'Rumack BH', 'Strehlke C']","['Acute Kidney Injury/chemically induced/therapy', 'Adult', 'Female', 'Fever/chemically induced/therapy', 'Humans', 'Hypertension/chemically induced/drug therapy', 'Hypotension/chemically induced/drug therapy', 'Monoamine Oxidase Inhibitors/pharmacology', 'Neuromuscular Diseases/chemically induced/drug therapy', 'Phenelzine/*poisoning', 'Structure-Activity Relationship']",https://pubmed.ncbi.nlm.nih.gov/6391305/
3902,Ertapenem,31300245,Subcutaneously administered antibiotics.,"['Colin E', 'Baldolli A', 'Verdon R', 'Saint-Lorant G']","['Age Factors', 'Anti-Bacterial Agents/*administration & dosage/blood/pharmacokinetics', 'Bacterial Infections/blood/*drug therapy', 'Ceftriaxone/administration & dosage/pharmacokinetics', 'Clinical Trials as Topic', 'Cohort Studies', 'Ertapenem/administration & dosage/pharmacokinetics', 'Humans', 'Infusions, Intravenous', 'Injections, Intravenous', '*Injections, Subcutaneous', 'Microbial Sensitivity Tests', 'Teicoplanin/administration & dosage/pharmacokinetics']",https://pubmed.ncbi.nlm.nih.gov/31300245/
3903,Ertapenem,17488146,Comparative review of the carbapenems.,"['Zhanel GG', 'Wiebe R', 'Dilay L', 'Thomson K', 'Rubinstein E', 'Hoban DJ', 'Noreddin AM', 'Karlowsky JA']","['*Anti-Bacterial Agents/adverse effects/chemistry/pharmacology/therapeutic use', 'Bacterial Infections/drug therapy', '*Carbapenems/adverse effects/chemistry/pharmacology/therapeutic use', 'Doripenem', 'Ertapenem', 'Humans', 'Imipenem/adverse effects/chemistry/pharmacology/therapeutic use', 'Meropenem', 'Thienamycins/adverse effects/chemistry/pharmacology/therapeutic use', 'beta-Lactams/adverse effects/chemistry/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/17488146/
3904,Ertapenem,36374566,Subcutaneously administered antibiotics: a review.,"['Jumpertz M', 'Guilhaumou R', 'Million M', 'Parola P', 'Lagier JC', 'Brouqui P', 'Cassir N']","['Humans', '*Anti-Bacterial Agents/adverse effects', 'Ertapenem', '*Ceftriaxone', 'Teicoplanin', 'Cefepime']",https://pubmed.ncbi.nlm.nih.gov/36374566/
3905,Ertapenem,38215770,"Efficacy and safety of a structured de-escalation from antipseudomonal beta-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.","['Lopez-Cortes LE', 'Delgado-Valverde M', 'Moreno-Mellado E', 'Goikoetxea Aguirre J', 'Guio Carrion L', 'Blanco Vidal MJ', 'Lopez Soria LM', 'Perez-Rodriguez MT', 'Martinez Lamas L', 'Arnaiz de Las Revillas F', 'Arminanzas C', 'Ruiz de Alegria-Puig C', 'Jimenez Aguilar P', 'Del Carmen Martinez-Rubio M', 'Saez-Bejar C', 'de Las Cuevas C', 'Martin-Aspas A', 'Galan F', 'Yuste JR', 'Leiva-Leon J', 'Bou G', 'Capon Gonzalez P', 'Boix-Palop L', 'Xercavins-Valls M', 'Goenaga-Sanchez MA', 'Anza DV', 'Caston JJ', 'Rufian MR', 'Merino E', 'Rodriguez JC', 'Loeches B', 'Cuervo G', 'Guerra Laso JM', 'Plata A', 'Perez Cortes S', 'Lopez Mato P', 'Sierra Monzon JL', 'Rosso-Fernandez C', 'Bravo-Ferrer JM', 'Retamar-Gentil P', 'Rodriguez-Bano J']","['Humans', '*beta-Lactams/adverse effects', 'Anti-Bacterial Agents/adverse effects', 'Ceftriaxone', 'Ertapenem', '*Bacteremia/drug therapy', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/38215770/
3906,Ertapenem,15566108,Appropriate use of the carbapenems.,"['Brink AJ', 'Feldman C', 'Grolman DC', 'Muckart D', 'Pretorius J', 'Richards GA', 'Senekal M', 'Sieling W']","['Anti-Bacterial Agents/classification/pharmacology/supply & distribution/*therapeutic use', 'Bacterial Infections/*drug therapy/epidemiology/microbiology', 'Carbapenems/classification/pharmacology/supply & distribution/*therapeutic use', 'Cilastatin/therapeutic use', 'Community-Acquired Infections/drug therapy/epidemiology/microbiology', 'Cross Infection/drug therapy/epidemiology/microbiology', 'Drug Resistance, Bacterial', 'Drug Utilization', 'Ertapenem', 'Humans', 'Imipenem/therapeutic use', 'Lactams/therapeutic use', 'Meropenem', '*Patient Selection', 'Pneumonia, Bacterial/drug therapy', ""Practice Patterns, Physicians'/*standards"", 'Protease Inhibitors/therapeutic use', 'South Africa/epidemiology', 'Surgical Wound Infection/drug therapy', 'Thienamycins/therapeutic use', 'Urinary Tract Infections/drug therapy', 'beta-Lactams']",https://pubmed.ncbi.nlm.nih.gov/15566108/
3907,Ertapenem,34933565,Ertapenem neurotoxicity in liver transplantation.,"['Martinez Delgado S', 'Minguez Sabater A', 'Ladron Abia P', 'Aguilera Sancho-Tello MV', 'Garcia Eliz M', 'Conde I']","['Anti-Bacterial Agents/adverse effects', 'Ertapenem/adverse effects', 'Humans', '*Liver Transplantation/adverse effects', 'Microbial Sensitivity Tests', '*Neurotoxicity Syndromes/drug therapy/etiology', 'beta-Lactams/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/34933565/
3908,Ertapenem,19189043,Levofloxacin-induced delirium.,"['Slobodin G', 'Elias N', 'Zaygraikin N', 'Sheikh-Ahmad M', 'Sabetay S', 'Weller B', 'Odeh M']","['Age Factors', 'Aged, 80 and over', 'Amoxicillin/therapeutic use', 'Anti-Bacterial Agents/adverse effects', 'Brain/*drug effects/physiopathology', 'Clarithromycin/therapeutic use', 'Confusion/chemically induced', 'Delirium/*chemically induced/physiopathology', 'Ertapenem', 'Hallucinations/chemically induced', 'Humans', '*Levofloxacin', 'Male', 'Ofloxacin/*adverse effects', 'Pneumonia/*drug therapy', 'Risk Factors', 'Sex Factors', 'Time Factors', 'Withholding Treatment', 'beta-Lactams/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/19189043/
3909,Ertapenem,25636928,Association between hypoalbuminemia and mortality among subjects treated with ertapenem versus other carbapenems: prospective cohort study.,"['Zusman O', 'Farbman L', 'Tredler Z', 'Daitch V', 'Lador A', 'Leibovici L', 'Paul M']","['Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/pharmacology/*therapeutic use', 'Carbapenems/pharmacology/*therapeutic use', 'Drug Resistance, Bacterial', 'Enterobacteriaceae/drug effects', '*Enterobacteriaceae Infections/complications/drug therapy/microbiology/mortality', 'Ertapenem', 'Humans', 'Hypoalbuminemia/*complications/*mortality', 'Israel/epidemiology', 'Middle Aged', 'Prospective Studies', 'Risk Factors', 'beta-Lactams/pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25636928/
3910,Ertapenem,24744302,The risk of seizures among the carbapenems: a meta-analysis.,"['Cannon JP', 'Lee TA', 'Clark NM', 'Setlak P', 'Grim SA']","['Adult', 'Anti-Bacterial Agents/*adverse effects/therapeutic use', 'Carbapenems/*adverse effects/therapeutic use', 'Child', 'Cilastatin/adverse effects/therapeutic use', 'Cilastatin, Imipenem Drug Combination', 'Doripenem', 'Drug Combinations', 'Ertapenem', 'Humans', 'Imipenem/adverse effects/therapeutic use', 'Meropenem', 'Risk', 'Seizures/*chemically induced/*epidemiology', 'Thienamycins/adverse effects', 'beta-Lactams/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/24744302/
3911,Ertapenem,20163277,Ertapenem.,['Congeni BL'],"['Anti-Bacterial Agents/chemistry/pharmacokinetics/*therapeutic use', 'Community-Acquired Infections/*drug therapy/metabolism', 'Ertapenem', 'Half-Life', 'Humans', 'Outpatients', 'beta-Lactams/chemistry/pharmacokinetics/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20163277/
3912,Ertapenem,36068705,"Sulopenem for the Treatment of Complicated Urinary Tract Infections Including Pyelonephritis: A Phase 3, Randomized Trial.","['Dunne MW', 'Aronin SI', 'Das AF', 'Akinapelli K', 'Breen J', 'Zelasky MT', 'Puttagunta S']","['Adult', 'Humans', 'Ertapenem/therapeutic use', '*Bacteriuria/drug therapy', '*Urinary Tract Infections/microbiology', 'Anti-Bacterial Agents', '*Pyelonephritis/drug therapy', 'Ciprofloxacin/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/36068705/
3913,Ertapenem,15308278,Beta-lactam antibiotics: newer formulations and newer agents.,"['Martin SI', 'Kaye KM']","['Amoxicillin-Potassium Clavulanate Combination/pharmacology/therapeutic use', 'Anti-Bacterial Agents/*pharmacology/*therapeutic use', 'Cefepime', 'Cephalosporins/pharmacology/therapeutic use', 'Ertapenem', 'Humans', 'Lactams/pharmacology/therapeutic use', 'United States', 'beta-Lactams/*pharmacology/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/15308278/
3914,Ertapenem,27851857,Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.,"['Solomkin J', 'Evans D', 'Slepavicius A', 'Lee P', 'Marsh A', 'Tsai L', 'Sutcliffe JA', 'Horn P']","['Abdominal Abscess/*drug therapy/microbiology/surgery', 'Adult', 'Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/adverse effects/*therapeutic use', 'Appendicitis/complications', 'Bacterial Infections/complications/*drug therapy', 'Double-Blind Method', 'Ertapenem', 'Female', '*Gram-Negative Bacteria', 'Humans', 'Intention to Treat Analysis', 'Male', 'Middle Aged', 'Peritonitis/*drug therapy/microbiology', 'Tetracyclines/adverse effects/*therapeutic use', 'Treatment Outcome', 'Young Adult', 'beta-Lactams/adverse effects/*therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/27851857/
3915,Ertapenem,37881901,Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients.,"['VanDorf S', 'Shah P', 'Yost CN']","['Humans', '*Ertapenem/administration & dosage/therapeutic use', '*Critical Illness', '*Meropenem/administration & dosage/therapeutic use/pharmacology', 'Male', 'Female', 'Retrospective Studies', '*Anti-Bacterial Agents/therapeutic use/administration & dosage', 'Middle Aged', 'Aged', '*beta-Lactamases/metabolism', '*Bacteremia/drug therapy/microbiology', '*Enterobacteriaceae Infections/drug therapy/microbiology', 'Enterobacteriaceae/drug effects/isolation & purification', 'Cohort Studies']",https://pubmed.ncbi.nlm.nih.gov/37881901/
3916,Ertapenem,32487528,Ertapenem-induced encephalopathy.,"['Adams R', 'Chopra P', 'Miranda R', 'Calderon A']","['*Akathisia, Drug-Induced/diagnosis/therapy', 'Anti-Bacterial Agents/administration & dosage/adverse effects', '*Delirium/chemically induced/diagnosis/therapy', 'Empyema/*drug therapy', '*Ertapenem/administration & dosage/adverse effects', '*Hallucinations/chemically induced/diagnosis/therapy', 'Humans', 'Male', 'Middle Aged', '*Neurotoxicity Syndromes/diagnosis/etiology/psychology/therapy', 'Treatment Outcome', 'Withholding Treatment']",https://pubmed.ncbi.nlm.nih.gov/32487528/
3917,Ertapenem,38353987,Efficacy and Durability of Intravenous Ertapenem Therapy for Recalcitrant Hidradenitis Suppurativa.,"['Nosrati A', ""Ch'en PY"", 'Torpey ME', 'Shokrian N', 'Ball G', 'Benesh G', 'Andriano TM', 'Zhu TR', 'Heibel HD', 'Hosgood HD', 'Campton KL', 'Cohen SR']","['Humans', 'Female', 'Adult', 'Male', 'Ertapenem/therapeutic use', '*Hidradenitis Suppurativa/diagnosis/drug therapy', 'Interleukin-6', 'Retrospective Studies', '*Antimicrobial Stewardship', 'C-Reactive Protein', 'Anti-Bacterial Agents/therapeutic use', 'Pain/drug therapy']",https://pubmed.ncbi.nlm.nih.gov/38353987/
3918,Ertapenem,28592240,"Randomized controlled trial of piperacillin-tazobactam, cefepime and ertapenem for the treatment of urinary tract infection caused by extended-spectrum beta-lactamase-producing Escherichia coli.","['Seo YB', 'Lee J', 'Kim YK', 'Lee SS', 'Lee JA', 'Kim HY', 'Uh Y', 'Kim HS', 'Song W']","['Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*therapeutic use', 'Cefepime', 'Cephalosporins/therapeutic use', 'Cross Infection', 'Ertapenem', 'Escherichia coli/*drug effects/enzymology/genetics/isolation & purification', 'Escherichia coli Infections/*drug therapy/microbiology', 'Female', 'Genotype', 'Humans', 'Male', 'Middle Aged', 'Penicillanic Acid/*analogs & derivatives/therapeutic use', 'Piperacillin/therapeutic use', 'Piperacillin, Tazobactam Drug Combination', 'Prospective Studies', 'Republic of Korea', 'Tazobactam', 'Urinary Tract Infections/*drug therapy/microbiology', 'beta-Lactamase Inhibitors/*therapeutic use', 'beta-Lactamases/genetics', 'beta-Lactams/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/28592240/
3919,Ertapenem,31943613,Higher rates of carbapenem-related seizures in older hospitalised adults.,"['Neo HY', 'Tan KT', 'Caroline C', 'Wei-Han Ng D', 'Pei-Ying Ho E', 'Lim JP', 'Hsien-Xiong Lee R', 'Choon-Kiat Tan N', 'Chien-Boon Lye D', 'Ding YY']","['Aged', 'Aged, 80 and over', 'Anti-Bacterial Agents/*adverse effects', 'Carbapenems/*adverse effects', 'Ertapenem/adverse effects', 'Female', 'Hospitalization', 'Humans', 'Imipenem/adverse effects', 'Logistic Models', 'Male', 'Meropenem/adverse effects', 'Seizures/*chemically induced/*epidemiology', 'Singapore/epidemiology', 'beta-Lactams/adverse effects']",https://pubmed.ncbi.nlm.nih.gov/31943613/
3920,Ertapenem,20502094,Ertapenem.,"['Parakh A', 'Krishnamurthy S', 'Bhattacharya M']","['Adult', 'Anti-Bacterial Agents/*pharmacology/therapeutic use', 'Child', 'Community-Acquired Infections/drug therapy', 'Dose-Response Relationship, Drug', 'Ertapenem', 'Female', 'Gram-Negative Bacterial Infections/drug therapy', 'Gram-Positive Bacterial Infections/drug therapy', 'Humans', 'Injections, Intramuscular', 'Injections, Intravenous', 'Male', 'Sensitivity and Specificity', 'Urinary Tract Infections/drug therapy', 'beta-Lactams/*pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/20502094/
3921,Ertapenem,18154543,Parenteral carbapenems.,['Shah PM'],"['*Anti-Bacterial Agents/classification/pharmacokinetics/pharmacology/therapeutic use', '*Carbapenems/classification/pharmacokinetics/pharmacology/therapeutic use', 'Ertapenem', '*Gram-Negative Bacteria/drug effects/enzymology', 'Gram-Negative Bacterial Infections/drug therapy/microbiology', 'Gram-Positive Bacteria/*drug effects', 'Humans', 'Imipenem/pharmacokinetics/pharmacology/therapeutic use', 'Infusions, Parenteral', 'Meropenem', 'Thienamycins/pharmacokinetics/pharmacology/therapeutic use', 'beta-Lactam Resistance', 'beta-Lactamases/biosynthesis', 'beta-Lactams/pharmacokinetics/pharmacology/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/18154543/
3922,azathioprine,30465775,Grand round: Autoimmune hepatitis.,"['Trivedi PJ', 'Hubscher SG', 'Heneghan M', 'Gleeson D', 'Hirschfield GM']","['Adolescent', 'Adult', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Clinical Decision-Making', 'Complementary Therapies', 'Drug Tolerance', 'Female', 'Hepatitis, Autoimmune/classification/diagnosis/*drug therapy/*immunology', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Male', 'Precision Medicine/methods', 'Prednisolone/administration & dosage/*therapeutic use', 'Recurrence', 'Risk Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30465775/
3923,azathioprine,30783322,Management of myasthenia gravis during pregnancy.,"['Bansal R', 'Goyal MK', 'Modi M']","['Azathioprine/administration & dosage/adverse effects/therapeutic use', 'Cholinesterase Inhibitors/administration & dosage/adverse effects/therapeutic use', '*Disease Management', 'Female', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/therapeutic use', 'Myasthenia Gravis/*drug therapy', 'Practice Guidelines as Topic', 'Pregnancy', 'Pregnancy Complications/*drug therapy', 'Pregnancy Outcome', 'Prenatal Care', 'Pyridostigmine Bromide/administration & dosage/adverse effects/therapeutic use', 'Severity of Illness Index']",https://pubmed.ncbi.nlm.nih.gov/30783322/
3924,azathioprine,3511372,Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs.,"['Austin HA 3rd', 'Klippel JH', 'Balow JE', 'le Riche NG', 'Steinberg AD', 'Plotz PH', 'Decker JL']","['Administration, Oral', 'Adult', 'Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Biopsy', 'Clinical Trials as Topic', 'Creatinine/blood', 'Cyclophosphamide/administration & dosage/adverse effects/*therapeutic use', 'Drug Therapy, Combination', 'Female', 'Glomerulonephritis/*drug therapy/etiology/physiopathology', 'Humans', 'Injections, Intravenous', 'Kidney/pathology', 'Kidney Failure, Chronic/etiology', 'Lupus Erythematosus, Systemic/*complications', 'Male', 'Prednisone/administration & dosage/adverse effects/*therapeutic use', 'Random Allocation']",https://pubmed.ncbi.nlm.nih.gov/3511372/
3925,azathioprine,9608317,Update on immunosuppressive therapy.,"['Singer NG', 'McCune WJ']","['Adult', 'Arthritis, Juvenile/drug therapy', 'Azathioprine/adverse effects/therapeutic use', 'Behcet Syndrome/drug therapy', 'Child', 'Cladribine/therapeutic use', 'Cyclophosphamide/administration & dosage/therapeutic use', 'Cyclosporine/therapeutic use', 'Drug Therapy, Combination', 'Granulomatosis with Polyangiitis/drug therapy', 'Humans', 'Hydroxychloroquine/administration & dosage/adverse effects/therapeutic use', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Liver/drug effects/injuries', 'Lung/drug effects', 'Lung Injury', 'Lupus Erythematosus, Systemic/drug therapy', 'Methotrexate/administration & dosage/adverse effects/therapeutic use', 'Pemphigoid, Benign Mucous Membrane/drug therapy', 'Retina/drug effects', 'Tacrolimus/therapeutic use', 'Thalidomide/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/9608317/
3926,azathioprine,25352005,[Optimized thiopurine treatment in chronic inflammatory bowel disease].,"['Kiszka-Kanowitz M', 'Theede K', 'Nielsen AM']","['Algorithms', 'Allopurinol/administration & dosage/adverse effects/metabolism/therapeutic use', 'Antimetabolites/administration & dosage/adverse effects/metabolism/therapeutic use', 'Azathioprine/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Dose-Response Relationship, Drug', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/metabolism/*therapeutic use', 'Methyltransferases/administration & dosage/adverse effects/metabolism/therapeutic use']",https://pubmed.ncbi.nlm.nih.gov/25352005/
3927,azathioprine,12765471,Immunosuppressive drug use in pregnancy.,['Petri M'],"['Adrenal Cortex Hormones/adverse effects/pharmacokinetics/therapeutic use', 'Azathioprine/adverse effects/pharmacokinetics/therapeutic use', 'Breast Feeding', 'Cyclophosphamide/adverse effects/pharmacokinetics/therapeutic use', 'Cyclosporine/adverse effects/pharmacokinetics/therapeutic use', 'Female', 'Fetal Diseases/chemically induced', 'Humans', 'Hydroxychloroquine/adverse effects/pharmacokinetics/therapeutic use', 'Immunosuppressive Agents/*adverse effects/pharmacokinetics/*therapeutic use', 'Lupus Erythematosus, Systemic/prevention & control', 'Maternal-Fetal Exchange', 'Mycophenolic Acid/adverse effects/analogs & derivatives/pharmacokinetics/therapeutic use', 'Pregnancy', 'Pregnancy Complications/chemically induced/*prevention & control']",https://pubmed.ncbi.nlm.nih.gov/12765471/
3928,azathioprine,20949566,Optimizing thiopurine therapy in inflammatory bowel disease.,"['Chevaux JB', 'Peyrin-Biroulet L', 'Sparrow MP']","['Azathioprine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/pharmacokinetics/*therapeutic use', 'Methyltransferases/metabolism']",https://pubmed.ncbi.nlm.nih.gov/20949566/
3929,azathioprine,24438369,Allopurinol enhanced thiopurine treatment for inflammatory bowel disease: safety considerations and guidelines for use.,"['Min MX', 'Weinberg DI', 'McCabe RP']","['Allopurinol/administration & dosage/adverse effects/*therapeutic use', 'Azathioprine/administration & dosage/adverse effects/therapeutic use', 'Drug Monitoring', 'Drug Therapy, Combination', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy', 'Mercaptopurine/administration & dosage/adverse effects/therapeutic use', 'Practice Guidelines as Topic']",https://pubmed.ncbi.nlm.nih.gov/24438369/
3930,azathioprine,25443224,[Role of thiopurine agents in ulcerative colitis].,"['Chaparro M', 'Gisbert JP']","['Azathioprine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Clinical Trials as Topic', 'Colitis, Ulcerative/*drug therapy', 'Crohn Disease/drug therapy', 'Disease Susceptibility', 'Dose-Response Relationship, Drug', 'Humans', 'Immunocompromised Host', 'Immunosuppressive Agents/administration & dosage/pharmacology/*therapeutic use', 'Infections/etiology', 'Mercaptopurine/administration & dosage/adverse effects/pharmacology/*therapeutic use', 'Meta-Analysis as Topic', 'Neoplasms/etiology', 'Prodrugs/pharmacokinetics', 'Remission Induction', 'Treatment Outcome']",https://pubmed.ncbi.nlm.nih.gov/25443224/
3931,azathioprine,21674420,"Immunosuppressive and cytotoxic therapy: pharmacology, toxicities, and monitoring.","['Wang T', 'Weigt SS', 'Belperio JA', 'Lynch JP 3rd']","['Adrenal Cortex Hormones/*administration & dosage/adverse effects/pharmacology/therapeutic use', '*Anti-Inflammatory Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/*drug therapy', 'Azathioprine/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Cyclophosphamide/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Humans', '*Immunosuppressive Agents/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Methotrexate/administration & dosage/adverse effects/pharmacology/therapeutic use', 'Mycophenolic Acid/administration & dosage/adverse effects/analogs & derivatives/pharmacology/therapeutic use', 'Time Factors']",https://pubmed.ncbi.nlm.nih.gov/21674420/
3932,azathioprine,29421584,Effective long-term solution to therapeutic remission in Inflammatory Bowel Disease: Role of Azathioprine.,"['Adam L', 'Phulukdaree A', 'Soma P']","['Azathioprine/administration & dosage/adverse effects/*therapeutic use', 'Humans', 'Immunosuppressive Agents/administration & dosage/adverse effects/*therapeutic use', 'Inflammatory Bowel Diseases/*drug therapy/enzymology/immunology', 'Methyltransferases/genetics', 'Polymorphism, Single Nucleotide', 'Remission Induction']",https://pubmed.ncbi.nlm.nih.gov/29421584/
3933,azathioprine,25166425,"Progressive, reversible sensorineural hearing loss caused by azathioprine.","['Jenkinson PW', 'Syed MI', 'Mcclymont L']","['Audiometry, Pure-Tone', 'Azathioprine/*adverse effects/*therapeutic use', 'Female', 'Hearing Loss, Sensorineural/*diagnosis/*etiology', 'Humans', 'Middle Aged']",https://pubmed.ncbi.nlm.nih.gov/25166425/
3934,azathioprine,4103984,Cyclophosphamide and human organ transplantation.,"['Starzl TE', 'Halgrimson CG', 'Penn I', 'Martineau G', 'Schroter G', 'Amemiya H', 'Putnam CW', 'Groth CG']","['Administration, Oral', 'Adolescent', 'Adult', 'Animals', 'Antilymphocyte Serum/administration & dosage', 'Azathioprine/administration & dosage/adverse effects', 'Cadaver', 'Consanguinity', 'Cyclophosphamide/administration & dosage/*therapeutic use', 'Drug Synergism', 'Female', 'Follow-Up Studies', 'Graft Rejection', 'Histocompatibility', 'Horses', 'Humans', 'Immunosuppressive Agents/therapeutic use', 'Injections, Intramuscular', '*Kidney Transplantation', '*Liver Transplantation', 'Male', 'Middle Aged', 'Postoperative Complications', 'Prednisone/administration & dosage', 'Time Factors', 'Transplantation Immunology', 'Transplantation, Homologous']",https://pubmed.ncbi.nlm.nih.gov/4103984/
3935,azathioprine,25378092,Pregnancy outcomes in women with inflammatory bowel disease following exposure to thiopurines and antitumor necrosis factor drugs: a systematic review with meta-analysis.,"['Mozaffari S', 'Abdolghaffari AH', 'Nikfar S', 'Abdollahi M']","['Adult', 'Azathioprine/administration & dosage/*adverse effects/therapeutic use', 'Female', 'Humans', 'Inflammatory Bowel Diseases/*drug therapy/epidemiology/immunology', 'Infliximab/administration & dosage/*adverse effects/therapeutic use', 'Pregnancy', 'Pregnancy Complications/*drug therapy/epidemiology/immunology', 'Pregnancy Outcome/*epidemiology', 'Prenatal Exposure Delayed Effects/chemically induced/*epidemiology', 'Tumor Necrosis Factor-alpha/*immunology']",https://pubmed.ncbi.nlm.nih.gov/25378092/
3936,azathioprine,31862300,Impact of Azathioprine use in chronic hypersensitivity pneumonitis patients.,"['Terras Alexandre A', 'Martins N', 'Raimundo S', 'Melo N', 'Catetano Mota P', 'Novais E Bastos H', 'Pereira JM', 'Cunha R', 'Guimaraes S', 'Souto Moura C', 'Morais A']","['Adult', 'Aged', 'Aged, 80 and over', 'Alveolitis, Extrinsic Allergic/*drug therapy', 'Azathioprine/adverse effects/*therapeutic use', 'Carbon Monoxide', 'Chronic Disease/drug therapy', 'Female', 'Humans', 'Immunosuppressive Agents/adverse effects/*therapeutic use', 'Longitudinal Studies', 'Lung/drug effects', 'Male', 'Middle Aged', 'Respiratory Function Tests', 'Retrospective Studies', 'Total Lung Capacity/drug effects', 'Treatment Outcome', 'Vital Capacity/drug effects']",https://pubmed.ncbi.nlm.nih.gov/31862300/
3937,azathioprine,29775790,Clinical Course of Nodular Regenerative Hyperplasia in Thiopurine Treated Inflammatory Bowel Disease Patients.,"['Simsek M', 'Meijer B', 'Ramsoekh D', 'Bouma G', 'van der Wouden EJ', 'den Hartog B', 'de Vries AC', 'Hoentjen F', 'Dijkstra G', 'de Boer SY', 'Jansen JM', 'van der Meulen AE', 'Beukers R', 'Brink MA', 'Steinhauser T', 'Oldenburg B', 'Gilissen LP', 'Naber TH', 'Verhagen MA', 'de Boer NKH', 'Mulder CJJ']","['Adolescent', 'Adult', 'Aged', 'Azathioprine/administration & dosage/*adverse effects', 'Female', 'Humans', 'Hyperplasia/chemically induced/*pathology', 'Inflammatory Bowel Diseases/complications/*drug therapy/*pathology', 'Liver Diseases/*pathology', 'Male', 'Mercaptopurine/administration & dosage/*adverse effects', 'Middle Aged', 'Thioguanine/administration & dosage/*adverse effects', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/29775790/
3938,azathioprine,30753377,Concerns and Side Effects of Azathioprine During Adalimumab Induction and Maintenance Therapy for Japanese Patients With Crohn's Disease: A Subanalysis of a Prospective Randomised Clinical Trial [DIAMOND Study].,"['Hisamatsu T', 'Matsumoto T', 'Watanabe K', 'Nakase H', 'Motoya S', 'Yoshimura N', 'Ishida T', 'Kato S', 'Nakagawa T', 'Esaki M', 'Nagahori M', 'Matsui T', 'Naito Y', 'Kanai T', 'Suzuki Y', 'Nojima M', 'Watanabe M', 'Hibi T']","['Adalimumab/administration & dosage/*therapeutic use', 'Adolescent', 'Adult', 'Aged', 'Anti-Inflammatory Agents/administration & dosage/*therapeutic use', 'Azathioprine/administration & dosage/*adverse effects/therapeutic use', 'Crohn Disease/*drug therapy', 'Drug Therapy, Combination/adverse effects', 'Female', 'Humans', 'Immunosuppressive Agents/administration & dosage/*adverse effects/therapeutic use', 'Japan', 'Kaplan-Meier Estimate', 'Male', 'Middle Aged', 'Patient Dropouts/statistics & numerical data', 'Prospective Studies', 'Risk Factors', 'Sex Factors', 'Treatment Outcome', 'Young Adult']",https://pubmed.ncbi.nlm.nih.gov/30753377/
3939,azathioprine,22170192,Safety of azathioprine use during pregnancy.,"['Natekar A', 'Pupco A', 'Bozzo P', 'Koren G']","['Antimetabolites/*adverse effects/therapeutic use', 'Azathioprine/*adverse effects/therapeutic use', 'Female', 'Humans', 'Immunosuppressive Agents/*adverse effects/therapeutic use', 'Pregnancy', '*Pregnancy Outcome']",https://pubmed.ncbi.nlm.nih.gov/22170192/
3940,azathioprine,4884653,Azathioprine in rheumatoid arthritis.,"['Mason M', 'Currey HL', 'Barnes CG', 'Dunne JF', 'Hazleman BL', 'Strickland ID']","['Arthritis, Rheumatoid/*drug therapy', 'Azathioprine/adverse effects/*therapeutic use', 'Clinical Trials as Topic', 'Drug Synergism', 'Female', 'Humans', 'Male', 'Middle Aged', 'Placebos', 'Prednisolone/administration & dosage']",https://pubmed.ncbi.nlm.nih.gov/4884653/
